0001144204-14-019555.txt : 20140331 0001144204-14-019555.hdr.sgml : 20140331 20140331170740 ACCESSION NUMBER: 0001144204-14-019555 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 10 CONFORMED PERIOD OF REPORT: 20131231 FILED AS OF DATE: 20140331 DATE AS OF CHANGE: 20140331 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NUTRA PHARMA CORP CENTRAL INDEX KEY: 0001119643 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] IRS NUMBER: 912021600 STATE OF INCORPORATION: CA FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-32141 FILM NUMBER: 14731006 BUSINESS ADDRESS: STREET 1: 12502 WEST ATLANTIC BLVD. CITY: CORAL SPRINGS STATE: FL ZIP: 33071 BUSINESS PHONE: (954) 509-0911 MAIL ADDRESS: STREET 1: 12502 WEST ATLANTIC BLVD. CITY: CORAL SPRINGS STATE: FL ZIP: 33071 FORMER COMPANY: FORMER CONFORMED NAME: CYBER VITAMIN COM DATE OF NAME CHANGE: 20000717 10-K 1 v372614_10k.htm ANNUAL REPORT

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-K

 

(Mark One)

 

xANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the fiscal year ended December 31, 2013

 

¨TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from _________ to ________

 

Commission File Number 000-32141

 

NUTRA PHARMA CORP.

 

(Exact name of registrant as specified in its charter)

 

California 91-2021600
   
(State or Other Jurisdiction of
Incorporation or organization)		 (IRS Employer Identification Number)

 

12502 W. Atlantic Blvd, Coral Springs, FL 33071
   
(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: (954) 509-0911

 

Securities registered under Section 12(b) of the Exchange Act:

 

  Title of each class Name of each exchange on which registered
     
  None None

 

Securities registered pursuant to section 12(g) of the Act:

 

Common stock, $0.001 par value

(Title of Class)

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.

 

Yes ¨ No x

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.

 

Yes ¨ No x

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

 

Yes x No ¨

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨

 

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of the registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. ¨

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

 

Large accelerated filer ¨   Accelerated filer ¨
 
Non-accelerated filer ¨ (Do not check if a smaller reporting company)   Smaller reporting company x

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act.

 

Yes ¨ No x

 

State the aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the registrant’s most recently completed second quarter: $9,833,758

 

As of March 31, 2014, there were 1,056,274,057 shares of common stock.

 

 
 

 

INDEX

 

Part I    
Item 1. Business 3
Item 1A. Risk Factors 19
Item 1B. Unresolved Staff Comments 24
Item 2. Properties 24
Item 3. Legal Proceedings 24
Item 4. Mine Safety Disclosures 26
     
Part II    
Item 5. Market for Registrant’s Common Equity; Related Stockholder Matters and Issuer Purchases of Equity Securities 26
Item 6. Selected Financial Data 31
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations 31
Item 7A. Quantitative and Qualitative Disclosures about Market Risk 35
Item 8. Financial Statements and Supplementary Data 36
Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure 36
Item 9A. Controls and Procedures 36
Item 9B. Other Information 36
     
Part III    
Item 10. Directors, Executive Officers and Corporate Governance 37
Item 11. Executive Compensation 39
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 40
Item 13. Certain Relationships and Related Transactions, and Director Independence 41
Item 14. Principal Accountant Fees and Services 41
     
Part IV    
Item 15. Exhibits and Financial Statement Schedules 42
     
Signatures   44

 

Nutra Pharma Corp and its wholly owned subsidiaries, ReceptoPharm, Inc. (“ReceptoPharm”) and Designer Diagnostics, Inc. (“Designer Diagnostics”) are referred to herein as “we”, “our” or “us” (ReceptoPharm and Designer Diagnostics are also individually referred to herein).

 

Forward Looking Statements

 

This Annual Report on Form 10-K for the period ending December 31, 2013 contains forward-looking statements that involve risks and uncertainties, most significantly, Item 7 (Management’s Discussion and Analysis of Financial Condition and Results of Operation), as well as assumptions that, if they never materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. The words or phrases "would be," "will allow, "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements.” All statements other than statements of historical fact, are statements that could be deemed forward-looking statements, including any projections of revenue, gross margin, expenses, earnings or losses from operations, synergies or other financial items; any statements of the plans, strategies and objectives of management for future operations; and any statement concerning developments, plans, or performance. Unless otherwise required by applicable law, we do not undertake and we specifically disclaim any obligation to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

 

 
 

 

PART I

 

Item 1. Business

 

Introduction

 

We were incorporated in California on February 1, 2000. We have conducted our operations since October 2003. We are a biopharmaceutical company that engages in the acquisition, licensing and commercialization of pharmaceutical products and technologies as well as homeopathic and ethical drugs for the management of pain, neurological disorders, cancer, autoimmune and infectious diseases. Homeopathic drugs are natural products that contain ingredients listed in the HPUS (Homeopathic Pharmacopoeia of the United States). An ethical drug is a licensed drug that has obtained Federal Drug Administration (“FDA”) approval after extensive pre-clinical and clinical testing. We seek strategic licensing partnerships to reduce the risks associated with the drug development process.

 

Our wholly owned subsidiary and drug discovery arm, ReceptoPharm, has carried out our homeopathic and drug discovery research and clinical development and has fully developed three homeopathic drugs for the treatment of pain:

 

  · Cobroxin®, an over-the-counter pain reliever designed to treat moderate to severe (Stage 2) chronic pain; and

 

  · Nyloxin® and Nyloxin® Extra Strength: stronger versions of Cobroxin®

 

Our business plan will continue its efforts to produce, market and distribute our Cobroxin® and Nyloxin® branded products both domestically and internationally.

 

From October 2009 until December 31, 2013, our operations have centered on the marketing of Cobroxin® and Nyloxin® and Nyloxin® Extra Strength, from which we have earned accumulated net revenues of $2,381,370, which includes a reduction of $503,958 for Nyloxin® sold during 2011 and returned in 2012. During fiscal year 2013, we earned revenues of $119,898 from sales of Nyloxin® and $2,300 from sales of Cobroxin®.

 

Additionally, ReceptoPharm has developed two drug candidates:

 

  · RPI-78M, to treat neurological diseases, including Multiple Sclerosis (MS), Adrenomyeloneuropathy (AMN), Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig’s disease ) and Myasthenia Gravis; and

 

  · RPI-MN, to treat viral diseases, including HIV/AIDS and Herpes.

 

ReceptoPharm has developed proprietary therapeutic protein products primarily for the prevention and treatment of viral and neurological diseases, including Multiple Sclerosis (MS), Adrenomyeloneuropathy (AMN), Human Immunodeficiency Virus (HIV) and pain in humans. These potential products are subject to FDA approval.

 

Our wholly owned subsidiary, Designer Diagnostics, has developed diagnostic test kits designed to be used for the rapid identification of infectious diseases, such as Nontuberculous Mycobacteria (NTM). These diagnostic test kits are currently being validated by National Jewish Hospital in Denver, Colorado. This process of validation has been ongoing since 2007. While these outside tests have proceeded, our business has exclusively focused on our drugs and we have not continued any activity in our Designer Diagnostics division since June, 2011. As results become available through the validation process and funding becomes available, we may revisit the technology and re-engage our efforts in Designer Diagnostics.

 

We continue to identify biotechnology related intellectual property and companies with which we may potentially be able to enter into arrangements, agreements or to potentially acquire.

 

Industry Overview of the Pain Market

 

Pain is the most common symptom for patients seeking medical attention. Acute and chronic pain affects large numbers of Americans, with approximately 100 million U.S. adults burdened by chronic pain alone. The annual national economic cost associated with chronic pain is estimated to be $560-635 billion. (Institute of Medicine, Relieving Pain in America, 2011).

 

The global market for pain management products, including prescription and nonprescription analgesics, reached over $50 billion in 2009 according to an August 2010 article published in the journal Nature Reviews Drug Discovery. The current market for pain drugs is expected to continue to grow according to Global Industry Analysts Inc., a market research firm that believes the aging baby boomer population will continue to trigger growth in this market resulting in a $35.5 billion US market size by 2015.

 

3
 

 

Our Products

 

Cobroxin®

 

We offer Cobroxin®, our over-the-counter pain reliever that has been clinically proven to treat moderate to severe (Stage 2) chronic pain. Cobroxin® is not currently being marketed. In August 2009, we completed an agreement with XenaCare Holdings (“XenaCare”) granting it the exclusive license to market and distribute Cobroxin® within the United States. In mid-October 2009, XenaCare began selling Cobroxin® online through its product website, www.Cobroxin.com.

 

In November 2009, XenaCare began selling Cobroxin® to brick-and-mortar retailers, including distribution to CVS in March 2010 and Walgreens in May 2010. On April 1, 2011, we notified our Cobroxin Distributor, XenaCare that they were in breach of our agreement. As a result of this, the distribution agreement was terminated effective April 10, 2011. XenaCare had a large stock of the product that they had ordered from us and we had allowed them to continue to market their existing inventory of Cobroxin. In October 2011 we discontinued their website at www.Cobroxin.com. All current traffic to that website is now redirected to www.Nyloxin.com. On June 10, 2013, we announced a new licensing agreement for the distribution of Cobroxin® with Cobra Pharmaceuticals, LLC. The new distributors expect to begin a direct response campaign by the end of 2014 with an eventual return to retail stores.

 

Cobroxin® is currently available as a two ounce topical gel for treating joint pain and pain associated with arthritis and repetitive stress, and as a one ounce oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps, and neuropathic pain. Both the topical gel and oral spray are packaged and sold as a one-month supply.

 

Cobroxin® offers several benefits as a pain reliever. With increasing concern about consumers using opioid and acetaminophen-based pain relievers, Cobroxin® provides an alternative that does not rely on opiates or non-steroidal anti-inflammatory drugs, otherwise known as NSAIDs, for its pain relieving effects. Cobroxin® also has a well-defined safety profile. Since the early 1930s, the active pharmaceutical ingredient (API) of Cobroxin®, Asian cobra venom, has been studied in more than 46 human clinical studies. The data from these studies provide clinical evidence that cobra venom provides an effective treatment for pain with few side effects and has the following benefits:

 

  · safe and effective;
     
  · all natural;
     
  · long-acting;
     
  · easy to use;
     
  · non-narcotic;
     
  · non-addictive; and
     
  · analgesic and anti-inflammatory.

 

Potential side effects from the use of Cobroxin® are rare, but may include headache, nausea, vomiting, sore throat, allergic rhinitis and coughing.

 

Nyloxin®/Nyloxin® Extra Strength

 

Nyloxin® and Nyloxin® Extra Strength are similar to Cobroxin® because they both contain the same active ingredient as Cobroxin®, Asian cobra venom. The primary difference between Nyloxin®, Nyloxin® Extra Strength and Cobroxin® is the dilution level of the venom. The approximate dilution levels for Nyloxin®, Nyloxin® Extra Strength and Cobroxin® are:

 

Nyloxin®

 

  · Topical Gel: 30 mcg/mL
     
  · Oral Spray: 70 mcg/mL

 

Nyloxin® Extra Strength

 

  · Topical Gel: 60 mcg/mL
     
  · Oral Spray: 140 mcg/mL

 

4
 

 

Cobroxin®

 

  · Topical Gel: 20 mcg/mL
     
  · Oral Spray: 35 mcg/mL

 

In December 2009, we began marketing Nyloxin® and Nyloxin® Extra Strength at www.nyloxin.com. Both Nyloxin® and Nyloxin® Extra Strength are packaged in a roll-on container, squeeze bottle and as an oral spray. Additionally, Nyloxin® topical gel is available in an 8 ounce pump bottle.

 

In September of 2012 we began distributing Nyloxin® through TCN International, a Network Marketing Company. TCN distributes products and software applications to approximately 400,000 independent agents in more than 30 countries, including more than 40,000 agents in the United States.

 

During June of 2013, we announced that New Vitality, a marketing and distribution company, had begun a test radio campaign to gauge the market acceptance of Nyloxin®. The 60-second ads ran for several weeks on radio stations throughout the United States. As a result of positive testing, New Vitality added Nyloxin® to their e-commerce website as they continue to advertise the product. In August of 2013, New Vitality had placed and received their first order of Nyloxin®. The order was pursuant to New Vitality's successful test radio campaign to gauge the market acceptance of the product. New Vitality will continue this campaign over the coming months and is expected to add television advertising in the second quarter of 2014.

 

In December of 2013, we announced an agreement with MyNyloxin.com for the exclusive rights to market and distribute Nyloxin® in the Network Marketing channel. MyNyloxin.com provides a business opportunity to their Distributors to earn commissions on the sale of our products through their Distributor groups. In January of 2014, we announced the first product shipments to the MyNyloxin Independent Entrepreneurs (MIEs). MyNyloxin conducts webinars, conference calls and live meetings to support recruitment of new MIEs as well as to provide product and business education.

 

We are currently marketing Nyloxin® and Nyloxin® Extra Strength as treatments for moderate to severe chronic pain. Nyloxin® is available as an oral spray for treating back pain, neck pain, headaches, joint pain, migraines, and neuralgia and as a topical gel for treating joint pain, neck pain, arthritis pain, and pain associated with repetitive stress. Nyloxin® Extra Strength is available as an oral spray and gel application for treating the same physical indications, but is aimed at treating the most severe (Stage 3) pain that inhibits one’s ability to function fully.

 

In December 2012, we announced the availability of Nyloxin® Military Strength for sale to the United States Military and Veteran's Administration. Over the past few years, the U.S. Department of Defense has been reporting an increase in the use and abuse of prescription medications, particularly opiates. In 2009, close to 3.8 million prescriptions for pain relievers were written in the military. This staggering number was more than a 400% increase from the number of prescriptions written in the military in 2001. But prescription drugs are not the only issue. The most common and seemingly harmless way to treat pain is with non steroidal, anti-inflammatory drugs (NSAIDS). But there are risks. Overuse can cause nausea, vomiting, diarrhea, heartburn, ulcers and internal bleeding. In severe cases chest pain, heart failure, kidney dysfunction and life-threatening allergic reactions can occur. It is reported that approximately 7,600 people in America die from NSAID use and some 78,000 are hospitalized. Ibuprofen, also an NSAID has been of particular concern in the military. The terms “Ranger Candy” and “Military Candy” refer to the service men and women who are said to use 800mg doses of Ibuprofen to control their pain. But when taking anti-inflammatory Ibuprofen in high doses for chronic pain, there is potential for critical health risks; abuse can lead to serious stomach problems, internal bleeding and even kidney failure. There are significantly greater health risks when abuse of this drug is combined with alcohol intake. Our goal is that with Nyloxin, we can greatly reduce the instances of opiate abuse and overuse of NSAIDS in high risk groups like the US military. The Nyloxin® Military Strength represents the strongest version of Nyloxin® available and is approximately twice as strong as Nyloxin® Extra Strength. We are working with outside consultants to register Nyloxin® Military Strength and the other Nyloxin® products for sale to the US government and the various arms of the military as well as the Veteran's Administration. We expect to complete this registration process by the end of the second quarter of 2014.

 

We are pursuing international drug registrations in Canada, Mexico, India, Central and South America and Europe. Since European rules for homeopathic drugs are different than the rules in the US, we cannot estimate when this process will be completed. Additionally, we plan to complete two human clinical studies aimed at comparing the ability of Nyloxin Extra Strength to replace prescription pain relievers. We originally believed that these studies would begin during the second quarter of 2010; however, these studies have been delayed because of lack of funding. We cannot provide any timeline for these studies until adequate financing is available.

 

To date, our marketing efforts have been limited due to lack of funding. As sales increase, we plan to begin marketing more aggressively to increase the sales and awareness of our products.

 

5
 

 

Pet Pain-Away

 

During June of 2013, we announced the launch of our new homeopathic formula for the treatment of chronic pain in companion animals, Pet Pain-Away. Pet Pain-Away is a homeopathic, non-narcotic, non-addictive, over-the-counter pain reliever, primarily aimed at treating moderate to severe chronic pain in companion animals. It is specifically indicated to treat pain from hip dysplasia, arthritis pain, joint pain, and general chronic pain in dogs, cats and horses. We are seeking distributors for the product now as we begin manufacturing for eventual sales in the second quarter of 2014.

 

Equine Nyloxin®

 

In October of 2013, we announced that we were in the process of launching the newest addition to our line of homeopathic treatments for chronic pain, Equine Nyloxin®, a topical therapy for horses that is packaged as a two piece kit: Nyloxin® Topical Gel comprises Step 1 and a solution of DMSO (dimethylsulfoxide) comprises Step 2. We have been working with trainers and veterinarians in the equine industry and have already identified distributors for the product. The Equine Nyloxin® represents the Company's first topical solution for the animal market. We expect to have it available in the second quarter of 2014.

 

Regulation

 

The active pharmaceutical ingredient (API) in Cobroxin®, Nyloxin® and Nyloxin® Extra Strength, Asian cobra venom, has an approved United States monograph under the Homeopathic Pharmacopoeia of the United States (HPUS), which allowed us to register them with the FDA as homeopathic drugs. A United States monograph is a prescribed formulation for the production of any drug or product that is recognized by law for a specific application and that may be introduced into commerce. The FDA requires this registration process to maintain full compliance of companies marketing and selling medicines classified as homeopathic. In August 2009, we successfully completed submission of final packaging and labeling to the FDA to begin selling our over-the-counter pain reliever, Cobroxin®. In December 2009, we completed our submission of final packaging and labeling to the FDA of Nyloxin® and Nyloxin® Extra Strength.

 

Manufacturing

 

ReceptoPharm oversees Cobroxin® and Nyloxin®’s manufacturing activities, both at its Good Manufacturing Practice ("GMP") certified facility and at a third-party manufacturing and bottling facility. ReceptoPharm is also responsible for acquiring appropriate amounts of Asian cobra venom required to manufacture Cobroxin® and Nyloxin®.

 

Subject to availability of funds, ReceptoPharm also plans to begin additional clinical studies for our pain relievers. These studies will be designed to compare the efficacy of Nyloxin™ Extra Strength to other prescription strength pain relievers. A ReceptoPharm study published in Toxicon, which is the journal of the International Society of Toxinology, showed that ReceptoPharm’s leading drug product for the treatment of pain (RPI-78) had pain-reducing effects that lasted four times as long as morphine without the negative side effects associated with opioid-based pain relievers. Another study published in the journal Neuropharmacology showed a new mechanism on the use of Alpha-Cobratoxin as a treatment for pain. Alpha-Cobratoxin is the main component of the cobra venom used in Nyloxin® and Cobroxin®.

 

The FDA requires those companies manufacturing homeopathic medicines to have their facilities certified as GMP. As of October 2005, ReceptoPharm’s manufacturing and laboratory facility has been fully compliant with its GMP certification. In March 2009, ReceptoPharm received an ISO Class 5 certification for its clean room facility. An ISO Class 5 certification is a type of classification granted for a clean room facility according to the number and size of particles permitted per volume of air. An ISO Class 5 clean room has at most, 3,500 particles per square meter.

 

Manufacturing Cobroxin® and Nyloxin® entails a two-step process, the first of which consists of ReceptoPharm manufacturing the bulk raw materials and completing the dilution levels of Cobroxin®’s and Nyloxin®’s active pharmaceutical ingredient ("API") as provided for in the Homeopathic Pharmacopeia of the United States, which is a compilation of continuously updated statements of Homeopathic Pharmacopoeia standards and monographs as recognized by that organization. Once this process is completed, the second step entails transport of raw materials to a third-party manufacturer that completes the final mixing, bottling and shipping processes.

 

We began limited manufacturing of Nyloxin® in November 2010. We scaled up manufacturing in the first quarter of 2011. Our production level is contingent upon product demand level and we can scale up as sales demand increases.

 

Marketing and Distribution

 

In August 2009, we completed an agreement with XenaCare granting them the exclusive license to market and distribute Cobroxin® within the United States. To maintain this market exclusivity, XenaCare was required to meet certain minimum performance requirements. On April 1, 2011, we notified our Cobroxin® Distributor, XenaCare Holdings that they were in breach of our agreement. As a result of this, the distribution agreement was terminated effective April 10, 2011. XenaCare had a large stock of the product that they had ordered from us and we have allowed them to continue to market their existing inventory of Cobroxin®. In October 2011 we discontinued their website at www.Cobroxin.com. All current traffic to that website is now redirected to www.Nyloxin.com. We plan to begin marketing and distributing Cobroxin® again. To that end, On June 10, 2013, we announced a new licensing agreement for the distribution of Cobroxin® with Cobra Pharmaceuticals, LLC. The new distributors expect to begin a direct response campaign by the end of 2014 with an eventual return to retail stores.

 

6
 

 

In December 2009, we began marketing Nyloxin® and Nyloxin® Extra Strength at www.Nyloxin.com. We began generating sales through the website in July, 2010. In September of 2012 we began distributing Nyloxin through TCN International, a Network Marketing Company. TCN distributes products and software applications to approximately 400,000 independent agents in more than 30 countries, including more than 40,000 agents in the United States.

 

During June of 2013, we announced that New Vitality, a marketing and distribution company, had begun a test radio campaign to gauge the market acceptance of Nyloxin®. The 60-second ads ran for several weeks on radio stations throughout the United States. As a result of positive testing, New Vitality added Nyloxin® to their e-commerce website as they continue to advertise the product. In August of 2013, New Vitality had placed and received their first order of Nyloxin®. The order was pursuant to New Vitality's successful test radio campaign to gauge the market acceptance of the product. New Vitality will continue this campaign over the coming months and is expected to add television advertising in the second quarter of 2014.

 

In December of 2013, we announced an agreement with MyNyloxin.com for the exclusive rights to market and distribute Nyloxin® in the Network Marketing channel. MyNyloxin.com provides a business opportunity to their Distributors to earn commissions on the sale of our products through their Distributor groups. In January of 2014, we announced the first product shipments to the MyNyloxin Independent Entrepreneurs (MIEs). MyNyloxin conducts webinars, conference calls and live meetings to support recruitment of new MIEs as well as to provide product and business education.

 

We are continuing our efforts to find strategic partnerships for the promotion, marketing, registration, licensing and sales of our products domestically and internationally.

 

Dependence on one or a Few Major Customers

 

With respect to Nyloxin® and Nyloxin® Extra Strength, we have been distributing the products online and to various retailers. We are seeking both domestic and international distributors for these products. It may be that a larger distributor may require exclusivity in the US or any particular foreign market. If so, we would be dependent on that distributor for those Nyloxin® sales. Currently, MyNyloxin.com is the exclusive global Nyloxin® Distributor in the Network Marketing channel.

 

International Drug Registrations

 

We are continuing our efforts to complete the registration process internationally. While many countries adopt similar regulation to the United States for registering homeopathic drugs, the international application process is more complex and may be lengthier. We will continue to seek qualified, well-funded distributors for the international distribution of Cobroxin® and Nyloxin®.

 

ReceptoPharm’s Homeopathic Drug Pain Relief Studies

 

MS Neuropathic Pain Phase IV

 

Pending adequate financing or revenues, we will continue our research and development into this area, with the ultimate goal of improving product claims for Nyloxin™ Extra Strength, which is a treatment for stage 3 pain. Our original start and completion dates were March 2010 and September 2010, respectively, which includes a 10-week patient trial period. We have thus far incurred costs of $5,000 with a total estimated budget of $130,000. Due to our poor financial condition, we have currently discontinued all of our clinical activities. We have no way of knowing at this time, if or when we will have adequate funding to reinitiate these trials.

 

Chronic Back Pain Phase I

 

Pending adequate financing or revenues, we will continue our research and development in this area, with the ultimate goal of completing development of our future product, Recet, which is an injectable version of Cobratoxin. Our original start and completion dates were April 2010 and November 2011, respectively, which includes a 4-week patient trial period. We have thus far incurred costs of $25,000 with a total estimated budget of $250,000. Due to our poor financial condition we have currently discontinued all of our clinical activities. We have no way of knowing at this time, if or when we will have adequate funding to reinitiate these trials.

 

Chronic Back Pain Phase IV

 

Pending adequate financing or revenues, we will continue our research and development, with this ultimate goal of improving product claims for Nyloxin® Extra Strength, which is a treatment for stage 3 pain. Our original start and completion dates were April 2010 and November 2010, respectively, which includes a 4-week patient trial period. We have an estimated budget of $250,000. We have not yet incurred any costs associated with the Chronic Back Pain Phase IV project. Due to our poor financial condition, we have currently discontinued all of our clinical activities. We have no way of knowing at this time, if or when we will have adequate funding to reinitiate these trials.

 

7
 

 

All of these studies have been delayed since June of 2010 due to our lack of revenues and funding. We will reassess our start and completion dates upon generating a sufficient amount of revenues, if ever.

 

ReceptoPharm – Research and Development

 

ReceptoPharm was engaged in the research and development of novel anticholinergic therapeutic protein products for the treatment of autoimmune and neurologic disorders, including Human Immunodeficiency Virus (HIV), Multiple Sclerosis (MS) Adrenomyeloneuropathy (AMN), Rheumatoid Arthritis (RA) and pain.

 

Drug Applications

 

We have set forth below a summary of ReceptoPharm’s proposed drugs and their potential applications.

 

Drug   Potential Applications
RPI-78M   MS, AMN, Myasthenia Gravis (MG) and Amyotrophic Lateral Sclerosis (ALS)
     
RPI-MN   HIV, general anti-viral applications
     
RPI-78   Pain, Arthritis
     
RPI-70   Pain

 

We believe that ReceptoPharm’s pharmaceutical products have a wide range of applications in a number of chronic, inherited and/or life-threatening viral, autoimmune and neuromuscular degenerative diseases, even though none of these products have FDA or other approval for the treatment of such diseases. These disorders target nerve cells, especially one specific type of cell receptor that is sensitive to the neurotransmitter, acetylcholine, which plays an important role in the transmission of nerve impulses at synapses and myoneural (muscle-nerve) junctions.

 

Primary Disease Targets

 

Through ReceptoPharm’s research program, our goal is to obtain required regulatory approvals of ReceptoPharm’s HIV, MS, and AMN products, so that they can be marketed. We plan to apply for Orphan drug status with the FDA to expedite approval for our AMN product; however there is no assurance we will obtain such status. ReceptoPharm secures confidentiality agreements prior to initiating contract research in order to protect any patentable opportunities.

 

Human Immunodeficiency Virus (HIV) Infection

 

The analytic firm GBI Research reported in November 2012 that the HIV/AIDS therapeutics market reached $13.5 billion in 2011 in seven top markets: the United States, the United Kingdom, Germany, France, Italy, Spain and Japan. GBI Research predicts these markets will continue to grow to reach $21.8 billion by 2018. According to UNAIDS, an estimated 35.3 million people were living with HIV in 2012 with 69% of all HIV sufferers in sub-Saharan Africa. There were 2.3 million new infections in 2012 and 1.6 million people died of AIDS-related illnesses. Since the beginning of the epidemic, more than 75 million people have contracted HIV and nearly 36 million have died of HIV-related causes. Growth in the HIV therapy market will continue to be driven by the rapidly growing HIV and AIDS population. In the absence of therapeutic intervention, the vast majority of individuals infected with HIV will ultimately develop AIDS, on average in about 10 years, which has a mortality rate approaching 100%. Experts say that the drugs currently available may extend life as much as 40 years, but all of these therapies have negative side effects and fail over time as the virus mutates. These facts make new therapies a necessity. The foregoing information was obtained from the World Health Organization website at www.who.int and the UNAIDS website at www.unaids.org.

 

To cause infection, HIV needs to gain entry into cells through the attachment to receptors on the cell membrane. These receptors are called chemokine receptors. There are two principal types, CCR5 and CXCR4. Different HIV strains use one of these types. A single drug that would block all of the chemokine receptors ("tropism-independent") could be more useful, for several reasons, than a mixture of molecules that would have to be used to do the same.

 

HIV infection therapy currently uses antiviral drug therapies that are associated with the virus’s attachment, fusion with and entry into the host cell. At the present time, there are 35-licensed antiretroviral drugs employed to combat HIV-1 infection and two licensed by the FDA that act as binding/entry inhibitory drugs.

 

8
 

 

New drugs and adjunct therapies with novel mechanisms of action or unique resistance profiles are needed in the fight against HIV. Constant innovation, in terms of efficacy, side effect profile and dosing are occurring. Current research and development for HIV is focused on adjunctive therapy, which when combined with existing HAART (Highly Active Anti-Retroviral Therapy) regimens reduce side effects, enhance the efficacy of existing treatments and delay the progression of the HIV virus.

 

Both of ReceptoPharm’s drugs inhibited HIV replication in MAGI cells by 50-60% and peripheral mononuclear cells by 90% in testing conducted by Dr. Juan Lama of the La Jolla Institute for Molecular Medicine in San Diego, California. Separate Phase I studies by Cure Aids Now of Miami, Florida, were conducted by Dr. Jamal with orally and parentally administered RPI-78M in HIV patients confirmed safety, tolerability and provided preliminary evidence of efficacy.

 

RPI-MN demonstrated the ability to inhibit the replication of highly drug-resistant strains of HIV isolates. Drug resistance has become a critical factor in long-term management of HIV infection with some viral strains developing resistance in as little as 3 weeks.

 

Multiple Sclerosis (MS)

 

Multiple Sclerosis (MS) is thought to be an autoimmune disease that primarily causes central nervous system problems. In MS, the insulating fatty material surrounding the nerve fibers, also known as myelin, which functions to speed signaling from one end of the nerve cell to the other, is attacked by cells of the immune system causing problems in signal transduction. MS is the most common of demyelinating disorders, having a prevalence of approximately 1 per 1,000 persons in most of the United States and Europe. According to the Accelerated Cure Project for Multiple Sclerosis, a national nonprofit organization, 400,000 people in the US are affected by MS and another 2 million globally, with 10,000 new cases diagnosed in the US every year.

 

People with MS may experience diverse signs and symptoms. MS symptoms may include pain, fatigue, cognitive impairment, tremors, loss of coordination and muscle control, loss of touch sensation, slurred speech and vision impairment. The course of the disease is unpredictable and for most MS patients, the disease initially manifests a "relapsing-remitting" pattern. Periods of apparent stability are punctuated by acute exacerbations that are sudden unpredictable episodes that might involve impaired vision, diminished ability to control a limb, loss of bladder control, or a great variety of other possible neurologic deficits. In relapsing-remitting MS, some or all of the lost function returns, however, the patient sustains an unceasing, often insidious, accumulation of neuronal damage. As the burden of neural damage grows, new lesions are more likely to produce irreversible impairment of function. Typically, about eight to fifteen years after onset, MS patients enter the secondary-progressive phase. Eventually, progressive MS sufferers become wheelchair-bound, and may become blind and even incapable of speech. There is currently no FDA approved drug that reverses the course of the progressive form of MS.

 

RPI-78M has shown efficacy in animal models (EAE) for MS and ReceptoPharm is planning new animal studies to gain more insight into the levels of protection that the drugs afford. In one study conducted in August 2007, all members of an untreated animal control group developed signs of disease with different levels of paralysis/muscle weakness. A similar group in the August 2007 study treated with RPI-78M showed no disease in 90% of the animals in both acute and chronic applications of the test. Moreover, there were no toxicities reported though the animals which received doses the equivalent of 280 times a human dose.

 

Furthermore, we believe that the ability to modulate the host immunostimulatory environment could form the basis of an effective strategy for the long-term control of autoimmunity in diseases like MS and Myasthenia gravis (MG) and is being studied as a therapeutic model for other neuromuscular diseases. Also, we believe our data suggest that it is possible that our novel therapeutic proteins could have a general application in autoimmune diseases based on human studies in Rheumatoid Arthritis and anecdotal reports from patients with Multiple Sclerosis.

 

In August of 1984, Biogenix applied for and received an Intrastate Investigational Drug (FSDHRS Protocol RA-1 (002)) from the Department of Health and Rehabilitation (HRS) in Florida that permitted the 4-week study of RPI-MN in 13 patients with Rheumatoid arthritis ranging in age from 49 to 81. Patients were enrolled for a period of 4 weeks; the results showed 30% to 49% improvement in range of joint motion, early morning stiffness and stamina (this data, along with other supporting intellectual property was acquired by ReceptoPharm from Biogenix). We believe that the data obtained from the examination of clinical efficacy in these three diseases can augment information from prior clinical studies and lead to the future investigation of treatments for other chronic conditions.

 

Adrenomyeloneuropathy (AMN) and Orphan Indications

 

Adrenoleukodystrophy, or ALD, is a genetically determined neurological disorder that, according to the Adrenoleukodystrophy Foundation, affects 1 in every 17,900 boys worldwide. The presentation of symptoms occurs between the ages of 4 and 10, and affects the brain with demyelination, which is the stripping away of the fatty coating that keeps nerve pulses confined and maintains the integrity of nerve signals. This process inhibits the nerves’ ability to conduct properly, which causes neurological deficits, including visual disturbances, auditory discrimination, impaired coordination, dementia and seizures. Demyelination is an inflammatory response and nerve cells throughout the brain are destroyed.

 

9
 

 

Adrenomyeloneuropathy (AMN) is the most common form of X-ALD, a maternally inherited type of ALD. AMN affects about 40-45% of X-ALD patients and usually presents itself in adolescence or adult life and may be preceded by hypoadrenalism. It is characterized by spastic paraplegia and a peripheral neuropathy, often being diagnosed as Multiple Sclerosis (MS). Nerve conduction studies in AMN show a predominant axonal neuropathy and show a loss of all axons. Lorenzo’s oil, a mixture of glyceryltrioleate and glyceryltrierucate, has been used for over a decade in an open, unblinded fashion with mixed results.

 

RPI-78M has been utilized in two clinical studies, which were completed at the Charles Dent Metabolic Unit located in London, England. The last trial was classified as a Phase IIb/IIIa study. These studies provided important safety data, showing RPI-78M to be well tolerated by the patients. Further study is warranted to provide data on the potential efficacy of RPI-78M to treat the symptoms of AMN.

 

Pain and Arthritis

 

Protein or peptide-based drugs are penetrating the pain market with neurotoxins taking the lead. Botox (Allergan) and Prialt (Elan) have the potential to substitute over the long-term for morphine and other opiates in chronic pain indications. Opiates, though potent painkillers, suffer from drawbacks because they are addictive, short acting, and drug-resistance inducing. We plan to assess the effects of several peptides in animal models of pain in association with Soochow University in China. Several peptides have demonstrated positive effects and the research and development continues.

 

August 2007 studies at Soochow University proved the potential of ReceptoPharm’s drug candidates, RPI-78 and RPI-70. When compared to Dolantin, an opiate-based drug subordinate to morphine, the effects were very encouraging. While Dolantin provided immediate pain relief it began wearing off just as RPI-70 began to take effect. The effects of RPI-70 do not seem dramatic in contrast to Dolantin, considering the quantity of drug employed in this animal model. The concentration of RPI-70 was approximately 100 times less than the opiate product. Also, RPI-70 showed real potential for combining with other pain killing medications. RPI-78 was calculated to be 150,000 times more potent than aspirin. This product can be injected systemically providing evidence of a more practical application than Prialt, which must be administered intrathecally (into the spinal cord). Opiate drugs induce tolerance and dependence. This problem is not encountered with RPI-70 and RPI-78.

 

In February 2009, ReceptoPharm filed a patent application with the United States Patent and Trademark Office for the use of RPI-78 as a novel method for treating arthritis in humans. Also in February 2009, ReceptoPharm, in collaboration with Soochow University in China published positive data from its recent animal studies on the use of RPI-78 (Cobratoxin) as a method for treating arthritis. In March of 2011, ReceptoPharm was issued a patent for the use of cobratoxin as an analgesic (US patent #7,902,152). In February of 2012, ReceptoPharm, in collaboration with Soochow University published another study that demonstrated a novel mechanism of action for the use of RPI-78 as a treatment for pain.

 

Market Values

 

Human Immunodeficiency Virus (HIV)

 

The analytic firm GBI Research reported in November 2012 that the HIV/AIDS therapeutics market reached $13.5 billion in 2011 in seven top markets: the United States, the United Kingdom, Germany, France, Italy, Spain and Japan. GBI Research predicts these markets will continue to grow to reach $21.8 billion by 2018. According to UNAIDS, an estimated 35.3 million people were living with HIV in 2012 with 69% of all HIV sufferers in sub-Saharan Africa. There were 2.3 million new infections in 2012 and 1.6 million people died of AIDS-related illnesses. Since the beginning of the epidemic, more than 75 million people have contracted HIV and nearly 36 million have died of HIV-related causes. Growth in the HIV therapy market will continue to be driven by the rapidly growing HIV and AIDS population. In the absence of therapeutic intervention, the vast majority of individuals infected with HIV will ultimately develop AIDS, on average in about 10 years, which has a mortality rate approaching 100%. Experts say that the drugs currently available may extend life as much as 40 years, but all of these therapies have negative side effects and fail over time as the virus mutates. These facts make new therapies a necessity. The foregoing information was obtained from the World Health Organization website at www.who.int and the UNAIDS website at www.unaids.org.

 

According to the Centers for Disease Control and Prevention, in the United States alone, an estimated 1,144,500 people are infected with an estimated 50,000 Americans becoming infected with HIV each year. The majority undergoes treatment for HIV-related conditions at an individual cost of $14,000 (HAART) to $34,000 (AIDS patients). According to DataMonitor; the HIV market was worth $9.3 billion in 2007. GBI Research predicts these markets will continue to grow to reach $21.8 billion by 2018, driven by the increasing prevalence of HIV worldwide and the longer life expectancy of patients receiving treatment.

 

10
 

 

Multiple Sclerosis (MS)

 

MS affects an estimated 2.5 million people globally with approximately 400,000 sufferers in the United States. There are 5 approved drugs for the treatment of this disease. The average annual cost of these drugs is $12,000 per person. In 2010, sales by one manufacturer, Biogen-Idec, were reported to be $2.5 billion for its drug, Avonex. According to a report by Piribo (Pharmaceutical Market Research), the total worldwide market for MS disease-modifying therapies is expected to grow at an 8.1% compound annual growth rate (CAGR) from 2010 through 2015, with sales reaching nearly $16.7 billion by the end of 2015 from $11.3 billion in 2010. ReceptoPharm’s MS drug, RPI-78M is considered to be a ‘Biologic’. Biologics represent the largest class of MS disease-modifying therapies by sales and by number of approved therapies. This sector is valued at $7.8 billion in 2010 and is expected to increase at a 2.5% compound annual growth rate (CAGR) to reach a value of $8.8 billion in 2015.

 

Adrenomyeloneuropathy (AMN)

 

AMN/ALD affects an estimated 30,000 people in the US with some estimates exceeding this number.

 

Current Technologies

 

ReceptoPharm, operating in its capacity as a clinical stage biotechnology company, created a process that safely modifies proteins derived from cobra venom. ReceptoPharm also has rights to a drug delivery method that uses an aerosol formulation, which is administered under the tongue. By using this shared aerosol delivery technology, oral delivery is attainable, an important step for a biologic product. The system is 50% efficient and affects drug delivery in approximately 40% of patients in which it was tested. Topical preparations are being examined for future applications in treatment of such conditions as pain and Rheumatoid Arthritis (RA).

 

Business Strategy

 

Pending adequate financing or revenues, ReceptoPharm seeks to develop proprietary pharmaceutical products for human illnesses that qualify for “Fast-Track” or “Orphan Drug” status under FDA regulations, which can expedite regulatory review. For some conditions, the FDA has created the “two animal rule” which permits ReceptoPharm to collect data from ongoing animal research for human treatment applications.

 

We believe the results from ReceptoPharm’s research will assist in getting its applications processed through the FDA’s “Fast-Track” approval process and enable ReceptoPharm to plan the commercialization of each product independently and/or through joint ventures, partnerships and licensing arrangements. “Fast-Track” denotes life-threatening illnesses, while “Orphan” status refers to serious ailments affecting less than 200,000 individuals nationwide. AMN qualifies under both labels because it is considered an orphan disease and has no known cure.

 

In the areas of HIV and MS, ReceptoPharm plans to conduct clinical studies of its HIV and MS drugs under development. These "Phase II" studies will either prove or disprove the preliminary efficacy of ReceptoPharm's HIV and MS drugs under development. ReceptoPharm is in the process of attempting to secure agreements with third parties to conduct such clinical studies.

 

We believe that ReceptoPharm’s proposed unique pharmaceutical products can be used alone or licensed for use in combination with other therapeutic products and may be of interest to other established pharmaceutical companies as a means of extending the patent life of their proprietary products.

 

Short-term Goal

 

Although we focused our drug development efforts from 2006 to 2008 on clinical trials for ReceptoPharm’s HIV drug, RPI-MN, our primary focus now is on RPI-78M for the treatment of AMN and MS. In January of 2007, ReceptoPharm began their clinical study in AMN. The clinical study, which was completed at the Charles Dent Metabolic Unit located in London, England, is classified as a Phase IIb/IIIa study. The study provided important safety data, showing RPI-78M to be well tolerated by the patients. Further study is warranted to provide data on the potential efficacy of RPI-78M to treat the symptoms of AMN.

 

Mid-term Goal

 

Our midterm strategy for the past three years has been to license ReceptoPharm’s AMN, MS and HIV technologies in our attempt to bring these technologies to market within 5 years, should we obtain adequate financing.

 

Long-Term Goal

 

Our long-term goal is the use of drugs developed by ReceptoPharm in the field of neurological diseases, infectious diseases and autoimmune disorders. Due to our limited financial and operational resources, this goal will require us to establish strategic partners or alliances with pharmaceutical companies, academic institutions, biotechnology companies, and clinical diagnostic laboratories, which will: (a) complement ReceptoPharm’s research and development efforts; (b) reduce the risks associated with undertaking the entire process of drug development and marketing; and (c) generate licensing based revenue streams. Additionally, we plan to continue identifying intellectual property and companies in the biotechnology arena as potential acquisition candidates.

 

11
 

 

Compassionate Release Programs

 

Certain countries, such as Canada and the United Kingdom permit their citizens to have access to investigational medications without being approved for any applications by their respective “FDA type” agencies, and permit physicians to prescribe drugs they believe are of possible benefits to the patients. Through these “Compassionate Release Programs” ReceptoPharm has supplied RPI-78M, its drug under investigation for MS and AMN, to physicians in the United Kingdom. The FDA does not offer this program.

 

Clinical Trial Applications

 

ReceptoPharm has developed Common Technical Documents (CTD) for both RPI-78M and RPI-MN that are used to support any clinical trial application. The CTD is a complete history of the individual drug, including all of the in-vitro and in-vivo work accomplished to date, as well as pre-clinical development work on the drug. Having these completed documents allows for expedited due diligence from regulatory bodies reviewing ReceptoPharm’s applications for trials and approvals. With these documents, ReceptoPharm has successfully applied for approval to conduct a clinical investigation in the United Kingdom under the regulation of the Medicines Health and Regulatory Agency (MHRA), which is the British equivalent of the US-FDA.

 

Current Research and Development Projects

 

Neurological Studies

 

Pain Studies

 

In an effort to further support Nyloxin® Extra Strength, ReceptoPharm had planned to complete two human clinical studies aimed at comparing the ability of Nyloxin® Extra Strength to replace prescription pain relievers. ReceptoPharm originally estimated that these studies would begin during the second quarter of 2010; however, these studies have been delayed because of lack of funding. We have no way of knowing at this time, if or when we will have adequate funding to reinitiate these trials.

 

AMN Phase II

 

ReceptoPharm has been conducting research and development in this area since February 2006 with an original expected completion date of September 2010, which includes a 12-month patient trial period that has already been completed. We have thus far expended approximately $400,000, because ReceptoPharm has completed its AMN Phase II project, there is no further budget for this project.

 

AMN Phase III

 

ReceptoPharm had planned to continue research and development, with the ultimate goal of completing development of its future drug, RPI-78M. ReceptoPharm’s originally estimated start and completion dates are July 2010 and December 2011, respectively, which includes a 12-month patient trial period. ReceptoPharm has thus far incurred costs of $5,000. ReceptoPharm has an estimated budget of $500,000. We have no way of knowing at this time, if or when we will have adequate funding to reinitiate these trials.

 

MS Phase II

 

Pending adequate financing or revenues, ReceptoPharm will continue its research and development, with the ultimate goal of completing development of its future drug, RPI-78M. ReceptoPharm’s originally estimated start and completion dates are October 2010 and October 2012, respectively, which includes a 12-month patient trial period. ReceptoPharm has thus far incurred costs of $40,000. ReceptoPharm has an estimated budget of $2,000,000. We have no way of knowing at this time, if or when we will have adequate funding to reinitiate these trials.

 

Currently, ReceptoPharm’s total estimated costs for all of the above projects are approximately $3,000,000.

 

All of these studies have been delayed due to a lack of revenues and funding. Upon obtaining sufficient revenues, if ever, ReceptoPharm will provide updated estimates of start and completion dates.

 

Research and Development

 

During 2013 and 2012, we had research and development costs of $697 and $3,046, respectively.

 

Dependence on one or a Few Major Customers

 

We have no customers with respect to our research and development projects since we have not received FDA approval for our drug candidates and have not licensed any of our technologies.

 

12
 

 

Marketing

 

We currently do not have a marketing program for our drug candidates because none of ReceptoPharm’s products have received FDA approval. Our lack of financing has hampered our efforts to navigate the regulatory process in a timely fashion; however, if and when we have FDA-approved drug treatments, we plan to develop a marketing strategy to market ReceptoPharm’s products through pharmaceutical companies, other biotechnology companies, and diagnostic laboratories. Our Chief Executive Officer will market the treatments to licensing and development officers of those companies and will otherwise direct our marketing program. Additionally, we will attempt to secure consulting agreements with marketing consultants who will actively market our products to such companies and/or provide our Chief Executive Officer with marketing guidance.

 

Potential Revenue Segments

 

Our potential revenue segments are composed of our attempt to generate revenues from license agreements, joint ventures in foreign countries and drug sales.

 

To date, we have not earned any revenues regarding any FDA drug candidate.

 

Product Liability

 

We maintain product liability insurance for our commercial products. Even so, product liability claims may result in significant legal costs related to our defense of such actions if damage amounts exceed our product liability insurance coverage. The design, development, and manufacture of drug products or diagnostic tests involves an inherent risk of product liability claims and corresponding damage to our brand name reputation, including claims of product failure or harm caused by the drug product.

 

Sources and Availability of Raw Materials

 

ReceptoPharm uses the raw material, cobra venom, for the drugs that it studies and in Cobroxin® and Nyloxin® production. We currently have one US supplier of cobra venom that we use according to product demand. In addition, there are other suppliers in China, Thailand and India. ReceptoPharm’s management is responsible for locating cobra venom suppliers on an as-needed basis, which involves obtaining a small test amount from a supplier for scientific validation of that raw material prior to purchase. Apart from cobra venom, we do not currently use raw materials in our business.

 

Compliance with Government Regulations and Need for Government Approval

 

The production and marketing of potential drug products as well as research and development activities generally are subject to regulation by numerous governmental authorities in the United States and other countries. In the United States, vaccines, drugs and certain diagnostic products are subject to FDA review of safety and efficacy. The Federal Food, Drug and Cosmetic Act, the Public Health Service Act and other federal statutes and regulations govern or influence the testing, manufacture, safety, labeling, storage, record keeping, approval, advertising and promotion of such products. Noncompliance with applicable requirements can result in criminal prosecution and fines, recall or seizure of products, total or partial suspension of production, or refusal of the government to approve Biological License Applications ("BLAs"), Product License Applications ("PLAs"), New Drug Applications ("NDAs") or refusal to allow a company to enter into supply contracts. The FDA also has the authority to revoke product licenses and establishment licenses previously granted.

 

In order to obtain FDA approval to market a new biological or pharmaceutical product, proof of product safety, purity, potency and efficacy, and reliable manufacturing capability must be submitted. This requires companies to conduct extensive laboratory, pre clinical and clinical tests. This testing, as well as preparation and processing of necessary applications, is expensive, time-consuming and often takes several years to complete. There is no assurance that the FDA will act favorably in making such reviews. Our potential partners, or we, may encounter significant difficulties or costs in their efforts to obtain FDA approvals, which could delay or preclude from marketing any products that may be developed. The FDA may also require post-marketing testing and surveillance to monitor the effects of marketed products or place conditions on any approvals that could restrict the commercial applications of such products. Product approvals may be withdrawn if problems occur following initial marketing, such as, compliance with regulatory standards is not maintained. Delays imposed by governmental marketing approval processes may materially reduce the period during which a company will have the exclusive right to exploit patented products or technologies. Refusals or delays in the regulatory process in one country may make it more difficult and time consuming to obtain marketing approvals in other countries.

 

The FDA approval process for a new biological or pharmaceutical drug involves completion of preclinical studies and the submission of the results of these studies to the FDA in an Initial New Drug application, which must be approved before human clinical trials may be conducted. The results of preclinical and clinical studies on biological or pharmaceutical drugs are submitted to the FDA in the form of a BLA, PLA or NDA for product approval to commence commercial sales. In responding to a BLA, PLA or NDA, the FDA may require additional testing or information, or may deny the application. In addition to obtaining FDA approval for each biological or chemical product, an Establishment License Application ("ELA") must be filed and the FDA must inspect and license the manufacturing facilities for each product. Product sales may commence only when both BLA/ PLA/ NDA and ELA are approved. In certain instances in which a treatment for a rare disease or condition is concerned, the manufacturer may request the FDA to grant the drug product Orphan Drug status for a particular use. "Orphan Drug" status refers to serious ailments affecting less than 250,000 individuals. In this event, the developer of the drug may request grants from the government to defray the costs of certain expenses related to the clinical testing of such drug and be entitled to marketing exclusivity and certain tax credits.

 

13
 

 

In order to gain broad acceptance in the marketplace of a medical device, our partners or we will need to receive approval from the FDA and other equivalent regulatory bodies outside of the United States. This approval will be based upon clinical testing programs at major medical centers. Data obtained from these institutions will enable us, or our partners, to apply to the FDA for acceptance of its technology as a "device" through a 510(k) application or exemption process. Once the data have been fully gleaned, it is expected that this process would take ninety days.

 

According to the FDA, a "device" is: "an instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent, or other similar or related article, including a component part, or accessory which is recognized in the official National Formulary, or the United States Pharmacopoeia, or any supplement to them, intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease, in man or other animals, or intended to affect the structure or any function of the body of man or other animals, and which does not achieve any of its primary intended purposes through chemical action within or on the body of man or other animals and which is not dependent upon being metabolized for the achievement of any of its primary intended purposes."

 

The FDA classifies devices as either Class I/II-exempt, Class II, or Class III.

 

Class III: Pre-Marketing Approval, or PMA: A Pre-Marketing Approval or PMA is the most stringent type of device marketing application required by FDA. A PMA is an application submitted to FDA to request clearance to market, or to continue marketing of a Class III medical device. A PMA is usually required for products with which FDA has little previous experience and in such cases where the safety and efficacy must be fully demonstrated on the product. The level of documentation is more extensive than for a 510(k) application and the review timeline is usually longer. Under this level of FDA approval, the manufacturing facility will be inspected as well as the clinical sites where the clinical trials are being or have been conducted. All the appropriate documents have to be compiled and available on demand by the FDA. The manufacturing facility is registered with the FDA and the product or device is registered with the FDA.

 

Class II: 510(k). This is one level down from the PMA and it is applied to devices with which the FDA has had previous experience. A 510(k) is a pre-marketing submission made to FDA to demonstrate that the device to be marketed is as safe and effective, that is, substantially equivalent, to a legally marketed device that is not subject to pre-market approval. Applicants must compare their 510(k) device to one or more similar devices currently on the U.S. market and make and support their substantial equivalency claims. The legally marketed device to which equivalence is drawn is known as the "predicate" device. Applicants must submit descriptive data and, when necessary, performance data to establish that their device is SE to a predicate device. Again, the data in a 510(k) is to show comparability, that is, substantial equivalency (SE) of a new device to a predicate device. Under this level of approval, the manufacturing facility is registered with the FDA and the product or device is registered with the FDA. Inspections under this classification are possible. All the appropriate cGMP and clinical data backing the claims made must be on file and available on demand by the FDA.

 

Class I/II Exemption: This is the lowest level of scrutiny. Most Class I devices and a few Class II devices are exempt from the pre-marketing notification requirements subject to the limitations on exemptions. However, these devices are not exempt from other general controls. All medical devices must be manufactured under a quality assurance program, be suitable for the intended use, be adequately packaged and properly labeled, and have establishment registration and device listing forms on file with the FDA. However, as described above, all the appropriate documentation including cGMP and clinical data supporting the claims being made has to be on hand and available on demand by the FDA. The data must be available to support all the product claims.

 

Sales of biological and pharmaceutical products and medical devices outside the United States are subject to foreign regulatory requirements that vary widely from country to country. Whether or not FDA approval has been obtained, approval of a product or a device by a comparable regulatory authority of a foreign country must generally be obtained prior to the commencement of marketing in that country.

 

Effect of Compliance with Federal, State, and Local Provisions for the Protection of the Environment

 

We have no present or anticipated direct future costs associated with environmental compliance, since we are not and will not be directly involved in manufacturing drug products as result of our research and development; however, we may be affected in the percentage licensing fees we receive, since a company may consider the environmental expense as an offset to a determination of the percentage amount we receive. ReceptoPharm produces a drug that has limited waste issues and related costs, but handles environmentally related matters through the FDA's Good Manufacturing Practices, the FDA mandated guidelines pertaining to the production of drugs in the United States.

 

14
 

 

Ability to Compete

 

The biotechnology research and development field is extremely competitive and is characterized by rapid change. Our competitors have substantially greater financial, scientific, and human resources, and as a result greater research and product development capabilities. Our competitors have competitive advantages with greater potential to develop revenue streams. Our competitors are located in the United States as well as around the world. We will attempt to compete by establishing strategic partners or alliances with pharmaceutical companies, academic institutions, biotechnology companies, and clinical diagnostic laboratories, which will enter into joint ventures, emphasizing that the drugs RPI-MN and RPI-78M possess the following properties:

 

  · They lack measurable toxicity but are still capable of attaching to and affecting the target site on the nerve cells. This means that patients cannot overdose.
     
  · They display no significant adverse side effects following years of investigations in humans and animals.
     
  · The products are stable and resistant to heat, which gives the drug a long shelf life. The drugs’ stability has been determined to be over 4 years at room temperature.

 

RPI-78M can be administered orally; however, ReceptoPharm has not yet developed an orally administered RPI-78M. RPI-78M has been routinely delivered by injection in a manner similar to insulin, but research over the past two years has given rise to administration by mouth. Oral delivery presents patients with additional “quality of life” benefits by eliminating or decreasing the requirements for routine injections. Should we receive adequate funding, ReceptoPharm plans to develop an orally administered RPI-78M by initiating new trials with an oral version of that drug.

 

Main Competitors (Biologics)

 

Competition is intense among companies that develop and market products based on advanced cellular and molecular biology. ReceptoPharm’s competitors, including Amgen, Sanofi-Aventis, Biogen-Idec, Cephalon, Genetech, Genzyme, Novartis, Regeneron and Bayer, which have far superior financial, technological and operational resources. We face significant competition from these and other biotechnology and pharmaceutical firms in the United States, Europe and elsewhere. Certain specialized biotechnology firms have also entered into cooperative arrangements with major companies for development and commercialization of products, creating an additional source of competition.

 

Any products or technologies that successfully address viral or neurological indications could negatively impact the market potential for RPI-78M or RPI-MN. These include products that could receive approval for indications similar to those for which RPI-78M or RPI-MN seeks approval, development of biologic or pharmaceutical treatments that are more effective than existing treatments and the development of other modalities with reduced toxicity and side effects.

 

Interferon-based drugs and their indications represent target markets for ReceptoPharm. Sales of interferon-based drugs annually exceed $6 billion and have attracted the participation of several major drug companies, including Bayer and Roche. Currently, there are five interferon-based drugs licensed in Canada and the U.S.; three for the treatment of the milder Relapsing-Remitting form of MS and two for Hepatitis C. These interferons are also used in the treatment of other conditions where treatment options are limited. The interferons for MS are Betaseron (Bayer), Avonex (Biogen-Idec) and Rebif (Serono and Pfizer). Since the launch of these drugs, the number of patients undergoing treatment has stabilized at current levels, indicating that there is a high turnover rate of patients in the administration of these individual drugs due to cost and side effects. Biogen developed Avonex in the early 1990’s and has been shipping the drug since late 1996. In the United Kingdom, the National Institute for Clinical Efficiency (NICE) has called for the withdrawal of Betaseron and another unrelated drug, Copaxone (Teva), from the market based on poor cost/effectiveness.

 

Schering (a Merck subsidiary) manufactures alpha-interferon (Intron-A) and Roche produces Roferon as the only treatments for Hepatitis C. Schering-Plough also developed the drug Ribavirin as a general antiviral agent which, when combined, with Intron-A, is a treatment for Hepatitis C. This combination is called Ribitron. Treatment with Intron-A costs $19,000 per year though initial treatment periods are usually for 12 months. It is the high cost and significant side effects that prevents the widespread uptake of this drug by the 4 million Hepatitis C sufferers in the US. Other companies producing interferon-based products include Amgen (INFERGEN) and Viragen.

 

Main Competitors (Venom-Based Drugs)

 

We view our main competitors as those who also engage in the development of protein-based neurotoxins as therapeutics. Employing venoms as therapeutics is not new. A large number of well-known pharmaceutical companies are developing novel therapies derived from snake venoms and other reptiles. Most of those using snake venoms employ the anticoagulant enzymes usually from viperids (adders and rattlesnakes) though elapids (cobra family) are also being investigated.

 

15
 

 

We have set forth below a summary of venom-based drugs and their potential applications.

 

Company Drug Application
     
Knoll Pharmaceutical Ancrod Anticoagulant from rattlesnakes
Sss    
Bristol-Myers Squibb Capoten Antihypertensive from Brazilian Pit Viper
     
Medicure Aggrastat Antiplatelet drug from vipers
     
Millennium Pharmaceutical Integrilin Antiplatelet drug from rattlesnakes
     
Amylin Pharmaceuticals Byetta Treatment for type 2 diabetes and obesity from Gila Monster
     
Elan Pharmaceuticals Prialt Intrathecal drug from cone snails for intractable pain

 

Current cobra venom-based therapies include Keluoqu, a pain-killing drug on the market in China since 1978. Keluoque contains cobrotoxin as its primary ingredient and is used to control severe pain in advanced cancer patients and for post-operative pain.

 

Designer Diagnostics

 

Designer Diagnostics developed diagnostic test kits designed to be used for the rapid identification of infectious diseases, such as Nontuberculous Mycobacteria (NTM). Currently, these test kits are being tested by National Jewish Hospital in Denver, Colorado. We will reassess our business plan with respect to Designer Diagnostics upon completion of testing at National Jewish Hospital. This process of validation has been ongoing since 2007. While these outside tests have proceeded, the Company has focused on our drugs and has not continued any activity in the Designer Diagnostics division since June, 2011. As results become available through the validation process and funding becomes available, we will revisit the technology and may re-engage our efforts in Designer Diagnostics.

 

Nanologix

 

On January 24, 2006, we entered into an agreement with NanoLogix whereby we exchanged our holding of NanoLogix common stock for the intellectual property pertaining to the manufacture of test kits for the rapid isolation, detection and antibiotic sensitivity testing of certain microbacteria. Designer Diagnostics owns 11 issued patents and has licensing rights to 18 issued patents related to the rapid isolation, growth, identification and antibiotic sensitivity of disease causing pathogens such as Tuberculosis ("TB") and Mycobacterium avium-intracellulare ("MAI"). The patented technologies are related to a technique known as "paraffin baiting". The researchers discovered that certain grades of paraffin wax, when used in conjunction with a microscope slide, and combined with a nutrient broth, provides for the rapid isolation, growth and identification of various disease causing pathogens. Designer Diagnostics marketed a diagnostic test kit based on this technology in 2006 and 2007.

 

Bio-Therapeutics, Inc.

 

On October 3, 2003, we entered into a non-assignable license agreement between Bio-Therapeutics, Inc. and us, which was then amended to make the license agreement assignable. This agreement was in settlement of a lawsuit that we filed against Bio-Therapeutics alleging that Bio-Therapeutics owed us $850,000 in connection with a merger agreement between Bio-Therapeutics and us that was cancelled.

 

The 2003 license agreement provides that for a non-exclusive license to certain intellectual property of Bio-Therapeutics, Inc., which consists of the following two distinct technology platforms:

 

  · Alteration of Proteins and Peptides - These include patented methods for altering the 3-Dimensional structure of certain proteins and peptides. The natural peptides bind to receptors in the body with toxic effects. This technology allows us to alter the structure of these peptides, preserving their receptor-binding characteristics, while making them non-toxic and therapeutic. Different receptors have various functions in many disease states. By the peptides binding to these receptors in a controlled fashion, certain disease symptoms may be treated. In connection with MS, binding to the acetylcholine receptor on the nerves allows for more efficient nerve conduction. With HIV, binding to chemokine receptors may prevent the virus from entering and infecting new cells.
     
  · Non- Exclusive License for “Buccal Delivery System”(“Buccal”) – An innovative aerosolized drug delivery system that is patent pending. Many therapeutic agents cannot be effectively delivered by aerosol formulation due to their large size and/or irregular shapes. Since these therapeutic agents cannot be ingested orally without being degraded by the digestive system, patients have no alternative but to directly inject these drugs. We have a non-exclusive license to the Buccal patent pending proprietary aerosol formulation, which greatly enhances the permeability of the mucous membranes found on the roof of the mouth and the back of the throat. This allows for the easy and efficient systemic delivery into the bloodstream of a much wider variety of proteins and peptides. This non-exclusive license for "Buccal Delivery System" and patent pending application includes claims that identify the active mucosal enhancer, its combination with therapeutic agents and the mode of delivery through aerosol. This may allow for the effective and pain-free delivery of peptide and protein therapeutics for the treatment of HIV and MS.

 

Patents, Trademarks, Licenses and Intellectual Property

 

We have the following patents expiring at various dates indicated below:

 

Bio-Therapeutics Patents

 

We hold the license to certain intellectual property belonging to Bio-Therapeutics that has either been granted a patent or is in the patent application process as follows:

 

U.S. Patent No. 5,989,857, Polypeptide compositions and methods was granted in November 1999 with 10 claims. The patent outlines a method of preparing a bioactive polypeptide in a stable, inactivated form, the method comprising the step of treating the polypeptide with ozonated water in order to oxidize and/or stabilize the cysteine residues, and in turn, prevent the formation of disulfide bridges necessary for bioactivity. This patent expires on May 10, 2016.

 

U.S. Patent No. 6,670,148, Compositions comprising bioactive peptides prepared without formation of native disulfide bonds was granted in December 2003, with 9 claims. The patent further describes a method of preparing a bioactive polypeptide in a stable, inactivated form, the method comprising the step of treating the polypeptide with ozonated water in order to oxidize and/or stabilize the cysteine residues, and in turn, prevent the formation of disulfide bridges necessary for bioactivity. The method can involve the use of ozonated water to both oxidize the disulfide bridges in a bioactive polypeptide, and to then stabilize the resultant cysteine residues. Optionally, and preferably, the method can involve the use of ozonated water to stabilize the cysteine residues, and thereby prevent the formation of disulfide bridges, in a polypeptide produced by recombinant means in a manner that allows the polypeptide to be recovered with the disulfide bridges unformed. This Patent expires on May 10, 2016.

 

U.S. Patent Application Number 11/415377, Buccal Delivery System, with 20 claims. The patent describes a delivery formulation and system for delivering inactivated bioactive peptides to the body. The formulation includes effective amounts of the peptide as well as a mucosal permeation enhancer selected from the group consisting of quaternary ammonium salts. The system can be used by spraying the formulation into the buccal cavity, e.g., to the roof of the mouth. This application is currently listed as abandoned as of December 2009.

 

U.S. Patent Application Number 11/431126, Immunokine composition and method with 31 claims. The patent describes a composition and method for preventing HIV infection of mammalian cells. One aspect of the invention relates to an anti-immunodeficiency virus immunokine capable of binding to a cellular protein in a manner that prevents HIV infection of that cell. The compositions can include either an active bioactive polypeptide, such as native cobratoxin, and/or an inactivated bioactive polypeptide, such as cobratoxin in which one or more of the native disulfide bridges have been prevented from forming. The term "immunokine" is used to refer to an inactivated bioactive polypeptide, whether inactivated by chemical, genetic, and/or synthetic means as described herein, with the proviso that a corresponding active bioactive polypeptides can be included where applicable (e.g., for in vitro use). This application is currently listed as abandoned as of June 2009.

 

ReceptoPharm Patents

 

ReceptoPharm has three issued and several patents pending with the United States Patent and Trademark Office. These patents include:

 

U.S. Patent No. 8,034,777, Modified Anticholinergic Neurotoxins as Modulators of the Autoimmune Reaction was granted in October 2011with 7 claims. The patent describes a method of treatment of a human patient suffering from Multiple Sclerosis comprising the administration of a disease-mitigating amount of a composition consisting of detoxified and modified alpha-cobratoxin in a saline solution. This patent is meant to protect and support our work in the production of drugs for the treatment of auto-immune diseases.

 

U.S. Patent No. 7,902,152, Use of cobratoxin as an analgesic was granted in March 2011 with 16 claims. The patent describes a composition of matter for an analgesic and its method of use is disclosed. The method of use is for the treatment of chronic pain, especially to the treatment of heretofore intractable pain as associated with advanced cancer. The pain associated with neurological conditions, rheumatoid arthritis, viral infections and lesions is also contemplated. The method includes administering to a host an alpha-neurotoxin that is characterized by its ability to blocking of the action of acetylcholine at nicotinic acetylcholine receptors. Currently, this would be applied to the Company's current and future drugs for the treatment of pain.

 

16
 

 

U.S. Patent No. 7,758,894, Modified elapid venoms as stimulators of the immune reaction was granted in July, 2010 with 14 claims. The patent describes a method of protection from infections by administering a detoxified and neurotropically active modified venom containing alpha-cobratoxin. Protection includes bacterial, viral and parasitic infections. This patent is meant to protect and support our work in our production of anti-infective treatments. Currently, this would be applied to RPI-MN and RPI-78.

 

U.S. Patent Application Number 11/217,713, Modified venom and venom components as anti-retroviral agents with 10 claims was filed in September 2005. The present invention describes a method of treatment of human subject suffering from infection with HIV, comprising administering a disease mitigating amount of a detoxified, modified cobra venom composition in an amount effective to ameliorate at least one symptom of said infection. This patent is meant to protect and support our work in the production of anti-viral treatments. Currently, this would be applied to RPI-MN and RPI-78.

 

U.S. Patent Application Number 11/784,607, Treatment of Autoimmune Disorders Using Detoxified Cobratoxin was filed in April 2007. The patent describes a method of treating patients suffering from autoimmune disorders comprising the administration of detoxified cobra venom. This patent is meant to protect and support our work in the production of drugs for the treatment of auto-immune diseases. Currently, this would be applied to RPI-78MN.

 

U.S. Patent Application Number 12/317,115, Alpha-neurotoxin Proteins with Anti-inflammatory Properties and Uses Thereof was filed in December 2008. The patent describes a method of treating an arthritic condition comprising the administration to a subject in need thereof an effective amount of a pharmaceutical composition comprising an isolated alpha-neurotoxin protein or an effective fragment thereof. This patent is meant to protect and support our work in the production of drugs for the treatment of inflammatory diseases.

 

Patents Assigned to Us by Nanologix, Inc. and Used by Designer Diagnostics

 

Because we have focused on our drugs, we have not continued any activity in the Designer Diagnostics division since June, 2011. As results become available through the validation process taking place at National Jewish Hospital in Denver and funding becomes available, we may revisit the technology and re-engage our efforts in Designer Diagnostics.

 

On January 24, 2006 we entered into an Agreement with NanoLogix whereby we exchanged our entire holding of NanoLogix common stock for intellectual property pertaining to the manufacture of test kits for the rapid isolation, detection and antibiotic sensitivity testing of certain mycobacteria. The agreement provides that: (a) NanoLogix has reassigned to us 11 key patents protecting the diagnostics test kit technology in exchange for our entire holding of NanoLogix stock represented by 4,556,174 shares of that stock; (b) NanoLogix has licensed to us the remaining 18 patents that protect the diagnostics test kit technology in exchange for a 6% royalty on the gross sales of the products based on the licensed technology or escalating minimum payments starting at $20,000 annually; (c) we issued to NanoLogix 1 million options of our restricted common stock at $.20 per share; and (d) we will allow NanoLogix to continue their use of these patents for development of their hydrogen technology and other technologies unrelated to medical diagnostic test kits.

 

On or about July 2009, we ceased paying the minimum royalties to Nanologix for the licensed patents and have allowed full rights to those patents to revert back to Nanologix.

 

We own 11 issued U.S. patents covering technologies related to growing, detecting, identifying, defining antibiotic sensitivity and designing apparatus for the detection of 32 different paraffin-eating microorganisms that were assigned to us by Nanologix, Inc. These patents will be used by our wholly owned subsidiary, Designer Diagnostics, should it again become operational.

 

U.S. Patent No. 5,989,902, Method for determining the antimicrobial agent sensitivity of a nonparaffinophilic hydrophobic microorganism and an associated apparatus was granted in November 1999 with 3 claims. The patent describes a method for determining a sensitivity of a nonparaffinophilic hydrophobic microorganism to an antimicrobial agent. The method includes providing at least one receptacle containing an aqueous broth including a carbon source and introducing the nonparaffinophilic hydrophobic microorganism into the receptacle. The method further includes placing into the receptacle (i) a slide coated with a hydrophobic material and (ii) a predetermined quantity of the antimicrobial agent to be tested. By observing the nonparaffinophilic hydrophobic microorganism growth or lack thereof on the slide, it can be determined whether the predetermined quantity of the antimicrobial agent is effective in inhibiting growth of the nonparaffinophilic hydrophobic microorganism on the slide. An associated apparatus is also disclosed. This Patent expires on November 13, 2017.

 

U.S. Patent No. 5,981,210, Method for determining a presence or absence of a nonparaffinophilic hydrophobic microorganism in a body specimen by using a DNA extraction procedure and a novel DNA extraction procedure was granted in November 1999 with 17 claims. The method of the invention involves providing a first receptacle and a second receptacle. The first receptacle contains a sterile aqueous broth and the second receptacle contains an aqueous broth including a carbon source. The method then includes placing into the first receptacle a first support surface having a paraffin wax coating thereon and placing into the second receptacle a second support surface having a hydrophobic material coating thereon. A body specimen, such as sputum, is then introduced into each of the first and second receptacles. The presence of a nonparaffinophilic hydrophobic microorganism in the body specimen is determined by observing (i) a lack of microorganism growth on the paraffin coated material of the first support surface and (ii) a presence of microorganism growth on the hydrophobic material coating of the second support surface. The presence of the nonparaffinophilic hydrophobic microorganism can be further confirmed by performing a DNA extraction. An associated DNA extraction procedure is also provided. This Patent expires on November 13, 2017.

 

17
 

 

U.S. Patent No. 5,935,806, Method and apparatus for speciating and identifying MAI (Mycobacterium Avium Intracellulare) and testing the same for antibiotic sensitivity was granted in August 1999 with 3 claims. The patent describes a method of speciating and identifying MAI in a specimen comprises placing a paraffin coated slide in a receptacle containing a sterile aqueous solution inoculated with the specimen, analyzing the slide after exposure to the specimen to determine the presence or absence of atypical Mycobacteria, and after the analysis step, if atypical Mycobacteria are determined to be present, performing at least one speciation assay to ascertain if the atypical Mycobacteria are MAI. A related apparatus is also disclosed for speciating and identifying MAI in a specimen comprising a paraffin-wax coated slide, a tube having a sterile aqueous solution contained therein, the tube adapted to hold the slide, and at least one speciation assay means for performing an assay to determine the presence or absence of MAI in the specimen after the specimen is introduced into the tube holding the solution and the slide. An apparatus and method for determining the sensitivity of MAI to different antibiotics and dosages thereof is also provided. This Patent expired on October 24, 2009 for failure to timely pay maintenance fees.

 

U.S. Patent No. 5,882,920, Apparatus for determining the presence or absence of a paraffinophilic microorganism was granted in March 1999 with 4 claims. The patent describes a method of determining the presence of a paraffinophilic microorganism in a specimen taken from a patient. The method includes providing a receptacle containing an aqueous solution and adjusting the solution to mimic the in vivo clinical conditions of the patient. The method then further includes inoculating the solution with the specimen and then placing in the receptacle a paraffin coated slide to bait the paraffinophilic microorganism. The slide is then analyzed after exposure to the specimen to determine the presence or absence of the paraffinophilic microorganism. An associated apparatus is also disclosed. This Patent expires on November 9, 2015.

 

U.S. Patent No. 5,854,014, Apparatus for testing paraffinophilic microorganisms for antimicrobial sensitivity was granted in December 1998 with 2 claims. The patent describes an apparatus for determining the antimicrobial agent sensitivity of a paraffinophilic microorganism from a specimen obtained from a patient. The apparatus includes a receptacle containing an aqueous solution, an amount of antimicrobial agent to be tested and the specimen. The apparatus further consists of a paraffin coated slide placed into the receptacle. This Patent expired October 24, 2009 for failure to timely pay maintenance fees.

 

U.S. Patent No. 5,846,760, Method for determining a presence or absence of a nonparaffinophilic hydrophobic microorganism in a body specimen and an associated kit was granted in December 1998 with 15 claims. The method of the invention involves providing a first receptacle and a second receptacle. The first receptacle contains a sterile aqueous broth and the second receptacle contains an aqueous broth including a carbon source. The method then includes placing into the first receptacle a first support surface having a paraffin wax coating thereon and placing into the second receptacle a second support surface having a hydrophobic material coating thereon. A body specimen, such as sputum, is then introduced into each of the first and second receptacles. The presence of a nonparaffinophilic hydrophobic microorganism in the body specimen is determined by observing (i) a lack of microorganism growth on the paraffin coated material of the first support surface and (ii) a presence of microorganism growth on the hydrophobic material coating of the second support surface. An associated kit is also disclosed. This Patent expires on November 13, 2017.

 

U.S. Patent No. 5,776,722, Method of testing a body specimen taken from a patient for the presence or absence of a microorganism and a further associated method and associated apparatus was granted in July 1998 with 40 claims. The patent describes a method of testing a body specimen taken from a patient for the presence or absence of a microorganism. A transport/isolator assembly is provided which includes a receptacle and a baiting assembly including a baiting section having disposed thereon a coating material. A baiting liquid and the body specimen are then introduced into the receptacle. The method further comprises securing the baiting assembly to the receptacle so that at least a portion of the coated section is introduced into the baiting liquid. The transport/isolator assembly containing the baiting liquid and the body specimen are then transported to a laboratory for subsequent observation of the coated section for growth or lack thereof of the microorganism. A further method of processing the body specimen and an associated isolator/transport assembly kit as well as an associated isolator/transport assembly are also disclosed. This Patent expires on September 25, 2017.

 

U.S. Patent No. 5,569,592, Apparatus for testing MAI (Mycobacterium Avium Intracellulare) for antimicrobial agent sensitivity was granted in October 1996 with 3 claims. The patent describes an apparatus for determining the sensitivity of MAI to different antimicrobial agents and dosages thereof is provided. The apparatus comprises a plurality of test tubes adapted to contain an amount of an antimicrobial agent to be tested and MAI complex organisms to be assayed and a separate paraffin coated slide adapted for placement in each of the test tubes. The growth of the MAI complex organisms on the slide can be used to determine the concentration of the antimicrobial agent necessary to resist MAI complex organism growth on the slide. An associated method is also disclosed. This Patent expired on October 29, 2013.

 

18
 

 

U.S. Patent No. 5,472,877, Apparatus for determining the presence or absence of MAI (Mycobacterium Avium Intracellulare) was granted in December 1995 with 6 claims. The patent describes a method of speciating and identifying MAI in a specimen comprises placing a paraffin coated slide in a receptacle containing a sterile aqueous solution inoculated with the specimen, analyzing the slide after exposure to the specimen to determine the presence or absence of atypical Mycobacteria, and after the analysis step, if atypical Mycobacteria are determined to be present, performing at least one speciation assay to ascertain if the atypical Mycobacteria are MAI. A related apparatus is also disclosed for speciating and identifying MAI in a specimen comprising a paraffin-wax coated slide, a tube having a sterile aqueous solution contained therein, the tube adapted to hold the slide, and at least one speciation assay means for performing an assay to determine the presence or absence of MAI in the specimen after the specimen is introduced into the tube holding the solution and the slide. An apparatus and method for determining the sensitivity of MAI to different antibiotics and dosages thereof is also provided. This Patent expired on December 5, 2012.

 

U.S. Patent No. 5,316,918, Method and apparatus for testing MAI (Mycobacterium Avium Intracellulare) for antimicrobial agent sensitivity was granted in May 1994 with 7 claims. The patent describes an apparatus and method for determining the sensitivity of MAI to different antimicrobial agents and dosages thereof is provided. The apparatus comprises a plurality of test tubes adapted to contain an amount of an antimicrobial agent to be tested and MAI complex organisms to be assayed and a separate paraffin coated slide adapted for placement in each of the test tubes. The growth of the MAI complex organisms on the slide can be used to determine the concentration of the antimicrobial agent necessary to resist MAI complex organism growth on the slide. An associated method is also disclosed. This Patent expired on May 31, 2011.

 

U.S. Patent No. 5,153,119, Method for speciating and identifying MAI (Mycobacterium Avium Intracellulare) was granted in October 1992 with 15 claims. The patent describes a method of speciating and identifying MAI in a specimen comprises placing a paraffin coated slide in a receptacle containing a sterile aqueous solution inoculated with the specimen, analyzing the slide after exposure to the specimen to determine the presence or absence of atypical Mycobacteria, and after the analysis step, if atypical Mycobacteria are determined to be present, performing at least one speciation assay to ascertain if the atypical Mycobacteria are MAI. A related apparatus is also disclosed for speciating and identifying MAI in a specimen comprising a paraffin-wax coated slide, a tube having a sterile aqueous solution contained therein, the tube adapted to hold the slide, and at least one speciation assay means for performing an assay to determine the presence or absence of MAI in the specimen after the specimen is introduced into the tube holding the solution and the slide. An apparatus and method for determining the sensitivity of MAI to different antibiotics and dosages thereof is also provided. This Patent expired on October 24, 2009.

 

Our business is dependent upon our ability to protect our proprietary technologies and processes. Despite our efforts to protect our proprietary rights, unauthorized parties may attempt to obtain and use proprietary information. We will rely on patent and trade secret law and nondisclosure and other contractual arrangements to protect such proprietary information. We will file patent applications for our proprietary methods and devices for patient treatments. Our efforts to protect our proprietary technologies and processes are subject to significant risks, including that others may independently develop equivalent proprietary information and techniques, gain access to our proprietary information, our proprietary information being improperly disclosed, or that we may ineffectively protect our rights to unpatented trade secrets or other proprietary information.

 

Employees

 

We employ a total of 3 employees, consisting of: (a) our Chief Executive Officer (b) Our Director of Marketing, and (c) our Interim President of ReceptoPharm. We utilize outside consultants, legal and accounting personnel as necessary and as funding permits.

 

Report to Security Holders

 

We are subject to the informational requirements of the Securities Exchange Act of 1934. Accordingly, we file annual, quarterly and other reports and information with the Securities and Exchange Commission. You may read and obtain a copy of these reports in Washington, D.C. Our filings are also available to the public from commercial document retrieval services and the Internet world wide website maintained by the Securities and Exchange Commission at www.sec.gov.

 

Item 1A. Risk Factors

 

You should carefully consider the risks described below regarding our operations, financial condition, financing, our common stock and other matters. If any of the following or other material risks actually occur, our business, financial condition, or results or operations could be materially adversely affected.

 

Our ability to continue as a going concern is in doubt absent obtaining adequate new debt or equity financing and achieving sufficient sales levels.

 

We incurred net losses of $4,342,964 and $3,612,351 for the years ended December 31, 2013 and 2012. We anticipate that these losses will continue for the foreseeable future. We have a significant working capital deficiency, and have not reached a profitable level of operations, which raises substantial doubt about our ability to continue as a going concern. Our continued existence is dependent upon our achieving sufficient sales levels of our Cobroxin® and Nyloxin® products and obtaining adequate financing. Unless we can begin to generate material revenue, we may not be able to remain in business. We cannot assure you that we will raise enough money or generate sufficient sales to meet our future working capital needs.

 

19
 

 

We have a limited revenue producing history with significant losses and expect losses to continue for the foreseeable future.

 

We have yet to establish any history of profitable operations. We have incurred annual losses of $4,342,964 and $3,612,351 during the fiscal years of operations ending December 31, 2013 and 2012 respectively. As a result, at December 31, 2013 we had an accumulated deficit of $41,986,820. Our revenues have been insufficient to sustain our operations and we expect our revenues will be insufficient to sustain our operations for the foreseeable future. Our potential profitability will require the successful commercialization of our Cobroxin® and Nyloxin® products.

 

We will require additional financing to sustain our operations and without it will be unable to continue operations.

 

At December 31, 2013 we had a working capital deficit of $4,259,938. Our recurring losses from operations and working capital deficiency raise substantial doubt about our ability to continue as a going concern. We have a negative cash flow from operations of approximately $0.6 million and $0.7 million for the years ended December 31, 2013 and 2012, respectively. We have insufficient financial resources to fund our operations.

 

As of December 31, 2013 we owe $566,399 to our Chief Executive Officer from funds borrowed from him.

 

Our Chief Executive Officer may be unwilling or unable to continue funding our operations.

 

Our Chief Executive Officer has historically funded our operations by providing loans to us. As of December 31, 2013, we owe Mr. Deitsch $566,399. Mr. Deitsch may be unwilling or unable to fund our operations in the future. If we have no other source of funding and we are unable to secure additional loans from Mr. Deitsch, our operations will be negatively affected.

 

To date, none of our prescription drug candidates have received FDA drug orphan status approval.

 

To date, none of our prescription drug candidates have received FDA drug orphan status, which would otherwise place our drug candidates on a “fast track” with the FDA application process. If none of our drug candidates can achieve that status, our operations and financial condition will be negatively affected.

 

We have a history of failed distributors, which has negatively affected our revenues and may continue to do so if we fail to locate a successful distributor.

 

Due to poor performance, we cancelled our distribution agreement with our Cobroxin® distributor, XenaCare in April, 2011. We have signed an agreement with Cobra Pharmaceuticals as our new distributor for Cobroxin®, but they have not yet ordered product or provided planned sales. To date, we have only limited sales of Nyloxin® through outside distributors. Most of the current sales are direct from the company or through the www.Nyloxin.com website. If we fail to improve our own marketing and distribution or fail to find a competent outside distributor our operations and financial condition will be negatively affected

 

If we cannot sell a sufficient volume of our products, we will be unable to continue in business.

 

To date, sales of Cobroxin® have been limited and inconsistent. Total sales of Cobroxin® have been $1,993,373 since the fourth quarter of 2009, with no significant sales since the second quarter of 2010.

 

To date, sales of Nyloxin® have been limited and inconsistent. During 2011, we sold $66,568 of Nyloxin®. During 2012, we sold $199,231 of Nyloxin®. During 2013, we sold $119,898 of Nyloxin®. If we cannot achieve sufficient sales levels of our Cobroxin® and Nyloxin® products or we are unable to secure financing our operations will be negatively affected.

 

We have a limited history of generating revenues on which to evaluate our potential for future success and to determine if we will be able to execute our business plan; accordingly, it is difficult to evaluate our future prospects and the risk of success or failure of our business.

 

Our total sales of Cobroxin® from November 2009 until December 31, 2013 are $1,995,673. Our total sales of Nyloxin® from January 1, 2011 to December 31, 2013 are $385,697. You must consider our business and prospects in light of the risks and difficulties we will encounter as an early-stage revenue producing company. These risks include:

 

  · our ability to effectively and efficiently market and distribute our products;
     
  · our ability to obtain market acceptance of our current products and future products that may be developed by us; and

 

 

20
 

  

  · our ability to sell our products at competitive prices which exceed our per unit costs.

 

We may be unable to address these risks and difficulties, which could materially and adversely affect our revenue, operating results and our ability to continue to operate our business.

 

Our growth strategy reflected in our business plan may be unachievable or may not result in profitability.

 

We may be unable to implement our growth strategy reflected in our business plan rapidly enough for us to achieve profitability. Our growth strategy is dependent on a number of factors, including market acceptance of our Cobroxin® and Nyloxin® products and the acceptance by the public of using these products as pain relievers. We cannot assure you that our products will be purchased in amounts sufficient to attain profitability.

 

Among other things, our efforts to expand our sales of Cobroxin® and Nyloxin® will be adversely affected if:

 

  · we are unable to attract sufficient customers to the products we offer in light of the price and other terms required in order for us to attain the level of profitability that will enable us to continue to pursue our growth strategy;
     
  · adequate penetration of new markets at reasonable cost becomes impossible limiting the future demand for our products below the level assumed by our business plan;
     
  · we are unable to scale up manufacturing to meet product demand, which would negatively affect our revenues and brand name recognition;
     
  · we are unable to meet regulatory requirements in the intellectual marketplace that would otherwise allow us for wider distribution; and
     
  · we are unable to meet FDA regulatory requirements that would potentially expand our product base and potential revenues.

 

If we cannot manage our growth effectively, we may not become profitable.

 

Businesses, which grow rapidly often, have difficulty managing their growth. If we grow rapidly, we will need to expand our management by recruiting and employing experienced executives and key employees capable of providing the necessary support. We cannot assure you that our management will be able to manage our growth effectively or successfully.

 

Among other things, implementation of our growth strategy would be adversely affected if we were not able to attract sufficient customers to the products and services we offer or plan to offer in light of the price and other terms required in order for us to attain the necessary profitability.

 

If we are unable to protect our proprietary technology, our business could be harmed.

 

Our intellectual property, including patents, is our key asset. We currently have 21 patents that we either own or have the rights to from third parties. 16 of these patents have been approved and 5 are pending. Competitors may be able to design around our patents for our Cobroxin® and Nyloxin® products and compete effectively with us. The cost to prosecute infringements of our intellectual property or the cost to defend our products against patent infringement or other intellectual property litigation by others could be substantial. We cannot assure you that:

 

  · pending and future patent applications will result in issued patents,
     
  · patents licensed by us will not be challenged by competitors,
     
  · our patents, licensed and other proprietary rights from third parties will not result in costly litigation;
     
  · pending and future patent applications will result in issued patents,
     
  · the patents or our other intellectual property will be found to be valid or sufficiently broad to protect these technologies or provide us with a competitive advantage,
     
  · if we are sued for patent infringement, whether we will have sufficient funds to defend our patents, and
     
  · we will be successful in defending against future patent infringement claims asserted against our products.

 

21
 

 

Should any risks pertaining to the foregoing occur, our brand name reputation, results of operation and revenues will be negatively affected.

 

We are subject to substantial FDA regulations pertaining to Cobroxin® and Nyloxin®, which may increase our costs or otherwise adversely affect our operations.

 

Our Cobroxin® and Nyloxin® products are subject to FDA regulations, including manufacturing and labeling, approval of ingredients, advertising and other claims made regarding Cobroxin® or Nyloxin®, and product ingredients disclosure. If we fail to comply with current or future regulations, the FDA could force us to stop selling Cobroxin® or Nyloxin® or require us to incur substantial costs from adopting measures to maintain FDA compliance.

 

The inability to provide scientific proof for product claims may adversely affect our sales.

 

The marketing of Cobroxin® and Nyloxin® involves claims that they assist in reducing Stage 2 chronic pain, while Nyloxin® Extra Strength and Nyloxin® Military Strength involves claims that they assist in reducing Stage 3 chronic pain. Under FDA and Federal Trade Commission (“FTC”) rules, we are required to have adequate data to support any claims we make concerning Cobroxin®, Nyloxin® and Nyloxin® Extra Strength. We have scientific data for our Cobroxin® and Nyloxin® product claims; however, we cannot be certain that these scientific data will be deemed acceptable to the FDA or FTC. If the FDA or FTC requests supporting information and we are unable to provide support that it finds acceptable, the FDA or FTC could force us to stop making the claims in question or restrict us from selling the products.

 

None of our ethical drug candidates have received FDA approval.

 

Our non-homeopathic or ethical products require a complex and costly FDA regulation process that takes several years for drug approval, if ever. None of the drug applications we have submitted to the FDA have received FDA approval. If we do not receive FDA approval for our drug applications, our operations and financial condition will be negatively affected.

 

If we are unable to secure sufficient cobra venom from available suppliers, our operating results will be negatively affected.

 

We secure cobra venom on an as-needed basis according to customer orders for Cobroxin® and Nyloxin® received by our distributor. If we do not have an available supplier to fill customer orders, there will be distribution delays and/or our failure to fulfill purchase orders, either of which will negatively affect our brand name reputation and operating results.

 

Our Cobroxin® and Nyloxin® products may be unable to compete against our competitors in the pain relief market.

 

The pain relief market is highly competitive. We compete with companies that have already achieved product acceptance and brand recognition, including multi-billion dollar private label manufacturers and more established pharmaceutical and health products companies, or low cost generic drug manufacturers. Most such companies have far greater financial and technical resources and production and marketing capabilities than we do. Additionally, if consumers prefer our competitors’ products, or if these products have better safety, efficacy, or pricing characteristics, our results could be negatively impacted. If we fail to develop and actualize strategies to compete against our competitors we may fail to compete effectively, which will negatively affect our operations and operating results.

 

If we incur costs resulting from product liability claims, our operating results will be negatively affected.

 

If we become subject to product liability claims for Cobroxin® and Nyloxin® that exceed our product liability policy limits, we may be subject to substantial litigation costs or judgments against us, which will negatively impact upon our financial and operating results.

 

Loss of any of our key personnel could have a material adverse effect on our operations and financial results.

 

We are dependent upon a limited number of our employees: (a) our Chief Executive Officer who directs our operations; and (b) ReceptoPharm’s employees who conduct our research and development activities. Our success depends on the continued services of our senior management and key research and development employees as well as our ability to attract additional members to our management and research and development teams. The unexpected loss of the services of any of our management or other key personnel could have a material adverse effect upon our operations and financial results.

 

22
 

 

We may be unable to maintain and expand our business if we are not able to retain, hire and integrate key management and operating personnel.

 

Our success depends in large part on the continued services and efforts of key management personnel. Competition for such employees is intense and the process of locating key personnel with the combination of skills and attributes required to execute our business strategies may be lengthy. The loss of key personnel could have a material adverse impact on our ability to execute our business objectives. We do not have any key man life insurance on the lives of any of our executive officers.

 

Risks Related to Our Common Stock

 

Because the market for our common stock is limited, persons who purchase our common stock may not be able to resell their shares at or above the purchase price paid by them.

 

Our common stock trades on the OTCQB, which is not a liquid market. There is currently only a limited public market for our common stock. We cannot assure you that an active public market for our common stock will develop or be sustained in the future. If an active market for our common stock does not develop or is not sustained, the price may decline.

 

Because we are subject to the “penny stock” rules, brokers cannot generally solicit the purchase of our common stock, which adversely affects its liquidity and market price.

 

The SEC has adopted regulations, which generally define “penny stock” to be an equity security that has a market price of less than $5.00 per share, subject to specific exemptions. The market price of our common stock on the OTCQB has been substantially less than $5.00 per share and therefore we are currently considered a “penny stock” according to SEC rules. This designation requires any broker-dealer selling these securities to disclose certain information concerning the transaction, obtain a written agreement from the purchaser and determine that the purchaser is reasonably suitable to purchase the securities. These rules limit the ability of broker-dealers to solicit purchases of our common stock and therefore reduce the liquidity of the public market for our shares.

 

Because the majority of our outstanding shares are freely tradable, sales of these shares could cause the market price of our common stock to drop significantly, even if our business is performing well.

 

As of December 31, 2013, we had 1,004,313,019 outstanding shares that were subject to the limitations of Rule 144 under the Securities Act of 1933. In general, Rule 144 provides that any our non-affiliates, who have held restricted common stock for at least six-months, are entitled to sell their restricted stock freely, provided that we stay current in our SEC filings. After one year, a non-affiliate may sell without any restrictions.

 

An affiliate may sell after one year with the following restrictions: (i) we are current in ours filings, (ii) certain manner of sale provisions, (iii) filing of Form 144, and (iv) volume limitations limiting the sale of shares within any three-month period to a number of shares that does not exceed 1% of the total number of outstanding shares. A person who has ceased to be an affiliate at least three months immediately preceding the sale and who has owned such shares of common stock for at least one year is entitled to sell the shares under Rule 144 without regard to any of the limitations described above.

 

An investment in our common stock may be diluted in the future as a result of the issuance of additional securities or the exercise of options or warrants.

 

In order to raise additional capital to fund our strategic plan, we may issue additional shares of common stock or securities convertible, exchangeable or exercisable into common stock from time to time, which could result in substantial dilution to any person who purchases our common stock. Because we have a negative net tangible book value, purchasers will suffer substantial dilution. We cannot assure you that we will be successful in raising funds from the sale of common stock or other equity securities.

 

Since we intend to retain any earnings for development of our business for the foreseeable future, you will likely not receive any dividends for the foreseeable future.

 

We have not and do not intend to pay any dividends in the foreseeable future, as we intend to retain any earnings for development and expansion of our business operations. As a result, you will not receive any dividends on your investment for an indefinite period of time.

 

Due to factors beyond our control, our stock price may continue to be volatile.

 

The market price of our common stock has been and is expected to be highly volatile. Any of the following factors could affect the market price of our common stock:

 

  · our failure to generate revenue,

 

  · our failure to achieve and maintain profitability,

 

23
 

 

  · short selling activities,

 

  · the sale of a large amount of common stock by our shareholders including those who invested prior to commencement of trading,

 

  · actual or anticipated variations in our quarterly results of operations,

 

  · announcements by us or our competitors of significant contracts, new products, acquisitions, commercial relationships, joint ventures or capital commitments,

 

  · the loss of major customers or product or component suppliers,

 

  · the loss of significant business relationships,

 

  · our failure to meet financial analysts’ performance expectations,

 

  · changes in earnings estimates and recommendations by financial analysts, or

 

  · changes in market valuations of similar companies.

 

In the past, following periods of volatility in the market price of a company’s securities, securities class action litigation has often been instituted. A securities class action suit against us could result in substantial costs and divert our management’s time and attention, which would otherwise be used to benefit our business.

 

Item 1B. Unresolved Staff Comments

 

None

 

Item 2. Properties

 

As of February 1, 2013, we leased approximately 2,000 square feet at 12502 West Atlantic Blvd, Coral Springs, Florida. Our offices are comprised of a reception area, conference room, 3 offices, 2 restrooms and 2 cubicle workstations. Our offices are adequate for our needs. Our lease term is for a period of 3 years. We currently pay monthly rent of approximately $3,800. We formerly leased approximately 3,235 square feet of office space at 2776 University Drive, Coral Springs, Florida from February 1, 2010 through January 31, 2013.

 

Since May 13, 2004, ReceptoPharm has leased their office space at 1537 NW 65th Avenue, Plantation, Florida for three consecutive two-year terms. ReceptoPharm's 5,500 square foot facilities include a reception area, conference room and five offices, a warehouse and a laboratory. On May 10, 2010 ReceptoPharm renewed the lease with Shelter Developers of America (“Shelter”) for the last two-year term beginning on June 1, 2010 and ending May 31, 2012. On July 9, 2012 ReceptoPharm entered into a new lease agreement for a five year period beginning on August 1, 2012. The lease calls for monthly payments for year 1 in the amount of $5,617, which includes base rent, common area expenses, real estate taxes and insurance.

 

Item 3. Legal Proceedings

 

OTC: BB Delinquency Notification

 

On May 7, 2012, our securities were removed from quotation on the OTC Bulletin Board (“OTCBB”) as a result of our failure to file our annual report, Form 10-K, by the due date of May 17, 2012, which included the 30-day grace period allowed. We were also delinquent in the filing of our first quarter 10-Q report for the three months ended March 31, 2012, which was due on May 22, 2012, including the 5-day extension. Pursuant to National Association of Securities Dealers (“NASD”) Rule 6530, OTCBB issuers that are cited for filing delinquency three times in a 24-month period and those removed for failure to file two times in a 24-month period will be ineligible for quotation by an NASD member and shall not be eligible for quotation until the issuer has timely filed in a complete form all required annual and quarterly reports due in a one-year period. As of December 5, 2012 we have been current in all of our filing requirements. As such, we are now listed on the OTC Markets as an OTCQB company.

 

Patricia Meding, et. al. v. ReceptoPharm, Inc. f/k/a Receptogen, Inc.

 

On August 18, 2006, ReceptoPharm was named as a defendant in Patricia Meding, et. al. v. ReceptoPharm, Inc. f/k/a Receptogen, Inc., Index No.: 18247/06 (New York Supreme Court, Queens County). The original proceeding claimed that ReceptoPharm owed the Plaintiffs, including Patricia Meding, a former ReceptoPharm officer and shareholder and several corporations that she claims to own, the sum of $118,928.15 plus interest and counsel fees on a series promissory notes that were allegedly executed in 2001 and 2002. On August 23, 2007, the Queens County New York Supreme Court issued a decision denying Plaintiffs motion for summary judgment in lieu of a complaint, concluding that there were issues of fact concerning the enforceability of the promissory notes. On May 23, 2008, the Plaintiffs filed an amended complaint in which they reasserted their original claims and asserted new claims seeking damages of no less than $768,506 on their claims that in or about June 2004 ReceptoPharm breached its fiduciary duty to the Plaintiffs as shareholders of ReceptoPharm by wrongfully canceling certain of their purported ReceptoPharm share certificates. In late 2010, Plaintiffs further amended their complaint alleging that ReceptoPharm violated Plaintiffs contractual and statutory rights by cancelling an additional 1,214,800 share certificates and failing to permit the Plaintiffs to exercise dissenting shareholder rights with respect to those share certificates. The damages associated with the Plaintiff’s claims could rise as the result of increases in our share price as the Receptopharm shares may be convertible into our common shares. The potential exposure may exceed $10,000,000 if the Plaintiffs are successful with all of their claims.

 

24
 

  

ReceptoPharm believes the suit is without merit and has filed an answer denying the material allegations of the amended complaint and asserted a series of counterclaims against the Plaintiffs alleging claims for declaratory judgment, fraud, breach of fiduciary duty, conversion and unjust enrichment as a result of the promissory notes. Plaintiffs have moved for partial summary judgment on their claims regarding the additional 1,214,800 shares, but not on their claims regarding the alleged promissory notes or the 1,750,000 alleged shares. In August of 2011, the Plaintiff's motion was partially granted. In September 2012, ReceptoPharm's attorneys filed a Motion to be removed as counsel. Their motion is currently being considered. ReceptoPharm is seeking new counsel to oppose the partial summary judgment. We intend to vigorously contest this matter.

 

Liquid Packaging Resources, Inc. v. Nutra Pharma Corp. and Erik "Rik" Deitsch

 

On April 21, 2011, Nutra Pharma Corp. and its CEO, Erik Deitsch, were named as defendants in Liquid Packaging Resources, Inc. v. Nutra Pharma Corp. and Erik "Rik" Deitsch, Superior Court of Fulton County, Georgia, Civil Action No. 2011-CV-199562. Liquid Packaging Resources, Inc. ("LPR") claimed that Nutra Pharma Corp. and Mr. Deitsch, directly or through other companies, placed orders with LPR that required LPR to purchase components from third parties. LPR sought reimbursement for those third party expenses in the amount of not less than $359,826.85 plus interest. LPR also sought punitive damages in the amount of not less than $500,000 and attorney's fees.

 

The Company and Mr. Deitsch then removed the action to the United States District Court, Northern District of Georgia, Civil Action No. 11-CV-01663-ODE. After removal, LPR amended the Complaint to assert that Nutra Pharma Corp. and Mr. Deitsch were the alter egos of the alleged other companies through whom the subject orders were placed and therefore should be considered one and the same. The Company and Mr. Deitsch moved to dismiss the Complaint on several grounds including statute of frauds, failure to state a claim, and jurisdiction (only for Mr. Deitsch). The Company and Mr. Deitsch believe the suit is without merit.

 

After June 30, 2011, at LPR's request, the parties mediated the dispute before LPR responded to the Motion To Dismiss. At the mediation, the parties worked out an agreement whereby we would purchase from LPR the components LPR purchased from third parties at an amount slightly less than the principal amount of the suit and on terms acceptable to us. The agreed price was $350,000.00 payable over 7 months in equal $50,000.00 amounts. This agreement was reached by us because it provided tangible value in exchange for the purchase price rather than incurring the expense of litigation, which would likely be substantial and not recouped. While we had counterclaims we could assert, we believe this was a practical resolution. The settlement allowed us to take possession of the components prior to full payment and, in exchange, provided security to LPR in the form of our stock valued at $400,000 at the time of issuance. The stock can only be sold in event of a default of the payment schedule. The litigation was dismissed in August of 2011. We made the August, September and November payments (totaling $150,000) in a timely fashion. We were late for the payment due October 15, 2011 and requested an accommodation from LPR, eventually paying an extra $5,000 towards that payment. At December 31, 2011, we had made total payments of $205,000 with an additional $150,000 owed. In order to allow us to skip the December payment, LPR agreed to another accommodation whereby we would pay both the December and January payment with an additional $10,000 on or before January 16, 2012. We were unable to make this payment and on January 26, 2012 signed an amended payment schedule adding an additional $15,000 for a total of $175,000 owed. Our CEO, Rik Deitsch, added additional collateral stock in a separate company that he held personally. $25,000 was paid in January, with subsequent payments of $30,000 due monthly on the 15th of March through the 15th of July, 2012. We failed to make the March payment and was subsequently called in default of the Agreement. Under the original agreement, if we are in default of the agreement, LPR has the right to sell shares of our free trading stock held in escrow by their attorney and receive cash settlements for a total amount of $450,000 representing the new total cash amount due to LPR by the Company.

 

On June 11, 2012, LPR sold their debt to Southridge Partners, LLP in an agreement to be paid out over time. In August, 2013, LPR cancelled their agreement with Southridge Partners, LLP.  As of December 31, 2013 LPR continues to hold the collateral stock. We are currently negotiating a settlement with LPR. Upon the settlement of the outstanding debt, LPR will return the collateral shares to the Company.

 

25
 

 

Involuntary Petition of Bankruptcy 

 

On August 31, 2012, certain former ReceptoPharm employees and a former ReceptoPharm consultant filed a Petition for Involuntary Bankruptcy against us in the United States Bankruptcy Court, Southern District of Florida. The Petitioners originally claimed they were owed $990,927 from Nutra Pharma in the form of accrued wages and promissory notes, but amended their claim to $816,662 in a subsequent filing. In response to the Petition, we filed a motion to dismiss the action which, if successful, would avoid the case being converted into an actual bankruptcy action. On September 30, 2013, the Company entered into a Settlement Agreement with the Petitioners, which is effective upon the court dismissal of the action. In full and final satisfaction of all claims, the Company settled the Agreement with the Petitioners for a total sum of $350,000.  $35,000 has been paid and a second lump sum payment is due within 8 months from February 12, 2014, the date the court dismissed the action.  The Parties executed mutual releases exclusive of releases under the Settlement Agreement.

 

Laurence N. Raymond v. Receptopharm, Inc. et al.

 

On December 30, 2011 Laurence N. Raymond ("Raymond") brought the case against Receptopharm, Inc. ("Receptopharm") and Nutra Pharma to recover approximately $300,000 that was allegedly either loaned to Receptopharm or owing to Raymond pursuant to an oral employment agreement. Dr. Raymond is one of the petitioning creditors that brought the above-described involuntary bankruptcy action. The settlement agreement reached in that action fully resolves all claims between the parties and specifies that this action will be dismissed with prejudice.

 

Paul F. Reid v, Harold H. Rumph et al.

 

On December 28, 2011 Paul F. Reid ("Reid") brought the case against Harold H. Rumph ("Rumph"), Receptopharm, and Nutra Pharma to recover approximately $330,000 that was allegedly either loaned to Receptopharm or owing to Reid pursuant to an oral employment agreement. Dr. Reid is one of the petitioning creditors that brought the above-described involuntary bankruptcy action. The settlement agreement reached in that action fully resolves all claims between the parties and specifies that this action will be dismissed with prejudice.

 

Item 4. Mine Safety Disclosures

 

None

 

PART II

 

Item 5. Market for Registrant’s Common Equity; Related Stockholder Matters and Issuer Purchases of Equity Securities

 

Market Information

 

Our common stock is quoted on the over-the-counter (“OTCQB”) under the trading symbol "NPHC". The following table sets forth the high and low bid prices for each quarter within the last two fiscal years.

 

    2012 Fiscal Year  
    High Bid     Low Bid  
First Quarter   $ 0.04     $ 0.0121  
Second Quarter   $ 0.0185     $ 0.009  
Third Quarter   $ 0.018     $ 0.006  
Fourth Quarter   $ 0.041     $ 0.0125  

 

    2013 Fiscal Year  
    High Bid     Low Bid  
First Quarter   $ 0.013     $ 0.0065  
Second Quarter   $ 0.0091     $ 0.0038  
Third Quarter   $ 0.0254     $ 0.0038  
Fourth Quarter   $ 0.02     $ 0.0071  

 

The above quotations reflect inter-dealer prices, without retail mark-up, markdown or commission and may not represent actual transactions.

 

Penny Stock Considerations

 

Our shares of common stock are "penny stocks" as that term is generally defined in the Securities Exchange Act of 1934 as equity securities with a price of less than $5.00. Our shares are subject to rules that impose sales practice and disclosure requirements on broker-dealers who engage in certain transactions involving a penny stock.

 

Under the penny stock regulations, a broker-dealer selling a penny stock to anyone other than an established customer or "accredited investor" must make a special suitability determination regarding the purchaser and must receive the purchaser's written consent to the transaction prior to the sale, unless the broker-dealer is otherwise exempt. Generally, an individual with a net worth in excess of $1,000,000 or annual income exceeding $200,000 individually or $300,000 together with his or her spouse is considered an accredited investor.

 

26
 

 

In addition, under the penny stock regulations the broker-dealer is required to:

 

  · Deliver, prior to any transaction involving a penny stock, a disclosure schedule prepared by the Securities and Exchange Commission relating to the penny stock market, unless the broker-dealer or the transaction is otherwise exempt;

 

  · Disclose commission payable to the broker-dealer and its registered representatives and current bid and offer quotations for the securities;

 

  · Send monthly statements disclosing recent price information pertaining to the penny stock held in a customer's account, the account's value and information regarding the limited market in penny stocks; and

 

  · Make a special written determination that the penny stock is a suitable investment for the purchaser and receive the purchaser's written agreement to the transaction, prior to conducting any penny stock transaction in the customer's account.

 

Because of these regulations, broker-dealers may encounter difficulties in their attempt to sell shares of our common stock, which may affect the ability of shareholders to sell their shares in the secondary market and have the effect of reducing the level of trading activity in the secondary market. These additional sales practice and disclosure requirements could impede the sale of our securities. In addition, the liquidity for our securities may be adversely affected, with a corresponding decrease in the price of our securities. Our shares are subject to such penny stock rules and our shareholders will, in all likelihood, find it difficult to sell their securities.

 

Holders

 

As of March 31, 2014, based upon records obtained from our transfer agent, there were 262 holders of record of our common stock. Our transfer agent records does not account for other holders of our common stock that are held in street name or by broker dealers as custodian for individual holders of our stock. We have one class of common stock outstanding.

 

Dividends

 

We have not declared any cash dividends on our common stock since our inception and do not anticipate paying such dividends in the foreseeable future. We plan to retain any future earnings for use in our business. Any decisions as to future payment of dividends will depend on our earnings and financial position and such other factors as our Board of Directors deems relevant. There are no restrictions contained in our bylaws or otherwise pertaining to our issuing dividends.

 

Equity Compensation Plans

 

Securities authorized per issuance under Equity Compensation Plans as of December 31, 2013 and 2012 are as follows:

 

Equity Compensation Plan Information

 

   Number of securities
to be issued upon
exercise of outstanding
options, warrants and
rights		   Weighted-average
exercise price of
outstanding options,
warrants and rights		   Number of securities
remaining available
for future issuance
under equity
compensation plans
(excluding securities
reflected in column (a))		 
Plan category  (a)   (b)   (c) 
Equity compensation plans approved by security holders   0    N/A    N/A 
                
Equity compensation plans not approved by security holders   0   $0.10    255,000 
Total   0   $0.10    255,000 

 

 

The figures contained in the above chart are composed of our 2003 and 2007 Employee /Consultant Stock Compensation Plans and two (2) option agreements we have with a corporate entity and our former Chairman of the Board/Executive Chairman, as follows:

 

27
 

 

2003 Plan

 

On December 3, 2003, our Board of Directors approved the Employee/Consultant Stock Compensation Plan (the "2003 Plan"). The purpose of the 2003 Plan is to further our growth by allowing us to compensate employees and consultants who have provided bona fide services to us through the award of our common stock. The maximum number of shares of common stock that may be issued under the 2003 Plan is 2,500,000. As of December 31, 2013 and 2012, we had issued a total of 2,495,000 shares under the 2003 Plan.

 

2007 Plan

 

On June 6, 2007, our Board of Directors approved the 2007 Employee/Consultant Stock Compensation Plan (the "2007 Plan"). The purpose of the 2007 Plan is to further our growth by allowing us to compensate employees and consultants who have provided bona fide services to us through the award of our common stock. The maximum number of shares of common stock that may be issued under the 2007 Plan is 25,000,000. As of December 31, 2013 and 2012, we had issued a total of 24,750,000 shares under the 2007 Plan.

 

Our Board of Directors is responsible for the administration of the 2003 and 2007 Plans and has full authority to grant awards under the Plans. Awards may take the form of stock grants, options or warrants to purchase common stock. The Board of Directors has the authority to determine: (a) the employees and consultants that will receive awards under the Plan, (b) the number of shares, options or warrants to be granted to each employee or consultant, (c) the exercise price, term and vesting periods, if any, in connection with an option grant, and (d) the purchase price and vesting period, if any, in connection with the granting of a warrant to purchase shares of our common stock.

 

Recent Sales of Unregistered Securities

 

With respect to the securities issuances described below, no solicitations were made and no underwriting discounts were given or paid in connection with these transactions. The Company believes that the issuance of these securities as described below were exempt from registration with the Securities and Exchange Commission pursuant to Section 4(2) of the Securities Act of 1933.

Private Placements of Common Stock

 

In January 2014, the Company sold 12,000,000 shares of restricted common stock to an investor at a price per share of $0.005 and received proceeds of $60,000. The Company issued 12,000,000 warrants to purchase common stock at an exercise price of $0.03 per share. The warrants expire on December 31, 2015.

 

In December 2013, the Company sold 10,000,000 shares of restricted common stock to an investor at a price per share of $0.005 and received proceeds of $50,000. The Company issued 10,000,000 warrants to purchase common stock at an exercise price of $0.03 per share. The warrants expire on December 31, 2015.

 

In October and November of 2013, the Company sold an aggregate of 11,000,000 shares of restricted common stock to five investors at a price per share range from $0.002 to $0.015 and received proceeds of $45,000. The Company issued a total of 1,000,000 warrants to purchase common stock at an exercise price of $0.10 per share. The warrants expire on December 31, 2014.

 

In the third quarter of 2013, the Company sold an aggregate of 21,000,000 shares of restricted common stock to two investors at a price per share range from $0.001 to $0.0042 and received proceeds of $45,000.

 

Shares Issued to Employees and Directors

 

On November 22, 2013, the Board of Directors approved a resolution for the issuance of a total of 34,630,000 shares of the Company’s restricted common stock to directors and employees of the Company. The issuance was valued at $484,820 ($0.014 per share), which was the fair value of the Company’s common stock on the date of issuance.

 

On September 3, 2013, the Board of Directors approved a resolution for the issuance of 1,000,000 shares of the Company’s restricted common stock to an employee of the Company. The issuance was valued at $22,900 ($0.0229 per share), which was the fair value of the Company’s common stock on the date of issuance.

 

Common Stock Issued for Services

 

During November, 2013, the Company issued 1,000,000 shares of the Company’s restricted common stock to a consultant for investor relation services for two months. The shares were valued at $17,500 ($0.0175 per share), which was the fair value of the Company’s common stock on the date of issuance.

 

28
 

 

During October, 2013, the Company issued 15,000,000 shares of the Company’s restricted common stock to a consultant for investor relation services for three months. The shares were valued at $267,000 ($0.0178 per share), which was the fair value of the Company’s common stock on the date of issuance.

 

During September, 2013, the Company issued 1,500,000 shares of the Company’s restricted common stock to a consultant for consulting services rendered. The shares were valued at $24,000 ($0.016 per share), which was the fair value of the Company’s common stock on the date of issuance.

 

During September, 2013, the Company issued a total of 1,500,000 shares of the Company’s restricted common stock to two consultants for consulting services rendered. The shares were valued at $34,350 ($0.0229 per share), which was the fair value of the Company’s common stock on the date of issuance.

 

During August, 2013, the Company issued a total of 6,000,000 shares of the Company’s restricted common stock to two consultants for investor relation services for six months. The shares were valued at $103,800 ($0.0173 per share), which was the fair value of the Company’s common stock on the date of issuance.

 

During August, 2013, the Company issued 2,000,000 shares of the Company’s restricted common stock to a consultant for investor relation services for one year. The shares were valued at $24,000 ($0.012 per share), which was the fair value of the Company’s common stock on the date of issuance.

 

During August, 2013, the Company issued 2,000,000 shares of the Company’s restricted common stock to a consultant for consulting services for six months. The shares were valued at $11,200 ($0.0056 per share), which was the fair value of the Company’s common stock on the date of issuance.

 

During July, 2013, the Company issued 2,000,000 shares of the Company’s restricted common stock to a consultant for consulting services for six months. The shares were valued at $8,400 ($0.0042 per share), which was the fair value of the Company’s common stock on the date of issuance.

 

During July, 2013, the Company issued 100,000 shares of the Company’s restricted common stock to a consultant for consulting services rendered. The shares were valued at $420 ($0.0042 per share), which was the fair value of the Company’s common stock on the date of issuance.

 

During July 2013, the Company signed an agreement with a consultant for investor relation services for three months. A $30,000 convertible note convertible at $0.005 per share was also issued (See Note 5). The Company also paid a total of $10,000 cash and issued a total of 15,000,000 shares of company’s restricted common stocks. The shares were valued at $85,500 ($0.0057 per share), which was the fair value of the Company’s common stock on the date of issuance.

 

During June, 2013, the Company issued 2,000,000 shares of the Company’s restricted common stock to a consultant for investor relation services for six months. The shares were valued at $8,400 ($0.0042 per share), which was the fair value of the Company’s common stock on the date of issuance.

 

During May, 2013, the Company issued 1,000,000 shares of the Company’s restricted common stock to a consultant for investor relation services for six months. The shares were valued at $5,300 ($0.0053 per share), which was the fair value of the Company’s common stock on the date of issuance.

 

During February, 2013, the Company issued 8,000,000 shares of the Company’s restricted common stock to a consultant for investor relation services for a year. The shares were valued at $64,000 ($0.0080 per share), which was the fair value of the Company’s common stock on the date of issuance.

 

During February 2013, the Company issued 1,500,000 shares of the Company’s restricted common stock to a consultant for investor relation services for two months. The shares were valued at $10,500 ($0.0070 per share), which was the fair value of the Company’s common stock on the date of issuance.

 

During February 2013, the Company issued a total of 3,000,000 shares of the Company’s restricted common stock to three consultants for marketing services for six months. The shares were valued at $27,000 ($0.009 per share), which was the fair value of the Company’s common stock on the date of issuance.

 

During January, 2013, the Company issued 10,000,000 shares of the Company’s restricted common stock to a consultant for investor relation services for a year. The shares were valued at $50,000 ($0.005 per share), which was the fair value of the Company’s common stock on the date of issuance.

 

29
 

 

Common Stock Issued for Debt Modification

 

On April 30, 2013, the Company amended the maturity dates of two notes of $250,000 each (aggregating $500,000) from two non-related parties to November 3, 2013. The Company issued a total of 4,000,000 restricted shares to the note holders in connection with the amendment at a fair value of $20,800. On October 30, 2013 and January 23, 2014, the parties amended the note of $75,000 and $150,000 to further extend the maturity dates to May 3, 2014 and August 3, 2014. The Company issued a total of 500,000 and 1,250,000 restricted shares to the note holders in connection with the amendment at a fair value of $9,500 and $13,750, respectively (See Note 5).

 

On November 1, 2013, the Company amended the maturity dates of notes $150,000 from a non-related party to August 3, 2014. The Company issued a total of 1,250,000 restricted shares to the note holder per the amendment at a fair value of $13,750.

 

On January 17, 2014, the Company issued a total of 1,000,000 restricted shares to the Michael McDonald Trust due to the default on repayment of the promissory note of $75,000. The shares were value at a fair value of $9,900.

 

Common Stock Issued with Promissory Note

 

In July 2013, in connection with the issuance of this promissory note to Michael McDonald Trust in the amount of $75,000 which is due in six months from the funding of the note, the Company issued 1,000,000 shares of the Company's common stocks with a fair value of $3,977. 

 

Common Stock Held in Escrow

 

On July 27, 2011 the Company issued 5,714,286 shares of free trading common stock in certificate form which is held in escrow as security under an agreement reached with Liquid Packaging Resources, Inc. (“LPR”) on August 2, 2011(See note 3 and 5).

 

Common Stock Issued for Settlement of Accounts Payable & Debt

 

Following the agreements with Coventry Enterprises, LLC (see Note 3) for $80,000, Coventry converted the note for a total of 15,119,481 shares of the company’s restricted stock during the first quarter of 2013 satisfying the notes in full.

 

Following the agreement with Coventry Enterprises, LLC (see Note 5) for $88,500, Coventry converted the note for a total of 31,416,845 shares of the company’s restricted stock during the second quarter of 2013 satisfying the notes in full.

 

Following the agreement with Coventry Enterprises, LLC (see Note 5) for $60,000, Coventry made the conversion for a total of 27,272,727 shares of the company’s restricted stock during the second quarter of 2013 satisfying the notes in full.

 

Following the agreement with Coventry Enterprises, LLC (see Note 5) for $20,000, Coventry made the conversion for a total of 8,810,572 shares of the company’s restricted stock during September 2013 satisfying the notes in full.

 

During June and August, 2013, one of the convertible Notes holders converted a total of 34,254,004 shares of the company’s restricted stock satisfying the notes in the amount of $125,000 with a fair value of $317,391 on the date of conversion (See Note 5).

 

During August and September, 2013, $150,000 of the convertible notes were assigned to third parties in the form bearing interest of 8% annum at with a conversion price for each share of Common Stock equal to 55% of the average of the daily volume weighted average prices of the Common Stock for the 3 trading days with the lowest volume weighted average prices during the 15 to 20 trading days immediately preceding the Conversion Date. Immediately following the assignments, the conversions for a total of 64,052,862 shares of the company’s restricted stock were made in satisfying the notes of $150,000 (See Note 5).

 

On September 16, 2013, one of the non-related party promissory note holders accepted a total of 8,472,750 shares of the Company’s restricted common stock as a repayment to discharge $25,000 of his outstanding loan and accrued interest of $11,120 with the Company (See note 5).

 

On November 25, 2013, one of the non-related party promissory note holders accepted a total of 4,360,000 shares of the Company’s restricted common stock as a repayment to discharge $25,000 of his outstanding loan and accrued interest of $11,956 with the Company (See note 5).

 

During September, 2013, Mr. Harold H. Rumph (ReceptoPharm’s CEO) accepted 14,800,000 shares of the Company’s restricted common stock as a repayment to discharge $37,000 of his accrued salary to the Company (See Note 3).

 

30
 

 

During June and September, 2013, Mr. Deitsch (Our CEO) accepted a total of 50,000,000 shares of the Company’s restricted common stock as a repayment to discharge $162,500 of his outstanding loan to the Company (See note 4).

 

During August and September, 2013, the Company issued 3,000,000 shares of the company’s restricted stock to settle the outstanding accounts payable in aggregate of $38,528 with two vendors. The shares were valued at $0.018 per share (See Note 3).

 

During September, 2013, the Company issued 25,000,000 shares of the company’s restricted stock and 25,000,000 warrants to purchase stock at an exercise price of $0.030 to settle the outstanding accounts payable of $112,621. The shares were valued at $0.015 per share (See Note 3).

 

Following the agreements with Coventry Enterprises, LLC for $70,000 in September 2013, Coventry converted the $60,000 of the note for a total of 15,584,415 shares of the company’s restricted stock during on March 12, 2014. The remaining balance of the note is $10,000.

 

Following the agreements with Coventry Enterprises, LLC for $100,000 in September 2013, Coventry converted the $90,000 of the note for a total of 23,376,623 shares of the company’s restricted stock during on March 12, 2014. The remaining balance of the note is $10,000.

 

Item 6. Selected Financial Data

 

As a Smaller Reporting Company, we are not required to provide information required by Item 6.

 

Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operation

 

Critical Accounting Policies and Estimates

 

In preparing the consolidated financial statements in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP), we have adopted various accounting policies. Our most significant accounting policies are disclosed in Note 1 to the consolidated financial statements.

 

The preparation of the consolidated financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Our estimates and assumptions, including those related to the ability to continue as going concern, legal proceedings, the recoverability of inventory, long-lived assets, the fair value of stock-based compensation and the fair value of warrant liabilities are updated as appropriate, which in most cases is at least quarterly. We base our estimates on historical experience, or various assumptions that are believed to be reasonable under the circumstances and the results form the basis for making judgments about the reported values of assets, liabilities, revenues and expenses. Actual results may materially differ from these estimates.

 

Estimates are considered to be critical if they meet both of the following criteria: (1) the estimate requires assumptions about material matters that are uncertain at the time the accounting estimates are made, and (2) other materially different estimates could have been reasonably made or material changes in the estimates are reasonably likely to occur from period to period. Our critical accounting estimates include the following:

 

Revenue Recognition: In general, we record revenue when persuasive evidence of an arrangement exists, services have been rendered or product delivery has occurred, the sales price to the customer is fixed or determinable, and collectability is reasonably assured. Provision for sales returns will be estimated based on the Company's historical return experience.

 

Accounts Receivable and Allowance for Doubtful Accounts: Our accounts receivable are stated at estimated net realizable value. Accounts receivable are comprised of balances due from customers net of estimated allowances for uncollectible accounts. In determining collectability, historical trends are evaluated and specific customer issues are reviewed to arrive at appropriate allowances.

 

Inventory Obsolescence: Inventories are valued at the lower of average cost or market value. We periodically perform an evaluation of inventory for excess, impairments and obsolete items. At December 31, 2013 our inventory consisted entirely of raw materials that are utilized in the manufacturing of finished goods. These raw materials generally have expiration dates in excess of 10 years.

 

Long-Lived Assets: The carrying value of long-lived assets is reviewed annually and on a regular basis for the existence of facts and circumstances that may suggest impairment. If indicators of impairment are present, we determine whether the sum of the estimated undiscounted future cash flows attributable to the long-lived asset in question is less than its carrying amount. If less, we measure the amount of the impairment based on the amount that the carrying value of the impaired asset exceeds the discounted cash flows expected to result from the use and eventual disposal of the impaired assets.

 

31
 

 

Derivative Financial Instrument: We do not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. Management evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported as charges or credits to income. For option-based simple derivative financial instruments, we use the Black-Scholes option-pricing model to value the derivative instruments at inception and subsequent valuation dates. For complex embedded derivatives, we use a Dilution-Adjusted Black-Scholes method to value the derivative instruments at inception and subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date.

 

Share-Based Compensation: We record share-based compensation in accordance with FASB ASC 718, Stock Compensation. FASB ASC 718 requires that the cost resulting from all share-based transactions are recorded in the financial statements over the respective service periods. It establishes fair value as the measurement objective in accounting for share-based payment arrangements and requires all entities to apply a fair-value-based measurement in accounting for share-based payment transactions with employees. FASB ASC 718 also establishes fair value as the measurement objective for transactions in which an entity acquires goods or services from non-employees in share-based payment transactions.

 

Accomplishments During 2013

 

On January 31, 2013 we relocated to our new corporate headquarters in the Lakeside Professional Village in Coral Springs, Florida. Our offices are comprised of a reception area, conference room, 3 offices, 2 restrooms, a break area and 2 cubicle workstations. These facilities are saving us more than $70,000 in annual costs and are more than adequate for our purposes.

 

On March 28, 2013 we announced that we had received notification that our patent for our pain drug and our trademarks for Nyloxin® had been published in India's Official Journal. The patent, "Use of Cobratoxin as an Analgesic," was published in the Official Journal No.: 09/2013 of the Indian Patent Office (IPO) on March 1, 2013. The Trademarks for Nyloxin™ are registered in India under Class 5, which represents a Pharmaceutical or a dietetic substances adapted for medical use. This allows for patent and brand protection, leading to eventual sales through Indian distributors.

 

In April 2013, we created a portal website for Nyloxin® Distribution to a buyer's club, Freedom 10. The Freedom 10 group is able to buy our products at a discount based on the volume of products sold.

  

On June 10, 2013, we announced a Licensing Agreement for the marketing and distribution of our original product, Cobroxin® with Cobra Pharmaceuticals. The terms of the licensing agreement state that Cobra Pharmaceuticals will be responsible for marketing, distribution, inventory control and customer service of Cobroxin®. They will maintain exclusive rights in perpetuity provided that they maintain minimum quarterly sales that increase over time.

 

On June 18, 2013, we announced that New Vitality, a marketing and distribution company, had begun a test radio campaign to gauge the market acceptance of Nyloxin®. The 60-second ads ran for several weeks on radio stations throughout the United States. As a result of positive testing, New Vitality will be adding Nyloxin to their e-commerce website as they continue to advertize the product.

 

On June 24, 2013, we announced the launch of our new homeopathic formula for the treatment of chronic pain in companion animals, Pet Pain-Away. Pet Pain-Away is a homeopathic, non-narcotic, non-addictive, over-the-counter pain reliever, primarily aimed at treating moderate to severe chronic pain in companion animals. It is specifically indicated to treat pain from hip dysplasia, arthritis pain, joint pain, and general chronic pain in dogs, cats and horses.

 

On August 19, 2013, we provided an update on our efforts to register Nyloxin® with US Governmental agencies. In December 2012, we had announced that we were introducing a stronger version of Nyloxin® to be called Nyloxin® Military Strength. we are registering the Nyloxin® Military Strength as well as Nyloxin® and Nyloxin® Extra Strength with US government agencies that will allow for the eventual sales and distribution of these products into the active military, US military base stores and foreign embassies.

 

On August 22, 2013, we announced that we had begun the process of registering our homeopathic treatment for chronic pain, Nyloxin®, in the country of South Africa. We stated a goal to begin marketing in South Africa by mid-2014.

 

32
 

 

On August 29, 2013, we announced that New Vitality, a marketing and distribution company, had placed and received their first order of the Company's all-natural, non-addictive pain reliever, Nyloxin®. The order was pursuant to New Vitality's successful test radio campaign to gauge the market acceptance of the product.

 

On October 08, 2013, we provided updates on the sales and marketing activities of TCN, a distributor of Nutra Pharma's over-the-counter (OTC) pain reliever, Nyloxin®. We announced the launch of TCNs global marketing and distribution campaign for Nyloxin®. In September 2012, we had announced the beginning of distribution efforts by the TCN group of direct distributors. Since that time, TCN has worked diligently to introduce Nyloxin® to approximately 40,000 distributors in the United States and almost 400,000 distributors globally. In August 2013, TCN re-launched their company as the "True Cash Network" and have subsequently expanded their internet presence. They have been working to overhaul their product offerings and have allowed their distributors personal websites under their www.MyNyloxin.com portal. Additionally, TCN has scheduled marketing efforts in the US that will include internet, radio and television.

 

On Oct 30, 2013, we announced that we were in the process of launching the newest addition to our line of homeopathic treatments for chronic pain, Equine Nyloxin®, a topical therapy for horses that is packaged as a two piece kit: Nyloxin® Topical Gel comprises Step 1 and a solution of DMSO (dimethylsulfoxide) comprises Step 2.

 

On November 11, 2013, we announced that New Vitality, a marketing and distribution company, had begun filming a commercial for Nyloxin®. Photos from the shoot were published to Nutra Pharma's Facebook page. The 2-minute infomercial is expected to run sometime in early 2014.

 

On December 2, 2013, we announced that MyNyloxin, a new Network Marketing company, will have the exclusive rights to market and distribute Nyloxin® in the Network Marketing channel. We continue to market the products through our retail and Direct Response distributors.

 

On December 6, 2013, we announced the launch of the MyNyloxin.com website. The website allows for product sales and information as well as allowing distributors to sign up and view the Network Marketing opportunity.

 

On January 7, 2014, we announced the initial shipment of products and payments of commissions to MyNyloxin Distributors. The Network Marketing opportunity is being aggressively pursued and is expected to grow throughout 2014.

 

Results of Operations

 

Status of Operations

 

Due to our poor cash position, lack of significant sales and inability to obtain financing, we have been unable to fully fund our operations since October 2011, including paying salaries for Nutra Pharma and ReceptoPharm employees. Paul Reid, PhD resigned as ReceptoPharm’s Chief Executive Officer in November 2011. Since that time our Director, Harold Rumph, has filled the role in handling ReceptoPharm's day-to-day operations, which presently are limited to accepting venom samples for validation, maintaining records for quality control, quality assurance and administrative duties consisting of paying ReceptoPharms bills. As noted in previous filings, we have been unable to proceed with ReceptoPharm’s studies since June, 2010; therefore, until we receive adequate financing or increased sales revenue, we have placed our drug development activities on hold and will focus all of our efforts on promoting our products that are already available in the marketplace.

 

33
 

 

We estimate that we will require approximately $600,000 to fund our existing operations and the operations of our subsidiaries ReceptoPharm and Designer Diagnostics over the next twelve months. These costs include: (i) compensation for three (3) full-time employees; (ii) compensation for various consultants who we deem critical to our business; (iii) general office expenses including rent and utilities; (iv) product liability insurance; and (v) outside legal and accounting services. These costs reflected in (i) – (v) do not include research and development costs or other costs associated with clinical studies.

 

We began generating revenues from the sale of Cobroxin® in the fourth quarter of 2009 and from the sale of Nyloxin® and Nyloxin® Extra Strength in January of 2011. Sales have been limited and inconsistent. Our ability to meet our future operating expenses is highly dependent on the amount of such future revenues. Future revenues from the sale of Cobroxin® and Nyloxin® are insufficient to cover our operating expenses and we may need to raise additional equity capital, which could result in substantial dilution to existing shareholders. There can be no assurance that we will be able to raise sufficient equity capital to fund our working capital requirements on terms acceptable to us, or at all. We may also seek additional loans from our officers and directors; however, there can be no assurance that we will be successful in securing such additional loans.

 

Comparison of Years Ended December 31, 2013 and 2012

 

Sales for the year ended December 31, 2013 were $122,198 compared to $203,290 for the comparable period in 2012. All of the sales in 2013 and 2012 were related to product sales. The decrease in sales is primarily attributable to an overall decrease in sales of Nyloxin®. 

 

Cost of sales for the year ended December 31, 2013 and 2012 was $41,165 and $147,647. Cost of sales includes the direct costs associated with manufacturing, shipping and handling costs, and write offs of Venom during 2012. Our gross profit margin for the year ended December 31, 2013 was $81,033 or 66.3% compared to $55,643 or 27.4% for the year ended December 31, 2012. The increase in our profit margin is due primarily to the write offs of venom of $117,800 at December 31, 2012.

 

Selling, general and administrative expenses (“SG&A”) decreased $214,271 or 8.1% from $2,656,742 for the year ended December 31, 2012 to $2,442,471 for the year ended December 31, 2013. Our SG&A expenses include office expenses such as rent and utilities, product liability insurance and outside legal and accounting services, and also include stock based compensation, which decreased $407,482 or 22.6% from $1,799,461 for the year ended December 31, 2012 to $1,391,979 for the year ended December 31, 2013. The decrease of $407,482 in stock based compensation was offset by overall increase of $193,211 in payroll, marketing and promotional expenses, consulting and legal fees.

 

Interest expense increased $3,904 or 2.5%, from $153,472 for the year ended December 31, 2012 to $157,376 for the comparable 2013 period.  This increase was due to an overall increase in short term indebtedness for the year ended December 31, 2013 compared to the year ended December 31, 2012.

 

We carry certain of our debentures and common stock warrants at fair value. For the year ended December 31, 2013 and 2012, the liability related to these hybrid instruments fluctuated, resulting in a loss of $1,135,677 and $400,488, respectively.

 

Loss on settlement of debt and accounts payable increased $231,181 or 50.6%, from $457,292 for the year ended December 31, 2012 to $688,473 for the comparable 2013 period.  This increase was due to an overall increase in settlement of debts and accounts payable through issuance of stocks for the year ended December 31, 2013 compared the year ended December 31, 2012.

 

Our net loss increased by $730,613 or 20.2%, from $3,612,351 for the year ended December 31, 2012 to $4,342,964 for the year ended December 31, 2013.

 

Liquidity and Capital Resources

 

During December 31, 2013 and 2012, respectively, we have negative cash from operations of approximately $0.6 million and $0.7 million. Our lack of cash, significant losses and working capital and stockholders’ deficits raise substantial doubt about our ability to continue as a going concern. For the years ended December 31, 2013 and December 31, 2012, we have experienced significant losses totaling $4,342,964 and $3,612,351, respectively and had an accumulated deficit of $41,986,820 for the period from our inception to December 31, 2013. In addition, we had working capital and stockholders’ deficits at December 31, 2013 of $4,259,938 and $4,219,449, respectively.

 

Our ability to continue as a going concern is contingent upon our ability to secure additional financing, increase ownership equity and attain profitable operations. In addition, our ability to continue as a going concern must be considered in light of the problems, expenses and complications frequently encountered in established markets and the competitive environment in which we operate.

 

34
 

 

As of December 31, 2013, we had $4,640 in cash and as of March 31, 2014, we had approximately $5,179 in cash and we owed approximately $558,740 in vendor payables. We currently do not have sufficient cash to sustain our operations for the next 12 months and will require additional financing or an increase in sales in order to execute our operating plan and continue as a going concern. Our plan is to continue to increase sales of our products and attempt to secure adequate funding to bridge the commercialization of our Cobroxin® and Nyloxin® products. We cannot predict whether additional financing will be in the form of equity, debt, or another form and we may be unable to obtain the necessary additional capital on a timely basis, on acceptable terms, or at all. In the event that these financing sources do not materialize, or that we are unsuccessful in increasing our revenues and profits, we may be unable to implement our current plans for expansion, repay our obligations as they become due or continue as a going concern, any of which circumstances would have a material adverse effect on our business prospects, financial condition and results of operations.

 

Historically, we have relied upon loans from our Chief Executive Officer Rik J Deitsch, to fund costs associated with our operations. These loans are unsecured, accrue interest at a rate of 4.0% per annum and are due on demand. During the year ended December 31, 2013, we borrowed a total of $151,718 from Mr. Deitsch and repaid a total of $216,100 to him including the $162,500 repayment through exchange of the 50 million shares of Company’s stocks.

 

As of December 31, 2013, we raised $285,000 and $75,000 through the issuance of convertible notes and promissory note, respectively. We also raised $140,000 through sales of common stocks.

 

Uncertainties and Trends

 

Our operations and possible revenues are dependent now and in the future upon the following factors:

 

  · Whether we successfully develop and commercialize products from our research and development activities.

 

  · If we fail to compete effectively in the intensely competitive biotechnology area, our operations and market position will be negatively impacted.

 

  · If we fail to successfully execute our planned partnering and out-licensing of products or technologies, our future performance will be adversely affected.

 

  · The recent economic downturn and related credit and financial market crisis may adversely affect our ability to obtain financing, conduct our operations and realize opportunities to successfully bring our technologies to market.

 

  · Biotechnology industry related litigation is substantial and may continue to rise, leading to greater costs and unpredictable litigation.

 

  · If we fail to comply with extensive legal/regulatory requirements affecting the healthcare industry, we will face increased costs, and possibly penalties and business losses.

 

Off-Balance Sheet Arrangements

 

We have not entered into any transaction, agreement or other contractual arrangement with an entity unconsolidated with us under whom we have:

 

  · An obligation under a guarantee contract.

 

  · A retained or contingent interest in assets transferred to the unconsolidated entity or similar arrangement that serves as credit, liquidity or market risk support to such entity for such assets.

 

  · Any obligation, including a contingent obligation, under a contract that would be accounted for as a derivative instrument.

 

  · Any obligation, including a contingent obligation, arising out of a variable interest in an unconsolidated entity that is held by us and material to us where such entity provides financing, liquidity, market risk or credit risk support to, or engages in leasing, hedging or research and development services with us.

 

We do not have any off-balance sheet arrangements or commitments that have a current or future effect on its financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures, or capital resources that is material, other than those which may be disclosed in this Management’s Discussion and Analysis of Financial Condition and the audited Consolidated Financial Statements and related notes.

 

Item 7A. Quantitative and Qualitative Disclosures About Market Risk

 

Not applicable. We have no investments in market risk sensitive instruments or in any other type securities.

 

35
 

 

Item 8. Financial Statements and Supplementary Data

 

The information required by this item begins on page F-1 and is attached hereto and incorporated herein by reference. The index to our annual financial statements as of and for the years ended December 31, 2013 and 2012 can be found under Item 15.

 

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

 

None.

 

Item 9A. Controls and Procedures

 

Section 1.

 

Evaluation of Disclosure Controls and Procedures:

 

As of December 31, 2013, we carried out an evaluation under the supervision and the participation of our Chief Executive Officer/Chief Financial Officer, of the effectiveness of our disclosure controls and procedures as of December 31, 2013, as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934 (“Exchange Act”). Based on that evaluation, our management, including our Chief Executive Officer/Chief Financial Officer, concluded that, because of the material weaknesses in internal control over financial reporting discussed in Management’s Report on Internal Control Over Financial Reporting below, our disclosure controls and procedures were not effective, at a reasonable assurance level, as of December 31, 2013. In light of this, we performed additional post-closing procedures and analyses in order to prepare the Consolidated Financial Statements included in this report. As a result of these procedures, we believe our Consolidated Financial Statements included in this report present fairly, in all material respects, our financial condition, results of operations and cash flows for the periods presented. A control system cannot provide absolute assurance, however, that the objectives of the controls system are met, and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, with the company have been detected.

 

Section 2.

 

Management’s Annual Report on Internal Control over Financial Reporting

 

During its evaluation of the effectiveness of internal control over financial reporting as of December 31, 2013, our management concluded that its material weaknesses in its internal controls over financial reporting include matters pertaining to: (a) lack of qualified accounting personnel; and (b) the need to enhance the supervision, monitoring and reviewing of financial statement preparation processes due to lack of qualified accounting personnel.

 

Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Our internal control over financial reporting is the process designed by and under the supervision of our Chief Executive Officer/Chief Financial Officer, or the persons performing similar functions, to provide reasonable assurance regarding the reliability of our financial reporting and the preparation of our financial statements for external reporting in accordance with accounting principles generally accepted in the United States of America. Management has evaluated the effectiveness of our internal control over financial reporting using the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control over Financial Reporting - Guidance for Smaller Public Companies. Under the supervision and with the participation of our Chief Executive Officer/Chief Financial Officer, our management has assessed the effectiveness of our internal control over financial reporting as of December 31, 2013 and concluded that it is ineffective because of the material weaknesses in our internal control over financial reporting described above.

 

Management’s report was not subject to attestation by the Company’s registered public accounting firm pursuant to temporary rules of the Securities and Exchange Commission that permit the Company to provide only management’s report in this annual report.

 

Changes in Internal Control over Financial Reporting

 

There were no changes in our internal control over financial reporting identified in connection with the evaluation required by paragraph (d) of Rule 13a-15 or 15d-15 under the Exchange Act that occurred during the year ended December 31, 2013 that have materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

Item 9B. Other Information

 

In conjunction with Item 9A above (Evaluation of Internal Controls over Financial Reporting) and following our management’s assessment and conclusion that our internal control over financial reporting as of December 31, 2013 is ineffective, because of the material weaknesses described above, we are actively seeking a new Chief Financial Officer.

 

36
 

 

PART III

 

Item 10. Directors and Executive Officers and Corporate Governance

 

Paul Reid, PhD resigned as ReceptoPharm’s Chief Executive Officer in November 2011. Since that time our Director, Harold Rumph, has filled the role in running ReceptoPharm operations.

 

Directors and Executive Officers

 

Our Board of Directors elects our executive officers annually. Directors are elected to hold office until the next annual meeting. A majority vote of the directors who are in office is required to fill vacancies of our Board of Directors not caused by removal. Each director, including a Director elected to fill a vacancy, will hold office until the expiration of the term for which the Director was elected and until a successor has been elected. Our directors and executive officers are as follows:

 

Listed below are our executive officers and directors as of December 31, 2013

 

Name   Age  

Position with the

Company

   Director Since
             
Rik J. Deitsch   46   Chairman, President and Chief Executive Officer*   2002
             
Stewart Lonky, M.D.   67   Director (1)   2004
             
Harold H. Rumph   83   Director   April 2008
             
Garry R. Pottruck   57   Director (1)   July 2009

 

(1) Dr. Lonky and Garry R. Pottruck are members of our Audit Committee and Compensation Committee.
   
*

Rik Deitsch also served as Chief Financial Officer until the appointment of Bruno Sartori in March 2012. Upon the termination of Mr. Sartori, Mr. Deitsch resumed the role of Chief Financial Officer in September, 2012

 

Rik J. Deitsch has been our President, Chief Executive Officer and a Director since November 7, 2002 and our Chairman of the Board from December 15, 2003 until June 1, 2005 and from April 1, 2006 to present. Mr. Deitsch served as our Chief Financial Officer from November 2002 until March 2012 and from September 2012 to present. From February 1998 through November 2002, Mr. Deitsch served as the President of NDA Consulting Inc., a biotechnology research group that provided consulting services to the pharmaceutical industry. NDA Consulting specializes in the research of peptides derived from Cone Snail venom and Cobra venom. In October 1999, Mr. Deitsch founded Wellness Industries, a private corporation that provides formulations, research and education in the dietary supplement industry. Research conducted by Rik J Deitsch provided some of the beginning fundamentals for the development of drugs being studied for the treatment of cancer and intractable pain. Mr. Deitsch has prepared several papers and posters on rational drug design using computer simulations. Mr. Deitsch received a B.S. in Chemistry and an M.S. in Biochemistry from Florida Atlantic University in June 1997 and December 1999, respectively. Throughout 1999 and 2000, he conducted research for the Duke University Medical School Comprehensive Cancer Center. Mr. Deitsch has served as an adjunct professor and has taught several courses for Florida Atlantic University's College of Business and Continuing Education Department. Mr. Deitsch also teaches physician CME courses internationally, lecturing on lifestyle choices in the prevention and treatment of chronic disease states. He is the co-author of two books: Are You Age-Wise, a book that reviews current research in healthy aging as it relates to lifestyle choices and supplementation and Invisible Killers, a book that outlines our exposure to environmental toxins. Mr. Deitsch has been the Chairman of Waiora's Scientific Advisory Board since April 2004. Waiora develops and markets natural, science-based dietary supplements and personal care products that provide healthy aging solutions.

 

Dr. Stewart Lonky has been our director since November 5, 2004. Dr. Lonky was a co-founder of the Trylon Corporation, a medical device firm located in Torrance, California, and served as its Chief Medical Officer from 1990-2005. Trylon Corporation developed diagnostic products for the early diagnosis of cervical and oral cancer, and in connection with that Dr. Lonky's responsibilities included product development, the direction of clinical research and interacting with regulatory agencies, including the U.S. Food and Drug Administration (FDA). In these roles he has been instrumental in successfully bringing a number of products to the medical marketplace. He has continued to be engaged in both clinical and biochemical research, and has published research articles in the peer-reviewed literature in the areas of cervical cancer and cellular pathophysiology. Since 2005, Dr. Lonky has held a similar position with another device company, Histologics, LLC. Dr. Lonky has been a practicing physician in the Los Angeles Area since 1982. He is Board Certified in Internal Medicine, Pulmonary Medicine, and Critical Care Medicine. Prior to entering practice, Dr. Lonky served as a full-time faculty member at the University of California, San Diego in the Department of Medicine, Pulmonary Division, where he was engaged in research in the biochemistry of lung injury. He was a National Institutes of Health (NIH) Postdoctoral Fellow from 1974-77. He has published over twenty articles and abstracts in the peer-reviewed literature during that time, and authored two book chapters.

 

37
 

 

Harold H. Rumph became our Director on April 10, 2008 when ReceptoPharm became our wholly owned subsidiary. Since November of 2011, Mr. Rumph has acted in the capacity as Interim President of ReceptoPharm. From May 2003 to present, Harold H. Rumph has been the President/Director of ReceptoPharm, Inc., a biotechnology company located in Plantation, Florida. From September 1988 to April 2003, Mr. Rumph was the President/Founder of Project Scheduling Services, Inc., a computerized scheduling services company to the construction industry, located in Pompano Beach, Florida. From 1962 to 1988, Mr. Rumph held managerial, marketing , and other positions with IBM, RCA, Xerox , Harris Corporation and was a founder and President of Biogenix, Inc., a biotechnology company located in Boca Raton, Florida. From 1953 to 1962, Mr. Rumph served on active duty with various responsibilities including Tactical Fighter Pilot and at Headquarters United States Air Force Intelligence with the United States Air Force. In 1953, Mr. Rumph received a Bachelor of Science Degree in Military Science from the United States Naval Academy in Annapolis Maryland.

 

Garry Pottruck became our Director and Chairman of our Audit and Compensation Committees after our December 31, 2008 year-end, in July 2009. Since January 2011, Mr. Pottruck has been employed as a tax principal at the CPA firm of Blum and Blum. From October 2005 until December 2010, he was a principal in the accounting, tax and consulting firm, Argy, Wiltse & Robinson, PC (“Argy”), headquartered in McLean, Virginia. From July 1997 through October 2005, he was managing partner in the certified public accounting firm, Friedberg & Pottruck, PA, located in Deerfield Beach, Florida until Argy acquired the firm. Friedberg & Pottruck specialized in providing accounting, tax and consulting services to physician practices. Mr. Pottruck held financial executive positions with several companies, both public and private, from 1984 through 1994. Prior to 1984, Mr. Pottruck worked for public accounting firms after graduating with a B.S. Degree in Accounting from the C.W. Post School of Professional Accountancy at Long Island University in 1979. He is currently a member of both the Florida and American Institutes of Certified Public Accounting, and is licensed as a Certified Public Accountant in both Missouri and Florida.

 

Section 16(a) Compliance of Officers and Directors

 

As of March 31, 2014, based on our review of Forms 3, 4, 5, and Schedule 13D furnished to us during the last fiscal year, all of our officers and directors filed the required reports.

 

Corporate Governance

 

a. Committees

 

(i) Audit Committee

 

On November 5, 2004, our Board of Directors established an Audit Committee. An audit committee charter was approved by the Board on March 14, 2012. Mr. Pottruck became the Chairman/Member of the Audit Committee as of July 29, 2009. Dr. Lonky also serves on the Audit Committee. During our 2013 Fiscal Year, our Audit Committee met three times in connection with our Fiscal Year audit, at which time the audit committee reviewed the audited financial statements and related notes. In addition, the audit committee met prior to the filing of each of the 2013 quarterly reports to review such reports. The Audit Committee addresses any questions it has to our Board members and officers, and our principal independent accountants.

 

(ii) Compensation Committee

 

On November 5, 2004, our Board of Directors established a Compensation Committee. We do not have a Compensation Committee Charter. Dr. Lonky serves on our Compensation Committee and Mr. Pottruck became our Compensation Committee’s Chairman as of July 29, 2009. During our 2013 fiscal year, our Compensation Committee met three times. Our Compensation Committee reviews all salaries, expenses, stock plans, and other compensation paid to our officers, directors, consultants, and others. Our Compensation Committee has not adopted any specific processes or procedures for considering executive and director compensation.

 

(iii) Nominating Committee

 

We do not have a Nominating Committee or similar committee performing similar functions nor a written Nominating Committee Charter. Our Board of Directors as a whole decides such matters, including those that would be performed by a standing nominating committee. We have not yet adopted a nominating committee because we have not sufficiently developed revenue-generating operations. We do not currently have any specific or minimum criteria for the election of nominees to our Board of Directors nor do we have any process or procedure for evaluating such nominees.

 

b. Shareholder Communications

 

Our Board of Directors does not have any defined policy or procedure requirements for our stockholders to send communications to our Board of Directors, including submission of recommendations for nominating directors. We have not yet adopted a process for our security holders to communicate with our Board of Directors because we have not sufficiently developed our operations and corporate governance structure. We have a toll-free number at (877) 895-5647 available on our website for our shareholders to contact us as well as a dedicated email address at investor.relations@nutrapharma.com.

 

38
 

 

c. Board of Director Meetings

 

We had six Board of Directors meetings during our 2013 Fiscal Year. Our corporate actions that were subject to Board approval were accomplished by Board resolutions. We request that all of our Directors attend our Board of Director meetings; however, we have no formal policy regarding their attendance.

 

d. Annual Shareholder Meetings

 

We held no annual shareholder meeting during 2013.

 

We request that all of our Directors attend our Annual Shareholder Meetings; however, we have no formal policy regarding their attendance.

 

e. Code of Ethics

 

We have a code of ethics that applies to all of our employees including its principal executive officer, principal financial officer and principal accounting officer. A copy of this code is available without charge on our website at www.nutrapharma.com. We intend to disclose any changes in or waivers from our code of ethics by posting such information on our website or by filing a Form 8-K.

 

Item 11.Executive Compensation

 

The following table summarizes compensation information for the last two fiscal years for (i) our Chief Executive Officer and (ii) the four most highly compensated executive officers other than the Chief Executive Officer who were serving as our executive officers at the end of the fiscal year (collectively, the "Named Executive Officers").

 

 

The following executive compensation disclosure reflects all compensation awarded to, earned by or paid to the executive officers below, for the fiscal years ended December 31, 2013 and 2012.

 

SUMMARY COMPENSATION TABLE

 

Name and
principal
Position		  Year  Salary ($)   Bonus ($)   Stock
Awards ($)		   Option
Awards ($)		   Non- Equity
Incentive
Plan
Compensation ($)		   Nonqualified
Deferred
Compensation
Earnings ($)		  All Other
Compensation
($)		   Total
($)		  
                                    
Rik Deitsch  2013   130,000    —    164,640    —    —   —   —   294,640  
                                          
Chief Executive Officer, Chief
Financial Officer, President and Chairman of the Board		  2012   130,000    —    517,200    —    —   —   —   647,200  

 

The following director compensation disclosure reflects all compensation awarded to, earned by or paid to the directors below for the fiscal year ended December 31, 2013.

 

DIRECTOR COMPENSATION

 

   Fees
Earned		           Non-Equity   Nonqualified         
   or Paid
in		   Stock   Option   Incentive
Plan		   Deferred
Compensation		   All Other     
   Cash   Awards   Awards   Compensation   Earnings   Compensation   Total 
Name  ($)(1)   ($)(2)   ($)   ($)   ($)   ($)   ($) 
                             
Rik Deitsch   130,000    164,640    0    0    0    0    294,640 
                                    
Stewart Lonky   0    108,220    0    0    0    0    108,220 
                                    
Garry Pottruck   0    96,460    0    0    0    0    96,460 
                                    
Harold H. Rumph   0    103,600    0    0    0    0    103,600 

 

39
 

   

  (1) Represents salary accrued during 2013

 

  (2) Represents stocks issued for services at a price per share of $0.014 during November 2013.

 

Director Compensation

 

There are no standard arrangements to which directors are compensated for services provided to us. Should we obtain adequate funding or sufficient revenues to justify standard arrangements for director compensation, we will consider whether to adopt such a compensation plan.

 

Stock Option Grants in Last Fiscal Year

 

We did not grant incentive and non-qualified stock options in 2013 to any executive officer or director.

 

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

 

The following tables sets forth, as of December 31, 2013, certain information with respect to the beneficial ownership of our common stock by each stockholder known by us to be the beneficial owner of more than 5% of our common stock and by each of our current directors and executive officers. Each person has sole voting and investment power with respect to the shares of common stock, except as otherwise indicated. Information relating to beneficial ownership of common stock by our principal stockholders and management is based upon information furnished by each person using "beneficial ownership" concepts under the rules of the Securities and Exchange Commission. Under these rules, a person is deemed to be a beneficial owner of a security if that person has or shares voting power, which includes the power to vote or direct the voting of the security, or investment power, which includes the power to vote or direct the voting of the security. The person is also deemed to be a beneficial owner of any security of which that person has a right to acquire beneficial ownership within 60 days.

 

Under the Securities and Exchange Commission rules, more than one person may be deemed to be a beneficial owner of the same securities, and a person may be deemed to be a beneficial owner of securities as to which he or she may not have any pecuniary beneficial interest. We are unaware of any contract or arrangement that could result in a change in control of our company.

 

The following table assumes based on our stock records, that there are 1,004,313,019 shares issued and outstanding as of December 31, 2013

 

Security Ownership of Management and Beneficial Owners

 

Name and Address of
Director or Executive Officer		   Shares of
Common Stock
Beneficially Owned		     Percent of
Common
Stock
Outstanding		  
             
Rik J. Deitsch
Chief Executive Officer/President
12502 W. Atlantic Blvd
Coral Springs, Florida 33071		     141,678,334       14.1 %
                 
Dr. Stewart Lonky
Director
12936 Discovery Creek
Playa Vista, CA 90094		    

20,220,000

       2.0 %
                 
Harold Rumph
Director
1537 NW 65th Ave
Plantation, FL 33313		     35,000,000       3.5 %
                 
Garry Pottruck
Director
10768 NW 18 Court
Coral Springs, Florida 33071		     17,765,000       1.8 %
                 
All executive officers and directors
as a group (4) persons		    

214,713,334

       21.4 %

 

40
 

 

Item 13. Certain Relationships and Related Transactions, and Director Independence

 

Loans by our Chief Executive Officer

 

During the year ended December 31, 2012, we borrowed a total of $164,779 from Mr. Deitsch and repaid a total of $149,478 to him. In addition Mr. Deitsch transferred $175,000 of our debt in a private transaction. The balance owed to our President, Rik Deitsch, at December 31, 2012 was $606,168, which includes accrued interest of $324,853. This demand loan is unsecured and bears interest at a rate of 4.0%.

 

During the year ended December 31, 2013, we borrowed a total of $151,718 from Mr. Deitsch and repaid a total of $216,100 to him including the $162,500 repayment through exchange of the 50 million shares of Company’s stocks. The balance owed to our President, Rik Deitsch, at December 31, 2013 was $566,396, which includes accrued interest of $349,466. This demand loan is unsecured and bears interest at a rate of 4.0%.

 

Subsequent to December 31, 2013 we received additional advances from Mr. Deitsch in the amount of $16,008 and repaid Mr. Deitsch $14,600. The amount owed to Mr. Deitsch as of March 31, 2014 was $594,089, which includes $355,301 of accrued interest.

 

Debt owed to our Directors

 

At December 31, 2013, we owed Garry Pottruck, a Director of Nutra Pharma, $180,000. The note is for principal amount of $200,000 with interest calculated at 10% interest for the first month plus 12% per annum calculated after 30 days from funding. The note was issued in the third quarter of 2010 and was expected to be repaid in six months to a year from the date of the loan.

 

Debt owed to ReceptoPharm’s Former President as of December 31, 2013

 

In addition, at December 31, 2013, we were indebted to Paul Reid, the former President of our wholly owned subsidiary, ReceptoPharm, in the amount of $123,189. This amount includes accrued interest of $43,363. This loan is due on demand and bears interest at a rate of 5% per annum. The loan is secured by certain intellectual property of ReceptoPharm. This Note is included in the settlement of the involuntary action.

 

Director Independence

 

Our common stock is quoted on the OTCQB; that trading medium does not have director independence requirements. Under Item 407(a) of Regulation S-K, we have adopted the definition of independence used by the American Stock Exchange, which may be found in the American Stock Exchange Company guide at (s) 121(A) (2) (2007). This definition states that our Board of Directors must affirmatively determine whether any of our directors have a relationship that would interfere with the exercise of independent judgment in carrying out their responsibilities of a director. Based on this definitional standard, our Board of Directors has determined that none of our Directors are independent.

 

Item 14. Principal Accountant Fees and Services

 

Audit Fees

 

The aggregate fees billed to us for fiscal years ended December 31, 2013 and 2012 by our current auditors, Liggett, Vogt & Webb, P.A., and former auditors, Kingery & Crouse P.A. were approximately $80,985 and $63,636 for professional services rendered for the audit of our annual financial statements and reviews of our interim consolidated financial statements included in quarterly reports and other services related to statutory and regulatory filings or engagements.

 

Audit-Related Fees

Audit-related fees represent review of registration statements or services that are normally provided in connection with statutory and regulatory filings or engagements for those fiscal years, and the aggregate fees billed for assurance and related services that are reasonably related to the performance of the audit or review of our financial statements and are not reported under Audit Fees. No such fees were paid to Liggett, Vogt & Webb, P.A and Kingery & Crouse, P.A. in 2013 or 2012.

 

Tax Fees

 

No such fees were paid to Liggett, Vogt & Webb, P.A and Kingery & Crouse, P.A. in 2013 or 2012.

 

41
 

 

All Other Fees

 

No such fees were paid to Liggett, Vogt& Webb, P.A and Kingery & Crouse, P.A. in in 2013 or 2012.

 

As of December 31, 2013, the Company did not have a formal documented pre-approval policy for the fees of the principal accountant. The Company has an audit committee which reviewed all fees to the principal accountant. The percentage of hours expended on the principal accountant's engagement to audit our financial statements for the most recent fiscal year that were attributed to work performed by persons other than the principal accountant's full-time, permanent employees was 0%.

 

PART IV

 

Item 15. Exhibits and Financial Statement Schedules

 

(a) The following Financial Statements are filed as part of this report under Item 7.

 

Report of Independent Registered Certified Public Accounting Firm F-2
Consolidated Balance Sheets F-3
Consolidated Statements of Operations F-4
Consolidated Statement of Changes in Stockholders' Deficit F-5
Consolidated Statements of Cash Flows F-6
Notes to Consolidated Financial Statements F-7

 

(b) The following exhibits are filed herewith or are incorporated by reference to exhibits previously filed with the SEC:

 

Exhibit Number/Description

 

3.1   Certificate of Incorporation dated February 1, 2000 (incorporated by reference to the Company’s Registration Statement on Form SB-2/A, Registration No. 33-44398, filed on April 6, 2001)
     
3.2   Certificate of Amendment to Articles of Incorporation dated July 5, 2000 (incorporated by reference to the Company’s Registration Statement on Form SB-2/A, Registration No. 33-44398, filed on April 6, 2001)
     
3.3   Certificate of Amendment to Articles of Incorporation dated October 31, 2001 (incorporated by reference to the Company’s Registration Statement on Form SB-2/A, Registration No. 33-44398, filed on April 6, 2001)
     
10.1   Agreement and Plan of Merger dated April 9, 2008 by and among Nutra Pharma Corp., a California corporation (“Nutra Pharma”), NP Acquisition Corporation, a Nevada corporation wholly owned by Nutra Pharma (“Acquisition”), ReceptoPharm, Inc., a Nevada corporation (“Receptopharm”) and the stockholders of Receptopharm (incorporated by reference from Form 8-K filed on April 14, 2008).
     
10.18   Patent Assignment Agreement dated January 24, 2006 between Nanologix, Inc. and Nutra Pharma Corp. (incorporated by reference from Form 10-K for period ending December 31, 2006)
     
10.19   International License Agreement between NanoLogix, Inc. and Nutra Pharma Corp. (incorporated by reference from Form 10-K for period ending December 31, 2006)

 

42
 

 

    20.3 License Agreement between Bio-Therapeutics, Inc. and Nutra Pharma Corp (incorporated by reference from Form 10-KSB for the period ending December 31, 2003)
     
    20.4 Amendment to License Agreement between Bio-Therapeutics, Inc. and Nutra Pharma Corp (incorporated by reference from Form 10-KSB for the period ending December 31, 2003)
     
14.1   Code of Ethics (incorporated by reference from Report on Form 10-K/A filed on May 7, 2004).
     
20.3   License Agreement between Bio-Therapeutics, Inc. and Nutra Pharma Corp (incorporated by reference from Form 10-KSB for the period ending December 31, 2003)
     
20.4   Amendment to License Agreement between Bio-Therapeutics, Inc. and Nutra Pharma Corp (incorporated by reference from Form 10-KSB for the period ending December 31, 2003)

 

 

43
 

  

21.1   Subsidiaries of the Registrant, Nutra Pharma Corp.
     
31.1   Certification of Chief Executive Officer and Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
     
32.1   Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
     
99.1   Form 8-K filed on April 14, 2008 under Item 1.01 regarding acquisition of ReceptoPharm, Inc. as Nutra Pharma Corp.'s wholly owned subsidiary and Exhibit 10.1 (April 10, 2008 Agreement and Plan of Merger) attached thereto (incorporated by reference to this Form 10-K for the period ending December 31, 2008).

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

NUTRA PHARMA CORP.  
   
/s/ Rik J. Deitsch  
Rik J. Deitsch, Chairman, President, Chief  
Executive Officer, Principal Financial  
Officer, and Principal Accounting Officer  

 

Dated: March 31, 2014

 

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities indicated.

 

Signature   Title   Date
         
/s/ Rik J. Deitsch  

Chairman of the Board,

President,

Chief Executive Officer, Principal

Financial Officer,

   March 31, 2014
    Principal Accounting Officer    
         
/s/ Garry R. Pottruck   Director   March 31, 2014
         
/s/ Stewart Lonky   Director   March 31, 2014
         
/s/ Harold H. Rumph   Director   March 31, 2014

 

44
 

Nutra Pharma Corporation

 

Consolidated Financial Statements

 

For the years ended December 31, 2013 and 2012

 

Report of Independent Registered Public Accounting Firm F-2
   
Consolidated Balance Sheets as of December 31, 2013 and 2012 F-3
   
Consolidated Statements of Operations for the Years Ended December 31, 2013 and 2012 F-4
   
Consolidated Statements of Cash Flows for the Years Ended December 31, 2013 and 2012 F-5
   
Consolidated Statements of Changes in Stockholders' Deficit for the Years Ended December 31, 2013 and 2012 F-6
   
Notes to Consolidated Financial Statements F-7

 

F-1
 

 

 

 

 

 

 

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

 

 

To the Board of Directors of:

Nutra Pharma Corp.

 

We have audited the accompanying consolidated balance sheets of Nutra Pharma Corp. (the “Company”) as of December 31, 2013 and 2012, and the related consolidated statements of operations and, changes in stockholders’ deficit and cash flows for the two years then ended. These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits.

 

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

 

In our opinion, the consolidated financial statements referred to above present fairly in all material respects, the financial position of Nutra Pharma Corp. as of December 31, 2013 and 2012 and the results of its operations and its cash flows for the two years then ended, in conformity with accounting principles generally accepted in the United States of America.

 

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the consolidated financial statements, the Company has experienced recurring, significant losses from operations, and has an accumulated deficit of $41,986,820 at December 31, 2013. In addition, the Company had respective working capital and stockholders’ deficits at December 31, 2013 of $4,259,938 and $4,219,449, respectively. These factors raise substantial doubt about the Company's ability to continue as a going concern. Management's plans concerning these matters are also described in Note 1. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

Liggett, Vogt & Webb, P.A.

 

LIGGETT, VOGT & WEBB, P.A.

Certified Public Accountants

 

Boynton Beach, Florida

March 31, 2014

 

 

F-2
 

NUTRA PHARMA CORP.

Consolidated Balance Sheets

 

   December 31,   December 31, 
   2013   2012 
         
ASSETS        
Current assets:        
  Cash  $4,640   $7,559 
   Accounts receivable   11,141    38,314 
Inventory   5,000    - 
   Prepaid expenses and other current assets   68,091    200,868 
       Total current assets   88,872    246,741 
           
Property and equipment, net   24,534    39,515 
Other assets   15,955    16,621 
       Total assets  $129,361   $302,877 
           
LIABILITIES AND STOCKHOLDERS' DEFICIT          
Current liabilities:          
  Accounts payable  $1,019,130   $800,860 
  Accrued expenses   957,682    964,673 
  Due to officers   689,588    723,386 
  Derivative warrant liability   323,172    18,727 
  Other debt   1,359,238    1,371,574 
      Total current liabilities   4,348,810    3,879,220 
           
Commitments and Contingencies (See Note 9)   -    - 
           
Stockholders' deficit:          
Common stock, $0.001 par value, 2,000,000,000 shares authorized;          
1,004,313,019 and 561,773,778 shares issued and outstanding at December 31, 2013 and 2012   1,003,062    561,774 
Additional paid-in capital   36,764,309    33,505,739 
Accumulated deficit   (41,986,820)   (37,643,856)
Total stockholders' deficit   (4,219,449)   (3,576,343)
Total liabilities and stockholders' deficit  $129,361   $302,877 

  

See the accompanying notes to the consolidated financial statements.

 

F-3
 

 

NUTRA PHARMA CORP.

Consolidated Statements of Operations

 

   For the years Ended December 31, 
   2013   2012 
Net sales  $122,198   $203,290 
Cost of sales   41,165    147,647 
Gross profit   81,033    55,643 
           
Operating expenses:          
Selling, general and administrative - including stock based compensation of $1,391,979 and $1,799,461, respectively   2,442,471    2,656,742 
Total other costs and expenses   2,442,471    2,656,742 
Net Loss from Operations   (2,361,438)   (2,601,099)
           
Other Expenses          
Interest expense   (157,376)   (153,472)
Change in fair value of derivatives   (1,135,677)   (400,488)
Loss on settlement of debt and accounts payable, net   (707,651)   (457,292)
Other Income   19,178    - 
    (1,981,526)   (1,011,252)
Net loss before income taxes   (4,342,964)   (3,612,351)
Provision for income taxes   -    - 
Net loss  $(4,342,964)  $(3,612,351)
           
Net loss per share - basic and diluted  $(0.01)  $(0.01)
           
Weighted average number of shares outstanding during the period - basic and diluted   743,492,967    402,996,638 

 

See the accompanying notes to the consolidated financial statements.

 

F-4
 

 

NUTRA PHARMA CORP.

Consolidated Statements of Cash Flows

 

   For the Years Ended December 31, 
   2013   2012 
         
Cash flows from operating activities:          
Net loss  $(4,342,964)  $(3,612,351)
Adjustments to reconcile net loss to net cash used in operating activities:          
Loss on settlement of accounts payable   707,650    357,292 
Loss on note payable default   -    100,000 
Depreciation and amortization   14,981    14,994 
Stock-based compensation   1,391,979    1,594,300 
Stock issued for loan extension   30,300    100,000 
Change in fair value of derivative   1,135,677    400,488 
In-kind contribution of interest   1,159    33,055 
Amortization of loan discount   3,977    - 
Changes in operating assets and liabilities:          
Decrease (increase) in accounts receivables   27,173    (38,314)
Decrease (increase) in inventory   (5,000)   117,800 
Decrease (increase) in prepaid expenses and other assets   (9,446)   28,678 
Increase in accounts payable   429,808    169,216 
Increase in accrued expenses   83,669    13,600 
Net cash used in operating activities   (531,037)   (721,242)
           
Cash flows from investing activities:   -    - 
           
Cash flows from financing activities:          
Common stock sold for cash   140,000    446,500 
Proceeds from payment of subscription receivable   -    8,000 
Loans from officers   181,718    164,779 
Repayment of officers loans   (83,600)   (49,478)
Proceeds from convertible notes   225,000    115,000 
Proceeds from other notes payable   75,000    79,000 
Repayments of other notes payable   -    (35,000)
Repayments of notes payable-related party   (10,000)   - 
Net cash provided by financing activities   528,118    728,801 
           
Net (decrease) increase in cash   (2,919)   7,559 
           
Cash - beginning of period   7,559    - 
           
Cash - end of period  $4,640   $7,559 
           
           
Supplemental Cash Flow Information:          
Cash paid for interest  $70,130   $77,314 
Cash paid for income taxes  $-   $- 
Non cash Financing and Investing:          
Note issued in settlement of notes and accounts payable  $709,146   $436,639 
Shares issued to satisfy debt  $1,646,832   $1,346,792 
Shares issued to satisfy debt-related party  $162,500   $254,700 

 

See the accompanying notes to the consolidated financial statements.

 

F-5
 

 

NUTRA PHARMA CORP.

Consolidated Statements of Changes in Stockholders' Deficit

For the years ended December 31, 2013 and 2012

 

           Additional       Total 
   Common Stock   Paid-in   Accumulated   Shareholder's 
   Shares   Amount   Capital   Deficit   Deficit 
    -    -    -    -    - 
Balance - December 31, 2011   326,337,959   $326,337   $29,793,723   $(34,031,505)  $(3,911,445)
Issuance of common stock in exchange for services to consultants   63,300,000    63,300    907,381         970,681 
Issuance of common stock in exchange for services to directors and employees   42,595,000    42,595    786,185         828,780 
Common stock issued in private placement   43,450,000    43,450    391,050         434,500 
Common stock issued in exchange for related party debt   17,000,000    17,000    237,700         254,700 
Common stock issued for modification of debt   4,000,000    4,000    96,000         100,000 
Common stock issued for conversion of debt   63,890,819    63,892    1,282,900         1,346,792 
Common stock issuable for private placement (1,200,000 shares)   1,200,000    1,200    10,800         12,000 
   Net loss                  (3,612,351)   (3,612,351)
Balance -December 31, 2012   561,773,778   $561,774   $33,505,739   $(37,643,856)  $(3,576,343)
                          
Issuance of common stock in exchange for services to consultants   71,600,000    71,600    669,770         741,370 
Issuance of common stock in exchange for services to directors and employees   35,630,000    35,630    472,090         507,720 
Common stock issued in private placement   42,000,000    42,000    98,000         140,000 
Common stock issued in exchange for related party debt   50,000,000    50,000    112,500         162,500 
Common stock issued for modification of debt   5,750,000    4,500    25,800         30,300 
Common stock issued for conversion of debt   193,759,241    193,758    1,453,074         1,646,832 
Common stock issued for settlement of AP   42,800,000    42,800    423,200         466,000 
Common stock issued to note holder, net of discount   1,000,000    1,000    2,977         3,977 
In-kind contribution of interest             1,159         1,159 
   Net loss                  (4,342,964)   (4,342,964)
Balance -December 31, 2013   1,004,313,019   $1,003,062   $36,764,309   $(41,986,820)  $(4,219,449)

  

See the accompanying notes to the consolidated financial statements.

 

F-6
 

 

NUTRA PHARMA CORP.

Notes to Consolidated Financial Statements

December 31, 2013 and 2012

 

1. BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Organization

 

Nutra Pharma Corp. ("Nutra Pharma"), is a holding company that owns intellectual property and operates in the biotechnology industry. Nutra Pharma incorporated under the laws of the state of California on February 1, 2000, under the original name of Exotic-Bird.com.

 

Through its wholly-owned subsidiary, ReceptoPharm, Inc. (“ReceptoPharm”), Nutra Pharma conducts drug discovery research and development activities. In October 2009, Nutra Pharma launched its first consumer product called Cobroxin®, an over-the-counter pain reliever designed to treat moderate to severe chronic pain. In May 2010, Nutra Pharma launched its second consumer product called Nyloxin®, an over-the-counter pain reliever that is a stronger version of Cobroxin® and is designed to treat severe chronic pain.

 

Basis of Presentation and Consolidation

 

The accompanying consolidated financial statements include the results of Nutra Pharma and its wholly-owned subsidiaries Designer Diagnostics Inc. and ReceptoPharm (collectively "the Company", “us”, “we” or “our”). We operate as one reportable segment. All intercompany transactions and balances have been eliminated in consolidation.

 

Liquidity and Going Concern

 

Our Consolidated financial statements are presented on a going concern basis, which contemplate the realization of assets and satisfaction of liabilities in the normal course of business. We have experienced recurring, significant losses from operations, and have an accumulated deficit of $41,986,820 at December 31, 2013. In addition, we had respective working capital and stockholders’ deficits at December 31, 2013 of $4,259,938 and $4,219,449 respectively.

 

There is substantial doubt regarding our ability to continue as a going concern which is contingent upon our ability to secure additional financing, increase ownership equity and attain profitable operations. In addition, our ability to continue as a going concern must be considered in light of the problems, expenses and complications frequently encountered in established markets and the competitive environment in which we operate.

 

As of December 31, 2013, we do not have sufficient cash to sustain our operations for the next year and will require additional financing in order to execute our operating plan and continue as a going concern. Since our sales are not currently adequate to fund our operations, we continue to rely principally on debt and equity funding; however proceeds from such funding have not been sufficient to execute our business plan. Our plan is to attempt to secure adequate funding until sales of our pain products are adequate to fund our operations. We cannot predict whether additional financing will be available, and/or whether any such funding will be in the form of equity, debt, or another form. In the event that these financing sources do not materialize, or if we are unsuccessful in increasing our revenues and profits, we will be unable to implement our current plans for expansion, repay our obligations as they become due and continue as a going concern.

 

The accompanying Consolidated Financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern.

 

F-7
 

 

Use of Estimates

 

The accompanying Consolidated Financial statements are prepared in accordance with accounting principles generally accepted in the United States of America which require management to make estimates and assumptions. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expense. Significant estimates include our ability to continue as going concern, the recoverability of inventories and long-lived assets, and the valuation of stock-based compensation and certain debt and warrant liabilities. Actual results could differ from those estimates. Changes in facts and circumstances may result in revised estimates, which would be recorded in the period in which they become known.

 

Revenue Recognition

 

In general, we record revenue when persuasive evidence of an arrangement exists, services have been rendered or product delivery has occurred, the sales price to the customer is fixed or determinable, and collectability is reasonably assured. Provision for sales returns is estimated based on our historical return experience. Revenue is presented net of returns and allowances for returns.

 

Accounting for Shipping and Handling Costs

 

The Company records shipping and handling costs incurred in cost of sales.

 

Cash and Cash Equivalents

 

We consider all highly liquid investments with an original maturity of three months or less to be cash equivalents.

 

Accounts Receivable and Allowance for Doubtful Accounts

 

The Company grants credit without collateral to its customers based on the Company’s evaluation of a particular customer’s credit worthiness. In addition, allowances for doubtful accounts are maintained for potential credit losses based on the age of the accounts receivable and the results of the Company’s periodic credit evaluations of its customers’ financial condition. Accounts receivable are written off after collection efforts have been deemed to be unsuccessful. Accounts written off as uncollectible are deducted from the allowance for doubtful accounts, while subsequent recoveries are netted against the provision for doubtful accounts expense. The Company generally does not charge interest on accounts receivable.

 

Accounts receivable are stated at estimated net realizable value. Accounts receivable are comprised of balances due from customers net of estimated allowances for uncollectible accounts.

 

Inventories

 

Inventories, which are stated at the lower of average cost or market, and consist mostly of raw venom that is utilized to make the API (active pharmaceutical ingredient). The raw unprocessed venom has an indefinite life for use. The Company regularly reviews inventory quantities on hand. If necessary it records a provision for excess and obsolete inventory based primarily on its estimates of component obsolescence, product demand and production requirements. Write-downs are charged to cost of goods sold. We performed evaluations of our inventory during the year ended December 31, 2013 and 2012 and recorded total allowances of $0 and $117,800, respectively.

 

Financial Instruments and Concentration of Credit Risk

 

Our financial instruments include cash, accounts receivable, accounts payable, accrued expenses, loans payable, due to officers and derivative financial instruments. Other than certain warrant and convertible instruments (derivative financial instruments) and liabilities to related parties (for which it was impracticable to estimate fair value due to uncertainty as to when they will be satisfied and a lack of similar type transactions in the marketplace), we believe the carrying values of our financial instruments approximate their fair values because they are short term in nature or payable on demand. Our derivative financial instruments are carried at a measured fair value.

 

Balances in various cash accounts may at times exceed federally insured limits. We have not experienced any losses in such accounts. We do not hold or issue financial instruments for trading purposes. In addition, for the year ended December 31, 2013, there were two customers that accounted for 19.6% and 15.3% of the total revenues, respectively. For the year ended December 31, 2012, no customers accounted for more than 10% of the Company’s total revenues. During 2013, the Company purchased 100% of its venom from one vendor.

 

F-8
 

 

Derivative Financial Instruments

 

The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. Management evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported as charges or credits to income. For option-based simple derivative financial instruments, the Company uses the Black-Scholes option-pricing model to value the derivative instruments at inception and subsequent valuation dates. For complex embedded derivatives, the Company uses a Dilution-Adjusted Black-Scholes method to value the derivative instruments at inception and subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date.

 

Property and Equipment and Long-Lived Assets

 

Property and equipment is recorded at cost. Expenditures for major improvements and additions are added to property and equipment, while replacements, maintenance and repairs which do not extend the useful lives are expensed. Depreciation is computed using the straight-line method over the estimated useful lives of the assets of 3 – 7 years.

 

Property and equipment consists of the following at December 31,

 

   2013   2012 
         
Computer equipment  $21,918   $21,918 
Furniture and fixtures   34,757    34,757 
Lab equipment   42,129    42,129 
Telephone equipment   12,421    12,421 
Office equipment – other   2,629    2,629 
Leasehold improvements   67,417    67,417 
Total   181,271    181,271 
Less: Accumulated depreciation and amortization   (156,737)   (141,756)
           
Property and equipment, net  $24,534   $39,515 

 

We review our long-lived assets for recoverability if events or changes in circumstances indicate the assets may be impaired. At December 31, 2013, we believe the carrying values of our long-lived assets are recoverable. Depreciation expense for the years ended December 31, 2013 and 2012 was $14,981 and $14,994, respectively.

 

Advertising

 

All advertising costs are expensed as incurred. Advertising costs were approximately $900 and $70,800 for the years ended December 31, 2013 and 2012, respectively.

 

Income Taxes

 

We compute income taxes in accordance with Financial Accounting Standard Board (“FASB”) Accounting Standard Codification (“ASC”) Topic 740, Income Taxes (“ASC Topic 740”). Under ASC Topic 740, deferred taxes are recognized for the tax consequences of temporary differences by applying enacted statutory rates applicable to future years to differences between the financial statement carrying amounts and the tax bases of existing assets and liabilities. Also, the effect on deferred taxes of a change in tax rates is recognized in income in the period that included the enactment date. Temporary differences between financial and tax reporting arise primarily from the use of different methods to record bad debts and /or sales returns, and inventory reserves.

 

F-9
 

 

On an annual basis, we evaluate tax positions that have been taken or are expected to be taken in our tax returns to determine if they are more than likely to be sustained if the taxing authority examines the respective position. As of December 31, 2013 and 2012, we do not believe we have a need to record any liabilities for uncertain tax positions or provisions for interest or penalties related to such positions.

 

Since inception, we have been subject to tax by both federal and state taxing authorities. Until the respective statutes of limitations expire (which may be as much as 20 years while we have unused net operation losses), we are subject to income tax audits in the jurisdictions in which we operate.

 

Stock-Based Compensation

 

We account for stock-based compensation in accordance with FASB ASC Topic 718, Stock Compensation (ASC Topic 718). ASC Topic 718, which requires that the cost resulting from all share-based transactions be recorded in the financial statements over the respective service periods. It establishes fair value as the measurement objective in accounting for share-based payment arrangements and requires all entities to apply a fair-value-based measurement in accounting for share-based payment transactions with employees. The statement also establishes fair value as the measurement objective for transactions in which an entity acquires goods or services from non-employees in share-based payment transactions.

 

Net Loss Per Share

 

Net loss per share is calculated in accordance with ASC Topic 260, Earnings per Share. Basic loss per share is calculated by dividing net loss by the weighted average number of common shares outstanding for the period. Diluted loss per share is calculated by dividing net loss by the weighted average number of common shares and dilutive common stock equivalents outstanding. During periods in which we incur losses, common stock equivalents, if any, are not considered, as their effect would be anti-dilutive or have no effect on earnings per share. Any common shares issued as of a result of the exercise of stock options and warrants would come from newly issued common shares from our remaining authorized shares. As of December 31, 2013 and 2012, the following items were not included in dilutive loss as the effect is anti-dilutive:

 

   2013   2012 
Options and warrants   154,916,667    57,256,667 
Convertible notes payable   98,506,398    44,642,858 
Total   253,423,065    101,899,525 

 

Reclassifications

 

Certain amounts in the 2012 Consolidated Financial statements have been reclassified to conform to the current period presentation.

 

Recent Accounting Pronouncements

 

We have determined that all recently issued but not yet effective accounting standards will not have a material impact on our Consolidated Financial statements.

 

2. FAIR VALUE MEASUREMENTS

 

Certain assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2013 are measured in accordance with FASB ASC Topic 820-10-05, Fair Value Measurements. FASB ASC Topic 820-10-05 defines fair value, establishes a framework for measuring fair value and expands the disclosure requirements regarding fair value measurements for financial assets and liabilities as well as for non-financial assets and liabilities that are recognized or disclosed at fair value on a recurring basis in the financial statements.

 

The statement requires fair value measurement be classified and disclosed in one of the following three categories:

 

Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

 

Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and

 

F-10
 

 

Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).

 

The following table summarizes our financial instruments measured at fair value as of December 31, 2013 and 2012:

 

   Fair Value Measurements at December 31, 2013 
Liabilities:  Total   Level 1   Level 2   Level 3 
                 
Warrant liability  $323,172   $-   $-   $323,172 
Convertible notes at fair value  $767,056   $-   $-   $767,056 

 

   Fair Value Measurements at December 31, 2012 
Liabilities:  Total   Level 1   Level 2   Level 3 
                 
Warrant liability  $18,727   $-   $-   $18,727 
Convertible notes at fair value  $588,091   $-   $-   $588,091 

 

The following table shows the changes in fair value measurements using significant unobservable inputs (Level 3) during the years ended December 31, 2013 and 2012:

 

Description  2013   2012 
         
Beginning balance  $18,727   $28,833 
Purchases, issuances, and settlements   243,147    - 
Day one loss on value of hybrid instrument   729,093    - 
Total gain included in earnings (1)   (667,795)   (10,106)
           
Ending balance  $323,172   $18,727 

 

(1) The gain or loss related to the revaluation of our warrant liability is included in “Change in fair value of derivatives” in the accompanying consolidated statement of operations.

 

The Company values its warrants using a Dilution-Adjusted Black-Scholes Model. Assumptions used include (1) 0.13% to 1.75% risk-free rate, (2) warrant life is the remaining contractual life of the warrants, (3) expected volatility of 124% to 236% (4) zero expected dividends (5) exercise price set forth in the agreements (6) common stock price of the underlying share on the valuation date, and (7) number of shares to be issued if the instrument is converted (See note 5).

 

The following table summarizes the significant terms of each of the debentures for which the entire hybrid instrument is recorded at fair value as of December 31, 2013 and 2012:

 

F-11
 

 

             Conversion Price -
Lower of Fixed Price
or Percentage of
VWAP for Look-back
Period		   
Debenture
Issuance		  Face      Default
Interest		  Anti-
Dilution
Adjusted		      Look-back
Year  Amount   Interest Rate  Rate  Price  %   Period
2013   564,376   8%-20%  n/a  $0.0036-$0.0064   50%-85%   10 to 30 Days
2012   902,369   6%-12%  n/a  $0.0070-$0.0137   15%-70%   5 to 20 Days

 

The following table shows the changes in fair value measurements using significant unobservable inputs (Level 3) during the years ended December 31, 2013 and 2012 for the Convertible Notes:

 

   Years Ended December 31, 
   2013   2012 
Description          
Beginning balance  $588,091   $206,863 
Purchases, issuances, and settlements   751,419    902,369 
Day one loss on value of hybrid instrument   1,656,802    479,422 
(Gain) loss from change in fair value   (582,423)   309,680 
Conversion to common stock   (1,646,832)   (1,310,243)
Ending balance  $767,057   $588,091 

 

3. SETTLEMENT OF ACCOUNTS AND NOTE PAYABLE

 

At January 2, 2012, the Company owed Bank of America approximately $80,000 representing the balance of a credit line originated on September 28, 2006. Bank of America assigned and sold this debt to Great Plains Capital Corporation (“Great Plains”). On February 3, 2012, Great Plains assigned the debt to Redwood Management, LLC (“Redwood”). At February 3, 2012, the Company owed Post Graduate Healthcare Education, LLC (“Post Graduate”) $109,500 representing the balance of a total debt of $149,500. Post Graduate assigned the debt to Redwood Management, LLC. The total amount of the Company’s debt assigned to Redwood was $188,608. Under a Securities Settlement Agreement, the Company issued a Convertible Debenture to Redwood for $188,608 payable within six months with interest at 6% annum. The full amount of principal and interest was due at maturity unless the Debenture was converted to shares of common stock in accordance with the debenture agreement, whereby such debenture could be converted into shares of our common stock at a price equal to 75% of the lowest closing price (determined on the then current trading market for our common stock) during the 15 trading days prior to conversion. Following the agreement Redwood accepted 18,737,894 shares of our restricted stock as satisfaction for the note and we recorded a loss of $42,958 on the settlement.

 

F-12
 

 

At March 22, 2012, the Company owed Alera Technologies, Inc. (“Alera”) $65,040 representing the balance of a purchase order for the production of Nyloxin™ products. Alera assigned the rights to the debt to Coventry Enterprises, LLC (“Coventry”). The Company issued a Convertible Redeemable Note in favor of Coventry in the amount of $65,040 bearing interest of 8% annum. Coventry was entitled to convert all or any amount of the this note into shares of the Company's common stock (the "Common Stock") at a conversion price ("Conversion Price") for each share of Common Stock equal to 55% of the average of the daily volume weighted average prices of the Common Stock for the 3 trading days with the lowest volume weighted average prices during the 20 trading days immediately preceding the Conversion Date. The note was satisfied on April 5, 2012 in exchange for 8,672,090 shares of restricted Common Stock.

 

At December 20, 2012, the Company owed Immunoclin, Ltd. (“Immunoclin”) $80,389 representing the balance of invoices for clinical services. The Company issued an $80,000 note payable at 8% to Immunoclin in exchange for the outstanding accounts payable. $20,000, $40,000 and $20,000 of the debt were assigned to Coventry Enterprises, LLC (“Coventry”) on December 20, 2012, January 7, 2013, and March 13, 2013, respectively. Coventry made the first conversion of 2,565,102 shares of Company’s common stock to satisfy the debt of $20,000 on December 20, 2012. The Company issued two Convertible Redeemable Notes for the remaining amount of $40,000 and $20,000 on January 7, 2013, and March 13, 2013. Coventry made the conversion of a total of 15,119,481 shares of the company’s restricted stock satisfying the remaining notes in full during the year ended December 31, 2013. The Company elected to account for these hybrid contracts under the guidance of FASB ASC Topic 815 Derivatives & Hedging. The fair value has been defined as the common stock equivalent value, enhanced by the fair value of the default put plus the present value of the coupon. The Company recorded a loss of $65,039 on the settlement and the change in fair value of derivatives in the amount of $4,885 during the year ended December 31, 2013.

 

During August and September, 2013, the Company issued 3,000,000 shares of the company’s restricted stock to settle the outstanding accounts payable in aggregate of $38,528 with two vendors. The shares were valued at $0.018 per share. The Company recorded a total loss of $15,472 on the settlement date (See Note 6).

 

During September, 2013, the Company issued 25,000,000 shares of the company’s restricted stock and 25,000,000 warrants to purchase stock at an exercise price of $0.030 to settle the outstanding accounts payable of $112,621 with one vendor. The shares were valued at $0.015 per share (See Note 6). The Company classified embedded conversion features in the warrants as a derivative liability. The warrants were valued at their fair value of $243,146 and $63,297, respectively using the Black-Scholes method at the commitment and re-measurement dates of September 16, 2013 and December 31, 2013, respectively. The Company recorded a loss of $505,525 on the settlement date (See Note 7).

 

During September, 2013, Mr. Harold H. Rumph (ReceptoPharm’s CEO) accepted 14,800,000 shares of the Company’s restricted common stock as a repayment to discharge $37,000 of his accrued salary to the Company (See Note 6).

 

4. DUE TO OFFICERS

 

At December 31, 2013 and December 31, 2012, the balance due to officers consisted of the following:

 

   December 31,
2013		   December 31,
2012		 
         
An unsecured demand loan from our President and CEO, Rik Deitsch. The loan bears interest at 4%. The loan balance at December 31, 2013 and 2012, respectively, includes accrued interest payable of $349,466 and $324,853.  $566,399   $606,168 
           
A loan from Paul Reid, the former President of ReceptoPharm bearing interest at a rate of 5% per annum, due on demand and secured by certain intellectual property of ReceptoPharm having a zero cost at December 31, 2013 and December 31, 2012. The accrued interest at December 31, 2013 and December 31, 2012 was $43,363 and $37,392, respectively.   123,189    117,218 
           
Ending balances  $689,588   $723,386 

 

During the year ended December 31, 2013, we borrowed $151,718 and repaid $53,600 to Mr. Deitsch. In addition, Mr. Deitsch accepted a total of 50,000,000 shares of the Company’s restricted common stock as a repayment to discharge $162,500 of his outstanding loan to the Company in year ended December 31, 2013(See note 6).

 

F-13
 

 

During June, 2013, 25,000,000 warrants to purchase stock at an exercise price of $0.10 per share were issued to CEO, Mr. Deitsch in exchange of notes payable. The warrants expire on December 31, 2014 (See note 7).

 

During the year ended December 31, 2012, we borrowed $164,779 and repaid $324,478 to Mr. Deitsch. Included in this amount, Mr. Deitsch assigned $175,000 of the debt to a third party on January 2, 2012 and accepted a total of 10,000,000 shares of the Company’s restricted common stock as a repayment to discharge $100,000 of his outstanding loan the Company in December 2012(See note 6).

 

5. OTHER DEBT

 

Other debt (all short-term) consists of the following at December 31, 2013 and 2012:

 

   2013   2012 
         
Note payable – Related Party   (1)  $180,000   $190,000 
Notes payable – Non Related Parties  (2)   412,182    593,483 
Convertible notes payable, at fair value (3)   767,056    588,091 
           
Ending balances  $1,359,238   $1,371,574 

 

(1)During the third quarter of 2010 we borrowed $200,000 from one of our directors. We repaid $10,000 each (total $20,000) during the third quarter of 2012 and 2013. Under the terms of the loan agreement, this loan was expected to be repaid in nine months to a year from the date of the loan along with interest calculated at 10% for the first month plus 12% after 30 days from funding. We are in default regarding this loan. At December 31, 2013 and 2012, we owed this director accrued interest of $121,137 and $86,387, respectively.

 

(2)At December 31, 2013 and 2012, the balance of $412,182 and $593,483 , respectively, consisted of the following loans:

 

·In May 2011, the Company received a loan for $25,000 from a non-related party. This loan was expected to be repaid no later than December 31, 2011, along with interest calculated at 10% for the first month plus 12% after 30 days from funding. This loan is guaranteed by an officer of the Company. On November 25, 2013, the non-related party accepted a total of 4,360,000 shares of the Company’s restricted common stock as a repayment to discharge $25,000 of his outstanding loan and accrued interest of $11,956 (See note 6).  The Company recorded a loss of $28,444 on the settlement date.

 

·In May 2011, the Company received another loan for $25,000 from a non-related party. This loan was expected to be repaid no later than December 31, 2011, along with interest calculated at 10% for the first month plus 12% after 30 days from funding. This loan is guaranteed by an officer of the Company. On September 16, 2013, the non-related party accepted a total of 8,472,750 shares of the Company’s restricted common stock as a repayment to discharge $25,000 of his outstanding loan and accrued interest of $11,120 (See note 6). The Company recorded a loss of $90,971 on the settlement date.

 

F-14
 

 

·In July 2013, the Company issued a promissory note to the Michael McDonald Trust in the amount of $75,000 bearing interest at a rate of 2% per month. The note is due in six months from the execution and funding of the note. In connection with the issuance of this promissory note, the Company issued 1,000,000 shares of the Company's common stocks (See note 6). The Company has recorded a debt discount in the amount of $3,977 to reflect the value of the common stocks as a reduction to the carrying amount of the convertible debt and a corresponding increase to common stocks and additional paid-in capital. The total discount of $3,977 was fully amortized over the term of the debt during the year ended December 31, 2013.   In the event of default, the Company would issue an additional 1,000,000 share of the Company’s common stocks on the date that is fifteen days after the maturity date (See Note 6). We are in default regarding this loan. The additional 1,000,000 shares were issued in January 2014 with a fair value at $9,900 (See Note 10). At December 31, 2013, we owed Michael McDonald accrued interest of $9,000.

 

·At December 31, 2012, the total amount of the Company’s debt assigned to Southridge was $483,482. In connection with the debt sales to Southridge, the Company recorded a loss on settlement of accounts payable for $63,490 in the statement of operations at December 31, 2012. During the first quarter of 2013, the suit was voluntarily dismissed involving debt held by Southridge for $483,482. The debt has reverted back to the original holders.

 

In April, 2013, $88,500 of the debt held by Michael McDonald Trust was assigned to Coventry Enterprises, LLC (“Coventry”) in the form of a Convertible Redeemable Note bearing interest of 8% annum. Coventry was entitled to convert all or any amount of the this note into shares of the Company's common stock (the "Common Stock") at a conversion price ("Conversion Price") for each share of Common Stock equal to 55% of the average of the daily volume weighted average prices of the Common Stock for the 3 trading days with the lowest volume weighted average prices during the 15 trading days immediately preceding the Conversion Date. Following the agreements with Coventry, Coventry made the conversions for a total of 31,416,845 shares of the company’s restricted stock during the second quarter of 2013 satisfying the notes in full at the fair value of $186,646.

 

In June, 2013, $57,800 of the debt was assigned to Coventry for a consideration of $60,000 from Baker Donelson Bearman Caldwell & Berkowitz, PC. in the form of Convertible Redeemable Notes bearing interest of 8% annum. The Company recorded a loss of $2,200 on the settlement during the year ended December 31, 2013. Coventry was entitled to convert all or any amount of the these notes into shares of the Company's common stock (the "Common Stock") at a conversion price ("Conversion Price") for each share of Common Stock equal to 55% of the average of the daily volume weighted average prices of the Common Stock for the 3 trading days with the lowest volume weighted average prices during 20 trading days . Following the agreements, Coventry made the conversions for a total of 27,272,727 shares of the company’s restricted stock satisfying the notes in full at the fair value of $167,495.

 

As a result of the debt assignments and conversions with Coventry, the remaining balance of the debt at December 31, 2013 is $337,182 which consisted of the following loans:

 

i.On August 2, 2011 under a settlement agreement with Liquid Packaging Resources, Inc. (“LPR”), the Company agreed to pay LPR a total of $350,000 in monthly installments of $50,000 beginning August 15, 2011 and ending on February 15, 2012. This settlement amount was recorded as general and administrative expenses on the date of the settlement. We did not make the December 2011 or January 2012 payments and on January 26, 2012, we signed the first amendment to the settlement agreement where under we agreed to pay $175,000 which was the balance outstanding at December 31, 2011(this includes a $25,000 penalty for non-payment).

 

The Company repaid $25,000 during the three months ended March 31, 2012. The Company did not make all of the payments under such amendment and as a result pursuant to the original settlement agreement, LPR had the right to sell 5,714,326 shares of the Company’s free trading stock held in escrow by their attorney and receive cash settlements for a total amount of $450,000 (the initial $350,000 plus total default penalties of $100,000). The $100,000 default was expensed during 2012. LPR sold the note to Southridge Partners, LLP (“Southridge”) for consideration of $281,772 in October 2012. The debt has reverted back to the Company (See note 9).

 

ii.As of December 31, 2013 and 2012, the Company owed University Centre West Ltd. approximately $55,410, which was assigned and sold to Southridge and subsequently reverted back to the Company .

 

F-15
 

 

(3)At December 31, 2013 and 2012, the balance of $767,056 and $588,091 consisted of the following convertible loans:

 

·In September and October 2011, the Company borrowed $250,000 each (aggregating $500,000) from two non-related parties. The principal of these loans were to be repaid with a balloon payment on or before October 1, 2012. On October 19, 2012 the parties amended the notes to extend the due date to May 1, 2013 and include a conversion feature that would allow the holders to convert some or all of their outstanding notes into restricted Company stock at a 15% discount to the average closing market price of the Company's stock traded over the previous 10 days. Interest on these loans is payable monthly beginning in November 2011 with interest calculated at 20% and 12%, each, respectively. At December 31, 2013 and 2012, the accrued interest payable was $6,664.

 

During year ended December 31, 2013, one of the Note holders made conversions of a total of 34,254,004 shares of the company’s restricted stock satisfying the notes in the amount of $125,000 with a fair value of $317,391 on the date of conversion. During August and September, 2013, $150,000 of the debts were assigned to three non-related parties in the form of a Convertible Redeemable Note bearing interest of 8% annum with a conversion price for each share of Common Stock equal to 55% of the average of the daily volume weighted average prices of the Common Stock for the 3 trading days with the lowest volume weighted average prices during the 15 to 20 trading days immediately preceding the Conversion Date. Following the assignments, the conversions for a total of 64,052,862 shares of the company’s restricted stock were made in satisfying the notes of $150,000 at the fair value of $475,519 (See note 6).

 

At December 31, 2013, the remaining balance of these two convertible notes payable of $75,000 and $150,000 were recorded at a fair value of $90,260 and $189,781, respectively. At December 31, 2012, these two convertible note payable of $250,000 each were recorded at fair value of $290,289 and $297,802, respectively.

 

On April 30, 2013, the parties amended the notes to further extend the maturity date to November 3, 2013. The Company issued a total of 4,000,000 restricted shares to the note holders in connection with the amendment at a fair value of $20,800. On October 30, 2013 and November 1, 2013, the parties amended the note of $75,000 and $150,000 to further extend the maturity dates to May 3, 2014 and August 3, 2014, respectively. The Company issued a total of 500,000 and 1,250,000 restricted shares to the note holders in connection with the amendment at a fair value of $9,500 and $13,750 (See note 6), respectively.

 

·On March 22, 2013, the Company issued a Convertible Debenture in the amount of $20,000 to Coventry Enterprises, LLC (“Coventry”). The note carries interest at 10% and is due on March 22, 2014, unless previously converted into shares of restricted common stock. Coventry has the right to convert the note, until is no longer outstanding into shares of Common Stock at a price which is lesser of $.0075, or (ii) fifty-five percent (55%) of the average of the three lowest VWAP prices of the Company’s Common Stock for the twenty trading days preceding the conversion date. In connection with the issuance of this convertible note payable, the Company encountered a day-one derivative loss of $24,931. Coventry made the conversions into a total of 8,810,572 shares of the company’s restricted stock satisfying the notes in full with a fair value of $188,747on September 4, 2013(See note 7).

 

In connection with the issuances of the Note, the Company also granted five-year warrants to purchase an aggregate of 2,600,000 shares of the Company’s common stock at an exercise price of $0.01 per share. The Company classified embedded conversion features in these warrants as a derivative liability. The warrants were valued at their fair value of $21,226 and $17,895, respectively using the Black-Scholes method at the commitment and re-measurement dates of March 22, 2013 and December 31, 2013, respectively.

 

·On July 10, 2013 and October 10, 2013, the Company issued two Convertible Debentures in the amount of $30,000 each (total $60,000) to Christopher Castaldo in connection with the agreements for investor relation services (See Note 6). The notes carry interest at 8% and are due on January 10, 2014 and April 10, 2014, respectively. The notes’ holder has the right to convert the notes into shares of Common Stock at a price of $0.005.

 

F-16
 

 

In connection with the issuance of this convertible notes payable, the Company encountered a day-one derivative loss of $83,157. At December 31, 2013, these convertible notes payable, at fair value, was recorded at $90,684.

 

·On September 3, 2013, the Company issued a Convertible Debenture in the amount of $100,000 to Coventry Enterprises, LLC (“Coventry”). The note carries interest at 10% and is due on September 3, 2014, unless previously converted into shares of restricted common stock. Coventry has the right to convert the note, until is no longer outstanding into shares of Common Stock at a price lesser of $.018, or (ii) fifty-five percent (55%) of the average of the three lowest VWAP prices of the Company’s Common Stock for the twenty trading days preceding the conversion date.

 

In connection with the issuance of this convertible note payable, the Company encountered a day-one derivative loss of $957,567. At December 31, 2013, this convertible note payable, at fair value, was recorded at $185,971.

 

In connection with the issuances of the Note, the Company also granted five-year warrants to purchase an aggregate of 20,000,000 shares of the Company’s common stock at an exercise price of $0.025 per share. The Company classified embedded conversion features in these warrants as a derivative liability. The warrants were valued at their fair value of $445,638 and $137,681, respectively using the Black-Scholes method at the commitment and re-measurement dates of September 3, 2013 and December 31, 2013, respectively.

 

·On September 12, 2013, the Company issued a Convertible Debenture in the amount of $70,000 to Coventry Enterprises, LLC (“Coventry”). The note carries interest at 10% and is due on September 12, 2014, unless previously converted into shares of restricted common stock. Coventry has the right to convert the note, until is no longer outstanding into shares of Common Stock at a price lesser of $.02, or (ii) fifty-five percent (55%) of the average of the three lowest VWAP prices of the Company’s Common Stock for the twenty trading days preceding the conversion date.

 

In connection with the issuance of this convertible note payable, the Company encountered a day-one derivative loss of $309,055. At December 31, 2013, this convertible note payable, at fair value, was recorded at $130,303.

 

In connection with the issuances of the Note, the Company also granted five-year warrants to purchase an aggregate of 15,000,000 shares of the Company’s common stock at an exercise price of $0.025 per share. The Company classified embedded conversion features in these warrants as a derivative liability. The warrants were valued at their fair value of $262,230 and $101,140, respectively using the Black-Scholes method at the commitment and re-measurement dates of September 12, 2013 and December 31, 2013, respectively.

 

·On October 7, 2013, the Company signed a secured convertible Promissory Note in the amount of $35,000 in favor of Southridge Partners II, LLC. The note was due on demand and carries interest at 10% annum. Southridge Partners II, LLC was entitled to convert the principal into shares of common stock at the lesser of $0.015 or a 50% discount from the lowest closing bid price in the 30 trading days prior to the day that the conversion is requested; and interest accrued was entitled to convert into shares of common stock at $0.001. In the evaluation of these financing arrangements, the Company concluded that these conversion features did not meet the conditions set forth in current accounting standards for equity classification. Since equity classification is not available for the conversion feature, it requires bifurcation and liability classification, at fair value. The Company also concluded that the Default Put required bifurcation because, while puts on debt instruments are generally considered clearly and closely related to the host, the Default Put is indexed to certain events that are not associated with the convertible note payable.

 

In connection with the issuance of this convertible note payable, the Company encountered a day-one derivative loss of $81,667. At December 31, 2013, this convertible note payable, at fair value, was recorded at $80,057.

 

F-17
 

 

·On October 27, 2011 the Company entered into a convertible note payable with a corporation. The convertible note payable, with a face value of $53,000, bears interest at 8.0% per annum and was due on July 31, 2012.

 

On December 5, 2011 the Company entered into a convertible note payable with a corporation which had a face value of $37,500, a coupon rate of 8.0% per annum and maturity date of September 5, 2012.

 

The convertible note payable is convertible, at the holder’s option, into the Company’s common shares at a variable conversion price which is 58% multiplied by the average of the lowest three (3) trading prices for the Common Stock during the ten (10) Trading Day period ending one Trading Day prior to the date the Conversion Notice is sent by the Holder to the Borrower. The conversion feature is subject to full-ratchet, anti-dilution protection if the Company sells shares or share-indexed financing instruments at less than the conversion price. The holder has the option to redeem the convertible note payable for cash in the event of defaults or certain other contingent events (the “Default Put”).

 

During October 2012, both of these notes were acquired by a third party from Asher Enterprises for an aggregate amount of $100,000, and then converted into 20,000,000 restricted common shares (See note 6).

 

·On February 3, 2012, the Company issued a Convertible Debenture in the amount of $40,000 to Redwood Management, LLC. The note carries interest at 12% and is due on February 13, 2013, unless converted into shares of restricted common stock. Redwood Management, LLC has the right to convert the note, until it is no longer outstanding, into shares of Common Stock at a price of Fifty Percent (50%) of the lowest closing price, determined on the then current trading market for the Company’s common stock, during the 15 trading days prior to conversion (the “Set Price”). On September 12, 2012, TCN International (TCN) completed the purchase and transfer of this note including penalties and unpaid interest, for the sum of $52,500. Redwood Management, LLC has acknowledged the full payment of the Note, in favor of Nutra Pharma Corporation and releases Nutra Pharma Corporation from all obligations under the Note. Upon the request of TCN, the Board of Directors of the Company approved the conversion of these notes into Restricted Common Stock of the Company,providing 7,500,000 shares of Nutra Pharma common stock to relinquish the total debt of $52,500 (See note 6).

 

·On March 16, 2012 the Company signed a secured convertible Promissory Note in the amount of $75,000 in favor of Southridge Partners II, LLC. The note was due November 16, 2012 and carries interest at 8% annum. Southridge Partners II, LLC was entitled after nine months to convert all or a portion of the principal and interest accrued into shares of common stock at a conversion price of each share equal to the Market Price multiplied times 70%. (the “conversion price”). The Market Price is equal to the average of the two lowest bids closing prices for the five trading days ending before the conversion date. In the evaluation of these financing arrangements, the Company concluded that these conversion features did not meet the conditions set forth in current accounting standards for equity classification. Since equity classification is not available for the conversion feature, it requires bifurcation and liability classification, at fair value. The Company also concluded that the Default Put required bifurcation because, while puts on debt instruments are generally considered clearly and closely related to the host, the Default Put is indexed to certain events that are not associated with the convertible note payable. On October 26, 2012, Southridge converted the note into 5,919,495 shares of the Company's restricted common stock (See note 6).

 

In the evaluation of these financing arrangements, the Company concluded that these conversion features did not meet the conditions set forth in current accounting standards for equity classification. Since equity classification is not available for the conversion feature, it requires bifurcation and liability classification, at fair value. The Company also concluded that the Default Put required bifurcation because, while puts on debt instruments are generally considered clearly and closely related to the host, the Default Put is indexed to certain events that are not associated with the convertible note payable.

 

The Company elected to account for these hybrid contracts under the guidance of ASC 815-15-25-4. The fair value has been defined as the common stock equivalent value, enhanced by the fair value of the default put plus the present value of the coupon.

 

F-18
 

 

The holder of this convertible note has substantial rights and protections regarding dilution if certain events, including a default were to occur. There are a number of events that could trigger a default, including but not limited to failure to pay principal or interest, failure to issue shares under the conversion feature, breach of covenants, breach of representations and warranties, appointment of a receiver or trustee, judgments, bankruptcy, delisting of common stock, failure to comply with the exchange act, liquidation, cessation of operations, failure to maintain assets, material financial statement restatement, reverse split of borrowers stock, etc. In the event of these events the lender may be entitled to receive significant amounts of additional stock above the amounts for conversion.

 

Furthermore, there are additional events that could cause the lender to be due additional shares of common stock above and beyond the shares due from a conversion. Some of these events include, but are not limited to a merger or consolidation of the Company, dividend distribution or spin off, dilutive issuances of the Company’s stock, etc. If the lender receives additional shares of the Company’s commons stock due to any of the foregoing events or for other reasons, then this may have an extremely dilutive effect on the shareholders of the Company. Such dilution would likely result in a significant drop in the per share price of the Company’s common stock. The potential dilutive nature of this note presents a very high degree of risk to the Company and its shareholders

 

6. STOCKHOLDERS' DEFICIT

 

Private Placements of Common Stock

 

In 2013, the Company sold 10,000,000 shares of restricted common stock to an investor at a price per share of $0.005 and received proceeds of $50,000. The Company issued 10,000,000 warrants to purchase common stock at an exercise price of $0.03 per share. The warrants expire on December 31, 2015.

 

In 2013, the Company sold an aggregate of 11,000,000 shares of restricted common stock to five investors at a price per share range from $0.002 to $0.015 and received proceeds of $45,000. The Company issued a total of 1,000,000 warrants to purchase common stock at an exercise price of $0.10 per share. The warrants expire on December 31, 2014.

 

In 2013, the Company sold an aggregate of 21,000,000 shares of restricted common stock to two investors at a price per share range from $0.001 to $0.0042 and received proceeds of $45,000.

 

In 2012, the Company sold an aggregate of 17,650,000 shares of restricted common stock to investors at a price of $0.01 per share and received $176,500. The Company issued a total of 17,650,000 warrants to purchase common stock at an exercise price of $0.10 per share. The warrants expire on December 31, 2014.

 

In 2012, the Company sold an aggregate of 27,000,000 shares of restricted common stock to one investor at a price of $0.01 per share and received $270,000. The Company issued a total of 27,000,000 warrants to purchase common stock at an exercise pric

\e of $0.10 per share in October 2012. The warrants expire on December 31, 2014.

 

Shares Issued to Employees and Directors

 

On November 22, 2013, the Board of Directors approved a resolution for the issuance of a total of 34,630,000 shares of the Company’s restricted common stock to directors and employees of the Company. The issuance was valued at $484,820 ($0.014 per share), which was the fair value of the Company’s common stock on the date of issuance.

 

On September 3, 2013, the Board of Directors approved a resolution for the issuance of 1,000,000 shares of the Company’s restricted common stock to an employee of the Company. The issuance was valued at $22,900 ($0.0229 per share), which was the fair value of the Company’s common stock on the date of issuance.

 

During October and December 2012, the Board of Directors approved resolutions for the issuance of a total of 26,875,000 shares of the Company’s restricted common stock to the Directors and Employees of the Company. The shares were valued at $569,400 ($0.022 and $0.014 per share), which was the fair value of the Company’s common stock on the date of issuance.

 

F-19
 

 

On February 3, 2012 the Board of Directors approved a resolution for the issuance of a total of 15,720,000 shares of the Company’s restricted common stock to the Directors and Employees of the Company. The issuance was valued at $259,380 ($0.0165 per share), which was the fair value of the Company’s common stock on the date of issuance.

 

Common Stock Issued for Services

 

During November, 2013, the Company issued 1,000,000 shares of the Company’s restricted common stock to a consultant for investor relation services for two months. The shares were valued at $0.0175 per share. The Company recorded an equity compensation charge of $17,500 during the year ended December 31, 2013.

 

During October, 2013, the Company issued 15,000,000 shares of the Company’s restricted common stock to a consultant for investor relation services for three months. The shares were valued at $0.0178 per share. The Company recorded an equity compensation charge of $267,000 during the year ended December 31, 2013.

 

During September, 2013, the Company issued 1,500,000 shares of the Company’s restricted common stock to a consultant for consulting services rendered. The shares were valued at $0.016 per share. The Company recorded an equity compensation charge of $24,000 during the year ended December 31, 2013.

 

During September, 2013, the Company issued a total of 1,500,000 shares of the Company’s restricted common stock to two consultants for consulting services rendered. The shares were valued at $0.0229 per share. The Company recorded an equity compensation charge of $34,350 during the year ended December 31, 2013.

 

During August, 2013, the Company issued a total of 6,000,000 shares of the Company’s restricted common stock to two consultants for investor relation services for six months. The shares were valued at $0.0173 per share. The Company recorded an equity compensation charge of $70,902 during the four months ended December 31, 2013. The remaining unrecognized compensation cost of $32,898 related to non-vested equity-based compensation to be recognized by the Company over the remaining vesting period of two months.

 

During August, 2013, the Company issued 2,000,000 shares of the Company’s restricted common stock to a consultant for investor relation services for one year. The shares were valued at $0.012 per share. The Company recorded an equity compensation charge of $8,351 during the four months ended December 31, 2013. The remaining unrecognized compensation cost of $15,649 related to non-vested equity-based compensation to be recognized by the Company over the remaining vesting period of eight months.

 

During August, 2013, the Company issued 2,000,000 shares of the Company’s restricted common stock to a consultant for consulting services for six months. The shares were valued at $0.0056 per share. The Company recorded an equity compensation charge of $8,446 during the four and one half months ended December 31, 2013. The remaining unrecognized compensation cost of $2,754 related to non-vested equity-based compensation to be recognized by the Company over the remaining vesting period of one and half months.

 

During July, 2013, the Company issued 2,000,000 shares of the Company’s restricted common stock to a consultant for consulting services for six months. The shares were valued at $0.0042 per share. The Company recorded an equity compensation charge of $8,400 during the year ended December 31, 2013.

 

During July, 2013, the Company issued 100,000 shares of the Company’s restricted common stock to a consultant for consulting services rendered. The shares were valued at $0.0042 per share. The Company recorded an equity compensation charge of $420 during the year ended December 31, 2013

 

During July 2013, the Company signed an agreement with a consultant for investor relation services for three months. A $30,000 convertible note convertible at $0.005 per share was also issued (See Note 5). The Company also paid a total of $10,000 cash and issued a total of 15,000,000 shares of company’s restricted common stocks. The shares were valued at $0.0057 per share. The Company recorded an equity compensation charge of $85,500 during the year ended December 31, 2013.

 

During June, 2013, the Company issued 2,000,000 shares of the Company’s restricted common stock to a consultant for investor relation services for six months. The shares were valued at $0.0042 per share. The Company recorded an equity compensation charge of $8,400 during the year ended December 31, 2013.

 

F-20
 

 

During May, 2013, the Company issued 1,000,000 shares of the Company’s restricted common stock to a consultant for investor relation services for six months. The shares were valued at $0.0053 per share. The Company recorded an equity compensation charge of $5,300 in May 2013.

 

During February, 2013, the Company issued 8,000,000 shares of the Company’s restricted common stock to a consultant for investor relation services for a year. The shares were valued at $0.008 per share. The Company recorded an equity compensation charge of $61,019 during the year ended December 31, 2013. The remaining unrecognized compensation cost of $2,981 related to non-vested equity-based compensation to be recognized by the Company over the remaining vesting period of one half month.

 

During February 2013, the Company issued 1,500,000 shares of the Company’s restricted common stock to a consultant for investor relation services for two months. The shares were valued at $0.007 per share. The Company recorded an equity compensation charge of $10,500 during the year ended December 31, 2013.

 

During February 2013, the Company issued a total of 3,000,000 shares of the Company’s restricted common stock to three consultants for marketing services for six months. The shares were valued at $0.009 per share. The Company recorded an equity compensation charge of $27,000 during the year ended December 31, 2013.

 

During January, 2013, the Company issued 10,000,000 shares of the Company’s restricted common stock to a consultant for investor relation services for a year. The shares were valued at $0.005 per share. The Company recorded an equity compensation charge of $50,000 during the year ended December 31, 2013.

 

On December 14, 2012 the Company issued a total of 1,000,000 shares of the Company’s restricted common stock to Roetzell & Andress for legal services for a one year term. The shares were valued at $0.014 per share. The Company recorded a prepaid equity compensation charge of $14,000 during the year ended December 31, 2012, and recognized an equity compensation charge of $14,000 during the year ended December 31, 2013.

 

During October, 2012 the Company issued a total of 15,100,000 shares of the Company’s restricted common stock to five consultants for marketing services for six months terms. The shares were valued at $0.0125 per share. The Company recorded an equity compensation charge of $108,534 and $80,216 during the year ended December 31, 2013 and year ended December 31, 2012.

 

During December, 2012 the Company issued 500,000 shares of the Company’s restricted common stock to a consultant for real estate consulting services for a six months term. The shares were valued at $0.0125 per share. The Company recorded an equity compensation charge of $1,042 during the year ended December 31, 2012. The remaining unrecognized compensation cost of $5,208 was recognized during the year ended December 31, 2013.

 

During August, 2012 the Company issued 3,000,000 shares of the Company’s restricted common stock to JPU Ventures, Inc. under agreement dated August 13, 2012. The agreement was for investor relations services for a nine months term. The shares were valued at $0.0125 per share. The Company recorded an equity compensation charge of $21,875 during the year ended December 31, 2012. The remaining unrecognized compensation cost of $15,625 was recognized by the Company during the year ended December 31, 2013.

 

On October 1, 2012, the Company issued 5,500,000 shares of the Company’s restricted common stock under the amended agreement with Mark Bergman, a consultant. The contract is for six months term. The shares were valued at $0.0125 per share. The Company recorded an equity compensation charge of $28,646 and $40,104 for the agreement during the year ended December 31, 2013 and the year ended December 31, 2012.

 

During October, 2012, the Company entered into an agreement for investor relations services with a Consultant. The contract was for a six months term and calls for the issuance of 1,000,000 shares of restricted common stock. The share was valued at $0.0125 per share. The Company recorded an equity compensation charge of $8,697 during the year ended December 31, 2012. The remaining unrecognized compensation cost of $3,533 was recognized by the Company during the year ended December 31, 2013.

 

F-21
 

 

On February 22, 2012 the Company engaged Capital Path Securities, LLC (“CPS”) as its exclusive advisor on a proposed placement by way of an equity line of approximately $10,000,000 of the Company’s equity or equity linked securities. All upfront fees have been waived by CPS. The Company will pay CPS a cash placement fee equal to 5% of all principal amounts invested from the source originated by CPS. In addition, 10,000,000 restricted shares were issued on October 26, 2012, and valued at $0.0125 per share. The Company recorded an equity compensation charge of $151,375 during the year ended December 31, 2012. The remaining unrecognized compensation cost of $21,625 and 125,000 non-vested shares was recognized by the Company during the year ended December 31, 2013.

 

Common Stock Issued for Debt Modification

 

On April 30, 2013, the Company amended the maturity dates of two notes of $250,000 each (aggregating $500,000) from two non-related parties to November 3, 2013. The Company issued a total of 4,000,000 restricted shares to the note holders in connection with the amendment at a fair value of $20,800.

 

On October 30, 2013 and November 1, 2013, the parties amended the note of $75,000 and $150,000 to further extend the maturity dates to May 3, 2014 and August 3, 2014. The Company issued a total of 500,000 and 1,250,000 restricted shares to the note holders in connection with the amendment at a fair value of $9,500 and $13,750, respectively (See Note 5).

 

On October 19, 2012 the Company amended the notes $250,000 each (aggregating $500,000) from two non-related parties originated in September and October 2011to include a conversion feature that would allow the holders to convert some or all of their outstanding notes into restricted Company stock at a 15% discount to the average closing market price of the Company's stock traded over the previous 5 days. The Company issued a total of 4,000,000 restricted shares to the note holders per the amendment. The shares were valued at $0.025 per share. (See note 5).

 

Common Stock Issued with Promissory Note

 

In July 2013, in connection with the issuance of this promissory note to Michael McDonald Trust in the amount of $75,000 which is due in six months from the funding of the note, the Company issued 1,000,000 shares of the Company's common stocks. The Company has recorded a debt discount in the amount of $3,977 to reflect the value of the common stocks as a reduction to the carrying amount of the convertible debt and a corresponding increase to common stocks and additional paid-in capital. The total discount of $3,977 was amortized over the term of the debt.  Amortization for the year ended December 31, 2013 was $3,977 (See Note 5).

 

Common Stock Held in Escrow

 

On July 27, 2011 the Company issued 5,714,286 shares of free trading common stock in certificate form which is held in escrow as security under an agreement reached with Liquid Packaging Resources, Inc. (“LPR”) on August 2, 2011(See note 3 and 5).

 

Common Stock Issued for Settlement of Accounts Payable & Debt

 

Following the agreements with Coventry Enterprises, LLC (see Note 3) for $80,000, Coventry made the following conversions for a total of 15,119,481 shares of the company’s restricted stock during the first quarter of 2013 satisfying the notes in full and recorded a loss of $65,039 (See note 3):

 

Date  Number of shares
converted		   Fair Value
of Debt
Converted		 
January 21, 2013   4,032,258   $37,619 
February 11, 2013   5,405,405   $42,510 
March 20, 2013   5,681,818   $40,414 

 

Following the agreement with Coventry Enterprises, LLC (see Note 5) for $88,500, Coventry made the following conversions for a total of 31,416,845 shares of the company’s restricted stock during the second quarter of 2013 satisfying the notes in full:

 

F-22
 

 

Date  Number of shares converted   Fair Value
of Debt
Converted		 
4/17/2013   7,133,333   $49,586 
5/16/2013   11,101,694   $64,930 
6/12/2013   13,181,818   $70,130 

 

Following the agreement with Coventry Enterprises, LLC (see Note 5) for $60,000, Coventry made the conversion for a total of 27,272,727 shares of the company’s restricted stock during the second quarter of 2013 satisfying the notes in full with a fair value of $167,495. The Company recorded a loss of $2,200 (See note 5).

 

Following the agreement with Coventry Enterprises, LLC (see Note 5) for $20,000, Coventry made the conversion for a total of 8,810,572 shares of the company’s restricted stock during September 2013 satisfying the notes in full with a fair value of $188,747.

 

During June and August, 2013, one of the convertible Notes holders made the following conversions of a total of 34,254,004 shares of the company’s restricted stock satisfying the notes in the amount of $125,000 with a fair value of $317,391 on the date of conversion (See Note 5).

 

Date  Number of shares converted   Fair Value
of Debt
Converted		 
6/25/2013   22,058,882   $188,352 
8/30/2013   12,195,122   $129,039 

  

During August and September, 2013, $150,000 of the convertible notes were assigned to third parties in the form bearing interest of 8% annum at with a conversion price for each share of Common Stock equal to 55% of the average of the daily volume weighted average prices of the Common Stock for the 3 trading days with the lowest volume weighted average prices during the 15 to 20 trading days immediately preceding the Conversion Date. Immediately following the assignments, the conversions for a total of 64,052,862 shares of the company’s restricted stock were made as followings in satisfying the notes of $150,000 at the fair value of $475,519(See Note 5).

 

Date  Number of shares converted   Fair Value
of Debt
Converted		 
8/28/2013   22,026,431   $167,493 
9/3/2013   20,000,000   $163,909 
9/4/2013   22,026,431   $144,117 

 

On September 16, 2013, one of the non-related party promissory note holders accepted a total of 8,472,750 shares of the Company’s restricted common stock as a repayment to discharge $25,000 of his outstanding loan and accrued interest of $11,120 with the Company (See note 5). The Company recorded a loss of $90,971 on the settlement date.

 

On November 25, 2013, one of the non-related party promissory note holders accepted a total of 4,360,000 shares of the Company’s restricted common stock as a repayment to discharge $25,000 of his outstanding loan and accrued interest of $11,956 with the Company (See note 5). The Company recorded a loss of $28,444 on the settlement date.

 

During September, 2013, Mr. Harold H. Rumph (ReceptoPharm’s CEO) accepted 14,800,000 shares of the Company’s restricted common stock as a repayment to discharge $37,000 of his accrued salary to the Company(See Note 3).

 

During June and September, 2013, Mr. Deitsch (Our CEO) accepted a total of 50,000,000 shares of the Company’s restricted common stock as a repayment to discharge $162,500 of his outstanding loan to the Company (See note 4).

 

F-23
 

 

During August and September, 2013, the Company issued 3,000,000 shares of the company’s restricted stock to settle the outstanding accounts payable in aggregate of $38,528 with two vendors. The shares were valued at $0.018 per share. The Company recorded a loss of $15,472 (See Note 3).

 

During September, 2013, the Company issued 25,000,000 shares of the company’s restricted stock and 25,000,000 warrants to purchase stock at an exercise price of $0.030 to settle the outstanding accounts payable of $112,621. The shares were valued at $0.015 per share. The Company recorded a loss of $505,525 (See Note 3).

 

During December 2012, the Board of Directors approved resolutions for the issuance of a total of 10,000,000 shares of the Company’s restricted common stock to Mr. Deitsch to discharge $100,000 of his outstanding loan the Company (See note 4). The shares were valued at the note payable amount due to the fact that it was a related party transaction. 10,000,000 warrants to purchase stock at an exercise price of $0.10 per share were also issued to Mr. Dietsch. The warrants expire on December 31, 2014.

 

Following the agreements with Coventry Enterprises, LLC (see Note 3), the conversions for 8,672,090 and 2,564,102 shares of the Company’s restricted common stocks were issued for settlement of accounts payable and a convertible note payable on March 29, 2012 and December 20, 2012, respectively. The shares were valued at $168,889 and $33,720, respectively, which was the fair value of convertible debts on the date of conversion.

 

Following the agreement with Southridge (see Note 5), the conversion for a total of 6,416,733 shares of the Company’s restricted common stock satisfying the note in full was made in October 2012. The shares were valued at $157,179, which was the fair value of convertible debts on the date of conversion.

 

Following the agreement with Asher Enterprises, LLC (see Note 5), the conversion for a total of 20,000,000 shares of the Company’s restricted common stock satisfying the note in full was made in October 2012. The shares were valued at $356,779, which was the fair value of convertible debts on the date of conversion.

 

Following the agreement with Redwood and TCN (see Note 5), the conversion for a total of 7,500,000 shares of the Company’s restricted common stock satisfying the note in full was made in October 2012. The shares were valued at $273,144, which was the fair value of convertible debts on the date of conversion.

 

Following the agreement with Redwood (see Note 3), conversions were made for a total of 18,737,894 shares of the Company’s restricted stock, satisfying the note in full. The shares were valued at a total amount of $320,531, which was the fair value of convertible debts on the date of conversion.

 

7. STOCK OPTIONS AND WARRANTS

 

Common Stock Warrants

 

From time to time, we issue warrants to purchase our common stock. These warrants have been issued for cash in conjunction with the private placement of shares of our common stock.

 

During December 2013, the Company issued a total of 10,000,000 warrants to purchase common stock at an exercise price of $0.03 per share in connection with the private placement offerings. The warrants expire on December 31, 2015 (See note 6).

 

During October and November 2013, the Company issued a total of 1,000,000 warrants to purchase common stock at an exercise price of $0.10 per share in connection with the private placement offerings. The warrants expire on December 31, 2014 (See note 6).

 

On September 16, 2013, the Company issued 25,000,000 warrants to purchase stock at an exercise price of $0.030 in connection with settlement of an outstanding account payable. The warrants expire on December 31, 2014 (See Note 3 and Note 6).

 

F-24
 

 

On September 3, 2013 and September 12, 2013, the Company issued 20,000,000 and 15,000,000 warrants, respectively, to purchase common stock at an exercise price of $0.025 per share in connection with issuances of convertible notes payable to Coventry. The warrants expire on September 3, 2018 and September, 12, 2018, respectively (See note 5).

 

During March, 2013, the Company issued a total of 2,600,000 warrants to purchase common stock at an exercise price of $0.01 per share in connection with issuance of a convertible note payable to Coventry. The warrants expire on March 22, 2018 (See note 5).

 

During June, 2013, 25,000,000 warrants to purchase stock at an exercise price of $0.10 per share were issued to CEO, Mr. Deitsch in exchange of notes payable. The warrants expire on December 31, 2014 (See note 4).

 

A summary of warrants outstanding in conjunction with private placements of common stock were as follows during the year ended December 31, 2013 and 2012:

 

   Number of shares   Weighted average exercise price 
Balance December 31, 2011   47,921,667   $0.10 
Exercised   -    - 
Issued   54,650,000   $0.10 
Forfeited/Expired   (45,315,000)   - 
Balance December 31, 2012   57,256,667   $0.10 
Exercised   -    - 
Issued   98,600,000   $0.01 – 0.10 
Forfeited   (940,000)   - 
Balance December 31, 2013   154,916,667   $0.082 

 

The following table summarizes information about fixed-price warrants outstanding as of December 31, 2013 and 2012:

 

   Exercise Price   Number 
Outstanding		   Weighted 
Average
Contractual 
Life		   Weighted 
Average
Exercise Price		 
2013  $ 0.01-0.10    154,916,667    1.97 years   $0.082 
2012  $0.10-0.15    57,256,667    2.04 years   $0.10 

 

As of December 31, 2013, the aggregate intrinsic value of all stock options and warrants outstanding and expected to vest was $0. The intrinsic value of each option share is the difference between the fair value of our common stock and the exercise price of such option share to the extent it is “in-the-money”. Aggregate intrinsic value represents the value that would have been received by the holders of in-the-money options had they exercised their options on the last trading day of the year and sold the underlying shares at the closing stock price on such day. The intrinsic value calculation is based on the $0.0075, closing stock price of our common stock on December 31, 2013.There were no in-the-money warrants at December 31, 2013.

 

F-25
 

 

8. INCOME TAXES

 

The Company’s tax expense differs from the “expected” tax expense for the years ended December 31, 2013 and 2012, (computed by applying the Federal Corporate tax rate of 34% to loss before taxes and 8.84% for California State Corporate Taxes, the blended rate used was 39.83%), are approximately as follows:

 

   December 31, 
   2013   2012 
         
Computed "expected" tax expense (benefit) - Federal  $(1,346,076)  $(1,115,374)
Computed "expected" tax expense (benefit) - State   (322,564)   (318,119)
Stock-based compensation   558,448    674,914 
Change in fair value of derivatives   452,390    159,500 
Change in valuation allowance   657,802    599,079 
   $-   $- 

 

Current portion of net deferred income tax assets:  2013   2012 
         
Allowance for doubtful accounts  $242,000   $242,000 
Reserve for inventory obsolescence   313,925    313,925 
Accrued salary   101,877    43,154 
Subtotal   657,802    599,079 
Valuation allowance   (657,802)   (599,079)
Current net deferred income tax asset  $-   $- 
           
Non- current portion of net deferred income tax asset          
Net operating loss carryforwards  $6,232,881   $5,575,079 
Valuation allowance   (6,232,881)   (5,575,079)
Non-current net deferred income tax asset  $-   $- 

 

Due to the uncertainty of the utilization and recoverability of the loss carry-forwards and other deferred tax assets, we have provided a valuation allowance to fully reserve such assets.

 

As of December 31, 2013, the Company has net operating loss carryforwards of approximately $15,580,000 available to offset future taxable income in various years through December 31, 2033.  The significant difference between such net operating loss carryforwards and our accumulated deficit of approximately $41,987,000 results primarily from stock based compensation which is considered to be a permanent difference.

 

The valuation allowances increased by approximately $658,000 and $599,000 for the years ended December 31, 2013 and 2012, respectively. The Company’s 2011 to 2013 tax returns are subject to examination by Internal Revenue Services and State Taxing Agency’s.

 

F-26
 

 

9. COMMITMENTS AND CONTINGENCIES

 

Operating Leases

 

In February 2010, Nutra Pharma entered into an operating lease for the use of office space. The lease expired in January 2013 and required monthly payments of approximately $9,000. In February 2013, Nutra Pharma entered into a new operating lease for monthly payments of approximately $3,500 for three years. ReceptoPharm leases a lab and renewed its operating lease agreement for five years in July of 2012. The lease requires monthly payments of approximately $5,000 beginning August 1, 2012.

 

Future minimum payments under these lease agreements, including the extension period, are approximately as follows:

 

Years ended

December 31,

  Amounts 
2014  $116,345 
2015   120,218 
2016   79,892 
2017   45,249 
Total  $361,704 

 

Rent expense in 2013 and 2012 approximated $114,889 and $183,000, respectively.

 

Litigation

 

Patricia Meding, et. al. v. ReceptoPharm, Inc. f/k/a Receptogen, Inc. 

 

On August 18, 2006, ReceptoPharm was named as a defendant in Patricia Meding, et. al. v. ReceptoPharm, Inc. f/k/a Receptogen, Inc., Index No.: 18247/06 (New York Supreme Court, Queens County). The original proceeding claimed that ReceptoPharm owed the Plaintiffs, including Patricia Meding, a former ReceptoPharm officer and shareholder and several corporations that she claims to own, the sum of $118,928.15 plus interest and counsel fees on a series promissory notes that were allegedly executed in 2001 and 2002. On August 23, 2007, the Queens County New York Supreme Court issued a decision denying Plaintiffs motion for summary judgment in lieu of a complaint, concluding that there were issues of fact concerning the enforceability of the promissory notes. On May 23, 2008, the Plaintiffs filed an amended complaint in which they reasserted their original claims and asserted new claims seeking damages of no less than $768,506 on their claims that in or about June 2004 ReceptoPharm breached its fiduciary duty to the Plaintiffs as shareholders of ReceptoPharm by wrongfully canceling certain of their purported ReceptoPharm share certificates. In late 2010, Plaintiffs further amended their complaint alleging that ReceptoPharm violated Plaintiffs contractual and statutory rights by cancelling an additional 1,214,800 share certificates and failing to permit the Plaintiffs to exercise dissenting shareholder rights with respect to those share certificates. The damages associated with the Plaintiff’s claims could rise as the result of increases in our share price as the Receptopharm shares may be convertible into our common shares. The potential exposure may exceed $10,000,000 if the Plaintiffs are successful with all of their claims. 

 

F-27
 

 

ReceptoPharm believes the suit is without merit and has filed an answer denying the material allegations of the amended complaint and asserted a series of counterclaims against the Plaintiffs alleging claims for declaratory judgment, fraud, breach of fiduciary duty, conversion and unjust enrichment as a result of the promissory notes. Plaintiffs have moved for partial summary judgment on their claims regarding the additional 1,214,800 shares, but not on their claims regarding the alleged promissory notes or the 1,750,000 alleged shares. In August of 2011, the Plaintiff's motion was partially granted. In September 2012, ReceptoPharm's attorneys filed a Motion to be removed as counsel. Their motion was denied on April 26, 2013 due to the current Involuntary Bankruptcy action filed against Nutra Pharma. The court has issued a stay in the proceedings pending the outcome of the Bankruptcy action. ReceptoPharm is seeking new counsel to oppose the partial summary judgment. We intend to vigorously contest this matter. 

 

Liquid Packaging Resources, Inc. v. Nutra Pharma Corp. and Erik "Rik" Deitsch 

 

On April 21, 2011, Nutra Pharma Corp. and its CEO, Erik Deitsch, were named as defendants in Liquid Packaging Resources, Inc. v. Nutra Pharma Corp. and Erik "Rik" Deitsch, Superior Court of Fulton County, Georgia, Civil Action No. 2011-CV-199562. Liquid Packaging Resources, Inc. ("LPR") claimed that Nutra Pharma Corp. and Mr. Deitsch, directly or through other companies, placed orders with LPR that required LPR to purchase components from third parties. LPR sought reimbursement for those third party expenses in the amount of not less than $359,826.85 plus interest. LPR also sought punitive damages in the amount of not less than $500,000 and attorney's fees.

 

Mr. Deitsch and Nutra Pharma Corp. then removed the action to the United States District Court, Northern District of Georgia, Civil Action No. 11-CV-01663-ODE. After removal, LPR amended the Complaint to assert that Nutra Pharma Corp. and Mr. Deitsch were the alter egos of the alleged other companies through whom the subject orders were placed and therefore should be considered one and the same. Mr. Deitsch and Nutra Pharma Corp. moved to dismiss the Complaint on several grounds including statute of frauds, failure to state a claim, and jurisdiction (only for Mr. Deitsch). Mr. Deitsch and Nutra Pharma Corp. believe the suit is without merit. 

 

After June 30, 2011, at LPR's request, the parties mediated the dispute before LPR responded to the Motion To Dismiss. At the mediation, the parties worked out an agreement whereby Nutra Pharma Corp. would purchase from LPR the components LPR purchased from third parties at an amount slightly less than the principal amount of the suit and on terms acceptable to us. The agreed price was $350,000.00 payable over 7 months in equal $50,000.00 amounts. This agreement was reached by us because it provided tangible value in exchange for the purchase price rather than incurring the expense of litigation, which would likely be substantial and not recouped. While Nutra Pharma Corp. had counterclaims we could assert, we believe this was a practical resolution. The settlement allowed us to take possession of the components prior to full payment and, in exchange, provided security to LPR in the form of our stock valued at $400,000 at the time of issuance. The stock can only be sold in event of a default of the payment schedule. The litigation was dismissed in August of 2011. We made the August, September and November payments (totaling $150,000) in a timely fashion. We were late for the payment due October 15, 2011 and requested an accommodation from LPR, eventually paying an extra $5,000 towards that payment. At December 31, 2011, Nutra Pharma Corp. had made total payments of $205,000 with an additional $150,000 owed. In order to allow us to skip the December payment, LPR agreed to another accommodation whereby we would pay both the December and January payment with an additional $10,000 on or before January 16, 2012. We were unable to make this payment and on January 26, 2012 signed an amended payment schedule adding an additional $15,000 for a total of $175,000 owed. Our CEO, Rik Deitsch, added additional collateral stock in a separate company that he held personally. $25,000 was paid in January, with subsequent payments of $30,000 due monthly on the 15th of March through the 15th of July, 2012. We failed to make the March payment and was subsequently called in default of the Agreement. Under the original agreement, if we are in default of the agreement, LPR has the right to sell shares of our free trading stock held in escrow by their attorney and receive cash settlements for a total amount of $450,000 representing the new total cash amount due to LPR by the Company. 

 

On June 11, 2012, LPR sold their debt to Southridge Partners, LLP in an agreement to be paid out over time. In August, 2013, LPR cancelled their agreement with Southridge Partners, LLP.  As of December 31, 2013 LPR continues to hold the collateral stock. We are currently negotiating a settlement with LPR. Upon the settlement of the outstanding debt, LPR will return the collateral shares to the Company.

 

F-28
 

 

Involuntary Petition of Bankruptcy 

  

On August 31, 2012, certain former ReceptoPharm employees and a former ReceptoPharm consultant filed a Petition for Involuntary Bankruptcy against us in the United States Bankruptcy Court, Southern District of Florida. The Petitioners originally claimed they were owed $990,927 from Nutra Pharma in the form of accrued wages and promissory notes, but amended their claim to $816,662 in a subsequent filing. In response to the Petition, we filed a motion to dismiss the action which, if successful, would avoid the case being converted into an actual bankruptcy action. On September 30, 2013, the Company entered into a Settlement Agreement with the Petitioners, which is effective upon the court dismissal of the action. In full and final satisfaction of all claims, the Company settled the Agreement with the Petitioners for a total sum of $350,000.  $35,000 has been paid and a second lump sum payment is due within 8 months from the date the court dismissed the action (See Note 10).

 

Laurence N. Raymond v. Receptopharm, Inc. et al.

 

On December 30, 2011 Laurence N. Raymond ("Raymond") brought the case against Receptopharm, Inc. ("Receptopharm") and Nutra Pharma to recover approximately $300,000 that was allegedly either loaned to Receptopharm or owing to Raymond pursuant to an oral employment agreement. Dr. Raymond is one of the petitioning creditors that brought the above-described involuntary bankruptcy action. The settlement agreement reached in that action fully resolves all claims between the parties and specifies that this action will be dismissed immediately upon the full settlement payments, pursuant to a confidential settlement agreement.

 

 Paul F. Reid v, Harold H. Rumph et al.

 

On December 28, 2011 Paul F. Reid ("Reid") brought the case against Harold H. Rumph ("Rumph"), Receptopharm, and Nutra Pharma to recover approximately $330,000 that was allegedly either loaned to Receptopharm or owing to Reid pursuant to an oral employment agreement. Dr. Reid is one of the petitioning creditors that brought the above-described involuntary bankruptcy action. The settlement agreement reached in that action fully resolves all claims between the parties and specifies that this action will be dismissed immediately upon the full settlement payments, pursuant to a confidential settlement agreement.

 

10. SUBSEQUENT EVENTS

 

Private Placements of Common Stock

 

In January 2014, the Company sold 12,000,000 shares of restricted common stock to an investor at a price per share of $0.005 and received proceeds of $60,000. The Company issued 12,000,000 warrants to purchase common stock at an exercise price of $0.03 per share. The warrants expire on December 31, 2015.

 

Common Stock Issued for Debt Modification and Default

 

On January 17, 2014, the Company issued a total of 1,000,000 restricted shares to the Michael McDonald Trust due to the default on repayment of the promissory note of $75,000. The shares were valued at a fair value of $9,900.

 

Common Stock Issued for Debt Conversions

 

Following the agreements with Coventry Enterprises, LLC for $70,000 in September 2013, Coventry converted the $60,000 of the note for a total of 15,584,415 shares of the company’s restricted stock during on March 12, 2014. The remaining balance of the note is $10,000.

 

Following the agreements with Coventry Enterprises, LLC for $100,000 in September 2013, Coventry converted the $90,000 of the note for a total of 23,376,623 shares of the company’s restricted stock during on March 12, 2014. The remaining balance of the note is $10,000.

 

F-29
 

 

Officer Loans

 

During January through March 2014, the Company received additional advances from our President and CEO, Rik Deitsch, in the amount of $16,008 and repaid Mr. Deitsch $14,600. These funds are unsecured, bearing interest at 4% and due on demand.

 

Involuntary Petition of Bankruptcy

 

On September 30, 2013, the Company entered into a Settlement Agreement with the Petitioners, which is effective upon the court dismissal of the action. In full and final satisfaction of all claims, the Company settled the Agreement with the Petitioners for a total sum of $350,000.  $35,000 has been paid and a second lump sum payment is due within 8 months from February 12, 2014, the date the court dismissed the action. The Parties executed mutual releases exclusive of releases under the Settlement Agreement (See Note 9).

 

F-30

 

 EX-31.1 2 v372614_ex31-1.htm EXHIBIT 31.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO

THE SECURITIES EXCHANGE ACT OF 1934 RULE 13a-14(a)/15d-14(a) AS

ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Rik J. Deitsch, Chief Executive Officer of Nutra Pharma Corp., certify that:

 

  1.  I have reviewed this report on Form 10-K for the fiscal year ended December 31, 2013 of Nutra Pharma Corp.;

 

  2.  Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

  3.  Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

  4.  The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  (a)  Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  (b)  Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

  (c)  Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

  (d)  Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting; and

 

  5.  The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons fulfilling the equivalent functions):

 

  (a)  All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

 

  (b)  Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 

 

Dated: March 31, 2014 /s/ Rik J. Deitsch
  Rik J. Deitsch, Chief Executive Officer and Principle Financial Officer

 

 

 EX-32.1 3 v372614_ex32-1.htm EXHIBIT 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED

PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Annual Report of Nutra Pharma Corp. (the “Company”) on Form 10-K  for the period ending December 31, 2013, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Rik J. Deitsch, Chief Executive Officer and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

     (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

     (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

/s/ Rik J. Deitsch  
Rik J. Deitsch  
Chief Executive Officer and Principle Financial Officer  
Date: March 31, 2014  

  

This certification accompanies this Report pursuant to §906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed by the registrant for the purposes of §18 of the Securities Exchange Act of 1934, as amended. This certification shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of this Report), irrespective of any general incorporation language contained in such filing.

 

A signed original of this written statement required by §906 has been provided to the registrant and will be retained by the registrant and furnished to the Securities and Exchange Commission or its staff upon request.

 

 

 

 

 

 GRAPHIC 4 lvw-logo.jpg GRAPHIC begin 644 lvw-logo.jpg M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``H'!PD'!@H)"`D+"PH,#QD0#PX. M#QX6%Q(9)"`F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$!`)C!&2T4^2CD_0#W_ MVP!#`0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T] M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P``1"`!+`M4#`2(``A$!`Q$!_\0` M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4% M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$! M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$" M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#TD^#-#Q_Q MY'_O])_\57SK-J-ZL\JK>W0`=@!YS>OUKZF/0U\HS_\`'S-_UT;^9H&CMOA? M"-;\5O:ZG)/NCP;H:GBR/_`'^D_P#BJ\E^#7_([2?] M>C_^A+7NU`7:=T<#X\\)00>%Y[O1EFM[BU(E;RYG^=!]X=?3G\*\@_M&]_Y_ M;G_O\W^-?34D:RQM'(H9'!5@>A!ZBOG#Q)H[Z!X@O-/8';%)^[)[H>5/Y&N6 MO&VJ/4P-7F3A+<[GX8+I^NP7EEJD;SW<)$B.TSY9#QCKV/\`.O1X-`TZVA$4 M5N50$MCS&/)^I]J\%\(ZV?#_`(FL[XG$0;9-[HW!_+K^%?1:L&4%2"",@CO5 MT&G'S.?'0<9^3.2\56'V&."XM#)'&3L<*YQGJ#U^M;`'4+IA9Q#>W^M;C/7L,M^ M%;5IX0TFTCAQ`\DD:@>8\SDL0.IYZUSWA:&.?78#/(V(%=X8_P"'>0`6^NW( M_$UWE1;6[+Y[1LCD_%.GBRA@N+,R1IG8X5SCV/6N;^TS_P#/>7_OLUZ-JEF+ M_39[<]77Y?8CD?K7FI!!((P1P1Z59!VN@VUGJ.E1RR19E7Y)#O;DCOUK>C18 MHU1!A5&`*XWP=>^3?R6K'Y9EW+_O#_ZW\J[2D`53N=/LY&>>>/G&6;<1T'UJ MY6=K+&6&*R0X>[?RSCLG5C^7\Z`*NDZ7;W%D+B>)LS,9%4NWRJ?NCKZ?SK6@ MMXK>+RXEVIZ9)_G4BJ$4*HP`,`#M1T'-`'ENI3SQ_&2UL$N)ULV*9@$K;#F, MD\9QUKU)5"*%48`&`*\GU25#\<+24.ICS'\X/R_ZL]Z]'U/Q!IFD63W-Y>1* MB#.`P+-[`#DFLH/>_SS7$LE=I?:C:IIDETMZD<:(7WHRG/'3G-.-[OF)J)?Q)\03H=K*\&FVF\S&,[7G9>"-W4+D]NN*M?#W M6->UI+R37O-0QE#"K0"(,&!YZ<]*S+?0)O"?Q*;571FTF]\P>>HR(&?G#^@S MWZRT:WM+RJ'BK5CIWA^YN[*[Q,B70E9"CQ"/:HP0<8]ZNZYK&/++V?-TN1[UQUL\9^.4TC,AB) M;YB1M_U/KTKN+Z_T+PS]MU5IH8WG1=\<9!,K+G&%'4G./RK.&SOW.BMHXVWL MB]J^D?VO+9!YYHH()3)(D4C(9?E("DCMDY_"O/\`X@33:?XST*VLYYX()=GF M1QRL%?\`>8Y&>>*])TR[:_TJTNW4(T\*2%1VW`''ZUYE\2I$?QYH!1@P7RPQ M!SC][WIU/ANB,-=U.5^9Z#+H,8UBTU"VEEA,)821"1MDJE2.5SC(.#FFV?A] M(;^^N[J:6XDN92Z*TC;(DP`%57_"Z675;_68]0GGN4CVA!)*S;?F;ISQTKT#1=*.CPW$`N)9HGG:2 M+S7+LBD#Y+]UC>!9$$J3*926N7)SC![)@\_@.!3] M<@CN?%^G0[8'=[2X!67.TG*8R!_P+'XUT^!Z48&(;>:XMC9VD;((Q'\S!H@V2<]B2.E= M/@=Q1M'H*`.=\(:I)>V,<%P/)EA@C`MV7D)MX?=T8'VZ=#S5/Q%?7Z< M'>/1G#MLE"K(W_+12._R'`_VC[5UV`!Z4;1Z"@#G1JU[<:L+>VE1H+R..>SF M$.5"`_O0QSU`QCI][V--M-*AB\7W:PK)Y+/5(7C%IJNZ>;$T99;J/ACAQR"!]WM_#@5V84*,*`!["D"J" M2``3U('6@#EK;Q!J-U;Q2P&&8SV$EPRK& MK:W$1;^QQ<8''45UP4#.`!GDX'6@`#H!0!Q,EUQVZ[T^T2VZW!C4YPI[_`$SD?A5S`!'` MIB011S22HBK))@.P'+8Z4`8L[QQ^-[)1*0TEG-N0R'&=T>WC.`<9_6L6PDNG M6SFA=_M_V>[^V\DD,#\NX>S=/;IQ7;X&3D'//8UOI>C4O!PO+@(IGL][@=`Q7D<^];&!Z"C`Q MC'%`'`_8PGP]>ZEBMAOTV$!X\[F;@G=GJV<>^5OM9(1#;L MN6ND?;EE/XD#'3;S72X'I2;5R#@9'0XZ4`U*'>(N?WF M?I\V>F#CK5SP[?7FHQW$]S<6\D:S20HD494C:[`$G)Z@"MG:N[.!G&,T``=! MB@!:***`"BBB@`HHHH`0]#7RC/\`\?,W_71OYFOJX]#7RC/_`,?,W_71OYF@ M:.Y^#7_([2?]>C_^A+7NU>$_!K_D=I/^O1__`$):]VH$%>8?&+0]\%IK,2\Q MGR)B/0\J?SR/Q%>GU0UO2XM:T:[T^;[EQ&4SZ'L?P.#43CS1L:T*GLZBD?-/ M45[Q\-M=_MKPG"DK[KBS/D29ZD#[I_+'Y&O"[BWEM+F6WG7;+"Y1U/8@X-=? M\+M<_LKQ4MK*V(+\>4<]`XY4_P`Q^->0'_5J6"J/Q.?RKNO8\5)O8P; M.Y:RO8;A.L;!OJ._Z5Z;&ZRQJZ'*L`0?4&O+*[GPI>_:=($3'+VYV'Z=O\^U M-B-RO.MQ^.:[S4;DVEC+*HRX&U!ZL>`/S-87B'21' MX?@*C8,*]-AE6>%)8SE'4,#[&O+:[;PC> M_:-+,#'Y[=L?\!/(_K38&_6;;?Z7K-Q<'F.W'D1_[W5C_(?A5J^NA9V4LY&2 MBY`]3V'YTW3;4V=A%$QS)C8>.[:7PCXWL? M$UDA\F=_WRCH6`PP_P"!+^H->BM=1:JMJELX>"=!.S#O'U`_$X_`&LXR;NGN M;U*:2C*.S+<4D5Q`'\LA!R!(FW'O@U5@U.RNLR62FY525\R&/%P5=1Z[3SCWZ5/]GAW[_*CWYSNVC.:\ MT^+=Q+I>JZ)J=FYBNXO,"NO4@%3@^HY/'O6C\3M+CZO M_P"BA4RDXV+IPC-2\E<]"L=6TW4+VXLH`1<6X#2Q20,A4'H>0*T!!$.D:?\` M?(IHM81>&Z"#SS'Y9?N5SG'YU-5KS,6UT&22)!$TDC*D:`LS,!*!U(SUK.\17]IJ,TGA=&W7M];ON`.!$F/O$_R'?Z5R?P M_P!1N+._N/"^JRM!?6>Y;1B`0!U8`'KZCVJ7.SL;1I7@Y=?T[GIBJ%&%``'8 M4,JN,,H(]"*HZ(;M]+BDO[A9YW&2RQA!^`K0JD8M6=AGE1Y!V+D=#BH;ZT^V MVY@+[8WX?Y021W`ST^M6:*8KD<,,=O`D,*A(XU"HHZ``8`J2BB@`HHHH`*** M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`YWQ'9F]U/34MKLV MM\@D>"4'HP`P&'\2GD$5G#7IH4U;4#I_E:C:Q00W,3`D(Q=@6!_B3:0V?0HV$'ZFMP*%`"@`#L*6@#F/$:MIFIV=_93""6]E6 MRG!/#*W23']Y.Q]\&HWU:XT][FTLD0&QN(8(K1P2]Q&VW+ALY_B;GI\IS75$ M`]11M&X-@9'>@#D-0O[K4-%\3"YGMS;6HF@C18R&)V*58G/J2.G45HZ-KR2V M,TNH2+:M"45H'',0/"G=_'NR,$<P/04R6WBGV>;&K>6P=HH[T`3+,+^/5HUC`) MS]GVKGC^YMWY[9]Z;H3/-=:8YD?SGMK@:C\Q!#;EQN]"#NQ[9QQ78X&[.!GI MFC:,DX&3U]Z`.)M[V>+PH$LI\!]4D@DF9R?*B,SO%`&!@<"@#,L3]OU6XOCS##FVM M_0X/[QOQ8!?^`^]073F7Q5'!.Y2WBLFF3G`WEMI;/JJX^FZMB*&.")8X45(U MX"J,`4R6UBFFBE=,R1$E&[C(P1]#Z4`^OWL+L+:20J/($[9(4G,K M9.5)R!ZD#)ZU7L[G3?\`A!--;57,J\HD;2D>8^3@,?8_;7=FMI)@Q82Q[&)Y[[648)Y_.E\=7-S#I#K'%-Y'RLTD4BJ2 MV\87D@XQDG'^-=&;:(W2W!3,J*45C_"#UQ]<#\JE(!ZB@#BM1GNI/$9GBP\2 MSVP,#-B=(-NHZ4R7L<=I>^7(88IIS@?[2E.K#C'<9JGJNHW@ET M!I[6[AC\^`A6E3+,4.X/R"<9`Y&,Y]J[,J&(R`<W=FB?3(S<\D_OMW5O M]O[V>]=2`!T%``&<`#/)Q0`M%%%`!1110`AZ&OE&?_CYF_ZZ-_,U]7'H:^49 M_P#CYF_ZZ-_,T#1W/P:_Y':3_KT?_P!"6O=J\)^#7_([2?\`7H__`*$M>[4" M"BBB@#Q3XLZ'_9WB--0B7$-^N6QT$B\'\Q@_G7#QR/%(DD3%71@RL.Q'(->X M_$ZVCO\`PVEFL9EOI9@UJB]W@ZG/2L^A]'>'] M=AUCPU;:JS*JM%NE]$9?O?D0:I>'+3^TM,O=2NT(DU=C(`PY2'&V-?\`OGGZ ML:\T\!ZE_Y?U^1Y?-"]O/)#(,/&Q4_A6MX5O?LNL+&QPDXV'Z]1_GWJ7Q?9 M?9]36X4?).O/^\.OZ8K"1VC=70X92&!]"*V.4]#N/]*U>WM^J6X\]_\`>Z*/ MYG\*O31+/"\4@RKJ5(]C5'1@\MJUY,NV6Z/F$?W5QA1^7\ZT:0SR^YMVM+J6 M!_O1L5-:7AF]^QZS&K'"3CRV^O;]?YU;\8V7E7T=TH^69=K?[P_^M_*N=!*L M&4X(.0?0TQ'HE[_I6I6MIU1/](E^@X4?GS^%:-9>AF2YMWOYUVR7."!Z*!@? MU/XUJ4AA113)-Y0^65#]BPR*`,GQ7H2>(O#MU8''F,NZ%C_#(.5/]/H:@\$Z M'/H/AJVMKQBUUMS)EL[/1`?09_G61IOC>^E\UMFL+G!%Q\V5&<-D9Y(R#6?-'XCI4*MO9=]3H/$WAN MS\4:2UE>;EYW1RK]Z-O4?X4FBQ:AIFE6]E>Q+FS#2F!9R`2`I*KQR.M597N8\SY>5[&!J?A M1O$OB"TO]8VI9V0_(M(ET^]4^6^"K+]Y&' M1A7.^"O&6H>+9+Y7M[6V^RE0,;FW9S[CTK<:[U>/6;6(Q6D^GRLR231;@\3` M$C(R1@D8J5RM774TFJD9^+=1LO!EIXB^S6LLNKT+6HO$.AP:C: M*T:SJ<+(.5()!!]>17-V7C34+OQY/X=-O:JL6\>>`Q)PH/W<^_K3ERNUR::G M'F2[:G;#IS2UR%OXWDA\:MX;U.U19F($5Q`Q*ME=PRIY''N:ZZJ33V,IP<+7 MZG"^*/!^JOXL@\2>'I8C=)M$D$S;0V!C@^A'!%1>+?">J>(GM-6T^V73]7M@ M-P:IQQQ79ZO=36.EW-W!Y9:")Y-K@D-M!..#QTKF_"/BG5?%FBW M-[%!9PS12&-8VW%6^4'DYXZ^E9N,;V[G1"I4Y5-=-#?T5M0:R3^TK:&U=45/ M)C?>`1U.?0\8'M6E7)^#?'4/BJ:XM7M6M;RW&YTW;E89P2#]:ZRKBTUH85(R MC)J2L%%*?,KV$X245/H7****9(4444`%%%%`!1110`4444`%%%%`!1110`4 M444`%%%%`!1110`4444`%%%)0`M%%%`!129Q2T`%%%%`!1110`4444`%%%%` M!1110`4444`%%%)0`M%%%`!1110`4444`%%%%`!1110`4444`(>E?*,__'S- M_P!=&_F:^D#X2@)_Y"FM#_N(2?XUCGX1>%R23!=$DY)^T-0!P'P:_P"1VD_Z M]'_]"6O=JY"Q^&6A:9<&>P:_MIBNW?%=NIQZ9%7SX1A(XU;6Q]+^2@#H*R=? M\3Z7X:M#/J=TD9Q\L0.9']@O4U3?P9!(A5]7UPJ>H_M!ZRI/A'X:FD,DJWTD MC=6>Z9B?Q-`%+P'J-UXS\37_`(CO(_+MK5/LME"3D1[N6.>[8`R?>O/?'&A_ MV!XKN[9%Q!(?.A]-K=OP.1^%>Z:#H-CX;TM;#349(%8O\S;B23R2:PO'O@E_ M%L-HUK/%;W5NQ&^0$AD/4<>X'ZUE6AS1T.K"5E2GKLS$^#VA^387.LS+\]P? M)AS_`'`?F/XG_P!!KTJJFEZ?%I.EVUC;C$5O&(U]\#K^/6K=7"/+&QE6J>TF MY&1XFLOMFC2%1F2']XOX=?TS7%:=:&_U""W7I(W/L._Z5Z60&!!&0>"*Q-&\ M/?V7?SW#2*X8%8@!RH)[_I5F1MJH10JC"@8`]*6BBD!F>(++[=H\R*,N@\Q/ MJ/\`ZV:X.SMFO;N&W3K*P7Z#N?RKT^L+2_#HT_5YKLNK1G/E*!RN3W_E3`VH MHUAB2-!A4`4#V%/HHI`%%%%`'F7Q7TR6QN].\2V/RS6\BQR,.Q!RA/XY'XBK M?BJT'CGP2VJ6JDF"(36Z^I`_>#^GU6NTUG2X-;TBYT^ZSY4Z%25ZJ>Q'N#S4 MMA8PZ=I\%E;J!#!&(U7V`Q6;A=OLSI5>T8]U^1Q_P_UMO$?AVRM926DL2%N" M?X@O^K_/@_\``:[=_N-]*R_#_AVS\-VDUO8@[)IFF8MC.3T'T`X%:4R&2,JL MC1D_Q*!G]:J*:6IE5E&4VX['E7PC@DGDUQ8[F6`G8-T84DT M)8-3N?,<7#CSG/,I>0[2?<[A4.@^#+'PTUPVESW49N,>9O97SC..HXZFI[_P MS#J=[:W%[>WLGV659HXA(JQ[@<@E0.:B$7%>9K6J1J3;OHS!^+G_`")0_P"O MJ/\`K6;>6$DWPDL;HW!DBMK5)FM90/*E`QP<8;Z1T.<9[U!)X3M)M#BT>6YNFT^)53R@X7Z%_)G./W\8<[0!_#@8[`<5ZA6+'X3TT: MV=7N$>ZO^-LL[9V8Z;5&`,?2MJG!-7N15G&=K;V,_P`0_P#(MZG_`->DO_H! MKA/A+!Z^S[KDC<(PS#Y%Y&>/TKT._LEU"SEMI)'2.5"C[,9*D8(Y M%9WAWPM9^&+=[?3I9_)=][)(P;)P!UQGM0XMR3'&HE2<>K(_#OA+2_"L@&?2MTL`I)(``SFL[7M#MO$6E2:?>-*L,A!)B?:V0 M*'28=-AGG2"*,1?>#,RCU)%-*VB1G)\WO2>I1N=/;7=/O4N;>-X+Y-B;I""L M?\)QC@Y^;\O2N,^'&IW'A[7[SPIJC;6WEH">F\=0/9A@C_Z]>GHI1%4L6P,9 M(`S^5<_JW@C3M8UB+5+F6Z2\AQL>%PF,'([64);/\SH2P5< ML0!ZFG5CZ[XPD:4QL+Z`#$A4$>8-V1GD8]:I:Q`AUY;R$VEU M.LT$?V9M_F@9Y9<-@8#;N01P>:ZLJ#U`/UI-B[MVT;L8SCG%`'$>=='RY;5Y M#J@DOA.H))P`^P$>F1'M_#'6M/PZ0VJ*UI(SVKZ="TOS$CS.N[)ZY MZ]JJW/B@6.D6;:8A@46RW`@N5R3&7VXW;NN,],XXSQ79-&CXWJK8Y&1G%*0" M>0*`.3OM;O--U+7Y4D6X6WA@DAMR#PIX9QST')/T[5+/K>HV^G?;R]M+:Q7: M*[0@2,T+8!.%.`P8]L\5T^!G..:155%PH``[`8H`YZSUN_?[8U]&L!TY)#=( MD9<$_>CVG//R=?>JMMK^J7NGZL;-K>6XM%CF@^3/F(R[BN`Q&>H!!ZXKK:KW M=K]JMS"LLD(.`6BP#CN.0>M`%;1KR34K4WN\&VG(>V&S:WEXX)^IR?IBN.M@ M$UO?"5=UUQU\N)B)=A&"<]/+&22,8XZYKT"-%BC6-`%10%4#L!2[0#D`9]:` M.:T_7[V]N;+`B_TB6:*:WVG?:[-V&//JH!SC.X8J'2O$LNIR:?!0'&PDD?CC)YK;?4=3&N-IY,2F98YK=Q$64(#^]!.>2.,=/O#WK>** M0`5!P(Y9_$BVB2Q&V=IXB&3:R/'CGKT//7&>HXJO9^([YM*L; MN\GM$2]F,)F6,A+?`?ELDY)*@#.`,UUFT<\#FDVJ000,'J,4`*26.5XU9XB2C$?=)&"1^'%/9%?&Y0<'(R.E`'(-XDN;&P0&*.S']DFX@ MAF#.PD7C9G(+<8]^:EO-3FDGOC;O$)SHWGQNF2P;YN!S@^HXS75D`D$@9'3V MH"@=`*`./7Q'?K#96T$MJ\DE@EPEQ,P5)WS@KDGMCG&3STK:\12Z?%I:MJQ_ MZ2MW?>1J\8MY+F228J5^49C"YP2YSD>Y/I7 M:%%(&5!P%-2?1PYOEA)BV#+9[X]\9Q[UL44` M8MG_`&7_`,2PJZ^>T)\K#'++M&[=Z_CWKG/!#QC0=.EOY(/+%Q*(BS'SC,9F M"CW&">*[L1H"2$7)ZG'6D$48((C4$=#@4`>7O<-:ZGJ-XTDJV]MXCC#F)B'" M,JKCTV9/(KHM'QCX;CC4>7-+?XEZ;;QDB*/29`%+$CAU`_'%4_!EM)>I>>8D4EM%JURQ9F M/F*5<%-I_N]:[C8I;<5&[UQS0J*GW5`^@H`X&-_]&\?_`#'Y7?9S]W]P#QZ< M^G>M?PT85M-+-X]MYTME&MN$)WLOE@R;_7D#FNF\I.?D7GKQUH$48.0B@].E M`'F=A-=)\.])?3'D.L->XA"$EW'G-N#>J[E(L:(#M15SUP,9H`\Q\,SR1 MZCHKEIW#ZA?1;86.2-QP9/5!C\#BMWPO?06-YXKGNYUCABU)OF=N`NQ>!^/8 M5V*QHA^55'T%)Y,9ZQI_WR*`.-62Y_X3?Q-]A^:Y7386MU)X\S#XX^N,U?\` M#[6C>'M$DOW;[6F_=M7=ZXYH`R_ M$%H^K:;<:7#,T4EQ$P+HV&08X/YX_#-)_M06Z%E@Y94W' MD`<;L;L=^/I5N[-JEJK:48SJ1LY#9JI^_P#*.OKSMZUN*BH/D4+]!BA8T4DJ MJ@GJ0*`.$N)+L>`-*FT]I6UMG@Y.?-:4L/,#]\?>SGC%:5B?)^).L"<[(Y+& M!H]YPK8+!B,\>F?PKJ0BABP4;CU..:&C1R-RJV.F1G%`',ZSHDFJ:;9"QN#: M:E:H9[20'`#C'##NIR01[TVVE76/"D^H7MDUK=Q+/NA8_P"JE"E6^O(.#Z&N MIVC=NP,COB@J"""`0>QH`Y3P=&B>#-(G3/VRYLXXBV[EL#.3[C).:@\-7#VV MFZOXJV)3_1HK"V,:!CA M2&;D>_`KM<``8'2DV*&W!1N]<W'%=M30B!MP5=WKCFG4`%%%%`!1110`4444`%%%%`!1110!R_BI4.M:(' M>!`S3AC/G9CRS][D=\54T;5KFWTO3K(R?94'ZBAD5P-RAL'(R,\T`ZMY7+0VUK' M)$G968D,?R%;FQ>?E'/7B@#E9];N]/O===ITE6&:`1QE2?)1U0%^OW1DD^X/ M-.N-?OX'DB22V9%OH+>.Y*';(D@&[@'JN>H./I74[1SP.1@\4@C0*%"*%'08 MX%`&9H-_/>P727;1M-;7,D!9%VA@IX.,G&0:Y+2SY>LVKP%9"-6N4,<+$2A, ML,MS@QCT^F/?T'`!.`.:`J@DA0"?04`,?-)#)N` M"E0*..VE"I;,1([`KRVXKCOC'XXJQHU[96.K^(#-/'&3?*J@MR?W M4?`'^\3T[DUT^T`Y`&?7%)Y:%@Q5=A<*"5^50."3D[LC!Y_#L616(+*"5. M1D=*-B[P^T;@,9QS0!RDE_.?',*7*7$*-:SH!YB!%4,F'^]U(!.<9Y'H:STO M8+6SU:[\.WBX,,:QP^:9"/GPUP0VVFV+-$Y=9LJ&SD\DC.#UY%2*?[0UUFSFWL!M'HTS#G_OE3CZL? M2M155%"J``.@`Q38H8X5*Q(J`L6(`QDDY)_.@#*U-V?7])M6)%N_FRL.SN@& MT'\RA4],C\"1^-2JBJ3M4#)R<#J:`.3L+EY-*U*WN61U2U2S#`.!QAAP*D6X9?#/AR[AD+7`:UCSG)YELK=0EK.TGF2G<3\I##D^N#R/2NSQS2%%+ABHW#H<12G[1NG.925($(7.".0?;`[DU/XFN)YO"&I2W4$ME)& MA\L>>,L<<'*G]*Z/8N<[1GZ4I`/4`_6@#G-=L;'5;NT@VF:ZNH]JNLC;8HAR MSC!QGD`>Y'H:K70TM?%-I%;7H@NX)5\UFG.2NW:L(7/.>#[?4UU@4#H`.W%) IL7.=HS]*`,#2[B"#Q+K<;7("@PD"27.#M.<9/Z45O&)#U13]110!_]D_ ` end EX-101.INS 5 nphc-20131231.xml XBRL INSTANCE DOCUMENT 0001119643 2012-01-01 2012-12-31 0001119643 2013-01-01 2013-12-31 0001119643 2014-03-31 0001119643 2013-06-30 0001119643 2012-08-01 2012-08-31 0001119643 2012-12-31 0001119643 2013-12-31 0001119643 2011-12-31 0001119643 us-gaap:CommonStockMember 2011-12-31 0001119643 us-gaap:AdditionalPaidInCapitalMember 2011-12-31 0001119643 us-gaap:RetainedEarningsMember 2011-12-31 0001119643 us-gaap:CommonStockMember 2012-01-01 2012-12-31 0001119643 us-gaap:AdditionalPaidInCapitalMember 2012-01-01 2012-12-31 0001119643 us-gaap:CommonStockMember 2013-01-01 2013-12-31 0001119643 us-gaap:AdditionalPaidInCapitalMember 2013-01-01 2013-12-31 0001119643 us-gaap:RetainedEarningsMember 2012-01-01 2012-12-31 0001119643 us-gaap:RetainedEarningsMember 2013-01-01 2013-12-31 0001119643 us-gaap:CommonStockMember 2012-12-31 0001119643 us-gaap:AdditionalPaidInCapitalMember 2012-12-31 0001119643 us-gaap:RetainedEarningsMember 2012-12-31 0001119643 us-gaap:CommonStockMember 2013-12-31 0001119643 us-gaap:AdditionalPaidInCapitalMember 2013-12-31 0001119643 us-gaap:RetainedEarningsMember 2013-12-31 0001119643 us-gaap:ComputerEquipmentMember 2012-12-31 0001119643 us-gaap:FurnitureAndFixturesMember 2012-12-31 0001119643 nphc:LabEquipmentMember 2012-12-31 0001119643 nphc:TelephoneEquipmentMember 2012-12-31 0001119643 us-gaap:OfficeEquipmentMember 2012-12-31 0001119643 us-gaap:LeaseholdImprovementsMember 2012-12-31 0001119643 us-gaap:ComputerEquipmentMember 2013-12-31 0001119643 us-gaap:FurnitureAndFixturesMember 2013-12-31 0001119643 nphc:LabEquipmentMember 2013-12-31 0001119643 nphc:TelephoneEquipmentMember 2013-12-31 0001119643 us-gaap:OfficeEquipmentMember 2013-12-31 0001119643 us-gaap:LeaseholdImprovementsMember 2013-12-31 0001119643 us-gaap:FairValueInputsLevel1Member 2012-12-31 0001119643 us-gaap:FairValueInputsLevel2Member 2012-12-31 0001119643 us-gaap:FairValueInputsLevel3Member 2012-12-31 0001119643 us-gaap:FairValueInputsLevel1Member 2013-12-31 0001119643 us-gaap:FairValueInputsLevel2Member 2013-12-31 0001119643 us-gaap:FairValueInputsLevel3Member 2013-12-31 0001119643 us-gaap:MinimumMember 2012-12-31 0001119643 us-gaap:MaximumMember 2012-12-31 0001119643 us-gaap:MinimumMember 2013-12-31 0001119643 us-gaap:MaximumMember 2013-12-31 0001119643 us-gaap:MinimumMember 2012-01-01 2012-12-31 0001119643 us-gaap:MaximumMember 2012-01-01 2012-12-31 0001119643 us-gaap:MinimumMember 2013-01-01 2013-12-31 0001119643 us-gaap:MaximumMember 2013-01-01 2013-12-31 0001119643 us-gaap:FairValueInputsLevel3Member 2011-12-31 0001119643 us-gaap:FairValueInputsLevel3Member 2012-01-01 2012-12-31 0001119643 us-gaap:FairValueInputsLevel3Member 2013-01-01 2013-12-31 0001119643 nphc:BankOfAmericaMember 2012-01-02 0001119643 nphc:BankOfAmericaMember 2011-12-04 2012-01-02 0001119643 nphc:CoventryEnterprisesLlcMember nphc:December202012Member 2012-01-01 2012-12-31 0001119643 nphc:CoventryEnterprisesLlcMember nphc:January72013Member 2012-01-01 2012-12-31 0001119643 nphc:CoventryEnterprisesLlcMember nphc:March132013Member 2012-01-01 2012-12-31 0001119643 nphc:PostGraduateHealthcareEducationLlcMember 2012-02-03 0001119643 nphc:ImmunoclinLtdMember 2012-12-20 0001119643 nphc:AleraTechnologiesIncMember 2012-12-31 0001119643 nphc:CoventryEnterprisesLlcMember 2012-12-31 0001119643 nphc:RedwoodManagementLlcMember 2012-01-01 2012-12-31 0001119643 nphc:RedwoodManagementLlcMember 2012-02-03 0001119643 nphc:CoventryEnterprisesLlcMember 2012-01-01 2012-12-31 0001119643 nphc:RedwoodManagementLlcMember us-gaap:RestrictedStockMember 2012-01-01 2012-12-31 0001119643 nphc:CoventryEnterprisesLlcMember us-gaap:RestrictedStockMember 2012-01-01 2012-12-31 0001119643 nphc:CoventryEnterprisesLlcMember us-gaap:CommonStockMember 2012-01-01 2012-12-31 0001119643 nphc:ImmunoclinLtdMember 2013-01-01 2013-12-31 0001119643 nphc:VendorMember 2013-01-01 2013-12-31 0001119643 nphc:TwoVendorMember 2013-08-01 2013-09-30 0001119643 nphc:CoventryEnterprisesLlcMember 2013-01-01 2013-12-31 0001119643 us-gaap:PresidentMember 2012-12-31 0001119643 us-gaap:ManagementMember 2012-12-31 0001119643 us-gaap:ManagementMember 2013-12-31 0001119643 us-gaap:PresidentMember 2013-12-31 0001119643 nphc:RikDeitschMember 2012-01-01 2012-12-31 0001119643 nphc:RikDeitschMember 2013-01-01 2013-12-31 0001119643 nphc:RikDeitschMember 2012-12-31 0001119643 nphc:NotePayableThreeMember 2013-09-30 0001119643 us-gaap:DirectorMember 2010-09-30 0001119643 us-gaap:DirectorMember 2012-01-01 2012-09-30 0001119643 us-gaap:DirectorMember 2013-01-01 2013-09-30 0001119643 nphc:NotePayableTwoMember 2011-01-01 2011-12-31 0001119643 us-gaap:DirectorMember 2013-01-01 2013-12-31 0001119643 nphc:NotePayableOneMember 2011-05-01 2011-05-31 0001119643 nphc:NotePayableTwoMember 2011-05-01 2011-05-31 0001119643 nphc:NotePayableTwoMember 2013-09-16 0001119643 nphc:NotePayableOneMember 2013-11-25 0001119643 us-gaap:DirectorMember 2012-12-31 0001119643 nphc:NotePayableTwoMember 2012-12-31 0001119643 us-gaap:DirectorMember 2013-12-31 0001119643 nphc:MichaelMcdonaldTrustMember 2013-12-31 0001119643 nphc:NotePayableTwoMember 2013-12-31 0001119643 nphc:NotePayableOneMember 2011-05-31 0001119643 nphc:NotePayableTwoMember 2011-05-31 0001119643 nphc:CoventryEnterprisesLlcMember 2013-06-30 0001119643 nphc:NotePayableThreeMember 2013-08-31 0001119643 nphc:NotePayableTwoMember 2011-09-30 0001119643 nphc:NotePayableTwoMember 2011-10-31 0001119643 nphc:ConvertibleNotePayableDatedFebruary32012Member 2012-01-01 2012-12-31 0001119643 nphc:ConvertibleNotePayableDatedMarch162012Member 2013-01-01 2013-12-31 0001119643 nphc:ConvertibleNoteOneAmendedMember 2013-01-01 2013-12-31 0001119643 nphc:ConvertibleNoteTwoAmendedMember 2013-01-01 2013-12-31 0001119643 nphc:ConvertibleNotePayableDatedOctober272011Member 2011-01-01 2011-12-31 0001119643 nphc:NotePayableTwoMember 2012-01-01 2012-12-31 0001119643 nphc:NotePayableThreeMember 2013-01-01 2013-12-31 0001119643 nphc:ConvertibleNotePayableDatedFebruary32012Member 2013-01-01 2013-12-31 0001119643 nphc:CoventryEnterprisesLlcMember 2013-03-01 2013-03-31 0001119643 nphc:CoventryEnterprisesLlcMember 2013-04-01 2013-04-30 0001119643 nphc:CoventryEnterprisesLlcMember 2013-06-01 2013-06-30 0001119643 nphc:ChristopherCastaldoMember 2013-07-01 2013-07-31 0001119643 nphc:CoventryEnterprisesLlcMember 2013-09-01 2013-09-12 0001119643 nphc:CoventryEnterprisesLlcMember 2013-09-01 2013-09-30 0001119643 nphc:NotePayableTwoMember 2013-01-01 2013-12-31 0001119643 nphc:ConvertibleNoteOneMember nphc:ChristopherCastaldoMember 2013-01-01 2013-12-31 0001119643 nphc:ChristopherCastaldoMember 2013-01-01 2013-12-31 0001119643 nphc:ConvertibleNoteTwoMember nphc:ChristopherCastaldoMember 2013-01-01 2013-12-31 0001119643 nphc:MichaelMcdonaldTrustMember 2013-04-01 2013-04-30 0001119643 nphc:LiquidPackageResourcesIncMember 2011-01-01 2011-12-31 0001119643 nphc:ConvertibleNotePayableDatedFebruary32012Member 2012-02-03 0001119643 nphc:ConvertibleNotePayableDatedMarch162012Member 2012-03-16 0001119643 nphc:CoventryEnterprisesLlcMember 2013-03-22 0001119643 nphc:ChristopherCastaldoMember 2013-07-10 0001119643 nphc:CoventryEnterprisesLlcMember 2013-09-03 0001119643 nphc:CoventryEnterprisesLlcMember 2013-09-12 0001119643 nphc:ConvertibleNotePayableDatedOctober272011Member 2011-10-27 0001119643 nphc:ConvertibleNotePayableDatedDecember52011Member 2011-12-31 0001119643 nphc:NotePayableThreeMember 2013-12-31 0001119643 nphc:SouthridgePartnersIillpMember 2013-12-31 0001119643 nphc:LiquidPackageResourcesIncMember 2011-08-02 0001119643 nphc:LiquidPackageResourcesIncMember 2011-12-31 0001119643 nphc:LiquidPackageResourcesIncMember 2012-01-01 2012-03-31 0001119643 nphc:LiquidPackageResourcesIncMember 2013-01-01 2013-12-31 0001119643 nphc:MichaelMcdonaldTrustMember 2013-07-01 2013-07-31 0001119643 nphc:TCNInternationalMember nphc:ConvertibleNotePayableDatedFebruary32012Member 2012-01-01 2012-12-31 0001119643 nphc:CoventryEnterprisesLlcMember us-gaap:RestrictedStockMember 2013-01-01 2013-06-30 0001119643 nphc:ConvertibleNotePayableDatedDecember52011Member nphc:October312012Member us-gaap:RestrictedStockMember 2013-01-01 2013-12-31 0001119643 nphc:October262012Member 2013-01-01 2013-12-31 0001119643 nphc:CoventryEnterprisesLlcMember nphc:RestrictedStockTwoMember 2013-03-01 2013-03-31 0001119643 nphc:CoventryEnterprisesLlcMember nphc:RestrictedStockOneMember 2013-06-01 2013-06-30 0001119643 nphc:NotePayableTwoMember 2013-09-10 2013-09-16 0001119643 nphc:NotePayableOneMember 2013-11-20 2013-11-25 0001119643 nphc:ConvertibleNotePayableDatedOctober72013Member 2013-10-07 0001119643 nphc:SouthridgePartnersIillpMember 2012-12-31 0001119643 nphc:CoventryEnterprisesLlcMember nphc:ConvertibleNoteOneMember 2013-01-01 2013-12-31 0001119643 us-gaap:ConvertibleNotesPayableMember 2013-01-01 2013-12-31 0001119643 nphc:CoventryEnterprisesLlcMember 2013-12-01 2013-12-31 0001119643 nphc:SouthridgePartnersIillpMember 2012-10-01 2012-10-31 0001119643 us-gaap:RestrictedStockMember 2012-10-01 2012-10-31 0001119643 us-gaap:RestrictedStockMember us-gaap:InvestorMember 2012-01-01 2012-12-31 0001119643 us-gaap:RestrictedStockMember nphc:OneInvestorsMember 2012-01-01 2012-12-31 0001119643 us-gaap:RestrictedStockMember us-gaap:InvestorMember 2013-01-01 2013-12-31 0001119643 us-gaap:RestrictedStockMember nphc:FiveInvestorsMember 2013-01-01 2013-12-31 0001119643 us-gaap:RestrictedStockMember nphc:CapitalPathSecuritiesLlcMember 2013-01-01 2013-12-31 0001119643 nphc:MichaelMcdonaldTrustMember 2013-01-01 2013-12-31 0001119643 nphc:EmployeesAndDirectorsMember us-gaap:RestrictedStockMember 2012-02-01 2012-02-29 0001119643 nphc:EmployeesAndDirectorsMember us-gaap:RestrictedStockMember 2013-09-01 2013-09-30 0001119643 nphc:EmployeesAndDirectorsMember us-gaap:RestrictedStockMember 2012-10-01 2012-10-31 0001119643 nphc:EmployeesAndDirectorsMember us-gaap:RestrictedStockMember 2013-11-01 2013-11-30 0001119643 nphc:EmployeesAndDirectorsMember us-gaap:RestrictedStockMember 2012-12-01 2012-12-31 0001119643 nphc:EmployeesAndDirectorsMember us-gaap:RestrictedStockMember 2012-02-03 0001119643 nphc:ConsultantEightMember us-gaap:RestrictedStockMember us-gaap:InvestorMember 2013-07-31 0001119643 nphc:EmployeesAndDirectorsMember us-gaap:RestrictedStockMember 2013-09-03 0001119643 nphc:EmployeesAndDirectorsMember us-gaap:RestrictedStockMember 2012-10-31 0001119643 nphc:EmployeesAndDirectorsMember us-gaap:RestrictedStockMember 2013-11-22 0001119643 us-gaap:RestrictedStockMember us-gaap:InvestorMember 2012-12-31 0001119643 us-gaap:RestrictedStockMember nphc:OneInvestorsMember 2012-12-31 0001119643 nphc:EmployeesAndDirectorsMember us-gaap:RestrictedStockMember 2012-12-31 0001119643 us-gaap:RestrictedStockMember us-gaap:InvestorMember 2013-12-31 0001119643 us-gaap:RestrictedStockMember nphc:FiveInvestorsMember 2013-12-31 0001119643 nphc:ConsultantOneMember us-gaap:RestrictedStockMember us-gaap:InvestorMember 2013-12-31 0001119643 nphc:ConsultantTwoMember us-gaap:RestrictedStockMember us-gaap:InvestorMember 2013-12-31 0001119643 nphc:ConsultantThreeMember us-gaap:RestrictedStockMember 2013-12-31 0001119643 nphc:TwoConsultantsMember us-gaap:RestrictedStockMember 2013-12-31 0001119643 nphc:TwoConsultantsMember us-gaap:RestrictedStockMember us-gaap:InvestorMember 2013-12-31 0001119643 nphc:ConsultantFourMember us-gaap:InvestorMember us-gaap:RestrictedStockMember 2013-12-31 0001119643 us-gaap:RestrictedStockMember nphc:ConsultantFiveMember 2013-12-31 0001119643 us-gaap:RestrictedStockMember nphc:ConsultantSixMember 2013-12-31 0001119643 us-gaap:RestrictedStockMember nphc:ConsultantSevenMember 2013-12-31 0001119643 nphc:ConsultantTenMember us-gaap:RestrictedStockMember us-gaap:InvestorMember 2013-12-31 0001119643 nphc:ConsultantElevenMember us-gaap:RestrictedStockMember us-gaap:InvestorMember 2013-12-31 0001119643 nphc:ConsultantNineMember us-gaap:RestrictedStockMember us-gaap:InvestorMember 2013-12-31 0001119643 nphc:ConsultantTwelveMember us-gaap:RestrictedStockMember us-gaap:InvestorMember 2013-12-31 0001119643 nphc:ThreeConsultantsMember us-gaap:RestrictedStockMember us-gaap:InvestorMember 2013-12-31 0001119643 nphc:ConsultantThirteenMember us-gaap:RestrictedStockMember us-gaap:InvestorMember 2013-12-31 0001119643 nphc:RoetzellAndressMember us-gaap:RestrictedStockMember 2013-12-31 0001119643 nphc:FiveConsultantsMember us-gaap:RestrictedStockMember 2013-12-31 0001119643 nphc:ConsultantFourteenMember us-gaap:RestrictedStockMember 2013-12-31 0001119643 nphc:JpuVenturesIncMember us-gaap:RestrictedStockMember 2013-12-31 0001119643 nphc:MarkBergmanMember us-gaap:RestrictedStockMember 2013-12-31 0001119643 nphc:ConsultantFifteenMember us-gaap:RestrictedStockMember 2013-12-31 0001119643 nphc:CapitalPathSecuritiesLlcMember us-gaap:RestrictedStockMember 2013-12-31 0001119643 nphc:ConsultantOneMember us-gaap:RestrictedStockMember us-gaap:InvestorMember 2013-01-01 2013-12-31 0001119643 nphc:ConsultantTwoMember us-gaap:RestrictedStockMember us-gaap:InvestorMember 2013-01-01 2013-12-31 0001119643 nphc:ConsultantThreeMember us-gaap:RestrictedStockMember 2013-01-01 2013-12-31 0001119643 nphc:TwoConsultantsMember us-gaap:RestrictedStockMember 2013-01-01 2013-12-31 0001119643 nphc:TwoConsultantsMember us-gaap:InvestorMember us-gaap:RestrictedStockMember 2013-01-01 2013-12-31 0001119643 nphc:ConsultantFourMember us-gaap:InvestorMember us-gaap:RestrictedStockMember 2013-01-01 2013-12-31 0001119643 us-gaap:RestrictedStockMember nphc:ConsultantFiveMember 2013-01-01 2013-12-31 0001119643 us-gaap:RestrictedStockMember nphc:ConsultantSixMember 2013-01-01 2013-12-31 0001119643 us-gaap:RestrictedStockMember nphc:ConsultantSevenMember 2013-01-01 2013-12-31 0001119643 nphc:ConsultantNineMember us-gaap:RestrictedStockMember us-gaap:InvestorMember 2013-01-01 2013-12-31 0001119643 nphc:ConsultantTenMember us-gaap:RestrictedStockMember us-gaap:InvestorMember 2013-01-01 2013-12-31 0001119643 nphc:ConsultantElevenMember us-gaap:RestrictedStockMember us-gaap:InvestorMember 2013-01-01 2013-12-31 0001119643 nphc:ConsultantTwelveMember us-gaap:RestrictedStockMember us-gaap:InvestorMember 2013-01-01 2013-12-31 0001119643 nphc:ThreeConsultantsMember us-gaap:RestrictedStockMember us-gaap:InvestorMember 2013-01-01 2013-12-31 0001119643 nphc:ConsultantThirteenMember us-gaap:RestrictedStockMember us-gaap:InvestorMember 2013-01-01 2013-12-31 0001119643 nphc:RoetzellAndressMember us-gaap:RestrictedStockMember 2013-01-01 2013-12-31 0001119643 nphc:FiveConsultantsMember us-gaap:RestrictedStockMember 2013-01-01 2013-12-31 0001119643 nphc:ConsultantFourteenMember us-gaap:RestrictedStockMember 2013-01-01 2013-12-31 0001119643 nphc:JpuVenturesIncMember us-gaap:RestrictedStockMember 2013-01-01 2013-12-31 0001119643 nphc:MarkBergmanMember us-gaap:RestrictedStockMember 2013-01-01 2013-12-31 0001119643 nphc:ConsultantFifteenMember us-gaap:RestrictedStockMember 2013-01-01 2013-12-31 0001119643 nphc:ConsultantEightMember us-gaap:InvestorMember us-gaap:RestrictedStockMember 2013-07-01 2013-07-31 0001119643 nphc:CoventryEnterprisesLlcMember us-gaap:RestrictedStockMember 2013-01-01 2013-03-31 0001119643 nphc:RikDeitschMember us-gaap:RestrictedStockMember 2013-01-01 2013-12-31 0001119643 nphc:CoventryEnterprisesLlcMember us-gaap:RestrictedStockMember 2013-04-01 2013-06-30 0001119643 nphc:NotePayableThreeMember 2013-07-01 2013-09-30 0001119643 nphc:RedwoodManagementLlcMember us-gaap:RestrictedStockMember 2012-10-01 2012-10-31 0001119643 nphc:SouthridgePartnersLlpMember us-gaap:RestrictedStockMember 2012-10-01 2012-10-31 0001119643 nphc:AsherEnterpriseMember us-gaap:RestrictedStockMember 2012-10-01 2012-10-31 0001119643 nphc:RedwoodManagementAndTcnInternationalMember us-gaap:RestrictedStockMember 2012-10-01 2012-10-31 0001119643 nphc:TwoVendorMember 2013-01-01 2013-12-31 0001119643 nphc:VendorMember 2013-01-01 2013-12-31 0001119643 nphc:CoventryEnterprisesLlcMember us-gaap:RestrictedStockMember 2013-01-01 2013-12-31 0001119643 us-gaap:InvestorMember 2012-01-01 2012-12-31 0001119643 nphc:OneInvestorsMember 2012-01-01 2012-12-31 0001119643 us-gaap:InvestorMember 2013-01-01 2013-12-31 0001119643 nphc:FiveInvestorsMember 2013-01-01 2013-12-31 0001119643 nphc:TwoInvestorsMember 2013-01-01 2013-12-31 0001119643 nphc:FiveInvestorsMember us-gaap:MinimumMember 2013-01-01 2013-12-31 0001119643 nphc:FiveInvestorsMember us-gaap:MaximumMember 2013-01-01 2013-12-31 0001119643 nphc:TwoInvestorsMember us-gaap:MinimumMember 2013-01-01 2013-12-31 0001119643 nphc:TwoInvestorsMember us-gaap:MaximumMember 2013-01-01 2013-12-31 0001119643 nphc:FiveConsultantsMember us-gaap:RestrictedStockMember 2012-01-01 2012-12-31 0001119643 nphc:MarkBergmanMember us-gaap:RestrictedStockMember 2012-01-01 2012-12-31 0001119643 us-gaap:StockOptionMember 2011-12-31 0001119643 us-gaap:StockOptionMember 2012-01-01 2012-12-31 0001119643 us-gaap:StockOptionMember 2013-01-01 2013-12-31 0001119643 us-gaap:StockOptionMember 2012-12-31 0001119643 us-gaap:StockOptionMember 2013-12-31 0001119643 us-gaap:MinimumMember us-gaap:StockOptionMember 2013-01-01 2013-12-31 0001119643 us-gaap:MaximumMember us-gaap:StockOptionMember 2013-01-01 2013-12-31 0001119643 us-gaap:WarrantMember us-gaap:MinimumMember 2012-12-31 0001119643 us-gaap:WarrantMember us-gaap:MaximumMember 2012-12-31 0001119643 us-gaap:WarrantMember us-gaap:MinimumMember 2013-12-31 0001119643 us-gaap:WarrantMember us-gaap:MaximumMember 2013-12-31 0001119643 us-gaap:WarrantMember 2012-12-31 0001119643 us-gaap:WarrantMember 2013-12-31 0001119643 us-gaap:WarrantMember 2012-01-01 2012-12-31 0001119643 us-gaap:WarrantMember 2013-01-01 2013-12-31 0001119643 us-gaap:ConvertibleNotesPayableMember 2013-01-01 2013-03-31 0001119643 us-gaap:ChiefExecutiveOfficerMember 2013-01-01 2013-06-30 0001119643 us-gaap:PrivatePlacementMember 2013-01-01 2013-12-31 0001119643 us-gaap:PrivatePlacementMember 2013-10-01 2013-11-30 0001119643 nphc:PatriciaMedingEtAlVReceptopharmIncFkaReceptogenIncMember 2006-01-01 2006-12-31 0001119643 nphc:PatriciaMedingEtAlVReceptopharmIncFkaReceptogenIncMember 2008-01-01 2008-12-31 0001119643 nphc:LiquidPackagingResourcesIncVNutraPharmaCorpAndErikRikDeitschMember 2011-01-01 2011-12-31 0001119643 nphc:LaurenceNRaymondVReceptopharmIncEtAlMember 2011-01-01 2011-12-31 0001119643 nphc:PaulFReidVHaroldHRumphEtAlMember 2011-01-01 2011-12-31 0001119643 nphc:InvoluntaryPetitionOfBankruptcyMember 2012-01-01 2012-12-31 0001119643 nphc:PatriciaMedingEtAlVReceptopharmIncFkaReceptogenIncMember 2010-01-01 2010-12-31 0001119643 nphc:LiquidPackagingResourcesIncVNutraPharmaCorpAndErikRikDeitschMember 2011-12-31 0001119643 nphc:LiquidPackagingResourcesIncVNutraPharmaCorpAndErikRikDeitschMember 2012-01-01 2012-12-31 0001119643 nphc:LiquidPackagingResourcesIncVNutraPharmaCorpAndErikRikDeitschMember 2012-12-31 0001119643 us-gaap:SubsequentEventMember 2010-01-01 2010-12-31 0001119643 us-gaap:SubsequentEventMember 2013-01-01 2013-12-31 0001119643 us-gaap:SubsequentEventMember us-gaap:InvestorMember 2014-01-30 2014-01-31 0001119643 nphc:OptionsAndWarrantsMember 2012-01-01 2012-12-31 0001119643 us-gaap:ConvertibleNotesPayableMember 2012-01-01 2012-12-31 0001119643 nphc:OptionsAndWarrantsMember 2013-01-01 2013-12-31 0001119643 us-gaap:ConvertibleNotesPayableMember 2013-01-01 2013-12-31 0001119643 nphc:HaroldHRumphMember 2013-01-01 2013-12-31 0001119643 nphc:TwoVendorMember 2013-09-30 0001119643 nphc:VendorMember 2013-12-31 0001119643 nphc:VendorMember 2013-09-16 0001119643 nphc:HaroldHRumphMember 2013-12-31 0001119643 nphc:RikDeitschMember us-gaap:RestrictedStockMember 2012-01-01 2012-12-31 0001119643 nphc:MichaelMcdonaldTrustMember 2013-07-31 0001119643 nphc:MichaelMcdonaldTrustMember 2013-01-01 2013-12-31 0001119643 nphc:UniversityCentreWestLtdMember 2012-12-31 0001119643 nphc:ConvertibleNoteOneMember 2012-12-31 0001119643 nphc:ConvertibleNoteTwoMember 2012-12-31 0001119643 nphc:UniversityCentreWestLtdMember 2013-12-31 0001119643 nphc:ConvertibleNoteOneMember 2013-12-31 0001119643 nphc:ConvertibleNoteTwoMember 2013-12-31 0001119643 nphc:MichaelMcdonaldTrustMember us-gaap:SubsequentEventMember 2014-01-16 2014-01-17 0001119643 nphc:CoventryEnterprisesLlcMember nphc:FiveYearWarrantMember 2013-09-03 0001119643 nphc:CoventryEnterprisesLlcMember nphc:ConvertibleNoteOneMember 2013-09-30 0001119643 nphc:CoventryEnterprisesLlcMember 2013-12-31 0001119643 nphc:CoventryEnterprisesLlcMember nphc:FiveYearWarrantMember 2013-12-31 0001119643 nphc:ConvertibleNoteOneMember nphc:CoventryEnterprisesLlcMember 2013-12-31 0001119643 us-gaap:ConvertibleNotesPayableMember nphc:FiveYearWarrantMember 2013-01-01 2013-03-31 0001119643 nphc:FiveYearWarrantMember 2013-01-01 2013-12-31 0001119643 nphc:NotePayableThreeMember nphc:CoventryEnterprisesLlcMember 2013-12-31 0001119643 nphc:CoventryEnterprisesLlcMember us-gaap:RestrictedStockMember nphc:January212013Member 2013-01-01 2013-03-31 0001119643 nphc:CoventryEnterprisesLlcMember us-gaap:RestrictedStockMember nphc:February112013Member 2013-01-01 2013-03-31 0001119643 nphc:CoventryEnterprisesLlcMember us-gaap:RestrictedStockMember nphc:Mar202013Member 2013-01-01 2013-03-31 0001119643 nphc:April172013Member nphc:CoventryEnterprisesLlcMember us-gaap:RestrictedStockMember 2013-04-01 2013-06-30 0001119643 nphc:May162013Member nphc:CoventryEnterprisesLlcMember us-gaap:RestrictedStockMember 2013-04-01 2013-06-30 0001119643 nphc:June122013Member nphc:CoventryEnterprisesLlcMember us-gaap:RestrictedStockMember 2013-04-01 2013-06-30 0001119643 nphc:June252013Member nphc:CoventryEnterprisesLlcMember us-gaap:RestrictedStockMember 2013-06-01 2013-08-31 0001119643 nphc:August302013Member nphc:CoventryEnterprisesLlcMember us-gaap:RestrictedStockMember 2013-06-01 2013-08-31 0001119643 nphc:August282013Member nphc:CoventryEnterprisesLlcMember us-gaap:RestrictedStockMember 2013-08-01 2013-09-30 0001119643 nphc:September32013Member nphc:CoventryEnterprisesLlcMember us-gaap:RestrictedStockMember 2013-08-01 2013-09-30 0001119643 nphc:September42013Member nphc:CoventryEnterprisesLlcMember us-gaap:RestrictedStockMember 2013-08-01 2013-09-30 0001119643 nphc:WarrantOneMember nphc:CoventryMember 2013-01-01 2013-12-31 0001119643 nphc:CoventryMember nphc:WarrantTwoMember 2013-01-01 2013-12-31 0001119643 nphc:CoventryMember 2013-09-03 0001119643 nphc:CoventryMember 2013-09-12 0001119643 nphc:CoventryMember 2013-09-30 0001119643 nphc:CustomerOneMember 2013-01-01 2013-12-31 0001119643 nphc:CustomerTwoMember 2013-01-01 2013-12-31 0001119643 us-gaap:ChiefExecutiveOfficerMember 2013-12-31 0001119643 nphc:ConvertibleNoteOneAmendedMember 2013-12-31 0001119643 nphc:ConvertibleNoteTwoAmendedMember 2013-12-31 0001119643 us-gaap:ConvertibleNotesPayableMember 2013-12-31 0001119643 nphc:SouthridgePartnersIillpMember 2013-01-01 2013-12-31 0001119643 nphc:ChristopherCastaldoMember nphc:ConvertibleNoteTwoMember 2013-12-31 0001119643 nphc:ModificationMember 2013-12-31 0001119643 nphc:ModificationMember 2013-01-01 2013-12-31 0001119643 us-gaap:SubsequentEventMember nphc:MichaelMcdonaldTrustMember 2014-01-16 2014-01-17 0001119643 us-gaap:InvestorMember us-gaap:SubsequentEventMember 2014-01-31 0001119643 nphc:MichaelMcdonaldTrustMember us-gaap:SubsequentEventMember 2014-01-17 0001119643 nphc:CoventryEnterprisesLlcMember us-gaap:SubsequentEventMember nphc:ConvertibleNoteOneMember 2014-03-12 0001119643 nphc:CoventryEnterprisesLlcMember us-gaap:SubsequentEventMember nphc:ConvertibleNoteTwoMember 2014-03-12 0001119643 nphc:CoventryEnterprisesLlcMember 2013-09-03 0001119643 nphc:CoventryEnterprisesLlcMember 2013-09-12 0001119643 nphc:CoventryEnterprisesLlcMember us-gaap:SubsequentEventMember nphc:ConvertibleNoteOneMember 2014-03-11 2014-03-12 0001119643 nphc:CoventryEnterprisesLlcMember us-gaap:SubsequentEventMember nphc:ConvertibleNoteTwoMember 2014-03-11 2014-03-12 0001119643 us-gaap:SubsequentEventMember us-gaap:ChiefExecutiveOfficerMember 2014-03-11 2014-03-12 0001119643 us-gaap:SubsequentEventMember us-gaap:ChiefExecutiveOfficerMember 2014-03-12 0001119643 nphc:HaroldHRumphMember 2013-01-01 2013-12-31 0001119643 nphc:CoventryEnterprisesLlcMember us-gaap:RestrictedStockMember 2012-03-01 2012-03-31 0001119643 nphc:CoventryEnterprisesLlcMember us-gaap:RestrictedStockMember 2012-12-01 2012-12-31 0001119643 nphc:HaroldHRumphMember 2013-12-31 0001119643 nphc:TwoVendorMember 2013-09-30 0001119643 nphc:TwoVendorMember 2013-12-31 0001119643 nphc:VendorMember 2013-12-31 0001119643 nphc:MichaelMcdonaldTrustMember us-gaap:SubsequentEventMember 2014-01-17 0001119643 nphc:InvoluntaryPetitionOfBankruptcyMember 2013-01-01 2013-12-31 0001119643 nphc:InvoluntaryPetitionOfBankruptcyMember us-gaap:SubsequentEventMember 2014-01-25 2014-02-12 xbrli:shares iso4217:USD iso4217:USD xbrli:shares iso4217:USD nphc:Warrant xbrli:pure 7559 4640 38314 11141 0 5000 200868 68091 246741 88872 39515 24534 16621 15955 302877 129361 800860 1019130 964673 957682 723386 689588 18727 323172 1371574 1359238 3879220 4348810 561774 1003062 33505739 36764309 -37643856 -41986820 -3576343 -4219449 302877 129361 0.001 0.001 2000000000 2000000000 561773778 1004313019 561773778 1004313019 203290 122198 147647 41165 55643 81033 2656742 2442471 2656742 2442471 -2601099 -2361438 153472 157376 -400488 -1135677 -457292 -707651 -1011252 -1981526 -3612351 -4342964 -0.01 -0.01 402996638 743492967 1799461 1391979 -3911445 326337 29793723 -34031505 326337959 970681 63300 907381 741370 71600 669770 63300000 71600000 828780 42595 786185 507720 35630 472090 42595000 35630000 434500 43450 391050 140000 42000 98000 43450000 42000000 254700 17000 237700 162500 50000 112500 17000000 50000000 100000 4000 96000 30300 4500 25800 4000000 5750000 1346792 63892 1282900 1646832 193758 1453074 63890819 193759241 12000 1200 10800 1200000 -3612351 -4342964 561774 33505739 -37643856 1003062 36764309 -41986820 561773778 1004313019 1200000 -357292 -707650 -100000 0 14994 14981 -400488 -1135677 33055 1159 38314 -27173 -117800 5000 -28678 9446 169216 429808 13600 83669 -721242 -531037 446500 140000 -8000 0 164779 181718 49478 83600 115000 225000 79000 75000 35000 0 728801 528118 7559 -2919 0 77314 70130 0 0 436639 709146 1346792 1646832 254700 162500 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">1. BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <i><font style="FONT-SIZE: 10pt">Organization</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Nutra Pharma Corp. ("Nutra Pharma"), is a holding company that owns intellectual property and operates in the biotechnology industry. Nutra Pharma incorporated under the laws of the state of California on February 1, 2000, under the original name of Exotic-Bird.com.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Through its wholly-owned subsidiary, ReceptoPharm, Inc. (&#8220;ReceptoPharm&#8221;), Nutra Pharma conducts drug discovery research and development activities. In October 2009, Nutra Pharma launched its first consumer product called Cobroxin<sup>&#174;</sup>, an over-the-counter pain reliever designed to treat moderate to severe chronic pain. In May 2010, Nutra Pharma launched its second consumer product called Nyloxin<sup>&#174;</sup>, an over-the-counter pain reliever that is a stronger version of Cobroxin<sup>&#174;</sup> and is designed to treat severe chronic pain.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Basis of Presentation and Consolidation</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The accompanying consolidated financial statements include the results of Nutra Pharma and its wholly-owned subsidiaries Designer Diagnostics Inc. and ReceptoPharm (collectively "the Company", &#8220;us&#8221;, &#8220;we&#8221; or &#8220;our&#8221;). We operate as one reportable segment. All intercompany transactions and balances have been eliminated in consolidation.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Liquidity and Going Concern</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Our Consolidated financial statements are presented on a going concern basis, which contemplate the realization of assets and satisfaction of liabilities in the normal course of business. We have experienced recurring, significant losses from operations, and have an accumulated deficit of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">41,986,820</font> <font style="font-size:10pt;"></font>at December 31, 2013. In addition, we had respective working capital and stockholders&#8217; deficits at December 31, 2013 of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4,259,938</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4,219,449</font>&#160;respectively.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">There is substantial doubt regarding our ability to continue as a going concern which is contingent upon our ability to secure additional financing, increase ownership equity and attain profitable operations. In addition, our ability to continue as a going concern must be considered in light of the problems, expenses and complications frequently encountered in established markets and the competitive environment in which we operate.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">As of December 31, 2013, we do not have sufficient cash to sustain our operations for the next year and will require additional financing in order to execute our operating plan and continue as a going concern. Since our sales are not currently adequate to fund our operations, we continue to rely principally on debt and equity funding; however proceeds from such funding have not been sufficient to execute our business plan. Our plan is to attempt to secure adequate funding until sales of our pain products are adequate to fund our operations. We cannot predict whether additional financing will be available, and/or whether any such funding will be in the form of equity, debt, or another form. In the event that these financing sources do not materialize, or if we are unsuccessful in increasing our revenues and profits, we will be unable to implement our current plans for expansion, repay our obligations as they become due and continue as a going concern.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The accompanying Consolidated Financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Use of Estimates</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The accompanying Consolidated Financial statements are prepared in accordance with accounting principles generally accepted in the United States of America which require management to make estimates and assumptions. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expense. Significant estimates include our ability to continue as going concern, the recoverability of inventories and long-lived assets, and the valuation of stock-based compensation and certain debt and warrant liabilities. Actual results could differ from those estimates. Changes in facts and circumstances may result in revised estimates, which would be recorded in the period in which they become known.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Revenue Recognition</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In general, we record revenue when persuasive evidence of an arrangement exists, services have been rendered or product delivery has occurred, the sales price to the customer is fixed or determinable, and collectability is reasonably assured. Provision for sales returns is estimated based on our historical return experience. Revenue is presented net of returns and allowances for returns.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Accounting for Shipping and Handling Costs</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company records shipping and handling costs incurred in cost of sales.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt"> &#160;</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Cash and Cash Equivalents</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">We consider all highly liquid investments with an original maturity of three months or less to be cash equivalents.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Accounts Receivable and Allowance for Doubtful Accounts</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company grants credit without collateral to its customers based on the Company&#8217;s evaluation of a particular customer&#8217;s credit worthiness. In addition, allowances for doubtful accounts are maintained for potential credit losses based on the age of the accounts receivable and the results of the Company&#8217;s periodic credit evaluations of its customers&#8217; financial condition. Accounts receivable are written off after collection efforts have been deemed to be unsuccessful. Accounts written off as uncollectible are deducted from the allowance for doubtful accounts, while subsequent recoveries are netted against the provision for doubtful accounts expense. The Company generally does not charge interest on accounts receivable.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Accounts receivable are stated at estimated net realizable value. Accounts receivable are comprised of balances due from customers net of estimated allowances for uncollectible accounts.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <i><font style="FONT-SIZE: 10pt">&#160;</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Inventories</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Inventories, which are stated at the lower of average cost or market, and consist mostly of raw venom that is utilized to make the API (active pharmaceutical ingredient). The raw unprocessed venom has an indefinite life for use. The Company regularly reviews inventory quantities on hand. If necessary it records a provision for excess and obsolete inventory based primarily on its estimates of component obsolescence, product demand and production requirements. Write-downs are charged to cost of goods sold. We performed evaluations of our inventory during the year ended December 31, 2013 and 2012 and recorded total allowances of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">117,800</font>, respectively.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Financial Instruments and Concentration of Credit Risk</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Our financial instruments include cash, accounts receivable, accounts payable, accrued expenses, loans payable, due to officers and derivative financial instruments. Other than certain warrant and convertible instruments (derivative financial instruments) and liabilities to related parties (for which it was impracticable to estimate fair value due to uncertainty as to when they will be satisfied and a lack of similar type transactions in the marketplace), we believe the carrying values of our financial instruments approximate their fair values because they are short term in nature or payable on demand. Our derivative financial instruments are carried at a measured fair value.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Balances in various cash accounts may at times exceed federally insured limits. We have not experienced any losses in such accounts. We do not hold or issue financial instruments for trading purposes. In addition, for the year ended December 31, 2013, there were two customers that accounted for <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 19.6</font>% and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 15.3</font>% of the total revenues, respectively. For the year ended December 31, 2012, <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">no customers accounted for more than 10% of the Company&#8217;s total revenues. During 2013, the Company purchased 100% of its venom from one vendor</font>.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Derivative Financial Instruments</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt"> &#160;</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. Management evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported as charges or credits to income. For option-based simple derivative financial instruments, the Company uses the Black-Scholes option-pricing model to value the derivative instruments at inception and subsequent valuation dates. For complex embedded derivatives, the Company uses a Dilution-Adjusted Black-Scholes method to value the derivative instruments at inception and subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <i><font style="FONT-SIZE: 10pt">&#160;</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Property and Equipment and Long-Lived Assets</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Property and equipment is recorded at cost. Expenditures for major improvements and additions are added to property and equipment, while replacements, maintenance and repairs which do not extend the useful lives are expensed. Depreciation is computed using the straight-line method over the estimated useful lives of the assets of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3 &#150; 7 years</font>.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Property and equipment consists of the following at December 31,</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2012</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Computer equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>21,918</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>21,918</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Furniture and fixtures</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>34,757</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>34,757</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Lab equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>42,129</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>42,129</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Telephone equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>12,421</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>12,421</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Office equipment &#150; other</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,629</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,629</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Leasehold improvements</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>67,417</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>67,417</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Total</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>181,271</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>181,271</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Less: Accumulated depreciation and amortization</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(156,737)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(141,756)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Property and equipment, net</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>24,534</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>39,515</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">We review our long-lived assets for recoverability if events or changes in circumstances indicate the assets may be impaired. At December 31, 2013, we believe the carrying values of our long-lived assets are recoverable. Depreciation expense for the years ended December 31, 2013 and 2012 was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">14,981</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">14,994</font>, respectively.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Advertising</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt"> &#160;</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">All advertising costs are expensed as incurred. Advertising costs were approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">900</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">70,800</font> for the years ended December 31, 2013 and 2012, respectively.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Income Taxes</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">We compute income taxes in accordance with Financial Accounting Standard Board (&#8220;FASB&#8221;) Accounting Standard Codification (&#8220;ASC&#8221;) Topic 740, <i>Income Taxes</i> (&#8220;ASC Topic 740&#8221;). Under ASC Topic 740, deferred taxes are recognized for the tax consequences of temporary differences by applying enacted statutory rates applicable to future years to differences between the financial statement carrying amounts and the tax bases of existing assets and liabilities. Also, the effect on deferred taxes of a change in tax rates is recognized in income in the period that included the enactment date. Temporary differences between financial and tax reporting arise primarily from the use of different methods to record bad debts and /or sales returns, and inventory reserves.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On an annual basis, we evaluate tax positions that have been taken or are expected to be taken in our tax returns to determine if they are more than likely to be sustained if the taxing authority examines the respective position. As of December 31, 2013 and 2012, we do not believe we have a need to record any liabilities for uncertain tax positions or provisions for interest or penalties related to such positions.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Since inception, we have been subject to tax by both federal and state taxing authorities. Until the respective statutes of limitations expire (which may be as much as <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">20</font> years while we have unused net operation losses), we are subject to income tax audits in the jurisdictions in which we operate.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <i><font style="FONT-SIZE: 10pt">&#160;</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Stock-Based Compensation</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">We account for stock-based compensation in accordance with FASB ASC Topic 718, <i>Stock Compensation</i> (ASC Topic 718). ASC Topic 718, which requires that the cost resulting from all share-based transactions be recorded in the financial statements over the respective service periods. It establishes fair value as the measurement objective in accounting for share-based payment arrangements and requires all entities to apply a fair-value-based measurement in accounting for share-based payment transactions with employees. The statement also establishes fair value as the measurement objective for transactions in which an entity acquires goods or services from non-employees in share-based payment transactions.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Net Loss Per Share</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Net loss per share is calculated in accordance with ASC Topic 260, <i>Earnings per Share</i>. Basic loss per share is calculated by dividing net loss by the weighted average number of common shares outstanding for the period. Diluted loss per share is calculated by dividing net loss by the weighted average number of common shares and dilutive common stock equivalents outstanding. During periods in which we incur losses, common stock equivalents, if any, are not considered, as their effect would be anti-dilutive or have no effect on earnings per share. Any common shares issued as of a result of the exercise of stock options and warrants would come from newly issued common shares from our remaining authorized shares.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> As of December 31, 2013 and 2012, the following items were not included in dilutive loss as the effect is anti-dilutive:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>2012</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div>Options and warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>154,916,667</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>57,256,667</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div>Convertible notes payable</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>98,506,398</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>44,642,858</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div>Total</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>253,423,065</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>101,899,525</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <i><font style="FONT-SIZE: 10pt">&#160;</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Reclassifications</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Certain amounts in the 2012 Consolidated Financial statements have been reclassified to conform to the current period presentation.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Recent Accounting Pronouncements</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">We have determined that all recently issued but not yet effective accounting standards will not have a material impact on our Consolidated Financial statements.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">2. FAIR VALUE MEASUREMENTS</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Certain assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2013 are measured in accordance with FASB ASC Topic 820-10-05, <i>Fair Value Measurements</i>. FASB ASC Topic 820-10-05 defines fair value, establishes a framework for measuring fair value and expands the disclosure requirements regarding fair value measurements for financial assets and liabilities as well as for non-financial assets and liabilities that are recognized or disclosed at fair value on a recurring basis in the financial statements.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The statement requires fair value measurement be classified and disclosed in one of the following three categories:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The following table summarizes our financial instruments measured at fair value as of December 31, 2013 and 2012:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="55%" colspan="11"> <div> Fair&#160;Value&#160;Measurements&#160;at&#160;December&#160;31,&#160;2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="43%"> <div>Liabilities:</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Total</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Level&#160;1</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Level&#160;2</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Level&#160;3</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>Warrant liability</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>323,172</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>323,172</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>Convertible notes at fair value</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>767,056</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>767,056</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="43%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="55%" colspan="11"> <div> Fair&#160;Value&#160;Measurements&#160;at&#160;December&#160;31,&#160;2012</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="43%"> <div>Liabilities:</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Total</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Level&#160;1</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Level&#160;2</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Level&#160;3</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>Warrant liability</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>18,727</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>18,727</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>Convertible notes at fair value</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>588,091</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>588,091</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160; <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="FONT-SIZE: 10pt">&#160;</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The following table shows the changes in fair value measurements using significant unobservable inputs (Level 3) during the years ended December 31, 2013 and 2012:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in 0in 0in 0.75in; WIDTH: 60%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="35%"> <div>Description</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2012</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div>Beginning balance</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>18,727</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>28,833</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div>Purchases, issuances, and settlements</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>243,147</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="35%"> <div>Day one loss on value of hybrid instrument</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>729,093</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div>Total gain included in earnings (1)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(667,795)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(10,106)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div>Ending balance</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>323,172</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>18,727</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">(1) The gain or loss related to the revaluation of our warrant liability is included in &#8220;Change in fair value of derivatives&#8221; in the accompanying consolidated statement of operations.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company values its warrants using a Dilution-Adjusted Black-Scholes Model. Assumptions used include (1) <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 0.13</font>% to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1.75</font>% risk-free rate, (2) warrant life is the remaining contractual life of the warrants, (3) expected volatility of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 124</font>% to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 236</font>% (4) zero expected dividends (5) exercise price set forth in the agreements (6) common stock price of the underlying share on the valuation date, and (7) number of shares to be issued if the instrument is converted (See note 5).</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif ">&#160;</div><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The following table summarizes the significant terms of each of the debentures for which the entire hybrid instrument is recorded at fair value as of December 31, 2013 and 2012:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 98%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="15%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="32%" colspan="3"> <div>Conversion&#160;Price&#160;-<br/> Lower&#160;of Fixed&#160;Price<br/> or&#160;Percentage&#160;of<br/> VWAP&#160;for&#160;Look-back<br/> Period</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="15%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>Debenture<br/> Issuance</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>Face</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="15%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>Default<br/> Interest</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="16%"> <div>Anti-<br/> Dilution<br/> Adjusted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="15%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="15%"> <div>Look-back</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>Year</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>Amount</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="15%"> <div>Interest&#160;Rate</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>Rate</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="16%"> <div>Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="15%"> <div>%</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="15%"> <div>Period</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>564,376</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="15%"> <div>8%-20%</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>n/a</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="16%"> <div>$0.0036-$0.0064</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="15%"> <div>50%-85%</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="15%"> <div>10 to 30 Days</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2012</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>902,369</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>6%-12%</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>n/a</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"> <div>$0.0070-$0.0137</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>15%-70%</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>5 to 20 Days</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="left"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The following table shows the changes in fair value measurements using significant unobservable inputs (Level 3) during the years ended December 31, 2013 and 2012 for the Convertible Notes:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0px:auto; WIDTH: 70%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>Years&#160;Ended&#160;December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2012</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="45%"> <div>Description</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Beginning balance</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>588,091</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>206,863</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Purchases, issuances, and settlements</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>751,419</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>902,369</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Day one loss on value of hybrid instrument</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,656,802</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>479,422</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>(Gain) loss from change in fair value</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(582,423)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>309,680</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Conversion to common stock</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(1,646,832)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(1,310,243)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Ending balance</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>767,057</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>588,091</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">3. SETTLEMENT OF ACCOUNTS AND NOTE PAYABLE</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">At January 2, 2012, the Company owed Bank of America approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">80,000</font> representing the balance of a credit line originated on <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> September 28, 2006</font>. Bank of America assigned and sold this debt to Great Plains Capital Corporation (&#8220;Great Plains&#8221;). On February 3, 2012, Great Plains assigned the debt to Redwood Management, LLC (&#8220;Redwood&#8221;). At February 3, 2012, the Company owed Post Graduate Healthcare Education, LLC (&#8220;Post Graduate&#8221;) $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">109,500</font> representing the balance of a total debt of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">149,500</font>. Post Graduate assigned the debt to Redwood Management, LLC. The total amount of the Company&#8217;s debt assigned to Redwood was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">188,608</font>. Under a Securities Settlement Agreement, the Company issued a Convertible Debenture to Redwood for $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">188,608</font> payable within six months with interest at <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">6</font>% annum. The full amount of principal and interest was due at maturity unless the Debenture was converted to shares of common stock in accordance with the debenture agreement, whereby such debenture could be converted into shares of our common stock at a price equal to 75% of the lowest closing price (determined on the then current trading market for our common stock) during the 15 trading days prior to conversion. Following the agreement Redwood accepted <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 18,737,894</font> shares of our restricted stock as satisfaction for the note and we recorded a loss of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">42,958</font> on the settlement.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt">&#160;</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">At March 22, 2012, the Company owed Alera Technologies, Inc. (&#8220;Alera&#8221;) $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">65,040</font> representing the balance of a purchase order for the production of Nyloxin&#153; products. Alera assigned the rights to the debt to Coventry Enterprises, LLC (&#8220;Coventry&#8221;). The Company issued a Convertible Redeemable Note in favor of Coventry in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">65,040</font> bearing interest of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">8</font>% annum. Coventry was entitled to convert all or any amount of the this note into shares of the Company's common stock (the "Common Stock") at a conversion price ("Conversion Price") for each share of Common Stock equal to 55% of the average of the daily volume weighted average prices of the Common Stock for the 3 trading days with the lowest volume weighted average prices during the 20 trading days immediately preceding the Conversion Date. The note was satisfied on April 5, 2012 in exchange for <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 8,672,090</font> shares of restricted Common Stock.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">At December 20, 2012, the Company owed <i>Immunoclin, Ltd</i>. (&#8220;Immunoclin&#8221;) $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">80,389</font> representing the balance of invoices for clinical services. The Company issued an $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">80,000</font> note payable at <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">8</font>% to Immunoclin in exchange for the outstanding accounts payable. $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">20,000</font>, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">40,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">20,000</font> of the debt were assigned to Coventry Enterprises, LLC (&#8220;Coventry&#8221;) on December 20, 2012, January 7, 2013, and March 13, 2013, respectively. Coventry made the first conversion of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2,565,102</font> shares of Company&#8217;s common stock to satisfy the debt of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">20,000</font> on December 20, 2012. The Company issued two Convertible Redeemable Notes for the remaining amount of $40,000 and $20,000 on January 7, 2013, and March 13, 2013. Coventry made the conversion of a total of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 15,119,481</font> shares of the company&#8217;s restricted stock satisfying the remaining notes in full during the year ended December 31, 2013. The Company&#160;elected to account for these hybrid contracts under the guidance of FASB ASC Topic 815 Derivatives &amp; Hedging. The fair value has been defined as the common stock equivalent value, enhanced by the fair value of the default put plus the present value of the coupon. The Company recorded a loss of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">65,039</font> on the settlement and the change in fair value of derivatives in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4,885</font> during the year ended December 31, 2013.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">During August and September, 2013, the Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 3,000,000</font> shares of the company&#8217;s restricted stock to settle the outstanding accounts payable in aggregate of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">38,528</font> with two vendors. The shares were valued at $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.018</font> per share. The Company recorded a total loss of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">15,472</font> on the settlement date (See Note 6).</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">During September, 2013, the Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 25,000,000</font> shares of the company&#8217;s restricted stock and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 25,000,000</font> warrants to purchase stock at an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.030</font> to settle the outstanding accounts payable of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">112,621</font> with one vendor. The shares were valued at $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.015</font> per share (See Note 6). The Company classified embedded conversion features in the warrants as a derivative liability. The warrants were valued at their fair value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">243,146</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">63,297</font>, respectively using the Black-Scholes method at the commitment and re-measurement dates of September 16, 2013 and December 31, 2013, respectively. The Company recorded a loss of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">505,525</font> on the settlement date (See Note 7).</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">During September, 2013, Mr. Harold H. Rumph (ReceptoPharm&#8217;s CEO) accepted <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 14,800,000</font> shares of the Company&#8217;s restricted common stock as a repayment to discharge $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">37,000</font> of his accrued salary to the Company (See Note 6).</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">4. DUE TO OFFICERS</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>At December 31, 2013 and December 31, 2012, the balance due to officers consisted of the following:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>December&#160;31,<br/> 2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>December&#160;31,<br/> 2012</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>An unsecured demand loan from our President and CEO, Rik Deitsch. The loan bears interest at 4%. The loan balance at December 31, 2013 and 2012, respectively, includes accrued interest payable of $349,466 and $324,853.</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>566,399</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>606,168</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>A loan from Paul Reid, the former President of ReceptoPharm bearing interest at a rate of 5% per annum, due on demand and secured by certain intellectual property of ReceptoPharm having a zero cost at December 31, 2013 and December 31, 2012.<br/> The accrued interest at December 31, 2013 and December 31, 2012 was $43,363 and $37,392, respectively.</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>123,189</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>117,218</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Ending balances</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>689,588</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>723,386</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">During the year ended December 31, 2013, we borrowed $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">151,718</font> and repaid $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">53,600</font> to Mr. Deitsch. In addition, Mr. Deitsch accepted a total of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 50,000,000</font> shares of the Company&#8217;s restricted common stock as a repayment to discharge $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">162,500</font> of his outstanding loan to the Company in year ended December 31, 2013(See note 6).</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">During June, 2013, <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 25,000,000</font> warrants to purchase stock at an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.10</font> per share were issued to CEO, Mr. Deitsch in exchange of notes payable. The warrants expire on <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">December 31, 2014</font> (See note 7).</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">During the year ended December 31, 2012, we borrowed $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">164,779</font> and repaid $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">324,478</font> to Mr. Deitsch. Included in this amount, Mr. Deitsch assigned $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">175,000</font> of the debt to a third party on January 2, 2012 and accepted a total of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10,000,000</font> shares of the Company&#8217;s restricted common stock as a repayment to discharge $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">100,000</font> of his outstanding loan the Company in December 2012(See note 6).</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">5. OTHER DEBT</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Other debt (all short-term) consists of the following at December 31, 2013 and 2012:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="clear:both;MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2012</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Note payable &#150; Related Party (1)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>180,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>190,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Notes payable &#150; Non Related Parties (2)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>412,182</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>593,483</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Convertible notes payable, at fair value (3)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>767,056</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>588,091</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Ending balances</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,359,238</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,371,574</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">(1)</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">During the third quarter of 2010 we borrowed $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">200,000</font> from one of our directors. We repaid $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10,000</font></font> each (total $20,000) during the third quarter of 2012 and 2013. Under the terms of the loan agreement, this loan was expected to be repaid in nine months to a year from the date of the loan along with <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">interest calculated at 10% for the first month plus 12% after 30 days from funding</font>. We are in default regarding this loan. At December 31, 2013 and 2012, we owed this director accrued interest of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">121,137</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">86,387</font>, respectively.</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">(2)</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">At December 31, 2013 and 2012, the balance of $412,182 and $593,483 , respectively, consisted of the following loans:</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 45pt; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="60"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt">&#183;</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In May 2011, the Company received a loan for $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">25,000</font> from a non-related party. This loan was expected to be repaid no later than December 31, 2011, along with <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">interest calculated at 10% for the first month plus 12% after 30 days from funding</font>. This loan is guaranteed by an officer of the Company. On November 25, 2013, the non-related party accepted a total of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 4,360,000</font> shares of the Company&#8217;s restricted common stock as a repayment to discharge $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">25,000</font> of his outstanding loan and accrued interest of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">11,956</font> (See note 6).&#160; The Company recorded a loss of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">28,444</font> on the settlement date.</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 45pt; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="60"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt">&#183;</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In May 2011, the Company received another loan for $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">25,000</font> from a non-related party. This loan was expected to be repaid no later than December 31, 2011, along with <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">interest calculated at 10% for the first month plus 12% after 30 days from funding</font>. This loan is guaranteed by an officer of the Company. On September 16, 2013, the non-related party accepted a total of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 8,472,750</font> shares of the Company&#8217;s restricted common stock as a repayment to discharge $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">25,000</font> of his outstanding loan and accrued interest of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">11,120</font> (See note 6).&#160;The Company recorded a loss of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">90,971</font> on the settlement date.</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 63pt" align="justify"><font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt">&#160;</font></div> <table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 45pt; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="60"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt">&#183;</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In July 2013, the Company issued a promissory note to the Michael McDonald Trust in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">75,000</font> bearing interest at a rate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2</font>% per month. The note is due in six months from the execution and funding of the note. In connection with the issuance of this promissory note, the Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,000,000</font> shares of the Company's common stocks (See note 6).&#160;The Company has recorded a debt discount in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3,977</font> to reflect the value of the common stocks as a reduction to the carrying amount of the convertible debt and a corresponding increase to common stocks and additional paid-in capital.&#160;The total discount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3,977</font> was fully amortized over the term of the debt during the year ended December 31, 2013.&#160;&#160; In the event of default, the Company would issue an additional <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,000,000</font> share of the Company&#8217;s common stocks on the date that is fifteen days after the maturity date (See Note 6). We are in default regarding this loan. The additional <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,000,000</font> shares were issued in January 2014 with a fair value at $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">9,900</font> (See Note 10). At December 31, 2013, we owed Michael McDonald accrued interest of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">9,000</font>.</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 63pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 45pt; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="60"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt">&#183;</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">At December 31, 2012, the total amount of the Company&#8217;s debt assigned to Southridge was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">483,482</font>. In connection with the debt sales to Southridge, the Company recorded a loss on settlement of accounts payable for $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">63,490</font> in the statement of operations at December 31, 2012. During the first quarter of 2013, the suit was voluntarily dismissed involving debt held by Southridge for $483,482. The debt has reverted back to the original holders.</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 63pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 63pt" align="justify"><font style="COLOR: #333333; FONT-SIZE: 10pt">In April, 2013, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">88,500</font> of</font> <font style="FONT-SIZE: 10pt">the debt held by Michael McDonald Trust was assigned to Coventry Enterprises, LLC (&#8220;Coventry&#8221;) in the form of a Convertible Redeemable Note bearing interest of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">8</font>% annum. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">Coventry was entitled to convert all or any amount of the this note into shares of the Company's common stock (the "Common Stock") at a conversion price ("Conversion Price") for each share of Common Stock equal to 55% of the average of the daily volume weighted average prices of the Common Stock for the 3 trading days with the lowest volume weighted average prices during the 15 trading days immediately preceding the Conversion Date</font>. Following the agreements with Coventry, Coventry made the conversions for a total of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 31,416,845</font> shares of the company&#8217;s restricted stock during the second quarter of 2013 satisfying the notes in full at the fair value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">186,646</font>.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 63pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 63pt" align="justify"><font style="FONT-SIZE: 10pt">In June, 2013, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">57,800</font> of the debt was assigned to Coventry for a consideration of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">60,000</font> from Baker Donelson Bearman Caldwell &amp; Berkowitz, PC. in the form of Convertible Redeemable Notes bearing interest of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 8</font>% annum. The Company recorded a loss of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2,200</font> on the settlement during the year ended December 31, 2013. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">Coventry was entitled to convert all or any amount of the these notes into shares of the Company's common stock (the "Common Stock") at a conversion price ("Conversion Price") for each share of Common Stock equal to 55% of the average of the daily volume weighted average prices of the Common Stock for the 3 trading days with the lowest volume weighted average prices during 20 trading days</font> . Following the agreements, Coventry made the conversions for a total of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 27,272,727</font> shares of the company&#8217;s restricted stock satisfying the notes in full at the fair value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">167,495</font>.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 63pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 63pt" align="justify"><font style="FONT-SIZE: 10pt">As a result of the debt assignments and conversions with Coventry, the remaining balance of the debt at December 31, 2013 is $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">337,182</font> which consisted of the following loans:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 63pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 63pt; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="84"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">i.</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">August 2, 2011</font> under a settlement agreement with Liquid Packaging Resources, Inc. (&#8220;LPR&#8221;), the Company agreed to pay LPR a total of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">350,000</font> in monthly installments of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">50,000</font> beginning August 15, 2011 and ending on February 15, 2012. This settlement amount was recorded as general and administrative expenses on the date of the settlement. We did not make the December 2011 or January 2012 payments and on January 26, 2012, we signed the first amendment to the settlement agreement where under we agreed to pay $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">175,000</font> which was the balance outstanding at December 31, 2011(this includes a $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">25,000</font> penalty for non-payment).</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1.25in" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 81pt" align="justify"><font style="FONT-SIZE: 10pt">The Company repaid $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">25,000</font> during the three months ended March 31, 2012. The Company did not make all of the payments under such amendment and as a result pursuant to the original settlement agreement, LPR had the right to sell <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 5,714,326</font> shares of the Company&#8217;s free trading stock held in escrow by their attorney and receive cash settlements for a total amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">450,000</font> (the initial $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">350,000</font> plus total default penalties of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">100,000</font>). The $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">100,000</font> default was expensed during 2012. LPR sold the note to Southridge Partners, LLP (&#8220;Southridge&#8221;) for consideration of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">281,772</font> in October 2012. The debt has reverted back to the Company (See note 9).</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 81pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 63pt; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="84"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">ii.</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">As of December 31, 2013 and 2012, the Company owed <em>University Centre West Ltd</em>. approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">55,410</font></font>, which was assigned and sold to Southridge and subsequently reverted back to the Company .</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 81pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">(3)</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">At December 31, 2013 and 2012, the balance of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">767,056</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">588,091</font> consisted of the following convertible loans:</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt">&#183;</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In September and October 2011, the Company borrowed $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">250,000</font> each (aggregating $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">500,000</font>) from two non-related parties. The principal of these loans were to be repaid with a balloon payment on or before October 1, 2012. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">On October 19, 2012 the parties amended the notes to extend the due date to May 1, 2013 and include a conversion feature that would allow the holders to convert some or all of their outstanding notes into restricted Company stock at a 15% discount to the average closing market price of the Company's stock traded over the previous 10 days</font>. Interest on these loans is payable monthly beginning in November 2011 with <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> interest calculated at 20% and 12%, each, respectively</font>. At December 31, 2013 and 2012, the accrued interest payable was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">6,664</font></font>.</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 2.25pt; MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">During year ended December 31, 2013, one of the Note holders made conversions of a total of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 34,254,004</font> shares of the company&#8217;s restricted stock satisfying the notes in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">125,000</font> with a fair value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">317,391</font> on the date of conversion. During August and September, 2013, <font style="COLOR: #333333">$<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">150,000</font></font></font> of</font> the debts were assigned to three non-related parties in the form of a Convertible Redeemable Note bearing interest of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 8</font>% annum with a <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">conversion price for each share of Common Stock equal to 55% of the average of the daily volume weighted average prices of the Common Stock for the 3 trading days with the lowest volume weighted average prices during the 15 to 20 trading days immediately preceding the Conversion Date</font>. Following the assignments, the conversions for a total of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 64,052,862</font> shares of the company&#8217;s restricted stock were made in satisfying the notes of $150,000 at the fair value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">475,519</font> (See note 6).</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 63pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">At December 31, 2013, the remaining balance of these two convertible notes payable of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">75,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">150,000</font> were recorded at a fair value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">90,260</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">189,781</font>, respectively. At December 31, 2012, these two convertible note payable of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">250,000</font> each were recorded at fair value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">290,289</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">297,802</font>, respectively.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">On April 30, 2013, the parties amended the notes to further extend the maturity date to November 3, 2013. The Company issued a total of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 4,000,000</font> restricted shares to the note holders in connection with the amendment at a fair value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">20,800</font>. On October 30, 2013 and November 1, 2013, the parties amended the note of $75,000 and $150,000 to further extend the maturity dates to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">May 3, 2014</font> and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">August 3, 2014</font>, respectively. The Company issued a total of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 500,000</font> and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,250,000</font> restricted shares to the note holders in connection with the amendment at a fair value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">9,500</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">13,750</font> (See note 6), respectively.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt">&#183;</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On March 22, 2013, the Company issued a Convertible Debenture in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">20,000</font> to Coventry Enterprises, LLC (&#8220;Coventry&#8221;). The note carries interest at <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10</font>% and is due on March 22, 2014, unless previously converted into shares of restricted common stock. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> Coventry has the right to convert the note, until is no longer outstanding into shares of Common Stock at a price which is lesser of $.0075, or (ii) fifty-five percent (55%) of the average of the three lowest VWAP prices of the Company&#8217;s Common Stock for the twenty trading days preceding the conversion date</font>. In connection with the issuance of this convertible note payable, the Company encountered a day-one derivative loss of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">24,931</font>. Coventry made the conversions into a total of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 8,810,572</font> shares of the company&#8217;s restricted stock satisfying the notes in full with a fair value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">188,747</font>on September 4, 2013(See note 7).</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">In connection with the issuances of the Note, the Company also granted five-year warrants to purchase an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2,600,000</font></font> shares of the Company&#8217;s common stock at an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.01</font></font> per share. The Company classified embedded conversion features in these warrants as a derivative liability. The warrants were valued at their fair value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">21,226</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">17,895</font>, respectively using the Black-Scholes method at the commitment and re-measurement dates of March 22, 2013 and December 31, 2013, respectively.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt">&#183;</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On July 10, 2013 and October 10, 2013, the Company issued two Convertible Debentures in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">30,000</font></font> each (total $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">60,000</font>) to Christopher Castaldo in connection with the agreements for investor relation services (See Note 6). The notes carry interest at <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">8</font>% and are due on January 10, 2014 and April 10, 2014, respectively. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">The notes&#8217; holder has the right to convert the notes into shares of Common Stock at a price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.005</font></font>.</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">In connection with the issuance of this convertible notes payable, the Company encountered a day-one derivative loss of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">83,157</font>. At December 31, 2013, these convertible notes payable, at fair value, was recorded at $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">90,684</font>.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt">&#183;</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On September 3, 2013, the Company issued a Convertible Debenture in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">100,000</font> to Coventry Enterprises, LLC (&#8220;Coventry&#8221;). The note carries interest at <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10</font>% and is due on September 3, 2014, unless previously converted into shares of restricted common stock. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> Coventry has the right to convert the note, until is no longer outstanding into shares of Common Stock at a price lesser of $.018, or (ii) fifty-five percent (55%) of the average of the three lowest VWAP prices of the Company&#8217;s Common Stock for the twenty trading days preceding the conversion date</font>.</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">In connection with the issuance of this convertible note payable, the Company encountered a day-one derivative loss of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">957,567</font>. At December 31, 2013, this convertible note payable, at fair value, was recorded at $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">185,971</font>.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">In connection with the issuances of the Note, the Company also granted five-year warrants to purchase an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 20,000,000</font></font> shares of the Company&#8217;s common stock at an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.025</font></font> per share. The Company classified embedded conversion features in these warrants as a derivative liability. The warrants were valued at their fair value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">445,638</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">137,681</font></font>, respectively using the Black-Scholes method at the commitment and re-measurement dates of September 3, 2013 and December 31, 2013, respectively.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt">&#183;</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On September 12, 2013, the Company issued a Convertible Debenture in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">70,000</font> to Coventry Enterprises, LLC (&#8220;Coventry&#8221;). The note carries interest at <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10</font>% and is due on September 12, 2014, unless previously converted into shares of restricted common stock. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> Coventry has the right to convert the note, until is no longer outstanding into shares of Common Stock at a price lesser of $.02, or (ii) fifty-five percent (55%) of the average of the three lowest VWAP prices of the Company&#8217;s Common Stock for the twenty trading days preceding the conversion date.</font></font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">In connection with the issuance of this convertible note payable, the Company encountered a day-one derivative loss of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">309,055</font>. At December 31, 2013, this convertible note payable, at fair value, was recorded at $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">130,303</font>.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">In connection with the issuances of the Note, the Company also granted five-year warrants to purchase an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 15,000,000</font> shares of the Company&#8217;s common stock at an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.025</font> per share. The Company classified embedded conversion features in these warrants as a derivative liability. The warrants were valued at their fair value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">262,230</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">101,140</font></font>, respectively using the Black-Scholes method at the commitment and re-measurement dates of September 12, 2013 and December 31, 2013, respectively.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt">&#183;</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On October 7, 2013, the Company signed a secured convertible Promissory Note in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">35,000</font> in favor of Southridge Partners II, LLC. The note was due on demand and carries interest at <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10</font>% annum. Southridge Partners II, LLC was entitled to convert the principal into shares of common stock at the lesser of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.015</font> or a <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 50</font>% discount from the lowest closing bid price in the <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 30</font> trading days prior to the day that the conversion is requested; and interest accrued was entitled to convert into shares of common stock at $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.001</font>. In the evaluation of these financing arrangements, the Company concluded that these conversion features did not meet the conditions set forth in current accounting standards for equity classification. Since equity classification is not available for the conversion feature, it requires bifurcation and liability classification, at fair value. The Company also concluded that the Default Put required bifurcation because, while puts on debt instruments are generally considered clearly and closely related to the host, the Default Put is indexed to certain events that are not associated with the convertible note payable.</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">In connection with the issuance of this convertible note payable, the Company encountered a day-one derivative loss of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">81,667</font>. At December 31, 2013, this convertible note payable, at fair value, was recorded at $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">80,057</font>.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: #333333; FONT-SIZE: 10pt"> &#160;</font></div> <table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt">&#183;</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On October 27, 2011 the Company entered into a convertible note payable with a corporation. The convertible note payable, with a face value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">53,000</font>, bears interest at <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 8.0</font>% per annum and was due on July 31, 2012.</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">On December 5, 2011 the Company entered into a convertible note payable with a corporation which had a face value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">37,500</font>, a coupon rate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 8.0</font>% per annum and maturity date of September 5, 2012.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">The convertible note payable is convertible, at the holder&#8217;s option, into the Company&#8217;s common shares at a variable conversion price which is 58% multiplied by the average of the lowest three (3) trading prices for the Common Stock during the ten (10) Trading Day period ending one Trading Day prior to the date the Conversion Notice is sent by the Holder to the Borrower</font>. The conversion feature is subject to full-ratchet, anti-dilution protection if the Company sells shares or share-indexed financing instruments at less than the conversion price. The holder has the option to redeem the convertible note payable for cash in the event of defaults or certain other contingent events (the &#8220;Default Put&#8221;).</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">During October 2012, both of these notes were acquired by a third party from Asher Enterprises for an aggregate amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">100,000</font>, and then converted into <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 20,000,000</font> restricted common shares (See note 6).</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt">&#183;</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">February 3, 2012</font>, the Company issued a Convertible Debenture in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">40,000</font> to Redwood Management, LLC. The note carries interest at <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 12</font>% and is due on February 13, 2013, unless converted into shares of restricted common stock<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">. Redwood Management, LLC has the right to convert the note, until it is no longer outstanding, into shares of Common Stock at a price of Fifty Percent (50%) of the lowest closing price, determined on the then current trading market for the Company&#8217;s common stock, during the 15 trading days prior to conversion (the &#8220;Set Price&#8221;).</font> On September 12, 2012, TCN International (TCN) completed the purchase and transfer of this note including penalties and unpaid interest, for the sum of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">52,500</font>. Redwood Management, LLC has acknowledged the full payment of the Note, in favor of Nutra Pharma Corporation and releases Nutra Pharma Corporation from all obligations under the Note. Upon the request of TCN, the Board of Directors of the Company approved the conversion of these notes into Restricted Common Stock of the Company,providing <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 7,500,000</font> shares of Nutra Pharma common stock to relinquish the total debt of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">52,500</font> (See note 6).</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt">&#183;</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On March 16, 2012 the Company signed a secured convertible Promissory Note in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">75,000</font> in favor of Southridge Partners II, LLC. The note was due <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> November 16, 2012</font> and carries interest at <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">8</font>% annum. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">Southridge Partners II, LLC was entitled after nine months to convert all or a portion of the principal and interest accrued into shares of common stock at a conversion price of each share equal to the Market Price multiplied times 70%. (the &#8220;conversion price&#8221;). The Market Price is equal to the average of the two lowest bids closing prices for the five trading days ending before the conversion date</font>. In the evaluation of these financing arrangements, the Company concluded that these conversion features did not meet the conditions set forth in current accounting standards for equity classification. Since equity classification is not available for the conversion feature, it requires bifurcation and liability classification, at fair value. The Company also concluded that the Default Put required bifurcation because, while puts on debt instruments are generally considered clearly and closely related to the host, the Default Put is indexed to certain events that are not associated with the convertible note payable. On October 26, 2012, Southridge converted the note into <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 5,919,495</font> shares of the Company's restricted common stock (See note 6).</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">In the evaluation of these financing arrangements, the Company concluded that these conversion features did not meet the conditions set forth in current accounting standards for equity classification. Since equity classification is not available for the conversion feature, it requires bifurcation and liability classification, at fair value. The Company also concluded that the Default Put required bifurcation because, while puts on debt instruments are generally considered clearly and closely related to the host, the Default Put is indexed to certain events that are not associated with the convertible note payable.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">The Company&#160;elected to account for these hybrid contracts under the guidance of ASC 815-15-25-4. The fair value has been defined as the common stock equivalent value, enhanced by the fair value of the default put plus the present value of the coupon.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">The holder of this convertible note has substantial rights and protections regarding dilution if certain events, including a default were to occur. There are a number of events that could trigger a default, including but not limited to failure to pay principal or interest, failure to issue shares under the conversion feature, breach of covenants, breach of representations and warranties, appointment of a receiver or trustee, judgments, bankruptcy, delisting of common stock, failure to comply with the exchange act, liquidation, cessation of operations, failure to maintain assets, material financial statement restatement, reverse split of borrowers stock, etc. In the event of these events the lender may be entitled to receive significant amounts of additional stock above the amounts for conversion.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">Furthermore, there are additional events that could cause the lender to be due additional shares of common stock above and beyond the shares due from a conversion. Some of these events include, but are not limited to a merger or consolidation of the Company, dividend distribution or spin off, dilutive issuances of the Company&#8217;s stock, etc. If the lender receives additional shares of the Company&#8217;s commons stock due to any of the foregoing events or for other reasons, then this may have an extremely dilutive effect on the shareholders of the Company. Such dilution would likely result in a significant drop in the per share price of the Company&#8217;s common stock. The potential dilutive nature of this note presents a very high degree of risk to the Company and its shareholders<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left">6. STOCKHOLDERS' DEFICIT</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <u>Private Placements of Common Stock</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">In 2013, the Company sold <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10,000,000</font> shares of restricted common stock to an investor at a price per share of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.005</font> and received proceeds of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">50,000</font>. The Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10,000,000</font> warrants to purchase common stock at an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.03</font> per share. The warrants expire on December 31, 2015.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">In 2013, the Company sold an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 11,000,000</font> shares of restricted common stock to five investors at a price per share range from $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.002</font> to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.015</font> and received proceeds of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">45,000</font>. The Company issued a total of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,000,000</font> warrants to purchase common stock at an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.10</font> per share. The warrants expire on December 31, 2014.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">In 2013, the Company sold an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 21,000,000</font> shares of restricted common stock to two investors at a price per share range from $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.001</font> to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.0042</font> and received proceeds of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">45,000</font>.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">In 2012, the Company sold an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 17,650,000</font> shares of restricted common stock to investors at a price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.01</font> per share and received $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">176,500</font>. The Company issued a total of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 17,650,000</font> warrants to purchase common stock at an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.10</font> per share. The warrants expire on December 31, 2014.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">In 2012, the Company sold an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 27,000,000</font> shares of restricted common stock to one investor at a price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.01</font> per share and received $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">270,000</font>. The Company issued a total of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 27,000,000</font> warrants to purchase common stock at an exercise pric</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">\e of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.10</font> per share in October 2012. The warrants expire on December 31, 2014.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><u>Shares Issued to Employees and Directors</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On November 22, 2013, the Board of Directors approved a resolution for the issuance of a total of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 34,630,000</font> shares of the Company&#8217;s restricted common stock to directors and employees of the Company. The issuance was valued at $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">484,820</font> ($<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.014</font> per share), which was the fair value of the Company&#8217;s common stock on the date of issuance.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On September 3, 2013, the Board of Directors approved a resolution for the issuance of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,000,000</font> shares of the Company&#8217;s restricted common stock to an employee of the Company. The issuance was valued at $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">22,900</font> ($<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.0229</font> per share), which was the fair value of the Company&#8217;s common stock on the date of issuance.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">During October and December 2012, the Board of Directors approved resolutions for the issuance of a total of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 26,875,000</font></font> shares of the Company&#8217;s restricted common stock to the Directors and Employees of the Company. The shares were valued at $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">569,400</font></font> ($<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.022</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.014</font> per share), which was the fair value of the Company&#8217;s common stock on the date of issuance.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On February 3, 2012 the Board of Directors approved a resolution for the issuance of a total of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 15,720,000</font> shares of the Company&#8217;s restricted common stock to the Directors and Employees of the Company. The issuance was valued at $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">259,380</font> ($<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.0165</font> per share), which was the fair value of the Company&#8217;s common stock on the date of issuance.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><u>Common Stock Issued for Services</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">During November, 2013, the Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,000,000</font> shares of the Company&#8217;s restricted common stock to a consultant for investor relation services for two months. The shares were valued at $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.0175</font> per share. The Company recorded an equity compensation charge of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">17,500</font> during the year ended December 31, 2013.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">During October, 2013, the Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 15,000,000</font> shares of the Company&#8217;s restricted common stock to a consultant for investor relation services for three months. The shares were valued at $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.0178</font> per share. The Company recorded an equity compensation charge of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">267,000</font> during the year ended December 31, 2013.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">During September, 2013, the Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,500,000</font> shares of the Company&#8217;s restricted common stock to a consultant for consulting services rendered. The shares were valued at $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.016</font> per share. The Company recorded an equity compensation charge of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">24,000</font> during the year ended December 31, 2013.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">During September, 2013, the Company issued a total of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,500,000</font> shares of the Company&#8217;s restricted common stock to two consultants for consulting services rendered. The shares were valued at $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.0229</font> per share. The Company recorded an equity compensation charge of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">34,350</font> during the year ended December 31, 2013.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">During August, 2013, the Company issued a total of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 6,000,000</font> shares of the Company&#8217;s restricted common stock to two consultants for investor relation services for six months. The shares were valued at $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.0173</font> per share. The Company recorded an equity compensation charge of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">70,902</font> during the four months ended December 31, 2013. The remaining unrecognized compensation cost of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">32,898</font> related to non-vested equity-based compensation to be recognized by the Company over the remaining vesting period of two months.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">During August, 2013, the Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2,000,000</font> shares of the Company&#8217;s restricted common stock to a consultant for investor relation services for one year. The shares were valued at $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.012</font> per share. The Company recorded an equity compensation charge of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">8,351</font> during the four months ended December 31, 2013. The remaining unrecognized compensation cost of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">15,649</font> related to non-vested equity-based compensation to be recognized by the Company over the remaining vesting period of eight months.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">During August, 2013, the Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2,000,000</font> shares of the Company&#8217;s restricted common stock to a consultant for consulting services for six months. The shares were valued at $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.0056</font> per share. The Company recorded an equity compensation charge of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">8,446</font> during the four and one half months ended December 31, 2013. The remaining unrecognized compensation cost of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2,754</font> related to non-vested equity-based compensation to be recognized by the Company over the remaining vesting period of one and half months.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">During July, 2013, the Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2,000,000</font> shares of the Company&#8217;s restricted common stock to a consultant for consulting services for six months. The shares were valued at $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.0042</font> per share. The Company recorded an equity compensation charge of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">8,400</font> during the year ended December 31, 2013.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">During July, 2013, the Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 100,000</font> shares of the Company&#8217;s restricted common stock to a consultant for consulting services rendered. The shares were valued at $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.0042</font> per share. The Company recorded an equity compensation charge of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">420</font> during the year ended December 31, 2013</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">During July 2013, the Company signed an agreement with a consultant for investor relation services for three months. A $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">30,000</font> convertible note convertible at $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.005</font> per share was also issued (See Note 5). The Company also paid a total of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10,000</font> cash and issued a total of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 15,000,000</font> shares of company&#8217;s restricted common stocks. The shares were valued at $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.005</font>7 per share. The Company recorded an equity compensation charge of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">85,500</font> during the year ended December 31, 2013.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">During June, 2013, the Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2,000,000</font> shares of the Company&#8217;s restricted common stock to a consultant for investor relation services for six months. The shares were valued at $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.0042</font> per share. The Company recorded an equity compensation charge of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">8,400</font> during the year ended December 31, 2013.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">During May, 2013, the Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,000,000</font> shares of the Company&#8217;s restricted common stock to a consultant for investor relation services for six months. The shares were valued at $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.0053</font> per share. The Company recorded an equity compensation charge of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5,300</font> in May 2013.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">During February, 2013, the Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 8,000,000</font> shares of the Company&#8217;s restricted common stock to a consultant for investor relation services for a year. The shares were valued at $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.008</font> per share. The Company recorded an equity compensation charge of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">61,019</font> during the year ended December 31, 2013. The remaining unrecognized compensation cost of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2,981</font> related to non-vested equity-based compensation to be recognized by the Company over the remaining vesting period of one half month.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">During February 2013, the Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,500,000</font> shares of the Company&#8217;s restricted common stock to a consultant for investor relation services for two months. The shares were valued at $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.007</font> per share. The Company recorded an equity compensation charge of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10,500</font> during the year ended December 31, 2013.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">During February 2013, the Company issued a total of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 3,000,000</font> shares of the Company&#8217;s restricted common stock to three consultants for marketing services for six months. The shares were valued at $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.009</font> per share. The Company recorded an equity compensation charge of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">27,000</font> during the year ended December 31, 2013.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">During January, 2013, the Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10,000,000</font> shares of the Company&#8217;s restricted common stock to a consultant for investor relation services for a year. The shares were valued at $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.005</font> per share. The Company recorded an equity compensation charge of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">50,000</font> during the year ended December 31, 2013.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On December 14, 2012 the Company issued a total of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,000,000</font> shares of the Company&#8217;s restricted common stock to Roetzell &amp; Andress for legal services for a one year term. The shares were valued at $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.014</font> per share. The Company recorded a prepaid equity compensation charge of $14,000 during the year ended December 31, 2012, and recognized an equity compensation charge of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">14,000</font> during the year ended December 31, 2013.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">During October, 2012 the Company issued a total of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 15,100,000</font> shares of the Company&#8217;s restricted common stock to five consultants for marketing services for six months terms. The shares were valued at $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.0125</font> per share. The Company recorded an equity compensation charge of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">108,534</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">80,216</font> during the year ended December 31, 2013 and year ended December 31, 2012.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">During December, 2012 the Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 500,000</font> shares of the Company&#8217;s restricted common stock to a consultant for real estate consulting services for a six months term. The shares were valued at $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.0125</font> per share. The Company recorded an equity compensation charge of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,042</font> during the year ended December 31, 2012. The remaining unrecognized compensation cost of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5,208</font> was recognized during the year ended December 31, 2013.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">During August, 2012 the Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 3,000,000</font> shares of the Company&#8217;s restricted common stock to JPU Ventures, Inc. under agreement dated August 13, 2012. The agreement was for investor relations services for a nine months term. The shares were valued at $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.0125</font> per share. The Company recorded an equity compensation charge of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">21,875</font> during the year ended December 31, 2012. The remaining unrecognized compensation cost of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">15,625</font> was recognized by the Company during the year ended December 31, 2013.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On October 1, 2012, the Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 5,500,000</font> shares of the Company&#8217;s restricted common stock under the amended agreement with Mark Bergman, a consultant. The contract is for six months term. The shares were valued at $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.0125</font> per share. The Company recorded an equity compensation charge of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">28,646</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">40,104</font> for the agreement during the year ended December 31, 2013 and the year ended December 31, 2012.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">During October, 2012, the Company entered into an agreement for investor relations services with a Consultant. The contract was for a six months term and calls for the issuance of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,000,000</font> shares of restricted common stock. The share was valued at $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.0125</font> per share. The Company recorded an equity compensation charge of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">8,697</font> during the year ended December 31, 2012. The remaining unrecognized compensation cost of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3,533</font> was recognized by the Company during the year ended December 31, 2013.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On February 22, 2012 the Company engaged Capital Path Securities, LLC (&#8220;CPS&#8221;) as its exclusive advisor on a proposed placement by way of an equity line of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10,000,000</font> of the Company&#8217;s equity or equity linked securities. All upfront fees have been waived by CPS. The Company will pay CPS a cash placement fee equal to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5</font>% of all principal amounts invested from the source originated by CPS. In addition, 10,000,000 restricted shares were issued on October 26, 2012, and valued at $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.0125</font> per share. The Company recorded an equity compensation charge of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">151,375</font> during the year ended December 31, 2012. The remaining unrecognized compensation cost of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">21,625</font> and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 125,000</font> non-vested shares was recognized by the Company during the year ended December 31, 2013.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><u>Common Stock Issued for Debt Modification</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On April 30, 2013, the Company amended the maturity dates of two notes of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">250,000</font></font> each (aggregating $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">500,000</font>) from two non-related parties to November 3, 2013. The Company issued a total of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 4,000,000</font> restricted shares to the note holders in connection with the amendment at a fair value of $20,800.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On October 30, 2013 and November 1, 2013, the parties amended the note of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">75,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">150,000</font> to further extend the maturity dates to May 3, 2014 and August 3, 2014. The Company issued a total of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 500,000</font> and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,250,000</font> restricted shares to the note holders in connection with the amendment at a fair value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">9,500</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">13,750</font>, respectively (See Note 5).</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On October 19, 2012 the Company amended the notes $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">250,000</font> each (aggregating $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">500,000</font>) from two non-related parties originated in September and October 2011to include a conversion feature that would allow the holders to convert some or all of their outstanding notes into restricted Company stock at a 15% discount to the average closing market price of the Company's stock traded over the previous 5 days. The Company issued a total of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 4,000,000</font> restricted shares to the note holders per the amendment. The shares were valued at $0.025 per share. (See note 5).</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><u>Common Stock Issued with Promissory Note</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">In July 2013, in connection with the issuance of this promissory note to Michael McDonald Trust in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">75,000</font> which is due in six months from the funding of the note, the Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,000,000</font> shares of the Company's common stocks.&#160;The Company has recorded a debt discount in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3,977</font> to reflect the value of the common stocks as a reduction to the carrying amount of the convertible debt and a corresponding increase to common stocks and additional paid-in capital.&#160;The total discount of $3,977 was amortized over the term of the debt.&#160;&#160;Amortization for the year ended December 31, 2013 was $3,977 (See Note 5).</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><u>Common Stock Held in Escrow</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On July 27, 2011 the Company issued 5,714,286 shares of free trading common stock in certificate form which is held in escrow as security under an agreement reached with Liquid Packaging Resources, Inc. (&#8220;LPR&#8221;) on August 2, 2011(See note 3 and 5).</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left"><u>Common Stock Issued for Settlement of Accounts Payable &amp; Debt</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Following the agreements with Coventry Enterprises, LLC (see Note 3) for $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">80,000</font>, Coventry made the following conversions for a total of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 15,119,481</font> shares of the company&#8217;s restricted stock during the first quarter of 2013 satisfying the notes in full and recorded a loss of $65,039 (See note 3):&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="clear:both;MARGIN: 0in 0in 0in 0.25in; WIDTH: 90%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Date</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Number&#160;of shares<br/> converted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>Fair&#160;Value<br/> of&#160;Debt<br/> Converted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="63%"> <div>January 21, 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>4,032,258</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>37,619</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>February 11, 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>5,405,405</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>42,510</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>March 20, 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>5,681,818</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>40,414</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Following the agreement with Coventry Enterprises, LLC (see Note 5) for $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">88,500</font>, Coventry made the following conversions for a total of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 31,416,845</font> shares of the company&#8217;s restricted stock during the second quarter of 2013 satisfying the notes in full:<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif ">&#160;</div><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="clear:both;MARGIN: 0in 0in 0in 0.25in; WIDTH: 90%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Date</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Number&#160;of&#160;shares&#160;converted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>Fair&#160;Value<br/> of&#160;Debt<br/> Converted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="63%"> <div>4/17/2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>7,133,333</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>49,586</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>5/16/2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>11,101,694</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>64,930</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>6/12/2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>13,181,818</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>70,130</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Following the agreement with Coventry Enterprises, LLC (see Note 5) for $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">60,000</font>, Coventry made the conversion for a total of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 27,272,727</font> shares of the company&#8217;s restricted stock during the second quarter of 2013 satisfying the notes in full with a fair value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">167,495</font>. The Company recorded a loss of $2,200 (See note 5).</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Following the agreement with Coventry Enterprises, LLC (see Note 5) for $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">20,000</font>, Coventry made the conversion for a total of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 8,810,572</font> shares of the company&#8217;s restricted stock during September 2013 satisfying the notes in full with a fair value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">188,747</font>.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>During June and August, 2013, one of the convertible Notes holders made the following conversions of a total of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 34,254,004</font> shares of the company&#8217;s restricted stock satisfying the notes in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">125,000</font> with a fair value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">317,391</font> on the date of conversion (See Note 5).</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="clear:both;MARGIN: 0in 0in 0in 0.25in; WIDTH: 90%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Date</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Number&#160;of&#160;shares&#160;converted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>Fair&#160;Value<br/> of&#160;Debt<br/> Converted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="63%"> <div>6/25/2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>22,058,882</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>188,352</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>8/30/2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>12,195,122</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>129,039</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">During August and September, 2013, <font style="COLOR: #333333">$<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">150,000</font> of</font> the convertible notes were assigned to third parties in the form bearing interest of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">8</font>% annum at with a <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">conversion price for each share of Common Stock equal to 55% of the average of the daily volume weighted average prices of the Common Stock for the 3 trading days with the lowest volume weighted average prices during the 15 to 20 trading days immediately preceding the Conversion Date.</font> Immediately following the assignments, the conversions for a total of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 64,052,862</font> shares of the company&#8217;s restricted stock were made as followings in satisfying the notes of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">150,000</font> at the fair value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">475,519</font>(See Note 5).</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="clear:both;MARGIN: 0in 0in 0in 0.25in; WIDTH: 90%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Date</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Number&#160;of&#160;shares&#160;converted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>Fair&#160;Value<br/> of&#160;Debt<br/> Converted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="63%"> <div>8/28/2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>22,026,431</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>167,493</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>9/3/2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>20,000,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>163,909</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>9/4/2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>22,026,431</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>144,117</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On September 16, 2013, one of the non-related party promissory note holders accepted a total of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 8,472,750</font> shares of the Company&#8217;s restricted common stock as a repayment to discharge $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">25,000</font> of his outstanding loan and accrued interest of $11,120 with the Company (See note 5). The Company recorded a loss of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">90,971</font> on the settlement date.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On November 25, 2013, one of the non-related party promissory note holders accepted a total of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 4,360,000</font> shares of the Company&#8217;s restricted common stock as a repayment to discharge $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">25,000</font> of his outstanding loan and accrued interest of $11,956 with the Company (See note 5). The Company recorded a loss of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">28,444</font> on the settlement date.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">During September, 2013, Mr. Harold H. Rumph (ReceptoPharm&#8217;s CEO) accepted 14,800,000 shares of the Company&#8217;s restricted common stock as a repayment to discharge $37,000 of his accrued salary to the Company(See Note 3).</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">During June and September, 2013, Mr. Deitsch (Our CEO) accepted a total of 50,000,000 shares of the Company&#8217;s restricted common stock as a repayment to discharge $162,500 of his outstanding loan to the Company (See note 4).</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">During August and September, 2013, the Company issued 3,000,000 shares of the company&#8217;s restricted stock to settle the outstanding accounts payable in aggregate of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">38,528</font> with two vendors. The shares were valued at $0.018 per share. The Company recorded a loss of $15,472&#160;(See Note 3).</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">During September, 2013, the Company issued 25,000,000 shares of the company&#8217;s restricted stock and 25,000,000 warrants to purchase stock at an exercise price of $0.030 to settle the outstanding accounts payable of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">112,621</font>. The shares were valued at $0.015 per share. The Company recorded a loss of $505,525 (See Note 3).</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left">During December 2012, the Board of Directors approved resolutions for the issuance of a total of 10,000,000 shares of the Company&#8217;s restricted common stock to Mr. Deitsch to discharge $100,000 of his outstanding loan the Company (See note 4). The shares were valued at the note payable amount due to the fact that it was a related party transaction. 10,000,000 warrants to purchase stock at an exercise price of $0.10 per share were also issued to Mr. Dietsch. The warrants expire on December 31, 2014.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Following the agreements with Coventry Enterprises, LLC (see Note 3), the conversions for 8,672,090 and 2,564,102 shares of the Company&#8217;s restricted common stocks were issued for settlement of accounts payable and a convertible note payable on March 29, 2012 and December 20, 2012, respectively. The shares were valued at $168,889 and $33,720, respectively, which was the fair value of convertible debts on the date of conversion.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Following the agreement with Southridge (see Note 5), the conversion for a total of 6,416,733 shares of the Company&#8217;s restricted common stock satisfying the note in full was made in October 2012. The shares were valued at $157,179, which was the fair value of convertible debts on the date of conversion.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Following the agreement with Asher Enterprises, LLC (see Note 5), the conversion for a total of 20,000,000 shares of the Company&#8217;s restricted common stock satisfying the note in full was made in October 2012. The shares were valued at $356,779, which was the fair value of convertible debts on the date of conversion.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Following the agreement with Redwood and TCN (see Note 5), the conversion for a total of 7,500,000 shares of the Company&#8217;s restricted common stock satisfying the note in full was made in October 2012. The shares were valued at $273,144, which was the fair value of convertible debts on the date of conversion.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Following the agreement with Redwood (see Note 3), conversions were made for a total of 18,737,894 shares of the Company&#8217;s restricted stock, satisfying the note in full. The shares were valued at a total amount of $320,531, which was the fair value of convertible debts on the date of conversion.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">7. STOCK OPTIONS AND WARRANTS</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <u><font style="FONT-SIZE: 10pt">Common Stock Warrants</font></u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">From time to time, we issue warrants to purchase our common stock. These warrants have been issued for cash in conjunction with the private placement of shares of our common stock.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">During December 2013, the Company issued a total of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10,000,000</font> warrants to purchase common stock at an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.03</font> per share in connection with the private placement offerings. The warrants expire on December 31, 2015 (See note 6).</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">During October and November 2013, the Company issued a total of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,000,000</font> warrants to purchase common stock at an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.10</font> per share in connection with the private placement offerings. The warrants expire on December 31, 2014 (See note 6).</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On September 16, 2013, the Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 25,000,000</font> warrants to purchase stock at an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.030</font> in connection with settlement of an outstanding account payable. The warrants expire on December 31, 2014 (See Note 3 and Note 6).</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On September 3, 2013 and September 12, 2013, the Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 20,000,000</font> and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 15,000,000</font> warrants, respectively, to purchase common stock at an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.025</font> per share in connection with issuances of convertible notes payable to Coventry. The warrants expire on <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">September 3, 2018</font> and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> September, 12, 2018</font>, respectively (See note 5).</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">During March, 2013, the Company issued a total of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2,600,000</font> warrants to purchase common stock at an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.01</font> per share in connection with issuance of a convertible note payable to Coventry. The warrants expire on <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">March 22, 2018</font> (See note 5).</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">During June, 2013, <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 25,000,000</font> warrants to purchase stock at an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.10</font> per share were issued to CEO, Mr. Deitsch in exchange of notes payable. The warrants expire on <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">December 31, 2014</font> (See note 4).</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>A summary of warrants outstanding in conjunction with private placements of common stock were as follows during the year ended December 31, 2013 and 2012:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 99%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>Number&#160;of&#160;shares</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>Weighted&#160;average&#160;exercise&#160;price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Balance December 31, 2011</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>47,921,667</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>0.10</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 39px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Issued</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>54,650,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0.10</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Forfeited/Expired</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>(45,315,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Balance December 31, 2012</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>57,256,667</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0.10</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 39px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Issued</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>98,600,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0.01 &#150; 0.10</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Forfeited</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>(940,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Balance December 31, 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>154,916,667</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0.082</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The following table summarizes information about fixed-price warrants outstanding as of December 31, 2013 and 2012<strong>:</strong></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.5in; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="25%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>Exercise&#160;Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>Number<br/> Outstanding</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>Weighted<br/> Average<br/> Contractual<br/> Life</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>Weighted<br/> Average<br/> Exercise Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="25%"> <div>2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0.01-0.10</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>154,916,667</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1.97 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0.082</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="25%"> <div>2012</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0.10-0.15</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>57,256,667</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>2.04 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0.10</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">As of December 31, 2013, the aggregate intrinsic value of all stock options and warrants outstanding and expected to vest was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0</font></font>. The intrinsic value of each option share is the difference between the fair value of our common stock and the exercise price of such option share to the extent it is &#8220;in-the-money&#8221;. Aggregate intrinsic value represents the value that would have been received by the holders of in-the-money options had they exercised their options on the last trading day of the year and sold the underlying shares at the closing stock price on such day. The intrinsic value calculation is based on the $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.0075</font>, closing stock price of our common stock on December 31, 2013.There were no in-the-money warrants at December 31, 2013.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left">8. INCOME TAXES</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The Company&#8217;s tax expense differs from the &#8220;expected&#8221; tax expense for the years ended December 31, 2013 and 2012, (computed by applying the Federal Corporate tax rate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 34</font>% to loss before taxes and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 8.84</font>% for California State Corporate Taxes, the blended rate used was <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 39.83</font>%), are approximately as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%" colspan="5"> <div>December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>2012</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Computed "expected" tax expense (benefit) - Federal</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>(1,346,076)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>(1,115,374)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Computed "expected" tax expense (benefit) - State</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>(322,564)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>(318,119)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Stock-based compensation</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>558,448</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>674,914</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Change in fair value of derivatives</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>452,390</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>159,500</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Change in valuation allowance</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>657,802</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>599,079</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left">&#160;</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Current&#160;portion&#160;of&#160;net&#160;deferred&#160;income&#160;tax&#160;assets:</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>2012</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Allowance for doubtful accounts</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>242,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>242,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Reserve for inventory obsolescence</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>313,925</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>313,925</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Accrued salary</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>101,877</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>43,154</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Subtotal</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>657,802</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>599,079</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Valuation allowance</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>(657,802)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>(599,079)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Current net deferred income tax asset</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Non- current portion of net deferred income tax asset</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Net operating loss carryforwards</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>6,232,881</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>5,575,079</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Valuation allowance</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>(6,232,881)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>(5,575,079)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Non-current net deferred income tax asset</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160; <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Due to the uncertainty of the utilization and recoverability of the loss carry-forwards and other deferred tax assets, we have provided a valuation allowance to fully reserve such assets.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">As of December 31, 2013, the Company has net operating loss carryforwards of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">15,580,000</font> available to offset future taxable income in various years through December 31, 2033.&#160;&#160;The significant difference between such net operating loss carryforwards and our accumulated deficit of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">41,987,000</font> results primarily from stock based compensation which is considered to be a permanent difference.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The valuation allowances increased by approximately $658,000 and $599,000 for the years ended December 31, 2013 and 2012, respectively. The Company&#8217;s 2011 to 2013 tax returns are subject to examination by Internal Revenue Services and State Taxing Agency&#8217;s.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">9. COMMITMENTS AND CONTINGENCIES</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><u><font style="FONT-SIZE: 10pt">Operating Leases</font></u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In February 2010, Nutra Pharma entered into an operating lease for the use of office space. The lease expired in January 2013 and required monthly payments of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">9,000</font>. In February 2013, Nutra Pharma entered into a new operating lease for monthly payments of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3,500</font> for three years. ReceptoPharm leases a lab and renewed its operating lease agreement for five years in July of 2012. The lease requires monthly payments of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5,000</font> beginning August 1, 2012.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Future minimum payments under these lease agreements, including the extension period, are approximately as follows:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 65%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Years&#160;ended<br/> December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>Amounts</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>116,345</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>2015</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>120,218</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>79,892</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>45,249</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Total</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>361,704</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Rent expense in 2013 and 2012 approximated $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">114,889</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">183,000</font>, respectively.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><u><font style="FONT-SIZE: 10pt"> Litigation</font></u></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><u><font style="FONT-SIZE: 10pt">Patricia Meding, et. al. v. ReceptoPharm, Inc. f/k/a Receptogen, Inc.</font></u><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On August 18, 2006, ReceptoPharm was named as a defendant in Patricia Meding, et. al. v. ReceptoPharm, Inc. f/k/a Receptogen, Inc., Index No.: 18247/06 (New York Supreme Court, Queens County). The original proceeding claimed that ReceptoPharm owed the Plaintiffs, including Patricia Meding, a former ReceptoPharm officer and shareholder and several corporations that she claims to own, the sum of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">118,928.15</font> plus interest and counsel fees on a series promissory notes that were allegedly executed in 2001 and 2002. On August 23, 2007, the Queens County New York Supreme Court issued a decision denying Plaintiffs motion for summary judgment in lieu of a complaint, concluding that there were issues of fact concerning the enforceability of the promissory notes. On May 23, 2008, the Plaintiffs filed an amended complaint in which they reasserted their original claims and asserted new claims seeking damages of no less than $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">768,506</font> on their claims that in or about June 2004 ReceptoPharm breached its fiduciary duty to the Plaintiffs as shareholders of ReceptoPharm by wrongfully canceling certain of their purported ReceptoPharm share certificates. In late 2010, Plaintiffs further amended their complaint alleging that ReceptoPharm violated Plaintiffs contractual and statutory rights by cancelling an additional <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,214,800</font> share certificates and failing to permit the Plaintiffs to exercise dissenting shareholder rights with respect to those share certificates. The damages associated with the Plaintiff&#8217;s claims could rise as the result of increases in our share price as the Receptopharm shares may be convertible into our common shares. The potential exposure may exceed $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10,000,000</font> if the Plaintiffs are successful with all of their claims.&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">ReceptoPharm believes the suit is without merit and has filed an answer denying the material allegations of the amended complaint and asserted a series of counterclaims against the Plaintiffs alleging claims for declaratory judgment, fraud, breach of fiduciary duty, conversion and unjust enrichment as a result of the promissory notes. Plaintiffs have moved for partial summary judgment on their claims regarding the additional <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,214,800</font> shares, but not on their claims regarding the alleged promissory notes or the <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,750,000</font> alleged shares. In August of 2011, the Plaintiff's motion was partially granted. In September 2012, ReceptoPharm's attorneys filed a Motion to be removed as counsel. Their motion was denied on April 26, 2013 due to the current Involuntary Bankruptcy action filed against Nutra Pharma. The court has issued a stay in the proceedings pending the outcome of the Bankruptcy action. ReceptoPharm is seeking new counsel to oppose the partial summary judgment. We intend to vigorously contest this matter.&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><u><font style="FONT-SIZE: 10pt">Liquid Packaging Resources, Inc. v. Nutra Pharma Corp. and Erik "Rik" Deitsch</font></u><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On April 21, 2011, Nutra Pharma Corp. and its CEO, Erik Deitsch, were named as defendants in <u>Liquid Packaging Resources, Inc. v. Nutra Pharma Corp. and Erik "Rik" Deitsch</u>, Superior Court of Fulton County, Georgia, Civil Action No. 2011-CV-199562. Liquid Packaging Resources, Inc. ("LPR") claimed that Nutra Pharma Corp. and Mr. Deitsch, directly or through other companies, placed orders with LPR that required LPR to purchase components from third parties. LPR sought reimbursement for those third party expenses in the amount of not less than $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">359,826.85</font> plus interest. LPR also sought punitive damages in the amount of not less than $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">500,000</font> and attorney's fees.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Mr. Deitsch and Nutra Pharma Corp. then removed the action to the United States District Court, Northern District of Georgia, Civil Action No. 11-CV-01663-ODE. After removal, LPR amended the Complaint to assert that Nutra Pharma Corp. and Mr. Deitsch were the alter egos of the alleged other companies through whom the subject orders were placed and therefore should be considered one and the same. Mr. Deitsch and Nutra Pharma Corp. moved to dismiss the Complaint on several grounds including statute of frauds, failure to state a claim, and jurisdiction (only for Mr. Deitsch). Mr. Deitsch and Nutra Pharma Corp. believe the suit is without merit.&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">After June 30, 2011, at LPR's request, the parties mediated the dispute before LPR responded to the Motion To Dismiss. At the mediation, the parties worked out an agreement whereby Nutra Pharma Corp. would purchase from LPR the components LPR purchased from third parties at an amount slightly less than the principal amount of the suit and on terms acceptable to us. The agreed price was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">350,000.00</font> payable over <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">7</font> months in equal $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">50,000.00</font> amounts. This agreement was reached by us because it provided tangible value in exchange for the purchase price rather than incurring the expense of litigation, which would likely be substantial and not recouped. While Nutra Pharma Corp. had counterclaims we could assert, we believe this was a practical resolution. The settlement allowed us to take possession of the components prior to full payment and, in exchange, provided security to LPR in the form of our stock valued at $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">400,000</font> at the time of issuance. The stock can only be sold in event of a default of the payment schedule. The litigation was dismissed in August of 2011. We made the August, September and November payments (totaling $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">150,000</font>) in a timely fashion. We were late for the payment due October 15, 2011 and requested an accommodation from LPR, eventually paying an extra $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5,000</font> towards that payment. At December 31, 2011, Nutra Pharma Corp. had made total payments of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">205,000</font> with an additional $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">150,000</font> owed. In order to allow us to skip the December payment, LPR agreed to another accommodation whereby we would pay both the December and January payment with an additional $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10,000</font> on or before January 16, 2012. We were unable to make this payment and on January 26, 2012 signed an amended payment schedule adding an additional $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">15,000</font> for a total of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">175,000</font> owed. Our CEO, Rik Deitsch, added additional collateral stock in a separate company that he held personally. $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">25,000</font> was paid in January, with subsequent payments of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">30,000</font> due monthly on the 15th of March through the 15th of July, 2012. We failed to make the March payment and was subsequently called in default of the Agreement. Under the original agreement, if we are in default of the agreement, LPR has the right to sell shares of our free trading stock held in escrow by their attorney and receive cash settlements for a total amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">450,000</font> representing the new total cash amount due to LPR by the Company.&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On June 11, 2012, LPR sold their debt to Southridge Partners, LLP in an agreement to be paid out over time. In August, 2013, LPR cancelled their agreement with Southridge Partners, LLP. &#160;As of December 31, 2013 LPR continues to hold the collateral stock. We are currently negotiating a settlement with LPR. Upon the settlement of the outstanding debt, LPR will return the collateral shares to the Company.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><u><font style="FONT-SIZE: 10pt">Involuntary Petition of Bankruptcy</font></u><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On August 31, 2012, certain former ReceptoPharm employees and a former ReceptoPharm consultant filed a Petition for Involuntary Bankruptcy against us in the United States Bankruptcy Court, Southern District of Florida. The Petitioners originally claimed they were owed $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">990,927</font> from Nutra Pharma in the form of accrued wages and promissory notes, but amended their claim to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">816,662</font> in a subsequent filing. In response to the Petition, we filed a motion to dismiss the action which, if successful, would avoid the case being converted into an actual bankruptcy action. <font style="LINE-HEIGHT: 115%; FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> On September 30, 2013, the Company entered into a Settlement Agreement with the Petitioners, which <font style="LINE-HEIGHT: 115%; FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> is effective upon the court dismissal of the action.</font> In full and final satisfaction of all claims, the Company settled the Agreement with the Petitioners for a total sum of $350,000.&#160; $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">35,000</font> has been paid and a second lump sum payment is due within 8 months from <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="LINE-HEIGHT: 115%; FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> the date the court dismissed the action</font></font> <font style="LINE-HEIGHT: 115%; FONT-FAMILY: 'Times New Roman','serif'; COLOR: black; FONT-SIZE: 10pt"> (See Note 10).</font></font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"><font style="LINE-HEIGHT: 115%; FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></font><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><u><font style="FONT-SIZE: 10pt">Laurence N. Raymond v. Receptopharm, Inc. et al.</font></u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On December 30, 2011 Laurence N. Raymond ("Raymond") brought the case against Receptopharm, Inc. ("Receptopharm") and Nutra Pharma to recover approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">300,000</font> that was allegedly either loaned to Receptopharm or owing to Raymond pursuant to an oral employment agreement. Dr. Raymond is one of the petitioning creditors that brought the above-described involuntary bankruptcy action. The settlement agreement reached in that action fully resolves all claims between the parties and specifies that this action will be dismissed immediately upon the full settlement payments, pursuant to a confidential settlement agreement.</font><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font>&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;<u>Paul F. Reid v, Harold H. Rumph et al.</u></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On December 28, 2011 Paul F. Reid ("Reid") brought the case against Harold H. Rumph ("Rumph"), Receptopharm, and Nutra Pharma to recover approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">330,000</font> that was allegedly either loaned to Receptopharm or owing to Reid pursuant to an oral employment agreement. Dr. Reid is one of the petitioning creditors that brought the above-described involuntary bankruptcy action. The settlement agreement reached in that action fully resolves all claims between the parties and specifies that this action will be dismissed immediately upon the full settlement payments, pursuant to a confidential settlement agreement.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left">10. SUBSEQUENT EVENTS</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <u>Private Placements of Common Stock</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">In January 2014, the Company sold <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 12,000,000</font> shares of restricted common stock to an investor at a price per share of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.005</font> and received proceeds of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">60,000</font>. The Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 12,000,000</font> warrants to purchase common stock at an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.03</font> per share. The warrants expire on <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">December 31, 2015</font>.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><u>Common Stock Issued for Debt Modification and Default</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On January 17, 2014, the Company issued a total of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,000,000</font> restricted shares to the Michael McDonald Trust due to the default on repayment of the promissory note of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">75,000</font>. The shares were valued at a fair value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">9,900</font>.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><u>Common Stock Issued for Debt Conversions</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Following the agreements with Coventry Enterprises, LLC for $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">70,000</font> in September 2013, Coventry converted the $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">60,000</font> of the note for a total of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 15,584,415</font> shares of the company&#8217;s restricted stock during on March 12, 2014. The remaining balance of the note is $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10,000</font>.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Following the agreements with Coventry Enterprises, LLC for $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">100,000</font> in September 2013, Coventry converted the $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">90,000</font> of the note for a total of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 23,376,623</font> shares of the company&#8217;s restricted stock during on March 12, 2014. The remaining balance of the note is $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10,000</font>.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><u>Officer Loans</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">During January through March 2014, the Company received additional advances from our President and CEO, Rik Deitsch, in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">16,008</font> and repaid Mr. Deitsch $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">14,600</font>. These funds are unsecured, bearing interest at <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4</font>% and due on demand.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><u>Involuntary Petition of Bankruptcy</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <font style="LINE-HEIGHT: 115%; FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> On September 30, 2013, the Company entered into a Settlement Agreement with the Petitioners, which is effective upon the court dismissal of the action.&#160;In full and final satisfaction of all claims, the Company settled the Agreement with the Petitioners for a total sum of $350,000.&#160; $35,000 has been paid and a second lump sum payment is due within 8 months from February 12, 2014, the date the court dismissed the action. The Parties executed mutual releases exclusive of releases under the Settlement Agreement (See Note 9).</font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <i><font style="FONT-SIZE: 10pt">Basis of Presentation and Consolidation</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The accompanying consolidated financial statements include the results of Nutra Pharma and its wholly-owned subsidiaries Designer Diagnostics Inc. and ReceptoPharm (collectively "the Company", &#8220;us&#8221;, &#8220;we&#8221; or &#8220;our&#8221;). We operate as one reportable segment. All intercompany transactions and balances have been eliminated in consolidation.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <i><font style="FONT-SIZE: 10pt">Liquidity and Going Concern</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Our Consolidated financial statements are presented on a going concern basis, which contemplate the realization of assets and satisfaction of liabilities in the normal course of business. We have experienced recurring, significant losses from operations, and have an accumulated deficit of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">41,986,820</font> <font style="font-size:10pt;"></font>at December 31, 2013. In addition, we had respective working capital and stockholders&#8217; deficits at December 31, 2013 of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4,259,938</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4,219,449</font>&#160;respectively.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">There is substantial doubt regarding our ability to continue as a going concern which is contingent upon our ability to secure additional financing, increase ownership equity and attain profitable operations. In addition, our ability to continue as a going concern must be considered in light of the problems, expenses and complications frequently encountered in established markets and the competitive environment in which we operate.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">As of December 31, 2013, we do not have sufficient cash to sustain our operations for the next year and will require additional financing in order to execute our operating plan and continue as a going concern. Since our sales are not currently adequate to fund our operations, we continue to rely principally on debt and equity funding; however proceeds from such funding have not been sufficient to execute our business plan. Our plan is to attempt to secure adequate funding until sales of our pain products are adequate to fund our operations. We cannot predict whether additional financing will be available, and/or whether any such funding will be in the form of equity, debt, or another form. In the event that these financing sources do not materialize, or if we are unsuccessful in increasing our revenues and profits, we will be unable to implement our current plans for expansion, repay our obligations as they become due and continue as a going concern.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The accompanying Consolidated Financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt">Use of Estimates</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The accompanying Consolidated Financial statements are prepared in accordance with accounting principles generally accepted in the United States of America which require management to make estimates and assumptions. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expense. Significant estimates include our ability to continue as going concern, the recoverability of inventories and long-lived assets, and the valuation of stock-based compensation and certain debt and warrant liabilities. Actual results could differ from those estimates. Changes in facts and circumstances may result in revised estimates, which would be recorded in the period in which they become known.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt">Revenue Recognition</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In general, we record revenue when persuasive evidence of an arrangement exists, services have been rendered or product delivery has occurred, the sales price to the customer is fixed or determinable, and collectability is reasonably assured. Provision for sales returns is estimated based on our historical return experience. Revenue is presented net of returns and allowances for returns.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt">Cash and Cash Equivalents</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">We consider all highly liquid investments with an original maturity of three months or less to be cash equivalents.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt">Accounts Receivable and Allowance for Doubtful Accounts</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company grants credit without collateral to its customers based on the Company&#8217;s evaluation of a particular customer&#8217;s credit worthiness. In addition, allowances for doubtful accounts are maintained for potential credit losses based on the age of the accounts receivable and the results of the Company&#8217;s periodic credit evaluations of its customers&#8217; financial condition. Accounts receivable are written off after collection efforts have been deemed to be unsuccessful. Accounts written off as uncollectible are deducted from the allowance for doubtful accounts, while subsequent recoveries are netted against the provision for doubtful accounts expense. The Company generally does not charge interest on accounts receivable.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Accounts receivable are stated at estimated net realizable value. Accounts receivable are comprised of balances due from customers net of estimated allowances for uncollectible accounts.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <i><font style="FONT-SIZE: 10pt">Inventories</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Inventories, which are stated at the lower of average cost or market, and consist mostly of raw venom that is utilized to make the API (active pharmaceutical ingredient). The raw unprocessed venom has an indefinite life for use. The Company regularly reviews inventory quantities on hand. If necessary it records a provision for excess and obsolete inventory based primarily on its estimates of component obsolescence, product demand and production requirements. Write-downs are charged to cost of goods sold. We performed evaluations of our inventory during the year ended December 31, 2013 and 2012 and recorded total allowances of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">117,800</font>, respectively.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <i><font style="FONT-SIZE: 10pt">Financial Instruments and Concentration of Credit Risk</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Our financial instruments include cash, accounts receivable, accounts payable, accrued expenses, loans payable, due to officers and derivative financial instruments. Other than certain warrant and convertible instruments (derivative financial instruments) and liabilities to related parties (for which it was impracticable to estimate fair value due to uncertainty as to when they will be satisfied and a lack of similar type transactions in the marketplace), we believe the carrying values of our financial instruments approximate their fair values because they are short term in nature or payable on demand. Our derivative financial instruments are carried at a measured fair value.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Balances in various cash accounts may at times exceed federally insured limits. We have not experienced any losses in such accounts. We do not hold or issue financial instruments for trading purposes. In addition, for the year ended December 31, 2013, there were two customers that accounted for <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 19.6</font>% and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 15.3</font>% of the total revenues, respectively. For the year ended December 31, 2012, <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">no customers accounted for more than 10% of the Company&#8217;s total revenues. During 2013, the Company purchased 100% of its venom from one vendor</font>.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt">Derivative Financial Instruments</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt"> &#160;</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. Management evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported as charges or credits to income. For option-based simple derivative financial instruments, the Company uses the Black-Scholes option-pricing model to value the derivative instruments at inception and subsequent valuation dates. For complex embedded derivatives, the Company uses a Dilution-Adjusted Black-Scholes method to value the derivative instruments at inception and subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt">Property and Equipment and Long-Lived Assets</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Property and equipment is recorded at cost. Expenditures for major improvements and additions are added to property and equipment, while replacements, maintenance and repairs which do not extend the useful lives are expensed. Depreciation is computed using the straight-line method over the estimated useful lives of the assets of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3 &#150; 7 years</font>.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Property and equipment consists of the following at December 31,</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2012</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Computer equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>21,918</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>21,918</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Furniture and fixtures</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>34,757</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>34,757</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Lab equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>42,129</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>42,129</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Telephone equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>12,421</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>12,421</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Office equipment &#150; other</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,629</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,629</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Leasehold improvements</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>67,417</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>67,417</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Total</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>181,271</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>181,271</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Less: Accumulated depreciation and amortization</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(156,737)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(141,756)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Property and equipment, net</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>24,534</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>39,515</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">We review our long-lived assets for recoverability if events or changes in circumstances indicate the assets may be impaired. At December 31, 2013, we believe the carrying values of our long-lived assets are recoverable. Depreciation expense for the years ended December 31, 2013 and 2012 was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">14,981</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">14,994</font>, respectively.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt"> Advertising</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt"> &#160;</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">All advertising costs are expensed as incurred. Advertising costs were approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">900</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">70,800</font> for the years ended December 31, 2013 and 2012, respectively.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <i><font style="FONT-SIZE: 10pt">Income Taxes</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">We compute income taxes in accordance with Financial Accounting Standard Board (&#8220;FASB&#8221;) Accounting Standard Codification (&#8220;ASC&#8221;) Topic 740, <i>Income Taxes</i> (&#8220;ASC Topic 740&#8221;). Under ASC Topic 740, deferred taxes are recognized for the tax consequences of temporary differences by applying enacted statutory rates applicable to future years to differences between the financial statement carrying amounts and the tax bases of existing assets and liabilities. Also, the effect on deferred taxes of a change in tax rates is recognized in income in the period that included the enactment date. Temporary differences between financial and tax reporting arise primarily from the use of different methods to record bad debts and /or sales returns, and inventory reserves.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On an annual basis, we evaluate tax positions that have been taken or are expected to be taken in our tax returns to determine if they are more than likely to be sustained if the taxing authority examines the respective position. As of December 31, 2013 and 2012, we do not believe we have a need to record any liabilities for uncertain tax positions or provisions for interest or penalties related to such positions.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Since inception, we have been subject to tax by both federal and state taxing authorities. Until the respective statutes of limitations expire (which may be as much as <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">20</font> years while we have unused net operation losses), we are subject to income tax audits in the jurisdictions in which we operate.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <i><font style="FONT-SIZE: 10pt">Stock-Based Compensation</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">We account for stock-based compensation in accordance with FASB ASC Topic 718, <i>Stock Compensation</i> (ASC Topic 718). ASC Topic 718, which requires that the cost resulting from all share-based transactions be recorded in the financial statements over the respective service periods. It establishes fair value as the measurement objective in accounting for share-based payment arrangements and requires all entities to apply a fair-value-based measurement in accounting for share-based payment transactions with employees. The statement also establishes fair value as the measurement objective for transactions in which an entity acquires goods or services from non-employees in share-based payment transactions.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <i><font style="FONT-SIZE: 10pt">Net Loss Per Share</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Net loss per share is calculated in accordance with ASC Topic 260, <i>Earnings per Share</i>. Basic loss per share is calculated by dividing net loss by the weighted average number of common shares outstanding for the period. Diluted loss per share is calculated by dividing net loss by the weighted average number of common shares and dilutive common stock equivalents outstanding. During periods in which we incur losses, common stock equivalents, if any, are not considered, as their effect would be anti-dilutive or have no effect on earnings per share. Any common shares issued as of a result of the exercise of stock options and warrants would come from newly issued common shares from our remaining authorized shares.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> As of December 31, 2013 and 2012, the following items were not included in dilutive loss as the effect is anti-dilutive:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>2012</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div>Options and warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>154,916,667</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>57,256,667</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div>Convertible notes payable</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>98,506,398</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>44,642,858</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div>Total</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>253,423,065</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>101,899,525</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <i><font style="FONT-SIZE: 10pt">Reclassifications</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Certain amounts in the 2012 Consolidated Financial statements have been reclassified to conform to the current period presentation.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <i><font style="FONT-SIZE: 10pt">Recent Accounting Pronouncements</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">We have determined that all recently issued but not yet effective accounting standards will not have a material impact on our Consolidated Financial statements.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Property and equipment consists of the following at December 31,</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2012</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Computer equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>21,918</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>21,918</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Furniture and fixtures</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>34,757</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>34,757</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Lab equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>42,129</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>42,129</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Telephone equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>12,421</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>12,421</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Office equipment &#150; other</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,629</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,629</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Leasehold improvements</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>67,417</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>67,417</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Total</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>181,271</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>181,271</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Less: Accumulated depreciation and amortization</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(156,737)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(141,756)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Property and equipment, net</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>24,534</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>39,515</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">As of December 31, 2013 and 2012, the following items were not included in dilutive loss as the effect is anti-dilutive:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>2012</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div>Options and warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>154,916,667</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>57,256,667</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div>Convertible notes payable</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>98,506,398</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>44,642,858</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div>Total</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>253,423,065</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>101,899,525</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The following table summarizes our financial instruments measured at fair value as of December 31, 2013 and 2012:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="55%" colspan="11"> <div> Fair&#160;Value&#160;Measurements&#160;at&#160;December&#160;31,&#160;2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="43%"> <div>Liabilities:</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Total</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Level&#160;1</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Level&#160;2</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Level&#160;3</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>Warrant liability</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>323,172</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>323,172</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>Convertible notes at fair value</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>767,056</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>767,056</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="43%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="55%" colspan="11"> <div> Fair&#160;Value&#160;Measurements&#160;at&#160;December&#160;31,&#160;2012</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="43%"> <div>Liabilities:</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Total</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Level&#160;1</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Level&#160;2</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Level&#160;3</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>Warrant liability</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>18,727</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>18,727</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>Convertible notes at fair value</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>588,091</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>588,091</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The following table shows the changes in fair value measurements using significant unobservable inputs (Level 3) during the years ended December 31, 2013 and 2012:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in 0in 0in 0.75in; WIDTH: 60%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="35%"> <div>Description</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2012</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div>Beginning balance</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>18,727</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>28,833</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div>Purchases, issuances, and settlements</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>243,147</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="35%"> <div>Day one loss on value of hybrid instrument</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>729,093</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div>Total gain included in earnings (1)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(667,795)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(10,106)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div>Ending balance</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>323,172</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>18,727</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">(1) The gain or loss related to the revaluation of our warrant liability is included in &#8220;Change in fair value of derivatives&#8221; in the accompanying consolidated statement of operations.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The following table summarizes the significant terms of each of the debentures for which the entire hybrid instrument is recorded at fair value as of December 31, 2013 and 2012:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 98%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="15%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="32%" colspan="3"> <div>Conversion&#160;Price&#160;-<br/> Lower&#160;of Fixed&#160;Price<br/> or&#160;Percentage&#160;of<br/> VWAP&#160;for&#160;Look-back<br/> Period</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="15%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>Debenture<br/> Issuance</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>Face</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="15%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>Default<br/> Interest</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="16%"> <div>Anti-<br/> Dilution<br/> Adjusted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="15%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="15%"> <div>Look-back</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>Year</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>Amount</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="15%"> <div>Interest&#160;Rate</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>Rate</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="16%"> <div>Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="15%"> <div>%</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="15%"> <div>Period</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>564,376</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="15%"> <div>8%-20%</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>n/a</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="16%"> <div>$0.0036-$0.0064</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="15%"> <div>50%-85%</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="15%"> <div>10 to 30 Days</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2012</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>902,369</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>6%-12%</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>n/a</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"> <div>$0.0070-$0.0137</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>15%-70%</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>5 to 20 Days</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The following table shows the changes in fair value measurements using significant unobservable inputs (Level 3) during the years ended December 31, 2013 and 2012 for the Convertible Notes:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0px:auto; WIDTH: 70%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>Years&#160;Ended&#160;December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2012</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="45%"> <div>Description</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Beginning balance</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>588,091</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>206,863</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Purchases, issuances, and settlements</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>751,419</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>902,369</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Day one loss on value of hybrid instrument</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,656,802</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>479,422</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>(Gain) loss from change in fair value</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(582,423)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>309,680</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Conversion to common stock</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(1,646,832)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(1,310,243)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Ending balance</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>767,057</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>588,091</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">At December 31, 2013 and December 31, 2012, the balance due to officers consisted of the following:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>December&#160;31,<br/> 2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>December&#160;31,<br/> 2012</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>An unsecured demand loan from our President and CEO, Rik Deitsch. The loan bears interest at 4%. The loan balance at December 31, 2013 and 2012, respectively, includes accrued interest payable of $349,466 and $324,853.</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>566,399</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>606,168</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>A loan from Paul Reid, the former President of ReceptoPharm bearing interest at a rate of 5% per annum, due on demand and secured by certain intellectual property of ReceptoPharm having a zero cost at December 31, 2013 and December 31, 2012.<br/> The accrued interest at December 31, 2013 and December 31, 2012 was $43,363 and $37,392, respectively.</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>123,189</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>117,218</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Ending balances</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>689,588</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>723,386</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Other debt (all short-term) consists of the following at December 31, 2013 and 2012:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="clear:both;MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2012</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Note payable &#150; Related Party (1)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>180,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>190,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Notes payable &#150; Non Related Parties (2)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>412,182</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>593,483</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Convertible notes payable, at fair value (3)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>767,056</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>588,091</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Ending balances</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,359,238</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,371,574</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">(1)</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">During the third quarter of 2010 we borrowed $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">200,000</font> from one of our directors. We repaid $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10,000</font></font> each (total $20,000) during the third quarter of 2012 and 2013. Under the terms of the loan agreement, this loan was expected to be repaid in nine months to a year from the date of the loan along with <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">interest calculated at 10% for the first month plus 12% after 30 days from funding</font>. We are in default regarding this loan. At December 31, 2013 and 2012, we owed this director accrued interest of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">121,137</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">86,387</font>, respectively.</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">(2)</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">At December 31, 2013 and 2012, the balance of $412,182 and $593,483 , respectively, consisted of the following loans:</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 45pt; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="60"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt">&#183;</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In May 2011, the Company received a loan for $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">25,000</font> from a non-related party. This loan was expected to be repaid no later than December 31, 2011, along with <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">interest calculated at 10% for the first month plus 12% after 30 days from funding</font>. This loan is guaranteed by an officer of the Company. On November 25, 2013, the non-related party accepted a total of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 4,360,000</font> shares of the Company&#8217;s restricted common stock as a repayment to discharge $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">25,000</font> of his outstanding loan and accrued interest of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">11,956</font> (See note 6).&#160; The Company recorded a loss of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">28,444</font> on the settlement date.</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 45pt; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="60"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt">&#183;</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In May 2011, the Company received another loan for $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">25,000</font> from a non-related party. This loan was expected to be repaid no later than December 31, 2011, along with <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">interest calculated at 10% for the first month plus 12% after 30 days from funding</font>. This loan is guaranteed by an officer of the Company. On September 16, 2013, the non-related party accepted a total of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 8,472,750</font> shares of the Company&#8217;s restricted common stock as a repayment to discharge $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">25,000</font> of his outstanding loan and accrued interest of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">11,120</font> (See note 6).&#160;The Company recorded a loss of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">90,971</font> on the settlement date.</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 63pt" align="justify"><font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt">&#160;</font></div> <table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 45pt; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="60"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt">&#183;</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In July 2013, the Company issued a promissory note to the Michael McDonald Trust in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">75,000</font> bearing interest at a rate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2</font>% per month. The note is due in six months from the execution and funding of the note. In connection with the issuance of this promissory note, the Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,000,000</font> shares of the Company's common stocks (See note 6).&#160;The Company has recorded a debt discount in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3,977</font> to reflect the value of the common stocks as a reduction to the carrying amount of the convertible debt and a corresponding increase to common stocks and additional paid-in capital.&#160;The total discount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3,977</font> was fully amortized over the term of the debt during the year ended December 31, 2013.&#160;&#160; In the event of default, the Company would issue an additional <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,000,000</font> share of the Company&#8217;s common stocks on the date that is fifteen days after the maturity date (See Note 6). We are in default regarding this loan. The additional <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,000,000</font> shares were issued in January 2014 with a fair value at $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">9,900</font> (See Note 10). At December 31, 2013, we owed Michael McDonald accrued interest of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">9,000</font>.</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 63pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 45pt; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="60"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt">&#183;</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">At December 31, 2012, the total amount of the Company&#8217;s debt assigned to Southridge was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">483,482</font>. In connection with the debt sales to Southridge, the Company recorded a loss on settlement of accounts payable for $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">63,490</font> in the statement of operations at December 31, 2012. During the first quarter of 2013, the suit was voluntarily dismissed involving debt held by Southridge for $483,482. The debt has reverted back to the original holders.</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 63pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 63pt" align="justify"><font style="COLOR: #333333; FONT-SIZE: 10pt">In April, 2013, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">88,500</font> of</font> <font style="FONT-SIZE: 10pt">the debt held by Michael McDonald Trust was assigned to Coventry Enterprises, LLC (&#8220;Coventry&#8221;) in the form of a Convertible Redeemable Note bearing interest of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">8</font>% annum. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">Coventry was entitled to convert all or any amount of the this note into shares of the Company's common stock (the "Common Stock") at a conversion price ("Conversion Price") for each share of Common Stock equal to 55% of the average of the daily volume weighted average prices of the Common Stock for the 3 trading days with the lowest volume weighted average prices during the 15 trading days immediately preceding the Conversion Date</font>. Following the agreements with Coventry, Coventry made the conversions for a total of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 31,416,845</font> shares of the company&#8217;s restricted stock during the second quarter of 2013 satisfying the notes in full at the fair value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">186,646</font>.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 63pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 63pt" align="justify"><font style="FONT-SIZE: 10pt">In June, 2013, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">57,800</font> of the debt was assigned to Coventry for a consideration of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">60,000</font> from Baker Donelson Bearman Caldwell &amp; Berkowitz, PC. in the form of Convertible Redeemable Notes bearing interest of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 8</font>% annum. The Company recorded a loss of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2,200</font> on the settlement during the year ended December 31, 2013. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">Coventry was entitled to convert all or any amount of the these notes into shares of the Company's common stock (the "Common Stock") at a conversion price ("Conversion Price") for each share of Common Stock equal to 55% of the average of the daily volume weighted average prices of the Common Stock for the 3 trading days with the lowest volume weighted average prices during 20 trading days</font> . Following the agreements, Coventry made the conversions for a total of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 27,272,727</font> shares of the company&#8217;s restricted stock satisfying the notes in full at the fair value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">167,495</font>.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 63pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 63pt" align="justify"><font style="FONT-SIZE: 10pt">As a result of the debt assignments and conversions with Coventry, the remaining balance of the debt at December 31, 2013 is $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">337,182</font> which consisted of the following loans:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 63pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 63pt; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="84"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">i.</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">August 2, 2011</font> under a settlement agreement with Liquid Packaging Resources, Inc. (&#8220;LPR&#8221;), the Company agreed to pay LPR a total of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">350,000</font> in monthly installments of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">50,000</font> beginning August 15, 2011 and ending on February 15, 2012. This settlement amount was recorded as general and administrative expenses on the date of the settlement. We did not make the December 2011 or January 2012 payments and on January 26, 2012, we signed the first amendment to the settlement agreement where under we agreed to pay $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">175,000</font> which was the balance outstanding at December 31, 2011(this includes a $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">25,000</font> penalty for non-payment).</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1.25in" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 81pt" align="justify"><font style="FONT-SIZE: 10pt">The Company repaid $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">25,000</font> during the three months ended March 31, 2012. The Company did not make all of the payments under such amendment and as a result pursuant to the original settlement agreement, LPR had the right to sell <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 5,714,326</font> shares of the Company&#8217;s free trading stock held in escrow by their attorney and receive cash settlements for a total amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">450,000</font> (the initial $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">350,000</font> plus total default penalties of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">100,000</font>). The $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">100,000</font> default was expensed during 2012. LPR sold the note to Southridge Partners, LLP (&#8220;Southridge&#8221;) for consideration of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">281,772</font> in October 2012. The debt has reverted back to the Company (See note 9).</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 81pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 63pt; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="84"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">ii.</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">As of December 31, 2013 and 2012, the Company owed <em>University Centre West Ltd</em>. approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">55,410</font></font>, which was assigned and sold to Southridge and subsequently reverted back to the Company .</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 81pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">(3)</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">At December 31, 2013 and 2012, the balance of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">767,056</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">588,091</font> consisted of the following convertible loans:</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt">&#183;</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In September and October 2011, the Company borrowed $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">250,000</font> each (aggregating $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">500,000</font>) from two non-related parties. The principal of these loans were to be repaid with a balloon payment on or before October 1, 2012. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">On October 19, 2012 the parties amended the notes to extend the due date to May 1, 2013 and include a conversion feature that would allow the holders to convert some or all of their outstanding notes into restricted Company stock at a 15% discount to the average closing market price of the Company's stock traded over the previous 10 days</font>. Interest on these loans is payable monthly beginning in November 2011 with <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> interest calculated at 20% and 12%, each, respectively</font>. At December 31, 2013 and 2012, the accrued interest payable was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">6,664</font></font>.</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 2.25pt; MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">During year ended December 31, 2013, one of the Note holders made conversions of a total of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 34,254,004</font> shares of the company&#8217;s restricted stock satisfying the notes in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">125,000</font> with a fair value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">317,391</font> on the date of conversion. During August and September, 2013, <font style="COLOR: #333333">$<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">150,000</font></font></font> of</font> the debts were assigned to three non-related parties in the form of a Convertible Redeemable Note bearing interest of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 8</font>% annum with a <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">conversion price for each share of Common Stock equal to 55% of the average of the daily volume weighted average prices of the Common Stock for the 3 trading days with the lowest volume weighted average prices during the 15 to 20 trading days immediately preceding the Conversion Date</font>. Following the assignments, the conversions for a total of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 64,052,862</font> shares of the company&#8217;s restricted stock were made in satisfying the notes of $150,000 at the fair value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">475,519</font> (See note 6).</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 63pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">At December 31, 2013, the remaining balance of these two convertible notes payable of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">75,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">150,000</font> were recorded at a fair value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">90,260</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">189,781</font>, respectively. At December 31, 2012, these two convertible note payable of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">250,000</font> each were recorded at fair value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">290,289</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">297,802</font>, respectively.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">On April 30, 2013, the parties amended the notes to further extend the maturity date to November 3, 2013. The Company issued a total of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 4,000,000</font> restricted shares to the note holders in connection with the amendment at a fair value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">20,800</font>. On October 30, 2013 and November 1, 2013, the parties amended the note of $75,000 and $150,000 to further extend the maturity dates to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">May 3, 2014</font> and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">August 3, 2014</font>, respectively. The Company issued a total of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 500,000</font> and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,250,000</font> restricted shares to the note holders in connection with the amendment at a fair value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">9,500</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">13,750</font> (See note 6), respectively.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt">&#183;</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On March 22, 2013, the Company issued a Convertible Debenture in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">20,000</font> to Coventry Enterprises, LLC (&#8220;Coventry&#8221;). The note carries interest at <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10</font>% and is due on March 22, 2014, unless previously converted into shares of restricted common stock. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> Coventry has the right to convert the note, until is no longer outstanding into shares of Common Stock at a price which is lesser of $.0075, or (ii) fifty-five percent (55%) of the average of the three lowest VWAP prices of the Company&#8217;s Common Stock for the twenty trading days preceding the conversion date</font>. In connection with the issuance of this convertible note payable, the Company encountered a day-one derivative loss of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">24,931</font>. Coventry made the conversions into a total of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 8,810,572</font> shares of the company&#8217;s restricted stock satisfying the notes in full with a fair value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">188,747</font>on September 4, 2013(See note 7).</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">In connection with the issuances of the Note, the Company also granted five-year warrants to purchase an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2,600,000</font></font> shares of the Company&#8217;s common stock at an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.01</font></font> per share. The Company classified embedded conversion features in these warrants as a derivative liability. The warrants were valued at their fair value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">21,226</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">17,895</font>, respectively using the Black-Scholes method at the commitment and re-measurement dates of March 22, 2013 and December 31, 2013, respectively.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt">&#183;</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On July 10, 2013 and October 10, 2013, the Company issued two Convertible Debentures in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">30,000</font></font> each (total $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">60,000</font>) to Christopher Castaldo in connection with the agreements for investor relation services (See Note 6). The notes carry interest at <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">8</font>% and are due on January 10, 2014 and April 10, 2014, respectively. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">The notes&#8217; holder has the right to convert the notes into shares of Common Stock at a price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.005</font></font>.</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">In connection with the issuance of this convertible notes payable, the Company encountered a day-one derivative loss of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">83,157</font>. At December 31, 2013, these convertible notes payable, at fair value, was recorded at $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">90,684</font>.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt">&#183;</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On September 3, 2013, the Company issued a Convertible Debenture in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">100,000</font> to Coventry Enterprises, LLC (&#8220;Coventry&#8221;). The note carries interest at <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10</font>% and is due on September 3, 2014, unless previously converted into shares of restricted common stock. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> Coventry has the right to convert the note, until is no longer outstanding into shares of Common Stock at a price lesser of $.018, or (ii) fifty-five percent (55%) of the average of the three lowest VWAP prices of the Company&#8217;s Common Stock for the twenty trading days preceding the conversion date</font>.</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">In connection with the issuance of this convertible note payable, the Company encountered a day-one derivative loss of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">957,567</font>. At December 31, 2013, this convertible note payable, at fair value, was recorded at $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">185,971</font>.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">In connection with the issuances of the Note, the Company also granted five-year warrants to purchase an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 20,000,000</font></font> shares of the Company&#8217;s common stock at an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.025</font></font> per share. The Company classified embedded conversion features in these warrants as a derivative liability. The warrants were valued at their fair value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">445,638</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">137,681</font></font>, respectively using the Black-Scholes method at the commitment and re-measurement dates of September 3, 2013 and December 31, 2013, respectively.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt">&#183;</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On September 12, 2013, the Company issued a Convertible Debenture in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">70,000</font> to Coventry Enterprises, LLC (&#8220;Coventry&#8221;). The note carries interest at <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10</font>% and is due on September 12, 2014, unless previously converted into shares of restricted common stock. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> Coventry has the right to convert the note, until is no longer outstanding into shares of Common Stock at a price lesser of $.02, or (ii) fifty-five percent (55%) of the average of the three lowest VWAP prices of the Company&#8217;s Common Stock for the twenty trading days preceding the conversion date.</font></font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">In connection with the issuance of this convertible note payable, the Company encountered a day-one derivative loss of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">309,055</font>. At December 31, 2013, this convertible note payable, at fair value, was recorded at $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">130,303</font>.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">In connection with the issuances of the Note, the Company also granted five-year warrants to purchase an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 15,000,000</font> shares of the Company&#8217;s common stock at an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.025</font> per share. The Company classified embedded conversion features in these warrants as a derivative liability. The warrants were valued at their fair value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">262,230</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">101,140</font></font>, respectively using the Black-Scholes method at the commitment and re-measurement dates of September 12, 2013 and December 31, 2013, respectively.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt">&#183;</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On October 7, 2013, the Company signed a secured convertible Promissory Note in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">35,000</font> in favor of Southridge Partners II, LLC. The note was due on demand and carries interest at <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10</font>% annum. Southridge Partners II, LLC was entitled to convert the principal into shares of common stock at the lesser of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.015</font> or a <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 50</font>% discount from the lowest closing bid price in the <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 30</font> trading days prior to the day that the conversion is requested; and interest accrued was entitled to convert into shares of common stock at $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.001</font>. In the evaluation of these financing arrangements, the Company concluded that these conversion features did not meet the conditions set forth in current accounting standards for equity classification. Since equity classification is not available for the conversion feature, it requires bifurcation and liability classification, at fair value. The Company also concluded that the Default Put required bifurcation because, while puts on debt instruments are generally considered clearly and closely related to the host, the Default Put is indexed to certain events that are not associated with the convertible note payable.</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">In connection with the issuance of this convertible note payable, the Company encountered a day-one derivative loss of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">81,667</font>. At December 31, 2013, this convertible note payable, at fair value, was recorded at $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">80,057</font>.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: #333333; FONT-SIZE: 10pt"> &#160;</font></div> <table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt">&#183;</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On October 27, 2011 the Company entered into a convertible note payable with a corporation. The convertible note payable, with a face value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">53,000</font>, bears interest at <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 8.0</font>% per annum and was due on July 31, 2012.</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">On December 5, 2011 the Company entered into a convertible note payable with a corporation which had a face value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">37,500</font>, a coupon rate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 8.0</font>% per annum and maturity date of September 5, 2012.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">The convertible note payable is convertible, at the holder&#8217;s option, into the Company&#8217;s common shares at a variable conversion price which is 58% multiplied by the average of the lowest three (3) trading prices for the Common Stock during the ten (10) Trading Day period ending one Trading Day prior to the date the Conversion Notice is sent by the Holder to the Borrower</font>. The conversion feature is subject to full-ratchet, anti-dilution protection if the Company sells shares or share-indexed financing instruments at less than the conversion price. The holder has the option to redeem the convertible note payable for cash in the event of defaults or certain other contingent events (the &#8220;Default Put&#8221;).</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">During October 2012, both of these notes were acquired by a third party from Asher Enterprises for an aggregate amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">100,000</font>, and then converted into <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 20,000,000</font> restricted common shares (See note 6).</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt">&#183;</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">February 3, 2012</font>, the Company issued a Convertible Debenture in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">40,000</font> to Redwood Management, LLC. The note carries interest at <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 12</font>% and is due on February 13, 2013, unless converted into shares of restricted common stock<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">. Redwood Management, LLC has the right to convert the note, until it is no longer outstanding, into shares of Common Stock at a price of Fifty Percent (50%) of the lowest closing price, determined on the then current trading market for the Company&#8217;s common stock, during the 15 trading days prior to conversion (the &#8220;Set Price&#8221;).</font> On September 12, 2012, TCN International (TCN) completed the purchase and transfer of this note including penalties and unpaid interest, for the sum of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">52,500</font>. Redwood Management, LLC has acknowledged the full payment of the Note, in favor of Nutra Pharma Corporation and releases Nutra Pharma Corporation from all obligations under the Note. Upon the request of TCN, the Board of Directors of the Company approved the conversion of these notes into Restricted Common Stock of the Company,providing <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 7,500,000</font> shares of Nutra Pharma common stock to relinquish the total debt of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">52,500</font> (See note 6).</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt">&#183;</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On March 16, 2012 the Company signed a secured convertible Promissory Note in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">75,000</font> in favor of Southridge Partners II, LLC. The note was due <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> November 16, 2012</font> and carries interest at <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">8</font>% annum. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">Southridge Partners II, LLC was entitled after nine months to convert all or a portion of the principal and interest accrued into shares of common stock at a conversion price of each share equal to the Market Price multiplied times 70%. (the &#8220;conversion price&#8221;). The Market Price is equal to the average of the two lowest bids closing prices for the five trading days ending before the conversion date</font>. In the evaluation of these financing arrangements, the Company concluded that these conversion features did not meet the conditions set forth in current accounting standards for equity classification. Since equity classification is not available for the conversion feature, it requires bifurcation and liability classification, at fair value. The Company also concluded that the Default Put required bifurcation because, while puts on debt instruments are generally considered clearly and closely related to the host, the Default Put is indexed to certain events that are not associated with the convertible note payable. On October 26, 2012, Southridge converted the note into <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 5,919,495</font> shares of the Company's restricted common stock (See note 6).</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">In the evaluation of these financing arrangements, the Company concluded that these conversion features did not meet the conditions set forth in current accounting standards for equity classification. Since equity classification is not available for the conversion feature, it requires bifurcation and liability classification, at fair value. The Company also concluded that the Default Put required bifurcation because, while puts on debt instruments are generally considered clearly and closely related to the host, the Default Put is indexed to certain events that are not associated with the convertible note payable.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">The Company&#160;elected to account for these hybrid contracts under the guidance of ASC 815-15-25-4. The fair value has been defined as the common stock equivalent value, enhanced by the fair value of the default put plus the present value of the coupon.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">The holder of this convertible note has substantial rights and protections regarding dilution if certain events, including a default were to occur. There are a number of events that could trigger a default, including but not limited to failure to pay principal or interest, failure to issue shares under the conversion feature, breach of covenants, breach of representations and warranties, appointment of a receiver or trustee, judgments, bankruptcy, delisting of common stock, failure to comply with the exchange act, liquidation, cessation of operations, failure to maintain assets, material financial statement restatement, reverse split of borrowers stock, etc. In the event of these events the lender may be entitled to receive significant amounts of additional stock above the amounts for conversion.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">Furthermore, there are additional events that could cause the lender to be due additional shares of common stock above and beyond the shares due from a conversion. Some of these events include, but are not limited to a merger or consolidation of the Company, dividend distribution or spin off, dilutive issuances of the Company&#8217;s stock, etc. If the lender receives additional shares of the Company&#8217;s commons stock due to any of the foregoing events or for other reasons, then this may have an extremely dilutive effect on the shareholders of the Company. Such dilution would likely result in a significant drop in the per share price of the Company&#8217;s common stock. The potential dilutive nature of this note presents a very high degree of risk to the Company and its shareholders</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">A summary of warrants outstanding in conjunction with private placements of common stock were as follows during the year ended December 31, 2013 and 2012:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 99%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>Number&#160;of&#160;shares</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>Weighted&#160;average&#160;exercise&#160;price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Balance December 31, 2011</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>47,921,667</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>0.10</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 39px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Issued</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>54,650,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0.10</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Forfeited/Expired</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>(45,315,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Balance December 31, 2012</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>57,256,667</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0.10</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 39px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Issued</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>98,600,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0.01 &#150; 0.10</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Forfeited</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>(940,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Balance December 31, 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>154,916,667</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0.082</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The following table summarizes information about fixed-price warrants outstanding as of December 31, 2013 and 2012<strong>:</strong></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.5in; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="25%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>Exercise&#160;Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>Number<br/> Outstanding</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>Weighted<br/> Average<br/> Contractual<br/> Life</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>Weighted<br/> Average<br/> Exercise Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="25%"> <div>2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0.01-0.10</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>154,916,667</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1.97 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0.082</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="25%"> <div>2012</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0.10-0.15</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>57,256,667</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>2.04 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0.10</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company&#8217;s tax expense differs from the &#8220;expected&#8221; tax expense for the years ended December 31, 2013 and 2012, (computed by applying the Federal Corporate tax rate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 34</font>% to loss before taxes and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 8.84</font>% for California State Corporate Taxes, the blended rate used was <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 39.83</font>%), are approximately as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%" colspan="5"> <div>December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>2012</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Computed "expected" tax expense (benefit) - Federal</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>(1,346,076)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>(1,115,374)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Computed "expected" tax expense (benefit) - State</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>(322,564)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>(318,119)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Stock-based compensation</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>558,448</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>674,914</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Change in fair value of derivatives</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>452,390</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>159,500</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Change in valuation allowance</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>657,802</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>599,079</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Current&#160;portion&#160;of&#160;net&#160;deferred&#160;income&#160;tax&#160;assets:</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>2012</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Allowance for doubtful accounts</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>242,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>242,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Reserve for inventory obsolescence</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>313,925</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>313,925</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Accrued salary</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>101,877</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>43,154</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Subtotal</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>657,802</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>599,079</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Valuation allowance</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>(657,802)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>(599,079)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Current net deferred income tax asset</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Non- current portion of net deferred income tax asset</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Net operating loss carryforwards</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>6,232,881</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>5,575,079</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Valuation allowance</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>(6,232,881)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>(5,575,079)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Non-current net deferred income tax asset</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Future minimum payments under these lease agreements, including the extension period, are approximately as follows:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 65%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Years&#160;ended<br/> December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>Amounts</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>116,345</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>2015</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>120,218</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>79,892</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>45,249</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Total</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>361,704</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 181271 21918 34757 42129 12421 2629 67417 181271 21918 34757 42129 12421 2629 67417 141756 156737 4259938 70800 900 14994 14981 117800 0 0 0 18727 0 0 323172 588091 0 0 588091 767056 0 0 767056 28833 0 243147 10106 667795 902369 564376 0.06 0.08 0.12 0.2 0.0070 0.0137 0.0036 0.0064 0.15 0.7 0.5 0.85 P5D P20D P10D P30D 206863 902369 751419 479422 1656802 309680 -582423 -1310243 -1646832 0.0013 0.0175 1.24 2.36 0 80000 2006-09-28 20000 40000 20000 109500 80000 65040 80389 149500 188608 188608 65040 0.06 0.08 0.08 The full amount of principal and interest was due at maturity unless the Debenture was converted to shares of common stock in accordance with the debenture agreement, whereby such debenture could be converted into shares of our common stock at a price equal to 75% of the lowest closing price (determined on the then current trading market for our common stock) during the 15 trading days prior to conversion. Coventry was entitled to convert all or any amount of the this note into shares of the Company's common stock (the &#34;Common Stock&#34;) at a conversion price (&#34;Conversion Price&#34;) for each share of Common Stock equal to 55% of the average of the daily volume weighted average prices of the Common Stock for the 3 trading days with the lowest volume weighted average prices during the 20 trading days immediately preceding the Conversion Date. 18737894 8672090 2565102 42958 65039 505525 15472 4885 117218 606168 566399 123189 0.04 0.05 0.04 0.05 324853 37392 349466 43363 164779 151718 324478 53600 175000 190000 180000 150000 593483 412182 200000 10000 10000 interest calculated at 20% and 12%, each, respectively interest calculated at 10% for the first month plus 12% after 30 days from funding interest calculated at 10% for the first month plus 12% after 30 days from funding interest calculated at 10% for the first month plus 12% after 30 days from funding 11120 11956 86387 6664 121137 9000 6664 25000 25000 57800 150000 250000 500000 2012-02-03 2012-11-16 2014-05-03 2014-08-03 The convertible note payable is convertible, at the holders option, into the Companys common shares at a variable conversion price which is 58% multiplied by the average of the lowest three (3) trading prices for the Common Stock during the ten (10) Trading Day period ending one Trading Day prior to the date the Conversion Notice is sent by the Holder to the Borrower On October 19, 2012 the parties amended the notes to extend the due date to May 1, 2013 and include a conversion feature that would allow the holders to convert some or all of their outstanding notes into restricted Company stock at a 15% discount to the average closing market price of the Company's stock traded over the previous 10 days conversion price for each share of Common Stock equal to 55% of the average of the daily volume weighted average prices of the Common Stock for the 3 trading days with the lowest volume weighted average prices during the 15 to 20 trading days immediately preceding the Conversion Date . Redwood Management, LLC has the right to convert the note, until it is no longer outstanding, into shares of Common Stock at a price of Fifty Percent (50%) of the lowest closing price, determined on the then current trading market for the Companys common stock, during the 15 trading days prior to conversion (the Set Price). Southridge Partners II, LLC was entitled after nine months to convert all or a portion of the principal and interest accrued into shares of common stock at a conversion price of each share equal to the Market Price multiplied times 70%. (the conversion price). The Market Price is equal to the average of the two lowest bids closing prices for the five trading days ending before the conversion date Coventry has the right to convert the note, until is no longer outstanding into shares of Common Stock at a price which is lesser of $.0075, or (ii) fifty-five percent (55%) of the average of the three lowest VWAP prices of the Companys Common Stock for the twenty trading days preceding the conversion date Coventry was entitled to convert all or any amount of the this note into shares of the Company's common stock (the &#34;Common Stock&#34;) at a conversion price (&#34;Conversion Price&#34;) for each share of Common Stock equal to 55% of the average of the daily volume weighted average prices of the Common Stock for the 3 trading days with the lowest volume weighted average prices during the 15 trading days immediately preceding the Conversion Date Coventry was entitled to convert all or any amount of the these notes into shares of the Company's common stock (the &#34;Common Stock&#34;) at a conversion price (&#34;Conversion Price&#34;) for each share of Common Stock equal to 55% of the average of the daily volume weighted average prices of the Common Stock for the 3 trading days with the lowest volume weighted average prices during 20 trading days The notes holder has the right to convert the notes into shares of Common Stock at a price of $0.005 Coventry has the right to convert the note, until is no longer outstanding into shares of Common Stock at a price lesser of $.02, or (ii) fifty-five percent (55%) of the average of the three lowest VWAP prices of the Companys Common Stock for the twenty trading days preceding the conversion date. Coventry has the right to convert the note, until is no longer outstanding into shares of Common Stock at a price lesser of $.018, or (ii) fifty-five percent (55%) of the average of the three lowest VWAP prices of the Companys Common Stock for the twenty trading days preceding the conversion date 4000000 500000 1250000 30000 60000 30000 0.08 0.08 2011-08-02 0.12 0.08 0.1 0.08 0.1 0.1 0.080 0.080 0.08 0.1 88500 60000 350000 175000 50000 25000 25000 5714326 1000000 450000 350000 100000 100000 75000 7500000 31416845 34254004 64052862 20000000 5919495 8810572 27272727 8472750 4360000 40000 75000 35000 53000 37500 483482 83157 957567 81667 24931 309055 52500 337182 281772 52500 63490 100000 17650000 27000000 10000000 1000000 10000000 1000000 15720000 1000000 26875000 34630000 26875000 0.0165 0.005 0.0229 0.022 0.014 0.10 0.10 0.014 0.03 0.10 0.0175 0.0178 0.016 0.0229 0.0173 0.012 0.0056 0.0042 0.0042 0.0053 0.008 0.0042 0.007 0.009 0.005 0.014 0.0125 0.0125 0.0125 0.0125 0.0125 0.0125 1000000 15000000 1500000 1500000 6000000 2000000 2000000 2000000 100000 2000000 1000000 8000000 1500000 3000000 10000000 1000000 15100000 500000 3000000 5500000 1000000 15000000 15119481 50000000 31416845 64052862 18737894 6416733 20000000 7500000 80000 317391 162500 188747 88500 167495 475519 320531 157179 356779 273144 25000 15472 505525 65039 90971 28444 125000 150000 176500 270000 50000 45000 45000 0.01 0.01 0.005 0.002 0.015 0.001 0.0042 17650000 27000000 11000000 21000000 10000000 80216 40104 17500 267000 24000 34350 70902 8351 8446 8400 420 8400 5300 61019 10500 27000 50000 14000 108534 1042 21875 28646 8697 151375 85500 32898 15649 2754 2981 5208 15625 3533 21625 P2M P3M P2M P8M P1M15D 47921667 0 0 54650000 98600000 45315000 940000 57256667 154916667 0.10 0 0 0.10 0.01 0.10 0 0 0.10 0.082 0.10 0.15 0.01 0.10 57256667 154916667 P2Y14D P1Y11M19D 0.10 0.082 0 0 0.0075 2600000 25000000 10000000 1000000 0.01 0.10 0.03 0.10 -1115374 -1346076 -318119 -322564 674914 558448 159500 452390 599079 657802 242000 242000 313925 313925 43154 101877 599079 657802 599079 657802 0 0 5575079 6232881 5575079 6232881 0 0 0.34 15580000 0.0884 0.3983 41987000 116345 120218 79892 45249 361704 118928.15 768506 500000 300000 330000 990927 1214800 10000000 1214800 1750000 359826.85 350000.00 P7M 50000.00 400000 150000 25000 5000 205000 150000 15000 10000 175000 30000 450000 816662 9000 3500 P5Y 5000 183000 114889 P3Y 2015-12-31 101899525 57256667 44642858 154916667 253423065 98506398 0 10000 100000 30300 0 3977 0 0 -3612351 -4342964 0 0 20 25000000 14800000 3000000 38528 112621 0.018 0.015 25000000 0.030 243146 63297 37000 10000000 100000 162500 186646 475519 25000 2200 0.02 3977 3977 1000000 20000 100000 70000 55410 588091 250000 250000 55410 767056 75000 150000 20800 1000000 21226 445638 262230 17895 137681 101140 2600000 2600000 20000000 15000000 0.01 0.025 0.025 90684 185971 130303 10-K false 2013-12-31 2013 FY NPHC 1056274057 NUTRA PHARMA CORP 0001119643 --12-31 No No Yes Smaller Reporting Company 9833758 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Following the agreements with Coventry Enterprises, LLC (see Note 3) for $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">80,000</font>, Coventry made the following conversions for a total of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 15,119,481</font> shares of the company&#8217;s restricted stock during the first quarter of 2013 satisfying the notes in full and recorded a loss of $65,039 (See note 3):&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.25in; WIDTH: 90%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Date</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Number&#160;of shares<br/> converted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>Fair&#160;Value<br/> of&#160;Debt<br/> Converted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="63%"> <div>January 21, 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>4,032,258</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>37,619</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>February 11, 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>5,405,405</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>42,510</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>March 20, 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>5,681,818</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>40,414</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Following the agreement with Coventry Enterprises, LLC (see Note 5) for $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">88,500</font>, Coventry made the following conversions for a total of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 31,416,845</font> shares of the company&#8217;s restricted stock during the second quarter of 2013 satisfying the notes in full:</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif ">&#160;</div><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.25in; WIDTH: 90%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Date</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Number&#160;of&#160;shares&#160;converted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>Fair&#160;Value<br/> of&#160;Debt<br/> Converted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="63%"> <div>4/17/2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>7,133,333</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>49,586</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>5/16/2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>11,101,694</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>64,930</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>6/12/2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>13,181,818</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>70,130</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif ">&#160;</div><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">During June and August, 2013, one of the convertible Notes holders made the following conversions of a total of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 34,254,004</font> shares of the company&#8217;s restricted stock satisfying the notes in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">125,000</font> with a fair value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">317,391</font> on the date of conversion (See Note 5).</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.25in; WIDTH: 90%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Date</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Number&#160;of&#160;shares&#160;converted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>Fair&#160;Value<br/> of&#160;Debt<br/> Converted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="63%"> <div>6/25/2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>22,058,882</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>188,352</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>8/30/2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>12,195,122</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>129,039</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">During August and September, 2013, <font style="COLOR: #333333">$<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">150,000</font> of</font> the convertible notes were assigned to third parties in the form bearing interest of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">8</font>% annum at with a <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">conversion price for each share of Common Stock equal to 55% of the average of the daily volume weighted average prices of the Common Stock for the 3 trading days with the lowest volume weighted average prices during the 15 to 20 trading days immediately preceding the Conversion Date.</font> Immediately following the assignments, the conversions for a total of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 64,052,862</font> shares of the company&#8217;s restricted stock were made as followings in satisfying the notes of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">150,000</font> at the fair value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">475,519</font>(See Note 5).</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.25in; WIDTH: 90%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Date</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Number&#160;of&#160;shares&#160;converted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>Fair&#160;Value<br/> of&#160;Debt<br/> Converted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="63%"> <div>8/28/2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>22,026,431</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>167,493</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>9/3/2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>20,000,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>163,909</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>9/4/2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>22,026,431</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>144,117</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 4032258 5405405 5681818 7133333 11101694 13181818 22058882 12195122 22026431 20000000 22026431 37619 42510 40414 49586 64930 70130 188352 129039 167493 163909 144117 2018-09-03 2018-09-12 2018-03-22 2014-12-31 20000000 15000000 25000000 0.030 0.025 0.196 0.153 no customers accounted for more than 10% of the Companys total revenues. During 2013, the Company purchased 100% of its venom from one vendor 2014-12-31 25000000 0.10 290289 297802 90260 189781 9500 13750 80057 259380 22900 569400 484820 569400 0.001 0.005 0.015 0.5 30 466000 42800 423200 42800000 3977 1000 2977 1000000 30000 10000 0.05 125000 250000 500000 250000 4000000 75000 3977 1000000 12000000 0.005 12000000 0.03 9900 10000 10000 100000 70000 60000 90000 15584415 23376623 16008 14600 0.04 1159 1159 25000 100000 conversion price for each share of Common Stock equal to 55% of the average of the daily volume weighted average prices of the Common Stock for the 3 trading days with the lowest volume weighted average prices during the 15 to 20 trading days immediately preceding the Conversion Date. 10000000 14800000 3000000 25000000 8672090 2564102 37000 38528 0.018 0.015 10000000 25000000 0.10 0.030 3 7 years 168889 33720 0 729093 0 19178 60000 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt">Accounting for Shipping and Handling Costs</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company records shipping and handling costs incurred in cost of sales.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 75000 20000 9900 20800 350000 35000 The gain or loss related to the revaluation of our warrant liability is included in “Change in fair value of derivatives” in the accompanying consolidated statement of operations. During the third quarter of 2010 we borrowed $200,000 from one of our directors. We repaid $10,000 each (total $20,000) during the third quarter of 2012 and 2013. Under the terms of the loan agreement, this loan was expected to be repaid in nine months to a year from the date of the loan along with interest calculated at 10% for the first month plus 12% after 30 days from funding. We are in default regarding this loan. At December 31, 2013 and 2012, we owed this director accrued interest of $121,137 and $86,387, respectively. At December 31, 2013 and 2012, the balance of $412,182 and $593,483 , respectively, consisted of the following loans: In May 2011, the Company received a loan for $25,000 from a non-related party. This loan was expected to be repaid no later than December 31, 2011, along with interest calculated at 10% for the first month plus 12% after 30 days from funding. This loan is guaranteed by an officer of the Company. On November 25, 2013, the non-related party accepted a total of 4,360,000 shares of the Company’s restricted common stock as a repayment to discharge $25,000 of his outstanding loan and accrued interest of $11,956 (See note 6). The Company recorded a loss of $28,444 on the settlement date. In May 2011, the Company received another loan for $25,000 from a non-related party. This loan was expected to be repaid no later than December 31, 2011, along with interest calculated at 10% for the first month plus 12% after 30 days from funding. This loan is guaranteed by an officer of the Company. On September 16, 2013, the non-related party accepted a total of 8,472,750 shares of the Company’s restricted common stock as a repayment to discharge $25,000 of his outstanding loan and accrued interest of $11,120 (See note 6). The Company recorded a loss of $90,971 on the settlement date. In July 2013, the Company issued a promissory note to the Michael McDonald Trust in the amount of $75,000 bearing interest at a rate of 2% per month. The note is due in six months from the execution and funding of the note. In connection with the issuance of this promissory note, the Company issued 1,000,000 shares of the Company's common stocks (See note 6). The Company has recorded a debt discount in the amount of $3,977 to reflect the value of the common stocks as a reduction to the carrying amount of the convertible debt and a corresponding increase to common stocks and additional paid-in capital. The total discount of $3,977 was fully amortized over the term of the debt during the year ended December 31, 2013. In the event of default, the Company would issue an additional 1,000,000 share of the Company’s common stocks on the date that is fifteen days after the maturity date (See Note 6). We are in default regarding this loan. The additional 1,000,000 shares were issued in January 2014 with a fair value at $9,900 (See Note 10). At December 31, 2013, we owed Michael McDonald accrued interest of $9,000. At December 31, 2012, the total amount of the Company’s debt assigned to Southridge was $483,482. In connection with the debt sales to Southridge, the Company recorded a loss on settlement of accounts payable for $63,490 in the statement of operations at December 31, 2012. During the first quarter of 2013, the suit was voluntarily dismissed involving debt held by Southridge for $483,482. The debt has reverted back to the original holders. In April, 2013, $88,500 of the debt held by Michael McDonald Trust was assigned to Coventry Enterprises, LLC (“Coventry”) in the form of a Convertible Redeemable Note bearing interest of 8% annum. Coventry was entitled to convert all or any amount of the this note into shares of the Company's common stock (the "Common Stock") at a conversion price ("Conversion Price") for each share of Common Stock equal to 55% of the average of the daily volume weighted average prices of the Common Stock for the 3 trading days with the lowest volume weighted average prices during the 15 trading days immediately preceding the Conversion Date. Following the agreements with Coventry, Coventry made the conversions for a total of 31,416,845 shares of the company’s restricted stock during the second quarter of 2013 satisfying the notes in full at the fair value of $186,646. In June, 2013, $57,800 of the debt was assigned to Coventry for a consideration of $60,000 from Baker Donelson Bearman Caldwell & Berkowitz, PC. in the form of Convertible Redeemable Notes bearing interest of 8% annum. The Company recorded a loss of $2,200 on the settlement during the year ended December 31, 2013. Coventry was entitled to convert all or any amount of the these notes into shares of the Company's common stock (the "Common Stock") at a conversion price ("Conversion Price") for each share of Common Stock equal to 55% of the average of the daily volume weighted average prices of the Common Stock for the 3 trading days with the lowest volume weighted average prices during 20 trading days . Following the agreements, Coventry made the conversions for a total of 27,272,727 shares of the company’s restricted stock satisfying the notes in full at the fair value of $167,495. As a result of the debt assignments and conversions with Coventry, the remaining balance of the debt at December 31, 2013 is $337,182 which consisted of the following loans: On August 2, 2011 under a settlement agreement with Liquid Packaging Resources, Inc. (“LPR”), the Company agreed to pay LPR a total of $350,000 in monthly installments of $50,000 beginning August 15, 2011 and ending on February 15, 2012. This settlement amount was recorded as general and administrative expenses on the date of the settlement. We did not make the December 2011 or January 2012 payments and on January 26, 2012, we signed the first amendment to the settlement agreement where under we agreed to pay $175,000 which was the balance outstanding at December 31, 2011(this includes a $25,000 penalty for non-payment). The Company repaid $25,000 during the three months ended March 31, 2012. The Company did not make all of the payments under such amendment and as a result pursuant to the original settlement agreement, LPR had the right to sell 5,714,326 shares of the Company’s free trading stock held in escrow by their attorney and receive cash settlements for a total amount of $450,000 (the initial $350,000 plus total default penalties of $100,000). The $100,000 default was expensed during 2012. LPR sold the note to Southridge Partners, LLP (“Southridge”) for consideration of $281,772 in October 2012. The debt has reverted back to the Company (See note 9). As of December 31, 2013 and 2012, the Company owed University Centre West Ltd. approximately $55,410, which was assigned and sold to Southridge and subsequently reverted back to the Company . At December 31, 2013 and 2012, the balance of $767,056 and $588,091 consisted of the following convertible loans: In September and October 2011, the Company borrowed $250,000 each (aggregating $500,000) from two non-related parties. The principal of these loans were to be repaid with a balloon payment on or before October 1, 2012. On October 19, 2012 the parties amended the notes to extend the due date to May 1, 2013 and include a conversion feature that would allow the holders to convert some or all of their outstanding notes into restricted Company stock at a 15% discount to the average closing market price of the Company's stock traded over the previous 10 days. Interest on these loans is payable monthly beginning in November 2011 with interest calculated at 20% and 12%, each, respectively. At December 31, 2013 and 2012, the accrued interest payable was $6,664. During year ended December 31, 2013, one of the Note holders made conversions of a total of 34,254,004 shares of the company’s restricted stock satisfying the notes in the amount of $125,000 with a fair value of $317,391 on the date of conversion. During August and September, 2013, $150,000 of the debts were assigned to three non-related parties in the form of a Convertible Redeemable Note bearing interest of 8% annum with a conversion price for each share of Common Stock equal to 55% of the average of the daily volume weighted average prices of the Common Stock for the 3 trading days with the lowest volume weighted average prices during the 15 to 20 trading days immediately preceding the Conversion Date. Following the assignments, the conversions for a total of 64,052,862 shares of the company’s restricted stock were made in satisfying the notes of $150,000 at the fair value of $475,519 (See note 6). At December 31, 2013, the remaining balance of these two convertible notes payable of $75,000 and $150,000 were recorded at a fair value of $90,260 and $189,781, respectively. At December 31, 2012, these two convertible note payable of $250,000 each were recorded at fair value of $290,289 and $297,802, respectively. On April 30, 2013, the parties amended the notes to further extend the maturity date to November 3, 2013. The Company issued a total of 4,000,000 restricted shares to the note holders in connection with the amendment at a fair value of $20,800. On October 30, 2013 and November 1, 2013, the parties amended the note of $75,000 and $150,000 to further extend the maturity dates to May 3, 2014 and August 3, 2014, respectively. The Company issued a total of 500,000 and 1,250,000 restricted shares to the note holders in connection with the amendment at a fair value of $9,500 and $13,750 (See note 6), respectively. On March 22, 2013, the Company issued a Convertible Debenture in the amount of $20,000 to Coventry Enterprises, LLC (“Coventry”). The note carries interest at 10% and is due on March 22, 2014, unless previously converted into shares of restricted common stock. Coventry has the right to convert the note, until is no longer outstanding into shares of Common Stock at a price which is lesser of $.0075, or (ii) fifty-five percent (55%) of the average of the three lowest VWAP prices of the Company’s Common Stock for the twenty trading days preceding the conversion date. In connection with the issuance of this convertible note payable, the Company encountered a day-one derivative loss of $24,931. Coventry made the conversions into a total of 8,810,572 shares of the company’s restricted stock satisfying the notes in full with a fair value of $188,747on September 4, 2013(See note 7). In connection with the issuances of the Note, the Company also granted five-year warrants to purchase an aggregate of 2,600,000 shares of the Company’s common stock at an exercise price of $0.01 per share. The Company classified embedded conversion features in these warrants as a derivative liability. The warrants were valued at their fair value of $21,226 and $17,895, respectively using the Black-Scholes method at the commitment and re-measurement dates of March 22, 2013 and December 31, 2013, respectively. On July 10, 2013 and October 10, 2013, the Company issued two Convertible Debentures in the amount of $30,000 each (total $60,000) to Christopher Castaldo in connection with the agreements for investor relation services (See Note 6). The notes carry interest at 8% and are due on January 10, 2014 and April 10, 2014, respectively. The notes’ holder has the right to convert the notes into shares of Common Stock at a price of $0.005. In connection with the issuance of this convertible notes payable, the Company encountered a day-one derivative loss of $83,157. At December 31, 2013, these convertible notes payable, at fair value, was recorded at $90,684. On September 3, 2013, the Company issued a Convertible Debenture in the amount of $100,000 to Coventry Enterprises, LLC (“Coventry”). The note carries interest at 10% and is due on September 3, 2014, unless previously converted into shares of restricted common stock. Coventry has the right to convert the note, until is no longer outstanding into shares of Common Stock at a price lesser of $.018, or (ii) fifty-five percent (55%) of the average of the three lowest VWAP prices of the Company’s Common Stock for the twenty trading days preceding the conversion date. In connection with the issuance of this convertible note payable, the Company encountered a day-one derivative loss of $957,567. At December 31, 2013, this convertible note payable, at fair value, was recorded at $185,971. In connection with the issuances of the Note, the Company also granted five-year warrants to purchase an aggregate of 20,000,000 shares of the Company’s common stock at an exercise price of $0.025 per share. The Company classified embedded conversion features in these warrants as a derivative liability. The warrants were valued at their fair value of $445,638 and $137,681, respectively using the Black-Scholes method at the commitment and re-measurement dates of September 3, 2013 and December 31, 2013, respectively. On September 12, 2013, the Company issued a Convertible Debenture in the amount of $70,000 to Coventry Enterprises, LLC (“Coventry”). The note carries interest at 10% and is due on September 12, 2014, unless previously converted into shares of restricted common stock. Coventry has the right to convert the note, until is no longer outstanding into shares of Common Stock at a price lesser of $.02, or (ii) fifty-five percent (55%) of the average of the three lowest VWAP prices of the Company’s Common Stock for the twenty trading days preceding the conversion date. In connection with the issuance of this convertible note payable, the Company encountered a day-one derivative loss of $309,055. At December 31, 2013, this convertible note payable, at fair value, was recorded at $130,303. In connection with the issuances of the Note, the Company also granted five-year warrants to purchase an aggregate of 15,000,000 shares of the Company’s common stock at an exercise price of $0.025 per share. The Company classified embedded conversion features in these warrants as a derivative liability. The warrants were valued at their fair value of $262,230 and $101,140, respectively using the Black-Scholes method at the commitment and re-measurement dates of September 12, 2013 and December 31, 2013, respectively. On October 7, 2013, the Company signed a secured convertible Promissory Note in the amount of $35,000 in favor of Southridge Partners II, LLC. The note was due on demand and carries interest at 10% annum. Southridge Partners II, LLC was entitled to convert the principal into shares of common stock at the lesser of $0.015 or a 50% discount from the lowest closing bid price in the 30 trading days prior to the day that the conversion is requested; and interest accrued was entitled to convert into shares of common stock at $0.001. In the evaluation of these financing arrangements, the Company concluded that these conversion features did not meet the conditions set forth in current accounting standards for equity classification. Since equity classification is not available for the conversion feature, it requires bifurcation and liability classification, at fair value. The Company also concluded that the Default Put required bifurcation because, while puts on debt instruments are generally considered clearly and closely related to the host, the Default Put is indexed to certain events that are not associated with the convertible note payable. In connection with the issuance of this convertible note payable, the Company encountered a day-one derivative loss of $81,667. At December 31, 2013, this convertible note payable, at fair value, was recorded at $80,057. On October 27, 2011 the Company entered into a convertible note payable with a corporation. The convertible note payable, with a face value of $53,000, bears interest at 8.0% per annum and was due on July 31, 2012. On December 5, 2011 the Company entered into a convertible note payable with a corporation which had a face value of $37,500, a coupon rate of 8.0% per annum and maturity date of September 5, 2012. The convertible note payable is convertible, at the holder’s option, into the Company’s common shares at a variable conversion price which is 58% multiplied by the average of the lowest three (3) trading prices for the Common Stock during the ten (10) Trading Day period ending one Trading Day prior to the date the Conversion Notice is sent by the Holder to the Borrower. The conversion feature is subject to full-ratchet, anti-dilution protection if the Company sells shares or share-indexed financing instruments at less than the conversion price. The holder has the option to redeem the convertible note payable for cash in the event of defaults or certain other contingent events (the “Default Put”). During October 2012, both of these notes were acquired by a third party from Asher Enterprises for an aggregate amount of $100,000, and then converted into 20,000,000 restricted common shares (See note 6). On February 3, 2012, the Company issued a Convertible Debenture in the amount of $40,000 to Redwood Management, LLC. The note carries interest at 12% and is due on February 13, 2013, unless converted into shares of restricted common stock. Redwood Management, LLC has the right to convert the note, until it is no longer outstanding, into shares of Common Stock at a price of Fifty Percent (50%) of the lowest closing price, determined on the then current trading market for the Company’s common stock, during the 15 trading days prior to conversion (the “Set Price”). On September 12, 2012, TCN International (TCN) completed the purchase and transfer of this note including penalties and unpaid interest, for the sum of $52,500. Redwood Management, LLC has acknowledged the full payment of the Note, in favor of Nutra Pharma Corporation and releases Nutra Pharma Corporation from all obligations under the Note. Upon the request of TCN, the Board of Directors of the Company approved the conversion of these notes into Restricted Common Stock of the Company,providing 7,500,000 shares of Nutra Pharma common stock to relinquish the total debt of $52,500 (See note 6). On March 16, 2012 the Company signed a secured convertible Promissory Note in the amount of $75,000 in favor of Southridge Partners II, LLC. The note was due November 16, 2012 and carries interest at 8% annum. Southridge Partners II, LLC was entitled after nine months to convert all or a portion of the principal and interest accrued into shares of common stock at a conversion price of each share equal to the Market Price multiplied times 70%. (the “conversion price”). The Market Price is equal to the average of the two lowest bids closing prices for the five trading days ending before the conversion date. In the evaluation of these financing arrangements, the Company concluded that these conversion features did not meet the conditions set forth in current accounting standards for equity classification. Since equity classification is not available for the conversion feature, it requires bifurcation and liability classification, at fair value. The Company also concluded that the Default Put required bifurcation because, while puts on debt instruments are generally considered clearly and closely related to the host, the Default Put is indexed to certain events that are not associated with the convertible note payable. On October 26, 2012, Southridge converted the note into 5,919,495 shares of the Company's restricted common stock (See note 6). In the evaluation of these financing arrangements, the Company concluded that these conversion features did not meet the conditions set forth in current accounting standards for equity classification. Since equity classification is not available for the conversion feature, it requires bifurcation and liability classification, at fair value. The Company also concluded that the Default Put required bifurcation because, while puts on debt instruments are generally considered clearly and closely related to the host, the Default Put is indexed to certain events that are not associated with the convertible note payable. The Company elected to account for these hybrid contracts under the guidance of ASC 815-15-25-4. The fair value has been defined as the common stock equivalent value, enhanced by the fair value of the default put plus the present value of the coupon. The holder of this convertible note has substantial rights and protections regarding dilution if certain events, including a default were to occur. There are a number of events that could trigger a default, including but not limited to failure to pay principal or interest, failure to issue shares under the conversion feature, breach of covenants, breach of representations and warranties, appointment of a receiver or trustee, judgments, bankruptcy, delisting of common stock, failure to comply with the exchange act, liquidation, cessation of operations, failure to maintain assets, material financial statement restatement, reverse split of borrowers stock, etc. In the event of these events the lender may be entitled to receive significant amounts of additional stock above the amounts for conversion. Furthermore, there are additional events that could cause the lender to be due additional shares of common stock above and beyond the shares due from a conversion. Some of these events include, but are not limited to a merger or consolidation of the Company, dividend distribution or spin off, dilutive issuances of the Company’s stock, etc. If the lender receives additional shares of the Company’s commons stock due to any of the foregoing events or for other reasons, then this may have an extremely dilutive effect on the shareholders of the Company. Such dilution would likely result in a significant drop in the per share price of the Company’s common stock. The potential dilutive nature of this note presents a very high degree of risk to the Company and its shareholders EX-101.SCH 6 nphc-20131231.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink 102 - Statement - Consolidated Balance Sheets link:presentationLink link:definitionLink link:calculationLink 103 - Statement - Consolidated Balance Sheets [Parenthetical] link:presentationLink link:definitionLink link:calculationLink 104 - Statement - Consolidated Statements of Operations link:presentationLink link:definitionLink link:calculationLink 105 - Statement - Consolidated Statements of Operations [Parenthetical] link:presentationLink link:definitionLink link:calculationLink 106 - Statement - Consolidated Statements of Changes in Stockholders' Deficit link:presentationLink link:definitionLink link:calculationLink 107 - Statement - Consolidated Statements of Changes in Stockholders' Deficit [Parenthetical] link:presentationLink link:definitionLink link:calculationLink 108 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:definitionLink link:calculationLink 109 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:definitionLink link:calculationLink 110 - Disclosure - FAIR VALUE MEASUREMENTS link:presentationLink link:definitionLink link:calculationLink 111 - Disclosure - SETTLEMENT OF ACCOUNTS AND NOTE PAYABLE link:presentationLink link:definitionLink link:calculationLink 112 - Disclosure - DUE TO OFFICERS link:presentationLink link:definitionLink link:calculationLink 113 - Disclosure - OTHER DEBT link:presentationLink link:definitionLink link:calculationLink 114 - Disclosure - STOCKHOLDERS' DEFICIT link:presentationLink link:definitionLink link:calculationLink 115 - Disclosure - STOCK OPTIONS AND WARRANTS link:presentationLink link:definitionLink link:calculationLink 116 - Disclosure - INCOME TAXES link:presentationLink link:definitionLink link:calculationLink 117 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:definitionLink link:calculationLink 118 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:definitionLink link:calculationLink 119 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:definitionLink link:calculationLink 120 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:definitionLink link:calculationLink 121 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) link:presentationLink link:definitionLink link:calculationLink 122 - Disclosure - DUE TO OFFICERS (Tables) link:presentationLink link:definitionLink link:calculationLink 123 - Disclosure - OTHER DEBT (Tables) link:presentationLink link:definitionLink link:calculationLink 124 - Disclosure - STOCKHOLDERS' DEFICIT (Tables) link:presentationLink link:definitionLink link:calculationLink 125 - Disclosure - STOCK OPTIONS AND WARRANTS (Tables) link:presentationLink link:definitionLink link:calculationLink 126 - Disclosure - INCOME TAXES (Tables) link:presentationLink link:definitionLink link:calculationLink 127 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables) link:presentationLink link:definitionLink link:calculationLink 128 - Disclosure - SUBSEQUENT EVENTS (Tables) link:presentationLink link:definitionLink link:calculationLink 129 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) link:presentationLink link:definitionLink link:calculationLink 130 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1) link:presentationLink link:definitionLink link:calculationLink 131 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 2) link:presentationLink link:definitionLink link:calculationLink 132 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Textual) link:presentationLink link:definitionLink link:calculationLink 133 - Disclosure - FAIR VALUE MEASUREMENTS (Details) link:presentationLink link:definitionLink link:calculationLink 134 - Disclosure - FAIR VALUE MEASUREMENTS (Details 1) link:presentationLink link:definitionLink link:calculationLink 135 - Disclosure - FAIR VALUE MEASUREMENTS (Details 2) link:presentationLink link:definitionLink link:calculationLink 136 - Disclosure - FAIR VALUE MEASUREMENTS (Details 3) link:presentationLink link:definitionLink link:calculationLink 137 - Disclosure - FAIR VALUE MEASUREMENTS (Details Textual) link:presentationLink link:definitionLink link:calculationLink 138 - Disclosure - SETTLEMENT OF ACCOUNTS AND NOTE PAYABLE (Details Textual) link:presentationLink link:definitionLink link:calculationLink 139 - Disclosure - DUE TO OFFICERS (Details) link:presentationLink link:definitionLink link:calculationLink 140 - Disclosure - DUE TO OFFICERS (Details Textual) link:presentationLink link:definitionLink link:calculationLink 141 - Disclosure - OTHER DEBT (Details) link:presentationLink link:definitionLink link:calculationLink 142 - Disclosure - OTHER DEBT (Details Textual) link:presentationLink link:definitionLink link:calculationLink 143 - Disclosure - STOCKHOLDERS' DEFICIT (Details) link:presentationLink link:definitionLink link:calculationLink 144 - Disclosure - STOCKHOLDERS' DEFICIT (Details Textual) link:presentationLink link:definitionLink link:calculationLink 145 - Disclosure - STOCK OPTIONS AND WARRANTS (Details) link:presentationLink link:definitionLink link:calculationLink 146 - Disclosure - STOCK OPTIONS AND WARRANTS (Details 1) link:presentationLink link:definitionLink link:calculationLink 147 - Disclosure - STOCK OPTIONS AND WARRANTS (Details Textual) link:presentationLink link:definitionLink link:calculationLink 148 - Disclosure - INCOME TAXES (Details) link:presentationLink link:definitionLink link:calculationLink 149 - Disclosure - INCOME TAXES (Details 1) link:presentationLink link:definitionLink link:calculationLink 150 - Disclosure - INCOME TAXES (Details Textual) link:presentationLink link:definitionLink link:calculationLink 151 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) link:presentationLink link:definitionLink link:calculationLink 152 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Textual) link:presentationLink link:definitionLink link:calculationLink 153 - Disclosure - SUBSEQUENT EVENTS (Details) link:presentationLink link:definitionLink link:calculationLink 154 - Disclosure - SUBSEQUENT EVENTS (Details Textual) link:presentationLink link:definitionLink link:calculationLink 155 - Disclosure - STOCK OPTIONS AND WARRANTS (Details 3) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 7 nphc-20131231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 nphc-20131231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 nphc-20131231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE EX-101.PRE 10 nphc-20131231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 11 R39.htm IDEA: XBRL DOCUMENT v2.4.0.8
OTHER DEBT (Details) (USD $)
Dec. 31, 2013
Dec. 31, 2012
Sep. 30, 2013
Note Payable Three [Member]
Aug. 31, 2013
Note Payable Three [Member]
Short-term Debt [Line Items]        
Note payable - Related Party $ 180,000 [1] $ 190,000 [1]    
Notes payable - Non Related Parties 412,182 [2] 593,483 [2] 150,000 150,000
Convertible notes payable, at fair value 767,056 [3] 588,091 [3]    
Ending balances $ 1,359,238 $ 1,371,574    
[1] During the third quarter of 2010 we borrowed $200,000 from one of our directors. We repaid $10,000 each (total $20,000) during the third quarter of 2012 and 2013. Under the terms of the loan agreement, this loan was expected to be repaid in nine months to a year from the date of the loan along with interest calculated at 10% for the first month plus 12% after 30 days from funding. We are in default regarding this loan. At December 31, 2013 and 2012, we owed this director accrued interest of $121,137 and $86,387, respectively.
[2] At December 31, 2013 and 2012, the balance of $412,182 and $593,483 , respectively, consisted of the following loans: In May 2011, the Company received a loan for $25,000 from a non-related party. This loan was expected to be repaid no later than December 31, 2011, along with interest calculated at 10% for the first month plus 12% after 30 days from funding. This loan is guaranteed by an officer of the Company. On November 25, 2013, the non-related party accepted a total of 4,360,000 shares of the Company’s restricted common stock as a repayment to discharge $25,000 of his outstanding loan and accrued interest of $11,956 (See note 6). The Company recorded a loss of $28,444 on the settlement date. In May 2011, the Company received another loan for $25,000 from a non-related party. This loan was expected to be repaid no later than December 31, 2011, along with interest calculated at 10% for the first month plus 12% after 30 days from funding. This loan is guaranteed by an officer of the Company. On September 16, 2013, the non-related party accepted a total of 8,472,750 shares of the Company’s restricted common stock as a repayment to discharge $25,000 of his outstanding loan and accrued interest of $11,120 (See note 6). The Company recorded a loss of $90,971 on the settlement date. In July 2013, the Company issued a promissory note to the Michael McDonald Trust in the amount of $75,000 bearing interest at a rate of 2% per month. The note is due in six months from the execution and funding of the note. In connection with the issuance of this promissory note, the Company issued 1,000,000 shares of the Company's common stocks (See note 6). The Company has recorded a debt discount in the amount of $3,977 to reflect the value of the common stocks as a reduction to the carrying amount of the convertible debt and a corresponding increase to common stocks and additional paid-in capital. The total discount of $3,977 was fully amortized over the term of the debt during the year ended December 31, 2013. In the event of default, the Company would issue an additional 1,000,000 share of the Company’s common stocks on the date that is fifteen days after the maturity date (See Note 6). We are in default regarding this loan. The additional 1,000,000 shares were issued in January 2014 with a fair value at $9,900 (See Note 10). At December 31, 2013, we owed Michael McDonald accrued interest of $9,000. At December 31, 2012, the total amount of the Company’s debt assigned to Southridge was $483,482. In connection with the debt sales to Southridge, the Company recorded a loss on settlement of accounts payable for $63,490 in the statement of operations at December 31, 2012. During the first quarter of 2013, the suit was voluntarily dismissed involving debt held by Southridge for $483,482. The debt has reverted back to the original holders. In April, 2013, $88,500 of the debt held by Michael McDonald Trust was assigned to Coventry Enterprises, LLC (“Coventry”) in the form of a Convertible Redeemable Note bearing interest of 8% annum. Coventry was entitled to convert all or any amount of the this note into shares of the Company's common stock (the "Common Stock") at a conversion price ("Conversion Price") for each share of Common Stock equal to 55% of the average of the daily volume weighted average prices of the Common Stock for the 3 trading days with the lowest volume weighted average prices during the 15 trading days immediately preceding the Conversion Date. Following the agreements with Coventry, Coventry made the conversions for a total of 31,416,845 shares of the company’s restricted stock during the second quarter of 2013 satisfying the notes in full at the fair value of $186,646. In June, 2013, $57,800 of the debt was assigned to Coventry for a consideration of $60,000 from Baker Donelson Bearman Caldwell & Berkowitz, PC. in the form of Convertible Redeemable Notes bearing interest of 8% annum. The Company recorded a loss of $2,200 on the settlement during the year ended December 31, 2013. Coventry was entitled to convert all or any amount of the these notes into shares of the Company's common stock (the "Common Stock") at a conversion price ("Conversion Price") for each share of Common Stock equal to 55% of the average of the daily volume weighted average prices of the Common Stock for the 3 trading days with the lowest volume weighted average prices during 20 trading days . Following the agreements, Coventry made the conversions for a total of 27,272,727 shares of the company’s restricted stock satisfying the notes in full at the fair value of $167,495. As a result of the debt assignments and conversions with Coventry, the remaining balance of the debt at December 31, 2013 is $337,182 which consisted of the following loans: On August 2, 2011 under a settlement agreement with Liquid Packaging Resources, Inc. (“LPR”), the Company agreed to pay LPR a total of $350,000 in monthly installments of $50,000 beginning August 15, 2011 and ending on February 15, 2012. This settlement amount was recorded as general and administrative expenses on the date of the settlement. We did not make the December 2011 or January 2012 payments and on January 26, 2012, we signed the first amendment to the settlement agreement where under we agreed to pay $175,000 which was the balance outstanding at December 31, 2011(this includes a $25,000 penalty for non-payment). The Company repaid $25,000 during the three months ended March 31, 2012. The Company did not make all of the payments under such amendment and as a result pursuant to the original settlement agreement, LPR had the right to sell 5,714,326 shares of the Company’s free trading stock held in escrow by their attorney and receive cash settlements for a total amount of $450,000 (the initial $350,000 plus total default penalties of $100,000). The $100,000 default was expensed during 2012. LPR sold the note to Southridge Partners, LLP (“Southridge”) for consideration of $281,772 in October 2012. The debt has reverted back to the Company (See note 9). As of December 31, 2013 and 2012, the Company owed University Centre West Ltd. approximately $55,410, which was assigned and sold to Southridge and subsequently reverted back to the Company .
[3] At December 31, 2013 and 2012, the balance of $767,056 and $588,091 consisted of the following convertible loans: In September and October 2011, the Company borrowed $250,000 each (aggregating $500,000) from two non-related parties. The principal of these loans were to be repaid with a balloon payment on or before October 1, 2012. On October 19, 2012 the parties amended the notes to extend the due date to May 1, 2013 and include a conversion feature that would allow the holders to convert some or all of their outstanding notes into restricted Company stock at a 15% discount to the average closing market price of the Company's stock traded over the previous 10 days. Interest on these loans is payable monthly beginning in November 2011 with interest calculated at 20% and 12%, each, respectively. At December 31, 2013 and 2012, the accrued interest payable was $6,664. During year ended December 31, 2013, one of the Note holders made conversions of a total of 34,254,004 shares of the company’s restricted stock satisfying the notes in the amount of $125,000 with a fair value of $317,391 on the date of conversion. During August and September, 2013, $150,000 of the debts were assigned to three non-related parties in the form of a Convertible Redeemable Note bearing interest of 8% annum with a conversion price for each share of Common Stock equal to 55% of the average of the daily volume weighted average prices of the Common Stock for the 3 trading days with the lowest volume weighted average prices during the 15 to 20 trading days immediately preceding the Conversion Date. Following the assignments, the conversions for a total of 64,052,862 shares of the company’s restricted stock were made in satisfying the notes of $150,000 at the fair value of $475,519 (See note 6). At December 31, 2013, the remaining balance of these two convertible notes payable of $75,000 and $150,000 were recorded at a fair value of $90,260 and $189,781, respectively. At December 31, 2012, these two convertible note payable of $250,000 each were recorded at fair value of $290,289 and $297,802, respectively. On April 30, 2013, the parties amended the notes to further extend the maturity date to November 3, 2013. The Company issued a total of 4,000,000 restricted shares to the note holders in connection with the amendment at a fair value of $20,800. On October 30, 2013 and November 1, 2013, the parties amended the note of $75,000 and $150,000 to further extend the maturity dates to May 3, 2014 and August 3, 2014, respectively. The Company issued a total of 500,000 and 1,250,000 restricted shares to the note holders in connection with the amendment at a fair value of $9,500 and $13,750 (See note 6), respectively. On March 22, 2013, the Company issued a Convertible Debenture in the amount of $20,000 to Coventry Enterprises, LLC (“Coventry”). The note carries interest at 10% and is due on March 22, 2014, unless previously converted into shares of restricted common stock. Coventry has the right to convert the note, until is no longer outstanding into shares of Common Stock at a price which is lesser of $.0075, or (ii) fifty-five percent (55%) of the average of the three lowest VWAP prices of the Company’s Common Stock for the twenty trading days preceding the conversion date. In connection with the issuance of this convertible note payable, the Company encountered a day-one derivative loss of $24,931. Coventry made the conversions into a total of 8,810,572 shares of the company’s restricted stock satisfying the notes in full with a fair value of $188,747on September 4, 2013(See note 7). In connection with the issuances of the Note, the Company also granted five-year warrants to purchase an aggregate of 2,600,000 shares of the Company’s common stock at an exercise price of $0.01 per share. The Company classified embedded conversion features in these warrants as a derivative liability. The warrants were valued at their fair value of $21,226 and $17,895, respectively using the Black-Scholes method at the commitment and re-measurement dates of March 22, 2013 and December 31, 2013, respectively. On July 10, 2013 and October 10, 2013, the Company issued two Convertible Debentures in the amount of $30,000 each (total $60,000) to Christopher Castaldo in connection with the agreements for investor relation services (See Note 6). The notes carry interest at 8% and are due on January 10, 2014 and April 10, 2014, respectively. The notes’ holder has the right to convert the notes into shares of Common Stock at a price of $0.005. In connection with the issuance of this convertible notes payable, the Company encountered a day-one derivative loss of $83,157. At December 31, 2013, these convertible notes payable, at fair value, was recorded at $90,684. On September 3, 2013, the Company issued a Convertible Debenture in the amount of $100,000 to Coventry Enterprises, LLC (“Coventry”). The note carries interest at 10% and is due on September 3, 2014, unless previously converted into shares of restricted common stock. Coventry has the right to convert the note, until is no longer outstanding into shares of Common Stock at a price lesser of $.018, or (ii) fifty-five percent (55%) of the average of the three lowest VWAP prices of the Company’s Common Stock for the twenty trading days preceding the conversion date. In connection with the issuance of this convertible note payable, the Company encountered a day-one derivative loss of $957,567. At December 31, 2013, this convertible note payable, at fair value, was recorded at $185,971. In connection with the issuances of the Note, the Company also granted five-year warrants to purchase an aggregate of 20,000,000 shares of the Company’s common stock at an exercise price of $0.025 per share. The Company classified embedded conversion features in these warrants as a derivative liability. The warrants were valued at their fair value of $445,638 and $137,681, respectively using the Black-Scholes method at the commitment and re-measurement dates of September 3, 2013 and December 31, 2013, respectively. On September 12, 2013, the Company issued a Convertible Debenture in the amount of $70,000 to Coventry Enterprises, LLC (“Coventry”). The note carries interest at 10% and is due on September 12, 2014, unless previously converted into shares of restricted common stock. Coventry has the right to convert the note, until is no longer outstanding into shares of Common Stock at a price lesser of $.02, or (ii) fifty-five percent (55%) of the average of the three lowest VWAP prices of the Company’s Common Stock for the twenty trading days preceding the conversion date. In connection with the issuance of this convertible note payable, the Company encountered a day-one derivative loss of $309,055. At December 31, 2013, this convertible note payable, at fair value, was recorded at $130,303. In connection with the issuances of the Note, the Company also granted five-year warrants to purchase an aggregate of 15,000,000 shares of the Company’s common stock at an exercise price of $0.025 per share. The Company classified embedded conversion features in these warrants as a derivative liability. The warrants were valued at their fair value of $262,230 and $101,140, respectively using the Black-Scholes method at the commitment and re-measurement dates of September 12, 2013 and December 31, 2013, respectively. On October 7, 2013, the Company signed a secured convertible Promissory Note in the amount of $35,000 in favor of Southridge Partners II, LLC. The note was due on demand and carries interest at 10% annum. Southridge Partners II, LLC was entitled to convert the principal into shares of common stock at the lesser of $0.015 or a 50% discount from the lowest closing bid price in the 30 trading days prior to the day that the conversion is requested; and interest accrued was entitled to convert into shares of common stock at $0.001. In the evaluation of these financing arrangements, the Company concluded that these conversion features did not meet the conditions set forth in current accounting standards for equity classification. Since equity classification is not available for the conversion feature, it requires bifurcation and liability classification, at fair value. The Company also concluded that the Default Put required bifurcation because, while puts on debt instruments are generally considered clearly and closely related to the host, the Default Put is indexed to certain events that are not associated with the convertible note payable. In connection with the issuance of this convertible note payable, the Company encountered a day-one derivative loss of $81,667. At December 31, 2013, this convertible note payable, at fair value, was recorded at $80,057. On October 27, 2011 the Company entered into a convertible note payable with a corporation. The convertible note payable, with a face value of $53,000, bears interest at 8.0% per annum and was due on July 31, 2012. On December 5, 2011 the Company entered into a convertible note payable with a corporation which had a face value of $37,500, a coupon rate of 8.0% per annum and maturity date of September 5, 2012. The convertible note payable is convertible, at the holder’s option, into the Company’s common shares at a variable conversion price which is 58% multiplied by the average of the lowest three (3) trading prices for the Common Stock during the ten (10) Trading Day period ending one Trading Day prior to the date the Conversion Notice is sent by the Holder to the Borrower. The conversion feature is subject to full-ratchet, anti-dilution protection if the Company sells shares or share-indexed financing instruments at less than the conversion price. The holder has the option to redeem the convertible note payable for cash in the event of defaults or certain other contingent events (the “Default Put”). During October 2012, both of these notes were acquired by a third party from Asher Enterprises for an aggregate amount of $100,000, and then converted into 20,000,000 restricted common shares (See note 6). On February 3, 2012, the Company issued a Convertible Debenture in the amount of $40,000 to Redwood Management, LLC. The note carries interest at 12% and is due on February 13, 2013, unless converted into shares of restricted common stock. Redwood Management, LLC has the right to convert the note, until it is no longer outstanding, into shares of Common Stock at a price of Fifty Percent (50%) of the lowest closing price, determined on the then current trading market for the Company’s common stock, during the 15 trading days prior to conversion (the “Set Price”). On September 12, 2012, TCN International (TCN) completed the purchase and transfer of this note including penalties and unpaid interest, for the sum of $52,500. Redwood Management, LLC has acknowledged the full payment of the Note, in favor of Nutra Pharma Corporation and releases Nutra Pharma Corporation from all obligations under the Note. Upon the request of TCN, the Board of Directors of the Company approved the conversion of these notes into Restricted Common Stock of the Company,providing 7,500,000 shares of Nutra Pharma common stock to relinquish the total debt of $52,500 (See note 6). On March 16, 2012 the Company signed a secured convertible Promissory Note in the amount of $75,000 in favor of Southridge Partners II, LLC. The note was due November 16, 2012 and carries interest at 8% annum. Southridge Partners II, LLC was entitled after nine months to convert all or a portion of the principal and interest accrued into shares of common stock at a conversion price of each share equal to the Market Price multiplied times 70%. (the “conversion price”). The Market Price is equal to the average of the two lowest bids closing prices for the five trading days ending before the conversion date. In the evaluation of these financing arrangements, the Company concluded that these conversion features did not meet the conditions set forth in current accounting standards for equity classification. Since equity classification is not available for the conversion feature, it requires bifurcation and liability classification, at fair value. The Company also concluded that the Default Put required bifurcation because, while puts on debt instruments are generally considered clearly and closely related to the host, the Default Put is indexed to certain events that are not associated with the convertible note payable. On October 26, 2012, Southridge converted the note into 5,919,495 shares of the Company's restricted common stock (See note 6). In the evaluation of these financing arrangements, the Company concluded that these conversion features did not meet the conditions set forth in current accounting standards for equity classification. Since equity classification is not available for the conversion feature, it requires bifurcation and liability classification, at fair value. The Company also concluded that the Default Put required bifurcation because, while puts on debt instruments are generally considered clearly and closely related to the host, the Default Put is indexed to certain events that are not associated with the convertible note payable. The Company elected to account for these hybrid contracts under the guidance of ASC 815-15-25-4. The fair value has been defined as the common stock equivalent value, enhanced by the fair value of the default put plus the present value of the coupon. The holder of this convertible note has substantial rights and protections regarding dilution if certain events, including a default were to occur. There are a number of events that could trigger a default, including but not limited to failure to pay principal or interest, failure to issue shares under the conversion feature, breach of covenants, breach of representations and warranties, appointment of a receiver or trustee, judgments, bankruptcy, delisting of common stock, failure to comply with the exchange act, liquidation, cessation of operations, failure to maintain assets, material financial statement restatement, reverse split of borrowers stock, etc. In the event of these events the lender may be entitled to receive significant amounts of additional stock above the amounts for conversion. Furthermore, there are additional events that could cause the lender to be due additional shares of common stock above and beyond the shares due from a conversion. Some of these events include, but are not limited to a merger or consolidation of the Company, dividend distribution or spin off, dilutive issuances of the Company’s stock, etc. If the lender receives additional shares of the Company’s commons stock due to any of the foregoing events or for other reasons, then this may have an extremely dilutive effect on the shareholders of the Company. Such dilution would likely result in a significant drop in the per share price of the Company’s common stock. The potential dilutive nature of this note presents a very high degree of risk to the Company and its shareholders
XML 12 R48.htm IDEA: XBRL DOCUMENT v2.4.0.8
INCOME TAXES (Details Textual) (USD $)
 12 Months Ended
Dec. 31, 2013
Schedule Of Income Tax Disclosure [Line Items]  
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate 34.00%
Operating Loss Carryforwards $ 15,580,000
Effective Income Tax Rate Reconciliation, State and Local Income Taxes 8.84%
Effective Income Tax Rate, Continuing Operations 39.83%
Income Tax Reconciliation Share Based Compensation Cost $ 41,987,000
EXCEL 13 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0`!@`(````(0`)X\5<$@(``$H?```3``@"6T-O;G1E;G1?5'EP97-= M+GAM;""B!`(HH``"```````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````````#,F4MNVS`41><%N@>!T\*B M^7&:!+8SZ&?8!FBZ`%9ZM@1+)$$RJ;W[4G(2!('KP*B!WHD%2^2[1QR<@>[\ M9MMWQ0.%V#J[8**K6KA?LY]W7R24K8C*V-IVSM&`[BNQF^?[=_&[G M*19YMXT+UJ3DKSF/54.]B:7S9/.3E0N]2?EO6'-OJHU9$Y?3Z06OG$UDTR0- M,]AR_IE6YKY+Q9=MOKTG"=1%5GS:+QRR%LQXW[6529F4/]CZ5\#CON_Y:$);4W%K0OIF^HS!MQW_[<+FEW.;\OB0`Y1N MM6HKJEUUW^<3**,/9.K8$*6^*\=KV9O6/G$?R1\71SY>Q)E!AO<;!Y_((4$X M%`B'!N&8@7!<@'!\!.&X!.&X`N$04Q00%*,*%*4*%*<*%*D*%*L*%*T*%*\* M%+$*%+-*%+-*%+-*%+-*%+-*%+-*%+-*%+-*%+-*%+-*%+,J%+,J%+,J%+,J M%+,J%+,J%+,J%+,J%+,J%+,J%+-J%+-J%+-J%+-J%+-J%+-J%+-J%+-J%+-J M%+-J%+/.4,PZ^U]F3;FI)#[^_CO"..:-JBRF74?QS)^W]T/?2FY,H/I'"KG3 M/3O`R]G'.'+C>1N;%]XI)2; M8M?[J+*+BQJZE/PC8C0=3Q0+\>QRI9$P4P>J/OH\^;*W-$UO>"_F?6*73HQ`GA,[RW;E0V8+J<_;J)I"RTF#%?.< MTQ')^R)C`YXFVEQ/]/^V.'$B2XG02.#S/-^*```:``@! M>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;',@H@0!**```0`````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````"\F4]KVT`0Q>^%?@>Q]UJ>F963E,BYE$*N M;?H!A+6V3&Q):+=__.V[N$5QH'F]F'[;T^?/]RZ(J:F;YO#T(?:G4)T#^OW[^Z_A$.3\I]BMQ]C MD7?I8^VZE,:/91DW73@V<3&,H<]OML-T;%)>3KMR;#;/S2Z4NERNRNER#[=^ MM6?QV-9N>FS%7/%T&O/1_]]\V&[WF_!IV'P_AC[]XXSRYS`]QRZ$E#=MIEU( MM9L?Q?+\1FR1-;OR#3DY'EPYMTB.KLAR=(7DV!U9CMTA.2ID.2I(CGFR'/-( MCE>R'*]0S@U;S@V24V424A.]6B(Y[.#`V+"-`WTC;`0*1*"R$:@0@<)&H$`$ M*AN!"A%H;"<;M+*QL]Q@FGLV`CU$H*_(1/85(G)UU8MI3*=#OEK/M](_:W@^ M.1HP&,*VBD"K"!O"`B%L;`@;A+!G0]A#"%=7A7#*K6=XR:/SLCS_XIB0LPE& MA.U>:%YANT5@;/2J;IF;_Q?'S(_^S@,4EFQEEVR%)=O8'#;(86.7;(-5RE^U M9,]&>=L['LZ2/'N6Y.$LB:T&BJG8);."Y8%M'.@;82-0(`*%C4"!"%0V@A!*NKW@1CUTRA_9JF_*GILO&] M?(SZ7W9L8&C8-H8N%C8!!1)0V0142$!E$U`A`8UM'8/>\>S>T\_-9_GJD_+Z M-P```/__`P!02P,$%``&``@````A`!A=HB\+!```CP\```\```!X;"]W;W)K M8F]O:RYX;6R4EUUSFD`4AN\[T__`<-\@'Y$F$]-!)`W3"*E@TKN=C:R1*8(# M6)-_WP-4/+!(PY6N>-X]YSW/?G#S[6T;"7]8FH5)/!'EBY$HL'B5!&'\.A&7 M_MV7KZ*0Y30.:)3$;"*^LTS\=OOYT\TA27^_),EO`03B;")N\GQW+4G9:L.V M-+M(=BR&)^LDW=([,.(_945230WCT:C^K=[%KYN\N./("\A M_=)!F*?\%.*RO*,CQ(@#8L5YF+\3.Z[<#Q-H8>&Z#97)HI!>A_`EM0.Y2!RK MF&!B$H4!!8O(E$8T7C'B%:$9DE"0A#)`@CQ2I*(BE=+KLXEX.>13M#LCR9JX M.X94-*2B]>;"J8`3M2M@?.W*Y0`9A#DJ&X2[!N MZY*^ME6FAF=[Q+TCCPO+LQS?\&W7(88S(]YR/L?&X&9?M67N#'M!GHR'I47F MEN$M%]8VM!9M:T,1ENI,S!Z?FN^>/>?9C!3!`*4]J-:-P_F8.R MC";N8^%X5>FSL5@8+=MP]V2.2-LQW3E4;/RR&K5>H9[+/('N?&[[98=*ATW7 M\6WGN^68=D-F#!M5C8[,$>@MIY[UE+!"<=TL$`*O\#L",>"6J'*_GN*]T\$I4\4J$P:"$\$I4 M\4J$P2`AW#05+T48#!+"32ON8/5N!8.64/_AA#W2&V9S&V_K="*5R7AW4?'J MA$$KDS,"Q&=O^9[BKF.>58[GTVG7D8/>:#2',!_[;WI,G8Y[K''T=IV<79G@ M!FL:8^T M6NW'-2%.@@HXPJ1I__V.&0+8.:7)31OPR_!XOLRLOKV7A?7&:YF+:FV3N6M; MO,K$+J\.:_N?OU]F"]N235KMTD)4?&U_<&E_V_SZR^HBZE=YY+RQP$(EU_:Q M:4Y+QY'9D9>IG(L3KV!E+^HR;>"R/CCR5/-TUSY4%@YUW<`IT[RRT<*ROL>& MV._SC#^+[%SRJD$C-2_2!OCE,3_)J[4RN\=$#?K=,Y7?C$#[ZVXB!1N\'GM$DWJUI<+,@:>*<\I2H'R1(L7W>& M'/U>/]LJ[%$9>5)6UC:D.^Q"0GS>-@%;.6_@TJR3Q+<2HBN2JT)%`NAZ1-CX M&/'G3K^2*+$B44%0:#'>`-L]&C7>>ZOP!GB-!!QT/XD2KVTPWK\X\/4WQR@) M6X<12DFTT`7)6$!=CT9N+]#`V"-@2FR`!;U9=!I*_!:,$6*")^-UPL*`A;T! MC0NR^WZ'*;'!-9A%+I0@UX*XGM>_MEU/QNN^'[!A7<,*'L%28BC8<1R-,,4H M`:<,H3;`IA0:6JBCJ7IDL*OII%@YRAAEH5E^FB+P@Y`-A:(A MJE-MU#*FT9181PN'',:@HF0*35-,H46/H"FQ@6;X)$8)HLVH%Q#F&;%/=$G@ M$C<:?*_YC<"Y<[_C6K6>=^$0$/1-C4-;RAJ7=XJ+F^FWB0\T;#28BF8:[+ M%D,"Z'RJ5X_X5.5Z$/'I\B#8X35.\Y3H-!UGZ(:!;^1IHDN8'])HR!4=4[7N M$>87>-CH-3PCA#%!#>*1B(2#@UH_)YV`M:?)4/PZENK<]V-AG]>PC,C%ZOL, MROL:W6A!?&J@)X;&)?`]]IG?'CHS"/9[#=!P2]QI.D#F,1J9'TV)KH'^0[U1 M['4/&B?'%X&]/3+"H6UU]8$:,VY=4'^^J",]=%*0VZ-B,61+AX0:_&*:?>(S M33/M,^.\N+-F;P^.A5&0,4%-U.;\S)V[AB"9$&@^A+%&*XS[/@C:I_2S;3$D M-OJRTV#^A>#+"!+0J"(U50U5Q%P:14$P.@(1%>N`_TOJ05](J^!Y,NO,0JKO&00PO M&G%JAYFM:&"`:G\>86#F,`*X&PO=V]R:W-H965TY(L])JM9=G0IP$-6"$2:?[[[>, M@6"[.Y.>S4,()Z<.5<=E8V^^OM:5\H(Z4N)FJYJ:H2JH*?"A;$Y;]>^_TB^> MJI`^;PYYA1NT5=\04;_N?OUE<\7=,SDCU"N@T)"M>N[[-M!U4IQ1G1,-MZB! M?XZXJ_,>;KN33MH.Y8IV7C0_YDW/9DDFM+AZ1J_/N^=)^*7#=@L2^K,K^;1!5E;H(OIT:W.7["NI^-==Y M,6D/-Y)\718=)OC8:R"GLT3EFGW=UT%IMSF44`&U7>G0<:L^F4%FFJJ^VPP& M_5.B*UG\5L@97[.N/'PO&P1NPSC1$=AC_$RIWPX4@F!=BDZ'$?BC4P[HF%^J M_D]\_0V5IW,/PVU#1;2PX/`6(U*`HR"CK6RJ5.`*$H!OI2YI:X`C^>MPO9:' M_KQ5+4>S7<,R@:[L$>G3DDJJ2G$A/:[_9:2AHEED-8K`=10Q7/6CX2MQS"X?NIQD,Q0*UP_\SAG#'/GL*5%$8T M,>C`4]EX`FZRUIJ/22;*%),R`+YOJ:QL/BA[A^.;,T<'!V8;H$L>MX&2J0U3 M,J$(1"(0BT`B`BD#N()\8TYV,"J[S^$*@O9]O"!*ADFV--,71BUD'&COF^%\ M=M'$F&R))^##D&1B3"'I!'P8DMUC<`Y`JDL'AD7(I0O.#YJG M3*-QHFG"'`X9QQY,6X,UGM!B$2/PICF^,*OCI8SM6VM/&)SD(9ET*6/:LO?9 M'0)G&2S%/V49C1,M<_AQ"QF'6>8ZKF$+A(@11,M<7B9>RMB>9RQ6P6%A21Z2 M21GK7I_=8W"FP:MF:=K]UPXE\TZMQ*X(&6>@W.`;G8??O%2,BS0[IQ\*"&1A,02DDA(*B'9$N$R]OF, MZ8+JPB1AFXUYG_>CY96J\(,IK8LAXUB0R;RB68;8^C-I>GG$$I)(2"HAV1+A MZC5AX[L<(EKPVO`U:/)/UCPH\45+ZUHXDKBJ'5_LXAMK+EN&$AE*92CC(+YT MNG5:=.?_*)UMPOC7J;`^A7`8&?I[.>"PM`L3^,:ZE3X'3E`BLU(9HL>?\8D0 MR$IGQQFV.:Y1=T(1JBJB%/A"CRIT99E1=HR"M*=SE/`/'+">5G2N"GAH!K`U ME/'8#&!#*.-/7@#34<9#/X"V?0\.Y4-42ITA'(, MC4[=CIW-V$V/V^$XL,<]G*F&GV&ULI)W;DMM&@FW?3\3Y!X?>VRH6BV25P_9$)NI^O]_>U++< M5HQE.21UN_OO9[.`!(E,`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`[3\QW_QTK0':/7.\@T/)KVQZ&_[?_%@YDG` MY3^^^969ITDS7WN7^_I),T_OUD\_(?:?.O/[[; MZ?ANKX[,\L^K^9)NIR.R_,=_\2C2F\'VZL#RHWA=G[:^G`7OOOGRYNG\MSYG:\^(ATZ(=2:\3`G+F)]>Z<70N>YGG<;_ MZ^?YSLZ/K_^E,^^W#1-+9M(EJD0L3[.7L;OYP%X^L%\/U*?3RTT.\H'#?.`H M'SBN!]8??/;`3A*1'MAI/G"60M=>@$GV`IR73+:?BY*8;V;,9=KU:D\9<96( M]&BO4VP:N$G$*F.>/]K;Q*2-[E+*:J-LQ_DI$ M>G#/^4!HIN1J9H1F`HIL)VD6&YH9N+91,P77-RJ>4VBGY2JY>#U#,U6W7YK? MBS3-7%T;:2;KVD@S6]=&>+J&8KZ&9L*N/;%VQJ:7,/#\#.T$;3=JIN-:<#/] MUD::^;0M,U^/;"N<+:;@Y+(4P]+)`LY*HD\Y+A$LI`3)$Z1."N)^33;SWG) M9,1%2WNGF[ZF.QD\+9DYM,LYZYDLD=\ M7Q*+2:;(0\D4K_!CR61[>BJ)?,(\ET@6$D*)Y"FA$6W$@-"8MH[,MQ;=@Q`: M^SK0=)Y!C7_K4/Z8>XS49XU93H^4V<0)/5(61SST>#F?9E,GL)FA1\WBA>Z1 M<[Z5O2F'/C^WLAD66-#09VCQ*K*BHZ1](\AQT-/9(6 MQZ)'TGQ//8Z6C[A'T\5&/G]8U-@CZJ(X_V-38X^IF5^QQ]-%WAIC\G1S\^7# M!:VI[&2O3^SU-(>2IR,Y/9[F#[G'TOR(QAY)BS\FL4?3Q>:T^]X2>SQ=;.9/ MK,?3QQ]/B=>P5-7L#BCVB%D%L:NPQ=9&? MC,0>50L/8X^L^9/O4;7,Z5&U^.-3]]5I'Y.=4)V5S#R?9^'>O7-H5Y_@PNH3Z#BX],^PPNH#Z#-[._D['/X`+J,[B`^@PNH#Z#"ZC/X`+J M,[B`^@S.6WKL,[B`^@S>S/[PQCZ#"ZC/X,VLTL8^@PNHS^`"ZC.X@/H,GF:G M9K'/X`+J,7BVR"==C\$EU&-P"?48/-_)SC^J'H-+J,?@$NHQN(3Z#"Y.X?L, MGF9O8E6?P0749W`!]1E<0'T&KT&=6J%+1CJU8KQ.+.E.G<@'JGQ@-Q_8RP?V MZX'52LE!/G"8#QSE`\?YP$D^<)H/G.4#Y_G`13YPF0]*X.3F@.Z-I((;B@(;BB(;BD(;BF,;BF,;B MF,;BF,;BF,;BF,;BF,;BF,;BF,;BF,;BF,;BF,;BF,;BF,;BF,;BF,;VF*[> MO(MSB5@5^5B/2'=C<-#&ZREXBTR7X:&-SD`(E#)(Z0.$;B!(E3),Z0.$?B M`HE+)*Z0N$;B!HE;).Z0N$?B`8E'))Z0>$8B!$;8J=!*-2A$8,U"Z]EP"IL7 M6+W`[@66+[!]@?4+[%]@`0,;&%C!P`X&EC"PA8$U#.QA8!$#FQA8Q<`N!I8Q ML(V1;8QL8V0;(]L8V<;(-D:V,;*-D6V,;&-D&R/;&-G&R#9&MC&RC9%MC&QC M9!LCVQC9QL@V1K8QLHV1;8QL8\4V5FQCQ396;&/%-E9L8\4V5FQC-6ICY_Q> MWXKMG-^_?$5VL?PY&+@H;+GA3Z]TR?OJ-'XGN[8FULSBY:K6R?:&_J=[]6=5 M`Y/-]:M/9MO9^N=N)V:GC-FS8O9K:J1X'"!QB,01$L=(G"!QBL09$N=(7"!Q MB<05$M=(W"!QB\0=$O=(/"#QB,03$L](A,!(X][(;`^-?6-(H]X8TL@WAK!Y M@=4+[%Y@^0+;%UB_P/X%%C"P@8$5#.Q@8`D#6QA8P\`>!A8QL(F!50SL8F`9 M`]L8V<;(-D:V,;*-D6V,;&-D&R/;&-G&R#9&MC&RC9%MC&QC9!LCVQC9QL@V M1K8QLHV1;8QL8V0;(]L8V<;(-E9L8\4V5FQCQ396;&/%-E9L8\4V5HV-]2[M:`1?Z5SE@S6R\U(&\`Z;]+']SOU@.S%W@Z M6W^4+]]GV,LWV$\#:T6DVS(.D#A$X@B)8R1.D#A%X@R)R0>D'A$X@F)9R1"8*1U:7"VAXI3&LG&SME;SX9WQ.8%5B^P>X'E M"VQ?8/T"^Q=8P,`&!E8PL(.!)0QL86`-`WL86,3`)@96,;"+@64,;&-D&R/; M&-G&R#9&MC&RC9%MC&QC9!LCVQC9QL@V1K8QLHV1;8QL8V0;(]L8V<;(-D:V M,;*-D6V,;&-D&R/;6+&-%=M8L8T5VU@U-M;GJ)/.F?3+.6K5N#@,L(D5FUB- MFM@YI]?OG';.Z9>?\F_A1_S+K;)S^_PG5&+-C)Q)5(EHS_#3P."9Q5XBTB;[ M:6!PDP,D#I$X0N(8B1,D3I$X0^(B04+;%]@_0+[%UC`P`8&5C"P M@X$E#&QA8`T#>QA8Q,`F!E8QL(N!90QL8V0;(]L8V<;(-L8>&Q?YCY%%]C'V M^%CFL)&1C8P]1BZV\B](L9.1G8SL9&0G(SL9V$?_Q# M_!<\/]//+^9IH+%3_19))^Z[[BZ2-]MN1P8T.&#EDY(B18T9.&#EE MY(R1S4G1,XQ[`S&G;J]@J\+\-.W7&!VLW:RYP7M-]C(L3Q@Y)"1(T:.&3EAY)21,T;.&;E@ MY)*1*T:N&;EAY):1.T;N&7E@Y)&1)T:>&5&[J+4H6S!B6JEMP3K*TMFNSO.A6 MMU6K4X:)KJ%]&8:A*A?\:`U#U2_6'^_R">5O&+H-VSKR\H"SCY;4+OC1&'ZJ M77".X6&$9HKZ! MUOIWBA?YC<[BI(;&GD6+I!6%W79D<$5AKT721OOMR.!&!XP<,G+$R'&#S.L; M!$T6\ZQ(G63`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`X8.63DB)'C!FDNR>A98CWI$).^)=93WL\9(^>,7#!R MR<@5(]>,W#!RR\@=(_>,/##RR,@3(\^,J%@D2P:GMXH%,Y7!&/ZI5O"^#"55 M*CC'D%*%@G.2EB)7GX5T3SY4)SC',%.K$IQCN*E5""V<,2U4DZCW5*=.>E.3H,&$8JN]% MX#-2B6#&,%0E8OTY;;W\P.,&2U?DS"*0WU#M?4EB45^34ZAI(I#G3-\ M,+44P;LRI-0R!.<86FH1@G,,,;4(P3F&FEJ$X!Q#3BU"<(ZAIQ8A.,J,4=+$,P8FD9#4RU!\+X,3=4>."=I.O)W7.V!.,?P5.V!>MZ>_CW9.O-VQ]^^<_N MN\]OW_VAXK6QO-?:SS^^?+D[3.I[O79;0_9EZ-A`(^\V58ND`K#;C@P6@+T6 M21OMMR.#&QTP2.D7M&'AAY9.2)D6=&5!J,&RL;S$JV04MT&1/O:^7?<(YAI$H#[\MP4JL- MG&-8J=4&SC&\U&H#YQAF:K6!Q#&FD-]6]CU]C"?%>T![QU;31*2 MBL!N.S)X:K+7(FFC_79D<*,#1@X9.6+DF)$31DX9.6/DG)$+1BX9N6+DFI$; M1FX9N6/DGI$'1AX;9/61>799Y1-G/#.B]I`D&9S=6G)@)LFV>KSY>HW*0QVS M0K*GI/4&WI&AHZH#YQA"JCIPCJ&DJD/^S(L7)SDY_.(D)8<)PTBU!GY*AI-J M#9QC6*G6P#F&EVH-G&.8J=;`.UJV*^&XJJ,/##,1158<`<%09Z MR/IR`\<8BNI[TYQC**KO37..H:B^W,`YXXIV^\+REJ_K?0%6&>H[Q'9[0GXI MXP1O(UNU2#KEWVU'!D^*]EHD;;3?C@QN=,#((2-'C!PS"`*K. MP#GCGG8[P_+^L%_1&>K;R:YWAD7Y$TMXS]EJDI!T^K_;C@R>D.RU2-IHOQT9 MW.B`D4-&CA@Y9N2$D5-&SA@Y9^2"D4M&KAJD/OV;Z"<7\G/YZPXQ[?FAY1O> MS2TC=XS<,_+`R",C3XP\,Z+.D"09G-WJ#,RL9!O.,?33\@+ORS!2G8%S#">U MO,`YAI5:7N`M,7".8:C6&#C'<%1K M#)QC6*HU!LXQ/%5KP!PM,C!C>*HKDSC'\%17)G&.X:D6&3C'\%2+#)QC>*HK MDSC'\%17)G&.X:FN3.(Z,HES#$]U9=)83JRQ@4;^(E4MDHK`;CLR>(JSUR)IH_UV9'"C`T8.&3EBY)B1$T9.&3ECY)R1 M"T8N&;EJD+H]]%2#:\ZX8>26D3M&[AEY8.21D2=&GAD)P6`,U\)*MD%+@J%? M6/DWG&,8&0PE@^%D,*0,AI7!T#(87@9#S&"8&0PU@^%F2'*.O`\'P\]@"!H, M0X.A:#`<#8:DP;`T&)H&P]-H>!H-3Z/A:30\C8:GT?`T&IY&P]-H>!H-3Z/A M:30\C8:GT?`T&IY&P]-H>!H-3Z/A:30\C8:GT?`T&IY&P]-H>!H-3RO#T\KP MM#(\K0Q/*\/3RO"T,CRM#$^K<4^[[6%YY[CU-0>S/=0WG.NN/62_:A,WQ^Y* M5]\ZNT52$=AM1P9/3?9:)&VTWXX,;G3`R"$C1XP<,W+"R"DC9XR<,W+!R"4C M5PU2MX>>6XU><\8-([>,W#%RS\@#(X^,/#'RS(C:`WH4#-?4'CC'T$_M@7,, M(]4>.,=P4NV!.,^`\`.,?P5.UA+*?;'E0`OJ4]+#?+UQ[R>Y9LUM#(9UY5BZ0B ML-N.#!:!O19)&^VW(X,;'3!RR,@1(\>,G#!RRL@9(^>,7#3(X'G_)6=<,7+- MR`TCMXS<,7+/R`,CCXP\,?+,B-H#>J3VP,Q*MD%+M/;`.2O_AG,,(]4>>%^& MDVH/G&-8J?;`.8:7:@^<8YBI]L`YAIUJ#YQC^*GVP#F&H6H/G&,XJO;`.8:E M:@^<8WBJ]H`Y:@_,&)ZJ/7".X:G:`^<8GJH]<([AJ=H#YQB>JCUPCN&IV@/G M&)ZJ/7".X6DT/-7:`^_+\%1K#YQC>*JU!\XQ/-7:`^<8GJH]8([6'I@Q/-7: M`^<8GFKM@7,,3[7VP#GCGG;;P_)V^ZEP6+O19)&^VW(X,;'3!RR,@1(\>,G#!RRL@9(^>,7#!RV2#- M94F+R=9T,SLD5YQRS3OEL)W7+*'2/WC#PP\LC($R//C*@_H$GJ#\Q4 M!F,(J-4'WI?AI/H#YQA6JC]PCN&E^@/G&&:J/W".X:;Z`^H# MYQB>:O4!<]0?F#$\U>H#YQB>:O6!,W#!RR\@=(_>,/##RR,@3(\^,J#Z@2*H/ MS*QL&]1$RP^` M,NX;EA_J.\UUEQ_RWQ#6#>26'4./9>@O6]4BJ0GLMB.#&^VU2-IHOQT9W.B` MD4-&CA@Y9N2$D5-&SA@Y9^2"DM#WR\F77'(-2,WC-PRH#YQB>JCY@CNH# M,X:GJ@^<8WBJ^L`YAJ>J#YQC>*KZP#F&IZH/G&-XJOK`.8:GJ@^<8WBJ^L`Y MAJ>J#YQC>*KZP#F&IZH/G&-XJOJ`.:H/S!B>JCYPCN&IZ@/G&)ZJ/G".X:GJ MPUA.MSXL[QWW#?6AON5RV2-MIO1P;/ M9PX8.63DB)%C1DX8.67DC)%S1BX8N6R0NC[4%Q5UC_05AUPS*KZ@#FJ M#\P8GJH^<([AJ>H#YQB>JCYPCN&IZ@/G&)ZJ/G".X:GJ`^<8GJH^<([Q9U3U M@7,,3U4?.,?P5/6!`;NX;ZD-]E[IN?=CJGE3&3;Z578ND)K#;C@R>*NVU2-IHOQT9 MW.B`D4-&CA@Y9N2$D5-&SA@Y9^2B08:[P26'7#%RS<@-([>,W#%RS\@#(X^, M/#'RS(CJ`XJD^L!,93"&?ZH/O"]#2=4'SC&D5'W@'$-+U0?.,<14?>`<0TW5 M!\XQ[-3J`^<8?JH^<(YAJ.H#YQB.JCYPCF&IZ@/G&)ZJ/F".Z@,SAJ>J#YQC M>*KZP#F&IZH/G&-XJOK`.8:GJ@^<8WBJ^L`YAJ>J#YQC>*KZP#F&IZH/G&-X MJOK`.8:GJ@^<8WBJ^H`YJ@_,&)ZJ/G".X:GJ`^<8GJH^<([AJ>K#6$ZW/BSO M/+=>'\;O+[U9WZBN6QMF>6VHH?J,M.?^8563LO4JG?_O-B/-)CO%+24D3-&SAFY8.22D2M&KAFY:9#!R7++&7>,W#/R MP,@C(T^,/#.BQH!35XV!F95J@Y;H>B7.6?DWG&,8J<;`^S*<5&/@',-*-0;. M,;Q48^`,G#!RRL@9(^<-4I^.SW8F.UL[6;V[X)1+1JX8N6;D MAI%;1NX8N6?D@9%'1IX8>69$_2'-^,'YK?[`3&4PNP:S,G#X\1A.JC_P8S:L M5'_@',-+]0?.,+%0@ MZIW5T&0VT3O*=O8C&;I7W#HTD&18JIO%K0=MSQ>;&SL;W4^G5"'6F-'0_#574(S%&'8,9P51UB_?+'ZCK/G?= M+8[WE5QM7I\MO8JS/,=P51UB_?%,MS9G6QL;^5F!(:M*!#]H0U:5",XQ9%6) MX!Q#5I6(]1=HL_X]P?R5-FQ5B^`'E&0=F=%J$>L/Z.73W6(&&:JJ1?#C2:J. M/9YDZAACF*H6L?Z\YEL;L\WM>::\:H0!&:ZJ1^"SUZ^V,F.XJE]MY1S#5?UJ M*^>,J]KI$=/\?M/C*P\O>/?7EF8[^;T>&JA^5YK-MZ:+['=`JH986WKH;+.S ML3F=9ZE[Q3;[[,'#%RS,@)(Z>,G#%RSL@%(Y>,7#%RS<@-([>, MW#%RS\@#(X^,/#5(+<#6]G1K.WL+>^:0$`PF&LQ*MD%-PJZ1LQ)P.,=0,AA. M!D/*8%@9#"V#X64PQ`R&F<%0,QAN!D/.8-@9##V#X6%;@#$>CX6@T'(W)T>8O3D^=-`R-AJ$Q&5KOJ>>RDFCX M&0T_H^%G-/RL##\KP\_*\+-*?C:S8OD#E=U941EV5H:=E6%G9=A9C=O9K0K+ M&\FM+SE`5:CO.]==:EAT7XXX';LY7;W4T")IU6"W'1D\$=EKD;31?CLRN-$! M(X>,'#%RS,@)(Z>,G#%RSL@%(Y>,7#%RS<@-([>,W#%RS\@#(X^,/#'RS(C: M`IH4#-M"9>08`H9D8/-.J`^`9_F'TH:2*@O\M`PI518X)VG9_!'=WLX?L"&E MF@+OR-!23:'.J1_,SFPQFV?OG2H*O"M#3!4%SC'45%'@'$-.%07.,?144>"< M)&C],F]N[4SS51'#3]6$>D]URO9T,LN.E4H"/A:5!&8,/542."?I.5)^5!(X MQ_!3)8%S##]5$CC'4%0E@7,,1542.,=P-!J.JBCPO@Q'510XQW!458%S#$=5 M%CBGZ^CV9)Z_$ZHJ<$IR=&3&JRI@CJH",X:EJ@J<8UBJLL`YAJ4J"YPS;FFW M+.B\OU,6O.N3ILO-NNL+\UG^>TH--'8D6R2=_^^V(X/G_WLMDC;:;T<&-SI@ MY)"1(T:.&3EAY)21,T;.&;E@Y)*1*T:N&;EAY):1.T;N&7EHD.:$8WNRR*]H M>.20)T:>&5%GJ&T;$4F=@9G*8`S_U!EX7X:2*@V<8TBITL`Y2$ZGBTF^ MUJ,%!HXQO-0"`^<89JHW<([AIGH#YQAVJC=PCN&G>@/G&(:J-W".(:D6&#C' MT%3=`7/4'9@Q-%5WX!Q#4W4'SC$T57?@'$-3=0?.,3Q5=^`UF^'L\UR6<2P5(L,_&@,2[7,P#F&I5IFP!QU!V8,2[7, MP#F&I5IHX!S#4BTT<(YAJ18:QG*ZW6%YS[BO6&BH;S&G^/;N#(MY=L51G([= MAZY9:$A(.OW?Y8WV6B1MM-^.K!Y.]F`.&#EDY(B18T9.&#EEY(R1T8>&'EDY(F19T94&I(F@_-;I8&9RF`,`54:>%^&DRH- MG&-8J=+`.8:7:@V<8YBIUL`YAIMJ#9QCV*G6P#F&G\$05)*K+DCC'\%27)7&.X:DN2^(Z+(ES M#$]U61+G&)Y&PU.U!MZ7X:E:`^<8GJHUU#ECK8'W9%BJ]0;.,2S5B@/G&):J M-6".5AR8,2S5B@/G&)9JQ8%S#$NUXL`YXY9V6X,^QOR:UK#$LY6&_#L'<5I# M(Q^05BV2"L!N.S)X@K37(FFC_79D<*,#1@X9.6+DF)$31DX9.6/DG)$+1BX9 MN6+DFI$;1FX9N6/DGI$'1AX9>6J0^JUY/MW*O\GYS!GJ#.B1.@,S*]D&+=%7 M&3AGY=]PCF&D.@/ORW!2G8%S#"O5&3C'\%*=@7,,,]49.,=P4YV!`L-=0W ME.NN->07>T['[CK7K#4D)!6`7=YHKT721OOMR.!YS`$CAXP<,7+,R`DCIXR< M-4A]1MIW&[9S#KE@Y)*1*T:N&;EAY):1.T;N&7E@Y)&1)T:>&5%M2)8,3F_5 M!F8J@S'\TU(#[\M04K6!``< MPU/5!LQ1;6#&\%2U@7,,3U4;.,?P5+6!69$_0&E4']@IC(80T#U M!]Z7X:3Z`^<85JH_<([AI?H#YQAFJC]PCN&F^@/G&':J/W!.\K/^-$+?&<]_ M\4/MH4YIB/*W6729TCHQV=8OW% M5O8!EXH#/QI#4!4'S%%Q8,805,5A_6DM+TS/?II%5RCQGI*>]<'L2S'D5&E8 M?RS3R6*ZDWWM7) M&9Z)%9.=8TSRH'T\]F;<6L]DD^]%-509$ M#$'5&/"9Z_(D9@Q%=7D2YQB2ZO(DSAFWM-L8EC>#^X;&4-]#;KTQS,LO-]10 M?1S_MMA8S&?9^TDU3?>B2R?_N\U(L]&6?EE[)_N5RKUBH_UV9-"H`T8.&3EB MY)B1$T9.&3ECY)R1"T8N&;EBY)J1&T9N&;ECY)Z1!T8>&7EBY)D1-8:DR>#\ M5F-8MVT^VYAF;YKZ#25.2?J-O(>K+W".8:3Z`N<83JHO<$ZRLCE!TD^E=S_= M4%G@$$-*E07.,;146>`<0TR5!JHR<$[2<^1M1Y6!*K2P#GCGG9+P_)^<-]0 M&NK;R*V7AD7YW8:Q>\TURPP)696&-#)X?K0W34C::+\=&=SH@)%#1HX8.6;D MA)%31LX8.6?D@I%+1JX8N6;DID$FFQNO?O[Q7S]O?+^1]<5;#KECY)Z1!T8> M&7EBY)D1=88TX0>GMSH#,Y7![!K,2L#AQV,HJ=;`C]F04JV!*H5!\XQ/-552IQC>*H5!\Q1?6#&\%1K#IQC>*JKE#C'\%17 M*7&.X:FN4AK+Z=:'Y:WBOJ$^U'>8Z]2'1?8Y7IS64/WAR'1GD:T15\U_OWZ+ MMW3CNI>SQ^['@GL%OM^.#)[&'#!RR,@1(\>,G#!RRL@9(^>,7#!RR<@5(]>, MW#!RR\A=@PS-MGN.>&#DD9$G1IX946=(+@Q.;G4&9E:6#>?L&CDK_89S#"'5 M&?@Q&TJJ,W".(:4Z`^<86JHS<(XAICH#YQAJJC-PCB&G.@/G&'JJ,W".X:@Z M`^<8EJHS<([AJ3H#YJ@S,&-XJL[`.8:GZ@R<8WBJSL`YAJ?J#)QC>*K.P#F& MI^H,G&-XJL[`.8:GZ@R<8WBJSL`YAJ?J#)QC>*K.P#F&I^H,F*/.P(SAJ3H# MYQB>JC-PCN&I.@/G&)ZJ,XSE=#K#5GY#:.^;#2^;=7].:5&L=#;0R.)CU2)I M]6"W'1D\-=EKD;31?CLRN-$!(X>,'#%RS,@)(Z>,G#%RSL@%(Y>,7#%RS!D/,8)@9##6#X68PY`S)SI&W\V`8&@Q%@^%H,"0-AJ7! MT#08GD;#TVAX&@U/H^%I-#R-AJ?1\#0:GD;#TVAX&@U/H^%I-#R-AJ?1\#0: MGD;#TVAX&@U/H^%I-#R-AJ?1\#0:GD;#TVAX6AF>5H:GE>%I97A:&9Y6AJ>5 MX6EE>%J->]HM#\M[R'W]@L-6?>NY[H)#=G%);*"1OS95BZ0>L-N.#)Z:[+5( MVFB_'1G<\L#((R-/C#PSHOZ`=WH,AFUAI=N@)^H/O*^5@<,YAI/J#[POPTKU M!\XQO%1_X!S#3/4'SC'<5'_@',-.]0?.,?Q4?^`GNJ]CK]0F]\QU>'SJ\[S8OTMI#Y1>XB_<7)]W& M/0#Z>^+@5*7:-MW+RY/F_1F&89OKVC87\?X2-S7@]=81C2^2HQK1V4DTB'&- MR&E,]D1+3+IE9,K(C)$[1NX9F3.R8&3)R(J1-2,;1AX8>63DB9$M(\][I+1' MMWO>:2PYQ8729<>)@M]&8:%4:5F7"@N'[W01E[]&#:R2C-CV3LF+;4QR8QN3 M_-C&&(Y45#C\S76Q[GES+R1'EGLA=]=CY81#$5UYW?STT)2!_WR&(S5E8!W# MDYHRL([A2DT96,?PI:8,K&,X4U,&UC&\J2D#ZB@E,&,85%,&UDD&;5GNFC*P MCF%131E8Q["HI@RL8UA44P;6229M^_LDE[8QAD\U9>"?Q_"II@RL8_A44P;6 M,7RJ*0/K&#[5E(%U#)]JRL`ZAD^5$E!'4P9F#)]JRL`ZAD\U96`=PZ>:,K!. MNT_K*6'WW+COF#*4CYO3C_)V-["+;OTZA.*69$L0&=I"D#,WV#,0RHZ,#O97A24P;6,5RI*0/K&+Y4=&`=PYE*#ZQC>%-3 M!M8QW*DI`^L8_M24@74,AVK*P#J&1S5E8!W#I9HRL([A4^4'U-&4@1G#IYHR ML([A4TT96,?PJ:8,IPJ88,K&/85$,&UC%LJB$#ZQ@VU9"AU-DOP\QQ7Z4'?"NE!V8,ERH] ML([A4J4'UC%_O20^[S>JSAHN+L_JW_.*\A%JR?;]"4A`8 M5)6C06!8(6FCZZIR=*,;1D:,C!F9,'++R)21&2-WC-PS,F=DPT$E*#\R\V>VH3S1V8)TW!Q[7,3RI],#O M9;A2Z8%U#%\J/;".X4RE!]8QO*GTP#J&.Y4>6,?PI](#ZQ@.57I@G>11D6\' MJ.H-1NF!=0R7*CVPCN%3I0?447I@QO"IT@/K&#Y5>F`=PZ=*#Z5.^9EZ>G+9 MG+=I]L#O9+A4LP?6,5RJ*QQ8QW"I9@^L8[A4LP?6,5RJV0/K&"[5[(%U#)=J M]L`ZADLU>V`=PZ5*#ZBC],",X5*E!]8Q7*KTP#J&2Y4>6*?=I_7TL'M$W.'L M`4)2`!A4E:/-8E@A::/KJG)THQM&1HR, M&9DP,W#,R9V3!R)*1%2-K1C:,/##RR,@3(UM&GAE1:D@V.;J^ ME1J8Z1N,84#-',KWVJ>NB\NKQKBQ9SA2F8%_8L.3R@RLDUQY_"-TS)UME+MKW?2Z82SHI(K]R+O3T_/&JE6YRK55,XNWE\V;L"O ML'"(G)]WWY\UGLFI,Y7X-S)LV3-\J:S`[V4X4UF!=0QO*BNPCN%.9074459@ MQG"GL@+K)'?J^\&QO*6LP#J&/Y456,?PIT8-K&,X5*,&UDD.;?O[)(^V,7H1]ZP0M)&UU7EZ$8WC(P8&3,R8>26D>D>V7]MV)TIK7_JA]IF+'/'R#TC MR9LM75[3!M8QS*EI`^L8 M]E2`8!W#H)HVL(YA424(UC%,J@3!.H9-E2!8QS"J$@3J*$$P8QA5"8)UDE%; MUJH2!.L8/E6"8!W#ITH0K&/X5`F"=0R?ZF0EUC%\JI.56,?PJ4Y68AW#IX7A M4R4(?B_#ITH0I4XZ#)+Y[-7)2OQ>R:=M.H9/E2#PO90@F#%\J@3!.H9/E2!8 MQ_"I$@3KM/NTGB!VSY/[C@11/H:NGB`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`#@WESX%&_*3KPSW-C,(8K=4(3OU?R MY7Z67S9-W#9-J)H'OI.C`C&%210?6,4RJZ,`ZADD5 M'5@GF;2E2^L:"-8Q7*IK(%C'<*FN@6`=PZ6Z!H)U#)?JK";6,5RJF03K&"[5 M3()U#)?JK";622YM63]*#ZBCF00SAD\UDV`=PZ>:2;".X5/-)%BGW:?U]+![ MF-QWI(?R&73U]-#XDE^&'`&PTK)&UT756.?IFY863$R)B1 M"2.WC$P9F3%RQ\@](W-&%HPL&5DQLF9DP\@#(X^,/#&R9>29$86'9).CZUOA M@9F^P1@&U!2"W\OPI*Z&8!W#E0H/K&/X4NF!=0QG*CVPCN%-I0?6,=RI],`Z MAC^5'EC'<*C2`^L8'E5Z8!W#I4H/K&/X5*,'U%%^8,;PJ*O^XV8<][(G.J1Y*\7;9UU5CBC&H M"66?`.$)7=>$KDYT8G3]1[ZI`:H_Q6WM]D3DC"T:6C*P863.R8>2!D4=& MGAC9,O+,2*]G,,F++2NFUS=TDA7;=(:&3G)BFTXR8QN3[-C&)$.V,+-GF+-GN+-GV+-G^+-G&+1G.+1G6+1G>+1GF+1GN+1GV+1G M^+0P?%H8/BT,GQ:&3PO#IX7AT\+P:6'XM#!\6A@^+0R?%H9/"\.GA>'3PO!I M8?BT,'Q:&#XM#)\6AD\+PZ>%X=/"\&F1?%I^E]3-O;J-[XB%X=+"<&G?<&G? M<&G?<&G?<&G?<&G?<&G?<&G?<&F_W:7U;+%[U%QS-+&[IKO]-DW=\@EUM='$ M9>,;<+&'6GIQOT+2E&%050["1OV;];!"TD;75>7H1C>,C!@9,S)AY):1*2,S M1NX8N6=DSLB"D24C*T;6C&P8>6#DD9&G/5*>ZZDK6!J');8L\C`.H8]%1U8QS"HH@/K)(NVM"!%!]8Q?*KH@#J*#LP8/E5T M8!W#IXH.K&/X5-&!=0R?*CJPCN%310?6,7RJZ,`ZAD\5'5C'\*FB`^L8/E5T M8!W#IXH.K&/X5-&!=0R?*CR@CL(#,X9/%1Y8Q_"IP@/K&#Y5>&`=PZ<*#VTZ M]?"@[_\A/)QI6@'A8;=98S#1/$)?=$NHY9.[7R$I!PRJRM&O)L,*21M=5Y6C M&]TP,F)DS,B$D5M&IHS,&+ECY)Z1.2,+1I:,K!A9,[)AY(&11T:>]L@^/+P[ MOZK_$ZZ'W[+F,R-*$^BKGN$]I0G6,>RH-,$ZAD.5)EC'\*C2!.L8+E6:8!W# MITH3K&,X56F"=0RO*DVPCN%6I0G6,?RJ-,$ZAF.5)E@G>;:E)RE-L([A4Z4) MU%&:8";YM/R&5&60!\I2S#3-QC# M?LH2_%Z&(Y4E6,?PI+($ZQBN5)9@'<.7RA*L8SA368)U#&\J2[".X4YE"=8Q M_*DLP3J&0Y4E6"=YM#U+L([A4V4)U%&68,;PJ=(#ZQ@^57I@'<.G2@^L8_A4 MZ8%U#)\J/;".X5.E!]8Q?*KTP#J&3Y4>6,?PJ=(#ZQ@^57I@'<.G2@^L8[13 MI0?447I@QO"IT@/K&#Y5>F`=PZ=*#ZQC^%3IH4VGGA[TN1K2@S&9V&W6G$PT M3NLHNB74\LG=KY`4!`95Y6@0&%9(VNBZJAS=Z(:1$2-C1B:,W#(R963&R!TC M]XS,&5DPLF1DQ#;:M7CZ[)9T84'=!$B@[, MO#GMZ(_3,[RGZ,#O9=A1T8%U#$,J.K".84E%!]8Q3*GHP#J&+14=6,B@[,&#[5]1"L8_A4UT.P MCN%370_!.H9/=3T$ZQ@^U?40K&/X5-=#L([A4UT/P3J&3W4]!.L8/M7U$*QC M^%370[".X5-=#\$ZAD]U103K&#Y5=$`=71'!C.%371'!.H9/=44$ZQ@^U141 MK-/NTWITV#W0[G#P`"\Z_)#\BHD??L?5)6C'_/#"DD;75>5 MHQO=,#)B9,S(A)%;1J:,S!BY8^2>D3DC"T:6C*P863.R8>1ACUR\#@JNKIJ7 MN3^RQ!,C6T:>&5%H0!LI-##3-QC#?0H-_%Z&(14:6,>PI$(#ZQBF5&A@'<.6 M"@VL8QA3H8%U#&LJ-+".84Z%!M8Q[*G0P#K)H&IQU4"[,796:&`=PZ4Z=XEU M#)\J-*".Y@W,&#[5O(%U#)]JWL`ZAD\U;V`=PZ>:-[".X5/-&UC'\*GF#:QC M^%3S!M8Q?*IY`^L8/M6\@74,GVK>P#J&3S5O8!W#IYHWH(Y"`S.&3S5O8!W# MIYHWL([A4\T;6,?PJ>8-;3KUT+![AMU_$!K*1]Z=7?R8OK@7W5#JQ](@EH:Q M=!U+-[$TBJ5Q+$UBZ3:6IK$TBZ6[6+J/I7DL+6)I&4NK6%K'TB:6'F+I,9:> M8FD;2\^QI.^M8=_J>VJL97:X#EY'+K/+=<5MY#([75?41BZSVW7%;.0R.UY7 MQ$8NL^MULYS(97:^;H83N0R2T`WJXE<9A'H9C21RRP# M'5P-G+X7Q5IF'>A@:>0RZT`'0R.760A@8>0RZZ#(K`/U\;AM9AVH3TI_;/3'IL,_]KE3249O\Y5]?OWW^ MQ^CE[[^]5O`2P/+)2X='S;K-V_@5W1(ZT[W8J^QS=M)(/_TW*O7202P-8^DZ MEFYB:11+XUB:Q-)M+$UC:19+=[%T'TOS6%K$TC*65K&TCJ5-+#W$TF,L/<72 M-I:>8TE=LMK=:4>J2\9:9H>K2T8NL\O5)2.7V>GJDI'+['9UR7C%QF`:A+1BZS!-0E(Y=9!.J2D, M7&8=J$M&+K,.U"4CEUD'&HE%+K,.-/**7&8=J$L&3B.L6,NL`XVH(I=9!QI! M12ZS#C1BBEQ]'=2[Y.[I(Q-(^E12PM8VD5 M2^M8VL320RP]QM)3+&UCZ3F6U"6KW9UVI+IDK&5VN+IDY#*[7%TR,7&;'JTM&+K/KU24CE]GYZI*1R^Q^=?$=7;*\V7Z]2S9O/=HM MH5J7[%XU3NWNOU'IPW402\-8NHZEFU@:Q=(XEB:Q=!M+TUB:Q=)=+-W'TCR6 M%K&TC*55+*UC:1-+#['T&$M/L;2-I>=84I>L=G?:D>J2L9;9X>J2D,7&;GJTM&+K/[U24CEUD`ZI*1RRP! M=.AIZ>ZHRMJOS#EY=?__JCCBM_>#UXJ\^\QDL* MSKN77N>-X:7+W4N7NU%D>.EJ]])5[J5YYT.Q[.1>6>N53?:5K5YYSKW2'W8^ M]*]SKQ2G'_K=S+L,3C\,<_7>I/.A=YM3ZBWURBK[RD:O/&1?>=0KV]PK1:'? MI9]]9:17)KE7>A++_^/75WZJ]O#7 MCS__\]-O+[-/7W[[^Y]??_CCY5>MJI-WN^]?7\J#^.6_?/O\3QWA__&'__K\ M30?X7__O[R^?_O;R94<+_O7SYV_I7[2"?OK?SU_^^W7E?ORW`````/__`P!0 M2P,$%``&``@````A`,;GXKPG!0``.10``!D```!X;"]W;W)K&ULG)C;DJHX%(;OIVK>@>)^"PD0#J7N:L^G5FMJ#M$0N\M/WC_./((G.(/$6GL+\JQ!5E2CPYH0?D--[0>LZNYFJ@U._N0LB`=;N2TGU/ M?4'>EJA:OUOTS]\AO625[TIV3"[3--RMPIA"9\,PL0%X2Y)WALYW+`07:[6K M)\4`;%-E1_?^QRG_([G,:'@XYC#:%B3$\O)V7R.:!="A(-/!%E,*DA,T`#Z5 M*&3.@`[Q/XOR$N[R8T\U2,>R=0,!KKS1+)^$3%)5@H\L3Z)_.(2N4EP$7T6@ MO(H@^/K@Q<;U8BAO%S_=`O,J`F4I8G5,;-G.,WE`QD5G0%FJD.=5R%4%RJL* M-I].R+Z*0%F*6!W'LDSBV(\/#$SR(B$H2Q7T?$+N507*4@5WD*F3)RR"P-G< M:,SBW$08=6RDN\83":&;7^]>PX][#95F0W>C8/CZH%79Q.))5,:6/#PL&I][ MQ50>^;G?[Z;)18'E$9+*SCY;;)&'0+J-*XSDNRDE*VJ M2,RT9,I;S^3`7`XLY,!2#JSDP*L<6)>!2M.0(R:X*9FR:=M*0(.!O(TFV%$8 MS>:EN!PT1K-!*V4'9>#>%E-LR;!.$,,5F5&=D53&=<*0D`E'(,_[N,LWFC[` MS!Y@YG5&:LVBE5BV$JLZ05S)@Z\/,.L&!DM3;?,`L_V>$6P%2]<3MF*T8"LY M,)0#(SDPE@,3'JCZP7:(:+QI$V.+S*R)D:;;O(F13+YH8%Q=O->RB9%&?-7$ M2.O;:Q-CB/=:-S&2BS=-C.2<;1-S[V?!%?#P>L(5C(8=7F5"VZXT.`/.P.=] MTHMI#EN)42LQ;B4FK<2TE9BU$O-68M%*+%N)52OQVDJL6XE-*[']CA!L!1L= MP59L1V+`SNW[9QF[JJ?"FG:W#I'\/^",56Q/#&0BXIB2_8=5!%D(N:8CS=A1 M%6E6&5<1A]A8EY>&294P=0-C2UJ$IE7",G7V7YP+,X$@#H)_(C&O$C8RV)]( M+*H$0DA'Q)5Z;2D@!KN+?)]5%<%8MQS'D=>P*H(P\W M`J+S/S&CK8#(*H+18+?[/XS&KA*-9A.IWP>5^!BUWQF`,PI>YN%R4F50G#)DAZ?DVK]?"RBJ0FS(1ZW422*^9"O6O) MS^)%M9Z8KB'I+ZOUMH[D^E6U'CF.8O/O7X!'GPQE"/K^%DIRD^P-Z@27^(/=ATU75&V(.]5ST^QAYLP2"N MW1H*)S=G_T!?_?00QIERHGM(4>^P%^B4G_WP'WER+MXJWY(X'?KU_P4``/__`P!02P,$%``&``@````A`$_;+?[K2``` MVY@"`!D```!X;"]W;W)K&ULI)U;D]NXH:W?3]7Y M#U-^CZ>E[E:K4YGL`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`5O9:V_O3-Z#BZGR_]&9O&,F^I!WZ?S-TV>RT^Z:Z0OIDGSN9RXDPG;QZJS3QQ%A_R MWME^NTV>.)LZGRUM\J''W<7"NAFJ%;[5+[/Z5@9[:V6DM]\Z7[;R."\^+#?E MK0QLY7%>?&AMOH.!K3S,.G5U-ELK!V=WW^0!VE[NF^_HSG;>.8L/>:NF;Y^] MVWGO+#YDG[>?[K;SWIDMCQ";W]&=63Y&+#[D[FR^?2_/,DV+#]EG\AT^>;1F M^M#Z3#?>?*R9"<97GF8K/+T9B)V,U>)#WJBWC]5./BGL+`\1FYMOI7,G'R+F MR\Y,W[Q)\]R7Q8>\?V=O/R?,,P[SY316;]YZK)CG:3Q?3K_IZA68"?D\3[_% MA[Q9VV^??O,\_>;+H?J>S?#6QFX\XBP]+GS>>,'?S@"\^9)?%BZO#5[[.:C MS>)#MIF_&8;=;M:L'+1VW\[F9",?MUX_Y0Z]>>],-O+!8K*Q,@/?/(\G&WD& MOGY:]N>M^WFRD>?@ZZ=L]!VGO?')KJ^)N&]#]\^_/E/ MOW_Y]P_Z?D%[ZNL_/BR^K9C\\=4RA^`F>W:Q>%TJ5AQ>V(2%ST_O-(T4>+\J MR__KSSN[\S_]^"_%[X^M)M::25^1LF*1M1>V>V7!?EEPT!3H_[N&9].-ONUA MUF3;HUPP4NFXT:QN4=';DZS(MJ?9-A>F1SL35TK:F;@L2=W$6[OMJ3J2I>I(EKJ9F#N8JFF7VFFWTG@[QU9* MAN98.5Z)YUBJYECJYEC7PVI"I>K@EJJ#6QHXL56CG+KILGZO5O,G=?.GZV$U M65(U65(U65(U65(U65)UV$K582MUAZW6.N:TEA!:2@9@+24#J):2`5++'9T&0"UM!D"M;`8XK:9T8E+3`*EE=P9`+24# MH)82QC0-8%JZ#$"ZLU$):2`3I+R0"; MI62`S&I>#8!9V@Q@64CV1J'L!5*M@?0#Z6*%8%,K->/!=%&M%TS+@E06[)4% M^V7!05.P>CF\4W[;=FAHCH8TQ1XZ-C0GAN;4T)P9FG-#G2T%P9 MFNM:L[-17#S=&)K;(4TQ%G>&YGY(4YS4'H8TQ27-XX!FMSA^/1F:YUHSWRC& MXL70A."(XI"H&(W0$K>*S[PR+BD$+0[26ET=A`-=9^B(8)+41HB>%(<6-,0P9/BP)J&")X4W*4A M@B?%I$M#!%>B`8)G.\7,3`,$UZ(A@B>ETQ#!U9KC$,&5:(C@EPM`:8#@>7E!DX8(GI:S8(C@:3DL0P1/ MBV-!&B)XL[A@34,$E]]AIR&"RV^JTA#!E6B(X/*J)PT17*;FO0&"9RL[LY=X M=;->/_&.)]V%O)=TRX)4%NR5!?MEP4%3L%S./RP+CLJ"X[+@I"PX+0O.RH+S MLN"B++@L"Z[*@NNRX*8LN"T+[LJ"^[+@H2QX+`N>RH+GLN`E%RS7N6?E-U,A M#(F*LW2(6927PT,[Q*N!J/9NA[TO*KW;J;`<^5#-A5!-AE#-AE!-AU#-A]!- MB.4>V2FS;N@FR9BHFSA+T7RCW+1N,JV*BJN-T$VP55%QN`[=I%N*ZEQ53<10 MS<303<4QHVYZCHFJ*1NJ.1NJ21NJ61NJ:1NZ>9MG6^PF:5=2S?45AR9\>6$5!R9\ M-0/CP(2O1=V$[P;*F=VQF]UCV]M-^#&1PT!T&(@=`V/-=5B,B3I2QD0=/&.B MCJ+WB?KU$ZEVXZ[HQC-4`QJJ$0W5D(9J3&,UIK$:TUB- M::S&-%9C&JLQC=68QFI,8S6FL1K36(UIK,8T5F,:JS&-U9C&:DQC-::Q&M-8 MC6FLQC168QJK,8W5F,9J3&,UIK$:T]2-Z?*46@7,U`WSF*@:^52-?*I&/E4C MGZJ13]7(IVKD4S?R8UWL)L.8J)H?J9H?J9H?J9L?8];=E!D3=;-H3-1-K#%1 M-]?&1-WT&Q-5,S)U,W*L6C5)4S5)4S5)4S5)][I)J@N,WN6$?E7[ELN)A5QW MQJS$+%,RI>4!$"2YBI MT$&U%HBPQPUUG*UW8?("HQ>8O<#P!:8O,'Z!^0L,8&`"`R,8F,'`$`:F,#"& M@3D,#&)@$@.C&)C%P#`&IC$RC9%IC$QC9!HCTQB9QL@T1J8Q,HV1:8Q,8V0: M(],8F<;(-$:F,3*-D6F,3&-D&B/3&)G&R#1&IC$RC9%I3$QC8AH3TYB8QL0T M)J8Q,8V):4Q,8V(:$].8F,;$-":F,3&-B6E,3&-B&A/3F)C&Q#0FIC$QC8EI M3$QC8AKW1FGLQ4H]LJL?*[T?5"RJ_?1.O^3MHN/.K+@])S::L7B9%3DK[N6" MI6UQ-]I^5N0J![E@;95#5!RAXA@5)Z@X1<49*LY1<8&*2U1(:%3>HN$7% M'2KN4?&`BD=4/*'B&14OJ`B!)@9>8L__:^/ M`J,7F+W`\`6F+[3X];I;]K<%L-7LS+8'MHD1#"V#O::*/=-"V$BF.Z\[K^P- M8QB8P\`@!B8Q,(J!60P,8V`:`^,8F,?`0$8&,C*0D8&,#&1D(".?"B,#&1G( MR$!&!C+R^3#R"3&V./98*T"*?$Z,?%*,C&-D'"/C&%LAV/+8 MV^S^(2:V/+:'F,6K&*H#=&R!'-6T1+9-;>O)2K4/(QD9R MW.YG1:YRD`O65CE$Q1$JCE%Q@HI35)RAXAP5%ZBX1,45*JY1<8.*6U3(> M%0^H>$3%$RJ>4?&"BA!8PDR%Q"Z,6>@X6XM58/("HQ>8O<#P!:8OM/CMOJ;B MC??5STY:^/*_ES\X:B*#&EM01UIM..]GJ93U]1TV%XD>AJ=D'[<>R#^TAHJFP4U80(66% M]H"1^\!;61P^>'+WCB;S]\7(#FQT>S1INJ390E<^B2\"4N_@XGCR)<'>Z"5! M+U/K_4;?DZD7UHN$?%`RH>4?&$BF=4O*`B!)8P M4R&Q"V,6.L[68A68O,#H!68O,'R!Z0N,7V#^0@O@R)))8`(#(QA:!IN&7A=O MJH5QAC`PA8$Q#,QA8!`#DQ@8Q<`L!H8Q,(V1:8Q,8V0:(],8F<;(-$:F,3*- MD6F,3&-D&B/3&/ET&)G&R#1&/B-&IC$RC9%IC$QC9!HCTQB9QL@T1J8Q,HVI MI7'DN)M:&O,2".:7EL)*^+\^7I)K4\CDEZ9\=AEY;'MKM#O6UQ;!5MPBJVJ'=V M'&ZHY7&UH>*6CM3RV$CT*./%GZ*AEL=>9PI)RV.OH=*F!;+1-)M4N+0\-HK! M\WUJ>6Q-!EV8Q]3RV.MNT1?F<6_T[-@+F!,]5_U[$N9KO7[$G,V*!U3&5C26 M,3M)3HQ[7B[SK9VIOO;KNQSW M))M;T^VMC?*!QR?&YHJ;NF;)#4MN M67+'DGN6/+#DD25/+'EFR0M+]);:!:D_O1N!2>^M94TR-`:#>MLMMY6Q'.NS MP67(8([Y9#+'-)G,]AB].]G=VBU^,*\7Z?)V&6P&`\Z0Z1SK!XP^>A\P M:PQ2]3VHSJYF1K,IM7+Q3+J+9#OST1/_/B[@:]:;AI;=3) M@%6O&EXUFL]T4VKY:A&]?'A5,]4)>_&__BE;+Q]>%NO\3G$*U.N(&\T( M93'3VFR97MPVVZF>9FG0&C.MC4]>HR@ZG7%M]W5S]5MDMRJPQ:-6;EMG'H%5O8V:? M#.O(F*8^JVU0*R:9WMC,C656QQK+K(YI,JIC&@-5O?J9^VR@JG=!LT\F=:S/ M&=0QC0&J7B'-_3%`U6NFV<<`5:^B9A\#5+VN&GWT`NLQ33_4ZHG7WQ5J%_7Z MH79G5CS;/DX:T=A0=I*<3_>ZDK7A<[^3Y$H';L1 M>1SW!)N3GWM\CT.EZBXXF:N67+#DEN6 MW+'DGB4/+'EDR1-+GEGRPA)%641(498UR=`8Y"G*Z/P:>B;./3'$TVIQO;Y9M%%&2Y M*8-0Y5CV,1A5CF4?@U+E6/11CF6-@:ER+/L8F"K'LD_&M!G2^5SIJG_.C!G2 M5E$O*BC!-NTTBLE)]/-'`4]FU9Z,72U<[V*!3P7759KJC+QS*M8,,Y\C!(AIT1H-. MY=:F.V-M&70JM[*/0:=R*_HHM[+&H#,9="JW@-&5*Q[;+P%2IE?MC M8*K4RCX&IDJM[&-@JM2*/DJM8YI^:M6CEKXKM2[J]5/K?+-*K8VH^3KQ#SL; M>O!)\76520G MV[HYHG]A'0PF@P&E4BMOE(&E4BO[&&`&@\Q@H!D,-K4`RWTVZ%1L91^#3\56 M]C$(56QE'X-1Q=;&IYFH4ZU8]">A,BLV%`U"E5G9QR!4F95]#$*56MDG(SI" MNH)KX]/L0/T,V%UT6]?GB=[13WY,5)(QK#H9,LPRM6VJ\J'70E:R_,#UER MQ)+C5M*RH>7H!M;%K)ZZW#_;.U0BRW9%"J$,L^!J4*L>QC4*H0RSX&I0JQZ*,0 MRQJ#4H58]C$H58AE'X/29%"J$,MM&90JQ+*/06DR*%6(Y;8,2I-!J4(LMV6< M315BVY^^?OSTFUZ(LZ&G2^F^W(\__/[3NS!9U.N'V'GUQ6HK&KE02YUD M&6(;YY%*^U6E@ZYD[67U(4N.6'+,DA.6G++DC"7G++E@R25+KEARS9(;EMRR MY(XE]RQY8,EC*VDN*0;R_U-/,'E]K4K_FN.YI]A:>/0%+]P-)5CD00FVT31] M'6@H+#E;"TC8,UK*Z#4M-6]XZ6^3XBMWV(!1RZ_L8^"H!5CV,8`,!I&*K]R6 MP:3B*_L85"J^LH_!I>(K^QAD*KZRC\%FR'#*K7M36W'#JN(KMY4)'?,Q(%5\ MQ;:T!LL:`]-H8*KXRFT9G"J^LH_!J>(K^QB<*KZRC\&IXBO[&)PJOK*/P:E6 M8=G'X#0:G"K`\%'>@/W.;+ST+X['NBK<-+>T#S*MGKBO;(DY*MSV3]UO% M<].KMPXHZZ[6J)\-K_N,5P7USE#,Y7X9R"KFLH\!K6(N^QC8*N:RCP&N'O3$ M/@:ZNL^8?0QX=9\Q^QCXZCYC]C$`UBHM^V2$1\X_BKGL8Y"K55KT4QC<*J8RSX&IXJY[&-PJIC+/@:GBKGL8W"JF,L^!J>*N>QC M<*J8RSX&I_JA+/L8G.H!3^QCXHT.+\5:9M-&V?!]M2J&6C/4.3*5Q= MLBTW7FF6&SLT-`::NN>8VS+@U#W'[&/@J45;]C$`U:(M^QB(:M&6?0Q(M6C+ M/@:F6K1E'P-4+=JR3R9UY%04,JEC&H-4I5GLCQ9M66.`JD5;]LF@CFQ7-#A5 MFN6V#$Z59MG'X%1IEGT,3I5FVZ MZYA]#$[UTUGV,3C57RQ$DC&CF-IDZR3+-8:;^J=-"5C*19 M]#UBEV.6G+#DE"5G+#EGR05++EERQ9)KEMRPY)8E=RRY9\D#2QY9\L229Y:\ ML$11%B>OHBQKEKBMY40+LNRS)'"]C\&D?CS+;1E4*LBRC\&E@BS[&&0JR#8^ M[=<*>DU7<3^+%F6Y)0--+BC$,L:@U&%6/8Q&%6(91^#43VUF'T,1O788O8Q&-5SB]FG M8'1[LEFBH^<6LXT!J1Y"I[,H^&<]FOVQN;99OGU1R7>WOCEZ(55SO:Q5V M53'?K)[RFKEL&M'C6)Y)__]*\_;TW+?\\XMBULU\.;8A#QK`1S"8;Y7M`M-RZNB/TSJ_*(R/8-K+XG7S12@:P44PV MMLJ]G>EK!*^_`"LL,GNM8EX]2UZI=+6C6QMJIO#(W#4>\]EN\0!X!=+&8F22 M*I".:?J!=#X42&<<2!?URD"ZV=^8.&E$(UU-G6092+'2?E7IH"M9>X%\R)(C MEARSY(0EIRPY8\DY2RY86/+(DB>6/+/DA24* MI`B%`BEKEKBMY42!E'V6!*[W,9A4(.6V#"H52-G'X%*!E'T,,A5(V<=@4RNK M[)/I;$]RCT&I M[A%F'X-2W2/,/IG2AIS-Z7RW>`>)LFGCTIV5MHJ'CVM%=54QW=DNHU#&(`-0W1S,/AG0]I"R6[XR6U&530PZ4Z:S:6A[NE$.@(%F,M!49.4. M9S3;Z;!=OBI;H15-%%K'-/W0NON=H751KPRMQ;2+DT8T-NLZR3*T8J7]JM)! M5[+V(OJ0)4-6]C&PU(];V<<`4S]N M91\#3:VCLH\!I]91VRC\&I;@=F'X-3W0[,/@:GNAV8?0Q.=3LP^QBW`[&-PJMN!V99]#&(5:=%' MD79,TXNT4ZVX]I_F-'Y#\*N^'V5WYF64;45C4;:3=%&V*UE[E;S?27*E@ZYD M;:5#EARQY)@E)RPY92:)36/+'D MF24O+`G!T$1#DPS-GJ%9$KB6MV`P&0PH@T%E,+`,!I?!`#,89`8#S6"P&0PX M@T%G,/`,!I_!`#08A`8#T6`P&@Q(@T%I,#`-!J?1X#0:G$:#TVAP&@U.H\%I M-#B-!J?1X#0:G$:#TVAP&@U.H\%I-#B-!J?1X#0:G$:#TVAP&C.G[2K/;+>Z M0S-F3$@Z*Q?_X[01 M-4>2'?TH8+O\,J15;+W+(72O5V=[/M_8+9[WM%_5.>A*UEY('[+DB"7'+#EA MR2E+SEARSI(+EERRY(HEUZVD'>CZ53$W/<'KRW.+<\IM3S%96!2*NYYBR..^ M58P@\<"21Y8\L>29)2\L469M$!K9I)`Q&],DPR>C-^:SA&\M:LJLW&>#1V56 M]C&(5&9E'X-)95;V,:A49F4?@TME5O;)9(Z-:1_.R7P^*^]#4F3EIC*?8TUE M0ML#10VY`BNW9!"JP,H^!J,*K.BCP-IHFJV:;6]43^+/B#:*YHEI_?N[E597 M3:;UKE%6Y:X8?"JKLH_!I[(J^QA\*JNRC\&GLBK[&'PJJ[*/P:>R*OL8?"JK MLH\!J+(J^V1`1R!66&4?`U&E5?8Q$%5@19^4$1W9+B56]LF4COD8G"JQ@-!F4)H-2Y57NCT%I,BA57AUKJY]7IV_,JPM]/Z]N%F$T3AO-&-N= M9)E7L=)^5>F@*UE[%7W(DB.6'+/DA"6G+#ECR3E++EARR9(KEERSY(8EMRRY M8\D]2QY8\LB2)Y8\L^2%)4JM"(52*VN2H=DS-$L"U_*FU,K],:!4:F4?`TNE M5O8QP%1J91\#3:56]C'@5&IE'P-/K;2RCP&H5EK9QT!4P95]#$@57-G'P%3! M%7T47%EC<*KLRCX&IUII91^#4ZVTLH_!J59:V- M:#2^9LDRON:2M5?&^YUOKG30E:RM=,B2(Y8(K:Y*AV3,T2P+7\J;XROTQ MH%1\91\#2\57]C'`5'QE'P--Q5?V,>!4?&4?`\]@\*E55V[+(%0W"K./P:AN M%&8?@U+=*,P^!J>*K^BC&X598W"JQ5?V,3C5XBO[&)QJ\95]#$ZU^,H^!J=: M?&6?S.E$/XY8/(E4[Z4N?OBHM5>V,3#5VBO[&)A&`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`4S&6?0P\%6/9QP!4,99],J,C)P_%6/8Q*%6, M91^#4\58]%&,98W!J6(L^QB<*L:RC\&I8BS[&)PJQK*/P:EB+/L8G"K&LH_! MJ6(L^QB<*L:RC\&I8BS[&)PJQK*/P:EB+/L8G"K&HH]B+&L,3A5CV)._;+0 M-&T$JR^%[571.ZN+->;]JLI!5S*277,[:R5'['+,DA.6G++DC"7G++E@R25+ MKEARS9(;EMRRY(XE]RQY8,DC2YY8\LR2%Y8HO.+D57AES1*VM1#H7F+V61*X MWB*KNQC<*KHRCX&IXJN[&-PJNC*/@:GBJ[L8W"JZ,H^!J>*KNQC<*KHBCZ* MKJPQ.%5T91^#4T57]C$X571E'X-315?V,3A5=&4?@U-%5_8Q.%5T91^#4T57 M]C$X571E'X-315?V,3A5=&4?@U-%5_8Q.%5T'?/I1=?%0YR^Y]%.K_7Z$79G MIXB;L14U%[*;NSL[_5N-4_OO*PFV*WE]\'U?OM_]8[?RVI6LO9H^9,D12XY9 M2<)1MSSKH@T%D,)`,!I/!@#(85`8#RV!P&0PP@T%F M,-`,!IO!@#,8=`8#SV#P&0Q`@T%H,!`-!J/!@#0:D$8#TFA`&@U(HP%IS)". M'#2BP6DT.(T&I]'@-!J<1H/3:'`:#4ZCP6DT.(T&I]'@-!J<1H/3:'`:#4ZC MP6DT.(T&I]'@-!F<)H/39'":#$Z3P6DR.$T&I\G@-!F<)H/39'":#$Z3P6DR M.$T&I\G@-!F<)H/39'":#$Z3P6DR.$T&I\G@-!F<)H/3O7%.^^%U\IWA=5&O M#*^[_;09-QM1NPHSV]G8+A]+W"HF4RF[9Q=OSPNCO9[1]GR^L5L\`GG?,SIH M92,G[4.6'+'DF"4G+#EER1E+SEERP9)+EERQY+J5-%-B=V,Z*[[PN.D)IE*4 MD^&VIYC,=W?FQ62XZRFF$FP43QJ[[REV=6=`?^8^]/Y]LJE[!_J"QU8P,I&> M6/+,DA>6*.,VG(UT)F06QS3)\,DHCOED&,QCT*B8RSX& MCXJY[&,0J9C+/@:3BKGLD[D<&]-,YI@FLSFFR72.:3*A8QH#4L5/+Q^)W&FXNJ1=+=VNK'@=B*FEBS MI3@[+Q)':A7]I#O;+5Y+OM"8 M&SEAR6FOF:$'>YWU%$,_]SRO%?T1NN@))J^M]!67K6)DCUVAR36;W+#DEB5W M++EGR0-+'EGRQ))GEKRP1$FW@7%DC)1T69-I'//)*(YI,HQC&H-$)5WN9A9.!9VMH-9>;,B#5:B[[&)!J-9=]#$BU MFLL^&=*1`YU6<]G'P%2KN>BCF,L:`U.MYK*/@:E6<]G'P%2KN>QC8*K57/8Q M,-5J+OL8F&HUEWT,3+6:RSX&IUK-91^#4ZWFLH_!J59SVC[V796+G7%S48T6 M/++DB27/+'EAB=(KDJ3TRIHE;FLYT;W([+,D<+V/P:32*[=E4*EU6O8QN-0Z M+?L89&J=EGT,-K5.RSX&G5JG91^#SV``JO3*;1F(*KVR3X:TR0VS^I%\2J_L M8D"J](H^2J^L,2A5>F4?@U*E5_;Y?Y2=VW(;1Y9%?\7A][%%D2(E1;CY;MG3=%H/OV\(1J]Y0N7 M7+KDRB77+KEQR:U+[EQR[Y('ESRZA#2K/)%F7?,*W5):2+/N\\KA8TU`)VFV\7[>C3Z9F(UMJ!87 M;DP"1,FS[M.$]-W[T=F:G+X;[5AABVWC?./-#N3:EFKT><@VVY9J](%(MFVH M%M\[V;:AV1RM,&*K;4,U<@JH9:NM^P34LM76?0)JV6KK/@&U;+5UGX!:MMJZ M3T`M6VW=)Z"6R5GW:5([ZHV`6=*MGRM@EC7([M,D=O2>F[R.-$U:1YHFJR-- M0"KI5G\NUB"[)N"4-L07:? M@%/6(+M/P"EKD-TGX)1TZSX!IZ1;]PDX)=VZ3\`IZ59]2+>K-(OIEJ7&-=W. MGO4BX79VW&*XW:SA=B[BS0S;:$>#LFZ]E_0Y=7NH+#UH9Y#T!^T.E:4'[;ED MWR4'+CETR9%+CEURXI)3EYR]2-;>OOG^^>%3")9:5ON$_`W>05PN4^`)*G6WW,`):G6 M?0(L2;7N$X!)JG6?`$WF:-TGH)-4ZSX]GW_Y'!A]5A-IW28`E"=&S7U>3S4. MEP&@A%E_-P&B!%GW"2`EQHY_JO$'*1EV+!G]X,S/FB+@D]E9_9'(KZX)^"2_ MND_`)_G5?0(^R:_N$_!)?G6?@$_RJ_L$?+*XV'T"0)F==9\>T!4#-V9GW2=` ME-E9]PD09796?-T>Q9[H^%ZWZ(!@D?1#='BI+ M1\8[@Z0_:'>H+#UHSR7[+CEPR:%+CEQR[)(3EYRZY,PEYRZY<,FE2ZY<7#)HTN(KTH2\=4U7:`)`"2^^KD")HFO>2Q^P1TLD/6?0(^F9-UGX!0YF3= M)V"4-<;N$U#*;*S[!)PR$ZL^1%C7!*"28MVG![6'9W-C;?Q`/'+LW&>N>;^Y M]?;-AQ$[Y%@_5P_JBE_EY%CW"3@EQ[I/P"DYUGT"3LFQ[M-S.O]WGN^1'7^0 M$63=*`"5(.L^`:@$6?<)0"7(ND\`*D'6?0)0";+J0Y!U30`J0=9]>E!7P$.0 M=9\`5)*L^P2@$F7=)P"5*.L^`:A$6?<)0"7*ND_`*5'6?0).B;+N$W!*E'6? M@%.BK/L$G!)EW2?@E"@[]WGY8-W@$1C\&59>+&;9K7&6E0P[TX\R[-;HUM!T M?2Y:Q>X@Z>/H]E!9&D=W!DE_T.Y067K0GDOV77+@DD.7'+GDV"4G+CEUR9E+ MSEURX9)+EURYY-HE-RZY=0894D,JQKND`3`$B&]7,%3))A MW2>@DBE8]PFX9`K6?0(RF8)UGX!-IF#=)Z"3*5CW"?AD#M9]`D*9@W6?@%%F M8=TGH)196/<)."7"J@_3L*X).&4IL?L$G!)AW2?@E`CK/@&G1%CW"3@EPKI/ MP"D1UGT"3DFP[A-P2H)UGX!3$JS[!)R28-TGX)0$ZSX!IR18]2'!NB;@E`3K M/@&G)%CW"3@EP;I/P"D)UGT"3DFP[A-P2H)UGX!3$JS[!)R28-TGX)0$ZSX! MIR18]PDX)<&Z3\`I"=9]`DY)L'.?>8)=WUH>7]__S?@ZTR_&UXVR.7:N69E> M>TD?1+?7^\K2(+HS2/J#=H?*TH/V7++OD@.7'+KDR"7'+CEQR:E+SEQR[I(+ MEURZY,HEURZY<YS\NGW/MW;T>+09A^]3,%6#+]ZCX!F$R_ND^`)M.O[A/`R?2K^P1X,OWJ M/@&@3+^Z3X`HTZ_N$T#*]*OZD%U=$U#*]*O[!)0R_>H^`:4\Y,E]`DIYR)/[ M!)SRD"?W"3CE(4_N$W#*0Y[<)^"4ASRY3\`IVV#=)^"4;;#N$W#*5_&X3\`I M7\7C/@&G9%?U81NL:P).V0;K/@&G;(-UGX!3ML&Z3\`IVV#=)^"4;;#N$W#* M-ECW"3AE&ZS[!)RR#=9]`D[9!NL^`:=L@W6?@%.VP;I/P"G;8-6'[+I*LSCY M^F&<7G]CRVJP#79VW&**Y1MEAPG>G[_[\L_OI^MST7`Y<Z@L#:$[@Z0_:'>H+#UHSR7[+CEPR:%+CEQR[)(3 MEYRZY,PEYRZY<,FE2ZY<7#)HTLFDT`S#32ON"WE9!(` M.'DE<+E/P.2DAW(^M[ILEVSP@P5<3@(P)P&9DP#-2<#F)(!S$M`Y"?";W^@-0IP&H MTP#4:0#J-`!U&H`Z#4"=!J!.`U"G`:C3`-0N`+4+0.T"4+L`U"X`M0M`[0)0 MNP#4+@"U"T#M`E"[`-0N`+4+0.UZ4%=\D'4!IUW`:1=PV@6<=@&G7\,DOZ@W:&R]*`]E^R[Y,`EARXY`DQCK/@&>Q%CW"0`E MQKI/@"@QUGT"2(FQZD.,=4T`*3'6?0)(B;'N\PKI4G:(L>X3<$J,=9^`4V*L M^P2<$F/=YY73^8?8^(9^P"@)UL\3,$J"=9^`41*L^P2,DF#=)V"4!.L^`:,D M6/4AP;HF8)0$ZSX!HR18]PD8)<&Z3\`H"=9]`D9)L.X3,$J"=9]71I=^AI%@ MW2?@E`3K/@&G)%CW"3@EP;I/P"D)UGT"3DFPZD."7:593+!O6PG6'UF\,3MN M,<&^?S?ZAH;IBVC%N+L;)'T8W1XJ2WMM9Y#T!^T.E:4'[;EDWR4'+CETR9%+ MCEURXI)3EYRYY-PE%RZY=,F52ZY=3>)0\N>70)"7:.VPJ22+"N M><5M*2=,QKK/*X'+?0(F2;!^KH!*0JS[!%P28MTG(),0ZSX!FX18]PGH),2Z M3\`G(=9]`D()L>X3,$J(=9^`4D*L^P2<$F+5AQ#KFH!30NSM">2_9=X/?V#<^!7APZ'+K'D4N.77+BDE.7 MG+GDW"47+KETR95+KEURXY);E]RYY-XE#RYY=`D9=@[;"H[(L*[I`DV`'[.P M?JZ`2#*L^P1,DF'=)^"2#.L^`9ED6/<)V"3#ND]`)QG6?0(^R;#N$Q!*AG6? M@%$RK/L$E))AW2?@E`RK/F18UP2M:NJFEVUJZJZ7[6GJHI<=:(CZ5:TMH:UY]X4'6-#F#X7W6- M'F!X7W6-+F#X7G6-/F!X7G0,QVNMT0<,MZNNT0<,IZNNT0<,EZNNT0<,AZNN MT0<,=ZNNT0<,9ZNNT0<,5ZNNT0<,1ZNNT0?31A\P2U*/;?0!LR!5U^@#9CFJ MKM$'#/^*CEF+6FOT`;,25=?H`V8=JJ[1!\PJ5%VC#Y@UJ+I&'S`K4'6-/N"N M?]4U^H"[^E77Z`/NVE==HP^Z1A\P?*G'-OJ`X4G5-?J`X4?5-?J``<9?=8L# MBMD7U__YZ0\&"6L?U][PM]GNI"W^^_-_OG[[_._]IW_].JNP6$R>O#$S6KQ- M_JY,)<_6C,V&(SSD$L^OS[>6WWT8W4SO7E7]H&6[EG9J:;>6]FIIOY8.:NFP MEHYJZ;B63FKIM);.:NF\EBYJZ;*6KFKINI9N:NFVENYJZ;Z6'FKIL988C@R7 MN[^0#$=JK7'!&8Y47>.2,QRINL9%9YM+U34N.]M8JJYQX7G:0M4U+CU/4ZBZ MQL7G:0E5U[C\/`VAZAH-,&ET`,.1>FRC!QB.5%VC"QB.5%VC#QB.%!W#D5IK M]`'#D:IK]`'#D:IK]`'#D:IK]`'#D:IK]`'#D:IK]`'#D:IK]`'#D:IK]`'# MD:IK]`'#D:IK]`%WMZJNT0?)P9/;EPV4X,IND_[O#D?FW&+,Z8!AH M;'X8?UG3QERT,!S9_##Z'I7N5=7_%MNNI9U:VJVEO5K:KZ6#6CJLI:-:.JZE MDUHZK:6S6CJOI8M:NJREJUJZKJ6;6KJMI;M:NJ^EAUIZK"6&(\/E[B\DPY%: M:UQPAB-5U[CD#$>JKG'1&8Y47>.R,QRINL:%9SA2=8U+SW"DZAH7G^%(U34N M/\.1JFLT`,.1JFNT``]7JKI&$_#PI*IKM`$/1RHZAB.UUN@#'G94=8T^X&%& M5=?H`QY65'6-/N!A1%77Z`,>-E1UC3[@84)5U^@#'A94=8T^8`UJU37Z@#6F M5=?H`^Z.5%VC#[@[4G6-/N#N2-4U^H#A2-%Q=Z36&GW`W9&J:_0!=T>JKM$' MW!VIND8?<'>DZAI]P-V1JFOT`7='JJ[1!]P=J;I&'W!WI.H:?<#=D:IK]`%K M$JNNT0>L.:RZ1A^PIK#H&([\M38?COSX];>GIV_;G[Y]^ND?_W[Z\NM3]_3[ M[U^_^_GS?_Y@//%VC3L70_F[+T^__/-[[K%\?+[1PN^6T4N,<6NES[.+U;:[S23=8^=CO-5PYXY;3YROD:)VJ],GW[L6N]M>VW'W=: M]65O>;9>?IVL?F M^^+DS7/?X+/?/,$AK[1/?//3[\^G7SZ\NN__OCZW>]/ MO]`];WZ8W5[[,K^O-O_+M\]_/M]B^^_/W[CG]OR_OSU]^I\GOHKES0^(?_G\ M^5O_%YKHQ__[_.5_GSOTI_\7````__\#`%!+`P04``8`"````"$`PL)_<_`$ M``#W%```&0```'AL+W=O-^?V?ER^1:51U7!SCC!5T8W[2 MRORZ_?67]8V5K]6%TMH`"T6U,2]U?5U95I5<:!Y7"W:E!5PYL3*/:_A8GJWJ M6M+XV/PHSRS'M@,KC]/"1`NK6 M)W/,Y7'Y^G;]DK#\"B8.:9;6GXU1T\B3U;=SP6DL++&W7QQ0\X&$W2GK:F$]DM7?N0H^#:=O@%V&ZU.0 M[[Q#)FS222(2DD@&]A(0>&&X;`%)&=3X?&4^G"X'PSMO+*9\"+@C6Y[;Y ME2I2*?F=@'39%8@( M=#U)ULC[]>,:LXVM,EIE9 M'LZ8P!]D&2'BV**U#/8-1$-(*L'$`ZNZH=4&WNU(,,L"PAIT83<5*,1>)APO M\KO=AZQ.&3/ZGN/@XX#4$WL[3*$.(5T-"COCB*R/=_A>[Y[0A_,`FG*WFQOL M[QV$QF^.-:A%9'W_:[8X([-E4(,"ZM6@4J5['2&K!&5W0&9DF4?=,)E8R0MAG^*3C+S60L\<)G`9)13A3*(X# MN>5TI22$WF<&/^;H[P-%*=XOC]4#!A//F?`8)J?EF>YIEE5&PM[X&9(#4Z#] MMCW?>G+XB8;R_0[.O9I#(JN]`,=.U_A,_XS+A%"E)1Y: M79O#GP.KX<"I>7N!`T8*)R;V`N`38_7]`S^/:8\LM_\!``#__P,`4$L#!!0` M!@`(````(0!_"D9@O0(``)0(```9````>&PO=V]R:W-H965TOWO,?865\_UQ5Z8E)QT6385:UD).\&U97K+Q:16Q/>8*NPDG,T1%%PRNX$/=2LT59$LHIH\*]*WJI7 MM9K.D:N)?#RT5U34+4CL>,7U2R>*44U7#_M&2+*KH.YG;TGHJW9W,Y*O.95" MB4([(.=:H^.:4S=U06FSSCE48&)'DA49OO%6MREV-^LNGS^<'=7%-5*E.'Z1 M//_&&P9A0YM,`W9"/!KT(3<_P6!W-/J^:\`/B7)6D$.E?XKC5\;WI89NAU"0 MJ6N5O]PQ12%0D''\T"A148$!^$0U-RL#`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`A>FY)=`YNNU204^='\)9/[`S4%[IR\.\==KDPX.^758?5XO]O^NI*SB1RB_>?*/3/ITR\'<1*+'EJBA7YB$A'I5T MVTMP__V8<_+W-W]+UC[Y3#',.#I1"@@W#5W9LEE0\0J\O'2):E!PN>&"+EL+ M,\:&ZV$BY]SJ*HTP8Z@T`R*H?BLHN*R<(=L.,X9L)R`"V:Y9T`L*+K:32NK5 M[WN,WD)&708!$VQI:!:,S(*Q63`)"LYU,?9G&A#!5F9>P;E1YV;!(OC(;T67 M`1&(JE.7/)6<.N"IY-3ASKJA=E>A3JC\7J@=RY2QE\KOF87CJ?WHD8A^F$NE M]&92?E>\U#:5_9YXH>SWO(N24]>3?;T1JY_\+EFF^3UZ9!/8VJ5=6P='K!@4 MG`^8L0.E,)'.Z/M8]A!IL5-8&"*5,)%+&2K5*":K;ZD69HPMU<-$+F7D1R/, MF+O4#".YM-%NK2C&J$X[S)B;ZH21T*:Z8<:4Z8617#JG'[Y^F#'J.P@3,A;2 M589AQFC*49C(I8U&&$?^/@[%Z%&.T:B."21OF:5HP+0NF;<%THABCFW6C&*/7]Z(8 MX_CT+9B!!3.T8$86S-B"F5@P4PMF9L',+9B%!;.T8)2R@8HVD.]+S89IH^E5 ME%=#4)190U"46T-0E%U#4)1?0U"D8N:UXORDTKS:IVHQWW4P\)&;J>KO!R&6-`7_08:;$SHP]N2DB4D:@@ M446BAD3=(_+'&U^%I/RG[TD#%9I(M)!H(]%!HHM$#XD^$@,DADB,D!@C,4%B MBL0,B3D2"R262"C%"'M.L>D4NTZQ[13[3K'QE.^\F!11;#[%[E.Q]M,&-W*C M7DO,^,&-2YM):5Q4%3TF9A]+2)21J"!11:*&1-TCD3!=N"\99H8$*321: M2+21Z"#11:*'1!^)`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`=E3L""J[%D1!+5,V*,QR11 MF;$PHBS,8QT+*\I*/=:Q,*.,3%G'PHZ2J*P3.#*R2^B!ZDYR-P/5*<@@&D:H MWN1XJ8T-Z,@_1E&BY$V M(QU&NHSTHI"L<2.C'P7I^S2(0K+&PYMA%)0SAH"C2,A(M7$D9%S<3Z(@O=K3 M*"1GW-Z:14&ZSIR1!2-+1B1GT7F2L\Q8V%-REG4L#"HYRSH6%I6<99U(D^J- M)3G+.O$FU8-6SGFAH+48N;H?,^X$Y$)W`CPHYJQ:1YFGF-;C MU5W>8(YC+>+56Q6A#6-SH1L#N'2BY+X%C.(5D0JK5!FI,5)GI,%(DY$6(VU& M.HQT&>DQTF=DP,B0D1$C8T8FC$Q]Q+-T)G5KCMIGK#%G9,'(DA&)5O2(1"LS M%G:4:&4="T/*L)5U+"PIPU;6L3"EY"KKQ-M2SU5W,<0?Y*JWAD+/5>.V8=%] M'9R$IM3DCG]+]^%*)DHYDLOG4K7'*+FM(-IG-FF^8J?A$]%GDN)VJ M)N)D,WEC*S76J#/28*3)2(N1-B,=1KJ,]!CI,S)@9,C(B)$Q(Q,?\7IE2IXN MZ5URRA(S1N:,+!A9,B*9:K&PFU6;XV%GJ/&S<2B^V+,^,%GB9$R(Q5&JHS4 M&*DSTF"DR4B+D38C'4:ZC/08Z?N(?X$F%U7F0\P!BPP9&3$R9F3B(_[8LU`P MKJNF+#%C9,[(@I$E(Y*DZ#,9G3)C849)4M:QL*,D*>M8&%*2E'4L+"E9RCKQ MIM33U%T9<9FF[G35C`R`(56]!15ZJAJ/,XH.KKHH,5+V$7\T(>MZPM-9*BQ3 MU63242HU#7$RQ_>,&&.7.F^IP4B3D18C;48ZC'09Z3'29V3`R)"1$2-C1B:, M3!F9,3)G9,'(DA')5G2;9"LS@24#O^4RH7N\DJV>CL=$WYVT\*1D*]KNYCB,ELA4[VU%WJF&H]VBPXNT"@Q4O81K_T< M)Y4SWZY<89&J)I(N9,W7^M98H\Y(@Y$F(RU&VHQT&.DRTF.DS\B`D2$C(T;& MC$P8F3(R8V3.R(*1)2,2IV@TB5-F+-PH<F%J?NEU9H<6JWLNKX,>/Y?]X8UA5]*.8D4V*D[".WQUF>SG7F5O^O\LVX M)UIAS:JAF=67A57L;..H%;8SPO[V)GG<"A<3H6IE06KI2WL7-] M+'PIW_$5IZ.GKKO2P7X0F_(61FB#V+SQ3*KH0S%'K,1(V4>""Y6H2_J*!5/E M3=48J3/28*3)2(N1-B,=1KJ,]!CI,S)@9,C(B)$Q(Q-&IHS,&)DSLF!DR8AD M*J]5LG"D9"KK!)Z,<;9D*NM8>%*^WX)U+%PIFJ>Y:@R^,4[VE"2)_GA>;-U*N MF,+U"R5&RC[BC5-SZ=2M,?N@H@&IC$Q`-N9Y57DK-4;JC#08:3+28J3-2(>1 M+B,]1OJ,#!@9,C)B9,S(A)$I(S-&YHPL&%DR(G&*1I,X9<;"C2JP8\P`2>*4 MMV7A28E3UK%PI<0IZUCX4N(T3D>/4SD^7XE3%S>'IL8JH&+*@V*.?(F1,B,5 M1JJ,U'S$R^UT7NXOZ/,8ZZS18*3)2(N1-B,=1KJ,]!CI,S)@9,C(B)$Q(Q-& MIHS,&)DSLF!DR8CD*3I-\I09"SM*GK*.A2'E.RU9)["DD.=1FVY*N8W*.A:V ME"^U9)UX8^IYZJXIN!R>6E[R>TL1]&&J,0NPF,+U"B5&RHQ4&*DR4F.DSDB# MD28C+4;:C'08Z3+28Z3/R("1(2,C1L:,3!B9,C)C9,[(PD>\KQ"+>./5DC4D M5]%IDJO,6-A1W_=73]N>'G!OD'887Q5>[]_DLQ=5?,1)274G?R-8=A7HE05'G1N9.ON0_S?>=N'%4^<>ZF4>4+T2]& M_4%>-7DG$TG<3=R<]F[_>/^Y^K'NK'8_-A_[J[?UBQR:Y'5>6F"W^>&>@;Q_ M'+:?[@5_;W5_'P__X?P$```#_ M_P,`4$L#!!0`!@`(````(0#=ZCD7QP,``/L+```9````>&PO=V]R:W-H965T M/A;NDZ7*"V0C5M\=I]P=S]M/GSC]6%LD=^PE@XP-#RM7L2HLL\ MCYU(3\=*3NDY39E^/+65H M7T/=S\$7+Y@<3P*V.X:*9&%9]5)@7H*C0#,+8\E4TAH$P*_3$-D:X`AZ M[J\74HG3VHT6LSCQHP#@SAYS\4`DI>N49RYH\Z\"!52>!Z@^2-Q.B: M"-=K8@!_WTB87Q/@^K&5H)B^3KCJE>:S>1@GR[[0Z9*>,JKWO4`";5:,7AQH M9K""=T@>C2`#-FVX8ABVX%<[`-9+DGO)LG;A%(*Y'-KF:1.G\Y7W!%M=7C'Y M%!.8B*U&R'V5M(4=V(T"'A0P5`%;]3]4(5ED%7K]7`=>RPHMR1JA4PH=>$V) M+"-V&@(Y1A'0*^,B;O>\=ER"H;L-QV-37*XPT%S#KBQ,Q%8C!ODZ\,N4G4;8 MZF&9]ZN7X+4+1@S*PLA6KS!)WTW!,@D32[MZ/A]VJQ@GA,ME%)D)NU&"X3NT M_?N52["MW'(U5YBX5Q[.HV!N2U>`D70=D"?'MV3K9[;A"U.V/+D1O'#?;AN9 M9,NWU.4*H^0G8>JGEI%;!1C)UX%;\O4S6WXRE1\D\JW^FPIDGEE!G-H;H#"J M@KO%(DE2J[FV"A&$\$(96C!>IJ;UA<$3^(%O+;3['8W19W)(&;UJW]XH"3;+ M#"-+7JXPZH1$810D]MM)`48;-OH1Z1(,O9@,)S.?1+:32#&) M[,810PU,((:3NO4_^M&2-*;'DQ;(^[6@&G#FM5%2Z\AL7U'#FW0:DI-3[TS_ MA5$5J4E(?9$;S(YXB^N:.R4]RREG`:^0(3I,8/>A=-:*YW(RNQ4/L^TM?!%F M\"&:\MRG&1@_C8,1>O3SAJ5A].K0$?^-V)&TW*GQ`43[LP0.,5/#F[H1M.LG MC3T5,'3U?T\P9&/XQOLS`!\H%?H&EO:&L7WS'P```/__`P!02P,$%``&``@` M```A`&)YJT#P`P``-0X``!D```!X;"]W;W)K&UL ME%==;YL\&+U_I?T'Q'T!0X`2)9D:NFZ3-FF:]G%-P$E0`2/L-.V_?Y\')X!- M1Y)<),$<'\[S;18?7\O">*$-SUFU-(GEF`:M4I;EU6YI_O[U='=O&EPD5984 MK*)+\XUR\^/JPW^+(VN>^9Y280!#Q9?F7HAZ;ML\W=,RX1:K:05WMJPI$P&7 MS<[F=4.3K-U4%K;K.(%=)GEE2H9Y[G]H(_&B,C&Z30R%^LN,7FN_V M`L+M@T5HV#Q[>Z0\!8\"C>7ZR)2R`@3`MU'FF!K@D>2U_3WFF=@O32^P_-#Q M","-#>7B*4=*TT@/7+#RKP21$Y4D<4\D'J@_W7)YB#9`[,9\NDCL[6?YD*-B+)`[(L34AWL()#?%Y6?G2_L%_` MI^D)LQYCB(J(SP@,!_TL!<$H!:.`VM9R`;@[;:[VW#'"FW40 M10EXZ'HE"(9(#Q[L1W['*\5)S&R`"51$/(50M`')]=H0O#3!\,XI?A2I3UY+ M3"C#&`7KJB M++A%&8)U95H*KR6F5Z:GFGZ?]`!%6'B+,`3KPGI>F6@2`Q'K`ZY!XDF(H@[G MVJ!I3!!94L_+Y=*>Y/%8VA):C?LAP@VH#=NE!\-&& M&=3;!1MD;Q\VG,#1FR&1H+YZ-$`\`I`>H8K$ECX0>4&<'`"J."T!UT2"E#QP M0C6/XW=!?7-2-6)GOUZCG`.JQK[?GI)@:EC(.B)3$%4?F'J#/D1?*B4B08H/ M=0].051]V.0'_KNRF.1H4/TX*B8)DL446#.U-KQA;9R\.MQ`+"_\=-=W5U6U M-G*N+)_W9D^?^Z?HZ\/E7D/$1$?T^:N*O&G\P,E[W.%'Y3.>+@'1YCJ>X9%) MR0_2CUBI49[2Y2&VI,V.QK0HN)&R`Y[`76B`W6KW=O#@XGE06U_C6P.NV]T- M.+37R8Y^3YI=7G&CH%N@=*P0PMO(8[^\$*QNC\X;)N"XWO[=P^L9A?.F8P%X MRY@X7^`#NA>^U?\```#__P,`4$L#!!0`!@`(````(0"^.*RQVP0``(P1```9 M````>&PO=V]R:W-H965T++^] M5:7Q2INV8/7*)#/;-&B=LUU1'U;FSQ]/#W/3:+NLWF4EJ^G*?*>M^6W]ZR_+ M,VN>VR.EG0$6ZG9E'KONM+"L-C_2*FMG[$1K^&7/FBKKX+4Y6.VIH=FN5ZI* MR['MP*JRHC;1PJ*YQP;;[XN<;EC^4M&Z0R,-+;,._&^/Q:D5UJK\'G-5UCR_ MG!YR5IW`Q+8HB^Z]-VH:5;[X?JA9DVU+X/U&O"P7MON7B?FJR!O6LGTW`W,6 M.CKE'%F1!9;6RUT!#'C8C8;N5^8C6:0D-*WUL@_0/P4]M])WHSVR\V]-L?NC MJ"E$&_+$,[!E[)E#O^^X")2MB?93GX&_&F-']]E+V?W-SK_3XG#L(-T^,.+$ M%KOW#6USB"B8F3D^MY2S$AR`3Z,J>&E`1+*W_GDN=MUQ9;K!S`]MEP#RJX2=/(7]J.5?\BB`RFT(@S&('G!2,W%-U!$9Z#(G%FGN.'\W[Y&YK>H`G/ MKRT)K'K"\+QO20LCUB=@DW79>MFPLP%5#3%I3QG?(V0!UD3DT>DQ%]=2`3G@ M1AZYE94)VQ&BW$+]O*X#XBRM5\AY/F#B*8:HB$0@>(*YV8TN2"6!!01&%I"S M_X$%M\)9B/5C(?B@I9%*!$*H;(3@0\7U5)JI@(".0@+J1R9QN?A%Q#D8RER* MN!_YZD(Q8J"X/K*B(A*!&-T7@JLJJ4#HWL,RLO=](85\NU[9Q8((UUN9$)/1 M2T&4?`Y8@(5D0J$3@Y8R.1NIX:# M=4;:0C%B_)Z1X[G$"U5/$@1X8RUNA(!O+EL%I^(WW>U`=9OGQ(7#^;;[7$EW M7_,N1@RZ'SJ1';FJ1PD")/>%X)+[XC?=_7#J/KFGI+B>SD"KA1@Q`X,@M'TM M0PD"/BLIV2\0H_="<-U[@="])[`Q[@]^CU:C/SVV!A`6V:7J M2`:$M$\4'<<.YH&VM5)91ZD>PKOCW>73HW4&VB:(!]"P37SB$6T?)0-"9H!- M&G4BVW$#32>5=50&O#5*#.X[L`@V5+6%Z"?6`$*O2.`'HL$--K MJ2QX<[R?!;92A86KU6_,1Q,XO/`^$EYJ'@-"YB#K7#H+4EE'9<#[X_T,L)NZ M_;C6'^DQF8B2J6@S%:6*2/6)]S7))[Y3/3N:P4I?'1VP0\H1G]S<8A@^^W8! MK6>\N_F32\<':NP'4Q$?9`=;8PO`P13GHHHV!YK0LFR-G+WPH3.`6]HH'0?B M1X??S31YS`?E2W)G`:/"%+]Q%C`.3.6/)`!#P85?(!1B%K?&Q6$6/F4'^F?6 M'(JZ-4JZ![?M60@UU^`TC2\=._43WY9U,`7W7X_PKP>%6`7C/6"=>>'#& M_U'6_P$``/__`P!02P,$%``&``@````A`-I/C[44`P``;0D``!D```!X;"]W M;W)K&ULG%9=;YLP%'V?M/]@^3V`22!-%%*U:[M- MVJ1IVL>S`P:L`D:VT[3_?M>8$*!M2I>'),#Q.??<>W-O-I>/98$>F%1<5!$F MCH<1JV*1\"J+\.]?=[,+C)2F54(+4;$(/S&%+[NJ^*;)D%_.#NHWG>D)9K*'<`CHRQ=?)TPU0,&04:QP\,4RP*"`#>4>")SB,\#YU@Z.PSI$"Y$TX4$8?1#>CG)1V4#-LHFZ2:4:WNC M+^._+#-_CXP!0]5ZP0>KH..URA:SZ&'"#C$P")"^09/S.?3D>:/F4(3!79>^ MD"PZ?AN!Q1#?:TK@=4\'ZM!Q??7SJ@8\4O7&A;68";[#]R@;\%L9MY@)RLNA M\K2,FT,C[V1<STLWZ+<:H05-$3=CZ-V))W9X M#7]]XUYH0:?4+P.O__)O9Z^,(MA=_Q.4'77#H,;MT%##<&]G@N_,3PC;#W;K MV:50,IFQ3ZPH%(K%WFPT`J.DN]MMVZMFV;K=`UAV-LX2 M1H.TZ])>:%$W*VF(7<_5':_@,``/__`P!0 M2P,$%``&``@````A``/7Q)@B!```6@\``!D```!X;"]W;W)K&ULG)?1CJLV$(;O*_4=$/<+F``)49*CA>VV1VJEZNBTO2;@)&@! M1YAL=M^^,PRAV)"`:OOGR4A?'.:YF+:FTRRS$-7J4BRZO] MVOSK^^O3PC1DDU194HB*K\U/+LTOFY]_6IU%_28/G#<&.%1R;1Z:YKBT;9D> M>)E(2QQY!2,[49=)`S_KO2V/-4^R]J:RL%W'">PRR2N3');U/1YBM\M3_B+2 M4\FKADQJ7B0-\,M#?I07MS*]QZY,ZK?3\2D5Y1$LMGF1-Y^MJ6F4Z?+KOA)U MLBU@WA_,2]*+=_MC9%_F:2VDV#46V-D$.IYS:(V MC%EHVIM5&Z"__9Y7'*(-ZX0KL!7B#:5?,[P$-]NCNU_; M%?BS-C*^2TY%\TV:8 M&A"1Y*/]?\ZSYK`V9X'ESYT9`[FQY;)YS='2--*3;$3Y#XE89T4F;F097=8FI#O<+F%]WC<+?[ZRWR&F::>)QAJF*N*+`I<"\'I&F/F0<3KJ%Q04 M(PJN`K)%=`&\>S97>^Y8,?-ZB4("$1J28+2\JWEP(<*;(*H#@(6_Z/T)DC3> M0!.HBOB60F$$DR'C[6BA>&U"`/K@+/Q0?7)$&K]=5G_N^D$0:&L;#R7>/'39 M4*+00;3NIT.Q1AX!$>%.L\6A)'I*%HA8O`P8^*'`\E MOA?XBD2AFS]"AV*=3DOUB#1$]Q1ZRI/;3(P5A>?/&.+U$U#HL+T-:L?M3$.Q M3C?K?6D7D(;HF.^%D$:C5!MJ1MFHX(4JWJ6TW<;$FW3,_XH!89(FI)2SM`2( MKXTJ;`QJ[#!V]\&U=^ETOA;$3C2?W!%7!E4VK,.#=;V3C:JW4DH"K8A%C$10 M+OIZHTGB3C*.KLJ(-?MQ1JKT*J-6RR)&HBOQFQY4V;!4/\Y&!5YET]L$(Q$% M9V'!:^#P,_OE2=OOL7*#,\A5E1CK]X#X]A9A5.V'I(&C-XU.='.ER6=:HO)I M7>.^OHMO:+"7(61]LHT;;R>:AJ"*>%.B!$E'&7K3+WF]YS$O"FFDXH3'%!=Z0W^U/T(] MN_C2K%V/\&B%U^U^`$XVQV3/_TCJ?5Y)H^`[L'2L.6RWFLY&]*,1Q_9\L14- MG&G:KP&ULG%9; M;YLP&'V?M/^`>"_7`$D44I5TW2IMTC3M\NR`"58!(]MIVG^_SY@03%*6+@_A MXN/#\3F^?*O;EZHTGC'CA-:QZ5J.:>`ZI1FI=['YZ^?#S=PTN$!UADI:X]A\ MQ=R\77_\L#I0]L0+C(4!##6/S4*(9FG;/"UPA;A%&UQ#2TY9A00\LIW-&X91 MUG:J2MMSG-"N$*E-Q;!DUW#0/"V,"T7F4$1B!M-QC.8_/.76YX`4]?&8D^TIJ M#&Y#3C*!+:5/$OJ8R5?0V3[K_=`F\)T9&<[1OA0_Z.$+)KM"0-P!C$@.;)F] MWF.>@J-`8WF!9$II"0+@WZB(G!K@"'IIKP>2B2(V_=`*(L=W`6YL,13^!T)7#L2=W8MB:U&U9ITCP1:KQ@]&##S M0#=OD)S'[A*(C^ZHL?1^O647^"1)[B1+;,*2`2+E?T,N:0=)CG' MN#IBKQ%<&VJ\G-Q1B@1+*3))J2U1+X"[U^:-OGN.\&<]1%,"#EVO M1()AM@P^/(^)4YC9`!/JB,T40M,&)$-M,DD?5LNT6[)3;((!O3GS:!1+ MHC!!&ZL;S!9N&(;12.40$T1>H$$TF;!HWB]3=AK+'*68*`P(&0S%'\F\A'DC MZO!_=,I.8YV!KB%1F(5:)1:;1*L^S:/1JXD"C-K MTW4LYQ17N]XW>O.I51/EPK*]WK$6KQU2YHQX$;=KC?DL%E"GM;0%E*88STK$`G%,JC@_R!.X+W?5? M````__\#`%!+`P04``8`"````"$`3Y_5O[0%```''@``&0```'AL+W=O?OS,#\)'6E99<5R*\F0J M"NDQ*3;9<;<4__W'?C!$H:KCXR8^%,=T*7ZEE?CC^<\_GCZ+\JW:IVDM@,*Q M6HK[NCXM)*E*]FD>5Y/BE![ARK8H\[B&G^5.JDYE&F^:2OE!4J933)V?MYD=//L^2LJB*;3T!.8DVM/_,C]*C M!$K/3YL,GH"$72C3[5)\D1>1/!.EYZ".IM2!%4EGJU[<:!OTIADV[C]T/]=_'IIMEN7X/=*CP1>;#%YLM, MJP0B"C(3125*27&`!L"WD&VJ?=+<:9-5'TZDP$77M.JMC,B M*0K)>U47^?\4DELI*J*T(O"W%9&5B6*HLJK=H3)K5>#ON2GCFS!O*T.-.>!]%:%>@=9Q5C8JCJ7#/T\6UY;%5DXB:-EZ+C4T+KJ%),A0EZ06]S..$@U`K\0>BE" M7"&9*N@F'\^&KC])'Y#:2GHLT>6<;L,YR*U2Q&+KT'183FK&8+UC3`CIQD"0P^0*++[#Y`H6*,O#==1)NM%FCA(D2%DK8*.&@A(L2'DKX*!&@1(@2T1#!&`\> M]XPGJX9AXTFMI0C]LC/5,+B1;T49O9DVN41=TVO0R*X^EQ0F2E@H8:.$@Q(N M2G@HX:-$@!(A2D1#!&,YK!>_83FIQ5O.360KRMRVG%X;LAPE+)2P4<)!"16QZ.;R[/#(?W7K@4F1-^:$T M0`D+)6R4<%#"10D/)7R4"%`B1(EHB@.R?7+_]D%E^!N][PX,]J<6F@:YS M;Q4KR@S8NJ:$VB2*HDW)IUO"-:EDHAH62M@HX:"$BQ(>2O@H$5""QD-NPL'% M([Q!<$ATC2@JI\)8#Z_WW[">U&*M-PS>>LH,64\).D9,)U/N%[MX-SIJLSWF36VC( M91PQ<<3"$1M''!QQ<<1K$:T9L^:SV9Q;I/H\H')A"_";A#@2#2*L]60OY'J$ M1ZRG6R?L.IY[R!79T8-!8-!ZBIP#)?-O^2:N8>&(C2,.CK@XXN&(CR,!CH0X M$K5(&ULXJ+BLP%CKR2[)'=;3395KZS7],J#0Q9U,H4'K4<1L5=JIGY^EFCM9 M(Q@;;XW#R,@W;^4R#,2S^;!+$0^_E8\C`8Z$.!(-(FP*D-V=ZQ08M[XC^^#< M+*_Q^YBK%AI,!:HS@)B="ME+AZ4`-[]9R'6;N:Y,6H-;#Z>R]BA@.XYM\]'+BFL(6QE"UQ8]H+9>E"WY+!]BQ6P#I.GAXJ(%>D5!2Y3-A@^5I!+[BO[OG>%S5GPM MR177`UW,>5^M=[ M_6RA*D%HN%O#]EQSI;Z8@?K]S:]_=1V$+[;Y\ M3,<(SKV]Z<(G.\]WC!#>^H^C8.^;QC;`G1Q[-!V/+T:.8;EJ+.'*V?`(<0S_ MTV%_MO&`[B1MYN9VW,(LKE:#D"23?7[L'1G3!0-M[!#5?J--NDQ)^\VZ[4"U6)55Y[ M6P#QN_\ MCVO%PL>QY%&BP)3LQ8\^:Q^MB/&2O2HEXO86,5 M>5&P89^Q,E^16XX9*!_,+\J/GF.X:%@ZJ47?9N9DQC_BQ4/I&;ZQ MK4DD M3XC)$[O,HA]T>P^Z'D[/FA,/P1D19$H5F[FBZ`\@+5BVG2UU9G-<#,"6FVM8 M=86F[^KP1DE>W[_L82G@P@(1O3>*O]?P[4??>)E,HX*8;X?`LZTMHGA<1PN0 MA#7KBSM]?1>-2Y#QHJ@0JNOKRQ,(O;M=KL4C72^7HH5.=?@5+/3-''\%"]7A M9RW,IDD@::)`9O*4T,*&P?C\PC" MS%1$,`<$R]EB>3$%(&-M$0TU*((9`+B@6B;SE797B4( M)'F5()#DU6C-.A*0^9-(@?:=Y%@E""1YE2"0Y-5+P1GX4KI7"0))7B4()'DU M6DT(C%5HBTN.58)`DE<)`DE>%59\)AD8CD5(]BI!(,FK!,'07DV75>NTL"Y6 M9L+JXV0L+.+UJ,?79JQHU0CKU`?/WT+/*#TH-[F`-6*\[>;:-G'OY_\,(0CO;=7&\MX]%S#1M>CM(]TK\U>\+Q4#CTN5+#)VOS"09CVFVQ M;>(A3C5"%A\:KB:T2VU\J_#J M"*%3%ERI);?>`0[%'SM8UQ?C<=QIYAVG7B`!7L*8'5D>9-ZEQ&>M2XP/9<@.;(W\_5N M,&"@>,<4SU$23/(3=N_C8V#^C(WZ.&?5$ MU5C,#[X7FILP.@TM.C94A6=6@6>2".+!TV=\K6)\L!.W/?J,#SVW4B>"7:2. M#^3B'E\D'_"$NX34X`)*ZCH\(A%`9R5%`$Z0@0!/$$QL`/24@0!6K"D"(&B. M`.#4L*)/',`1Y&Q(X$`^)(Q_JB$AQZ1:,D.>4,NJ]`OCUVBI,^FWEYE)O@6B MYV:&-S4`>@U9E6)EI1CB=HBTW`3PIL8$.LRZ8J:\257.EV80DG0!0VX12`-U M%A''2I)S88&9(21@`CY2HR.N$"3-C#&@&`D%6AB1LF,I*D12#K!R9NV(J*T42 M"+(R)/6$K!1),-C;L^[ MZF8OP$H;'/4(*S'EXT,K6U7:#"[\*EM7-Q*D$4/4 M69`-`L-"-@;T=X)!.`T%A2G,DBE$;G:R!T/Z\X6:"?$D36?8S!01G;)9(UGI MX#!=RQMQ@+\&"N!!!7X.=$I;G&FA*LP8&Q?A MMC=R)R7ZQAV3>IMF!S8O=,+;T^@-<'\Q>NGJN"])6*I#A^)KBLP"W-=+DLHZ MLIA>V`F[4RAR%QITY3%@8=27M4RN:#6=<%6]";P.LW:5/9DP.QG@QKI2+KP. M]JR:H1D"%.>V8?.`0+T8GA13PU>K%^LO>,=.,Z]>+Q(X^)*K.U29:MJ$:?_1 M+@_C8(9D[0*!FH?VY7TH4;L4$(PH)F,5`#-\IE='''!BWV@?SJ25@,5GJY24'0(=J9G.4I6(BR9NG[`Z&;[+ M+%&IQ>GLWJ8BA/,XY!&YKST!.W<5R<;=Z9(KM>=`^`3&63WB]F'&9>=73H,N M\*JFV(:@YS)7FEY;A7D5H%_F?.Z3OBJKD@:G=IIJNCB9'MP%3-RID8MU`I>9 MQ?E;5A4'9P>45W$-+NTPF7#:CQ9`_"L=R8FY"C0SFQ0S37O4G4*I0_ZFD714 MWH.N=2T;EAF=\(IDRJ0`]Y49G5"GC=%?F1:0+K)E"\DI3!*>0#34,:<35[I, M$\+;?VT*$>IDQCP-&?=$FR:IX0*=D$LJ7+%YM'"TG:T!AC,O7P8J MP'V]&8B21'B(=4DX%!`[FS8$/4N"%BF@PXJX*LJ`'MR%=&>\73,H:\UBA?6J M8ZK@_/8AQ44)WKS%EP@$H.XTT_-J4<%CV,Q-8RZK%JM4!6_,C^>(Q[>0K[M^ MJCHC?&4<+L)M3^*OE@YYEI5_+@`]F%M#S?@NS'74A&>M9#V!(8.F&1D-FB&1 MP1H2[GLWJC.:-&CQ/3[KH`GW9YNY>BKZ4M8V@U- M#-#ZF#@ET/@I&775[9!`NX0I@^_$'N^"#Z.H;,8N!`Y71=,%0;6%BL?NZKC6 MJ:)H7^)(AGB1ATN<`<,6: M%]"?V+P]\0)+'GI?24/KCPYXIN2^9$+P-+8Y<$6U2TX4QI=<.;P\OBLS>R,( M@F$Z^+5-3`."N\U4;@)V7JDT"&5).M7E/>!T2Z/9(`O+<%UT0SNXA1UY(`C[ M.)#LAG<*/EA]I4['OU7.E#<;5"SK1N%U9`\'RX9G[^&E:W@SPLTA@(=YW<8; MD[O'UVGP05M9N1_9/*%QY@FJ8^Y'UO9S M3ML?9U26\5-.QL=2W.P#7Q052H(%UQ$(;Q^ MEDO2D[GYI*SA(5Z9(#8>P23W`LA_$&FVW$9+'`F@$>\M]Y.Y99G#6A@O?N.1],$\A+Z1\8\- M*2S]N83@H]\R&6R*B)[D=EPS?H`GO:5&Q&J?Q`XN?WC&_,LA)&;$O8@0/`^8 M1\B]%<+#21-OLC&,L+A$>'#SY4S$44;AE/$WPW)HA4;YO:RA^M\^ MYX\!C.P>&O#PU>@!@=EZ``RU-7?&P0[OLP]7:O[ZS]%C?X%,R;=^L#Y[821B MI>:OW^/SE"&*H7\/Z>9]`,_HA;_*P;=6ZG_O;B^7;^_TZ=EB?+LXTV;F_&PY MOWU[-M?6MV_?ZLOQ=+S^'YC,L=W@ZGFBK=2G,-Q?C4;!YLETC.##E:CAPC>D(J"+D*;/B6GRB;@/^8 M;UNIY$T,/SKW`V##&2"I$J,`GZ;X$0>Y^3\```#__P,`4$L#!!0`!@`(```` M(0"^B-M5?I\``&Q+`@`4````>&POV MIN\'F'=("/18`DB:Q3/=MCUB%;L.HMA7?;'? M8*X&F`&$>8"YG7L]2C_)?/]:$9F1F54EJKO=>X#I1MN6*B/CL&(=_G6(R&_^ MY?WM('M7C"?]T?#;)YWUC2=9,>R.>OWA];=/?KQXN;;_))M,\V$O'XR&Q;=/ M'HK)DW_Y[C__IV\FDVG&N\/)MT]NIM.[K[_Z:M*]*6[SR?KHKACRY&HTOLVG M_'5\_=7D;ESDO^^F7YW/.K.;HOA-#L<]K(7PVE_^I"=#'T$)IX]_?'\.%MY M]LU7T^^^^4JO^&N=S>SU:#B]F?!.K^@U'Q\7W?5LJ[.:;6YTMIH/7^?C\N%V M\^%O9T,>;LQ_LYQL.L/?O^H/B^QD6MQ._JW9VY?-'\(*WQ;7_'V=D/AV]?'V9';]Z>-5N$?HZ@W#@?0+%>\3[[U^*AV>[+C8V- M3J=SL+O=(L/1;#SF]>QE?]*EBY^+?"QB9L?YM#VAM;7.YMI6I]E]F,;+_J`8 M9T>\>#T:M^=P?IL/U.!M<3<:3^&_[&AT>YMG/_R/'D()/RI&`S6?AF.[B%CD4_0";WL9#*9%>/F>%^>CIH_A3Y^ M-QK,AM-\_`!7L>.MRO/Q:(NSF:7@WXW>SD8Y=/F9(Y& MP\EHT._!C[WL>3[(A]T"GD!%31;IDU1A;+;Z"]/-)Q.Z^+KU.)_<-'\[[)K^ MFV3CHEOTW^67@Q9SG`S?%;^7%>]1MQ/X&!V=C:8W2%"W-I/F MH!>C*8*\O,W9&"4^1LFJT^*/L_Z=>'HU&Q8M,KZQ(7W1\X>:_RPJED$_O^P/ M^M-^T:9929^[_&$><7@^GK%[D0;-\8]G138=9:.KJWYW#I\=(V_O\FG_79'= MYV/3LW$V+:7CR^P5ERT"U.D9.V`YS=F@SF[[4Q'2-PL&E)K#W-(X>WI>%-GI M:%ID!\^:;W[Y\9.IJ;R5C74T?7:' M$G^7#V8%!FP5W1__R2:N$O/9]&8T[O^IZ/TFZ_!P>W6KL[6ZT3DP?MC9[:SN M[6WQSWY\H2\-T',6K-1IED\S1*:XO80IHYVU1BB8EOP<]GIPP6@(G69"OG]&=8%[%%, M^QC.?UND4L04F*2P/^7&9$]9?F\T&.3C288H.J%;C%%_N[5[S:7.;>Y[]ZBF MHVIOV^T3;2H]73BCCZZR-\P?*4/=+B+":3'-)OE@GLB`,NEB[L/OQZ,)Q!F/ MKOHMH0QC@A*B;FA)QCF6#/%;S9!`)CBP;<][M_VA@2Y3"VM9?]@=S`QNV!9E ME_D$1N^"3-"ZMBK-;Z6SNG7063W8W"56;[5Q5O0AVH?GT9#@MF-,T$J;Y_.@F1R>Q M[NPJ[PC:W,U%J($I=%O@(6HR]-,W?MUD,4_>N+^\GH^G2EK'7)L7B[Y6< M9FOB$X"'S&>O/Y@)8CQ.HG\J^M4Y"N0Q8OM(778N([/6EI`FP6IJLZXKG/LF8C_KK53>QV[?%FD0 M8Y'V.!7E*,WX%_)H)"7;3P M;(`_/VU)\=_:GS'X`C;[J_KN]8'%0%]'2\7MW6#T4+0%^._9][(U'"4TAD$= M\4#K.].+".`@!^I@\A>PH=F/I2\^=O1D\-I&CPO'1*`(H/L\K)JNX?&]?.Z\ MQ'2WA)!`I*6%?.QL%KW[U\P!9@^1K6B/EFU-I(=FT'[SL\:7KV+FY+-XPR:P M^-5E,XCZHZ%G6A@[MENB9UKOS.,95RNIM3]L!9\>^]ZR=,?N#ZA_A&"-'PPCFM&O\N:O>9T+A*-]'=3T?G^8-6-HD07QK*&8+ MT%5N=H[];+8]+NZ8<-^UG4!??JL8YI_LAV9C`S:IMB$Z)9,]Q:.`FYK-'1)I ML8L`>?.-PV1P\:;UWULD'P84#'$EQ+08EL'7Q#%NN5`X]\3U)\!Q$+;]Z9GF M65*V"FNUT,:"5_N+PET+VD/V15&P^6$G/`R?&E1MNEH28Y`9_DS.9& M-05%JY]\2E":+UWUA\#`3TA739$2]NR9>=*$FW/"'^H612]XF5!&D$9<-)E= M3KKC_IUIO&IGF^^_@IG#RXOB;@1TJVYC(^/2%IO49X-*P*!/^S*O0\3R$\W= ML;:&48";LRVG,M$2/_N%6M]K-?S5'*ED$`(6[_IDH[++AVS>WLU[\6DO2)KD MJV+@>?MG[($72.YH*.=$ZW+?L-EQ:$G"8G&;\]G=G;OT!$CL!6G^-/?64@K6 MRH12*&&176RVZLJKG^N@GV)@NV9S*D9GR@J,FZRT)G`JA5WA\WI48BBVF1N6 M:)+GW-WMT!'&1^&>R=5\8+VT\7+&>'YX?G*>O7F9G;U]IR=__CZ]>';G_7L_.3[TY.7)T>'IQ?9X='1FQ]/+TY.O\_.WKPZ.3IY<=Z< M^W.B#V2VKK(S0CW(;V68SF>WM\J\\.R\?STTC*Z\JAM#\ML3KKV:]!H70)3>J=SEAV=L;^W^:L;GRWGCU]DO[XA+`3],T-@XIF M<.\=F4H",>`\BH*O^L)]G[,?+ MXG(\TXY;GIM8?_(Z,7ZT!!,CPA7KSWOCWOKK&F]3IFQ4O$7-^/1 M[/HFZQ.MO`>##Q[66#"SDGWH]_H,M4H.MUO<34=&PE5$E3S[T[_\^7^D/__E MS_\3*M86B7KOS;KTVQO/KHF;`>A1]P^9>#@?=V^,MWH%D=21Y:,2.+G.(-D; MH@5*-5!?<-#H>I#/AI0G@!GI_JH_)O[):!.*"L;:'0V+DF'#>FSXY7CTOA]P M&&O6_\_XETS/X0"A4>[DVR>3&6K5+>*3KZ@X^)/_W-G0W[KLIFW1+343'?TR M?HG'X$TN^K=L_VEQG[T=W>9#/;W*;_N#A]"#?OC*AIQ^]_%_^QXD\_B51EJ% MO)D(O@8WK9DO)>+DL"F&K0_9Q\#?">N'2*C#*3AJ*C]?X-[R;!.U*;(N'#(D M^*E7;5]>YP\JL8#U:MM=VY.)\'YOX::Q@S M^*7_GW*S2I.^GMP1D?OVR9WTQ_A=\>0[4R"0JLW&\UBW%+RDHL@-*YJR9N)D M\VI6L*XWI30+\XK,2KC!B#8380HH$#UL.MP39VA\$D_(%:^R`)Q.T_0U"=*X MB_6PLLK'+K#C[+B?7P]),?6[$]?'>C?5Q]E3=)8,EF6JLB<:%Z]!9NW):H;R MGDU0V?:G^X(_9>@W?AW-QM+DZ]E/&!#S\UDI,Z78"=<,)]@"6I/B6JM:SPX' M`S.-X])BDG:?*"R`-K;MN?1*C$EV0P8$&%O@&@_Z9.7,]*&,I+>];H-W&A9J M^MTK*LBP0J%TX?N1B,W6D/X/"KVJ#GLS&R>[MF@?R.)B(0Q%T40`)[NV7IF' M>K5,SV056]C'0O$CF4]"P=*(MG,88P\#R+ZZ3VKK=#3I*]>CQ,^.R&"H"CI* M-:`Q/C9M+F<3\@Z3B5';Z*,TV+A/"0%SPR>C\(,%KV;2TA':*1$&)Z21&"@H M;=]S&J/V\=B;&76-M[)-3G-_=W5_Q[R]I"`H%RN><2,9W8_&A,M M`Q^%C(K&M#AXR.O\Y<__72$552ZP^_.J!6P6JYL[!ZL'6_LVYY7MUZ,9:L#&Z;P)-X\E-_\[J:P*_ MYE-EEH1(R&F;Y(28##O6('9C4)_3_(G?@BB1)),#-_UL5$64F`*3E'8)FB.UA8>FLXC]E.O(3%6ZUD]]%+6ATII[D;)X*-Q@:[1Y"( M'1;6KKJ&QQ%Z]WZ6;,4Z3I?*S/2FU31D4B_#$=/VFBU(F_>81T!45T#]=!@3 M7.A5#L%"`651&MO!URB@!BR(!`D)+.!D].-4?2WD(ZXH#P3]]3)[J M/J1L1!-#FP&/PT&V&4NI89JPFP\UWSL8NP^.OZ?F1F5P\P0PLYU&%O)W>7\@ M"3-%^!7&K'P-/ZY&D/@*+"#.P;6ZU7R=M*M&ZU59PYQ):%PU,&%5:Z@-4QI& MXZ^H\5(79!-6K+1LSQF98FE4N\&R<^&YHJ82OZB',HT.#%P'.V;4@W8R+\F&/LJNI6"-(Y M[R'9UT$%H!99Q@.\@5@7U!\P0T8M^;&M-ELR?0%5%"$NL=!1:=#1'E6H(,%" M@4(1$LG3SI-T@<7=1`U6*)IC".7'1+5N$QQ@>FL)235"H`G5*]:M@#W\"".Z M8QW_.O_=U%;;UMZ:+H6MAJBJR43N]N1F-"/,RC;P<[4#GT.I']WJOP"UB3E: MTL:Z6/G" M!EE^=05.#5M]!\;4+L;]JX&L=*.TE8HIA)@3$NQ[878\`6:U=WR4GM0Q+XBY MYH)U]>V84\%AKP*X9U-*V-&MF&0V`[Q&OZ+&` M$A`"2@&NI!A5MT9E:;JYZYGGMRP<=@4<]AEW^V,0*2H`:SF!82P(A`\DOH.@ M?:7_2KI%\'UO@R%NI6P'+O7XM]YUQ,%6E2K,:ME;2NJMZ]3L+5J"G1)C?M,X M7'(RC')ARM;'U.2DC&5-P'$@O!FA6!P9YMP33!<;"2>HW#A(1/&>@D.V1$ZJ MU>E4G@\5I([74$O!+&)OM)-HF!N4[0C@S@&-GG."VU($EW&"+N1LP!1-C3E1 MW.L]9*.K7H&ID4L5[1\L9KY?9#H:*TM&,>ZEA![A9(QUG-ZT5LY'&Q?3V5@! MSTFY(:0VK$HR0.,;ED>DL9L+8JFQ84SW6M:AL!.,]^]*-TMY7@@5^Q:S`FU& M]\X.LE3A46OC#BL%IF;G`.P[F09U\0/_4LDG7A\$;^XG6B&G"J-KO=D-9@7Z M#\RG91QE/#PZX,I:F#1$<#$0L[&@'K.8WHR+@LB54(!5(;K)(SK/[!E=HA[,YE^S.PB>2(AV M3,IX6WV:RN&8C(&+R%)1?R-BO1%F!OQ.\#H?LX ME%L'O-.S(A:TJ^)"HI%8FGDMVC(!Y;'9._BJ#(X)>!L](]LS>]>9U3@EF9W) M&SL3%M5:B?*J.G`$K9M"G3R*)E<;7*U1&X&:@*V8:RQ@=MU(1:#%!1QYP*HD M*)4]F"B:0.MQ?D_8>F@``6IA#2BMDB]D[&>(4;T?GIUD3Q4TPZ3>68*N6]!0 MM@7%+@W#Y(E&7M!67F5>G8J*ZOQ!F$BZ MA1D*LCPT=$&.K8D'I%MP.>[2AP`=!W,8&8$155C3ZHVI9)E$D:7 M!#,QQTG/KE#8="BFI!#=2^KCQIH:$%<08T4TO(-)5^!B-0$)0&[XCG\86@(H M"0]PW$P(GC/*H%CK6;I2^^BL;_2.]NQZ-.IA!:D7,4<;W82*D$IH:"4!UHHT M256Z15@$8CC2V(SBV.QT$LC^X+2R[=;YM(1YX8X5XH\L9:73V5O=5PYS:>"O M\B%/4`]CDGRR/^K@2#%;'88U<;DZ0-#0FUXQDRZ!@I+E/3\S>J6^$'-+"US$^$]E%T-8%,N.9!%@4,4` M`BG5QBN1:]/BM;!2%)*[%`I^&D`QT,R"'LK0A4?)^["%5I-GU%C_(G4Q(2,@ MJS_E8"Z9R"2'`!J3HG!M0T"J6Y!F-B_<'IA$DW1V_H":N0-N3D'"8)?(U$D%@'E@$)%-JR?98T]S@F M+W4A#OO4/EB?FJ_18`H);@'F@N/)-%I*/%2=FE/U#BTRF@&O5$-3,JM<*O0L MD07V4?I('1;,!L%3%8(/H<0+1_B5W#%4(`N9IAP4B0DPB,5:U"R.8"_U0HQ6 M!6?0P&II%I!9K,1&6E#^;D:MPT3N9`VU61/V=IE2,4<(BF.$V)1[G.>9XT(% MKEAPF)Y6RX"=@_7=+XRU.COK6U^(L\0\4SLB&URY24/;9"\UT^73V*0L.1VZ M/BKEF6(81+:S48Z9PMSZ^.O9,=`>;M6Q;'?T0N,,0J&U9=PZ&]Z5+(4;.D_X MD(?CK[W1N,4CQY4&F*LPF_KP@B7'<4NX)-9/6#A5,0@_Z0"P%`QC93XFXL:% MJ@U>+0$!Y&0O./>$"K,H>!=[BT)F^U]7<:-@<>!6.%0;I97.EUA&CAXN=E65 MBX2WTZDY+(T*$/FWBG^+;EQ1U(!T!6[!R(,.3#TI`]&3':N6RP3%"]4/B^9C MC,>>U]D`G9?H5]_8I*]JPD)#@BH$APV*Q,`E,$DTJ([I24?2%N:4K5\S[8;6 M1&9S*.#Y6#&2XEDH107\8!_B$*8HQ--)9]Z]"[`CM3)SYDX2I\S*L9%//GDO)KYUWR1'R2^A800U-7?4F`QD66YS)X5R: MP28*%BE:*>0CRB3^A%YV#"!2A'UD,GSLD^>E\[M&`TI*I/ M_98\!$?R_NZ3E21V6P'M^62PC&,XP1HS'"UY"+'JRR1R5F=.20B_Q)0'/`9[ M*69JP%IVA"FA9B27#5YS?Q8=5JF;A+,3`7!+%Y8%+8,A#RX/=I6;&8P7/5.F M*0VAO:L,LE4Q9A!7:<^G62\?U-=LFRW^1_XM^`8J9`*`,<0".(A?60*#?ZD%?L4DM#E4-$11Q,( M1UDO4MMRCH>6,Y!8*5%$05W`@3VW^'::`=:'RLBU0BL*6OJH(0@.`*H=FV!= MDD`[*ZLZ!S_6"NK.E5PA?(TI"Q*E[(ZS7.E4UT8)9CP$]?G;%J4J_RW;,^0P M6;Y)Y>J%G>6D&CS40JZ(D8[N-3$8/O5FFI925I)ED$Z+F]9LL=+\X25A4=L] MTU0$:FTGFZU>Y9>+^[PH!L7=C0IO%@[[QB["J)X;52QIV1I)QSI4I%%CH7:K MR>1K12Z2XI$['+E''H0!5;I?;6G&5I+"$)K<0G:[#$RC7\`SVA1L=F6[ZOD" MG'L\$)QJ;5O@`@%>A!J)@%L5S#ZL;V)`5X_S%-ISE3B55J0Y M"<&B3C_E%\NC6NEL4X/3,;ZP/Q]L-P!I^;R281:CX!.>?48%A=_:^Y1 M**5A8V0;&K7:&JY.7"(`RBNF]BA'-$I3G&2SV*<.(>QUB"C$3+=L8)RQP8C.U7)^9$#/Y)M4)!D+B M!I.1@TW"\;DR%C5I3Y# M(XXMPC!,=C&?G($`E<]E*]3HY8UMA!IP"*O091GREY_(O"-!B?P:-C8W0IN, ME%U2.JC<,IL"Y5214TLP$D'CYRK(J%PA1;W1FL/@29GN&R%^_C_4Z0N(W\>) M1[-'']*8"*?4\KIR.J!(E?684IZ@S%JI%XUS8`?,AS^#H(H7B15CBE+<$K*J MYG.R\QX/JIS]0?\7E6IY1Q/"$IY;PD$-;&)\X5[0B> MVQ^LXH/Z'FB.8%^"6F*\RM9K@JBG*1&)4:YG/UJ9F4B<$-'U@,ND!;E"?1-F M4"6`3SVH&3`#)O%6(03^2R&LVVX:X.%&:LZ&,+AG=LI:PQ`8\^BC3&RRBLHJ M93FW"\'S04;_0*1G`GB16VD_^D089U&)Y+E=NO+4E#\A05B-SV#AH(P4XUA4P3*(U=AY>GPCQNT1BN+6Q?JOQMVVM-H(E$L\;$]5OBBG)D(.H^"Z6*"YUJW M=:>$15[ILJLS-OM<+/-8T=>;BMZ+%WQL10_)I:JB0@GV0.X4+U)+=VRO\LLA+1Z%MQ$T.,$91@L=$#P%`:OS97)>8K" MYUJW7!B[&45(=@QE=6%W!"I5&?<`SL-6#E6*H?@+?H*JVS"]T)'<6T#%9:F? MDO!KY5P1L9"GB@V!S_C:?DM7R>9H9A)7<6%.^7#.FX$,7[LZUI^U?]2]C[N" MMOS=+&0(2[M."PE70F`6.J3?4)PQ+.Z53/.KHNK#>78&NHQ)!A+<5U3)H9^< M'5,$Z.9#F\TRA*?958$I$OJW3`.:&06AO*-\!+FDD;&/TS,2":FOT3$GFMH*ZZXKFFFWY%?M]B#DK]L(0P=TI[-AF^+>@"[%?P\"M6FT9MB!5JJ ME0LP"B4)X>;>RH$OM7I:PH2=K$+*F!F8"M5-&:J7BL?HL?,MJ!:O(AR7;X4) MF3//T@``$=HA,8,0&FVN\:<`M4N_0-X6GH8L'].BKXHYN$C(=NP!Q>$L+AL; M@)F8@\592(+=U5D5B!MQ?#PW8*$M=QCEG'R22*WUO3P\>9O][O#5CR^RUR\. MSW]\^^(UUQ&<-Y?U4OFFWZEH"8T4RZFY`F_A;0&+7EARZ'^3I-)C9@.'+@@! ME?PSU\\.&X&8E-ET-B9)?BEEI$TBUR#JFPLI)83\SY'&M)\Y-E.QHP0+108$?V906;R(/8(79;/PWOB/H]:DU#\M>V)3K\/1OVJXR`5&$!NB@M,A?*SN MDT"->.&>"Q[T7T%!0;E/ON/2#[/`6#&LQ;MAIJC]1_!@T(/56)76FXL.+U": M91,&#HAT_MH5X4C4I=9<38Z1E5P(%K&R.5YMK'`[U_KC<;?N8WE%Q'Z0=;[& M$_=3.ZSTCS.L@VK3K.#=9,9J^N+AP9)4J$"2C';C#]21"4C]`<6KC/XJKK+W^T`]I#:?_R@DIS63E23H3GU^0F!CQ]"(J0*_0.E3_2TT[H3^@4ZRC"/?1*CV2$O6'6U=2FMI`!"$NB5#B.K6ZH>)BFA M#1Y#Q;`*-:0S(FMV9'O-KS4D5KMZG/21GFL0@>/R#"FPOG()*GNGP8'V'MR= MJVN.O`^G*#.2,G?9BHSUZ3J?UZI)DK-6GF&,]U/Z%1XBV<9ZA_I"U&EG?6_G MBTSU;6N'>HX):-WR`H)!?GI.FL1S$.<+7W`VTKC MFN%[-R*$H^]J6'5]9W/;!M_Y0V.+6Y"-IJ)W1WT$9]>L M,S$KD+$.TI2$I\X^E)0\W7U6NM$6'_!7PM1FRO)Y_LT<6N6RM*B*.62_G?F? M[CUK7W4.N4`DP7\.>9**U44CJ"*'$RCQ5-_/&((JLIW/MBJ:5*H_9'X-ZULM M4U@-N2DP1EE@XR9?;PIY8/E;HJCY">GY*>.:>_'95LFUMTYF?_Q@!O[CAY:& M?Z63%Q\_,-V7.N@7&C;E=T23,S:867-82C> M;17'TP.WS3??/(XD:CXX"9JN^?M+RHJ:OQW/OV+UQ&Z;F+2N7CU4`*C51ZC, M:_X>"_6:OR]>\8[&(7TV;YP+I*@%^OZ?@@#2@*:[7!#]0,6I M(EPM<""6F7S\@!65#-;P8I-43[_'+C]S$VH!04<[=0O8?*E2!:)HC"I*^S9; MGK^XN'AE01Q=(1FNC3RWJR5/WUR\R,X.?SY\_NI%\S6DF-*H,K2S)+)SKK,. M:^:LV$O+[G'?PVGVVYQ,_IA;Y.R+>_Q;>C>:;M0>E3KYT`Z&Q/L' M&B5*^_:-(]3QG4?X!'#41RSA1&E24V&ES=A?N;E^L%:6!:MUKDL/[#LO>S5Z^.PBV,]LS[ MA[CE#9%E_RWJGNE\\_><+3,T%75?:VM!J&$C?L8 M=R@,6TY^/_5@*V`[J'6SESAU7AO\#-A%UXA6D?'C:";%%W$P M*9B5C@\6H^:Q\GC2?Q]+CRV=659;X,(!Z%3GA!M53@F%\+9.&Q\C4M MS*YNH0XGGAN?#?V8.$Q4S4\-NR7$8K:&XPP:I8I'"JM9'!"XT2%3EE?DH3Y[ M7!`7L(H0:!]:E&77U7C,-QU1;D1M5%:ODY6Z[8"X%N)$/($287)U3H$*K0KS7%K'F0'NQ9>Z6%!-8HLA24: M0*9";#H@$2N'-5Y)BW+O%>2R6U6HH-C;XHCCP79":8V?A+0\_\3&^-DX!:/0 M'M$^#86`I8$H&:G`9W`<=:/;YNK!SGY$XI7+V7*.4`RO[=+5S<5*]Y"O-^;9 MA8)+NKV6X%]RV:L]=/G?W5G=V/Z4^,>S3*A>"5I<$(5&\?@J^QKN`?W+O_\O M*&T/E"6S:502#(W1WC>XS M:@W>XS(N;K_ENZ"D3EO)=1$N*8YZY_C?+:-!=.'=J$IH>L8)"1[['T)3Q1 M^VP/]F6/SS`>;"0RG\A[2LN&E"Y.?R&]$7DR:,0-@7QW8AM#3=_8G39)\N?7 M+$J^O24NUP5=(7+3X#LF0_\Z=&:[>C_D#X-U=W4(B=CMJ/I#:C4N#SB#\L/90E%%J? M0Y-$P;*2'!Z16\`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`=%I9 M#H<;M3*@WHI01ZZS&H8F'0Z'F&Z_LEGGL>P:*?N`7%FQ>H:86+V-31,^X'LO M_5^PXR1/NS?.L_:&?%R!#GQM!6*0F.TOTL=^T[]^CS-J?R6^+A#Q-@.P3.2$ MLOL(MJ6_MH@=;N\&Z=[:A#EWMAJ^T_2[0[Q#=*:MZPS[3SBF'R[2!/+KSLQJ MI72:2@`PI.&^LPAX.)@O_%RRSI"'N)Q?[`2O!UI*I4?R`DC@-;MW1,MH?R^H M.2S%S<)VN>=O[=S(0NHU:;K9(L`%HM,BX^/[LPN?5M"C6[M;Q@J2U:T#^#35 MHZU128QH#8&/6SFG8%,EULNPJ9T0NQR-Q^;'8L3YY#K67]25)J$F8F5GB\"M MF3YIM)(]3\`:Y2<+DB>5,DM@^(Z[7-)`=1C^-^NUSBZ^3Z784GAD;-E0;=C" M9>2HLM^+8ZK_ZH8&K;B=I/@76[-/\`W,26`TX9O=[=6]O8,:WTA?;._MR[@D MB]!=5%7]C(79')BOIJVJ;,Q*9\\@7U3'YJW2)U<.MUWP;KC+YU"+/: M5$J[FK`BWT^:CR#_=E8,EINMD8UMLV)B8MG*4K$HFK64\=Y<_/#B;7;\XOE% MT\KXM77'RHTM2QKN<$G:)_HPNC[UXW(Q&ZFBE$?>W6'R8#37:EJF\E3(/UH6 MW2'R-GQC^\RV;T[UE-XH@S9VP88^8)B^9C?G;;;*KHZ2#%%-0HBVU(I'J/-I MDC-1FLY=I$.HBK%8-.O:J#,]^4O#5&[1O:9728;R@^MV=UM4H\YW'N!]ZKY3 MB+C4$B'SQMV,A-V*Z3.))_/RZAK]Q71=F1%1\@P.M!\M]!TKE!`<*H'"E.!! M#LQ0">PW')M0F7*T!:E7<]U@YVH$W=CA[DP)&)*#;A!85[$ITJ=7/%)EW7L\ M@"J(<%\NOI3E>6RH\"4+(U=.-I2)Q5!"569>KHA$Q7*D@V8R:V9OQ,UH6VC6 MM=+9[*Q2>V'T7>$+/5O[#?>E978_,;:6':&E!MC&`^SL^P:N[!QL$8G:RNJ6 M76>Y%F%.V\)V;<3'_]/DW),A<43[/!S?)]0D(I8G><6MRK+C9 M"B=DK>@^5AZ:.A6X_#3[4(8\`*AIJX%_I38+9H9IY+\NLU1S9*[7""KUWSJ+ M#QID/N'^SV@V`CG0@\/LE*R2%R%X*H&8JRBFLPSM_=[C\-W!9AYQ>#:9\_/`I)CO86#W8 MZWP&D_UV1O[2H;5$,BJQF!=2LOJ6O^CB&=GV&+AXS3?C\F*0O>X>\ZT%`BX7 M8X5EL2/J)0G\!BRYW.W$2`F3F]UR/]O&0LLH6$"G21U):2K]DTXJ(9"DQF\S M(6F:@=ZW2UC1]'S:QBH-RMRJ%A?C^F:R&HNLZ_-`BLYR$-M(35.07);UFGI( M-T[I@*3$P8"@`D=*F\TAX19;NB?"CXLK93)L@64AO5;;38)2!!CX/VUC\0$O M6IOZ-3]134,?U2';.26;B*D]>N1"H\F=+N:W7#\59ES4H4DTQI*2#$XI^1_Y MKVOL5_AL'FI1ZW;L5:Y0RM#7)*2DO`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`Z/;LJQ4_[(@TKP=<"^W&&0BS MX+:C8?:=6\4R*,$X#3$4449 MC6Q(31ZE&X/I2?%:Y=&M$I"*EC^Q#LD^+`4J%4^(2L7G54MRWT>Y?VCJN;YQ M`Y1F_ZR7=`EIUDHN+'2>?*;<;NZM;LJ-W-QK;,A2N6T4/SU**G?W`!H[#5M, M:M"QOVYDJXFA&S>_)D((/]4]#44E'5#57R6A-3TPF491-(-/6SHSN+)%'DVQ M-S]BR!@+$KL+@FS]UG)PZT/!CR<9.J$Z*T_!6!F$=97K'U+/SH`PN:JQ"&%/ M"!)S&T-2X_WJ[*WJ*>N8SSJR:F4"YQE-4%`.1Z68MCRE)OUBCBI>BXYT$L!W MLJI-:')9GJ4.LZ=41TZV7X9,T9JFA4(K#["$YX!`B[$ENB0`82F("I*6'S8U MUS?O<2J`##I)7-V]H\.QY,'K+@F3T_95'?M73L@VPFV8)+YKJN?EMMIDT=") MY["I=$+%04R_?.B5(9ZB2L[T.(KE`I1A3^]%0%E-(CE18(3N\?F\&8'M0=WAC/;$I`8CH50'`CB*].L5,'(L,!VQ:"P22699U:):,=-*B*:?YY( M.>54BF:4U"WA^CPR4\`,5^M;]Z*?G370KDQT(6ABK9N[#=45UFV0PPY^ MQS)S!QWF82`3NEE@=!]*%2E;XCO:H_%0=\FB;D),W#_E4TVLCGLJGV]E.PB2 M&:SP!9%*`KW2T0I.8];"=U()*HDAWY21UXD'JXV+?XTQ`/.>@I10*1)-0H?M M$77""3BWKJ).XCLI>3:DR`8ZOCJS^NSJH=5GBY-,[_7"X7V;S^8^2?Z]3:F. M-]WIZ!)0@X`%=ECN?46NJ\))!VWV[#.'/+=DESJFO$ M?WBM/9]EMB)KA/((E4$4XR=5X/Q#R^X;)S!W*+,DE1B,6@W/BK6=76I<8C^7 MWX#$3NB#3"V_.N[L7&0])S[2W*-2^\'P>\"!#7(2&GEE!^=[XZ#C?#BWL"J8 M?X_Z*7_03G@![:N`NKI-&+>1\*J*$C:#V-J9FJ>Q,%;&#LOH(NDI,%7&-K,_ M"*_+*V=.PMD_5X@`79NC1[40R,LRH6K0)987C9%3ML%E%3A8[0AU5J4/#(]G-!GGMS MXPOC;U+:E,;S7:AZ4G=^M+*AUUH1RC@WB?4*CN[N=@.#+M:DQVXXEGEXW+3E M10JB^ZEBO'&W+0B0@G!8/0&;6]NKFSO;V+#T.*4ZZ2[S_Q?Y$;;KU3F03D`N M07@:_OX67ZK<0GOX/CJC,[EJKF6@/"?N-KR^_??+RY9;][PE?E1B_ MI#!"0>EOGUS8]_U.B_OL[0B?7T^O_B][Y[K45I+M^5=1.%S1K@CL0@@P=/2I M"`IP%WULPS%4U73TG#@A0&"U!2(D9)?[->;3?/.S^,GF]U\K,W?NBVZ`R]4] M'=$7(VWESERY[E?:RL-,[>NV/OAN=&3>1Y+H/$`<6X+PJ?ZC;[^*NS$XX'./ MHNNQ/2H$N*/HK[NY`C)[]XJI"Z;"4DG^5,D=YZJP=1]1"+;AR=W^=!1+, MJG'-IP!>63F%!,BX6]U86]G:S&N^YA*EA6*,W+GH1@IEZ83!"`A#AJ(]I+Y= M)XJZT=XNQQ03B64.N2:UP<\US:)74$_#)C,OF4N7R!GU_A#$->TBTIJ=JS!) M)6TJG(18-*VV72=I;VVO/$<+EKQ*E0J-+-LUT"G;2K)$NRII&[7M5#:SIMU0 M.&EG4,W$UBIO*NW&`5HDUJ,G>/UKQ^M00P!FIIIP,:'?%.I]IBZ4PWT@;Q)Y M+(A&TG&M)TKO$+7+A('D@/.W3-@'?U^0Z;JR)%O`,ZZS%O7.3,B&RZ(4D3H( M2Z2(FEX\ML$L;3IH.XY5TV!A5D\3UK#?>2#"MG>]RL&S;J\/LB9\5+DXL_*F MPR^HGK9.&[GZQ6'I/4.<6CJ64U)8;YOXG.9A7:E]0<"ZVO%V,XK=2\TH@C#) M3.E08PI,8RQBT28"AE0^P;=<#*&,0YT.W4ZZ,)I":<>,^0H].6Z"FHC4#@P& M)1+U+G=79SB-2N"&O9A]JDWD?+..U'*7(D3$*!N;Y< M>26PU'N.K>P2CAM[<;AWB5744$1+P&2>K:Z"Q]+&G_3[=`P@I/^1AKGXV36_`\/:&L@HF1KV%E\I);T$*%KFAUUUX/AE#P`3J60\H-N?`R>$[5.I MM'@WXGCO(AK"N+=..[NWQD"7747&W+96MC"N-YXO)5,;Q2BH;S7"S6JM&M0\ M7W^N:T\MD4!4\=^".!NR\P^:F6F$9KK)UX:'V9WZA(Y+RY$D/0F,>6JF0BH8 M@`I2*62W4D9*$6-@^8UQG5K^B3(*6*/2`%'XJ]K2HN"A+&J6*V=$)*>]0Y$/ M5]`(3\;IZ.Q2+60@MYQ#/FP]8XE3N MA6;\L$Q%0:A7Z_<3W[8@K)`G8]R(7^1^.7W=@Z/?2D+NDO."<7XC;6.WJSC$ M^5"V!&1=%_VQB9'KM)I%QD_5G&?@@=?8'")+`%(VT@D[$FN@[8JRQ\2Z4T6< MI2W`$_"P!"$0PP$!!.L&%]>@XD<5R!8O`*.#_H)W>@Z[-V&4BY`2Y\SX><#_ MU7J8;`Y5.S='$%1Y9')FE*]W<29);E)[XWFCXNN"'BJ;\5(.5^BUN"0!5:Z" M,]!R97.KZL(PC"VXGNM0]U4K@HO=,#'V#-H7>N!'FM.K&U2K[C3D]`B9[\=4T6$[J_4&!E^'J9)D$QUI_Q\PU37*]-P"$Z'(X"!GS-,[6@<'RO#8+2P@4[6#G9/UPYBNQ5ICVQE+>Q)* M0\JGK,`B`E[Q7)UE'C+9_'HX4RUE[--21XFU&_CH4L5-JIFJ=)8])0/)X[X` M1&NIX5+9U12:PNI+G#\\%-[J8#>W$RQ"8WDP*7OG-N$GLQ-#UQL9*CBR:MU` MYQS/&K;C4H)?:`/EX1Q\@K$4YDF18F##+RY]OD-9#+/7T``A;C]967:`U+UJ*6KP\^@`S4(>=TDWFUF#.^`:2F/NXU/T-1G)I MM$[E]95R_+(F:/-DZX`B4\@[S!W182X,7Z(\)'OC:>^L.QGC@\5[RL@C&\N$ ME\VRFHJ1%_B+(JO!W,%A1":;)`F;C\2HE).@AJ6Q*AA%2-?PED;: M?J7Y=L`[IE+A\R)5@P@6&39=T-@JON1!`%'U3JQ-E78,S]0+E>["RLH/5ZND MG)K[E2PU'*,4,)J>2T]@TW]T2:!E[QENP[8P1.5P,\^>9-'MJ05+6I"C07 MKKSD:O;VA2(LLC!&3/""X'U=XZ,N2E(490,7X95&@]\,U$Z8*C2]LQ(A"1+) M`R4:!!3ECRWF_LI`/T7,)L^YI;[R"<6*%"![__,]I!1XP9`7:"TD6M,@+?\V M=CK7NJ%@4P2:NB*C.Z@U.T`;([3BQG^DKQSX%L#S@W=P&N5XG0L3^_7$AH[K M)XI,/.7"S][VX&2DZ\;9O^`!U<>WH40YC`J*Y*:\7#;A8$>LV[^HKW6F5XB^ M$I]EMAKA*S%`EYK5"_(=>R)2$5( M@PT,V;L4L(M;Q*3@&3BTY?;2X3ACZ=;`O$JM(<\J\25+4K5Y?]`%5X@LOS8? MM:4`A-'EAFZ$F;*.1:8$[3`J?I0'0.TLI?!+IBT&)Z=C5!" M8V/9[`UQ3+^W(KR$2[UZ.!AN*@)PQZSG/R1YL;0+(73YY2:I=FH:I>'W+Y"9 M5U\9CYPE^?6M8TPIN)LV6'1,#O%=1RV)58-&1-2+)F`HV$I3QN8])3R<'^.] M=46I(Q"\BHX!G&M9Q#@3?F`^P&78D(5OB4);L8@3MV5-ZF(+ M>^WUA+VVCB"N*^7*)0W#B!3%48T*QJVI3QD;L,Q:IO32MM>4>Z^TT`%>0Q?T M?))\UI_!L-&9@*#KH#\,F<.K3_9L(NJ05I%ALY%O6P:Y6@!IB>P6_;'$L(QH MWI02>`M\+2^Y@I!XWS=QYFJ$6$Z!Z:73YHCF')T>\)@<\&OM)W1C4`-I[FN0A32B_XAEV<\:]HKY7I":%.B3#A";3O"BU MGO&&LF7N;1LJ7;L"W_,$;5G;-^I>`?BR=%_&IC*4,?:C M=;,$SC0S1M?)Q;R+3"%7MVXM@?;YZC?,$=!S2-KJLLY#3JJ+0/RE-U0T-@6Q M`X_$?X!BB>#C02"R`R*%FG"P72W.#PR1JHD&9="2 MS69RV8-_>[E\/,^_D?_+(_^?*E%]28&`OP\S,&/G>+>UU=YXRG_6-I[23EQO M*))73./_?J/>4GF%G;[7/,P6S@=083U[ZD)ZHL$D.$'1PP2XD M&&*38G/?W`S90C0&U-+,&FMR`H3#[AU.N9V70K@`FE&;T$Q8Z.H?A4[)]:L!C- M75I.$Z_-!XV_N:?#XL;#$P5Z!%<-_P)C&,@I-XAD1/BWXG(J%L1^PE=F>GDH MJL2VL`H\*MYNS[)`B!9@(RA+_"BA@8)!5C-^Q5V>\D46<@G0*XV+=E>'F2]9 M-S%[8:M[RJ69GA^?4CRBN.>:*^/%Q$H?:.3&M;"QB*]%=[BT3Y1<1U<+'=A+ MPL;!0_8M+VZ^H>``$R(5-QEV*+0Y[7U4MQM>&C%3*[BEEV^96)\J*RMP"S6; MX";T$4,&&8UT6[34MY1RK^T>#@)6A)4BWP3K^MAHW(`B;U`BZYE1@./N!O.& M!JEZ9,"G0%:$I'SLJO%H#M?2G7LJ>0!0N$;B*05<"SM0$`A%AMRG=!$8HQ**7/]>C;&/JLZ\4KDF' MZEU=T_;'^)8",/A^,INTSV4(= M#LY'PQNXDMUS2F@*`_<.2J7#D^.=S]SQ\/7^XQQ.,/ M-!=GG,=!K;_XL?3$L,`?6OL>*7PM9]W?=A`W(SC3?]<6GOJ;O6P8\HQA'PP% M7FAS1Y;UWVLQ#/C,`ZV"!S!(;HOJUM!I&V+XFM!"2G`]&V.:WFQ8R]6'O.7, MEU?@`3NQ>/&&74:@$Q/'9S0I-C(+_5E<%XE7%SRLV7Y2FKND(J%5A+ULU9SU MP"BFI=MWJLEV:;GI(P(:,Y2G`*[DK.;0[4JO2COI#$":81Y!"8XKFN->A@*6 M.`-IIV@,U&"*PV?HM02SH$L:'U?:"-VLXJ/8;@+,7>"#&5PA>R8 M@3*-QPCTEE67E+=,TYY-N1;GXD.QF72#7QTA%H$B$?*E$$*%4Q&2.=G-!>2: MIX7.`V2VGSL!LHI/_]MC\*O/W1=NF^3R#3.>.U,]\\D5+_L!8G"5+*;61"5,8BQC4;1?V`SE M-P5]5'6K&?021R#X07KI6+PE6\7O,VU![FSKZGPNY*"-+<.?U`#<2KC6"Z%" M`6FY#59F5)=?4-."HF*&46-W&]]=T^4!<9%Q`'`+4=00_%@'B).2LRW-W8Q#VJH))#W!;Z2FB< M@M>.Q1ZYF@7M9?@$&<7/0WWU;P+N=.L57K&VLN)EHR>CNHS.D'KHUU(2"9*'7+!5@ M5C.A&I,N+]P%D22NX,R11&VD2>U\D]%8G,S`P`^/F_1AD$QCG\,AB$LM M\X3<@4=B^FROKN4PO=#$-V6,W2]]:T?)H9MHPN^[Q>\&!)H8J-6EQ%J"6I`]Q M_^O,.\]$NW$`&5)"P[?=P<7#LP.-`EO_.KB@0^EPV<&FJ7YJ0S)#4#PT4W@` MA,"O^2`(<7]=;P[L8G^+KZ_DR1=\?YBMXTK*2&B6H3&%_TR9%!>S/]7!"+7? M0MNAF*?0T!:RODI6PP[MOKT8GE40HEF14?Z!/&788ZN9.6;YFU;.)G,9@6U) M5Z\50ML(/6VB$+*G+),YTZEH%VX*L14XB!##,MDCC97$TBMBKO<48VJN74E- MU@/<-:TLE-*[X'5/9R[%U.W,Z([@>&CF,D?C6$+H/`B],`_R_B"D._0,]GQ? M;VAF`2U"7TM`<.,A-/<-2O]M$IIZ9,N!/`W1HHMN!JAH:#ZW']H4FE-(;5GU MMKN0]6=!ALB?`^>] MI[-@V=O/S#$#=U`!JDYNB9V'X-:(FP?@UI&(ID,QDU]>57MG'Y87:Q;2W?TO M5U:(4/)C+6DM9)&9.QN+'@1=F)ZFZ3K=ZTEW-)-Y-Z6O9&)R;BQK2>Z]($O* M]*`[@S!D!BS*DJH@)':8'#(,E!%">M2E0M49/MY3$KX9]F[_H1$V/@]NY_H< M6>!(.2`!EZ3+Z%@50G;-;#0%F.S,J[DNC"ST.@VDY,_T3(VI9-E(2[.2EFYNKC;-H(,'T*;;J\PR M[:Q[$).^"6OMDC-BEB5EOYGQ0+V*?\_+0B,!3;\"1(99*0]CGY+I.6""D_*1 M(U^J,7+E8OX:/2T+4<[#@']%!O!BS"A,5%I*/]I@B..6V8P9I2WVNJD$E+EK M&UG?/>7O7XY^:OU,(BN)J^,PTVYB:=^%!:X,C_,X.R_4;0?H%`\IBBR.6#.] MR&,M<\Q2_>,B3/-!KIZ,.[(9ON#=R^7+3@6'[/(K+OR[X@)R,"9*><_\2DY9 M4&[-5K\C*?NM2^N(,XNRRU5#%16',C9U=,D(%<1)I&WBX2[*8+R64JR:^K*R M9AQVKFQ\F&O>TH!9YZ]T+V@S]$9[L6,EE]*"MV"KZ)=WX;HEN><995%G@=H4 MD(549$[FOJYY!!1\8;LI$Z$"^4B$-?9J1SFC4MVO1H<2RL0>[DTZTQ03.+M& MP_4L4T>Y#`]RB=SA]O,O2*H=9'#GRU%J83Y!I36-M7=]V563@MWN39]&V_2) M@[:.U8".YF#BP?2*LVF`NT?'-@80AJ)J`.J)!I.QJCVZY^_[8Y!ZJ)H&*L1N MZ'-%;GK,HU>/F0^X20@&%DH>5?N6)V+Y=;_V54Q$K45P3QK'**=DF M%?[%*N]XE;7+L]W2ZQ%5>7)#=K?28I1N:14=5HSWH_XN(,*Z>F&08E'%09';1M_ZV]6IX;H4YJG%JL`&;1N=$ M5(K22K=?:G7EQ5"$PZ]QUWO)1IS78K6$=Y@I*'R,J6:MCJ%#IXS8`6TR>_2W MG+C3`+J(O01`S)UC=Y_.\'L8P#,/@-$Z,:3]*B-W*JU.2S&@&2`O#81L0E=' MS/+LJ;M@9<;MR*A/B6=VU?'^D4-ML#?4)[KZIC)1%16&*ENT)$)@_UHS)='X M;:3D"=PA7L']:50A5/&;-`8KTXK"O+ZR?"BK147G!H*(501JXI.F]QV5&])6 M?X=\RZ*JX`'Z>&UXAXX>E3ZKP41]N.+#X>BCERN"(J_Z9V^[O4'KU=G>\)I) M(/2[FY#8Q(I^9)O_B4B.D]Q2CS[5R?)49MDGL7R!=2$G0%`RA/AEG3C<29,B MJK>&JZ,;QEE6.C=^]OE3?K$JI"]R@:BR1+*DOK7U_7=HTO]<+'W4NQBHU%1O MLGN+^RR]C,Z?D`V*^^3,2G'YH7Y@TTQTMJ+7FWV<19IM(V)?,II&*!PW:@7+ M3Z!&U<5:R7SE77JZJ,J50Y!>?;S,E,9P[M!]B;K,="=^)MD!;(=`MY+44MZ8 M'"WQ:-H3RWS^M.//>4)QM)5F6#RN.#_V%\UDA5Q:(?%_[(%)G&#?1GM7D?

FB&>0U"O.E.D7^6^.*(XV%4H=<$\KX\X+TKVNA6]OMP%,BH**=,[OS,1OQ@;CNKM[C5JNP?3'4?&!M M57B9C'KXE*SZ&;,!QJCAKY7J0"=-[>"Q&KVJZVCZ39K*=9'>`=<)8L5-S4P3 MPD/25J\;0HAE3R,7=].0[>"]`S)C_:(_@A%A&##_VGI6*!+3Z[<.<-'K M/5)N9Y=>4_CRQ;LV26/OY$,P.]_^\?.G*NCV0)WJ9Z^M8\;G3ZSBIZ@^X!#` M95;]X@6#.#]_^KD[F-06'5Y\_M1T=UCZRE=I6"L!O'2IB]_I1KQ3'-+WN%.R M9-=IY+:U7NU?M.B=0GAJM[#,I?ZQ"MCB2CY_\COY_&GZ+3P4Y'Q^5A,U^+M= MM8)N,A(@HKCVG'S`M>=W)($[@,MQHC91M4V9`VVGRMIW)CT3J=#ZG]R+@G,U M\*PI+&9Y;`P]4!LXS'28WFGJ7^`JA:X\GY4$YUNY0O)QF`584^/V//CRETG( MP,S<^!B.RLN$@505A==FJ<8N%W.X*[_/,.OW/.6[G#57I5XI(>7/-(B[]>O5 MX(_C&WI#_,>C&U0F8@B]1]\'J`:A*N:>;M#-VY66+S5G:O>_Y+3PP/)28ZE@ MB90GA_=I-WJ#`/56O8:!IAN=DH'O*JFR44]-/YX-EKTM6AX?L+>[*<3N@4"GU M:JW727V^K36D[52?A\:2(..#W5E@\)1WA,5MD)7US*/JXZJ5W.PLMT9>1YM3=6=7KJ: M6S=LD_1)R4RJH0A'0N"T.0K MJO>*M];D"4!.7COV;;Z\DARY'XRI-G-]YG<$XVTJ/NX)XS5P9WU]41@'Z9*0 M.4+Y%;5)/W9'ZC3T(VVH)USUB M3S37>G(X&;7*)\PHU+.\OL1AVTR>4D9C.&V-1LOGS2AP?>J!9RD/&>QB;OJT M_`K83!/W<;;#MIR@[3;R77-?1^+B#1;9&%HD-ER%\ M0;O#<_J"SW,QMA?(("[L7VQQF.KG3XM@2`TQ&J#DK+0!`V:"21PV^V7J_`+X M4J^LP,=O8<=39E)KT-3B\#:YQ[#"S36&09V(\T+!Q(<:4G+1!^86RQ0@W5@E M_0)'[R(@C3E9(:`H@,[J(\'^0K>9YOA]1HI9Z['EI25@%*^+1,^?F;2,J7E3 M2;'@.V4ZG`%E'?Q:+B98G4V`"4Y4N9)YN[YFBH\\LZB@-+,TQR8^V`'$XGHL M+$_3!GB(2,:S/+![-VPJ]2LTR_HA?-7HBEG'+N M02\TZFN=*>=W!I.DM:_*Z:5'Q)%O.!BFC,E\`'63@PI/!- M87],%E]I/^>F9O6'^F(0K(W6"6DQ2T`S&Z?S.P!G9V-SY?E7`V>+A+F,E$;)Z*!7'^?7'O`.=G"^,3>2T05&7-(BH+)U=Y8O8!@^66B M=^JP\>2$R?3*M//\F/D1K2'E5&V]T*DM2-N0I=!TO@LZG%Q?!BLH[6"ZRA7T M<%,N&V:E!1!$<2CD*MPKTV>O%^"0J6/F3MK+7:!1TC81SUQW+6?C(:"QGFGD M#=#`N92,O,R#E['Y:`T_B+76<-"*:DF#\\FM!B)8FD30-*,FN;C:G=MBIB6^ MEJTQ#P`AL<]^D('%0_A\V006CXS++R-4RFKZ(WJ4U5H6R5C$PK23IQ$U$8\8 M2.H#GRMG(H/"Y<"[8PA_*BR+@SLXMLK@((76X;%5/EB&9PUQPD!U9@9$YUH# M-*/X@JMAIS\$G:WFG84;T"\"3EJ_538TFS"+`"[8.`$Z"\%#0<((CGL36(FE MF`$;Q(HVOW^X4K+P`46:4\'12V@R%362W`@MLG+FTN!VV]$@ORLY)WE#)(<2 M??N%E.5M9#*A$*6Z=QV"'YO5:!$L(-3-_212JM/P%\@C^5)EL\TL(3WW^ M%.)3S+?YE<&/_7'O\R>V?%;+[/@!ORR3&8HRU@"T=G7I_;!.+6WDP'*EJX^_ M&(XN\,WVSK_;__6&V8&UGTU[\5IU)95M,-'M_[34G+GZ97I-]8MIRW?*#RJ4 M^_V)W#B%P\,C%RIBL$=.;.#= MZ]Z'UILAY4[Z]J)[97%*6T$??#% MS*M^%1&O^OF.ATFK'^^&6BQJ**I?O>Q?U)`T[M;'@59_(01YVH0<[6>4Z8C4 M:EJRGM9/-JIKK3VC(JOQ)SO-5^KBMO"0$XB#RL?]LR)34[4A[B7VR<,$1:#P M1DZC+]`9\0_A/H0AJGR$)\=J_&-NRH;E??"0C;1V)5L%;F(RE"R@E3*$O4?? MOML//:9'Z^-R@DA5&;>]Z;'(-U36P@J@\UA33,+P9-/FS<2P1S5J1/Y/WDQZ M8?_Z*2L\Q:3H?23/D"*<%$"H[C\-1O(M>W9KEN==&!^$*'NQ7D?[BQ%9-I:_ M+VQ0=3Y`\&WO8SJ(_=DG+\]`E9QI@RX@SF8WZJ1:WUBT[L.F"N@3JT`H_K!+%P>O=PU?[K9.=_[5?,Y;) M*=6L4@`0V MHY@'0NH+:XA.5V8E9=+:?;76^P?6#-T);&PU311W?NJ0; MU[2+W7B>1Q%$CTH`>G+:N^Y=]&^_;3V-1ZPBRC)+V*EJ"S#(':\T"I$*N^O4MBHU/I%7.Z^=/UST^8;)GMSBF4P"A^MXWGNUE#ZO"CS)9*8^G,(K>F!G;]9WNA"P- M#X)7USOF?4-*+:N?_[PP"%HR!>#3G3`D_#2@I2E8, MXZ/".DH!=*;OB]2",C-5"-$.2>:\E;H=CCC>UM\\.)J8ME+RI?\CBA:Q`!0RPFB@QJZR3\/^F%$B\]+O@: M*<(M,ZSS[U8O-$028A90:"S;!3EUH-)^BJ9:;S2?$,HZCKTO="4N:$ZZOTK% MV;F$DZ&^_=]Q#2AH`Z\.3E[MXSLW1_KNX>N3@]=_WG^]>U!7$-@U$SC=%:Z7 M2/5G?197BN=T)_OLW^6ZQ@S=8?M9:ZG-'H(4`(OCOU3=4XV+'5PC^DY'5'A8 MFS]J34K3Z$$F0S$XE'5.R!BDE5%%'$!2BX2A3:G6ED7L5SRPQY"_LI@E!O_B MS;G\G@6^D4K=]27:]>U;""`D89EU4B$<0SP;I)EO&G_9C$W#>S[DC#WM>X'W MT;<`!Z,?4E,1#-5)2,LRT1C:*;A"?G`H(Q"D4.^##JOX=@*_`R(5`]FBUC[) MR4>0H1^P@"AM+`=>`!`AY?D`\OS*TQZ%4G1]`>TH.4XT<,5)@MDJ;A1)&2^.^IM(6%4%X+6WB^EQ36(#U M@YQ?4#CO_4H`Z-D?6^VMM?7GWZUNMI[(^_/7(3UOCBA1R'K$(W!K5(@]DM=O];(X`10Y2;HKP;]L@!P$;&O-9VQM]H+Q_` M`>T$=YR('03=6ME>V\)S0W01M87MP7&A6;U%F8MC*H.MSP<41IL9:`QN4\GF M#J\*V5.TS>N=PTMP>)R9/6Q.=7[Y_IH+I5BRP7W`6=T4@ M_`N7NHD$2T]#^T%S-A9G/$@.S;->14FN`LF.;?UL_OJ,BP M`^'*P,RR*[RFQIL4JPVH`:CZRA%W+"&/,!WX9RY;*W3BYM;+2'H:BV?,#MR_Z'6Z-N9"AS`;7CX4G`#^>/^*&6-!)L*JNM M$OC[_E!KGN?+@2/6'DMM;8QD\3I,S+(-\]XYG)_(CJ1;+^J_VW0*M(1RAT]> MVNR7B]/1?@9,I7>CYU=`RQ?)XTA2IV:E:^\9N%MA'Y9F$$22WQ']A1K>ZTI! MQ!RP:\C=ZM`I3R$!TU3J@#DP$?+H1T1,Q,^U2]Z%T:'+BTJ_5:W(@/$+#I^Y&-V,V':'FF91$PF#=9>: M(O7=5YD.`K!-_R?+?SR6#\/.*@=T0CT_)O9<65S??E_"Q%,0%Q[M`!A/W+6K MQ13^@-7S@9!$QFK!!:[',)_$W02Z-!3>D#'P>=]*PMN":6C%Q`42\^9Q,7;X M?+BA[B7\3TY;7I"?/.)[>$R\%)9+V4'7T#CR4\;8C[H3%"^G?4&F3/C&6;DH MX]7:TX0<%][7NT:7>6M-_SFVS*&=U-EGMC=S)5SAF3@W3?9&!6[068W5 M5]F8TNY')JWUBND$-_:![M=#T+3""2M+"$CLHKI;,4J]HJTZ)K-7[<9XTE#< M^5!0CP$8S`@EN70!]+X(0DP*43@A8O62]&>HSAA9$;27[EG6H_A]]Y:+(F:0 M<*KURL4BS`'R0E"ETQ>K`TG%_A)88P?=U MM/7K6W'\'[K7[T:3F]LSG+F>SA3P.B!;;C(YE;*'T:U10`A@@[&WD"FB M+^!#T+2`!N+1.3%VW^06C#?[3X_5WEM6C!51B4+0Y&)0<3C)\$:-U?Q=4_#I M6>L7.5.Q.!"\1)/ZET/\.V-N1=Q>:E,8='\+==58@FGP<_M)H,GGL#$_-3H^ M;]P?]=^U'KWIOWN$/\G*=+ZF)J_3-!?M'B9<<<./_YUR(BD)EJ-@1PN'4H(= M3#>9`,D`,"E1._*$T.P7,F#^*>]J1?8+`@4&M&L4!7MY`5^%@OD;$V:E]>?> M<'39[]+*H/^^/Z"WB.G*F$/&AY[N_ORTO4TQ'HKZ7`@\>43ODT??EHV?*;>= ME9JLX",GD]'8NZQ(OB&/C07$7TA)@-G(PQ+8 M4)%B*^&0:.4%`SJC:: M,C'2^`4X-AVIVFVAU&I[<[/S]'!OG_#U!>S1W]X=D.G/C42+1UO932HWNW'] MQ:^\X1SBB_EQC778>09Z1^]R:%:%?^*BNH)E"?L^O%6F+^^/[MZ(=N)&`1/U M.AZA@=10>B':&[HMHA3V']WA<027K<2QGI7VIP4:CN&"F..BJJL_E^VC@`.T M.PX6_B6D\/F(SJ.(RPU+?X`^Z:-H_,19X4CJY7FJ>Q-1YHE!_74;`5K8^Y.7F-VWLGAH'6!-R+WIG7;GDV1YZL8?[R.V]M!HQ17\L(IT2$9WQB84>6+SE>X#E')X"U-E0Y&DX/^.S5E@#2A9F@` MZU?P`UABVXB>(4(2)?J7M_ANU#D7GLWGVTW-^6\=*-%"27=]`9AI>+J M#'*!\T&'K%6VC$SM3MUQ_#O4'!7>7YV"(KK6E,V?XC=/+`E`.!/[7GRKI4DV MQDTKGD<38J!MBYO8&(A3)F0,>Y:9$ZL&B`F;AF0O#+R*_0(+9:Q3\G%N%KG3 M.5#'/2^8X`'B=>Q+>^%A0A:C;NNQ!TMNR90@O"\TAUK\I<:O*B%CV8<-?$AH MZI!1QD-XS4*E)6A[CX+-EGXER)$<`@'4]*$G3#,4%-4S+_'[_HWAHII M,V&'06B+4QK;[4)5(M8R'"+_A'("O\2<.^7)\IJZOAB7"^LW[]G14P0RB@(@ M_BZT(4%EQ4*SVYQ<1SYX)?+R[I?A4O5&EHD_CIV>+1@?+C1X8.-^(NH:$/T: MR^`T2`MYLF1VAK2'CB,&YPWH8H_&,U[QR0'!?;G+C;H&_T%$X*SU*7`;%$25K(-9S/ M$28,313*QV"?1`LO:6_P,TC;D]VCOIY_H_"A48=?@3001XT`_5[X;02HKD`[ M+/8"C<`U]2L.C-&7217!#4LZ1>.@^]46RQ\02 MY6O3,N8&-6S7&"!WS^BLXI&E?I-^&Y5>DD@\%L%G$A7SP!PLN9(#T>B\X/OH M[!F&%-+\\7IP$J7TS2CJY*/P(B1;*OPD^%YT"G^_Z[,JSK.)8*36]C@@$H+&3).>^VS%KU*#2\3\PFI]!V3:/*X]$FY,$:E M4)A=9I5XC!\('4*N%$AVC5&`-F#N<#E%4Q\>VP[``>'?5N46S8!&\M/%K^ M(Q[6?Y2,_H7\'M&7S1O*;9^"6`[W@,,Q!F*D5T"5)9=WC\#:\*-&!(C6FV.: MLIM0%!3=#>[!5CJZ2"6'20$'<-$]UD@IR%QP+1NLV:.[\H&@+`BYJR;K"RH" M^N==5VSB>^5IB)Q%+$D!-<==@E$R!4UQ>[RM=DZT=32=OB28PXX$$M.&0J[B M!PNX"1157['[FC,+&**TUPII'F\AVC8WUXP*,VXI>,$DC.;<`D)Q#D@6CV(J M:H1K\.GR2&YC!K/?8HO&/4DX"[$.?NWJ[OLA0D1`A@7)\A)OXN(4>C%FS9*F M`DG1(>^ZXO>UL&>AJ\6^]&Z!!7(@%(#`2XNAVB6B3)S?19>V$8]G#"IEI/5( MSD?QQJTRB=1[IKN/QV5O@83]S`8Y!18-/2](ZH+YPQ7&BO`&TD,<^4V,R]MU MMN!`F;W!$L./0?=H?GW^)%/,-`<)(QNB86S5"2;T_J1/W@T7G_)CY,*6`!"[ M`M>VHLT6K$NYE5`3[+[R\SL.HZ&YV7_<"\U^VZOUSDDONW@/4/E;K_&>HS.I M8VN186*AN)!A0BHDZ2=E;D9A2YX^[X,(VJVF19\\"LOC0CPU)^!M@6F1R@-7 MR5_+[SP)RC[DQX)8B0I!2EEY(&F>D@-!,QK:]4A3H,QF\Q@.W^%5EQ:K;G`" MUS`R-'N+M,[05YDO`E2P664=L6M/4)/6YHS/XUI1UM%D9U3`DAN4FRC@XTU@ M]D974$&?J$TP"'*8$'=_WWMZ3DKTJ']JM%)$6QJH[@1*R<17(;ZCK6Y\2OX' MQPB/L9O-JCAE@?K@95'L@A)JK20%;R4Q$5>7!);Q8AIV6,SD(4I"9M1EK1(3 M@1KY99N,VBB&;`Y7<1M"BC`)"_(5S"$=JJ;W(+INO\_D6)287S!:<(3"VGJA M1, MWHO$,H(ZOE$3P^P.T4T41XZ^`RLK-GU$G>=;^0@F.^V>F]Q5)$"61S])FS0] M[+K*382S9WZ/8JI'=A?A@@"'5),I0T>"8:LGD@=`<:KH-8@2$TB9%[/.VFMU>V<8)7#SP3:KNF]\I+6\L+?E%4/+/] M))I"W#(V8&CM2]4%[W#VRKS>M1MY_-QU$F1RH2J["9U^6*C<`L_CT+XU0.1: MC2YRYP*?6PG+.DW&-C*OAGX+&MY@A%:;P;E_(U35@S?N[%%>B2[=(5N,1ST- MA>[Y!N#98<1<#:KW@DYL1;@$>##/Y/O,=U?85FO5_FM?`SR'(;GW M):IG#;/V"-AA7MQ#A"L,PN?3T M*2B&E!1':W08%(U9M^LF[@\[QP?'K<,7K:,W^\'2J0O_@F=N4JUPKVCWVJLI#<4CJ7 M6>1DU#V'9['*(6@Q*L8FR09B0>J[EUD.ML,.4#.6^1%73]$R(3YSM+SIC]^1 M:&5F?ZY_QJ5UK[GB'%Q/#*(XN@^T%J=[#,J8[E4P]]`5'7E*$5".W0^W;H MF"P-L.00U-&9G+4P#>YWK;:#GX!"]JYE-@>J#4@12/--E_FM2EYVO&.X`,WM M79.#<&;7OA0A/`Q[.Q'!U)G;3*2B/Z,%7F?PN..0!R"&M<,5G9.M9!=UG,8B M@U7*;\*&,[>F+GERZQ0E+E>[H`7>.BV8)%Q!B4+-E22Y2%H\&7"DU)@-@7:- MSA(VA&*4-FR%\"&.Z`YH^2T@M/[3^$RM.\*+G8,WK9]W7OZTWWJUOW/\TYM] MK_Q],@7:"5J')'+BIB87"-%X0,;^:"(JQBI?'.*LL6NY(F-6>)#E?OQX2A"E M<:F2"+OK'F>LO\C)]P#SR2'"'#&^_P:1/07*>^B?)\-6T,,76?GPY,?]-ZV] M_1].IBZ:K@Z1P]S]_/'RYQ[[_P(LXP<$"[^** M[06%J>H\C!MW%\"";V[L[3K_J+S^E]@7=?$71HZ0__HP"[7.WW/>TV;^+KF0 M_10P*H00?GWL:.E!4-E`06)LDOGOSN\9-XJU2K$6/CO6(,6D[LN^UP=*SYV_ MXLPJ^X6.%XJK7X7B:E4MPS:./`/&$Q&JU?D+[.MAY,I>CZXC@_&WK2<_'>^U M'M>TYQ^Z8]@HN"`C51NW>]B!41^'UH)\=]Q'5]6X3]2:7&8&E;SUMY=]8BP' MXN+_75?/K=?0J-"%6G][9?"E;R3(A#J[P6+YWK6'J'A[T*EOMVB4^D&1?:>V8 M"Z)ZA:[IC5$@S@N&,^U6G!=ZI>!KZXT*(9B:,NT7#PL=*4,8M%,1'E_NL]:T M3I&_D)YL:K[@RY>?239,69,.#6]@;)HL%-S-F5,0<-3=^'E'_&< MX8#&G\/Z_6#8[,G*;-7:6OYAK=93LLD@^H'P\MNK+M7V>Q;0-+6]NNT_4)M\ M-L$M26X)6I7KQ5()<=\SQ5A!;CSH[=5OHIM/:B*.3:4$B=F-E'Y)AA#!5_>@ MN4=5:EYX,KGFZ>&[ZNNH)HF?40M@FJ=HE#_/AZ/J[F9JP9A%P1(_;V&:X_&A MEJ8!VG_HM*:T5-P-!Z=8GOYO4[A-$V@Q6F3XD&Y2W7%:\H0Q0].6G*J>SF/: M=1HCPE%8L-7-_*U=9[7)W%5V`0H_)L]+[G#0:D_?[M3?K-WA-YVIO]EI:.QG MUK26D@DM":63V(;37$/,OG-)?ZMX_4M*%`= M(8=JXOXXPA.AXL`WBF]).1'!&B*$ M,A`M(RA]MNUIB7:>E%V`72/;3V>\-G;-.ZW3BW\F9S&N-4MX4D<%7[ACT`YV M&L$]AZEEU%_TJ)%QAD'_3T]K4@J^O2%VON0=X1I(CU1%*4%"$H`1)RST(_,4ZS!H<4(K;7OB&UO7OVMMP+O#%MW2^E M(!*X^&C"0=(KXMZ4B?-8J6Y$F@*[5F\B4L-T[FJPLU.:A?A:T:]XC98.7]R] M!6VSX.2\P;FG__/KZFI[^W]4U)(NUN_`T\,LC;_`3"!H=YK%2;RGMX.R-H>Y M0Q2U`S/P6W(TYLZ+#:?CAVQ+03PQ`B,6#E\D\#LG41)O($_YGBY#_A*A(O*\ M&N@<^-NV$:6>I8A$+#C0&SIN$H@1,S+0UN(V;#@-BPTI)0RX0C7&M,%)E^I# M=,U@HV!`#'%>XWO4MC4*C,T M5E+T3,GJ6O'J=N*1LT)%G%^G8(E%+LL2V1MD01TB"J.VWORX;'M,TJ3#(^Z2 MS=!>B%/TD@F,9-866::`Q`7?GA4;/H:T>Y!#?5*'4/3P_I5YV2#VI!R._&Q\ MYKU<-T!`OQZ4OZ-"?'84TL M.\6D;-?!+/>='6U^'YOXO[>^#\!I1D\"MI49+,D`L!YI<5H8TDH(!6C-G9BC MNPM+B[T*@H]B\]M!Z/;.V'-?D/.1OSGV@`->B?R$:\Y188U=*>-62PI]V0YI MDAH/+%S-1PA9@%#A"RHE0"9/@IP?,$3)KN:WC?7$V+(4GZ[)JPOHE[Q;.)WD MR_MG9\CC9Z>W'QX8&B.^.NENS7T>Q:\&7D5_TY4_BJSW[7<;^_[>VL*+\\WO M0FMJ>I75BI!>P?Y*K)1V8)74V5K@%O1/M?`=,?%9#,;BY?E;Y_J+KRBVQ*?+ M?H6M[%2$;),?!@!/KQ57U_@/I&KCT%>M*WGMS+=B_'=E<7V9XJWI\%(J:)ZB M$1,AV$'SYS-*10+PM;HV*0[)EV4V@KP]!;&,BWD6MA&DG8KK+Z'AK:VL(=,E M2:V!9,6$\PU=XP[L]+/0N(?I$/>,!(OC1!6YN8S@/Y`,H>`F'J?`0*@QQ1E. ME:Y%Z#DXDG8LN:I.)MBB[[P7Y6TQ;CX4H+A4!RA"9%>87I0N8;Y/3E7V5$MN MS,<$9H4I8C%OA^%,O'(+>P+RNV+PX]%?_4 M/DJG#AL@TG%0!9M.AJ<3HI^M3VE.+BXV)+B$U9DW>)`+)DFW?:CSLT'08RG2 M.B)[+ZU9*U0O(K8^?H'LC-60>%@3)]I23(-E+A2(? M\98R<#!FW/Q*DD,]_W]9X:$E,P@N]XO(@%2&E6N6R+!.->/5QR.7951,F755 MEIZL+JZO(9'\1J^YV7$MO/ES/>=EH<&VUOC[>,]75E87'R][[/'"$H5U']651J_?_".R>/)XN3Y6@??;1$0774BU(; M^:5X9^2`)L//HQ%%_SBC(\98:9X=(70D&C/#Z?3 M'^$%B/0&"D'PXAM"A`/B2;.S8UE96:LP23DH)YZ=8LL9MF%=W+U[.-:U=8CQ MY>PV(.246DGVO%::2:V92\0NQ$/5;%PUCV6SBB4M>1P3*$"P%T67XVLEY1H@ M7-@I"*2R!07$,0V$=0:9/BG%Q/0S#MWZ41P;HL1GSM,'_HD@:BIW@-3^$BNE6` MXC$\6=H]Q4>$:.5&VPB5>41VSS5_DMU7A"E4-K,F(-\C[V@'P&.]=>VSG`YT M=X9;F**Q9KHEP6'*T1C86@`CT)@Z3XQ1'9CZ<-^2DAR=/3/?I$'=/O;0UI,_ M0K5?PN_]2VDKJF(FNP&*?>2O$V>P2[;%\:YP2TVSLIL9HR>RIRZN,;JUBU(C M3D]#VPI]"'1,CG!N@!GNM)$+JZ$:CIS+9K[UZ`4H]82Z/1B[MG071P"'DFU""< M;&X1'Q'W6K#3*L)W#=/`T>_'9US1'X;DN5C%2D=5N=NS*VH86'TV=5[YZL/[ MXLZ)^\M8%X-GP3KS>.,PI^PG.?:P//T=3/7F/E@TS6'X;HLW!QJ@I)-"0,1G MY1]H_1I!,?6]^T!MT>EY0A(0Y"G;IR#B")7V#5AAT%;8HZ<>.@4XRR$?%YL0 M0X;T=:[_)A_``\Z:>'7X4I'H`0D0FYRGIG`'6RATU#&`?5 MY0S)]]`4#0)[C;C)/.8J-T?]!OG2L/;J2Z>QS>\++NU_,L]?B.=)[,>R;0P( M,KWF(O@8P'+$*RD;#]AV.'3>1KQ<(#L%H+MQ(VOU=M:!/>^]='ET;8\Z*QX+ MH5X'/D7_=E'CX`-&H+L=9<"=%IDX`H5Q% MY%#O//PN"EWATG:YIG:#3C//0N*.?03_:9"9?2.,E[9N!VG*I#3`DXJ[`37E M]R!H3-#3X>8>*C+S]V*3TW.2/C;WOH)Z@=5C74;,I<>//UP3HGG*W;!+93O. M(^+QD.*?I$E.X>)<,]V%NPN+W^0.V+L+:'@0.B-*V>I$3]SX\>,ZN[A\CQZC M&BC:8/.1IB!0CTV##4,*4'U2O%I(79NY9IE-+*5W#[8R-F"AF:]!S#8!^X;U M&%=G#AJOP'`,&HIVA1UT$>WI)?*Z_K)E90B$MV6;EMY,!PU3?1FMJCA/;X86 M(0(WL467-MV<%OFVNUQ43@:YCIR$"P^Z\IGP6ZOEE'4+W!]MS)R<:K@BK-K( MV,+;%?.G:2_X2;5B08Q+N5\R0N/:EX&X$]+M)RK3(5"K/-./4Z9SU`_E_^!/ M$SOZ/MX6XPP_0J>>6GT!RK,%'%L+_(G,R>@&T;*LU*P]A6>$F&<+0PG70GI> MC%86A+!88KU]*U*`B%;W M15G_HJP7M@,(,DJZ<+(H3?Y\99V',PF4@8D$G%),\>F02(`%OGA07 MA3?DDK>>CP_UP[Z/T,^R8/3F#D":$*FW<;#9/%E:?<#_)JL/`KI7#A`QX=X` M:5$%38+&`"/FWKH0,F=BT)$R:'8=LD(N2,E3S::`2U[T&*2AH%HBNI+QHI*S MZO4*Y2/U$D4QMZRTU%SK`X82[G8VX2G41U#RL=)'J&VIISRKY;)6OT'PTWOG M\`S(6*CJ;9XD456V4+7*I2PLZ@SN<7F$!=CFA(515L9I@XU*52B86\G4F+TP MR9F((D=31V7OK]D"^!)%3(@R$Y\BACE7[D&*+H02A/-"5,^M3->,8F0^ZD)B M2-HU&CPB M*\>:Z%)$J&P"62. MM>7\#')#TC!X(H05931P@'08ZIQCK&]U]PZKL%F&L0*?:+&I?&8PN4Q58@'# MG:U)^F_X;[G'9'@'01>;EPG9(<4.1<&$3@.DB!7:;:P$&_VN7);8RZXU9&*1I/J3*FY7E M4F:L:3F10'/9CS0Q)%:G3R_4HS6$F4*#3%2FUG(&*&R^AP/F/D M3=^2.^"!HBFK@TJTKTK*0,7?M<"<.$87"G]57W+4F^+%[LZ"G'@@SO@]\>Y>B[,FZ:-N>,. M"K`ILD@3VZ[\=6"W2<56\#Y!^W`486NK(2&L/T1S;EB3$:4RN6U>8=U_^?KV M/\N"!L^&@'A"IC.8!D,`%<]2UG%3`'.!"C&".7%H2KLJ%[!Q&4L([X<*B7?R M\`_966L,#5@H?.49@T.5/E%!.@9N#:.,;D"3O?-83HTD9Q@$D,ZO_3YC00G1 M]S=1Q8R'+$'#(KQ%H?D2\FHEKJFSR)RX@^$X<[LG@]N=;:?/Y$/:Z`6$R(UV MHO(N-)=%L&8OSM[=O:N/?[C]]"?:7PRWCT;NUCAU\PB\,I1GGX??3#S<+0(@ M7O!./-@R1L6%W#A6N61VVNP%]3AC_01;*99DG8WEBHBE[%Y>_@!Z&J#`-,#! M,MSEK);W0O9QW<.]5<4,=&CZN>WLN\$D^WM$(?1]!ZA$[]]GDA1^J`&(F9F? M1LB.>FG%U=_@!7EG3C=D"T%OF%2^%=\@4=^\7[\4#WLFAC9*5#,'_U:%Z$$N MPE#>-_S!]N'AKN&-"=XR0%H>&.SEWHO#[69_X^\;3W>WF_N1!<9=&-K&2?,< M1>,MR"#(.1U"6AK]]='HK\NCOSX>_?5;1`#H?.CJ86]_V`2SZ')]0O9CS%"L M?SS$>C:C\V\J(/ZA29#H\+!1;JBLG_4XPK45_M&&2L,?30=7TG7--+OGFX/- M\0HQYG+_F!A3$@9-9T(OLXG[P.#$AY:U3\!&\U=\N(3KG#3?G.!Q>(M9%Z"C MX[L0J;)[?C0XPXUSPD2:PY.CMQ>7YY=OY*S8N1AN[B?IF]@YR;YXV='MV;A" MLQLZ>FRV:7LZ0]D\PL9V?K0O)P.33+$+^"'=$#ZTLS$S)@3'#6YAL/K[*2^/ M-4OKZ1SWSCL>P,LCG`Y$P]T>#W;"[%4TNI^@3!;BW0G@ISS=QI@BH%-3X+O5 M]#_XZ8[@:5WOV^IAKW!DQS[@5;R5^]5"C;S]1J_4L$MF9T;EHS;V-:A'G>FT M&M6_^J"F0PX."[8@R57UE_[RNV->G]:_6W<9Z5&H..ZM,^:.M5,**W+!(.)/ MIX-B1'R,5C16)Y0ED&>>H%?/Y)[$47/N31/0!=)^G\MRO/M+!W!&S M[R6V-S/]+?GG!YSS]1ZA7/7ZYHLXU(=ZT7AZ?\'$9C#)RGE(H!5=?7Q"4*]]N!E!301TA/8B!V;&8QN\C.],P$]#-'?<5' M.&5:E].B*OY4TH%J@"F>S0&<-198T':Z\+]W;!KT MHM))^UG/)5I?*D;YY51XN4X$&\$C$IWK/(4R)([$!IT5]<^P9Q4X"P5Y]HDT MOP$_3Y&?+<;^*V!6_"[YTY=[0%RF(KAU\X/8\R.%[4'(F^,>5!RJF?L>=`0; MDV7S9:&H0I(=2Q'YP'T5.Q:#63/$;#]9;!Q`EFX"'CIB9OGS7V6HO;^+-M!! MMM5/Q+WJ-]#Q%0^Z_9-\6XK/,C4`S5VSK4??2N95M"J!JV+[>N( MB'ANKT/PMT6JM%^*5/#F&]B`CZD43W01C]JSR^M3:EHB;&.@ZM5`-A"L[Q3% MN^\0@?4D.@.0*-6\H"J":Q[?6FT*9N4SJK_^SC)SZ#VL@ODDX8U@RKKYYCF. M.ID]PG<:Z*4XK:QKZ#AGN(SL!2_:T#XTZFAMWAW;$+MC]-#=B.K)CEC`UP'U MK8125$^R0X8OOMMLP],'`-FB?W,)_=EC@T9?58$:<##EN M>%!GWX<:O/#3D*6A@YD_KS7P95FHS;QG(3S=T$/K/4G4\3P"F?6]?T51JL$E MN6HOJK#3258`-O#0PL>A6BRBO3>@0^%Q5YK_A5J$3XP?"64R_KE>15+)!V[0 MYMNS$\#F?R)IT6"-8J6OH?Y&J'8O!1H4A3(V"6A$$D'G3?L9Z;Q#NV7)@ED$ MN*>`J;`F=E&FZ:$I@Z&63$G+]?YTZAZ,4*^-2=R#):0\@+MAS&9M=GIUOVJ; MX$V:!T3]7K0^Z+FZ_YAT((?#&Y("25*/EF5S*C>?1;;4H_]CN=/51D^ZM/DA M9>#UL.,2(7B%/RX]\;C7A=7UY<65)\M-.R^7^NJR8)GO!S:F]S>7)[$K92C! M@K1C#/#S"MF<"(90O'+*HXV+6"H/4(:6:!`<\S4NJ"$M(>Y8>]/DHD_#HP(" MY*_PT#@7J=WTFPR8$;Z2"!*LKQR,IS'.?(_[^YFQ+V3NB)IXN8DQ]9/`3!)P72XJ%3 MT#';H!W#1*H)=+9!YB:E:"F%X]:\MNS^RN)R*+G8JZ%F1[^6BSJ@SULZ*YJQ M8F8@;Y,1V%)EZ?*0XYV+!\,X6ER),V>'H1@+)A4CD7U+:;S`J:\#,]V.3#S, MBK/(("!GNA=9'U%C>&5E)>9$$!I#)K+-Z9ACM:"6621UX5$)7PB+*X/XA_F? M("(%@46OTL=0%J>Q-C$TQ]\992TAO'\<90$B!3#.&&49Z%F^>\&^DU.FB-:+ MB?P0&6:]T7JQB.BZP=FD%+%!.XC%9APB<<\\X3"8*P[+>([XB6=S*$E)84MT M>G/VD_\:"F9J$"].J'@BW<;`C21EZT?-=?[\X6J1;<:MN"1X1RZBVTL5E44L M@*[9EBE'36N*>RL[<,$&CN4:20`!W1UQ9L%0Y,J1R&E)W/1OO$@Y9R7&TBQMGX\S5L\THY][PX57[9S[+1`,3Q?DEXTN3#,!$G!R7^RRPE/G6?*@+`U M2=^A.RM5JG^/X9!W8P!#@&O[4#VHRHX6\BG74)USW.-P>/E9:6\$5&@S%4$; MM`&T*QS1$Z+#+!?-'U"U24X8<7>_SWNZ62*3[[@[>&+8PAB6FR-D+H2Q((,Y>;2ILK/93IK1F0A)'_`D@Y4HJ!"1T0+"&@+;9/#*6P`'#?BUACM$R6[X!P\(6*D,/,;379Q9:>"/6S%&`_7AY_J.NJJWS M[0F1SB@@>9DN;:9-.HR7REF1.`"]6`128!>748D.L7JVL?CCS\ZCI+8`Q"KY MB/%^M`;ND,:API%M`5@4$AI^\N]L2RJE<\PWAO;2#,,6QUUFXW\F4'X!8/L) M7A+NMS'W+]9X:.FCK9!UIN[\5DAL:"H4(EK794NNYF`3C20E:Z2"P(E.[44G MUKTME`ETI15$Q2X'^D?9N'N>W_/ MLV:K"P5L/I4W5A[;K?O;W05!D\X+%L!1!+V]=>E$O+VWRM=H*NLQ43PQ.#]6 MJC>E\^GT!WC-%E`.P!E?-$^)?J7@-]BSY\?O`4EH_GWZ[NK/_/GZ!_;\]I_4 M3MU\6%_!S4*&(`"JK%0!)`X]N@S!%9?BR?)R"JD846#VI4CDS%>:T>)$JPV, MM5",,M<<%P82%7S"%5?J@.YXR"J>1^SS--$OCE#(M>4(;$*1\]T9/KD>Y M+86D,V&U)>-"8ITN$GJA[^R_] M/\$2:>S"`$B@4NV2833:J?8`L95L-_1Z`R:U2Y3`]OT/W/XAUV*@?`LOZFQX!2*$$% M`B&!YL0+:)L[2(=FL)I@PV:E28)#R;+(],(7M/!""4287IIQ]3 MOBS"=92/&-DEPES/(PAG>1+Y_?-(JW#.]-(^BH6E@!#@%*3-T,J2_;.HI-5# MA$N$=T"&J('";M--B/8QA[``"(:5RFP7%E@IO,%.&3\JO/(.3V34H#B58ZD5 MTVNL^\%X:>>9GXC6=D,W\1U,^XI)DN?,@LWRKIE*6]Q?8/F5:<3#Z[:,).OV M[2OR*&0LS"F[O[$\A1"$R%Q>6\(,";!][]N0A8936>MC8(B+#2:C/DHO2UL+IQ7\F5=2>T%AFV!G);MEW7FMI\S?3=5Q<KO]@4:,4`.^RLRXKT M\>4%,CEX:WK5AV;'>T(BA0>DK_RE2J\[2.35;%M^[%`O^5J:IT\7%QC69G=W M?W#@X;LQ^$F2S+>S\L\8FX,?((]$/X['5HQ19*?Q*$7V5=T8VAT[KU@EI-YC M/%K$WP=O5O='K'S[P9LZ-GF[0K'AV,3+%)$.85D.1,B>Z/S8N81Q.+G\B]*F M:RYU#6V&32"B5];KG3%&8KY1M!L9Y%*^G"@3#%+(C`&3L+ALLN1P/=HNUM?0 MU&:,&%(_9C$52TB)L%#U+MH6/PI))O6/,\8/;,T.<3CS)&)N#>YK24F=U)3R MQTZIZ2T]S3D:;#0?-P6KV--\88HW@IUB#^IE5]U6>1B\?-?O.K$6]SZ_Z[N> MUM`0$[SK>N`'ZK36W=01+&C(CI!7-]RS/0HW=[!59[-&PWLLL>3".@ZQ0C/3 M%CKV$<041'IBTH@I\RAPB\4/_Q6A.S.5?#IDYP$1M/N*ZO^JH_S!*GSSN",L)6%,\`W1 M6^]#U"<'BXJ!>QO"PI&I%^%W-$&Z]QND^IPGW5'=9G_BAAV,2)*\@WE=BJD]PV9^,,`L$OO!+:F[X`U4=X"E3LL#:$SDHF#XV>U=_+>M,LG4_PQ?NR'=?XQZ^[IY1-V+WXBT)(+HB#JO=N_OCPBI#9$ MOUV,Z495Z@O<7C0]E`=A:2](W[L*27Y^>6S(9_(4US.PBP%A!N^6O'86.890 MGO6[H5$V8MA,TE7BM7H0_,.5"E>/O@&(&@%BR8=ML]DB7%?1.,W]??QJ9W?O M.HE!G=O\ZF+J/3'M^'EGK!S/=I!SERP$_A41<6RGV<[KS\98D=V'X>R@7DZ4 ML@>*W)@B(:H>/C4_O&SV<=NAM9G?)"MBMIB/_RPE$_7?ZJTBAZI(T?(R(!&] MRA*@ZJ$#`5FH_UZIR1:KM$,B&H",J;'/G<*?91`PG:U_UKE*%4U$.K9I9/H. M>4U8=0/R9"38!EI6V'<]G:K;=#_4;_R'R6LFQ'[R1"(/WFT(?*T M)+O1-A84A]%]O)49)1Z/MU&@#S:B.1I1'G1\3N[\)UUCGF:3)^/-?EJ-K+I`=U(=R0%%B&R@GJ0Y7X;@HK9!LKW\<");(IU&D_?PUALT MUR38(GM'&D*0@JX5)J0`@S$G3]%LS,53-AM-^C,*S:V'5U;7ZQD\$$UKG@YS M&X*\[H9O6ME.GMFA6=X M2-CE?'M#H!-AV_.-KW,9;>L)I7GGA\E'-B8%A+Y1G.@<.Z0J06.S+)6.P?Y, MT@FAZ/<:%TBLKLRH1ZGEAW`Q*4NS]XDE.28F4<7NKA0T)%F_(U*,2?6N':"Y MN/GA&8_,PJ1F&)./[BFK]2E%K-]E0@!1W+!^9F%*=7%!W$I;#:X9; MAWD"/>9&FY=A""!9(/6:=V1092:'] M^`(_?X8`5;$_IG9USF*#P&\@"UFU[?R#IZ@XQQ8^C,[LJF'0G^MU1N8?SR=T M\+K3`8J*U%H+KMQXKQJB0;YM#[,I4,4]D.(_8)5^2=3WFPME+_U&PQ*4C1)& MD3)%X879]*GP]R8AAZZ>Y[WEH1^>#/VPY#_(^MD'$+M_#BZPV;\VK#3=,Q[> M>E0_Q.X9-!O79!![L37+8A$U`(^KPPY&K,;.Q@[K@<.&1)Z0;1&<7-@6E#A/ M7P-%U?^K0UJ5]H8/$9E+D5X*ATAQ1E@A9&[@5:_7,N?W;S`+4A]K!#&YY2T? MG06OZ5.73>M)APU5(,^C$"$+^8!(LR\@^.I++`SS!YS@Z*8 M"M"\V#_<>;'GX+C?;;Q\N;%W>%!JE#Z30`[Q81I2%7\V\8T^/!D8PEG9(@\F M`Q]]JL[L]^T.9^KP_"&SR<4S)Q>9Z,_US3;QS%G MKW-<'X/6#R;$)(0-W9U!1)31.Q$-E(N$S4H*AUUL8$P6%GJ@Z-+0.2(&C'2$ M_$J4]='MW?2\V3T[[=RR>TN>.XS=)\2<+ZWWOE\\E,YL5X)NT_,@,!R8SJJ:&"3=C.BJB]8]ZU?*K/S3BSV:[$2:, MU_U;%],D.4OL,X`//+'Z,ZUR1@-.B?3N8L4E&^WF[*C?F/VK32\U3;ES,J%(^`+1ZO=/)*W"S^9C^[4GS MW7:DT-Y9CE0]"6&!9>7,"Q02H`-.@&]06KC-_I;9DW]`Q:7_J#E`_XBS&,L! MU;:/[ZA1CH18K"\[748?@GEWUQ"?GI%/>@TW%[[='69<^;1;1U*OZ,65I;HB M:9EK3**KUPSV:D(VN(1WD@/#/+$5 MUK,J%ZB$XDQNQIZ0(#MJK_31NAL(_OG.X?-M2UO-YHN]PYV]OV[O;>[, M

*?13T!X^U4=#HR>KR*H1\]J;>[_/%Q M_6,K:T2G3WI"*[>2^;7J#:L&,S/7TW8-YMV?`+[[$X[G<>2[W2E^`I43W&.U M1'LH%STO_*I8.$Q"NS*TT/WIW7GS3%M&+,>/B\TW50F-&9_C``DH%6+'M\2_ M8//"T*4B&M=W5[=''P9'-JN[LJ_P6ZW4NRCKTIG5N[N1YT2V:6X3YW:D$.$Q M)NRL(#7'EQG#57!2&)ZEJ:J=`:6I82&T!<#K_/YM@I;A81*@MPQ;J_91OYD? MS`*^W^O!WN@$&B!94W'X>*Q;C&`G*NYM*D;WUL;L"9QL#UC-<^5GM:. M8NHPR_ID@T^\]SCKMID*%+2$0"GPU'K2]4?-KEX"[%DS&T82RQ%1_<%)G1$* MN@CV+NC=#F'FF!:<,`6CA4!L>_K$;.9;5YRN@$[#SL\:+F^@V>-.YM[#.);? MOF1?ZY^H(4^]%"6FW8B4P5-XUB&)ZN6"BUV<"*](62'UBJB+97I>_?=H9R0R M*HZU:_,02]9<_%HK5JO^M!K^1G$,S#W7^J>W"3[$ABJ?FV+.A MP*NT8XA`S2ZV1R2IY'SH[-S!JZ<'V__]"I&AV?[6!(>YZT[U\GQ8YAP\W[.? M!GB^932&Q*_.@]#-:!S!,D4!P25+82R9OH;T!.?PO:PN&5<--T7V(KT.>M=> M0044H87$9%6M3[B=UC3>MCT&-C13JZ^B,;WNNF/$M3^$^+0N27Q]\_HYYP!>7#VJ!CT(8Z5N"TR3%"/1 M2T4LXGN1`LSE3:*.1B:+;&=$:P,0:HAHS2=$L5DBZ/#W+S%0U>5Y.)&\YT2 MK8LF1C3,`;^M96>?W11_BYUBYG[777"M.K#8R$:ZIV"*D>+SNVVK#=LTD/#2E&Q7>-^ MZ/T7(;>U@VY/("&?U[Q\NA&60T'!)AD%#*X;`(`K4M*O#"@(>PS_>UFZNL#9 M-)GD:49!CC;"NEOI+3'B.^NT^A-%U$/U)J.#20;TA_E1DM-TEN6OFI`(%/*[ M88XM%T;O$:P9>*7MF%^!=`[&/K$,RO/OQ`#&QUS[H!`*:@O->%A.9@OR``7D M!\GJ7#(:*M;GBFS<2PC@]8R0^/L9?5"!X=HS3M/>/J2QBI)92(!^NLB&T^L7 MIP=P4+1CN/\7SHM/H.CPK:LHF00HV.2'WU"T?D4T`!R_!]"+3P!/^K:*D@A( MTW2HDOG@9Q MMW1L*[XQLY6M18VH8$VEB=]U)IX%<>!T%W;%1CO8P^&VAB-;P)9)$Q!76KOG M@3]M^H_`\B\```#__P,`4$L#!!0`!@`(````(0"?7H'KRP0``.H1```8```` M>&PO=V]R:W-H965T&ULE%A=;ZLX$'U?:?\#XKT!8\Q'E.3J M0M7=*^U*J]5^/!/B)*@!1T";]M_OF'%C;-HL>6F;^G!\9CQS!F?U[:T^.:^\ M[2K1K%VR\%V'-Z785>=^V_S\T^HBVN?N MR'GO`$/3K=UCWY^7GM>51UX7W4*<>0,K>]'610\?VX/7G5M>[(:'ZI,7^'[D MU475N,BP;.=PB/V^*OFC*%]JWO1(TO)3T8/^[EB=NP^VNIQ#5Q?M\\OYH13U M&2BVU:GJWP=2UZG+Y8]#(]IB>X*XWTA8E!_C$OE\`G8="IS&G M7NH!TV:UJR`"F7:GY?NU^YTL\R!TOJX9!M M."=Y`ELAGB7TQT[^"Q[V)D\_#2?P1^OL^+YX.?5_BLNOO#H<>SAN!A')P):[ M]T?>E9!1H%D$3#*5X@0"X*=35[(T("/%V_#[4NWZX]JET8+%/B4`=[:\ZY\J M2>DZY4O7B_I?!!%%A22!(J&@7JT'BR!AA$7_S^*AHB'`QZ(O-JM67!RH&MBS M.Q>R!LD2F#^/"$*1V.\2/#P"8CLXAM<-I2OO%3)7*D@VA00F(I\B:'B%>"#K MJ@TBGJ]-@B&OKJ.UL2OM(#]#2#B"1"8BOX4PI,$^\Z5)\-H%;BW-VCA#2#SD M-(Q"W](U7HX92Z_+ABB(;+XH";9$Q5=:S!="V""*$!(2V6'*\'812/3MK0)>?9 M;+.08$N7E8\,(:@K"-G(!X9\YN-UFH+372O!D)7>(TN"+5E6.C*$H"S"4J:W M15G&>A0%.BQ#%H&2FI^N`6T)FYBK9%R[2EF0TDAOC=(4"R*H'R2Q;FI3W'W& MCZ8--G2UL%!W.Q8_00R8PA5CN5Q^$V+*DTX\N]0(^O;884/KT#*%4;GS24JH M=@>5/*1!2"+[4R-,==*/YZM#]S;469G)"&)PZY3%46(596XB(NA271VF.&G+ M\\6AB1OB=,FHDQT;?92D+-&^I3(W1L0!I8D.T!1WUS"0[UAVLUI;9PJC*CZ@ M9.)N!H*`^^GX3&W66+AMNV0Z#T)['BB,JCG*TH!:\G,+$A,6Z\8RY=TU%I>RB-BQIOK\E<-<@MBR`NLJ2'S&$,?W*[&X2ES M>C!=1RA3850U^C[U(SN-!H1%)/ZJ&(.[QL>`MM39_JPPJM*B.`JI;_53;F(H M\UE,-<9,H_3RV2X8H/./79!91Y@I#`I\"$D*KV^C9L!S-D%41I&,F$R)=TV1 M8#I%F#8R=<+C*?(0!B0-;4_*%8\*@\*HH:$N:%.@=/51#N>U-%S$;=-FENME M"H/W'?+9BXR!^/1%!F_K>)D]%P?^>]$>JJ9S3GP/+>,O9-.T>%?'#[TX#Y?7 MK>CACCW\>83O5#C<;/T%@/="]!\?Y+&PO=&AE;64O=&AE;64Q+GAM;.Q93V_; M-A2_#]AW('1O;2>V&P=UBMBQFZU-&\1NAQYIF9984Z)`TDE]&]KC@`'#NF&7 M`;OM,&PKT`*[=)\F6X>M`_H5]DA*LAC+2](&&];5AT0B?WS_W^,C=?7:@XBA M0R(DY7';JUVN>HC$/A_3.&A[=X;]2QL>D@K'8\QX3-K>G$COVM;[[UW%FRHD M$4&P/I:;N.V%2B6;E8KT81C+RSPA,S*A/D%#3=+;RHCW&+S&2NH!GXF!)DV<%08[GM8T0LYEEPETB%G; M`SYC?C0D#Y2'&)8*)MI>U?R\RM;5"MY,%S&U8FUA7=_\TG7I@O%TS?`4P2AG M6NO76U=VJ^>?__J^5/TZOF3XX?/CA_^=/SHT?'#'RTM9^$NCH/BPI???O;G MUQ^C/YY^\_+Q%^5X6<3_^L,GO_S\>3D0,F@AT8LOG_SV[,F+KS[]_;O')?!M M@4=%^)!&1*);Y`@=\`AT,X9Q)2"M.69EN`YQ MC7=70/$H`UZ?W7=D'81BIF@)YQMAY`#W.&<=+DH-<$/S*EAX.(N#UO5D"53,+2L?VW9`X8NXS'"LY1ZMAUC_J" M2SY1Z!Y%'4Q+33*D(R>0%HMV:01^F9?I#*YV;+-W%W4X*]-ZAQRZ2$@(S$J$ M'Q+FF/$ZGBD".S1P1%H$B)Z9B1)?7B?-AOZ'&(KA\1JCX_M\+H>SHX;.1DC56#.M!FC=4W@K,S6KZ1$0;?7 M85;30IV96\V(9HJBPRU769O8G,O!Y+EJ,)A;$SH;!/T06+D)QW[-&LX[F)&Q MMKOU4>86XX6+=)$,\9BD/M)Z+_NH9IR4Q>Q,O91&\\!)0.YF.+"XF)XO14=MK-=8:'O)QTO8F<%2&QR@! MKTO=3&(6P'V3KX0-^U.3V63YPINM3#$W"6IP^V'MOJ2P4P<2(=4.EJ$-#3.5 MA@"+-2[\JIB4OR!5BF'\/U-%[R=P!;$^UA[P MX7988*0SI>UQH4(.52@)J=\7T#B8V@'1`E>\,`U!!7?4YK\@A_J_S3E+PZ0U MG"35`0V0H+`?J5`0L@]ER43?*<1JZ=YE2;*4D(FH@K@RL6*/R"%A0UT#FWIO M]U`(H6ZJ25H&#.YD_+GO:0:-`MWD%//-J63YWFMSX)_N?&PR@U)N'38-36;_ M7,2\/5CLJG:]69[MO45%],2BS:IG60',"EM!*TW[UQ3AG%NMK5A+&J\U,N'` MB\L:PV#>$"5PD83T']C_J/"9_>"A-]0A/X#:BN#[A28&80-1?F#R` MY+<&ULG-M;/TTK2MW'_]N=\-?N2G M7AZ&__QM?UD,!V65'3;9KCCD#\-?>3G\^OCG'_?O MQ>E[^9KGU8!4.)0/P]>J.MZ-Q^7Z-=]GY:@XY@?RE^?BM,\J\NOI95P>3WFV MJ1?:[\;3R40;[[/M8<@JW)WZU"B>G[?KW"S6;_O\4+$BIWR7563[R]?ML3Q7 MVZ_[E-MGI^]OQR_K8G\D)9ZVNVWUJRXZ'.S7=][+H3AE3SNRWS\5-5N?:]>_ M=,KOM^M341;/U8B4&[,-[>ZS,3;&I-+C_69+]H`>]L$I?WX8?E/NTJDR'#_> MUP?HWVW^7K9>#\K7XMTY;3?A]I"3HTW.$ST#3T7QG5)O0YO(PN/.TG9]!M+3 M8),_9V^[ZJ_BWY_:`HY%RR0_MQ6&;3F[=%.1\6^N*\-=&4F>HC19W<A%UCJ#/>1#U,W,,DUXQPGM*N MT5O[/B8ANR2-]%1)NQAHAXFOF(6PO8D7:,; M!K_-Z16C?.2>RQ#ISC^1(;H4ER&Q824VF*R!W6II["RQP18;'+'!%1N\B`WAN>&CBBY&)>IAXAXFZ6%2N>%.'[F-CB=B77?[^,1[_&(WS8:/S>OUOF0J;!FP/ M]/6%,%6X;)`T9*R.A)BXBH6)C8F#B8N)AXF/28!)B$F$28Q)@DG:$)U]0&"T M!FY\R.C$WPTA8_.$[9!I\T[(&&)=KJ[ID_E'PNOYXY72%O/%8F((\[YF(R0I MM+@B^KPS-K4Y,*5`&+TZG%"N")<3UVIXC9!LJ<\5T;O;$7!`H4#8TK`K^`%* MA$#<`,EV)IBD4L(GB\Y)MI/5;S"FL*G,=L)T31R--4BR+RM,3$PL3&Q,'$Q< M3#Q,?$P"3,*&L.M7ZX8QX@#I6L2TQG@E"2:IE/!9(TGX3-;H8L*X3.OT9@Q) MLP:)23^])JN25+$PL3%Q,'$Q\3#Q,0DP"1O2#,_G\X6J*L*D=\29Z6RF:]I4 M&%;%>%4))JF4\(FCL[6?Z-W8)&^[=S/43N\FFPEN;J"0F/0;#RAQD-BXBH.) MBXF'B8])@$F(281)W)`FMZ23%$YB@FND4L*GC4[CMM,F_]".?H=$Z-<,59@9 M7C9(TB.M,#$QL3"Q,7$P<3'Q,/$Q"3`),8DPB1O2I$PE,>-'?0FND4H)GS(Z MF=M.6<\1&YL#;O=IVESHPY<*0]*T06+B*A8F-B8.)BXF'B8^)@$F(281)G%# MR$Q__::13%X(8Z$$%TFEA(\;G=9MQPUT:FP6N!TS8RY<#TM%-E7R M*O+H"IFB.+''>M@O57&L'YAX*BKR.$[]\I4\?I63[P=/1@0_%T5U_H6NX/)` MU^/_````__\#`%!+`P04``8`"````"$`QW@[,LT)``#O2@``&0```'AL+W=O MWBY[__GW]Y?BWZO/JT/3^M==2CO^[_+NO_WPS__ M';_7KV5YZK$*A_J^_WHZO2V'PWKS6N[7]:!Z*P_L-\_5<;\^L1^/+\/Z[5BN MGYJ%]KNA.1K-AOOU]M`7%9;':VI4S\_;3>E4FQ_[\G`218[E;GUBVU^_;M_J M<[7]YIIR^_7Q^X^WOS;5_HV5>-SNMJ??3=%^;[]9AB^'ZKA^W+'7_98U=7S:<#*#<6&ME^S-;2&K-+#W=.6O0+^MO>.Y?-]_YNQ+,:C M_O#AKGF#_KLMW^N+[WOU:_7N'[=/R?90LG>;[2>^!QZKZCNGX1-O8@L/6TM[ MS1XHCKVG\GG]8W?Z5_4>E-N7UQ/;W5/VBO@+6S[]=LIZP]Y15F9@3GFE3;5C M&\"^]O9;'@WVCJQ_-?^_;Y].K_?]\6PPG8_&!N.]Q[(^>5M>LM_;_*A/U?Y_ M`AFRE"ABRB+L?UG$F`XFYG2^N*7*6%:9?%8Q!^9B:DQG-VP+VVKQ@EBYK[\B M@VV$*,/JR3+F?&!,1K=LBS$[5V'?W+PQ0[&KFCWOK$_KA[MC]=YCAQ/;&?7; MFA^Y[[..@.W?FB7WYX,U,NZ&/UG:-M+8 MPK"O'V9F6*I9M>N0*LY9\/CQ5;NTP:,-/FT(:$-(&R+:$-.&A#:DM"&C#3EM M*$0#^]KYC@S9+OK83^QP4/93]S%YWAU<\]UQ?I/L<\/GFJR12=[[MB'":8OQ M1"WB"G+YDJS16#5>EYFJQN\R,]4$;4,W)VR3Z9QL2$BS6M2G!XAW`Y(^=_CE@?"DE8+1A11L)+T6R1 M<8`MC"Y;4#A0N$),13!,8[*@^]2#-7PH`BA"*"(H8B@2*%(H,BAR*`J=4.+% MYYDNKU7UUT!+B*CTF` M28A)A$F,28))BDF&28Y)H25JSO@TXN5YD4_AX"MR@R]&\T;F,FR)M'D3=33$ MP55<3#Q,?$P"3$))#'/)CXF`2:A)*)CZ^S7X$N.\6H23%),,DQR3`HM4=/&IVMOZ-?$ M[*[:K]'I5_Y)#90R2!Q)@XF+B M8>)C$F`22O)YQE1C&.$2,28))BDF&28Y)H66J"'CD[F7(;MR>";F@-6PD3&M M;>@FBF78('%P%1<3#Q,?DP"34!+9Z8W:O5Z$B\28))BDF&28Y)@46J+&C4_R M?B%N8FY8C5MK"EDT!(U;%^[66!VW"PPZ02N1-JPX9L%N(J+ MB8>)CTD@B0A;QR=T0EPCPB3&),$DQ23#),>DT!(U;>Q4^(7SJ,D7(UW;F!S% MMD3:M(DZ&N+@*BXF'B8^)H$D(FV3CNO,$!>),(DQ23!),?8,%\DQ*;1$C1OK6)3>37\3U.2<]FKD-=@2:;JL%28.)BXF'B8^)@$F(281 M)C$F"28I)IDDIICX M5F8\QG0V5R)QO+1GFE;R]YI$.IBXF'B8^)@$F(281)C$F"28I)ADF.28%%JB MANVV6P9FQRV#,8FZ+9$F1"M)1`X-]O'^!;F"=52QX%=\:M_NXM5XF/B8!)B$ MF$28Q)@DF*289)CDF!1:HJ:,WC,`P[..>P5C.GEKPAL!*TP<3%Q,/$Q\3`), M0DPB3&),$DQ23+(.8HW)Q&C>@4B/4FB)FC0^&7]Y\@1)$W/WZDF3=$6V"2?X M5Y@XF+B8>)CXF`28A)A$F,28)))\#N%I1Y_B(ADF.2:%EB@QXY_IOB%F#2?7 MFQ-R/K,ETITV,7$P<3'Q,/$Q"3`),8DPB3%),$DQR3#),>%/#N(7A^+O8IM/ M&G\,;43*Q'.!Q--A]N7QI5R5NUW=VU0_^#-_^*'RT?KQ/*)O$_Z,$=*^,I;L M62?M=MM7+*__F][QURRAP"P]N''"MCCAM[6+V6Z/KYL#W5O5SZS31L- MYNR"]2@>6"1^.%5OS;-M'JL3>]!0\^TK>[!4R9X:,!HP_%Q5I_,/?`4?CZIZ M^#\```#__P,`4$L#!!0`!@`(````(0!*R:;<*`,``/,(```9````>&PO=V]R M:W-H965T,Z:;6K__O5P$]N65*3)2<4;FMJO5-JWR\^?%GLNGF1)J;+`H9&I72K5 MSAU'9B6MB9SQEC;PI."B)@HNQ=:1K:`D[Q;5E>.Y;NC4A#6V<9B+CWCPHF`9 MO>?9KJ:-,B:"5D0!ORQ9*X]N=?81NYJ(IUU[D_&Z!8L-JYAZ[4QMJ\[FC]N& M"[*IH.X7%)#LZ-U=G-G7+!-<\D+-P,XQH.#SY8L^?Z+8/DWUE`(&]JD&[#A_$E+'W-]"Q8[9ZL?N@;\ M$%9."[*KU$^^_TK9ME30;0P%Z;KF^>L]E1D$"C8S#VNGC%<``'^MFNG)@$#( M2_=_SW)5IK8?SG#D^@CDUH9*]<"TI6UE.ZEX_=>(T,'*F'@'$Q_H#\^]F1=C MA,/_NSB&J"OPGBBR7`B^MV!HX)VR)7H$T1RYZ7<1PMG&?(-#MH5N<:-%:LCPK="L#K&:'R(>/;J1]1M%BCZ"YHMI6Y M`=X]FS=Y[[G"#WK)B`02&I+HM'R8ILM$>A'H!@!Q'/?^!M)H@H$F'"O6EQ0C M1C"YGE$O2FT(H@\I"/&88&4T4=?>&^0'H1M-(<<2A+`?O9,DS/WUE'K1E'*" ML#(:;"A]S\/AB:#+>CU6H!BAI*]TE&0X9KS<92T>L\63%Z^,Q*!A'`?!9`K6 M0T$8!0DZ.8S`HFO`M'@,-NB)F3XC,6`!]OS$[0,QD0T%""?8/0E&8/J\&^PF MEQ/3XC%8$$XW#:,Q9"&.8G?ZW1T*<)*XT3N]3*XAT^(Q61R??$UF1F.^#:Z,VX_[FR_`<``/__`P!02P,$%``&``@````A`$33ZVDR`P``?PH``!D` M``!X;"]W;W)K&ULE)9=;YLP%(;O)^T_(.[+-R%$ M(56AZE9IDZ9I']<.F&`5,,).T_[['6.28B=EZ4T2PN.7]WQP[/7M2U,;S[AG MA+:)Z5J.:>`VIP5I=XGY^]?#S=(T&$=M@6K:XL1\Q(@W]6D8X=U9K\&KD&]4_[[B:G30<26U(3_CJ( MFD:3KQYW+>W1MH:X7]P`Y4?MX>),OB%Y3QDMN05RMC1Z'G-LQS8H;=8%@0A$ MVHT>EXEYYZXRUS/MS7I(T!^"#VSRVV`5/7SI2?&-M!BR#742%=A2^B30QT+\ M!8OML]4/0P5^]$:!2[2O^4]Z^(K)KN)0[A`B$H&MBM=[S'+(*,A87BB4*- M(CZX'^][EK<,W7#Q?Q5;.AH"O$<<;=8]/1C0-?!,UB'1@^X*E"]'!*$(]D[` MPQ(PRZ`,SYME[*SM9TA=/C+I.>.I1'9.^,$)L<'7R1R$/#4GTNY#\>9-BD7` MF<;$I'O2'P)))1-,F(5*9'.$XA$>-/4X[TW`B0G:)V_!(E:?G$HF&M+K!?"F M:QG.9@#%&81WO3,!:\XB[<&I9,+!F>_ZL1>JUK,90'$&37^],P'KSO1Z2D8Z M-#;%('1M!I/5W*AGH\M/KJX^-.4+QZ,(_VF_NQC4'.=&6P17K'#9*)>6RYRP:ET,C,.Q0C>M)VUY49C@GG M_:=-BW2$Y`S6&_"=F[*Z\@@A=]@.[?!WU.](RXP:E]`SCA7!(.KE`4)><-H- M.^J6.!7!)*3]>B"/*Z>BX^0<``/__`P!02P,$%``&``@` M```A`*NJ;7[9`@``9P<``!D```!X;"]W;W)K&UL MC%5=;YLP%'V?M/]@^;U\!0)$(56[KMND39JF?3P[QH!5P,AVFO;?[QHG+B1K M%QY"@'///>?>RV5]_=2UZ)%)Q45?X-`+,&(]%27OZP+_^GE_E6&D-.E+THJ> M%?B9*7R]>?]NO1?R036,:00,O2IPH_6P\GU%&]81Y8F!]?"D$K(C&BYE[:M! M,E*.05WK1T&P]#O">VP95O(2#E%5G+([07<=Z[4ED:PE&O2KA@_JR-;12^@Z M(A]VPQ45W0`46]YR_3R28M31U9>Z%Y)L6_#]%,:$'KG'BS/ZCE,IE*BT!W2^ M%7KN.?=S'Y@VZY*#`U-V)%E5X)MP=9MA?[,>Z_.;L[V:_$>J$?M/DI=?><^@ MV-`FTX"M$`\&^J4TMR#8/XN^'QOP7:*25637ZA]B_YGQNM'0[00,&5^K\OF. M*0H%!1HO2@P3%2T(@%_4<3,94!#R-)[WO-1-@1=++TF#10APM&5*WW-#B1'= M*2VZ/Q84'J@L270@@?.!)%QZ<92DV04LOE4T&KPCFFS64NP1#`WD5`,Q(QBN M@/G?CL"*P=X8<(%AJ$&L@BX\;K(\6ON/4#IZP-Q:#/PZ3.@0/B1UF2';Y9D- MV&0VM352;NV-:9H7(;,TBWD:T[H%#,#;1DT0X"8FLGSA;%@%%A-/,$N'F"D` MR-2H41"_.CS'4IN@`H-+5\8LCQV_56`Q812,K0B\Q0M@)@"2306\;=V`3Q,G M)XDM)AW3ADF2!7`XR"SUL^\+#8BW+'\>/7*/*3G MBOX_#R;H5%'J'%M%%G-4!-W(LRB?'@X_JY#Y1$Q>P,OFTP2=ZLD1..J=`]@SPVD9M^( MK'FO4,LJ"`V\%&9$VDUI+[08QFVS%1HVW/BW@0\:@Y&PO=V]R M:W-H965TE+P'G'I]SS[W79G'])#OTR+41JJ\PB1*, M>,]4+?I-A7]\O[N:860L[6O:J9Y7^)D;?+W\^&&Q5WIK6LXM`H;>5+BU=IC' ML6$ME]1$:N`]1!JE);6PU)O8#)K3VF^279PF21Y+*GH<&.;Z$@[5-(+Q6\5V MDO40OYFU8,YH5-LDOH)-7;W7#%E!R`8BTZ89\]*4:2S>\WO=)TW8'O M)S*E[(7;+\[HI6!:&=78".CBD.BYYS(N8V!:+FH!#ES9D>9-A6_(?%7@>+GP M]?DI^-ZHOHN=0;&B3:\!:J:V#WM?N+]@944R(0!':V[LG7"4&+&=L4K^"B!RH`HDZ8$$G@<2DD;I+"-9_G^6.&3D M#=Y22Y<+K?8(A@8TS4#=")(Y,#MG$ZC/V\[`DMMSXS;YK8`VT(W'Y:PL%_$C ME)`=,*MS3#HB8A`?,P#5TPS^K>S`D"%&HW*9)".OSVX5,-,33#XB7BD#S>7* M#ESAU+M-$S(=*8-H"!<^3$@^F68CX)4FI'6YI@.?:!XI@V8(9T$S35(R>UL3 M9NQR30<^T3R6+FB&<-`LREGYEZ;F[Y%TX!/)8G01)$,X2$ZS='J5+=XC MZ=`-UT4X30/=\*]4;T1O4,<;F,XD*J!6.EP6 M86'5X$_-6EDXY/ZUA3N=PY%*(@`W2MF7A;N.QJ_$\C<```#__P,`4$L#!!0` M!@`(````(0`2'\(<6P0``(81```8````>&PO=V]R:W-H965T&ULE)C=CJ,X$(7O5]IW0-Q/P)"?3I1DU(!Z=Z1=:32[,W--P$E0`V:QT^E^ M^ZW"0+"=H>F;))"/\CEENRK.]O-KD5LOM.89*WLI#O[C7+[\_[WW[975C_S,Z7"@@@EW]EG(:J-X_#D3(N8SUA% M2_CFR.HB%G!9GQQ>U31.FX>*W/%<=^D4<5;:,L*FGA*#'8]90B.67`I:"AFD MIGDL0#\_9Q7OHA7)E'!%7#]?JD\)*RH(<VOYPM5JY/`+<.E(NG M#$/:5G+A@A4_)43:4#*(UP:!]ZO\WOMX$+\-`N]M$.+-5L1=^ZOI2N9M$'CO M@[QGPY$I:;(=Q2+>;VMVM6"M@VE>Q;ASR`8"=JF5B>B3_:M<0Y(QR"-&V=FP M22&-'";\9>]NG1>8TJ0E`DG`:T\0E0@[`NOHT M-+3F0*LM07HSN,+?\MA;,,#=$M0"9^(`%I-6-X.D%B4AFF&'O-KBL MIW<8#8E&$=4"]KWILR"[I#(+6AD)\*<_V%0L:/L]O,,8%LPP-T2U@,UON@79 M*A4+VCH/B-E./<."R=STM0MI#%$M8`><;D'VRZ$%WRA'9D_UC7)D,H:%,42U M@&UPN@79-!4+1CD::ZSM5G@7P>,R+L=54]36#SX" M5`#O_T'9_P\``/__`P!02P,$%``& M``@````A`,4:R44=!0``710``!D```!X;"]W;W)K&ULE%A=DZHX$'W?JOT/%.]7#(J@I=X:179OU=VJK:W]>&8P*C5`+&#&F7^_ MG82.!*+BBTCGG$Z?=`>:++]_YIGU0>$X57*B>5R-V)D6 M,')@91[7<%L>G>I(:XJ].Z;E";WDRQ%T>EV_OYV\)R\_@XC7-TOI+.+6M/%G\.!:LC%\ST/U) MIG&"OL5-SWV>)B6KV*$>@3M'!MK7/'?F#GA:+_VL MEV*!_DWII6K]MZH3N_Q6ION?:4%AM2%//`.OC+UQZ(\]-P'9Z;$CD8$_2VM/ M#_%[5O_%+K_3]'BJ(=T>*.+"%ONOD%8)K"BX&;D>]Y2P#`*`7RM/>6G`BL2? MXGI)]_5I94]F(\\?3PC`K5=:U5'*7=I6\E[5+/]/@DCC2CIQ&R=P-3BY0YPT M1+@V1`)Q!A[Q9GSZ.\QIPX3K&=QMB(8K93+5.3N$(">2!OA5TWC^E>2`;*4=2J2MW5RF M*)&#H2!;?EWWZE?$NY$8*`,U]TP/=XL(##=$PTW*#A%(B=!@HFCZ(-CA^CAX M98-O%;OK!GKT&XGQ18(G[H3XW0Q*P%1L2)'!-H,$OMLIBEV7$+4);A!,)BH$ M31JL<5N:*%N?/U5N/&PPBYRGJ_2"KDJ)\81*?^:/O6X2)8"X6I$%\PS$$1VAXJ(EW=JVWR_V:Y&!= M4W]O2HQ9$XYAF"$:3)IP#,$1&AYJFC^CB8,[FKK/@8W$W*M#1&"P(1I,P*`RN M32+;BONOQP9DKDXUB+&&RF*J3S6(\$A9'DOC'<)P:;*?:$OK[SLB03>DX2#& M&MZ#[]0@PB-E>2R-]P?#I1`A&'!*TF")N]B!"D!3=)>DR^#9EJ]#. M9O^EQ[\W82UD]V;L41M$JTG5.*8NM4>)E,6T,+I&W@`,URC;A;9&PV:4(-F' M&SM4@ET')B5L+))C;$=[G$CCN.-9,+O1C1/>$`S7*-N'B:\^$S;"`53PU;3M MF\*^:=N[!;T-'4^`#9PU"*V)5Q4[^[- MKTO8/%L4ZIJKGFEW]84H?I+3N`>3U"E/9N3W?4[+(]W2+*NLA+WS4Q?^\%96 M>2*T(0OXZ@9^QQZ2!7Q9]^TOQ(X)C/`IG`.,1@`^,U7C#Q:J#P?7_ M````__\#`%!+`P04``8`"````"$`'8A]P"8#``#'"0``&0```'AL+W=OTT[;_?.3BAF&PTVTT;S.N7YYS7X61Y\UQ7UA,5DO%F9?N.9UNT MR7C.FOW*_O']_L/,URU8[%C%U$MG:EMUMGC8-UR0 M705U/_L1R<[>W<6%?MDUZ">C1SGX;,F2'S\*EG]F#85N0TZ8P([S1Y0^Y+@$F]V+W?==`E^% ME=."'"KUC1\_4;8O%<0=0T58V")_N:,R@XZ"C1/$Z)3Q"@#@KU4S/!K0$?+< M_3^R7)4K.TR<>.:%/LBM'97JGJ&E;64'J7C]2XO\DY4V"4XF(="?[@=.,(_] M.'G;Q=5$78%W1)'U4O"C!:<&GBE;@F?07X`S5A9"?S1'7^O?2H4:T>06758V M''?8+B&?IW6#TC5#YD_'/7SR@H1A1,`=DV M>@&\>[9@]-Q+11CU$H,$.C0DP6Y%?ST'9R+,^ MCG/6&IVS'T>IGR3);)3S4!//@MB0&)@X`P]%;/63#%.*0Q&F&M&`Z^#[':-.SD.^B322:?SV$O"=#X*VM!$41+! MQ'G5:%(]-_58J:G8TRVM*FEE_(`S,8`71K_:S^O;`-_0H_4-SG%<=_L;,$9; MLJ=?B-BS1EH5+<#2`Y("XX5^<+ M?$#_$VS]&P``__\#`%!+`P04``8`"````"$`8]!^OTP'```J'P``&0```'AL M+W=OPN(\Q8!N#QA/% MG*5=:;7*[EXS&-MHC+&`R21OO]4GZ.XB'D\T-R'S=55!_5W=E)N'S]_K\^Q; MV795<]D:UGQAS,I+T>RKRW%K_/,U_K0Q9EV?7_;YN;F46^-'V1F?'W__[>&U M:9^[4UGV,XAPZ;;&J>^OOFEVQ:FL\V[>7,L+C!R:MLY[^+,]FMVU+?,]=:K/ MIKU8K,TZKRX&B^"W]\1H#H>J*,.F>*G+2\^"M.4Y[^'YNU-U[42TNK@G7)VW MSR_73T537R'$4W6N^A\TJ#&K"S\[7IHV?SI#WM^M95Z(V/0/%+ZNBK;IFD,_ MAW`F>U"VF8CP]4H'^K\K63_C_K3LUK MTE;[/ZI+"6K#/)$9>&J:9V*:[0D"9Q-YQW0&_FIG^_*0OYS[OYO7M*R.IQZF M>P49D<3\_8^P[`I0%,+,[16)5#1G>`#X=U97I#1`D?P[O;Y6^_ZT->RU,7LJ MNSZN2"AC5KQT?5/_QP8M'H(YV]P9KMS96<]7[L*QX%[W!G%X$+B*)W#FF]5J MN=ZX$.7&[9?<$Z[<U18I_26<'W7HWK<#Z[W/:K)"H/669CW^>-#V[S.8/%""737G&P%E@_11($Q MF8:2^UG%0:F1(%](E*T!64!1=;!,OCW:F_6#^0U*N^`V.VQCJ1:!L"!U3,*& M.HAT$.L@T4&J@TP")H@P*`%E_@%*D"A$"9'#3@!)&BUM82%<0AU$.HAUD.@@ MU4$F`25M6)@?D#:)LC7@7ZD`7#7/';>!13(8:342#":#%HA$B,2()(BDB&0R M412!#><#%"%10!%U36PT2;C1+4D&DT$21")$8D021%)$,IDHDL#&*4LR_?H1 MFP$QIIF+)]YQ`OO+,//VQE.U"`8CX18B$B$2(Y(@DB*2R41)%/;^^Q,EQFJB MG'C#\@\0"1&)$(D121!)$S]%@)*8X1B09R(U`Z6`D`F4R47*WH&>6DV<-RIST MCOVI*IYW#3PPO-(GMB0'&A'>GI`@JB@T[M:05<$HY,CV6$^SL!RUZJ/10*02 MZ0.^MWX$4D0N\LAJSQ M"0.,0H'8[PK2CT48Q0*-L1*!1L<4HTP@ZJCF1UH5*3\RY:Y+?N!,S;*<*NMQ ME%09LF!KE`I;DS\`)4A]6.Z@42B0[&CI[ZQ(6&UH?:S6:\?37FNQ,!EC)P+= MC)T**Q9[O5A;:ZU]R(0)C:UJ2+H;2<,W:H3W0G*-,&1)>Z'%D$U_LO(&'5E% MW,H9"R+&C@E'4O@4.V:*HYH?:56D_.ZO$=[CR*DRI-6(MM(#BUFYHR`A1YM1 MD$@@FQ:$93NH9F(<*!%>8Z!4(![(YM(>RA=/)E1[0&(F'ETF6RWGBKC5;= M,3>1]N1$>-V,G0HK%MNU'4<_BLB4V*J>I`F[H>?7YOJS=D-^$?%63A:4H=NK.:S1]YX$L4Y.>0=S!!>IEO2?_K#" MZ-J3]U>$(FP58Y1@E&*4*4A1`Y:VHL;M78-:J[N&0&,R`48A1A%&,48)1BE& MF8+4_+0.DNP:OS3;-FXN!5)G6SL+"D8KL3N&&$48Q1@E&*4890I2U=#ZS3=F M&S>9-D?R;",48JL(HQBC!*,4HTQ!:GZD2?N(M6VS;D]>VP*ILZWMY<%H-#!"5=%'[`5\;*(M(AHAGZ%H;X5& M;!BAK3@:<6"$]E#:"'S3^C+I`3>9O@<$FLH$;C`9?PGQJ7K:C7=+'TX@)R19 M^7!@-\'7/AQY37#7AQ.B"0Z:3TF>$<6G=(6>WR?=+`X%K;\?3H[`+P`_FAR! MQM\G+2Z.!OV_3SI=/)+""&EX\4@&(Z3OQ2,[S]]-I^-!-E-YAIX/9SLX$AQ_ M0"Y3'K$'J4P-))X/ISLX%!R!0"+4PQRF';Y47O-C^6?>'JM+-SN7!U@N"_HS MI67?.MD?/6^ZGIH>OE72_NL$WZ1+.))8D!;ET#2]^`-N;0Y?N1__!P``__\# M`%!+`P04``8`"````"$`'^V"4+`0``!#8```&0```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`YT#DP.;`*N*0A])&A4_X1(N%9<)#H?[CJ0A"9SN[/H MJH@7]-\X`.9S[N==L*')T1O-N$G3F_2Q M`"*!*"`:B`%B4\(B0HO-3XB(:X4BDLZ)\6C$_;T+1L="TIOT(0$B@2@@&H@! M8E/"0D*+41J2\K;3+0;.N/6\Z_%=(+2^])D?C_+9WQMUU000"40!T4`,$)L2 MYB@M^><[ZHRYHX$L^^G?`!%`)!`%1`,Q0&Q*F%-K<_WZWI5E%NUIA5HYI+_8[M&N#.^M)5<>Q"D1X4B_]ECZJQCSI MLB_ODJY"&ZT6;J^L>YM6%HRJ;."8OKQKPX8VVIZQ0%0DG--(%#PFH=6YW%IS MGP-*G48D.N25M%,B$I'J4`R@[E"L:!#9#A7\<]HD46,G_/-*AK:8+G)WE4<5 MK03)2IMEK>FLYGU%T:&T8K7())SLK!;M>*@6(_H?'Q&J,XEMZPX=;=MT5J'M M);9M.Y.V;3XPG+HY/W!>"['`>531T$L"-^'.-31NW"RJVYNU(%'[BET29&=5 MM5&:5'6UR,:\ZDQB0SH@ZD'7D.FL?$/3Y7BRR%)I.Q-_^YC*V1U4S;$IGFD@E4N"2$IGG4=)ZIK*(S92/)K'I5$&*UK)NYPK MK*@[JUC1="A6M*PB]\^IG<2_CXV$()E2MSUB(Z%>PD@(5C&!PMU^TS2:'UT0 M9&+JLQPL^S%2P8:/CG,9-WOB\FLZSV6Y9XSRBU/-C$?UM^_;>CISN M3ZZ5;'(%%!>!QH77644D$$E$"I%&9!!9AKC?3GC!2**I?F+*!+V6CAV/%G%4 M-)1$YR@A)Q1^R>:OB,7I"AV7"]Y1IZ62CI[H7U!>:?\\6L0YUU2`!"*)2"'2 MB`PBRQ#WSTFDQ#\WI<<+=_9W*A5>6[&MSR.6BAZUJG1T8R4K*JHEGF/G30X/R->2+!N>K2(*UA3`Q*()"*%2",R MB"Q#W#^W)R?^MN56M&R/#(BEQ%L1.IJ2DE45]QG>Y6R+/S%)<"NO M/6(I`2302B)2B#0B@\@RQ/USNVV6DJJFWQ!.[2"UWZ;9Z.MW[D[&-L'J5$;Z MBDG>D@,"WN-!>WJ->WI`+"-A3X_S1J"51*00:40&D66(^^=VU2PCLW%[S#/P MUQ@ZKX%)$[9L^A/O;_/CG"947,2%72"2B!0BC<@@L@RQ<(P'Z8;6FNN&@-)T M(Q*()"*%2",RB"Q#W+^";OA8NL+^.3V0S.[C^\G8JX=TD0TH2VE^ MMQVM8DJ#$HEKG$0KA4@C,H@L0]SE0:IFC*HFH"1_#2*!2")2B#0B@\@RQ/US M>B))J5,U]8C<.)%;+T-8;GMETF6M&??/I:MWKD3&P^2-*UUMJ)Z M_;*,IY9-L$J00"01*40:D4%D&>+Y*$B:*:V-`W?/,0J<@);46+)[9C=A3;3J MLB@0240*D49D$%F&>"P&B24:B[E@"(A<[IQI$`E$$I%"I!$91)8A[M_[8NG$ M[$-M1$=KX3@CNMJC-.'Q?CK,OI)5_P+*,T((H%((E*(-"*# MR#+$,C(IZ)FSCJ3:BIFK7M&DMWC!BE![))7]#B)B<9*P^IU[N\D@K=%:9_T+ MPB(Y'0Q6R2F50"01*40:D4%D&>*IR+1&NS'5R]/W=A.4'0&Q5`1!0>MD7`U' MV6HH8L7$JHY'B;S'@Z3"!*5"0$GX&T0"D42D$&E$!I%EB/M7D`H?$_L35`\! MD>]II+,9TD2K;I43B"0BA4@C,H@L0SP<@Y3(Q,L.V@RZGM\%E"I#1`*11*00 M:40&D66(^U=0(O74S;^!6F2"6B2@+-OYK5VTZF(F$$E$"I%&9!!9AG@T!FF1 M"6J1@-CD]E8)$F@E$2E$&I%!9!GB_CD9D-T'?$!W3KR:8,,\"`P^L_-[OE"1 MQ:*OV*5?HI5"I!$91)8A%HOI()736O.M-:#$F0:10"01*40:D4%D&>+^%51. M/9NWIW3'A:<;$=E)=D#IWAI1LI;#WEJTJN/-(>_R(+4S]=(F'84!L92``!)H M)1$I1!J10609XOX5U$X0G@-7VRG*GX#(]R0?=;S!;F\$FFC533>!2")2B#0B M@\@RQ,/AQ%&R&IT8EL70#$E-`$I%"I!$91)8A[E]!2IWUP\44E5-` M;`)Z*T))PG$"EJSJ*(%YCP>IG2FJG8!81KQ5@@1:240*D49D$%F&N'\_2^U, M4>T$E,V_[$:\B59Q_OFVD@!)M%*(-"*#R#+$HS%([4Q1[024]+Q!)!!)1`J1 M1F0068:X?P6U4YWSZ_H4]4U`;/X%Y7)B_I6LQN^(\'R9T9RIV`6$90[J"51*00 M:40&D66(^_>SY,X,Y4Y`V?S+#W>B53?9!"*)2"'2B`PBRQ"/QB"Y,T.Y$Q#+ MMK=*D$`KB4@ATH@,(LL0]Z\@=SYV=SE#_1-0EN[\?"=:Q70'_1-_@)!HI1!I M1`:198B%8SY(2[767%`$E.2V0200240*D49D$%F&N'\%+34^ZTG%.9[O!)2N MMQ$=6V^+5N-WSG?F@P1/:YVE!`YSFF"59$D@DH@4(HW((+(,\904!,^'#M/G MJ'<"RB9@?KP3K?H)B$@B4H@T(H/(,L2C,4COT,M&^?%.0,OXVF*#2""2B!0B MC<@@L@QQ_PIZ9TY?&3GU5(U[&S8[R`J(33]O1>CH]"M9)>\>\0X/DCONG:>\ MFZ!MFF#%IA]82;12B#0B@\@RQ/W[67)GCG(GH&SZY:<[T2I./]]6$B")5@J1 M1F00689X-`;)G3G*G8"2GC>(!"*)2"'2B`PBRQ#WKR!WW*\-`T_2YZAU`N*Y MGL0C&W]K&:UBKE'KH)5"I!$91)8A%HO%(*W36O.--:`TUX@$(HE((=*(#"++ M$/>OH'4^M+$N4/H$E&4[/S>*5GVV$4E$"I%&9!!9AG@T!LFH!9X;!<2R#+^%:3.QYZ_=.\` M9",]H"S=\;3&*]MHU:<;D42D$&E$!I%EB(=CD-:AHP)P&81-$ZS2R8U((E*( M-"*#R#+$_2MHG0^F&[7/TJ,LW?F94;2*Z>XK=DBBE4*D$1E$EB$>CD$ZBKYC M"^GVJ-VC?YT\]]I_(O5O6](W< M]M0)2L94,G8"("]9S&[B7T%()78=^D2N5T'7HUZE2">6'?M.0LF4KD,/.I5* MZ#KTT$^IA*Y#C\L42F:4!7ILHU1"V:9'&$HEE!_Z\;]0,J'KT$/(I1+RAQ[) M+91,J0?T,&NIA*Y#SU262B@_]'AAJ83R0P_F%4HF=!UZ-:A40M>A-U5*)=0: MO3%1*IE22?MIJWQ<3R@_]-A]J0[EAQY!+Y2,J0?T7FZIA#REUU=+)=0W>O&S M5$(]H%<02R74`WHAKU1"F?./'.3^U'0=^FQ&H4Y-UZ&O-Y1*J#7ZBD"IA,8! MO5!?*!E3?NA5]%()C41Z*[M00NX4O:'+%Z]>48_ITU&%EBJJ0M\R*I34U"_Z MM$ZIA+)&GWC!$K&\H<].(M?+&U/B]&GV+Z5V[LCQHM_NPH7V[]Q@*?`ODYLO M_M/O>7+=^"Y4N*/171S<%+\V?-=]0_0)][?5M_4_5[MOF]?]Q?/ZD3;747MD ML_,?@??_.(3OC7W='NC;[>VGQY[H8_UK^G+ER/UT\KC='KI_4.2N^\__?_Z_ M`````/__`P!02P,$%``&``@````A``[FG26>'0``-K$``!D```!X;"]W;W)K M&ULK)UM;]M(EH6_+[#_P?#WB46]63*2#&*1]0+, M`HO%OGQV.TIB=&P%EKO3_>_W%%G%NK=.M2VZ/3,8=S]U6=8YMT@>T1+Y_I]_ MW'\_^WW_>+P[/'PX;][-SL_V#[>'SW#A^./_V]/3CZN+B>/MM?W]S?'?X ML7_`R)?#X_W-$_[U\>O%\S@?9KAZ/&6.PY8)K__X[>[',G]W?7OFO#X?'FU^^0__?7_Z MK\-/M[_[^NT)_5Y!4E!V]?G/=G^\A:68YMU\%6:Z/7S'"\#_G]W?A;4!2V[^ MZ'_^O/O\].W#^6+];G4Y6S0H/_ME?WPR=V'*\[/;WXY/A_O_&XJ:.-4PR3Q. M@I]I$OSC,QLLX@;+O,$B_]9G-L1KZE\N?I[VF]9Q`_Q,&YSVFR[CAO@9-UR_ MNVQFV\4E?OVV<3O\/.F%7@R-[-=%>_-T M\_']X^'G&?8VM.KXXR;LN\T5)DL+8OC5XQ+YJQ6"I1$F^11F^7`.$6C^$>OZ M]X^+Y>;]Q>]8BK>QYIIK&EVQ2Q5AW85IVQ)T)3`EL"5P)?`"7,"$T0FLP3=P M(LP2G$@:KA/(ULP+V:DB;=*6H"N!*8$M@2N!%T#)QL[U!K+#+#@8J`6PU3JO M8PUVD7&5K'7);BP9O2#2$3%$+!%'Q$NB',%AY@T<";/`$;5/K&9:[W4L>LZ2 ML62TA$A'Q!"Q1!P1+XFR!`\?5`+N'XV/G%JMS[QZ*T M64ND(V*(6"*.B)=$"<6!_W2AH5@+'0B$)@T[(BV1CH@A8HDX(EX2I0KKZW15 MH5BK&D@SP_(0_2L/8[DJB6\9=8P,(\O(,?(**<'8ZTX7'(JUX$CZ(-:?B79$ M6B(=$4/$$G%$O"1*%<[/IZL*Q5I5)/@ANKC01Z3=6#0VD4A'Q!"Q1!P1+XD2 MVB#8GJZTK]92$Q(=9-0RZA@91I:18^05TOI"!BE2UWSU#D>EJ;EK"#,XRZ1V M73<1P5S1YF71YER5-FP9=8P,(\O(,?(*:3="-!%N/']V:88@HR1')+M-J$T; MYJJ.D6%D&3E&7B&M+R2-T_7%7");&I%NZ:ILZ5B56TJH:P@91I:18^05TI)# MDCA=:(=+?+ MI!S>M8?C>S:H9=0Q,HPL(\<(%R;$;]1NA.`AW'AA!QYBBI(<41:S:PBUC#I& MAI%EY!AYA;2^$#1.US?$$J4O(MW2RW(''JOR#DRH:P@91I:18^05TI)#"#E= M4XP\#177!';-6)4E$^JXRC"RC!PCKY"6C.Y,D!RJB]`1D5S%A-J& M4,?(,+*,'".OD-(WGQ2J^FJM+Z+R?4#Q-G\GRL:F5EA78:;";(6Y"O.::>E% MWGK^`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`N.9`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`PC MR\@Q\@HI?9LBDSW?VKY:ZTL(FD3P*B^/Y:K4Q)91Q\@PLHP<(Z^0ECPI>&TX M>"64F[5CU#+J&!E&EI%CY!72^MXJ>&TX>"6DNKTM+X_EJMQM#EY<91A91HZ1 M5TB[,2EX;3AX)22[S<&+JSI&AI%EY!AYA;2^MPI>&PY>">ENEY?'%K`V'K(1D:V-51BU7=8P,(\O( M,?(*:7U%R`K7N5^7J3<W)Y,2Q7I0:WC#I&AI%EY!AYA;0=>*FG!Z]- MJ"Z"242YM[M4E5'+J&-D&%E&CI%72.G;3@I>?;76%U&Y)Y>7O$39V-0*ZRK, M5)BM,%=A7C,M?5(`VW(`2RCW<<>H9=0Q,HPL(\?(*Z3U%0'L^8/TEE-60GIO M+2]OY:K<6$Y97&4864:.D5=(2YZ4LK:64Q54=(\/(,G*,O$):7Y&R M7F@I1ZGM@)H9PD1^G[0M+V*)LMS4O&EB7:7.5)BM,%=A7C,M?5*DVG*DB@C7 M#M/+WS%J&76,#"/+R#'R"FE]DR+5EB-50GIO+:]7Y:KD0LNH8V0864:.D5=( M2YX4I;8RM'*:[J&!E&EI%CY!72^HHH]<+>RG%I.Z!PN5OLK.7EJE25 M;^C09B0W+*Z&=+DJK07#R&:4YUK.BG=?+E>EN;Q"VIB0B<1W15\P)B:HK.]Z M.R"U+T>4J]I4!1='^Y:SXBI!EZO2*S>,;$9RKN+]BLM5:2ZOD'*AF179*T3M M9O4N7.]^^G9W^^OU(8#J3>47N'M\O*=\/XO.9,/,'\[1@?0Z=HGA(F-BN+-K M>`6HRSL0;NU*#/=V'9C8%C=W'5C_4]A;A'G<\377I5^,>[[*"0M7)L6R9L:Y M+#$<;,,]]I?-?%N&EE2"6_NE%P4WAJEP$Z7$X$9D<:K98CY?%3L@[!F*Q&2P M9YPL+YAF4^R"<$?-O[A<-T4)O)*S%UY-BGC-C#->8CA*#UXMFC(,I!+<.2[Y M`J^&J7`?O<3@U]TK-OYROFF)?AE=R M]L*K2=FPF7$X3`Q'_.C5JECMV,N&S<12@%>1K:57D6T&K]:;!O\EKV@R>#5. M]KQ7:O[E;-D4[\C@E9R]\&I2SNS?^Q5O>T>6%PC,B8$T,YA##`N)&-8-,7A! M##L4,2B5K%`Z*5;VN9F4QJR)$Y`X#A9V0_Q8EO88B"<&\<0@GAC$$X-X8A`O M62%^4N9L9APZ$^L/F<7DD])=,^-X-[*\7F`C![P*@XU4!QN)P49BL)$8;)2L M4#HIYS4S#GJ)A;\`CFMHL2T."!`_;"K.PUA#(\N;TG$7?HQE:?G!#V+P8V1R MNC+NB;(T'2P:-P4K+`KI[.3$AR<"T76TQ(1V^,&AK\(@GNH@GAC$CTR*+U.> M*!/BQTU)?'^'>R'^=3DOW2<_YS?I?-(ORG/"?S9/!GG"S;4\EZJ2QFR>UJ4T0MW/U?OM3" MK!!M)I@U)"'U6S$?(2=&M17DUI8GW M]E=Q+S$9]Q(;XEZS"&F/\UZJRF]*X%9\%3CWCF>&VMJ*9<,ON)PU%;=B23][ MX58(2!/,:PE8E@YQ.`%,1QSB&$ODJQ0&M*04/KJ MKW$TZ4;_RH0Q:^5FX2EU^A@"7\:RM&_"%V+PA1A\(09?B,$78O!%LL*7:5$P M/05`B8_Q,!\EH)08E!*#4F)02@Q*B4$I,2B5K%`:@IQ8`2^==&+N4TK'+"C; MS`>'L4RTF1C$$X-X8A!/#.*)0;QDA?@0T2:('Q*=/BQ&IMI,#&TF!J7$H)08 ME!*#4F)0*EFA-.2Q"4J'^*:51H8?XZ%W.:-0KIXED,Z8XZ:I]1!/#.*)03PQ MB"<&\9)I\?U-_D\7'Y\)H,0G)MO,#(\+&C(?;A67E3+#`X.H#D\,(H9'!A'# M,X,D*Y2&P#1!Z9"OM-*!O?3>*SY70,7JS.0**:YYX?E)XV]('L$/8O!C9'*Z M(L_"HK$L30>+)"LL"D%J@D5#[M(6#4QHWS7QR0*"83%0'<03@WAB$#\R*9[> M>^4R(7[<%*P0'T*/$/^Z]U[I*0/R)!!9N)2=7@E,&3*6-B7F+E$(5QC"%MH: MMN1"Z4OQO@2+(M>EEX-5(2&]T7P^6VTVFZ+Y,(AF@T'C;-F?2D!.9<,O:#:;Q:J8'G;) MZ0N[0G2:8%=,6LJN@>5W7RN^U!X?<(`#7FHB[(K;J2/LP+#7!^>Q]V]7V(%T MSH1=L2K/!KO&V9ZWJ_@%V]F"_C"AIB_L"OEK@ETQKBF[Q@B77^AR5KP(++"Q M3#A&##L<,?A##/X0P[Y%#&M%LD)\R%]"?#CFO.XC=$UZ!((R9HQWPAA^(Y\V MSF.R5>)K[X-E,]&2$& M,&902MM"*3$H)0:EQ*!4LD)IR&83E,8HIY0.#*>2W.;*)>'XV`1]QJEL6KDD MS)O"CW'3M$+@Q\CR*^%/`(BRM"DL&C<%TQ;U3STXW:+XD`052R(3VG>X[@'G M/YP+UE88'O!(=7C"(S$\XG%D4GQQJ,5C'\>R+%ZQ0GR(:T+\ZV))>JZ"7#:1 MZ5@2H39E2(RR$*XPA"TR6_;[%VS)A=(7BB6B3A@C)RR,"5%.&//"(2(]2T$Y M,*3!'$M6Y=\^L4IBC8PED2$$I%<*/X8ZG.G">1:Q9+Y>+HI`#H-H-A@4MT2D M&-\\5F))*HNQ9'V)ZYSZ-([GA\KI"[M"P)M@UY`']4Z4@F.Z*+R:%Q=:8==0 MHV))9'@7*NR*=4,LF<^&_V@]L(MF@UWQ5>!X\:Q=ZA'T!`AU1!JS8NX66J$[`5_&LK1'P1=B\(48?"$&7XC!%V+P M1;+"EQ#FA"\O'8YC]E/B91Z,B4T]1B(F-F902MM"*3$H)0:EQ*!4LD)I"'-" MZ=]8`3$6*A/&J"A70)$BL`+&,K$"B,$78O"%&'PA!E^(P1?)"E]"@A.^O+0" MAL"'"9."ZT8]1B*M@%B7CPM8Z\2@E!B4$H-28E!*#$HETTK[YSNRT2;B4$\,8@G!O'$()X8Q$M6B`_9:(+X(4II\9'E]D$I,;29&)02 M@U)B4$H,2HE!J62%TA!K)B@=4I!6&IENW-Q-!F8E!*#$J)02DQ*"4&I9(52D-V$4I??]I. M#X50)HS)2![/Z>_Y:=.\2\"7<=.T*N`+,?A"#+X0@R_$X(MDA2\AZ0A?_FB6 M-[=7G_]L]\?;_0-.3K-PFYSQ2P3IB1%*O`Q+:040@U)B4$H,2HE!*3$H)0:E MDA5*0W812O_&"H@I2)DP,/45G&7Y)@K'@+$L=1N^$(,OQ.`+,?A"#+X0@R^2 M%;Z$I"-\>6D%A/+B:R3QH1/R:S8-,R@=MA5U4$H,2HE!*3$H)0:EDFFE_=,@ MA-+7KX#T7`FY`A+#[Q>9CCX%D,OR"F#6-(32O[$"8G92)HQY2JX` M^DN4>DQ%[U7;,(,OXW1II<`78O"%&'PA!E\D*WP)^4CX\M(*B'%*B9<1*ZT` M8E!*#$J)02DQ*"4&I<2@5+)":0A#0NG?6`$Q5BD3QJ@E5@!?)E5/M4@K8-PT M=1N^$(,OQ.`+,?A"#+Y(5O@2HI/PY:45$).6$B_35UH!Q+`"B$$I,2@E!J7$ MH)08E$I6*`UA2"C]&RL@QBIEPABUY`J@2WCJ21=I!8R;BA5`#+X0@R_$X`LQ M^")9X4N(3L*7EU9`3%I*O$Q?:040PPH@AA5`#$J)02DQ*"4&I9(52D,8FJ!T MR$[J+5]^=H5L,UVGRV6II1`?I\NG18@G!O'$()X8Q!.#>,D*\2$?31`_Q"DM M?F#BNUP7QV_[_5-[\W3S\?W]_O'K?K?__OUX=GOX+;R%:'!78<'/'O=?/IQ? MXT5>]:\4UHS;C&/S,#8/U[UX;!'&^MLS\-@RC/6OC,=686Q5GW,=QOJ_N?!V MEV&L_QL-C2W#=GA[57N=R[`=WI!4QX)VA/+JV#:,]+T(?AVBN--6%.?'ZZ M-F<3YL0GCJMC8<[A3Z$TYSST:/C3*8\%??@H46W.>7@M^#1-;6P6^H"OM5;' M@I_XUF=U+,R)KS+6QIHP)[XZ41T+<^+K`]6QH`$?N*^,;;',<+>>V@@6&>YS M4QO!R\!]8&HC>!'X3G]M!"\!WV"OC4`POJ]=&=E@&]SGK3:";7"#M-H(E@#N M%58;P0+`7;8J(UNT'W>AJHU@!\7MFRHC&VR#.X?61K`-[KE9&X'7N/]D;01> MX\Z-M1%XC;L8UD;@->[_5QFYQ#:XY71M!-O@YA6U$7B-^Q;71N`U[OA;&X'7 MPP=6RKWF$E[C5K*5;=;8!@\VJ(U@&SP2H#)R":]Q(JN-P&O<6+XV`J]QD_7: M"+P>KH.4KWJ-;?#XG,HV:VR#!\_41N`U'L)2&X'7>'Q);01>XU$>M1%XC8=@ M5$96V*9^EEQAF_HY,ISFD4=JL\%K/"2K,K*&UWA@5&T$7N-12Y61<&JLGQG# MB;%^7ES!ZWK*6,'K>L98P>MZPEC!ZWJ^6&*;^MEPB6WJY\(0+>K)(@2+>JY8 MPNMZJEC"ZWJF6&";^ADPG`#KY[\0)^II(H2)>I98PNMZDEC"ZWJ.6&`;?*JI MTNT%ML$'>&HC\!J?5:F-P.MZ?EC`ZWIZ6,#K>G:88YOZ&3FXW-SE9$0)>I)8HYM\&GPVC;P&E^:J(W`:WQ#H#8" MKX?/P95'L3F\QA\.*MOT\:':GP;;_$5V@-?UY-`'L>JQJH]AU>-.`Z_K&0SM MJ6Z!#:J]:>`SOK=>4PF?\27MV@A\QA>2:R/P&5_CY1'4AY=<[?6GYNI3?39L M49GK.K2YQL,.5>&?EE>?FOI1.AS4*EMX1,AM;'PP>4K?#*D-A8^P'R%3W#7.HT/CLPP5MT/,=:$ ML?J<6"+X6EYMC6#E8+W5QZ[Q50UHK^YUT-Y`>W4,VAMHKXY!>P/MU3%H#QJJ M1P:,S<-8;=5@;!'&:BL'JS;L!-4QW"WN*MP+CMM1Q?$& M-Y'#KZH.70>;^UM@\"\+=TJ!E=7VA#NFP,KJ6+@E"JRLCH5;HX27616'6X*$ ML9J\:TC`:ZVME!V&\%)K0[B%WU6X01]KPVWM,%+[35`V@[+J?+BS'X0-0Q>C MR<>/[W_ M#O?]/W[;WWS>/X8"%'\Y')[2O^`57_P\//[:7SKZ^/\"````__\#`%!+`P04 M``8`"````"$`2ZC3]7\,``"^00``&0```'AL+W=O3BU'RL:K8_+O8K.)A;O_XL7\9?:\.QUW]>C=VKJ;C4?6Z MK1]VKT]WX__\&7VZ&8^.I\WKP^:E?JWNQC^KX_B/^W_^X_:]/GP]/E?5:401 M7H]WX^?3Z6TYF1RWS]5^<[RJWZI7VO)8'_:;$_WS\#0YOAVJS4/CM'^9N-/I M?++?[%[',L+R<$F,^O%QMZV">OMM7[V>9)!#];(YT?B/S[NWHXZVWUX2;K\Y M?/WV]FE;[]\HQ)?=R^[TLPDZ'NVWR_3IM3YLOKS0'WN^VA M/M:/IRL*-Y$#Q6->3!83BG1_^["C(Q"RCP[5X]WXL[,L_?EXJL?-MY?3 MO^OWI-H]/9]HNF=T1.+`E@\_@^JX)44IS)4[$Y&V]0L-@/X[VN]$:I`BFQ_- M[_ONX?1\-_;F5[/KJ>>0^>A+=3Q%.Q%R/-I^.Y[J_?^DD:-"R2"N"D*_/4'. M.'K*D7Z5HSN]SF3^_^<#Q6CG2KSY$[\IW9]%XFS4'[T MJ_VT0DEHGP68>[& M-&%TRAQI,?A^[[O>[>0[G3OD%.$$7)J(58:=/JZEG;:0KL$-@AM$-D@MD%B@]0& MF0UR&Q0V*`W`M*/L^QW:B3"TF+-4]+E8*V5#2U.;KW-NLFY-6D&!A$`B(#&0 M!$@*)`.2`RF`E"9ATM+EXG=(*\*0M/PTGW'A5LKHG+:M2:LMD!!(!"0&D@!) M@61`@K1>BBU>:B[]K9V!IIMP!(""0" M$@-)@*1`,B`YD`)(:1*F&)42`Q03UEPQ11;M\K@&$@`)@41`8B`)D!1(!B0' M4@`I3<+DH3-G@#S"FLLCB3.EC#4RZIJ?INO.JDTI1"&B"%&,*$&4(LH0Y8@* M1"5#3#U:G`:H)ZRY>HH8R04D`!("B8#$0!(@*9`,2`ZD`%*:A,E#R\P`>80U MET<1OEK=6+G5&K6I!20$$@&)@21`4B`9D!Q(`:0T"5-,]`8#)&O,N68:&3F% M*$`4(HH0Q8@21"FB#%&.J$!4,L3%$H6QV4^':"?*H]-_;-:MX;736G7)!BA$JPA1C"A!E"+*$.6("D0E0TP_=UCO MT)AS_30RKK"(`D0AH@A1C"A!E"+*$.6("D0E0URL8;V#B[V#1CS9K)N_Z\ZJ M339$(:((48PH090BRA#EB`I$)4-13UBOQ!/WTO-M^7=54W]%ZUE.+>/0T53YC%:\&6%=7A:A%UMFU1A0HM"!U MNULJGO6((43'2*,I7<8,3^M69-='IE@=]' M2%A@KHFHK,T$Z4F$9M`J$U0A;IY-$CE3^C4TL8:X=I59M\('"GFTT+>.KFLY MALJ*KMYZBB.,%5\4*V&QN`ZB:!Z@@ZJQ31TD%3&&H_,S?:4-T.>W)#6GG37^6&BM($YIJ(0MC4Y.\M'JJ<-J62 M2%2OAE)6TJ[=UDI/?*`071S$6?3)GWF.T,J62CJRC(%8L8IU/OL2O4?Y2ICY MP@4)RM4Y?^8TYKS"5LA:37R[']9F1L8HI%:3V;4[F^-JHOV,C-'(7+XP8Y05 M_0B5<37143!CO&&%=&-N:2)KZX]6$^5)&=3FA@YV?C515F9N8*SXHE@)B\7. M')%4[,SY(#=4J6N<(DT$NC)_L)IH,S,W9#!JK<7L+6[F8C&Q3Q'M9^:&\OL@ M-]10V779M[KJA(7GRMC5[]]:4SPLBA6R$L>W6S!M9B:.#*87E87?IY>R,2Y" M&"G6PR*-VG4-+FB)LI(IR,415>C_O>!ZJI8ULTDB>Z6Q6P;E27<'N[-*>E[+ MM<"9^0NJ6Z!PT8YF.JE=?I!.:JPR_,T5OL:)8Z'Q:Y&7=*L$06(0D01HAA1@BA%E"'*$16(2H:XB#1?+`4_6+F$N;6" M*\0O[E;-O_9:JR[5`(5H%2&*$26(4D09HAQ1@:ADB.LGRESS%/Y`/UD5FS?) M/87,9`,4H%6(*$(4(TH0I8@R1#FB`E')$!=+E)X#Q%*5K+FP273=H;5X29!2 MTD!!A[IUV??M[JNSTBD9(8H5$L^&VS7>]ZT.,$''M-=Q9EV8,W3,.V3LT78L M.BL]^I(A+KPHAP<(+ZMGBJ=CK^@IOZ7R&E&`*$04(8H5LE2V6L,$'=->QYG5 M6F3HF'?(5-ER+#HKK43)$%/9']8A-.9\+57(R.4UH@!1B"A"%"M$S^GUT21H ME6HKEO$SZ[J

(5-2JR(K.BL]B)(A+NFP!L.7W829N`HQ2:65@0*T"A%% MB&*%F*00/M567%*KBLXP?*X=Z3T>K5;1PTKFRA6D?0XX]7UA;B6E1/0%3]-A MN%/'&OA:.=&C4#W(0".ZQK?+)G2>H=X;ZRYF5ID:=;%T^%@CV?3\HDQ-M%57 MWZ;]>[2JE4P[=@>4:W3V@(HNO&C&+JAO2QVWV16?.;MU.E]:^-@C*>306W1B M.#1SUEF\5A9&>QQH)[.>ZYDYM3>>T=8E-NIB=3.G.BNG&5+_K8P$_5*%1*?9 M)I0_LZ[#F;(RCB?O8G6.<#Q%%[[W'DC)`O-I$BW-Y==67W5`QK55(Z,"1!0@ M"A%%B&)$":(4488H1U0@*AGB8O7U;!Z=)\0'OF_B8]^FD9FZ_LRJ(M:=E4[* M`%&(*$(4(TH0I8@R1#FB`E')$-=6]%,#$E&U7V8B2N2+95R&EA_%RN_X]M7A MJ5I7+R_'T;;^)CYXI9/B_K;%\FO_3Y[A-"-@RHRW-%[+V%I<^X:7'S;1; MV.+2EN;1#FSQ:$M3R<`6&@$](NN)YM$(J!?NVS*G+TI5G1802Z^'0QZTZ/>-F926 MQ80=RR&EY>,]V$)*RP('MI#2]"(C[H>^R?[<.VMB]SWV*S'-?9QVW3?'G_WE M9_G-MSTDD7U]@6@6>R>1YK!WVFD&>R>0YJ]O^JB16XH"#J6@?FXINK6^+0O: MTC>!5$HO1:'M#;?5RW;N%NNNE M*(XQ&K7/2U$CXQ;JCY=)[Y:51T+3'0/RF;1325_/OVV>JG)S>-J]'D&PO=V]R M:W-H965T@,D%$H54Z5;=K;0K MK59[>7;`)%8!(]MIVK_?&3NA0$A+7I(P&9\S9VYX>?M2Y,XSDXJ+,G;)R'<= M5B8BY>4V=O_\?KB)7$=I6J8T%R6+W5>FW-O5YT_+@Y!/:L>8=@"A5+&[T[I: M>)Y*=JR@:B0J5L(_F9`%U?`HMYZJ)*.I.53D7N#[,Z^@O'0MPD(.P1!9QA-V M+Y)]P4IM023+J8;XU8Y7ZH16)$/@"BJ?]M5-(HH*(#8\Y_K5@+I.D2P>MZ60 M=).#[A>W,/D%;+E(,"3+LC61:[:[*X M(Y'KK98F07\Y.ZC&;T?MQ.&KY.EW7C+(-M0)*[`1X@E='U,TP6'O[/2#J#::AOZ8@+NS84H_<(1TG62OM"C^62=B@K)8)K1[JNEJ*<7! M@7J#MZHH=@]9`/`I)HM01WDI2(@.0=:($KO0J,"O(+//JR"<+;UGR$9R]+FS M/O!9^Y#:PX-HZI`@C&9(_>DY,:,S,F.Z,)0[:VC2!/TTXVMHT!GRW0@^",,: MUS);GTG#YRT%+8'@,EP@.@-S.[=1A]HZ#:"&1FE28[F#&;;;A2X\I1G/F2CJ M/%L+@2FHZQF$\SJNEN!9F_7]BJ)SF\I:@`JGJ]DI81L7U4S\^0C\WZ?`4W1-]E<)Q;C2U:3X2CCXN ME-T#L)_JS8#O-.C'CJ;)!4U7[09ROAR.ICY-/>LA#`?,$SG?#T=31]/T@J:K M-@1<.;KC>S1-W@;*7BKLF[M@&$(X)5;6^O+S#K`\UW[9+&V MEQRO_@&ULK)U;<]LXDX;OMVK_@\OW ML47J:%62KV+Q?-S:^G;WVK&56#6VE;*4R;%_N]P^[E^^?+O_GW\F'U>7%X7CW M\G#WM'_9?KK\>WNX_-?G__R/C[_VKW\<'K?;XP59>#E\NGP\'G^LKZ\/]X_; MY[O#U?[']H5:ONU?G^^.]+^OWZ\//UZW=P^=TO/3=3B9+*Z?[W8OE]K"^O4< M&_MOWW;WVVA___-Y^W+41EZW3W='ZO_A[\\Q]WSW^L?/'Q_N]\\_ MR,37W=/N^'=G]/+B^7Z=?W_9O]Y]?:+K_BN8W=VS[>Y_P/SS[OYU?]A_.UZ1 MN6O=4;SFF^N;:[+T^>/#CJY`N?WB=?OMT^678-TNP\OKSQ\[!_WO;OOKX/S[ MXO"X_Y6^[AZJW7'_\W#N(S%T:3_O+5A>=I+HTF_36:\ZME,+F9*M^>^$3R0==7^CNRKS=&D_ZR MYFF'!A1R.@)4[)D0.&_P@CYXZ!]&=7;6]04<,.H?W,_I5;B:!_/%&R$3<,RH M?QC=\[P:?/[[N?UW0&D@N M.ORX4RMJL%96>:+J#^^G[N]F+DU99>6+,O/IDH:4YN2!EIL_/X?!]./UG[1$ MW!N96Y0)I,2&)=1ZH,Q&/HA]D/@@]4'F@]P'A0]*'U0^J'W0^*!UP#7YNGP_X7!E1CF<777+P!D!S[LLP2J1#V(?)#Y(?9#Y(/=!X8/2!Y4/:A\T/F@= M(+Q+<^^?\*XR0[<<$VN$3OF_%^G]#R0&D@!)@61`!']6]$*M%0&(@ M"9`42`8D!U(`*8%40&H@#9#6)<*KE&"-\*J2EEXUY*9?K#=`(B`QD`1("B0# MD@,I@)1`*B`UD`9(ZQ+A0IJEPH4JS0CG5^3RD8F&,B2]:XB,V:5<+#:]4!^S M0&(@"9`42`8D!U(`*8%40&H@#9#6)<+AM'8*AY]>"92T]*HA3LP"B8#$0!(@ M*9`,2`ZD`%("J8#40!H@K4N$"RFB1KA024L7&B(#<^4%9B_4!R:0&$@")`62 M`R%*B,:->?&?^/%JI7J@Q51C"A!E"+*$.6( M"D0EH@I1C:A!U`HDO:QJCA%>UB4*);'LK%NUJZ`<[P8NH`BE8D0)HA11ABA' M5"`J$56(:D0-HE8@Z5)52(QPJ:D[7)<:)`(WG/B!VTOQ6$1JET:.18PH090B MRA#EB`I$):(*48VH0=0*)+VLRH417C;5A>ME@]S`!12I[2O?I8`2E$H198AR M1`6B$E&%J$;4(&H%DBY5M<((EYK2PG5I7VTX*VX(&V*]E`U<0+':MY..3Q"E MB#)$.:("48FH0E0C:A"U`DDOJW)BA)=-]>%ZV2U(NBW%30`H0A0C2A"EB#)$ M.:("48FH0E0C:A"U`DF7JH)AA$M-?>&ZM"\YW,`-_16WE[*!"R@.`"6(4D09 MHAQ1@:A$5"&J$36(6H&DEU5-,<++I@1QO>Q6)29P`44!H!A1@BA%E"'*$16( M2D05HAI1@Z@52+I4%10C7&KJ#]>E&E$VPB&Y"0!%!LTH+[.9<.@]RHBM%-M* M$*6(,D0YH@)1B:A"5"-J$+4&:4\(+X=^<:8?!UVIYX+'Q]W]'[=[\@K5#P,5 MQI0>^^B'09T56;,9-"-5QZW>EOK&2#E#%!D4TDCUBBMO1S*V0OUPL*E9/]JI ME;*FPM#;5LZL%-O*T59AI5Q;7K]**\6V*K156RG7EK>#U5@IMM4*6W(R=QRRUZAZ_ M3L-IL/3NR@F+6-LIHY.V,R,UI>7!Z;K7@YQM6?,%HY/FR[/,5VS+FJ\9G33? ML-3O/=.R2&=;CKLJ%$>,NZDKW7'72*VZUGE3OT8-M13-:9[?D4%"<6#N(<3>5KCON4/QN0D`1HAA1@BA%E"'*$16(2D05HAI1@Z@52$XE M5:>.<*DI:UV7:D2%.4^2C3J60\6O@R*#9`XW]6KKV$JQK011BBA#E",J$)6( M*D0UH@91:Y"^;.EE6@R%E]^7PRDK7@ZGT5LYG)82XZ'1&SE<+V2'`TRE82_E MK*68P_52;"LWBDZWBF%;WMI96BFV5:&MVDJY_8(<#OK5"EMR'%5Q/&*VF%K: MG2T:B1P.4!0:9!.C&%'"R&94*2.KF"'*&5G%@I%5+!%5C*QBS<@J-HA:1@,Y MG*J71[C4E->N2S5Z*X9;YBFW9WM>,3O:^8:G?.J9EB8$,3E7Y(T9=;PJX M#V[4RJ4&[XT,3DLY>4HTI#@PZD91YRGSU6IRX]VL$F/(L9V>93LS4F]E<-#U MXBSSY5GF*R/E]+X^RWS#BK_W3,LBHC29VLI'K*DJ^D>$0BF,. M480H1I0@2A%EB')$!:(2486H1M0@:@62+AVWU3#%K09&E2=/=>WKWBT,DGGRU-_K-%).0AH91"M: M=X!^XI^@CZT`SX$$S:16RIBQBV&W8&56@,WDPHQTT[@Z>(IUL$%N&HHH8F1S MNQA1PL@FA2DCJY@ARAEA4C@=5Y5VXMX]P92@;@H33KV-Y8U1I*=&[/6(D:N( MZ0%+_3;W25C"FDX9G32=L90V':Y64V_9S5D"TZHIF1;S9^"9`%6I_%"@$_?\ MIBQ`6N458!NCZ"0/D4&4C[$K8X-FZBD$O7PRFP8S/W5&0RD:R@Q2ZT:?J(>A MO^4E;,GYHLHI=UEYPRVZ^A+KAT8SFDFV!U/O:C934[;9,8\0Q0;-U#C\^7D9 MWM!+7O)1;8):*:*,#;GQ-.`6MU/2+:JP<-WROM56ER?"6Z9BD=F#OZM.&BK4 M1!`99)>2F*5T$'U8+);+&V\:)RQC]VE31M92QLA8"B;!Q(OKG$5PZY$.B$E? MO1%".GDG>SP;;CL+7;7):,/(C1>M2!MV+!4;*=J58)2@8LI25C%C9!5SH2B" M8>:GX>\*ALZ*7%$,\@HU;_)NC)0;#(PH?OLYARLQ2^GE]G/STRL@W?7!RP;9*-VPE$41HAA1@BA%E"'*$16( M2D05HAI1@Z@52+K4S^/5FONN5W!48N+'M$$RIKU-K`TKN@/0*W*8QRB5($H1 M98AR1`6B$E&%J$;4(&H%D@,PKLZ@E`V\K%%WUY6FQZ7B,YUWNPD#(SLT&T01 MHAA1@BA%E"'*$16(2D05HAI1@Z@52+I49;)NOOK&"J037^%2@^2<\&KQS:R7 MX@D0(8H1)8A21!FB'%&!J$14(:H1-8A:@:2750X^PLLZ91=>-L@-7$#1#%", M*$&4(LH0Y8@*1"6B"E&-J$'4"B1=JI+Z$2Y5XE[.I]'<=2F@:`8H1I0@2A%E MB')$A44V1Z="7Y:SI97B"54AJA$UB%J!A)?G?@5S>GGHQ*67#7*]C"A"%"-* M$*6(,D0YHL(BU\O>[F5II7HO(ZH1-8A:@:27_;KF#2^;8L4IA.<:"2\#BE`J M1I0@2A%EB')$A46NE[V]AM)*62]#[VN4:A"U`DDOCRMIYEC2&"2\K*4<%*%4 MC"A!E"+*$.6("HM<+WL;,:65LEZ&WM]DN:=^UYS+'2,<($H190;)?LV]RBM'Q8(5Z39N M+VCNWTV-U$)_KYHZX%TAJM%\8Y%KWIMZK96BRY8C-JY:FF.U9)#TS,S?"S12 M8L2T+0?%*)4@2A%E!LE.S+TB($?%8E@1;L.ZJPN[\UP910?5:+Y!U`HDQV)< M>3G'\M(@>D>5PWMCD./E"%&,*$&4(LH,BE+6<6,D5!<>(MESE)6L6`D%;UEL&0IJU@QDHK>!*U9RBHVC(2B?WMK M6:I3E,--BF*XW[@E*7&O@M"(TN?AXP*;N1&PBW?$*.QTYHO9=.FMR3&+6*V$ MD;B5+[Q[1MB=OF^,IRZ?W:T,6@K5$-,Z/'QN8\,"]AE;Q&C9Z=Q, MPNG"FV8QBUBMA!'=/1PG>1,[M5*\:&<6N8HPGN9"["<6PXI>5TN6LHH5(QII MV]6EMR+4+&7/@#06N8K>BM"R5/>)8CQ5WCIB/#MQ.3\-6MH@VR"*$,6($D0I MH@Q1CJA`5"*J$-6(&D2M0-*EJG8]?XI0TNDO>8PHP)QH\%;KC97BP(T0Q8@2 M1"FB#%&.J$!4(JH0U8@:1*U`TLOCRGE*8<#+!CD;@"QE480H1I0@2A%EB')$ M!:(2486H1M0@:@62+OU':O<%UNX&N4?C$$4&J9/.3M1[M]_82G'4)XA21!FB MW"#=+^D*OY)^5Y:ZP`+;(.$*+>6@R$@M]8'P$(](6@'K!6V&6ABE5FKX5IM9 M`=;)#1KRB:K">%VC03I]YU_HFLV]\QND_M@!AA.C1LH]0&B0>X*'D;V')JB8 MLI3U2<;(*N9"48:!6Q*^?`G>QDBY)W6&%/&D#BO^_L6!A$7L M-E-ZENV,%3D&%RL_%B.=KFQXB6X&Y:R!4O$R(YO M;!#UMCL=.`]F@9>2):QE#:6,K*&,D3Z\-)2&YBR"E=!"9?'G3Q^=\XOIHY$7 M2U[JOND^1AX!-,@]1VH0G:-0+@D6\\5JXN47"5I*T5+&4CI,9LN;6>@9REED M($PH-$;X1$E[R:=&XGVS<.EEZIN%D;*C&S&RHQLSTJ/[8;X*9_XWHB0L8RVE MC*REC)$Y0#>Y(>_*YW1NO/W">LY*P\C:RICQ$=(I\$$GG;F+(011+=($4'O M\Q:FX)U=6'^\96/#4C8<(H-4S/L\N%[;%'8_>^#KIS_..6'96O/#3V;9SJD?_JHK^F8;G[>OW[6;[]'2X MN-__5+^8LE2K=8_US[G6!;5T"P>T+*FE"RN_)9BOU9?) M#?0@(&NT$@ZUD#6=4($U\BA]'=6`3DB]UAF7KS,E7].;<@,Z-VOZ1MP!'I`& M?;'K4`MYFKZ,=*B%/*VS4/_S`_*TWO&&%NJS?M7(:Z$?`OHR.&KJXX<^G3Y\ M4)X^>FB,O\S67_3+DMX'WZJQ'_H`&L7!0:0Q'!Q"&L'!<*#Q&QH^>GZU5MOW MZ%AZC+56N_C80D^SUFHS'UOH"19U=ZB%JK:U*JU0AXJ8=:RK$<\G5)>0SI!7 MZ,`*]6W(&IU;H;X-M=#Q%>K;4,N&>JT>P`STC5K44:_4X!EOH2>5: M/97!%GI@N58/9["%GDBNU0,9;"FII1QLH6-":_7L&77HM!!9&VJA0T-K=?X' M=>B@"\7!T-2CPQG4,A3\=*"`6H;"GYYV4\M0#VZI![>#+1MJ48_JL6]TN(I& M8:B%SEC1*`RUT%$K&H6A%CIQ1:,PU!*%BW6LW_7P(Y%:LL$6^MJ,M?I2#.PU M?0G&NAELH3<;U^KE1=2AEQ77ZGU$;+F=T@I$+\0.M=`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`#\]^S^UO<-A.3ZSP_G<_SP[9>G[Q_.%^MWJ\ULT<#\[//^^*1O?9/G9S<_ MCT^'^_\;C)K0U-#((C2"OZ&1^>+=ZR;4Q-])QXJQUA\K_DX\UEVH MB;^G'>O%D-V^LW373]?IUA"")_QQ_7?D`WEVC-]Y(%^MH0I['?/-=M MT%]\(Y]\*Q_.X0>J']'9__C8K!;O+_Y`_[P)-E<5&VG11@O?&7VS70E4"70) M3`EL"5P&+A"$,1+HZ&4D_'B9&`G?BH]$].$J@A2:>>%VM(A5NA*H$N@2F!+8 M$K@,"+@Z$45$$S%$ M+!&7$Q$`S#!E`-Z0=]\*(B*'P$KZ>Q6,7@K):#*&A(@BHHD8(I:(RXD("?*? MA^3EON"->\_C$5\%@NEDS#RF7QF+=C2*U3HBBH@F8HA8(BXGPE',]:<[ZHVE MHX'LQM'>$NF(*"*:B"%BB;B<"*_0OT[WRAM+KP:RQ%D@2]^F2-]H-*:/B"*B MB1@BEHC+B7`4H^UT1[VQ=#20+'U$.B**B"9BB%@B+B?"*XR;W"M_2IZOWJ$/ M3SP5^7:DPX'(@;DM,CL:C9DEHHAH(H:()>)R(F+0H/?E07AY"NJMI:L19P9DGYNLJ(D0W&\&[(L_)*E;L M&"E&FI%A9!GA>F?HD7U.9#B\.LG"\4JZ!RTC7`XH3S>AKB&D&&E&AI%EY`22 M_GGU<;I_0:OD*1V0G)37LS*EHU5**2'5$-*,#"/+R`DD7?;JXG27@Q;)70XH M3RFAKB&D&&E&AI%EY`22_GE1D?GWYFG:B\UBGHY(#.!U4V8[5$P!ZE+%V`$4 M(\W(,+*,G$`R&EZ,9-%X90`'Z9)G.U5U>"C:C5#G,E3 MFBN ME.XY*ZZ(9+J+%9$V68WI9J08:4:&D67D!)+A\%(HZ_TO3]CS()RR'AY1GFZ2 M5QU;*4::D6%D&3F!I']>Y&3^^=&]7KQ+J\UR/2M9I6R30%-LI1D91I:1$TA&P\NDT[,=1%6>;=)9[9Q0 MQT@QTHP,(\O("23]FZ3&YJS&`BHNI\HUKF254DH"3;&59F08649.(.FRETFG MIS2(JCREI+/:.:&.D6*D&1E&EI$32/KG=4_FW[\P7_N6"FD2D!S!Y<+7?+1* MZ2:DV$HS,HPL(R>0"(>_!Y>'X^7YNK>6+D>4SC0MHXZ18J09&4:6D1-(^E>H ML5?\8\6U&%`Q@LLUKF0UII218J09&4:6D1-(NCQ)<2U8<464IY05%ULI1IJ1 M8609.8&D?Q7%]:9UZP4+KHC$`-Z4RU_)*F6;!1=;:4:&D67D!)+1F"2X%BRX M(LJSS8*+K10CS<@PLHR<0-*_0G"],H!952T&)`?PIESC2E8II6/%B!1;:4:& MD67D!)(N3U)5"U95$>4I957%5HJ19F08649.(.G?)%6U8%45D1REY1I7LHKY MZQ@I1IJ18609.8&DRY-4%2X!2V41$'IQ=*9EU#%2C#0CP\@R<@))_[Q^R535 M*Z,TJ)U,-2X&5(S290N61X%Y#M-NN&[*=>CDE5*Z=`6*D:D MV$HS,HPL(R>0='F2/%JR/(HH3RG+([92C#0CP\@R<@))_PIYY"]G5QB+$Q_A M\$_B%=>R$FM"Q$QH&)&+E><0L4L"ATCQ4@S,HPL M(R>0<'DU23?UUM+EB%)G;!EUC!0CS<@PLHR<0-*_0C>]<4;VDWB1ZXCD\"V7 MHI+5.'P9*4::D6%D&3F!9"PF":H5"ZJ(\ERSH&(KQ4@S,HPL(R>0]&^2H%JQ MH`I(#M]MN=Z4K%)*65"QE69D&%E&3B#I\B1!M6)!%5&>4A94;*48:4:&D67D M!)+^_7L$U8H%541B^&[+A:ADE7(=VDH14VRE&1E&EI$32,9BDJ!:L:"**!UY MRZACI!AI1H:19>0$DOX5@LI/U6][5&/%8BLBF>YRD2I9I72SV&(KS<@PLHR< M0#(3U);/76TN6`,F=:1ATCQ4@S,HPL(R>0]*\BMK:[ MMSQ;MV:]%9$

4"5K(:1S`CQ4@S,HPL(R>0#,]%WB#?WBO?^T;*93'@/"N4\QA&ZPRU`6$!YS\ M9@#S65.H,94,8C,Z-K,<6S;)*C13Z'2;#&(S+C;3'Z`(R6:2ZNJMI>\!98ZV MC+J(AETU_$8&BI&.*,711)0J6D8NHHI_A>IZ>11O6%D%Y%^#0><(&SELRU7+ M:+49\]1%)"L62V`J6FV'3M'LFJ)I'2U2TR:B%YNVT>K9IEVTZ)N6W6*2.MNP M.@O(OUN1PK8K5XN"%=Y0B%VU2Q4C4M&JZ6.T6&Y6Q22JHT5JQW`[-EH]VXZ+ M%GT[,B"3Y-R&Y5Q`LA_MRB65:)62W474[XO33T$JHB&SRWDS+[J5CA:I'1-1 M:L=&]&P[+EI4>L@DL;=AL1=0T4.*R:P-5J*'#&VA8NHA`\*K'?T^*W.$1+X8 MJ+D=DPX@MF.CU;/MN&A1Z2&%.GQEIF$)Z-_#P(FEZ"'%2:*-5BFS740ILRJB M,/;7W$'"CZ5F3*R3FK$1/=>,BP:5_N&EW+]ZKMWX1HKSS8"*;E->Z8:*HML, M%?%Z3$RWBE;^Y/['Q_5FV=#$$BKE$PNU8U]MQT6+2K>9)#,W+#,#$MUF6UXX M1*.4[BX@O#^2XC&TCI<>AEFS\O=@2.F"Y M*8R+-I6N4\C95V86Q0FC#49Y5XC(]\4D!8M3KXI68YNL4DJ'MK*U9\56FI%A9!DY@:3+DW3GEG5G0-F1MXPZ1HJ19F08649.(.F? MUUN9D'SY++<=U!D>_XZ9N8I(CM+B,KM-5K%BQT@QTHP,(\O("21=]CKL=)>] M=3$G!Y2/4D+=EI!BI!D91I:1$TCZYY70Z?X-NDFD=$#%*"W.Q.UVM$HI):38 M2C,RC"PC)Y!TV2NFTUT>])5P.:`\I82Z+2'%2#,RC"PC)Y#P;U?1:OYAJXD/ M]_;-R+X<$3P;3[+8.%D*GS99C;EFI!AI1H:19>0$DK$HI-;+,]8NZ*=LQHHH MRS6CCI%BI!D91I:1$TCZ5Y%4;WL69<>:*B*9[E*=)ZN4[M!6"IIB*\W(,+*, MG$`R'),TU8XU543IR%M&'2/%2#,RC"PC)Y#TK]!4;U;0.Y9;$$H.GQ.!IS@I/*QKL;7MY-3,682-#S\Y$ M=[FRE9EE78!U6,4.@2$[!(88`D,,@$H.GQ.!IS@I/*[IL\M,LS8Q%663Y,QT5A@`,=9]_HB6SB!T$X1AJ M81O9R!".LJ5"`B(XHT6LA>"$EOBQCV8V2:8-YN4T&+0;IIML#)1+@;$J[K_% M`T-@0M7E<"-MM=PUZ_6ZJ(K.,IK%JHC.^*N1(3JCG;\OM]K,5]P:(C1:Q9J( M4&#])VB*[E,(O?*&P$D/0S4S%H`CPR#-`E:&VX<[K:KV7JQ M*VHB;J-5]!1Q"RS=WD7<1CL?M^5RO<17;XK6$+?1*K:&N`6V\$DMXE:HQ3?& MC55D,PLL[W!T)S=:R?X6:J[[_C;'+:?Y8K8NSMB(VV@6/47$H,GA*# MI\3@:&)PG!N=S M5CCOI=<$YP>EEJ\=-.([`C'-P2Z-7*29&-),#)X2@Z?$X"DQ>)JSPE,OH29X M&A272'-@F!R3(&H*B8L^/IK%E,)Y8G">&)PG!N>)P7EB<#YGA?->!TUP/L@F MX?S`>K4_-#Y\GW'XY-[]_O';OMW?W1W/;@X__;<7_>3R\?W(AT]#XOLM*_]Q MR/XQ<"J;[5"&4P_"1F7-S-?KGX?ALOZ#D[U4X;*YK]>K22Y;^+)>&W+9TI?U MWI9E.QPF5FYJ1SGS1XF%C6J9/THL!53+_%'B:KA:YH\2UX_5LJTOZ]-$1XEJ MN!E0J;6#:U@8KY4@.5A2KI6L4=)?&M'O;%#2/V9&)3@XK.!56MNB#FXKUTI0 M!W=?:R6(.NY;5DIV"#KNXM5*$'+<_ZJ5(."X%50I62,&>%NJ5H(8X#VC6@G\ MP>LXM1+X@Q=9*B5;'!L>=ZJ5X-CPZ$^E9(48X,W;2LD:,<`[J[42_`Y>WZR5 MX'?PXF.M!'T'[P?62M!W\&9=I62%.MC#H5:".MC]H%:"6&,O@%H)8HVWZ&LE MB#5>**^5(-9X%;M2LD0=[/A3*T$=[)53*T&LL:5,I62%6&,SEEH)8HT5^5H) M8HU-/2HE2]3!_G"U$M3!SFJU$L0:&Y#52A!K;-U5*T&LL9%5K02QQA90E9(% MZF#3T%H)ZF"[S5H)8HU=*6LEB/6@',J98H%8#RJ_+%DBUL.E7UDR1QVL6-5^ M!W6P/7.M!+'&+L:U$L0:^__62A!K[(5;*T&LL8MLI62..OA@0:T$=88':I:"6*-'- M6`_/UE()8HT7.2JMS1'KX3GLLDZ#.I`-E3H-ZCQS%D>LGSF'(];U,W@O0JJQ M;A#K84FF/#8_5=6.#!6JN4&8JU%&D*LQ1HBKO;D7/K7>[%?9+OM%-(Z77S.[ M[)?$N`SU-KY>[>C\FI&O5RO#9[T_54>(3UHM,C[-->X'5(5_6EY^"I\-+V/O M)[5*#;R*>>G?MF0?\7;EI7^!DDO@_=)[7VL/WB^]][4RU%OY>K4^@'HK7Z]6 M=K6%NWC0E8_D:@NW\#QHK02=#4]2UDK0W?#`(4HNQB#AT^8_KK_M__OZ\=OM MP_'L;O\5\GO6OP[[.'P&PO=V]R:W-H965T&ULC)1;CYLP$(7?*_4_6'Y? M'&!S(0I9;39*NU(K554OSXX9P`K&R'8N^^\[Q@E[2:ON2X+-X?.9,P.+NY-J MR`&,E;K-:1R-*(%6Z$*V54Y__MCX-!6SG0%>]`^IAB6CT80I+EL:"'/S M'H8N2RE@K<5>0>L"Q$##'?JWM>SLA:;$>W"*F]V^NQ%:=8C8RD:ZIQY*B1+S MQZK5AF\;K/L4WW)Q8?>+*[R2PFBK2Q%H7UP36^OC)R.++[(%#!O;Y!NPU7KGI8^%W\*'V=73F[X! MWPPIH.3[QGW7Q\\@J]IAM\=8D*]K7CRMP0H,%#%1,O8DH1LT@+]$23\9&`@_ M]?]'6;@ZI^DD&D]':8QRL@7K-M(C*1%[Z[3Z'43Q&14@R1F2HOOS_21*9N-X M//D_A05'?8%K[OAR8?21X-#@F;;C?@3C.9(OE04?0ZW_*A5K])![3\DI3CM6 M8;$]A^4L7;`#1BK.DM6U)'ZM>+@H?"?0W6`1"W]I\>^A7YQXL7?BF^"MK<(& ML@=KR9MSKQ7I[2!YY00#>K\3+\XIPH>#9\_8X"U(IGU@<9K%V30;#NX5.-0> M&PO=V]R:W-H965T&ULG)K;;N,X$H;O!]AW,'R?6!1UL((D M@Y'$WAU@!A@L]G"MV$HBM&T9EKK3_?935%4259&0;-_8GKFD/#TMU&RP7]6'3;IO#R\/RO__Y+KJ^.FRK77NH'Y8_ZV[Y MZ^,_?KE_:T]?N]>Z[A<0X=`]+%_[_GBW6G6;UWI?=;?ML3Y`RW-[VE<]_#R] MK+KCJ:ZV0Z?];A4&0;+:5\UAB1'N3N?$:)^?FTU=MIMO^_K08Y!3O:MZ&'_W MVAR[]VC[S3GA]M7IZ[?CS:;='R'$4[-K^I]#T.5BO[G[_>70GJJG'>C^H:)J M\QY[^.&$WS>;4]NUS_TMA%OA0%W-V2I;0:3'^VT#"FS:%Z?Z^6'YF[HS4;!< M/=X/"?I?4[]UH[\7W6O[]L]3L_VC.=20;:B3KO#4B>W<1IH!?CBJ>[Z+XT-N5QLOG5]N_\_0HI"89"0 M@L`W!5'JXB":@L`W!0FC6Q4%R04#B2@&?+^K@3_/5`%ZAU3`]_L`TKG.*TSG M4)VRZJO'^U/[MH`I#PGKCI5=0.H.`MJR:"BNORQ0#]OG-]MIZ`IT!W/I^^,Z MOE]]A_)O",D]2,*1PH.D'"D]R)HCQH-D'\@*5'Y(A:J/I4Y+M/##$CX_)&;! M1]@A"SDBZ:#_1F=*19'(0C%&=)AH+06.@3!+,YV&FA_&C)$;'<&,CX//XS"% M,"7/5VAAH5#Q0^>(P,S\2(*L(1+QD`,4F,6?Z1_R5,Y&,5,$$PA#&0L\;[;: M3D)H*(0B@C*R-$C6(A/%&(`R!F(NE./V+$BU#&`0@$]/*IE$6(272[2=A$0Q MC7)$_`,8ZE0@@4D8-`:.S-D@9HI@.I-K=-I.0F[G!C_&+"F MA&`N!J4>L7BHB3!F\DARUEA<7EFT([RRTAG9RU!( MB'\05%E$,!U6:[!68MV7\V',),)+:TW&Y7+1FG"YTB"IL<%1HS+9:(SX3*E25((T0RV,N4XBWFD),0O99@;9A+A:JW= M&*F=-H(*S@$)R3<5CD?QTPB7.=57BGT>"5Q#LF)02UII'0J M-R-.*'`'8C=B0))DX`HY88CPYY0+A5DXGKGGW5\(;2]>V$Q,SIP8_QCP'$,( MY<(J=7:L5)AAC_&*BL&`9S,2CUE!69B3!F\DA<[55.R=Z\ MEFH_M[U!2DX,2H$[WHZ0@A&1ZRU*!F1@'43=#0'^5'"=5UFDT+5(F;,)(^,? M`U5U;*(&H8Z4D@XU$<9,(ESM54XI=)U2)DX5.3%457B*(6M2,`*:)5`R0,$3 M&4D8(ORYX$*%23IS#W;-DG-A'B+C'P.5%9'WC^+-4K66GBJ@B/P1"D6*[[D M1!3K0%IE0X@_JUSL59Y)NYY)!=(T$>0?!)46XU`^K-@LC,04*>?CF$F$Z[W* M-6G7-:E`U"4G",5$B7LGK.!$Z"S)4@`:3L'"#1/A3RI7"LP5B];VDHM67&7E M&B'_(*BRB%`RK%1W*YX/8R81+O$XO^AMK]Z>0BKS)-VC5-2HE5EA/D'P35=.R:K$Z/5$0FHIC)`W&UPC1- M7Z!KURR!E^&ER@FB#4?)A]T%M8_''XL8Y4P,XXGQ:<6Y0&&69@2Z)LFYHZ3' M#N@FTE&8)>+RKB!FK/%S?$.ERWG$3!^)RQ0N:4:FQQTIY]R"$+V]$84JBR*Q M2Q5ZS,!TU?".#Y\.)4-T8F\7!2*,8JG_K$XOS:%; M[.IG>*86W*:PH9[P_3#\T;?'X5VCI[:'][J&/U_A/;X:7D0*;@%^;MO^_8=] M`^WCS<#'OP$``/__`P!02P,$%``&``@````A`#3>M$))`@``X`0``!@```!X M;"]W;W)KFXVM`!Q!0F,S6CG7 MIHQ948'B-M(M-/BFT$9QATM3,ML:X'FW2=5L$,<3IKAL:""DYA:&+@HI8*G% M5D'C`L1`S1W6;RO9VC--B5MPBIO-MKT36K6(6,M:NF,'I42)]+ELM.'K&G4? MDA$79W:WN,(K*8RVNG`1XE@H]%KS(WMD2)I-V^ MZ_T7D&7E<-IC%.1UI?EQ"59@0Q$3#<:>)'2-!>"9*.F=@0WAA^ZZE[FK,CJ< M1./[>)A@.%F#=2OID92(K75:_0Y!R0D5((,3!*\G2#*)1H/Q_<,-%!8JZ@0N MN>.SJ=%[@J;!G+;EWH))BN2SLE!'K_5?4E&CA\P]):/H=E1A<3R[69*,IVR' M/16GF$6(P?-K3!_!L)J^)"SCLJ3WFWS.[(-]9M]T7\HB/+A,,QR]GV?X=QXO M?8C6^'\^ORFCF.151?Q6:8@9AS[@EXK'FPJ"T\(@%)@2/D%=6R+TUKLHP9W] MT][@\T'GT?X%&JSE);QP4\K&DAH*W!I']^@H$RP:%DZWW9C7VJ&UNML*_R2` MS8HC#"ZT=N>%_PCZ?]/L#P```/__`P!02P,$%``&``@````A`/E'UN:N!@`` MKAP``!@```!X;"]W;W)KTSB&0(E[4-;\,GX^,QX MCH,?WWT[[&=?RZ:MZN/*$PO?FY7'=;VICB\K[Y^_/\X3;]9VQ7%3[.MCN?*^ MEZWW[NG77Q[?ZN9+NRO+;@81CNW*VW7=Z6&Y;->[\E"TB_I4'F%D6S>'HH./ MSP[J_B:!8 MGV.;#Q?A#]6ZJ=MZVRT@W!*)7JXY7:9+B/3TN*E@!5KV65-N5]Y[\9`'PEL^ M/1J!_JW*M];Y_ZS=U6^_-=7FC^I8@MJ0)YV!Y[K^HJ&?-OHK>'AY\?1'DX$_ MF]FFW!:O^^ZO^NWWLGK9=9#N$%:D%_:P^?ZA;->@*(19R%!'6M=[(`!_SPZ5 M+@U0I/AF_GVK-MUNY:EH$<:^$@"?/9=M]['2(;W9^K7MZL-_"#(KZH-(&T0! M>SLN%S()11C].,H2&9D%?BBZXNFQJ=]F4#4P9WLJ=`V*!XA\7AGRZ-=Z;:FP M1AWDO8ZR\J#<814MY.?KDQ#1X_(K:+JVF&P$0Q'Y&:%3`?1ZCK!RE^.XZFXE000\A3$"A^YEH,&3:F5B(N(^+Y!`3.!@F6WX+ M0;A!D/NY:?#*@X7WHB0^HX:0V&1S'JA`IM&@BF&?$XB*A%2AZ*,0U4ZH>X@$D?'P5$#!#I%\(%O(4@'"/*\38W#:8""I$R;H@)C8*Q'T17NN%)^ M&/;KH]1TC[Z?&G9T0DWRHA,(LFE-+V4[VX+VVBL;5.CV[-"ZK^F:IUC7EFQYQBV'TVTZX=S-,@8!+G MP@7()(J'")3C)+\08X;!]F=F02@@G$\2?YC;*D@\(TJE_VZ41BHX>>VI\BA6*M(K.@ M\8:&Y7830OGI_GT_/^SVQ#*<5Q2K&8)L.8&5.O5DZ;D(V,G0KV[K"[ MKY^8IWAFN7-8$$^>):CG77FX!.AVU^@QP_A!,0K$NENDWZ'YFD8A8\%9" M$5$0.\=`FMI)3B%'G(+OQI,&U-BR95?Q`NQ&+4$R9 MS(0\9TW*$2,C""$(@FHWR23DB$DHUF4S"T+M8C*UE<[UB#B]7G63+$*.6$0P MU+.9.K.@*YO!]8^Y(LR):/I%>OIN-4^QW1IPG[`@6WCF[:'O&*B>1?`E4(+, M(.YK)PH]@#0]QX)000M"@J%,Q,6^)8A8)HD_+)*RG&09"BV#LN.684%6/@GO MCEP]C'(N3N<-A%*;Y!9JQ"V"X5AKA7.](`Z=F6U>80:\8B` MG=?G76PC%H15)Z(@2A0[R^<4HH(HOO8S)USA_(21F:W++83T%S%TI@;OF_!#5Y_,G&ULE%A- MCZ,X$+V/M/\!<>^`^29*,FJ">G>D66DUFID]$^(DJ`%'F'2Z__V6*0+89"'= MAW3`SX_WJLHNG-77]R+7WFC%,U:N=;(P=8V6*=MGY7&M__KY\A3H&J^3OFCR^K*ZM>^8G26@.&DJ_U4UV?EX;!TQ,M$KY@9UK"R(%515+# M974T^+FBR;Z95.2&99J>4219J2/#LGJ$@QT.64ICEEX*6M9(4M$\J4$_/V5G M?F,KTD?HBJ1ZO9R?4E:<@6*7Y5G]T9#J6I$NOQU+5B6[''R_$R=);]S-Q8B^ MR-**<7:H%T!GH-"QY]`(#6#:K/89.!!AURIZ6.O/9!F30#E12B#7D2&=@Q]BJ@W_;B%DPV1K-?F@S\4VE[>D@N>?V#7?^B MV?%40[I=<"2,+?4I1!1H%I8KF%*6@P#XU(I,E`9$)'E?ZQ8\.-O7I[5N M>PO7-VT"<&U'>?V2"4I=2R^\9L6_""(M%9+8+0G\;TF(]6D2IR6!_SV)%;C$ M]>:E&&BKB5*S_X@6!$B3/@F6M MPYJ!Z1R2_+9Q?7MEO$%BTA83C3%$1FQO")$%01OCC2:6!NCM1$,RAJ+OY_*F M38"%MAMKA#>`NQ-K*4+&"-N1(?$8XOH]1E(+61^JO85X6K68!+4V$`EIEC5$ MB(&L=48\&;&=1<13",D%/&;H8EJ]`#=KIE/F*M(BA/A-L3PY)`R\P#(5^1+& M]CW'#E2>&#'PV3VJ?Y)D`*KZ<0,"K!CP75E=A!BW<>!8;AC:@8S8(N*^-JSP M*82DWON,>@%6U6N[\OU$"$&5ZP:[^$8(?XX MX`AX0#:!%C^,N-@N;;@W'?EFEFI`68Y1"QJ*<'VUZN^`E-*+)R%2#HCH8(/R M$6:\>3/8]Z#%='N:&R@1CQIJ:-822"VF.Z"1&7S8D*>'R&9$SU/,/)`9[)2R M&;63$00-1;B!LMEL[X!ZI>T+PYBGA\AF1.,;F)DI+VR3L@EE949DJI+%C3,1Q_'U@KR3$#B21;9BNB#CV<#NZ:.;#P8'EA9X6ET.]=HQ=7,M5^V_*:A<23++(5T30'5F86.[98 M.1NC\D+0H+S*9K:#5D6YIGG,M91=Q:K6@N+N[W8GZ MV1*G'>5^1)9PPH+[1C<`!]USU.SO2U9\37_WQ8[^;?&^.W;8]7$_9Y7PZ:0Z;]F%[>+J>_O5G M>;&83KI^?7A8[]I#OK<]R^KV:S; M/#?[=7?9OC0'N/+8'O?K'OX\/LVZEV.S?I!.^]TLF,^3V7Z]/4P5P^IX#D?[ M^+C=-'F[>=TWAUZ1')O=NH?[[YZW+QVR[3?GT.W7QV^O+Q>;=O\"%/?;W;;_ M*4FGD_UF53\=VN/Z?@=Q_V#1>H/<\@]"O]]NCFW7/O:70#=3-TIC7LZ6,V"Z MN7K80@0B[9-C\W@]O66K.EQ,9S=7,D%_;YNWSOK_I'MNWZKC]N%?VT,#V88Z MB0K2^Z?IR M*QBGD\UKU[?[_RD;IID41Z`YX!,YDLLXG8?L$R2A)H%/31+$EU$0IPO)0LFVA,^T?/,6TVU)WQ^YE9AL\I;A4]<\,Q; M76I/^#QCP9EJ#MEK^;I?WUP=V[<);&"H?_>R%N.`K8`*FTQEU[3=>UT'[29( M;@7+]12"@([J8*M\OXF2^=7L.[3W1MO<41OF6F1H(7I9T.8^4/A`Z0.5#W`? MJ"U@!DDPF8`>_PV9$"PB$QC#'0)#:@(O;+1`E]P'"A\H?:#R`>X#M04X8<.N M_`UA"Q88,$X#>.6]TS:P0TR7)%XJC(G)!4$*@I0$J0C""5+;B),1F#:_(2." M!3+B[@FO]'?:Z%1*C(E)"4$*@I0$J0C""5+;B),2F*1V2L:/(!P&PEA&CG=\ MIY`4,FXJ'R6A5WMCA&XY00J"E`2I",()4MN($R@,_O,#%<9NH`J!0#&&C"`Y M00J"E`2I",()4MN($Q7TEQV5&/)P!$,2/CGF!8\;L$;@Y+`J&WF5-4:8E9P@ M!4%*@E0$X02I;<3)`6Q$.P>G6U@8NX$JQ*XL07*"%`0I"5(1A!.DMA$G*DB\ M'94ZOB]3*&W_O-U\NVNA+'#@C40;PC&M#F_!X0:K$!8,;4R07"$!?)C*!TMO MY!?&""M?$J0B""=(K1!U0T[\#&3U+R=`DK@9T)"=`@KE&DJ9E#S!G'DSK1@, M3`(TE$0FN=5@)903T'C'!!\,D*;6T%A*A,"Q)-U([4&\8_&9DD/J04;VPYV& MG-B5E07E:*4>/81<*RA4(C2T4H70X,@I5",D'=V2"R5CQ2>G62*>@<;:W`Y5 M22`G5`4QF)RFBZ,D]N87A"UV"$M-R7*$;$>V6+J.!5HM9']IIGA*- M!O8*H9/L'*V0G;$X3+W96Z.19'?S*`30E_*HE9,EI)FV"N1S MKU;XQA$[NT`KM:DNPB"($R^J$FT&IFJX!63B:(5,;,&85Z(:;=2SN/T\P(0: MLO+SP3[2VLE.BH*!G//:(:349Z1$@N*R-?.G]%@_B)4I#3.E&2NB7/ MM*,SEY3C8ABNA;9:)'(()?"UR]P[7TI*5*'70,014D3Q!%6=(%*@VQTPMP8W9R M@=I9P!W:0@F>2..?[=$Y"6V+*V9PQ`N44*BA44JBB$*=0[4!N MW$(!>G$'4*WS5:X8.OXN4U!B%R-*O,&::4>H+,Z,7$,@?K5@([I/,8,!^I1( M8^L^8_6>[C,&2%,C#=5%,#"=%)T^KZ2U.YTU9`6:42A':!@,!85*A(:D50@- MCIQ"-4(C\7U*UP94UVI(C#&SN:/$V]P96@WG:(Z0[4B'!UJIHS6(X.<2[R`I MT63@KA`ZR-H<2N/1LD`8P5Z,8A<:D77*:MH(#8 MK/G@B%"!5NJX#5FX##RY7:+)0%11(HY6[Q/5:$+/[4#(3BLE7SJW)8FWA00O M9,JN9I1Z3\69=H0ICVG)-62?VPBIXY;-V2+U!$!)B2KTLG>9NBDM`**0Q;[D M48+3Z1VM0=W>\01()I=Q-9^&TF%>%AIBH%#%P!R5,I2I MHDS<8QK5,@Z3FQ2A/:VD?*U[E(!UZY M&,\58:HTN<7$$=),X[FRF=Q<03"_GBM!XNTT!7DSR6OL+%!6SDS2CJ>56J$] MF7@^-$./2D&Z0&4\3VI-;LQ.+E`["[B9%6+U1!>>)P6%B/)3JU5P8L93IJV< MGM-6\'"$4ZQ`,YA_B)6(#>U:(62Y)WF' M4J:MG$Y27."(P19(/\B>DCI6PXKHR*EC[3BZE1>RT*K\!T-9B4AGT"C(.Z;\ MKVO$=[O^H!EQ'%%"VDI_R1"$P6+AG8$E):\0@@UJ=APAYVBER.,XC>EC*-K0 MQ@D]D?RET2U)W'&D(:^)_-&MK>PF0FCHF`(A\0W]]YN+9#1_:&2))(0&*HZ0 MIAK/%AI1F11ZDOMKV:)*7/(2F>2IFPRMALF1:RB!G?=^BQ3H*!ZCC1F=W6@V M\%=G\7-T/,U?HYES%^$@?9P]'7HBW4_U>=-@X9"BG4$&ADD(5A3B%:@=RTR$$IY6.TZ=UJ.2I$[*&AF`R MM!J@G$(%A4H*513B%*H=R(U/"$$K/E'N+[U=$"I%Z82N(:?:"_^;!W2TLV$< M<;\7U*JD4$4A3J':@=QL>,KT@VI3.0KA"]4E'WL5LWI#5+VUMV^.3TW6[';= M9-.^BK<_X4N.FRL#JU=3[\(`WDV5.H!<">&*?#^%7(G@BER67(GABI3YY$H" M5Z1B)U=2N")/5O\*+#.Z"BPRN@8L,;H"+##*OUC!ZQ)0=7]=!A?@"V9Z)5^N MX)6#$9S-5^(7?'H%?K%?B1_EZ17X:AA\QM@JN,)'K\"+Q+>CM8(7C.7KN'XD M4-Q1>U':D7NZC5:W:E/-#!.\*/RR?FK^O3X^;0_=9-<\0BO-Y8LC1_6JL?JC MU[\GW+<]O",,D@U>$857PAOXN7\N7B!Z;-L>_X!LS,Q+YC?_!P``__\#`%!+ M`P04``8`"````"$`?Y#.]M(#``#W#@``&0```'AL+W=OA2V:^Z[`BYDE:'$/W MOW^?;FY=1ZJH2**,%RQTWYAT[W9_?-E>N'B6)\:4`PR%#-V34N7&\V1\8GDD M9[QD!?QSX"*/%#R*HR=+P:)$#\HSC_K^TLNCM'`-PT:,X>"'0QJS1QZ?93TB`X=.&S MGGS@KVI>D]E@%@W,M00M@0`9+Q#!D+E=VULKM0&-2`U--3XU@G7JNK@FLFS7 M85U/IJ5R.245@MNI3`12X?YKML=J"B^"V[PFLFY*F`<#+8(V/7H/(+B=RD2( ML9"FA'6;5[N&3V/U:'0[616"+WM1".[N M1JE0$EVBZ7VB2`^TLABG:"U10`;,@DQR"XVVLE6&T:,)-[2E:;4:H\DX`>S9 M>N,0$\("7AV$#+0=F600&FUI,G[0MTZX@QN:/FXW?)59_5:%K,69#S3<)`\@ M71.H0GU"+!O`AEM#=3\1U/4#8D+6RBP&!$UR!-*UA"K4)ZC'%$8(ZCH"Z;6$ MH%\0G60)&MUNM2K4(XA:EO#QRFBT1=WK`P/O5#K)!S3:RC;H`_3_^H`>:&7I M]8'K2:+UIJ.3?$"CK6R#/H#&/-X'--JB-M9@^<#U7-(6,LD':-<'JE!?E_7X M`%G"\?;>Z#'EW3]#UP[RNC(?D3BF!;2R=@!.'U]YA#F MXF(>%"_UX7_/%=PW],\37#`9G*U]K.J!<_7^@`GJ*^ON-P```/__`P!02P,$ M%``&``@````A`-Q2:H0,"0``^B<``!D```!X;"]W;W)K&ULK)K;)^P#8V!U?"5L`G3E5;6WNX=L`)K@%,82>9 M>?MM69(E=7L([,Y<#.1S=]OZU6JWC!]^^W8\=-ZS2YD7I\>NW;.ZG>RT+7;Y MZ?6Q^]>?T9=QMU-6Z6F7'HI3]MC]GI7=WZ:__O+P45R^EOLLJSH0X50^=O=5 M=?;[_7*[SXYIV2O.V0F.O!278UK!GY?7?GF^9.FN=CH>^HYE#?O'-#]U>03_ M*![EDA[2"ZR_W^;F4T8[;6\(=T\O7M_.7;7$\0XCG M_)!7W^N@W3\4E?3[`N+_9;KJ5L>L_2/ACOKT49?%2]2!B^(K,UWL&`+G/O&.ZAGX_=+992_IVZ'ZH_A(LOQU7\%T>S`B-C!_ M]SW(RBTH"F%ZCL>U;617'?[B1+4+Q((X(`I\BB#/L.6//]H8LRA7/@?"$3^%IPX7> MXND*3_B4GMJ%7SDE7%`]8O@4CF,UX"M^0^$'G\)OT!O9UF0PNC[$D?"#3^'G M.+<-$=9H?:7P*8=XHS@3X0F?TM/NV:[UV738D'\\'5@BBJF^\9QVDTKP18[T M)F5MF3_LB_`<]US'&XWK++PR*;9,(/;EM@ON\Q50+Z@@K=+IPZ7XZ$"5@LLN MSRFK>;;/PLFEQ$_?+*X?K2U85"S*$POSV(4Y@V530D%XGWK>X*'_#HMX*VQF MU,8V+>;2@JU8%C;`(,0@PB#&(,%@@<$2@Q4&:PPV&NB#DHV<,)<_0TX6ALDI MA9A)H/1UD';20KH$&(081!C$&"08+#!88K#"8(W!1@.&=I!]/T,[%@8*NI:* MKN.:8LV$#52G)E^'ILF\,6D$)20D)"(D)B0A9$'(DI`5(6M"-CHQI(7[Q<^0 MEH4!:T;4P:;0D)"8D(B0E)"%D0LB1D19P3$A`2$A(1$A.2$+(@9$G(BI`U(1N=&/+`RC'DX;?D M'NNXJGV^_3HK>&_:DF@#N/7R&S(+8JK&"70;,H7FA`2<3"#7M5Q$E3$D;I$@ M%O1/FM_(S.%86J.)HX]'*)QA,*KWM_48D?"2Y?-'D_,D\7":%AW1U8/]3Z)'M60 M`@K#'5(P:U,*3FP+M-:D0%>!?],OU`::?D@ MD9Y]-"&$U<#Z04;(*'5@4Q/6?M*N_*;8B5&+'/EL#;N#AU$UZ?K MP-&GU428Z;DA$*\FD_&0%1.R1(21GAM-*+4H6ZH)MX+<4%:NB_;@B:V'-Y5A M[9JNS']J.]A3.%Q3.$*)XZ)MPUQX0NE1185[RJ(R<=OT$C;:'8A&BN5EP?IH MZAJYF27"BJ>@*0YKUOZ_."P*JC0]B>.X%6A?0J MTE%/IR:6TJ(EG;B5*#7C'CSAUO\-PB^H&B;&J4SU6)MW3;T_BW/]).J3HL2[ M1=A^R@R9V1RYC)BG9.T4/:5\+'O[EJ$M+YJ>F2VL]!8+=3*+I!?1(%,IL.HE]CI?0C*&2= M"UMBJHI$%,44)10M*%I2M*)H3='&0(9^4&WNT:\V-VN(1&K,VO(LJ>-*(5UEY+A65DIE?=BF MRO=UZ=`8X7Y"($W2.44!12%%$46Q0-!?R]$DU&HAK6"<*N,]U"\LJ>-*(=T1 M=8IK924O8F,@4U+6\-Z1N**+5N5AYG!D2$I00*U"BB**8H$,24GXA;0R)47= M_9*&7TE'V"Y+M=8M;&.XF@JR#OL.!7E#;BQ]CN!GX_KI@&/9Z,+GL%^N^UO5 MI@8201_:)!%I4T-A9>YZ/-2?12J6U""6B&_&?M`^)])*]=V+]C.B;F4I'=6` M5A)='=!:A6*YPRW@ MEBVE#01B+<^UF1-G,S,:W6(C%4N&C^49[?J2VA^Q)-1O(9#Q&,+UT'UX*:.K M\:Q4K"OC6:OP3"GR?'=C!#:G"6^//FEJZ#8(WK5ART?;!O%79_@O_R>]IB?7?X)M(3TPS[\5-7"AS[\1D,Y=%P^J[3T"#1>/FNKVHXX<*1M&'#/@R-M`X'2#4?:S@-] M&FC2=B0:^?`S"SW_##S8C8P>@>[7G[<>@2;89_]N\3\J\13@N:C@G:OZ@<`>WK'+ MX$40JPBJ.0?<.I^\];>]%\```#__P,`4$L#!!0`!@`(````(0#$74Y? M_`@``+4F```9````>&PO=V]R:W-H965T>'*9LMII/RO*OWU?GU8?K7G^G=CYO=H?RM&UF]:4\ MPS'/Z^N\N5S+[;X+.AWGSF(1S$_;ZCP5"NOK+1KURTNU*^-Z]W8J MSZT0N9;';0OC;P[5I4&UT^X6N=/V^N7MK3Q>0>*Z.5?N]$YU.3KMU\7JN MK]OG(\S[&_.V.]3N_K#D3]7N6C?U2SL#N;D8J#WGU7PU!Z7'^WT%,^!IGUS+ MEX?I$UL7+IO.'^^[!/U=E>^-]O])5J^'%I;;AQGQB:WWW^.RV4%&06;F^%QI M5Q]A`/#OY%3QTH",;+\]3!VX<+5O#P]3-YCYX<)E0)\\ETV;5EQR.MF]-6U] M^I\@=3-2(JX4@4\IXC@SS_'#9:5-U\5#90+USDB:L\3&$:4!$-U/K71]\/ M[N=?H3YWDK.Q.GILQ+]?\:/RO90[;YL:G'&#\S6A3XONC_7,"N. M2V?!7+/H$_6]FKI``D]E-5,B($%!]^'*\[) MYHP%HL_80F*)"+?)#_C$0E(K*K,XN844>I2QO`Q\LSXM7M].P!WO!T889]@% MFE.4$(.]I/4JWURV"%FA6J48(3V0+5=F8(*L95<0=\SU@D5(#L@42;UZAM"H M>HXL5&?,=T/29PLD=>IF'KEK(C[QMCP*NP7G();@A@F(P:)I>20SC23+Z>YR MI!U4@:B5($OLHCO7<7QZ>J3(Z96R?@BHE",+E=B2,;)$!7+$G9=N'J'PC?R, M;Y^.38I+^#.CN)9D?2(9Q_K5CQ$*5'X3A,12^_[2\Y9FK:5(Z84RA'JA'"$A M%(3>BI$1%4@9J!CNK[2*^20CTHWI92(@HTQHQ49,D(PJ47&XM@FRQ-IZON.N M%C0CEE`FHV``*)2;0LQ?^0LB5"!EH$:XO=(R\E-G+9,>34^4@(S2\0)B-2,9 M:-2."%QJ#5FRED'7A`*X45^0,R6UA3*,ZH5RA(20OUHM0FLWR7$/U`XW8;^< M*>GD]$P)2%O1B#\2@:/,*"#)XK6M&M1`OT8:5(ZB.0Z996I?(),0&[]`KFBC M%RB,"YA-F[N^D33^65^Z!P"?;$VN0IJ5@#HC8EZ1^RSKBOC8Y>;;!"A2>R^2'(K!%D]E"+4)RU#J&?E M-E0@9,\/VLP/S*]CFSM/0J37DYX3(4NK>H1&76*"+''B.QX\LR?G6XJ47CM# M:%0[1];'V@52[!/!(?YSO#`Z-DF<\HY]L_!",KE(!L(XL%AC"<&:(I0@2]@) ME[DKA]P%I$CIA3);*$?6QT(%4FP[X1#+^5-VHA,AF1IPHEY(;LPC&0C=#M,2 M2TBW$P@)%\`6;!D27Y+:0AE&:;L,(2'DNH1#DYOP(XT=7HO\$)RMD3(TJM'!!K5(R&QZ'?#N9+7ZY4R*:XIY0A) MI>%,=+H"(AV*'$J1##0ZE`KL$R#E>]N3 MVH&9A+1C,<=Q]8&%$6C.GICA3PYTV_@Z`C*=$'U>%B&K7[D8(5A`U)F!U&0J3^B+N)D-672"RA`.IWI/XPD-].*IK=NY'6ZV<8.*Y?(,VN M0GAW9;0*;VO=G0I)K'#JVL,%\8Z+>&WA5%Y?RZ@\'IO)KG[C[Z]`\WZ\5[!X MN6;CK>''3&AI%/?7\`/?`!ZLX2`;?J]OQ\3A&GZ`&L"7 M:_A-Q\:SY1I^I[%QN$-?)W"K;'^3P3?YX#?P4M%3MW6LT<)@!Y0VSAI>#+"O ML''AY:0!_,E;/XG3;:ZN`"\-7;:OY;^WU]?JW$R.Y0LL"KS&`K;E*EX[$G^T M\FG3<]W"ZT+=@Z<#O!Y6PN]`"_Y3\DM=M_@'C&BN7CA[_#\```#__P,`4$L# M!!0`!@`(````(0#)1+G,L`0``-H/```9````>&PO=V]R:W-H965T,)P<\]./&/4_3)?.\L3[C MKAH7Y()[^,N1#%TUP<_AY(V7`5<'9M2U7N#[L==53>]R#]EPCP]R/#8UWI/Z MNNOJ>]QUU?#T?/E4D^X"+AZ;MIG>F%/7Z>KLRZDG M0_78@NY7%%:U],U^6.Z[IA[(2([3`MQY/%!;\\I;>>!INSXTH(!NNS/@X\9] M0%F)0M?;KMD&?6_P=53^[XQG:`8>"7FBU"\'"H&Q9UF7 M+`._#\X!'ZOG=OJ#7'_%S>D\0;HC4$2%98>W/1YKV%%PLP@BZJDF+00`_SI= M0TL#=J1Z9=]K%ZK'MYIE;E]-U78]D*L#[0";.5XJVEPH`V\R95SLG,0?Y1"2 M1YT\4"\;%_H8TC-"X;ULHVBU]EZ@6&K!R6T.TAD[R:"50=WN3:`P@5(!/%`T MRX+L_P^RJ!!P@1*!=`T0!V:&I;0DQ]WD\P$-8*^ M43(1ID:,N>`D"BDV9,R468>%%!92JH@F!1K#E$(/AG]99=0+:-/*+/;UR'-! MNB5NILSB+*2PD%)%-'$@1!5W.S^4S#3(M7.!K)1LA&FBJ]K-)&FVMY#"0DH5 MT4*&3K\_9$K60Q;(:FZ,G87L+:2PD%)%M/@@>_?'1\EZ?!Q!2*V4,$V-/>6L MY+V]]S/RWM]A:IQCQ4R2J2A51)-!+S;*X7J[,BA9E\$174:P,D]-SE)E6$AA M(:6*:#%#'=X?,R7K,0O$9T,@\%%H;#K_.TKFTMD+!&IA'A[(VG1!2IE;A.)E M&.F.2]6Q)@C!F7F_(L;6)4DHD)J,I7>"$+#;D9A<=%&8J>\M4D@6XAH"/T!& M19:2PJ]9ZCQ#=-#=74J,;8C@DQ(&")W.D!CSQ!G(&CYX39!,+LI)(NN];(-HR`T.K^4C`_20R???Y8FQJ]PVXY.39[I8P(*;KN>8?[2R>,,A@M4B('O MDFS'EC+P?9+!&6GSRR2#D]+&X27UP$K'\)/3%]8'_#S(X)IG^\F7&5R:;/PA MS![X2\U<(,S@(F(;Y%$&TQYP;S:`E]6E.N'?JN'4]*/3XB-LEL_:;>!O,_YC M$HEZ)!.\J5C.SO"&QG`!]Q?0FT=")OF#+C"_RK=_`P``__\#`%!+`P04``8` M"````"$`:A5_7BL$``"&$0``&0```'AL+W=O'5-T]TAYIM=J/:P).@@H88=JT_W[' M#*4,I(;NH2*),%'QGOG-I?MO_^LOV*JIG>>&\-B!"(7?FI:[+C67)^,+S2"Y$R0NX M6;9RZ5OY5%:F!AA4\V)(4ZG-.:/(G[)>5%CD(IG M40WZY24MY4>T/)X3+H^JYY?R(19Y"2&.:9;6[TU0T\CCS8]S(:KHF,&\WY@; MQ1^QFXM1^#R-*R'%J5Y`.`N%CN>\MM861-IODQ1FH-)N5/RT,[^SS<%V3&N_ M;1+T;\JOLO?=D!=Q_:U*DS_2@D.VP2?EP%&(9X7^2-2_8+`U&OW4./!G923\ M%+UD]5_B^CM/SY<:[/9@1FIBF^3]D2I6AJ0D>BM M^7M-D_JR,QU_X05+AP%N'+FLGU(5TC3B%UF+_#^$6!L*@]AM$`?4M_?MA;WR MF.=/1[%043/!QZB.]MM*7`U8-?!,649J#;(-1%8S\R$_MV<&4U)COJM!S5"@ M)=CQNO=\MK5>(85QRX1CQJ;$84PX;H=8H*\3"5,?BG2_3/^'2#4($FT:/9$# M"2$R;H_Q.P7-5`\Z@FB$!_4UZA.HX)T)L3MMJ\�T2")KMLQ>Q@D."#!B#" M8'9]8D(HBV@VI2MTWM"#9K:$\CH-.H(HE'UOUYQT=NJ8)J_T9Y`I+65K=F*IO?P M]7TB:WV/+`5369[_6:;05F1T*=,11!N#K=G/V3Q?FU%3QK:03J86H3H'C4/O M+<-:KRUX+8/N.F[@#:N)!J#25,V>O>P85OB^-,__K`=H<`MI4X=Q;B-4WZ!5 MS+08ZSU\=K4#&C_=`"%#Z+8(+#!:A.J$,'?D4=%THXSV+T,&+79M9J^I_H,& MH-+N:ACJ56T@S?,'A3=L(6WJ,,YMA.H;=(Z9%F/QG[!8UR%:BW4(U3GH(A.[ M&`M_?ZN,+48&+68VF#RT^&N`2KNK>;!Q]X`7$OKHL(5N^]>F#N/<1JB^01>9 M:3$V@@F+==VBU:E#B$Y[T%#T%C?TQ"YNF;8-^Z--_/5]*NRN#F*/.XCG#_I_ MV$*WW-!LXS._&=4G=-"&AD_0?=:+@*HI!6>H_&B%F5SH#R* M&LZ_S=<+_-[!X;2Y7`!\$J+^N%`G]>X7E/W_````__\#`%!+`P04``8`"``` M`"$`3`AC0Y4)``#U+@``&0```'AL+W=OZWGY\B M*;%8'+>5W9MVYV.Q7%4LZI=DWO_R[707Q_& M__Y#_KP]YOC]6Y>!A_+^KQ+X]_^^G^H[I\J0]%T8S@X5P_C`]-\[:> M3.K=H3AMZ[OJK3ACY*6ZG+8-_KR\3NJW2['=MY-.QTD\G*O#^5;;;V==K>X.VTO7][??MY5IS>X>"Z/ M9?.]=3H>G7;KWU_/U67[?$3>WZ)TN[.^VS^8^U.YNU1U]=+%_4.%86;NWBF/.VJ(P+`OZ-3J5H#%=E^:S\_RGUS>!@G\[O98II$,!\] M%W4C2^5R/-J]UTUU^J\VBHPK[20V3O`9<')E8F(FXM-.Q+=>F9":"?@T$Q97 M[>&M30^?QCZ>W47I=*ZRN_(]'K(QIR(:LNHV1,9(S(AB1+B'Q8?5NCT\9 MT_@TB:98LJ[#T^7,JVEOU165(\&1)(C$K>Y6G*OI]590QC1N0YRZ,I(S(AB1 M+B'QHKU; M:QJT14[%.?%UX_]U9V8LZ1X$@2 M1"-7VG1[Y%K)2.0&N05F*(\8$AQ)@FB82GAN#]/(E%M@C:((.\>I\-*OL#9; M]#/SJ$/NQ!6=*'HKNS22()J-4IK;LS&ZU,>TB32BV<0K=KNES4@V#`GCS+&2 M!-'0E>+<'KK1)S=T@Z;M360\C7PA5+<-N/)$BVYWY!9!3;JUBY9L"LY MBN9)Z@F"M(Y:WS0OI52WYV5TS_&D7]WA'6*M)) MQ-,X\GI46A/]..;>$Z-F0Y+0*D5NP46MSF4NR^;"BV`"VA`"1+4S#RM&'UTU\>@;GW8 MQ54;D/4QJ'UJ;CT+=?U`=\;JN_`,-(M3KPVEM0@LCY*Y_SDUHY5N:@9!*[OM ML60KIXU0>'N!RM%W*ILQUW2+4L"MQNII2\WP$:>G::*F6)G'.4<"8XD031,):ZWAZFEV+UB82.V M:J%:T*FPKX2.65_B?JIE(F`G*:/A*S6]/7RMO21\@]PV9BB/&1(<28)HF$H9 M;P]3ZR@)TT@K?=[RK^J9>LQ0T@TS6]$\P$2`2^K;*%2_N4)2!KT%BKLP6T3;W7HUDO55??^.KSUUP*TD0S4H) MWNW%U_)(>L>@/H`L9BCG2'`D":)A*I5RPE3%7^#]\?#:*T>>UAA$:^^)8!9W M5GWM&1+<2A)$DE(O`]VDKE_$6VL:N45.[3G*.1(<28)HF(-4,N$J:9#W.F?E MWT$[9EV)`TP$F*2,AC](*A,NE1:Y56;JF7,KP9$DB(;I2:7J\!EJ.?#:DG`- MM8CVMW\#V5OUQ3>^^L0%MY($T924KCF;]@?];530N;`G3!@SCG*.!$>2(!JF MDC4GS,]67JNC>VU,#**5]Y],>JN^\MU$BP2WD@31E)36.2G]H/)&&=W*,[', M$H9RC@1'DB`:9DA2%\M/7-83+JD6T>)[3]M9;V4KG7,D.)($T:P&22KZQ106]3%E'.4<"8XD033,09J:CIF77\'F`@P21D- M?Y"FIEQ3+7*KS#656PF.)$$TS("F?NJN,>6J:I';X;.I_V#:6_7EYZK*K21! M-*E!JIIR5;7(K3T3VIQ;"8XD031,3U6O2U#*Q=,@O\.]5XV98]:76'MS'U1% MP$Y21L,?I*`I5U"+W"IS!>56@B-)$`TSH*"?N&M,N7Q:1/O;?R+MK?KB&U]] MXH);28)H2H/D,^7R:5$?0,91SI'@2!)$PU0*Y\CG#_I;67M"8Q`ML/_8F796 M?8$9$MQ*$D0BGPV2R-::1FZ14V".[P:N\1;3R_N-H M;]55GB/!D22(IC1(-G&:CT6N4?O^37O6Y_7TB;!3<7DMLN)XK$>[ZEV=Q4,3 M/-YW6!\4W*2KM>H.9.6/S*8X0]C^L,%&U.G"]BR>/Y(F\):$O*4I1MI0V9P9 M1MI#@FQDCI'VIR8VLL!(^^L&&UEBI'UV\4<2S,%]>B#3!'-P:QP:075P>QD8 M25$=W-&%1E`=W"V%1F*,M+\OL=@P!V\M`G,2S,%[@M`(:HW'[=`(:HTGW-`( M:HT'Q=`(:HUGL\!(C#EX81L:P1R\(@V-H-9XS1@:0:WQ9B\T@EKC]5A@)$&M M\48J,!*A.CA($!B),0>_]81&4&O\EA(:@3?\?!$:0:WQTT!H!+7&R_C`"(H3 MK`U*$ZP,"A.L"\H2K$J$#'%*)?#-$3+$*1`^DD7).L/O_7P$)Q_6ZG``'\'1 M!G@+C>"0\5.P6NKK`YXVJKPAKAHYP)_2]9,^Q.QO%W4M"4S8H%/;1IUT$W#H M^&W[6OQC>WDMS_7H6+S@0CAM?V&^Z&/+^H_&_#;Y7#4X;MS^3'G`\?("YU:G MZ@W$2U4U]@_4:-(=6'_\$P``__\#`%!+`P04``8`"````"$`QQ0V4\(*``"R M,0``&0```'AL+W=O_?S\>9M_:<[_O3@]S=A?,9^UIU[WL3V\/\S__X+^MY[/^LCV] M;`_=J7V8_VC[^>^/?__;_6=W_M*_M^UE!AY._'K?]7??1 MGJ#DM3L?MQ?X]?RVZ#_.[?9EJ'0\+,(@6"Z.V_UI+CUDYRD^NM?7_:XMNMW7 M8WNZ2"?G]K"]0/_[]_U'K[T==U/<';?G+U\_?MMUQP]P\;P_["\_!J?SV7&7 M-6^G[KQ]/D#O#_(EE3?O?7SK'_O/JOS_N4?^U,+V89Q$B/PW'5? MA&GS(A!47I#:?!B!?YUG+^WK]NOA\N_NLV[W;^\7&.X$(A*!92\_BK;?04;! MS5V8"$^[[@`=@+]GQ[V8&I"1[??A\W/_?,UAL,%3]QU8L79:!,STA9-/C%/E_,P2FAG#R)+P\S"$( M&/P>IO6WQR1A]XMO,!5WRF9#;1R+7%N(>2?<%BXH76"V@6-!5#8L+A^0=C""VP& MU@2(XA3'N5$VL$3&6;+$)OEH,N:"D)(03DA%2$U(8Q.4$=AF?D%&A!?("%X3 MSM!OE-&UE(PF8TH(*0GAA%2$U(0T-D$I@(M<]WB@"^\LX M\E&Z%1[!N2Y/>^$#IT22 MU"0@EV1E2*%LS-HH">&D5B4)"T#JCI,O#B*M@C8-5*!5&WQYC%J8)[DZN+-AJG"*%0F$\HE(CY2>(PC!Q5A6GGBI=#3;K M,2-L[:RK6EM)Y]%JR1R+!KG&&1(2R1*%/\F0%%1PTNG<;YA$Z5)E*&+N0:\L MPN'KBA)[LA*S)HBV8H.?)`[$_SC77-L83Y5"X.EJAF1[H70>APESUF>#7.,, M"34U/4-2>Z$,292N=(829TKG3%J@.:30Q;*9;IGI7-LS[;T&;:3G!%44%12Q"FJ**HI:A#"\0DI,CT^*5S0 M=C%J&;->H]19Z#GL%>)@M@]=@TQ%LH>6QDK/,DY199#MR]5AQDK[:A#"B1$Z M97IBI*I!B;&%CAIX@@I&4$D1IZ@RR`[9E5_&RH1LMXA#%L+$"ODO*3!QM#D2 M3"&AE'0O4#I``:!T7-<:@S56 M8PJQ0)WC+%H[4S+7)I8<4\B68QI)Q;1BD?B#MV-./56Z&FS45XY2;:6T7IJL M'474(-)"!QQ&QA0:C41NQ*G5R90"?TF!6ZECF`2VTE M4\T8)'V9.D<6UT;&565<71>T$1*A-[&BED*3)M)443BX0@(Y),&QE7E49P;%V;1ZI!Z7T5,)HCNYV9PUPF+//;^-E5F$RI=)3$FM.$45135%#4(X9"&?IB\H);;L(27Z*P\) M*B@J*>(45135%#4(X?ANDF0AE60*P=EJUBN59,;*#.FHTDQ%*LEH14Y199#M MRSG_:F.E.]$@A!,CE,OT@9=4VFK:1W MMEY'B>.[0;YQDFX291$590H949:02S)E8HLR7FTX'<6.F94U!4 M4L0IJBBJ*6H0PB$[(DM\O8O6XFT*]3A_\C/UB`HPC5`ZB)8W5B8=RI<];0CB MM&)%44U1@Q!.QTW*,*+*4"/3\YRB@J*2(DY115%-48,0CN\F91A19:C03V2$ ML3)#*GVABE1&T(JB00@GYB;]&%']J)!U4.84%125%'&* M*H/LD)UMLS96)F395=^YZ4C*OW2S$U&EJ1"2$8I9V2D\9J6'<5JULLSL;+@R MPC(SZ1C5+"`\`X3>FK[Y2W6&-G^)C(Q(W.,.7=0C389?.,DW21(X253]XY"(>MV1[Y&*E\7/+;GMS9O#X=^ MMNN^BE=$$S&6(Y;OKVZB*!-J`*8G*8FA9'#NEC`H@:=.GCIL"25#^MTZ(=21 M2YR4)%`RO+M*2L`;7`AXVHE"Z%OH*8$##DJ&9#O>X$W=)U^-#;S!.[SNZMAO MH`FOO4B8I^6G.'N2;P*[CB!R;[*@I]ZP(6IOT`Q:AN>;OG0DV<8;=`[IR+TE M!92(TX9Z`[V1B3.'EH#LR&I0$+Z2)93X>@U'%91XO;$T$\\>J#=X_@21^DHV MX2K;P)=C6B>'$O%=G9844"*^GM,2N*#)Q)=T6@+W-)FXA?&5K*%DV,^=<8;O M]E#B\P:7-S"7?"45-.-M!1KQM@%-^/PTT("/;R"3&V\FX=EC)AXWT0@+*!%/ MF&@)/&/,Q',F6@*/&F$LO9$P"`6>M]$Z&^B:SU<.'?/Q`KKE:Z%89_!B%O5? MI!F\L$0YAR`&OA@'$-Z8_]B^M?_ MMGKN+O"N_/#C._S;B!9>?0[N0-Z_=MU%_P(-+\9_;?'X/P```/__`P!02P,$ M%``&``@````A`)7&\$_-!0``!!8``!D```!X;"]W;W)K&ULK)A;CZLV$,??*_4[(-Y/".0"L39[M`E7J96JZK1]9@E)T(8X`O;V M[3O&-MB>G'2WVI=E\V/FCV<\M@?NOK_5)^NE;-J*GM>V.YG:5GDNZ*XZ'];V M7S_B;X%MM5U^WN4G>B[7]GO9VM_O?_WE[I4V3^VQ+#L+%,[MVCYVW84X3EL< MRSIO)_12GN'.GC9UWL'/YN"TEZ;,=[U3?7*\Z73IU'EUMKD":3ZB0??[JBA# M6CS7Y;GC(DUYRCL8?WNL+JU4JXN/R-5Y\_1\^5;0^@(2C]6IZMY[4=NJ"Y(= MSK3)'T\0]YL[SPNIW?]`\G55-+2E^VX"<@X?*(YYY:P<4+J_VU40`4N[U93[ MM?W@DLQ=VL[]79^@OZORM57^M]HC?4V::O=;=2XAVS!/;`8>*7UBIMF.(7!V MD'?*A#;/WL\F#66,B#TQE M;<,88%I:J+B7^\7H$H*8;/!-JYNL946K"28;&B"R`2Q"1(3I";(%.!` M$H9,0*%\02:8"LN$C&$CP9@:SPA;6DB7T`21"6(3)"9(39`I0`M[]B5A,Q58 MITH!>(%9`,(&2GRHDJ61BL%DR`4B$2(Q(@DB*2*92K2,P&+_@D)@*I`1?4T$ M>KP;870K)8/)D!)$(D1B1!)$4D0RE6@I@6U,3",(["_# MS'NKJ9Z+[6`DW4)$(D1B1!)$4D0RE6B!+C\3*#/6`Q5D-2S_+2(A(A$B,2() M(BDBF4JTJ*"^/CY]S%B/BA-_W-2VB(2.!*NE/0,#C)^O#$-/26([QITD+ER*@18VEO89FP]>./ M"0D%"L:$1!)Y?4&XW@S53(R%$NDU"J42"2'7]UPT^^J(].RP1LC(SFSUR1W2 M%=V46A0<&9F:ZXMB*QRU3'''@+_/]=N(L`IF0\W%V#&15J-C*M'HF&F.>B98 M_Z-DXC_6@>B6U)`Y4BI\ZW*DK0.._/D03"2LX%22:RK&CHFT&AU3B4;'3'/4 MXV-MCQ+?_SH+V9N\<30(9,STPIQI[NB.>ULH'/V;>ULDK?Q^F2R#U2(PJCN6 M(QBU$^EU4SN55ES;]V:SP'@GR31M/9^@?2N?/^CE9[V%>A`Q%>,@XJB?9_Y$ M_K&%O[G797,HM^7IU%H%?68?4CS6J@QX^,KST&^K!M^PKS^LS$SN$7A'O,)G M!%Z5,'^8DP>8<7QC,R?P(G&%+PCTW5?XDD#GBGGF$VAF,(?-E;!M`]^!/9:$ M5^_`5DNBJW=@AR5L+\%JL-$2MJ7@.[#?$K:SX#L9W&$;#+ZS\=P"+?4]K)'^P!P_?;^W\! M``#__P,`4$L#!!0`!@`(````(0#V,TW$*Q<``&R"```9````>&PO=V]R:W-H M965TF9;[^'$BFRZC!.Y+LOD^D?B[2J6"H=T1+]\6]_/MQ? M_'%X>KX[/GZZK#Y,+B\.C[?'+W>/WSY=_N\_S"_KRXOGEYO'+S?WQ\?#I\N_ M#L^7?_O\G__Q\>?QZ;?G[X?#RP5&>'S^=/G]Y>7']=75\^WWP\/-\X?CC\,C M6KX>GQYN7O#/IV]7SS^>#C=?NDX/]U?3R61Y]7!S]WC9CW#]])XQCE^_WMT> MZN/M[P^'QY=^D*?#_?KM]Q^_W!X??F"(7^_N M[U[^Z@:]O'BXO7;?'H]/-[_>P^\_J_G-;1R[^P<-_W!W^W1\/GY]^8#AKOH# M99\W5YLKC/3YXY<[>.##?O%T^/KI/Y^ M_-D^W7WY^]WC`>'&1/DI^/5X_,V;NB\>H?,5]3;=%/SWT\67P]>;W^]?_N?X MTQ[NOGU_P7POX)+W[/K+7_7A^18AQ3`?I@L_TNWQ'@>`_UX\W/G<0$AN_OQT M.<4'WWUY^?[IL/T_6B M6BS]<9_HN0P]\7?DL:Y"3_P==:PXU[ICQ=^1Q[H)/?'W?<=ZU<]NERSUSH/Y.=ML-FQ324M]M'")Z,?MM:@T\<>=Y/.)=3^8H M(\/,5TM5#O:#4>Q6$VF(&"(M$4O$Y40XBEK_?D>]L70TD,UPMN^)U$0:(H9( M2\02<3D17B&_GDF1@6GN?#1E$U,K!^E.[S4A@74W59V`4C>#C$ M6M?/P62(-)&&B"'2$K%$7$Y$2"JZLY:Q#DC5"Q6.?;(:G&74,#*, M6D:6D1-(NNPU1*::WG"Y5QRX-L0CWU4!996#40],^+AF.Z@.'*7X_N*=[*P##8QQG7J M%E'#R#!J&5E&3B`9=J\1LN"\$?:@*+*K][1'JK!L=*8-5M&_.G6,J&%D&+6, M+",GD'39BXOWNQRD2.YR0'EA(51/"36,#*.6D67D!)+^>2&0^7>V8)D&19&[ M/HB,=!)4*[TV&3NF`-6,&D:&440]$\)EM.7 MBAF+DHB$*%GIA)DAF+DH`*Q>/_1Y3,BJ)$ M%89=M#I9/%B4I&YQ)AI&AE'+R#)R`LFPCQ(E,Q8E`:GBH6X"]\DJ^E*4RV%[1C6CAI%AU#*RC)Q`TC\E2M[P MCY6'_VJX]R]=`*N5DM_[9)6F=.@84<-6AE'+R#)R`DF71RD/K&-V_N53VB,N M'CZO\V0Y\XZF&X:4AUH3V$6K4\4CV<08UXP:1H91R\@R<@*)L,]'*8_.6BJ/ M@/PG#%*K6BE!MD]6R656'FQE&+6,+",GD'1YE/*8L_*(*%,>C&I/#J&5D M&3F!I']*>?A\7R#8(Y<&YRQ)(I*21%T_]\DJS35+$K8RC%I&EI$32,9BE"29 MLR2)*)_K8)50S58-(\.H9609.8&D?TH8G;Y0^$>M_%4AJYH1R2E556V?K-*4 MAK%2%!JV,HQ:1I:1$TBZ/$KNS%GN!%2X4"A5<>Z%8I`;J2(NIFHU<38L20)2%PH5EGVRBL[4C!I&AE'+R#)R M`DF7O:)XM\J<]_I#G%P!I7-D'ZT2JADUC`RCEI%EY`02_BT*PNB,"T4WC*PJ M$3&F56E&X;DIPKI M+EJ=JBK))H4]B)Q5^MJ*K0RCEI%EY`2285=:Y?3U:\&2)"!95=9ZB359)9?[ ML=`QHH:M#*.6D67D!)(NCY(D"Y8D$:42LF=4,VH8&48M(\O("23]4Y+D3/FY M8*T2D:@J:[W(F:SBQ-:,&D:&4@$T647_:D8-(\.H9609.8&DRZ/D MRI+E2D#9Y6_/J&;4,#*,6D:6D1-(^E<03>O-.<\$+WG])B)96/3B:+)*TQW& MR@H+6QE&+2/+R`DDPS%*)BU9)@7$A66IU,B9ZK0;A@J+NC3OHM6IPI)L4MB# M!DJUIF$KPZAE9!DY@638E91YH["P8EGV2!46O3B:K)++0\>(&K8RC%I&EI$3 M2+H\2K$L6;%$E,Z1/:.:4319Q:FM&36,#*.6D67D!)+1&"58EBQ8(LIG.U@E5+-5P\@P:AE91DX@Z9]7 M*=ELOW$"!TV33VE`T8UHX:18=0RLHR<0-(_I7SZ"U;W/L'+][O;WW9'W(/`IC#5,[PKWK]!OF)! M%!#>RXESN&=4!X2GG/QKY]-)I41BDPSB,"8.TUU\N\]ODU481MW5V&00AW%Q MF.X`94B46"JXCD<:!]]9$*UZ)'PG5$>K?O\&_\I\P\A$E.+81I0Z6D8NHH)_ MH]3/BM5/0/ZMC/0=Y5HO/4>K)#/JB&1'M>C61*MUGQ35IE)#FVB1AFXC.CFT MC5:O#NVB13>T3`LE[=Y("UYH6O6H$L5OH^X6]\$*3^/'5*U3QXB::%5U,9K- M5PM51$VT2..T/(Z-5J^.XZ)%-XX,R"@YY]]04FN\`X14'7Q.Q6\U4!=;P.&U`.(`XCHU6KX[CHD4A0Y0Z?..480FX MZI'*$'61V$>K-+-U1&EFFXC"N;_D!`D?EH9I8Y\TC(WHM6%<-"CDAY*'YUUK M636N>J321M^`!RN1-GU'O"82I[N)5O[B_L?GY6I>46$)G?+"0N/8-\=QT:*0 M-E[LO?\\"M(PDYFK'HFT6>L;AVB4IKL.J-_9J9,6343^@H_3"%L?Z<>`#0_4 MQEY)H]B(7A_(B8%$J5TK%>HSQS^#_WZ)UHT@JTU`*FWTW72PRM,FHBQM(NK3 MYA=LV+2:Z<2)-EGB1)1&LA'%D9"`"S5U+MIPZJR5G#U=<3IK%91>RB)UXBFQ M#U9X23.B.J`\42)*'0UW;*-5EA@1I8Y.=)2)H+3I625DS9(U()$+,_0-G;LAYYML%>8?/O'18M" MLB@AK(/YC^./U^Y]LAN`-0ODB-)E=,^H9M0P,HQ:1I:1$T@FD5*R734Y9X^9 M-8O%>"92V'M-B`>E4]@)-6FD:&48M8PL(R>0 M#+M76UEPWJC4O3;+GP9:]T@N!F_416>?K*(S-:.&D6'4,K*,G$#292^3WN]R M+ZJ$RSW*OV5:$ZH9-8P,HY:19>0$DOZ-TFUKUFT1R>*A[O[WR2I-:1@K+QZ$ M#'=L&5E&3B#A\D8)L]-9W%E+O1$0%X^-4C)G%H]N&"H>Z@YJ%ZU.%8]D,X2= M4"#OKG4V/5/%0NF6?K)++0\>(&K8RC%I&EI$32+JL MQ,H;+K,HV024SI$]HYI1P\@P:AE91DX@Z5]!E)SQ].2&)4E$>57!AL92)NZ3 M59S8FE'#R#!J&5E&3B`9BU&29,.2)*)\KH-50C5;-8P,HY:19>0$DOX5A-%Y MSSEM@GS);OXCDM.M[V6259KN,%:*4,-6AE'+R#)R`LEPC))"&Y9"$:4CWS.J M&36,#*.6D67D!)+^*=US]OW&AB511'*VE3C>)ZLTVV&L%+.&K0RCEI%EY`22 MT?#"Y-TJ<..ME63H$4N&:J+4R)F:H1^'1(.Z9]\-9J=40V8TA+[`L/>C/W9\ M9KHWP>:/Q+#[(S%L_T@,^S_F3$Q`-5'2ZO2EM#>74Q"9T`_3B9)5V/:R7TW* M!'M=8'">[.`\,3A/#,X3@_,Y4\Z/DD[5A+73P-*I`T^#76+PE!@\)09/B<%3 M8O"4&#S-F?)4*29_-IRA**H):ZF!R;*CSA!$A307HD(,42&&J!!#5(@A*L00 ME9RIJ"B=]5;RLYZJ)CTK%2`E7,XN0(.D28L9BYE:V4,!"F:G"]!@E!4@8I@# M8I@#8I@#8I@#8IB#G*DY4/KGK3E@D5-->J8*D(H0$G`PRYPG!N>)P7EB<)X8 MG"<&YW.FG!^E=JH)RYV!I6(#3X-=8CC5B,%38O"4&#PE!D^)P=.<*4\+NN?, MO3HGK'RJR&0-TFM^F5F6`BQ^"G8(#-DA,,00&&((3,Y48+R">;<$P@^'D`8: M6)INI$"P2PPI0`PI0`R>$H.GQ.`I,7B:,^EIMPUUYFE?$$<^7E6%S:SSI<#( M\H>,"@S;4/:,,QBVOLWN]?@AH,WS(L.H]G>A%X&B6?:N'P/0:"9OD=-_L+N:; M:KE#1$B$9#A`+K?GU'I8]7-UF$SDR? MH)%$X`+#GRQP>JFU"OMJ9P^$('"A:_]-]F:]F"QG&]43<1NLLK@-'QH9LFJP M\],PGR_G^,$?-1KB-EC%GHA;8#.?HRIN7O_\^W$+*DK$+;`\X>C1@BILURWS M+?1<=ODVQ7>@T]EDJ:[8B-M@%CU%O@T?&AGB-MAUZ3O!MZZ;Q50-A\`-9K$K M`A=8*>&4.M0)][ZO1*NX/[>(W*NJL=OMFF9K]/=D53<.W;:J"R*V[Q^$64I] M9;3/C&+TU51:FM\IE+\'D16.09U?^P1GYDUPOF@RD0"YDHM;/4M M=M[N&*:9[.`I,7A*#)X2@Z?$X&G.E*=>-XWP-,@LX>D@O;)IKO2*=R4VVH[. M#UVS'"<&YXG!>6)PGAB&W,HCAQS*(X=@ MVQ7[_7,0-M$6=28P>7=:Z37X*IEESO=J**L]<)X8G"<&YXG!>6)P/F?*>2\J M1C@?-$B>@&+7[5!GF&&:0]]TNP)/B<%38O"4&#PE!D]SICSU*F"$IT$T"$\# MPQDW9#B>O%;?K%5BW^U09YC!^6&XF`YPGAB<)P;GB<'YG"GGE6 M.4YZIO\YS_X7&A\.3]\.^\/]_?/%[?%W_U.=%43TYX\#C[\D6BVNM[X)+JLV MKU3P.Z-0!,6VI6_K'AKD?BO?UJVD<]O:MW6SJ-JV*`HXEOZA1M7FJQGZH6J4 MCF7:_1YJ)R>YW]3WZ^[^N&WFVSK]KMJV6+_'L6"EL?1Y:,-==_E8)OY8L/Y= M[.>/!2O&Q39_+%@WY38<1C='KQR+GR.L]7&_'5;!?%MYCB9^CK!X5.SGYPCK M)]RVW5376WPGQ"UXAN/:/S%1:H';>+"@U`*G\95\J66.EJ+'&SB,KW9+?>`N MON4LM M#N26[7J)6)='@Z=XM(W[[-;P%$^`E5K@#YZ=*K7`'SQBQ"W;Q>9ZBW?-N06; M2ES[+1P*+4O$`#L=E%J0(=@CH-2"#,'K\MRR7)2RV(&UZLY9;M8GJ]Q48>W(+=F1"#TE'O%IAM;!E4ZH.CQF8[ MI18<-;:>*;7@J+%I2ZD%1XW]2PHM!SL!T?MVSG*WA:G!^T^+WD MN,]NCJS"EFNE%F0(-BLKM"R0(=BZBUNV,Q2Z_C>M5#W&+L[7?L]D[K.;(3K8 M6KC4@J/N12R-AJ/N+Z:J93M'V<>.@H71T.(W7BVU(*^Q/VFI!1F"G3U++<@0 M['/)+=LI8H#54F[!SVM<^Q^S*+4@!OC-AU(+8H"GXTLMB`%^.8!;MC/$`,N2 MW(*-^!&W8@QFB`%VAR_U00RPKWJI!3'`]N.%EDYX%#VMX.DKJ@.>OJ(YX&E9 M<7C!4=8;7FZ4U887&Q#PA:.>PM.RTIC"TZ+.V/F3OC06W"S.)YPLS>86A;HL MXG`6%I.I@H-8&R^X4<%!K`F76N`@5CU++7`0RWJE%A2B?AE?G6I^(?<:*QNE M\7`O/[W&S7NI#?UFOE_IT]!OYON5VK90+J7Q=M[=TI'[V2QQG[4%OO57J@+? M^4IVG>X/O$^UYJ0S]\F%_IYS'1#Q]7 M;H.$1/[X+YC0[VJ8P.?/'W_[K[Y98W^ M'R_A!99?CR\OQX?N79;OAYLO![QK/O$_*?SU>'R)__`?\//X]%OW*_.?_T\` M````__\#`%!+`P04``8`"````"$`F#N&VR8(``#!(0``&0```'AL+W=O\%LNZ]FLW1W*4]'>U9?R#%>>Z^94=/"U>9FUEZ8L]KW3Z3AS MYO-@=BJJ\U0PK)M;..KGYVI71O7N]52>.T'2E,>B@_6WA^K2(MMI=PO=J6A^ MO%Z^[>K3!2B>JF/5_>I)IY/3;IV_G.NF>#I"W#^95^R0N_]"Z$_5KJG;^KF[ M`[J96"B->35;S8!I<[^O(`*>]DE3/C],']DZ=Q;3V>:^3]!_J_*]U?X_:0_U M>]I4^S^K.SYEV]1$6`/].3A67!F2D^/DP=>#&U;X[/$S= MX,Y?S%T&YI.GLNV2BE-.)[O7MJM/_Q-&3%()$E>2P*OO0L*$AD9U/"1&$`%G.21LSQ, M8>W@WH*"WS:^N[R?O8'J=M)F2VV8:1&B!9<8IXUL(+:!Q`92&\AL(->`&21A MR`3HQLX$WP5?S`1GX9G`&+8(J-0X5MAH@2Z1#<0VD-A`:@.9#>0:8(0-&\X. MVX.PQS<_UIL[@5"T>C/?,\/:2AO8`(,H`M,D'$R&T`D2$R0A2$J0C""YCA@) M@,YA)^`WZLY9("/F%EB9\6ZET;64#"9#2@@2$R0A2$J0C""YCA@I@?KK*;FN M!6[<1XXKWDH$VLE0>;9_/5!N;`8J MD=6PVT."1`2)"9(0)"5(1I!<1XRH0%]Z5.(\OUM`%KI#M?NQK:$LT`5'RNI" M[Q8=G7.8P0J$.2I8@D0"<5;]$>#,F6L6/1ZN8]$3R>$-K.E@PX\1X+#:939< M1XY<L0$B20BYB)^:,4$28A72FPR@N2Z MEQ$5[*O;H^+&9E0"8:`>;7=:AW4HC?JI4YS%HVY6@XNET5+4GZV8Q9L0WO06 MWNPSWESG-9+%8)BY/5N]M9DN"3&X@\K7:FX*.Y163C]IR^&%WQDVFNH.,5JQ M/C^NM_"MKIB@A>))U0)0\!E:?4R%\,KH](6*. M@H,>@]A"@Y"%UA5BM:U06AD*&1R1*T8K45GF0$I,I25HH2N$\&1H]2%/CA8C M"N&CTNT)D8.5GA`!60JQSH*022M5V0@A5=D8(=E2`BH00I.BCZ+)$/J()D># M$7WP,4E+QV\=ITS.6GJ6!&0U%FN*#J6C(1OAZ*B3.$8K?GZ_;8*%QTACD4ZZ M;`A/]BE/CA8CLN%3EI:G3QJ+G,GTA`C(D,W2_LG`1W/>5775",A1,T0LK?K3 M_6W#ELQ9D'U$B%+T4D090GQ,&"?*C169G85/:%I&N'+@0"^OXEI`E M&]_L$J&T,F0CN`S92$C(YAOS@X5+A"-M=.$0I@SOATP@0-\J78XV(]+A$YR6 MJ$^D(^8]HP7+$5#M^!`40H0B($,H$E*."75,):0Y9@@IQ]QP-(7`9SDMOM]K M(6(@-,*6,Z(^FWB6T$,FC`PI2`B"5S/-TCIZ8W24/=/S7:LY)6BA:^,6Z@P= M!;6[\IDEX!PM1L3"9[TKR?Q>7S[Z>:--^WS_V#M+0/WN-\H'J1NYX]FVLG10J&QP<(@K%%$HHE%(HHU!N0&9RK'FR;W+^'737 MKSXY$Q.CKF]'0KJ^?2)P9:6R,3@B%%.KA$(IA3(*Y09D9H./8IHXKW.3ZDR9814 M.4+]VQQ3*GS`^MM2$5.:D2X)P=[1TF4]:`BAU??'O]I'D81<,6 M7ZR,,,0$(27$%"%!Y7F!YRQ]BRI31DB5(^1R39O9XC/5W\Z6&,R,;$E(%Q<9 MJAUA9&A+^@6]MAPX^QUW'EBG="P=727*!"%=6P87F[/E:N4[%E>&CHHK1VA$ M7'QNNY*NVX8`/HQ;0X"$M"%`O#<5+\U.9?-2AN7QV$YV]2M_)PJM^?A1O>&T/N,+/7NJS=?A;X3XQQ,>!*[U8K2NP M`]9J57(B<`G[%5IW"%%XWZP`OKQ['[;V')XRN&!8_P;-TUO+89 MX??6C^*QFA7@UEO#2PWJ$"W6\.B9XNEB#8^3*0X'#00]=FLX.R#HL2O0C<%G M[.XI7.&M$^XS&Q8,+]`OQ4OY5]&\5.=V MG?>#[0'^5**$)\US/F0]UW6'7_@-AC^^V/P?``#__P,`4$L#!!0`!@`(```` M(0#Z^A%)31```#]>```9````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`D5Z6^H6%_5U;29=U<_4;$.%>EOX8KO[#8YV/E.?T,C M+G(GKCH+%>AO7Z&)P3I1L0D5Z6_?W:MJ/AU/9R[*)RK2-.VZ2'_[*YZNL`@5 MZ&]?X607K_UXZ(:76!Z6GS_MMC\N:,Y2QO>O2[<"C&^HL7Y<^;X>1]I;`XU& MF&ODBVOE]I)Z3V-H3[/CC\_3>O'I^@\:T:M@38RR`2"`*B`9B@-B4L(C0 M8O,3(N):H8BP.3$=<7_O@M&ID!Q-CB$!(H$H(!J(`6)3PD)"BU$:DO*NTR\& MSKCSO._Q72"TOAPS/QGET^!HU%<30"00!40#,4!L2IBCM.2_WU%GS!T-9'&< M_BT0`40"44`T$`/$IH1Y1>,K]'PN%G]?K?U6W\AK1-:S/T2[]K@ MSGHR[E1/9],"$9Y4BVY/J$;C"9\`\EC>)UV%-NIC"/71QNTKU$8V<,RQO&_# MAC:ZGK%`T&Q,`U%PF#;JWF-GS#WV)/48B`C$BS"WBTD@"FIIL#%`;%J+>47S MZOU>.6/NE2=C&CW)[,P2U0:CYI@64:@VGF>;O@Q&\R[_X_F(_L='@(*&]7L: M-KSA!39LTX99N,:DOM\?K\Z:!RR@,5TAB5C-'6N#5=4)^Z!GW)5):<7U0?96 MXRY"];@:S[/QK7J3V)"./>C'O.FM?$/3Q:2>9SFTO8F_U4BUS]B)(I"!`U>( MKI$L4EYL96-KFDU8D.F1[ZA MZ7P^6F1*U+*&^.!Q.BJ)U.DEA):*?+8%E(R!-B`V4GS%)BZ#,EC1JMWG7&%% MW5O%BJ9'L:)E%;E_3A8E_GUHKQ@';97(X(#82*@6,!)\Q22!(E1LTN4)UYG> MJO$+S62ZJ"9S/LQ4WX5T=/CKG6[`==;HIZ>B9_@65E?;/HWF<YA^Q;FCF1GBWJ,VHBX5V>XE8G&: MBGAOR+OJ-$[2U3.I\(J(]<^C).[M&)!`)!$I1!J10609XOXY49+XUZVNS?SJ M?"J\FF&N>L1FQ1&EL<[60>%TBY\[J554;JS'M"FQ'I_.2&?-)4"/DE4*D4`D M$2E$&I%!9!GB_I64SWLR4GG1DF8DH#0C$:6QSC-2M!I'IW^=%-&ZUZ*2`0240*D49D$%F&>#@&Z88*=4-`+-U! M-Z3I!B2QHD*D$1E$EB'NG]NRLPGXP73[S9_-R*`'R+DDW=D-3DMG>)UJ2,,! M2**50J01&426(1:.R2!1TEGS12B@--V(!"*)2"'2B`PBRQ#W+Q,EI_>3"2J1 M@,B_-*7YW7:T.LY@1!*10J01&426(>[R(%4S0543$$NIMTJ00"N)2"'2B`PB MRQ#WS^F);`97(]KCS^36RY!TNDZ.RJ3/6AM1FNYXN^M/'\M6;]R)39S\2/I[ MIIM>K+!N>K2(IY9MU^;M98($(HE((=*(#"++$,^'4Q.)?^Y.;$H3:>#N.?&B MA#GNT8(:2Y;33/*WH2)9]5D4B"0BA4@C,H@L0SP6@\32!,520(DS+2*!2")2 MB#0B@\@RQ/U[6RR=&=:HC28>I?(UHC3A\7XZS+YCQ<2J>N,>C\83&YUGNNEE M"1N$'K&,`!+=96A"QD$H$2E$&I%!9!GB&7'*(9M][SJ2FGC)02WWT^8N():1 M($S"Z6#V.XB(-=)4O'%O5P_2&ITUUQH!I4=2B`0BB4@ATH@,(LL02T6=:0VW M$%;5XOR]75U M:"41*40:D4%D&>+^%:3"Q\1^C>HA(/(]R4>5S9`V6O733""2B!0BC<@@L@SQ M<`Q2(C4JD8`2&=@B$H@D(H5((S*(+$/W=M$J M9MNWE4P1B58*D49D$%F&>#0&:9$:M4A`2<];1`*11*00:40&D66(^^=D0+;S M?4!WUEY-I/M@0%FN\WN^:!5S'91)7/LD6BE$&I%!9!GBL1BD:-=TIW6E%5Z/,"8CMK4>9DZSEN+>6K*IX<\BZ M/!VD=CIK+@$"2N+?(A*()"*%2",RB"Q#W+^"V@G"<^!JZR9M=K0=4#8#XPVV M?T@N6AUG("*)2"'2B`PBRQ`/QR`I-44I%1!+-THIM)*(%"*-R""R#''_"E+J M73]<3%$Y!91.P(A.3<"B514E,._Q(+4S1;43$,N(MTJ00"N)2"'2B`PBRQ#W M[V>IG2FJG8"R^9?=B+?1*LX_5#MHI1!I1`:198A'8Y#:F:+:"2A);8M(()*( M%"*-R""R#''_"FIG_)Y?UZ>H;P)B\R\H%_H3C]I@`XP5$ZO)&R[8"2U+:(!"*)2"'2B`PBRQ#W[Z?)G1G* MG8"R=,=#&Y_N:-7G5B"2B!0BC<@@L@SQ<`R2.S.4.P&Q=*/<02N)2"'2B`PB MRQ#WKR1WWK/)'=F*'<"8AE!N8-6$I%" MI!$91)8A[M_/DCLSE#L!9?,O/]R)5G'^H=Q!*X5((S*(+$,\&H/DS@SE3D`L MV]XJ00*M)"*%2",RB"Q#W+^"W/G8W>4,]4]`6;KS\YUH%=,=5%+<<"5:*40: MD4%D&>+A&*2E9EXXI4=:`26Y;1$)1!*10J01&426(>Y?04N][TG%&8JG@-AZ M&Y32:7D;*R:K\N2-\YUFD.#IK+G@"2A-"2*!2")2B#0B@\@RQ%+2%`3/AP[3 MNX8RU[T$RB9@?KP3*B8!$H@D(H5((S*(+$,\&H/T3H-Z)R#_90NOYQ`)1!*1 M0J01&426(>Y?0>\T]%V+#0&R1WW$EKN,FB;-E@E`T`@DH@4(HW((+(,=-0\\26]0ZP3$ M+^%6349+9XQR^7H6T1"402D4*D$1E$EB&>CX+4^<#F M1U\XR'?]@-RED^4P/]>)5L?E$)%$I!!I1`:198C'8I#0F:/0"8A<[IUI$0E$ M$I%"I!$91)8A[E]!Z'QH\W,3+--X`679SH]UHE4?((%((E*(-"*#R#+$HS%( MZKAW4'*7`TI>">ZM(A*()"*%2",RB"Q#W+^"U/G8\Y?N#;K<]Z+6B:@Q)D6D4`D$2E$&I%!9!GB_A6T MSL?23<_1Y^D.*)O=^9E1M#K.;D02D4*D$1E$EB$>CD$ZBDZ&P&6/NJ7U>48(2]T77[L6(O*2AZ]"-4J%O#5V';AH* M)7.Z#LGM4DE%)=V7RO+KS&LJZ<(()5,JZ3[GDYA7\I*)70=^M6H5$+7H=];2B5T M'?KIH51"^:%#^T))0UF@X58HF=)UZ#&64@FU1H]3E$HHV_1H0:%D1M>A'^5+ M)90?^GVZ5$+YH5]V"R4U]8`>,BV43.DZ]*QCJ82N0VJT5$+7H0?F2B64'WIP MJU1"^:&'F`HE-;5&;S*42B94,BF6T'7H*J'\T$/5I1(:!_2( M<:%D0GVC%S)+)=0#>C6P5$(]H!?E2B74`WK%K%1"^?'WN_ELK"D_].9-H4Y% MK=';_:42\H=>="^5T'7H%?%2"8U$>ENZ4#*A'M![QJ42&B'T.FZA9$S1H<\Z ME4JHU_2=H5()]8T^>U,HJ:@']/F54@GEASX#4BJA'M#7*+!$-#?TR4CDNKDQ M)4Z?Y?Y2O`(Y7_3==:G0_AT-YM)8_E+??/$_CD#J*?.EAMQ,*G&*;!?8ZV-# M]/GNU^6W]3^7NV^;E_W%T_J!-LM1=P2S\Q\`]_\XA.^'?=T>Z,/=W:?$'NE# M[6OZ].3(_13RL-T>^G]0Y*Z/GW[__'\!````__\#`%!+`P04``8`"````"$` M)GV[%,$1``!07```&0```'AL+W=O'L]^7[UNUYOG+^?!Q>C\;/5\M[E?/__X?%N=GV]WM\_WMX^9Y]>7\S]7V_!]?__ZWS[\VK[]M'U:KW1EY>-Y^.7_8 M[5Z6EY?;NX?5T^WV8O.R>J:2[YO7I]L=_?/UQ^7VY75U>]\;/3U>AJ/1[/+I M=OU\KCTL7X_QL?G^?7VWBC=W/Y]6SSOMY'7U>+NC^F\?UB];]O9T=XR[I]O7 MWWZ^?+K;/+V0BV_KQ_7NS][I^=G3W;+X\;QYO?WV2+_[CV!R>\>^^W^`^Z?U MW>MFN_F^NR!WE[JB^)NO+J\NR=/7S_=K^@4J[&>OJ^]?SJ^#93<;G5]^_=P' MZ+_KU:^M\_]GVX?-K^QU?5^OGU<4;6HGU0+?-IO?E+2X5XB,+\$Z[5O@GZ]G M]ZOOMS\?=__:_,I7ZQ\/.VKN*?TB]<.6]W_&J^T=193<7(13Y>EN\T@5H/^> M/:U5UZ"(W/[1?_Y:W^\>OIR/9Q?3^6@`DP.&8V-(G\8P&%U,PNE\T7_]`&7LZ)-K>&0P`^IVNA>H_F=:>')46()]!Z+_8=.+>3"Z&K_3$`'W&O4_ MQG)QG"5WF\#VF\,A#;B[J/_A6KYCPAU%C28V.1S/2SVV^J$:W^YNOWY^W?PZ MH_F/0K-]N56S:;!4[GB0ZDZP'[9OC5H:KLK+M7+SY9RZ!0W(+4TUOW^=3L+/ ME[_3]'!G-#>H":0B8H6:"Y3;V`>)#U(?9#[(?5#XH/1!Y8/:!XT/6A]T#KBD M6.\#3DW[5P1!T M7F_62/8B=I0"R8#D0`H@)9`*2`VD`=("Z331/UY$E29($56=O%VH[';WL+[[ M[69#D:!$9&`:&%.2IE,WY40&6Y,)&3J!]!Y_D18Y+1)K$KJ3Q\)[(B9[S3[\ MQL]DW[+97N-^_53._OE>Q(X*<%3N-:XCKT;57L2.:G#4[#6NH[FL4;L7L:/. M=23:C4(DVFV@?6CAQ@VDU+*!-'%B'P&)#=$+:Y5,)T!2L,I`DP,IP*H$306D M!JL&-"V0SK42(53KPA-BV,ME$`T*:,YRNOE"MFK$JOF^?\:,7,-@<24-$U8M M^M70.!P'<^]!FK+$^LX8'?2=&]688N!4W:M!P;ZL^Y+10??54>YK]F7=-XP. MNF]9]79D.I;TOF6[JW65NV`]/';4'H`W>`P*J&O9X(U'LODBHPK[+2ZS&-6^ MA.%`NVM5&/3M/I_-1U-ORDG1=S94*?"=&]58/N*@W4T-;-7+H]Q71[FOC@NFVFR.ZG=]0*1EA`\&]_T'F@*<-(P1#&B!%&**$.4 M(RH0E8@J1#6B!E&+J!-(#B6UC#MA*)E5GQM2C6CGBJ,>XRJS*F4M#/U>S*O95&.3X*JW*]>7-G955L:\: M?356Y?KR,S:K8E^=\"7;42T/W79\Y\%C5I/N:-&(!B1_7:1V7-5HL2AFY"1N MB%)&UC!C9`US1`4C:U@RLH85HIJ1-6P86<,64<>H-Y0AI3SAE)`JN9?#:?1> M#F=4-E.)E84*/'WLDP!XWB:LTIE*L)B'7A=*66%=9XP.NLZ-ZKT4#FI>'N6^ M.LI]S;YL[1M&!VO?LNK-P'2L&,C@U'+VA(&D5[_B26X6Q.]D<%KEY"EQ,&`X MT.K&4.E8,I#!J>7P">VN5\^BW37JLPTYD:AEHNOZHZ=8>KE)WVEGA>G$V_FX40L` M-0]1(^WG#N\Q%5D-S_4QH@11BBA#E",J$)6(*D0UH@91BZ@32+0']2S9'H>? ME;U<3NR,Y!#W-O,BJ]I'&5&"*$64(@.*%JD]CW9)GD1HAA1@BA%E"'*$16(2D05HAI1@ZA%U`DD0^JO,C^4 MK(>X^#1()NMC;V:)C(J24-N?M2_*P]6A>C@*O#&0&!LW445&X% M_-6%<"/#=-K*,<25HT%.XALABAG9!#-!E#*RF6G&R!KFB`I&F)F&:JESPM#2 M*R,QM,QBR:C2A7K7/.<*Q]VNB4*M$=P*4&-5$ MG3#\_G4>7M&%*+G[F:*C#%'.CN@K;*5"?SM2&,JPJ#37'64?FVUULBP>9> M)_*W]D.M$IW((#N5)*S2G>C3;#:?7WG#.&6-[8X9(^LI9V0\!:-@Y/7K@B68 M/8>G9<^]W.M".GNFA1D/D,BH1'_1*AKBK$J,BMJ148J&&:NL8<[(&A;"4'8& ME57__SN#RUSZ66^G)&\7II9%2B,VA#U2;[[CTP$QN5GBX'SWG0=\;H MH.^<56_.\@4KL,.HG86#\?SWYH6B,G@X3#,9'S[V;F1'8N1DC8AB1`FB%%&& M*$=4("H158AJ1`VB%E$GD.BZX],2\5[NA72?B-NN%D[\,RDVM(&/$26(4D09 MHAQ1@:A$5"&J$36(6D2=0#+*?FY^>+FC'M;>0]0@W#\8^_GL!_C]]R]IF MG$Z\I\4-J]RQ[ST((JOA.3=&E"!*$66( M8_K-2$SZ_HWDR*ILE(TO.\825*6(,D0YH@)1B:A"5"-J$+6(.H%DE$]+UL>8 MK#.RP8H0Q8@21"FB#%&.J$!4(JH0U8@:1"VB3B`94I5MNTG,.W.43L[=U'6L MT=0-*:`850FB%%&&*$=4("HMLE,;K:CDNJ&R*AY0-:(&48NH$TA&667I)T19 MR;WGK48BRH!BM<-+AHXJ090BRA#EB`I$I45NE+UMHLJJ;)2AJ@VJ6D2=0#+* MIZTXJ!-#E#5RXA<9E8-B1`FB%%&&*$=4("HM0C+*_XOS05K3:GO<'@D83 MRASLU#7U)N+(&%(HN(EB1M+0F_,25EG#E)$T](9>QBIKF#,2AC-OLBQ890U+ M1M+0FP8K5EG#FI$T]`9HPRIKV#(2AO[A3L>JWE`V]VE+7SHJ@7;5:#IZXUPV M,C93.WG'C,+>9CJ;C.?>G)RPQ%JEC,2C?.8]*S)6V4&>,Y*&WBQ6L,I^8\E( M&L+`-!&PAC4;4I^WG7WF_<:&5;:J+2/YC=XHZ5C5?Z-LS]/6W1-<=QLTU8=B M=,[N]<*(!?8P(V8T[]OS:A2.9]XP2UABK5)&%#XG2-[`SJR*9X3<(M<0VM/L M%MAO+(<-O:I6K+*&-2,QS.;>C-"PRAZVMQ8Y59U[,T+'JOX;97NJY>SQJR+U M"/'G78UPKU?-Q,+U!_=Z>S^PU^OU]1M6N9FKIXFLAILZ1I0@2A%EB')$!:(2 M486H1M0@:A%U`LFF/FT!/,$%,".13/M_;!59E8VR\67WVA)4I8@R1#FB`E&) MJ$)4(VH0M8@Z@424Z3DE>_WA++*7RY4N(QNL"%&,*$&4(LH0Y8@*1"6B"E&- MJ$'4(NH$DB'UE[4?2ADI/_"G+H/2T==L4UVT&S42B`'<&CX>#D7VXIVB8L%N#\LZ3YF>=>[O;P+T'NM!!Z9^=#\9^KL$JNY:*&=D63@R:S?K$=CX- M)H&7+:9L91UEC*RCG)&^P#*4(1XHD_G5Q'_%2L&2@8YR6F8\ MQ6,S#6JT16% M5QXN%BP9Z"G#.?V)+\*8*B]>!])(=J`Y3$=:)3J0079O,#'N9WJU^"F8T0L! MQ]"#P%5F[.@VMNU!1L4W"U!&QRG:(V*`9_:[]Y#4P>VOW,WT7OO_3>F\LI^@[.\IW;E1SO9\S]$=? MA?`MGGOJF.5@0(^[:]>[D1W0(&<9JU^WJ=_A][1Z_;&*5H^/V[.[S4_U*DU* M%KY^WF/SGL_Q>'FMMQ:]$KJ*M%37<*AC0K)87E.% M![Q1B5H"#I5<44D_.7K>;J:CI8ZN%I>TUTN+*$_S5JJ/TL:*`G)FQZ@ M_O>$]!I4^HN0`9LQV="MOZ$2LJ&;:EA"[U2]'JX956Q`?Q/2EP]QU3`#_'JR MO`Z&`TEQ'#"XH=8::JR;&;W\=4@?4(UT.NL%BLZ>EC4]_O!'TQ'44NW`8PF= M1"W51CR6T.D357BHA%8V2[7\0!M*])<)9=Q80KD[V0R5T&43JMM0(]*=$ZK; M4`E=/:&Z#95$5&MU>((UH*/&I3I#P1(Z7ERJHQ0LH5/&I3I1P1(Z;%RJ@Q4L MH=/$I3I,P9**2JK!$KKBLU3GQFA#-WW(VU`)7?A9JKL[:$.75*BDG[R]'D(7 M*ZADJ'?290`J&1J8=%)-O6JH!C=4@YO!DHA*U#$[UHTN1E$K#)70_2AJA:$2 MNB9%K3!40K>EJ!6&2N)@LDSTGVEY,:!7(BSSP1)ZP<%2O;X`:TVO*UBV@R5Q M2#U>/_G][Z$2]4=;Z"V>+^D=8@-\L4R&VB9;+.EM6J@O%TMZ.1;R9K&D=UTA MI_=\T*_H>^;EOK+T/N>7VQ^KYO;UQ_IY>_:X^DX/J5&?F+WJ-T+K?^S,9?1O MFQV]R;F_E_Y`;^Y>T9GWZ((6.]\WFQW_@[[Z7B^CVJ^ MUTWR""ENC70B68NS%#C3W66R8&&Y:IWF(1[?%EHMWO@5OEP],P:JI,ORL!B/7[:;@/R[C*C0)Y>V#[ M-]/=J?DI;R[7RT0*W(R2_,R+>=?H$);RC++'OI'$H[.?1D=(S#*<468-"^ZW1\F M>9&$920[*[:"1J-XLY9?%\E M);EEMB1]+FD\M7N6F;[U8I2G!,7A.T%S@6QS-V`-2:X2MH4TU+8UEK> MK$DJ>=D1]!^D[<+H/&!!*CM]8XU+BID$6Q6L>:F?\T+(TK[GY9-8$B*%90*@ M&:P?V]CV,[VRKWLU`I[VD95"XP0F]CW&5.9$A(LI+J7"\G6O[;EVT3AN#&VJ MB!R6(8])R!?R65-MRMO.MS&XG`F>TPQ+DJ$!SC%+"8H.(OT,'DWQQTM$$E:J M=II`?('"`@JVU:Y2WP2RY^J`TJ3UK0:?X;C+DYT!Y?1E\-[NV#H;.)$?H7"$ MIC,O\H+8B?TP0$XP1%$RF2@3,'+\&9H[=XF')IX3)3-O`L1(B8V\.+ZKYZLU M'-<-$X#6^D$8*RE#T(U#@(]\UYNI9<-X[,W0T!NH):(X='^/P[LA\`$%0KX& MB,)I%73CZMZ9S9QCT?B!&T[`G?/74_N"Z8D?U^FH8W3#(/:#7U[@^D<843*( MO#\))!!Y\Z-IU%=)O1GTG`ME[H^4%L7X`8Z^DO*N7#KHKFHZE*IX'^*5-:Q8 M2L_M.NJDM>5$2FE]UB^_P+GZ`N=:R3E6W2&1F,)W;7LI["X[/46]\?2 M8TV=-OTZZK3I[R-U/.]W>./IL3+%K5.A4SZ$O8FJ"Z<\13I] M'0&=>GLB6$D9;+V*^K`"19U_/4>]G_9.N"YL%1"I?2BA36'5-=!?'^I%]!QU ML`??D"K]<*)%O4/:==CK[M[U4/8FDB/D0NJ!-P[H_:$5+7)(,6KG-_&[` M&D.O6N:5"/0G[)%D&\SA1-5>SYM_"+MW==Z][$+GW!JSS-W?@OT?``#__P,` M4$L!`BT`%``&``@````A``GCQ5P2`@``2A\``!,````````````````````` M`%M#;VYT96YT7U1Y<&5S72YX;6Q02P$"+0`4``8`"````"$`M54P(_4```!, M`@``"P````````````````!+!```7W)E;',O+G)E;'-02P$"+0`4``8`"``` M`"$`-BMB=ST"``";'@``&@````````````````!Q!P``>&PO7W)E;',O=V]R M:V)O;VLN>&UL+G)E;'-02P$"+0`4``8`"````"$`&%VB+PL$``"/#P``#P`` M``````````````#N"@``>&PO=V]R:V)O;VLN>&UL4$L!`BT`%``&``@````A M``2.EU9[!```QP\``!@`````````````````)@\``'AL+W=O&UL4$L!`BT`%``& M``@````A`-5Z,B1<2P``U[T"`!D`````````````````<1@``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`-WJ.1?'`P``^PL``!D````` M````````````Z\L``'AL+W=O&PO=V]R M:W-H965T&UL M4$L!`BT`%``&``@````A`-I/C[44`P``;0D``!D`````````````````(MD` M`'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@` M```A`$^?U;^T!0``!QX``!D`````````````````7N0``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`/MBI6V4!@``IQL``!,````````` M````````D:`!`'AL+W1H96UE+W1H96UE,2YX;6Q02P$"+0`4``8`"````"$` M0>6/U0@(```5-@``&0````````````````!6IP$`>&PO=V]R:W-H965T#LRS0D``.]*```9```````` M`````````)6O`0!X;"]W;W)K&UL4$L!`BT`%``& M``@````A`$K)IMPH`P``\P@``!D`````````````````F;D!`'AL+W=O&UL4$L!`BT`%``&``@````A`'YB*B:* M`@``:@8``!D`````````````````<<,!`'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A M`,4:R44=!0``710``!D`````````````````P\H!`'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`!_M@E"P$```0V`` M`!D`````````````````]]H!`'AL+W=OZP$` M>&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`#V!\6Y8`P``Y0H``!D````````````` M````:18"`'AL+W=O&PO=V]R:W-H965T M&PO=V]R M:W-H965T&UL4$L!`BT`%``&``@````A`-H,6(`,"```7B@` M`!@`````````````````\T8"`'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`.@JA)"*!```:1$``!D````````````````` MF%@"`'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``& M``@````A`-Q2:H0,"0``^B<``!D`````````````````RFL"`'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`)7&\$_-!0``!!8``!D````` M````````````3IP"`'AL+W=O&PO=V]R M:W-H965T&UL M4$L!`BT`%``&``@````A`/KZ$4E-$```/UX``!D`````````````````$<(" M`'AL+W=O&PO=V]R:W-H965T&UL4$L% 3!@`````\`#P`5A```&SK`@`````` ` end XML 14 R46.htm IDEA: XBRL DOCUMENT v2.4.0.8
INCOME TAXES (Details) (USD $)
 12 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Effective Income Tax Rate Reconciliation Amount [Line Items]    
Computed "expected" tax expense (benefit) - Federal $ (1,346,076) $ (1,115,374)
Computed "expected" tax expense (benefit) - State (322,564) (318,119)
Stock-based compensation 558,448 674,914
Change in fair value of derivatives 452,390 159,500
Change in valuation allowance 657,802 599,079
Income Tax Expense (Benefit) $ 0 $ 0

XML 15 R33.htm IDEA: XBRL DOCUMENT v2.4.0.8
FAIR VALUE MEASUREMENTS (Details 2) (USD $)
 12 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Fair Value Measurements [Line Items]    
Debenture Face Amount $ 564,376 $ 902,369
Debenture Interest Rate, Minimum 8.00% 6.00%
Debenture Interest Rate, Maximun 20.00% 12.00%
Debenture Default Interest Rate      
Minimum [Member]
    
Fair Value Measurements [Line Items]    
Debenture Conversion Price, Anti-Dilution Adjusted Price $ 0.0036 $ 0.0070
Debenture Conversion Price, Percentage of VWAP for Look-back Period 50.00% 15.00%
Debenture Look-back Period 10 days 5 days
Maximum [Member]
    
Fair Value Measurements [Line Items]    
Debenture Conversion Price, Anti-Dilution Adjusted Price $ 0.0064 $ 0.0137
Debenture Conversion Price, Percentage of VWAP for Look-back Period 85.00% 70.00%
Debenture Look-back Period 30 days 20 days
XML 16 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 17 R25.htm IDEA: XBRL DOCUMENT v2.4.0.8
STOCK OPTIONS AND WARRANTS (Tables)
 12 Months Ended
Dec. 31, 2013
Equity [Abstract]  
Schedule Of Warrants Issued [Table Text Block]
A summary of warrants outstanding in conjunction with private placements of common stock were as follows during the year ended December 31, 2013 and 2012:
 
 
 
Number of shares
 
Weighted average exercise price
 
Balance December 31, 2011
 
47,921,667
 
$
0.10
 
Exercised
 
-
 
 
-
 
Issued
 
54,650,000
 
$
0.10
 
Forfeited/Expired
 
(45,315,000)
 
 
-
 
Balance December 31, 2012
 
57,256,667
 
$
0.10
 
Exercised
 
-
 
 
-
 
Issued
 
98,600,000
 
$
0.01 – 0.10
 
Forfeited
 
(940,000)
 
 
-
 
Balance December 31, 2013
 
154,916,667
 
$
0.082
 
Schedule Of Warrants Outstanding [Table Text Block]
The following table summarizes information about fixed-price warrants outstanding as of December 31, 2013 and 2012:
 
 
 
Exercise Price
 
Number
Outstanding
 
Weighted
Average
Contractual
Life
 
Weighted
Average
Exercise Price
 
2013
 
$
0.01-0.10
 
154,916,667
 
1.97 years
 
$
0.082
 
2012
 
$
0.10-0.15
 
57,256,667
 
2.04 years
 
$
0.10
 
XML 18 R50.htm IDEA: XBRL DOCUMENT v2.4.0.8
COMMITMENTS AND CONTINGENCIES (Details Textual) (USD $)
 1 Months Ended 12 Months Ended 1 Months Ended
Aug. 31, 2012
Dec. 31, 2013
Dec. 31, 2012
Dec. 31, 2010
Patricia Meding, et. al. v. ReceptoPharm, Inc. f/k/a Receptogen, Inc. [Member]
Dec. 31, 2008
Patricia Meding, et. al. v. ReceptoPharm, Inc. f/k/a Receptogen, Inc. [Member]
Dec. 31, 2006
Patricia Meding, et. al. v. ReceptoPharm, Inc. f/k/a Receptogen, Inc. [Member]
Dec. 31, 2012
Liquid Packaging Resources, Inc. v. Nutra Pharma Corp. and Erik "Rik" Deitsch [Member]
Dec. 31, 2011
Liquid Packaging Resources, Inc. v. Nutra Pharma Corp. and Erik "Rik" Deitsch [Member]
Dec. 31, 2011
Laurence N. Raymond v. Receptopharm, Inc. et al. [Member]
Dec. 31, 2011
Paul F. Reid v, Harold H. Rumph et al. [Member]
Dec. 31, 2013
Involuntary Petition of Bankruptcy [Member]
Dec. 31, 2012
Involuntary Petition of Bankruptcy [Member]
Dec. 31, 2013
Subsequent Event [Member]
Dec. 31, 2010
Subsequent Event [Member]
Feb. 12, 2014
Subsequent Event [Member]
Involuntary Petition of Bankruptcy [Member]
Commitments And Contingencies [Line Items]                              
Loss Contingency, Damages Sought, Value         $ 768,506 $ 118,928.15   $ 500,000 $ 300,000 $ 330,000   $ 990,927      
Cancellation Of Share Certificate (in shares)       1,214,800                      
Potential Exposure       10,000,000                      
Additional Shares Claimed (in shares)       1,214,800                      
Alleged Shares Claimed (in shares)       1,750,000                      
Reimbursement Expenses For Third Party               359,826.85              
Component Agreed Price               350,000.00              
Component Agreed Price Period               7 months              
Component Agreed Price Monthly Installments               50,000.00              
Loss Contingency Stock Value               400,000              
Loss Contingency, Damages Paid, Value             25,000 150,000              
Loss Contingency Late Fee               5,000              
Loss Contingency Damages Paid Value Total               205,000              
Loss Contingency Additional Payments Agreed             15,000 150,000              
Loss Contingency Accrual, at Carrying Value             175,000 10,000              
Loss Contingency Damages Due Monthly             30,000                
Loss Contingency, Damages Awarded, Value             450,000                
Loss Contingency Damages Sought Amended Value                       816,662      
Lease Rent Payments Monthly Basis                         3,500 9,000  
Operating Lease Renewed Term                         5 years    
Payment On Monthly Lease and Rental Expense 5,000                            
Operating Leases, Rent Expense   114,889 183,000                        
Lease Term                         3 years    
Litigation Settlement, Amount                     350,000        
Payments for Legal Settlements                             $ 35,000
XML 19 R42.htm IDEA: XBRL DOCUMENT v2.4.0.8
STOCKHOLDERS' DEFICIT (Details Textual) (USD $)
 12 Months Ended 0 Months Ended 0 Months Ended 12 Months Ended 3 Months Ended 12 Months Ended 12 Months Ended 12 Months Ended 1 Months Ended 12 Months Ended 0 Months Ended 1 Months Ended 12 Months Ended 1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended 1 Months Ended 12 Months Ended 1 Months Ended 12 Months Ended 1 Months Ended 12 Months Ended 1 Months Ended 12 Months Ended 1 Months Ended 12 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Nov. 25, 2013
Note Payable One [Member]
May 31, 2011
Note Payable One [Member]
Sep. 16, 2013
Note Payable Two [Member]
Dec. 31, 2013
Note Payable Two [Member]
Dec. 31, 2012
Note Payable Two [Member]
Oct. 31, 2011
Note Payable Two [Member]
Sep. 30, 2011
Note Payable Two [Member]
May 31, 2011
Note Payable Two [Member]
Sep. 30, 2013
Note Payable Three [Member]
Dec. 31, 2013
Note Payable Three [Member]
Aug. 31, 2013
Note Payable Three [Member]
Dec. 31, 2013
Convertible Note One [Member]
Dec. 31, 2012
Convertible Note One [Member]
Dec. 31, 2013
Convertible Note Two [Member]
Dec. 31, 2012
Convertible Note Two [Member]
Dec. 31, 2013
Convertible Note One Amended [Member]
Dec. 31, 2013
Convertible Note Two Amended [Member]
Dec. 31, 2013
Investor [Member]
Dec. 31, 2012
Investor [Member]
Dec. 31, 2013
Two Investors [Member]
Dec. 31, 2013
Two Investors [Member]
Maximum [Member]
Dec. 31, 2013
Two Investors [Member]
Minimum [Member]
Dec. 31, 2013
Five Investors [Member]
Dec. 31, 2013
Five Investors [Member]
Maximum [Member]
Dec. 31, 2013
Five Investors [Member]
Minimum [Member]
Dec. 31, 2012
One Investors [Member]
Dec. 31, 2013
Michael Mcdonald Trust [Member]
Dec. 31, 2013
Vendor [Member]
Dec. 31, 2013
Two Vendor [Member]
Sep. 30, 2013
Two Vendor [Member]
Dec. 31, 2013
October 26, 2012 [Member]
Dec. 31, 2013
Restricted Stock [Member]
Investor [Member]
Dec. 31, 2012
Restricted Stock [Member]
Investor [Member]
Dec. 31, 2013
Restricted Stock [Member]
Roetzell Andress [Member]
Dec. 31, 2013
Restricted Stock [Member]
Five Investors [Member]
Dec. 31, 2012
Restricted Stock [Member]
One Investors [Member]
Dec. 31, 2013
Jpu Ventures Inc [Member]
Restricted Stock [Member]
Dec. 31, 2012
Redwood Management Llc [Member]
Feb. 03, 2012
Redwood Management Llc [Member]
Oct. 31, 2012
Redwood Management Llc [Member]
Restricted Stock [Member]
Dec. 31, 2012
Redwood Management Llc [Member]
Restricted Stock [Member]
Sep. 12, 2013
Coventry Enterprises Llc [Member]
Sep. 30, 2013
Coventry Enterprises Llc [Member]
Jun. 30, 2013
Coventry Enterprises Llc [Member]
Apr. 30, 2013
Coventry Enterprises Llc [Member]
Mar. 31, 2013
Coventry Enterprises Llc [Member]
Dec. 31, 2013
Coventry Enterprises Llc [Member]
Dec. 31, 2012
Coventry Enterprises Llc [Member]
Sep. 03, 2013
Coventry Enterprises Llc [Member]
Mar. 22, 2013
Coventry Enterprises Llc [Member]
Dec. 31, 2012
Coventry Enterprises Llc [Member]
Restricted Stock [Member]
Mar. 31, 2012
Coventry Enterprises Llc [Member]
Restricted Stock [Member]
Jun. 30, 2013
Coventry Enterprises Llc [Member]
Restricted Stock [Member]
Mar. 31, 2013
Coventry Enterprises Llc [Member]
Restricted Stock [Member]
Jun. 30, 2013
Coventry Enterprises Llc [Member]
Restricted Stock [Member]
Dec. 31, 2013
Coventry Enterprises Llc [Member]
Restricted Stock [Member]
Dec. 31, 2012
Coventry Enterprises Llc [Member]
Restricted Stock [Member]
Jun. 30, 2013
Coventry Enterprises Llc [Member]
Restricted Stock One [Member]
Mar. 31, 2013
Coventry Enterprises Llc [Member]
Restricted Stock Two [Member]
Dec. 31, 2013
Capital Path Securities Llc [Member]
Restricted Stock [Member]
Oct. 31, 2012
Southridge Partners Llp [Member]
Restricted Stock [Member]
Dec. 31, 2012
Rik Deitsch [Member]
Dec. 31, 2013
Rik Deitsch [Member]
Restricted Stock [Member]
Dec. 31, 2012
Rik Deitsch [Member]
Restricted Stock [Member]
Oct. 31, 2012
Redwood Management And TCN International [Member]
Restricted Stock [Member]
Nov. 30, 2013
Employees and Directors [Member]
Restricted Stock [Member]
Sep. 30, 2013
Employees and Directors [Member]
Restricted Stock [Member]
Dec. 31, 2012
Employees and Directors [Member]
Restricted Stock [Member]
Oct. 31, 2012
Employees and Directors [Member]
Restricted Stock [Member]
Feb. 29, 2012
Employees and Directors [Member]
Restricted Stock [Member]
Nov. 22, 2013
Employees and Directors [Member]
Restricted Stock [Member]
Sep. 03, 2013
Employees and Directors [Member]
Restricted Stock [Member]
Feb. 03, 2012
Employees and Directors [Member]
Restricted Stock [Member]
Dec. 31, 2013
Consultant One [Member]
Restricted Stock [Member]
Investor [Member]
Dec. 31, 2013
Consultant Two [Member]
Restricted Stock [Member]
Investor [Member]
Dec. 31, 2013
Consultant Three [Member]
Restricted Stock [Member]
Dec. 31, 2013
Five Consultants [Member]
Restricted Stock [Member]
Dec. 31, 2012
Five Consultants [Member]
Restricted Stock [Member]
Dec. 31, 2013
Management [Member]
Dec. 31, 2012
Management [Member]
Oct. 31, 2012
Asher Enterprise [Member]
Restricted Stock [Member]
Dec. 31, 2013
Two Consultants [Member]
Restricted Stock [Member]
Dec. 31, 2013
Two Consultants [Member]
Restricted Stock [Member]
Investor [Member]
Dec. 31, 2013
Consultant Four [Member]
Restricted Stock [Member]
Investor [Member]
Dec. 31, 2013
Consultant Five [Member]
Restricted Stock [Member]
Dec. 31, 2013
Consultant Six [Member]
Restricted Stock [Member]
Dec. 31, 2013
Consultant Seven [Member]
Restricted Stock [Member]
Jul. 31, 2013
Consultant Eight [Member]
Restricted Stock [Member]
Investor [Member]
Dec. 31, 2013
Consultant Nine [Member]
Restricted Stock [Member]
Investor [Member]
Dec. 31, 2013
Consultant Ten [Member]
Restricted Stock [Member]
Investor [Member]
Dec. 31, 2013
Consultant Eleven [Member]
Restricted Stock [Member]
Investor [Member]
Dec. 31, 2013
Consultant Twelve [Member]
Restricted Stock [Member]
Investor [Member]
Dec. 31, 2013
Consultant Thirteen [Member]
Restricted Stock [Member]
Investor [Member]
Dec. 31, 2013
Consultant Fourteen [Member]
Restricted Stock [Member]
Dec. 31, 2013
Three Consultants [Member]
Restricted Stock [Member]
Investor [Member]
Dec. 31, 2013
Mark Bergman [Member]
Restricted Stock [Member]
Dec. 31, 2012
Mark Bergman [Member]
Restricted Stock [Member]
Dec. 31, 2013
Consultant Fifteen [Member]
Restricted Stock [Member]
Dec. 31, 2013
Modification [Member]
Dec. 31, 2013
Harold H. Rumph [Member]
Stockholders' Equity Note [Line Items]                                                                                                                                                                                                            
Stock Issued During Period, Shares, New Issues                                                         1,000,000         10,000,000 17,650,000   1,000,000 27,000,000                                               10,000,000           34,630,000 1,000,000 26,875,000 26,875,000 15,720,000                                                            
Common Stock Price Per Share (in dollars per share)                                                                   $ 0.03 $ 0.10 $ 0.014 $ 0.10 $ 0.10 $ 0.0125                                             $ 0.0125               $ 0.014 $ 0.022   $ 0.014 $ 0.0229 $ 0.0165 $ 0.0175 $ 0.0178 $ 0.016 $ 0.0125         $ 0.0229 $ 0.0173 $ 0.012 $ 0.0056 $ 0.0042 $ 0.0042 $ 0.005 $ 0.0042 $ 0.0053 $ 0.008 $ 0.007 $ 0.005 $ 0.0125 $ 0.009 $ 0.0125   $ 0.0125    
Stock Issued During Period, Shares, Issued For Services                                                                       1,000,000     3,000,000                                                                         1,000,000 15,000,000 1,500,000 15,100,000         1,500,000 6,000,000 2,000,000 2,000,000 2,000,000 100,000 15,000,000 2,000,000 1,000,000 8,000,000 1,500,000 10,000,000 500,000 3,000,000 5,500,000   1,000,000    
Debt Conversion, Converted Instrument, Shares Issued     4,360,000   8,472,750 34,254,004         64,052,862 64,052,862                                         5,919,495                 18,737,894 18,737,894                       31,416,845 15,119,481 31,416,845   8,672,090 27,272,727 8,810,572   6,416,733   50,000,000 10,000,000 7,500,000                               20,000,000                                      
Debt Conversion, Converted Instrument, Amount     $ 25,000   $ 25,000 $ 317,391         $ 475,519 $ 475,519                                                           $ 320,531                         $ 88,500 $ 80,000 $ 186,646     $ 167,495 $ 188,747   $ 157,179   $ 162,500   $ 273,144                               $ 356,779                                      
Gain(loss) on settlement of debt and accounts payable (707,651) (457,292) 28,444   90,971                                                 505,525 15,472                                   2,200                 65,039                                                                                        
Debt Conversion, Original Debt, Amount           125,000         150,000                                                                                                           162,500 100,000                                                                        
Common stock issued under subscription agreement - $0.05 per share                                       50,000 176,500 45,000     45,000     270,000                                                                                                                                                    
Common Stock Issuable For Subscription Agreement Value Per Share                                       $ 0.005 $ 0.01   $ 0.0042 $ 0.001   $ 0.015 $ 0.002 $ 0.01                                                                                                                                                    
Common stock issued under subscription agreement - $0.05 per share (in shares)                                       10,000,000 17,650,000 21,000,000     11,000,000     27,000,000                                                                                                                                                    
Allocated Share-Based Compensation Expense                                                                       14,000     21,875                                             151,375                           17,500 267,000 24,000 108,534 80,216       34,350 70,902 8,351 8,446 8,400 420 85,500 8,400 5,300 61,019 10,500 50,000 1,042 27,000 28,646 40,104 8,697    
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized                                                                             15,625                                             21,625                                             32,898 15,649 2,754           2,981     5,208       3,533    
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition                                                                                                                                                       2 months 3 months               2 months 8 months 1 month 15 days                              
Equity, Fair Value Disclosure, Total                                                                                                                                           569,400 569,400   484,820 22,900 259,380                                                      
Convertible Debt 767,056 588,091                       75,000 250,000 150,000 250,000                                               188,608     70,000           65,040 100,000 20,000                                                                           30,000                        
Cash                                                                                                                                                                                   10,000                        
Placement Agent Fees                                                                                                                           5.00%                                                                                
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Period Increase (Decrease)                                                                                                                           125,000                                                                                
Debt Instrument Maturity Date Amended Amount One                                                                                                                                                                                                         250,000  
Debt Instrument Maturity Date Amended Aggregate Amount                                                                                                                                                                                                         500,000  
Debt Instrument Maturity Date Amended Amount Two                                                                                                                                                                                                         250,000  
Stock Issued During Period, Shares, Restricted Stock Award, Gross           4,000,000                       500,000 1,250,000                                                                                                                                                                   4,000,000  
Proceeds From Notes Payable 75,000 79,000                                                     75,000                                                                                                                                                  
Amortization of Debt Discount (Premium) 3,977 0                                                     3,977                                                                                                                                                  
Convertible Debt, Fair Value Disclosures 767,056 [1] 588,091 [1]                       90,260 290,289 189,781 297,802 9,500 13,750                                                                                                                                                                      
Notes Payable, Current 412,182 [2] 593,483 [2]   25,000 25,000     500,000 250,000 25,000 150,000   150,000                                                                 57,800                                   100,000                                                                            
Assigned Debt Consideration Amount                                                                                           60,000                                                                                                                
Debt Instrument, Convertible, Terms Of Conversion Feature             On October 19, 2012 the parties amended the notes to extend the due date to May 1, 2013 and include a conversion feature that would allow the holders to convert some or all of their outstanding notes into restricted Company stock at a 15% discount to the average closing market price of the Company's stock traded over the previous 10 days       conversion price for each share of Common Stock equal to 55% of the average of the daily volume weighted average prices of the Common Stock for the 3 trading days with the lowest volume weighted average prices during the 15 to 20 trading days immediately preceding the Conversion Date. conversion price for each share of Common Stock equal to 55% of the average of the daily volume weighted average prices of the Common Stock for the 3 trading days with the lowest volume weighted average prices during the 15 to 20 trading days immediately preceding the Conversion Date                                                       The full amount of principal and interest was due at maturity unless the Debenture was converted to shares of common stock in accordance with the debenture agreement, whereby such debenture could be converted into shares of our common stock at a price equal to 75% of the lowest closing price (determined on the then current trading market for our common stock) during the 15 trading days prior to conversion.       Coventry has the right to convert the note, until is no longer outstanding into shares of Common Stock at a price lesser of $.02, or (ii) fifty-five percent (55%) of the average of the three lowest VWAP prices of the Companys Common Stock for the twenty trading days preceding the conversion date. Coventry has the right to convert the note, until is no longer outstanding into shares of Common Stock at a price lesser of $.018, or (ii) fifty-five percent (55%) of the average of the three lowest VWAP prices of the Companys Common Stock for the twenty trading days preceding the conversion date Coventry was entitled to convert all or any amount of the these notes into shares of the Company's common stock (the "Common Stock") at a conversion price ("Conversion Price") for each share of Common Stock equal to 55% of the average of the daily volume weighted average prices of the Common Stock for the 3 trading days with the lowest volume weighted average prices during 20 trading days Coventry was entitled to convert all or any amount of the this note into shares of the Company's common stock (the "Common Stock") at a conversion price ("Conversion Price") for each share of Common Stock equal to 55% of the average of the daily volume weighted average prices of the Common Stock for the 3 trading days with the lowest volume weighted average prices during the 15 trading days immediately preceding the Conversion Date Coventry has the right to convert the note, until is no longer outstanding into shares of Common Stock at a price which is lesser of $.0075, or (ii) fifty-five percent (55%) of the average of the three lowest VWAP prices of the Companys Common Stock for the twenty trading days preceding the conversion date   Coventry was entitled to convert all or any amount of the this note into shares of the Company's common stock (the "Common Stock") at a conversion price ("Conversion Price") for each share of Common Stock equal to 55% of the average of the daily volume weighted average prices of the Common Stock for the 3 trading days with the lowest volume weighted average prices during the 20 trading days immediately preceding the Conversion Date.                                                                                                        
Debt Instrument, Interest Rate, Stated Percentage                       8.00%                                                         6.00%     10.00%           8.00% 10.00% 10.00%                                                         4.00% 4.00%                                        
Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures, Total                                                           25,000,000 3,000,000                                           2,564,102 8,672,090                   10,000,000                                                                           14,800,000
Accrued Salaries                                                                                                                                                                                                           37,000
Accounts payable                                                               38,528                                                                                                                                            
Restricted Stock Par Or Stated Value Per Share                                                           $ 0.015 $ 0.018                                                                                                                                              
Warrants Issued For Common Sock                                                           25,000,000                                                                   10,000,000                                                                            
Class Of Warrant Or Right, Exercise Price Of Warrants Or Rights                                                           0.030                                                                   0.10                                                                            
Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures, Total                                                                                                         33,720 168,889                                                                                                
Stock Issued During Period, Value, Restricted Stock Award, Gross           $ 20,800                                                                                                                                                                                             $ 20,800  
[1] At December 31, 2013 and 2012, the balance of $767,056 and $588,091 consisted of the following convertible loans: In September and October 2011, the Company borrowed $250,000 each (aggregating $500,000) from two non-related parties. The principal of these loans were to be repaid with a balloon payment on or before October 1, 2012. On October 19, 2012 the parties amended the notes to extend the due date to May 1, 2013 and include a conversion feature that would allow the holders to convert some or all of their outstanding notes into restricted Company stock at a 15% discount to the average closing market price of the Company's stock traded over the previous 10 days. Interest on these loans is payable monthly beginning in November 2011 with interest calculated at 20% and 12%, each, respectively. At December 31, 2013 and 2012, the accrued interest payable was $6,664. During year ended December 31, 2013, one of the Note holders made conversions of a total of 34,254,004 shares of the company’s restricted stock satisfying the notes in the amount of $125,000 with a fair value of $317,391 on the date of conversion. During August and September, 2013, $150,000 of the debts were assigned to three non-related parties in the form of a Convertible Redeemable Note bearing interest of 8% annum with a conversion price for each share of Common Stock equal to 55% of the average of the daily volume weighted average prices of the Common Stock for the 3 trading days with the lowest volume weighted average prices during the 15 to 20 trading days immediately preceding the Conversion Date. Following the assignments, the conversions for a total of 64,052,862 shares of the company’s restricted stock were made in satisfying the notes of $150,000 at the fair value of $475,519 (See note 6). At December 31, 2013, the remaining balance of these two convertible notes payable of $75,000 and $150,000 were recorded at a fair value of $90,260 and $189,781, respectively. At December 31, 2012, these two convertible note payable of $250,000 each were recorded at fair value of $290,289 and $297,802, respectively. On April 30, 2013, the parties amended the notes to further extend the maturity date to November 3, 2013. The Company issued a total of 4,000,000 restricted shares to the note holders in connection with the amendment at a fair value of $20,800. On October 30, 2013 and November 1, 2013, the parties amended the note of $75,000 and $150,000 to further extend the maturity dates to May 3, 2014 and August 3, 2014, respectively. The Company issued a total of 500,000 and 1,250,000 restricted shares to the note holders in connection with the amendment at a fair value of $9,500 and $13,750 (See note 6), respectively. On March 22, 2013, the Company issued a Convertible Debenture in the amount of $20,000 to Coventry Enterprises, LLC (“Coventry”). The note carries interest at 10% and is due on March 22, 2014, unless previously converted into shares of restricted common stock. Coventry has the right to convert the note, until is no longer outstanding into shares of Common Stock at a price which is lesser of $.0075, or (ii) fifty-five percent (55%) of the average of the three lowest VWAP prices of the Company’s Common Stock for the twenty trading days preceding the conversion date. In connection with the issuance of this convertible note payable, the Company encountered a day-one derivative loss of $24,931. Coventry made the conversions into a total of 8,810,572 shares of the company’s restricted stock satisfying the notes in full with a fair value of $188,747on September 4, 2013(See note 7). In connection with the issuances of the Note, the Company also granted five-year warrants to purchase an aggregate of 2,600,000 shares of the Company’s common stock at an exercise price of $0.01 per share. The Company classified embedded conversion features in these warrants as a derivative liability. The warrants were valued at their fair value of $21,226 and $17,895, respectively using the Black-Scholes method at the commitment and re-measurement dates of March 22, 2013 and December 31, 2013, respectively. On July 10, 2013 and October 10, 2013, the Company issued two Convertible Debentures in the amount of $30,000 each (total $60,000) to Christopher Castaldo in connection with the agreements for investor relation services (See Note 6). The notes carry interest at 8% and are due on January 10, 2014 and April 10, 2014, respectively. The notes’ holder has the right to convert the notes into shares of Common Stock at a price of $0.005. In connection with the issuance of this convertible notes payable, the Company encountered a day-one derivative loss of $83,157. At December 31, 2013, these convertible notes payable, at fair value, was recorded at $90,684. On September 3, 2013, the Company issued a Convertible Debenture in the amount of $100,000 to Coventry Enterprises, LLC (“Coventry”). The note carries interest at 10% and is due on September 3, 2014, unless previously converted into shares of restricted common stock. Coventry has the right to convert the note, until is no longer outstanding into shares of Common Stock at a price lesser of $.018, or (ii) fifty-five percent (55%) of the average of the three lowest VWAP prices of the Company’s Common Stock for the twenty trading days preceding the conversion date. In connection with the issuance of this convertible note payable, the Company encountered a day-one derivative loss of $957,567. At December 31, 2013, this convertible note payable, at fair value, was recorded at $185,971. In connection with the issuances of the Note, the Company also granted five-year warrants to purchase an aggregate of 20,000,000 shares of the Company’s common stock at an exercise price of $0.025 per share. The Company classified embedded conversion features in these warrants as a derivative liability. The warrants were valued at their fair value of $445,638 and $137,681, respectively using the Black-Scholes method at the commitment and re-measurement dates of September 3, 2013 and December 31, 2013, respectively. On September 12, 2013, the Company issued a Convertible Debenture in the amount of $70,000 to Coventry Enterprises, LLC (“Coventry”). The note carries interest at 10% and is due on September 12, 2014, unless previously converted into shares of restricted common stock. Coventry has the right to convert the note, until is no longer outstanding into shares of Common Stock at a price lesser of $.02, or (ii) fifty-five percent (55%) of the average of the three lowest VWAP prices of the Company’s Common Stock for the twenty trading days preceding the conversion date. In connection with the issuance of this convertible note payable, the Company encountered a day-one derivative loss of $309,055. At December 31, 2013, this convertible note payable, at fair value, was recorded at $130,303. In connection with the issuances of the Note, the Company also granted five-year warrants to purchase an aggregate of 15,000,000 shares of the Company’s common stock at an exercise price of $0.025 per share. The Company classified embedded conversion features in these warrants as a derivative liability. The warrants were valued at their fair value of $262,230 and $101,140, respectively using the Black-Scholes method at the commitment and re-measurement dates of September 12, 2013 and December 31, 2013, respectively. On October 7, 2013, the Company signed a secured convertible Promissory Note in the amount of $35,000 in favor of Southridge Partners II, LLC. The note was due on demand and carries interest at 10% annum. Southridge Partners II, LLC was entitled to convert the principal into shares of common stock at the lesser of $0.015 or a 50% discount from the lowest closing bid price in the 30 trading days prior to the day that the conversion is requested; and interest accrued was entitled to convert into shares of common stock at $0.001. In the evaluation of these financing arrangements, the Company concluded that these conversion features did not meet the conditions set forth in current accounting standards for equity classification. Since equity classification is not available for the conversion feature, it requires bifurcation and liability classification, at fair value. The Company also concluded that the Default Put required bifurcation because, while puts on debt instruments are generally considered clearly and closely related to the host, the Default Put is indexed to certain events that are not associated with the convertible note payable. In connection with the issuance of this convertible note payable, the Company encountered a day-one derivative loss of $81,667. At December 31, 2013, this convertible note payable, at fair value, was recorded at $80,057. On October 27, 2011 the Company entered into a convertible note payable with a corporation. The convertible note payable, with a face value of $53,000, bears interest at 8.0% per annum and was due on July 31, 2012. On December 5, 2011 the Company entered into a convertible note payable with a corporation which had a face value of $37,500, a coupon rate of 8.0% per annum and maturity date of September 5, 2012. The convertible note payable is convertible, at the holder’s option, into the Company’s common shares at a variable conversion price which is 58% multiplied by the average of the lowest three (3) trading prices for the Common Stock during the ten (10) Trading Day period ending one Trading Day prior to the date the Conversion Notice is sent by the Holder to the Borrower. The conversion feature is subject to full-ratchet, anti-dilution protection if the Company sells shares or share-indexed financing instruments at less than the conversion price. The holder has the option to redeem the convertible note payable for cash in the event of defaults or certain other contingent events (the “Default Put”). During October 2012, both of these notes were acquired by a third party from Asher Enterprises for an aggregate amount of $100,000, and then converted into 20,000,000 restricted common shares (See note 6). On February 3, 2012, the Company issued a Convertible Debenture in the amount of $40,000 to Redwood Management, LLC. The note carries interest at 12% and is due on February 13, 2013, unless converted into shares of restricted common stock. Redwood Management, LLC has the right to convert the note, until it is no longer outstanding, into shares of Common Stock at a price of Fifty Percent (50%) of the lowest closing price, determined on the then current trading market for the Company’s common stock, during the 15 trading days prior to conversion (the “Set Price”). On September 12, 2012, TCN International (TCN) completed the purchase and transfer of this note including penalties and unpaid interest, for the sum of $52,500. Redwood Management, LLC has acknowledged the full payment of the Note, in favor of Nutra Pharma Corporation and releases Nutra Pharma Corporation from all obligations under the Note. Upon the request of TCN, the Board of Directors of the Company approved the conversion of these notes into Restricted Common Stock of the Company,providing 7,500,000 shares of Nutra Pharma common stock to relinquish the total debt of $52,500 (See note 6). On March 16, 2012 the Company signed a secured convertible Promissory Note in the amount of $75,000 in favor of Southridge Partners II, LLC. The note was due November 16, 2012 and carries interest at 8% annum. Southridge Partners II, LLC was entitled after nine months to convert all or a portion of the principal and interest accrued into shares of common stock at a conversion price of each share equal to the Market Price multiplied times 70%. (the “conversion price”). The Market Price is equal to the average of the two lowest bids closing prices for the five trading days ending before the conversion date. In the evaluation of these financing arrangements, the Company concluded that these conversion features did not meet the conditions set forth in current accounting standards for equity classification. Since equity classification is not available for the conversion feature, it requires bifurcation and liability classification, at fair value. The Company also concluded that the Default Put required bifurcation because, while puts on debt instruments are generally considered clearly and closely related to the host, the Default Put is indexed to certain events that are not associated with the convertible note payable. On October 26, 2012, Southridge converted the note into 5,919,495 shares of the Company's restricted common stock (See note 6). In the evaluation of these financing arrangements, the Company concluded that these conversion features did not meet the conditions set forth in current accounting standards for equity classification. Since equity classification is not available for the conversion feature, it requires bifurcation and liability classification, at fair value. The Company also concluded that the Default Put required bifurcation because, while puts on debt instruments are generally considered clearly and closely related to the host, the Default Put is indexed to certain events that are not associated with the convertible note payable. The Company elected to account for these hybrid contracts under the guidance of ASC 815-15-25-4. The fair value has been defined as the common stock equivalent value, enhanced by the fair value of the default put plus the present value of the coupon. The holder of this convertible note has substantial rights and protections regarding dilution if certain events, including a default were to occur. There are a number of events that could trigger a default, including but not limited to failure to pay principal or interest, failure to issue shares under the conversion feature, breach of covenants, breach of representations and warranties, appointment of a receiver or trustee, judgments, bankruptcy, delisting of common stock, failure to comply with the exchange act, liquidation, cessation of operations, failure to maintain assets, material financial statement restatement, reverse split of borrowers stock, etc. In the event of these events the lender may be entitled to receive significant amounts of additional stock above the amounts for conversion. Furthermore, there are additional events that could cause the lender to be due additional shares of common stock above and beyond the shares due from a conversion. Some of these events include, but are not limited to a merger or consolidation of the Company, dividend distribution or spin off, dilutive issuances of the Company’s stock, etc. If the lender receives additional shares of the Company’s commons stock due to any of the foregoing events or for other reasons, then this may have an extremely dilutive effect on the shareholders of the Company. Such dilution would likely result in a significant drop in the per share price of the Company’s common stock. The potential dilutive nature of this note presents a very high degree of risk to the Company and its shareholders
[2] At December 31, 2013 and 2012, the balance of $412,182 and $593,483 , respectively, consisted of the following loans: In May 2011, the Company received a loan for $25,000 from a non-related party. This loan was expected to be repaid no later than December 31, 2011, along with interest calculated at 10% for the first month plus 12% after 30 days from funding. This loan is guaranteed by an officer of the Company. On November 25, 2013, the non-related party accepted a total of 4,360,000 shares of the Company’s restricted common stock as a repayment to discharge $25,000 of his outstanding loan and accrued interest of $11,956 (See note 6). The Company recorded a loss of $28,444 on the settlement date. In May 2011, the Company received another loan for $25,000 from a non-related party. This loan was expected to be repaid no later than December 31, 2011, along with interest calculated at 10% for the first month plus 12% after 30 days from funding. This loan is guaranteed by an officer of the Company. On September 16, 2013, the non-related party accepted a total of 8,472,750 shares of the Company’s restricted common stock as a repayment to discharge $25,000 of his outstanding loan and accrued interest of $11,120 (See note 6). The Company recorded a loss of $90,971 on the settlement date. In July 2013, the Company issued a promissory note to the Michael McDonald Trust in the amount of $75,000 bearing interest at a rate of 2% per month. The note is due in six months from the execution and funding of the note. In connection with the issuance of this promissory note, the Company issued 1,000,000 shares of the Company's common stocks (See note 6). The Company has recorded a debt discount in the amount of $3,977 to reflect the value of the common stocks as a reduction to the carrying amount of the convertible debt and a corresponding increase to common stocks and additional paid-in capital. The total discount of $3,977 was fully amortized over the term of the debt during the year ended December 31, 2013. In the event of default, the Company would issue an additional 1,000,000 share of the Company’s common stocks on the date that is fifteen days after the maturity date (See Note 6). We are in default regarding this loan. The additional 1,000,000 shares were issued in January 2014 with a fair value at $9,900 (See Note 10). At December 31, 2013, we owed Michael McDonald accrued interest of $9,000. At December 31, 2012, the total amount of the Company’s debt assigned to Southridge was $483,482. In connection with the debt sales to Southridge, the Company recorded a loss on settlement of accounts payable for $63,490 in the statement of operations at December 31, 2012. During the first quarter of 2013, the suit was voluntarily dismissed involving debt held by Southridge for $483,482. The debt has reverted back to the original holders. In April, 2013, $88,500 of the debt held by Michael McDonald Trust was assigned to Coventry Enterprises, LLC (“Coventry”) in the form of a Convertible Redeemable Note bearing interest of 8% annum. Coventry was entitled to convert all or any amount of the this note into shares of the Company's common stock (the "Common Stock") at a conversion price ("Conversion Price") for each share of Common Stock equal to 55% of the average of the daily volume weighted average prices of the Common Stock for the 3 trading days with the lowest volume weighted average prices during the 15 trading days immediately preceding the Conversion Date. Following the agreements with Coventry, Coventry made the conversions for a total of 31,416,845 shares of the company’s restricted stock during the second quarter of 2013 satisfying the notes in full at the fair value of $186,646. In June, 2013, $57,800 of the debt was assigned to Coventry for a consideration of $60,000 from Baker Donelson Bearman Caldwell & Berkowitz, PC. in the form of Convertible Redeemable Notes bearing interest of 8% annum. The Company recorded a loss of $2,200 on the settlement during the year ended December 31, 2013. Coventry was entitled to convert all or any amount of the these notes into shares of the Company's common stock (the "Common Stock") at a conversion price ("Conversion Price") for each share of Common Stock equal to 55% of the average of the daily volume weighted average prices of the Common Stock for the 3 trading days with the lowest volume weighted average prices during 20 trading days . Following the agreements, Coventry made the conversions for a total of 27,272,727 shares of the company’s restricted stock satisfying the notes in full at the fair value of $167,495. As a result of the debt assignments and conversions with Coventry, the remaining balance of the debt at December 31, 2013 is $337,182 which consisted of the following loans: On August 2, 2011 under a settlement agreement with Liquid Packaging Resources, Inc. (“LPR”), the Company agreed to pay LPR a total of $350,000 in monthly installments of $50,000 beginning August 15, 2011 and ending on February 15, 2012. This settlement amount was recorded as general and administrative expenses on the date of the settlement. We did not make the December 2011 or January 2012 payments and on January 26, 2012, we signed the first amendment to the settlement agreement where under we agreed to pay $175,000 which was the balance outstanding at December 31, 2011(this includes a $25,000 penalty for non-payment). The Company repaid $25,000 during the three months ended March 31, 2012. The Company did not make all of the payments under such amendment and as a result pursuant to the original settlement agreement, LPR had the right to sell 5,714,326 shares of the Company’s free trading stock held in escrow by their attorney and receive cash settlements for a total amount of $450,000 (the initial $350,000 plus total default penalties of $100,000). The $100,000 default was expensed during 2012. LPR sold the note to Southridge Partners, LLP (“Southridge”) for consideration of $281,772 in October 2012. The debt has reverted back to the Company (See note 9). As of December 31, 2013 and 2012, the Company owed University Centre West Ltd. approximately $55,410, which was assigned and sold to Southridge and subsequently reverted back to the Company .
XML 20 R37.htm IDEA: XBRL DOCUMENT v2.4.0.8
DUE TO OFFICERS (Details) (USD $)
Dec. 31, 2013
Dec. 31, 2012
Due To Officers Disclosure [Line Items]    
Due to officers $ 689,588 $ 723,386
Management [Member]
    
Due To Officers Disclosure [Line Items]    
Due to officers 566,399 606,168
President [Member]
    
Due To Officers Disclosure [Line Items]    
Due to officers $ 123,189 $ 117,218
XML 21 R47.htm IDEA: XBRL DOCUMENT v2.4.0.8
INCOME TAXES (Details 1) (USD $)
Dec. 31, 2013
Dec. 31, 2012
Current portion of net deferred income tax assets:    
Allowance for doubtful accounts $ 242,000 $ 242,000
Reserve for inventory obsolescence 313,925 313,925
Accrued salary 101,877 43,154
Subtotal 657,802 599,079
Valuation allowance (657,802) (599,079)
Current net deferred income tax asset 0 0
Non- current portion of net deferred income tax asset    
Net operating loss carryforwards 6,232,881 5,575,079
Valuation allowance (6,232,881) (5,575,079)
Non-current net deferred income tax asset $ 0 $ 0
XML 22 R9.htm IDEA: XBRL DOCUMENT v2.4.0.8
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 12 Months Ended
Dec. 31, 2013
Basis Of Presentation and Summary Of Significant Accounting Policies [Abstract]  
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]
1. BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 
Organization
 
Nutra Pharma Corp. ("Nutra Pharma"), is a holding company that owns intellectual property and operates in the biotechnology industry. Nutra Pharma incorporated under the laws of the state of California on February 1, 2000, under the original name of Exotic-Bird.com.
 
Through its wholly-owned subsidiary, ReceptoPharm, Inc. (“ReceptoPharm”), Nutra Pharma conducts drug discovery research and development activities. In October 2009, Nutra Pharma launched its first consumer product called Cobroxin®, an over-the-counter pain reliever designed to treat moderate to severe chronic pain. In May 2010, Nutra Pharma launched its second consumer product called Nyloxin®, an over-the-counter pain reliever that is a stronger version of Cobroxin® and is designed to treat severe chronic pain.
 
Basis of Presentation and Consolidation
 
The accompanying consolidated financial statements include the results of Nutra Pharma and its wholly-owned subsidiaries Designer Diagnostics Inc. and ReceptoPharm (collectively "the Company", “us”, “we” or “our”). We operate as one reportable segment. All intercompany transactions and balances have been eliminated in consolidation.
 
Liquidity and Going Concern
 
Our Consolidated financial statements are presented on a going concern basis, which contemplate the realization of assets and satisfaction of liabilities in the normal course of business. We have experienced recurring, significant losses from operations, and have an accumulated deficit of $41,986,820 at December 31, 2013. In addition, we had respective working capital and stockholders’ deficits at December 31, 2013 of $4,259,938 and $4,219,449 respectively.
 
There is substantial doubt regarding our ability to continue as a going concern which is contingent upon our ability to secure additional financing, increase ownership equity and attain profitable operations. In addition, our ability to continue as a going concern must be considered in light of the problems, expenses and complications frequently encountered in established markets and the competitive environment in which we operate.
 
As of December 31, 2013, we do not have sufficient cash to sustain our operations for the next year and will require additional financing in order to execute our operating plan and continue as a going concern. Since our sales are not currently adequate to fund our operations, we continue to rely principally on debt and equity funding; however proceeds from such funding have not been sufficient to execute our business plan. Our plan is to attempt to secure adequate funding until sales of our pain products are adequate to fund our operations. We cannot predict whether additional financing will be available, and/or whether any such funding will be in the form of equity, debt, or another form. In the event that these financing sources do not materialize, or if we are unsuccessful in increasing our revenues and profits, we will be unable to implement our current plans for expansion, repay our obligations as they become due and continue as a going concern.
 
The accompanying Consolidated Financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern.
 
Use of Estimates
 
The accompanying Consolidated Financial statements are prepared in accordance with accounting principles generally accepted in the United States of America which require management to make estimates and assumptions. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expense. Significant estimates include our ability to continue as going concern, the recoverability of inventories and long-lived assets, and the valuation of stock-based compensation and certain debt and warrant liabilities. Actual results could differ from those estimates. Changes in facts and circumstances may result in revised estimates, which would be recorded in the period in which they become known.
 
Revenue Recognition
 
In general, we record revenue when persuasive evidence of an arrangement exists, services have been rendered or product delivery has occurred, the sales price to the customer is fixed or determinable, and collectability is reasonably assured. Provision for sales returns is estimated based on our historical return experience. Revenue is presented net of returns and allowances for returns.
 
Accounting for Shipping and Handling Costs
 
The Company records shipping and handling costs incurred in cost of sales.
 
Cash and Cash Equivalents
 
We consider all highly liquid investments with an original maturity of three months or less to be cash equivalents.
 
Accounts Receivable and Allowance for Doubtful Accounts
 
The Company grants credit without collateral to its customers based on the Company’s evaluation of a particular customer’s credit worthiness. In addition, allowances for doubtful accounts are maintained for potential credit losses based on the age of the accounts receivable and the results of the Company’s periodic credit evaluations of its customers’ financial condition. Accounts receivable are written off after collection efforts have been deemed to be unsuccessful. Accounts written off as uncollectible are deducted from the allowance for doubtful accounts, while subsequent recoveries are netted against the provision for doubtful accounts expense. The Company generally does not charge interest on accounts receivable.
 
Accounts receivable are stated at estimated net realizable value. Accounts receivable are comprised of balances due from customers net of estimated allowances for uncollectible accounts.
 
Inventories
 
Inventories, which are stated at the lower of average cost or market, and consist mostly of raw venom that is utilized to make the API (active pharmaceutical ingredient). The raw unprocessed venom has an indefinite life for use. The Company regularly reviews inventory quantities on hand. If necessary it records a provision for excess and obsolete inventory based primarily on its estimates of component obsolescence, product demand and production requirements. Write-downs are charged to cost of goods sold. We performed evaluations of our inventory during the year ended December 31, 2013 and 2012 and recorded total allowances of $0 and $117,800, respectively.
 
Financial Instruments and Concentration of Credit Risk
 
Our financial instruments include cash, accounts receivable, accounts payable, accrued expenses, loans payable, due to officers and derivative financial instruments. Other than certain warrant and convertible instruments (derivative financial instruments) and liabilities to related parties (for which it was impracticable to estimate fair value due to uncertainty as to when they will be satisfied and a lack of similar type transactions in the marketplace), we believe the carrying values of our financial instruments approximate their fair values because they are short term in nature or payable on demand. Our derivative financial instruments are carried at a measured fair value.
 
Balances in various cash accounts may at times exceed federally insured limits. We have not experienced any losses in such accounts. We do not hold or issue financial instruments for trading purposes. In addition, for the year ended December 31, 2013, there were two customers that accounted for 19.6% and 15.3% of the total revenues, respectively. For the year ended December 31, 2012, no customers accounted for more than 10% of the Company’s total revenues. During 2013, the Company purchased 100% of its venom from one vendor.
 
Derivative Financial Instruments
 
The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. Management evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported as charges or credits to income. For option-based simple derivative financial instruments, the Company uses the Black-Scholes option-pricing model to value the derivative instruments at inception and subsequent valuation dates. For complex embedded derivatives, the Company uses a Dilution-Adjusted Black-Scholes method to value the derivative instruments at inception and subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date.
 
Property and Equipment and Long-Lived Assets
 
Property and equipment is recorded at cost. Expenditures for major improvements and additions are added to property and equipment, while replacements, maintenance and repairs which do not extend the useful lives are expensed. Depreciation is computed using the straight-line method over the estimated useful lives of the assets of 3 – 7 years.
 
Property and equipment consists of the following at December 31,
 
 
 
2013
 
2012
 
 
 
 
 
 
 
 
 
Computer equipment
 
$
21,918
 
$
21,918
 
Furniture and fixtures
 
 
34,757
 
 
34,757
 
Lab equipment
 
 
42,129
 
 
42,129
 
Telephone equipment
 
 
12,421
 
 
12,421
 
Office equipment – other
 
 
2,629
 
 
2,629
 
Leasehold improvements
 
 
67,417
 
 
67,417
 
Total
 
 
181,271
 
 
181,271
 
Less: Accumulated depreciation and amortization
 
 
(156,737)
 
 
(141,756)
 
 
 
 
 
 
 
 
 
Property and equipment, net
 
$
24,534
 
$
39,515
 
 
We review our long-lived assets for recoverability if events or changes in circumstances indicate the assets may be impaired. At December 31, 2013, we believe the carrying values of our long-lived assets are recoverable. Depreciation expense for the years ended December 31, 2013 and 2012 was $14,981 and $14,994, respectively.
 
Advertising
 
All advertising costs are expensed as incurred. Advertising costs were approximately $900 and $70,800 for the years ended December 31, 2013 and 2012, respectively.
 
Income Taxes
 
We compute income taxes in accordance with Financial Accounting Standard Board (“FASB”) Accounting Standard Codification (“ASC”) Topic 740, Income Taxes (“ASC Topic 740”). Under ASC Topic 740, deferred taxes are recognized for the tax consequences of temporary differences by applying enacted statutory rates applicable to future years to differences between the financial statement carrying amounts and the tax bases of existing assets and liabilities. Also, the effect on deferred taxes of a change in tax rates is recognized in income in the period that included the enactment date. Temporary differences between financial and tax reporting arise primarily from the use of different methods to record bad debts and /or sales returns, and inventory reserves.
 
On an annual basis, we evaluate tax positions that have been taken or are expected to be taken in our tax returns to determine if they are more than likely to be sustained if the taxing authority examines the respective position. As of December 31, 2013 and 2012, we do not believe we have a need to record any liabilities for uncertain tax positions or provisions for interest or penalties related to such positions.
 
Since inception, we have been subject to tax by both federal and state taxing authorities. Until the respective statutes of limitations expire (which may be as much as 20 years while we have unused net operation losses), we are subject to income tax audits in the jurisdictions in which we operate.
 
Stock-Based Compensation
 
We account for stock-based compensation in accordance with FASB ASC Topic 718, Stock Compensation (ASC Topic 718). ASC Topic 718, which requires that the cost resulting from all share-based transactions be recorded in the financial statements over the respective service periods. It establishes fair value as the measurement objective in accounting for share-based payment arrangements and requires all entities to apply a fair-value-based measurement in accounting for share-based payment transactions with employees. The statement also establishes fair value as the measurement objective for transactions in which an entity acquires goods or services from non-employees in share-based payment transactions.
 
Net Loss Per Share
 
Net loss per share is calculated in accordance with ASC Topic 260, Earnings per Share. Basic loss per share is calculated by dividing net loss by the weighted average number of common shares outstanding for the period. Diluted loss per share is calculated by dividing net loss by the weighted average number of common shares and dilutive common stock equivalents outstanding. During periods in which we incur losses, common stock equivalents, if any, are not considered, as their effect would be anti-dilutive or have no effect on earnings per share. Any common shares issued as of a result of the exercise of stock options and warrants would come from newly issued common shares from our remaining authorized shares. As of December 31, 2013 and 2012, the following items were not included in dilutive loss as the effect is anti-dilutive:
 
 
 
2013
 
2012
 
Options and warrants
 
154,916,667
 
57,256,667
 
Convertible notes payable
 
98,506,398
 
44,642,858
 
Total
 
253,423,065
 
101,899,525
 
 
Reclassifications
 
Certain amounts in the 2012 Consolidated Financial statements have been reclassified to conform to the current period presentation.
 
Recent Accounting Pronouncements
 
We have determined that all recently issued but not yet effective accounting standards will not have a material impact on our Consolidated Financial statements.
EXCEL 23 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%]C-&(V86-F,%]E,&$S7S0X.#)?839E8U\W.#!F M,S$Q,3!A93,B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-O;G-O;&ED871E9%]3=&%T96UE;G1S7V]F7T-H M83$\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I7 M;W)K#I7;W)K#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-%5%1,14U%3E1?3T9?04-#3U5.5%-?04Y$7TY/ M5#PO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I. M86UE/D]42$527T1%0E0\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I.86UE/@T*("`@(#QX M.E=O#I%>&-E;%=O M#I.86UE/E-43T-+7T]05$E/3E-?04Y$7U=!4E)! M3E13/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O#I%>&-E M;%=O#I7;W)K#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E M;%=O#I%>&-E;%=O#I%>&-E M;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-/34U)5$U%3E137T%.1%]#3TY424Y'14Y#2453 M7SPO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O M#I.86UE/@T*("`@ M(#QX.E=O#I%>&-E M;%=O#I.86UE/D9!25)?5D%,545?345!4U5214U% M3E137T1E=&%I;#PO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I. M86UE/D9!25)?5D%,545?345!4U5214U%3E137T1E=&%I;#$\+W@Z3F%M93X- M"B`@("`\>#I7;W)K#I%>&-E;%=O#I. M86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I7;W)K#I7;W)K#I7;W)K#I.86UE/@T*("`@(#QX M.E=O#I%>&-E;%=O M#I.86UE/E-43T-+2$],1$524U]$149)0TE47T1E M=&%I;',\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I7;W)K#I7;W)K#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DE.0T]-15]405A%4U]$971A:6QS/"]X.DYA;64^#0H@("`@/'@Z M5V]R:W-H965T4V]U#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I7;W)K#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O M#I%>&-E;%=O#I.86UE/E-50E-%455%3E1?159%3E137T1E=&%I;'-? M5&5X=#PO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O6QE#I!8W1I=F53:&5E=#X-"B`@/'@Z4')O=&5C=%-T'1087)T7V,T8C9A8V8P7V4P83-?-#@X,E]A M-F5C7S'0O:F%V M87-C3X-"B`@("`\=&%B M;&4@8VQA'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)S$P+4L\'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M2!796QL+6MN;W=N(%-E87-O;F5D($ES'0^)TYO/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^)SQS<&%N/CPO2!6;VQU;G1A'0^)SQS<&%N/CPO M'0^)UEE'0^)SQS<&%N/CPO3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]C-&(V86-F,%]E M,&$S7S0X.#)?839E8U\W.#!F,S$Q,3!A93,-"D-O;G1E;G0M3&]C871I;VXZ M(&9I;&4Z+R\O0SHO8S1B-F%C9C!?93!A,U\T.#@R7V$V96-?-S@P9C,Q,3$P M864S+U=O'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO M3PO=&0^#0H@("`@("`@ M(#QT9"!C;&%S2!A;F0@97%U:7!M96YT+"!N970\+W1D/@T*("`@("`@("`\ M=&0@8VQA'0^)SQS<&%N M/CPO'!E;G-E'0^)R9N M8G-P.R9N8G-P.SQS<&%N/CPO'0^)SQS<&%N M/CPOF5D.R`Q+#`P-"PS,3,L,#$Y(&%N9"`U-C$L-S7!E.B!T97AT M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^ M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT M/3-$)W1E>'0O:'1M;#L@8VAAF5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$;G5M<#XR+#`P,"PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0O:F%V M87-C3X-"B`@("`\=&%B M;&4@8VQA'0^)SQS<&%N/CPO3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO6%B M;&4L(&YE=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S'!E M;G-E*2P@;F5T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q+#DX M,2PU,C8I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0O:F%V87-C3X- M"B`@("`\=&%B;&4@8VQA'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA&-H86YG92!F;W(@'0^ M)SQS<&%N/CPO&-H86YG92!F;W(@ M'0^)SQS M<&%N/CPO65E'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO&-H86YG92!F M;W(@'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO65E'0^)SQS<&%N/CPO&-H86YG92!F;W(@ M2!D96)T("AI;B!S:&%R97,I/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`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`@("`@("`\=&0@8VQA'1E;G-I;VX\+W1D M/@T*("`@("`@("`\=&0@8VQAF%T:6]N(&]F(&QO86X@ M9&ES8V]U;G0\+W1D/@T*("`@("`@("`\=&0@8VQA'0^)SQS<&%N/CPO'!E;G-E'0^)SQS<&%N/CPO6UE;G0@;V8@;V9F:6-E'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA M'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPOF%T:6]N+"!#;VYS;VQI9&%T:6]N(&%N M9"!06QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P M="!4:6UE6QE M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<^(#QF;VYT('-T M>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^,2X@0D%325,@3T8@4%)%4T5.5$%4 M24].($%.1"!354U-05)9($]&(%-)1TY)1DE#04Y4($%#0T]53E1)3D<@4$], M24-)15,\+V9O;G0^/"]D:78^(#QD:78@6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN M(#!P="<^(#QF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)B,Q-C`[ M/"]F;VYT/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE. M.B`P:6X@,&EN(#!P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$ M)T9/3E0M4TE:13H@,3!P="<^3G5T2P@4F5C97!T;U!H87)M+"!);F,N("@F(S@R,C`[4F5C97!T;U!H87)M)B,X M,C(Q.RDL($YU=')A(%!H87)M82!C;VYD=6-T2!R M97-E87)C:"!A;F0@9&5V96QO<&UE;G0@86-T:79I=&EE&EN/'-U<#XF(S$W-#L\+W-U<#XL M(&%N(&]V97(M=&AE+6-O=6YT97(@<&%I;B!R96QI979E2UO=VYE9"!S=6)S:61I87)I97,@1&5S:6=N97(@1&EA M9VYO2!T2!A;F0@1V]I;F<@0V]N M8V5R;CPO9F]N=#X\+VD^/"]D:78^(#QD:78@6QE/3-$)T9/3E0M1D%-24Q9.B`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`R,#$S+"!W92!D;R!N;W0@:&%V92!S=69F:6-I96YT(&-A'0@>65A2!A9&5Q=6%T92!T;R!F=6YD(&]U2!F=6YD:6YG.R!H;W=E=F5R('!R;V-E961S(&9R;VT@&5C=71E(&]U'!A;G-I;VXL(')E<&%Y(&]U2!S:&]U;&0@=V4@8F4@=6YA8FQE('1O(&-O;G1I;G5E(&%S M(&$@9V]I;F<@8V]N8V5R;BX\+V9O;G0^/"]D:78^(#QF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG3X\9F]N="!S M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X\+V1I=CX@ M/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE3X\:3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z M(#$P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)RPG2!O9B!I;G9E;G1O6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)RPG3X\:3X\9F]N="!S='EL M93TS1"=&3TY4+5-)6D4Z(#$P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG2!A6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG3X\9F]N="!S M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X\+V1I=CX@ M/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE3X\:3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z M(#$P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)RPG3X\9F]N="!S='EL93TS1"=& M3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X\+V1I=CX@/&1I=B!S='EL M93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/E1H92!# M;VUP86YY(')E8V]R9',@3X\:3X\9F]N="!S='EL M93TS1"=&3TY4+5-)6D4Z(#$P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%- M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P M:6X@,&EN(#!P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/ M3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/CPO9&EV/B`\9&EV('-T>6QE M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1J M=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^5&AE($-O M;7!A;GD@9W)A;G1S(&-R961I="!W:71H;W5T(&-O;&QA=&5R86P@=&\@:71S M(&-U28C.#(Q-SMS(&5V86QU M871I;VX@;V8@82!P87)T:6-U;&%R(&-U2!D;V5S(&YO="!C:&%R9V4@:6YT97)E M6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG M3X\9F]N M="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/DEN=F5N=&]R:65S+"!W:&EC M:"!A2!R M96=U;&%R;'D@65A6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<@ M86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P M="<^)B,Q-C`[/"]F;VYT/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0[34%21TE..B`P:6X@,&EN(#!P="<^(#QI/CQF;VYT('-T>6QE/3-$)T9/ M3E0M4TE:13H@,3!P="<^/&9O;G0@6QE/3-$ M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4 M+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<^(#QF;VYT('-T>6QE M/3-$)T9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/CPO9&EV/B`\9&EV M('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<@86QI M9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^ M3W5R(&9I;F%N8VEA;"!I;G-T6%B;&4L(&%C8W)U960@97AP M96YS97,L(&QO86YS('!A>6%B;&4L(&1U92!T;R!O9F9I8V5R2!A&EM871E('1H96ER(&9A M:7(@=F%L=65S(&)E8V%U2!A6QE/3-$)T-,14%2.F)O M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0[34%21TE..B`P:6X@,&EN(#!P="<^(#QF;VYT('-T>6QE/3-$)T9/3E0M M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/CPO9&EV/B`\9&EV('-T>6QE/3-$ M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4 M+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1J=7-T M:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^0F%L86YC97,@ M:6X@=F%R:6]U2!A="!T:6UE&-E960@ M9F5D97)A;&QY(&EN'!E65A6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG M6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN M(#!P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE: M13H@,3!P="<^)B,Q-C`[/"]F;VYT/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-, M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1J=7-T:69Y M/CQI/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^/&9O;G0@3X\9F]N="!S='EL M93TS1"=&3TY4+5-)6D4Z(#$P<'0G/E1H92!#;VUP86YY(&1O97,@;F]T('5S M92!D97)I=F%T:79E(&EN"!E;6)E9&1E9"!D97)I=F%T:79E6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA M;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<^(#QI/CQF M;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/CPO M:3X\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E, M63I4:6UE3X\:3X\9F]N="!S='EL93TS1"=& M3TY4+5-)6D4Z(#$P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T-,14%2.F)O M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0[34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/CPO9&EV M/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P M="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@ M,3!P="<^4')O<&5R='D@86YD(&5Q=6EP;65N="!I'!E;F1I='5R97,@9F]R(&UA:F]R(&EM<')O=F5M96YT2!A;F0@97%U:7!M96YT M+"!W:&EL92!R97!L86-E;65N=',L(&UA:6YT96YA;F-E(&%N9"!R97!A:7)S M('=H:6-H(&1O(&YO="!E>'1E;F0@=&AE('5S969U;"!L:79E6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG65A3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G M/B8C,38P.SPO9F]N=#X\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H M.R!&3TY4+49!34E,63I4:6UE6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)RPG3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO M9F]N=#X\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49! M34E,63I4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N M;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q M,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4 M+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P M,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S M='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I M9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C M9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXR,2PY,3@\ M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO'1U6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q) M1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5. M1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@ M8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXS M-"PW-3<\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT M.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C M8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!& M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXT,BPQ,CD\+V1I M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M6QE/3-$)U1% M6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%# M2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U! M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@ M/&1I=CXR+#8R.3PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!& M3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@ M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4 M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXR+#8R.3PO9&EV/B`\ M+W1D/B`\=&0@6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4 M+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9 M.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED M.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$ M24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED M.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X M('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L M.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO"!S;VQI9#L@ M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4 M+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D]. M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED M=&@],T0Q,"4^(#QD:78^,3@Q+#(W,3PO9&EV/B`\+W1D/B`\=&0@6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4 M+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9 M.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED M.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/ M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/B@Q-#$L-S4V*3PO M9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@ M=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`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`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@ M-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXR-"PU,S0\+V1I=CX@/"]T9#X@/'1D M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-4 M64Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U3 M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=( M5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXS.2PU,34\+V1I=CX@/"]T9#X@ M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M6QE/3-$)T-, M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1J=7-T:69Y M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT M/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@ M,&EN(#!P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M M4TE:13H@,3!P="<^5V4@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG2X\+V9O;G0^/"]D:78^(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)RPG3X\:3X\9F]N="!S='EL M93TS1"=&3TY4+5-)6D4Z(#$P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<@86QI M9VX],T1J=7-T:69Y/CQI/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P M="<^("8C,38P.SPO9F]N=#X\+VD^/"]D:78^(#QD:78@&EM871E;'D@)#QF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG65A2X\+V9O;G0^ M/"]D:78^(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG M&5S M/"]F;VYT/CPO:3X\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!& M3TY4+49!34E,63I4:6UE3X\9F]N="!S='EL M93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X\+V1I=CX@/&1I M=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G M/E=E(&-O;7!U=&4@:6YC;VUE('1A>&5S(&EN(&%C8V]R9&%N8V4@=VET:"!& M:6YA;F-I86P@06-C;W5N=&EN9R!3=&%N9&%R9"!";V%R9"`H)B,X,C(P.T9! M4T(F(S@R,C$[*2!!8V-O=6YT:6YG(%-T86YD87)D($-O9&EF:6-A=&EO;B`H M)B,X,C(P.T%30R8C.#(R,3LI(%1O<&EC(#&5S M/"]I/B`H)B,X,C(P.T%30R!4;W!I8R`W-#`F(S@R,C$[*2X@56YD97(@05-# M(%1O<&EC(#2!D:69F97)E;F-E M2!A<'!L>6EN9R!E;F%C=&5D('-T871U=&]R>2!R871E2!F6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@ M,&EN(#!P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/CPO9&EV/B`\9&EV('-T>6QE/3-$ M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4 M+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1J=7-T M:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^3VX@86X@86YN M=6%L(&)A'!E8W1E9"!T;R!B92!T86ME;B!I;B!O M=7(@=&%X(')E='5R;G,@=&\@9&5T97)M:6YE(&EF('1H97D@87)E(&UO2!L:6%B:6QI=&EE"!P;W-I=&EO;G,@;W(@<')O=FES:6]N6QE/3-$)T-,14%2.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%2 M1TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE M/3-$)T9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/CPO9&EV/B`\9&EV M('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<@86QI M9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^ M4VEN8V4@:6YC97!T:6]N+"!W92!H879E(&)E96X@"!A=61I=',@:6X@=&AE(&IU6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG65E2!D:79I9&EN9R!N970@;&]S2!T:&4@=V5I9VAT960@879E2!I M6QE/3-$)TU!4D=)3CH@,&EN.R!724142#H@ M.3`E.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E.R!/5D521DQ/5SH@=FES M:6)L92<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!A;&EG;CTS M1&QE9G0^(#QT6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@ M,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO M6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!& M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!& M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE"!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)U1%6%0M04Q)1TXZ M(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE M6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4 M+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5)) M1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P M,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T-,14%2.F)O M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0[34%21TE..B`P:6X@,&EN(#!P="<^(#QI/CQF;VYT('-T>6QE/3-$)T9/ M3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/CPO:3X\+V1I=CX@/&1I=B!S M='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%- M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P M:6X@,&EN(#!P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/ M3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/CPO9&EV/B`\9&EV('-T>6QE M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1J M=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^0V5R=&%I M;B!A;6]U;G1S(&EN('1H92`R,#$R($-O;G-O;&ED871E9"!&:6YA;F-I86P@ M6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<^(#QF;VYT('-T M>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/CPO9&EV/B`\ M9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4 M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG&5D.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D M/CPO=&0^/"]T7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA M'0@0FQO M8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=B!S='EL M93TS1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O M;6%N+"!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN M(#!P="<^(#QF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)B,Q-C`[ M/"]F;VYT/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE. M.B`P:6X@,&EN(#!P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$ M)T9/3E0M4TE:13H@,3!P="<^0V5R=&%I;B!A'!A;F1S('1H92!D:7-C;&]S=7)E(')E<75IF5D(&]R M(&1I6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN M(#!P="<^(#QF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)B,Q-C`[ M/"]F;VYT/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE. M.B`P:6X@,&EN(#!P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$ M)T9/3E0M4TE:13H@,3!P="<^3&5V96P@,3H@56YA9&IU2P@9F]R('-U M8G-T86YT:6%L;'D@=&AE(&9U;&P@=&5R;2!O9B!T:&4@87-S970@;W(@;&EA M8FEL:71Y.R!A;F0\+V9O;G0^/"]D:78^(#QD:78@2!L:71T;&4@;W(@;F\@;6%R:V5T(&%C=&EV:71Y*2X\+V9O M;G0^/"]D:78^(#QD:78@6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN M(#!P="<^(#QF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)B,Q-C`[ M/"]F;VYT/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U! M3$E'3CI,969T.R!415A4+4E.1$5.5#H@,&EN.R!724142#H@,3`P)2<^(#QT M86)L92!S='EL93TS1"=-05)'24XZ(#!I;CL@5TE$5$@Z(#$P,"4[($)/4D1% M4BU#3TQ,05!313H@8V]L;&%P6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED M.R!415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!4 M15A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@] M,T0Q,B4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4 M15A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z M(#0P,"<@=VED=&@],T0Q,B4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT M9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO M"!S;VQI9#L@ M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,B4^(#QD:78^)B,Q-C`[/"]D M:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/ M3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,B4^(#QD M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=. M.B!C96YT97([($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)T-,14%2.F)O M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0[34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/CPO9&EV M/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U!3$E'3CI,969T.R!4 M15A4+4E.1$5.5#H@,&EN.R!724142#H@,3`P)2<^(#QT86)L92!S='EL93TS M1"=-05)'24XZ(#!I;CL@5TE$5$@Z(#$P,"4[($)/4D1%4BU#3TQ,05!313H@ M8V]L;&%P6QE/3-$ M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=. M.B!C96YT97([($9/3E0M4U193$4Z(&YO6QE/3-$)T)/ M4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C M96YT97([($9/3E0M4U193$4Z(&YO6QE M/3-$)U1%6%0M04Q)1TXZ(&-E;G1E"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,B4^(#QD:78^ M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C M96YT97([($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@] M,T0Q,B4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4 M15A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z M(#0P,"<@=VED=&@],T0Q,B4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT M9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO M"!S;VQI9#L@ M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,B4^(#QD:78^)B,Q-C`[/"]D M:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/ M3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)B,Q M-C`[/"]F;VYT/CPO6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<^(#QF;VYT('-T>6QE/3-$)T9/ M3E0M4TE:13H@,3!P="<^/&9O;G0@6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P M="<^(#QF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F M;VYT/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%- M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U!3$E' M3CI,969T.R!415A4+4E.1$5.5#H@,&EN.R!724142#H@,3`P)2<^(#QT86)L M92!S='EL93TS1"="3U)$15(M0D]45$]-.B`C.65B-F-E(#!P>"!S;VQI9#L@ M0D]21$52+4Q%1E0Z(",Y96(V8V4@,'!X('-O;&ED.R!-05)'24XZ(#!I;B`P M:6X@,&EN(#`N-S5I;CL@5TE$5$@Z(#8P)3L@0D]21$52+4-/3$Q!4%-%.B!C M;VQL87!S93L@3U9%4D9,3U6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E"!S M;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[ M($9/3E0M1D%-24Q9.B!4:6UE"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=. M.B!C96YT97([($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED M=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS M1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!4 M15A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%- M24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O M;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F M9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[ M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/B@V-C"!S;VQI9#L@5$585"U!3$E'3CH@ M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G M('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U! M3$E'3CH@6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q M,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4 M+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9 M.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M"!S;VQI9#L@1D].5"U7 M14E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q% M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U! M3$E'3CH@6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%# M2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U! M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@ M/&1I=CXQ."PW,C<\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%- M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0G/CPO9&EV/B`\ M+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4 M:6UE3X\9F]N="!S='EL93TS M1"=&3TY4+5-)6D4Z(#$P<'0G/B@Q*2!4:&4@9V%I;B!O2!I6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG2!V86QU97,@:71S('=A M6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`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`P,#`@,7!X('-O M;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO&5D)B,Q-C`[4')I M8V4\8G(O/B!O6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ M(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E M;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE M/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED M.R!415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO6QE/3-$)U1% M6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T)/4D1% M4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT M97([($9/3E0M4U193$4Z(&YO"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE M/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!& M3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@ M1D].5"U325I%.B`X<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1% M4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W M:61T:#TS1#$P)3X@/&1I=CXU-C0L,S6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E M6QE/3-$ M)U1%6%0M04Q)1TXZ(&-E;G1E"!S;VQI M9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q-B4^(#QD:78^)#`N,#`S M-BTD,"XP,#8T/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=. M.B!C96YT97([($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E M;G1E7,\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1% M6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q) M1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E7,\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E M6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)RPG3X\9F]N="!S M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA M;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX] M,T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)B,Q M-C`[/"]F;VYT/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0G(&%L M:6=N/3-$8V5N=&5R/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U! M3$E'3CIC96YT97([(%1%6%0M24Y$14Y4.B`P:6X[(%=)1%1(.B`Q,#`E)R!A M;&EG;CTS1&-E;G1E6QE/3-$)T)/4D1%4BU"3U143TTZ M(",Y96(V8V4@,'!X('-O;&ED.R!"3U)$15(M3$5&5#H@(SEE8C9C92`P<'@@ M"!S;VQI9#L@0D]21$52+5))1TA4.B`C.65B-F-E M(#!P>"!S;VQI9"<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!A M;&EG;CTS1&-E;G1E"!S;VQI9#L@1D].5"U714E'2%0Z(#6QE/3-$)T)/4D1%4BU" M3U143TTZ(",P,#`P,#`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`P,#`[($9/3E0M M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E' M2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^-S4Q+#0Q.3PO9&EV/B`\+W1D M/B`\=&0@6QE M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!! M1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)4 M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS M1#$P)3X@/&1I=CXY,#(L,S8Y/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4 M15A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%- M24Q9.B!4:6UE2!O;F4@;&]S6)R:60@ M:6YS=')U;65N=#PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!& M3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@ M0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q) M1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD M:78^,2PV-38L.#`R/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%, M24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4 M:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)U1% M6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%- M24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO6QE M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%, M24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4 M:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!4 M15A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!& M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/B@Q+#,Q,"PR-#,I/"]D M:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4 M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U! M3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-) M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z M(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS M1#$E/B`\9&EV/B0\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU" M3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@"!S;VQI9#L@ M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^-S8W+#`U-SPO M9&EV/B`\+W1D/B`\=&0@"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I M=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C M,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-4 M64Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U3 M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0 M.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@] M,T0Q,"4^(#QD:78^-3@X+#`Y,3PO9&EV/B`\+W1D/B`\=&0@&5D.R<@8V5L M;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T M7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T* M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA6QE/3-$)TU! M4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE. M.B`P:6X@,&EN(#!P="<^(#QF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P M="<^,RX@4T545$Q%345.5"!/1B!!0T-/54Y44R!!3D0@3D]412!005E!0DQ% M/"]F;VYT/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE. M.B`P:6X@,&EN(#!P="<^(#QF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P M="<^)B,Q-C`[/"]F;VYT/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0[34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^070@2F%N=6%R>2`R+"`R,#$R M+"!T:&4@0V]M<&%N>2!O=V5D($)A;FL@;V8@06UE2!O M=V5D(%!O6QE/3-$)T9/ M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6%B;&4@=VET:&EN('-I>"!M M;VYT:',@=VET:"!I;G1E6QE M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1J M=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^070@36%R M8V@@,C(L(#(P,3(L('1H92!#;VUP86YY(&]W960@06QE2!%;G1E6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG7,@=VET:"!T:&4@;&]W97-T('9O;'5M92!W96EG:'1E9"!A=F5R86=E M('!R:6-E2!P6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P M="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@ M,3!P="<^)B,Q-C`[/"]F;VYT/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1J=7-T:69Y/CQF M;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^070@1&5C96UB97(@,C`L M(#(P,3(L('1H92!#;VUP86YY(&]W960@/&D^26UM=6YO8VQI;BP@3'1D/"]I M/BX@*"8C.#(R,#M);6UU;F]C;&EN)B,X,C(Q.RD@)#QF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG&-H M86YG92!F;W(@=&AE(&]U='-T86YD:6YG(&%C8V]U;G1S('!A>6%B;&4N("0\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG M2!%;G1E2`W+"`R,#$S+"!A;F0@36%R8V@@,3,L(#(P,3,L(')E M2X@0V]V96YT28C.#(Q-SMS(&-O;6UO;B!S=&]C:R!T M;R!S871I2!I2`W+"`R,#$S+"!A;F0@36%R8V@@,3,L(#(P,3,N M($-O=F5N=')Y(&UA9&4@=&AE(&-O;G9E6)R:60@ M8V]N=')A8W1S('5N9&5R('1H92!G=6ED86YC92!O9B!&05-"($%30R!4;W!I M8R`X,34@1&5R:79A=&EV97,@)F%M<#L@2&5D9VEN9RX@5&AE(&9A:7(@=F%L M=64@:&%S(&)E96X@9&5F:6YE9"!A6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T-, M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1J=7-T:69Y M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT M/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@ M,&EN(#!P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M M4TE:13H@,3!P="<^1'5R:6YG($%U9W5S="!A;F0@4V5P=&5M8F5R+"`R,#$S M+"!T:&4@0V]M<&%N>2!I6%B;&4@:6X@86=G6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG2!I28C.#(Q-SMS M(')E6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG&5R8VES92!P6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN M(#!P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE: M13H@,3!P="<^)B,Q-C`[/"]F;VYT/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-, M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1J=7-T:69Y M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^1'5R:6YG(%-E<'1E M;6)E2!T;R!T:&4@0V]M M<&%N>2`H4V5E($YO=&4@-BDN/"]F;VYT/CPO9&EV/B`\+V1I=CX\=&%B;&4@ M8F]R9&5R/3-$,"!S='EL93TS1"=W:61T:#HQ,#`E.R!T86)L92UL87EO=70Z M9FEX960[)R!C96QL3X-"CPO:'1M;#X-"@T* M+2TM+2TM/5].97AT4&%R=%]C-&(V86-F,%]E,&$S7S0X.#)?839E8U\W.#!F M,S$Q,3!A93,-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8S1B-F%C M9C!?93!A,U\T.#@R7V$V96-?-S@P9C,Q,3$P864S+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C M:&%R'0^)SQS M<&%N/CPO'0^)SQD:78@6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P M="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@ M,3!P="<^)B,Q-C`[/"]F;VYT/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[5$585"U!3$E'3CI,969T.R!415A4+4E.1$5.5#H@,&EN.R!72414 M2#H@,3`P)2<^(#QT86)L92!S='EL93TS1"=-05)'24XZ(#!I;CL@5TE$5$@Z M(#$P,"4[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P6QE/3-$)T)/ M4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C M96YT97([($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E M6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q) M1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!! M1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)4 M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS M1#$P)3X@/&1I=CXU-C8L,SDY/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4 M15A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%- M24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT M.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C M8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!& M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXV,#8L,38X/"]D M:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4 M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N M;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@5$585"U!3$E'3CH@;&5F M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[ M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I M9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS M1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E' M3CH@6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%# M2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U! M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@ M/&1I=CXQ,36QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@] M,T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4 M15A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%- M24Q9.B!4:6UE"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P M,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4 M+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D]. M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=% M24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXW,C,L,S@V/"]D:78^(#PO M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q% M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG M3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B8C M,38P.SPO9F]N=#X\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!& M3TY4+49!34E,63I4:6UE3X\9F]N="!S='EL M93TS1"=&3TY4+5-)6D4Z(#$P<'0G/D1U65A6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N M)RPG6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN M(#!P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE: M13H@,3!P="<^)B,Q-C`[/"]F;VYT/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-, M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1J=7-T:69Y M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^1'5R:6YG($IU;F4L M(#(P,3,L(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)RPG&5R M8VES92!P3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z M(#$P<'0G/B8C,38P.SPO9F]N=#X\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5! M4CIB;W1H.R!&3TY4+49!34E,63I4:6UE3X\ M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/D1U65A M6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)RPG2`R+"`R,#$R(&%N9"!A8V-E<'1E9"!A('1O=&%L(&]F(#QF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG M6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG3X-"CPO:'1M;#X-"@T*+2TM+2TM/5]. M97AT4&%R=%]C-&(V86-F,%]E,&$S7S0X.#)?839E8U\W.#!F,S$Q,3!A93,- M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8S1B-F%C9C!?93!A,U\T M.#@R7V$V96-?-S@P9C,Q,3$P864S+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I M=B!S='EL93TS1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@ M3F5W(%)O;6%N+"!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E"!S;VQI M9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[ M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([ M($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^ M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%, M24=..B!C96YT97([($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q) M1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5. M1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@ M8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXT M,3(L,3@R/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L M969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D]. M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=% M24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXW-C6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4 M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1% M4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H M=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/ M3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@ M=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`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`Q,'!T.R!615)4 M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS M1#$P)3X@/&1I=CXQ+#,U.2PR,S@\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W M:61T:#TS1#$P)3X@/&1I=CXQ+#,W,2PU-S0\+V1I=CX@/"]T9#X@/'1D('-T M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)V-L96%R.F)O=&@[5TE$5$@Z(#$P,"4[($9/3E0M4TE: M13H@,3!P="<@8F]R9&5R/3-$,"!C96QL6QE/3-$)T-,14%2.F)O=&@[34%21TE..B`P:6X@ M,&EN(#!P="<^/&9O;G0@6QE/3-$)T)/4D1%4BU"3U143TTZ("-D M-&0P8S@[($)/4D1%4BU,1494.B`C9#1D,&,X.R!0041$24Y'+4)/5%1/33H@ M,&EN.R!"04-+1U)/54Y$+4-/3$]2.B!T6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG2X\+V9O;G0^/"]D M:78^(#PO=&0^(#PO='(^(#PO=&%B;&4^(#QD:78@6QE/3-$)T)/4D1%4BU"3U143TTZ("-D-&0P M8S@[($)/4D1%4BU,1494.B`C9#1D,&,X.R!0041$24Y'+4)/5%1/33H@,&EN M.R!"04-+1U)/54Y$+4-/3$]2.B!T6QE/3-$)T9/3E0M4TE:13H@,3!P="<^*#(I/"]F;VYT/CPO9&EV/B`\ M+W1D/B`\=&0@3X\9F]N="!S='EL93TS1"=&3TY4+5-) M6D4Z(#$P<'0G/D%T($1E8V5M8F5R(#,Q+"`R,#$S(&%N9"`R,#$R+"!T:&4@ M8F%L86YC92!O9B`D-#$R+#$X,B!A;F0@)#4Y,RPT.#,@+"!R97-P96-T:79E M;'DL(&-O;G-I6QE/3-$)T)/4D1%4BU"3U143TTZ M("-D-&0P8S@[($)/4D1%4BU,1494.B`C9#1D,&,X.R!0041$24Y'+4)/5%1/ M33H@,&EN.R!"04-+1U)/54Y$+4-/3$]2.B!T6QE/3-$)T)/4D1%4BU"3U143TTZ("-D-&0P M8S@[($)/4D1%4BU,1494.B`C9#1D,&,X.R!0041$24Y'+4)/5%1/33H@,&EN M.R!"04-+1U)/54Y$+4-/3$]2.B!T6QE/3-$)V9O;G0M6QE/3-$)T)/4D1%4BU"3U143TTZ("-D-&0P8S@[ M($)/4D1%4BU,1494.B`C9#1D,&,X.R!0041$24Y'+4)/5%1/33H@,&EN.R!" M04-+1U)/54Y$+4-/3$]2.B!T6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T)/4D1%4BU"3U143TTZ("-D-&0P8S@[($)/ M4D1%4BU,1494.B`C9#1D,&,X.R!0041$24Y'+4)/5%1/33H@,&EN.R!"04-+ M1U)/54Y$+4-/3$]2.B!T6QE/3-$)T)/4D1%4BU"3U143TTZ("-D-&0P8S@[($)/4D1%4BU, M1494.B`C9#1D,&,X.R!0041$24Y'+4)/5%1/33H@,&EN.R!"04-+1U)/54Y$ M+4-/3$]2.B!T6QE/3-$)V9O M;G0M6QE/3-$)T)/4D1%4BU"3U143TTZ("-D-&0P8S@[($)/4D1%4BU,1494 M.B`C9#1D,&,X.R!0041$24Y'+4)/5%1/33H@,&EN.R!"04-+1U)/54Y$+4-/ M3$]2.B!T6UE;G0@=&\@9&ES8VAA2!R96-O6QE/3-$)T9/ M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T-,14%2.F)O=&@[34%21TE..B`P:6X@ M,&EN(#!P="<^/&9O;G0@F4Z(#$P<'0[)SXF(S$X,SL\ M+V9O;G0^/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]- M.B`C9#1D,&,X.R!"3U)$15(M3$5&5#H@(V0T9#!C.#L@4$%$1$E.1RU"3U14 M3TTZ(#!I;CL@0D%#2T=23U5.1"U#3TQ/4CH@=')A;G-P87)E;G0[(%!!1$1) M3D6QE/3-$)T-,14%2.F)O=&@[ M34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T M>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^26X@2G5L>2`R,#$S+"!T:&4@0V]M M<&%N>2!I&5C=71I;VX@86YD(&9U;F1I;F<@;V8@=&AE(&YO=&4N M($EN(&-O;FYE8W1I;VX@=VET:"!T:&4@:7-S=6%N8V4@;V8@=&AI2!H87,@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)RPG65A2!D871E("A3964@3F]T92`V*2X@5V4@87)E M(&EN(&1E9F%U;'0@6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)B,Q M-C`[/"]F;VYT/CPO9&EV/B`\=&%B;&4@6QE/3-$)T-,14%2 M.F)O=&@[34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@F4Z(#$P<'0[)SXF(S$X,SL\+V9O;G0^/"]D:78^(#PO=&0^(#QT9"!S='EL M93TS1"="3U)$15(M0D]45$]-.B`C9#1D,&,X.R!"3U)$15(M3$5&5#H@(V0T M9#!C.#L@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D%#2T=23U5.1"U#3TQ/4CH@ M=')A;G-P87)E;G0[(%!!1$1)3D6QE/3-$)T-,14%2.F)O=&@[34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX] M,T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^070@ M1&5C96UB97(@,S$L(#(P,3(L('1H92!T;W1A;"!A;6]U;G0@;V8@=&AE($-O M;7!A;GDF(S@R,3<[6%B;&4@9F]R("0\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@)U1I;65S($YE=R!2;VUA;B2!D M:7-M:7-S960@:6YV;VQV:6YG(&1E8G0@:&5L9"!B>2!3;W5T:')I9&=E(&9O M6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@ M,&EN(#!P="`V,W!T)R!A;&EG;CTS1&IU3X\9F]N="!S='EL93TS1"=#3TQ/4CH@(S,S,S,S,SL@ M1D].5"U325I%.B`Q,'!T)SY);B!!<')I;"P@,C`Q,RP@)#QF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M4TE:13H@,3!P="<^=&AE(&1E8G0@:&5L9"!B>2!- M:6-H865L($UC1&]N86QD(%1R=7-T('=A2!%;G1E6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)RPG2!A M;6]U;G0@;V8@=&AE('1H:7,@;F]T92!I;G1O('-H87)E2=S(&-O;6UO;B!S=&]C:R`H=&AE(")#;VUM;VX@4W1O8VLB*2!A="!A M(&-O;G9E6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z M(#$P<'0G/B8C,38P.SPO9F]N=#X\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5! M4CIB;W1H.R!&3TY4+49!34E,63I4:6UE6QE/3-$)T9/3E0M4TE:13H@,3!P="<^26X@2G5N92P@ M,C`Q,RP@)#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)RPGBP@4$,N(&EN('1H92!F;W)M(&]F($-O M;G9E2!R96-O6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG2=S(&-O;6UO;B!S=&]C M:R`H=&AE(")#;VUM;VX@4W1O8VLB*2!A="!A(&-O;G9E7,\+V9O;G0^("X@1F]L;&]W:6YG('1H92!A9W)E96UE;G1S M+"!#;W9E;G1R>2!M861E('1H92!C;VYV97)S:6]N3X\ M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X\ M+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4 M:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%- M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P M:6X@,&EN(#!P="`V,W!T)R!A;&EG;CTS1&IU6QE/3-$)T)/4D1%4BU" M3U143TTZ("-D-&0P8S@[($)/4D1%4BU,1494.B`C9#1D,&,X.R!0041$24Y' M+4)/5%1/33H@,&EN.R!"04-+1U)/54Y$+4-/3$]2.B!T6QE/3-$)T)/4D1%4BU"3U143TTZ M("-D-&0P8S@[($)/4D1%4BU,1494.B`C9#1D,&,X.R!0041$24Y'+4)/5%1/ M33H@,&EN.R!"04-+1U)/54Y$+4-/3$]2.B!T6QE/3-$)T9/3E0M4TE:13H@,3!P="<^:2X\+V9O;G0^/"]D M:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C9#1D,&,X M.R!"3U)$15(M3$5&5#H@(V0T9#!C.#L@4$%$1$E.1RU"3U143TTZ(#!I;CL@ M0D%#2T=23U5.1"U#3TQ/4CH@=')A;G-P87)E;G0[(%!!1$1)3D6QE/3-$)T-,14%2.F)O=&@[34%21TE..B`P M:6X@,&EN(#!P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/ M3E0M4TE:13H@,3!P="<^3VX@/&9O;G0@2!A9W)E960@=&\@<&%Y M($Q04B!A('1O=&%L(&]F("0\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M)U1I;65S($YE=R!2;VUA;B2`R,#$R('!A>6UE;G1S(&%N9"!O;B!* M86YU87)Y(#(V+"`R,#$R+"!W92!S:6=N960@=&AE(&9I2`D/&9O;G0@6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN M(#!P="`Q+C(U:6XG(&%L:6=N/3-$:G5S=&EF>3X\9F]N="!S='EL93TS1"=& M3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X\+V1I=CX@/&1I=B!S='EL M93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE6QE/3-$)T9/3E0M4TE:13H@,3!P="<^ M5&AE($-O;7!A;GD@2!D:60@;F]T(&UA:V4@86QL M(&]F('1H92!P87EM96YT6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG28C.#(Q-SMS(&9R964@=')A9&EN9R!S=&]C:R!H96QD M(&EN(&5S8W)O=R!B>2!T:&5I2!A;F0@2`H4V5E(&YO M=&4@.2DN/"]F;VYT/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[ M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[ M34%21TE..B`P:6X@,&EN(#!P="`X,7!T)R!A;&EG;CTS1&IU6QE/3-$ M)T)/4D1%4BU"3U143TTZ("-D-&0P8S@[($)/4D1%4BU,1494.B`C9#1D,&,X M.R!0041$24Y'+4)/5%1/33H@,&EN.R!"04-+1U)/54Y$+4-/3$]2.B!T6QE/3-$)T)/4D1% M4BU"3U143TTZ("-D-&0P8S@[($)/4D1%4BU,1494.B`C9#1D,&,X.R!0041$ M24Y'+4)/5%1/33H@,&EN.R!"04-+1U)/54Y$+4-/3$]2.B!T6QE/3-$)T9/3E0M4TE:13H@,3!P="<^:6DN M/"]F;VYT/CPO9&EV/B`\+W1D/B`\=&0@3X\9F]N="!S M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/D%S(&]F($1E8V5M8F5R(#,Q+"`R M,#$S(&%N9"`R,#$R+"!T:&4@0V]M<&%N>2!O=V5D(#QE;3Y5;FEV97)S:71Y M($-E;G1R92!797-T($QT9#PO96T^+B!A<'!R;WAI;6%T96QY("0\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B2!R979E6QE/3-$)T)/4D1%4BU"3U143TTZ("-D-&0P8S@[($)/4D1% M4BU,1494.B`C9#1D,&,X.R!0041$24Y'+4)/5%1/33H@,&EN.R!"04-+1U)/ M54Y$+4-/3$]2.B!T6QE/3-$ M)T9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/CPO9&EV/B`\+W1D/B`\ M=&0@6QE/3-$)T-,14%2 M.F)O=&@[34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@6QE/3-$)T-,14%2.F)O=&@[34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX] M,T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^070@ M1&5C96UB97(@,S$L(#(P,3,@86YD(#(P,3(L('1H92!B86QA;F-E(&]F("0\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N M)RPG3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B8C M,38P.SPO9F]N=#X\+V1I=CX@/'1A8FQE('-T>6QE/3-$)V-L96%R.F)O=&@[ M5TE$5$@Z(#$P,"4[($9/3E0M4TE:13H@,3!P="<@8F]R9&5R/3-$,"!C96QL M6QE/3-$)T-, M14%2.F)O=&@[34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@F4Z(#$P<'0[)SXF(S$X,SL\+V9O;G0^/"]D:78^(#PO=&0^(#QT9"!S M='EL93TS1"="3U)$15(M0D]45$]-.B`C9#1D,&,X.R!"3U)$15(M3$5&5#H@ M(V0T9#!C.#L@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D%#2T=23U5.1"U#3TQ/ M4CH@=')A;G-P87)E;G0[(%!!1$1)3D6QE/3-$)T-,14%2.F)O=&@[34%21TE..B`P:6X@,&EN(#!P="<@86QI M9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^ M26X@4V5P=&5M8F5R(&%N9"!/8W1O8F5R(#(P,3$L('1H92!#;VUP86YY(&)O M7,\+V9O;G0^+B!);G1E6%B;&4@=V%S("0\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B3X\9F]N="!S='EL M93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X\+V1I=CX@/&1I M=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE3X\9F]N M="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/D1U28C.#(Q-SMS(')E6EN9R!T M:&4@;F]T97,@:6X@=&AE(&%M;W5N="!O9B`D/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N M)RPG2!V;VQU;64@=V5I9VAT960@879E7,@:6UM961I871E;'D@<')E8V5D:6YG('1H M92!#;VYV97)S:6]N($1A=&4\+V9O;G0^+B!&;VQL;W=I;F<@=&AE(&%S6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="`V M,W!T)R!A;&EG;CTS1&IU6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG'1E;F0@=&AE(&UA M='5R:71Y(&1A=&4@=&\@3F]V96UB97(@,RP@,C`Q,RX@5&AE($-O;7!A;GD@ M:7-S=65D(&$@=&]T86P@;V8@/&9O;G0@'1E;F0@=&AE(&UA M='5R:71Y(&1A=&5S('1O(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)RPG2`S+"`R,#$T/"]F;VYT/B!A;F0@/&9O;G0@6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/ M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/ M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T-,14%2.F)O=&@[ M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[ M34%21TE..B`P:6X@,&EN(#!P="`P+C5I;B<@86QI9VX],T1J=7-T:69Y/CQF M;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/CPO M9&EV/B`\=&%B;&4@6QE/3-$)T)/ M4D1%4BU"3U143TTZ("-D-&0P8S@[($)/4D1%4BU,1494.B`C9#1D,&,X.R!0 M041$24Y'+4)/5%1/33H@,&EN.R!"04-+1U)/54Y$+4-/3$]2.B!T6QE/3-$)V9O;G0M6QE/3-$)T)/4D1% M4BU"3U143TTZ("-D-&0P8S@[($)/4D1%4BU,1494.B`C9#1D,&,X.R!0041$ M24Y'+4)/5%1/33H@,&EN.R!"04-+1U)/54Y$+4-/3$]2.B!T6QE/3-$)T9/3E0M1D%- M24Q9.B`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`G5&EM97,@ M3F5W(%)O;6%N)RPG2X\+V9O;G0^/"]D:78^(#QD:78@6QE/3-$)T)/4D1%4BU"3U143TTZ("-D-&0P8S@[($)/4D1%4BU,1494 M.B`C9#1D,&,X.R!0041$24Y'+4)/5%1/33H@,&EN.R!"04-+1U)/54Y$+4-/ M3$]2.B!T6QE/3-$)T9/3E0M M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/CPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T-,14%2.F)O=&@[ M34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/D]N($IU M;'D@,3`L(#(P,3,@86YD($]C=&]B97(@,3`L(#(P,3,L('1H92!#;VUP86YY M(&ES2!I;G1E2`Q,"P@,C`Q-"!A;F0@07!R:6P@,3`L(#(P,30L(')E M2X@/&9O;G0@6%B;&4L(&%T(&9A:7(@=F%L=64L M('=A6QE/3-$)T)/4D1%4BU"3U143TTZ("-D-&0P8S@[($)/4D1%4BU,1494 M.B`C9#1D,&,X.R!0041$24Y'+4)/5%1/33H@,&EN.R!"04-+1U)/54Y$+4-/ M3$]2.B!T6QE/3-$)T9/3E0M M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/CPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T-,14%2.F)O=&@[ M34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/D]N(%-E M<'1E;6)E2!I6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="`P M+C5I;B<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE: M13H@,3!P="<^)B,Q-C`[/"]F;VYT/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-, M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="`P+C5I;B<@86QI9VX],T1J M=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^26X@8V]N M;F5C=&EO;B!W:71H('1H92!I65A6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N M)RPG2!C;&%S2X@5&AE('=A6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T)/4D1%4BU"3U143TTZ("-D-&0P8S@[($)/ M4D1%4BU,1494.B`C9#1D,&,X.R!0041$24Y'+4)/5%1/33H@,&EN.R!"04-+ M1U)/54Y$+4-/3$]2.B!T6QE M/3-$)T9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/CPO9&EV/B`\+W1D M/B`\=&0@6QE/3-$)T-, M14%2.F)O=&@[34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P M<'0G/D]N(%-E<'1E;6)E6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG M6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@ M,&EN(#!P="`P+C5I;B<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$ M)T9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/CPO9&EV/B`\9&EV('-T M>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA M;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="`P+C5I;B<@ M86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P M="<^26X@8V]N;F5C=&EO;B!W:71H('1H92!I65A28C.#(Q-SMS M(&-O;6UO;B!S=&]C:R!A="!A;B!E>&5R8VES92!P6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N M=#X\+V1I=CX@/'1A8FQE('-T>6QE/3-$)V-L96%R.F)O=&@[5TE$5$@Z(#$P M,"4[($9/3E0M4TE:13H@,3!P="<@8F]R9&5R/3-$,"!C96QL6QE/3-$)T-,14%2.F)O=&@[ M34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@F4Z(#$P M<'0[)SXF(S$X,SL\+V9O;G0^/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=" M3U)$15(M0D]45$]-.B`C9#1D,&,X.R!"3U)$15(M3$5&5#H@(V0T9#!C.#L@ M4$%$1$E.1RU"3U143TTZ(#!I;CL@0D%#2T=23U5.1"U#3TQ/4CH@=')A;G-P M87)E;G0[(%!!1$1)3D6QE/3-$ M)T-,14%2.F)O=&@[34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1J=7-T M:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^3VX@3V-T;V)E M2!S:6=N960@82!S96-U2!C;VYC;'5D960@=&AA="!T M:&5S92!C;VYV97)S:6]N(&9E871U2!C;&%S2!E;F-O=6YT97)E9"!A(&1A>2UO;F4@9&5R M:79A=&EV92!L;W-S(&]F("0\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M)U1I;65S($YE=R!2;VUA;B6QE/3-$)V-L96%R.F)O=&@[5TE$ M5$@Z(#$P,"4[($9/3E0M4TE:13H@,3!P="<@8F]R9&5R/3-$,"!C96QL6QE/3-$)T-,14%2 M.F)O=&@[34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@F4Z(#$P<'0[)SXF(S$X,SL\+V9O;G0^/"]D:78^(#PO=&0^(#QT9"!S='EL M93TS1"="3U)$15(M0D]45$]-.B`C9#1D,&,X.R!"3U)$15(M3$5&5#H@(V0T M9#!C.#L@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D%#2T=23U5.1"U#3TQ/4CH@ M=')A;G-P87)E;G0[(%!!1$1)3D6QE/3-$)T-,14%2.F)O=&@[34%21TE..B`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`G5&EM M97,@3F5W(%)O;6%N)RPG6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="`P+C5I;B<@86QI9VX],T1J=7-T M:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F M;VYT/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%- M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P M:6X@,&EN(#!P="`P+C5I;B<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE M/3-$)T9/3E0M4TE:13H@,3!P="<^/&9O;G0@3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B8C M,38P.SPO9F]N=#X\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!& M3TY4+49!34E,63I4:6UE3X\9F]N M="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/D1U2!A('1H M:7)D('!A6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T)/4D1%4BU"3U143TTZ("-D M-&0P8S@[($)/4D1%4BU,1494.B`C9#1D,&,X.R!0041$24Y'+4)/5%1/33H@ M,&EN.R!"04-+1U)/54Y$+4-/3$]2.B!T6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/CPO M9&EV/B`\+W1D/B`\=&0@6QE/3-$)T-,14%2.F)O=&@[34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@ M3X\9F]N="!S='EL93TS1"=&3TY4 M+5-)6D4Z(#$P<'0G/D]N(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)RPG2!I6UE;G0@ M;V8@=&AE($YO=&4L(&EN(&9A=F]R(&]F($YU=')A(%!H87)M82!#;W)P;W)A M=&EO;B!A;F0@2!A<'!R;W9E9"!T:&4@8V]N=F5R6QE/3-$)T)/4D1%4BU"3U143TTZ("-D-&0P8S@[($)/4D1% M4BU,1494.B`C9#1D,&,X.R!0041$24Y'+4)/5%1/33H@,&EN.R!"04-+1U)/ M54Y$+4-/3$]2.B!T6QE/3-$ M)T9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/CPO9&EV/B`\+W1D/B`\ M=&0@6QE/3-$)T-,14%2 M.F)O=&@[34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G M/D]N($UA2!.;W1E(&EN('1H92!A;6]U;G0@ M;V8@)#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)RPG2!A;'-O(&-O M;F-L=61E9"!T:&%T('1H92!$969A=6QT(%!U="!R97%U:7)E9"!B:69U2!C;VYS:61E6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N M)RPG2=S(')E2!C;VYC;'5D960@=&AA="!T:&5S92!C;VYV M97)S:6]N(&9E871U2!C M;&%S&5D('1O(&-E28C,38P.V5L96-T960@=&\@86-C;W5N="!F;W(@=&AE M2!R97-U;'0@:6X@82!S:6=N:69I8V%N="!D2!A;F0@:71S('-H87)E:&]L9&5R6QE/3-$)T9/ M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF M:7AE9#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT M9#X\+W1D/CPO='(^/"]T86)L93X\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO'0^)SQD:78@#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E#L@ M1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-E2!I&5R8VES92!P M6QE/3-$)T-,14%2.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%2 M1TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM M97,L(%-E3Y);B`R,#$S+"!T:&4@0V]M<&%N>2!S;VQD(&%N(&%G9W)E9V%T92!O M9B`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA M;B6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG M'!I3XF(S$V,#L\+V1I=CX@ M/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE#L@1D]. M5#H@,3!P="!4:6UE6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N M)RPG6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-E3Y);B`R,#$R+"!T:&4@0V]M<&%N>2!S;VQD(&%N(&%G M9W)E9V%T92!O9B`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S M($YE=R!2;VUA;B&5R8VES92!P6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@ M,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E3Y);B`R M,#$R+"!T:&4@0V]M<&%N>2!S;VQD(&%N(&%G9W)E9V%T92!O9B`\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B&5R8VES92!P3Y<92!O M9B`D/&9O;G0@#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!& M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)RPG3XF(S$V,#L\+V1I=CX@/&1I M=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE#L@1D].5#H@ M,3!P="!4:6UE6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)RPG28C.#(Q-SMS(')E65E(&]F('1H92!#;VUP86YY+B!4 M:&4@:7-S=6%N8V4@=V%S('9A;'5E9"!A="`D/&9O;G0@6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E3Y$=7)I;F<@3V-T;V)E6QE/3-$)T-,14%2.F)O M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0G/B`F(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!& M3TY4+49!34E,63I4:6UE#L@1D].5#H@,3!P="!4:6UE6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/ M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA M;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E3X\=3Y#;VUM;VX@4W1O8VL@27-S M=65D(&9O#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E2!I2!C;VUP96YS871I;VX@8VAA65A#L@1D].5#H@,3!P="!4 M:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE. M.B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-E6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)RPG65A#L@ M1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-E6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG28C.#(Q-SMS(')E6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N M)RPG6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4 M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E3Y$=7)I;F<@4V5P=&5M M8F5R+"`R,#$S+"!T:&4@0V]M<&%N>2!I6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG2!R96-O#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@ M,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E2!C;VUP96YS871I;VX@8VAA MF5D(&-O;7!E;G-A=&EO M;B!C;W-T(&]F("0\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S M($YE=R!2;VUA;B3XF(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS1"=# M3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE#L@1D].5#H@,3!P="!4:6UE65A6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)RPGF5D(&)Y('1H92!#;VUP86YY M(&]V97(@=&AE(')E;6%I;FEN9R!V97-T:6YG('!E3XF(S$V,#L\+V1I=CX@/&1I=B!S='EL M93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE#L@1D].5#H@,3!P="!4 M:6UE"!M;VYT:',N(%1H92!S:&%R97,@=V5R92!V86QU960@870@)#QF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG M2!R96-O3XF M(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49! M34E,63I4:6UE#L@1D].5#H@,3!P="!4:6UE2!I6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG3XF(S$V M,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E, M63I4:6UE#L@1D].5#H@,3!P="!4:6UE2!I28C.#(Q-SMS(')E2!C M;VUP96YS871I;VX@8VAA65A6QE/3-$)T-,14%2.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%2 M1TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM M97,L(%-E3Y$=7)I;F<@2G5L>2`R,#$S+"!T:&4@0V]M<&%N>2!S:6=N960@86X@ M86=R965M96YT('=I=&@@82!C;VYS=6QT86YT(&9O6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG M6QE/3-$)T9/ M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-E3Y$=7)I;F<@2G5N92P@,C`Q,RP@=&AE($-O;7!A;GD@ M:7-S=65D(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)RPG28C.#(Q-SMS(')E"!M;VYT:',N(%1H92!S:&%R97,@ M=V5R92!V86QU960@870@)#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)RPG2!R96-O#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@ M,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E2P@,C`Q,RP@=&AE($-O;7!A M;GD@:7-S=65D(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)RPG28C.#(Q-SMS(')E"!M;VYT:',N(%1H92!S:&%R M97,@=V5R92!V86QU960@870@)#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)RPG2!R96-O6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E3Y$=7)I;F<@ M1F5B6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG2!C;VUP96YS871I;VX@ M8VAA65A6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)RPGF5D(&)Y('1H92!#;VUP86YY(&]V97(@=&AE M(')E;6%I;FEN9R!V97-T:6YG('!E#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-, M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE M=R!2;VUA;BP@5&EM97,L(%-E2!R96-O3XF(S$V,#L\+V1I=CX@/&1I=B!S='EL M93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE#L@1D].5#H@,3!P="!4 M:6UE2`R,#$S+"!T:&4@0V]M<&%N>2!I2!R96-O3XF(S$V,#L\ M+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4 M:6UE#L@1D].5#H@,3!P="!4:6UE2!I28C.#(Q-SMS(')E M65A6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$ M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4 M+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P="`P M<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE3XF(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS1"=# M3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N M)RPG28C.#(Q-SMS(')E6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG M6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E3Y$=7)I;F<@3V-T;V)E2!I6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)RPG3XF(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS1"=# M3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE#L@1D].5#H@,3!P="!4:6UE2!I28C.#(Q-SMS(')E6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)RPG2!R96-O6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG3XF M(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49! M34E,63I4:6UE#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)RPG28C.#(Q-SMS M(')E6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)RPG2!R96-OF5D(&-O M;7!E;G-A=&EO;B!C;W-T(&]F("0\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@)U1I;65S($YE=R!2;VUA;BF5D(&)Y('1H92!#;VUP86YY M(&1U65A#L@ M1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-E2!I6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N M)RPG65A3XF(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS M1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE#L@1D].5#H@,3!P="!4:6UE M2!E;G1E6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG M6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)RPG2!R96-O6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG2!T:&4@0V]M M<&%N>2!D=7)I;F<@=&AE('EE87(@96YD960@1&5C96UB97(@,S$L(#(P,3,N M/"]D:78^(#QD:78@3XF(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS1"=# M3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE#L@1D].5#H@,3!P="!4:6UE&-L=7-I=F4@861V:7-O2!W87D@;V8@86X@97%U:71Y(&QI;F4@;V8@87!P2`D/&9O M;G0@2!W:6QL('!A>2!#4%,@82!C87-H('!L86-E M;65N="!F964@97%U86P@=&\@/&9O;G0@2!#4%,N($EN(&%D9&ET:6]N M+"`Q,"PP,#`L,#`P(')E6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG2!R96-OF5D(&)Y('1H92!#;VUP M86YY(&1U65A#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-, M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE M=R!2;VUA;BP@5&EM97,L(%-E3XF(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5! M4CIB;W1H.R!&3TY4+49!34E,63I4:6UE#L@1D].5#H@,3!P="!4:6UE2!A;65N9&5D('1H92!M871U2!D M871E6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)RPG#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@ M,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)RPG2!D871E6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)RPG2`H4V5E($YO=&4@-2DN/"]D:78^ M(#QD:78@3XF(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB M;W1H.R!&3TY4+49!34E,63I4:6UE#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG2!I#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@ M,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E2`R,#$S+"!I;B!C;VYN96-T:6]N('=I M=&@@=&AE(&ES2!N;W1E('1O($UI M8VAA96P@36-$;VYA;&0@5')U2!IF5D(&]V97(@=&AE('1E MF%T:6]N(&9O65A#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!& M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E3Y/;B!*=6QY(#(W M+"`R,#$Q('1H92!#;VUP86YY(&ES3XF(S$V M,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E, M63I4:6UE#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E3X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)RPG#L@ M1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[5$585"U!3$E'3CI,969T.R!415A4+4E.1$5.5#H@,&EN.R!72414 M2#H@,3`P)2<^(#QT86)L92!S='EL93TS1"=C;&5A6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/ M3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&-E M;G1E6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@] M,T0V,R4^(#QD:78^2F%N=6%R>2`R,2P@,C`Q,SPO9&EV/B`\+W1D/B`\=&0@ M6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ M(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@ M(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T M=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXT,BPU M,3`\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[ M(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!6 M15)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T M:#TS1#$R)3X@/&1I=CXT,"PT,30\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E2!%;G1E6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG M6EN9R!T:&4@;F]T97,@:6X@9G5L;#H\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@)U1I;65S($YE=R!2;VUA;B6QE/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF:7AE9#LG(&-E M;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT9#X\+W1D/CPO M='(^/"]T86)L93X\9&EV('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D]. M5#H@,3!P="!4:6UE6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P M,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z M(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO3XF(S$V,#L\+V1I=CX@/&1I=B!S='EL M93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE#L@1D].5#H@,3!P="!4 M:6UE2!M861E('1H92!C M;VYV97)S:6]N(&9O6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG3XF M(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49! M34E,63I4:6UE#L@1D].5#H@,3!P="!4:6UE2!M861E('1H92!C;VYV97)S:6]N(&9O6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N M)RPG28C.#(Q-SMS(')E6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E3X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@)U1I;65S($YE=R!2;VUA;B3XF(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5! M4CIB;W1H.R!&3TY4+49!34E,63I4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P M,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z M(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I M9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C M9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z M(#0P,"<@=VED=&@],T0Q,B4^(#QD:78^,3@X+#,U,CPO9&EV/B`\+W1D/B`\ M=&0@6QE/3-$)U1%6%0M M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[ M(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!6 M15)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T M:#TS1#$P)3X@/&1I=CXQ,BPQ.34L,3(R/"]D:78^(#PO=&0^(#QT9"!S='EL M93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/ M3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ M(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@ M(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T M=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXQ,CDL M,#,Y/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE3XF(S$V,#LF(S$V,#L\+V1I=CX@/&1I=B!S M='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE#L@1D].5#H@,3!P M="!4:6UE6QE/3-$)T9/ M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG2!V;VQU;64@=V5I9VAT960@879E7,@:6UM961I871E M;'D@<')E8V5D:6YG('1H92!#;VYV97)S:6]N($1A=&4N/"]F;VYT/B!);6UE M9&EA=&5L>2!F;VQL;W=I;F<@=&AE(&%S#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U!3$E'3CI,969T.R!415A4 M+4E.1$5.5#H@,&EN.R!724142#H@,3`P)2<^(#QT86)L92!S='EL93TS1"=C M;&5A6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E M"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q% M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E"!S;VQI M9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0V,R4^(#QD:78^."\R."\R M,#$S/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@ M=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!! M1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)4 M24-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S M;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^,C(L M,#(V+#0S,3PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E M6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$ M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4 M+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S M($YE=R!2;VUA;BP@5&EM97,L(%-E3Y/;B!397!T96UB97(@,38L(#(P,3,L(&]N M92!O9B!T:&4@;F]N+7)E;&%T960@<&%R='D@<')O;6ES2!N;W1E(&AO M;&1E3XF(S$V,#L\+V1I M=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE M#L@ M1D].5#H@,3!P="!4:6UE2`H4V5E(&YO=&4@ M-2DN(%1H92!#;VUP86YY(')E8V]R9&5D(&$@;&]S3Y$=7)I;F<@4V5P=&5M8F5R+"`R,#$S+"!-6QE/3-$)T-,14%2.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%2 M1TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM M97,L(%-E3Y$=7)I;F<@2G5N92!A;F0@4V5P=&5M8F5R+"`R,#$S+"!-28C.#(Q-SMS(')E2`H4V5E M(&YO=&4@-"DN/"]D:78^(#QD:78@3XF(S$V,#L\+V1I=CX@/&1I=B!S M='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE#L@1D].5#H@,3!P M="!4:6UE6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG2!R96-O#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E2!R96-O6QE/3-$)T-,14%2.F)O M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA M;BP@5&EM97,L(%-E6%B;&4@86UO=6YT(&1U92!T;R!T M:&4@9F%C="!T:&%T(&ET('=A'!I#L@ M1D].5#H@,3!P="!4:6UE28C.#(Q-SMS(')E2X@ M5&AE('-H87)E#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-, M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE M=R!2;VUA;BP@5&EM97,L(%-E28C.#(Q-SMS(')E6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E3Y&;VQL;W=I;F<@=&AE(&%G M28C.#(Q-SMS(')E6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4 M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E3Y&;VQL;W=I;F<@=&AE M(&%G#L@1D].5#H@,3!P M="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%2 M1TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM M97,L(%-E&5D.R<@8V5L M;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T M7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T* M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO'0^)SQD:78@3X\9F]N M="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X\+V1I M=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE M&5R8VES92!P3X\9F]N="!S='EL93TS M1"=&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X\+V1I=CX@/&1I=B!S M='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/D]N M(%-E<'1E;6)E6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG&5R8VES92!P2!I2P@=&\@<'5R M8VAA2X@5&AE('=A6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)RPG2X@5&AE('=A3X\9F]N="!S M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X\+V1I=CX@ M/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P M<'0G/D1U6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6%B;&4N(%1H92!W87)R86YT'!I6QE/3-$)U1%6%0M04Q)1TXZ(&-E M;G1E6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO"!S M;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D M:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D]. M5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%- M24Q9.B!4:6UE6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!& M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#&5R8VES960\ M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4 M+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D]. M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=% M24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXP+C$P/"]D:78^(#PO=&0^ M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N M;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W M:61T:#TS1#$R)3X@/&1I=CXM/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4 M15A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%- M24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)4 M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS M1#6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!& M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P M)R!W:61T:#TS1#6QE/3-$)T)/ M4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@ M6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%- M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P M:6X@,&EN(#!P="<^(#QF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^ M)B,Q-C`[/"]F;VYT/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[ M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[ M34%21TE..B`P:6X@,&EN(#!P="<^(#QF;VYT('-T>6QE/3-$)T9/3E0M4TE: M13H@,3!P="<^/&9O;G0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P:6X@,"XU:6X[ M(%=)1%1(.B`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`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@ M-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXU-RPR-38L-C8W/"]D:78^(#PO=&0^ M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N M;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(')I M9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE'!E8W1E9"!T;R!V97-T M('=A&5D.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D M/CPO=&0^/"]T7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA M"!$:7-C;&]S=7)E(%M!8G-T6QE/3-$)TU!4D=)3CH@ M,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@ M,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG'!E8W1E9"8C.#(R,3L@=&%X(&5X M<&5N2!A6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4 M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)TU!4D=)3CH@,&EN.R!724142#H@,3`P)3L@ M0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S93L@3U9%4D9,3U6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E"!S M;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[ M($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E M6QE/3-$)U1%6%0M04Q) M1TXZ(&-E;G1E6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/ M3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#

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`Q,'!T.R!615)424-!3"U! M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@ M/&1I=CXT-3(L,SDP/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%, M24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4 M:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P M)R!W:61T:#TS1#$R)3X@/&1I=CXV-36QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P M,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N M;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ M(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U3 M5%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9 M.B!4:6UE6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T-,14%2.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%2 M1TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM M97,L(%-E6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)TU!4D=)3CH@,&EN.R!724142#H@,3`P)3L@0D]2 M1$52+4-/3$Q!4%-%.B!C;VQL87!S93L@3U9%4D9,3U6QE/3-$)U1%6%0M04Q)1TXZ M(&-E;G1E"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4 M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@ M=VED=&@],T0Q,B4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL M93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U7 M14E'2%0Z(#0P,"<@=VED=&@],T0Q,B4^(#QD:78^)B,Q-C`[/"]D:78^(#PO M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U19 M3$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO3PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!6 M15)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T M:#TS1#$R)3X@/&1I=CXT,RPQ-30\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO"!S;VQI M9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\ M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!& M3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@ M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$ M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@ M=VED=&@],T0Q,B4^(#QD:78^-3DY+#`W.3PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU" M3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!& M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/ M4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R M:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G M('=I9'1H/3-$,3(E/B`\9&EV/B@V-3"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@ M;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/ M54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=. M.B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^ M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]- M.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q M)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]4 M5$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!& M3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@ M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$ M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@ M=VED=&@],T0Q,B4^(#QD:78^+3PO9&EV/B`\+W1D/B`\=&0@"!D M;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z M(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=2 M3U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E' M3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D]. M5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,B4^(#QD:78^+3PO9&EV/B`\+W1D M/B`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`Q,'!T M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W M:61T:#TS1#$R)3X@/&1I=CXV+#(S,BPX.#$\+V1I=CX@/"]T9#X@/'1D('-T M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X M('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[ M($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P M,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@ M;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/ M54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=. M.B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3(E/B`\9&EV M/B@V+#(S,BPX.#$I/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%, M24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4 M:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!4 M15A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%- M24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O M;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F M9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[ M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3(E/B`\9&EV/B@U+#4W-2PP M-SDI/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU" M3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@ M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9% M4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X M('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B0\ M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P M,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$58 M5"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4 M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU4 M3U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T M:#TS1#$E/B`\9&EV/B0\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1% M4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@#L@1D].5#H@,3!P="!4:6UEF%T:6]N(&%N9"!R96-O=F5R86)I;&ET M>2!O9B!T:&4@;&]S2UF;W)W87)D#L@1D]. M5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA M;BP@5&EM97,L(%-E69O2!F M3XF(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!& M3TY4+49!34E,63I4:6UE#L@1D].5#H@,3!P="!4:6UE2`D-C4X+#`P,"!A M;F0@)#4Y.2PP,#`@9F]R('1H92!Y96%R28C.#(Q M-SMS(#(P,3$@=&\@,C`Q,R!T87@@&%M:6YA=&EO;B!B>2!);G1E6QE/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U M=#IF:7AE9#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R M/CQT9#X\+W1D/CPO='(^/"]T86)L93X\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA M'0^)SQS<&%N/CPO6QE/3-$)TU!4D=) M3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%- M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P M:6X@,&EN(#!P="<^(#QF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^ M.2X@0T]-34E4345.5%,@04Y$($-/3E1)3D=%3D-)15,\+V9O;G0^/"]D:78^ M(#QD:78@3X\9F]N="!S M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X\+V1I=CX@ M/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P M<'0G/DEN($9E8G)U87)Y(#(P,3`L($YU=')A(%!H87)M82!E;G1E2`R,#$S(&%N9"!R M97%U:7)E9"!M;VYT:&QY('!A>6UE;G1S(&]F(&%P<')O>&EM871E;'D@)#QF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG M6UE;G1S(&]F(&%P<')O>&EM871E;'D@)#QF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T-, M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1J=7-T:69Y M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT M/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@ M,&EN(#!P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M M4TE:13H@,3!P="<^/&9O;G0@6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<@86QI M9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^ M)B,Q-C`[/"]F;VYT/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[ M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0G M(&%L:6=N/3-$8V5N=&5R/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$58 M5"U!3$E'3CIC96YT97([(%1%6%0M24Y$14Y4.B`P:6X[(%=)1%1(.B`Q,#`E M)R!A;&EG;CTS1&-E;G1E6QE/3-$)TU!4D=)3CH@,'!X M.F%U=&\[(%=)1%1(.B`V-24[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N M;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-4 M64Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U3 M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=( M5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXQ,38L,S0U/"]D:78^(#PO=&0^ M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N M;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/ M4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L M969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%, M24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4 M.B`U<'@[($9/3E0M1D%-24Q9.B!4:6UE"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@] M,T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT M.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C M8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!" M3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P M,"<@=VED=&@],T0Q,B4^(#QD:78^,S8Q+#6QE/3-$ M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4 M+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1J=7-T M:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F M;VYT/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%- M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P M:6X@,&EN(#!P="<^(#QF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^ M4F5N="!E>'!E;G-E(&EN(#(P,3,@86YD(#(P,3(@87!P6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N M)RPG6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<^(#QF;VYT('-T>6QE/3-$)T9/ M3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/CPO9&EV/B`\9&EV('-T>6QE M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<^(#QS=')O;F<^ M/'4^/&9O;G0@6QE M/3-$)T9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/CPO9&EV/B`\9&EV M('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<@86QI M9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^ M)B,Q-C`[/"]F;VYT/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[ M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[ M34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T M>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^3VX@075G=7-T(#$X+"`R,#`V+"!2 M96-E<'1O4&AA2!N;W1E2!W2!B92!C;VYV97)T:6)L92!I M;G1O(&]U2!E>&-E960@)#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)RPG2!D=71Y+"!C;VYV97)S:6]N(&%N9"!U;FIU M2!N M;W1E2!G2!J=61G;65N="X@ M5V4@:6YT96YD('1O('9I9V]R;W5S;'D@8V]N=&5S="!T:&ES(&UA='1E3X\ M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X\ M+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4 M:6UE3X\9F]N="!S='EL93TS1"=&3TY4+5-) M6D4Z(#$P<'0G/DUR+B!$96ET2!F;W(@37(N($1E:71S M8V@I+B!-6UE;G0N($%T($1E8V5M8F5R(#,Q+"`R,#$Q M+"!.=71R82!0:&%R;6$@0V]R<"X@:&%D(&UA9&4@=&]T86P@<&%Y;65N=',@ M;V8@)#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)RPG2!W92!W;W5L9"!P87D@8F]T M:"!T:&4@1&5C96UB97(@86YD($IA;G5A6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)RPG6UE;G0@6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)RPG3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z M(#$P<'0G/B8C,38P.SPO9F]N=#X\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5! M4CIB;W1H.R!&3TY4+49!34E,63I4:6UE3X\ M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/D]N($IU;F4@,3$L(#(P M,3(L($Q04B!S;VQD('1H96ER(&1E8G0@=&\@4V]U=&AR:61G92!087)T;F5R M2!N96=O=&EA M=&EN9R!A('-E='1L96UE;G0@=VET:"!,4%(N(%5P;VX@=&AE('-E='1L96UE M;G0@;V8@=&AE(&]U='-T86YD:6YG(&1E8G0L($Q04B!W:6QL(')E='5R;B!T M:&4@8V]L;&%T97)A;"!S:&%R97,@=&\@=&AE($-O;7!A;GDN/"]F;VYT/CPO M9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN M(#!P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE: M13H@,3!P="<^)B,Q-C`[/"]F;VYT/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-, M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1J=7-T:69Y M/CQU/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^26YV;VQU;G1A M3PO9F]N=#X\+W4^/&9O;G0@2!S971T;&5D('1H92!!9W)E M96UE;G0@=VET:"!T:&4@4&5T:71I;VYE6QE M/3-$)TQ)3D4M2$5)1TA4.B`Q,34E.R!&3TY4+49!34E,63H@)U1I;65S($YE M=R!2;VUA;B6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P M="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@ M,3!P="<^/&9O;G0@6QE/3-$)T9/3E0M4TE: M13H@,3!P="<^)B,Q-C`[/"]F;VYT/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-, M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1J=7-T:69Y M/CQU/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^3&%U3X\9F]N="!S='EL93TS1"=& M3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X\+V1I=CX@/&1I=B!S='EL M93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/D]N($1E M8V5M8F5R(#,P+"`R,#$Q($QA=7)E;F-E($XN(%)A>6UO;F0@*")287EM;VYD M(BD@8G)O=6=H="!T:&4@8V%S92!A9V%I;G-T(%)E8V5P=&]P:&%R;2P@26YC M+B`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`R,#$Q M(%!A=6P@1BX@4F5I9"`H(E)E:60B*2!B2`D/&9O M;G0@2!A8W1I;VXN(%1H92!S971T;&5M96YT M(&%G6UE;G1S+"!P=7)S M=6%N="!T;R!A(&-O;F9I9&5N=&EA;"!S971T;&5M96YT(&%G6QE/3-$ M)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF:7AE9#LG(&-E;&QS<&%C:6YG M/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT9#X\+W1D/CPO='(^/"]T86)L M93X\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO#L@1D].5#H@,3!P="!4:6UE M6QE/3-$)T-,14%2.F)O M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA M;BP@5&EM97,L(%-E6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E3Y);B!*86YU87)Y(#(P,30L M('1H92!#;VUP86YY('-O;&0@/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)RPG3XF(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS1"=# M3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%2 M1TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM M97,L(%-E3Y/;B!*86YU87)Y(#$W+"`R,#$T+"!T:&4@0V]M<&%N>2!I3XF(S$V,#L\+V1I M=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE M#L@ M1D].5#H@,3!P="!4:6UE3XF(S$V,#L\+V1I=CX@ M/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE#L@1D]. M5#H@,3!P="!4:6UE2!C;VYV97)T960@=&AE("0\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@)U1I;65S($YE=R!2;VUA;B6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG M6QE/3-$)T-,14%2.F)O M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA M;BP@5&EM97,L(%-E3Y&;VQL;W=I;F<@=&AE(&%G2!%;G1E6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG28C.#(Q-SMS(')E6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T-,14%2.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0G/B`F(S$V M,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E, M63I4:6UE#L@1D].5#H@,3!P="!4:6UE3XF(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB M;W1H.R!&3TY4+49!34E,63I4:6UE#L@1D].5#H@,3!P="!4:6UE6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG3XF(S$V,#L\+V1I M=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE M#L@ M1D].5#H@,3!P="!4:6UE3XF(S$V,#L\+V1I=CX@/&9O;G0@ M&5D.R<@8V5L M;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T M7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T* M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4 M:6UE6QE/3-$ M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4 M+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<^(#QI/CQF;VYT('-T M>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^0F%S:7,@;V8@4')E3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B8C,38P M.SPO9F]N=#X\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4 M+49!34E,63I4:6UE3X\9F]N="!S='EL93TS M1"=&3TY4+5-)6D4Z(#$P<'0G/E1H92!A8V-O;7!A;GEI;F<@8V]N2`B=&AE($-O;7!A;GDB+"`F(S@R,C`[=7,F(S@R M,C$[+"`F(S@R,C`[=V4F(S@R,C$[(&]R("8C.#(R,#MO=7(F(S@R,C$[*2X@ M5V4@;W!E6QE/3-$)W=I9'1H.C$P,"4[('1A M8FQE+6QA>6]U=#IF:7AE9#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN M9STS1#`^/'1R/CQT9#X\+W1D/CPO='(^/"]T86)L93X\2!$ M:7-C;&]S=7)E(%M0;VQI8WD@5&5X="!";&]C:UT\+W1D/@T*("`@("`@("`\ M=&0@8VQA6QE/3-$)TU!4D=)3CH@,'!T(#!P M>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P M="<^(#QI/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^3&EQ=6ED M:71Y(&%N9"!';VEN9R!#;VYC97)N/"]F;VYT/CPO:3X\+V1I=CX@/&1I=B!S M='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z M(#$P<'0G/D]U'!E6QE/3-$)T9/ M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$9F]N M="US:7IE.C$P<'0[/CPO9F]N=#YA="!$96-E;6)E6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P M="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@ M,3!P="<^/"]F;VYT/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^ M)B,Q-C`[/"]F;VYT/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[ M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[ M34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T M>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^5&AE6QE/3-$)T-,14%2.F)O M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0[34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/CPO9&EV M/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`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`P M:6X@,&EN(#!P="<@86QI9VX],T1J=7-T:69Y/CQI/CQF;VYT('-T>6QE/3-$ M)T9/3E0M4TE:13H@,3!P="<^57-E(&]F($5S=&EM871E2!O9B!I;G9E;G1O6QE/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA M>6]U=#IF:7AE9#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^ M/'1R/CQT9#X\+W1D/CPO='(^/"]T86)L93X\2!;4&]L:6-Y(%1E>'0@0FQO8VM=/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#XG/&1I=B!S='EL93TS1"=-05)'24XZ(#!P="`P M<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE3X\:3X\9F]N="!S='EL93TS1"=&3TY4+5-) M6D4Z(#$P<'0G/E)E=F5N=64@4F5C;V=N:71I;VX\+V9O;G0^/"]I/CPO9&EV M/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P M="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@ M,3!P="<^)B,Q-C`[/"]F;VYT/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1J=7-T:69Y/CQF M;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^26X@9V5N97)A;"P@=V4@ M&5D(&]R(&1E=&5R;6EN M86)L92P@86YD(&-O;&QE8W1A8FEL:71Y(&ES(')E87-O;F%B;'D@87-S=7)E M9"X@4')O=FES:6]N(&9O6QE/3-$)TU!4D=)3CH@,'!T(#!P M>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P M="<@86QI9VX],T1J=7-T:69Y/CQI/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE: M13H@,3!P="<^06-C;W5N=&EN9R!F;W(@4VAI<'!I;F<@86YD($AA;F1L:6YG M($-O3X\9F]N M="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X\+V1I M=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE M3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z M(#$P<'0G/E1H92!#;VUP86YY(')E8V]R9',@2!497AT($)L M;V-K73PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQD:78@3X\ M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X\ M+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4 M:6UE3X\9F]N="!S='EL93TS1"=&3TY4+5-) M6D4Z(#$P<'0G/E=E(&-O;G-I9&5R(&%L;"!H:6=H;'D@;&EQ=6ED(&EN=F5S M=&UE;G1S('=I=&@@86X@;W)I9VEN86P@;6%T=7)I='D@;V8@=&AR964@;6]N M=&AS(&]R(&QE6QE/3-$)W=I9'1H.C$P M,"4[('1A8FQE+6QA>6]U=#IF:7AE9#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL M<&%D9&EN9STS1#`^/'1R/CQT9#X\+W1D/CPO='(^/"]T86)L93X\2!497AT($)L;V-K73PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M)SQD:78@3X\9F]N="!S M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X\+V1I=CX@ M/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P M<'0G/E1H92!#;VUP86YY(&=R86YT'!E;G-E+B!4:&4@0V]M<&%N>2!G96YE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN M(#!P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE: M13H@,3!P="<^)B,Q-C`[/"]F;VYT/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-, M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1J=7-T:69Y M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^06-C;W5N=',@2!;4&]L:6-Y(%1E>'0@0FQO8VM=/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=B!S='EL93TS1"=-05)'24XZ M(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/DEN M=F5N=&]R:65S+"!W:&EC:"!A2!R96=U;&%R;'D@65A&5D.R<@ M8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D/CPO=&0^ M/"]T6QE/3-$)TU!4D=)3CH@,'!T(#!P M>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P M="<^(#QI/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^1FEN86YC M:6%L($EN3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/D]U7!E('1R86YS86-T:6]N6EN9R!V86QU97,@;V8@;W5R(&9I;F%N8VEA M;"!I;G-T6%B M;&4@;VX@9&5M86YD+B!/=7(@9&5R:79A=&EV92!F:6YA;F-I86P@:6YS=')U M;65N=',@87)E(&-A3X\9F]N="!S M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/D)A;&%N8V5S(&EN('9A2!I M;G-U2X@1F]R('1H M92!Y96%R(&5N9&5D($1E8V5M8F5R(#,Q+"`R,#$R+"`\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B2!P=7)C:&%S960@,3`P)2!O M9B!I=',@=F5N;VT@9G)O;2!O;F4@=F5N9&]R/"]F;VYT/BX\+V9O;G0^/"]D M:78^(#PO9&EV/CQT86)L92!B;W)D97(],T0P('-T>6QE/3-$)W=I9'1H.C$P M,"4[('1A8FQE+6QA>6]U=#IF:7AE9#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL M<&%D9&EN9STS1#`^/'1R/CQT9#X\+W1D/CPO='(^/"]T86)L93X\2!;4&]L:6-Y(%1E>'0@0FQO8VM= M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=B!S='EL93TS M1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE3X\:3X\9F]N="!S M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/D1E3X\:3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B`F(S$V,#L\ M+V9O;G0^/"]I/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%2 M1TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE M/3-$)T9/3E0M4TE:13H@,3!P="<^5&AE($-O;7!A;GD@9&]E2!R96-O2!U M2!U2P@:7,@2P@4&QA;G0@86YD($5Q=6EP;65N="P@4&]L:6-Y(%M0;VQI8WD@5&5X="!" M;&]C:UT\+W1D/@T*("`@("`@("`\=&0@8VQA6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0[34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1J=7-T:69Y/CQI/CQF M;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^4')O<&5R='D@86YD($5Q M=6EP;65N="!A;F0@3&]N9RU,:79E9"!!6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P M="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@ M,3!P="<^)B,Q-C`[/"]F;VYT/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1J=7-T:69Y/CQF M;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^4')O<&5R='D@86YD(&5Q M=6EP;65N="!I'!E;F1I='5R97,@9F]R M(&UA:F]R(&EM<')O=F5M96YT2!A;F0@97%U:7!M96YT+"!W:&EL92!R97!L86-E;65N=',L M(&UA:6YT96YA;F-E(&%N9"!R97!A:7)S('=H:6-H(&1O(&YO="!E>'1E;F0@ M=&AE('5S969U;"!L:79E6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N M)RPG65A3X\9F]N="!S M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X\+V1I=CX@ M/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG3X\9F]N="!S='EL93TS1"=& M3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X\+V1I=CX@/&1I=B!S='EL M93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE6QE M/3-$)U1%6%0M04Q)1TXZ(&-E;G1E"!S;VQI9#L@1D]. M5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^ M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^ M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C M96YT97([($9/3E0M4U193$4Z(&YO6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W M:61T:#TS1#$P)3X@/&1I=CXR,2PY,3@\+V1I=CX@/"]T9#X@/'1D('-T>6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO'1U6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q% M.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I% M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@ M-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXS-"PW-3<\+V1I=CX@/"]T9#X@/'1D M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[ M(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!6 M15)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T M:#TS1#$P)3X@/&1I=CXT,BPQ,CD\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4 M+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D]. M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=% M24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXR+#8R.3PO9&EV/B`\+W1D M/B`\=&0@6QE M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!! M1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)4 M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS M1#$P)3X@/&1I=CXR+#8R.3PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ M(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-4 M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU" M3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@ M1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU" M3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!& M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/ M4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R M:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[ M($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED M=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$ M)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1) M3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@ M0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-! M3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI M9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^,3@Q+#(W M,3PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ M(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-4 M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU" M3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@ M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9% M4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H M/3-$,3`E/B`\9&EV/B@Q-#$L-S4V*3PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S M;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q M-C`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`Q,'!T.R!615)424-!3"U!3$E' M3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I M=CXR-"PU,S0\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%# M2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U! M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@ M/&1I=CXS.2PU,34\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@ M,&EN(#!P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/CPO9&EV/B`\9&EV('-T>6QE/3-$ M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4 M+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1J=7-T M:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^5V4@2!B92!I;7!A:7)E9"X@070@1&5C96UB97(@,S$L(#(P M,3,L('=E(&)E;&EE=F4@=&AE(&-A6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)RPG2X\+V9O;G0^/"]D:78^(#PO9&EV M/CQT86)L92!B;W)D97(],T0P('-T>6QE/3-$)W=I9'1H.C$P,"4[('1A8FQE M+6QA>6]U=#IF:7AE9#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS M1#`^/'1R/CQT9#X\+W1D/CPO='(^/"]T86)L93X\2P@17AP96YS960@061V97)T:7-I;F<@0V]S="!;4&]L:6-Y M(%1E>'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG M/&1I=B!S='EL93TS1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM M97,@3F5W(%)O;6%N+"!4:6UE3X\:3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B!!9'9E3X\9F]N="!S='EL93TS1"=&3TY4 M+5-)6D4Z(#$P<'0G/D%L;"!A9'9E2`D/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)RPG&5D.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X\='(^ M/'1D/CPO=&0^/"]T"P@4&]L:6-Y(%M0 M;VQI8WD@5&5X="!";&]C:UT\+W1D/@T*("`@("`@("`\=&0@8VQA6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P M="!4:6UE6QE M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<^(#QI/CQF;VYT M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^26YC;VUE(%1A>&5S/"]F;VYT M/CPO:3X\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49! M34E,63I4:6UE3X\9F]N="!S='EL93TS1"=& M3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X\+V1I=CX@/&1I=B!S='EL M93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/E=E(&-O M;7!U=&4@:6YC;VUE('1A>&5S(&EN(&%C8V]R9&%N8V4@=VET:"!&:6YA;F-I M86P@06-C;W5N=&EN9R!3=&%N9&%R9"!";V%R9"`H)B,X,C(P.T9!4T(F(S@R M,C$[*2!!8V-O=6YT:6YG(%-T86YD87)D($-O9&EF:6-A=&EO;B`H)B,X,C(P M.T%30R8C.#(R,3LI(%1O<&EC(#&5S/"]I/B`H M)B,X,C(P.T%30R!4;W!I8R`W-#`F(S@R,C$[*2X@56YD97(@05-#(%1O<&EC M(#2!D:69F97)E;F-E2!A M<'!L>6EN9R!E;F%C=&5D('-T871U=&]R>2!R871E2!F6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P M="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@ M,3!P="<^)B,Q-C`[/"]F;VYT/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1J=7-T:69Y/CQF M;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^3VX@86X@86YN=6%L(&)A M'!E8W1E9"!T;R!B92!T86ME;B!I;B!O=7(@=&%X M(')E='5R;G,@=&\@9&5T97)M:6YE(&EF('1H97D@87)E(&UO2!L:6%B:6QI=&EE"!P;W-I=&EO;G,@;W(@<')O=FES:6]N6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%- M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P M:6X@,&EN(#!P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/ M3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/CPO9&EV/B`\9&EV('-T>6QE M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1J M=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^4VEN8V4@ M:6YC97!T:6]N+"!W92!H879E(&)E96X@"!A=61I=',@:6X@=&AE(&IU6QE/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF:7AE9#LG M(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT9#X\+W1D M/CPO='(^/"]T86)L93X\6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0[34%21TE..B`P:6X@,&EN(#!P="<^(#QI/CQF;VYT('-T>6QE/3-$)T9/ M3E0M4TE:13H@,3!P="<^4W1O8VLM0F%S960@0V]M<&5N6UE;G0@87)R86YG96UE;G1S(&%N M9"!R97%U:7)E6UE;G0@=')A;G-A8W1I;VYS('=I=&@@96UP;&]Y965S+B!4:&4@ M65E6QE/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF:7AE9#LG(&-E;&QS M<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT9#X\+W1D/CPO='(^ M/"]T86)L93X\6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE M6QE/3-$)T-, M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[34%21TE..B`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`P,#`@,7!X('-O;&ED.R!415A4 M+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5)) M1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!4:6UE#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q M,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P M)R!W:61T:#TS1#$S)2!C;VQS<&%N/3-$,CX@/&1I=CXT-"PV-#(L.#4X/"]D M:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D]. M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1) M0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$ M,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[ M($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5. M1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@ M;6ED9&QE.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U7 M14E'2%0Z(#0P,"<@=VED=&@],T0Q,R4@8V]L6QE/3-$)U1%6%0M04Q)1TXZ M(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE M6QE M/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF:7AE9#LG(&-E;&QS<&%C M:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT9#X\+W1D/CPO='(^/"]T M86)L93X\2!;4&]L:6-Y(%1E>'0@ M0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=B!S M='EL93TS1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W M(%)O;6%N+"!4:6UE3X\9F]N="!S='EL93TS1"=&3TY4+5-) M6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X\+V1I=CX@/&1I=B!S='EL93TS1"=# M3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/D-E6QE M/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[ M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[ M34%21TE..B`P:6X@,&EN(#!P="<^(#QI/CQF;VYT('-T>6QE/3-$)T9/3E0M M4TE:13H@,3!P="<^4F5C96YT($%C8V]U;G1I;F<@4')O;F]U;F-E;65N=',\ M+V9O;G0^/"]I/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%2 M1TE..B`P:6X@,&EN(#!P="<^(#QF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@ M,3!P="<^)B,Q-C`[/"]F;VYT/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-E3X-"CPO:'1M;#X-"@T*+2TM+2TM/5]. M97AT4&%R=%]C-&(V86-F,%]E,&$S7S0X.#)?839E8U\W.#!F,S$Q,3!A93,- M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8S1B-F%C9C!?93!A,U\T M.#@R7V$V96-?-S@P9C,Q,3$P864S+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R2!/9B!3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O M;&EC:65S(%M!8G-T'0^)SQD:78@2!A;F0@97%U:7!M M96YT(&-O;G-I6QE/3-$)T-,14%2.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE. M.B`P:6X@,&EN(#!P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$ M)T9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/CPO9&EV/B`\9&EV('-T M>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA M;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U!3$E'3CI,969T.R!415A4+4E.1$5. M5#H@,&EN.R!724142#H@,3`P)2<^(#QT86)L92!S='EL93TS1"=-05)'24XZ M(#!I;CL@5TE$5$@Z(#$P,"4[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%, M24=..B!C96YT97([($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@ M/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q) M1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@ M=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE M/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ M(&-E;G1E6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q) M1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5. M1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@ M8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXT M,BPQ,CD\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ M(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@ M(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T M=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXQ,BPT M,C$\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!& M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXV-RPT,3<\+V1I M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@ M(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T M=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXV-RPT M,3<\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@ M=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!! M1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)4 M24-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S M;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^,3@Q M+#(W,3PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M"!S;VQI9#L@5$585"U!3$E'3CH@ M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G M('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U! M3$E'3CH@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z M(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT M9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$58 M5"U!3$E'3CH@6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@ M5$585"U!3$E'3CH@&-L=61E9"!F6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D]. M5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<@86QI M9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^ M07,@;V8@1&5C96UB97(@,S$L(#(P,3,@86YD(#(P,3(L('1H92!F;VQL;W=I M;F<@:71E;7,@=V5R92!N;W0@:6YC;'5D960@:6X@9&EL=71I=F4@;&]S6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<@ M86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P M="<^)B,Q-C`[/"]F;VYT/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0[5$585"U!3$E'3CI,969T.R!415A4+4E.1$5.5#H@,&EN.R!724142#H@ M,3`P)2<^(#QT86)L92!S='EL93TS1"=-05)'24XZ(#!I;CL@5TE$5$@Z(#DP M)3L@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S93L@3U9%4D9,3U6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O M;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT M.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C M8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!" M3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P M,"<@=VED=&@],T0Q,R4@8V]L6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!& M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1% M6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%# M2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U! M3$E'3CH@;6ED9&QE.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@ M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,R4@8V]L6%B;&4\+V1I=CX@/"]T M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D]. M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=% M24=(5#H@-#`P)R!W:61T:#TS1#$S)2!C;VQS<&%N/3-$,CX@/&1I=CXY."PU M,#8L,SDX/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R M:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G M('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U! M3$E'3CH@6QE M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/ M3E0M1D%-24Q9.B!4:6UE"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N M;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q M,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!"3U)$15(M5$]0.B`C,#`P M,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,R4@ M8V]L6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P M,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@6QE/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF M:7AE9#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT M9#X\+W1D/CPO='(^/"]T86)L93X\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA6QE/3-$)TU!4D=)3CH@,'!T M(#!P>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN M(#!P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE: M13H@,3!P="<^5&AE(&9O;&QO=VEN9R!T86)L92!S=6UM87)I>F5S(&]U6QE/3-$)TU!4D=)3CH@,&EN.R!724142#H@,3`P)3L@0D]21$52+4-/ M3$Q!4%-%.B!C;VQL87!S93L@3U9%4D9,3U6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`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`\+W1D/B`\=&0@6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT M.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!& M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXW-C6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[ M(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!6 M15)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T M:#TS1#$R)3X@/&1I=CXM/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4 M+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9 M.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!& M3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@ M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4 M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXM/"]D:78^(#PO=&0^ M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N M;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1% M6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%# M2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U! M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@ M/&1I=CXW-C6QE/3-$)TU! M4D=)3CH@,&EN.R!724142#H@,3`P)3L@0D]21$52+4-/3$Q!4%-%.B!C;VQL M87!S93L@3U9%4D9,3U6QE/3-$)U1% M6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T)/ M4D1%4BU"3U143TTZ(",P,#`P,#`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`\+W1D/B`\ M=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-4 M64Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U3 M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=( M5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXM/"]D:78^(#PO=&0^(#QT9"!S M='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[ M($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q) M1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5. M1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@ M8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXM M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!& M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W M:61T:#TS1#$R)3X@/&1I=CXQ."PW,C<\+V1I=CX@/"]T9#X@/'1D('-T>6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4 M:6UE6QE/3-$ M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4 M+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<^(#QF;VYT('-T>6QE M/3-$)T9/3E0M4TE:13H@,3!P="<^5&AE(&9O;&QO=VEN9R!T86)L92!S:&]W M"!S;VQI M9#L@34%21TE..B`P:6X@,&EN(#!I;B`P+C"!S;VQI9#L@0D]21$52+5))1TA4.B`C M.65B-F-E(#!P>"!S;VQI9"<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG M/3-$,"!A;&EG;CTS1&QE9G0^(#QT6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU" M3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([ M($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&-E M;G1E6QE/3-$)U1%6%0M M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q) M1TXZ(&-E;G1E6QE M/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=2 M3U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E' M3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I M=CXQ."PW,C<\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO2!O;F4@;&]S6)R:60@:6YS=')U M;65N=#PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-4 M64Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@0T],3U(Z M(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI M9&1L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^-S(Y M+#`Y,SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-4 M64Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@0T],3U(Z M(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI M9&1L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^+3PO M9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@ M;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/ M54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=. M.B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^ M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]- M.B`C,#`P,#`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`Q,'!T M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W M:61T:#TS1#$P)3X@/&1I=CXS,C,L,36QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@ M,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R M;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$ M.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B M;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)#PO M9&EV/B`\+W1D/B`\=&0@6QE/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF:7AE9#LG(&-E;&QS M<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT9#X\+W1D/CPO='(^ M/"]T86)L93X\'0^)SQD:78@6)R:60@:6YS=')U;65N="!I#IA=71O.R!724142#H@.3@E.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA M<'-E.R!/5D521DQ/5SH@=FES:6)L92<@8V5L;'-P86-I;F<],T0P(&-E;&QP M861D:6YG/3-$,"!A;&EG;CTS1&-E;G1E6QE/3-$)U1% M6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E M6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P M,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z M(&YO&5D M)B,Q-C`[4')I8V4\8G(O/B!O6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E M6QE/3-$)U1% M6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E M;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E M6QE M/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@ M,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO M6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%, M24=..B!C96YT97([($9/3E0M4U193$4Z(&YO"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-4 M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ M(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@ M(V-C9F9C8SL@1D].5"U325I%.B`X<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T M;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=( M5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXU-C0L,S6QE/3-$)U1%6%0M04Q) M1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q-B4^(#QD M:78^)#`N,#`S-BTD,"XP,#8T/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4 M15A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M M04Q)1TXZ(&-E;G1E7,\+V1I=CX@/"]T9#X@/'1D('-T M>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$ M)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E7,\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q) M1TXZ(&-E;G1E6QE/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF:7AE9#LG(&-E;&QS M<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT9#X\+W1D/CPO='(^ M/"]T86)L93X\6QE/3-$)TU!4D=)3CH@ M,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@ M,&EN(#!P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M M4TE:13H@,3!P="<^5&AE(&9O;&QO=VEN9R!T86)L92!S:&]W6QE M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1J M=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)B,Q-C`[ M/"]F;VYT/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0G(&%L:6=N M/3-$8V5N=&5R/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%- M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U!3$E' M3CIC96YT97([(%1%6%0M24Y$14Y4.B`P:6X[(%=)1%1(.B`Q,#`E)R!A;&EG M;CTS1&-E;G1E6QE/3-$)T)/4D1%4BU"3U143TTZ(",Y M96(V8V4@,'!X('-O;&ED.R!"3U)$15(M3$5&5#H@(SEE8C9C92`P<'@@"!S;VQI9#L@0D]21$52+5))1TA4.B`C.65B-F-E(#!P M>"!S;VQI9"<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!A;&EG M;CTS1&-E;G1E"!S;VQI9#L@1D].5"U714E'2%0Z(#6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/ M3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#

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`P,#`[($9/3E0M4TE: M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z M(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^-S4Q+#0Q.3PO9&EV/B`\+W1D/B`\ M=&0@6QE/3-$ M)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1) M3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@ M0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-! M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P M)3X@/&1I=CXY,#(L,S8Y/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4 M+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9 M.B!4:6UE2!O;F4@;&]S6)R:60@:6YS M=')U;65N=#PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4 M+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T], M3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ M(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^ M,2PV-38L.#`R/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=. M.B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE M6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO6QE/3-$)U1%6%0M M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9 M.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$ M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=. M.B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE M6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4 M+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4 M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5) M1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/B@Q+#,Q,"PR-#,I/"]D:78^ M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-4 M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$ M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E' M3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P M,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E M/B`\9&EV/B0\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@"!S;VQI9#L@1D]. M5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^-S8W+#`U-SPO9&EV M/B`\+W1D/B`\=&0@"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P M,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q% M.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I% M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C M,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q M,"4^(#QD:78^-3@X+#`Y,3PO9&EV/B`\+W1D/B`\=&0@&5D.R<@8V5L;'-P M86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\ M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA6QE/3-$)TU!4D=)3CH@,'!T(#!P M>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P M="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@ M,3!P="<^070@1&5C96UB97(@,S$L(#(P,3,@86YD($1E8V5M8F5R(#,Q+"`R M,#$R+"!T:&4@8F%L86YC92!D=64@=&\@;V9F:6-E6QE/3-$)T-, M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1J=7-T:69Y M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT M/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U!3$E'3CI, M969T.R!415A4+4E.1$5.5#H@,&EN.R!724142#H@,3`P)2<^(#QT86)L92!S M='EL93TS1"=-05)'24XZ(#!I;CL@5TE$5$@Z(#$P,"4[($)/4D1%4BU#3TQ, M05!313H@8V]L;&%P6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P M,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z M(&YO6QE/3-$ M)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I M9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C M9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXU-C8L,SDY M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!& M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W M:61T:#TS1#$P)3X@/&1I=CXV,#8L,38X/"]D:78^(#PO=&0^(#QT9"!S='EL M93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/ M3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9 M.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R M;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$ M.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B M;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q M-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C M,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@ M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4 M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXQ,36QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI M9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[ M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!& M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@ M5$585"U!3$E'3CH@6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)4 M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS M1#$P)3X@/&1I=CXW,C,L,S@V/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4 M15A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%- M24Q9.B!4:6UE6QE/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF:7AE9#LG M(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT9#X\+W1D M/CPO='(^/"]T86)L93X\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N M/CPO'0^)SQD:78@6QE/3-$)V-L96%R.F)O=&@[34%21TE..B`P:6X[ M(%=)1%1(.B`Q,#`E.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E.R!/5D52 M1DQ/5SH@=FES:6)L92<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$ M,"!A;&EG;CTS1&QE9G0^(#QT6QE/3-$)U1%6%0M04Q)1TXZ M(&-E;G1E6QE/3-$)T)/4D1%4BU"3U143TTZ M(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ M(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E M;G1E6QE/3-$)U1% M6%0M04Q)1TXZ(&-E;G1E2`H,2D\ M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)U1%6%0M M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=2 M3U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E' M3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I M=CXU.3,L-#@S/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=. M.B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE M6%B;&4L(&%T(&9A:7(@=F%L=64@ M*#,I/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$ M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=. M.B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE M6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4 M+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5)) M1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO"!S;VQI9#L@1D]. M5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@ M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-4 M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ M(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U3 M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!" M04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%, M+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^ M(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T)/4D1%4BU" M3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@ M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9% M4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H M/3-$,24^(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T)/4D1%4BU"3U143TTZ("-D-&0P8S@[($)/4D1%4BU, M1494.B`C9#1D,&,X.R!0041$24Y'+4)/5%1/33H@,&EN.R!"04-+1U)/54Y$ M+4-/3$]2.B!T6QE/3-$)T9/ M3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/CPO9&EV/B`\+W1D/B`\=&0@ M6QE/3-$)T-,14%2.F)O M=&@[34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@6QE M/3-$)T-,14%2.F)O=&@[34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1J M=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^1'5R:6YG M('1H92!T:&ER9"!Q=6%R=&5R(&]F(#(P,3`@=V4@8F]R6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG65A6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z("TP+C(U:6X[ M($U!4D=)3CH@,&EN(#!I;B`P<'0@,"XU:6XG(&%L:6=N/3-$:G5S=&EF>3X\ M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X\ M+V1I=CX@/'1A8FQE('-T>6QE/3-$)V-L96%R.F)O=&@[5TE$5$@Z(#$P,"4[ M($9/3E0M4TE:13H@,3!P="<@8F]R9&5R/3-$,"!C96QL6QE/3-$)T-,14%2.F)O=&@[34%2 M1TE..B`P:6X@,&EN(#!P="<^/&9O;G0@6QE/3-$)T)/4D1%4BU" M3U143TTZ("-D-&0P8S@[($)/4D1%4BU,1494.B`C9#1D,&,X.R!0041$24Y' M+4)/5%1/33H@,&EN.R!"04-+1U)/54Y$+4-/3$]2.B!T6QE/3-$)T-,14%2.F)O=&@[34%2 M1TE..B`P:6X@,&EN(#!P="<^/&9O;G0@F4Z(#$P<'0[ M)SXF(S$X,SL\+V9O;G0^/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$ M15(M0D]45$]-.B`C9#1D,&,X.R!"3U)$15(M3$5&5#H@(V0T9#!C.#L@4$%$ M1$E.1RU"3U143TTZ(#!I;CL@0D%#2T=23U5.1"U#3TQ/4CH@=')A;G-P87)E M;G0[(%!!1$1)3D6QE/3-$)T-, M14%2.F)O=&@[34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1J=7-T:69Y M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^26X@36%Y(#(P,3$L M('1H92!#;VUP86YY(')E8V5I=F5D(&$@;&]A;B!F;W(@)#QF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N M)RPG2!A;B!O9F9I8V5R(&]F('1H92!#;VUP86YY+B!/;B!.;W9E M;6)E6QE/3-$)T-,14%2.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%2 M1TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE M/3-$)T9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/CPO9&EV/B`\=&%B M;&4@6QE/3-$)T-,14%2.F)O=&@[34%21TE..B`P:6X@,&EN M(#!P="<^/&9O;G0@F4Z(#$P<'0[)SXF(S$X,SL\+V9O M;G0^/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C M9#1D,&,X.R!"3U)$15(M3$5&5#H@(V0T9#!C.#L@4$%$1$E.1RU"3U143TTZ M(#!I;CL@0D%#2T=23U5.1"U#3TQ/4CH@=')A;G-P87)E;G0[(%!!1$1)3D6QE/3-$)T-,14%2.F)O=&@[34%2 M1TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE M/3-$)T9/3E0M4TE:13H@,3!P="<^26X@36%Y(#(P,3$L('1H92!#;VUP86YY M(')E8V5I=F5D(&%N;W1H97(@;&]A;B!F;W(@)#QF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG2!A;B!O9F9I8V5R(&]F('1H92!#;VUP86YY+B!/;B!397!T96UB97(@ M,38L(#(P,3,L('1H92!N;VXM2!A8V-E<'1E9"!A('1O M=&%L(&]F(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)RPG28C.#(Q-SMS(')E6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%- M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1% M3E0Z("TP+C(U:6X[($U!4D=)3CH@,&EN(#!I;B`P<'0@-C-P="<@86QI9VX] M,T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)V9O;G0M6QE/3-$)V-L96%R.F)O=&@[ M5TE$5$@Z(#$P,"4[($9/3E0M4TE:13H@,3!P="<@8F]R9&5R/3-$,"!C96QL M6QE/3-$)T9/ M3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/CPO9&EV/B`\+W1D/B`\=&0@ M6QE/3-$)T-,14%2.F)O M=&@[34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/DEN M($IU;'D@,C`Q,RP@=&AE($-O;7!A;GD@:7-S=65D(&$@<')O;6ES2!N M;W1E('1O('1H92!-:6-H865L($UC1&]N86QD(%1R=7-T(&EN('1H92!A;6]U M;G0@;V8@)#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)RPG"!M;VYT:',@9G)O;2!T:&4@97AE8W5T:6]N(&%N9"!F M=6YD:6YG(&]F('1H92!N;W1E+B!);B!C;VYN96-T:6]N('=I=&@@=&AE(&ES M2!N;W1E+"!T:&4@0V]M<&%N>2!I M2!A;6]R=&EZ960@;W9E2!W;W5L9"!I6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG3X\9F]N="!S='EL93TS1"=& M3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X\+V1I=CX@/'1A8FQE('-T M>6QE/3-$)V-L96%R.F)O=&@[5TE$5$@Z(#$P,"4[($9/3E0M4TE:13H@,3!P M="<@8F]R9&5R/3-$,"!C96QL6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT M/CPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T-,14%2.F)O=&@[34%21TE..B`P:6X@,&EN(#!P="<^/&9O M;G0@3X\9F]N="!S='EL93TS1"=& M3TY4+5-)6D4Z(#$P<'0G/D%T($1E8V5M8F5R(#,Q+"`R,#$R+"!T:&4@=&]T M86P@86UO=6YT(&]F('1H92!#;VUP86YY)B,X,C$W.W,@9&5B="!A2!R96-O6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F M;VYT/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%- M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P M:6X@,&EN(#!P="`V,W!T)R!A;&EG;CTS1&IU6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG7,@=VET:"!T:&4@;&]W97-T('9O;'5M M92!W96EG:'1E9"!A=F5R86=E('!R:6-E2!P2!M861E('1H92!C;VYV97)S:6]N6EN9R!T:&4@;F]T97,@:6X@9G5L;"!A="!T:&4@9F%I6QE/3-$)T-,14%2.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%2 M1TE..B`P:6X@,&EN(#!P="`V,W!T)R!A;&EG;CTS1&IU3X\9F]N="!S='EL93TS1"=&3TY4+5-) M6D4Z(#$P<'0G/DEN($IU;F4L(#(P,3,L("0\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@)U1I;65S($YE=R!2;VUA;B2!F;W(@82!C;VYS:61E2!W87,@96YT:71L960@=&\@8V]N=F5R="!A;&P@;W(@86YY(&%M M;W5N="!O9B!T:&4@=&AE7,@=VET:"!T:&4@;&]W97-T('9O;'5M92!W96EG:'1E9"!A=F5R86=E M('!R:6-E6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="`V,W!T M)R!A;&EG;CTS1&IU3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/D%S(&$@6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)B,Q-C`[ M/"]F;VYT/CPO9&EV/B`\=&%B;&4@6QE/3-$)T-,14%2.F)O M=&@[34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/D]N(#QF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG2!,4%(@82!T;W1A;"!O9B`D/&9O;G0@6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)RPG2!F;W(@;F]N+7!A>6UE;G0I+CPO9F]N=#X\+V1I M=CX@/"]T9#X@/"]T3X\9F]N="!S='EL93TS M1"=&3TY4+5-)6D4Z(#$P<'0G/E1H92!#;VUP86YY(')E<&%I9"`D/&9O;G0@ M6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N M)RPG6QE/3-$)T9/3E0M4TE:13H@,3!P M="<^)B,Q-C`[/"]F;VYT/CPO9&EV/B`\=&%B;&4@6QE/3-$ M)T-,14%2.F)O=&@[34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@6QE/3-$)T)/4D1%4BU"3U143TTZ("-D-&0P8S@[($)/4D1%4BU,1494.B`C M9#1D,&,X.R!0041$24Y'+4)/5%1/33H@,&EN.R!"04-+1U)/54Y$+4-/3$]2 M.B!T2!#96YT2`D/&9O;G0@2`N/"]F M;VYT/CPO9&EV/B`\+W1D/B`\+W1R/B`\+W1A8FQE/B`\9&EV('-T>6QE/3-$ M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4 M+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z("TP+C(U:6X[($U!4D=)3CH@,&EN M(#!I;B`P<'0@.#%P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$ M)T9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/CPO9&EV/B`\=&%B;&4@ M6QE/3-$)T)/4D1%4BU"3U143TTZ M("-D-&0P8S@[($)/4D1%4BU,1494.B`C9#1D,&,X.R!0041$24Y'+4)/5%1/ M33H@,&EN.R!"04-+1U)/54Y$+4-/3$]2.B!T6QE/3-$)T9/3E0M4TE:13H@,3!P="<^*#,I/"]F;VYT/CPO M9&EV/B`\+W1D/B`\=&0@3X\9F]N="!S='EL93TS1"=& M3TY4+5-)6D4Z(#$P<'0G/D%T($1E8V5M8F5R(#,Q+"`R,#$S(&%N9"`R,#$R M+"!T:&4@8F%L86YC92!O9B`D/&9O;G0@6QE/3-$)T)/4D1%4BU"3U14 M3TTZ("-D-&0P8S@[($)/4D1%4BU,1494.B`C9#1D,&,X.R!0041$24Y'+4)/ M5%1/33H@,&EN.R!"04-+1U)/54Y$+4-/3$]2.B!T6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F M;VYT/CPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T-,14%2.F)O=&@[34%21TE..B`P:6X@,&EN(#!P="<^ M/&9O;G0@3X\9F]N="!S='EL93TS M1"=&3TY4+5-)6D4Z(#$P<'0G/DEN(%-E<'1E;6)E2!B;W)R;W=E9"`D/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG M6UE;G0@;VX@;W(@8F5F;W)E($]C=&]B97(@,2P@,C`Q,BX@/&9O;G0@2!S=&]C:R!A="!A(#$U)2!D:7-C;W5N="!T;R!T M:&4@879E2=S('-T;V-K('1R861E9"!O=F5R('1H92!P3PO9F]N=#XN($%T($1E8V5M M8F5R(#,Q+"`R,#$S(&%N9"`R,#$R+"!T:&4@86-C65A6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N M)RPG6QE M/3-$)T-/3$]2.B`C,S,S,S,S)SXD/&9O;G0@6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/CPO9&EV M/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P M="`P+C5I;B<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M M4TE:13H@,3!P="<^070@1&5C96UB97(@,S$L(#(P,3,L('1H92!R96UA:6YI M;F<@8F%L86YC92!O9B!T:&5S92!T=V\@8V]N=F5R=&EB;&4@;F]T97,@<&%Y M86)L92!O9B`D/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="`P+C5I M;B<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@ M,3!P="<^)B,Q-C`[/"]F;VYT/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="`P+C5I;B<@86QI9VX],T1J=7-T M:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^3VX@07!R:6P@ M,S`L(#(P,3,L('1H92!P87)T:65S(&%M96YD960@=&AE(&YO=&5S('1O(&9U M2!D871E('1O($YO=F5M8F5R(#,L M(#(P,3,N(%1H92!#;VUP86YY(&ES6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG2!D871E6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG2!I6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N M)RPG3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P M<'0G/B8C,38P.SPO9F]N=#X\+V1I=CX@/'1A8FQE('-T>6QE/3-$)V-L96%R M.F)O=&@[5TE$5$@Z(#$P,"4[($9/3E0M4TE:13H@,3!P="<@8F]R9&5R/3-$ M,"!C96QL6QE M/3-$)T-,14%2.F)O=&@[34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@F4Z(#$P<'0[)SXF(S$X,SL\+V9O;G0^/"]D:78^(#PO=&0^ M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C9#1D,&,X.R!"3U)$15(M M3$5&5#H@(V0T9#!C.#L@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D%#2T=23U5. M1"U#3TQ/4CH@=')A;G-P87)E;G0[(%!!1$1)3D6QE/3-$)T-,14%2.F)O=&@[34%21TE..B`P:6X@,&EN(#!P M="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@ M,3!P="<^3VX@36%R8V@@,C(L(#(P,3,L('1H92!#;VUP86YY(&ES28C.#(R,3LI M+B!4:&4@;F]T92!C87)R:65S(&EN=&5R97-T(&%T(#QF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)RPG28C.#(Q-SMS(')E6EN9R!T:&4@;F]T97,@:6X@9G5L;"!W:71H(&$@ M9F%I65A&5R8VES92!P6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P M="`P+C5I;B<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/CPO9&EV/B`\=&%B;&4@6QE/3-$)T)/4D1%4BU"3U143TTZ("-D-&0P M8S@[($)/4D1%4BU,1494.B`C9#1D,&,X.R!0041$24Y'+4)/5%1/33H@,&EN M.R!"04-+1U)/54Y$+4-/3$]2.B!T6QE/3-$)V9O;G0M6QE/3-$)T)/4D1%4BU"3U143TTZ("-D-&0P8S@[ M($)/4D1%4BU,1494.B`C9#1D,&,X.R!0041$24Y'+4)/5%1/33H@,&EN.R!" M04-+1U)/54Y$+4-/3$]2.B!T2!I6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T-,14%2.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%2 M1TE..B`P:6X@,&EN(#!P="`P+C5I;B<@86QI9VX],T1J=7-T:69Y/CQF;VYT M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/CPO9&EV M/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P M="`P+C5I;B<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M M4TE:13H@,3!P="<^26X@8V]N;F5C=&EO;B!W:71H('1H92!I6%B;&4L('1H92!#;VUP86YY M(&5N8V]U;G1E6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG M6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P M="`P+C5I;B<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/CPO9&EV/B`\=&%B;&4@6QE/3-$)T)/4D1%4BU"3U143TTZ("-D-&0P M8S@[($)/4D1%4BU,1494.B`C9#1D,&,X.R!0041$24Y'+4)/5%1/33H@,&EN M.R!"04-+1U)/54Y$+4-/3$]2.B!T6QE/3-$)V9O;G0M6QE/3-$)T)/4D1%4BU"3U143TTZ("-D-&0P8S@[ M($)/4D1%4BU,1494.B`C9#1D,&,X.R!0041$24Y'+4)/5%1/33H@,&EN.R!" M04-+1U)/54Y$+4-/3$]2.B!T6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)RPG28C.#(R,3LI+B!4:&4@;F]T92!C87)R:65S(&EN=&5R97-T(&%T(#QF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG M2UF:79E M('!E28C.#(Q-SMS($-O;6UO M;B!3=&]C:R!F;W(@=&AE('1W96YT>2!T7,@<')E8V5D:6YG M('1H92!C;VYV97)S:6]N(&1A=&4\+V9O;G0^+CPO9F]N=#X\+V1I=CX@/"]T M9#X@/"]T3X\9F]N M="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X\+V1I M=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE M3X\9F]N="!S='EL93TS1"=&3TY4 M+5-)6D4Z(#$P<'0G/DEN(&-O;FYE8W1I;VX@=VET:"!T:&4@:7-S=6%N8V4@ M;V8@=&AI6%B;&4L('1H92!#;VUP86YY M(&5N8V]U;G1E6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG M6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P M="`P+C5I;B<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/CPO9&EV/B`\9&EV('-T>6QE/3-$ M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4 M+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="`P+C5I;B<@86QI9VX] M,T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^26X@ M8V]N;F5C=&EO;B!W:71H('1H92!I6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N M)RPG6QE/3-$)T9/ M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%- M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P M:6X@,&EN(#!P="`P+C5I;B<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE M/3-$)T9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/CPO9&EV/B`\=&%B M;&4@6QE/3-$)T)/4D1%4BU"3U14 M3TTZ("-D-&0P8S@[($)/4D1%4BU,1494.B`C9#1D,&,X.R!0041$24Y'+4)/ M5%1/33H@,&EN.R!"04-+1U)/54Y$+4-/3$]2.B!T6QE/3-$)V9O;G0M6QE/3-$)T)/4D1%4BU"3U143TTZ M("-D-&0P8S@[($)/4D1%4BU,1494.B`C9#1D,&,X.R!0041$24Y'+4)/5%1/ M33H@,&EN.R!"04-+1U)/54Y$+4-/3$]2.B!T28C.#(R,3LI+B!4:&4@;F]T92!C87)R:65S(&EN=&5R M97-T(&%T(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)RPG2!C;VYV97)T960@:6YT;R!S:&%R97,@;V8@6QE/3-$)T9/3E0M1D%-24Q9.B`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`G5&EM97,@3F5W M(%)O;6%N)RPG6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%- M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P M:6X@,&EN(#!P="`P+C5I;B<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE M/3-$)T9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/CPO9&EV/B`\9&EV M('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="`P+C5I M;B<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@ M,3!P="<^26X@8V]N;F5C=&EO;B!W:71H('1H92!I6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)RPG2!U2X\+V9O;G0^/"]D:78^(#QD M:78@6QE/3-$)T)/4D1%4BU"3U143TTZ("-D-&0P M8S@[($)/4D1%4BU,1494.B`C9#1D,&,X.R!0041$24Y'+4)/5%1/33H@,&EN M.R!"04-+1U)/54Y$+4-/3$]2.B!T6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/CPO9&EV M/B`\+W1D/B`\=&0@6QE M/3-$)T-,14%2.F)O=&@[34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@3X\9F]N="!S='EL93TS1"=&3TY4+5-) M6D4Z(#$P<'0G/D]N($]C=&]B97(@-RP@,C`Q,RP@=&AE($-O;7!A;GD@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)RPG2!C;&%S2!A;F0@8VQO2!R96QA=&5D('1O('1H M92!H;W-T+"!T:&4@1&5F875L="!0=70@:7,@:6YD97AE9"!T;R!C97)T86EN M(&5V96YT6%B;&4N/"]F;VYT/CPO9&EV/B`\+W1D/B`\+W1R M/B`\+W1A8FQE/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%- M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P M:6X@,&EN(#!P="`P+C5I;B<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE M/3-$)T9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/CPO9&EV/B`\9&EV M('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="`P+C5I M;B<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@ M,3!P="<^26X@8V]N;F5C=&EO;B!W:71H('1H92!I6QE/3-$)T9/ M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA M;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX] M,T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T-/3$]2.B`C,S,S,S,S.R!&3TY4 M+5-)6D4Z(#$P<'0G/B`F(S$V,#L\+V9O;G0^/"]D:78^(#QT86)L92!S='EL M93TS1"=C;&5A6QE/3-$)T)/4D1%4BU"3U143TTZ M("-D-&0P8S@[($)/4D1%4BU,1494.B`C9#1D,&,X.R!0041$24Y'+4)/5%1/ M33H@,&EN.R!"04-+1U)/54Y$+4-/3$]2.B!T6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT M/CPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T-,14%2.F)O=&@[34%21TE..B`P:6X@,&EN(#!P="<^/&9O M;G0@3X\9F]N="!S='EL93TS1"=& M3TY4+5-)6D4Z(#$P<'0G/D]N($]C=&]B97(@,C6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG2`S,2P@,C`Q,BX\+V9O;G0^/"]D:78^(#PO M=&0^(#PO='(^(#PO=&%B;&4^(#QD:78@2!D871E(&]F(%-E<'1E;6)E3X\9F]N="!S='EL93TS1"=&3TY4+5-) M6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X\+V1I=CX@/&1I=B!S='EL93TS1"=# M3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6%B;&4@:7,@8V]N=F5R=&EB;&4L(&%T('1H92!H;VQD97(F(S@R,3<[2!T:&4@879E6%B;&4@9F]R(&-A2!F6QE/3-$)T-,14%2.F)O=&@[ M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[ M34%21TE..B`P:6X@,&EN(#!P="`P+C5I;B<@86QI9VX],T1J=7-T:69Y/CQF M;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/CPO M9&EV/B`\=&%B;&4@6QE/3-$)T)/ M4D1%4BU"3U143TTZ("-D-&0P8S@[($)/4D1%4BU,1494.B`C9#1D,&,X.R!0 M041$24Y'+4)/5%1/33H@,&EN.R!"04-+1U)/54Y$+4-/3$]2.B!T6QE/3-$)V9O;G0M6QE/3-$)T)/4D1% M4BU"3U143TTZ("-D-&0P8S@[($)/4D1%4BU,1494.B`C9#1D,&,X.R!0041$ M24Y'+4)/5%1/33H@,&EN.R!"04-+1U)/54Y$+4-/3$]2.B!T2`S+"`R,#$R/"]F;VYT/BP@=&AE M($-O;7!A;GD@:7-S=65D(&$@0V]N=F5R=&EB;&4@1&5B96YT=7)E(&EN('1H M92!A;6]U;G0@;V8@)#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)RPG2`Q,RP@,C`Q M,RP@=6YL97-S(&-O;G9E6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)RPG2QP6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@ M,&EN(#!P="`P+C5I;B<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$ M)T9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/CPO9&EV/B`\=&%B;&4@ M6QE/3-$)T)/4D1%4BU"3U143TTZ M("-D-&0P8S@[($)/4D1%4BU,1494.B`C9#1D,&,X.R!0041$24Y'+4)/5%1/ M33H@,&EN.R!"04-+1U)/54Y$+4-/3$]2.B!T6QE/3-$)V9O;G0M6QE/3-$)T)/4D1%4BU"3U143TTZ("-D M-&0P8S@[($)/4D1%4BU,1494.B`C9#1D,&,X.R!0041$24Y'+4)/5%1/33H@ M,&EN.R!"04-+1U)/54Y$+4-/3$]2.B!T2!S:6=N960@82!S96-U6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)RPG2!C;VYC;'5D960@ M=&AA="!T:&5S92!C;VYV97)S:6]N(&9E871U2!C;&%S&5D('1O(&-E6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="`P+C5I;B<@86QI9VX],T1J=7-T M:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F M;VYT/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%- M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P M:6X@,&EN(#!P="`P+C5I;B<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE M/3-$)T9/3E0M4TE:13H@,3!P="<^26X@=&AE(&5V86QU871I;VX@;V8@=&AE M2!C;&%S6%B;&4N/"]F;VYT/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="`P+C5I;B<@86QI9VX],T1J=7-T M:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F M;VYT/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%- M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P M:6X@,&EN(#!P="`P+C5I;B<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE M/3-$)T9/3E0M4TE:13H@,3!P="<^5&AE($-O;7!A;GDF(S$V,#ME;&5C=&5D M('1O(&%C8V]U;G0@9F]R('1H97-E(&AY8G)I9"!C;VYT6QE/3-$)T-,14%2.F)O=&@[ M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[ M34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T M>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/CPO9&EV/B`\ M9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="`P M+C5I;B<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE: M13H@,3!P="<^5&AE(&AO;&1E2!P2!W:71H('1H92!E>&-H86YG92!A8W0L(&QI<75I9&%T:6]N M+"!C97-S871I;VX@;V8@;W!E6QE/3-$)T-,14%2.F)O=&@[ M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[ M34%21TE..B`P:6X@,&EN(#!P="`P+C5I;B<@86QI9VX],T1J=7-T:69Y/CQF M;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/CPO M9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN M(#!P="`P+C5I;B<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/ M3E0M4TE:13H@,3!P="<^1G5R=&AE28C.#(Q-SMS(&-O;6UO;G,@2!O9B!T:&4@9F]R96=O:6YG(&5V96YT2!H879E(&%N(&5X=')E;65L>2!D:6QU=&EV92!E M9F9E8W0@;VX@=&AE('-H87)E:&]L9&5R2X@4W5C M:"!D:6QU=&EO;B!W;W5L9"!L:6ME;'D@6QE M/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF:7AE9#LG(&-E;&QS<&%C M:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT9#X\+W1D/CPO='(^/"]T M86)L93X\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO#L@1D].5#H@ M,3!P="!4:6UE6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG M#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U!3$E'3CI, M969T.R!415A4+4E.1$5.5#H@,&EN.R!724142#H@,3`P)2<^(#QT86)L92!S M='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,&EN(#`N,C5I;CL@5TE$5$@Z(#DP M)3L@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S93L@1D].5"U325I%.B`Q,'!T M.R!/5D521DQ/5SH@=FES:6)L92<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D M:6YG/3-$,"!A;&EG;CTS1&QE9G0^(#QT6QE/3-$)T)/4D1% M4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@ M,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO M6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)U1% M6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%# M2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U! M3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@ M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,B4^(#QD:78^,S6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO3XF(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H M.R!&3TY4+49!34E,63I4:6UE#L@1D].5#H@,3!P="!4:6UE2!M861E('1H92!F;VQL;W=I;F<@8V]N=F5R M6QE/3-$)W=I9'1H.C$P M,"4[('1A8FQE+6QA>6]U=#IF:7AE9#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL M<&%D9&EN9STS1#`^/'1R/CQT9#X\+W1D/CPO='(^/"]T86)L93X\9&EV('-T M>6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P:6X@,"XR-6EN M.R!724142#H@.3`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`Q M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P M,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^ M(#QD:78^-RPQ,S,L,S,S/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4 M+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9 M.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M"!S;VQI9#L@1D].5"U7 M14E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT M9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R M;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(')I M9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F M9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXQ,2PQ,#$L M-CDT/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N M;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P M)R!W:61T:#TS1#$R)3X@/&1I=CXV-"PY,S`\+V1I=CX@/"]T9#X@/'1D('-T M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M6QE/3-$)W=I9'1H.C$P M,"4[('1A8FQE+6QA>6]U=#IF:7AE9#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL M<&%D9&EN9STS1#`^/'1R/CQT9#X\+W1D/CPO='(^/"]T86)L93X\9&EV('-T M>6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE3Y$=7)I;F<@2G5N92!A;F0@ M075G=7-T+"`R,#$S+"!O;F4@;V8@=&AE(&-O;G9E28C.#(Q-SMS(')E6EN9R!T:&4@;F]T97,@:6X@=&AE(&%M;W5N="!O M9B`D/&9O;G0@6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T-,14%2.F)O=&@[ M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[ M34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@ M5&EM97,L(%-E6QE/3-$)TU! M4D=)3CH@,&EN(#!I;B`P:6X@,"XR-6EN.R!724142#H@.3`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`Q,'!T.R!615)424-!3"U!3$E'3CH@ M8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U7 M14E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^,C(L,#4X+#@X,CPO9&EV M/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4 M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG7,@=VET:"!T:&4@;&]W97-T('9O;'5M92!W96EG:'1E9"!A=F5R86=E M('!R:6-E2!P6QE M/3-$)TU!4D=)3CH@,&EN(#!I;B`P:6X@,"XR-6EN.R!724142#H@.3`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`Q,'!T.R!615)424-!3"U! M3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@ M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^,C(L,#(V+#0S M,3PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO&5D.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X\ M='(^/'1D/CPO=&0^/"]T7!E.B!T97AT+VAT;6P[(&-H87)S M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@ M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M M;#L@8VAA'0^)SQS<&%N/CPO'0^)SQD:78@6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<^(#QF;VYT('-T>6QE/3-$)T9/ M3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/CPO9&EV/B`\9&EV('-T>6QE M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0[5$585"U!3$E'3CI,969T.R!415A4+4E.1$5.5#H@ M,&EN.R!724142#H@,3`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`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$ M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@ M=VED=&@],T0Q,B4^(#QD:78^,"XQ,#PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4 M+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D]. M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=% M24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXM/"]D:78^(#PO=&0^(#QT M9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!! M1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)4 M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS M1#$R)3X@/&1I=CXU-"PV-3`L,#`P/"]D:78^(#PO=&0^(#QT9"!S='EL93TS M1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I M9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C M9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXP+C$P/"]D M:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4 M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE'!I6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4 M+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4 M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5) M1TA4.B`T,#`G('=I9'1H/3-$,3(E/B`\9&EV/B@T-2PS,34L,#`P*3PO9&EV M/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W M:61T:#TS1#$R)3X@/&1I=CXM/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4 M15A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%- M24Q9.B!4:6UE6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%# M2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U! M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`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`Q,'!T.R!615)4 M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS M1#$R)3X@/&1I=CXP+C`X,CPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@ M,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA M;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<^(#QF;VYT M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^5&AE(&9O;&QO=VEN9R!T86)L M92!S=6UM87)I>F5S(&EN9F]R;6%T:6]N(&%B;W5T(&9I>&5D+7!R:6-E('=A M6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA M;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<^(#QF;VYT M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/CPO9&EV M/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U!3$E'3CI,969T.R!4 M15A4+4E.1$5.5#H@,&EN.R!724142#H@,3`P)2<^(#QT86)L92!S='EL93TS M1"=-05)'24XZ(#!I;B`P:6X@,&EN(#`N-6EN.R!724142#H@.#`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`Q,'!T.R!615)4 M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS M1#$R)3X@/&1I=CXQ-30L.3$V+#8V-SPO9&EV/B`\+W1D/B`\=&0@65A6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO65A6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M&5D.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$ M,#X\='(^/'1D/CPO=&0^/"]T7!E.B!T97AT+VAT;6P[(&-H M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U% M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O M:'1M;#L@8VAA"!$ M:7-C;&]S=7)E(%M!8G-T'0@0FQO8VM= M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=B!S='EL93TS M1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE#L@1D].5#H@,3!P="!4:6UE"!E>'!E;G-E(&9O65A2!A<'!L>6EN M9R!T:&4@1F5D97)A;"!#;W)P;W)A=&4@=&%X(')A=&4@;V8@/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)RPG&5S+"!T M:&4@8FQE;F1E9"!R871E('5S960@=V%S(#QF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG&EM871E;'D@87,@ M9F]L;&]W#L@1D].5#H@,3!P="!4:6UE6QE M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0[5$585"U!3$E'3CI,969T.R!415A4+4E.1$5.5#H@ M,&EN.R!724142#H@,3`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`M($9E9&5R86P\+V1I=CX@/"]T M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO'!E8W1E9"(@=&%X(&5X<&5N6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I M9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q% M.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I% M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@ M-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXU-3@L-#0X/"]D:78^(#PO=&0^(#QT M9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO6QE/3-$)U1% M6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%# M2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U! M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@ M/&1I=CXQ-3DL-3`P/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%, M24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4 M:6UE6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4 M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1% M4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H M=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/ M3E0M1D%-24Q9.B!4:6UE"!S;VQI9#L@5$585"U!3$E'3CH@;&5F M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[ M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I M9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS M1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E' M3CH@6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U! M3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-) M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z M(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS M1#$E/B`\9&EV/B0\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU" M3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X M(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C M9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T M;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=( M5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@/"]T9#X@/'1D('-T M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$58 M5"U!3$E'3CH@6QE/3-$)W=I9'1H.C$P,"4[('1A M8FQE+6QA>6]U=#IF:7AE9#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN M9STS1#`^/'1R/CQT9#X\+W1D/CPO='(^/"]T86)L93X\"!!'0^)SQD M:78@6QE/3-$)TU!4D=)3CH@,&EN.R!72414 M2#H@,3`P)3L@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S93L@3U9%4D9,3U6QE/3-$ M)U1%6%0M04Q)1TXZ(&-E;G1E"!S;VQI9#L@5$585"U!3$E'3CH@ M8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE M"!S;VQI9#L@1D].5"U7 M14E'2%0Z(#0P,"<@=VED=&@],T0Q,B4^(#QD:78^)B,Q-C`[/"]D:78^(#PO M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U19 M3$4Z(&YO"!S M;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,B4^(#QD:78^)B,Q M-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT M97([($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO3PO9&EV/B`\+W1D/B`\=&0@"!S M;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F M9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[ M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D M:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P M(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C9F9C8SL@1D].5"U3 M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=( M5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXT,RPQ-30\+V1I=CX@/"]T9#X@ M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@ M/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q) M1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5. M1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@ M8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U7 M14E'2%0Z(#0P,"<@=VED=&@],T0Q,B4^(#QD:78^-3DY+#`W.3PO9&EV/B`\ M+W1D/B`\=&0@6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%, M24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4 M:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!4 M15A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!& M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3(E/B`\9&EV/B@V-3"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@ M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9% M4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H M/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=" M3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@ M6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!A"!S;VQI9#L@1D].5"U714E'2%0Z(#0P M,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS M1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q) M1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5. M1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@ M8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U7 M14E'2%0Z(#0P,"<@=VED=&@],T0Q,B4^(#QD:78^+3PO9&EV/B`\+W1D/B`\ M=&0@"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO"!S;VQI9#L@ M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO M=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D M;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[ M(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!6 M15)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P M>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,B4^(#QD:78^ M+3PO9&EV/B`\+W1D/B`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`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=% M24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXV+#(S,BPX.#$\+V1I=CX@ M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ M(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-4 M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU" M3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@ M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9% M4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H M/3-$,3(E/B`\9&EV/B@V+#(S,BPX.#$I/"]D:78^(#PO=&0^(#QT9"!S='EL M93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/ M3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@ M,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P M,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E, M13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+ M1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%, M24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3(E/B`\ M9&EV/B@U+#4W-2PP-SDI/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4 M+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9 M.B!4:6UE6QE M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U! M3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-F9F-C.R!&3TY4+5-) M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z M(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS M1#$E/B`\9&EV/B0\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU" M3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X M(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C M8V-F9F-C.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T M;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=( M5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@/"]T9#X@/'1D('-T M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$58 M5"U!3$E'3CH@6QE/3-$)W=I9'1H.C$P,"4[('1A M8FQE+6QA>6]U=#IF:7AE9#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN M9STS1#`^/'1R/CQT9#X\+W1D/CPO='(^/"]T86)L93X\'0O M:F%V87-C3X-"B`@("`\ M=&%B;&4@8VQA'0^ M)SQS<&%N/CPO6UE;G1S M(&9O'0^)SQD:78@6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%- M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P M:6X@,&EN(#!P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/ M3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/CPO9&EV/B`\9&EV('-T>6QE M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0G(&%L:6=N/3-$8V5N=&5R/B`\9&EV('-T>6QE/3-$ M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4 M+5-)6D4Z(#$P<'0[5$585"U!3$E'3CIC96YT97([(%1%6%0M24Y$14Y4.B`P M:6X[(%=)1%1(.B`Q,#`E)R!A;&EG;CTS1&-E;G1E6QE M/3-$)TU!4D=)3CH@,'!X.F%U=&\[(%=)1%1(.B`V-24[($)/4D1%4BU#3TQ, M05!313H@8V]L;&%P6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ M(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@ M(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T M=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXQ,38L M,S0U/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED M.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X M('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L M.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!4:6UE"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E' M2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S M='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1% M6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%# M2T=23U5.1#H@(V-C9F9C8SL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U! M3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@ M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,B4^(#QD:78^,S8Q+#&5D.R<@8V5L;'-P86-I;F<] M,T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X- M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA2!/9B!3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S(%M,:6YE($ET M96US73PO'0^ M)SQS<&%N/CPO2!/9B!3:6=N:69I8V%N="!! M8V-O=6YT:6YG(%!O;&EC:65S(%M,:6YE($ET96US73PO'0^)SQS<&%N/CPO2!/9B!3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S(%M,:6YE($ET M96US73PO'0^ M)SQS<&%N/CPO2!/9B!3:6=N:69I8V%N="!!8V-O M=6YT:6YG(%!O;&EC:65S(%M,:6YE($ET96US73PO'0^)SQS<&%N/CPO2!/9B!3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S(%M,:6YE($ET M96US73PO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO7!E.B!T97AT M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^ M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT M/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO2!/9B!3:6=N:69I8V%N="!!8V-O=6YT M:6YG(%!O;&EC:65S(%M,:6YE($ET96US73PO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO2!686QU871I;VX@4F5S97)V97,\+W1D/@T*("`@("`@("`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`Q,2!W M:71H(&EN=&5R97-T(&-A;&-U;&%T960@870@,C`E(&%N9"`Q,B4L(&5A8V@L M(')E2X@070@1&5C96UB97(@,S$L(#(P,3,@86YD(#(P,3(L M('1H92!A8V-R=65D(&EN=&5R97-T('!A>6%B;&4@=V%S("0V+#8V-"X@1'5R M:6YG('EE87(@96YD960@1&5C96UB97(@,S$L(#(P,3,L(&]N92!O9B!T:&4@ M3F]T92!H;VQD97)S(&UA9&4@8V]N=F5R>*`F7,@7,@=VET:"!T:&4@;&]W97-T('9O;'5M92!W96EG:'1E9"!A=F5R86=E M('!R:6-E2!P6%B;&4@;V8@)#2X@070@1&5C96UB97(@,S$L(#(P,3(L('1H97-E('1W;R!C M;VYV97)T:6)L92!N;W1E('!A>6%B;&4@;V8@)#(U,"PP,#`@96%C:"!W97)E M(')E8V]R9&5D(&%T(&9A:7(@=F%L=64@;V8@)#(Y,"PR.#D@86YD("0R.32!I2!I2!H87,@=&AE(')I9VAT('1O(&-O;G9E2!E;F-O=6YT97)E9"!A(&1A M>2UO;F4@9&5R:79A=&EV92!L;W-S(&]F("0R-"PY,S$N($-O=F5N=')Y(&UA M9&4@=&AE(&-O;G9E&5R8VES M92!P2X@3VX@2G5L>2`Q,"P@,C`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`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`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA2!O;F4@;&]S6)R:60@ M:6YS=')U;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]C M-&(V86-F,%]E,&$S7S0X.#)?839E8U\W.#!F,S$Q,3!A93,-"D-O;G1E;G0M M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8S1B-F%C9C!?93!A,U\T.#@R7V$V96-? M-S@P9C,Q,3$P864S+U=O'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO&EM=6X\+W1D/@T*("`@("`@("`\=&0@ M8VQA'0^ M)R9N8G-P.R9N8G-P.SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)S4@9&%Y'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)S(P(&1A>7,\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO2!O;F4@;&]S6)R M:60@:6YS=')U;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO2!B;W)R;W=E9"`D,C4P+#`P,"!E86-H("AA M9V=R96=A=&EN9R`D-3`P+#`P,"D@9G)O;2!T=V\@;F]N+7)E;&%T960@<&%R M=&EE65A2X@3VX@ M07!R:6P@,S`L(#(P,3,L('1H92!P87)T:65S(&%M96YD960@=&AE(&YO=&5S M('1O(&9U2!D871E('1O($YO=F5M M8F5R(#,L(#(P,3,N(%1H92!#;VUP86YY(&ES2!D871E2X@5&AE($-O;7!A;GD@:7-S=65D(&$@=&]T86P@ M;V8@-3`P+#`P,"!A;F0@,2PR-3`L,#`P(')E2X@3VX@36%R8V@@,C(L(#(P,3,L M('1H92!#;VUP86YY(&ES2!C;VYV97)T960@:6YT;R!S:&%R97,@;V8@2!T7,@<')E8V5D:6YG('1H M92!C;VYV97)S:6]N(&1A=&4N($EN(&-O;FYE8W1I;VX@=VET:"!T:&4@:7-S M=6%N8V4@;V8@=&AI6%B;&4L('1H92!# M;VUP86YY(&5N8V]U;G1E6EN9R!T:&4@;F]T97,@:6X@ M9G5L;"!W:71H(&$@9F%I65A>*`F7,@8V]M M;6]N('-T;V-K(&%T(&%N(&5X97)C:7-E('!R:6-E(&]F("0P+C`Q('!E2!U2!I2`Q,"P@,C`Q-"!A;F0@07!R:6P@,3`L(#(P,30L M(')E2X@5&AE(&YO=&5SXH"9(&AO;&1E6%B;&4L('1H92!#;VUP86YY(&5N8V]U;G1E6%B;&4L(&%T(&9A:7(@=F%L M=64L('=A2!C;VYV97)T960@:6YT;R!S:&%R M97,@;V8@2UF:79E M('!E>*`F7,@0V]M;6]N(%-T M;V-K(&9O2!A;'-O(&=R86YT960@9FEV M92UY96%R('=A>*`F7,@8V]M;6]N('-T M;V-K(&%T(&%N(&5X97)C:7-E('!R:6-E(&]F("0P+C`R-2!P97(@2!U2!H87,@=&AE(')I9VAT('1O(&-O;G9E2UF:79E('!E>*`F7,@0V]M;6]N(%-T;V-K(&9O2!A M;'-O(&=R86YT960@9FEV92UY96%R('=A>*`F7,@8V]M;6]N('-T;V-K(&%T(&%N(&5X97)C:7-E('!R:6-E(&]F("0P M+C`R-2!P97(@2!U2X@3VX@3V-T;V)E2!S:6=N960@82!S96-U2!C;VYC;'5D960@=&AA="!T:&5S M92!C;VYV97)S:6]N(&9E871U2!C;&%S6%B;&4L M(&%T(&9A:7(@=F%L=64L('=A6%B;&4L('=I=&@@82!F86-E('9A;'5E M(&]F("0U,RPP,#`L(&)E87)S(&EN=&5R97-T(&%T(#@N,"4@<&5R(&%N;G5M M(&%N9"!W87,@9'5E(&]N($IU;'D@,S$L(#(P,3(N($]N($1E8V5M8F5R(#4L M(#(P,3$@=&AE($-O;7!A;GD@96YT97)E9"!I;G1O(&$@8V]N=F5R=&EB;&4@ M;F]T92!P87EA8FQE('=I=&@@82!C;W)P;W)A=&EO;B!W:&EC:"!H860@82!F M86-E('9A;'5E(&]F("0S-RPU,#`L(&$@8V]U<&]N(')A=&4@;V8@."XP)2!P M97(@86YN=6T@86YD(&UA='5R:71Y(&1A=&4@;V8@4V5P=&5M8F5R(#4L(#(P M,3(N(%1H92!C;VYV97)T:6)L92!N;W1E('!A>6%B;&4@:7,@8V]N=F5R=&EB M;&4L(&%T('1H92!H;VQD97+B@)ES(&]P=&EO;BP@:6YT;R!T:&4@0V]M<&%N M>>*`F7,@8V]M;6]N('-H87)E2!P97)I;V0@96YD:6YG(&]N92!42!P2!T:&4@2&]L M9&5R('1O('1H92!";W)R;W=E&5D(&9I;F%N8VEN9R!I;G-T6%B;&4@9F]R(&-A M2!A('1H:7)D('!A2`Q,RP@,C`Q,RP@=6YL97-S(&-O;G9E2!S:6=N960@82!S96-U2!A;'-O(&-O;F-L=61E9"!T:&%T('1H92!$969A=6QT(%!U M="!R97%U:7)E9"!B:69U2!C;VYS:61E2!A;'-O M(&-O;F-L=61E9"!T:&%T('1H92!$969A=6QT(%!U="!R97%U:7)E9"!B:69U M2!E;&5C=&5D('1O(&%C8V]U;G0@9F]R('1H97-E(&AY8G)I9"!C;VYT M2P@9&EV:61E;F0@9&ES=')I8G5T:6]N(&]R('-P:6X@;V9F+"!D:6QU M=&EV92!I2!O9B!T M:&4@9F]R96=O:6YG(&5V96YT2!H879E(&%N(&5X=')E;65L>2!D:6QU=&EV92!E9F9E8W0@ M;VX@=&AE('-H87)E:&]L9&5R2X@4W5C:"!D:6QU M=&EO;B!W;W5L9"!L:6ME;'D@2!A;F0@:71S('-H87)E:&]L9&5R3X-"CPO:'1M;#X- M"@T*+2TM+2TM/5].97AT4&%R=%]C-&(V86-F,%]E,&$S7S0X.#)?839E8U\W M.#!F,S$Q,3!A93,-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8S1B M-F%C9C!?93!A,U\T.#@R7V$V96-?-S@P9C,Q,3$P864S+U=O'0O:'1M;#L@8VAA'!E8W1E9"!$:79I9&5N9"!2871E/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP+C`P)3QS<&%N/CPO'0^)SQS<&%N M/CPO2!2871E/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,C0N,#`E/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^)SQS<&%N/CPO M'!E8W1E9"!6;VQA=&EL:71Y(%)A=&4\+W1D/@T* M("`@("`@("`\=&0@8VQA'0O M:F%V87-C3X-"B`@("`\ M=&%B;&4@8VQA2!%;G1E2!%;G1E2`W+"`R,#$S(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C M;&%S2!%;G1E2!%;G1E'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)U1H92!F=6QL(&%M;W5N="!O9B!P2!S=6-H(&1E8F5N='5R92!C;W5L9"!B92!C;VYV97)T960@:6YT M;R!S:&%R97,@;V8@;W5R(&-O;6UO;B!S=&]C:R!A="!A('!R:6-E(&5Q=6%L M('1O(#7,@<')I M;W(@=&\@8V]N=F5R'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO2!H87,@=&AE(')I9VAT M('1O(&-O;G9E2UF:79E('!E7,@0V]M;6]N(%-T;V-K(&9O'0^)T-O=F5N=')Y(&AA2UF:79E('!E7,@0V]M;6]N(%-T;V-K(&9O2!W M87,@96YT:71L960@=&\@8V]N=F5R="!A;&P@;W(@86YY(&%M;W5N="!O9B!T M:&4@=&AE2!V;VQU;64@=V5I9VAT960@ M879E2!W87,@96YT:71L960@=&\@8V]N=F5R="!A;&P@;W(@86YY(&%M;W5N="!O M9B!T:&4@=&AI'0^)T-O=F5N M=')Y(&AA2!T7,@<')E8V5D:6YG('1H92!C;VYV97)S:6]N(&1A=&4\'0^)T-O=F5N=')Y('=A M2!V;VQU;64@=V5I9VAT960@879E M7,@:6UM961I M871E;'D@<')E8V5D:6YG('1H92!#;VYV97)S:6]N($1A=&4N/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'1I;F=U:7-H;65N="!/9B!$96)T M/"]T9#X-"B`@("`@("`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`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA M'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO2!4;W1A;#PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO&5C=71I=F4@3V9F:6-E'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[ M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@ M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E M>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO65A2P@8V]N2`R,#$Q+"!T:&4@0V]M M<&%N>2!R96-E:79E9"!A(&QO86X@9F]R("0R-2PP,#`@9G)O;2!A(&YO;BUR M96QA=&5D('!A2X@3VX@4V5P=&5M8F5R(#$V+"`R,#$S+"!T:&4@ M;F]N+7)E;&%T960@<&%R='D@86-C97!T960@82!T;W1A;"!O9B`X+#0W,BPW M-3`@2`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`H=&AE(")#;VUM M;VX@4W1O8VLB*2!A="!A(&-O;G9E7,@ M+B!&;VQL;W=I;F<@=&AE(&%G2!,4%(@82!T;W1A M;"!O9B`D,S4P+#`P,"!I;B!M;VYT:&QY(&EN2`Q-2P@,C`Q,BX@5&AI2!D M:60@;F]T(&UA:V4@86QL(&]F('1H92!P87EM96YT2!A;F0@'!E;G-E9"!D=7)I;F<@,C`Q,BX@3%!2 M('-O;&0@=&AE(&YO=&4@=&\@4V]U=&AR:61G92!087)T;F5R2!#96YT&EM871E;'D@)#4U+#0Q,"P@=VAI M8V@@=V%S(&%S2!R979E7,N($EN=&5R97-T(&]N('1H M97-E(&QO86YS(&ES('!A>6%B;&4@;6]N=&AL>2!B96=I;FYI;F<@:6X@3F]V M96UB97(@,C`Q,2!W:71H(&EN=&5R97-T(&-A;&-U;&%T960@870@,C`E(&%N M9"`Q,B4L(&5A8V@L(')E2X@070@1&5C96UB97(@,S$L(#(P M,3,@86YD(#(P,3(L('1H92!A8V-R=65D(&EN=&5R97-T('!A>6%B;&4@=V%S M("0V+#8V-"X@1'5R:6YG('EE87(@96YD960@1&5C96UB97(@,S$L(#(P,3,L M(&]N92!O9B!T:&4@3F]T92!H;VQD97)S(&UA9&4@8V]N=F5R>*` MF7,@7,@=VET:"!T:&4@;&]W97-T('9O;'5M92!W96EG M:'1E9"!A=F5R86=E('!R:6-E2!P6%B;&4@;V8@)#2X@070@1&5C96UB97(@,S$L(#(P,3(L M('1H97-E('1W;R!C;VYV97)T:6)L92!N;W1E('!A>6%B;&4@;V8@)#(U,"PP M,#`@96%C:"!W97)E(')E8V]R9&5D(&%T(&9A:7(@=F%L=64@;V8@)#(Y,"PR M.#D@86YD("0R.32!I2!I2!H87,@=&AE(')I9VAT('1O(&-O;G9E2!E;F-O M=6YT97)E9"!A(&1A>2UO;F4@9&5R:79A=&EV92!L;W-S(&]F("0R-"PY,S$N M($-O=F5N=')Y(&UA9&4@=&AE(&-O;G9E2X@3VX@2G5L>2`Q,"P@ M,C`Q,R!A;F0@3V-T;V)E2!E;F-O=6YT97)E9"!A(&1A>2UO;F4@9&5R:79A=&EV92!L;W-S M(&]F("0X,RPQ-32!H87,@=&AE(')I9VAT('1O M(&-O;G9E2!T7,@<')E8V5D:6YG('1H92!C;VYV97)S:6]N M(&1A=&4N($EN(&-O;FYE8W1I;VX@=VET:"!T:&4@:7-S=6%N8V4@;V8@=&AI M6%B;&4L('1H92!#;VUP86YY(&5N8V]U M;G1E65A&5R8VES92!P2!C;&%S2X@5&AE M('=A2X@3VX@4V5P=&5M8F5R M(#$R+"`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`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`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A2!#96YT2!%;G1E2!%;G1E2!%;G1E2!%;G1E2!%;G1E2!% M;G1E2!%;G1E2!%;G1E2!%;G1E2!%;G1E2!%;G1E2!%;G1E M2!%;G1E2!%;G1E2!%;G1E2!%;G1E6%B;&4@5'=O(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S M2`S,2P@,C`Q,3QB6%B;&4@5'=O(%M-96UB M97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S6%B;&4@5'=O(%M- M96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S6%B;&4@1&%T960@3V-T;V)E6%B;&4@1&%T960@1F5B2`S+"`R,#$R(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S M6%B;&4@1&%T960@36%R8V@@,38L(#(P,3(@6TUE;6)E6%B;&4@1&%T960@36%R8V@@,38L(#(P,3(@6TUE M;6)E6%B;&4@6TUE;6)E6%B;&4@5&AR964@ M6TUE;6)E6%B;&4@5&AR964@6TUE;6)E6%B;&4@5&AR964@6TUE;6)E6%B M;&4@5&AR964@6TUE;6)E'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M3PO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)VEN=&5R97-T(&-A;&-U;&%T960@870@,C`E(&%N9"`Q M,B4L(&5A8V@L(')E3QS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO6%B;&4L($-U'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO2!$871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO2!H87,@=&AE(')I9VAT('1O(&-O;G9E2UF:79E('!E7,@0V]M;6]N(%-T;V-K(&9O'0^)T-O=F5N=')Y M(&AA2UF:79E('!E7,@0V]M;6]N M(%-T;V-K(&9O2!W87,@96YT:71L960@=&\@ M8V]N=F5R="!A;&P@;W(@86YY(&%M;W5N="!O9B!T:&4@=&AE2!V;VQU;64@=V5I9VAT960@879E2!W87,@96YT:71L960@ M=&\@8V]N=F5R="!A;&P@;W(@86YY(&%M;W5N="!O9B!T:&4@=&AI'0^)T-O=F5N=')Y(&AA2!T7,@<')E8V5D:6YG('1H M92!C;VYV97)S:6]N(&1A=&4\'0^)T-O=F5N=')Y('=A2!V;VQU;64@=V5I9VAT960@879E7,@:6UM961I871E;'D@<')E8V5D:6YG M('1H92!#;VYV97)S:6]N($1A=&4N/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)T]N($]C=&]B97(@,3DL(#(P,3(@=&AE('!A'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)U-O=71H'0^)SQS<&%N/CPO2!V;VQU;64@=V5I9VAT960@879E7,@:6UM961I M871E;'D@<')E8V5D:6YG('1H92!#;VYV97)S:6]N($1A=&4N/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)V-O;G9E'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M2!);G-T86QL M;65N="!087EM96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO2!! M;6]U;G0\+W1D/@T*("`@("`@("`\=&0@8VQA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'1I;F=U:7-H;65N="!O M9B!$96)T+"!!;6]U;G0\+W1D/@T*("`@("`@("`\=&0@8VQA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'1I;F=U:7-H;65N="!/9B!$96)T/"]T9#X-"B`@("`@("`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`@("`@("`@/'1D(&-L87-S/3-$;G5M M<#XS+#DW-SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO7,\+W1D/@T*("`@("`@("`\=&0@ M8VQA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO2P@1F%I'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO7,@ M9G)O;2!F=6YD:6YG+B!792!A2X\+W1D/@T*("`@("`@/"]T2P@8V]N2`R,#$Q+"!T:&4@0V]M<&%N>2!R96-E:79E9"!A(&QO86X@9F]R M("0R-2PP,#`@9G)O;2!A(&YO;BUR96QA=&5D('!A2X@3VX@4V5P M=&5M8F5R(#$V+"`R,#$S+"!T:&4@;F]N+7)E;&%T960@<&%R='D@86-C97!T M960@82!T;W1A;"!O9B`X+#0W,BPW-3`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`H=&AE(")#;VUM;VX@4W1O8VLB*2!A="!A(&-O;G9E7,@+B!&;VQL;W=I;F<@=&AE(&%G2!,4%(@82!T;W1A;"!O9B`D,S4P+#`P,"!I;B!M;VYT:&QY M(&EN2`Q-2P@,C`Q,BX@5&AI2!D:60@;F]T(&UA:V4@86QL(&]F('1H92!P M87EM96YT2!T:&5I2!A;F0@'!E M;G-E9"!D=7)I;F<@,C`Q,BX@3%!2('-O;&0@=&AE(&YO=&4@=&\@4V]U=&AR M:61G92!087)T;F5R2!#96YT&EM871E;'D@)#4U+#0Q,"P@=VAI8V@@=V%S(&%S2!R979E6UE;G0@;VX@ M;W(@8F5F;W)E($]C=&]B97(@,2P@,C`Q,BX@3VX@3V-T;V)E'1E;F0@=&AE M(&1U92!D871E('1O($UA>2`Q+"`R,#$S(&%N9"!I;F-L=61E(&$@8V]N=F5R M2!S=&]C:R!A="!A(#$U)2!D:7-C M;W5N="!T;R!T:&4@879E2=S('-T;V-K('1R861E9"!O=F5R('1H92!P6EN9R!T:&4@;F]T97,@:6X@=&AE(&%M;W5N="!O9B`D,3(U+#`P,"!W M:71H(&$@9F%I2!V;VQU;64@=V5I9VAT960@879E7,@:6UM961I871E;'D@<')E M8V5D:6YG('1H92!#;VYV97)S:6]N($1A=&4N($9O;&QO=VEN9R!T:&4@87-S M:6=N;65N=',L('1H92!C;VYV97)S:6]N>*`F7,@6EN9R!T:&4@;F]T97,@;V8@)#$U M,"PP,#`@870@=&AE(&9A:7(@=F%L=64@;V8@)#0W-2PU,3D@*%-E92!N;W1E M(#8I+B!!="!$96-E;6)E'1E;F0@=&AE(&UA='5R:71Y(&1A M=&4@=&\@3F]V96UB97(@,RP@,C`Q,RX@5&AE($-O;7!A;GD@:7-S=65D(&$@ M=&]T86P@;V8@-"PP,#`L,#`P(')E'1E;F0@=&AE(&UA='5R:71Y(&1A=&5S('1O($UA>2`S+"`R,#$T(&%N9"!! M=6=U2!I2!%;G1E>*`G2DN(%1H92!N;W1E M(&-A2UF:79E('!E>*` MF7,@0V]M;6]N(%-T;V-K(&9O2!M861E('1H92!C;VYV M97)S:6]N>*`F7,@2!A;'-O(&=R86YT960@9FEV92UY96%R('=A2!C;&%S2X@5&AE('=A2!I;G1E2!I2!%;G1E>*`G2DN(%1H M92!N;W1E(&-A2!E;F-O=6YT97)E9"!A(&1A>2UO;F4@9&5R:79A M=&EV92!L;W-S(&]F("0Y-36%B;&4L(&%T(&9A:7(@=F%L=64L M('=A2!%;G1E>*`G2DN(%1H92!N;W1E(&-A2!C;VYV97)T960@:6YT;R!S:&%R97,@;V8@2!E;F-O=6YT97)E9"!A M(&1A>2UO;F4@9&5R:79A=&EV92!L;W-S(&]F("0S,#DL,#4U+B!!="!$96-E M;6)E6%B;&4L M(&%T(&9A:7(@=F%L=64L('=A2!.;W1E(&EN('1H92!A;6]U;G0@;V8@)#,U+#`P,"!I;B!F879O M2!A;'-O(&-O;F-L=61E9"!T:&%T('1H92!$969A=6QT M(%!U="!R97%U:7)E9"!B:69U2!C;VYS:61E2!E M;F-O=6YT97)E9"!A(&1A>2UO;F4@9&5R:79A=&EV92!L;W-S(&]F("0X,2PV M-C2`S,2P@,C`Q,BX@3VX@ M1&5C96UB97(@-2P@,C`Q,2!T:&4@0V]M<&%N>2!E;G1E6%B;&4@=VET:"!A(&-O2!T M:&4@879E2`S+"`R,#$R+"!T:&4@0V]M<&%N>2!I*`G2DN($]N(%-E<'1E;6)E2QP2!.;W1E(&EN('1H92!A;6]U;G0@;V8@)#*`G2DN(%1H92!-87)K970@4')I8V4@:7,@97%U M86P@=&\@=&AE(&%V97)A9V4@;V8@=&AE('1W;R!L;W=E2!C;&%S6%B;&4N($]N($]C=&]B97(@,C8L(#(P,3(L(%-O=71H M2=S(')E2!C;&%S6%B M;&4N(%1H92!#;VUP86YY(&5L96-T960@=&\@86-C;W5N="!F;W(@=&AE2!P2!W:71H('1H92!E>&-H M86YG92!A8W0L(&QI<75I9&%T:6]N+"!C97-S871I;VX@;V8@;W!E6]N9"!T:&4@>*`F7,@ M>*`F7,@8V]M;6]N2!H:6=H(&1E M9W)E92!O9B!R:7-K('1O('1H92!#;VUP86YY(&%N9"!I=',@'0O:F%V87-C3X-"B`@ M("`\=&%B;&4@8VQA2!%;G1E2`R,2`R,#$S(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C M;&%S2`Q-B`R,#$S(%M-96UB97)=/&)R M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T* M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA6%B;&4@3VYE(%M-96UB97)=/&)R/CPO=&@^#0H@("`@ M("`@(#QT:"!C;&%S2`S,2P@,C`Q,3QB6%B M;&4@3VYE(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S6%B;&4@5'=O(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`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`@("`@(#QT9"!C;&%S'0^)S@@;6]N=&AS/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^)S$@;6]N=&@@,34@9&%Y'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO6%B;&4L($-U'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^ M)T]N($]C=&]B97(@,3DL(#(P,3(@=&AE('!A'0^)SQS<&%N/CPO7,@=VET:"!T:&4@;&]W97-T('9O;'5M92!W96EG:'1E9"!A M=F5R86=E('!R:6-E2!P2!V M;VQU;64@=V5I9VAT960@879E7,@:6UM961I871E;'D@<')E8V5D:6YG('1H92!# M;VYV97)S:6]N($1A=&4\'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO2!H87,@=&AE(')I9VAT('1O(&-O;G9E2UF:79E('!E7,@0V]M;6]N(%-T;V-K(&9O'0^)T-O=F5N=')Y('=A2=S(&-O;6UO;B!S=&]C:R`H=&AE("8C M,S0[0V]M;6]N(%-T;V-K)B,S-#LI(&%T(&$@8V]N=F5R7,@=VET:"!T M:&4@;&]W97-T('9O;'5M92!W96EG:'1E9"!A=F5R86=E('!R:6-E'0^)T-O=F5N=')Y('=A2!V;VQU;64@=V5I9VAT960@879E7,@:6UM961I871E;'D@<')E8V5D:6YG M('1H92!#;VYV97)S:6]N($1A=&4\2UF:79E M('!E7,@0V]M;6]N(%-T;V-K M(&9O2!A;6]U;G0@;V8@=&AE('1H:7,@;F]T92!I;G1O('-H M87)E2=S(&-O;6UO;B!S=&]C:R`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`Q,2!W:71H(&EN=&5R97-T(&-A;&-U;&%T960@870@,C`E(&%N M9"`Q,B4L(&5A8V@L(')E2X@070@1&5C96UB97(@,S$L(#(P M,3,@86YD(#(P,3(L('1H92!A8V-R=65D(&EN=&5R97-T('!A>6%B;&4@=V%S M("0V+#8V-"X@1'5R:6YG('EE87(@96YD960@1&5C96UB97(@,S$L(#(P,3,L M(&]N92!O9B!T:&4@3F]T92!H;VQD97)S(&UA9&4@8V]N=F5R>*` MF7,@7,@=VET:"!T:&4@;&]W97-T('9O;'5M92!W96EG M:'1E9"!A=F5R86=E('!R:6-E2!P6%B;&4@;V8@)#2X@070@1&5C96UB97(@,S$L(#(P,3(L M('1H97-E('1W;R!C;VYV97)T:6)L92!N;W1E('!A>6%B;&4@;V8@)#(U,"PP M,#`@96%C:"!W97)E(')E8V]R9&5D(&%T(&9A:7(@=F%L=64@;V8@)#(Y,"PR M.#D@86YD("0R.32!I2!I2!H87,@=&AE(')I9VAT('1O(&-O;G9E2!E;F-O M=6YT97)E9"!A(&1A>2UO;F4@9&5R:79A=&EV92!L;W-S(&]F("0R-"PY,S$N M($-O=F5N=')Y(&UA9&4@=&AE(&-O;G9E2X@3VX@2G5L>2`Q,"P@ M,C`Q,R!A;F0@3V-T;V)E2!E;F-O=6YT97)E9"!A(&1A>2UO;F4@9&5R:79A=&EV92!L;W-S M(&]F("0X,RPQ-32!H87,@=&AE(')I9VAT('1O M(&-O;G9E2!T7,@<')E8V5D:6YG('1H92!C;VYV97)S:6]N M(&1A=&4N($EN(&-O;FYE8W1I;VX@=VET:"!T:&4@:7-S=6%N8V4@;V8@=&AI M6%B;&4L('1H92!#;VUP86YY(&5N8V]U M;G1E65A&5R8VES92!P2!C;&%S2X@5&AE M('=A2X@3VX@4V5P=&5M8F5R M(#$R+"`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`F7,@8V]M;6]N('-T;V-K+"!D=7)I;F<@=&AE(#$U('1R861I;F<@ M9&%Y6UE;G0@;V8@ M=&AE($YO=&4L(&EN(&9A=F]R(&]F($YU=')A(%!H87)M82!#;W)P;W)A=&EO M;B!A;F0@2!A<'!R;W9E9"!T:&4@8V]N=F5R7,@96YD:6YG(&)E9F]R92!T:&4@8V]N=F5R2!C;VYC;'5D960@=&AA="!T:&5S92!C M;VYV97)S:6]N(&9E871U2!C;&%S&5D('1O(&-E2!C;VYC;'5D960@=&AA="!T:&5S92!C;VYV97)S:6]N(&9E871U M&5D('1O(&-E M6)R:60@8V]N=')A8W1S('5N9&5R M('1H92!G=6ED86YC92!O9B!!4T,@.#$U+3$U+3(U+30N(%1H92!F86ER('9A M;'5E(&AA2!T:&4@9F%I'1R96UE;'D@9&EL=71I=F4@969F96-T(&]N('1H92!S:&%R M96AO;&1E2X@5&AI'!E8W1E9"!T;R!B92!R97!A:60@;F\@;&%T97(@=&AA;B!$96-E M;6)E7,@9G)O;2!F=6YD:6YG+B!4:&ES(&QO86X@:7,@9W5A2!A;B!O9F9I8V5R(&]F('1H92!#;VUP86YY+B!/;B!.;W9E;6)E>*`F7,@6UE;G0@=&\@9&ES8VAA2`R,#$Q+"!T:&4@0V]M<&%N>2!R96-E:79E9"!A;F]T M:&5R(&QO86X@9F]R("0R-2PP,#`@9G)O;2!A(&YO;BUR96QA=&5D('!A>*`F7,@6UE;G0@ M=&\@9&ES8VAA2!N;W1E('1O('1H92!-:6-H865L($UC1&]N M86QD(%1R=7-T(&EN('1H92!A;6]U;G0@;V8@)#65A2!D871E("A3964@3F]T92`V*2X@5V4@87)E(&EN(&1E9F%U;'0@ M2!W M87,@96YT:71L960@=&\@8V]N=F5R="!A;&P@;W(@86YY(&%M;W5N="!O9B!T M:&4@=&AI2!V;VQU;64@=V5I9VAT960@879E7,@:6UM961I871E;'D@<')E8V5D:6YG M('1H92!#;VYV97)S:6]N($1A=&4N($9O;&QO=VEN9R!T:&4@86=R965M96YT M2!M861E('1H92!C;VYV97)S:6]N M>*`F7,@6EN9R!T:&4@;F]T97,@:6X@9G5L;"!A M="!T:&4@9F%I2!W M87,@96YT:71L960@=&\@8V]N=F5R="!A;&P@;W(@86YY(&%M;W5N="!O9B!T M:&4@=&AE7,@=VET M:"!T:&4@;&]W97-T('9O;'5M92!W96EG:'1E9"!A=F5R86=E('!R:6-E2!M861E('1H92!C;VYV97)S:6]N>*`F7,@2P@=&AE(')E;6%I;FEN9R!B86QA;F-E(&]F('1H92!D96)T(&%T($1E M8V5M8F5R(#,Q+"`R,#$S(&ES("0S,S2!I;G-T86QL;65N=',@;V8@)#4P+#`P,"!B96=I;FYI;F<@075G=7-T(#$U M+"`R,#$Q(&%N9"!E;F1I;F<@;VX@1F5B2`R,#$R('!A>6UE;G1S(&%N9"!O;B!*86YU87)Y(#(V+"`R M,#$R+"!W92!S:6=N960@=&AE(&9I2`D,32!F;W(@;F]N+7!A>6UE;G0I+B!4:&4@0V]M<&%N>2!R97!A:60@ M)#(U+#`P,"!D=7)I;F<@=&AE('1H*`G2D@9F]R(&-O M;G-I9&5R871I;VX@;V8@)#(X,2PW-S(@:6X@3V-T;V)E2!O=V5D(%5N:79E2`N/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T M86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T M7V,T8C9A8V8P7V4P83-?-#@X,E]A-F5C7S'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA6UE;G0@07=A'0^ M)SQS<&%N/CPO'!I'!I&5R8VES92!P'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO7!E M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@ M/&AE860^#0H@("`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`@("`\=&%B;&4@ M8VQA"!2871E(%)E8V]N8VEL:6%T:6]N($%M;W5N M="!;3&EN92!)=&5M"!E>'!E;G-E M("AB96YE9FET*2`M($9E9&5R86P\+W1D/@T*("`@("`@("`\=&0@8VQA'0O:F%V87-C M3X-"B`@("`\=&%B;&4@ M8VQA2!O8G-O;&5S8V5N8V4\+W1D M/@T*("`@("`@("`\=&0@8VQA3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA"!2871E(%)E8V]N8VEL:6%T:6]N+"!A="!&961E M2!);F-O;64@5&%X(%)A=&4\+W1D/@T*("`@("`@("`\ M=&0@8VQA"!2871E(%)E8V]N8VEL:6%T M:6]N+"!3=&%T92!A;F0@3&]C86P@26YC;VUE(%1A>&5S/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$;G5M<#XX+C@T)3QS<&%N/CPO7!E.B!T97AT+VAT M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@ M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$ M)W1E>'0O:'1M;#L@8VAA7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@ M8VAA'1U86PI("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`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`@("`@("`\ M=&0@8VQA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO2!!8V-R=6%L+"!A="!#87)R>6EN9R!686QU93PO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO2!$86UA9V5S(%-O M=6=H="!!;65N9&5D(%9A;'5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`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`@("`\=&%B;&4@8VQA2!;365M8F5R73QB&5C=71I=F4@3V9F:6-E'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M2!097)I;V0\+W1D/@T*("`@("`@("`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htm IDEA: XBRL DOCUMENT v2.4.0.8
STOCK OPTIONS AND WARRANTS (Details) (Stock Option [Member], USD $)
 12 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Number of shares, Begining Balance 57,256,667 47,921,667
Number of shares, Exercised 0 0
Number of shares, Issued 98,600,000 54,650,000
Number of shares, Forfeited/Expired (940,000) (45,315,000)
Number of shares, Ending Balance 154,916,667 57,256,667
Weighted average exercise price, Begining Balance (in dollars per share) $ 0.10 $ 0.10
Weighted average exercise price, Exercised (in dollars per share) $ 0 $ 0
Weighted average exercise price, Issued (in dollars per share)   $ 0.10
Weighted average exercise price, Forfeited/Expired (in dollars per share) $ 0 $ 0
Weighted average exercise price, Ending Balance (in dollars per share) $ 0.082 $ 0.10
Maximum [Member]
    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Weighted average exercise price, Issued (in dollars per share) $ 0.10  
Minimum [Member]
    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Weighted average exercise price, Issued (in dollars per share) $ 0.01  

XML 25 R29.htm IDEA: XBRL DOCUMENT v2.4.0.8
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1)
 12 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]    
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 253,423,065 101,899,525
Options And Warrants [Member]
    
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]    
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 154,916,667 57,256,667
Convertible Notes Payable [Member]
    
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]    
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 98,506,398 44,642,858
XML 26 R28.htm IDEA: XBRL DOCUMENT v2.4.0.8
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) (USD $)
Dec. 31, 2013
Dec. 31, 2012
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]    
Total $ 181,271 $ 181,271
Less: Accumulated depreciation and amortization (156,737) (141,756)
Property and equipment, net 24,534 39,515
Computer Equipment [Member]
    
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]    
Total 21,918 21,918
Furniture and Fixtures [Member]
    
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]    
Total 34,757 34,757
Lab Equipment [Member]
    
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]    
Total 42,129 42,129
Telephone Equipment [Member]
    
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]    
Total 12,421 12,421
Office Equipment [Member]
    
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]    
Total 2,629 2,629
Leasehold Improvements [Member]
    
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]    
Total $ 67,417 $ 67,417
ZIP 27 0001144204-14-019555-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001144204-14-019555-xbrl.zip M4$L#!!0````(``")?T2R7N`+#F8!`.H,%``1`!P`;G!H8RTR,#$S,3(S,2YX M;6Q55`D``R_9.5,OV3E3=7@+``$$)0X```0Y`0``['UY<^,XEN?_&['?@>/= MZ)Z-2#MYZ,RLJ@FGCRKW.&V'[:KNV8T-!TQ"$B8I4L7#MGIBO_L^@)1$4KQ% M4J2$CNHJVR*%AX??._'P\-._?A$^+=?_OM_^^E?3D^%7[&!+>1@37A="I?(0<\64G_8J_<%Z4PZZPOP@R*= M?D?6J2Q*/>'_B+TOOO\_X>KI63@5WM_?SS3X!H=]PYEJSH73 MT]4XWY`-8\#W_./;XZT@GTG^9Q^OEDZ^T'\+0+9A?S$6,_7GDYGC++Y\_DR_ MTG#A"QF-84G1>4S_?@5!E\]3C_5 MR/J%X,.#S]Z'ZT>WOOI=8<]*X_'X,_MT_:A-XAZ$+Y4^_^/[[9,ZPW-T2@S; M088:HH6DT!Y]GMAF3Y:&:6]X3ZQ>T/#"PBI=WL1WQI^1I5JFCC]/D.J\S^E M+\KA%S5,XM^!#V+&P1_J+/YY^DG,"\1XP[83_XKW6XL[`2GH=/8EYP[=,I0HOU.Q-DO[*5]3^(F<6'GH*??]P&0`V" MEP(;^/0$)%@0?J*"\,5F$'_$$X$)QA=GN<`_G]ADOM`I?MG?9A:>_'Q")?QT M)<5G'[9V(GR&+_(4Q85I./C#$9ZPZH#^84H"AO#4A.I_2`#.#Z+T`O]0Z#R; MDORB>#][)*W?P(9#G*7_M_5?B4;_/B'8$AC9.#3-% M\M/GZ,NKH3Y'Q@I1L,`6,;4H!2#7E@/J%O^RPKXHK;YG\]GJJP+3T38OP3^* MM!E<\U\)DA08?/4GGX?^=ZP2U`*<`:`-3A6Q!LZ(HXV6@Y^[K>5&);0]Y>,::T>VV+*3Y]CA]C,^7,<;2U`1RX, MG&L:H:A!^@,BVHUQ@1;$03K'P^JQ5`8=-C8>L8.(@;4K9!G$F-H<%*O'XCES M8&B(#^JYU6B9U>A$^B(,(6YTNF%T.@&M4&:,:Z6Y0`3(,2U4P>U4UNA M%39\W*-NJT?=05/'P=0),+5,,X5S[=Q?:IF_U/RN`@_'NN+P[`,;W,BTU-Q!:]$8-KBUZ("U:`@-++98N`ZV*&<6E/X@'!XL$\9P ME@\Z#'YN:.N'OBV?EPO<;5#DFES`?L2QZ9`]"?GEV@4Y<%P+`W>NR0?]R>;P MB(-',J<.&R&WZ)4KCMC)T:+]+]OL.6PX/&,=+V9@6CDHDD&1Q*3#AL;]9$)4 MCHMT,Q++I,/&Q2U&-IZ9NG8S7UCF&_/2N9,1BXX45ATR1A0>HW0O1FDLF\%C ME([&*(TAA,HW0J1FG.@O`8I:LQ2F/[*->(6'\@ MW<4W!CCA]BU^P[H4Q,CZ@6_+]8^_P6(A2YTMV>/=ADG>^6T]O\VP0XYFXY$B MO2.'6IT/6I['8YSLQ MR-R=!['QB(QIQ^/>P!16?PI-])`]"EA3]'$D:QJK&\S6N.Y.J0_)VZQI+"@5P_ MD+=8S7&\#C'`"54\_#Z8MO.KA307OOXWC'1GIB(+7VFNBFA[L10L'Q).\W)A M7\$(_+/A2N5;\;+H8>%F/G<-4]6)<>MHQ[#L,1/>7P&-7,=MDM$FO#JVT#-6 M9X:IFU."[1OC*.0[>=[[6^]FFN,5\4X.:<7+>1Z=7//$:R"T=]/4OB,#3=DQ MQB-9^>1Y'2.FZT_A<517CNKB%VAP?Z`! MA+?_KH].H#U3"PMKQ+E&*M$[BY)UVZK$ M&3'(!%G`L<*P,MI@11R_**+?7/'=Y'#Y$N'"_A`S*H$8<7RJB,UI%^XWM2B/ MTC(E$]F->;"PS98GJ%R>B:.#+-X8&GDCFHLZ7A*>,)U-+\80"PYL)V:K!<4J M#W2\"Q[EP2&ON,)7O"TKWEC["J[36Z'3&V]M\4A^7&+BP"(=@ZL7G2U/2*5$ M!!P:W/./7G#.(7%8/E\@971G.O@!+=&KCI]G%L:A+9>9:3G/V)I?XE>GN[N# MZ_V+^.FP18]GPYZ<@5`.J*ZE%U\NB855)YPL/"[?+\R!O:RV6-MJ!UV_]:K+ M?-7WMNI5.(--I(<#UH&#I15@*>D>U@X6*1`Y2"%7XMWDCL2:"7M"C50&-5+3 M\297,5U6,;6!I;]1,?!SC(JY-WBLLF'"_E1,OX2*@9?VA!INF-IAF-J$&C\L ME@;;&1&.EKV@)9H-D09U;86!ANAO+3LW+?LQ+>$=,>E4[M=?Y<#=SQ8DP1JK M:>&ZO4VZO;'"%B[D+1#RYNYD(>H,8?V[JID&TK5G6'#GND^=]V.O-E7J; ME'J]R\YS02UUV"/A>2/+SJ5][])>\[(/UCN1_*!*W,SWE9(9U%B@,HHU[+PV MJ26U2:,&RM*XEF^=EJ^Q)$T2N7%OZ;)+8J/'$BY,XPU;#H&9!YA`]WFT:_QJ MT<[>M".R?*3`*,:>/6WN=>.40PHKO<[;`XZS7,SAY2KY4081^CDP0<-:J#^# M:4R=@\%5_&SB8!7E!D=2?B2!7\"1E,@-CJ24*MT4Y7ZO.B;P2::WITC<]N5@ MSYZ0UM;*WK`WSX.YO0=S'?3,>=*O%4F_3EBVW#$=SQYT)'O0-J0I@6-Q"N^: MUI+-J"ADE#*'XY2:(-,+0*;']R];"IE>&!,#CLZ/\R.;^CFRV.C,:7\-R M2_YTB?:`U!]HBA^Q;;J6BNT;XR@BT8S)\Y*4F&O"^=9P)[>&&[EAG$%%\=L_ MI4*%5X:WLS(\#!.EOG915)WPY'DK,J'A0XG*J2S7M>;#%TGD,?M^0YKP:@]/ MI1K;XWL^`Y?P=DGXN$;CS[=$V[KF4EU:G:KT(3\0T>$#$=%SRO*P+JCD.CMS MB54VTSZ'2D[V[`LJS3-3=6>WF^N+NA*4(#.80NP3&` M+G[.R8!K,*_2GI/;+>XN4?I,Y0M8)<K/L4SOEC=0V['/PITOBN6E7_R4OB)M]`D%Q0,C=OW4X8I%DVGN(G2Q M@<.KX%,3LV)<2EM9Q;_:+ANDR5;W1"83FC)O%UI'6YFH%HZ<].BX(FZA?\)& M3V+Z_H#=JN8W570RB0([* M0XMTT1C4@!IZO?`*-?RJX3;=7!9!#;ULN#!J0C<45WQV"92-.,P,[GT'F];? M*4<*HT+_M_6^M M)X=_2EC+%?]!0+]5BK]E47@"\J_)&]?\!P)_IOEC%I0+0%I&$RV(@_0'Y,R> ML.I:Q"''6I2^/[2GY,I2EXUBFKX[D*YL/ILXPFW5F%-#AS!EE_D ML1<_7LT7NKG$V#Z'H8B%U:@[\4P<'=]/;@R-O!'-1?J1Z-+8>?M82V%:M4Y$ M)Q*$8O$-"/:2/*X#YO$7,'&8#=WL\DP6#IKNSK] M\BLRG3G9".6;DCL`/);;;81VW5G-?>^)1N^.J*\9[.;N"&X2N$G8#:W:6X'S^FWNLM:@8INXM8(78!\0 M?/=>@+T/_'(7@;L([<AL8NM>*G^X>!W_Z7Z^T#P)BD?Z8_# M-T!JW`#)T=GF<`7M&`W%9NDC73&YF-4H9CF:;W(Q.U`QBUXQRX/=5$G)0&MM%B8[87.8T(QC`D=FIQ,P'-A=`C9W3^IT3ZY-U\KV3G@8 M4(ESLV%V=^#.+5I%@D;>>!BP5Z.04T;7ZW0LR'PB'QR8[0?F>IF.!I?X#1L< MF1U`YF:AC@6;SWF0R;WF:E*"V>#JEE3QZ#2OF%WI^6P`E[1JCL/I>30Y%[;# M%+8[P@LO&A.U#;.YH!V;H#V_8SU/,HB+6D7%%QMV1EBOPO<1X M-G!A.PYA"U;O$,O!/&)KL%PJR'`N<,& M"I^ZB.57&Z7J$%!,=UJ+N$Y'KO1CV<6QV42!5#Z7YKCAF<0QCM!Z$/JWA?L' MT.B"G;HQCO%&FN1[8>)8PV%8#PR_(^O'-VQ-YXAKR`P-N<4JCLGZBRXGW'87 MJWZ<<--=.S[YM7+U7>[&H5D(FDDW'_)N#+P;PW$ET$<$K3YB?M#/''/@6T4W+* M^V!TXE#W/OI@=!K8O(U&)W"]AS8:W88U[\+1$6#OHPM'IZ'-#SPW&#+P`\]\ MVZ3LM@D_4-;@83+:DLW MH'D#$][`A,MJ57:5]S]IV++R_B=<7FNK6N3M4WC[E$,5`MY]A7=?.5!H\^8M MO'G+00.<]W[AO5^ZCV+>.H:WCCDP2//.,[SSS$'`>[B!-_PN)##HZ72B?2F)A1+.7 M:K'PB8C.Z9\^F:XSLX@VQ33`-K`%9FYQ#*YJRL0YIEN)Z7-[AJV-/\83VNE) MNUAV<6BW$MI;]O7<=:B.Z!M_.' MF>0RL)*;AM6]@5?4LDSP-K,XMFH[A'XL9U5EZ=%<,M MCJ[T'`<'5X$T!\=6HYKKY3LQR-R=A]Y&QK2C(6HS:JT411NFKOX48CT'>MU` M1Q\I#U'.AIAQ!3M#%W)>IR);@^;_RL;;(NYC!O.\RY-L^9#.5-;7A3 MFX/)Q8:AS;LE\&X)787TN7UOK*$LO3#^W"^HG0TB\SOZ3].B?+7O)_2$Q;FA M7?WI`@.>L.I:Q"'8[C9F`DRJCFX$0,F]H$B@LIC(O5)_6I.HZ/]N.C MS>HF(0;BL.H8K%H6=C!4_Y MY.ZA0[7-%K%,LIDCO&A>ER.\-3Y?JN[^.[(L,!W!#Y\Z&=B\BRFG*U@.P_W"<#^;=?N(=+@V;#$,]ZX-ZPNLHC#D MVK"],-R[-FP(AC)'6DFD'8(EY&O?NK5O(*\7WK7D&&@'!CJX,\FATT+HM"P3 ME=CHW7C#ED->=4Q;D-I^#](0E(ZB"^OJXU2&=`M*3717#_:GGA$\N?K`JNN0 M-WP_F1`5\Z/?.8Y^IS"N8X"KJW5TO-E[L,@;C/"@(Y79A)#2B+""])]6HB<;#1 M1&`"'Q`MW2;H.]:(,;URSO4_'K&*%XZYF"%K?F.HUS^0_YN]64W<-(&[Y@&&FP-[[R3=D_+#< MA:,NCPY,N?C!MWQ"B!(#B!*YYW]HGC]+RLCM- M3_LS@T]OQV@6.OAW05X:&SMX606^7#VRSYY,&[Z4F M+[AAAY)M\$?\JM!06\=SF+Q&=%9YM3G;?/6AZJZ&M6O+G-,:4]=!7H[J"ED& M.#[V`[:>P-7!WY;Q7]!MJ:B5*=Y%.@F+PD.4%"3GJ-7E<&X:SFVN&VXKK,/> M+E?0[4)T&Q5T^QSO^(M'N8)N'9S;K*"[`>O@AG\XY6G@^\F%A37B7".5Z*3K MIS>29\24XC8C.&Y6*75QO"ZIC[TE_NC`LK<;X$.'F,5Q($*O[P`[7^\]7<_> M6*<*D&]IP!>[/8L-DBT-ZI=L;OQ;8/SWV9Q M`7/XLC4)!H?\&]NE(B)^1T@9&S4,])939PCKWU7--)"N/0-BG6.`9?*\]V6F MA@UWQ^;KOJ]U;WN(&C!JOQOD#5LV;2$#,[3PWT&QWCK:,2`E=>H'5IX56?5( M"O#>"*5F;TUCZAQ,FYOXV3`$)+'AJ!;_^=WDBQ]@PR$OOL+U?9OT?6.=?;F^ M;Y^^W]?BQAJ,-D<*=Q MJEIXIZCB6/[O;_=(5&HRPH%2@.(>6$%0MK/84/T"!UTQT-6ZYHT%"-QZ M=D@QM#W\-& M32/%!X4=3ZH)?$7P/+/P$=[-PO`5SP9NU.LWZH70^C=DN,A:RA)]V7N*,M*S M;)3;5*@V-:,YBTN[!^DV1%/55)$6&3G@@$?7VI]]##ZZ920:N56IM/A=XU>+ M\E?B\L?E+T[^X@#"!;`Z`?R.+%GDLL=E+T;V(MC@8L?$KA=[F^`YH$.7AKDD MJ:"('J[@94-PBZWM#*#V)_%UBUZO3?88NWE`9';O'RZ/X0E[C8<;'; M3>S^YAI8DKG<9>4;(FSB@G?$@C<("-ZH=(83$"7WN>#E$+P@F[C@-2MX@S*" M-ZHIQHL7O'-WZMJ.DB]=PH.\_$'>%E^Y\!VQ\(T"PK..Q#)8]8'Z+XQ7&`"R`7P*8%L'?T`MCC M`L@%,*57NK=D05%*ZL#XXM>41@Y`/#E`(N7F`;]VO!MZQK08 MX*,,J1;D&9TPPTO7K5WLQF\$*([R2*>*`T5Y11BK6<#VT"ZCS2A/Z#^0!]U' MC]2J<=+D<7[0:'S!V[;@DES?@D?#)+[@+5CP6AHA)#DNKNV86#9RZ3)Z4AX`H-[@[D`,[$4?VR+'#7 MC($M^X;H^B)I"Z][4$C>[DJ=.G#`ECSISBJ^]/M<^C:;L<)M M[3WD/&(="-"H=[!\MI!A(Y5RUOZV#'[B%2P=0=/[NEK/EZ$A_]*T]6:W-O;$ MEWQEVGNY`>+BT.E4%R]$V9OQ749+;\9(N`C,#C7=]?A>P+Z+ M=3T_H.!60L1YJ'(K(9=H

*69!$8FIR>KDQ M_P*58-H4JGB(%>8(WPA@D?"$!9]QH0H+W27%2BS4.X6/S/5YGG!F$>.7TJQT M;$Z-2;S80W$%L5`JNIA;/4_">1"QJDLOS59?IZ=1_#844^OC^Z!@V8N9"+S\ M@3O\FM2D-&-\/"A1">_BTNP[^L?=RCN$@Y%KHFGV-SMMU#M(R3,>:Z'^TW%PD[77M:*ADILY3;D/Q>D"?X:].$)9. M;V]TVS4Z:U6]/#5^U]9Q\H#PE2)4Y M^%')*2@K1:F#P]P9#H4'J49)I/01B4EK64=XU&Z<7B71;&GE?-U\L3P[-Q(N(7Y0 MQ/WHD,'B`1G$#R&@;&.1#1M1^<_&@RD+FB1B?"3S)U3GCZ[L:4`%6WQA3!C# MK<\"AU$,E&]RY9E1-C*6P,VSE-Q"!"P/B#H\K?8+D0#N^J$6TS5;M;0SUTMH M+9T'T2Y2S$7N$R<&B?7 MM!*-4N^.,#F:'*K"X\M\B@!5:(U'8K'58!UEE]+'PQRL/!LY;6X:31E6^D19 M,1ELR8>S3W_-`LDIE/3W&(-.1\1T"B.PA%Y4?]GL_"S(2^JDK<$,,TO;F=1L MS=EY,LU(/FG:36I(:0'2=<_ M.T7Z[1PK$LZI(N&$*A)V5(7849._A!F688:X8"Z+,59RK'U&1QX(2-(AR"*S M_H/F^0PC/X7ZE]3T3HN/><0#@S0UKTIS.("K9J/!=)YAPWQB05E?US`2KC?A M'X`;QT3:#$@M3.+P2.7!MPJG(S'G.8#B M:E5"M-'T2>+]64R_])8TF8?7"S7<:KN;ZM3]SD=M2/9W^6*HO))6_'9-.EU* MH*ZX9R)(G%'3)&MY7^FMH]!=O^WKS__?]=')^==_?O]PSB:P+GWP]?O99Q2> M`,A'[?>O9]>_?B`73XX8T=BN(GHKCW_4/EW\./O\X^CTXOS\Y/(*7DK)BO.( M+>'\HW;QK\\_OIQ?_/Y!PS`X++]1GUF:YT#T\0M?&58 MQ*6_OKBLO?$*5`"ULWNP*KP=%JB*1)L1A1[94T^'^M/)Z?_]YX^+W[Z?`>)L M>S*Q[;:DXRGWY82Y1?T,_+XNG#/7<3SVBE=5,C36@/>79T`5HK^N'JS+D[.S MK]__>?2#O[R?^M)?']0:3F0:^M@828]&1:6*2@^:2B41GQ/Z7UOB\TL2^A3. M$0.N'BBTLRVT/QK6W61.S:&R:?#:XU(-PES#I;H]?=@?2H]/1:Z*7!6Y2B14 MV[5)SZT;98[*`MX>,:=V-?Z>J1OF6'I\*G)5Y*K(52)9VJZ!>LT\-I]B%=;6 M):H,^I,,X.T1BVI7W3=,O6<:TN-3D:LB5T6N$DG4=JW3"VJV447R!T;RD@CW=DWG:VPK=L@JG`S@R58((9$] MTF3!A#$R='.X-7>@HG9%[8K:#U""MVV>1]$'G/62S!+>U]DI-H>AWC4S[.WU M7RN;YWJ@&ITR8IHW8J0Q6-X9_8$^[`[?*PI7%+ZG%-XS]&%_<-`4+HE,;]V&=C*+XG2^GH/335BQ@SR.UKMAF#AHX62.8^TDKIM3 M][C!CLM[Q:;XV5X]5NF++]KEEV;E19N'&N,`S&;G"O?T\<@HTW/SPXOA)>-> MZ25[.KOXL0-,JH-/3AR:H8H#$DZ#2#S]68Q4J/SQ&<-/!@)YFY0BAT2;ED2$XB,GU:?82/EPJ.$N\<=L_47ENA M%>./Q(!#N&L/7$'%^8VA0P.7:'AB/JGTA$]V1`9X!?JK8X6.]BG`?[]+Q^Z: MG8]?3JX^9;\:']_7?NTTVQ#0LW##.#*2=L@S6"T0A?LEGD(HCAT0133W&8Q$HQ& M1XKU8C'7BTZ9SS:#,\(,L!MQ*+\`NB,+AUN&#)#B`PNEH:,^VG.$/P9"%4>C M[M2=WU%6=8'Y>/!_/P&T`S&[$=F^Z:A-81#^-B M1)$)T%F(S@#V8.%B?/1KKC!E^X:[1W=KG9X%,(MQ=ZG9#Y\0I);F,PZ5(&<< MWUH<.HK\*X&+%-+TW_*!P9^P0!&T&?P-G\2!>[!'&CX*"H_ET1HAXXF2\!8: MK9JMH"[!*VS["@?GYM-S]0SW1.51`&^+X"_373K4)`TDG>"4)BRIA M$M?_#42S5R5,+JLXP_?$U[9P/+FR`X=`(YZ%@/I/`N+# M<6T.INN+`9.P`E]W?Z;>KC)/JF;,U13.[A,.',;A"F#XT.%>$/V=^`XL`](0 M:`5=2F)^[C,LG-%^6SA7,9SL$9VB5CS&+5L[JP,/:]^`O5(T!XQ1P=0@_"UC3A@*2XDJ)J>:#0XXT3NXY#N%668$?%F>7N2C,@RB?5%CDY:*K8Z(=KX,#OO\8X MR!;X@AM-43>PW%",;K>X?C)C5@2F"!\B3IR3#P]/3YCVC(=$%"Y;.D<\M M)0M,G&>!3R9@\3V9B`!MD.`"8&P!ZVV`Y@7NEA]^Q'&,D]RSG>$"FX#9&YGS M#%E2%4>?K="'/467+*357NY<&^^WZ/D..M$Y:$(:G)A&1Z:$3JLZ.AXXJI[( M:OG5IBGCEF>+&K,:X9-+#'-0='&EU$YKYWOXN4(PX^#;DP^F?2"ZC;`'>S65?OE?8'&CS\$HA\TKJ/`5TA(F@KUQ. M1U,>S&B=#`@TNFE`-S!7YNA"4H#@$'ZR^R#Q'+*$@(L=97N%$R,CQ0\*#C56 MQ"Q!"'J#OZC`[$91P@-0Y''CRD(Z&YP]L-!VN5>+[SR8X^&'W(''%RN77T=_1#0)RSW+]@HV(WCS^T'&3MEW9LMOL_"B/1'=!FHOP M&Z(FG[CD`U.?WQ;'1+%4E/8JT7-0K3,U`L65GL'G9Y29.SGUUOMN%N&_V> M/C8&^F#PG+YMLI&Z(H`G$T!_J)O]'<&_U-6'LG6#J&/[IX%/J7MHIH#E"/N8 M6PMR5VZ)]^]I^X_7*DO:?"$VW/[Q2.]W!GIW_)P9Q[)1O"*!YY!`KZJ8^ MZN\`"1R``&A7[]^-UJW;O.FO7X0JC2IH]KMZS^SJG<%SBE9E(W]%(ZW8BQU# M'XW'>M_<`1J1H+)Y=W(4-B085/,1+D,W""\IP/B#V9X515E!PXF#L1W,YCAC MD1VZY&MZ>H*"V=GO!(7JL:D2H%?=]JE(!T]K1D1B&95S@YU,C)*"^%_J4LWR MY.,P0R//#@FIO*#*2P#A>9'4 M91CX`6;KTT%S+O3B9"?3V'M>@D16*#4K'^.664NVOHR\Y*GXK^4XOXN$_*QP M1A1[8=IG2,C)B"9=8ALB+L MCL$3:C!M92._.MYA[O)4[K"LJ:SH_?`2?F+N)#_9=/WJV]/QW"^L^!<)6'DF MDE5NS;)3"L`^)!3QN[DFHVC)1CK<%*/&FR;O9H+#3F:H&"K%:-\1J%*,%!O= M(21N#199&F_+#&K33;85B2H2520JI2B4+#)=)QU/>:>I,+>HGX'?O>GS+P-X M;3:WEBP@_+PN[88^-IZ3#Z2H5%&IHM(=2EJ3+(NW3GQ^24+?I>:`Z)6>N`_X M\]:J563(590!O#VJQ6AY"D1/'_:?4URAR%61JR+7@Q6J[=JDY]:-,D=E`6^/ MF%.[&G_/U`US+#T^%;DJFT\#GVU?HLJ@/\D`WAZQJ';5 M?Z8A/3X5N2IR5>0JD41MUSJ]F$RP9W.>@2P.I]_YJ`7QE(6'K%/)`-X> M,:R68U3ZX+`M`!G`4]2JJ'6GI&N[]NHYLR(V#3P'J\C"X*Y0(GB@2M5S4^HE M0_9!-D!Z%J,;#/6><=!1+D7RBN0/C.0E$>[MFLZ[T>'K0`P.60HA)+)'FBR8 M,$:&;@ZWY@Y4U*ZH75'[`4KPMLWS*/J`K7R2F1@CY;!YR&R7CW#$)&AKAD._ M_YL/9#Q0C4X9,X>QO_]"NEW#N[[[I8Z3FP]907OV.`3) M4/Z";@G2S(%HUQXQ>WJ_VU.TKFA]_VF].];[QG-FF.P-K>_?")/-G;ZKO<&O M["ES$H]=3$[\V'5<+\%>[%?,3D(W=EGT^<'V$HHE_MQNVR?4/;S8+!Q';71)U\+NKWJEL[@;LUFDW;.0)E5JKL\1@6,Z M4C1I7A!%FA71-WDC?Y0^\X%H1;4D?[V6Y.,-'-SE,-R'<>@:H!^>/9J&S#'NM8ZP7-FHI(P[BWPM#:8I&#*E7:YLS* M?D\?&SLRXUX10/,$T!_J9G]'\"^U$U^VI(HZMG\:^'OJ@9^JC_@Z0P`$(@';U M_MVH@%+SZ[>B"IK]KMXSNWIGL`/SZQ6-;,=>[!CZ:#S6^^8.T,AV`H1+@8P4 MJK]6P/JK_M<(`U-_70(E"XKLPP3TYN.(::32GT_MPO+9<.>O?A2'"77NN,;] MO"0`V3N$`.1U*;PHPEC);&:%[G]A$SA&>Y)-SG;ST]5FS(J2D#DX['ABN:%V M9WD)P[CCVH#F=B*/JV_H'H8:-TX_/MQ88Z^K8HW2P%(,1/7[1>7#,)8@T[X` MC\G!^QYQJ%+R>4NAM\ M[EHWKD<:Q8>#0>(^AIN?ZZ-0"0.R8/"6F`Y@G?ZN(9Z-V;/A\R@-=F<;MDF2R;0:UA1%VSJQO# MY_BH%)DJ,GTU,CV2'H.*0!6!2HU!1:`'3:!*T,MB@317OU-G@2Q7K)4R#;>% M?QDJ5F0`;_?95(.@UK"IX6"H=_H#Z?&HR/2@R71KZIXB4$6@BD`5@>X\@2I! M_^B>F9+5/JEBG[TK]ME4*K!3X=WPOY0I3[[QZ54!G!#7*H_&NF=\7/2'Q29*C)5E12*0!6!*@*5`#Q%H$K0 M-U3J(_^0JB>/D%HQ>^IT:OFW+/KJMS*$JK]+0ZBR]9\U=6H:W$=:#'^Q^8EJ ML&IALM2L4/:A)1%^,7)O?7?BVAB[2OS@)F+A':WE^O,$GGI'>9!:][WF)"&] M"59?,"N,-.8[S%%SJEZK=*V:6CMF-P.;(?VF@6CQQ/GG+]>U?U\Z+OSG>-@O MO'_PU%*X2G1\Y::$,%IZX%5+Z;97AM/M+XN+,Q;9H3O'<7W/$(>[F5R\DYGB MQH;)K[LQ^$HA<`T"#Z=68[?3^^OXZ`&F5.U>*MP!@=K9/5@5W@X+5$6BS8A" MR5(=ZJ3C)W;K^C@)7+NQ/,NWMQ8*EB$50`;P=M]#W""H-8Q():S(`)ZBTO54 M:H[T4?4*DDTK.Y<%6=]+Q,0GMJ11@`<*,H0?D)/Z*'.V)Q[(D.2@<< MS)(!O%>W8MH/OIY>G%_\R)3ZUIA8KZL;O:W)6D6_>TN_[=#K06>W2")O4]7C MR1QJX]'4QLBLA1;X3/."*((?1!P[F&C3Q4WH.IJ;Y0DTEF/8%/S,K1+]R MI+TSWA^R8O;=OJ*(6R;L*N+>8>SOOY!NU];^[#L2Y&K) MH)-MU+F[<)N<(*$B)(FQ_()$F2<"OJMAO2V/(U?$KHC]]8A]N^F-,M#ZFOKW ME]?:9A7MM:7T#;UD9PJ/FQSU^ MPI)6#-('2:C=5QLC:VY4"B/PXQB99NPZAV+LJ>-C_@< MOM2R[6`VM_P%*DYVX).&3;N*8O@/)@?09N8LI)U%Q^O/?>?Z+CRA?<**!@R_ M4C9%S=?/W,@&1"W$;AL$NM6%X]CS'M$YJ??^'E/CXTRO:0>27Y^&# ME<1!ML1XU-8TXZ7];*]\>/2\JFDIZ]Z>"@:+0(B4H4M;:*[2HV_(8OT&; M?4B>!VS7++8AZ:YHX1QA.Z#L#"Y#UR[,;:=7!?G,\.VM@7-#ZJ M7RY\(R@\?LE"/`OKEA67*#[]K]]/+O._38I?/@^"GT"E;E`Z4&4U\LA1#%_11:-G.TB95X<8F? MX099])PB+H6G)X#RE*24$J2#95!/_-@MZ:-GKI>DS2S3STX<]*`R.;7"9Y_& MX>!=<54I0:E!2\DDVR%07EG3WQEO09WD_%]FA8>"WCU!V MFJFC&=0_K/@`;;O=06+-S5,HDQME-29%YK!6.),39S6\\JW"UT[AZ["B--L, M!VPJH&G,8M_8YNVU!U0\"_(];,"R#63W!SV].QPH?&\;OAF9W7 ME;@O@EWA]O$7U__%DA]P=6DW(+;&JOE+Y[C3Z0Z.Z+^#GOR'(),DEA''-8RY MWWE[-.HKSBP-?$TBU^A@?5.WHYU9B^._@[9%A;E&N-@?"=\=C3Y;:-#@ONW MIE_(;O=M>'+7A17=&[+^#RL7C%["!DZDGF8MM,!G?.91X.>3B98FIARR`B8#>'O$NE*87T?T&OJ@#R9$1XUA5!2\&R9O M;SC6>^9!TZLDPK==D_?=/RW7?\]E[R0,9B(1MYR'>\@JF`S@R<2UI#$/WO5' M)K"H[GOIT:>HU M#]\;=>JY>9"2(?SU#Z#98MC7,7C?@<7;`XNW:VY-/"N:5S3?JHD,--XU.KK9 MVYX**@.-2R+2VS63/_N.!&E5,FAP&V]T%VZT$R14W[A]+#>82/K8C)4FTU"'@Z'>Z3^GV8FZ.NKJ;.OJ;.6J;#DK4H:KLJ8MB?/RK@6TD:77;_R% MSGT7>I\\N6=)J??)6<*N@XO)Q+59^/+>)J-#Z&UR$J]H*U+]U-2IP8C0(S4G M8>@B"L1AX_%&+HYTQ/2'N-@P174@V=PFY)RXW_HF(3D#+78%*>OQI_3P> MW8\#V?0N=^,8JL+^ES@WMMF-8U/I]LI^&^G067E+^U?#K##\1`SO0O7^[L\P M4HQ8TCZ4VS"1]Q;4IDN2%8DJ$E4DJ@(YSY..)[Z6^!&SDQ",;(?-T$CW`LOG MR8]!$FJ7(8MC2-[>JQA'U/ZQ@TU%77%.&/-BK7> MV^*?A8UOK?(-<'<`?'?.[-B]8]Y"A]5L+W'@="S;#A/FY,O/K059K,%$^TNW M-]9[@P&M\I>NV=-'_>[Q(;L+90!O]XNHV\U^ZP\&>G=\T.5<,H"GR'0]F0XZ M`]T8C*3'X_YG=#27O=.XF;PWR3LR@"=3_OAVX).R:YBCQW05"V;#$7 M[.-+*_&T'\QU=!&=#F>L:#&#D4"P_\U";G37>XF7ZST&P6QI;KTT*>!_9R8GG:/`S@^_%BZ;53 MZP[?:FG_92$68/`7/S)"?UR,A:`UOV2*/WXM[=Z*M+_TNGIWT!76^A",H(K9 MKTSW;:7(RU7CUEB*O-0&EF%V=6.D_`"*Y@^(YHVA;AK*J;!]74DY%0[+:I,E M_+DEHTZ:D*@B;IFPJXA[A[&__T*Z78=&N993]?/=G8JT-F*6NUMR]K2PYFBL M]T<';8$H8C\48A^:7;T[&APRL>_97/V=Y'@YC#^.C&,[K?5J(&"W5(:Y/ M9]Q.E>*C(=ZULD3;8U;(7ZXJ%%5AS.OYV66N7U,%B+N/P%VH+Y3%HZ+8Z-:1 MN'L530<$JBK>VDV\'1"HBD0/)KCP/8A95JLG#J;?^:C]8)Z%?7TN+4Q8?&>H MKO6R8_?`ZZ",44<'!B<]'A69'C:9C@^>3"61J^UFUJ%H$Z_?`+PE7%QY[ MI[K.;QL\F:JFY!ZT9IBZ,3KH06LR@*?H];%M',9=O3=ZC@=^;^A5$H';KB'+ MAQC%$S16$KXXAX'PVH/9.36!3M3P'5,O#!QD<='*1HOD#HWDUD4`6H:_J MUP[+'I$EO*9*?!1QRX-=1=P[C/W]%]*J?DT60T25].Q)28^A=_MCW>RJ"C9% M[H=![D-#[P][ATSNCZUAVY6RHE6U/:5RGNH+BO5XFXIW,H(J512%C[A&3L_I MV*-,)3W__.6Z\&EZ5=+'J0@I)YAX4T MG7(7CK_=\W[&(3]WQN-90JT]L3HTGKJAH_V16&',0BP9-3M&1[NG6N(PN&>. M]I?:%5-1]-<*>_ZK_M<(BV7_NLP.\:N_B(+8\[2\F/?U><]:CP$SK4K<#&UU$?-N3A*SJTJ$3Y7X5S[B!2X"70+Z1DJ7RVUE<;)+HS1E&KK1'9;IB)K0 M-OF6T4#OCLHOJ>MN^RC6W.K4YX^E"NRC5/[5L$20C7UDK"T/OU7JX-XI(DH= ME`$+:?KO+AS_WJB#&V1@<>HY"CJ1]LKED<@IU*K3T%:/0R?!&VUH-Z)$RX&+ MEEY_'K\62QMTE .\&2ZL17B]E-X*TP`SEJ1MW=0")VOOO;-6J"(,;B( M.0UF<\M?@!RQ&0@1,`?%]!(PN)KU0?17N"`LS0_\HU!4),VQW!>'@FXVJ_U` MP^^@V0K/564I_'M7C>@<>/CO;6(!<<:,CW6!SP+>U"V5\`*!Q]J%KWT/[O@9 MP&&3/L%QO'2^:$JS.>U;XQX26*S)(])Z>G=0XW.*IG#'HLK6.3\8F<;P8X3Z M3!RZA&P[F,$)PG:P!QU0@46(7Z#?!0G!<2,;EKME[=,I[!=1$B1Q%%L\F8![ M:7#N3NM>"4,?B^SI;$/OKA@O,M`&[X]S44?3=PHW&M43?J.CJ/%]F2.]U^M5 M#LHGQ$8LCCURD)%G2QJ'1I.<5&F62K/<%?5%:9;2HN:0-$L06-A`5>F7NZI? M7J'22(=@#+:L8(+R,33U85\IF$THF(99V=`*!?,U]P&7&<1>F>JA^'WCS7`B!WX M/D8KX3%2F_&/B(XTRDD)/Q6TU"*O45W2P*-_I+/RKU%);8P>HRE-K:BH+=$` M"50NB9#:):LNZ%"5A":@\I!-<"0XO9CW)!%`ED$3*K&3<(R)ZV%;8;B@P1;9 MEOE7\_8G!"'IKO!QB"'J@-.#Z]LALR*Z:I5WX=.@1.";<%(Y&&!'<#2V-7?! M?*@<+#,!/`&J`\K\88K\K)`BFQ\"1FZ<94IX?\Q'S2]'^ M`E0%'^Y73A#L3LR'%XETY6MP'R3`F.@RH,U6.+E7NQGKC*PR;H763DF.8$O' MR$HF+EBKS.>V*K=<\9F9%TD?5_>5GY_1>5^?=9DG6RZ)O=8-S_'224IC MR;W<9E/FF3+/E'FFS#-EGCTV^U$D/7+EKJQ6QJ+RMI;A(V7_J%_V:`#C(7SR#O(EOXS&3 M`0`UKN@,PAZ)8E#`TIT$8`]:"&-4-\W./-8*I4T\-%&NJQ$&>)2X,:'F+O`` M,#!N09\&+1ZM/=(SX/,[7(<.<,H\"DD4T$H'(%#!%3W^)-E7:'U@$,.R?Z:F M2A"ZMRXJ@=/``_D8*?5BVWL7;.[_=.E_]50)M^ID#K21*JC-5M^,]/YR]*7\ M^V,./+OG*9FN\!HAN1>9U&F`=AU8!9]1JP8P(YQT>7Y^JKU+N9O9^9@^E7UD M?'R?WDRX!&1M6EJQX^@/YC`V(S9!"O^2[ZAAC]&HXC&R?#^9'3?ZBNRH*$3K MQR[P1H=[#@AN#6=P8EV8OZB("[(&N=/*A^;[_??ICNQ8`WK-C.D M'0OY(?+&&4@PAHT84#J(A^C512#RM=.HR9W-F.."0(#]S3&>[Z1/%@[B#/Y>D8]?LNH#`C>MFA1;2_&KYY=B9CFL MX$V*2.0@>&V%D4&$]8R!/NKUU_G^[/5Q9$Y`A?.+0+3[U>+2+J@$L1M-%NE3 M/C4)AEN-CB4D-;K=N8.@\3CO:*`/>N5,P@T2<=OB8I=%W.\G$%NPFG8*$O2> MP;4@;.,_\*?P)S"3^+^Z=GEZ7)6&:V1AU+HPU%9(PU=-Q]7-)>PO9TL\TC$M MC1QG4S_AXQ8).Z*8HK?"4&4N'ZA@61YL;HJ7K=A[U.W.\Q& MWN0AR2E8G"^M^)41;RI4\B0W/9[U:SGI1ZH9Q/Z%2JKIYT_PDJIH2#/1D`N_ M43WJ)+E%WZ/)"Q7*8B.AOE96T2K(=#\N_L[=/Q(79P/:/ZU;%"0_6!0DH8V. MRJ^^?5SR5)Y?_B@Z*_<-@Z,CK4$@P^`EN0:I'$RDQ_G:%W834I:(^+LIRC.*Z.$VT7TI MBRS2;ID/6K\G,J=FH**`!FQA)Q"J9_$C5LZ\$?I!OC!EU#A4Z!*#JO^3J_J9 M-D.;!5V_D,9B:J(\@BM.02''99"&\.[A%<+'D$6#+/B.DY955$S2`O%-,7^& MT^<]JQ!/L\IY7;8EUZ?PE$NM5PHE&36ZGO&.?,VN;WN)PU#A;+U6!%!K>3%W MVV#AC4#)>ZF#6P8)R%TU0T;&"WA[V0G4?%?%.AHI]3F$:Y2FZW)_SS]J&TE/G;JY-*Y!H#21&[V!6S=0%,I8DB65>D M;'+NY;+FI;!1DYGYGA-WZ^_)P$NK27U,:,C\<'C)D,:CP',R;U0E905',8-` MIV#P94G%RA\JA8.1AMIUVILC0Q\.S26EZL*.`Z$A/"H-(^4M>:K\>).TDI&1 M*[^$\DOLBF6\CWX)Y9C80IHFR>E-?2I3!D]U!+@LF^&7?_-=`)T07?^A8L^;S,'AP9SR_1-J.X_V^WC/6=!S7"Q9D%F?'<^)2OR3L MZ>/D)F)_)'`PWF*]W)3&LGM\?;L2M(K)*U&[JUA()]3OPO'OCZA]6C_H)D5; M<4)[9N@U/OB@.!,[>\N:^'6QHEBN[M6J3[5BMDKD[3865(&@W.+P:['=',JB M@M>QTF&PI:%9=1YM/E7*NKW%U@,Q2JF&(\DU/FS19.4^6.JSY[*(^U_GH>O; M[MQ*PS61D)B\)4&IJZ%H1`"JA!=@'JSH=X?NXQ`>FP3PA?2HLPA1DS!>Y`YD M8\Q?("),!!"/*C&GD+4)^VYNK871+C8S`I_LECD(R\E-O/%,/14;#@R#]F=&V#;Q\YR:B^6I:9I[GZ) M&-R\E#3-B\C3%-QB^W`,_3?>UU);T=C2[+PEY!GF6YTN6'FJ206X1ZC)2XTK M4J@;+PMNKVRG72]%9I&5>C&*U1NE;_LE2YG:;E"\6G M6.[&\V!J-"BYZJKK2\E2HF[R34O%4/M2]Y16,`?5"JBFZICS^A']5:NC!L"H M^Z8^&I@O9M9T/4C08#_'.LZ-3%/&^=6NF27,M(@7$Q$S&K>,&'.,=?WF.L3L('O9 M:=YX(1H4:=U.D3&N=6!-DC#&X2<%1U:YURD\D_E?NFD9?C$S.VM;W=;$MMK6 MID7-@:L9PH_E%TU6M[X16B%!O&4>:7:6FE_0Q)+4TYABBNYG=L[&8]!'>^6R MAM_N5"MZ!%;IM)J$$QV>G#IZRWRGR1<)8[7N756Q\(I$6N6VANSQZIZBM'XZ`4@'YW0\%JX"\#%A0`7FY`_(7OB@<-,VBVK0D M^8O>TS-V`^>2\*[]+08"S!IQ_:)FFX6Y)SCO@KN)\RDLS:H;Y8WS8*B8MA)4 M#KVG:XGOL2C*8L#>(K6[><2SV"1KQ:R[9N/Y^2E/1>UT5L*91M13)0DW'X/= M1-TY-9R>R,J1]=#BCI&+=_Y[KO:;[$ MXFB"U9=S%MJH>+WK]]^^7^&YYM$!X6;^U^\GE\O>ZB6G:JT'.[Z'5RW*;N>R MJ[G@=W>67\<[!;33BJZGC[M& M!;#U3<4(\>W-BAP9';U?K61LNJE8^X%'8S32A[UR;[2@F"?5XYPY5\6'825M(+USW#'6@(]#V>@( MRBX7V\.`Y,0%8D`FX#C,JRUT)(HY?.?/,O^>71E3P. M:T)C:(UB`"K+?^^L\:1@1+W6E])V5F63:W4WZ72\H(+;?6UWG']//J%IZ()^ M.,>PW:F%70&=8&70)I]8@?:]"\B`KX8:91"Z-+`IO",W07E2Y75F&]*PU-9< M1\NY@@Z-R!2>H[0YGR"S'OV=1Z[3CZJQO"9WEYU"04478;+-KJ*EAN^K?$%- M4S\HX9W^:H)5YK2636UE9MR:Z`IY3[IE>ZA38^> M[>B#4>\I]T1*&E+6R^'HS:$E)O?AS#\N#_4^X/'FA-K@7E-8\(8]?7QT'C*-9&2A/:9 M_@\N.MVIK8XXN/"TN<8S=CCQZ5ZOKP^Z9>=K\P'J1GEJ=Z@/1FN2"]H,?2]9 M$"KZK?Q'N^ZY4/XC&;"@_$<[Y#\RY*L;&!Z$_\A0M0,K'$CF#OJ/:C0CY3^2 M;?/[X#_J=L9ZIU\98;X#_J-N1^]VNLI_)#'][X#_"`>RUG;$D-'-L^R:.1QO MC#DP=;/;=L>#9L.6AF[TUHX2>@UOC*&*$90[9D\<`G=,6GHP MK//%I$/KM(C929AI!ERCOPR#&>AO`1CKE.C>KF>F6]/<$0NMK;N`C/>:R;G: MUZ_DI"GX8-#0$.X0A\TH/1[^V89GQD]FQ^LVS2<'^[$;>[Q?<='_D8]WJ#@Y MJIHF]-'ER_>G#9]`0^`R-O!9R.3[AQ':%3"WIL=#]5 MM;+BI7'1AQ.(UL<+/F"BXK%QT=+](V$XXNJCF%&14IT84[`*\QMPW7C50[5C MPU=^H`S5]FS`-#<*)JX/9AR>!&G]MZS0#3FS-`(^C,/)SB5BM:9&-G*>L>SX M'#>FOA`1?#0)0C`?L40G"4-2;VVB"3Z,'8[4"AU>H`,'C9WW4AO'IEW#M7/1 MY5+[1^Y.A"7O+-4'%^E*TQ M,G:7#PJT<3Y._#+)WNB4WGC#;"N)&,TA3IE,=5K!"FRAX_'$M0V>,R8$'9XSMCCYO<(#I9)6+TVFN?4;O32BK^34R3J[]T5MMEGBQ._) MW*O4=U-*M"I,!8N9K[TS.N^U:_&],VN!%\$-'!S3B)^@05KZ:]G)%S/Q@@R. M[T%,WD?T50&RQ,9_Y6U.Q/<^\0'%8<4&O:YU,]%2R#&C]TCQ_62F)\AX)&;YFXI'0'V`B90YCP4F0!'J>,F=]^5?$4Q^8[1B>-7 M76!TP'S'E0XNG"8TFH6+H_+6NGD(0[8535-O+?F-$+T.=S'19E.G4D"S-6`M M=/7A<\++]([\O'DB9L$]5/RJ[W]$7DJ1T-Y(Y1/:'>PH'Q"TON$FA0I7]A-2$T`>>UE=8Z@-)4XO?I* MG!_,N0]`._]F^1:/,E=3/-I/YBB?6;7,)CM@(^N/(ZILGEI:T^2NCU>=W!,* M;>*5M3;Z$YHS?L&Z&NTR*ZGIY"4UE50.^HH.E@`@(.5YL86EVY&_S[^O2[]A7)TR"DKZ/.4*$P7HK!@LP\<5PM.)/[?< M/+-$STXE2F;-.W;-)>_5>FJS[)]^<.\QYU9`2M,RP"*<"=LO+P0H9GA]3^`0 MM$N@L1FRI-Q+Q[.;00=$HV#E4V1$6/"BX`88L<7321*?K'+QOF/MM[D@,9&C M@^\%U.C":K?`)(%/SL!,`9LFK";]:]8<+/`[`56!=BKF#EV6'_FE+]V6\I(Z M+N@2BAME8N1Q7%?+4#K'4JH16?:>ZX.U%O'H/^_62[DFKT!<3[%Q#B%/1)E" MNZ^$*U-(!BPH4TAZ4XB/33$&7)62-5E]V&BR>J."/Y]U/:@Q`%\E'7ZY2STE MPS?YBD(KF'M"7,#$9EA:AHF_8J-&"24C2@30;A@\4AWPMV+2H4HO5^GEKY->KA53K0:I M85Y@&[FS)O6#M!#>Z>MC8ZSW*F/'ZBO*_QJM\A,I@V@'`EN*NRGN)DGQC)3W M8ZXB5,#SQ:FGC8O=_ZSY/(`M MI#$+"RN_&!A!(>X-1$84,WC)?Q+G5HCS&\O_&2;SV%Y@3,MS(Y*Y%0.Q!`S% M@Q8YOV(`:/5OR,K5_P^.!@P?@D<&]$!F.4;IO%=L&$RP,Y$U1-R#M#BC"ZHT6L3!C2-\$=*_APN,Z2XUG) MP%?>_)W"CS(`ETZO.7W&G6^P!.WKAJJ`R9Z M!PHA[,1QT5"[X1P5LVWGF+TZF>B"S][5=#ZK"UB7[M:D>%#BND3UY[0^`"[6 MI4-"^$!U%M]!3\UM@&Q)G`WL':\53[P%UA@13Z'X.PD>O,A3B]``W"G&WE+` ML#(@V62"6GON3:](1BAQD7"7VX(3!/'7D M9MW-B[4(>8-LSH"@`'(0J<'*<"4H"PXU^ MIMI^9I*@?S".2J!O,-#%+WEDKQ"I$]>/HA\?>&"/GCGRK$60Q!\F+E@2'S=& M]++UP^PG)]M,\<\J_EWTA?M*V477N&[V%=*'X9';_2?Q"8?ZX40:26.7HS>%X#-'A^/WV:1N=.+\_.3RRMXIPT(L^81^ZA= M_.OSCR_G%[]_T.[<""V`S0%]084>[+,8T$]W\>MG'@`TS/E#X>]9$+,`JF93 M=5WJWKS^WW/8FQ^$,\LK'U_UYBTY1#]J`,?UU].3\W1IP$$%NZL348WQR1E068)F"I1I<[]#_-F#]HI+4(HI0!6G,9W.]D-^9`!Y/\ M9Z[:*)3*C-+NVS?(EH#Q`&\QET#_G:$/@CGY$8A`8\%C)IKBYI_P^.6AH+T8 MD'D>._9(]-1!7@?O41 M;`7?+6HUCD[_3;1G$IAVB9,3V)^?>&^MC,^S+)C/*9ZS@>>T64;X>B MGXW=9>C_HN@\/8K.L>@%*C,)M$CAKR?BS,$3Z6)"_VM+Q'T6NHVS+>PW!][N MB+0&8:ZYRT?2HW(W196B5$6I.RERNF.IK"KN89=>V]BC6]P@S#6WN-_3!_V\ M:$]FG.ZFX&F59'?<"%)6CB0B1QJ+YDL03A@F2?SR^6&..;72*QD2>NS7W'!I MM,=WO;[>Y=/OWDN/X]V4/'*1L#)Y=IQ252"I$D@RI==&]NAB;]7!WA_J9G^@ M`DG;!T\92CIJR>`[5ZLG"1]`J("A,]+TPTYCW;58SH$.A7V4([ M3JDJ1E2M:I9>+=FF8`(<:DZ0W"`U2JJ7-AE&,OH]?6RH.)($X"D+:Z.%-9(_ MOOU*DJS2QW3'6JL\H57*ANXJ%WEOD!>W6#%VJ<5*MOYCVNCQMB?4\82WX:`N M*^Y_J?GY!&\#[TAZ`Q2@$04_T MJ^JDTGPGE?R?XW[ARZ..ZJM2SXG-ONJK(BWAD\N881SL1)-^C,%.[*-TE7[), M2)4'@*?29)D>Y=^RK;P%?71GQH6F6>/#YC9Y,;:(Y\Z;OI MD%\2-AM'!NG:.YQKF,1\_*@UGWN+=.;0%^;@<%W8;3@/0IQ=A.^A'X))?9[* M&!_ZV.AK1\>CZHOQ^$X!;?!?W[6T*YRZ M6#B!:]P(GQQ\X_'#I<^3"$@EKC(90=5H6WPP)5D6@SHE"RY*$ZZ7B:^BK?I&[0-R7GY[L;YK.)&[_7 MCE+WY;9B&3+DW\@`G@3QMNV`5=>4Q]"[O8'>&0ZVUI9'D:4BRQJR-(R^WAWV M#IHL)9&@[39^>XH$I>#7MBA"AEP`&<:ZC1& M(%''!TV=DDC3=NW1JSBP?Q[=6)C]@7DT($(I&>J0U2@9P).)+4E=HM3OC_1> M;R0]0A6]*GK%GP=#K-[M28_0_1>L+9NI4\N_99KK:Q/+#;4[RTLHZ]1AH7MG M82JR*J20':^[P[/:-0=Z?5/OC@^ZJ$(&\!2]/KI#QECO;V^6C0ST*HF,;3F8 MFLE8%*^BN2I6$6!#]D/6L)Z;-2@9SJ4:C"*W5=$?ZJ/.0;?J4#1_8#3?'X_U MSG!\R#0OB91OUY+>(0U]F^QMU425[6"XP;3/QR:M2#-IYO4.2PVA4I=$71)U M29ZM-.QV?Y`F^GRL[AERQB8L#'%0SL-)%+$X.O&=<]>Z@75BET4O;A?2E;5= MR*$V(7CN#6])[?4:[,-!-R=MP7&:`%G#CQF[F`?%9YTQ)W( M/W'IHN6_Q]9#_HM%]V:YI<>^EK!(7*U;@G8_JK%7@Z006$:@JJ=6]=0[A,3= MJ^`\(%!5L>INXNV`0%4D*E%PH-T4@),TW$]]#]&%%4\23[-L.TC\6`W8D!VG MTO&:?9,O;.]3"5%IHI,%9GNDC1M-]3^@T4LO..RU/7O0.T)PH46W(#& MQ2+0@K:752=#X$0&\%0.\"-95M?HZF-3_@$RBEX5O2IZE4G$MFRPVG:8,-B] MY5GAXI`U*I6P>V`)NT;'T$=#^8?6*II7--\4S?>ZNM%7U=[;E^KM&LY7R4T< MQ-OKU2F#^B8#>+)%R22R1IJ,IFVYW$Q1NZ+V5Z3V+1>:R4#MD@CQ=DWS?ZDB ME M4&=PJD(Y9.U-E<6JLEA5%JLNB;HDZI+LA3[1KA]@^QY`&51'&<\#=="J/(6RKT*O+>9?SOOZ!NU_#_'OA'FBVL?]'$`GNL*T>`Q.#)E!&\ M'?BD9%J*/!5Y*O+A%;O^K>8%4:395A@N)D%X;X6.JJB6 M':D'7JHZT,VNJ8]&AO285(1ZT(3:U_O#OFI@+H5(;==,E2BO3`8U:JM9-W+9 M`=O(NFG74GB7R=^#GAVL:'R?:3P3W0=-XY+([I;-X<`_LF7.+Y-!B]MNZDPC MX:9#29UYO<.2*75&71)U2:0\+'5)5NL4^S:;Y$GS1%:/)?F2Q$G(OKF^.TMF M/T`OL;Q+:S&#'Z(O07B1NN[/F14U,*2D)^N0DL)\$?[//,Z&@?PGB6)WLL@P MN#1&HS(>@Q\IT#6=J387QZDE/I"4%D]9Q."*P7EJUFW(&/U11PW02Y!8\`D- MCI7Y$3IY``-NX.B:!4M:\WD8/+@S*V;>`A1%;1*@"TB,Q$@'75[RQ+C/]E5ACEE,?@+CKXYYOP%WKTC-EL=L/"_)&NH3]#=NYF M[1V2KLJR[I:`R''1W(QG`4Y'6#7WGC('>[6VM MM:8,9"H+,VK.,;^"&1UT`U49P),I?U+JAK^&V=%-8R0]0@^`*[6N(@T.6?;( M`-X><:5V=:7A6!^-M];83P9RE84IM:XJ;:T1LPRB1R7H2->(N5UUJ]?7S9[J MX2@!8VM7V[K>9AMF&>27RC-0>0:/88C=@:$/.P?MO'UJML'.IAZ\(&>@FHAP M&6)U8+RX]"P_/O&=SW\D[AQ7^F=(M8+%#(.3Z,+/,@O,2F9!_XV6^"Y_\K>K MLS>:PVP7J"C"`_B',3+,H9'#LOZUS6WRWZ?!;)[$+,R^\HVBC$F$"Z]<]]/B M>C%G)P]N5(%RL!9*TQ@;HRT`^24)85-`$O"U+^X#_A2]#,[A6CB[O6%_N`4X MSZV;AO`X6@M?SS3,\1;@NV8>FT\#GS4$Y7C]G30!SBU`>3&9N'9#(/8ZZR_D M8"MX),8[#3SGZVP>!G<\P^AE\;K7\A*EUE*R*@VX8(6*^S MO$@$G-AV,DL\*V;.&9N'L"X5.,//'L,?8(&3&3;D^B]]OG+QQ]L+O0VZ"0#3 M'^3@-+7!+0!>D9+]]1J+T1\,N\/V`/?G4_O#[T'X$^S#4VON@NGXA+VOUT)Z M9G\\[H+TJWG)TL$[=[!/-X(G/C_,F1^Q%=GL9B&;O4)#_?4*Q[`SZG0*)[GT MQF?O:4V&?7^]>C!^VHZ**'_&^:P7X49O/.[ENRF^ZQG[6'-P^ MOJ9#[+,>#&+$_1,\%?T-(M$8ELAF]2L;V5SUJ-8+LV?MZXR%[AT\<<>^6&Z( MCU/U2OIA6K.R6.]B2+_ZU0=E.CIG=\PSBO(L>^#3(OOQ5Y>%5FA/%_3XLDCK MKQ=IG2)1/`Z&5X/=?#'LZP6@S+!W7PK[8(,,'`W-H13P=]NA^\%Z.2H'[NMA M?S'=#]8+;9EA?SG=KU<.NF;7&)HO/X#3P"?%XL9C9^PFSKY\YD:V%T3H&GB\ MN!RL5R+ZHU%G7)#>CWAWP]MMZ8JNUUDZTD'\\HNY7B^2#^*77\?URM;62;NB M&P[6:TO#P;!3-)E??[LMW<1'*TJ20/SBFSA+8XS[*I[L9ANNUF@*YOCHP MLI[F&F?)<+V^9?:Z1F\HT9'^TW+]"S^GY*]^%(<)/7H9,NRG]72"VN`OZAB= M`C/8N(&F=KP.:>MUI\%@.!SW7[!EY'+Y0_!6QLNO'Z_&#]?K.N..V1V,B^RJ M_H4-;*QZ=.NUFOZ@UQT.7KJQKUAQSJ+XAQ6SSY,)L_'4+UF(I>C6+<./?UC^ M;9I2]0R2+2HI<[B'13!,8(+'G95`/'%SKP'I&E(?=39".I(+4NOA>3@=&9L@ M-W]_`F^#77UK81/5`>X_>1/VQ%C1<_F-$P3W79L9:.UG_K'*/ M*D+VWW,6_OMJ:I61WZ,+W1EV5N%_S49;@I`3TF,@'#P>0J,[E`3"[E-P.'P" M#KLK!=#K0_AX'(Z>`.&@]P((:YC!OP(/_OL[PX(!YIS`UX`)T+?^=6_-'R-0 MGH++C1J$T1>1]:?LLF7P'HW(\3JU@43,4`+H2C+R"<@;KU,5"#H9<%>![O&X M6Z<>$&F.&@;O/`A^?K+LGY?4>Z_AFS;NOOG'9?^L=L?E%S>\P\K=#U1^R=3>;+*@I7\9V4+,^X#/L&SU#)M3\YH?,\MS_,@?]>N=!!+S@ MU\5-Z#HYN\$Q?-NB]6YG?3RI-QSWS(*!_TAXFCV&]NFJVUD?9#(&_<&H\_)S MJ'7K?@_B,Q:YMSXF\IY$OS+G%BBO\`"^8HL4LCZ6U>V,X6CJ@EE/!;'UPWH- M.EH?[SKJC\R>61OZ>^YID?Y2D.?P919=6@LKLV=AD>O@-)C-`O\J#NR?)[F\ MWR)5K0]E'1E=HV/VND(_>RY\;1[2:U#3^F#7D3'H#49=LZ%#6A*:)R#@9G.4 MA]$/-_KY)62LZ-)MUFKH=@9K+$GAQ3&Z-;)]PS;;!>^Q%D>W,]P(GC'LMP,> M5A#80`%@#C,;C!"V<>%]VH[0!XYMZY M#O.=QX)7AL!8YVA;D8ZQ81/5S9^[/KN8G(;,<3$"2T#R*.P%L,78\FF*PI)] MC+LWN;CY9/D_+R8G,Y",ML71XC#WG-U:WF<_QN66,&.LU]Y&V#PE!^U16WP, M7%_AE:+D"DZBXM8&2#H]LOBO@Q="A[35Z0R..N,C<[0>CLJ62O(/,`DZ!=:* MW:#3.P(U9J:QF[QH8B:H[,QT"T;>C_Q_(3*UP,\2(^$O;U6E%O=V#_AGJ-T7T"Z.MU MG6>@?46X!R?WW9;`9R(0X;%]GL\0/;`^,U]AY)!CK?8P5+MLJ%"E1 MGGB`^6MF3_W`"VY=%GWU'XN3#173_4[OM8%YV@VK@+/>+S;J=$ M^+?7+)SA=U[EMI@;"L!ZY=M2W%\-TTL3-VKX!+4/?!3O^\&<^R!POEF^=4M^ MOL<#L\&O-!H-.J,26]NTX0WAB+4H>@$V[H5ICK58G*)=^P MZ=6Y35[ M887WP7Z+;PR2L/Q6V+Z%(,(KV1\)``F/___9^];FMG%D[>^GZOP'EL]F=Z9* M3@B2X"79297CRXQW?2O;DWGG_>)B1,CF"45J2"J.]]"N0 M(K5);?K1NT8SSCSXN/A^HB^(?-!+U24;2\G&6HEIL?V7G'*FW+N1Y`; M_))4$<-?^?O_J-:'J#CT/Y'?IS5*5>U#ZH"5$@_L\H<_I_JQ&H>%!N2^MOQ5 MDB&3^RH9=V1C!4TD(@+EW[%2-[A2-SO-M5G\U;%=[T7ZEJ3C2,]9/L[R0XDH M>:"K9Y-7DQ^J1<5:3JI,K3E/SJFH(A>?Y$ZGR''3?IJD[@=:=N#,$4+\'&TK M[NI#2^?YZIE)AF$2_$4.:'VUQ!_&+W*)FRUA.>^7/'JVPPVG9R5O_Z?*F=]0 MSJ_.DM()JF%:5"*D.-8>F*KH9*C'E2KSN3)U0Y$M>=!4+6,Y>=R)/4">2*H[ MQ2]D90I\$C-,"&NR?JJ`3YL"=0ADI2W:5M-D%M(C\!F%;\_0[*=4\=Z,G0A6Y$TH?EC8$-6K8WBKW MK*3F/`A<,;O!]1GY3A#F];W4F;\.CE.H0H90@3VB,U?H9.M!E5-T]\]!;8"< M:Y%0RQ\#4!L#8GE6HZZIE;1%874WD5,<&B@K,9KC:<;+4 M'CB->T53WG@G:`O.I-KCR+V`(--&(P1HJ16\XT=QB^,(P_E/'*_GB`WCL9/ M8O8RKWBVKAE&L>CY1OE:P%(\!U3%PJV'#0RJH8(PEELTR[HB74]Z&1=.?6R\ M[FE&#@M+OA:P-!P7MC,$JGH^0B\")0V`ITEXR0ETD>-S']P_N6'ZA9*`/;5T M5P;"=GH``^:RCD2DHX"#-V( M3V6A\DI^FYV(OU',G`.&?#[[^/U3B%#!L?H4A/$BT:3.BVTW`=N!4Z4XR%MO1 MX_P*FG_,YHUJB4ZIBXY7A[L(;I.$#9$4_:-UD7!RL.HAV7ST2B*-&P"!W+X+ M"NO-3\ MF(!H!W/1UJ@[B.I&M`"C7<2B)VZ(?S_%$0HD>X*_)ZER&E6>8.M0 MFLR3+/^>F("KT<=_+AG]:[_J7J-KKYF/&K,!#HJ/\I-BZ2X$]'7CHSI\7N,2 MH,B\JLUX>[J]+\\'S75'4X%J:Z<%W)+JL\I%OZ62S0C6&[%WDZ\X9^A*2BZ'JZE*L.$Z+>!:`VL:XZ%R> MC;C2.Y]Z#52FG*$"X!!LO,32'RJ\<1SAYSC(*:1B!?YCS,8!$AS:H0P',3IX M'M7#H2QPF*W@J)__7W28,)3O&IN,Y*8YN6T-JJJ?FEY*&:\>G^;ZSS+OE!OE M?SR?VBS1+BRVBM$Q#X*/B;Q=W1M)[`S&BD_'QH!`@&$)$5OM,\-\2 MFA;?^Q2$(18]'/QEDT;[D:D=?+SVI4PK)6"-)/+0A(%9ZO:5['1J)C\CZA81 MBK!4^*D'R3/4[(K4V)L[J'AO9)*ABY^PICTG]Y1L#^M)05ES MMUVB8(J2ZR[DUDNB52ZY1;2JTY%*E:AUN,RU7VAW_G(3@&\DQXW&R969;*`7 M^KJXUY3=5$IUO?3F3/I`HL?DTM,WE"KP+$3?W(#X:E(/S0`5I[@(-S0D37CP M<6UM>$WW?,A5M*#^;9_!CW]'II^I'WQ\*V67B:15,L](NK@XEI[L]$YD2.C/ M3_+%ZC+"]G'L>I(;2\E5-CQN_B,JS/<1?;FMH`>Y6XSX5V?N)'Z1L@0SZ2&*2Z*-/=H3S\U2%"IXC\>SP.Y^OW M9-?OR*XM>_A3N55ON7J MAIF_<2N^/FU8G$37IJ453:Z)DT=,I+^1-B5P1%3V)]?]&0\47KL.D^&:+1

_T&M4?G\;KDYH.9W06O'RF=;^ M%O;PK;-=M\OTG-ZVXYVVY&9ZBR*4/TWM-;=ES:5.$P/212.GB\9J7\5&&![A MV1,*CVV\Q7E.(*B((/55I39`5/:X.F MY2"HNAY)+8]?PR`2RS!LY+>U\B'T#54NDC*L^6AB/3`]4M)2>,N"?'+H2.NN M<5,W9&;I?&X`'44?/CGB9DJ)DE5DT.`SJ+Y>_B@R3#X9^NLEHV165E0F@8)8 MG2C3YD3A_$.%_"RU,PDUN:5&W'F16P':^L%[]K;I['2UJ0Q:K M[`ME+ERX?\U=Y\8>?R6=KU$4S+%U)URN6I/3A`R0)&0L&KYP)>NHA&TW\2VM MT#NI04_U+BL\8`K2?'TF"[5#-)K,+_^P]0JX1`V:G\$UF57L-^F+"[:.U'@` M,V1\B58VH5U2=*:O!+58]+[K=(S9EW,4]A`7Q.1A.K&G6,3HQG8=3H?;99*3TA@>IQ`( M&QXM<26'W!5Z3GXEYH!KB%,1*)P.#:"IBB[H55N*WPKH\DA[_?&+UJFIWC#EUSCD+4ZG<5<&F3BR/V9RP7=!L*XBWM3+E MKPJ>L2AW!)Y334RN!K[2:IU]F#26]:.-BUBKB[7"J3[&@4M)S"J1R*AOU/I* MQ3:BC.+%[TU"]M*UHB77\Z:&"8"#6%A(6;D%!2V5F--4@20]3=7;7EM7'\6"(('.\QUE M6'"Z#VFL#NXKR1L@[#A[@M.$B#H&M8\/3UG9X!H;V=9(0JYJ58!L3Z/:`\". M@\J::MLZKFE3=*'"JL9V!%C2@/@`:%AZKJE./[?LS@=XQN.T>&3@- MBA3-4D&7\/%XMMP=4N-U)I(M&5;J#YG+"4B"<^59`:QPS+`17E7&%3=$%7U"]?`GXLQ6B6E]%!\LUV=$OD5NI:-&'K M7)UABVQ+RB40(&Z8\],!7\?VS,7;^8T=/]VA,2G*ZW81$H8"(>$!:M/FO(JJ M2D71(1`=WJ:N*+G\&>5!L=)U^W0Z\X(7A")L%"Q:;13F6&FOC9H:HPN$C@$T ME*UQ5%Y1I%^.ND\S;$+1!NNO7XH$0L.*;E(._AXYRB\\8$MJ)!`05O&GMJ9' M2JD9V2]'(F'@AGJ4G%S2>CO)%Y.*:_@;R<>94;]^J:!\H0\S%#XD,N89T9(+ M74"'V8EL$ZZZX(V\AS>:>['MQZ>D^A(?]E;L:;K/6CEKZ:T_N2O25K=U^]48 M0UQC%,7J!OS6=B!3?.`5I2/L8'GQOE_LECAVH'6$?&7F8_A)VZ".*=B>EXANM+?-:9`WG:CT M@`$93G1W/Z:Y:71D.95R1L7/A\29D+&YX,SLDS/Z%D&K"ZV0G9DMM'KGJ$5! M/&!%6C'$WX8HT$+V9=?&=>_;2T/2A`S3Q03I?D-:(3D+YOS^Q=M954PA2S:; M7EV=9$HYP]MY5VN**62W:MFYO?M%987ZSOW>&6@ABS4#K?4YU'?H&_([@RUD MI&X#]KT(Z.TL"D(&[6)^]+F2GGIBNK(=VH2LVLP=V*>!=N4.]B1@5K!J>YZ> MS\@3V8*V0UL%JU@V7H]]2$X:]2U$LX+;5N[>JLZ?H-PP1L-=V"JX?+N*<]0Y M@]T&*/X/\KPCWPE15-,I5*3"JF(O=^_W(U9RE?E04P&L"@8S4/KTUY"CE=C, MJ8F\@M7:?D4]ZJ+"*W-0%6\%6[@,LZZD M4\6NXH+M`W@_28M6%2^J,&RAW)#TYV=!>(?";TE?)L&[;H-WYXOT:JF6L[;& M5:],#S<((-((!L!=HKK+V(%(VQ=0J475-LCJQ7L.9:'@+)(JO`N4=U=5`06.NZ\`JZZBZ5`621S>)>HZC`"`V6!&WI@=[@: MKC,=R@+W^W9)+0<;(8/R*SOQ##FN!F6!0X^Y0V0/.;($Y5=Q9MJ-@!0$`H]!Q+`C$[U8.F>\MQK\@$#A0#7_CZR=L!H'`B0K`';)].XZV02!PKAK\ MWM-EB`X"@,[@-[$`B#@=:FO<"`$.W:@*>^9LA/7AB'80A"GM;XC M;16J%.5*Z#@"@*695/=-<;0]-$`0-]GW0?6P,4K+T33KWP(5`0M^2/U;-M8;=)Z#P+FT??LQZ<75@;Z( MF.^FH1JF-8A^/PTK,Y84IKP0+$L)%0'#7<T9HO.P"/?N1_[0I5:ZS(G8-3WW;`M+1([()-)85?!-BNRD^%KGY>6VK)! MA5W46@6&:E6Q#?L`W)T]R"Y^#71EK:%$CV1LM>(]5-D5LX%I&EJ5?D_MWFE` M93=#4149JEO;9K9H^JN<%LK0`,;0U*4G0U]EMUA1H6X,CIHM6/6<1G2*H0*M MR@&[79H(+ZMBKFTT'H2N.V.GA_M5T_(DT34'3ME[6W$+)4L7GU&?E. M71QBV>(TQ5-,+;],5T987.>N0_?1Q7O-J@]/#ZX$3L,[P%R92R1N M"K$3^Y[3]PY`EH.(`3*Y*;DA2OG9]N8H_?'OOH/"N_F7:!RZLZ0#U2/&,%WK MFM1)4QZ*";9]EK;9R:Z`-@'6+T/-R\%2+/',LU1?!L]2FQFB%$.K7RD8#I:B-"MB7KN].Y]/"MVW_ ML<2,A$*54S(22PJWO682[>^B)%8H&0AV1Q-96M3^EEFE"\ON+'@L)6J?PPK= M7$K+,-8G42"O=4!'1J&FA\OVK,T!]DQ5Z[:(0/KNJCOK#M#5\1E)J$,BV%F^ MVEZV1)HE*KM+5YL+ETC3Q-7=Q_:H6K8B][Q@3.1+OO[)CI"#MX\9P@#(]TZ_ MDS^*'9AZNKVGL]W=IJR0?A/5\'7(2@]WJG2V>UR3@:QME9&=*YT'Z<:+:R[H M0NK5@"@=;(T\2'=EI/W5NB$/E=,.B^%!NF$C38LV+%;$2S`T*<5&-W*D,W0T M%0Z)E)TH;TV`.@IZ\P'2OT+7ESH3J,)V>71=K MHQN*KC&C#>F8WVE5-KK)*+UZ`].``^*BAU`!W4)T[:Z`/M#3><=UUN@>H?31 M2;>,(='22U,F2#\()05G:N_+M7 M00(?.8FPT7V`52K_^^,@BJ^"^$^$11T'C[[['^0,H]UH$SJ/V`C`_:JT;W@J6'S,H7 MXOQAAJSKPQ;=AY;V8RCRC[.9='J4HWO@KF\"^2O[KYSIWHY%=!O>M4HI^;J1 MKYWT?@Y==`/@-9_%*U/T-'GU+`BS'Y'/B944V(4\0DL_^'BC7/8P8*4\[M0H M#C=UT3+P**K[41Q`.*_)T=\R]Y/Q%23=618>1G,_C%M.]--E;([<@$L`3X8R M%.6O.PI#L.=F%:9$[A`)=JNI1119YP4YVRKG`AT2&B7DX:*^&M( MMO-S/WWQKV$0;>K#U*$BB30YTW0J-:4#Y-LCMT.-%.BM8)DZW5MI^.3B'6F" MW,SIE;ZG?\T5:+^@017`5LDM0;X]H]FSH]$MJRA@KU8M,LL+N,_H%(0@<^,'Q#H?V(%G;(#3ZTH-YL=$`%11D% MO$"+BX$@#979CSCO73Q]N02)#T(/>QX0JCDG%^W<7BD9Y(!TMT\"H?)VKVI` MBN;EL*:'4"F]ZFM5>Y0,;S0JU$IK=:B$"O8MZT+NAZI:2;96ATJH+."KFE4E M1Y%A+71"509;WG8JDC+00>G0%A`J6[AC@]+Y::7EB6&^JM-*Y^RW/`,L$?;3 MXJ>FLG7ZCST[PO#^L,F+XNOPEGRU\(WE+Z/LMQ%3DYG64_:D_"_O8CM.\*74 M$O"!3R;].K4*?0S/'L=4ZSH`NR>)9;8Z!!3,[<]TC9*$3I8 M-1R!)%?U3Z"=4/1N'_UN#4KQ8-5P4$CJ*?@3@$M@[6,U&DO2_:,XJ^WIE]ZSRP?3/:MTU@Z)6*'*8-3G)%YS8 M+L!"TX'%8>8^N)F'XR?\PN-5$Y9$B,VV@JSF$[=)%VD7OYIT$XVR=J*%M97; M2517!=(_%3W?4H`O?GMH]67#U.,G%TTPI^-Y['[#)\()9K6-I@JZ*G`<2WK& M;H6!W-Z)%>D;QH'MLG&BL(6!GG^)7,>UPY<[F^3L)X\NP2IR;I+[Q+KL8)_V M.%Z,=AM8!1(=06=0%VV22G:.;J>S4#2EV#A0'$C[^/N8X-6L]&U3TO*,%S*9 M4WU0MP.^NR5`JY:$5Q/\PL(X]\?!%-W;W\FM(W_L>FYB8BQ_G)5?^H1\-''C MH_@,X0.W[9'SSSP.PI?5]S%L$1<.!99M=!X"`*!JY$JQM"KO-L@H3!:*#':I MC4.@:KILZ-LE(SGY8HOR(AC;WO(S2.@V"P677?#B4`4FR-=)KBA0-WA8P\>/Q$CH/G_IGMALDB3\+XR4:$;9(Z$Y-3:!M:<&E^ MUA*I,U"LP6-7Q=.@HEJM@.(,_^(A)VB"PA"?R.WO1U&$XH@\,3W>>U[P;/MB MJ6842$[1:#+W\.^"N<].JJ#`V5M_2Y)=SU"(V?8?+XB*VV'X,@G"I,1/!0[9NS6$ M!F3KZV8ANI&?9IJ]&>N*JICY2KQMRK^N[?@T/:ZLQ9R>9]P18(G1%09Z%#@M MQKBCT`@#GC*UB&=O?IQ)VH%\-*GLG:^V?*>3"1H3)T'!X5H\?[;N32YTPYW- M2\('^?9!+8A(HVYCL>&TGP40FL7").*+BPCB]IS#A9ZQ]&BDF1^F67$\1#W% MY<\BF8ZN/T]2(A/.`K\.+H6'2[5,E8>K3!81)V&;WEU>MU9@F8;,\WN*^[!7 MBHKPQZ.S.;G7EUT%R3)YHI-Y=8.2TR(5`%W58-E\$1&C)HAS__XY^!/98969 MS]ZD@2(KP*R,8R5)?2BDWV)5,.S=VK!,2ZF#92E*;32D"FI5,.Q=7(-*OEM) M=4EJ8JD`@-,@1P>&K%5&0(N=;$#)NO:(_/'+B3VU'U%T%\P?GV)&-H6LKY8H M67^XL4G=4M>^1"3;]#0^\C[C%0?-XF"&EYHI7H;.OMK93_![EFT)TI2#"S=V M'],E"(N^GFO`:E*ID,4"ZZ59N$''1=46#6:.!K-C&C@-*`W=A++>/P<`Y'8K M\'#A_C5WG1M[_-5^Q$^Z11&>,>.D%<7GJWD$"OLX"&Y_"[RY']OARPV*DWK(UY-/MO\U MG,_B\4LEP&RCR+)D2S%J`$Y,P6-R>/8\.Q4PL0"/24[DQ!UO/KC).:ARU\N; M2`*M`C1S:=VR(170WP0QW@!=VSO]/@NB^<:TX%X!\P('A0S:-00%?$>.DZ@> M/O4FS!U[MCO=6/&X5Y0"=3N+P[H!2Q&OYZ''K!GCD,`*U-0$!LP-:QF0`E*\ MC$Z_S,,HO<>5!HA(C1726#Q-RQW6MLRVU51HF8K^UES$0?GHBHO8X@;;T2,^ M4SBLJCK;@<]JV)?`)T/_=K6"E>#A`F86X-T2;'#P\<:X9*`J5L_=^+%+#.K) M>SGWH]CVO.30,BR@#/M+R:Q.]O"6("RP0NWJ26XT[XY&EN4GZL@P+/=NWILB;\9>"8[&QL@877JQT,1T6(6Q?'8";E\5-^%KD M9$OK`Z]==&U*-JPI69;<49P$U/`/![-M&C(G0,C<-,IQM4U&;XIAR&S/77H^ MJLD&8\DYF2]LKR%-$T,6\.@QE](5+C%K(KEYCX9G4!@RQ[84,JWRZ`24(O66 M'>%%IA(E[3G]#)EM4)JDSI;"5(!U#$7@)!YTBU?1Q6*::Y-%0%Q**E_YB?0FNK]82>WR;&P+EF&2YUBZ8UW#2L:R&33FC9+;0Q-(2_5'4W+WI[J.%SI8;*SU`4S+@OF&Z*U(NS4*'K+*1'A&+(H6%)JQ-I/C MTTOY`TITI58]TQWG_IA?K:6_`1`(2FJ:KBDF-'=X`(J+]U"47Z3*T'HEVMTF MGZ)`('BJ0%535%G?Y<5WK6WVDKQQ4F-K M9YNO\C)&RWMU.Y(RY@'=:Z#>LTFM(M]2VZ4.U1Q7]Z6M"Q:.3>_K?P%X,H"DYM_=O1T$P;?7+QZ?'KY/4+.N9\>8TAQ M5W)3(5E@*ER68''/=M?DN&\F62\X6:/&=N!TAC.]E$%\>>E&L/Z-3V@2A*N[ M)V3GB$,["!W7M\.7\QA-(W*-"W\S##P/?_4<0\<[4XWCG<(.Y1VJ.E!4F+NB MUZ'TVR>*I2ULC]2AAJTP:[UP5H]$K952JZ$-7(N`\\IFDC'H%Z^FS9&,\FW2 M]^\2#TPR/"?88(A`#4D!\>^L.5%Y+UJK&KW:?T^P_>@_IEZA-%'P%BM!Z))2 MR6EY1O)$O$A=3W+-UX1,[<_(=XJ>L`O71]>3XQ`Y;HPAN9Y;4OC3*-2*YE;V M;0W3=DC*)['7H$K$@::9NT:5N:)*MI:51>^?@]HJ)>#K4CO7J$6-I.SL[=DA.=%6W26:64N<3>9/X7`U;4.E?P4Q.;8Q$'?J#SHASD7J!' MVSO%9\-2,@1,HM4UL7H(V?Q87)2@:0M^\<30 M'7R.*:4KL$7X);K#92'?=B(@61#ARREQ6\Q"O&=$%]YX$U!ATBA&.&6@35W/ MK_*B`-LG)J<>)#*16;=)<8QJC4@,7I%H`T)@;0TRWKWEU<%PL9/G(3\'50&S MW5+459.Z>'^U73\B?AJ$-[33[\1K,W>CIR2[+/'3"P8OJRA]$2>G1K2BY&%R MQ>4<_Q;.Q$_(#G.^Q?4R7HE-9N0:08^?;.1=CAV2H>_&QJDNE?5*4 MC<=`AKB=1'B:X.1$V9J%@\A'5KK\NV^G#T#.XGM=C1[',K.*56XY0C)OKQ/3 MA(SY[[.`5#JWYQ[;Y&P`2MS"VG`[O436M9/"*I]A?1E)QD=]4)06E@_.C;RB M:41)55UHZX'(W5AHD2H(K4H-VJ":;748[0J=,ZQ_]]UD8XM?CHGPZ`^\!E[$ MCJ#4G*QJJ(%.I*:DX%1"-DW9`IV01R467?L%R^LB\!]CIAW"*8.LP,Z&G9*< M,J$$).EL%1$CU,+V=`-&>J=D-=88=F)*=1-N^X$KZZO MG&-^-7W=$"5*O-!E0:*D-GSEDUSE8PVG.K(BFP*A+C:(;IA(#W7IK0I@I+]0<$HT`]HEUHB[@M,_YSA=-ECJS*#C5'I6@*+H5%"B3+XF0.H:>0]G M>-DGA3)+VM(+3'^VB:!I4%?-SI&O_%A55^%&H\ZI)JWHBJ+2L:B6P;?DSS!X M-[U-"PX42#/]-=AV"U#QU*9;!'>)O%_]99M+0`9`JZV_6VKLWE`=1/J@;ZL1 M?%MS7>"FU!`P-AM(@2M)2K]-WI7V1U*D8F-Y2D2/[=W;`BO>P7P(3=U;4V2A MWN5I1HA"[]%]-2]O7[7I$MH=P5YYP1=]5TFPAL1JKOW5SZZ08$3I"8,D]4E1 M>&R3JH%.((B6;7Y9LFX6NO-QA.T(79/AY)A9)K0,4`-A5KRQU%18FBV0=/\,_J7&+R332MQ??2SUV\YM3`>N^VSSX>/9GV9MSC\V_ M^SZTB8E_]S+]$FPJ:KFM^/TC86'Y=^23B?:`HG828>+,X)6?&6A MH._&`"'4%4.3H9$*QG__NK2WZ!$O\F2?N;*G-9205."]^OW^]DBZ^>WH]O)( M.KZ^OO0[]#^1Y__:#9_\.V5'@(R?Q%(8U9,"KVU60A[[AT>LR M?%[4$SMS/43WN1%Z-Z3?33VR9,A3AF[1C`3G\4PB#=/JO!HO@'^BJ##DI8]> M%R$1[1B/RN-:JV6A-^/%[P[/1/P0:?DNB=RMM_V7O#R%]ZR+<3/_XKGC,R^P MRT+&RXPVZN5L[ZQEJJI!JH*4OJ9XQWO\A)RYA]+\CU7N4CY1\SXQ";!@G[RU M7'@AJO#:^771[>_GE^]E^19C/_[_D$ZN[ZZ?R\!\O=[ M=XHBZ0H]2[?!U/9'Z0]&TAU>V"?2P=\?XP\2];CCB].CV_=?@O@I?=+AV='E M^<6?[ZE'?4A^=W?^_T_35WVH+<:!9'ONH__+P?_.H]B=O"12G06D4R11@_@) M238I')J6$7]VXR=I88U).7-L)%U<'$L_10A)Q`Z2U)^E21!*?R/P)ICF!;X\ M)ND?E&3_&/TC(C+](\.^PI=(9,8NFON1UBELE#B#Y*I,U<-'E9?,@G1J?D^M)D[GD2 MWACQ(\W9Q_<=[Z9L;D2/&@41ZM40S>XS'GRR0R=]GMN,L_IZ1YV$<.4'#A92_G9[_ M^AL9!V7V/?=[9_'[3+I/U_?WUY?OI?])'502F'V7HL!SG8R;E"S)2]A*Q;[_ M\P++[0(. MI*%?S)&*O!_J(0^URAYJXA]9P4\\)?E!#B:K M7Q)K+O^[XQ].`=[%88VEO(V%^M/1\;]_O;W^_>H$:]MX/)F,QQ6HR-3U_OJF M5%[_LGUL"+U("A@E=E"-P>^7A*GK.![J>$'8W3%N&WU(+F26P[\Y.CDY MO_KU\#:5`BZLT<%1(J]SHF&[71DIT!R\0NSUO:J^_^T'57-EG0K5&.G`&KP2 M=*CC`]GC)\G_NCJAG:$O8;*+@RWOXL(P=W-5:V\4=V>;;A%SR3X,1YJ<_#?X M(=UK[,`WVA:AENRDFC*"0![\,+[^G;2R/55I)[VTP_$3WD+WA^$AP'M%VVB+ MF$NW4=T$(Q/LC[,[J+'#VD9;A%JVCMM%W2:1S]=)H%["+-PAS!0:99J`!/2GUD:K`@7,,TBPAA^9U*>1;OUV?.8G)YB[2`+R0) M(TQB\AGV9$J^)RD$'Z3D,X>>_1+,X_<3]SMR/G!C^\OGA\L_.8L_OUOF+14/L7:?<<^N6/+R1W;C)7NTSMV<-"JIW>L_ISE>2S_OL_RV(D1 MWV=Y#,EO51_W+?W:6T?WC[!HY<$#V,$5'6DJGM]?WWZON,.LS83 M/#1K!$U]\$HPZ+!42]M[MRD>\!W0M[I_#R$$.01XKR@FU6UJ!P`C((.1;FW- MW;]7V=<2E.HVMT/71I:ZS^T8PB;:;7:'_@XH^T/P`."]HDVTV\0.H([`/K-C M"/!V?Q/M-K/#D$=@>YOH$+14-+-C'],>:DR[W224M)BW]*^YCY("$D?S1_S; M-+-T)`7XI\O,BF6MLR3[))*>`L\AA78X22'X^YWEA&@C!6HC64Y/;TUR0C9E M?"2I.4FWJZ261IOB`P6NE31)DW]L:6*[H?0MJ>C8]FM58(Q4BRI6$J1('5(X M"K]P-7YIV9"K--WH[=HR,3A]WA<+V>>3[/-)7D%VP3Z?Y$<;\7T^R=Y7UFX^ MB?Y.@7M7V@#@[?-)>LDG4921#,V1:2J#UXB]PN\32FHGE`#3'*GPAU;RP6SP MW6:4F.]4>9]1,@!XKR@8UG%&B3("%AP!96O+TUYE7TLPK-N,$J!8I##TX,=Q M`-&P(;NY=^C&Q1<=VO1?I6^#-IPC32M934L(^^U#REF4T MK_!L\FKR0U6*TU8V^%$O6:,"\G,O>"9LG.>^]ZD>-L_49NDK<(HIU[=7Z/7M9$,E9&I*XU# MIHG^)\%?.UK!2Q2_-)K:>ORT;.IBG4]F77?Q4\V`(YC5JUR\=A\DW0=)]T'2 M`<#XP4)F^R#ICS;B^R#I*_2A;C5(:KY3S'V0=`#P]D'2WH*DBC[25#!XC=@K M_#Y(6C](JALCS?JA5_7!;/#=!DFM=^H^1CH`>/L8J>@6G#CNELZ[(8_I7F4' MOL=V'"/5U9$E[V.D0]A$N[UV;[W3]J?@`D"C"*@GB+@DJG4?1'#GW MY#OWZ'O\R0O&7S_^]W_]]W])TC_GT>&C;<_>%[^WC#V<^U$1/Y1@*1' MQ/A1MVCRR\&-#![POV2SO@]D]4%-__RPZ%*0ZYAPX8TOD_0B![D7Z-'V\._< M^.7HNQL]9$V%%4"^G'Z*8%L)1<*?]R\SE'SZ=IG]D&2>I)^?1P3+T;,=.HL/ M'DBN\\O!F3V.7>?!)+HS]]U4[C3B=B`Y:.QB'8Y^.3B_.COXJ,FJHD#SG^_J M43,\8A>-'D&GS`(^LU"3R;^OA]E+.U3D+DE5!$C538#_&02I6HY4_4&54U*/ M,)$>,(1XJC@`-6E5^;0:($EP'#"ME77U!>A=ZJK&)Q4`(`/=TEX/JZ1."U"Z MI!4*T*J"X:P!>HY6L[8M@&E58)>TZGQ:\;!"TS25`=.:9FZK8GM0/VNK(:"O M"K`@GC6#(-;,$6NM]JR$6,4<$+&FD,8JNJ:"`1/;$5OWNY,\H?+!1]70@56!RXR-(;'8 MRXD5*$P:-06"*K-]@#1V?3P%*IM!60-53/UV&=R1LRC0V!Q:T-0'QN'`#IX` M,AG4-4O=WCS>C4,FT)D4&OC-VZ-P-PZ4P&!2"$Q3A54./'UP.+S3(S#9+"J6 MK&[/MMF5HR*PV"SJ!EX3!\;B$,^%BLSA4;7DH6GC$`^!"OO``C0-`*,='E8AA$K$V&]=`6=M1\AQA[M0IB9C.8@!P+U_#NK"55=P@5(% M;A+?SMX?G7Z?N>'+#0K=P!$\,2VK1)#KX-&-_4+"X`443T$8WZ-P2F39H,#: M0GKUD+@M-\K41.B<>?CDHLGI=S2>Q^XW/"`3=XS"O,BWR,,,.3=V&+_"G"]%?6 M,$I.$>_\TB''$[(1&#QCFH(1\8C#?L#H*9C/R'>"L`84$1]T92B+M>#8LZ/H M>K)86L-;DEZ%IT$XQKO8#2D-LOQEE/TVZ@8F93\MEK\\5KR>R6_E_+&HCOB= M44";`]5)4&51$A38,@F!3S*40YNL:;=N]!6O2>0']B-BN,GR6QNVQX,I"JG= M>>VYGU[*EWLU;Z_,YB%:PPRLG%.&)6]GV*BM6!R;PL4&U9:P?4+^^&EJAU]/ M4#0.W1GYN0A(2F(LE1](XPQX)-GC,;'_D),4YID&(>EV8OL2D-_DBA*1>CE1 M5K0G1'@6S%'T5LHJ7J6UK7*?E#`5XR<[P@\EB7SD.2Z>6OAKP52:A/C_2.N5 M;\F"PF"G#''IBEW57*,HT1C[.,MF+)V>:56*Z\D=-CCP%UT4'=N>AYQ/+_RE M)J^9/*OEWHU)AN*Y[[C?7&=N>R7:*9#ML-I@6D+5S2+<-C,Z?SE6DNG;]I:T MLJ")@4P*6B1E+$[<:.P%T9Q4J=H,7J$M<&I-O@C\QYAI>ZMLQYIBR8II%:8D M3]R.$5(KLP!"MM-+L0Q35K:(<.T457T,V0XI/(2Z/"2`E8=0XWB*3#R&8$@( M\1`>X1.W@YR*0-FN'`O*0QO(>C#9L6&@&G!0.&OZ-31V`->496@T@IDZADH^ M67)H43+'@?)P.IUYP0M"T9'OG+@A&L=!&''WRYK.'!TU`%O]UL<>KL_-1@-1NZQ47>_T:FW.UI[GSJ%768&6].190F# M/.TWR31>X\C7&W'G\/ETFJU92T984_>?TG6QR*)PSC"SF\"R;Z(X7C65=2IH M5]-9*Y;]3AUTV[F[6B>3UG1R2517F1KA8LNPAR".W#M+&T=5^? MSJLFP-K(YC65-%HP/0Z)[L4JGM,=9^>H.%\O@)GPC;9EP@EB>11V6N@ZB^9S MEAU?>+RV?)F#A.A"AF[8[$^<:WXK]FN\%/OXI.BWD`(;3WO[4$(#W="G1!5> M+>#).EZ1(A5\F6:?6`$&`1?=/VWF[>BU&P[+ND5G,(X'_.^B5%*U<'N47;UV M#V_@CAX5PN=A&&'*-(BO@BA\DUP$JPB4_%V1;W?R!F[?/0[VI#"_R7%W*#72 MF>_D\VT4.A_[=8KF]C=Z&?D=9+3=1^N/?;_#D>DP'`WP0QS8CDZM;OKH8;`] MK'`.VS-F[G'.F=CZ&YSSL,-TO-/K*I=U6#1,K7<1$`!ICZWQUV MO8&UP?V^8R_*':.V87LNKE^I!9GX;Y$GR!=_!IJT)^Z<"DT`:4,ZKN)@2IQ[ M/H=_+EDUV=@D!USBKX)B45;5#M^^.ART^)E4X\)PJP&1ZH&3P+S"PB[*)TMR MJM6>8\UK3M]\=5L^L[`Z;/<2>;6Y M-BG2!NV>2,[G&1P\_H[?/QJJ[:D_K[<7JB;,=SG5ZTUZ-%1WU%3O<*H`[99R M:3'2>45T25;^GJ5Y-UU[']P[C#,/JCT4=T.E2I"K+)TR%N:76;K4ZU+=4(ZF MBX#%[Z8A.IGA-6!=T;E2'S/^S0'URG^[-//!R3([Y_6DYS]L48''9L@#=?= M_%.]%?4[W+[D'$>.#D1@W@7*"1.UP]Y+C'HFJ^#@E7&M"@,=# MH<'=Z@XE=D?O^GM$Q.KDZ7X7#8./B*A=>PWUP:5#]!KNTS/Q.$U&NX<]OEM# MQ>Z<3E_,J0SNT*K7.C+X\!3<,0&\7[;G[H3K4"Y^9(3;G4H^).&VQ[P.0043 MI=&.KLJJ5K\_3M5IKR/@U.Z8^WNA=,?)86!Z1SJ&?Q[-,6K/$P_WO+WKL,/: MG4C^W>F<47L:>OQ`)&^[*NU/RNM=+EOUO-%@4.W2Z4[(AS^&[X__NXPK]?O^ M<.@>["9A/3^%CP0)>M:?DQS#%@B/MTQ;$^T/-V1^?SJVY^`=T-VC^@Q=`P6J M1/O(5KQBD7_WI-IQS]!@J*O<1KS;6\UD+^='@)VJW%K?6KL3_9@H-=I91APT M-:RU$<"H=)R'_X9HDRA\G39T2/!?_ADEH5QV_[:8T0[OWO'&HIIQ-X@>"*D# MM%*,MX*"KWGT(HGBOSZ!PX-#?OY0N!RV(6:\XY*<0YVP9'B]MG&QSK*M+K7* M90KXO'B\>@W,[D&C<;MO7BE%UX!V)^BU.8./T9?7+"KRZ:);K^NX0X/%?A`W M=\0"Y4`]EQ[!)<,29+5FYM=>]Z2?RB)C^PZ`C0=/?IVJC:T5Y<9QJIX%TX5% M'@V.PG.IM4AL+5"\06P5J>5Y:MX^@!70-HA?PR"*;ZV;-`9'LP+'6;6YNH6-#G<;I!Z=RQ0NCUSO6BY M9&$$H@E0KC(V9:%\OCP%"PO`9UTZFAO.[]XUG?>L^#"[3+,9,.[V0*!22JZF ME.[`Z%T2Z%MW7]\;EXKA9[%M7'':XD<@:C/P>=0,%O MWYUSUXS7N$-35RU]-V3KETI+W=+F/LRMF.,.;3&CH>_VQM\1 M08%X=5;@(0@Z[O(R-=<;#AS]]HJ#$U3,&WX*XB##FBWWOLX3[$N<[O0,[V,3 MQKU=%_$;LMD!T!K<,"-:\2QWX*9YAX?4X^/>CC[LD>>.#&QW@6[$:96C!Q@^ M9#SRIN(H<`FQ2.M1'A;=?O)X]T#[;WN+KR[@SON M]`*M![A+\CBGU>6BS&]\(>-]SL[OV(AR\$NO#GT%V`&/?+2;)L>YG/(J2T$9 M%+=7<4":''-:*TINY05L#"!_SMEL';^-;KJYRQ7$QF!$+-^Z94&6&]G^[KMV M]+9(*WU7WNO8V747^6BD7X-V7\2/2\AOZ;7N>GM2WW=W^_]WIN/G)&-!'/V' MA7\/HN1M"D*9_'8[R2*M_`=K=$GU5-!J]\XTE#J"<%C(6^1^QUN$?! MX'\H%BP#WQ.525#0?273=-DTF-!&Z/9+!#1"-VQY/\C:"-D^[.^,'7^T-W3U MQ5:P&#>@>M7XW7?0>3[>\9*;2G]0-[RW.\RCU0IH"7;JMR`)8_CQ(LV+JS2. MIK?JW>MW.%K_R:_B)??RK?/OSC_^_;:R/Z3)(;/Z!;7T"Y36SGJBWVVO+7;S]V_G'%Y.T6/"53B_/W[UY^S\O M*DN]I+]]>O._?^-;O51@1`G__PH\$9#/>?+7)UBFBF:WZ@7WD?QA!OC+C2L+ MTL,B>,2D/%8$)%4M(*DEZ6HA87-<[3DN)Y=^KC9Y#MA]*TQW(?B78+EZ^9,S M[+W<1N`1@WVM79BSD()PF+Q`B]K?FG1,Z=Q<)NNBQ>SZ"L+7SZQIBR.\U4P M!7#H>_C[*@A#\;M:/U,_A0H8_<>L_!&WP=_TH8LN`E]7"WS-9L$Z+O0FIZ;I MST?9ZS[>\:ZFREA=*\KMK68?LF@>`;;E\TU7I5?=R?U[#?;T02L4:6_2<-O: M(6N0//9T1(U+?5^>V/'&I#O./^SKA#_$E.UXQTN-W-ZH0V&F'84J'=Y&130G M6,MK>>IT1@.RX'^E,3PBHA/>[X*DB_9>E5,*Z^(D#M=!'G=.>_(!7LF MJS<#ON5NBG8U"*&(-\OGMP_4]:2/Z:H&M'OA>'_V;P]E^I5)XV92>"1M_"+]94^RE*TD(NB6+UX_GRS MV9Q]G63Q69K-GX,.ZC_'/S_'!Y^(YPO`YJ]/@+8T[O[D5UQ<+@_V2SRUR!"M MGP2R+H[>Z5^'!P/P[N6'<3!A,7WZNU,V956!W@-@^1788!G#\FC&67+Z^9,) M!@3=Z3J;L@H%$&?C`#C6;A.M0/`VX+Q@R8 MG:(GG9?X##7-@)=+OA1WF)((`&?S_[Y;E!O`::GF=3@R)! M-GUB"?_)4<1*!4W$[_B."W5:_"/XWHYS$4\\GP%+G);G4SWL9A8:=F6A?C,+ MW1/=_H.AV\?[![NA.W@<$C-X\NOKLI>J6$19:/VQ!@^29P-XVZ+CRC2E"B$)YM>^9]2^4LE40P=,.?YAZS9[R-[7`"OC9,[V'JVY? ME\(--&MGUN<$+_*B)[$52S:6Q6F06,$\8R1)^+87$%SZ6X_YL!3-$K-_CS6FTU6R=8*!"Y,+B'P`66=V4,,)_YZ!RP?5AL.[D%H@)A**!CLI;MLZL#XGU M'N)F`A7(H+U>:XL,J'3P5;)(.Z[R8;&!W1]R6\!KV)4-T&]R_)?HK>T/K MZ2>&:`#+#Y\A?:H9,,$%.0%]XH[LP6``IH_@S\L+8-%NG'7A*-AJP;(??"7X M2KUWV'*&^S,6G(;OVK[WV!C+<7M[,M:X9X]]IXVQ_K&.;VM>;!=1T@&66L&! MP"]I=LMW%2&/R`]9[Z:O*4%D489(Q2@\O8`0^!S=";A#B*-""5@#:"3<(F`# M"%315^E=*9^*\8&QE--,\(P\*OP^X0?Z.A%!L)H'B$1E MAC\,NU20K"6%@WBT:9O^^&5N\$'>2(+%<:8ZZ&0XA" MI7M/_C4E'K9M/!T\L["9=`^/2\:(ZT7"HG'63_)MT$$)&KC[H MRP+9=Q:!=F,)UVUC.UQKZU4<(96"PI05J-=<8X:I=2CAAG#M,IJS2 MFC-FGD?SA%NI\J4$Q$0GX*R!P^8V"CTM0&4D\]M;%M54HHFN-0$V\1I1T!GB MCD*RMD/8>]R3@MN0B$$J;U%`O5RT-)!FS"H4<[Z."D)49BIQ5@H$"O46$1P^ MOZ%1)<1SP6*RDAJ1"$Y%I&M)$:Z(^"PY>,-@O82R2$5IP5K0C=$Y$?9\!?M* M+C@9C6R/FS)%8+EQ@WU`!/1#E'432RN4!8SX@Y6$(C@GL38\X/&+ZK1;">XM_A#X.7^@`;??",F\2MN;JGXG'U,?7=B:_\V8;N[C9N M9UVJ&(PPE-D;`8T\9KL\\&40,LWVY22>B)'F!8*$#L!['`V\ROE.F]U`?LH: M4CGHDZ2:ANI;>$UR/KN53R$GY90$!E.(?$`<;B2$3YS1T!X.AL)I2YB20L^W M1Q4I;!0SCB+%L*%02[3X4$O`O0J^`*0@MBS.X<^O0(268!XO0(HW#,"C+@3X M./L")"_^8UM7%V=5J6R1R7R'4.Z,E6P7L=WV:+OZ!O>1>I:7A_5#[N\O]]41 MVV91WE-X7=]V,89S_7V%]RZB.?3!_'O@XG"W&U\%8,@CET6NDM!=U@&OJ"A> M3UH&48(0:.FI_51FFS3PZ(%2=[`@[+@ M,?W83OH>UT1`<(KW@$>C!%_9%G/JX3/BD0D#`(A*`@O'$V@@B9D(!Q/KDDTR M\GW%WUV15]"1Y&*^,8*RW)JS!)@V%A'.$HXDI[>VWS#*ER0Y,[U^0>AR8?+F M0TJD%,"V7SC;JM,C8(%O->?35*[1KJGGN0[M,RTO5KGS&`.\4H^D2AQHAS(3`<0*H@+;GLP M_R(0W,I>\.J.^))1R`$H9?3/M?J[(`,(2Q=:7\@@-ZER?BJ*KAS]?`TKE%2C M(]:D=[7.,$=0;'G#=72UB8T7`3^0##4>?B]':^G9OC.P^^YP1RYIADA*7<@U M$?G2(`@LGV;I!KUJ^"(HGJ`HTBQAMP2T2`%"N)TO-.!,A:AE$@9">L@B`4<7 M$=;/I-A15DX$ZR+ZY,<7<&T[,.[(L7W?17)]F!:ID*Y.@8YDG#)9,WY&JAS6 MW54^D-^E:/AS$I%6!UZ_0&W.0/I!--\6X9D5K%99^I4F3T"EG7@>^)8]6Q,U MY:[A!IQ0!GWH8]5-$M^VXW*$:IN_77[R'[#\-.I:?AH?IMI6@^[XX5H9=ZD6Q4#4(1YRB?R_J`BDU%$T8:#2F`%05Z`GHQ1K M3;S"A/&S##L3X]RB,J!7VPOM'\BE=H)(CCI!U+8`2$JKG1[B+ M62/JA\LV2C1_W)NU1R*O#)OM70'_$%C5<^W1T-V778D;2!BPT%C'N\2M@I'J M,P`#")T\9UPI^-473]HB?*RO;5+#TG$0I/1K)54RFQ(L0J*,78MM@1KW;'KW=-*U MVK_9.BNP#T*S@V:M#9Y1>KPO,X)Z^*@*WUJ;B2RMZ:S#>4P8JT37JU%]_4F+ M-6M.Q^UA$M>P^A)M(I("VNE"BT8VZ4"B7#H,G#P#6D#H6/%1]:3:Z2=\*FX1 M;\3%LQ:ZZB]/[% M+:WW`6OUW`"5#1..\"M$7T1:@1S.99W$+,^5TP,*=RHOBJYFK!N:5[3\^$)D M@%1"0WI^\IAPOP($E&IA%K8",=,#K&QI&!\Z.6X">12,I6T`GE=)3LYZ/6!@ M]"^?1M$S*J3?GLXPT['B=^I:3\$B/FLPB=R@"_OUW_\ZO]HV@X91J#6+Q0:V MN35MF6F_-&.N&FHZ-9PT:5*3]UA"+C'+>(](<'N*OEPY&J`510;VN.^<[X4CK]9SM)J(!\O]6H$\1Y M:LVI1RRTD%5.R3$6HQBD8%80O"ZPBX6:O,6K**E>8`_;NWMJ6CZ(A1/L0Z+[ M4,K8Y`1O.:*.)EK,5)!3O%,EFD4`(U(A#%E8$X5)SS-G)?R4G]1/7\Z6\`W4 M:C(C2IH*EAZM<8RV]#+UICFZ&501<:]%5Z.K4JNM MZZ*0?LTTP5`D`5"'+T!M%^D*+>9%@(6(,&VT2F7=&55()"XNX--"$7629#>D MA=ROXK3)G MDP873-_S[JX"\_OJP%'?=CR_Q>O.6=NFAI-J5VI!!?G/P]&@TEW:/XC+(+/H M#^,S5*'_;MT&PUMP1C^?[KZ6 MW/4>MRD?##Q[V!_)@,<'->4[/?&=L_SCJ4WP1/M]_K?2F\ZWO\WO>D.7=OMRT11S[&=0>]A]*:S;R`D MPQZ_3FO*O@%+O*C)X,&K[.EJ4;^S$+H]I:T7%5=J2Z1:G?Z+YAJE):7D^K,JHI M(J&^9)EQ$H6"BP6E^KVJ;HI0Y3L\]MS@"$B5-FU?^1V#I:\ M":)8S5I42"T@M:VH()I'"/4DFH&>"]1P6'D+A[E#12N;6HJTZ3:A+'$?E76U M5CN&QHX3-@W6.:/N'@!ZM2YR+B23@IH9^6V3.07UHL60.P[4TX0"'(/:CGE_ M%S(FHW8?X\J119J+:28='&K`"T$=KZHH/4!)>#*K*GC44P5>#-5FDFN/NZA:QV MF2F=:L-\)UZ?+#%5DTT].CKK\4%)7E%&]M"4,&7+^GK_B**9=U"T1+X>^QVW M@(?P`^L]](7U"IZ5(YXUL)N5.<-":IVZS02TS..WI?KGV2WEL*0K+NJ$:)M' MPY4N^E6K\$8_6TL0O&@51WPDN<9%%M:%>\I/^\^4+1&>LE1H MAFNL][ZRQ'KJ])Y9U^)[K\'BK.@2L++#F9E_-0U4P<0&"@_P`\B^H0('A2T` M_XVG!,7W7O%FJ4P_`*-)"+^]GOR;1E%3RON?PDE/%PRT$GA@T6D8Q7PX=Y7! MD7'%$1D>)?7'YLK6"4_Q5"JPTHP9.K,@ZV[10'K%%!!-.<25!"=G`3X_BRT; MK>J.=YAB.VU4/T5*P$KERN?N\9(Q`!6?$]I63'Q0Z*FIZ#+Z%-TK>K=8_N!BNT_LG"3IMCUG01SV7!MN**U3J=;#>#+ M00"5MA7Q^_Y!>P-,>\3P16,8;^^1=;_$D-VZ4M%ZKXS6*YXM?<4&'L:IZ@@C M!M%:Q1E`N&]2/XEV.TT_-0:!=ML0G])&FISJHO$)-A#(PZA)%\._UQ7O> MNI<$8N;Y*7STC(J5,2M$]X,6WX8(29+/Y`T1Y<0F>G1$$M7:CD^O$W&9$^/D?=[\%+_E`_LP)[&XG5#..36GRKKFDC0M&=!+<:S"3#P:V1AQ$>CR.$E") M.?=$Y[[BZ(4V@>U4%75/M]WX^,[1& M=6DSIVLL!E)O[%3-86Y2J2@A],]-;5GZ9Y03-12;\+Y$]W93GO)'C/XC1G^@ M&%T/8]6HH*8A2A]'NB)KZ M,G'6\EB`A1;THA<*TK)@6NBNT7P=A3*%=?[IPAHYWBG\S_5.!WP#K6B`_MV$ M;O-A,W*@A:]O"`22'AY'IA.))Y8L<`>5(C#+$!2ERU%+(!:?P"3SRW*U2MF9 MATD5(\9MS+TAN#@Q6&`\#@8PX^\;P^,K8_)P0IYNG9&M.XI! MIW0*8D8P9?SNHL`"]V3"8=./>4I#1:!'YG,:,U>W,I6K3X`$R`EQM(S$>0*] MXC7?:<7S&W+N*M.=]?(I?J.3T&;E4=>)YR0CCX3\%P`T(%S+#S,F3D%>X$,9 M-ZHQ15A?!I\X!1#4W4!R&C=#V`J\\8;!)O]>AW.A[2;J3G&,Q.(H+\2=969` MI2%#XR M#'"^RJB!R%EF],5)&ZK1?#Z<5%YW)=S,27K#-$\\E\/!:D3HDC>[+].,YZ`E M@Y8K;?,GJ4D=4C[+ATZZ#D&#YTL@(9],V&TJ^NO%L[B"N(]1A_$3S=%5""4F M]&P2"*D>-:$(P/9E<\YHY27@FOJ8329Q=7D^CYAQ"KN[,(?ZD86HY^`FJ*47Y$#0!F/%\><8- M+Z,CYJ;T!6E`Y*A%0.3'Z0:LO](=60(Y-IMANE($P02;'#,P(80CPX%[Y7/[V0YR M-7P=QNY!,`:PS`/"5S7`Y[\\QR6B%_@O8?!_4$L#!!0````(``")?T24]KSH MZ`H``*F=```5`!P`;G!H8RTR,#$S,3(S,5]C86PN>&UL550)``,OV3E3+]DY M4W5X"P`!!"4.```$.0$``.5=46_CN!%^+]#_H/J>'TG:3B1+HJC$CD;.T^9\G.%\_(;DD$-27WY] MFH7>`PA).3MM=0\.6QXPGP>4W9^VOM]=M7]I>;_^]8]_^/*G=MO["@P$B2#P MQ@NO1R)R)XC_0Z[EO>Y!]^!G3_UQW&U_(Z)]=-C]Y/WK\-/)T:>3P\-_>_\= M?ON?=SFZ\]K>X^/C0:`T1$;#@<]G7KNMZPDI^S$F$CQE&).GK6D4S4\Z'5W^ M:2S"`R[N.T>'A\>==<'6LN3)DZ2ITH_'Z[+=SC^^78_\*:_2&DU M>7+=SY\_=\S_544E/9%&_IK[)#)-56J75UA"_U=[7:RM?VIWC]K'W8,G&;14 M&WC>%\%#N(6)9PPXB19S.&U).IN'VG#SVU3`Y+3%YE-?-_-Q]V@I_],%9Y*' M--`TG9-08QU-`2+9\K32[[?]E.TL5@S,IT3,B":AH\MT+#HZRKXM6CA2'@`S M8)$<3`9S[5RJ<5]K:I&R'=I\0>3T*N2/VS`YH6L+%I\32972H0"IU)NF.&/! M*)[-B%@,)B-ZS^B$^H1%9[[/8Q:I'C]49OD4JH!Y6S5;P-F+X8X/)JH.-0A5 M,'Q#;@N6#*(IB!Z,HPI6)&2V8$%?C=PSN"-/E2A,26VEK\QF-#).K5Q!>;OF M7$TJU1S+JJ7F_M&#B-#PO;K)_$INZ;C.KNNE=5 M;SD79<\V^R3TX]#X[+6R,&4[/$7``@C6UFOM;XDO3/2CZ@RYGZHGU'$7%^E& M6E5C@JL)D6,38<6R?4_(O*,;KP-A)->_F.9L'W97@=9/JY]_.Y/21#9+S2$9 M0VCJ^VVSP+I!ZC#O(A9"L55JY7.YA+$)_LY$VFXB_+5*]6>&O'38NBK1D7K4 MTMK:5,4N:_F)X+/\=EM5R*WVQE)5S>=:+0E;'A4#6,;OK9)G",%EP+S\PGZA(,@/@<1+8:A7DRP0(_10O,((W-V5ELV.D`>G`;'R MD"QTK.@>)6\*X*+,,4C>!(&;*!%#4*EK662:1E<1#L13?RH#,1#)(:2<.A?A M1G'H`@CQNJ@'0JVF(_H`5X0*LP MJG@YGND6AZ`'*N*BMGG,1;A19+H`PK\O57#8K88-JAN(EH<>KKFTY=$WRM65 M15I;<*5<:'GR(59>\-*$YS#A`A+'."Z?%!7*`R@C8M%7C6YV,)6DXD39=]]G M$0B0]J34#FM%T/ER72";X]IA(R">2E?XM+4.O22W-`**WZ'C9)8>>4V!F.BO M0EDX%'QBG4]3I1`0:W'/34)2IB,F8D1"D+?P`"P&>]HS4Q(!(3ENE%GC;9J- MF(P++J/!Y"OG@5G'@GB@/LB1BM2L2[UBH6909$-0OE1HUS];:0#:]-79!Z*8F`YE+'S:X1-T"4]\KZ MAMVOA#+MP@/VDL[J,S6PQ&9?1@5F0P$1>;(M!IQ5-)%-=W2(>Z`&(34*4#C4 M(*3`QU1.-0*=QQQ;UWKELDWEM006XE2]R6AF,9>E(1C$Z??G,&"% M[5P%<_9=ED()#)2Y[Y;F`'!?B*#(3;S<:J\A-9%_5VFH)B,>J`860"3T8/FO M;3>BDIJ:U@@0:?N&@C]01=[YXKL$9=SS/(.115 M$=X[WJJ`W\TV7BF;-SR"E0T]F)`XS(M='&3VG;L\S.5+B?JV`'HP%^!3@TW] M'<+J98^S&1<1_8_YW7KDUT5\[TBO!A_QNF2D@F`X5U%#<,%G.DPO([Q(8&\I M+@*\D\/#!<.P.1K6ES*&X(J;L\R7>HDC\ZDJ%]D[LLHAY]/U9PQ]\&5K,6^[ MT9[^=Y#=.[(K8,]G_2\H9M[-=5N?K6,]-8&8/:Z7%RYLBYJ*>O;6'2JV0[YK M_(+4-=;/:]"*KI"2^T#4IW#G4_T9*=6K%SO4Z@&$@/7I@+4/ES[V]5J%'\@Y MW!JD:-<$J=N4;[%4D/U`SN"XP=)%L=&9:_[&S?&JS&?$/Q;Y&?@%_*-(Y2\O M;_V-LL#ASD9>X;WE-@]L`9,HE68D4K/3C,8S"[$.LGO+LP/V M`MI1[+<5-,H5983Y.TAR.BM&X#`[3'(Z-P/B8UP*DP\0F/.F>I=+/^HUF+C= M9W:01>``V^D<.2_KE6%_SP1ITIQ;M0Y9+/-\HW@L?4&-#8FG38NV=ZMJV3MV M7]4*F*]`I+&8R]Q#(J)%R0%-N]C>T>X&&_'9S65X5 M1W=6B!]`1:WF3(!S;\Y([2W+5M2('VE*VJW/?3CLO16+?`AVTY`1YV23`X\C MM<4B>TMM,>3=)%X+0NH7,Y)&).>+HC#:17+OV'-&[IXB?=>#^MOX%%4-1_EW M_:X]!BCF68'7@%D)(NAK+C0Y/]Z_@H7XZ'SJ[;#RPXR%2&W;U5NKHJ'NL;T& M0'IU*O-EO1J&UUT]R8'\F5A/ZR&14DUJ$)2CJJ0%08\J(R[[#$(%?(A' MWB2.:JSN"WM->.-^8S_B^05PG74,N8R%]<"%DW0#673"A?,)TIQOKM8P6^WF M/G@=`&[!YVH1&BYCF@(KSZ(K"/3K1?IB=:P_$_J[JM,4:]H;MRB&B'B.+`MRII#]%M0 M(KZ56H)H?7!?%5@>UM?PEAR%(7_4!WRJCP:5E#?'0[:)VCD56W-`WZTCHL^T MH-,GN:U2=5U'W3#);&*_`DI:#D&7<:`H>\?4"@IQ-.W0HU_!J47)GA!L08AT M]QWQ`.CT1>@R023]Y_GB@KYI?D&$6$RX>"0BL*U$*VE!VH.R))9V(AO*9H^9 MK_-HNY[]X=V.$^GXJ:\"T,B>E"^KZ+O(JC6,`WRN@L MG@U71W=ZUJ\-.FNH^3L-=O,&UL550)``,OV3E3+]DY4W5X"P`!!"4. M```$.0$``.V]6W/DMK(N^#X1\Q]Z?)[M5NFN%+E'E1JWQB_OLDR%(5JPH)@"102&KYQ59+`)A??K@F$IG__)^OL_C# M"\OR*$U^_F'TT]X/'U@2I&&43'[^X;?'ZQ]/?_CP/__C__P__OE__?CCAU]8 MPC*_8.&'K_,/EW[A/V9^\"U_J_]A]-/HIZ,/\,/!Z,?/?O;C_M[H\,/_LW?X MC_W#?^SM_;\?_O?=Y__OP]7#XX_O5K%O^49I./^WM[!Q_?"OY0E_S':QZME?Y^ M\%9V]/%_?;Y]"*9LYO\8)7GA)\&J%F]&5&]T=G;VL?HK%,VC?^15_=LT\(M* M54JY/J`E^+]^?"OV(__5CZ/]'P]&/[WFX5(N*!,6R\\T&SCZ6/_Q!U#7AP__ MS-*8W;.G#Y6L_RCFS^SG'_)H]AQSC-7OIAE[^OF'Y'D:<$8.1OOUI_['19KD M:1R%G-%/?LS5\C!EK,A_^,`;_>W^9@UF4@)9SU,_F_FB;#4T37[4@`ZN_2C[W8]+]IGY M>9G5PZH]I?)F+,LY,B3HR+JD;28'13N6)3TP).F!=4G;#T&MU@Q(_<"*(JY: M'S\M!G,.8_U+6K`[?^Y_C5EG".V;-H#GLF2/Z?@)9J=JU]!VCA!7MR17>Y5* M6S$@Y1CV5MDE^UJTU]QV50ORM-<8VH*)L;.]0>T^6-1MF9)X_%R=BF`H_N%G MF=]I+54U9%W6-G._LB7KTK99_94M69>V8^]5MV=`\IL$/LH>_=%;6-N*5.UYE;1AY.P]FT5%M;.!3@.G9WZ.8$FW`YM.8SN1N;V66[1I8NR7 M7W/V9PE?NWKI=I!"6[`G78HPINU5I?D>!GEO`KMQ]#]N27<6%00$';!L5-9WZ4V)%VT71O M8:MV?IRQV5>6F91TO=V^8DY!HBPHO[(?ERHP**RP];XB)VEQ;G0LO36X%`QZ M;)1$?&JZA>;6/@0K"DM"%KY]BDO4YWJSNGR%3\9IL/:=F-\0IYD0487FR<^_ M5I#*_,>)[S]_Y+/A1Q87^=MOJOGQQ[W1XDKX?RQ^[2UO*P`OQ/Y7 M%E??]O#"WG[C$.5(\D=N4-*1NBKH[>^O2;RB]SQ;EQVZV%NKB][6:EY_RM*9 MEOH6WTR54I&=G(XMD2J9#";DKOA3$BM&( M2=YWQ5=3R,NUA59`U'9AP&1SN&&;``D]8JV+J<+PB#ER-A,:X,C;VI?9Y&I] M?VF5K!4P,6F'KD@[SW-8\L^_YMQ;K9`0ME[0VS^TR9%HG]IS(1/(+Z;BR"T5 M%V7&74RT&=DH[XWV#O;<4R/0MHP6,0@Q/\?.YC<_GW+S&/SOZL\R>O'CRF!6 M7/A9-H^2275;*IOR=.I[^T=4V!.3@LQZVMC$I)XX&W2+>^%[%C`0&_9,7UBQ M0"X;>Y)JWO[Q$"E40A(S=^J*N9N$FU73;`YB2IAJ%O/V3X?(S!8$,1-GKIBX MR]BS'X57K\^PLV+JP2,L[^V?#9$;'`MR3-XCL;W0W59X=#83K>:R+0P(&R-W M8R:%4WTQOXO]^@("5LUGOI>5SV:R:MZ!32N$Q1&D@(10Y\P647GTU#B_I$F@ M'%#"\MZ!58.$+;)P+`A+SJP1M9#*>KQ4E2E;%&!$F MG9DRWLYZ"S=H_?/N>@7O@("Q0JE\^7%7@`AARZ6-(BM9N`U43IBXCG=`P#K1 MG3,)*(0V9P:*-5_Y<=:<6=3\J2M[!R>#)5(3'<*H,T/'),E!ZI"`Z*.H=$C"2*=2-#[4M)`@S M[AP_PC"JA;GSH_`FN?"?H\*/&[++#GK*RMXA"2M9!_8TL2%\.K.NW//G&0D+ MK_PL@9D]AV-K.2MC[FB]C)6#\JFN[!T2L+ITXE,3&\*G,_O+-M96ZYYW2,#B MTHDO!`O"CS-#BVHM[W'3X!W2,K(8L%#C.!%>%X=80/]Q_1'*[I^FK(??&N`[ ME2-G9^2N[U2.;)Z-V[Y3.4+=K@52__U.9=MMW:9!JL\[E2/TIEN!YIV]4QGM M[5FU11EYJ((;-C!`[^RE"@DB^U:E<>Z#C0"_-N(;A.IR!]A$ M:!HUL-K>$0D[1XME3Q<4L:\;T-5HYIW1,)Z MT8>O3332ARR.CKE(Y/,!'G&/G5W==S[BVCP5M3WB'JM/0BNI_S[B;FYW80-+ M-1;#$;H15\%Y?X=6E$S^ M&FRCI'=,P">FW9(F`$#NJ)H7XZ=?TC2L;DY8]A(%+'](8_G9!ZOD'1-P?FG% MD0(+L7/J+UF:YW=9^B2]9&^4\HYIVGQP0C:%)W8&79Q>DLGB3;1."8'W!ZUHTX-$+7##35*PC.6% M>EG;*.F=$#A8Z>EKIV(W"4"K8K3G<#R\RUCAO\JV M]9I->"<$#F%]^&P%E%J`""Y\SJ5G(/_5*\=?1OFTSM/%,R4I&);6]4X('.?Z M4JM&2"TT1/5<F_1A4(Z,6B@(%&F7'8UW0N"XWH<[.3)J M@2%6F^9KT$+]D+`$R5<7R)_84YJQ1A8EF%$R'P2/$C^;5]L\'L<):H*&XPIT MO5.0;HZL?=4[/2.P%>ZWT[*L'&I1+I9`%CKZQ!(F-[XB-0#>X'?9$F#48EG` M'E'+S+!6SCLA8,CK-;]OH:$6?^+M;=R;^R9/NA6<)^%E%)>%U.%.4=,[(>#( MU8<['7S4(E/\P:+)%(0[?P'0$_:EY.H9/U7R-]S2]$GNUJ!W0N`96Q_N>\"6 MA\(@Y>XW^.=MIX-[WG9*Z7G;J>[SMM._G[>)G8!LF@[Z^/Z==GC?5L-Y?[Y_ M5DT$9GS_T/BM**+WY_MW."#?O[9\T?7]6VQL67B1SOCF:)&,%I\-A16\4P(7 M'.T6.!R'U"&0P/[M8NHG$Y;?)(),O4/FWECI3\HH"(;>8VY%1N%(3E/;LF^_8;.E3[ MB%D)!45L3V>*+:+[.D.TD=W:-9ZE?E[;.ENWH-JBLK^/&>5='W[_RLF"-/;XRT"_`)>!\:7@F5 M>,V]]>BU,IKC6[]A4``!ET/3*Z<2L+D7(AT&.!?CU#199#VY$S<"`"C&0B@R^`3@Z/VG$+6[R[2Y(5E_#IL_%3_7$1? M8_;``BA9R%/@]6K7&^T/Q0!D$"^U%QW2WFVA;V@V#,H:BG'))&!S+T14TSWW M%NE_VM5J!:`-T]#4`IVYE*9MB>MXYM5K!L`-T\34!IZYC*8=ML65Q:LHXL[6 MI;4&O-$>T1".'7;$(F3F\I9VV`_WX6J[`8YHF(-+$YFY3*8=QM5C^B4MV*_5 M%7>78=6LS_&\&XNM`)BY%*4=!E4/HK;J)_]^ M3!%_J_H?_QDEH20<1X_6^+7K4/;^_6%22U?:+?+"Z&`H\Z-$?I(91G7?\@S^ M=?;HT-V[MHXO>T8'E'*S5`K$3!/;V'3A@>PKFL^@ MPUDY4S*R5@X0$3#9;'5U,1,"R8D]F/GLO^IQT"SGD8CKJO5[J>*HYL^B:U/E5P!>J=*HYP M%Z-!G2J,QWVR:9+L=>S@C"FX1?`0.X<8B"ADU0/43.`G-+8#BHC8><4$3;2. M+T;Y(GNN^<(*O@NXR]*7"/85G^:_P21]DRSSXYP'1?12N;&(8DKK9*$Q\@&8 MT&AZ%DH649/(B9W$.EXE'!/P"C3)BM;]PS%JVW,6O&#M6NN>PC$5O4/++'1,6G[Y#Y+LR+Z2Q4`5*,]02@9J*`CLZ)O#H MTRW2QRT@3UVEVF_H\A=NZS4CB>;=9Q3L])?"(B+JCIWZ@#M%0+M02F6EZ;>&$`1>"E[:ZYQO1`+6EI<]-0Y^&\C/+J MA'"7L5E4SF3G;E5=F-G^#:G75`NU5*>@C8S!]N*2U?]OX%]X(FN88O0;`0T. MSN+:%AVUG*C;\K]9`^#X4*5WA>'!8#V"HZ7,[-JJ'6]$(0U\6^IT.X`2.,'< MJAL0;I(7&`!I)G^4+:T'4`E82VUQO`648*[2#9%AI7F&'<@E>V)9QL*WA'2+ M3GJ>YZQH1[9.@Z`<`JYPMGJ!O@:HQ?#`9RW!OY7Z-8%6Y#ISH`)V!IMQV?(MU8"Y@BZF$5(M.FH^?6I`MJP9`"9@.[).MU@&U4"[- M[MF(.=EB8&_4`I@$[`>['=="%<@CQ;AEFCL6:I@$L2H`D(`98+<<;^-'WDTY M,PXV)Q]-@K$J`)"`U\YNY^MM_`C!YGSM5I]O?KRY<&#[;'5-[_1]C]%6:D"8 MI&:GTU2+-4,+Z)F`%X_]86]"2TB7+'?%C4D24V+9^2 M#M2F&5`$`;-N.WM<>WP(T>ZR<`L1G$./SK(Y=-0J@&MKAC?J>Z.SP9E:6P!# M.'7FD?=0/C_7S[;\^"V4RDWRE&:S:LK1L+!KM@#P"5C<6H80:0,-8=:A(U[M M$\R]A*4W\ZMB`(2`9:R5UK'K]TU0"#LN7>32&7OT7_G>44'06DF`0\"@980C M`2Z$)F=&JC=L7](D@!]7=ZU)*-BS<1_L.,W+C&G,FWV;!H41,'>U7RC[8T8Z MB3/[5G4"K-]=C22$-XL!$`)G9#-T(">=+;1(U!@*N:5DM#6+`1`"UBF;M&VC M16BS\NY3QP"%%`=A"1P);5"C1HU0M+_S((V?_#S*QT]WL/?B6X/%H_&'@K>- MXU@I$)N1MN7^.XZC()Z;S96I3QS'BC$%MPB>]Q?'T:J5VTP<1S3J)HKH_<5Q M/!U0',>V?&G&<1S6MJ'=K@'9B?:10[9S,->X=[!G;N/=1R)LMV&F86_?JK%8 MN#LQ39)@$V](+^]A]W.7I;"C*.9W,4>;A/S>Y)E+^6G^"-]6[(,T:H.J;&YP MM39$)DD73_':BB"VDT+EYE(KUVR-VH#:JIE<>ZNES5!+@C>A$MN#[81@6INT MW3!--@HWCQA7%BQ;RJW,<8/4`)0$+C:T!QZR]Y9A(Q8)^[K,0+W<"LFME*_\ MIUQ)'EX),!*XV^C)GPJ>[91&M_Y7]4!"2H*$!&XI.A(@Q60[1O0CB]GS-$V8 MINZQ\B`M`7?&/@S(D1F+Y6QF`AL_P09:@S-I>4!&X`*IY[0E048L=/,M]W/D M28)O9L]9^E*G\U(R)ZD%IVX"CH,]^5/BHQ9N&<7[2R9/JR&O"&`=>@O:-06U MT8"YH,N&0GD&03DKJ_MGG1#A*$1)QS#U"5"@0V?&W70AL[JB%AX:%5<>&5I6 M#8`Z])YT/*\L\/,#,$+,W">0W)Z*R("V!IXV*<2#8U.-8B-V37*1)`'-\'4WB/LJ_ M:3E;26H!2IM7]406,:4"B%VM;,FKY7,CJ<7/LU;-\=I+FI(*30:WL%&[5['# M(:U%SA*9J@7/8,K*MSE_G.`G,W%!+BF!6`OJ@2%8[S`PYNX/%.I^_)[JJ7M9 MD$M(8&_12]V;8*CE<+SG!OF$A5=^EL#RFJ]=3L'B&\ECN*HJPY3@T*O)LG&X MK1K,I7A$AMH?:?9ME9X`&V?KI4`TAUY/NS#?B_!2R[%8/??B+B1P<.17?\*7 M]'AA`.70#6I'PPR#32V9XGE81??-`>`B%YC,<6*KL'>P[S"3P8ZXQ&!32XK8 M=-"0L-@L!D#>AQ>4C+]MP/12']:Y&><\CE^]=0-M9"^*C&=8)0#Y/GQ09*RJ MX)O+7XAL8)89EGCNY2H0XU.:??>S,(=9(JIWX)>PK\I%L7]:MN"=NGSQL(N- M3UM=4$M?N'7PNF,9_X4_8;+83[)J7%D.WRGM:!QK:(!:!L-MLQ)+@BEHY-LE M6R:^:67O%M3GV-_OF.^B"FH9"5$WR*N\B&;\1/U;SI[*^#:2+^2MVO%&HT.' MKQ!VU"VZJ$2>>7"'/J?7?I15`9D_,Y^'7JN>6)B,(B+\P*W*/51>RSOH$B*Z MC8!2?TZ\!NSF;)H+<$=-'7T)-C(J)._!LW*)\=-\^>.O$6S@LF`ZOV4O+%;< M^.HU`#JV.=7I7_ZJ.!5/8FU`$O/$%`+>!J&\+FS5#FC"JC%)^PZX#7$*ZO5Q M$W,&==8#:-T@.^@*9/U1ET+?),\E+(4<_4@=Q@&O!6@)9&SH,%853&-(B?FD MBN3=[\3G_A(E`8\#JWRN(27FL2J2]Z`3GP=+E`1<&JSRN8;4F/NJH0`&D?\U MBJLXWAK9'@2E`95K"U+[0Y02#S&7UTN612]^$;VP)=;QT^J7;S!D=^2Z30!^ M`F%W4&*PV[W29W*'9P5"%Y#S8YX]'^;5I=S9C>#B7N5W)@Q,QM_>/) MCZS>"9D)^X\:2E%$Q&QB)FBB9=XRRA=9P]5.M^B'KF-"M5\CNX&D:LUJP/XC M*J:_)>E7[A?&EXSZX'_/8#T/`,G":RPHLRQ*)M6M]A+C79D%4S]G^8,?UVGF M_"2`?[&BJ']VSG2%C'KW6])QOPX^HN%OX"NN1?<./EU M_C6+PIL$CF2E.BR99@O<7<*UTV_WSM(.)#&+'A=YG*QFU)7(^5T&I]%7";O* MNJ`UU]Z"W6G51">U_1&Q)[3,+[A3>\*1N?=;ANT)-'U\CL2QJU5(WH,]H67T MM"/ZGCJ'Z(%F`PAPTRP$2`NXANAQL2T[LP,BOWE;; MY&L_8.'[9V8'BAB)\!U86]@&YBQO+CW"W;U],1XWG:V M>O_$?UUWUWI"T&:V9;N@*==A%4S1WPDY.8^23HCJ"^_WJ1="8B=KULTX1TQVU`$K/>.WI(>6SU1&_\*>TQ&AN[`VYB%PC.>@"M2P@'78'L'8:% MIWK'!'(+=QBK"J8QI,3N0W;P3NB$^D%^>Q/7&A^Q&Y9_#_K"MGU#U%A%02J6W_ES?VD,!^D>TXMT-DN3^@W/:I7%[$1= MVP.TU)T%$'M2/\2#>,QL,EFU'=OHJ;ET<&9MHR@VUT^3JQ MSJ``@_,Y33A.W6?-HGJ@4?JNRB>HJ[(&-F(&T`U!E68N87E`1L.E64/_8N(D ML(C9*XT11LO^:)XYLN;%/_PL\Y-":5!<*P>("+A(2X:)F!T!!F+&P98O:4YM M'J5M+T\;.(@9]#H\Y3BU>J#M\I+F="M',"HX,7M4)_736D2Z\*!:)IQ9CSJ^ MI#EU>/Q'N[J8"8'DQ"+,=7Q)<^HPL&-;#K8EI^:3NUSKSO.\G%5RY3P9R77& M6--;7.=^1M$$*(#Z6XMMBT,WD.8<CKP+&X$E$#] MQ40[IF4PS?GOVN?Z,GJ)0I:$/9AN-N$=G%%_2]&-YVV09!R#5S>OXZ=%CJ'\ M/`FY57]AU.]C#S=LO929S/'"WNF9LXWZ4AK,F"XN")W$YME5:$-7*5!A16W( M3<=BGK/@ITGZ`H,IJCF#'S:I@E]YMVSBQU=)`3,Q8EX0E`*P-H^T6@8&&0WK MA*$`K!BY=15?"X,:1C>+@,16CTQ**P*JQ6UE;\MMQ3IM4=,T#`8]5&[!K(Q< MH'[RDV^P@,Y8%@4^>@3%BH*L#D^AXLXJN"E%)3=F)D:T>\_"[VD:?O83?U(O M37$@5S)>`R1V&/I?6]FXYV<(Q9BQ%RSF.6^8\LF"9IG$XBEM\D"CKP&B"QP\.U-@$J M`,8,PJC/&$^2GLVON''F.8MREBO'@*R.=[CG\*RKK78U!-O.>I_\;RR[3!,6 MYVGRB?'3:W+AQ^%W%L>?6/8M_1X5?]TIF&C5".!R^$*@Q6K<&I,Y:S%"UFWT M9QF%=W[PC8?_8'E:9H'&[*2H!L([=(K6)D0+A?78"I^#D#<=/F9ECOLM8$5! M2(=^Q]JJ1B6W'OW@9C8KDS2`@K=%*%>OH"@(Z?#*3UN]J.1RL^7NS6OGW_TL M?(2O*)Q"ULH!%)NG+<-V&PD$A`UGSE(/4]@3?_)S%G*O(X!>)[3G7D7U&2;_ M-%^5N?/G_'<5KA6X).29ZK_X,Z;TEK/Q.5"LU=.AMIN*@&[$`&M-"TCW-('7])LBD0E/(.-[:(I+<$*`!$M^:L(*N/HM.GL!R(9_4$IUQ6495)-=L4 M'M&M.4-'']W26%/Z*EFU%.R;,U1QVBK&I$<4;,X<\1G@3$<':OUN%00! M7:EZ0VSEZ5I8'B`2 M"-:F&$):M#7Q(%2Y=V(U&CW@<-]Y](`.:YP:$L*>L[=I9AZA'^X/(6I`18"8 M.0DLA#%G+]F,,49L;3-.G6IU.W#V#JX1_DBYLFV5!6ADXP=4`T9,$X(#H<;9 MX[7;*&'CIXN,A1'/<54]OU(L9%@5`.@\Q$#[-4R.!J'+V?LSD;2W_*%3IIP7 M556]4[N^I]J+FIP1?1:WP2%L.C.16&:3UH)GBU;ELF?N7IW)M;Y<$$1T^&^FM<`P0HG-GI@;AE%DE(1V715[X21@ED[8[MA"5!UJD&PA,(K*/'B3X>Y!DIE128?I;-81IHF;UZ MO1H`);#0M1M,:CP(<>Z,$&DR>639C$LNF_P:Q0`(!4_"=K/8\(NIQ MS"5$1O)C6OBQ?%93U?8.#PCLOEM/;GJP$(:`4VE";8;M\(*(&`.;S/BJ1&AU#LS,T"S1C-9_,<-J[+Q-'7 MS"_*3)]IC;9`)0[?>QK9@NB"1'AWYI6Q6!X6HB[S>:R05:\$JL1-+%0E5M=O M")0QN!-Y%X0(W<[,+-*IHLI?P^2WR3+W[\E"[%V>*_7A8TG<2`=PE^A=A$3ODE]5 M%0`/[E2BAPDAT9FY"!;I#.:;!S_VLXCE[7W"77MJP$#:=68/6+5KC M+)I$(!C_;7U)I&_O$]3U1J.CP5&IBPIA\G3GZ1PN2_:8CI^>8"'(WC(9&TEA MO-YPE/,8_7"B6FH1VV2IZGF'7:R?B)`/P92%90QKX-IGI8F,975`.)OG)CR5 ML9[6!/M`-1HZR1FZ3U2/4<$AWL#*^!*%I1\KWF\(RX,ZG#_>T.1,/#E)4!%+ M7+PEZ1]1,;UG<>6`D$^CY\?T2IZ>H&-+H`T:62@JR M"_[))E%>)3'02,ZX7A1P$3BC=QJ,8E[%`(GE6;[+&'<0T^!KHR2@(7#R-DB7 M$!^Q7,QKNP9N@TV#;],T!J'>SIZRSRW:X+4!IS@[')[A.N?=V M?9`[ZQ+,:6<'N2.;EYT]#G*5UEH?Y([P9`[_C@>Y(YNG=%,'N2,T<(($U=\' MN;@T0]&1\PQ%O7:T`C3&$C3^G4QF&5WTR.I+[:ZYBHYVG$/F"'W?[P*:@%`AN\UF/O9T#BL5<1L\N)"C,&EL9-<]&5@-#*)=D5(W;VMZ6 MVTYV3XNJIK$^]="YV=XPYW@-5-1R0&Z)JK$7%];PSNS&J-,/H(\K7Y.M)B!S MV1P)\D5C>;%!G'+=<6:7V7ELH6.'D;PZNPAT!6HNB:49MM\D[O;R6:,VP':X M>^G-KS9"!05@V`.GSDWIM#-33K"3\7,9^K0#5O(6L?T\=IE-6BR*-; MZE0&(*Y3VW;VFFL!D%KR4%>1U\ZL9C[?Q0:H+5AJJ4CM/KL]LYMY?:?\HOC, M92E5A!?YS&,WK2@!1RRHJ#*/PI>1:&3\]L(#+ MS]_D^W',PD_SOA%&]%OFWBE#/FF:@4\MLRF%*#2@F2$?47M@EF=*W>&;FW$Q M91E?5#I%3+!@N;R5O,:15_!&HV-W`0^7%P+KMD?DV8Y.->_P9.P[.=91"5Q>"O`RYJ)H/>K`-J)I"*N]'M@O#[&WW MS-@^&;18[=(%:QL0L4-$J=:J8T%W[M2UJPQ4WE(Q1D_O"97V+J]VXQN+F&[[81D\1"]610UJT`JL$A=C6 M[8]SK3$2>X?2E+\=HRM4!)[M]F1N#0NUIQL;&=^6:6569CBIQ5%=&V`3>,K; M@4)M;';>:72GM#(GWJ9^HC_TL"H`D$!`K0[DR0')'W4XM/QVBK1DP_-1QP*, MU.#6=6=6"SLF8)M7IU(3L%S%G6S`N)?[H&S`AD(WG=J\%#5IYD#=K"7`B-E] M'8;Q.:5A%)%PI4FN#E!BAF2GM-.RK.R"?[*6Z[<&Z<-3&C'K);IO9X6N`!&+RV24+EJ+ MG$G>5(M9!QNV^O)@G.A?'2S+@K34S%R;0T!^;;"!Q)@E6>.RYGNJ?U7S5A:D MI&:9:J?O#23F[,*(PAOFS(84W)G[#/J8CHY[D;?5AG=XYO"UA@7J$(3FP@X9OPUMWN"J M@^#*Z@%4"JGN]2`CCW@GAV`D]9"O/_G?6':9)BS.T^03X\Z+R04,M^\LCC^Q M[%OZ/2K^NE/,]*T:`6`.;8[:K'3`9#U(S&])5`6J*>87+"DR]@?+B]LBE),C MK02".[0@:I.A@<%S69FD`114JEQ0U#O:*% M4SN_XE/AU/B_2YRG++OR\@#E. M<5N+5O#.#AR:X?1U+I7H!3TA<$::%`XB!^KN9/KZJ.H M<4!8#L1S:XQ!52;5;%-X1+?FCJ1]=$O#^M)7R2H3S('!LRA[+JHIZF!/?0\I M+`P"NXZZ*NZHH@,H#@#1M+F#YYL#B,9]KZ`H".G0MM).RZCXB([-'3H77X;? MZNJX612$=&A%Z:3C;?$1'9L[*R['T&B_Q8S1+`R".C2?=)PQM@$@FG;FQ]TM M8>O1GDVCR4Y<[06`$&X<.FT//ZWFD=7D35V3ME9TB_N%/2T@W>OOG,#]%$MC M]TZFGRF/`79JS6FQ\6_E:!2OOG>W_ M&S&GH0J$.7,VD8W/*]^]8.5!7!)^^>Z8VU`%PIRS2`<_5D"WBMNO]=Y M02NN`5/*4.)PXF]H9=`0YMS%C]D65KV1PNH`1*L7'OI/:644:+/6!(7PYB[L MK6G>:.UB31.H#!)ASM+T?X_4CN+-,B`>A6"-\NXO6*&V,2"J=1;$JJ M7'[$%7AH-QKQ-W#5ZU&UA@=ARYGMPR1;M+8*!FE3[1*.K$4G4!HUL/)<;@+/ MR*1C0;!Y4,!!U&\MNH#2,H&5Y_(2",O14_V;Z<+)9C4M/P';7?X"(4"&V'\Q/ULD M]),S(2S,@T83.%ZVU;\,"Z)U9\$#=Y_>X6A$8,GO$JJY-4B$:VW<52I9N_Q4_T;;CV[9AR,/I\: M;8%*")PG^M.L#15AWYVO!?<'NT57GF>Y!MN(Y7CR2]9FLLS M17=I$)1#(%-9IWPQ/?`BG<&9^P:^DVM"Z[3';38`X`=Z5FF##R'7G#GG@15% MG6/H?)(Q5DL$6JP9Y'DX0'1O[*=P!Y!!^HW3AG:2D\H^A4\XX.!K;U MU4>%4&(NTH5@#E@39M1B4ERO"``(>.Z8F!1%N!!BS`7"4,GQ.4V*:3SGV/PX MYG]>^#QW)0QM$``[#*1AC4@%7H1@OU3-H.P!O8%5(/F`B+5HTBFV)UW95(VP%X`SM5]X")L&@RO@JV M>;IZY6\EA6N<9DWOZ'"(QVM=8`@WSGQ<[K(T8"S,KT$%FCXN6!4`.+`3N!XB MA#*G/BZKZZO%U18+5Z#K[52]S1(95+HU!,H8V$&O#TZ$=&<.,>NXK_V`H0ND MJ@H`'-BI4`\10IDSMYA+.-N\^$7TPF[3/!\GJW]+2<,J`<\O=H`98@[S#;@$)Z0)80XA0[,P#Y1=02\[[)(->*9KK)=PJZP+D@9X&-*$A;+J+@;L^P[_YR?`T M.X"@Z3:COP9*&@$E#/2RJ"U&A&AG=AJ84[(B^JM:.^H.>1GE%:2[C,VBV"532V@(F^;<6\[#,*I; M7QGS^*SQVW.:7*Y'%=DZWZNK`HA!'NYUD8GI.7/V6JGQ7D.QO]DHZ9WM#_3@ M)P2"\.+T,=)J'SW.HDD$@JW,#?JG#$%=@#RPPV)+:`B;U!X750Y6!M\6R=L# MU0QT(],#+M(3S!EO%J$T\G%9Y(6?A"#=M1]E4H="61T0>X@+H!H2PH0YCYV2"?(N@"0[@QY\%DXV`CD%NVI]2HS6,<#VP9;(\. M8=6<`04-F+`ZV-S!CI;=)$%&)#6LQ\SG<]RE/]>/P:=HARMCH#>;77!BI#N+1G/U9QD5 M<[V=NK*.-QH=#D+#+_&<[F,_^G()U]K)10S2>\=\'R_(ZD3DQ_%VCVVA,\'F M5`D&Z;30&$@9%O\(4MBMOA97]9.GGW_(V601#&+Q=Q@"+/SY!QA)S-4$]1@5 M/"7+31)&+U$(W5N19498'M1A\WI"*\V,'F7BV4D"2LRQLTW$EJ1_1,6TBAL- M`N;3Z/DQO4H*'JM1EX[3.6/Y>1)>1AD+H&(N3VH@J0*R$]@?=AIP@O57"10)\6S2[IY# M+_"30B<9T691[^B8@,'5%!DH0"0FDP42=%(2;18%&0E<*)HG80,@\JK3!@E0 M3GLL-`J#G`0"EED@8A,BXL1I-`'.ZO.*M4)8&.0D<%=@B@H)1.0ZR,*HT!T0 M2^D(V.O-CX4F.LR@XVH'_=E/_#HGO3+I[691`$3`DFZ`+CE`A#%S&0;/\RG+ MKO@%WG,6Y8I%1%@8!"5@S#8U<"00$2[,A76#_8/V(B(JR^WM!#Q235$A@8A0 M833+X.+#UVF9Z:XDJ[)<3@+O8LPO)UL0$2K,G<8;WX9=A385R[)0;?QHBP8>,< M?A5-IMK'CD9A+ND[6KAE&!$VS!W%5Q__$ND;"%=EN9SO,H_J@_ M23TVAN_)NUPN-A$BMYGF?`8:XS%NLUXT2W-9W^6"(0")$&+NT-TT&;-8?U/; M+,UE?9_&VVV0""'F3MY-TW&4%:S%=+56GLO[CLRX"I@(+;9.X6UH62_/Y7V7 MQETA3(06C("H&!9;)4'&TW=T^$`! M(B28.X[_Z@/>\-?[/(8OJ M&UGX8?,B%G[EW;*)']<`$#=C02GOR*K!RIIS,0H%\2WM>36NRX'"3W2S"(CL MUN\75>.VMK?E1E3=\[F@1573\+7MH7.5Z^R!N9/TOY[+WUG"T]+G-TD@G_%% M94%PPYU?1XF?!)$?W\8*-:,5O".7!E9M72OD M1Q1N[KA[F05W?E:`$+E2UZ*R(*9#RZFVFG'1$0V;.[_>1K!RAW=^\,V?1,GD MGN5IF04:,XBR(@!PN(/4UKTF#H0(<\?8>Q9^3]-PY8NF[/!X#1#9H2E46_4J M`(C.35X?O\!7L_G*Z4P]SE=#0#1O\*K8?XX*/[[SB^D#"\H, M=*2C>VDM$-VA65-?^QH@$/T;3.R=EL4TB\()6RT\SXJ]#%X%A'9HR=3?S:@0 M(*_;S%T'WT??+EE4Y('"(+-9#L1S:)S4G]"%8B-:-7>GN[6.G"?A8Y!4L9$2 MO_YNRZ44;8';C88PQ[=&A+#D[&5W%?WV$;ZB>("_5@XZG$WKC/6']P(P""_. MGEY7L3L_^3D++](93U);IWWC`3_KCI9_FJ_*W/GSJO-Q7"MP27@7^\D7?\:4 M[[-M?`X4:]70H?UV7T"WN%_8TP+2O9QEIGHGW8N&W9),/U,&$'"6)FLCYKKR M,9RPO'=$X<;2WB0A[BP252`LF[26K'U;&8\`*\^C'1%P3]H5=3JZ0+@S9W79 M^+XRC`%6GLM+P(_))7>;ND"X,V>WJ;-52+;E@E(P)=@TPEO;E*-0$"V;L\ZL M/HIN8(3E0#RK)G?EQA95F52S3>&1&#;F3#!]=$MC5]=7R:K-V)$YR\R__*3T ML_EH#_ZTK[B1WBX*PCJ\QI!T4H&B4?$1'9N[]K]F7S-=)8O*@I@.=T#MM(S+ MCZC9W-W_9P`TU='Q5D$0T.$VI9V"$>$1[9J[Z#]_SJ)81[M;!4%`AW\6[.X?J[<2 M@J(@I$.?M4[]>%M\1,?F3G5O7];6<%/`P9SH$.$1[1ITXVZ,'_(O"44&_$5""S0.C=2^&MD@1 MNIW=03>E5-X@;Q<&4%9/I-KN!6UY4+/9!(BPYO`FMS=K-.R[NZ!/90,^=I9[ M]R9Y83FTK;R)7R\(H`@\W\;&BI@:$0*$#G-G:!ZZ\'>6A,J\"EL%04`"<37U M5"Q#@*C8W%GZ\7OZ1JTZE.Q&21"10`BT%DK&("!:-G>:K@+<:>I95-8[WB/@ MM--"TS@()-V!P=1GT:NFIK=+@H@$HI>UT#,&`=&R03_VE!5_L3@^3\*,Y0I% M"PN#H`[M%QUT+4&!J-O@Q2DL#YJ]6E#4&^T=#&;'H0"!J-KDXT=7T=DDN MX[#V'2@&1,_FKE$_1\'49_'G(.1?"!^S,E<$Q<5K\#`UP^K@2BR(_LU=M-:[ M3;G&FV7XVQL"00M;Z%@@/:)5KL,744>Q&,2X=`??0=EMI`0!$O1U.A(;L M+-RO567K?"L#2[G-_FW?E+D.!.&BP]'1(!?J-PNK4@##ZO6`OFUR7;$2[3<% M1_3?,US7CO5/S,K8@0B5]?#485JKUVA6SI24K)4#2!06BLW.+J9"(#E"0L^H M7CU(`.5ID=`L!U`(1$/5)6%;<3U MDCW4,6X4J[AN$Z"`048D[(83(=K9Y;2.],K[,/U&0`DT$I^W8ZT[\TW8"/?. M;JH=<$]K][+[3J#<^YATVTZ:IT?E(U>L/(A-X$ZI[5@3')#E`!$^S-DA-CZO M?+B*E?>.1P1NGLSSL0$0X<.9X>(B]O-\_/2'SY_F%N/LGM^G*;9`:!V`.,A' MK9K`$.Z<&3J$XBI7-DDM@.GVJ:PF$2W8:P)#^'-F*+'"'ZVMB`TB59N-,W-7 M_`L1\EHBU59#7!I$)G";H1P<@I5,A@=1O;E[_[6/*W<5XM(@*H$X)KU5OX$' M4;TSH\IMFDP*ELTNV=="$@1#5AR`#=JY&\>$D.7,,+(IJ7*Y$5?P1B.[LYKV M5@%7O1Y5:W@0MIR9,DRR16MC8)`VY7[`:,+Q%Y85$4P'?%Y0[@BP\EQN`BN3 M="P(5B4%'$3]1K.:-;^OW!5@Y;F\!"ZW>JI_$PZB?J.)Q3?H/X?Q'K*P[2!8 MJ\:E)W#)U7\LB%`AG!A-+[[1)[IPLEF-2T_`S:W_`!&A0CAQ9@9XF*99\:B_ M@1:6Y]ALVFZL;Z%EJ)#,\'O./"JVA-6(J2NLP4,46GT(H+V/ENE?D[$U2!AG MSAPPS')&:S=MECS5AGJTU\'6@%X?%>S.G_/90>,J;[LL%YC`/9Y\+`AOB5`L MF-+-O3QH?%SCOFZ[+!>4P).:/DK?Q((IW=PSA.;'>79N?;6O2G-A">S+>BE^ M"PVF>F>/YJL=S$V>ERR\++,HF=3!.ZIXQ?D7]KWZDW2'IM6`=^SRW"/9J]U& M";LIV(RO(/M[Z`K2`B1&L4G3P&R6)I5,=UD4,!"FD@0_`(G+@[RNX_IU(44# M$\:!,]<#:0>J?W^=9@\L>P$LG8?;5D/>\;[K<$O6AAT"%J/>F><"7S?JPSK? MWRZ.[2R\2?(B*WDH^":`#I3:TF/HQ39S:4]2XYSJ))!)+QW[8=M8*Z@'G(^V%-?!BGYDPJR`[A M=S\N6?WKWQ+XZ$/Y-0^RJ)+D?`*',M[[L.URGS8!M^M`PYVWU/UQ8WR;L^8T MMOU<)'[(YCM`D4B5W"V.1JW:\XZ/7,<[-G%TZH`9X]B<\4ACUV]L4.LU"LA= M1UXV/:K;`,_XN5DQXC="@)L#-F$X$)96-=U9FRLE7;M M1UFU=;N,\B!.\U*X`5;6\49[1T.V/*B`8>RY>R2U\NE2&(TV2@*@XR%O5<1P M$'[VG9GY+OQ\*B,%_LQ%'_(LVL"`J=_[V`^J<\;Y!/YSS80W7TA)$/)D MB(J6P\%T[NS!DS*Y,9;;&%;:<86C5LS*DI_7Z^E-$F0,*EVR^O]2W[0=R7K3N#Z^UP@$/UZG,K'DOJ5!C MG<*94>PN2P/&POP:%,1UD"]\7"6T8U4X1-<)L?L0J\"%4>?,*`03#IRMZ_!. MM@N8[.HG,EN2E1U.>@AFQYT`6*L4C$6"F`_X>YY\_+1R8;MF?)\NV\RT;HLK9<@+ M8U?`6"]P%@9H'V)1H=@W]6Z;)W49HNN@:05@O<:=4UD09`#JP8_]+&+Y M8M=QGG#C>*#<@VG4YL"':%]N#Q'CUIE%"T3G^Y2-'64+;E6U.?`A+_;Z$#%N MS85>VIA$[OQLG-5+CY9+MV9U#F>(3GD=,&*4F8O,]!;"<_DF<^%C#K)A-$FJ M<+&'N(/2Q(7102LV\]4K[/.BG%6OJY=_S!=_;1TR7=$<5\V0[14],"/=X=!= MP"?).R`[NV?MID%EAT/>0AG"CW49=_&F6N+J>&$H;P^4,V@GR#Z@L1ZQ,+V! M+CZNE`'B?%LHZ9_KOUW3$7LMJOOJ-WG7M/3]^_>?DK+(_&?8:,S\GX)T]K'2 M4B5?[4R4P_[Q;=*[9(4?Q?D/_S$@%[8E;39\TU9]XNS(W4U_,&5A&%;?`QK[A'1_;=.OQXWA[4)NF&1GY9E6$3`;P=<`>%O\(TJ2`P7T55RW^ M_$/.)HNGDXN_QRDT_O,/!1SWW>7Q_.\TX^&V\OI2%J:2>CY]8`%WJ(F4R0LU M6P"5.4]0;*D?B#M;*[V(NY*S"QT-V961+K7;``W02)7Q"99E87,)2 M(_FXU;,;O65X`[F8.V<'@_9Y[<_L/G'77BPW]"I1?E-PL?J=.=MV4C^M1:L+ M#\K4NNXV(*]Z">V;Y0"1PUL,M*MC&X0MR9'<$">@RXL@N.RR`L_":-D\J54[>!,?PMF(A(!Q:V:DNPH#0N50.S"H?9" M:IJ@W^[@9'%_VC<&2B$PM5ON21VU@CV4&.J4]4M]G9_4\)4W5^:_!FHEL(;1 MGK90M6'.%D/MC8W+X#>T%GNCX&O>\8E#]]5A]$94;=@U[5![8V.W\`?C3BTL M/']AF3]A:[XON]GDR20`]9-(XD.YU[92)=*3W>6QZ6RIV]C%+$>LK0YM5!`@ MP^&C,B+]VH)&D>[MSE&CKP[6-TBN^K:^%$`#@:31Q#MV6W4BO=I=5J2^"A!L MM%QU[9:B`"$$;B.)]^]..D4Z^2DQ3\@#)ZZ0_(T(U_*MCFOC5F'O^-3=P?E- M&J6_X5I!Z!,VC2=RIT%$@9B];5ON]^#)M\15^SGPJ2!-^.!7I?Z6U0-%VK1" MM',7$!"GH!B'1,SA;D-0I9>5L#P@(Y+W6ZU_,7$26,1R3L^L^E%*-WMZ2A9/`I4>/[>!:(3_YE-AXY6NT`5B9UVA&>HZ\70=X1G M5OTG3.T(SU!?+0FL][DC/#L=U(ZP`W/O;4=X1L!K1#),M':$9Z@19"#/&D[V MR-@INJU0&U`&_T[A9(^&+6)#KQ+E-P4?_#L%0$%K'>G"`]UW"IU\Y$_V"-@. MMKJZF`F!Y-3>*71Z*W*R1\"/0Y>#;5CN?57/="\AT$?@$5;/_DQ%C>_M=<-P M_,E/]@@\`",Q*ZO5)'_U0.9.[Q$:A>'U=X@Z@9.?0[^O086H.QG9M"Y9#U$G M\4XSJZ+W<*7)U_0O_DQE"VX6`_`V32V.HMQ4C(J[S39X8M>9;P(JK\76"P(6 MJ_8:;3/RMH+E1#3%)W91V8,*6B;E[IQ8N()$(O;S;]<&O/V]O0/46(F6!6D) MO,\1]>IU72L`&+M;U%'S20LUGRRE)&!$[*+F-0#4;@U97&6R\K-B_@BK7`X' M:WXF^#1O_D5UQZO=".C@'<:VDZSZ;55#[5:S(:1R,=HN#)B(A,)K28.:S"9` M8E>?!DBCM8NPR9YJG^$N%Y$@HQ:EBQOHQT\7&0NCXMH/HCA2'DZQ M*@#PW\L`+5<$M2A6(FEO^45GIIR$556]LQ.K?D3:ZZJ<$7T6M\%1"]IDF4U: M"ZHM6I6KJ;G$P[_#IU/\M+E5!L0CX,JD-S8$YMIM*/+0.08T?)&^P,R=S>4Z M7B\%HA$XP7?6L@@,HF=G5A<[CW//K$:XHK?5T-`& M\U8$B)F3P$(8>I4^X;]#K869%5[\[],\*=PPG(@)H%SM*3S M"Y8S,09$Q1T,'7(5/WY/M52\+`?B$7C;UDG%&Q@0%3L,'9YF!7=%YUGL>$([ MU5Y!5!Y&]K^9K1_7`D*PPXC:&Z*J[<#B&M!_:>11E2A?DZTF((0OAR&B#?)% M;'=@D#CEOL"9V\E%FKRPK(A@"OF2%BR'B85/)^K;;UD]@$S`@4PZD)!+<#4J MA$!G+BA]']7\SG+^CB8)KUZ?60`_/J;\5XVW-N>32<8FL%6^28HL@M$3_.[' MI/8OL)!F01,.`/?22H-8P,APZF2KD1)G],[\HLF`(4`#M+ MD\H'HX*G,,M(:@($`N'J['225BI`6#1NK10+R2A9L66W9@G=R\$Z2!79A M5:`*A%UG'F'\/':3Y$565DY0?E%F43&_A`57LIS@E>!,3L"B;7>J5Z%'*#;W M=.^MS\%2$65S-`XLO MTRZP##+!7#T]P?D@>F'+]N]AY;EG09IPIZ2:A5E:RE-\=6T*-C'FUC'][V/Q M6[HT`Q!LSJG"$"W]U"V8-SMA?@\Q5Y9^(HL90NNE&5;'&^U9C>*A=?W2=NV#YAQ>T>ZPZW11B[&8/,CI#Q'U8LH-"#?)M1]EE=U\_'3) MJK>ZH"3T*-NI,<#I\%[2^)FPAPZ(A?)1(+ED3RS+6`@%SO.<%3F'5:LJCM/O M?B*]"^_?..C,X57E#J>-UCHA%DP(V5[I=([U&M[9T7O=D(J`RL,+.;6AMLR[ MBSY#?7M>Q"?#C<[-MUB1_Y6_\(Q8SK49<6TJS:F]&O5.#LT95EM((K6LMFT' M0+@QK1I0O6!![0;_;RNKP)[B_"%P#T([F%EQW_0!V^]H1`]1Z;V-V0X]-@_9 MS$HL+(A1OLB:6;=FDR^LN"CA-PO/O=8@-^SW*6P8$!%GIQ_GR<'6=9I=I^;5X*F/X&]_C MRQ9B\Q\#G1)XRM.Q*VCV*T-*,F:&1;;VW>2^27@,FC2;8SO]GLT"=@)O78QT M$'/J(!;47`/3FB=7$BYL`OG5[#E.YVSMS_WFGQ8?`ET2>#RRZ[FGM8*(67"W M(/Z2I7F^T%B;OM.L!T@)/!&QVQ6V\1*SJ6K8@CO0C#;BG1P1>$!BEW,%>&K! MWB7*Z':J`9@$'HW8Y7@3+;6@[B*!OZ1)8/`,JVH.%./P6?9?.G-..._JW.J'@KH`8";V"Z$ZC9(50*H!9*7F,56^FG MWU9@U0ZH@L#3%^M]0:T":A'JY2KIO%``6`+!BZSS+<`L#TSO]`J^4YILQ)RU MBKFW_,YEE/,KT#)CRAMWO=J@T`ZGI2X"2R_3U35!4)NF#OSZO(T>!=8R761_ MWXP+KL!LVDWU;\9U*>QP%XY:0H=\%V[5)&GF+AS/+HG]WX:<#N@MORQ?9 MNW`M3\7.#XT,M.Z='#NT*?9<<8WK@=A5>2=S@NSP?.S0MFB(:Q4\8F]_=+IF MAW=A?9H%/;FV+>YFR,L50.Q*6@SH`HX!45)"=U_T^S1IWRU$C8`.'%H2K78" M'*ZQB^%VS[A:/>KKUA#@B.\0],0C]44%54^!)AQZBXX88"C M8\0;TQL(QE586]ADIB2]BJ!Z=W'%E]U,*"-F=FI3'>#9M$0(;4]M%(\8'K21 M_6U[$APY":9>4?'8P0"%IU89KF6#2HITA=Y;PI.@#-D"12WINDB^R!JCU M.22_+@O8C7T&C<_*V2(287Y9:KBIM6L()B@"[HG=%],N:,D:CZ00;I+'[^E_ M,3_3WPYJM.6=G!!P5;3._R9@8L8G?13P56:N$RQ;`ZT0\&;<13?8@$S,N*2- MXSHM,V/]8-D8Z(1`D.T==(,-Q,0>(FC"Z$\]H"?@FF:=[QKF<"Q0)IV5)%^3 MV9>TZWHG9^82YDH^J(KY(:T''6#GAJ*6&A186O50O0LC4?DU9W^6(-85?XWX MEBQ39B(2UP"5V/1R:16U0X,[Q#`DPT;,*B2059W!%:L#"*T>1O5-1#(&M$EK M@B)F)3).&S&3D6'^R%J--J169MT5EO=.3@G8`!0#2(NU)AYB5IY;T.>DOA.% MK:IB==LN#)AL'M!WL[!AL(A98];%U)H;L2J`S^J!6GM%PU2O0]0F'&(V$\-T MT5K)S/&F6L/,>=?<^446!9'_F?%DT%?%>?S[/0O8ZX2+-GGA@VB[[=1]\N653DP51.<_^600,$S%FM"3<%W%S,!8Q[ MO\P8?]AY[\]G:1)N]DO>5Q4<:[<`D`B\HFS/94N`YD(JH)-Q&5_?LRC\_5_WI>SYZF:*54]$)]`>+4.DZL.+'/Q"["(:&4.^^;'S']A6?[[_V*)'_@9 M^Q4$@@D@UQI*+9H`4`0BG;7FJC5"<^$&4+_AES0ND\+G"5J+2H'CIT]^\BTK MGXM@+B=,JS(`(1`YK#55+;"9BP*`O7:>PJF!99?LA<4I'&OS\=/YC,&6RO\] MWYB-Y82U;@@`$G"F:4U>1YSRU_X.SH'\G='2'C&_]&?^A.4/:3F9%EAF>.VZ MWLF9:[_]KG=)+3$BM)J+!GK!8X/$L5]/$M6[@0N6%74T"OR*3UH+1"<03;C' M59\&.H08<\F-[M("I(_\^.KUN7H,@NX--PN"@*[3F?52/P((T;@Y2\EY&$9U MZQ7E^47L1[.5/\&FWI'B(*SKC&"]M"^%A7!@SJ!Q'L=LPD(]`@1E04S7";GZ M:1_%A%PUF[,GP#EL]K7,\LHS81%$-K].L\=IE(5W?E:@H9_5-0&"ZWQ7O6C1 M18B09,Z`L`PO>#[)&`NK//82/YRMLM[IGNO`!7V]9.\1M2W,(Q]9KICJM%:1!UT*=V&2J$`'.G=44W>$P+/]:D0U@78`SZ M3*^/$:'*W#%_0Y35>??MC4*]6&JRA54',(,V`[2"B7#F+,/$IO!U=IWSH@I\ M!;]LN6R)ZP/TH9H:.N!$7*8-NC,(9XC+\FW#VF[V7-4#\0=M>M##A]#C+!F$ M6.IS'G&.==PU-BM[IZ.AFC':@D28-6?7D-U$G<^J)W5M3FEH?8#SG@YM"IP( M;>8L(-4CRWN`\K8@+^:#3WXN]&975P+!AWH:TP6'L&+.QK'^!A:$8=]9^,BR M&<8(6@$$'O2.7P$,8:*#C0-UM:LZP3A9]()*#(#!.TAUM?!ORZ:V90$0:-A;\'4@B&:=!:A8 MN9@]L**H7Y:?SWA&8=F(0"MYHY'+*%1FQH4*'<*A,XO%VY;E.LUNV<2/5V++ M7B9*:@%.E[&DC+"HAH<\`-[;>1B1C:>O+J/7+B/TW4HBBN"%O=,N:X1AT97Q M:-<*>J<;U_P[C#R+*5#0(?Y'W`\^:=Y\R^*=];Z MC8#B;)H2V@6>%5`J)K\M/F+!19I"*M_T;A<&3%:M"]J/K]O2H":S"9!8:!$# MI-%Z@FV3/0N!15#W);Y+R.97,+5GSUF4PXXH5CR`D=4!Z0F\S\3&A.!(I09# M+&*(N:!8I_LV[7J6UBXI&&(10\R&4SK=MVKDZQT%JV)`F[0F*&*10XS31FOA M,LV?A0@BE*)@G>X3>'FK&$!:K#7QV`X'4KM@?_%GV-HD*`62T4GBH5R/4`#6 MPVVL/HK.2L)RWNF!VTP;J,JDFFT*;S\L1@_=TICE^RI9-9L;C';Q+S\I_6R^ M/^)_DA\Y!$5!6-,?WJDH61161#3]<,3;2WC\EL/ M+O'9S_;WU!K>*`;"N79$TE:N4'1JL1XJIS6-$_%:.8!BTQYHZ1PL@&`N1(.A M_;`;F33 M;TT+Y@)-_-V]&HJEL6TDT\^4^T]GYH1[EO,(G`4+JV>22G."L#Q`)!`?S]XD M@=URH*J0!_)P[SC1*>F*%?O5K8X7!5*%>ZF0R2J@9=IP MC'E=H.,FR6&`^I(K7&$YD(Y`?.M6XT,$P)AW!*+>A[0LIED43AB7,6%9?A/% M\;,B"+*L$LA-X,Z\A>(UT-C.CG(YF][P:3'QZT\HHKP+2X.D!`)-M]"[#(8Q M%P4S2\%-\L)R:%LY^Z\7]$9[+J.P=IOQA1"L^S5\CH*IS^+/0PPU!08C'G^T#.#_7(IE^*U=.]%)(Y!PJ2?HU'5@=8?W?4HZV+ M;$U0YIPRB/)&ZW!OFD#E#=+`T[*>'CGTR-$<0EJT-?&8\R0QZI%Z-#B[,PK# M>@*/[KZ31VYMQ*C*I)IM"F\_!T;F$TI-G.)3TQEUD@F! MDC5!]189I`I_!TOCD1^J?1VRM@"9RUM"DS)B.P.#W"EW!N9\16Z2ES0NDP). M[7>LJ!0W?OKD)]^R\KD(YO)U2JLR1T1AT9(/%L&RU0:=N2PH"$]_^'`0+_*K MU^>(B\-OP#%6!$6]4[LS7">?RUMI(`(Y%'FZ$A?Y-M+@VTV>ERR\++,HF=3" M5E<1^<8E0G43\4N6YO)T(ET:A*/(*8&7:]TB3O1!C/0'=X]+N-1W(+$T4,BR M$$=!X.5;-]XV42!<.+-&7,1^GH^?8"[AD\DXNX\FT^)+R54Q?GI@`72V(F+Y MA1_'+/PT7Y3+%P5E@[1GR]QP0,'FVX5U,]"1KN+,\4>(ZNH5SEM17O?QY1\[ M]P]%MEI0?J1$= M;,OA#_Y$MJ75;X1K8:BFI]8H$:Z=F9O$T\NF-U;KZ7>S`4!O-QSFSF=@!"'" MKS,3%N^@E_6=4//R79F;7EJ/8QWJ>JH##"'1F7%I=0.U2K^N9!"OQ/4S5$.1 M$A7"G3-ST.(E27Z=9K=LXL&!3-J50)"Z'O:.=!\3_Y>93S M:9[E?`&OM)N$#^5LYF?S\=-#-$FBIRCPH?L%`>]__-XIC:,@8F\!]$?M0NFK.XZV/1%A\?3,->ZJ*N"E$=O0.J=MNM*F?H@E/;#<'VAY M2Q+N&+O+IS"NFLYA"GV[%)>[6V+E06H"1PF]02?8NLAA4S$%_8 MU#D59/4`*0'W@"X$MH!G+,L"B5VBTG!CI'W0G.M(?-:.+184)Z)^'(6_#1)7P!$5'=S^&&S=\.OO+>O-SXJLR"H MJGAG7=S8#0F.V0)DQ4%@FQ=1PA.^GA+7!X`:PWLXC2\S0B^<`[7"TF!UO#.K M;M):)V$U;>)Y3@&*V.FT*:3R_+%=V#NSZ]FL'W1&KG5D-X/@(79B-,`1K5.A M0;(LG.*Z+&GU\G_/)E%>\*,-WTTCRYFHJ'?F,@-8UT4-1V+E,->.BPL`D_GQ M#>SJ7O^3S:5D;)0%#`X]7/JQ(81BY4BF2\=%F64@U'64!W[\7\S/KI+P$L8_ MP@A6')`X?#G5E10Y&F,9\[H/D^LH9MD%2#1),_D@62OIG5G-.&%UB`B`&$N: MUX6(Q\P/X:3[,)]]36.$@K4RT'D<6@NZ*E\`P4KJO);+1#J;I4FUJ:B=K\=E MD1=^PD65KQF2BH#.H<-5SP5$BNZ[[+^8''\GTGZ/7E@?IXF+*R>N(GN495U8,,^P`5=`Y*YO'?= M>?K]+1!2=4;"QHZP+(`8X(HO@6(N5UZ/TTEM/KAGSVG&+URYX12=TF15`-(` M]P%J1.9R['4GZ:[\&D?!=9SZ(C\!83D0?H#+/P)#GH!OA]?QU:%UFL;P_?P2 M&@^B8N';W_TRWM3[^%O)S;RBAG=V1B24`W9++RGMG1W;M%4)+^FU]"F^9$(1 MN+VBE\8;YI+R`]);G&K,K5!<&N#9M%6UBF*+:G^=+"4:8W?LVGJ79[O%RGMG M)VYOSY6:U%)\$XRQJ_,=J)[&I;AI#G;GU[Q(&+L_4F<7%13USDY=I\:5=V6! MWE$8QBZ\$55?LZ\9__)(0]>BLB"EZT2YK96-XS!VGVTV9>Z9RYBLW70LA&#L M6AI1[_ES%L4CC7S:6P6]T=Z^0RM#-QUC*(Q=.J.]>#XZUNG%:\6X<`Y-!5V[ ML0B#L>ME;/TK$S;:UUC\-LIQ\1Q:F3LN?6(0YBZ#)4K>/])34BJGY@ST7UP0.ULD5EN9R#VS5+@)B[GU4I_+"%P@_7Y1S<%EH"Q.W5 M:Q6SI[;9(V9!02GO[-CYRYN6YD`4!84;5=0ZM5G$.[,;E5II"T35B%T$->6F M<%G:2M4T;'\]=*XR\W6Y`T5MKCQF6#:_X@$SX3";L_PV#E2I#?$Z(+YC_^7M M#BPTLJH@R&\^';QUY^ER)-=`PG(`Q>9AU,:,+\&!7/VX2QA5A3'QI_FJS*+B'L5KA6X)+R+_40K0HR-SX%BK>Z"]:,,;=,M[A?V MM(!T+[?YIX;?O6BLQF3ZF6IMW^]@CC`5)7XM/YLR'(ZP/$"D$$'UP`B#,N"(__S M(__N5YAP*N7\_U!+`P04````"```B7]$SJ]`6R-^```5[P8`%0`<`&YP:&,M M,C`Q,S$R,S%?;&%B+GAM;%54"0`#+]DY4R_9.5-U>`L``00E#@``!#D!``#M MO6MS)#>2(/C]S.X_X+K'VB2S9*E8I6Z-NF=VC<6'Q!E6D4NF2MLF6QL+1B"9 MT149D8H'J[+/[K\?'O'&.R(2`&OW0[=8I#L"_H3#`;C_VW__LDO`,\R+.$O_ M_0^GKU[_`<`TS*(X??KW/_RROCKYUS^`__[?_N__Z]_^GY,3\!-,81Z4,`*/ M!W`1E,$Z#\)/18,/3E^=OOHS0#^\/3UY'^0G;UZ??@]^>_W]7]]\_]?7K_\7 M^'_OWO]_X/)A#4[`Y\^?7T5HA)*,\"K,=N#D!'\GB=-/CT$!`9I86OS['[9E MN?_K=]]A^"^/>?(JRY^^>_/Z]=OO&L`_4,B_?BGB`?3GMPWLZ7?_\_W-0[B% MN^`D3HLR2,,."P_#PSO]\<"X-]D85`25BGG!800^%\G#=@) M_M7)Z9N3MZ>OOA31'Q`/`/BW/$O@/=P`,H&_EH<]_/<_%/%NG^")D]]M<[CA MSR+)\^\P_G><-@L'`R;8.6!4KF^\2:LEL_LL,O>%7 MP[$!<3DLLBH/H1&WJ!R&TPH>#:>%%DJ$C.,!F)[\\O"'_]:B@=L-:!%!@PE^ M:W#_U[_1*8SH.LN'<@ORL)DD^E%!6`WQ79BA57Q?G@QHW.39;@KGZ]ED4]C3 MEYH#A5P'CYV)RU2O!G2G9,U,Q>KT&P'Q26L&W!7J!X>U#C3A/`F*XG;S4&;A MI[,O<:&C%"R.._W@S'^L*@0$9!M`@)"C06`^J8M(!$+-D?/?GA*=%04L"XV5 M;`QH75V8F8YUA`(H%Z'9$T6;WL>LC<-FS/?AX7+]X%Z)^2HPUER9_&VKZWF5 MY\B&M+66@7>DO.R\^3J\`C6D9\JLGG\S[X#`_]47Y18H#%_'I=IB3]7/@V)[ MED;X/Y>_5_%SD*!)%6?E>9#GASA]^A@DE2S^T\2W;@JZ=#&JA1!`D$:`_-!# M78&S$C38@*"[-98Y%!YIYGLFHW0<^9R`1_@4IRF6!(K6Z&>/2E.7X3L611#I MG((6FQ[-R"^,/=P$IV!Q<0_#K$+3N8GHGX:6*--9\#2URE*+034VX M3DFH4Q%'TO"R=V0\>:KDW-D[%>8J@C3EX,YK9VAW4Q[N$%=+M#W`6X,]SE++ M`PTYF@,?+J6"=884?`4(`O&%+8H'P8R4B<*!9OSI0M_9L-GM?%C&IKHR5 M74-1[&GY31P\QDE:0>7WV[OKF>GU]^0#./ER`A_7M^7_^?'MS<7G_\*<_OOWQ;^#B M\NKZ_'KMWLA,575L=]/TU(DIZA_=RI!23#LF#,UVU M.DD,Q)/3W2:_?!<<<')9_Y1CC.#L?(.9N?`LH(;T)%EF/O\]A72O^'*E$1UA MR#3&JL+G%8Q82Y3KO`C'A=H+Y\_1'`P+>`N!<^4WIJ+)%GNA_W(=XIB`C@+9 MLX*+"JZSV\TF#E%P=IOW0S6U.>@@6[<++8K&JH60P#H##1JXS0>[$$^,93)I M90:R&LV]T>BKW-AZ3/7-HAG!/'X.RO@97@5Q3BZMW&ZZ7S;V?I`9D_80]DU* MGSI&^UJH=O$YK``>AEZ,6X&?\JPHNC\ZMK!%*/TG_0GL)YMEXV)B."CTQ-'@PD/S=F#6$VE[]P# M%Z6RNTST&B5XO4CL:B9T7:JXUJ2'EV)Z&5SW:JZ_@?=GYWZ>[79QN2/7Y=/H M/$M+Y#I@&J*9271,]/04#/F38>NCMDUEBPE"0/E,S4&U(E9C&;+4Z$LI4FJ5;.5OBZ*"A[K=9.! M)>C-O:!S_Y?7KUZ_/@7[(`?/E(PWJ]>O7S?_`\4VR/'%@*K<9GG\3QC]#9RB M/WR_>GOZ=O7Z]$=B07_^R^GJAQ_>HO_]:X,0$V;0&\55B6MMD=@J*,$%#.'N M$46&;T_1QY#"$"#TPQL_S(VGJ#P;$VNIQ5.4*"()B""Y"^+H.CT/]C%:YGO3 MDQVG:"#;/U?1H8@YFFB1`,8"URFH\5!\UC-5QXAK M'W,08ZAZ]BSJ'I9!G,+H,LAQDJHX"\-J5R6XW-8%W,1A+-O"Z"!;MR@MBL9J MUR"!!@M\T\,#-:(@0+)E4),HZY,142CWEJ2O=6-+,E4YF_6(QO?.));#`W90 M@8@S8[9*50=$[PW6=R3/RC*/'ZL2YUWP:>9=X#HOH$4/S0L4#%52V[!YUJ!% MQ;NCGB5H^B/O^:UQ&C*?VW8+;HE\#%MI2^Y@7/I%K<*1'ETV-[IWS;M.SG>5 MWMR)G4S?P)(]N!EK?G5\R5(SM,E4JH4F>/46(],(?46." M"Q`R(-C>9%/-R:L3K&UF%7P3IR#*DB1`"R&*QVBFU),S!DW%E.1!];32B;F1 M>11G;0I;S\Q8+)?FQ:%!;E84`708WIB2/BFU"3%G$%[9C$B[)+8B5RV'-D*/ ML$SLH\%P;QOMW'7LPKO3.CT:A@812TAP:@Q#-5(:`D^''!K!;7=>:6()`S3W MYC"D0L\F>CB>&886-4/KR%3$.#41CI(I[42H839K#H;9#K9EZS4R5T(,!Y4( M17-G*_UA2-!K2.'!_EE3!&P90`W^6\Q^!@DL[N$S3"LH+R?%0-K/P>,@2 M>;@L1G(0(D@H8)?4@K1U(N"T+DR-`#"&Z_#`E))LXXO6J_6(C0/TE,B>+9!' M@W=YMI'>AAE`6=?VX1S'2D&?/=(_NSRBUYGE7C)+FYK+D?I8584BM_A&;(]; MTZ(0N2[_JM/,2()C_Y689/[,"ZL&MBE`[$^[HVED-+4E/#@[5>H1\_A*3XDL MAMHP06,^T6;-"5HZSJ)=G,9X4O@U9SU-602N.8#]P%R7,B9>IXBKNH-U0@*; M(7)C2HX#^=D4/O4H#(84GH`X#9.*7,@G.1.`&U!'`&T4\;"DL36.F/[E=/7V MQ]/5CS_06_[HGS_\^./J^[^H;#0!P` M-NY%9SUC<=RM9YSYBQ<"`DQK,$O+#=F)TDQHH/?[ZBKZ+17^%$U2ZI-P79,K MDP.+H*FM&Q1RZMA"']J=%0SF+-;_.@/Y#08\UBU[,]673AQGE?"?`-8W4.-D MJ4_JSBJ+4-%%FF)/Q3]D:3:<36UT&IL9#5SKZJ]##Z-3/9S6'FJT;[W9YTRA MC!;&D"]L-FU$6]O&%F.H:C:/J4J(A%ZJ]S@,I(-CJ?%,H"G&LK^DZ1195D5?]:+&] MRV$9?)'E7K6'L)^8U:>.R8KY%_X)H MHPXVN%H?O4&*]N11.Y`'"X>IHC+IXDE::M<0"SQ!B*9X^04OFIZ.'97$&-#E*S&R+B0\*+X]7XBN(B3+*BRJ%&D<4I])%M"[X\ M!,LRH;<]B)D]TA90P:CJ]S$[*!EXE2E2_"8ACE.?5C\SX2(?@H[KFFHMW+?>M)[3ZE3VJD*MS=I\1)UA:BC9=HJ-+DN>?H. M;K(<4KAU\`46:!W+@RR/XC3(#]RP> M"FX%U_M/DNGN/ME+>H-'\M'&_,EG5V#P84"^3)L1=M\&S<=7@)B@2W]AE[7X M_`!'IPWK:J]3XF'=.QL+ILJ_M6W!3FT[/#35VO&^@RF47R`48CAR-+RY"YP$ M`FVRM>";&MIQM2Q]&N[R[#DN\"40I&(:MFC3(QU'!O:]B=`.^)Y`8006+Y7A METCO`E)UH;LM)+M$)D"P?VE,-'/F"A4&/"&0H`_J^$:8]O3QC:X3]D:7>\V7 MZPYS+4M#<6Q6;:H?4-UN)A9PTL)W4,M)CRY6RYJW<;>;0;.N04T\G][-&4F0 MK8MD+#X'NDFG@\TE2TG][R^Q[&J4`L^=+@KH8/IU4"7KX)"^(4B?=$TF$:&. MJ<5A3[=&<[G(=D$L6^X%\-9U231OE0Z!WRBH!THD9?U8>33X[L`AW<0I)%M1 M'2_4`W;G>OHS%J]YOV$PFL3Q0%'$[!:Z&`&O+>\C-$MM^%!?0Z<,A;TR&B;E M"]3T$%38)!$J+:IS4>5HY#O" M=5*6C?[Z*LN;=\2W*>\<;N(X=FMJ3J"3NUFN:T$!.@B@H]25".L_H8&Z!_!H M*#>Y@*6HQF#$5 M6Z97F7V*\_-LLGR@;RPBE**37PBG592;MNL43Z/\DI&E$]URM: M")]FK`\O6@'FK`Q&A'^H2&LRO#8,^IA-71S8\91KPN"[PN^\K%5"[6=UE@E= M)VLK=%Y_SA8)G`YR^=CQ^#[2 M0DA]A-#R_SA,1_&DH)<$(3F3F1)+LF-XX2A%]!G'D/48 MH!W$/^>H2VN_2'E_7[FO2=P?F<39@:$&C6OLH>J7A3G>.J'I':L';3)C?A8`=M,]R,:Q`O_(Z30/$A[`1Y(FUIM M%_0BXJYY_B@59/I>MD.2F[9^4&3;)0TWKY?U-@']>`])+^N[("\/@HH+"XWK MA>,RX<.@)N.6\I\G`7KA/(T[,2MB].`6+]*?F'F="/LZA1R6N'7_H?1;%FS@4/7*<,(87?E)$ MG[Y+7)$A5L39@?XH_GD^76)Y3@Y;Z*Z'UM3+\M"=Z9*Y'D1\?6)K!]5S3CS2 M/75)4I/5#N?D]GJLT&VFIQ$-XH6K$5)HX&N:AQ4OP-EHDVOB;5Y$(*7I>GK1 MT5?C>^16K!_ZS/<^2[W?$WO(\RQ%YH&K@]QNZ,]E_)C`!Q@BR#*6]B69.:Z# M5X'S^&#@XD`=3W7#XH?UO8%!-[*+&W3'8HG(#88='Z0AE]UWE@N8!?LDD@RY-&1>;%V:/O+SQ[%KJ(Q6@Z MCTGFLL3F!E>-GG_/27,41]L;71K%AHU'>#FWG:;2RU@J(9M[F.[%GF8JG88' M:X0++^V2@9%=\_<[$XSZ&!YIXMTGW6$\\4D3[C]QG)+E&U`&+W@FTVO@E+Q+ MNDPF6N*AOC;'-.7^TQ3;/M*1$[F%WO3FF'+>-!K`BPPPES+CRTOTE4PS@@^! MT00J1;N784.6LSLO_,T$^I:Z9-3QPQM/HVNMVD=-$E,]TCG3'._"&\`+[\*E MS/1JC_?>18M*7>_B760S@5:]F.;E.ABQP6H?)UEU,,2EK;,/60E_)K5QIT0O M0WPOW`N/+N/899T!/`"@(_CG772(Y#F7,L./2R&@U9!):R"2?8T+TDC.0]^B M0^D20[1P%$O>FR#2'HURI\]AI3^[OXS3>53NEY$=P MUF4_GN=8^O7?P6\4P@/Y&)=GGPJSY"@?-9<\5'A725BL8`1`,7YNK"`4CZ:FBD(K% M7K6PQ',A'=`B&+T[_%+`Z#JMV^ZE3V=A&3^3RQ.\GGP:JKC4!^QWP5V*,[S> MCT2KFZ%Q+:)O\.@@3K\%[0=`]X65H/&FRB*.O<<^.J\(GS;$^DG_T:[7<-`. M^5?WWF!9*V):^1[!A*QZF*ZYI]Q1].%+:L[*SZ!]54>+@HEAG]Q#3%R=P,+5U MINE%-%;UXWS.NLT?B6MCA>Y]!ON)]D.`]2GHS\/8X%T3&UP+8@-O@@`'S"PS MD+?,3)N>VC@7C7XFY24K&E;Y&C@(#TH.UJ=01PO"QVN"(/F@(VQ^',).#M*F4K;=QP3M&>\+R_"8AWEU).'NR MYOHHS<@P!^=H$ZQR$0>"3^CJT2_@)J@2X=4?.8XK=\&=O]1+D+/V&@74.%[X M!BU2&I=`SH];.S@.%=,<@189DE/T8(=5'ML[<0993N.4((\+$I&@'Q$*;JM# MWW*13^`?,4M:W^"/)Q!;F,`!J,S+WC[I`DLFC(G@T<\)Q#^VA45Q=LN-,WOIQ39\118C@!;#CXMLVG3T;L0FF`YX M9#I,[ZEI$"(*JIDKOT,"_0NC-:Q(=`E-;D(VET[R0BA^AMW"WOWN`Y3E"S5P M'2R::GK81:7Y^PJ0$+Q.VZ$@O/\GA.PF_IY#VSDMRXB(V@1QWEW]C%H\'U9- M31UDETPC!;1G5==IF,.@0'$Q_6\OW78>[.,R2#32\2:#6+]1'@]A#=9\%G44A,L1@GKHH`E[5*4Q,%CG/B2O#97W;%53M5;E^;9 M)+!0O'V+XHO\'H80N1&TM96=;AN.XX&1RNG4M-,V8XVUEPP#>N.X72/GDMS@ MX==E#B!E6E2KFE^]6B@'J:W#M*1?+/)B=0+C'5?4P_I,#0,R`CY@81\ MMT9LHOIJZS;7>Q^"6_&%"P-<#XQ9?6RO"ER/=-5B[J;2@+!^3"J]7^%'/"JX M4C!1[QP;4UXA)]QMVDWMB4'WPZ18JO2M"N."'K*'AF5`'K4M0E.SQGEJ6P)- MU#(OJ1J^E+=*$MN;._`+>YO$4>CEWB2MP!J_`7#\OF!Y[BAO$[NW^V7L8]G7 M1Y[YBJLX#=+PB.\:C3_@B^\PYXRA#VD_\/+?-<[GU?A=XZ9ECE?/$Y:U(DW/ M,LN$['D8-.T0PJBX0EPC55411W'=>5PUBMS>D#@/#5SK?D&'GK$:-S@`(X$& MB_9H(-6S"*++]BU3J!I4_BJRI&ZX@%35K3>:)2'B9HH@(5BS"/-X3A]2=?8GN19J.8O>JI#&->MR-K&DDUVS#8I3'+K@=PQ959(? MZ>L%'+]0/\/G@.M+F-.L>'`OD(]O M'F8GT5.)P>MM8R#D$8#C`X4Y=)!PG!;0E9%BM5JFAJ4PY3.US<3-@MAK#6>P M'C)83I=#E@;Y:MAOF>C76FA`"5D-PQXEY'FL>R/14"[9JBC5+#4.MZC'M>.ULA/G7-+&EG"2U]3MCT&=26IX M$F628CQ+!PG2;6-\E!:MC4'NT%`OB4_2R-\'\N M?Z_BYR#!LZ1M;<87_B3!@=DPU@,&0RJY5S+P^P3R0V^$5=/;BG.IU>4UMYGT MXNLZWT3M[=RX=Z55?-1MHK7CY7NZREKL\5#M]]25!DG3%^`ZW63YCOAM MG78/NB/8[_R@31M3PJ:'V36!`#UD;VZ)'9-(#RZ!&>HGT_5BBG+:?+910J0; MY5T01Q(3&X(Y>(8QF"7['H'^&>"_NWY1(9TI47+R)A#?J8IK8/=*SE,#]FV$ M2`>LOC+*=G`=?,$!ID)C1Y`NW@Z-YLIY1X-KGQ,0+W17->&Q^I+IEQC!!Q7F MJ@;GA8]8+^SN2?!2\`$1AW[$C^`+\IP@C3@7@"_B(DRRHLJA1C@T?V@G>Y>9 MW."J*AYS!>I103LLV>?P+N2#;FAOPJLC\`8-1?,4'0\P1]JA/8BZEK(/WHYH M.>.P^*`'YU1H0<13B>T/P>P_KAG.DM4[G/:B?W?\LD4]T::\9CPN6D^3=Z2D MKG?ORGEJPKP[$>J(S<:.;7U/F3H/P1PT;AS,4E8NU_$67#'10??R,@,%VGL6 MFP.(A'=A[#:39)6!;1XITH1E:COKG#@)P9W5=%8<4PSJ.1_U/&E:*6?5]&5J MZ\\)DCY!^-AH6%QV4,B9M'/J$867GK2.77DO)%T?%"G,1U30V8:'SK*]Y2?!EK_KN@B,GM ME/X@)(9ZJ':[(#^05U+Q4QIOXC!`<59=U08K_!V:1*C3Z)_!WQ\I]Z60;'Y];8]OJ?(!4'NH\0"QR8)#+#]D.@^](@ M,8(_!LC7'*=&?&->M@3S7HP7D]CJH@Y-::CV?-L5"MX^XMBMFY-.-"!'L^YS M%%2,30"#`P+?4V2_5F,=N8QU4E\H;O5+9R%4X'FA83(O*U(Q;U8::P2YMAJE M*S=0-9N]>1Y+HS,R$8*#+CR"F;,EAA]+D^,INVUI9.QG>]&H>6\Q$[W-\G(- M\QV>EHZO%2'8STZ+9L[FT1#@"88DCQ\]/ M].@*M[`@I4Z#1">BE6+9?_THI8'QI&A17F=HIUL_F_?)DVI(@WEVIRN*&0T>DPCGK-0'Y^[1^_EKG8MH$T!>TZ1EC**:J`MP(HA+"CWB MH_;'K"I!A,@LL[;:A>O##[E)#,X^=.QAAG&23@JJZ$4(:=M8K5$^ M.7(^=\=*(F.MS81CD,.!JJ*=._GENZ#`UZ+H(WJ]5*3I4`Z2E,;4)QJ=14FQW+U: MU#J5ZEXP^GHVI2$3X1-!?TZI.%/262#D:#[HELS]"93+&P]OB1S'UJ+TSOI* M9O%Y;;;;Q26]#YM&M'_.$TQ#X[>T9N/8?SAK2">OUTN-3XO_]$?PRH]/DBCS M^G.Z.#W371WO;SJ0G]HKX5F>?FL M^6!(C.*@:)5P]FP!IP844%BOE@R5&-A233HR<*=&6BDA,8YS19*F.EA-\L9E M'YL.ES:ASKWH*93-\*CW?H2\#3SH!4,R-`>ACY0*=M'O@:_HD\@#^*W^KS>6 M8IQ9STW\>Q5'<7DPVTK(T:Q;CX(*IIM8`SX(CWTS'JM$ MV;0='9T;VXZ^PMFSG5\*>+NY+,IX%Y2PD%C+&-"Z?3`S'2L/`L!/?5L0?Y<4 M+5*R6:38M`6^#HVU7Z9`-ANHH(BO@OC\S8:^CMP/7Q?&F>H=Z^2CAF>+A`>D.I! M"PW-W;NYNMJSQ74>1!#-CCQXJ&ME]1JOTUE*;%$3W[HMZM+%O&'!>$1#Z2N< M!A5TN/Y:I5=$V[1/(RT>V^<$%;9Y7PLGR[/\H+\\BE$ M=JBQ>TM+KEWL#2T=U;)ZA!.B">4D,7X?%Y_.]A@`\^\'4GOTU'K71L$2@]C;-8""?/]C`O#W=(&B6* M*_&F;X]9KV]&^D/8+Y&C3QVG23U!12J(DA8A\9=Q,4B-7G[9P[2`T>B/$DLU&\:ZM1I2.=;?'L0@9[X"S1A@#.*? M_?K,`YL6/47CQU8]7=T=/'$S29F(4-P];=-),C3OP/Q=/"V1X^1IFW;21$>Y M+-<-(.^=S[,=MEQ:,7U?EU&_)CM1%$_CE;M0'@!,&LU-]0!CFKG/Z.M"`?UQ M5H".5#<_K,JF!:=;!K38PQS0L5I4)\A0MV\4=S,FL M]9=.):;]NC-*6IA"-#4&0"BT'(:_"ZH;ZJS6X-'31:8HCXDBVLP&Q5F.YA1G MT3T,DZ`H2&8-X04J4[GD5&`=;E3>ODE3*H(1E>(&SBDKIIF7^.U7^NN\Q$^ M9G]?>PR.,7N\^B/XH4__,Z#[#F@^!/"70.]3Y'40$X%ZYS7L,C+38.1FS,AL M%B.M[J&/9L?,%OO(1CRG)W@[M;85X75:E'E%2PQBJ]$;QQ$5\9M7JMR.>1BP"J),C[;0"0]]JTA,?M6+TVYJY;`TPQV&%K\LG6 MNHB;.=\B$<#B.EW"WQ@-YLKQF%$LL\EZ)&21KLW3S!E]C1PP=%#S6,#W5&'- MC#CM^2>1"W/>06B6"Q!XL,GVOX@K^_GPF,<1Y].](@Z&#FW"D*[WI8SA1FDY#+,<[TH#/R.VR0Y#X/YF>HME MXSGA9*9'=?I#.H_M#*C7C&\D'L#_0.]K9LEJ>3HKCL&JM21;;UJD=>Z(60,J&7K(J6/_WQ[?=_Z[6U++D>(]C1 MU_+CQK($VZONLFK#U[8@%Z>"\O;HTC,^G5[IED_L]'O6]]9MVK]^W>M?[X>C M6(*\K"&O-";/S>F67!_%9U4ZRKC(%N+7(,\#Y)JNBZ*"D>EN08[M:F.@H$EF M/`TJH+C>&,]70*%A^&Y((C]2+]'"G%:[1YB3^SJ?8?RT+6%T$B!V!T]HT?X" M\S`N(-CG:#DKP#=9#I"-H[\6^#R=/+8OOB4-J@MREIZ1VV84D/ZF2N,2@93; MH$3C8Y"J+$KT-5)2KB13>(1/<9HV->8@^E\]MP,,\A5XAD6)$R?X;U_V,,3_ M0%$"_O6JF2(14CN[,L;_K$=GQL,#]2C/>D(?3KLWZR?\=QBUWT-3Z+Z&?X]X ML($Q^;&>*`IW(A31Y)BNYN/^[')T')M@0Z/OU19UP;>=XDSUPY(A7#MC&75: M_JHW@.]N^672.M%!FQ"KW"A];AU5-ZI_/D5IJ0K'HFFF+C90EYL-6H#B9]B^ M2;P/2E+(-@WC)":ZH?1.RPSK<.,UB0LRRVX'!+W6C'A,,!S4&\]V;)YD1^") MFRW>=(L1;__FFHL+SW$!-S#/<;STY:PH(.F:=A,'CVB^^)[E!*=A.*)#?V%* MN\Q5-&,1X>1Y9)TS_]*LMO]Q#OK].G&Q@4D_S#K/$=>HMY?)%>'"8C@WIH0,<&S>`` MC0[:X0$=WV-?;PR8VG6<#6Q'YG,4.;D2]Y%Q1Q<;NY0YK7[%&1 M]WNH=KL@/]QN'N*GE#P13\*\G=)[B,_+)!HHQ'!0$EXT=[9..H7L%RN@ MP!XHED($;`UT#?[;4Z"K*D]C'!DCO;Z*O^"?"J4.R9"LJY&4`J9:>`-,O%4# M[I$VJ>4Q5BA=8/7OD2!9<'4;R*Q3/DO(8) MW&^S%&I*6PQO5^:2>3.GMPVH?_)7<7^@!7JLM[>.T,NT^F&(`-[ZZB&:]UAO M*)Q72J/%^O%JH<%W>TI#DFW;+(FN=_L\>R:=.]31AQ3+N@+):6`6G@8:],$] M4B8-D3"]YW7EX2AS>A.G\+J$.UZ.:,G!7TX&M<^1XV11\1<`^83K5751S5DL MG2I0&P_26#_E63$IFUHC^I.\:B@QS%L1M",='Z)]_XS2CB*"UED9).Z7#CV5 MTDZN@'9T8;']\9,A#DUX-;7II8_Z1VWD?_"/+SZNBS'9HI5"<:_*` MK;L"[HS'>DJ`0`OES0FEF-UCQ5+QVIZ*?`AV\'8SF(_RU%&"8UUA9/,?ZPV& MQ=N-H?YX=*BH%,98CS0E,>=-%MIE)+`97)Z_Y<-:?F7%GR]S\XV`]73`><9$ MR>WA`QHEJQWV$]>Z1B/%X"L[:ZKQ9JB*2U+5<][&EU?X,NT>QC@^A9= M)4S1;D"&87=G()T[;#S5*;5 M#<=QIYJ:=,HTM#_$"O2\94]UO4G+3Q*P4(?-I>M`E:_3?546Q+1.U>\W9%CN MU)1+@TPI*<(*$!1PZL&A@(%>*5=;R9HUQO/M>N-N79Q MA>)6N]Y.TJZW7FG7VPG:]=9S[7IKKEUU687FP);V1W,86;DMO MO+E@K2<7]?Y4(!2+KU&Z*E1GCT69!Z'L^B87VO[K$^Z\\HT1#F48Q*/:Q>]VC*;>-*_*WQ=4V^%-<^U-@NKG]HT,2Y!M(6'L=H M@XUL#]6M99.3VW MRK37+T^$.*=D6E[Q["!)(N@5@ MK2D>8%DF-"XS3(`>>2Y>)%&/S6_-1"S`\P#]B=2[RE'QZ15H)P/(;%9M^5G\ M8J:9T0J0.:UH5Q7\SVY2;E=$'V308U/<8-!W1L71V:3U;/"%,\GU^8`5'ZIS MQF#1@=I;M7Y)T-T/;W_8NAV7P16*!&KC6;4^'GK$V$E.[34&' MU>\%C1\38T2WCX:GT$5NGX(G3%V M87XLN\E_;>\&,Y6(TP-*#@KB\\FQ"!0'#Q1^7L M[5YZEBL1>P%:1X-<&<%UBG8KL"AQLY^V!=`=S/%CM>`)DAY`N-=Z78E?VU*, MQW5L3N9\4-I<,R1I,+7J]9[JAJU[3^&!5TUK")_L46G?V/-$> MY$8_RQB\]PS!E^-XAF;SMFU"G,E1P]@WJ`3E>[(1P^49]- M:&V!#'58\5R^9Y]'&.[YFV/_F6W0EKHF*4M!5).)?AUAH7:)+->/VR?8X^"* MUF1C=!5=](YLZ8\%*?`5A_!4.Y*0CN$X:I#3IXP0>NC-/_``@(S@4QQ@3&?M M<<8TK+/53 MJ!5:7F_7@5;&C[^>W9%VE#=9]NGD,0@_88`XB_R)!XRI/P,[>F+;%+[9$Z$& M)?B\C<,M^=4.5WF+RP,&"<`3BL-1P!`<_O3'MS_^K0!E'I`K87':_K'`I[H8 MH42,`OLD".$K"OH.&P1', M#I;;+`)Q`:J"#H?CE;@D#C)(*&A>K!`-&<(OT90>*C>0=LA%J(GIN=(SCTFTR\U>Y28P` MWAW=*YB[1!U*:A?HKV=3$H$=0QGOX";'Q3:)8T#F'4$4Y>_P&Y//6^0U8(Y\ M0)CM]D%ZP/YC'Y#27U$%V_I>89;G,"Q!47?<]$<>7[( MT%ZLB)]2O"B<%3_#Z`D)HP?PD_S9^IQ!'6R"9G"`-5C>B3^^+@^Z\H1 MA_<"\*"N=TH+,N,;_/MOZ9T<;#L@W.+$(`Y(?+K%/=\$V(W3,OH_8\GO[=;( M6XT[>H6^_C6,UMEYMMMEZ4.9A9_.NOOGHG!@^GAV0X49=*O?N]2#@78TL,X` M'0^0`<&9A14V@+CN8Q!%B00QR?M?<%0]/@$A2!X[Q44 M#0@-8_K\&#Y/<1V>S/4`@]!E&?.W%];\&N1HUZAN$CB"LQY\C.?)U.NE?_?H M[3Z7L^,%4,)6!^^8SHJBVNU)_@"7L;[*(>P?8DK40W\(=Z^&U-1)GOSWD%>T M:CG&MW*H9OHRQQ&=3EZ-:&JL\+&'D;JZM4A<(SA$*\C'+$$+/GYC,L$F18-X M895""G7UM1D`="-X:IB6275MFW+=U;%.'<7UPSXOXNFGV\W9#N9Q&,B;H'%!;??RYLV6[;))1+789A5_C2N8]UH`8& M'31`X`I5L)+3GD_&N2\:K=:F@6+KJM(,_;[+BO*G/(@J%.[\#(.DW(9!#B^C M*B1I>*6VZ^/;U7T#NIA2(P@5-+B@0P8MMH9E6%,I4P$.%&R:]&:HVUD"\V`- MPVV:)=E3#(OK5*%@,@R[*B6=.W.-#P.#/C1`X+XHC5H,`S71E<&L%_6VV5(4:VYLTF1EJY:CI`;;X(' M'1,9'=[JVL>L_=`GW&DZA4F1I>]@D.^"]#Q(HL\P2=[!_%/V.2[_>:>P9,-! M;.^AS"AD=U<('S0#@'H$T`P!VC'`G3<+Q"2ICC9EDT4Z0QMOXM^K.+H+PD_X M26JM">H@0XEF5^/45+#5K#$&J%%`B^-3T*$IFX$6&0EFAMZ\#R/\4"%:YU4A MOCTB!K6K'_S9CG6B@0($S!:K/25XV`8Y?!<4,#K/=KB;-4F(G.'K;3055[P[=#!WP0'_ MCLR\FWX:W2&!?`AV4-GP[SB?LZZ21^*:3+.=GT39T)BQB1Q?7>Q9&HKJRCS& M1^_D$K'RZJX`WKJNB^;-GD@T5"63Y3 M&,^1.3D@`'XLN1*N#H\`)"Q=1)["M4\`YTJFPM5F(%7IO$9_$[<:E<#:?OO.G2_[\)2"@3>O M5P!#>K"\*/D]>AVM8O8,J?]'D%9!?O@!_T4NFNSU]JQ8T!]!R]HXS4R9WAV'`Z5N_I"SD\3!S)V>PQ3U\ M]5C`WRNT#%[B@S"-E(X0P_Y.6CCWL:ITD("`^A%^:LJ`V=CJ","I!JE3.6(< M'[1(&#,*],B?_(I*%AJZY#;3,9J0,M,A@'>M1<)%B]$@]\N6%NL5BN-V$>N] MKUZ0Q_E$3(:K:)IY3/-AN+I_!V;JNR*`/26-A4DUA\ M/]2*0Q=[AR:%^!4,Q00-ZJINYP-ZV*X;W,\@,)M!H'/K$FFGEJG)5=.MW5VG M<4D;<%X$I;2NN!:V%S;'TJ1M<1TJN'#^L'H&;3QCTZ+-M:4)]%''SJ3*..?I M2(&+Z,$(5],\S](B1@$!/?86-<;30[/\B$1)!7/9H<:@S3T&.$[;Y+TT[%^X+G) M(L>XG4&81OD\F317&@Q*A^Q'*Z%L<)Z8Q M1UMH6+&,,9`.CCC&_G'DS7^F3[:5G:_?DB*N][+F11'5]:)[\4.(F M!=*&JE,&\:@M,H="TQ[(=`CG756_*EJU/(,/E+K;G^K8J7X'9[F1>M!J%6]6 MBMM-UX7B"@:X(Y9^FD=G+->Y'RUZS5JPDH'(J4K7P*,>RR='=3S2,WW2'6:; M]#5=NSVKGIK;M>UN,FW/D&[NY(EB<5T4%8Q4O91-!G)BU4:4AC%L$?*O)0![FG@M+4-A3RPSF9FRK/,TVU4P?5[F]) MY>]STIRNN$[;W^.&;#=94ZU`H+@:_`A0?F28=`1DFZ/\9#P.^ MP0,Y:C=]=()C0X)MVJRY'@OKX!LJL8LVI7@:MVGW;VFX($9RV&:40X&XC>@* M8'!PFX+N=ZX7_#F$9&I"[*YW*KT2]_:4*]6,X[2'NL'Q[>:B@NOL=K.)0[24 MKG''/=$AFAS'[M&98O[,3*D@4#P0$\-8=IVC>3!M/#(=UJ(/TYHF`E/=C#Z/!>(=:\VM< M;N]A0LX+BVV\7V>7\D8FDT=RKVE*6ODZ>#O003P(Z(^"'=RE+_U39LI9J;LF M0K:GU5TG!>5;.A;4NEYR9LO6"6C;7/CSCD[$Y;'2R%EL3ROND/!PSR^U4C"0 MUG6"G2M3KJB!\$@C!!P>*X24O7-J__2#L8NX").LJ')X$Z?PNH0[8;DQ-9[E MFD!J.IB-V"BP[K#`;Q@/$$37@;:N@(:%@XRD8\^=-,>L3:_T*L]Q]<4T^H`X M0?\A<3%:V-;=CAY-3$WBYHB]1G.;P#@F#3:=J8%^C1VLL7+-N1Q,WUMN\*%` M<[URG:VW<1[=!7EYD-\-UD.V?#58DR+F=X@RI?JH=FOKB.G0I8U)0C=2Q3W65,3R3!5=[3%8D_# M/F0E+.K%DF0S(%'[&!;G";;^30RCH!0#W" M"M28;B._^20BSTZPP=\2U=OG:X\VIL$(*2@U:N'<#7N'J!>XVA?+R[GQ8NXE"P7RY&XL:#B!` M#Y8:);L'V2$UKY<1^OISIBWT'JPSH??G*Q4Z`O10Z`R[14(7\'I6&_CV-5/O M.[B07'2+@AK<)@0WCSA5-88W&\5VJWA#&F7OWP?J1,8`]2#@S0^X><2I+PHV M3;2CAN;3Y7HIJI5*PQ]'* M*_B8XSX[;]6MKDQ'\48K^30::F4S"'CK5_.L:;+5U4JE8(^CE;0OT%]FZ21G M#&\TDD>?H3[6;9_^\F*T42A375U4"-1)`:I^0E6CYX84SV5Q*BX=*HULD^$> M:)^1;"3%EE2"F=-V+@ZW`4S>AU&6!DFTSJM"?(U8B6&Y$9UL[LQ-1P]07P6EL*\N(Z39"_7#062Y>=\"@J8I&8+ M#QH$0#`42G+L4\WEB+D&-S=WOJB\EH(-7R?J:]<,Q5^??R#73%-R&2](Y!HO M@K:KZL(Y,W31Q,F( M;S6ZB@N`+2_J@ADSZU\#!]YZUEAJ=F^`S9-QEGC80&%]2NW/FS'4N] M/3KP+`,AX?5`XDI&SY@3N0]FJU(WF]/O90WC]<\>8L9O81O/WUC MX-N'P(Y\^VC&8M]^^L8ON4MYSO?M8H;/D/W_.&5[W(]%/H2Q*^G1_,8"_A^G M6*IO?9$JCYL#88I9:;>)3JE_7Y$/[J2I#F?6J@9,7EU6E'&>U\9&SG8?RNB3 M0KP2Y5%B>E0POZ'%K)XZ+<7LNF"=/9JL7@/7TSO]6O`/(>JZ^8`.!>A835%]_%R[&0]0<#*B%RUF M?>>#U>:VS@"GXL,OJ3W[29FLX@$=[KA%EAMN4@8[[M*Y:)=&/'1E/ M1_4W9F(%G977+LN$5-T\>\HAI-^,RYB MYP(\-'F^2:E,7F9/1S3Y]UE:;I,##D*"),%_O@L..WX:=NZ`?KD(&>7FA@;J MX4!O/%`/Z+%7>?%,6,01F7!!Y*!PR4](6SQLD9,B#HJ4!T6>"_^'QB\@``E\ M"A*P"\H2=P1,T6]V-=<>@R(N?'=H2H=AY.@TO<6R#O`.ID%2'J@D#?S<",^Y M.QO3H66P-1*@6'ZY)G\)FNIF5!3AS4Y76GA?DQ*G85)%R'W$U*\,/0WV+FAG M5%0)04II=$1S)9^W<;@%<0&RJD0FE48X5Q*0'FR/`?IR"$&QA;#T=;O$-4V5 M1Y'8Y;*.XR+8!4_X.6$/]EC,JH4N0WB0WCY$P\=@,C$5#Y`;E^>G%Y^@)_)GR:?5O8&\.MTLD_9 ME%,XA$\A?#YZ/#:1WIPK,GIJ=(XH4-)EE^+N5]?I>5!LI2U%]/&=+\HBNK16 ML-XOKU.`T9UW%GGA)$Y=JG5IY#48Z:W4NR"">!,0HB$\7*RE1JA:L34L\+@N M@QZR),9I`,4XWKF0,9U3[:P>Q\O,P8NF>2DGHR)ZF&P0N!E\O%(&<4K:&&7U M"6OCGEZ`#^):M:DODICT<7W2U-2D8ASO?-*D3!_'/GW.9KYHFI?R23H)4,T` M:.29ZF3I"W!)DY*:!A9]E-.1RR^(P04W5:&-Z=SML+08'2DT>'[Y%;^)FGE2 M(J&*?U8"*4*$?K?QK_VBOGUI'G+PC?O/R2XDX7,7%%D^J[@XIBE9TD*SG M,:44C'5N"-PT.ETYC3>6("33(<1F/E*M5^,,Z+BFZPH;M.;+$C? M9U&\B4-N,-.L\2)HN]&O<,YL09"B`+(Z?I5;PB!FU3&#.3M5?.2XS9((^RYA\DU-*#@M&6`M,NWG?WH9$+^],>W/_Y-GQI[6S2U8@WW M9KI:-4/9+W?[)#M`6*#UK6GJ6EPIF&J(8 MJ(>V'.9U6L&W/P.T[5'U1.2"6N^;PIDMIQE%#>53/T0)I\=M3N1L7D3:RF:( M7%!7TI:U0NQ)VZ-&B!)."Z1]E#:(S=@(3MNZ!\#.)#Z8L4SF&-!#J;,<%\E= MQ.X9DK^*GV'W!<5R+P"V*WG1C,>2QW"@!^B+Y*4<'TA>@]V+V+RNN;NV=!TC M]T3((N8*+'MAT9X56YA?XL(>^SPN%.Y<`&Q7R*(9,]E%#`7X0.@: M[)XA^?_85Q]A6E9(0-=I*!<\']:NW`7S'8L=@8$&#B!`7\0N8_=`ZFI>S\E2 M'5*8/QVNXC1(PSA(;A*%Y"4(EC-4DIDS:1T*"UI@@*!]402E"(;9'#W^SU") MBSQL>FXIM8$/:U<1!/-ERG0A>;;MT3P2OXS=`\FK>3WG!"G^O8JCNR#\%#S% MZ=-]+23U2J"!:/E<28,2YI2&X(`6";18/JT8VC(:'G.8"6C.KB#8QV60W`7E M]@&&N"YK#-4N1(5E><>@HH'9/U`$@#%`A^*3A]&3RW![82"411N/WIBW';WQ MI^GHC6&7SAMEPU%[48A:%(H&G0(YS%"/^_C3!8S+(MS*=8*%LZL(G'F.I8]` M0`WCB\1%W!V(6<[:.;O-(*V"_'"JT8R0"VIYK\F=+;/5I%#@]+57G:HDK!YN M-%5\GI,KAH^YKKSYL)8SQ?SY,HGB&LPWDX>!MY2W\_M`Z\B7"^JD#[1"RDT?:,\$+6$UKPWT4<3=;.!TS)D'ZF9/ MK3#J9D_ME[@EK.;NJ8]HW=H]WIUW>-?J[^Y3Z"WD,,^DCQ!Z][5',TDF;"]O MUZ`UDF2G7HE:PFJA04\6]S+/=^]A$I0PPOGWPSH/TB((\0NFXMVA_Q=%=*5OQ%4^(\2,L7L'AS9>Y=Q5_\D[68R\-+5@H6S[E;E<'RGS!)SM(( MR44A:@&PY5M6@ADS87H-!VI`7V0NY?CPTI6:W?8B]9]AD)3;\R"'M_E3D,;_ M)&52[N$S3"OX0.\2*W(,^D-8C^X-J!OK&44%&!?TD5>@1@Y!U-1CC<, MT^3HEZHJ\Q$F@WBIKL+\A8'">I/;,!?I%*6=F@L1WIA)^YD69;,7:%(PS(=Y5`1%Q?_171H=YB^G#=)4!2WFU^#/,>U>O)[O/=3A%L2'.L+EFS^S%,J#(M+%M?0:)$"!-Z; M`$HIC?'BHRD*Q_JDC(FD6'[HE##JD6B5-U&.AE2T-&OA.*8>O*#?4D4Q(FB[ MJY9PSF.]:`!!K2#^A"]RM@^6*QV>+Z4`RL!%!.U0`61!RT@!/(I8Y&P7*\`Q MBKOM=EE**HC>Y7$([V!.>F:*5$`,;[OPDW#>;`$H#`IH/U0"C/N@TAZH#NO6 M+D0!^"9.090E29`7N,4(*/!OOW59?=J`LKMFPG45ZFP#0DIL@=%=%YM66<>H M8I>.:7C2^)G^_BK+'V#^C"8[N0$T9R"_&D'S*)W2*[G^*QH(-",=R98BS2B08="?2AA=IT69DT6)]MHYE7@R_2&L M^S`#ZMC';X\EZ'!7H,4&';H?':+<4FG3,DVU=6R3TU35E37>YO%3G`9)U_)* MWPRYN([MCT^/4B4;-(]ZLKTXNK3:3\VD"AF2;QY"8D%RUZ`TG[DM;MC`X"/> MJ]%?_Y)&:)M3/19A'N]QP-JVAQ1E$.:-Z:!)SG3Z];<9@`S9_(D,"OJC=EU3 M75C=,7AQ/@BV*=T5H;OHTQVTW6)/P+^\?O7ZSUV.PVF[V&,H1LV%NF4L;1=; MYT4T&.3ZPN,"KH+M:K2(GU@F/4IVBH\)Q#LAWC?)Q`S2IX;C.4NOFM(M35XV M@]$T"M?!U:[0LQ3M5\H%TWSN7#:LMW$!8-T)?-1R<"_/!1,?2+A&TC%<'^A1 MOGB2NQ#EDV?XBN6COWY::+'P3W=0+^(_;0X8!(!TS)<8`4[FQOP0T$(B>DXX M.%-/N/$@I?;E!H1FWD,G(ISB.BRV8$_(X)!.\UU0P`CI_1ZF!=&HRR_X1UZ\ M:#J`_4;LNI0Q11@;1.KT3@@JZ.."&MEQE_:I!-[#,'M*8T()BF(BN(%YCDBD MGNZ1D!OV1G*?BS+34J83^@05M6>!3?_3^OR*/\%>NL#)+^ MW\^SHOR0E7^'92WI9,_"OPDS1,0WO7WKHH M.QZT/9&OQZ.*..W(S:Z:S2W.<_6F])6ZWYG<7]HGM]S?Z'#_J_#54D]CS8%K MN!F+MT##+8RJ!-YN^`2>X>OE3V2+7+P[=#!WP8'<,L%DKW'N479!=+EOV+\[ MNB!_F#1./3;>!(IL'/0_`!X/`\#Z(]3XP6_D.QZ\9EI*VPVYF)%&E[]7<7GHFJTIWGAJCV#=8O1I8QNL($Q`4/%[/7(A)T@C M0-'[S?5\>0]J*,>Q'D\2HE=:JGPY:C"&CYHJ?%5JH*O>O#(UEN<$?75;590< M`=R2S+ZRL"@'ULW+E-%\^8<]%,B#!XI*5G-?#XCY;%$Y5+&"*%2@DR]NJ[(H MD8W'Z=.'2J5@5^,'J?`>\.@P3$(.I=U9:!MKZ][Z&=,?GB ML5Y@T8/%,LA+53;!!A/I'_`NHJ@?H[V#3W&*3X7?!0E^OG14/ERFD9]`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`_4T5_/L_2,@_"L@J2-$GA3+X3/7I$B+-Q['@]+ZT7@J"OT'7:%S M>6TQ][.-X08%+V%5QL]H`[M!X4NNK/8CQ;*?R9'2P"1L,#1HP4$-[X$6&*"SJ4S<-'"#=;M9HWUN@;1/:6BE#5AUD^QJF0Q&C:GWU6M$@ M%_VSA^I1S*LO,T;]#`5F<9N4Q\]!"=$B'I*3;.5B*4*POVT2S9R)L"@@:"$] M6ASE[&>V4QJ\]^AVG.)2Q$=:'#N-<).7$#_ASO"O>IFFLZ>GG+QHOD[+/$Z+ M."3=ZN9G/R[+W=$_A_S"2F=%ZV86L\,K#/RZ]'[TG9^H)T@;7[I07K= M*\$\R@4C*QVN$$RYA&"\NE-V;*^U]/O"A5S6BU\WZC,+?-/)FW5#9TY?R[JA MQ7]GZT9O=O^[K1LS!&-AW9@CF*]@W=#W6I;6#5.7]36M&XYJTLR=V%>X@CBL M8*._C+SL]Y5N9&1[15'(Z.4^?;'B[.RO.WS-;9';*^+9KL.>DG M3Q*TA`#1P;(.IMUC9BU:1-?LL&-KT`#%JT]Z"*8;#_92R8JRL,(*3VQB4;JZ M2HJ?&PIC^CX=.;U]0VA(":6=PHD?*UXYOD2@;VB#*P6F5G8L5W`'<_(U4?;` M>`2/7,.8-G-;NL,WIO$0+O?.#@BU^^!XOE=1,6"]A82,*HU+^C;8Q--X[6*X M!JSO:B36.\/E7&XV*/:)G]&V&C$2KH,O]VB/C1N^IF&X]83YQH?3-8_"%5=]R MZJ^`;^KO?+L"9R6HOP7:CXV-S6T6X]BLP]O8"J<'_O3'M]__#=:[4O(/4"(. MP(9ICS73P$G#,ODT'LD7;R.A MU<"?D%%(WHV,TW,6T/'C[_ED3_$%9'AO/8%*OS5M74^YG5OSARR-8%2AP`G% M1+5;XB'N(9'JE6(Q`KDS!8'B?@/32"E&#)LHJ_'`PCV^^2`RV:0*2*DHHQ# ML*FWJD6[5>V-F*//%B1)F4/\[_I/V!^BH=,R3BL\8+9'0Y"C2!"491X_5B7. MH&#$D+"SD&J!ZV3G+`\W2#$MX-Z"9TR19DF2? M#\]C3K1+/+;V!G%X/`KT) M1J(9Y4VVD!DA'HX=LQ177,6.:?1=O$6-@T5^@W:4D*],6;.*2F]%B0 MJDJ2A6S"6-;7K2GTCA6;H\HK@,;!:LY9B=#B13\`AE\`OS7?$&B\K<5J"9XT M)/;"^Q1Q)&I8U8N4`_*-O[I?L";K_GA]FJGX#JT=_=#\KDZ3W,,"YBC41C[J M+`SS*DB*5I.OLOPBJQ[+396@O^'C7]E)Q3$^YMY?+,$Q+8>"?V[_T"8VFX^1 MW6WSN57G;'!1?=!\$C3?],R_'(.''0"A@?A.A"^_P#MT`[O4"[/E!J<.(2X@0/9 M8X&F5(3P>$D"K:3J\O36U]`>(2(8DLQ`'6BB8(R3,2AH;K%6D#8R8_*2O?.U M$J)=31X@+G9YVX+F.%L&NTY1+N1B!KNY1?V+5^'>X!E-&M6W:(K+W3[)#G#P MYWFAGM&'?`SSS#@U(\0;G%=C-]U\:@6:CPU@O`_NYG&.6!/B3Q$D@6B!\BR. MFV!4$V*XR1;ET`']E&=%46^-3?S)$,^]>QC1H67M!*=-!GEFM0J"'M!^`!_+ M>FA^/)526I-8GQP:!WML,<%2)(.X-QL9A5HV)$NO+FU1/U(B4U*!(C*V*!-: M/_IXGF>NGTJSTU1.+XX_IAUT^&!E`QJ6.KPXUATKO*K,.*"0'$5(SQ\\-"]6 M]0S.&7PRH`^(`0L>(:J'\\+D-*B>;8O=-U[26>($SB"4$Q`:GBGZ:=.ZUJ!C M[&:FX-`+W-)KCNG3#8ZS@SP_;+(+>YJ4T:IEZ.P+`0X#!&)Z9 ML1&QV(5E+6T)IBU4T^;44-4*J[1/76WU:H?9>91YF\S^..Y-4T'G]*UF-XSW MNTTIQ2]UP\FJZX0]ITA7?8F:)\?'/IC>F)(%8U[?MJ!2.G$$&[[@$0Y.H MXHP;(P_A%D85[E[2W@*_B(L0!155#J57K'4P[=[[T**%2;W72-A`>@\D.D1/ MKDWK"VIPM&XJ)7M.6JL(SN2:,HN,;MW=+\.3J8667D+!&-<<"B9SR.:2LZ!M MC=>EQ0W+GL>9E#7Q*DEBE";P-_UQ9#)L6IIY8L._/(:.24\HI31O6"_77H-J M0_I+BK\UEUX02WQ;74U+,RUG+*[]QGE;C>&V+<9@["7X@WCB$P04:JL[OH/: M5JSHAO#1UJV2ZMZ&9;JK9[%JQ5V^`))1$;2I`WE1^&B9LF9UL6^[Y'`YVV,OAD7N#Q1$:/M,"VR_HCB&ER.?1?@ M\@6]N;I^V#/9N>C4'5JR.MQ"W<;:Q&BW(8-X@LU[`'[JVPS=?NY+\FTH\T MZ'OWACA-8<7Y,'-M]6RL?9H7,%<\W,LR6!D# MD$;]Y269+*/`TXU6H+T>FNT5TJ'%K+8WF+]&VZ=XOLWBT5Z4R;7 MD6Z??8EEH1(/V+K#YPP@YL\OR+/EX M#S$EV7X;Y+OK-+SZ%-2_0;X._?L]Q+WK1>O7]/'LKFLSZ!ZK7#,4H&.!RQ*< M)>`CZ(^'K\D`-"+HAB2_^HV.ZJC(P)$YL0*P?`6"Y!5X?M40?H?')&UL7X'- M=Y^^ZW.D_K6<)]9"A+F6,0@=EC&+&79^$_]>Q=%=$'X*GM`,[FME*M"7/GZH MRCP@@@G.LWR/8IO+//YT'W^Z@'%9A%NYQ2\QLEW;7X07[,*#!P7MJ*`=EACZ M1T!&!G1H@,$G#$:P[`],:&/TND8&'T"- MSEOZ:4S@@VTO0^NKEMAN:=_WEG9<]CKQ9BDW5]ZA&4[4W%EA>95+;#;"4=;!!9)>`*8"1D210-_`P(HC]V-)FP5Y2RYU5+ MVJN:-K]L1E<#1V&NB?K-Z7M1%662'.UC&."]UNWD7I)_R:E^&![G!:2+;?G>B1Q'[ZJ+%`PTB MKBC2H?I@6HM2EQE09_$1@X%&CAXN&*OCG+([6YB4,+^`SS#!3U**V\W9#N9Q M&'PL1N&DW(HF#&2Y*,\$2IGG"70,T`V";:L>!GPLV`V6!\9V),*SCO#G@IM' M]<04)ZOXL'[1//T^SI']39S"ZQ+N>`>K!KC>'-WWZ3$\OL>H@."ZUC<3>>F> MXPN$9?&@%M<(:6=TN`AVP1,L'K+J:5OB+26J..Z5-8)LWI,K:N%S'FUF0K.\=:XFF62!#1N(\]-SV%>TA+>XNM5 M"BS+'EI%`^.;>P@X(J(OO'LX#L.?Y8D!WZ"-?8%_6WSK\KFZ,64?*AR8X,@M M[-.(_DVH`6&'[?H1N)X9#9=/`QN:DP+/2B28.$@NO^Q)\4IASIL%M)SDYLR4 M2?XV,*`!(\">(=C$16)02W:UOB63-]+5M(NI(4H(9U:&@+S-Z715"?E&[U M"SJB*`6@2B/TIQ)9:HCQ"]=&J3"*@6EJ6<0<`TT2^`0C/>ODPEHV3?Y\&)-3F^FJ%$]8AOGT5V0EP>1.>I@VC5.+5K&^C)`:AIH%P"A`8('"*+#]?3E4:5ESI/( M&H2[^8!&V-`8T_81$2YXALP=$[O'P[FV=WU+&UB_J9G-.PS89[A@V]E3#F%T ME\>A.*G$A;6>[.?-EY/A/'5DH>Z-:V&K:$!)20 M/49T;8\R;1\?G2A4?6&;NX-YG`G#8!F&>_MKYZZGS8#">V:,7A$QV3*%5-`_ MD%3MB[',H4TH[9-G$`M;*:FQEQRNTP)YNH2##_@*LJB"PTJ!,O/ M@R0S5YWP`P+M\K["2R!!R\!-:"!==O`CP]:N<:Z+5NX."I"EY-^/08*/,D&Q MA;BAI`>GL4HC&;Y+TK,0UY>7[H(XFG9UJ8?IR<6E/BWZMWLPEL>7EHY$E/L+ M2XSFZ5U7$JC=K$L\>A M:[#+*AJDXO858`,AV",%)BG?"";!`4>KM,(9!NH%MIZM=B.KD"UU7)-8SC[' M?H"4P-.T5@&N4]L5T:,TAKZOIZX>2,H!NK#LET+:%+O7I>VL]0!1311Q`&5& MHMQ]$L1HR`TV??*+!#X%"=@%90ESSUR`U/!D#D'#ZI9S#]U%D*9R)-U#:WH( M,;I3)R&A2FE,O=M+;<%3BNV/IWA1]$UQ%P8$#N.&WC6M?4-=G>:B_:N(.Z%W M1LCO/0P>5#8I'64XT]Z4/>(B1%1]%N792BNT(HWX7&1"KE/49[@;*)R8I1XB MNUY5^13IIW5K1(_3U4+>GEKL2(NOH;2%[UGR"E*S,80WX( MR\W>N@X`W@4%MT^%#I)E3Z&@@+$=#`\P0I M[JW-TU0X)@^WF>TR7\T-L$<\BG-;U[&>H8'KF\X,JQZV4T*?@Y]AM(;Y3F31 M$@2[UBR;N:*[%ZBA`09W:,2>DZ!ENR8T7,`BS.-'2&VV1$#-C:X9UJ.(KEDW,L!1A6UCZ[.87-/T(PIX^RDT385CNWW>]YX4.\Z5 M'9$&JTDQ'5,P4*"Y6U=94-L#<+`E%41+U,,[#E&=3E!_\RB8(5Y88$+?TH]V MC/OVO2!96UPO)(R*LGO!92-'0OZ'8"=J,\J%LAP+CN/.)(9PW%95P=;CN M2UBZB#R%_4`%<*YD*NS\.9"JM.&GI:A6/>4V`XV7X^`QJ\J>CXG#V'VA#I%^ M"'1SX>:D_Q&D59`?WISB/\G+XG-![>HH?[9CF==0X,TIP'"^%&^7L'H@:R6? M9XC["C[F>/!3#7GS8>T*7##?L<0;,'#JE\AE[![(7,WK&4)_'^1O7JOES8#9 M%34[R[&4$022KE<"%K!V(%LI7^UE#AZJQP+^7N&R3L_H_];!8R)+'/#!K><- M!+-FFGJT8(#`@=\(I`?MR&5L'^^UU3R?T\]MM[U.2YBG`;V(K6C=)H"VW*5- M-&?F_&*W!0-(7QR$G.O#;F,:+)\A_U^#/$!;[,LO^QBW8Y+5?.*"VI4\?[9C ML==0@(*YK^[DWZRU]E%ZT[[`;U\_;R%]XO8YR#$2B`M0A%L854G[E@7BRGV&=J]1G%1E_`P?8%CE M<1E#-+,PJ2(872'Z<*69JJS;!5P&>8K[$Z))DR*N[P[\`03I)2M?M1Y'')>' MS*WS'C#HH)VGPBQJU#BVL:9.KNU2FNG31_7$0J3)-8&:KW0RA.[579QRFR:E M67>]L-;C5FF_TF6UD$?G8GC;-[V$\V8/10DHZ7?7`/L2I*O8/[H[I,-[UUY( MV['2!U+'BP.:\3WQ9^9\T5W;FY$!5B[0&QN?9#:CXV"?-CQ8`?H%MU<:7C23 MW"\A$ZULX=B(9V+V_,\'6)X'Q?8NSYYC--MWAU\*&%VG5W$:I"&:YEF(R"($ MT4<1%?I=?4,&N5&)XYD[L'6/,YL33',1B-^F%UO0#`D>#^`;/"K:6G\+VH%! M-_(*=&.#;O#542OOD.KK*E=S%.Z$F#O['G,#6[9H[8_8BU^G))SQE M_#(^CQ^K9C&.I238-!ZQPHP-0J4M%H/R79:7\3_K!?L"/I87<1'B9?HNA[NX MXMUW-,"U'TQKT,,IO=#B8(W"6*!!`]_4B,=J\J4;`"]`6)(%*8AJ-/?VHJU[ M3!AJIGC.0\SK]!F9^!%"3.V!?0DQ]3EA&&*V`[L.,37->7'^$-YLDNQS0;>L M<9ASULP1P=!$8=G:72!=]C<$I+:F-;M74W+6&%Y M212"1=YHU7ANC=2<*.RE2/TFI%QU@_<3\GJ<4A511-(Z-,J2),A[D((`PZ9U M:FKDV/R,U-%B;-NKY8CC[?-@'Y>2^T2:>/9C6@4=DO[1]68/U"@>G&,8"8<) M_/0E8T_-[F$9Q"F,&BM0ZI<(P;IB"6?./DZ@@%WFVQ]%DK-_K$$ZO%^D%@:N MK8,+66ZR')?BHO=S2+R!KR<5I^(34_T17%7+T*!-\M24U%?JHX,.'Y`!P*D? MY2@FT$F>"W;DX$9">.<-@W!+*U(0'M`2C[VA<7=>>MZ$"[.3'J$2:+2%R6C+ M[F"_3^(07[\%.9H&^591H6^-YN"\>(VY80CJ8)A9A<7W[LBKW&[.1[=L=$7%O#`WDM., M5>0C&C3+Y3=KAC!V5X+1_,::0/_L08@@9.;`MX@Y.4.$Z\^9CA09,+N"9&?) MK&>?,^"7/`6<'8A4RE:++YEP%[[KHJA@=%'E:/6BU[/)'KFXAT69QR':'Q,P M4K#U`RQO-U=9OH%Q62$8R:*QP-CVWT@MP`_F015IY$@'!734^J'"BF:52%63 M9NBZ@249?`5PM@:M6+T/2'/#5E]C+:4ZS-.M9?5FAHLPNR&_S!Q2:UU5' MFV22R'5JH]MUJ?I4L9OLD98B7'";`XI=]Z5JDZ4N=TC3:41A4]=M)@<%)8UV M9NU2IL@F\XX9I%6KZ_V+H;(.5J-)FCKO`1VY[DNM')GN>;;;9>D#^K;(F*0H MUA_426;/>:)&;VC7*P""!Q0!8`S'C]6F$!)30B*ZE-4UAG!-NY"2Y84Y:*C8 M^)&:GG[9"\[.DZ`H;C?US&[S^_AI6]Y6)?)):818+XF]U*C60RL-:I@38XR" M?6V-A!TR05N!'J+[4$A74.-(QTQ*,_SMSP$B)_KYOMKMM_+M'@_2KG?ESG6L M&10(_/P*$#A?=GYB/@]\C8K)%@\@<4LKM.H'29#CNP=5CDN/GJ71!T0M_8?L M&%('V_YAI!9-S)$DQ0(-FGNO8B`;YA325#!6-0['UL5=<,"'`LWMTGC]3A@UUSHERJJ!:UU'=>AA"]L_EJ!#6H$>6GL9V;TZ M:HMJK(6&RN0J`O9E7Z-BORR9*.#]#&7XD)6P#A76"%"A"B)HNXH@G#/C M/A!@$_P!`NJ+$LC9/E`!'9X[/^0DJ6W>>=)/>59,.-A4C>?+8::2;I,#3#*8 M^/R2#.D^)IRE`9KGDR;B7VXE7'_.C%;"'KS3E;`_;^5*B*]X>.($5>R7K80" MWB]PCM;+&5\%<2YM<2O'<7.2)IB_\`2J!P\P@OO.KH:42'IV;#`]]+P9[2$^ M-R1G/AQX:"L=]VA-K7$S3.%\F\=%F>VW,#\/T&>22.$8)0AVC4`V<^9$K(,% M#;`OKE$I@8%2:+)_CD9DZ3/,RQ@%H3@>;;*+K>KAM$Z2%97X`H_)")9UQH0V M1HDZ9$"PV_U&YTM!-X)+MSJ+SJN!)PU[5*>$ZCT=S'7^Q5Q/AX8T44F7LZSZ MB_AU0W0;EADRXA_4/1(,!W%J7TH*52;66A@9`C1C>-6`89)49:IH(M(YU?AK M1W*61I=I&9>'ZY36QT9^Y>P11>!!*$RGZ^%:KM2O1P]S/%.CD;*@%!'T,,%O M#:YK/3.1U["JO[&P3'-,!0Q?/67/WT4PINDE],,XJX1^U/L58-=,2%SL6*`@?U*IR"&;+U,2@ MCJ6#(P6JW:J$C-%]=5!S^;BJ<(Y4,0^2ZS2"7_X3'J2ZP,`Z4`9VO@)MJ`$! M@00(U`=]$'";50@IJX^E$?65K"L4G`?)WV&07Z;1!?_2DQS`LNDUE?(>'PL91@G0V7'K#1+Y%$,`ZL>7Q?(5&30$] MV1A(N[KZ:`=Z(9O'D+M:/>.]9*0L#]T!`A]WE: MHF"]'4W!>U=]/>E!.]22_IQ5.D+R"]YI",-UL7X(6'[<7<>O,$G^,\T^IP\P M*+(41N1:(^_(5@/'P5Y#/'_!-@,CG'S"&*!!H1=;`W_#P@(SO0?"SL,[,N.OV$&YA5"60]I2B]^T*-)GN M!2Z,R!67-?Q2ODLD]=2FC&3W'MPD6ADMKP+Q*Y,R>*P2M#>.VFO`^#)TVCY2[[U,I[7=PXY!Z,\1^KKK M"]+3E7YP?7"NQMNM-M+-3W2S4`KMI*((.V=N#9&>"3J_4JC!`?@@Z>Q+S(MGI-`N[LISYLR_%%\T333(B1[X#0.[OI(L9SOGCKNM1((VS#PU$N"\W#2=)!Y$!/$$2*P(=U\YQW-%_A M,UX*5Y_O^/!Z5S'Q]38N>,]VVT>ZD!)$2^*Z#IMDVL-]GRM6G5D.[1G?KSVH M'H,-H6P[K]$<69=%`?QYJL5CZL@YB3DZWR4I"S"Q<$YE;WE>,"NBM,/9RPL1T^K$KG?LJCY+:@X M+V2VJQR7SM&-$,-QKDOJ;,;Y+B_\C*8,Y(FOY0\W+C<;&);Q,[Q.PVP'U\$7 M7/+Y'F)JXB2FIRZD,X],7:8/93>*F48M<];XS.$+V=%`G&O7*.("6^RQP9LH\ MJ,,PX-2OPF)"%@_;"58N`@"G/[%*]$*6#L0 MK)2O,\3Z'U4*3]^HY+:@W_RKKJ"'D"X$/9JK0-!O_M5#0?/8S!&TF,=ST@)HBF3$ MMVI1\V$M;_GY\V4V^`T8>.N5P&7L'N[0NC?&PC]>P^$_KVFT+_W4^@< M=O.%+N2UO>1,+RMYEM(V*-LLB6!>7/Y>Q26OGIT^JO4$C08U8VWJ9ZJ#M.YH M4R,!BG6DFX]E5@;)S?(4K?&X(!G15?10__3'MS_^#;R91HE4^8`VCY_)HS4[:6,87QZ:JPD,/#0V,Y>Q>0L/*V,`?0C81E]X5;"7MT M85C(8:Z$%[HRO.#J<`=S_(O@"9Z:+`\#-/?KPY`*]0*Q`AV&A\L#1RC*]4$H M$8?*]0ZFX787Y)\N8!'F\9[WNDO&!SZ^>W43T*6C=RTJZ.%ZJ((RT2EU42VW M&6O:%;E$^`R11\T+^:K&!;6[KO%GRS3!HW=#:S!?UC8)IP>KFY+-,Z2-8B)- M8?,@[?3_>0M3TNZX?CL-X@(4]37#")09>(3T-36,5K@JS?GY MW_]^\O[]R<4%H.^7V:Y8``K\"'MMY2-S*@0^,: M:ZTM-Q@>9"(7TA7!"[1E%,7N<[7KM"ASX@9O-)^K<3&P> ML4(&O.=J2@%8/`G-TJ<2YCL\+:W$N0C!_JFG:.;,62<"/,&0I-3>RK=+!/'TKM/5T&C0KFS]378'`K@"&!@2\][@7Q;?XZI#[N%8ID7%HJRF.&;YHN/?J:7)7/^0N MCT-UZLP7XH-JC]]U?K](,&1:TXX)F M8%"/[#)1?`2NX%+G>T+R'N:TJ#G.MN$, MRG`&*\FR5N,JZ=:;]QI]I&%PI&L M^IX$K6W-L+W[+%WM,^I=ZK'=KX`+*8H\@SA32WPRF[K-^45PT,]@*\?QT"2& M=$XU@*:#/1[F)>@Z1[KFFBT4[8RH$&UAT*>**BG)@:AT6\J'M1N]">;+Q!YH MO]F#\V7/*>/V(#Q0LWI>5J(>^0H)1YF*X,!:SS_PYLM).M1@`,/Y(G,9M\?) M!06KEY%Y_*P^U^#`.I-Y?[XRF>-;=?[)G.&V2.8"5B\B\X?XBZ[(>Z"N)-Z? MK43@",P_>3.<%HA;P.9EI`V?8:HM[SZP,XD/9BR3.0;T4.HLQT5R%[%[SJ-_ MO,NAS=(NJAQ%B+1?"&FBMLYPHOIG\D96I`SZ^):+`^C3Q10,(%OBNHT@1:Y[ MVM`6@V"=T8,).L*1,F\H@G_,"GAS)"+/L]TN2^DS[Z9;8)F!%--%7T6O0`I+ MTC,P+D)2;/B;.*W["W[KM)?B=*IQ6I'3\`>G%8>-$R,J=OP'VOT'7U,%!2Q+ MBNTZKVAJML."$I-L=D[=H.@?55%BOA7K["R*8BS>(+D+XN@Z/0_V<=G\XS_C M-&JRE2*7,W4TR_6'IM+,O+7O!L*>IQL*8'1PG8)ZM/;?>,#V@,"A>UJ,!=?I MR2=,$[*,,H\?J[+N9AH?ET8M;[2";"-*?OL5WYH-.\GLL M:=S1.9K_>3&VGUJ8ZV7V%C[F-9@ M."T0MX#-RRS3B4DV:PCM;*%.=/-9%-(_R?.X+EJKA2Q?QMH_PT3_P&(([6U%RO7AQ14-EL_J&Y-_>@?SIUV@<`(<0-N]8]B9LMUC\D^@!O)%UD(.CQK( M2-F[T$65C9&S'X*[NZZRT7;U%-07R2LX+[RW(F3[#"VX2X*0'-*=/:'_NX)0 MV+^0!VE7]MRYCL7>`@$"!3"8RR,/K4FC@*[@G;7N6V("0LP&H;L^HA!KS$!Q M5>IB+\%,CFK?X3YZN(TH3`O:%1?75GDB,WQWZ$#N@@.9].<@CSYDZ2TILD?? MC'5WA@MZ!GQ='SU=U`=/DBRVQ3E83Y7;Y"]S_00/?/)(^C_VOPYZG\=%AOIP M]10`F<,*H%F@8;PYZFL(:&BD"IH;XY$F!5QQPI\:>WS M-@ZW8-C'7,==YBHM>0>KK\]'-<*GIQP^D7_C;T\WQ?$XOADD0^=$ MLVS&J0W4;^-4$BTTT9;,K]A8^:IO:+(RO3_^ZKG^G,UZ651QFB+!Z-?"KBIDIOXF7MG8.(X+F).(SHYT2?!7P$R`ND'WHZQ M`NTH@`X#R#CN0X5)XN4$I5-E:W%CS'_`3:J_WD.TI8]#-%$"18\F87F[NZ>B!0C]1TQKK=T/LI!>@-MP)D0+*>U$.ZV2XQA)VX3DO>Y?$S"@?:.X'&F4EV M`$^2DQS*]/.3-3)HL=U:^$(4[FNJ]G*JW"=>15JIEWN5JZ0]B_L`/Y^%I.84 M#B;R+$4_TAD5=UD2AP?Z_VOXI7R'IO%)8GOF0UFWP@G4CK45#0&Z,4CKNNIR,YE5`@.[A,(9L[> M+4"`76].3\XJ]`3`7CQ0![ MRN7#(9%:(LQ>65<<%B.`L``00E#@``!#D!``#MO6MSXSBR-OA](_8_]/;[N;LMWSTQ<]YP^=+M.:Z2 MUW9WOR/))W!*) MS+__SV^+Z(=7EF9A$O_CQ]'/!S_^P&(_"<)X]H\??W^^_>G\QQ_^YW_\G__' MW_^OGW[ZX5<6L]3+6?##Y[TX]_TOV7O^'T<^CGT]^@'\#@__WA__]\/'_^^'FZ?F'GW[X^O7KSP&TD)C][*C7_[7Q_LG?\X6WD]AG.5>[*]K\69$]487%Q>_E'^% MHEGXMZRL?Y_X7EZ*2MFO']`2_+]^>B_V$__II]'A3T>CG[]EP8\@@Q]^^'N: M1.R137\H._"W_.V%_>/'+%R\1+SCY6_SE$W_\6/\,O>YF(]&AU7]_W&=^,6" MQ?EE'-S$>9B_W<73)%V4O?[Q!][N[X]W&]V/"R#A9>Y!(<[#+[S,+_)F?H%> MMNSGK1>F?WA1P3XR+RM2QC^6&700J6^A9T\LSZ.RO?'TTO>3`AH&,7Q*0O:W=1IS$*?KPOVG(RGT]"'H6A"\V8]"ST9YW.67K//N4$O:G5L\)F8:C[9@H7=W,.)3#QQ#-8CD*C7DE;L<%D\3EC_RJ@_9M7PTEKMZJ% M_GSPLC`;3Q]2ED&;Y0P-N)^*Q<)+W\;3IW`6AZ#'H"O+"0C$\9!$(1?(^_\; M8+#S.2O:$F?07L`W)!^\B*_J3W/&C`B1M.&8F6>^-NR+E_>/=;6N&X.1MF)[ MO33NG;"VS;73N$<[-;M91XW[)6FCNS6U62_Q=NRNK\:]$]3M=JTU[J%&6QVL MN^8T(PTXGNFO6>Z%T;ZF^M77NER!'[P4.C9G.70BLK$<;S5(@['1?BD;4<%] MN%_6&DSS8_VM7>S'SZD3?3<3]-!IVBG8Y[:C),%.UTW-,C2ST] MZKRGYD-0J[6]6`T;0S!OVO8)R7R.$%>WO.=X@BFU(G0\';_PJPF^@V^XW\`: MZTB6YFH@;<7FZ=.<[=VJ'?3'7&)H"]VR]IHXV"NU7(G,C;74DD; MW=K0S#55I[&]]-EWJ[D' MVI;=Q>TN_ILU[PB7[7G=7!R=K46DV]FE6$K_O8SY/\^2UU\"%O["^\__40+YZ6"T]-[[ M'_#3JC>U3CQ7CEX[O9<5APZ?;W2XSNIENMEY+_7?FX=_[E"ZZ7^X+/'+2SFP M?_+G8;32AFF:+!I)=MF;1!=8D4$7DW+%X+-*DL*,\X\?81\,,*IEWTN6RVRGV:>]U*1RZ(\>_]EF^7ESY/5?',5>1F,VW+RO/P6 M9@*JE74F%^<7+OE64[9)L28@,<^'O>*YCNPZ67AA+"%XM_#DXN+`);.:3(GI MQ>"(>3URP&N+>1D61W8',A$-6%45&!.]&J]Z>,2T'A.FM5J7'MDLY,M1G'_R M%MA2*RHZN3@^(TCC%BV[5.)8Q!2>D*?P"B20>M$=;$Z__2=[DW*X51:`.]TK MM2-1"$;,XBEA%J^*E,OH-LS@G/A?S$MOXN`:5AR$2*PXP*<>OP5W]/;XG,2(DC9P(08K8N"+.U7`F2Q2*I;'!/1A@W"C M#"`=]9$M`0B$+A?6&].A]<#2,`GD6U!A64!^V$?Z)&`0&OM@K*FVTQ6F6_A- M9:G9*0\2..XSG0@@A%+*AII-1/R$I$_HJC2@[^7!0@H'(9.^R>9/%D7_&2=? MXR?F94G,@KLL*U@JW:HB=>"8U)'.8B2I-3D<'9@/&DK1EMCD*E(B&,@36<0G[O$Z,CJPI_3K,E$KA=TM"1YP> M.W3$)-!S#,A0=%STJL6!MM>[6)@B',M#JP8H=#*[5YXWV=)):P,ZA MJV$GZ);.$)-5`SA.+W:U)2X>6VIH0QE'LO#:#L:5+/:`R4@S:@<8/7$U]K0Z MJC,:S1H"R$Z]2%OP)!ZQ3>`/90SOQ*%W<>+;ZH/.60^I`N2<.]N!;@<5UMEJ M8G4`B-.W+WJ"1G:7'1R-WZVJMTR53;WJK*%X-X#CUE^F`&VPM50FAL^&_?T6Y M#^'L',#IV6R[):L&,B)Q^.E<4=1"L!0O@H*B_)ZQ\?0FR\,%B$@6$V2S(,B! MQ$5)Y\H@@FTIK`0%^A\9[(,*]LC\!/8$9JN*LBY(BX0;4N=*HBD)2W$K*.C- MTSQ\>8%=(TCP-R\.H/W959+E^LJCU\!D-'+[WG=O*F0D#SK1,UIL9;ULSFT: M\'_XWM_K2L!2T@\(LQ%_5,X!=^C^\>T_"+,Q` M`)\C5L&7Z)!6?9`:B5OKSG7(0!J6(H50T*&[F%N"DO1-?^K!JH!L2/B*=JXI M<@%8"D-"03E`>C[C@8\XF,4B3%Y;F;P^15T6JA5W: M2QD*05MC=)L`X9'PV.YV!I*0_] M.4E1$T3U?=@%M>1@*[0/!95Y2,,DK2)1/3*?QX4O/5U*F0;_762E,]TUR_PT M+`%+]]MF38$POP]#83/!V(HP1$'+/K&O-<^I-(GAGWXEP&J$Z<]4IDV!,+\/ M(V,SP=@*@.3,^J#!ZN\SY[FC#GR@WUGKL;F0Y*55]U:[Q_5U2>'SKSJ M5MW#4B")"TX.21R(M86+;#1W,?V5]F@G]\P%"8N:@"L%J6(D?^4[X@F":(U> M,5/(Y0H"ATZ^(PL#]UZ2]P@O/*'Q0L]\I&XBH)/BJ(61.LN8EEO^9D'8QY%B M<),8Q&:\B\"2CQ:%TTZ%;AF:4IO/K?*3T<$1B6M-`5:\[H`8D$/20\I>O#!87EJK!ZZP_(3& M,U]S9G$T0W(HVI"+[F9L0FD+9C0+[Z"PYPKA[*P_(3&\VUSJG$T0_*8J0`JY^<)C;?532?F"?XJ MVMSSQ/V,?!]ZG\,HS,,RW/!NT$<-&XAN$Q,:[ZB-K%U&V(;D7%(#KF\-PRO! MP**QQS8B5*D38I1#>$X83KM(#^ M[@A)3K>XSH3&<^3FC$M@V4I/18'TC<0!X[0^(ZK95U>>T'A1W%`--/'9RGE% M0A]6+]56J8G&T_6/[X*4.;OK-C&A\8:XJ6Z8H$3<4'IICBM/L_<)=\;7W11@ M528TG@@WU``I*H3Q7K[!,]H1"-9,&H]\&[*,X$'X-;;.N3MHA.W MR=\UR<*'^0X6A-=>6O`N@R"L@#QX87`77WDO(2PU-=RR8[VR\H3&B^=&W&NB M0[2AEW:\1Y9[82E[Y?+(J(/[EY3S.&:X.Z\H3&6^5&VJ")#M&&7EKZ M=N5DM-Y/:#PI;L0V@@9AU]BDYWX[K]K]M+C)F]!X]6OW#@='BNB$L5EO6R=Z ME"*A?-/Q5X($_%'O28,4QAW[4K4*L%5[8WQ"XC!GD2?Q5*`KB@&E3'CRYRPH M(C:>7L)H#\*HX!;K)^87:3DEWGSSHP+FF5M@@\=D*=Y%O!UC0RO\M?6/`1\D MSIV=JV97HNLLJ<.>5[;5Q*,KFX`O!R[-["\31/TOR9I8M2ID;V"G%5@$7BKDLF=)4Y089L*`.I;M1?WN.Y M&U*[-PR?DEQG:,DK3BXL+C9K]>!:<97$0&$&?)06I.PNRPH6F&[N=%L"("26 M)AUQ2W=U9H#MAQ]T,/GIYF7\X]L,H+&E4#CP;S8(X M2-PZ*AE3;?Z;0BNI^2-\6.?3I8QB'BV+QR,F.'KRW$L)MDHY?&,_4 M&<_NF9:_BKF<7]JR'K;V,L?-RZX8!)@G;HD7.!(=O2V(:0D(4 MU*/WP]LS?%N1&D6C-HC*Z5'0)N'B=5U;"$/(KX)[@,.7E0E7-&J#J$B<\K19 M-52*;:1#2,Y2^5.S=`7R(UM\9JG\J"2J`2(A<5^LS9Z8?"FZ(>1PN2W2..1G M&)#-;?B-_RM3L9Q:QEWD2,TW*L/(`D83[F/NY+<[=X29/7ZARK)%Q2:W)T0.(ZO"7M2H26TK/8G:;; M'#?O)?D-[34.PG,:=ZR[4[EM&=E*#D/SU/YKFF2-##QE19"04VNA;:X-C_(U M&5A+.\-2UZ&PZA%]H/-^Y>0`_X[84K:7BR3-E\995#@2I;+U"1!]OTV+6NIG M5UJM$^5<5(H:LQGOD5-5[21#TH%3ZZ/C&6TE`5NY=AR'\UE?';'@@P=H??8T M9XQG)^`LS&$`^8#/Z-(3V?/!IP*>6"[0^Z;DWK)-T%C;BZ[&+<0BWA6A:>AVZ!:GL25@F!%PI2!4C&<+U7AV9\C9OM_!D M=$##[*"@"KFVP?`,X8YN-Y67SIA=;R=.2,0I-Q^KFPB&QF/ISL^Y`[P%E^W17S[;F/_O^=DYB3N]CGVVS\](G*,M-FD1X5@`90#&X9AB\>" MRD.82WDDJ?=,H1J/"23U0#PDK%E->#<`2-*WO`=^<.?G_;[O1W<>MF7DUA^> MQ,;YQ<+,I?RUGF$-_/],M.8]=;9G1P0.*QG8@M4W^9"LL0;!86'&9(O,13<67B M,6,O0P>-X2L[BDBNMP[='BU:C-7)@J6J>^O=PI.C4;^?K2J'*89Y M"+=$_,ID/-U`J#QXH75`+"1L+!AA8GH5<$C>!3V!_D;LO;OR.UQ168!&XCBE MD+U@-X6C&<*="NP^?1!;6O+P&&9?M`)'2FJ!:/I]_Z&D5H!( M2:W)Z."(A`>'DCY-UG>@N0UDA+UK7LY;XQC?)(L+UY`6S-@:'9,"A M]\X^?TWT2%H5Y*A(K*NM2-J&XSAH3W_=84!\0X@+)5A\K0O)5L@?M\8/;MV. M6?#N7[$1;*;,`RJSB2@KPWKHU%QJG73$R*(IB-;!=[I,U_=GDGZ!SE]Y+V'. M>R>>9C9+`:Q^&SSE_**(;87'H?#D<#>-J_2:<[LP",2I-71/0QP#CFB"L4F- M@B9C$0 M0K^-ZGKL[T)&>.]EB(&[F&>R2M(W'CBC.HF!)--7)K/EX95`0/WVKM?3"94` M$`W9[:Y),NNO#1]FR;I5R\-,IC=PNHX?@T[V6R$;0GU6YB/-`TOY#]Z,B=1&IQJ7<+_O`?0F#PT9("JR+YMC5_=$ M+/;G(,8OURSST_!%L=?0JL\%-N09IHDP$!^=@00PO\GR<,$-+;]G;%I$]Z%\ MKV+4SF0T.NYW7`(];6HB%$2KVE@_]^P4?.N%:1D?[B/S>`K?TC7281K457_6 M685UO'=EU6#[:2\`CE!>4F];O`9TC(0+G5IX@AV>"M80W%Y7&#^\K?[Y6P@[ MV]2?O]VS5Q8I'#ST&I@<';F?8%5\BB=-$X!#<),52FD7N=+#PZ@=$!^)L"TF M9"O411_V$#QU5PCOXI M#]&SDM-XNO[Q700RAQ'=)D!V)![6HK1BU\$F\"SY#@=L&L8A;^77(@QXDB(" M$?NNV>=<9$Z1F_15M4%N),)C&*J%-C);CLK.@U?)K*E.(I1W8D[=N@Z@8TX] MIF4F085G:$X]QOVJ>K59LAX)RKW+I8HV\<2H`C4$2VG[D%`CXCG4*JZ0I0\# M1#*Z=#FXL9+10Y'ZV)Y'E64&%Z:==H78-2]YVYSQ74DKP$EF_L]3ID7\31ZO\(2 MSGU9Q_%O;Y_3,+B+84-?J-.L:[;`_8F(+I=:JF8&#=9PLX<4 M#O[?)+JAK`L2)VK]UU(*37QM3<47E3;$;,:=]+X?4_$Q_8L#*YLJ]#;!V&1< M;:INXH"FA=!)W/IN+(14'2Z/>^!P>6SN<'D\$(=+PSBC)[3=)H]1\]`6AB'8 M^QH$$#TA8:[?XD)"6+W?0W!+_!C&X:)8*$G;*`?P2;@>[C`B)D[0]R%8[SYZ MW_2HJY<#^"3W5C/3XA:GM"U31O5$.)]S\/JA$F@1_5F'8!,WXE'BUH1KNY"F1*Z M7SH:S/W2Z0G1^Z53IW>R^L(SO%\ZQ4.T]`'J?N`WZK^!3O?DP`#N': MRE%`CU,2[[E,R%:HBS[L(=R<=?"$_Y269X(^GPK%P+"ZO87;ZU7.&5&C";H8 M:*,:0CB./;S>/:-O#SE#71^T$5JZU_OKY0.)EP]G]`TYN,XZDI>EV\ZC,_I6)5S/C%`.ZJ92X-/_*76![[:;M@:3H M>]GLJH@%S$.ZQ]S'7IW^JYJV>W7.]Q-I!W-:L@)E72/E@N7I*8X]2-OB.J-SDZIVW8.D/?WVC@&L+EQA8Z MY26&L#R(@\0['0W.Q&1+4`WA+N)/+TV].%?>/FR4`_@D7O%(N!&3*4`QA/<\ MA@\?SXD:3903[Q:&(=P?-'CX>$XB7/<6%Q+"ZOT>PNN=A@\?SYU:$%!&Q,0) M^CZ$@-L-'SZ>D_#+TJ5NM^^6;,=]N"T_I^TZM;NV::.R9*>EX?ERF67%HL22 M\=2+MREC]=B(#2N/!2?>:V;^/$ZB9!:R["Y6L(C7`)A.C^+:O*D@N#65H[Z4KX`]?;OA MUJ.7-,Q8IAQQLCJ3XP.G1V)MMM0@2/A6HUN/+RR]3F(694G\@?$#;GSE1<%7 M%D4?6/HE^1KF_WY0\&C4",C$J2!G15`4D#D_/6NQ@O;=EOW6Z57AY5Q@+NGL?B;$E!RIT8RHN+#V_K,@_>&_^M M%,9:(G'P$'GQ)V_!E+ZG77P.V""13EN@(HA9NC,A("K9,R])EN5IR*^\RJ=. M:J<[47F0!XG@*]UQ+=8MB3`0Y7`<5[V*SR990`2E)L8W/LJB\0L9:/>=X0/Q[:@:^:7`_CP`/YV*-\BB\H"-O=/IL4" M%S"#(T#8<>P9^4\O+KST[8S_1<[-;DG`Y?ZELC8S6/\17AS;:3Z"".:C(S4M M.P4!E?N'P=JL(-U'[LWW98*Q="XI/F?L7P5_",:MPAH'3*0&R(3$Z4#_J"D% M@I#;LX>JNPC5)T>L#LB%QDY?1ILVTW5,"-?]L@]M852>YH3E01XDGIXK"--B MN8X(8;AG)J1.GIT?'SJ]M6PP;:OA('3WRSQCY[GY\6$/GIN7I(G9EJ!"6.[7 M>]=:K"'EE+U3%N1`PCXC(4G,*H($8;1?SV'OPYB-IU?0UY`G<"O?FRAF:*P* M2(6$1[C^Y"Q'@O#;KS>S(HCW_#%&JIRB554GYVX=]?18U&=^%QNB`8X-3']` M/Y-4;L.HEP$L)+;)>C(76#1VP2#$.+8P/7]-=+C9*C:Y<.N)UYH>(1[D(8!C MCY_?/&@T^.VQ6+S,Y23ME@1<)$Q&C7G"("%4]I!L!IN1-*&=5'A%"YYU=B]M[/UQ*N>FGZ!M,72KM.-1`2 MK:5<:R"K$2&T&YN;*-!^G\2S9Y8N.&K9M%TK!D(@86TPG)]W$"`T&EN5.IR( MWY-D"V:@YR3GO9;-QZK:D^,C$N==XVE9#QC";R]3?6R%E)<:^S=*@BAH7>1H M#58A"(3//6?8Z&*UK0AF] M;6L7LAX/?`W+X*!1_I(!U%OFY46JKR<:;8$X:=T?-=FXZ<)$M*:7D=R6B^(2 MYBHUS5HJY5.&,G<:"V3'=+.&0)`]M-\TP8@HBX60;@[#_HU+/%=S_N0ENXM7 MO[]G4Y,IBGXC(,`>FG5,\2$*TDM+'X>6<6PL&\V80,82%:T"]'LG5"O"JEXOJ_I0L'5@DD0^+RVW21D.-!F.ZE";#TJZJ6 MN^N"YU^M7CI4R^#6P\7R]>,G!EI_FZ13%N:*K&^MVYY.M7-HFKR(.MS70)=IP^AK-Y?O.-I7Z8L0?08;;Z8[;\JS3!:X/F0)H] M/!PV1XJ$%^W7&U`A?#VW(%55D%(/3X=ZJ!#N^^7E![N6%*;$)R_RTI!EYILY M56V050]OF;6!(4K0+^?`30OJ.`UG(:#AOU:7L?H69D'=R6ATTD,-T,6%*$"; MIZ5[S@IR7;#G9#R=PC*7OJ?Z=I'Y8WEPXAE)RN'G13HIOB6U)L?'(VM[Z"=_ MSH(B@IW`AKRD.;YE=:!S)`ZY2OD)MM-J7'2R?S37Q^;S1Q:5W&3S\.4YN9%G&FG8$HB0Q`E: MPJ^F0NC@'$):\'5^"8U!LB&D'U\`RFWS"?^ MEWD2`9+W4[OL\*JL#()RGS97CTWD'*L)T5*.%N1*%@5=>V"Q/_-EX M.GY9^I<[.=O>Q=!!MNJ/QKD6J3'9LJ7LU:V@65K+$Q+N(C)Y8G?^.S"&<*Q= MP5I:N2N?!SIV0M/^$+/ZS2Y)36]*O#L`*-I:,F M!;)_39,L>TB3:2AUG%^7FIQ2]7G#Z=SNOJ7C8_A"];=[4: MF)R2,._+:45697V`EA*%4M"+E:3XDL47JW>)ZCLU6-E;WIX'U,><6Y'>5Q`"X`,QKMX\/;)JDK"KW['UC M&0P]A+W\K--7_<`S4!4E2*J]IA*9TT.OGJY/R"Q!&DW1ZU8_'8RE=+ M17]!!$OI?F`QDU\P(#5`,`,XVTB@V&.*#EX7^91Q1G-:`+>5WM>Y:[/H MH>XS-%4`K&&\USTY,!^I>WNO>T)B7Z64W^;XT<0U!,=F2^]U3YP:@S7Y$D^2 M$D1#<&MV^%[WA(0)4,*OID+HX!R"FW2K][HG)*Q^C;@3JX$8XA":S(ZH!%\Q2+[:KA#>.U; MQM9]AJ\H]G8;Y4!L3BTGK?9T`B26?+'=OGY9FG]8<)4LN!%@24;*X_*7/@L? MWM9EX-!3/MKDLE@+)`X>(B_^Y"V8>`#!)F%8&&B%6I.R%8\AIWJI%; M<7Z5ZXNP/(B#A#]P=U2+54LB#$N>XQ9T(V/^S[/D]9>`A95:P#^VM0%^FMRS MF1=5ZRZRS`A*`5BG7L*-%AD4ARWO[SVRICCZ;Q>97(R0R_7+,PS_PY.GD*RP$FIZ95L8P%=E1QQVUY5#O>CR5I_IY756.#+2P_ MN3CHWQRH@:BU7S5)AC4VS<(:DPLB>=UQPC09KN.QY13=D\AF%X=.C9R-1JH! M,EL.S6Y#F^T[N:S;X"`&](K'MRG4(?D]OZ-MEI1)HS:(S.DFK;5V:&.TY11- M02T>TL1G+"C];TN[,C_LI[#1E;^,D54#(;F_(6^C"&IPMMR**6C`(WNIK#O9 M>&J@`;)J("3W,C`;9;G=BN`!!+"5[]L><($=2N? M>.9ST#QMF1=%+/CPUC;IHW[+W-6DWT8$.P)`M*Q?SG44\HF"./MM=FB!&E&B M-D;,/;]8*>,.\"7385JY\O,KSC1>J(@K3([/&CQ.L71ULS*4;UYAJ.+P2ZH! M'!+/663"1FYQE*B&\)C%;I3^8QH1CM34(93+@0WA;4O[D/UN3^&:5$G7R%T\ M0WB*8L>S`N1!8KYN/(0EJ(;P$,6>=\5H1"2^OX0Q,_^*"A')S'&?DIPM+P2? MH2"3.ZZ)2W-\-.9>J?P%9A(IGB$\%]F0R+U.QA1A!2X1$L&8K,R^V["&\)R$ M:W*V5.7:C1XWU/"]13@-6:!.!VC0"DB;Q)-@*;-B93!&.:"<`'7L9OJPE@B) MU\$M>=]`,Z#8_LO;NQ`@F'ZAQ<5;&UBD%HHU;5!8O2<7_7XUT9GZ_%' M730DXL'>)UZL/_JQ*B`D$H&X&JB`'%)7N0$<&YT=ADBR9WMVE_6U$]LSB80: M,F$WLCT/)$.LI4!*YWTX,J&/122@AF!O=AA+Z9R$>4O"KZ9"Z.`<@@'[.DR9 M#VTK7\1O%@0!D+"*->)-K`(B@(,T7C>ZHC@^IV$1:3CA2T`-(8B2O0N*XW-Z M%I!-OLRN)TH\;JW=ZMN)<:Q_-[$J"]#H&2NV)2^_E]C"XM96K7&)]#71OT)Z M+PO0Z!D4S&C:PN(V'A!"4\W^5>LY=PT.QK"J0^M.-]I8W),(T631<81C(,(<;0%^_T* M1!U(5E8/Y$/"G&6@`P:X'`<^ZM)IZ^*0A'6JS9Y[&PW-$$;JK23?21ZUW777 M&IE<'/7RV-L`)*$X1QU'U[R@,5P-C8LH%%NQAP@'V#R^<&H/1D6_R]!NMVW% M`+([E=Z'_RK"X,'SOW@S]LBRI$A]EMW%OGSR5%0#Q$X-NF(&!/.C%@Y;L7OL M,OBS[Z`>]6\)P6&9ZR0E$#<#I=WK3Y4D&P%63'+E5/29'/TS"8,>X5 M&[,TNPNCZ$7.EK02H'5JW]4F3`,%C8`Y"'7/5Y_**&^Q5_5/SIFX-,!T:K'5 M)DO6?1HY-!&6/GA?6'J=Q"S*DO@#X\Y[\17,#U]9%'U@Z9?D:YC_^T&QIADU M`D)Q:I#5YK0!*IKQ9WZ/PS)P3OYV!7))V9\LR^_S0,ZIM!*@=6I>U>90`X7C M�(9W>+11$G/A14,B4H.CDYXZY@&Y7EREL,4KO`+0"M,+HZ< M6C[T^9(C0,AR[&'SP-(PD244$Y0"Y>NE+0J%@E#CV-BQ[BEJ>PW?+@C`(&3VZ^G1$++$GKC- MB291$;$N=2<$1"7[]5;*3IK8$[?))[OG6JQ;$F$@RN$X/MA6AY6O<+#RDXO# M[XIP#6$@A#LV"&WU6?F>!RL/&&GL*!P2OB4,A/!^!1I[*CYG[%\%".F&FZ=U M'LN*:\"L1\-QN.ES61DLA.I^)807(%3O(+$Z(!<:1F,9;=I,US$A7#LVAOW? M([53<;T,8*'Q>ETN;,&DNXL""4G@(GF[M=&GW&<+RT]&!R>3%RG.0))[A2#D0.3+(`2&L.7<3VNBT\MR*E><@202C:,G: M-B"$-[T M1_9277UDXVE=$-*+77$5$`Z)#703'9!C0@C?\ZNR+M:!\B$=R_)'T'H^@>JO M!SLU050D]MY-Z->"AFB!L5V*@A:\0]3."2&N`((AL4EOPKD,$4*UL8&*`M7M M,_^3!D&P).ZVFFA1 M&\2(*AD;_RBH$KYSKHNET:FBW@`(KK=G2Q.$B&KL.>4D^F(HSZ/2=_)REC)6 MH0GSL"0!V7#H503PO3L[FB!#:.UEIDE%R%#^-RS";`AK1^3.)]';UPN7A3Q/R]?/32E M&VT0A$7"Y]NZ&B@0(^JQ9[.AOGH\,.AG_B:?P%7U`'KO3G$&P!!.C0V%^^+T MVEO`?B)[\,*@3')M0.MV51!`[RYUS;`AY/;2("BU2'QB7\L_-3;BK!H`P?7V M)&Z"$%&-/=O[],?]^J>[^,K+YL\\%[G!X!?6!U$,YEPN`8APO6>#7'.N*Y-# M9+R.2]L!T?3N;K<%4$0'R%K>MB$UWNNP]I(G/6)#=@O@T7?:P*B"W1FT066^W_]KP$(V@8=RK5JC[ MQ(L_)D$X#?U2]-CT+BX-,'OGC*N$@["V9W/"\7P'?ME:R=S=! MG@4/8->]!O57>TDC(+G>7N":HD3THU_!XF#:2_/PWR4_E?)?AUDIAX>4+<)B M(5,+55V04V\/^IK@$"7H5SRY3?G\'GL5=A:\0]:V[`GJ@IQZ=]5K"`Y1`L4SN/+C:$U7XE5J@]051L^;9* M3BX.>WM\%T)!Z-QK7LLNCGSC-)R%`&EMK-(_ZPGJ@K!Z=^`W!(=HPKY"W77J MD5GZGUI\92MO#^39VPU>"\"(`CD.L+>,+I>-BSS+O3@`2+=>F$H=M65U`&L_ M5W@U*(1`Q[E`W_O]G#P4J3_W,G:5+!9)7.I@N5E1T8C7G%ST]"F<+C2$4L<) M$Z2]APFG!*`U0M4M@!QZMV-K!%%,]46_#'-KQP%NCMQV)OC$Y&=N15V04X\W M<5K@$"5P_/IU*T#ONRUQM?QPNT&49.*(.88M@!QZ=QW3"")"=;]L;%MG4@%8 MV>YF7$4]7%BK#CU8;7'"]6U>:HD348U\)++J.U@=?R>9)5(L% M,YY6NVHNA.+[.FR"M.+DZ/:5ST/2O>80I*0^=) MK+\Z(M:YTJN!$@\?$N:?;!F>\3V5H=S4LUT:X)%9]H221RTZ8B1BHO9EO-$F M"LVA*2T_N3AS:G-12E^+K#H6)/&T6[K^Z<6%E[X=:J2?%A2=7)P['5$:4A?0 MA`)!DD@YSN[&/J>\NR,-BD1E`9I33X)F'.%(D*"\;DGZZ*6'!VI^MHH!(*<. MG,VH$8)`8K`X]M-\2<-H=*;F9:<@G#_<.NDUHP;#@;RZ<3UFWD:G.F-FHQA' MY#1*:=-!(T*!N%8XWA(4,1L=:NP'MLIQ3$YO1!KN!L0P$".">VH.3_2HJ9?C MF)S>/#2G1@`#.:#NRTL%6VR*69'E1QJ[@-V2')A3A>DD.K(=''10(PI!CX\$3>\G+7AZI.1*5Y>!Z>-B10$%X?TE8&%E$(=_;-O!X:?)/9MYT4V\)5 M\@J`T[<;[A`%1^V,9?>1+Y_^9'4`J]-=GUCV0L.V"@1"6+^NV,O72)*[)6$Y MP$_&#U!C1I1@0#C"SA)0^I%\_*0,/9A[=UF64> MF%(8:XG$P4/DQ9^\!7YWU>7G@`T2;_\$*B+6I>Z$@*ADO\(%;;UY1-<+:7F0 M!XE@#]UQ+=8MB3"0^^^^O5:J3]OW[PY0VMXHJQH@DSYY-VBA01CN5R`@5W'` M+TY)K")2@G5T0@\HHBK]>LJTUY"#IR36DR[48P,BHAAM+&ADO$&?H<$"4`W( M*?1DZUU#*S.E\%.8MZ>J"G2-Q`*K(T"1\5*%S)+?)X70K<]A'K'Q]"X.PM

K-XB9(WQC(X1EZ'*?.A8B:WP4JJ`%`2]QF-^!',\DJH M)'U<>4Z((LJ].!_'3&5/WRDZ.3DE\3S?%H/G]-=+E;%05@)$+K MV.=N"R))!]E:;Z&<]LBK%09P)'+&=\#?-DB23K2WX2M;]UFQ#@H+`S@2]U>V M&)2`).ENN^ZK[O!;02(13,+^R*OC<^N&:^>T\M&+O>IN1'GULUT4A$#BF:D% MDN40B?KT9G.6KIT>%$ZCHL*`CH31R-8HE8"DZ?0+VS#M]5%4EH>0('&/8HM! M"4B:3L'KWMXF1:J[2*[+WP3 MSN;:I\5:80YO4'L9&4K''LE*$C^%^J;N=5D.;J!+X0Y(Q_[(:INI_DSZ7)MA MW,:UZ=!@NH71L>^N>A:-3-;">FD.<*"+H0"F8S=;C6LG%NF?*NJE.<"AWE[L MPG3L3*MQ!16F.3.84S?*B74!6#<*>808Q\:4I[<8]K9OMV'LQ7[H1(<:QQ>,^A+4T>/#\+]XLC&>/+$N*U->8YI05 M`;73;:`V99I($/X<6SH>6?`U28*UCZER>.$U`*=3@[(V8RH("%7.;1N6@ZF= MN+48:].E!H$0YMK_Q'L)^(CL+ZV4;_B MM#6+#7IRYC[,=<,0(@(@")']"LZ$@*ADO\+9V`D0 M>D+CCK`[KL6Z)1$&HAR.;4Q;'59&/,'*P^KJ-JG/OAG7D09"N7.SU$:GE8%2 ML/(<)`EG*I>4;TL#H=RQ>>N!I6$BVS`*2L&LY3[IH.%V$86!T.+8B+7NJ3PM M\78YP.0^ZZ!(S%(VZGU'^'!LG5KFXAWQ'&*'BIODW:*`S'W&0;&X1;?)&`"$ M&L>FJ%4*7@UN1&4!F_N<@]KDX`@0=AS;ICZ"$.8ZU.P4!%3N3)E_5X.4G8*`RGUZ06U2D.XCI#AVBOF4O)9]Y)G$1W):!$4!F7MO/VUB M4``(-:[]8)BO2XV@*"!S;UW5I@8%@%#CV$KQSR)Z&VGPLET.,#FU31INR82] M1QAQ;$08^WG"]4>#%$'1R:='BJWI0)B@(R2L=^O5&S"P"AQO'9_[V[VL344?7HW(]T'R'% M\:F_/KPU#3*C#60].O.C`!!J^A5VMGS;Q8WO:?[VG'IQYOGE4Z\/;_6_*-P9 M]!L!R;DW*S3T=3!%B01S[Y='2QV:THUAMS!(@L3+<%/NU!I0QXD1E)Z<')!RE#`C" M82`4.;:'/(7?-`G:+0FX2,36,Z`'`X&0X]@B\IBP_-\LBB[C`"2KX$=8&-"1 M"&EA0)$$!\(2@<0^FF-(4'0R.CCJT=Y-`0-AR+&E9!SK$K1;D@/KVPX.18'0 MX]I!(O3G'HL^^@'O5O"<%IDB9C9>@TUW"?;)59M[W,K`E'_R[E_\@3&A3LJ8IBI%@'=9L`J;GW"FVX3)IA1#1C7]:1 M_6F&\@I4OQ&0'(G#O1G3S;6ECAK1%\>VFD^\R^O#@/+-+58>,)*XW#%E17#B MD4-$:'1LT]GJL_(=+59^QX5P[MBS M9=G?K.J^:K$5EP9\).RZ2@H$D[(,$<*88X^7C1XKUU5Q:KKT/WAO77XVKE=VR'!R)>Q6Y M\(7F=Q0-0I5C0T^MPQK7)[ME.3@2]M0V5&VC0:AR_-"IWF&>=%J?K'5I#I#$ MQJ8573MX$,)1Q>+)"[A/*2ASP!'"0(_AXK+`U2J#F5R1C50(00:VX3(#_#J M]]LD?6+I*XBA\4#?:6AR>DC5+=_"@$?@(GK3KR@\?+M3&6DRP+$TU[#@+L[R MM.!1\>LB&$D4QJRAR:G;]Y^M%:8)7+'"C`Z,[5P49AJE`"X721'GK51FV01( MSWT@U4Z590,HIB;&MC(*:O(K'**R^R3+6#:.;[[E,+4683;GH,=3+A>)?BCK M3DZ/J1I+]11#$R&F$<9F-0H:L3D8QFDX"P$5_]5TQA#4!7GU^^2AB1#3"&/K M72>G#F0W]8<7%:SZ^?<8.OQ4?,[\-"Q17,Y25F;FD5HA&K8),G,?]+GQZ:4] MQO7*? MLTE]@VUM.M%K%*1&U4F_^7QB`AU3&&.C:)L)Q!.&?&%M:?<2X/R5ES"%6)0[,GI/7Y[\+F?P/[=,>&N,E`1D9_WD1PX(HZI?L=N42=*Q'.FP`QF7X"MI MKJ^QLFJ?<1?[*8-*UZSZ?ZE_])[ZP)GKIPW8E:@P)7?L=I`#J MVLO?'PE5]R3C&+40Z[?`(]'VV-!G#!2CW+'?JAK';):R6?G?'%!SXC?;X5+I MYP&@#5Q,"1R_1]94YN>O2"RY5,/ MB;9@5;A5[Q4WE_%Y\B%EB[!8R*X`576Y MI/IM:=*%B"C#8:]-B@(+JC2XG[HV?V+;3\N(.4A,)?IECJQ/?%=%FHI]2R2E MN33Z;8'`06$4.[9=7F99.(MA%U,Y568A=*N2MO2.HS1?IDX M-T]"M2F+O_3-QM.UI^TMX\Z-[-T+C,_,GEH^GMTDZ96&N MV$^V;INGB^JG<[-M$6`:UZ],(I>^GX(DGKS(2T.6+?=BES&_ZO&5>U.-VEQ: M_;SX,`>)J42_C)^`E^_>MK;G!BJAJLVEU>_=C#Y(3"6,;9@=O)?9FNP>O'2< M5LNKUO,8S>I<$/WT%VZ`$J/;<2C)]YC?J_`#RT<^``AC5U*%8^WG]E(3&<+B M4<\LCZ+@\#??8.<<9JP,7K+Z8[;\JW&>$45S7)[]-E2U0(UI4;^,E;(GH]T< M1K2;!CD?]WMK:4D"F*;U*WNOJ3`:WKG+VP.)]MR1NPUL3)':F&I!A+_490@H MOBRE^_?MWS>$R[[EI8O).]`=\<9%GGHOL/M:>#_[R:+Z<@FL\V5'I\V"D]/3D;.AZ,]94$2PMBE=13/,5_19X>1@ M[1L@*!)A6D7T(4/4+G1DU/9J\O_H_7>2\F"I6>42`$.WDN<3\[G/6:A,:*O9 M`HB,1-X7RSH@5C0CF8C5J%]["`W`RD#KVFV`V$BDHS%BN;&BU#&+5:5?%[JU MC8(R!_I.61`#B9PVAKQ)=HR[Z,0D]^OBM=?5R`)]$]A-=ZG;[CN0*ZQ5UC=]_KBQ0LKU2Z\9!T-_/ M.FQ+7$@(\>]#+Y?VOG&19[D7!V$\^U2HMO2VOP4DD]A,V%(HR^HJ%QL6.LA4 M?5\J7Z[<2W.Z/GQU$_7[5:(LDIMY8R!4$CNDCG6QH5RP5V9]#%/5=CS^6KE" MQ)7HE%=J]K\&E)#8$=*>-E'!80Y'WZ,NUR[&WR75H2X+OC8Y/7/J&]T/748% MA]T^:^OR1:7+<1F)(GAV[\G?[_WL&9&\LI25&1$;HLK&QO-J/WL3!T/1XS\9 M=Y%CP24L.-Z,;7C2[4>[93T`\DBX$O1&Y]7"1$:"\%?IPO3#3&->\V!G"[P!PO& MUYZB'I*ZX%X2-S?JPC$[D*5T(;@W[^%3NG++RP/XJ!Q.Z[F3$RV M!-40//.7JJ_T+-PH!_!)W"-+N!&3*4#Q_7G>GQV0N#AM-O=NP?@^7>G/#DC< M%FYQ(2&LWN]!N-(W\L<^.R!QX;7#B)@X0=\'X4K?Z!7$V0&)&QE=ZG;[/@17 M>N&*<:_A)B^O"`(B<:_0;$'4P38$?W4*$9;.#DB8V'4H-U`6+=2VG,9[<4M$ MVE7L[("$E:RY$G8DDL%YFG_>%E'E;']9Y/,DY>FA?X\!8LV4_1!Y:Z^([ZB.D[K$?(9&87#WZ2KS;'3@;++H51"VLQ$)^Y^( M/F2`VX4^A'M5OH)_\A8JLWV]&(`G84"TS*9897:!#^%.]1V5\C)ULR`(@(3] M<9<4.7GUWKN]+46"M?..5F92_@74*(R6!6@D;( M%DM3L0SA#K:.3+F<[A8&09"P')E2IU:`.KXAW-A>S4,VA8.\7^3A*XRC*1SE M4^7]K:06B(:$P00C#;F[40$:PA7O4_$Y"X/02]^>O'+.+$/G*SQ-L3H@%A)N M:GM9`A12&,(5<`T8WTV-I[7Y4KD"J"M/S@Y).,8IF$3HUX1GZQ[7[2DZ#5]A MYH3]LE^.&N5B(*X`$B%A1]/E#CEK2[#9NA-URC:_0AA/KZ"O87[K^6$4*H\) M6!60RO=C09,+P=95'SG5N.=7*:ER/5!5G5S0>$`H9U&?^5ULMB["[-I\_H!^ M)OCV?J<,8"%QCM.3N<#JLPO&5D`CN\1<):\@AO1-3LUF*94?SF;I66< M][LX3\,X"_TRPWF'3Q\:]VER=DC";&M+0RWKOQWQ(L/&V$`YA&="B"B7#T_X M1$9F]*C[!/22,*;W]>N8T`TB7N/OH\CM8R1P;3G MB.YR2U_VG#P4J3\',8"@%DE4VF;LXR].B]//R\B(-\[=K MV&9(%D*\TN1B.$FG\$5*A1]1D'W=1"AF#5@9P_0-S:^'E@5L).Z*]C`3[,)& M7AKNZRI!06F51/4V29<3%\Q;*F8%50`I#7-?]P2CZ!&>>W:=0""NV<5P$NO@ M"T%SR2!ZUN;Z8L^A0NYB^"=[]KZQ]_`@+N*"K'IQ'69^E&1%RC2"A$AJP1;O MT-K\?#.=PB$T?&6K#S[")N&1^4G,'08K75PD18RF.&C2#$`@,8\KI2R8H!M! M'4+LCI47V7).T7JEAM69C`[YV^(>096&->0/OZF=NQ8XS]H'%;!KF ME_DM`Y!>Q(=8`5UZVY"9SH;'QG=`_$X=B]JIC7CZZ4!`E@*L4+`2(M(I9_K+ M.+B'+T>U\X"Y(F(M@22=NE[L4=7D(K`4786P,GU*^!FT\$NOO^5P$Y_>KY), MZW#7IGV0NE.OA3TJ7A/!6(H!TR9Y*;(S0T!>S;G!YRZ^]<*TO,H93Z]9^E%O4W7:2L%2_!CW26X5,KA>HH$"EUG&\HP+I!)R%"5?O5CJ M6-*^<9"VTYO[/4Y7QE*Q%*:&U-*YN1W54:W-&I.+D^%NX450;<6HR9/9_Y""BX,K$\H[:'!Q;W@UTF^\: M0KYK4-K@6S4*H\>]-=[&D+@?V+Y59&F[X,KG(9^1;!ZWV/<%HBQ M5XL(I@CB^::A.`9D3M^1`-^K+7];'EX>@?#TE7%!7_I^6GA1MCK6WB;I=5)\ MSJ=%!'_CYR/97L7^QX`/$LM=0T72U$I+8B)AN$?6TF:8[V(>ORQ)W[#5M&6S M(#<2#P:MJ)<]@5@RN?=D_MOPUHR#I2TGNUF\1,D;V_ASN[G/X$/``XD7>/N> M]XQ%9,GJ3U)5?TV3+%M*VT3SZO5`2B3>V76K2+N(!V2)U[A]:*`D:".3LQ,2 MK_"ZU1@%_-8V_(M*?^+R&7U`2W_6@FQVD@01D7AYUZV&;..U%8Q^^UJ'AD)\ M2F+?HLU!U1R(U.D#O_V;'?0D,J0,UCM2&+^P%##'LWN^6GMI^C9-4OX`RLBF M@+<"(B1Q*=:R[;=!FC=#HB1Q/N&SC5)+836T?R) M[X2:*<]&11`4B>B7G6N+`+6M;`*.G5VNDCA+HC#@*KJZVH1MP7*FA;\^E!3, M60X"=)*6OG*U6'5.VPEFI\9D*V*S"P<(9;+YC8(3&M'W9?)4>#2L8?SEQ[+K M,'!`8MLF(,O<3^7@KQ>B2[>.`Q([*!57!GXJ!\Y?B%H>O3)?%;SPA$:"#?/1 MNHE@")XCXJ?5MVP3\ZL>1>L MH[8+OBAUO%;7A(Z2N(I5RE+@#:"+[J]-J<"+U?VC3%WZS+>I(SR0I?7.!2)A=8G M9Z=.;4_&6B&>*:Q)8D"NT8VN(V57;Z=.#\:6-$4%D(23\?XFGP9Q9]HT"S)V M[Q>QG^E&+H(!N2"+A7&5Q##*"AAHZSLF8Z42-0+RK$(\_(^&F;+:@#,&,C!:3!D6:],+(1& M[0"QI\[,2RLE7N^0&->^]Z<,B@MMC>H`C\1KI`:<(!8H;=!_&2`%=A\2#S?T M.6Q@A<2S'_6*^?96R$,2#BXJK@RLD(>HK:!?E^5"I=>Y.)=7A!%#P^[<0-D8I M_+OX^6OR7\Q+]6<4C;8F9VRJT:@TD2L+?:Q]* MM`5Z0#9(;1G<)D5J38M6C8$\2;B8[4&)MC"3,$ON58?:*PY(CH3O<.?:4@&U M9*AT_H)&9:9TZ+WHR%IYUL!:B<=[*/-\6S'YFB`=A#&QN)S MQOY5`-(;'KKI&;ZG,C6*:X!(W*<0T.,-,3#*<`W!NB@`J#0RHG5`+"0L"E+6 MM(FN8QJ"M7$+XD>V^,Q2?9JK\I,S&L\E%7QID5Q'-`0[XGV8A[/JHAHVAHH9 M>[QNC2(7<;C26CG%V?]`RP6+W,US:IZ@)Q$ M\/,&BX(.,%MYLKJ)5UYDL*U]3CUH/?OC?['8\T%6OP$8F+8RK5%LT`0(A(05 MSIAI8XRVHFAVY*?]FD0%B#U]>V!YR#LYGG[PXB]I\9+[;W*ZM2J#$$CX_1@3 M;8".1@Q+[!'J'(YR++UFKRQ*7D!IQ]/+!8,MK/='MK4$R>DV;@B$0\+R9DQ] M0Z0T@E":7Z?<:V1P4M:=G%VX?X33Q%!CB+!U=$@2AAO^TG$%\NW:6W@SECTE MQ6R>E]F&918<55V0D_L7./J$(I8=/92V@D%V,^1Y=-,H\JJEJWP]=,72O(J( MB=^?2FL!;!+9LQJ1JXT/H95&8J&')`?DH1?=?'LI+XG1T]9V00#G]'C5GCP$ M$L(7#;/:91"$5<]*9Y05`AQYLY?"VB6@UZF6\IND_1Y'J;!@Y?F M:)(U=4T`[S[L3BM*=3$B#B4TC%:KA!:7LY2QX`'.:.J,X[6RD_,#]\%NVFUG M4%0(<30,3Z)N/\`1.T$G5KP&P"7M(]",Q#HVA$H:!B91YS\"_GGT=A=GN1=% MI51,>!54!T&XCQ-CG604*,(X#5O2UN&X?`>+F0WD%0`L::N1FE4%-(1'8W,1 MA><08IO(@Q<&S6Q&JYH@JJ%:C+8P(NI`PUZTA>#>R]DMTQW3R](`L^?V(1DN MA#X:=B&%`C[SUS*:9`KK@@AZ;CW21XD03<.@M`5C;5=Y?VA5;3`TN<:J@R!Z M;G`R`HHPWLMWB]O`JYSGEWD9W!)^-%RNQ?5!;/TU:C5`BB@(#80N0IS9Z-7%UNTR]Y1%O6<*=>KSPY'_779&8*$]$+&C8T MV1WUY:)\T6QR*D?K@RB&=4A7($5(IV%M*]_7/X(8WC$AG-*PIVT&3P`@["L+GEFZP/A$*P#8GI_1%-`0'O=L3T/=XDOU&\=+ M_2LA@`BX:I8N"_R.#?>-UZ@,0NCYH')*(OZ$_,4B!#B+!E-Q+B^2&)F`M2UK2)KF-R&VF+4B3$ M\T,2T184?&F17$=D*6R6Y5!JI8?^)V^!S;>"4@"'1$P$]1R+=MY2)*JNN$#G M1V&YR?F1>PN.2,I2,NI]MQ0GRBX=__3BPDO?#D?\3_*MIZ`H`'/_H$\OR,-;D1E`9O[ASC:Y.`(;,5ELLO.1R\]/%`3LU4,$+GW MT-'F1-AY6S&4G.[A2@6]2"F,MD3AXB+Q8NA'I\G/`!@ECC4!%D$U_9T(81*2F1Y;Q<,,Y M"\J7A@^\3OK8_S.&L7SU\UU@RO"8QHW MURBI[>^OC_^ZOZZV%<Y^-#M8X*Z+_L@S:5JYLFP4GHP.W@7^; MK69"$"2OJC^&_MQCT4<_X+T*GM,B4ZQE>(W):.0V%&6#<:=$X_@:FYR3Y`G) M7+,J&X`4CN.[<)*^DB#X+MJZT^2)^X@Q(C%+V:CWW?'U+W;R8WXYC$OOJ$/%N4]0%K"Y M#[XJ%KCHP(<2).&+8CJW2\#82BQ$BEOE7"ZNP-6=A-5?PI<> MP1MX;*44LNZ_]\JSGX/J?DIR-HZ9TH]/6)Z#).$P+>5`8,11`+*5%JA3UIZ_ M)D:LKM]/I*BCO%8^8K5@H=PIS4?3R"(1"L96DAQ"K M>LLD4H5'YZ4QYV*,Z1"\@\=6SAV[4^Y=_)I$!<@V?7M@>9E(;CS]X,5?TN(E M]]_D\Z]690Z?QF0LYTN\OT:J<+&0V.ZV]"C,4!0,C80ZMN(A)/Z7NRPK M6'!=I&$\JX"61OALRWQ>VN!_39-,'C.A28-P1CRG:*"0JXD5S+92]KB_.'T` MF-)``:M"'#H9>[,YW=LX;"7A<4KA5>1EV7@*LQZ?]L;I8SB;YY\*O@T93Y^8 M#XJ=ARR[\J*(!1_>EN6R94'9E-"R96X_HF&I;J(L=L#;2B=$3\-NOK'4#[-J M/*W^V%BM%,UQ<=*X";>F2WJ(!Y&-Z.9?19B_W7IA6J8>O0XS/TJR(I4M.F@= M+AB*AP@]55#!ZB#_D(,)8VVRY%9.V5RP69(+H7^G#CD8)'Q%OTQY'$\%+^.V MD@HH"^YBV",7ZQ1J(PG5NDUPL9&P#372`4.4B'+TR]5-B;DZ4%4'K58JLM$0 M%R&)X"?=*(H(*Z(N_3(H/J2)SUB0W8(@.3POYON?W^.,;ZKA)"Y?,31J-:37!D&A67Y MHY>S,N)I\`"G(D[83'8XT&^$BZZ_!DICG(B*],LH*9X!MQT&C=>([09`9#0" M'UI<)A",B%KL.=NXO0GDFDV](LKKKC3*Q-;2>EQ._=TRZ$!#5*!?EDC[&MXQ(!3_/^;AE?QHD_D9B1M>D2"Q6_S=_@\AXOL*5R4*_O(RB?E` M5ST4E-6;G)[3N),5D*:@%XRZS$A*KD[C^MI\!M["8#]*^YXW MFCS,>1*%@5%Z^D[#2K=+69/-ZSEJ ME_L>]ZY$G$65C)GL7"4^H+UB&'`MDE@ODM%.V$-[`5Z&$&`#&$/>QD$ M807@P0N#N_C*>PES2?X-K7H@'A([6U.>-4"Y34ADR],B!SFPX,9+XS">91HA MR4050"`D;DU-69:A<9O9B,:QE(A_O?'.:A.!VS1'%M_V;9PBI$QN%Y[06&T1 M@C`VA2@L)4-ZJ9[UY5Z:NWVT6;ITCHL\R[TX@$E(QNMVV0F-Q=6,5B$(2[F1 MVK.*I903/PLM'VQ4/]\FZ1-+7T,?P,4B@T6C=K@/5V\H;H'05I:E=MY(9N37 MO;%;L8\W!,*AM00WI5\%T58*IAP6B_VP+U;HYZ^)E:$/[8!@^K-HMT!H*R/3 M_JA'E-F<>[PA$$U_EO8V$&UE:]KGQ%\JM(;OL7$;W"]S$*Q+T-G*!;7_E;XE MX^)&0"BT;JS:#70Q/%OYIO8^R%?SULTWO[P`AG]N)!<5/TJRTBZ(CM;%EIWU M7XG85OHKAT]JBWS!W]1V$NIA"MI66:^^3"X?P,0G":>B7)#692+;;`)'0 M>-IF9=(0H[.5\FO_$T1+QL6-@%!(>&=;&OAB>+;RBE%XK2;3^/7S__&T%CMD M'5Q*9?9OVNYD=-@?0Z-%Q+9RG;6Q/NPA_&,'>J79,(BY/R9,FY!MI2RKR^O7 M(@SXJU[[RQ6_6FUOX]!J!<335\.F`3Y;2K/6N$M&?\YL[8':RG)& MP;CTB>5WL9\LV+T\M\-&N4> M>A,'/7;Y'1WUYU98@<)6JC,1K3UX-OY0"GK.\M`'^(-]0SXZZEV\H]$1K1LU MM7RQ^707UA#>D3_R0:5X,[XJ,QD=T[K9JI$AIFVKZT-X#EY"4K\N7)<"Z"2. M(%M<2`BK]WL([[L_AG&X*!9*TC;*`7P25M\=1L3$"?H^A*?<'[UO>M35RP%\ M$F9<7>IV^SZ$%]EMG^Q2B5^MO=AA&-R^OR9V;WI"B]0MJFQ#O5@+-3Y[.DZ<'NA):/-"I6O?/<">[^W,]% M;YD5LLY[0>K.@/UZW,`SA[/B)Y7Q->DB3US#@:8Q_SW@*NO$+2X&0>';I MY^%KE>&'`GY;_I''YE?O*>Q\``1.RT:[I0KHG:4U[)9.NQ3N.AM>6I^2 ML.O:Y%3KIOL4M0GW,GG3ANO&(_.3V`\CMH'Y.=&4L,;TT\7G@!,2QFJSR:@[ M25@ZR'?B8/4K[+TXM'$M1=)X>NG[/$M2]N"](2=*_4B2?/PW]@[7Y/J(#,2!HU]*9&Y;&B$C[/H'O;!`\'Q M0+8LSE0J)*X`@B%A+]FWTLBD82O*7-<._CR37^+%-_S^(=.+$[!=97)^3L+4 MO=>%1RD/6['F*,P3UZR\1`M?V7J]7?\&$I:N.HJZ(.+O2GT,!=,Z:AVA#8S6 M:Q*\,`B$A/5VWYJ"28)&?#M+IIG:1FL\+5-*AUEYHGM(V2(L%C([BZHNS,C? MI>)H"H9&S#P[>@223!ELR:Y9]?\UV2W?9FD8[O0;`>GW\&[`%!^-.'E=*^-\SE(8F`Q6X<^1-%2-43N3T1F)"P13XG751PF]=>0\0KN87?AW,4^A MGJ3RX$;2>B`F$G;]KC1D!VKKT'JD-0+6UQ?8M5TOD=Q\X^8!]CX\+K.,Y6:J MHM,@"):$6W57.J0O@]8Q_$@KE_H&2;LNB(O$I4'7"],&7%N!^,AN9]("$(3> MYS!2!=S3J0Y"(W$GT*&."!';BJI'04W:>8YTYF(%@B9Q[RI_L^R60U47Q$7",&"3?.2: M0T\4MB(D=A#SM([@$$"V)U^-!9* MZR"+A*P`F_B5B5YTJH&02)B+]CNSB*5`(U"CI0`H[\,C&T\-5$56#81$PDS4 MO:JHI=`ZA"/16:667\!@4MFJ!2(B82O:[YPB%,*0(D36P7)':PW3,U8%A$/" MY+-?#=F5@*U`D^ZSP=2G3$WEP*J`:$CX`NYWG=F50.MPE5T^7%EWO=[Q^F*) MG6S4-2?G0Y\=C`2!Z(&^-7A3#YZ=SQ7MY-J970Z((N$@V/V\8T-.B%::9YUQ M?D?!17$9!_S_>*C35R_B8[(*'[5MH)B]VAK=_$T21<581I1\/1:`.&1,/J;Z841.$0S>FF1 M?7^VPQ_R2)VQUL5`""2,\T:<81Y7V[`0;GN9!:=ZNO/L?>/'.`6]&R5!%"1L MZE88%B!#2.ZE_?-=+I^2V(=_KMUKXD!P.W;1J$3<+B;KY% M:(\:"8+72T?>TA!4/2@?2=2E7@R$0,)89H=,Q%ZQ@Q(`E(1AJ`MBU;@1@BTXH>XY)OL'+PNS\?2A M3EX^C:=/X2P.IZ'OQ?GR;0J/5Y]$H<\?:C@(USY.9UZ\?".^CB=? M];H.8CQ=LN]%ZU#S&OL;*^U/H/.NYNA6`-;#XQG4Z4,D=P:U_2D0&PDS@44= M$"\8W0C.4KQ[[2GI[[]P<)^]C)6,_?]02P,$%`````@``(E_1'VZ4Q@R&``` M"T$!`!$`'`!N<&AC+3(P,3,Q,C,Q+GAS9%54"0`#+]DY4R_9.5-U>`L``00E M#@``!#D!``#M75USVSB6?9^J^0]<;]76[H/CR$ZZ.]G.3,FVG&C'MC26DNZI MJ:DIF(0EKBE0#9*V-5O[W_<")"52!$"0DIWK6;XD%DF`Y^!`#__\6D1 M.`^41W[(/AWTWKP]<"AS0\]GLT\'7Z<7AS\=.'_\P^]_]_._'!XZGRFCG,34 M$7XX?';WCOGKV_??3Q^]_'MV[\Y M_S.^^E]G,)DZA\[CX^,;#W*(90YOW'#A'!Z*]T3NG"Z($Q,^H_$U6=!H25SZ MZ6`>Q\N/1T\4D/H`=T05E\$?+%.;TC21!_.O@M M(8%_YU/OP`&N+/K(EG/7,C^9H/3LX\F;D,_@D;>]HU^O+B<2;9YSX+/[TM-/ MMSS(GS\Y$K=O243SQ\5=+UXG*#[\_BB]N7XT,.3[ZR5D7,S4-SSLLR@FS-V` MJ(#.*/8^?/AP)._FCR;1X8R0Y?KA.Q+=RD>S&[+@#M_V#M=%]]$-$Q;S59EC M1-TWL_#A*+NI2I9P#F:H2Y?=%0F/RPD]ZJO3P`W%>^B3.U<_+^XH$OCL@4:Q M.DEZ3Y&($=^-U&GD+9&D5TX2^:XZ`=Q0/`X"Q*LEC932R#L*6%&\Y)J7P!W% M6SRZY-05]5]K7Q^."'=Y&%!`X,:']&D9$$;BD*\NX/>Z0$+&DH4Z$R_F1P+Q M$3QT"$]1[KOK=/6)L@30DCC.SX2Q$)H8:)KD;W%EN?3979C]A`O"OC\*P%-( M[H@_OMX,C:V#9'<>NHEH:?K,&[#8CU=#R!6>$.\Z<'PH(.,3Z_?G"#QZYS-? M(NV][4'[F"3B&SGX^V<_C][[:S3R+JC=@?Y-^@802YR;2BXTC2E2P(W";0OS9(=E>0H9-E6I[.016'@>\)H3TD@&K[)G-(X2D72 MWS8K=`RR3*`(:291,1\GR\A)<^KD:2//F$`+'\]I[`.R&JW*SYJ%.[$7SOEK M*>._=4):"KDNWVAT-UJ*`2.`450XS7-F`=^9!-SDZ(1WSB;/3KJ=I*NIC#:) MS**^;R-J5S_W(/+9G+`9C89L$H?N_3P,/)C*P=3)=_W8K+0QI5GN'^SESM[B M^,PION??_O7DPW\ZV=LZX?C: MZ5^?.Y.O5U?]F[^(>Y/AY^OAQ?"L?SUU^F=GHZ_7T^'U9V<\NAR>#0>3SAP, MYG!!?/Z-!`F]HD24N:Q.J<[J6T8!>V^W!;SH#V^<;_W+KP/G:M"??+T97(&, MG28F328TCE.?].@NJT(1U+#K,*9CLB*W`4T%LGC.K%9O6ZW)8#J]E`J)>I75 MI8FL;]>CZ<`9]__2/[T<=.J9O'P)G8:C.V@!88"1N?5*E\R:'&]K<@Y59SH" M/:"%&]QT-<=4]B,8O/%S>IM-0S8_S65^LEWFH^F7P8US/CB==L5M:JAT\[_& MT[O>NTI3-!V=_>G+Z/(<;#X;I@^@!@P[16H5&2VEKP.Z@E\(YV3=H>MNFI5Y MKU3&&8W%4"SM&W[IW]STNU[=+,V0P9]T2I[R<73Q@EF"'[8E&%Z?C:Z@6^C_ MV@UO:Z:IBX4?RY$K6#S,'L5DA++-9,;T@%F4'[=%`4FNAE,YO)6UXFPDYR&# MZVX24M=J);<1_2T!OH.'S?RC@-Z938T2U25*;^ M,;-2S5PDG71M?"6EUDY]SRQ2O=^D$^:YI\7G-"9^L(=Y<9Z16?)G7DF3PHV=N=7F,:4ZFX9?9K*L>=J3RSJ4SI M4YSDH;M[S,]L-A6GT7[-)@/1&4]C9VUI2&)\PBQPQ1FE===VPX<=M>K5BU77 MX5=<5'5J=7UX>[V.Z_6JZW4K/JI:O;J.M+5>)_5ZG=3H5?%=U>IUTNG55J_2 MB,;F0;-V%6]6K7;=Z&,OT>XJ.1NG,FM;=8+91<)W6K?_VEP:82KOF#6K>+$J MWYN[$65+34I5S?2`4:%W%?>13J&N]C0*#2C5G,I5LR85/TTQ.*"K,"UD*%46 MW4VS*!4OB$*4KHZT#-THU1;#?;-$%3^&(7BCJT8[*54>Z-4^9M:M2=!-5]-V MC[ZIUC;],V;E&L7?=%5N9\EZ-IK5.!#?51P<%J)U/L1=9*NVEK6/FB6L^#EL M).R:S&8!<*5F4G'=+%'%75$.@>L:PU9B]'1JU#5Z%4^$4HZNF6LJ2*EIT]\V MBO.^XH10B],U8+O%C98:-(OGS*)5O!0UD:-=B[<7]4H5SOYQLY85YX:=EEV- M;!,.7)Y^:6Z:]:IZ.JH!P5U]:Z]->FW-Z]^E`',MQF!^] M\7<@_>9I$>2/B#<8#K60BF^74_;B/(OL8`+S41>02;BD/(:.\2@'?^`<[9$8 M*-*46%E$G+0"7".[B28],R=R]"561F2B%^'>;I#<>FP=WQXTGOS%'F;TF\"8L.Q&8@\70L0 MZG-V+%^?)Q#O?6_[1N-!.9H7RY;K!KQ-QQ:8P*D2);]O2L0 MU6%`-DB*Z?(?.V-1'3!D!::8=85@VG@4(\5Y>;SYIRA92,9?!)I,6"(WGC=E82IY&_-&B MPII/Q+(JD.U4N^JD/LRK&9*07;<&8SX&K7W/*_/22Y0=0R@!R8WS/:#?1[CFL]DPI@LQT3IP2/;4IX.8)V(<*Y^"D:,?>E.9 MSDO2@U(.'.8'@0BCS9^-$DCLQXFX^YF'R3)_B0_9IQ-C,13^>VO@FH*0L^UA M%"74.T\$G;&$*T.YT\L7(9]0_N"[-!HQ6BZ!10@-!^$K51G>V/+6MFR: M3*)2*J_`)%JPE\4XYOX#-$+C`!IYD>2UFD.51QM3,)<&/C/8E76Y)@U@6B-. M`H(_;V@@NB;HC>)5NF7\ZS0+.VX[M1K6I8;/?)ZC=&2QBX17H2=7P:?X7Z?Y M5'FT,15S:>`SB^:LY9*R?XJNQ9))TP+!W[W8(F[1&LAA2KXB\55803V)%NV` MH1C0M0$[L97E-0W%H.'&G(9$C9XBBF+7GB(X]';EB9>1:UA.N:A2ZD77?!P M<4.79)5:A8C(<;F?QG?<4)="]X#3MW^A2?!I!!SI"%C"6+CW%^_86[:1TX#9?-;NC(>*B`Z4S.G5,O M">CH[L)G8`(^"88,(":;@Q"PL6L&N9;W^A3H5U@`C;#7EL27U2WW/456FSA! MY.71@H&]?6@S?S568L_`JO7&R-J(L%;K/(8V[=!0$K0%:\UUE,0B),Z#^=@K M(6Q`K&&]\Q%/+_X]VXL_SB$E=Y-;.BP7R![(:(KIDMP.?DO\I;AT11>W&W=" M9@->N("YW,M^R%>!TN"?PL_E',;'^%CHH3V#R5[Z3!I-]/W#,/9$0]>:P=,! M/4NB.%Q0CD9L-2P-AU]"?@_/GY&E'XO5.#O/]=(0YWCO4[UMH!H^^A/5,#6B M)I1-B"&J:G7X=&,ZF"<6!LIRRRCIFANRF$*UC<=0@*+NSM8"BGJU3*_NQS*M M1W=-L%KQ_18&\/\OU)_-8^KU'RB'M&,.P\=OCV2Y*^$]C&<;H;6B?!F&]Z?$ MO4^][V6[S0%_5Y;;`/6AB0]BL0F\K^AIRR[#B#@4*X=#)EU4_7A=/1"[C]M3 MTHXBV/WHKB]#4`F:_E&)2NL,]A[#T+LB#$Q=6D?@HB%B`J?S]H=1_)D3+R$Q M_4))$,]=PNG`2](``$SL[*%JN/8#:*"FU)VS,`AGOG!!X&%G`J=M<<3::+X: MB-YFR?T(QJB(]#+#T[80]Y2?0R,81"$[I6(=,CLC@?=(@^"4\OOPT8__,<9# MLB%>W4S7AVF8-X9.!BKN#8W"!#IW5.99BU##[,KU0@;E,>4P_4##1HE*PV"X M6"0L=`.?7<8>&@9*5+HV?OWF_I/_\C,#F/9X_B+]ZKPU[=E&5DO@7!8U@O*O M0M(.=EVISO%;L7(1C?VH86DX_!=A"8Q)?Q2+=-`P4('2-4*$N_/>"2KX"DRZ M84L4^3-&/3$K$:N'?(^F+^\OA(<*\^?X6NA&ROFD6I%R&N['.?7,S.L9U'X7 MJ7Y!PN2W,N.T^6RW^12*R'=5CU!GN%);*`T0/3?^:3B=^SP-1-F7W3Z74]42 MOX9](9YNQ"B:IE8-JY[#]#'$R*$`R\X5E8'4F?'GT%QK%F-P@-?AT-D>7L7SB!->D7(-+%^^;]8RX&CDE*C.#DQY& M!F54=9;4.T;%08-+P^+//52ND3(<;1!Z"&>05I@;\GZ*F3Q/%B)#_,D",3M<;JR!;,?:`=2]L4TIM"3 MQZN]^0-?T#:VH-MS/B<+,A,A";[WXF$4>^!=A6]/?7-IR,Y(-$?O#+7GT+X0 MTJ8UP.\3;\ZE?:'LNV'XGH72NJ7($@Z>EF(#MN@EBZ'IBJ#U>"5\*/@^B)A@:J@-%LL@7%$JMLT_]SF%^0>/T(S& MC>CTCKDH"<08`M-W`"6J6@:8O@(H4=4SF$-C@I%#$9&J%!E>M M%F@(5"%IO\7/*=_$\*$AH,&E"V%9)M_@5\)QA=6I8>FZP!6C?+9:+YC%%.QI MP*:+`N!N[E''1$0-RR)N$P8=Z",W-1AUK5:ZM&I,XOF$N@GWQ4D:F+2J`VC] MR>D2]0>GR]K/33?^_3GUX\B=HZ%1A60.+NSA^A2C1*4;HV2?K)%14,,RADCB M(J#`I!NCP!`@0(9>@4D;)L^9`I,N7.@Q',J3 MOS#!5X'2>3#%"G!\#-2PM)MW/.%CH`*EFP.$-/X'#8(^\SB-\%#0X-*.A5AQ MXT9,[F,]-#LNF!S)>FBZ;6&RS:[.`B(^V^!110?,A@5R^^ZM+4+DM?W$?M@[EG7(6I]0\I5YD$EAV][UYU','SAWXU6O>[YWO]BQ M795'>H#!ONQB'U\6@VX;?`K]NL328ZU6VMOYJ`U2IAOZ#MEZ_R>Q?E0> M'P.OQ!QOU9*/OFM>`CNQ(RP\?T.;2)[?PBACC)J[-L6L] MP5N)X8_\6A;$=D,CRA]D/%'?=7D"JHLY+A-'!;]@\')#6]F96.U*_[4U;NT. MCLE.;-`V:SQDRWM*Y,FX"U&,:14,HQ<=V^^GX3!Q,8SG_5A<$&9S%LH=9RE# MN=-S/5;=<(X`;M[*,@Z74&(+*,V+>Y)=@0PQ14^TA]X\ M9.3;=0)\QB)?6^[N(4$>,JA M`5AMW4B"BQOJ>]^^$!X&WI>;9+&"J\H[/`N(OZ`>`IVTR+1; M]`9T1CUT-)2PM%M$^XO;A$?R6KYPZR+DFUVT$,]L;,#7^3^DC]J3'W\PUR\U MW@;D4G<]BAWK3?`:,*JN1G]1]]T^%%12,"R:W/2,*^D,WM=B\N=:0V_`;,?R M$CK("_JB-;-A&Z0#;,=O>V4]^M7Q=OCMR&_ZVVP;B2BM&J]';3V#1O*?)WE+ M\'JH*Z`WXCP)D]D\AED-\^C+;XJQ%^XJ"KHRH$2XW-<;ID19H4+%`,-`SJM@RL]=SO?ZD8FA"FI*!@YMQ%#3,2& M:HG?9*5HU"N@,6ZU?PU_XSPK8(.LE@"RLP**D,QA^,>XMF-3HJI;"H>+@AJ6 M?BFNH#I@^M$@$ZT#;Z@O_M&*6_?*[^2DQ:;MPD9OP MN^9Q1VB4T$.K'8Z(`1ND6=V%_)%P+RV*]6:&4<^VLWB1T4D]6`W?=,$.&KW* M.:K=&FA-M&0:UGL1\BS^ ML'"P>6O_]L[DC.`TA(J?@M&8G0J4Y3>3/"3]ZQ*:B/04U^\OC!5(NZJ%:EAZ_),R*R^-QLE",C5J?T*3X-"F.P M3-TXO_[2*\):`#<:=Y1->`1`;`X]'4)K0F@-8 M!F0N>4RCX2HD,W9,H\8JI)U7SR&*H6P%>O?582(S@21"5!0[PF^S^`D1>UN< MQNWI<`TF%9BTWT-6O1]08:\@TF[JQJ@\``D/]"HD`_;C]^BPER'I[#V9)5%\ M@NLCF@J4$?_Q3PCQET'5G4J&Z\AS-:PZ#N]P$,!(/>@F,:;2HPU:#' M--Y48#)L"(AO/SS?<1.AW2GHXSI6>ZC:6)K_AG&Y7.(P M#8L+>'Q/G-V8'=(B?OS)9U[>*F)>D]664:U)RRVI$9IT"5_?KS2VJ>QF&]/'\%67QH:$:%6%D M1K.PT*G+<"YV;`+6\/'J+Y3P[&L%&FH:7(+%ST>1.Z<+(@G]'U!+`0(>`Q0` M```(``")?T2R7N`+#F8!`.H,%``1`!@```````$```"D@0````!N<&AC+3(P M,3,Q,C,Q+GAM;%54!0`#+]DY4W5X"P`!!"4.```$.0$``%!+`0(>`Q0````( M``")?T24]KSHZ`H``*F=```5`!@```````$```"D@5EF`0!N<&AC+3(P,3,Q M,C,Q7V-A;"YX;6Q55`4``R_9.5-U>`L``00E#@``!#D!``!02P$"'@,4```` M"```B7]$7QS3:AEB``#4.@8`%0`8```````!````I(&0<0$`;G!H8RTR,#$S M,3(S,5]D968N>&UL550%``,OV3E3=7@+``$$)0X```0Y`0``4$L!`AX#%``` M``@``(E_1,ZO0%LC?@``%>\&`!4`&````````0```*2!^-,!`&YP:&,M,C`Q M,S$R,S%?;&%B+GAM;%54!0`#+]DY4W5X"P`!!"4.```$.0$``%!+`0(>`Q0` M```(``")?T2^_LWE"&H``&TF!P`5`!@```````$```"D@6I2`@!N<&AC+3(P M,3,Q,C,Q7W!R92YX;6Q55`4``R_9.5-U>`L``00E#@``!#D!``!02P$"'@,4 M````"```B7]$?;I3&#(8```+00$`$0`8```````!````I('!O`(`;G!H8RTR M,#$S,3(S,2YX`L``00E#@``!#D!``!02P4&``````8` ,!@`:`@``/M4"```` ` end XML 28 R44.htm IDEA: XBRL DOCUMENT v2.4.0.8
STOCK OPTIONS AND WARRANTS (Details 1) (Warrant [Member], USD $)
 12 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Class of Warrant or Right [Line Items]    
Warrants, Weighted Average Number Outstanding (in shares) 154,916,667 57,256,667
Warrants, Weighted Average Contractual Life 1 year 11 months 19 days 2 years 14 days
Warrants, Weighted Average Exercise Price $ 0.082 $ 0.10
Minimum [Member]
    
Class of Warrant or Right [Line Items]    
Warrants, Exercise Price 0.01 0.10
Maximum [Member]
    
Class of Warrant or Right [Line Items]    
Warrants, Exercise Price 0.10 0.15

XML 29 R30.htm IDEA: XBRL DOCUMENT v2.4.0.8
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Textual) (USD $)
 12 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Dec. 31, 2011
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]      
Accumulated deficit $ (41,986,820) $ (37,643,856)  
Working Capital 4,259,938    
Total stockholders' deficit (4,219,449) (3,576,343) (3,911,445)
Advertising Expense 900 70,800  
Depreciation and amortization 14,981 14,994  
Inventory Valuation Reserves $ 0 $ 117,800  
Operating Loss Carryforwards Expiration Dates 1 20    
Concentration Risk, Benchmark Description no customers accounted for more than 10% of the Companys total revenues. During 2013, the Company purchased 100% of its venom from one vendor    
Property, Plant and Equipment, Estimated Useful Lives 3 7 years    
Customer One [Member]
      
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]      
Concentration Risk, Percentage 19.60%    
Customer Two [Member]
      
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]      
Concentration Risk, Percentage 15.30%    
XML 30 R31.htm IDEA: XBRL DOCUMENT v2.4.0.8
FAIR VALUE MEASUREMENTS (Details) (USD $)
Dec. 31, 2013
Dec. 31, 2012
Dec. 31, 2011
Liabilities:      
Warrant liability $ 323,172 $ 18,727 $ 28,833
Convertible Notes at Fair Value 767,056 [1] 588,091 [1]  
Fair Value, Inputs, Level 1 [Member]
      
Liabilities:      
Warrant liability 0 0  
Convertible Notes at Fair Value 0 0  
Fair Value, Inputs, Level 2 [Member]
      
Liabilities:      
Warrant liability 0 0  
Convertible Notes at Fair Value 0 0  
Fair Value, Inputs, Level 3 [Member]
      
Liabilities:      
Warrant liability 323,172 18,727  
Convertible Notes at Fair Value $ 767,056 $ 588,091 $ 206,863
[1] At December 31, 2013 and 2012, the balance of $767,056 and $588,091 consisted of the following convertible loans: In September and October 2011, the Company borrowed $250,000 each (aggregating $500,000) from two non-related parties. The principal of these loans were to be repaid with a balloon payment on or before October 1, 2012. On October 19, 2012 the parties amended the notes to extend the due date to May 1, 2013 and include a conversion feature that would allow the holders to convert some or all of their outstanding notes into restricted Company stock at a 15% discount to the average closing market price of the Company's stock traded over the previous 10 days. Interest on these loans is payable monthly beginning in November 2011 with interest calculated at 20% and 12%, each, respectively. At December 31, 2013 and 2012, the accrued interest payable was $6,664. During year ended December 31, 2013, one of the Note holders made conversions of a total of 34,254,004 shares of the company’s restricted stock satisfying the notes in the amount of $125,000 with a fair value of $317,391 on the date of conversion. During August and September, 2013, $150,000 of the debts were assigned to three non-related parties in the form of a Convertible Redeemable Note bearing interest of 8% annum with a conversion price for each share of Common Stock equal to 55% of the average of the daily volume weighted average prices of the Common Stock for the 3 trading days with the lowest volume weighted average prices during the 15 to 20 trading days immediately preceding the Conversion Date. Following the assignments, the conversions for a total of 64,052,862 shares of the company’s restricted stock were made in satisfying the notes of $150,000 at the fair value of $475,519 (See note 6). At December 31, 2013, the remaining balance of these two convertible notes payable of $75,000 and $150,000 were recorded at a fair value of $90,260 and $189,781, respectively. At December 31, 2012, these two convertible note payable of $250,000 each were recorded at fair value of $290,289 and $297,802, respectively. On April 30, 2013, the parties amended the notes to further extend the maturity date to November 3, 2013. The Company issued a total of 4,000,000 restricted shares to the note holders in connection with the amendment at a fair value of $20,800. On October 30, 2013 and November 1, 2013, the parties amended the note of $75,000 and $150,000 to further extend the maturity dates to May 3, 2014 and August 3, 2014, respectively. The Company issued a total of 500,000 and 1,250,000 restricted shares to the note holders in connection with the amendment at a fair value of $9,500 and $13,750 (See note 6), respectively. On March 22, 2013, the Company issued a Convertible Debenture in the amount of $20,000 to Coventry Enterprises, LLC (“Coventry”). The note carries interest at 10% and is due on March 22, 2014, unless previously converted into shares of restricted common stock. Coventry has the right to convert the note, until is no longer outstanding into shares of Common Stock at a price which is lesser of $.0075, or (ii) fifty-five percent (55%) of the average of the three lowest VWAP prices of the Company’s Common Stock for the twenty trading days preceding the conversion date. In connection with the issuance of this convertible note payable, the Company encountered a day-one derivative loss of $24,931. Coventry made the conversions into a total of 8,810,572 shares of the company’s restricted stock satisfying the notes in full with a fair value of $188,747on September 4, 2013(See note 7). In connection with the issuances of the Note, the Company also granted five-year warrants to purchase an aggregate of 2,600,000 shares of the Company’s common stock at an exercise price of $0.01 per share. The Company classified embedded conversion features in these warrants as a derivative liability. The warrants were valued at their fair value of $21,226 and $17,895, respectively using the Black-Scholes method at the commitment and re-measurement dates of March 22, 2013 and December 31, 2013, respectively. On July 10, 2013 and October 10, 2013, the Company issued two Convertible Debentures in the amount of $30,000 each (total $60,000) to Christopher Castaldo in connection with the agreements for investor relation services (See Note 6). The notes carry interest at 8% and are due on January 10, 2014 and April 10, 2014, respectively. The notes’ holder has the right to convert the notes into shares of Common Stock at a price of $0.005. In connection with the issuance of this convertible notes payable, the Company encountered a day-one derivative loss of $83,157. At December 31, 2013, these convertible notes payable, at fair value, was recorded at $90,684. On September 3, 2013, the Company issued a Convertible Debenture in the amount of $100,000 to Coventry Enterprises, LLC (“Coventry”). The note carries interest at 10% and is due on September 3, 2014, unless previously converted into shares of restricted common stock. Coventry has the right to convert the note, until is no longer outstanding into shares of Common Stock at a price lesser of $.018, or (ii) fifty-five percent (55%) of the average of the three lowest VWAP prices of the Company’s Common Stock for the twenty trading days preceding the conversion date. In connection with the issuance of this convertible note payable, the Company encountered a day-one derivative loss of $957,567. At December 31, 2013, this convertible note payable, at fair value, was recorded at $185,971. In connection with the issuances of the Note, the Company also granted five-year warrants to purchase an aggregate of 20,000,000 shares of the Company’s common stock at an exercise price of $0.025 per share. The Company classified embedded conversion features in these warrants as a derivative liability. The warrants were valued at their fair value of $445,638 and $137,681, respectively using the Black-Scholes method at the commitment and re-measurement dates of September 3, 2013 and December 31, 2013, respectively. On September 12, 2013, the Company issued a Convertible Debenture in the amount of $70,000 to Coventry Enterprises, LLC (“Coventry”). The note carries interest at 10% and is due on September 12, 2014, unless previously converted into shares of restricted common stock. Coventry has the right to convert the note, until is no longer outstanding into shares of Common Stock at a price lesser of $.02, or (ii) fifty-five percent (55%) of the average of the three lowest VWAP prices of the Company’s Common Stock for the twenty trading days preceding the conversion date. In connection with the issuance of this convertible note payable, the Company encountered a day-one derivative loss of $309,055. At December 31, 2013, this convertible note payable, at fair value, was recorded at $130,303. In connection with the issuances of the Note, the Company also granted five-year warrants to purchase an aggregate of 15,000,000 shares of the Company’s common stock at an exercise price of $0.025 per share. The Company classified embedded conversion features in these warrants as a derivative liability. The warrants were valued at their fair value of $262,230 and $101,140, respectively using the Black-Scholes method at the commitment and re-measurement dates of September 12, 2013 and December 31, 2013, respectively. On October 7, 2013, the Company signed a secured convertible Promissory Note in the amount of $35,000 in favor of Southridge Partners II, LLC. The note was due on demand and carries interest at 10% annum. Southridge Partners II, LLC was entitled to convert the principal into shares of common stock at the lesser of $0.015 or a 50% discount from the lowest closing bid price in the 30 trading days prior to the day that the conversion is requested; and interest accrued was entitled to convert into shares of common stock at $0.001. In the evaluation of these financing arrangements, the Company concluded that these conversion features did not meet the conditions set forth in current accounting standards for equity classification. Since equity classification is not available for the conversion feature, it requires bifurcation and liability classification, at fair value. The Company also concluded that the Default Put required bifurcation because, while puts on debt instruments are generally considered clearly and closely related to the host, the Default Put is indexed to certain events that are not associated with the convertible note payable. In connection with the issuance of this convertible note payable, the Company encountered a day-one derivative loss of $81,667. At December 31, 2013, this convertible note payable, at fair value, was recorded at $80,057. On October 27, 2011 the Company entered into a convertible note payable with a corporation. The convertible note payable, with a face value of $53,000, bears interest at 8.0% per annum and was due on July 31, 2012. On December 5, 2011 the Company entered into a convertible note payable with a corporation which had a face value of $37,500, a coupon rate of 8.0% per annum and maturity date of September 5, 2012. The convertible note payable is convertible, at the holder’s option, into the Company’s common shares at a variable conversion price which is 58% multiplied by the average of the lowest three (3) trading prices for the Common Stock during the ten (10) Trading Day period ending one Trading Day prior to the date the Conversion Notice is sent by the Holder to the Borrower. The conversion feature is subject to full-ratchet, anti-dilution protection if the Company sells shares or share-indexed financing instruments at less than the conversion price. The holder has the option to redeem the convertible note payable for cash in the event of defaults or certain other contingent events (the “Default Put”). During October 2012, both of these notes were acquired by a third party from Asher Enterprises for an aggregate amount of $100,000, and then converted into 20,000,000 restricted common shares (See note 6). On February 3, 2012, the Company issued a Convertible Debenture in the amount of $40,000 to Redwood Management, LLC. The note carries interest at 12% and is due on February 13, 2013, unless converted into shares of restricted common stock. Redwood Management, LLC has the right to convert the note, until it is no longer outstanding, into shares of Common Stock at a price of Fifty Percent (50%) of the lowest closing price, determined on the then current trading market for the Company’s common stock, during the 15 trading days prior to conversion (the “Set Price”). On September 12, 2012, TCN International (TCN) completed the purchase and transfer of this note including penalties and unpaid interest, for the sum of $52,500. Redwood Management, LLC has acknowledged the full payment of the Note, in favor of Nutra Pharma Corporation and releases Nutra Pharma Corporation from all obligations under the Note. Upon the request of TCN, the Board of Directors of the Company approved the conversion of these notes into Restricted Common Stock of the Company,providing 7,500,000 shares of Nutra Pharma common stock to relinquish the total debt of $52,500 (See note 6). On March 16, 2012 the Company signed a secured convertible Promissory Note in the amount of $75,000 in favor of Southridge Partners II, LLC. The note was due November 16, 2012 and carries interest at 8% annum. Southridge Partners II, LLC was entitled after nine months to convert all or a portion of the principal and interest accrued into shares of common stock at a conversion price of each share equal to the Market Price multiplied times 70%. (the “conversion price”). The Market Price is equal to the average of the two lowest bids closing prices for the five trading days ending before the conversion date. In the evaluation of these financing arrangements, the Company concluded that these conversion features did not meet the conditions set forth in current accounting standards for equity classification. Since equity classification is not available for the conversion feature, it requires bifurcation and liability classification, at fair value. The Company also concluded that the Default Put required bifurcation because, while puts on debt instruments are generally considered clearly and closely related to the host, the Default Put is indexed to certain events that are not associated with the convertible note payable. On October 26, 2012, Southridge converted the note into 5,919,495 shares of the Company's restricted common stock (See note 6). In the evaluation of these financing arrangements, the Company concluded that these conversion features did not meet the conditions set forth in current accounting standards for equity classification. Since equity classification is not available for the conversion feature, it requires bifurcation and liability classification, at fair value. The Company also concluded that the Default Put required bifurcation because, while puts on debt instruments are generally considered clearly and closely related to the host, the Default Put is indexed to certain events that are not associated with the convertible note payable. The Company elected to account for these hybrid contracts under the guidance of ASC 815-15-25-4. The fair value has been defined as the common stock equivalent value, enhanced by the fair value of the default put plus the present value of the coupon. The holder of this convertible note has substantial rights and protections regarding dilution if certain events, including a default were to occur. There are a number of events that could trigger a default, including but not limited to failure to pay principal or interest, failure to issue shares under the conversion feature, breach of covenants, breach of representations and warranties, appointment of a receiver or trustee, judgments, bankruptcy, delisting of common stock, failure to comply with the exchange act, liquidation, cessation of operations, failure to maintain assets, material financial statement restatement, reverse split of borrowers stock, etc. In the event of these events the lender may be entitled to receive significant amounts of additional stock above the amounts for conversion. Furthermore, there are additional events that could cause the lender to be due additional shares of common stock above and beyond the shares due from a conversion. Some of these events include, but are not limited to a merger or consolidation of the Company, dividend distribution or spin off, dilutive issuances of the Company’s stock, etc. If the lender receives additional shares of the Company’s commons stock due to any of the foregoing events or for other reasons, then this may have an extremely dilutive effect on the shareholders of the Company. Such dilution would likely result in a significant drop in the per share price of the Company’s common stock. The potential dilutive nature of this note presents a very high degree of risk to the Company and its shareholders
XML 31 R8.htm IDEA: XBRL DOCUMENT v2.4.0.8
Consolidated Statements of Cash Flows (USD $)
 12 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Cash flows from operating activities:    
Net loss $ (4,342,964) $ (3,612,351)
Adjustments to reconcile net loss to net cash used in operating activities:    
Loss on settlement of accounts payable 707,650 357,292
Loss on note payable default 0 100,000
Depreciation and amortization 14,981 14,994
Stock-based compensation 1,391,979 1,799,461
Stock issued for loan extension 30,300 100,000
Change in fair value of derivative 1,135,677 400,488
In-kind contribution of interest 1,159 33,055
Amortization of loan discount 3,977 0
Changes in operating assets and liabilities:    
Decrease (increase) in accounts receivables 27,173 (38,314)
Decrease (increase) in inventory (5,000) 117,800
Decrease (increase) in prepaid expenses and other assets (9,446) 28,678
Increase in accounts payable 429,808 169,216
Increase in accrued expenses 83,669 13,600
Net cash used in operating activities (531,037) (721,242)
Cash flows from investing activities: 0 0
Cash flows from financing activities:    
Common stock sold for cash 140,000 446,500
Proceeds from payment of subscription receivable 0 8,000
Loans from officers 181,718 164,779
Repayment of officers loans (83,600) (49,478)
Proceeds from convertible notes 225,000 115,000
Proceeds from other notes payable 75,000 79,000
Repayments of other notes payable 0 (35,000)
Repayments of notes payable-related party (10,000) 0
Net cash provided by financing activities 528,118 728,801
Net (decrease) increase in cash (2,919) 7,559
Cash - beginning of period 7,559 0
Cash - end of period 4,640 7,559
Supplemental Cash Flow Information:    
Cash paid for interest 70,130 77,314
Cash paid for income taxes 0 0
Non cash Financing and Investing:    
Note issued in settlement of notes and accounts payable 709,146 436,639
Shares issued to satisfy debt 1,646,832 1,346,792
Shares issued to satisfy debt-related party $ 162,500 $ 254,700
XML 32 R32.htm IDEA: XBRL DOCUMENT v2.4.0.8
FAIR VALUE MEASUREMENTS (Details 1) (USD $)
 12 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Fair Value Measurements [Line Items]    
Beginning balance $ 18,727 $ 28,833
Purchases, issuances, and settlements 243,147 0
Day one loss on value of hybrid instrument 729,093 0
Total gain included in earnings (667,795) [1] (10,106) [1]
Ending balance $ 323,172 $ 18,727
[1] The gain or loss related to the revaluation of our warrant liability is included in “Change in fair value of derivatives” in the accompanying consolidated statement of operations.
XML 33 R40.htm IDEA: XBRL DOCUMENT v2.4.0.8
OTHER DEBT (Details Textual) (USD $)
 12 Months Ended 12 Months Ended 1 Months Ended 12 Months Ended 3 Months Ended 12 Months Ended 1 Months Ended 12 Months Ended 0 Months Ended 1 Months Ended 12 Months Ended 12 Months Ended 0 Months Ended 1 Months Ended 12 Months Ended 12 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended 1 Months Ended 12 Months Ended 12 Months Ended 0 Months Ended 1 Months Ended 0 Months Ended 1 Months Ended 12 Months Ended 12 Months Ended 12 Months Ended 12 Months Ended 3 Months Ended 12 Months Ended 3 Months Ended 12 Months Ended 9 Months Ended 12 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Dec. 31, 2013
Convertible Note One [Member]
Dec. 31, 2012
Convertible Note One [Member]
Dec. 31, 2013
Convertible Note Two [Member]
Dec. 31, 2012
Convertible Note Two [Member]
Dec. 31, 2013
Convertible Note One Amended [Member]
Dec. 31, 2013
Convertible Note Two Amended [Member]
Dec. 31, 2013
Five Year Warrant [Member]
Oct. 31, 2012
Restricted Stock [Member]
Dec. 31, 2013
October 26, 2012 [Member]
Mar. 31, 2012
Liquid Package Resources Inc [Member]
Dec. 31, 2013
Liquid Package Resources Inc [Member]
Dec. 31, 2011
Liquid Package Resources Inc [Member]
Aug. 02, 2011
Liquid Package Resources Inc [Member]
Jul. 31, 2013
Michael Mcdonald Trust [Member]
Apr. 30, 2013
Michael Mcdonald Trust [Member]
Dec. 31, 2013
Michael Mcdonald Trust [Member]
Jan. 17, 2014
Michael Mcdonald Trust [Member]
Subsequent Event [Member]
Oct. 31, 2012
Southridge Partners II LLP [Member]
Dec. 31, 2013
Southridge Partners II LLP [Member]
Dec. 31, 2012
Southridge Partners II LLP [Member]
Dec. 31, 2013
University Centre West Ltd [Member]
Dec. 31, 2012
University Centre West Ltd [Member]
Dec. 31, 2013
Immunoclin, Ltd [Member]
Dec. 20, 2012
Immunoclin, Ltd [Member]
Sep. 12, 2013
Coventry Enterprises LLC [Member]
Dec. 31, 2013
Coventry Enterprises LLC [Member]
Sep. 30, 2013
Coventry Enterprises LLC [Member]
Jun. 30, 2013
Coventry Enterprises LLC [Member]
Apr. 30, 2013
Coventry Enterprises LLC [Member]
Mar. 31, 2013
Coventry Enterprises LLC [Member]
Dec. 31, 2013
Coventry Enterprises LLC [Member]
Dec. 31, 2012
Coventry Enterprises LLC [Member]
Sep. 03, 2013
Coventry Enterprises LLC [Member]
Mar. 22, 2013
Coventry Enterprises LLC [Member]
Dec. 31, 2013
Coventry Enterprises LLC [Member]
Convertible Note One [Member]
Sep. 30, 2013
Coventry Enterprises LLC [Member]
Convertible Note One [Member]
Dec. 31, 2013
Coventry Enterprises LLC [Member]
Five Year Warrant [Member]
Sep. 03, 2013
Coventry Enterprises LLC [Member]
Five Year Warrant [Member]
Jun. 30, 2013
Coventry Enterprises LLC [Member]
Restricted Stock [Member]
Mar. 31, 2013
Coventry Enterprises LLC [Member]
Restricted Stock [Member]
Jun. 30, 2013
Coventry Enterprises LLC [Member]
Restricted Stock [Member]
Dec. 31, 2013
Coventry Enterprises LLC [Member]
Restricted Stock [Member]
Dec. 31, 2012
Coventry Enterprises LLC [Member]
Restricted Stock [Member]
Jun. 30, 2013
Coventry Enterprises LLC [Member]
Restricted Stock One [Member]
Mar. 31, 2013
Coventry Enterprises LLC [Member]
Restricted Stock Two [Member]
Jul. 31, 2013
Christopher Castaldo [Member]
Dec. 31, 2013
Christopher Castaldo [Member]
Jul. 10, 2013
Christopher Castaldo [Member]
Dec. 31, 2013
Christopher Castaldo [Member]
Convertible Note One [Member]
Dec. 31, 2013
Christopher Castaldo [Member]
Convertible Note Two [Member]
Nov. 25, 2013
Note Payable One [Member]
May 31, 2011
Note Payable One [Member]
Sep. 16, 2013
Note Payable Two [Member]
May 31, 2011
Note Payable Two [Member]
Dec. 31, 2013
Note Payable Two [Member]
Dec. 31, 2012
Note Payable Two [Member]
Dec. 31, 2011
Note Payable Two [Member]
Oct. 31, 2011
Note Payable Two [Member]
Sep. 30, 2011
Note Payable Two [Member]
Dec. 31, 2011
Convertible Note Payable Dated October 27 2011 [Member]
Oct. 27, 2011
Convertible Note Payable Dated October 27 2011 [Member]
Dec. 31, 2011
Convertible Note Payable Dated December 5, 2011 [Member]
Dec. 31, 2013
Convertible Note Payable Dated December 5, 2011 [Member]
October 31, 2012 [Member]
Restricted Stock [Member]
Dec. 31, 2013
Convertible Note Payable Dated February 3, 2012 [Member]
Dec. 31, 2012
Convertible Note Payable Dated February 3, 2012 [Member]
Feb. 03, 2012
Convertible Note Payable Dated February 3, 2012 [Member]
Dec. 31, 2012
Convertible Note Payable Dated February 3, 2012 [Member]
TCN International [Member]
Dec. 31, 2013
Convertible Note Payable Dated March 16, 2012 [Member]
Mar. 16, 2012
Convertible Note Payable Dated March 16, 2012 [Member]
Mar. 31, 2013
Convertible Notes Payable [Member]
Dec. 31, 2013
Convertible Notes Payable [Member]
Mar. 31, 2013
Convertible Notes Payable [Member]
Five Year Warrant [Member]
Sep. 30, 2013
Note Payable Three [Member]
Dec. 31, 2013
Note Payable Three [Member]
Aug. 31, 2013
Note Payable Three [Member]
Dec. 31, 2013
Note Payable Three [Member]
Coventry Enterprises LLC [Member]
Oct. 07, 2013
Convertible Note Payable Dated October7 2013 [Member]
Sep. 30, 2013
Director [Member]
Sep. 30, 2012
Director [Member]
Dec. 31, 2013
Director [Member]
Dec. 31, 2012
Director [Member]
Sep. 30, 2010
Director [Member]
Debt Instrument [Line Items]                                                                                                                                                                        
Note payable - Related Party $ 180,000 [1] $ 190,000 [1]                                                                                                                                                                   $ 200,000
Repayments of notes payable 0 35,000                                                                                                                                                           10,000 10,000      
Debt Instrument, Interest Rate Terms                                                                                                           interest calculated at 10% for the first month plus 12% after 30 days from funding   interest calculated at 10% for the first month plus 12% after 30 days from funding     interest calculated at 20% and 12%, each, respectively                                             interest calculated at 10% for the first month plus 12% after 30 days from funding    
Interest Payable, Current                                   9,000                                                                     11,956   11,120   6,664 6,664                                               121,137 86,387  
Notes Payable, Current 412,182 [2] 593,483 [2]                                                       57,800                                               25,000 25,000 25,000       500,000 250,000                           150,000   150,000              
Debt Instrument, Maturity Date             May 03, 2014 Aug. 03, 2014                                                                                                                     Feb. 03, 2012     Nov. 16, 2012                            
Debt Instrument, Convertible, Terms of Conversion Feature                                                     Coventry has the right to convert the note, until is no longer outstanding into shares of Common Stock at a price lesser of $.02, or (ii) fifty-five percent (55%) of the average of the three lowest VWAP prices of the Companys Common Stock for the twenty trading days preceding the conversion date.   Coventry has the right to convert the note, until is no longer outstanding into shares of Common Stock at a price lesser of $.018, or (ii) fifty-five percent (55%) of the average of the three lowest VWAP prices of the Companys Common Stock for the twenty trading days preceding the conversion date Coventry was entitled to convert all or any amount of the these notes into shares of the Company's common stock (the "Common Stock") at a conversion price ("Conversion Price") for each share of Common Stock equal to 55% of the average of the daily volume weighted average prices of the Common Stock for the 3 trading days with the lowest volume weighted average prices during 20 trading days Coventry was entitled to convert all or any amount of the this note into shares of the Company's common stock (the "Common Stock") at a conversion price ("Conversion Price") for each share of Common Stock equal to 55% of the average of the daily volume weighted average prices of the Common Stock for the 3 trading days with the lowest volume weighted average prices during the 15 trading days immediately preceding the Conversion Date Coventry has the right to convert the note, until is no longer outstanding into shares of Common Stock at a price which is lesser of $.0075, or (ii) fifty-five percent (55%) of the average of the three lowest VWAP prices of the Companys Common Stock for the twenty trading days preceding the conversion date   Coventry was entitled to convert all or any amount of the this note into shares of the Company's common stock (the "Common Stock") at a conversion price ("Conversion Price") for each share of Common Stock equal to 55% of the average of the daily volume weighted average prices of the Common Stock for the 3 trading days with the lowest volume weighted average prices during the 20 trading days immediately preceding the Conversion Date.                           The notes holder has the right to convert the notes into shares of Common Stock at a price of $0.005                   On October 19, 2012 the parties amended the notes to extend the due date to May 1, 2013 and include a conversion feature that would allow the holders to convert some or all of their outstanding notes into restricted Company stock at a 15% discount to the average closing market price of the Company's stock traded over the previous 10 days       The convertible note payable is convertible, at the holders option, into the Companys common shares at a variable conversion price which is 58% multiplied by the average of the lowest three (3) trading prices for the Common Stock during the ten (10) Trading Day period ending one Trading Day prior to the date the Conversion Notice is sent by the Holder to the Borrower       . Redwood Management, LLC has the right to convert the note, until it is no longer outstanding, into shares of Common Stock at a price of Fifty Percent (50%) of the lowest closing price, determined on the then current trading market for the Companys common stock, during the 15 trading days prior to conversion (the Set Price).       Southridge Partners II, LLC was entitled after nine months to convert all or a portion of the principal and interest accrued into shares of common stock at a conversion price of each share equal to the Market Price multiplied times 70%. (the conversion price). The Market Price is equal to the average of the two lowest bids closing prices for the five trading days ending before the conversion date         conversion price for each share of Common Stock equal to 55% of the average of the daily volume weighted average prices of the Common Stock for the 3 trading days with the lowest volume weighted average prices during the 15 to 20 trading days immediately preceding the Conversion Date. conversion price for each share of Common Stock equal to 55% of the average of the daily volume weighted average prices of the Common Stock for the 3 trading days with the lowest volume weighted average prices during the 15 to 20 trading days immediately preceding the Conversion Date                
Stock Issued During Period, Shares, Restricted Stock Award, Gross             500,000 1,250,000                                                                                 60,000   30,000 30,000         4,000,000                                                      
Debt Instrument, Interest Rate During Period                                 8.00%                         8.00%                                                                                                            
Settlement Agreement Initiation Date                           Aug. 02, 2011                                                                                                                                            
Debt Instrument, Interest Rate, Stated Percentage                                         10.00%         8.00% 10.00%             8.00% 10.00% 10.00%                           8.00%                         8.00% 8.00%       12.00%     8.00%         8.00%                
Assigned Debt Consideration Amount                                 88,500                         60,000                                                                                                            
Settlement Agreement Consideration1                           175,000 350,000                                                                                                                                          
Settlement Agreement Consideration Monthly Installment Payment                           50,000                                                                                                                                            
Settlement Agreement Penalty Amount                           25,000                                                                                                                                            
Settlement Agreement Damages Paid Value                       25,000                                                                                                                                                
Stock Issued During Period, Shares, New Issues                         5,714,326     1,000,000                                                                                                                                        
Settlement Agreement Settlement In Cash Total                         450,000                                                                                                                                              
Settlement Agreement Settlement In Cash Initial Amount                         350,000                                                                                                                                              
Settlement Agreement Settlement In Cash Penalty Amount                         100,000                                                                                                                                              
Settlement Agreement Penalty Expenses                       100,000                                                                                                                                                
Proceeds from notes payable 75,000 79,000                           75,000                                                                                                                                        
Debt Conversion, Converted Instrument, Shares Issued                     5,919,495                                                           31,416,845 15,119,481 31,416,845   8,672,090 27,272,727 8,810,572           4,360,000   8,472,750   34,254,004               20,000,000       7,500,000           64,052,862 64,052,862                
Debenture Face Amount 564,376 902,369                                       483,482                                                                                 53,000 37,500       40,000     75,000               35,000          
Derivative, Loss on Derivative                                                       309,055         4,885       957,567                   24,931   83,157                                               81,667                      
Assignment Debt Consideration Amount Total                                       281,772                         337,182                                                                       52,500                              
Extinguishment of Debt, Amount                                                                                                                                         52,500                              
Accounts Payable                                           63,490                                                                                                                            
Loss On Loan Modification                   100,000                                                                                                                                                    
Debt Conversion, Converted Instrument, Amount                                                                                 88,500 80,000 186,646     167,495 188,747           25,000   25,000   317,391                                   475,519 475,519                
Gains (Losses) On Extinguishment Of Debt (707,651) (457,292)                                             65,039               2,200                     65,039                 28,444   90,971                                                          
Accounts Payable, Interest-bearing, Interest Rate                               2.00%                                                                                                                                        
Amortization of Debt Discount (Premium) 3,977 0                               3,977                                                                                                                                    
Debt Instrument, Unamortized Discount                               3,977                                                                                                                                        
Additional Shares Issuable Upon Default                                   1,000,000                                                                                                                                    
Convertible Debt 767,056 588,091 75,000 250,000 150,000 250,000                                 55,410 55,410     70,000             65,040 100,000 20,000                                                                                                
Debt Conversion, Original Debt, Amount                                                                                                                 125,000                                   150,000                  
Stock Issued During Period, Value, Restricted Stock Award, Gross                                     1,000,000                                                                           20,800                                                      
Warrants Outstanding Fair Value                                                       17,895         17,895     21,226 101,140 262,230 137,681 445,638                                                                                        
Warrants To Purchase Common Stock Share                 20,000,000                                     15,000,000         2,600,000                                                                             2,600,000   2,600,000                    
Warrants To Purchase Common Stock Per Share Value                 $ 0.025                                     $ 0.025         $ 0.01                                                                             $ 0.01                        
Derivative, Gain (Loss) On Derivative, Net (1,135,677) (400,488)                                                             185,971                               90,684                                                                      
Convertible Notes Payable Fair Value Disclosure                                                                                                                                                           130,303            
Convertible Debt, Fair Value Disclosures 767,056 [3] 588,091 [3] 90,260 290,289 189,781 297,802 9,500 13,750                                                                                                                                 80,057                      
Debt Instrument Convertible Conversion Price Including Interest Accrued                                         $ 0.001                                                                                                                              
Debt Instrument, Convertible, Conversion Price                                         $ 0.015                                                             $ 0.005                                                                
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger                                         50.00%                                                                                                                              
Debt Instrument, Convertible, Threshold Trading Days                                         30                                                                                                                              
Equity, Fair Value Disclosure, Total                                     $ 9,900                                                                                                                                  
[1] During the third quarter of 2010 we borrowed $200,000 from one of our directors. We repaid $10,000 each (total $20,000) during the third quarter of 2012 and 2013. Under the terms of the loan agreement, this loan was expected to be repaid in nine months to a year from the date of the loan along with interest calculated at 10% for the first month plus 12% after 30 days from funding. We are in default regarding this loan. At December 31, 2013 and 2012, we owed this director accrued interest of $121,137 and $86,387, respectively.
[2] At December 31, 2013 and 2012, the balance of $412,182 and $593,483 , respectively, consisted of the following loans: In May 2011, the Company received a loan for $25,000 from a non-related party. This loan was expected to be repaid no later than December 31, 2011, along with interest calculated at 10% for the first month plus 12% after 30 days from funding. This loan is guaranteed by an officer of the Company. On November 25, 2013, the non-related party accepted a total of 4,360,000 shares of the Company’s restricted common stock as a repayment to discharge $25,000 of his outstanding loan and accrued interest of $11,956 (See note 6). The Company recorded a loss of $28,444 on the settlement date. In May 2011, the Company received another loan for $25,000 from a non-related party. This loan was expected to be repaid no later than December 31, 2011, along with interest calculated at 10% for the first month plus 12% after 30 days from funding. This loan is guaranteed by an officer of the Company. On September 16, 2013, the non-related party accepted a total of 8,472,750 shares of the Company’s restricted common stock as a repayment to discharge $25,000 of his outstanding loan and accrued interest of $11,120 (See note 6). The Company recorded a loss of $90,971 on the settlement date. In July 2013, the Company issued a promissory note to the Michael McDonald Trust in the amount of $75,000 bearing interest at a rate of 2% per month. The note is due in six months from the execution and funding of the note. In connection with the issuance of this promissory note, the Company issued 1,000,000 shares of the Company's common stocks (See note 6). The Company has recorded a debt discount in the amount of $3,977 to reflect the value of the common stocks as a reduction to the carrying amount of the convertible debt and a corresponding increase to common stocks and additional paid-in capital. The total discount of $3,977 was fully amortized over the term of the debt during the year ended December 31, 2013. In the event of default, the Company would issue an additional 1,000,000 share of the Company’s common stocks on the date that is fifteen days after the maturity date (See Note 6). We are in default regarding this loan. The additional 1,000,000 shares were issued in January 2014 with a fair value at $9,900 (See Note 10). At December 31, 2013, we owed Michael McDonald accrued interest of $9,000. At December 31, 2012, the total amount of the Company’s debt assigned to Southridge was $483,482. In connection with the debt sales to Southridge, the Company recorded a loss on settlement of accounts payable for $63,490 in the statement of operations at December 31, 2012. During the first quarter of 2013, the suit was voluntarily dismissed involving debt held by Southridge for $483,482. The debt has reverted back to the original holders. In April, 2013, $88,500 of the debt held by Michael McDonald Trust was assigned to Coventry Enterprises, LLC (“Coventry”) in the form of a Convertible Redeemable Note bearing interest of 8% annum. Coventry was entitled to convert all or any amount of the this note into shares of the Company's common stock (the "Common Stock") at a conversion price ("Conversion Price") for each share of Common Stock equal to 55% of the average of the daily volume weighted average prices of the Common Stock for the 3 trading days with the lowest volume weighted average prices during the 15 trading days immediately preceding the Conversion Date. Following the agreements with Coventry, Coventry made the conversions for a total of 31,416,845 shares of the company’s restricted stock during the second quarter of 2013 satisfying the notes in full at the fair value of $186,646. In June, 2013, $57,800 of the debt was assigned to Coventry for a consideration of $60,000 from Baker Donelson Bearman Caldwell & Berkowitz, PC. in the form of Convertible Redeemable Notes bearing interest of 8% annum. The Company recorded a loss of $2,200 on the settlement during the year ended December 31, 2013. Coventry was entitled to convert all or any amount of the these notes into shares of the Company's common stock (the "Common Stock") at a conversion price ("Conversion Price") for each share of Common Stock equal to 55% of the average of the daily volume weighted average prices of the Common Stock for the 3 trading days with the lowest volume weighted average prices during 20 trading days . Following the agreements, Coventry made the conversions for a total of 27,272,727 shares of the company’s restricted stock satisfying the notes in full at the fair value of $167,495. As a result of the debt assignments and conversions with Coventry, the remaining balance of the debt at December 31, 2013 is $337,182 which consisted of the following loans: On August 2, 2011 under a settlement agreement with Liquid Packaging Resources, Inc. (“LPR”), the Company agreed to pay LPR a total of $350,000 in monthly installments of $50,000 beginning August 15, 2011 and ending on February 15, 2012. This settlement amount was recorded as general and administrative expenses on the date of the settlement. We did not make the December 2011 or January 2012 payments and on January 26, 2012, we signed the first amendment to the settlement agreement where under we agreed to pay $175,000 which was the balance outstanding at December 31, 2011(this includes a $25,000 penalty for non-payment). The Company repaid $25,000 during the three months ended March 31, 2012. The Company did not make all of the payments under such amendment and as a result pursuant to the original settlement agreement, LPR had the right to sell 5,714,326 shares of the Company’s free trading stock held in escrow by their attorney and receive cash settlements for a total amount of $450,000 (the initial $350,000 plus total default penalties of $100,000). The $100,000 default was expensed during 2012. LPR sold the note to Southridge Partners, LLP (“Southridge”) for consideration of $281,772 in October 2012. The debt has reverted back to the Company (See note 9). As of December 31, 2013 and 2012, the Company owed University Centre West Ltd. approximately $55,410, which was assigned and sold to Southridge and subsequently reverted back to the Company .
[3] At December 31, 2013 and 2012, the balance of $767,056 and $588,091 consisted of the following convertible loans: In September and October 2011, the Company borrowed $250,000 each (aggregating $500,000) from two non-related parties. The principal of these loans were to be repaid with a balloon payment on or before October 1, 2012. On October 19, 2012 the parties amended the notes to extend the due date to May 1, 2013 and include a conversion feature that would allow the holders to convert some or all of their outstanding notes into restricted Company stock at a 15% discount to the average closing market price of the Company's stock traded over the previous 10 days. Interest on these loans is payable monthly beginning in November 2011 with interest calculated at 20% and 12%, each, respectively. At December 31, 2013 and 2012, the accrued interest payable was $6,664. During year ended December 31, 2013, one of the Note holders made conversions of a total of 34,254,004 shares of the company’s restricted stock satisfying the notes in the amount of $125,000 with a fair value of $317,391 on the date of conversion. During August and September, 2013, $150,000 of the debts were assigned to three non-related parties in the form of a Convertible Redeemable Note bearing interest of 8% annum with a conversion price for each share of Common Stock equal to 55% of the average of the daily volume weighted average prices of the Common Stock for the 3 trading days with the lowest volume weighted average prices during the 15 to 20 trading days immediately preceding the Conversion Date. Following the assignments, the conversions for a total of 64,052,862 shares of the company’s restricted stock were made in satisfying the notes of $150,000 at the fair value of $475,519 (See note 6). At December 31, 2013, the remaining balance of these two convertible notes payable of $75,000 and $150,000 were recorded at a fair value of $90,260 and $189,781, respectively. At December 31, 2012, these two convertible note payable of $250,000 each were recorded at fair value of $290,289 and $297,802, respectively. On April 30, 2013, the parties amended the notes to further extend the maturity date to November 3, 2013. The Company issued a total of 4,000,000 restricted shares to the note holders in connection with the amendment at a fair value of $20,800. On October 30, 2013 and November 1, 2013, the parties amended the note of $75,000 and $150,000 to further extend the maturity dates to May 3, 2014 and August 3, 2014, respectively. The Company issued a total of 500,000 and 1,250,000 restricted shares to the note holders in connection with the amendment at a fair value of $9,500 and $13,750 (See note 6), respectively. On March 22, 2013, the Company issued a Convertible Debenture in the amount of $20,000 to Coventry Enterprises, LLC (“Coventry”). The note carries interest at 10% and is due on March 22, 2014, unless previously converted into shares of restricted common stock. Coventry has the right to convert the note, until is no longer outstanding into shares of Common Stock at a price which is lesser of $.0075, or (ii) fifty-five percent (55%) of the average of the three lowest VWAP prices of the Company’s Common Stock for the twenty trading days preceding the conversion date. In connection with the issuance of this convertible note payable, the Company encountered a day-one derivative loss of $24,931. Coventry made the conversions into a total of 8,810,572 shares of the company’s restricted stock satisfying the notes in full with a fair value of $188,747on September 4, 2013(See note 7). In connection with the issuances of the Note, the Company also granted five-year warrants to purchase an aggregate of 2,600,000 shares of the Company’s common stock at an exercise price of $0.01 per share. The Company classified embedded conversion features in these warrants as a derivative liability. The warrants were valued at their fair value of $21,226 and $17,895, respectively using the Black-Scholes method at the commitment and re-measurement dates of March 22, 2013 and December 31, 2013, respectively. On July 10, 2013 and October 10, 2013, the Company issued two Convertible Debentures in the amount of $30,000 each (total $60,000) to Christopher Castaldo in connection with the agreements for investor relation services (See Note 6). The notes carry interest at 8% and are due on January 10, 2014 and April 10, 2014, respectively. The notes’ holder has the right to convert the notes into shares of Common Stock at a price of $0.005. In connection with the issuance of this convertible notes payable, the Company encountered a day-one derivative loss of $83,157. At December 31, 2013, these convertible notes payable, at fair value, was recorded at $90,684. On September 3, 2013, the Company issued a Convertible Debenture in the amount of $100,000 to Coventry Enterprises, LLC (“Coventry”). The note carries interest at 10% and is due on September 3, 2014, unless previously converted into shares of restricted common stock. Coventry has the right to convert the note, until is no longer outstanding into shares of Common Stock at a price lesser of $.018, or (ii) fifty-five percent (55%) of the average of the three lowest VWAP prices of the Company’s Common Stock for the twenty trading days preceding the conversion date. In connection with the issuance of this convertible note payable, the Company encountered a day-one derivative loss of $957,567. At December 31, 2013, this convertible note payable, at fair value, was recorded at $185,971. In connection with the issuances of the Note, the Company also granted five-year warrants to purchase an aggregate of 20,000,000 shares of the Company’s common stock at an exercise price of $0.025 per share. The Company classified embedded conversion features in these warrants as a derivative liability. The warrants were valued at their fair value of $445,638 and $137,681, respectively using the Black-Scholes method at the commitment and re-measurement dates of September 3, 2013 and December 31, 2013, respectively. On September 12, 2013, the Company issued a Convertible Debenture in the amount of $70,000 to Coventry Enterprises, LLC (“Coventry”). The note carries interest at 10% and is due on September 12, 2014, unless previously converted into shares of restricted common stock. Coventry has the right to convert the note, until is no longer outstanding into shares of Common Stock at a price lesser of $.02, or (ii) fifty-five percent (55%) of the average of the three lowest VWAP prices of the Company’s Common Stock for the twenty trading days preceding the conversion date. In connection with the issuance of this convertible note payable, the Company encountered a day-one derivative loss of $309,055. At December 31, 2013, this convertible note payable, at fair value, was recorded at $130,303. In connection with the issuances of the Note, the Company also granted five-year warrants to purchase an aggregate of 15,000,000 shares of the Company’s common stock at an exercise price of $0.025 per share. The Company classified embedded conversion features in these warrants as a derivative liability. The warrants were valued at their fair value of $262,230 and $101,140, respectively using the Black-Scholes method at the commitment and re-measurement dates of September 12, 2013 and December 31, 2013, respectively. On October 7, 2013, the Company signed a secured convertible Promissory Note in the amount of $35,000 in favor of Southridge Partners II, LLC. The note was due on demand and carries interest at 10% annum. Southridge Partners II, LLC was entitled to convert the principal into shares of common stock at the lesser of $0.015 or a 50% discount from the lowest closing bid price in the 30 trading days prior to the day that the conversion is requested; and interest accrued was entitled to convert into shares of common stock at $0.001. In the evaluation of these financing arrangements, the Company concluded that these conversion features did not meet the conditions set forth in current accounting standards for equity classification. Since equity classification is not available for the conversion feature, it requires bifurcation and liability classification, at fair value. The Company also concluded that the Default Put required bifurcation because, while puts on debt instruments are generally considered clearly and closely related to the host, the Default Put is indexed to certain events that are not associated with the convertible note payable. In connection with the issuance of this convertible note payable, the Company encountered a day-one derivative loss of $81,667. At December 31, 2013, this convertible note payable, at fair value, was recorded at $80,057. On October 27, 2011 the Company entered into a convertible note payable with a corporation. The convertible note payable, with a face value of $53,000, bears interest at 8.0% per annum and was due on July 31, 2012. On December 5, 2011 the Company entered into a convertible note payable with a corporation which had a face value of $37,500, a coupon rate of 8.0% per annum and maturity date of September 5, 2012. The convertible note payable is convertible, at the holder’s option, into the Company’s common shares at a variable conversion price which is 58% multiplied by the average of the lowest three (3) trading prices for the Common Stock during the ten (10) Trading Day period ending one Trading Day prior to the date the Conversion Notice is sent by the Holder to the Borrower. The conversion feature is subject to full-ratchet, anti-dilution protection if the Company sells shares or share-indexed financing instruments at less than the conversion price. The holder has the option to redeem the convertible note payable for cash in the event of defaults or certain other contingent events (the “Default Put”). During October 2012, both of these notes were acquired by a third party from Asher Enterprises for an aggregate amount of $100,000, and then converted into 20,000,000 restricted common shares (See note 6). On February 3, 2012, the Company issued a Convertible Debenture in the amount of $40,000 to Redwood Management, LLC. The note carries interest at 12% and is due on February 13, 2013, unless converted into shares of restricted common stock. Redwood Management, LLC has the right to convert the note, until it is no longer outstanding, into shares of Common Stock at a price of Fifty Percent (50%) of the lowest closing price, determined on the then current trading market for the Company’s common stock, during the 15 trading days prior to conversion (the “Set Price”). On September 12, 2012, TCN International (TCN) completed the purchase and transfer of this note including penalties and unpaid interest, for the sum of $52,500. Redwood Management, LLC has acknowledged the full payment of the Note, in favor of Nutra Pharma Corporation and releases Nutra Pharma Corporation from all obligations under the Note. Upon the request of TCN, the Board of Directors of the Company approved the conversion of these notes into Restricted Common Stock of the Company,providing 7,500,000 shares of Nutra Pharma common stock to relinquish the total debt of $52,500 (See note 6). On March 16, 2012 the Company signed a secured convertible Promissory Note in the amount of $75,000 in favor of Southridge Partners II, LLC. The note was due November 16, 2012 and carries interest at 8% annum. Southridge Partners II, LLC was entitled after nine months to convert all or a portion of the principal and interest accrued into shares of common stock at a conversion price of each share equal to the Market Price multiplied times 70%. (the “conversion price”). The Market Price is equal to the average of the two lowest bids closing prices for the five trading days ending before the conversion date. In the evaluation of these financing arrangements, the Company concluded that these conversion features did not meet the conditions set forth in current accounting standards for equity classification. Since equity classification is not available for the conversion feature, it requires bifurcation and liability classification, at fair value. The Company also concluded that the Default Put required bifurcation because, while puts on debt instruments are generally considered clearly and closely related to the host, the Default Put is indexed to certain events that are not associated with the convertible note payable. On October 26, 2012, Southridge converted the note into 5,919,495 shares of the Company's restricted common stock (See note 6). In the evaluation of these financing arrangements, the Company concluded that these conversion features did not meet the conditions set forth in current accounting standards for equity classification. Since equity classification is not available for the conversion feature, it requires bifurcation and liability classification, at fair value. The Company also concluded that the Default Put required bifurcation because, while puts on debt instruments are generally considered clearly and closely related to the host, the Default Put is indexed to certain events that are not associated with the convertible note payable. The Company elected to account for these hybrid contracts under the guidance of ASC 815-15-25-4. The fair value has been defined as the common stock equivalent value, enhanced by the fair value of the default put plus the present value of the coupon. The holder of this convertible note has substantial rights and protections regarding dilution if certain events, including a default were to occur. There are a number of events that could trigger a default, including but not limited to failure to pay principal or interest, failure to issue shares under the conversion feature, breach of covenants, breach of representations and warranties, appointment of a receiver or trustee, judgments, bankruptcy, delisting of common stock, failure to comply with the exchange act, liquidation, cessation of operations, failure to maintain assets, material financial statement restatement, reverse split of borrowers stock, etc. In the event of these events the lender may be entitled to receive significant amounts of additional stock above the amounts for conversion. Furthermore, there are additional events that could cause the lender to be due additional shares of common stock above and beyond the shares due from a conversion. Some of these events include, but are not limited to a merger or consolidation of the Company, dividend distribution or spin off, dilutive issuances of the Company’s stock, etc. If the lender receives additional shares of the Company’s commons stock due to any of the foregoing events or for other reasons, then this may have an extremely dilutive effect on the shareholders of the Company. Such dilution would likely result in a significant drop in the per share price of the Company’s common stock. The potential dilutive nature of this note presents a very high degree of risk to the Company and its shareholders
XML 34 R2.htm IDEA: XBRL DOCUMENT v2.4.0.8
Consolidated Balance Sheets (USD $)
Dec. 31, 2013
Dec. 31, 2012
Current assets:    
Cash $ 4,640 $ 7,559
Accounts receivable 11,141 38,314
Inventory 5,000 0
Prepaid expenses and other current assets 68,091 200,868
Total current assets 88,872 246,741
Property and equipment, net 24,534 39,515
Other assets 15,955 16,621
Total assets 129,361 302,877
Current liabilities:    
Accounts payable 1,019,130 800,860
Accrued expenses 957,682 964,673
Due to officers 689,588 723,386
Derivative warrant liability 323,172 18,727
Other debt 1,359,238 1,371,574
Total current liabilities 4,348,810 3,879,220
Commitments and Contingencies (See Note 9)      
Stockholders' deficit:    
Common stock, $0.001 par value, 2,000,000,000 shares authorized; 1,004,313,019 and 561,773,778 shares issued and outstanding at December 31, 2013 and 2012 1,003,062 561,774
Additional paid-in capital 36,764,309 33,505,739
Accumulated deficit (41,986,820) (37,643,856)
Total stockholders' deficit (4,219,449) (3,576,343)
Total liabilities and stockholders' deficit $ 129,361 $ 302,877
XML 35 R45.htm IDEA: XBRL DOCUMENT v2.4.0.8
STOCK OPTIONS AND WARRANTS (Details Textual) (USD $)
 3 Months Ended 12 Months Ended 2 Months Ended 12 Months Ended 6 Months Ended
Dec. 31, 2013
Mar. 31, 2013
Convertible Notes Payable [Member]
Dec. 31, 2013
Vendor [Member]
Sep. 16, 2013
Vendor [Member]
Sep. 30, 2013
Coventry [Member]
Sep. 12, 2013
Coventry [Member]
Sep. 03, 2013
Coventry [Member]
Dec. 31, 2013
Coventry [Member]
Warrant One [Member]
Dec. 31, 2013
Coventry [Member]
Warrant Two [Member]
Nov. 30, 2013
Private Placement [Member]
Dec. 31, 2013
Private Placement [Member]
Jun. 30, 2013
Chief Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                        
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value $ 0                      
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value $ 0                      
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price (in dollars per share) $ 0.0075                      
Warrants To Purchase Common Stock Share   2,600,000               1,000,000 10,000,000 25,000,000
Warrants To Purchase Common Stock Per Share Value (in dollars per share)   $ 0.01               $ 0.10 $ 0.03 $ 0.10
Debt Instrument, Maturity Date               Sep. 03, 2018 Sep. 12, 2018      
Warrants Expiry Period   Mar. 22, 2018                   Dec. 31, 2014
Warrants Issued For Common Sock     25,000,000 25,000,000   15,000,000 20,000,000          
Class Of Warrant Or Right, Exercise Price Of Warrants Or Rights     0.030 0.030 0.025              
XML 36 R6.htm IDEA: XBRL DOCUMENT v2.4.0.8
Consolidated Statements of Changes in Stockholders' Deficit (USD $)
Total
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Balance at Dec. 31, 2011 $ (3,911,445) $ 326,337 $ 29,793,723 $ (34,031,505)
Balance (in shares) at Dec. 31, 2011   326,337,959    
Issuance of common stock in exchange for services to consultants 970,681 63,300 907,381  
Issuance of common stock in exchange for services to consultants (in shares)   63,300,000    
Issuance of common stock in exchange for services to directors and employees 828,780 42,595 786,185  
Issuance of common stock in exchange for services to directors and employees (in shares)   42,595,000    
Common stocks issued in private placement 434,500 43,450 391,050  
Common stocks issued in private placement (in shares)   43,450,000    
Common stock issued in exchange for related party debt 254,700 17,000 237,700  
Common stock issued in exchange for related party debt (in shares)   17,000,000    
Common stock issued for modification of debt 100,000 4,000 96,000  
Common stock issued for modification of debt (in shares)   4,000,000    
Common stock issued for conversion of debt 1,346,792 63,892 1,282,900  
Common stock issued for conversion of debt (in shares)   63,890,819    
Common stock issuable for private placement 12,000 1,200 10,800  
Common stock issuable for private placement (in shares) 1,200,000 1,200,000    
Net loss (3,612,351)     (3,612,351)
Balance at Dec. 31, 2012 (3,576,343) 561,774 33,505,739 (37,643,856)
Balance (in shares) at Dec. 31, 2012   561,773,778    
Issuance of common stock in exchange for services to consultants 741,370 71,600 669,770  
Issuance of common stock in exchange for services to consultants (in shares)   71,600,000    
Issuance of common stock in exchange for services to directors and employees 507,720 35,630 472,090  
Issuance of common stock in exchange for services to directors and employees (in shares)   35,630,000    
Common stocks issued in private placement 140,000 42,000 98,000  
Common stocks issued in private placement (in shares)   42,000,000    
Common stock issued in exchange for related party debt 162,500 50,000 112,500  
Common stock issued in exchange for related party debt (in shares)   50,000,000    
Common stock issued for modification of debt 30,300 4,500 25,800  
Common stock issued for modification of debt (in shares)   5,750,000    
Common stock issued for conversion of debt 1,646,832 193,758 1,453,074  
Common stock issued for conversion of debt (in shares)   193,759,241    
Common stock issued for settlement of AP 466,000 42,800 423,200  
Common stock issued for settlement of AP (in shares)   42,800,000    
Common stock issued to note holder, net of discount 3,977 1,000 2,977  
Common stock issued to note holder, net of discount (in shares)   1,000,000    
In-kind contribution of interest 1,159    1,159  
Net loss (4,342,964)     (4,342,964)
Balance at Dec. 31, 2013 $ (4,219,449) $ 1,003,062 $ 36,764,309 $ (41,986,820)
Balance (in shares) at Dec. 31, 2013   1,004,313,019    
XML 37 R35.htm IDEA: XBRL DOCUMENT v2.4.0.8
FAIR VALUE MEASUREMENTS (Details Textual)
 12 Months Ended
Dec. 31, 2013
Fair Value Measurements [Line Items]  
Fair Value Assumptions, Expected Dividend Rate 0.00%
Minimum [Member]
  
Fair Value Measurements [Line Items]  
Fair Value Assumptions, Risk Free Interest Rate 0.13%
Fair Value Assumptions, Expected Volatility Rate 124.00%
Maximum [Member]
  
Fair Value Measurements [Line Items]  
Fair Value Assumptions, Risk Free Interest Rate 1.75%
Fair Value Assumptions, Expected Volatility Rate 236.00%
XML 38 R22.htm IDEA: XBRL DOCUMENT v2.4.0.8
DUE TO OFFICERS (Tables)
 12 Months Ended
Dec. 31, 2013
Due To Officers [Abstract]  
Due To Officers [Table Text Block]
At December 31, 2013 and December 31, 2012, the balance due to officers consisted of the following:
 
 
 
December 31,
2013
 
December 31,
2012
 
 
 
 
 
 
 
 
 
An unsecured demand loan from our President and CEO, Rik Deitsch. The loan bears interest at 4%. The loan balance at December 31, 2013 and 2012, respectively, includes accrued interest payable of $349,466 and $324,853.
 
$
566,399
 
$
606,168
 
 
 
 
 
 
 
 
 
A loan from Paul Reid, the former President of ReceptoPharm bearing interest at a rate of 5% per annum, due on demand and secured by certain intellectual property of ReceptoPharm having a zero cost at December 31, 2013 and December 31, 2012.
The accrued interest at December 31, 2013 and December 31, 2012 was $43,363 and $37,392, respectively.
 
 
123,189
 
 
117,218
 
 
 
 
 
 
 
 
 
Ending balances
 
$
689,588
 
$
723,386
 
XML 39 R36.htm IDEA: XBRL DOCUMENT v2.4.0.8
SETTLEMENT OF ACCOUNTS AND NOTE PAYABLE (Details Textual) (USD $)
 12 Months Ended 2 Months Ended 12 Months Ended 1 Months Ended 12 Months Ended 1 Months Ended 12 Months Ended 0 Months Ended 1 Months Ended 12 Months Ended 12 Months Ended 1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Dec. 31, 2013
Vendor [Member]
Sep. 16, 2013
Vendor [Member]
Sep. 30, 2013
Two Vendor [Member]
Dec. 31, 2013
Harold H. Rumph [Member]
Jan. 02, 2012
Bank Of America [Member]
Dec. 31, 2012
Redwood Management LlC [Member]
Feb. 03, 2012
Redwood Management LlC [Member]
Oct. 31, 2012
Redwood Management LlC [Member]
Restricted Stock [Member]
Dec. 31, 2012
Redwood Management LlC [Member]
Restricted Stock [Member]
Feb. 03, 2012
Post Graduate Healthcare Education Llc [Member]
Dec. 31, 2012
Alera Technologies Inc [Member]
Sep. 12, 2013
Coventry Enterprises LlC [Member]
Dec. 31, 2013
Coventry Enterprises LlC [Member]
Sep. 30, 2013
Coventry Enterprises LlC [Member]
Jun. 30, 2013
Coventry Enterprises LlC [Member]
Apr. 30, 2013
Coventry Enterprises LlC [Member]
Mar. 31, 2013
Coventry Enterprises LlC [Member]
Dec. 31, 2013
Coventry Enterprises LlC [Member]
Dec. 31, 2012
Coventry Enterprises LlC [Member]
Sep. 03, 2013
Coventry Enterprises LlC [Member]
Mar. 22, 2013
Coventry Enterprises LlC [Member]
Dec. 31, 2012
Coventry Enterprises LlC [Member]
Common Stock [Member]
Dec. 31, 2012
Coventry Enterprises LlC [Member]
December 20, 2012 [Member]
Dec. 31, 2012
Coventry Enterprises LlC [Member]
January 7, 2013 [Member]
Dec. 31, 2012
Coventry Enterprises LlC [Member]
March 13, 2013 [Member]
Dec. 31, 2012
Coventry Enterprises LlC [Member]
Restricted Stock [Member]
Mar. 31, 2012
Coventry Enterprises LlC [Member]
Restricted Stock [Member]
Jun. 30, 2013
Coventry Enterprises LlC [Member]
Restricted Stock [Member]
Mar. 31, 2013
Coventry Enterprises LlC [Member]
Restricted Stock [Member]
Jun. 30, 2013
Coventry Enterprises LlC [Member]
Restricted Stock [Member]
Dec. 31, 2013
Coventry Enterprises LlC [Member]
Restricted Stock [Member]
Dec. 31, 2012
Coventry Enterprises LlC [Member]
Restricted Stock [Member]
Dec. 31, 2013
Immunoclin, Ltd [Member]
Dec. 20, 2012
Immunoclin, Ltd [Member]
Line of Credit Facility, Amount Outstanding             $ 80,000                                                          
Line of Credit Facility, Initiation Date             Sep. 28, 2006                                                          
Assigned Debt Consideration Amount                                 60,000               20,000 40,000 20,000                  
Long-term Debt, Gross                       109,500 65,040               80,389                             80,000
Long-term Debt                       149,500                                                
Assignment Debt Consideration Amount Total               188,608                       337,182                                
Convertible Debt 767,056 588,091             188,608         70,000             65,040 100,000 20,000                          
Debt Instrument, Interest Rate, Stated Percentage                 6.00%         10.00%             8.00% 10.00% 10.00%                         8.00%
Debt Instrument, Convertible, Terms of Conversion Feature               The full amount of principal and interest was due at maturity unless the Debenture was converted to shares of common stock in accordance with the debenture agreement, whereby such debenture could be converted into shares of our common stock at a price equal to 75% of the lowest closing price (determined on the then current trading market for our common stock) during the 15 trading days prior to conversion.           Coventry has the right to convert the note, until is no longer outstanding into shares of Common Stock at a price lesser of $.02, or (ii) fifty-five percent (55%) of the average of the three lowest VWAP prices of the Companys Common Stock for the twenty trading days preceding the conversion date.   Coventry has the right to convert the note, until is no longer outstanding into shares of Common Stock at a price lesser of $.018, or (ii) fifty-five percent (55%) of the average of the three lowest VWAP prices of the Companys Common Stock for the twenty trading days preceding the conversion date Coventry was entitled to convert all or any amount of the these notes into shares of the Company's common stock (the "Common Stock") at a conversion price ("Conversion Price") for each share of Common Stock equal to 55% of the average of the daily volume weighted average prices of the Common Stock for the 3 trading days with the lowest volume weighted average prices during 20 trading days Coventry was entitled to convert all or any amount of the this note into shares of the Company's common stock (the "Common Stock") at a conversion price ("Conversion Price") for each share of Common Stock equal to 55% of the average of the daily volume weighted average prices of the Common Stock for the 3 trading days with the lowest volume weighted average prices during the 15 trading days immediately preceding the Conversion Date Coventry has the right to convert the note, until is no longer outstanding into shares of Common Stock at a price which is lesser of $.0075, or (ii) fifty-five percent (55%) of the average of the three lowest VWAP prices of the Companys Common Stock for the twenty trading days preceding the conversion date   Coventry was entitled to convert all or any amount of the this note into shares of the Company's common stock (the "Common Stock") at a conversion price ("Conversion Price") for each share of Common Stock equal to 55% of the average of the daily volume weighted average prices of the Common Stock for the 3 trading days with the lowest volume weighted average prices during the 20 trading days immediately preceding the Conversion Date.                              
Debt Conversion, Converted Instrument, Shares Issued                   18,737,894 18,737,894                         2,565,102           31,416,845 15,119,481 31,416,845   8,672,090    
Fair Value, Option, Changes in Fair Value, Gain (Loss)                                         42,958                              
Gains (Losses) On Extinguishment Of Debt (707,651) (457,292) 505,525   15,472                             2,200                         65,039   65,039  
Derivative, Loss on Derivative                             309,055         4,885                                
Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures, Total     25,000,000   3,000,000 14,800,000                                           2,564,102 8,672,090              
Accounts Payable     112,621   38,528                                                              
Restricted Stock Par Or Stated Value Per Share     $ 0.015   $ 0.018                                                              
Warrants Issued For Common Sock     25,000,000 25,000,000                                                                
Class Of Warrant Or Right, Exercise Price Of Warrants Or Rights     0.030 0.030                                                                
Class of Warrant or Right, Outstanding     63,297 243,146                                                                
Accrued Salaries           37,000                                                            
Debt Conversion, Original Debt, Amount                                               $ 20,000                        
XML 40 R24.htm IDEA: XBRL DOCUMENT v2.4.0.8
STOCKHOLDERS' DEFICIT (Tables)
 12 Months Ended
Dec. 31, 2013
Stockholders' Equity Note [Abstract]  
Schedule Of Debt Conversion Shares Issued [Table Text Block]
Following the agreements with Coventry Enterprises, LLC (see Note 3) for $80,000, Coventry made the following conversions for a total of 15,119,481 shares of the company’s restricted stock during the first quarter of 2013 satisfying the notes in full and recorded a loss of $65,039 (See note 3): 
 
Date
 
Number of shares
converted
 
Fair Value
of Debt
Converted
 
January 21, 2013
 
 
4,032,258
 
$
37,619
 
February 11, 2013
 
 
5,405,405
 
$
42,510
 
March 20, 2013
 
 
5,681,818
 
$
40,414
 
 
Following the agreement with Coventry Enterprises, LLC (see Note 5) for $88,500, Coventry made the following conversions for a total of 31,416,845 shares of the company’s restricted stock during the second quarter of 2013 satisfying the notes in full:
 
Date
 
Number of shares converted
 
Fair Value
of Debt
Converted
 
4/17/2013
 
 
7,133,333
 
$
49,586
 
5/16/2013
 
 
11,101,694
 
$
64,930
 
6/12/2013
 
 
13,181,818
 
$
70,130
 
 
During June and August, 2013, one of the convertible Notes holders made the following conversions of a total of 34,254,004 shares of the company’s restricted stock satisfying the notes in the amount of $125,000 with a fair value of $317,391 on the date of conversion (See Note 5).
 
Date
 
Number of shares converted
 
Fair Value
of Debt
Converted
 
6/25/2013
 
 
22,058,882
 
$
188,352
 
8/30/2013
 
 
12,195,122
 
$
129,039
 
  
During August and September, 2013, $150,000 of the convertible notes were assigned to third parties in the form bearing interest of 8% annum at with a conversion price for each share of Common Stock equal to 55% of the average of the daily volume weighted average prices of the Common Stock for the 3 trading days with the lowest volume weighted average prices during the 15 to 20 trading days immediately preceding the Conversion Date. Immediately following the assignments, the conversions for a total of 64,052,862 shares of the company’s restricted stock were made as followings in satisfying the notes of $150,000 at the fair value of $475,519(See Note 5).
 
Date
 
Number of shares converted
 
Fair Value
of Debt
Converted
 
8/28/2013
 
 
22,026,431
 
$
167,493
 
9/3/2013
 
 
20,000,000
 
$
163,909
 
9/4/2013
 
 
22,026,431
 
$
144,117
 
XML 41 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 42 R7.htm IDEA: XBRL DOCUMENT v2.4.0.8
Consolidated Statements of Changes in Stockholders' Deficit [Parenthetical]
 12 Months Ended
Dec. 31, 2012
Common stock issuable for private placement (in shares) 1,200,000
XML 43 R3.htm IDEA: XBRL DOCUMENT v2.4.0.8
Consolidated Balance Sheets [Parenthetical] (USD $)
Dec. 31, 2013
Dec. 31, 2012
Common stock, par value (in dollars per share) $ 0.001 $ 0.001
Common stock, shares authorized 2,000,000,000 2,000,000,000
Common stock, shares issued 1,004,313,019 561,773,778
Common stock, shares outstanding 1,004,313,019 561,773,778
XML 44 R17.htm IDEA: XBRL DOCUMENT v2.4.0.8
COMMITMENTS AND CONTINGENCIES
 12 Months Ended
Dec. 31, 2013
Commitments and Contingencies [Abstract]  
Commitments and Contingencies Disclosure [Text Block]
9. COMMITMENTS AND CONTINGENCIES
 
Operating Leases
 
In February 2010, Nutra Pharma entered into an operating lease for the use of office space. The lease expired in January 2013 and required monthly payments of approximately $9,000. In February 2013, Nutra Pharma entered into a new operating lease for monthly payments of approximately $3,500 for three years. ReceptoPharm leases a lab and renewed its operating lease agreement for five years in July of 2012. The lease requires monthly payments of approximately $5,000 beginning August 1, 2012.
 
Future minimum payments under these lease agreements, including the extension period, are approximately as follows:
 
Years ended
December 31,
 
Amounts
 
2014
 
$
116,345
 
2015
 
 
120,218
 
2016
 
 
79,892
 
2017
 
 
45,249
 
Total
 
$
361,704
 
 
Rent expense in 2013 and 2012 approximated $114,889 and $183,000, respectively.
 
Litigation
 
Patricia Meding, et. al. v. ReceptoPharm, Inc. f/k/a Receptogen, Inc. 
 
On August 18, 2006, ReceptoPharm was named as a defendant in Patricia Meding, et. al. v. ReceptoPharm, Inc. f/k/a Receptogen, Inc., Index No.: 18247/06 (New York Supreme Court, Queens County). The original proceeding claimed that ReceptoPharm owed the Plaintiffs, including Patricia Meding, a former ReceptoPharm officer and shareholder and several corporations that she claims to own, the sum of $118,928.15 plus interest and counsel fees on a series promissory notes that were allegedly executed in 2001 and 2002. On August 23, 2007, the Queens County New York Supreme Court issued a decision denying Plaintiffs motion for summary judgment in lieu of a complaint, concluding that there were issues of fact concerning the enforceability of the promissory notes. On May 23, 2008, the Plaintiffs filed an amended complaint in which they reasserted their original claims and asserted new claims seeking damages of no less than $768,506 on their claims that in or about June 2004 ReceptoPharm breached its fiduciary duty to the Plaintiffs as shareholders of ReceptoPharm by wrongfully canceling certain of their purported ReceptoPharm share certificates. In late 2010, Plaintiffs further amended their complaint alleging that ReceptoPharm violated Plaintiffs contractual and statutory rights by cancelling an additional 1,214,800 share certificates and failing to permit the Plaintiffs to exercise dissenting shareholder rights with respect to those share certificates. The damages associated with the Plaintiff’s claims could rise as the result of increases in our share price as the Receptopharm shares may be convertible into our common shares. The potential exposure may exceed $10,000,000 if the Plaintiffs are successful with all of their claims. 
 
ReceptoPharm believes the suit is without merit and has filed an answer denying the material allegations of the amended complaint and asserted a series of counterclaims against the Plaintiffs alleging claims for declaratory judgment, fraud, breach of fiduciary duty, conversion and unjust enrichment as a result of the promissory notes. Plaintiffs have moved for partial summary judgment on their claims regarding the additional 1,214,800 shares, but not on their claims regarding the alleged promissory notes or the 1,750,000 alleged shares. In August of 2011, the Plaintiff's motion was partially granted. In September 2012, ReceptoPharm's attorneys filed a Motion to be removed as counsel. Their motion was denied on April 26, 2013 due to the current Involuntary Bankruptcy action filed against Nutra Pharma. The court has issued a stay in the proceedings pending the outcome of the Bankruptcy action. ReceptoPharm is seeking new counsel to oppose the partial summary judgment. We intend to vigorously contest this matter. 
 
Liquid Packaging Resources, Inc. v. Nutra Pharma Corp. and Erik "Rik" Deitsch 
 
On April 21, 2011, Nutra Pharma Corp. and its CEO, Erik Deitsch, were named as defendants in Liquid Packaging Resources, Inc. v. Nutra Pharma Corp. and Erik "Rik" Deitsch, Superior Court of Fulton County, Georgia, Civil Action No. 2011-CV-199562. Liquid Packaging Resources, Inc. ("LPR") claimed that Nutra Pharma Corp. and Mr. Deitsch, directly or through other companies, placed orders with LPR that required LPR to purchase components from third parties. LPR sought reimbursement for those third party expenses in the amount of not less than $359,826.85 plus interest. LPR also sought punitive damages in the amount of not less than $500,000 and attorney's fees.
 
Mr. Deitsch and Nutra Pharma Corp. then removed the action to the United States District Court, Northern District of Georgia, Civil Action No. 11-CV-01663-ODE. After removal, LPR amended the Complaint to assert that Nutra Pharma Corp. and Mr. Deitsch were the alter egos of the alleged other companies through whom the subject orders were placed and therefore should be considered one and the same. Mr. Deitsch and Nutra Pharma Corp. moved to dismiss the Complaint on several grounds including statute of frauds, failure to state a claim, and jurisdiction (only for Mr. Deitsch). Mr. Deitsch and Nutra Pharma Corp. believe the suit is without merit. 
 
After June 30, 2011, at LPR's request, the parties mediated the dispute before LPR responded to the Motion To Dismiss. At the mediation, the parties worked out an agreement whereby Nutra Pharma Corp. would purchase from LPR the components LPR purchased from third parties at an amount slightly less than the principal amount of the suit and on terms acceptable to us. The agreed price was $350,000.00 payable over 7 months in equal $50,000.00 amounts. This agreement was reached by us because it provided tangible value in exchange for the purchase price rather than incurring the expense of litigation, which would likely be substantial and not recouped. While Nutra Pharma Corp. had counterclaims we could assert, we believe this was a practical resolution. The settlement allowed us to take possession of the components prior to full payment and, in exchange, provided security to LPR in the form of our stock valued at $400,000 at the time of issuance. The stock can only be sold in event of a default of the payment schedule. The litigation was dismissed in August of 2011. We made the August, September and November payments (totaling $150,000) in a timely fashion. We were late for the payment due October 15, 2011 and requested an accommodation from LPR, eventually paying an extra $5,000 towards that payment. At December 31, 2011, Nutra Pharma Corp. had made total payments of $205,000 with an additional $150,000 owed. In order to allow us to skip the December payment, LPR agreed to another accommodation whereby we would pay both the December and January payment with an additional $10,000 on or before January 16, 2012. We were unable to make this payment and on January 26, 2012 signed an amended payment schedule adding an additional $15,000 for a total of $175,000 owed. Our CEO, Rik Deitsch, added additional collateral stock in a separate company that he held personally. $25,000 was paid in January, with subsequent payments of $30,000 due monthly on the 15th of March through the 15th of July, 2012. We failed to make the March payment and was subsequently called in default of the Agreement. Under the original agreement, if we are in default of the agreement, LPR has the right to sell shares of our free trading stock held in escrow by their attorney and receive cash settlements for a total amount of $450,000 representing the new total cash amount due to LPR by the Company. 
 
On June 11, 2012, LPR sold their debt to Southridge Partners, LLP in an agreement to be paid out over time. In August, 2013, LPR cancelled their agreement with Southridge Partners, LLP.  As of December 31, 2013 LPR continues to hold the collateral stock. We are currently negotiating a settlement with LPR. Upon the settlement of the outstanding debt, LPR will return the collateral shares to the Company.
 
Involuntary Petition of Bankruptcy 
 
On August 31, 2012, certain former ReceptoPharm employees and a former ReceptoPharm consultant filed a Petition for Involuntary Bankruptcy against us in the United States Bankruptcy Court, Southern District of Florida. The Petitioners originally claimed they were owed $990,927 from Nutra Pharma in the form of accrued wages and promissory notes, but amended their claim to $816,662 in a subsequent filing. In response to the Petition, we filed a motion to dismiss the action which, if successful, would avoid the case being converted into an actual bankruptcy action. On September 30, 2013, the Company entered into a Settlement Agreement with the Petitioners, which is effective upon the court dismissal of the action. In full and final satisfaction of all claims, the Company settled the Agreement with the Petitioners for a total sum of $350,000.  $35,000 has been paid and a second lump sum payment is due within 8 months from the date the court dismissed the action (See Note 10).
 
Laurence N. Raymond v. Receptopharm, Inc. et al.
 
On December 30, 2011 Laurence N. Raymond ("Raymond") brought the case against Receptopharm, Inc. ("Receptopharm") and Nutra Pharma to recover approximately $300,000 that was allegedly either loaned to Receptopharm or owing to Raymond pursuant to an oral employment agreement. Dr. Raymond is one of the petitioning creditors that brought the above-described involuntary bankruptcy action. The settlement agreement reached in that action fully resolves all claims between the parties and specifies that this action will be dismissed immediately upon the full settlement payments, pursuant to a confidential settlement agreement. 
 
 Paul F. Reid v, Harold H. Rumph et al.
 
On December 28, 2011 Paul F. Reid ("Reid") brought the case against Harold H. Rumph ("Rumph"), Receptopharm, and Nutra Pharma to recover approximately $330,000 that was allegedly either loaned to Receptopharm or owing to Reid pursuant to an oral employment agreement. Dr. Reid is one of the petitioning creditors that brought the above-described involuntary bankruptcy action. The settlement agreement reached in that action fully resolves all claims between the parties and specifies that this action will be dismissed immediately upon the full settlement payments, pursuant to a confidential settlement agreement.
XML 45 R1.htm IDEA: XBRL DOCUMENT v2.4.0.8
Document And Entity Information (USD $)
 12 Months Ended
Dec. 31, 2013
Mar. 31, 2014
Jun. 30, 2013
Document Information [Line Items]      
Entity Registrant Name NUTRA PHARMA CORP    
Entity Central Index Key 0001119643    
Current Fiscal Year End Date --12-31    
Entity Filer Category Smaller Reporting Company    
Trading Symbol NPHC    
Entity Common Stock, Shares Outstanding   1,056,274,057  
Document Type 10-K    
Amendment Flag false    
Document Period End Date Dec. 31, 2013    
Document Fiscal Period Focus FY    
Document Fiscal Year Focus 2013    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Public Float     $ 9,833,758
XML 46 R18.htm IDEA: XBRL DOCUMENT v2.4.0.8
SUBSEQUENT EVENTS
 12 Months Ended
Dec. 31, 2013
Subsequent Events [Abstract]  
Subsequent Events [Text Block]
10. SUBSEQUENT EVENTS
 
Private Placements of Common Stock
 
In January 2014, the Company sold 12,000,000 shares of restricted common stock to an investor at a price per share of $0.005 and received proceeds of $60,000. The Company issued 12,000,000 warrants to purchase common stock at an exercise price of $0.03 per share. The warrants expire on December 31, 2015.
 
Common Stock Issued for Debt Modification and Default
 
On January 17, 2014, the Company issued a total of 1,000,000 restricted shares to the Michael McDonald Trust due to the default on repayment of the promissory note of $75,000. The shares were valued at a fair value of $9,900.
 
Common Stock Issued for Debt Conversions
 
Following the agreements with Coventry Enterprises, LLC for $70,000 in September 2013, Coventry converted the $60,000 of the note for a total of 15,584,415 shares of the company’s restricted stock during on March 12, 2014. The remaining balance of the note is $10,000.
 
Following the agreements with Coventry Enterprises, LLC for $100,000 in September 2013, Coventry converted the $90,000 of the note for a total of 23,376,623 shares of the company’s restricted stock during on March 12, 2014. The remaining balance of the note is $10,000.
 
Officer Loans
 
During January through March 2014, the Company received additional advances from our President and CEO, Rik Deitsch, in the amount of $16,008 and repaid Mr. Deitsch $14,600. These funds are unsecured, bearing interest at 4% and due on demand.
 
Involuntary Petition of Bankruptcy
 
On September 30, 2013, the Company entered into a Settlement Agreement with the Petitioners, which is effective upon the court dismissal of the action. In full and final satisfaction of all claims, the Company settled the Agreement with the Petitioners for a total sum of $350,000.  $35,000 has been paid and a second lump sum payment is due within 8 months from February 12, 2014, the date the court dismissed the action. The Parties executed mutual releases exclusive of releases under the Settlement Agreement (See Note 9).
XML 47 R4.htm IDEA: XBRL DOCUMENT v2.4.0.8
Consolidated Statements of Operations (USD $)
 12 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Net sales $ 122,198 $ 203,290
Cost of sales 41,165 147,647
Gross profit 81,033 55,643
Operating expenses:    
Selling, general and administrative - including stock based compensation of $1,391,979 and $1,799,461, respectively 2,442,471 2,656,742
Total other costs and expenses 2,442,471 2,656,742
Net Loss from Operations (2,361,438) (2,601,099)
Other Expenses    
Interest expense (157,376) (153,472)
Change in fair value of derivatives (1,135,677) (400,488)
Loss on settlement of debt and accounts payable, net (707,651) (457,292)
Other Income 19,178 0
Total other income (expense), net (1,981,526) (1,011,252)
Net loss before income taxes (4,342,964) (3,612,351)
Provision for income taxes 0 0
Net loss $ (4,342,964) $ (3,612,351)
Net loss per share - basic and diluted (in dollars per share) $ (0.01) $ (0.01)
Weighted average number of shares outstanding during the period - basic and diluted (in shares) 743,492,967 402,996,638
XML 48 R12.htm IDEA: XBRL DOCUMENT v2.4.0.8
DUE TO OFFICERS
 12 Months Ended
Dec. 31, 2013
Due To Officers [Abstract]  
Due To Officers [Text Block]
4. DUE TO OFFICERS
 
At December 31, 2013 and December 31, 2012, the balance due to officers consisted of the following:
 
 
 
December 31,
2013
 
December 31,
2012
 
 
 
 
 
 
 
 
 
An unsecured demand loan from our President and CEO, Rik Deitsch. The loan bears interest at 4%. The loan balance at December 31, 2013 and 2012, respectively, includes accrued interest payable of $349,466 and $324,853.
 
$
566,399
 
$
606,168
 
 
 
 
 
 
 
 
 
A loan from Paul Reid, the former President of ReceptoPharm bearing interest at a rate of 5% per annum, due on demand and secured by certain intellectual property of ReceptoPharm having a zero cost at December 31, 2013 and December 31, 2012.
The accrued interest at December 31, 2013 and December 31, 2012 was $43,363 and $37,392, respectively.
 
 
123,189
 
 
117,218
 
 
 
 
 
 
 
 
 
Ending balances
 
$
689,588
 
$
723,386
 
 
During the year ended December 31, 2013, we borrowed $151,718 and repaid $53,600 to Mr. Deitsch. In addition, Mr. Deitsch accepted a total of 50,000,000 shares of the Company’s restricted common stock as a repayment to discharge $162,500 of his outstanding loan to the Company in year ended December 31, 2013(See note 6).
 
During June, 2013, 25,000,000 warrants to purchase stock at an exercise price of $0.10 per share were issued to CEO, Mr. Deitsch in exchange of notes payable. The warrants expire on December 31, 2014 (See note 7).
 
During the year ended December 31, 2012, we borrowed $164,779 and repaid $324,478 to Mr. Deitsch. Included in this amount, Mr. Deitsch assigned $175,000 of the debt to a third party on January 2, 2012 and accepted a total of 10,000,000 shares of the Company’s restricted common stock as a repayment to discharge $100,000 of his outstanding loan the Company in December 2012(See note 6).
XML 49 R11.htm IDEA: XBRL DOCUMENT v2.4.0.8
SETTLEMENT OF ACCOUNTS AND NOTE PAYABLE
 12 Months Ended
Dec. 31, 2013
Debt Disclosure [Abstract]  
Short-term Debt [Text Block]
3. SETTLEMENT OF ACCOUNTS AND NOTE PAYABLE
 
At January 2, 2012, the Company owed Bank of America approximately $80,000 representing the balance of a credit line originated on September 28, 2006. Bank of America assigned and sold this debt to Great Plains Capital Corporation (“Great Plains”). On February 3, 2012, Great Plains assigned the debt to Redwood Management, LLC (“Redwood”). At February 3, 2012, the Company owed Post Graduate Healthcare Education, LLC (“Post Graduate”) $109,500 representing the balance of a total debt of $149,500. Post Graduate assigned the debt to Redwood Management, LLC. The total amount of the Company’s debt assigned to Redwood was $188,608. Under a Securities Settlement Agreement, the Company issued a Convertible Debenture to Redwood for $188,608 payable within six months with interest at 6% annum. The full amount of principal and interest was due at maturity unless the Debenture was converted to shares of common stock in accordance with the debenture agreement, whereby such debenture could be converted into shares of our common stock at a price equal to 75% of the lowest closing price (determined on the then current trading market for our common stock) during the 15 trading days prior to conversion. Following the agreement Redwood accepted 18,737,894 shares of our restricted stock as satisfaction for the note and we recorded a loss of $42,958 on the settlement.
 
At March 22, 2012, the Company owed Alera Technologies, Inc. (“Alera”) $65,040 representing the balance of a purchase order for the production of Nyloxin™ products. Alera assigned the rights to the debt to Coventry Enterprises, LLC (“Coventry”). The Company issued a Convertible Redeemable Note in favor of Coventry in the amount of $65,040 bearing interest of 8% annum. Coventry was entitled to convert all or any amount of the this note into shares of the Company's common stock (the "Common Stock") at a conversion price ("Conversion Price") for each share of Common Stock equal to 55% of the average of the daily volume weighted average prices of the Common Stock for the 3 trading days with the lowest volume weighted average prices during the 20 trading days immediately preceding the Conversion Date. The note was satisfied on April 5, 2012 in exchange for 8,672,090 shares of restricted Common Stock.
 
At December 20, 2012, the Company owed Immunoclin, Ltd. (“Immunoclin”) $80,389 representing the balance of invoices for clinical services. The Company issued an $80,000 note payable at 8% to Immunoclin in exchange for the outstanding accounts payable. $20,000, $40,000 and $20,000 of the debt were assigned to Coventry Enterprises, LLC (“Coventry”) on December 20, 2012, January 7, 2013, and March 13, 2013, respectively. Coventry made the first conversion of 2,565,102 shares of Company’s common stock to satisfy the debt of $20,000 on December 20, 2012. The Company issued two Convertible Redeemable Notes for the remaining amount of $40,000 and $20,000 on January 7, 2013, and March 13, 2013. Coventry made the conversion of a total of 15,119,481 shares of the company’s restricted stock satisfying the remaining notes in full during the year ended December 31, 2013. The Company elected to account for these hybrid contracts under the guidance of FASB ASC Topic 815 Derivatives & Hedging. The fair value has been defined as the common stock equivalent value, enhanced by the fair value of the default put plus the present value of the coupon. The Company recorded a loss of $65,039 on the settlement and the change in fair value of derivatives in the amount of $4,885 during the year ended December 31, 2013.
 
During August and September, 2013, the Company issued 3,000,000 shares of the company’s restricted stock to settle the outstanding accounts payable in aggregate of $38,528 with two vendors. The shares were valued at $0.018 per share. The Company recorded a total loss of $15,472 on the settlement date (See Note 6).
 
During September, 2013, the Company issued 25,000,000 shares of the company’s restricted stock and 25,000,000 warrants to purchase stock at an exercise price of $0.030 to settle the outstanding accounts payable of $112,621 with one vendor. The shares were valued at $0.015 per share (See Note 6). The Company classified embedded conversion features in the warrants as a derivative liability. The warrants were valued at their fair value of $243,146 and $63,297, respectively using the Black-Scholes method at the commitment and re-measurement dates of September 16, 2013 and December 31, 2013, respectively. The Company recorded a loss of $505,525 on the settlement date (See Note 7).
 
During September, 2013, Mr. Harold H. Rumph (ReceptoPharm’s CEO) accepted 14,800,000 shares of the Company’s restricted common stock as a repayment to discharge $37,000 of his accrued salary to the Company (See Note 6).
XML 50 R23.htm IDEA: XBRL DOCUMENT v2.4.0.8
OTHER DEBT (Tables)
 12 Months Ended
Dec. 31, 2013
Debt Disclosure [Abstract]  
Schedule of Short-term Debt [Table Text Block]
Other debt (all short-term) consists of the following at December 31, 2013 and 2012:
 
 
 
2013
 
2012
 
 
 
 
 
 
 
 
 
Note payable – Related Party (1)
 
$
180,000
 
$
190,000
 
Notes payable – Non Related Parties (2)
 
 
412,182
 
 
593,483
 
Convertible notes payable, at fair value (3)
 
 
767,056
 
 
588,091
 
 
 
 
 
 
 
 
 
Ending balances
 
$
1,359,238
 
$
1,371,574
 
 
 
(1)
During the third quarter of 2010 we borrowed $200,000 from one of our directors. We repaid $10,000 each (total $20,000) during the third quarter of 2012 and 2013. Under the terms of the loan agreement, this loan was expected to be repaid in nine months to a year from the date of the loan along with interest calculated at 10% for the first month plus 12% after 30 days from funding. We are in default regarding this loan. At December 31, 2013 and 2012, we owed this director accrued interest of $121,137 and $86,387, respectively.
 
 
(2)
At December 31, 2013 and 2012, the balance of $412,182 and $593,483 , respectively, consisted of the following loans:
 
 
·
In May 2011, the Company received a loan for $25,000 from a non-related party. This loan was expected to be repaid no later than December 31, 2011, along with interest calculated at 10% for the first month plus 12% after 30 days from funding. This loan is guaranteed by an officer of the Company. On November 25, 2013, the non-related party accepted a total of 4,360,000 shares of the Company’s restricted common stock as a repayment to discharge $25,000 of his outstanding loan and accrued interest of $11,956 (See note 6).  The Company recorded a loss of $28,444 on the settlement date.
 
 
·
In May 2011, the Company received another loan for $25,000 from a non-related party. This loan was expected to be repaid no later than December 31, 2011, along with interest calculated at 10% for the first month plus 12% after 30 days from funding. This loan is guaranteed by an officer of the Company. On September 16, 2013, the non-related party accepted a total of 8,472,750 shares of the Company’s restricted common stock as a repayment to discharge $25,000 of his outstanding loan and accrued interest of $11,120 (See note 6). The Company recorded a loss of $90,971 on the settlement date.
 
 
·
In July 2013, the Company issued a promissory note to the Michael McDonald Trust in the amount of $75,000 bearing interest at a rate of 2% per month. The note is due in six months from the execution and funding of the note. In connection with the issuance of this promissory note, the Company issued 1,000,000 shares of the Company's common stocks (See note 6). The Company has recorded a debt discount in the amount of $3,977 to reflect the value of the common stocks as a reduction to the carrying amount of the convertible debt and a corresponding increase to common stocks and additional paid-in capital. The total discount of $3,977 was fully amortized over the term of the debt during the year ended December 31, 2013.   In the event of default, the Company would issue an additional 1,000,000 share of the Company’s common stocks on the date that is fifteen days after the maturity date (See Note 6). We are in default regarding this loan. The additional 1,000,000 shares were issued in January 2014 with a fair value at $9,900 (See Note 10). At December 31, 2013, we owed Michael McDonald accrued interest of $9,000.
 
 
·
At December 31, 2012, the total amount of the Company’s debt assigned to Southridge was $483,482. In connection with the debt sales to Southridge, the Company recorded a loss on settlement of accounts payable for $63,490 in the statement of operations at December 31, 2012. During the first quarter of 2013, the suit was voluntarily dismissed involving debt held by Southridge for $483,482. The debt has reverted back to the original holders.
 
In April, 2013, $88,500 of the debt held by Michael McDonald Trust was assigned to Coventry Enterprises, LLC (“Coventry”) in the form of a Convertible Redeemable Note bearing interest of 8% annum. Coventry was entitled to convert all or any amount of the this note into shares of the Company's common stock (the "Common Stock") at a conversion price ("Conversion Price") for each share of Common Stock equal to 55% of the average of the daily volume weighted average prices of the Common Stock for the 3 trading days with the lowest volume weighted average prices during the 15 trading days immediately preceding the Conversion Date. Following the agreements with Coventry, Coventry made the conversions for a total of 31,416,845 shares of the company’s restricted stock during the second quarter of 2013 satisfying the notes in full at the fair value of $186,646.
 
In June, 2013, $57,800 of the debt was assigned to Coventry for a consideration of $60,000 from Baker Donelson Bearman Caldwell & Berkowitz, PC. in the form of Convertible Redeemable Notes bearing interest of 8% annum. The Company recorded a loss of $2,200 on the settlement during the year ended December 31, 2013. Coventry was entitled to convert all or any amount of the these notes into shares of the Company's common stock (the "Common Stock") at a conversion price ("Conversion Price") for each share of Common Stock equal to 55% of the average of the daily volume weighted average prices of the Common Stock for the 3 trading days with the lowest volume weighted average prices during 20 trading days . Following the agreements, Coventry made the conversions for a total of 27,272,727 shares of the company’s restricted stock satisfying the notes in full at the fair value of $167,495.
 
As a result of the debt assignments and conversions with Coventry, the remaining balance of the debt at December 31, 2013 is $337,182 which consisted of the following loans:
 
 
i.
On August 2, 2011 under a settlement agreement with Liquid Packaging Resources, Inc. (“LPR”), the Company agreed to pay LPR a total of $350,000 in monthly installments of $50,000 beginning August 15, 2011 and ending on February 15, 2012. This settlement amount was recorded as general and administrative expenses on the date of the settlement. We did not make the December 2011 or January 2012 payments and on January 26, 2012, we signed the first amendment to the settlement agreement where under we agreed to pay $175,000 which was the balance outstanding at December 31, 2011(this includes a $25,000 penalty for non-payment).
 
The Company repaid $25,000 during the three months ended March 31, 2012. The Company did not make all of the payments under such amendment and as a result pursuant to the original settlement agreement, LPR had the right to sell 5,714,326 shares of the Company’s free trading stock held in escrow by their attorney and receive cash settlements for a total amount of $450,000 (the initial $350,000 plus total default penalties of $100,000). The $100,000 default was expensed during 2012. LPR sold the note to Southridge Partners, LLP (“Southridge”) for consideration of $281,772 in October 2012. The debt has reverted back to the Company (See note 9).
 
 
ii.
As of December 31, 2013 and 2012, the Company owed University Centre West Ltd. approximately $55,410, which was assigned and sold to Southridge and subsequently reverted back to the Company .
 
 
(3)
At December 31, 2013 and 2012, the balance of $767,056 and $588,091 consisted of the following convertible loans:
 
 
·
In September and October 2011, the Company borrowed $250,000 each (aggregating $500,000) from two non-related parties. The principal of these loans were to be repaid with a balloon payment on or before October 1, 2012. On October 19, 2012 the parties amended the notes to extend the due date to May 1, 2013 and include a conversion feature that would allow the holders to convert some or all of their outstanding notes into restricted Company stock at a 15% discount to the average closing market price of the Company's stock traded over the previous 10 days. Interest on these loans is payable monthly beginning in November 2011 with interest calculated at 20% and 12%, each, respectively. At December 31, 2013 and 2012, the accrued interest payable was $6,664.
 
During year ended December 31, 2013, one of the Note holders made conversions of a total of 34,254,004 shares of the company’s restricted stock satisfying the notes in the amount of $125,000 with a fair value of $317,391 on the date of conversion. During August and September, 2013, $150,000 of the debts were assigned to three non-related parties in the form of a Convertible Redeemable Note bearing interest of 8% annum with a conversion price for each share of Common Stock equal to 55% of the average of the daily volume weighted average prices of the Common Stock for the 3 trading days with the lowest volume weighted average prices during the 15 to 20 trading days immediately preceding the Conversion Date. Following the assignments, the conversions for a total of 64,052,862 shares of the company’s restricted stock were made in satisfying the notes of $150,000 at the fair value of $475,519 (See note 6).
 
At December 31, 2013, the remaining balance of these two convertible notes payable of $75,000 and $150,000 were recorded at a fair value of $90,260 and $189,781, respectively. At December 31, 2012, these two convertible note payable of $250,000 each were recorded at fair value of $290,289 and $297,802, respectively.
 
On April 30, 2013, the parties amended the notes to further extend the maturity date to November 3, 2013. The Company issued a total of 4,000,000 restricted shares to the note holders in connection with the amendment at a fair value of $20,800. On October 30, 2013 and November 1, 2013, the parties amended the note of $75,000 and $150,000 to further extend the maturity dates to May 3, 2014 and August 3, 2014, respectively. The Company issued a total of 500,000 and 1,250,000 restricted shares to the note holders in connection with the amendment at a fair value of $9,500 and $13,750 (See note 6), respectively.
 
 
·
On March 22, 2013, the Company issued a Convertible Debenture in the amount of $20,000 to Coventry Enterprises, LLC (“Coventry”). The note carries interest at 10% and is due on March 22, 2014, unless previously converted into shares of restricted common stock. Coventry has the right to convert the note, until is no longer outstanding into shares of Common Stock at a price which is lesser of $.0075, or (ii) fifty-five percent (55%) of the average of the three lowest VWAP prices of the Company’s Common Stock for the twenty trading days preceding the conversion date. In connection with the issuance of this convertible note payable, the Company encountered a day-one derivative loss of $24,931. Coventry made the conversions into a total of 8,810,572 shares of the company’s restricted stock satisfying the notes in full with a fair value of $188,747on September 4, 2013(See note 7).
 
In connection with the issuances of the Note, the Company also granted five-year warrants to purchase an aggregate of 2,600,000 shares of the Company’s common stock at an exercise price of $0.01 per share. The Company classified embedded conversion features in these warrants as a derivative liability. The warrants were valued at their fair value of $21,226 and $17,895, respectively using the Black-Scholes method at the commitment and re-measurement dates of March 22, 2013 and December 31, 2013, respectively.
 
 
·
On July 10, 2013 and October 10, 2013, the Company issued two Convertible Debentures in the amount of $30,000 each (total $60,000) to Christopher Castaldo in connection with the agreements for investor relation services (See Note 6). The notes carry interest at 8% and are due on January 10, 2014 and April 10, 2014, respectively. The notes’ holder has the right to convert the notes into shares of Common Stock at a price of $0.005.
 
In connection with the issuance of this convertible notes payable, the Company encountered a day-one derivative loss of $83,157. At December 31, 2013, these convertible notes payable, at fair value, was recorded at $90,684.
 
 
·
On September 3, 2013, the Company issued a Convertible Debenture in the amount of $100,000 to Coventry Enterprises, LLC (“Coventry”). The note carries interest at 10% and is due on September 3, 2014, unless previously converted into shares of restricted common stock. Coventry has the right to convert the note, until is no longer outstanding into shares of Common Stock at a price lesser of $.018, or (ii) fifty-five percent (55%) of the average of the three lowest VWAP prices of the Company’s Common Stock for the twenty trading days preceding the conversion date.
 
In connection with the issuance of this convertible note payable, the Company encountered a day-one derivative loss of $957,567. At December 31, 2013, this convertible note payable, at fair value, was recorded at $185,971.
 
In connection with the issuances of the Note, the Company also granted five-year warrants to purchase an aggregate of 20,000,000 shares of the Company’s common stock at an exercise price of $0.025 per share. The Company classified embedded conversion features in these warrants as a derivative liability. The warrants were valued at their fair value of $445,638 and $137,681, respectively using the Black-Scholes method at the commitment and re-measurement dates of September 3, 2013 and December 31, 2013, respectively.
 
 
·
On September 12, 2013, the Company issued a Convertible Debenture in the amount of $70,000 to Coventry Enterprises, LLC (“Coventry”). The note carries interest at 10% and is due on September 12, 2014, unless previously converted into shares of restricted common stock. Coventry has the right to convert the note, until is no longer outstanding into shares of Common Stock at a price lesser of $.02, or (ii) fifty-five percent (55%) of the average of the three lowest VWAP prices of the Company’s Common Stock for the twenty trading days preceding the conversion date.
 
In connection with the issuance of this convertible note payable, the Company encountered a day-one derivative loss of $309,055. At December 31, 2013, this convertible note payable, at fair value, was recorded at $130,303.
 
In connection with the issuances of the Note, the Company also granted five-year warrants to purchase an aggregate of 15,000,000 shares of the Company’s common stock at an exercise price of $0.025 per share. The Company classified embedded conversion features in these warrants as a derivative liability. The warrants were valued at their fair value of $262,230 and $101,140, respectively using the Black-Scholes method at the commitment and re-measurement dates of September 12, 2013 and December 31, 2013, respectively.
 
 
·
On October 7, 2013, the Company signed a secured convertible Promissory Note in the amount of $35,000 in favor of Southridge Partners II, LLC. The note was due on demand and carries interest at 10% annum. Southridge Partners II, LLC was entitled to convert the principal into shares of common stock at the lesser of $0.015 or a 50% discount from the lowest closing bid price in the 30 trading days prior to the day that the conversion is requested; and interest accrued was entitled to convert into shares of common stock at $0.001. In the evaluation of these financing arrangements, the Company concluded that these conversion features did not meet the conditions set forth in current accounting standards for equity classification. Since equity classification is not available for the conversion feature, it requires bifurcation and liability classification, at fair value. The Company also concluded that the Default Put required bifurcation because, while puts on debt instruments are generally considered clearly and closely related to the host, the Default Put is indexed to certain events that are not associated with the convertible note payable.
 
In connection with the issuance of this convertible note payable, the Company encountered a day-one derivative loss of $81,667. At December 31, 2013, this convertible note payable, at fair value, was recorded at $80,057.
 
 
·
On October 27, 2011 the Company entered into a convertible note payable with a corporation. The convertible note payable, with a face value of $53,000, bears interest at 8.0% per annum and was due on July 31, 2012.
 
On December 5, 2011 the Company entered into a convertible note payable with a corporation which had a face value of $37,500, a coupon rate of 8.0% per annum and maturity date of September 5, 2012.
 
The convertible note payable is convertible, at the holder’s option, into the Company’s common shares at a variable conversion price which is 58% multiplied by the average of the lowest three (3) trading prices for the Common Stock during the ten (10) Trading Day period ending one Trading Day prior to the date the Conversion Notice is sent by the Holder to the Borrower. The conversion feature is subject to full-ratchet, anti-dilution protection if the Company sells shares or share-indexed financing instruments at less than the conversion price. The holder has the option to redeem the convertible note payable for cash in the event of defaults or certain other contingent events (the “Default Put”).
 
During October 2012, both of these notes were acquired by a third party from Asher Enterprises for an aggregate amount of $100,000, and then converted into 20,000,000 restricted common shares (See note 6).
 
 
·
On February 3, 2012, the Company issued a Convertible Debenture in the amount of $40,000 to Redwood Management, LLC. The note carries interest at 12% and is due on February 13, 2013, unless converted into shares of restricted common stock. Redwood Management, LLC has the right to convert the note, until it is no longer outstanding, into shares of Common Stock at a price of Fifty Percent (50%) of the lowest closing price, determined on the then current trading market for the Company’s common stock, during the 15 trading days prior to conversion (the “Set Price”). On September 12, 2012, TCN International (TCN) completed the purchase and transfer of this note including penalties and unpaid interest, for the sum of $52,500. Redwood Management, LLC has acknowledged the full payment of the Note, in favor of Nutra Pharma Corporation and releases Nutra Pharma Corporation from all obligations under the Note. Upon the request of TCN, the Board of Directors of the Company approved the conversion of these notes into Restricted Common Stock of the Company,providing 7,500,000 shares of Nutra Pharma common stock to relinquish the total debt of $52,500 (See note 6).
 
 
·
On March 16, 2012 the Company signed a secured convertible Promissory Note in the amount of $75,000 in favor of Southridge Partners II, LLC. The note was due November 16, 2012 and carries interest at 8% annum. Southridge Partners II, LLC was entitled after nine months to convert all or a portion of the principal and interest accrued into shares of common stock at a conversion price of each share equal to the Market Price multiplied times 70%. (the “conversion price”). The Market Price is equal to the average of the two lowest bids closing prices for the five trading days ending before the conversion date. In the evaluation of these financing arrangements, the Company concluded that these conversion features did not meet the conditions set forth in current accounting standards for equity classification. Since equity classification is not available for the conversion feature, it requires bifurcation and liability classification, at fair value. The Company also concluded that the Default Put required bifurcation because, while puts on debt instruments are generally considered clearly and closely related to the host, the Default Put is indexed to certain events that are not associated with the convertible note payable. On October 26, 2012, Southridge converted the note into 5,919,495 shares of the Company's restricted common stock (See note 6).
 
In the evaluation of these financing arrangements, the Company concluded that these conversion features did not meet the conditions set forth in current accounting standards for equity classification. Since equity classification is not available for the conversion feature, it requires bifurcation and liability classification, at fair value. The Company also concluded that the Default Put required bifurcation because, while puts on debt instruments are generally considered clearly and closely related to the host, the Default Put is indexed to certain events that are not associated with the convertible note payable.
 
The Company elected to account for these hybrid contracts under the guidance of ASC 815-15-25-4. The fair value has been defined as the common stock equivalent value, enhanced by the fair value of the default put plus the present value of the coupon.
 
The holder of this convertible note has substantial rights and protections regarding dilution if certain events, including a default were to occur. There are a number of events that could trigger a default, including but not limited to failure to pay principal or interest, failure to issue shares under the conversion feature, breach of covenants, breach of representations and warranties, appointment of a receiver or trustee, judgments, bankruptcy, delisting of common stock, failure to comply with the exchange act, liquidation, cessation of operations, failure to maintain assets, material financial statement restatement, reverse split of borrowers stock, etc. In the event of these events the lender may be entitled to receive significant amounts of additional stock above the amounts for conversion.
 
Furthermore, there are additional events that could cause the lender to be due additional shares of common stock above and beyond the shares due from a conversion. Some of these events include, but are not limited to a merger or consolidation of the Company, dividend distribution or spin off, dilutive issuances of the Company’s stock, etc. If the lender receives additional shares of the Company’s commons stock due to any of the foregoing events or for other reasons, then this may have an extremely dilutive effect on the shareholders of the Company. Such dilution would likely result in a significant drop in the per share price of the Company’s common stock. The potential dilutive nature of this note presents a very high degree of risk to the Company and its shareholders
XML 51 R19.htm IDEA: XBRL DOCUMENT v2.4.0.8
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
 12 Months Ended
Dec. 31, 2013
Basis Of Presentation and Summary Of Significant Accounting Policies [Abstract]  
Consolidation, Policy [Policy Text Block]
Basis of Presentation and Consolidation
 
The accompanying consolidated financial statements include the results of Nutra Pharma and its wholly-owned subsidiaries Designer Diagnostics Inc. and ReceptoPharm (collectively "the Company", “us”, “we” or “our”). We operate as one reportable segment. All intercompany transactions and balances have been eliminated in consolidation.
Liquidity Disclosure [Policy Text Block]
Liquidity and Going Concern
 
Our Consolidated financial statements are presented on a going concern basis, which contemplate the realization of assets and satisfaction of liabilities in the normal course of business. We have experienced recurring, significant losses from operations, and have an accumulated deficit of $41,986,820 at December 31, 2013. In addition, we had respective working capital and stockholders’ deficits at December 31, 2013 of $4,259,938 and $4,219,449 respectively.
 
There is substantial doubt regarding our ability to continue as a going concern which is contingent upon our ability to secure additional financing, increase ownership equity and attain profitable operations. In addition, our ability to continue as a going concern must be considered in light of the problems, expenses and complications frequently encountered in established markets and the competitive environment in which we operate.
 
As of December 31, 2013, we do not have sufficient cash to sustain our operations for the next year and will require additional financing in order to execute our operating plan and continue as a going concern. Since our sales are not currently adequate to fund our operations, we continue to rely principally on debt and equity funding; however proceeds from such funding have not been sufficient to execute our business plan. Our plan is to attempt to secure adequate funding until sales of our pain products are adequate to fund our operations. We cannot predict whether additional financing will be available, and/or whether any such funding will be in the form of equity, debt, or another form. In the event that these financing sources do not materialize, or if we are unsuccessful in increasing our revenues and profits, we will be unable to implement our current plans for expansion, repay our obligations as they become due and continue as a going concern.
 
The accompanying Consolidated Financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern.
Use of Estimates, Policy [Policy Text Block]
Use of Estimates
 
The accompanying Consolidated Financial statements are prepared in accordance with accounting principles generally accepted in the United States of America which require management to make estimates and assumptions. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expense. Significant estimates include our ability to continue as going concern, the recoverability of inventories and long-lived assets, and the valuation of stock-based compensation and certain debt and warrant liabilities. Actual results could differ from those estimates. Changes in facts and circumstances may result in revised estimates, which would be recorded in the period in which they become known.
Revenue Recognition, Policy [Policy Text Block]
Revenue Recognition
 
In general, we record revenue when persuasive evidence of an arrangement exists, services have been rendered or product delivery has occurred, the sales price to the customer is fixed or determinable, and collectability is reasonably assured. Provision for sales returns is estimated based on our historical return experience. Revenue is presented net of returns and allowances for returns.
Shipping and Handling Cost, Policy [Policy Text Block]
Accounting for Shipping and Handling Costs
 
The Company records shipping and handling costs incurred in cost of sales.
Cash and Cash Equivalents, Policy [Policy Text Block]
Cash and Cash Equivalents
 
We consider all highly liquid investments with an original maturity of three months or less to be cash equivalents.
Trade and Other Accounts Receivable, Policy [Policy Text Block]
Accounts Receivable and Allowance for Doubtful Accounts
 
The Company grants credit without collateral to its customers based on the Company’s evaluation of a particular customer’s credit worthiness. In addition, allowances for doubtful accounts are maintained for potential credit losses based on the age of the accounts receivable and the results of the Company’s periodic credit evaluations of its customers’ financial condition. Accounts receivable are written off after collection efforts have been deemed to be unsuccessful. Accounts written off as uncollectible are deducted from the allowance for doubtful accounts, while subsequent recoveries are netted against the provision for doubtful accounts expense. The Company generally does not charge interest on accounts receivable.
 
Accounts receivable are stated at estimated net realizable value. Accounts receivable are comprised of balances due from customers net of estimated allowances for uncollectible accounts.
Inventory, Policy [Policy Text Block]
Inventories
 
Inventories, which are stated at the lower of average cost or market, and consist mostly of raw venom that is utilized to make the API (active pharmaceutical ingredient). The raw unprocessed venom has an indefinite life for use. The Company regularly reviews inventory quantities on hand. If necessary it records a provision for excess and obsolete inventory based primarily on its estimates of component obsolescence, product demand and production requirements. Write-downs are charged to cost of goods sold. We performed evaluations of our inventory during the year ended December 31, 2013 and 2012 and recorded total allowances of $0 and $117,800, respectively.
Concentration Risk, Credit Risk, Policy [Policy Text Block]
Financial Instruments and Concentration of Credit Risk
 
Our financial instruments include cash, accounts receivable, accounts payable, accrued expenses, loans payable, due to officers and derivative financial instruments. Other than certain warrant and convertible instruments (derivative financial instruments) and liabilities to related parties (for which it was impracticable to estimate fair value due to uncertainty as to when they will be satisfied and a lack of similar type transactions in the marketplace), we believe the carrying values of our financial instruments approximate their fair values because they are short term in nature or payable on demand. Our derivative financial instruments are carried at a measured fair value.
 
Balances in various cash accounts may at times exceed federally insured limits. We have not experienced any losses in such accounts. We do not hold or issue financial instruments for trading purposes. In addition, for the year ended December 31, 2013, there were two customers that accounted for 19.6% and 15.3% of the total revenues, respectively. For the year ended December 31, 2012, no customers accounted for more than 10% of the Company’s total revenues. During 2013, the Company purchased 100% of its venom from one vendor.
Fair Value Measurement, Policy [Policy Text Block]
Derivative Financial Instruments
 
The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. Management evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported as charges or credits to income. For option-based simple derivative financial instruments, the Company uses the Black-Scholes option-pricing model to value the derivative instruments at inception and subsequent valuation dates. For complex embedded derivatives, the Company uses a Dilution-Adjusted Black-Scholes method to value the derivative instruments at inception and subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date.
Property, Plant and Equipment, Policy [Policy Text Block]
Property and Equipment and Long-Lived Assets
 
Property and equipment is recorded at cost. Expenditures for major improvements and additions are added to property and equipment, while replacements, maintenance and repairs which do not extend the useful lives are expensed. Depreciation is computed using the straight-line method over the estimated useful lives of the assets of 3 – 7 years.
 
Property and equipment consists of the following at December 31,
 
 
 
2013
 
2012
 
 
 
 
 
 
 
 
 
Computer equipment
 
$
21,918
 
$
21,918
 
Furniture and fixtures
 
 
34,757
 
 
34,757
 
Lab equipment
 
 
42,129
 
 
42,129
 
Telephone equipment
 
 
12,421
 
 
12,421
 
Office equipment – other
 
 
2,629
 
 
2,629
 
Leasehold improvements
 
 
67,417
 
 
67,417
 
Total
 
 
181,271
 
 
181,271
 
Less: Accumulated depreciation and amortization
 
 
(156,737)
 
 
(141,756)
 
 
 
 
 
 
 
 
 
Property and equipment, net
 
$
24,534
 
$
39,515
 
 
We review our long-lived assets for recoverability if events or changes in circumstances indicate the assets may be impaired. At December 31, 2013, we believe the carrying values of our long-lived assets are recoverable. Depreciation expense for the years ended December 31, 2013 and 2012 was $14,981 and $14,994, respectively.
Advertising Cost, Policy, Expensed Advertising Cost [Policy Text Block]
Advertising
 
All advertising costs are expensed as incurred. Advertising costs were approximately $900 and $70,800 for the years ended December 31, 2013 and 2012, respectively.
Income Tax, Policy [Policy Text Block]
Income Taxes
 
We compute income taxes in accordance with Financial Accounting Standard Board (“FASB”) Accounting Standard Codification (“ASC”) Topic 740, Income Taxes (“ASC Topic 740”). Under ASC Topic 740, deferred taxes are recognized for the tax consequences of temporary differences by applying enacted statutory rates applicable to future years to differences between the financial statement carrying amounts and the tax bases of existing assets and liabilities. Also, the effect on deferred taxes of a change in tax rates is recognized in income in the period that included the enactment date. Temporary differences between financial and tax reporting arise primarily from the use of different methods to record bad debts and /or sales returns, and inventory reserves.
 
On an annual basis, we evaluate tax positions that have been taken or are expected to be taken in our tax returns to determine if they are more than likely to be sustained if the taxing authority examines the respective position. As of December 31, 2013 and 2012, we do not believe we have a need to record any liabilities for uncertain tax positions or provisions for interest or penalties related to such positions.
 
Since inception, we have been subject to tax by both federal and state taxing authorities. Until the respective statutes of limitations expire (which may be as much as 20 years while we have unused net operation losses), we are subject to income tax audits in the jurisdictions in which we operate.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]
Stock-Based Compensation
 
We account for stock-based compensation in accordance with FASB ASC Topic 718, Stock Compensation (ASC Topic 718). ASC Topic 718, which requires that the cost resulting from all share-based transactions be recorded in the financial statements over the respective service periods. It establishes fair value as the measurement objective in accounting for share-based payment arrangements and requires all entities to apply a fair-value-based measurement in accounting for share-based payment transactions with employees. The statement also establishes fair value as the measurement objective for transactions in which an entity acquires goods or services from non-employees in share-based payment transactions.
Earnings Per Share, Policy [Policy Text Block]
Net Loss Per Share
 
Net loss per share is calculated in accordance with ASC Topic 260, Earnings per Share. Basic loss per share is calculated by dividing net loss by the weighted average number of common shares outstanding for the period. Diluted loss per share is calculated by dividing net loss by the weighted average number of common shares and dilutive common stock equivalents outstanding. During periods in which we incur losses, common stock equivalents, if any, are not considered, as their effect would be anti-dilutive or have no effect on earnings per share. Any common shares issued as of a result of the exercise of stock options and warrants would come from newly issued common shares from our remaining authorized shares. As of December 31, 2013 and 2012, the following items were not included in dilutive loss as the effect is anti-dilutive:
 
 
 
2013
 
2012
 
Options and warrants
 
154,916,667
 
57,256,667
 
Convertible notes payable
 
98,506,398
 
44,642,858
 
Total
 
253,423,065
 
101,899,525
 
Reclassification, Policy [Policy Text Block]
Reclassifications
 
Certain amounts in the 2012 Consolidated Financial statements have been reclassified to conform to the current period presentation.
New Accounting Pronouncements, Policy [Policy Text Block]
Recent Accounting Pronouncements
 
We have determined that all recently issued but not yet effective accounting standards will not have a material impact on our Consolidated Financial statements.
XML 52 R15.htm IDEA: XBRL DOCUMENT v2.4.0.8
STOCK OPTIONS AND WARRANTS
 12 Months Ended
Dec. 31, 2013
Equity [Abstract]  
Shareholders' Equity and Share-based Payments [Text Block]
7. STOCK OPTIONS AND WARRANTS
 
Common Stock Warrants
 
From time to time, we issue warrants to purchase our common stock. These warrants have been issued for cash in conjunction with the private placement of shares of our common stock.
 
During December 2013, the Company issued a total of 10,000,000 warrants to purchase common stock at an exercise price of $0.03 per share in connection with the private placement offerings. The warrants expire on December 31, 2015 (See note 6).
 
During October and November 2013, the Company issued a total of 1,000,000 warrants to purchase common stock at an exercise price of $0.10 per share in connection with the private placement offerings. The warrants expire on December 31, 2014 (See note 6).
 
On September 16, 2013, the Company issued 25,000,000 warrants to purchase stock at an exercise price of $0.030 in connection with settlement of an outstanding account payable. The warrants expire on December 31, 2014 (See Note 3 and Note 6).
 
On September 3, 2013 and September 12, 2013, the Company issued 20,000,000 and 15,000,000 warrants, respectively, to purchase common stock at an exercise price of $0.025 per share in connection with issuances of convertible notes payable to Coventry. The warrants expire on September 3, 2018 and September, 12, 2018, respectively (See note 5).
 
During March, 2013, the Company issued a total of 2,600,000 warrants to purchase common stock at an exercise price of $0.01 per share in connection with issuance of a convertible note payable to Coventry. The warrants expire on March 22, 2018 (See note 5).
 
During June, 2013, 25,000,000 warrants to purchase stock at an exercise price of $0.10 per share were issued to CEO, Mr. Deitsch in exchange of notes payable. The warrants expire on December 31, 2014 (See note 4).
 
A summary of warrants outstanding in conjunction with private placements of common stock were as follows during the year ended December 31, 2013 and 2012:
 
 
 
Number of shares
 
Weighted average exercise price
 
Balance December 31, 2011
 
47,921,667
 
$
0.10
 
Exercised
 
-
 
 
-
 
Issued
 
54,650,000
 
$
0.10
 
Forfeited/Expired
 
(45,315,000)
 
 
-
 
Balance December 31, 2012
 
57,256,667
 
$
0.10
 
Exercised
 
-
 
 
-
 
Issued
 
98,600,000
 
$
0.01 – 0.10
 
Forfeited
 
(940,000)
 
 
-
 
Balance December 31, 2013
 
154,916,667
 
$
0.082
 
 
The following table summarizes information about fixed-price warrants outstanding as of December 31, 2013 and 2012:
 
 
 
Exercise Price
 
Number
Outstanding
 
Weighted
Average
Contractual
Life
 
Weighted
Average
Exercise Price
 
2013
 
$
0.01-0.10
 
154,916,667
 
1.97 years
 
$
0.082
 
2012
 
$
0.10-0.15
 
57,256,667
 
2.04 years
 
$
0.10
 
 
As of December 31, 2013, the aggregate intrinsic value of all stock options and warrants outstanding and expected to vest was $0. The intrinsic value of each option share is the difference between the fair value of our common stock and the exercise price of such option share to the extent it is “in-the-money”. Aggregate intrinsic value represents the value that would have been received by the holders of in-the-money options had they exercised their options on the last trading day of the year and sold the underlying shares at the closing stock price on such day. The intrinsic value calculation is based on the $0.0075, closing stock price of our common stock on December 31, 2013.There were no in-the-money warrants at December 31, 2013.
XML 53 R13.htm IDEA: XBRL DOCUMENT v2.4.0.8
OTHER DEBT
 12 Months Ended
Dec. 31, 2013
Debt Disclosure [Abstract]  
Other Debt [Text Block]
5. OTHER DEBT
 
Other debt (all short-term) consists of the following at December 31, 2013 and 2012:
 
 
 
2013
 
2012
 
 
 
 
 
 
 
 
 
Note payable – Related Party (1)
 
$
180,000
 
$
190,000
 
Notes payable – Non Related Parties (2)
 
 
412,182
 
 
593,483
 
Convertible notes payable, at fair value (3)
 
 
767,056
 
 
588,091
 
 
 
 
 
 
 
 
 
Ending balances
 
$
1,359,238
 
$
1,371,574
 
 
 
(1)
During the third quarter of 2010 we borrowed $200,000 from one of our directors. We repaid $10,000 each (total $20,000) during the third quarter of 2012 and 2013. Under the terms of the loan agreement, this loan was expected to be repaid in nine months to a year from the date of the loan along with interest calculated at 10% for the first month plus 12% after 30 days from funding. We are in default regarding this loan. At December 31, 2013 and 2012, we owed this director accrued interest of $121,137 and $86,387, respectively.
 
 
(2)
At December 31, 2013 and 2012, the balance of $412,182 and $593,483 , respectively, consisted of the following loans:
 
 
·
In May 2011, the Company received a loan for $25,000 from a non-related party. This loan was expected to be repaid no later than December 31, 2011, along with interest calculated at 10% for the first month plus 12% after 30 days from funding. This loan is guaranteed by an officer of the Company. On November 25, 2013, the non-related party accepted a total of 4,360,000 shares of the Company’s restricted common stock as a repayment to discharge $25,000 of his outstanding loan and accrued interest of $11,956 (See note 6).  The Company recorded a loss of $28,444 on the settlement date.
 
 
·
In May 2011, the Company received another loan for $25,000 from a non-related party. This loan was expected to be repaid no later than December 31, 2011, along with interest calculated at 10% for the first month plus 12% after 30 days from funding. This loan is guaranteed by an officer of the Company. On September 16, 2013, the non-related party accepted a total of 8,472,750 shares of the Company’s restricted common stock as a repayment to discharge $25,000 of his outstanding loan and accrued interest of $11,120 (See note 6). The Company recorded a loss of $90,971 on the settlement date.
 
 
·
In July 2013, the Company issued a promissory note to the Michael McDonald Trust in the amount of $75,000 bearing interest at a rate of 2% per month. The note is due in six months from the execution and funding of the note. In connection with the issuance of this promissory note, the Company issued 1,000,000 shares of the Company's common stocks (See note 6). The Company has recorded a debt discount in the amount of $3,977 to reflect the value of the common stocks as a reduction to the carrying amount of the convertible debt and a corresponding increase to common stocks and additional paid-in capital. The total discount of $3,977 was fully amortized over the term of the debt during the year ended December 31, 2013.   In the event of default, the Company would issue an additional 1,000,000 share of the Company’s common stocks on the date that is fifteen days after the maturity date (See Note 6). We are in default regarding this loan. The additional 1,000,000 shares were issued in January 2014 with a fair value at $9,900 (See Note 10). At December 31, 2013, we owed Michael McDonald accrued interest of $9,000.
 
 
·
At December 31, 2012, the total amount of the Company’s debt assigned to Southridge was $483,482. In connection with the debt sales to Southridge, the Company recorded a loss on settlement of accounts payable for $63,490 in the statement of operations at December 31, 2012. During the first quarter of 2013, the suit was voluntarily dismissed involving debt held by Southridge for $483,482. The debt has reverted back to the original holders.
 
In April, 2013, $88,500 of the debt held by Michael McDonald Trust was assigned to Coventry Enterprises, LLC (“Coventry”) in the form of a Convertible Redeemable Note bearing interest of 8% annum. Coventry was entitled to convert all or any amount of the this note into shares of the Company's common stock (the "Common Stock") at a conversion price ("Conversion Price") for each share of Common Stock equal to 55% of the average of the daily volume weighted average prices of the Common Stock for the 3 trading days with the lowest volume weighted average prices during the 15 trading days immediately preceding the Conversion Date. Following the agreements with Coventry, Coventry made the conversions for a total of 31,416,845 shares of the company’s restricted stock during the second quarter of 2013 satisfying the notes in full at the fair value of $186,646.
 
In June, 2013, $57,800 of the debt was assigned to Coventry for a consideration of $60,000 from Baker Donelson Bearman Caldwell & Berkowitz, PC. in the form of Convertible Redeemable Notes bearing interest of 8% annum. The Company recorded a loss of $2,200 on the settlement during the year ended December 31, 2013. Coventry was entitled to convert all or any amount of the these notes into shares of the Company's common stock (the "Common Stock") at a conversion price ("Conversion Price") for each share of Common Stock equal to 55% of the average of the daily volume weighted average prices of the Common Stock for the 3 trading days with the lowest volume weighted average prices during 20 trading days . Following the agreements, Coventry made the conversions for a total of 27,272,727 shares of the company’s restricted stock satisfying the notes in full at the fair value of $167,495.
 
As a result of the debt assignments and conversions with Coventry, the remaining balance of the debt at December 31, 2013 is $337,182 which consisted of the following loans:
 
 
i.
On August 2, 2011 under a settlement agreement with Liquid Packaging Resources, Inc. (“LPR”), the Company agreed to pay LPR a total of $350,000 in monthly installments of $50,000 beginning August 15, 2011 and ending on February 15, 2012. This settlement amount was recorded as general and administrative expenses on the date of the settlement. We did not make the December 2011 or January 2012 payments and on January 26, 2012, we signed the first amendment to the settlement agreement where under we agreed to pay $175,000 which was the balance outstanding at December 31, 2011(this includes a $25,000 penalty for non-payment).
 
The Company repaid $25,000 during the three months ended March 31, 2012. The Company did not make all of the payments under such amendment and as a result pursuant to the original settlement agreement, LPR had the right to sell 5,714,326 shares of the Company’s free trading stock held in escrow by their attorney and receive cash settlements for a total amount of $450,000 (the initial $350,000 plus total default penalties of $100,000). The $100,000 default was expensed during 2012. LPR sold the note to Southridge Partners, LLP (“Southridge”) for consideration of $281,772 in October 2012. The debt has reverted back to the Company (See note 9).
 
 
ii.
As of December 31, 2013 and 2012, the Company owed University Centre West Ltd. approximately $55,410, which was assigned and sold to Southridge and subsequently reverted back to the Company .
 
 
(3)
At December 31, 2013 and 2012, the balance of $767,056 and $588,091 consisted of the following convertible loans:
 
 
·
In September and October 2011, the Company borrowed $250,000 each (aggregating $500,000) from two non-related parties. The principal of these loans were to be repaid with a balloon payment on or before October 1, 2012. On October 19, 2012 the parties amended the notes to extend the due date to May 1, 2013 and include a conversion feature that would allow the holders to convert some or all of their outstanding notes into restricted Company stock at a 15% discount to the average closing market price of the Company's stock traded over the previous 10 days. Interest on these loans is payable monthly beginning in November 2011 with interest calculated at 20% and 12%, each, respectively. At December 31, 2013 and 2012, the accrued interest payable was $6,664.
 
During year ended December 31, 2013, one of the Note holders made conversions of a total of 34,254,004 shares of the company’s restricted stock satisfying the notes in the amount of $125,000 with a fair value of $317,391 on the date of conversion. During August and September, 2013, $150,000 of the debts were assigned to three non-related parties in the form of a Convertible Redeemable Note bearing interest of 8% annum with a conversion price for each share of Common Stock equal to 55% of the average of the daily volume weighted average prices of the Common Stock for the 3 trading days with the lowest volume weighted average prices during the 15 to 20 trading days immediately preceding the Conversion Date. Following the assignments, the conversions for a total of 64,052,862 shares of the company’s restricted stock were made in satisfying the notes of $150,000 at the fair value of $475,519 (See note 6).
 
At December 31, 2013, the remaining balance of these two convertible notes payable of $75,000 and $150,000 were recorded at a fair value of $90,260 and $189,781, respectively. At December 31, 2012, these two convertible note payable of $250,000 each were recorded at fair value of $290,289 and $297,802, respectively.
 
On April 30, 2013, the parties amended the notes to further extend the maturity date to November 3, 2013. The Company issued a total of 4,000,000 restricted shares to the note holders in connection with the amendment at a fair value of $20,800. On October 30, 2013 and November 1, 2013, the parties amended the note of $75,000 and $150,000 to further extend the maturity dates to May 3, 2014 and August 3, 2014, respectively. The Company issued a total of 500,000 and 1,250,000 restricted shares to the note holders in connection with the amendment at a fair value of $9,500 and $13,750 (See note 6), respectively.
 
 
·
On March 22, 2013, the Company issued a Convertible Debenture in the amount of $20,000 to Coventry Enterprises, LLC (“Coventry”). The note carries interest at 10% and is due on March 22, 2014, unless previously converted into shares of restricted common stock. Coventry has the right to convert the note, until is no longer outstanding into shares of Common Stock at a price which is lesser of $.0075, or (ii) fifty-five percent (55%) of the average of the three lowest VWAP prices of the Company’s Common Stock for the twenty trading days preceding the conversion date. In connection with the issuance of this convertible note payable, the Company encountered a day-one derivative loss of $24,931. Coventry made the conversions into a total of 8,810,572 shares of the company’s restricted stock satisfying the notes in full with a fair value of $188,747on September 4, 2013(See note 7).
 
In connection with the issuances of the Note, the Company also granted five-year warrants to purchase an aggregate of 2,600,000 shares of the Company’s common stock at an exercise price of $0.01 per share. The Company classified embedded conversion features in these warrants as a derivative liability. The warrants were valued at their fair value of $21,226 and $17,895, respectively using the Black-Scholes method at the commitment and re-measurement dates of March 22, 2013 and December 31, 2013, respectively.
 
 
·
On July 10, 2013 and October 10, 2013, the Company issued two Convertible Debentures in the amount of $30,000 each (total $60,000) to Christopher Castaldo in connection with the agreements for investor relation services (See Note 6). The notes carry interest at 8% and are due on January 10, 2014 and April 10, 2014, respectively. The notes’ holder has the right to convert the notes into shares of Common Stock at a price of $0.005.
 
In connection with the issuance of this convertible notes payable, the Company encountered a day-one derivative loss of $83,157. At December 31, 2013, these convertible notes payable, at fair value, was recorded at $90,684.
 
 
·
On September 3, 2013, the Company issued a Convertible Debenture in the amount of $100,000 to Coventry Enterprises, LLC (“Coventry”). The note carries interest at 10% and is due on September 3, 2014, unless previously converted into shares of restricted common stock. Coventry has the right to convert the note, until is no longer outstanding into shares of Common Stock at a price lesser of $.018, or (ii) fifty-five percent (55%) of the average of the three lowest VWAP prices of the Company’s Common Stock for the twenty trading days preceding the conversion date.
 
In connection with the issuance of this convertible note payable, the Company encountered a day-one derivative loss of $957,567. At December 31, 2013, this convertible note payable, at fair value, was recorded at $185,971.
 
In connection with the issuances of the Note, the Company also granted five-year warrants to purchase an aggregate of 20,000,000 shares of the Company’s common stock at an exercise price of $0.025 per share. The Company classified embedded conversion features in these warrants as a derivative liability. The warrants were valued at their fair value of $445,638 and $137,681, respectively using the Black-Scholes method at the commitment and re-measurement dates of September 3, 2013 and December 31, 2013, respectively.
 
 
·
On September 12, 2013, the Company issued a Convertible Debenture in the amount of $70,000 to Coventry Enterprises, LLC (“Coventry”). The note carries interest at 10% and is due on September 12, 2014, unless previously converted into shares of restricted common stock. Coventry has the right to convert the note, until is no longer outstanding into shares of Common Stock at a price lesser of $.02, or (ii) fifty-five percent (55%) of the average of the three lowest VWAP prices of the Company’s Common Stock for the twenty trading days preceding the conversion date.
 
In connection with the issuance of this convertible note payable, the Company encountered a day-one derivative loss of $309,055. At December 31, 2013, this convertible note payable, at fair value, was recorded at $130,303.
 
In connection with the issuances of the Note, the Company also granted five-year warrants to purchase an aggregate of 15,000,000 shares of the Company’s common stock at an exercise price of $0.025 per share. The Company classified embedded conversion features in these warrants as a derivative liability. The warrants were valued at their fair value of $262,230 and $101,140, respectively using the Black-Scholes method at the commitment and re-measurement dates of September 12, 2013 and December 31, 2013, respectively.
 
 
·
On October 7, 2013, the Company signed a secured convertible Promissory Note in the amount of $35,000 in favor of Southridge Partners II, LLC. The note was due on demand and carries interest at 10% annum. Southridge Partners II, LLC was entitled to convert the principal into shares of common stock at the lesser of $0.015 or a 50% discount from the lowest closing bid price in the 30 trading days prior to the day that the conversion is requested; and interest accrued was entitled to convert into shares of common stock at $0.001. In the evaluation of these financing arrangements, the Company concluded that these conversion features did not meet the conditions set forth in current accounting standards for equity classification. Since equity classification is not available for the conversion feature, it requires bifurcation and liability classification, at fair value. The Company also concluded that the Default Put required bifurcation because, while puts on debt instruments are generally considered clearly and closely related to the host, the Default Put is indexed to certain events that are not associated with the convertible note payable.
 
In connection with the issuance of this convertible note payable, the Company encountered a day-one derivative loss of $81,667. At December 31, 2013, this convertible note payable, at fair value, was recorded at $80,057.
 
 
·
On October 27, 2011 the Company entered into a convertible note payable with a corporation. The convertible note payable, with a face value of $53,000, bears interest at 8.0% per annum and was due on July 31, 2012.
 
On December 5, 2011 the Company entered into a convertible note payable with a corporation which had a face value of $37,500, a coupon rate of 8.0% per annum and maturity date of September 5, 2012.
 
The convertible note payable is convertible, at the holder’s option, into the Company’s common shares at a variable conversion price which is 58% multiplied by the average of the lowest three (3) trading prices for the Common Stock during the ten (10) Trading Day period ending one Trading Day prior to the date the Conversion Notice is sent by the Holder to the Borrower. The conversion feature is subject to full-ratchet, anti-dilution protection if the Company sells shares or share-indexed financing instruments at less than the conversion price. The holder has the option to redeem the convertible note payable for cash in the event of defaults or certain other contingent events (the “Default Put”).
 
During October 2012, both of these notes were acquired by a third party from Asher Enterprises for an aggregate amount of $100,000, and then converted into 20,000,000 restricted common shares (See note 6).
 
 
·
On February 3, 2012, the Company issued a Convertible Debenture in the amount of $40,000 to Redwood Management, LLC. The note carries interest at 12% and is due on February 13, 2013, unless converted into shares of restricted common stock. Redwood Management, LLC has the right to convert the note, until it is no longer outstanding, into shares of Common Stock at a price of Fifty Percent (50%) of the lowest closing price, determined on the then current trading market for the Company’s common stock, during the 15 trading days prior to conversion (the “Set Price”). On September 12, 2012, TCN International (TCN) completed the purchase and transfer of this note including penalties and unpaid interest, for the sum of $52,500. Redwood Management, LLC has acknowledged the full payment of the Note, in favor of Nutra Pharma Corporation and releases Nutra Pharma Corporation from all obligations under the Note. Upon the request of TCN, the Board of Directors of the Company approved the conversion of these notes into Restricted Common Stock of the Company,providing 7,500,000 shares of Nutra Pharma common stock to relinquish the total debt of $52,500 (See note 6).
 
 
·
On March 16, 2012 the Company signed a secured convertible Promissory Note in the amount of $75,000 in favor of Southridge Partners II, LLC. The note was due November 16, 2012 and carries interest at 8% annum. Southridge Partners II, LLC was entitled after nine months to convert all or a portion of the principal and interest accrued into shares of common stock at a conversion price of each share equal to the Market Price multiplied times 70%. (the “conversion price”). The Market Price is equal to the average of the two lowest bids closing prices for the five trading days ending before the conversion date. In the evaluation of these financing arrangements, the Company concluded that these conversion features did not meet the conditions set forth in current accounting standards for equity classification. Since equity classification is not available for the conversion feature, it requires bifurcation and liability classification, at fair value. The Company also concluded that the Default Put required bifurcation because, while puts on debt instruments are generally considered clearly and closely related to the host, the Default Put is indexed to certain events that are not associated with the convertible note payable. On October 26, 2012, Southridge converted the note into 5,919,495 shares of the Company's restricted common stock (See note 6).
 
In the evaluation of these financing arrangements, the Company concluded that these conversion features did not meet the conditions set forth in current accounting standards for equity classification. Since equity classification is not available for the conversion feature, it requires bifurcation and liability classification, at fair value. The Company also concluded that the Default Put required bifurcation because, while puts on debt instruments are generally considered clearly and closely related to the host, the Default Put is indexed to certain events that are not associated with the convertible note payable.
 
The Company elected to account for these hybrid contracts under the guidance of ASC 815-15-25-4. The fair value has been defined as the common stock equivalent value, enhanced by the fair value of the default put plus the present value of the coupon.
 
The holder of this convertible note has substantial rights and protections regarding dilution if certain events, including a default were to occur. There are a number of events that could trigger a default, including but not limited to failure to pay principal or interest, failure to issue shares under the conversion feature, breach of covenants, breach of representations and warranties, appointment of a receiver or trustee, judgments, bankruptcy, delisting of common stock, failure to comply with the exchange act, liquidation, cessation of operations, failure to maintain assets, material financial statement restatement, reverse split of borrowers stock, etc. In the event of these events the lender may be entitled to receive significant amounts of additional stock above the amounts for conversion.
 
Furthermore, there are additional events that could cause the lender to be due additional shares of common stock above and beyond the shares due from a conversion. Some of these events include, but are not limited to a merger or consolidation of the Company, dividend distribution or spin off, dilutive issuances of the Company’s stock, etc. If the lender receives additional shares of the Company’s commons stock due to any of the foregoing events or for other reasons, then this may have an extremely dilutive effect on the shareholders of the Company. Such dilution would likely result in a significant drop in the per share price of the Company’s common stock. The potential dilutive nature of this note presents a very high degree of risk to the Company and its shareholders
XML 54 R14.htm IDEA: XBRL DOCUMENT v2.4.0.8
STOCKHOLDERS' DEFICIT
 12 Months Ended
Dec. 31, 2013
Stockholders' Equity Note [Abstract]  
Stockholders' Equity Note Disclosure [Text Block]
6. STOCKHOLDERS' DEFICIT
 
Private Placements of Common Stock
 
In 2013, the Company sold 10,000,000 shares of restricted common stock to an investor at a price per share of $0.005 and received proceeds of $50,000. The Company issued 10,000,000 warrants to purchase common stock at an exercise price of $0.03 per share. The warrants expire on December 31, 2015.
 
In 2013, the Company sold an aggregate of 11,000,000 shares of restricted common stock to five investors at a price per share range from $0.002 to $0.015 and received proceeds of $45,000. The Company issued a total of 1,000,000 warrants to purchase common stock at an exercise price of $0.10 per share. The warrants expire on December 31, 2014.
 
In 2013, the Company sold an aggregate of 21,000,000 shares of restricted common stock to two investors at a price per share range from $0.001 to $0.0042 and received proceeds of $45,000.
 
In 2012, the Company sold an aggregate of 17,650,000 shares of restricted common stock to investors at a price of $0.01 per share and received $176,500. The Company issued a total of 17,650,000 warrants to purchase common stock at an exercise price of $0.10 per share. The warrants expire on December 31, 2014.
 
In 2012, the Company sold an aggregate of 27,000,000 shares of restricted common stock to one investor at a price of $0.01 per share and received $270,000. The Company issued a total of 27,000,000 warrants to purchase common stock at an exercise pric
\e of $0.10 per share in October 2012. The warrants expire on December 31, 2014.
 
Shares Issued to Employees and Directors
 
On November 22, 2013, the Board of Directors approved a resolution for the issuance of a total of 34,630,000 shares of the Company’s restricted common stock to directors and employees of the Company. The issuance was valued at $484,820 ($0.014 per share), which was the fair value of the Company’s common stock on the date of issuance.
 
On September 3, 2013, the Board of Directors approved a resolution for the issuance of 1,000,000 shares of the Company’s restricted common stock to an employee of the Company. The issuance was valued at $22,900 ($0.0229 per share), which was the fair value of the Company’s common stock on the date of issuance.
 
During October and December 2012, the Board of Directors approved resolutions for the issuance of a total of 26,875,000 shares of the Company’s restricted common stock to the Directors and Employees of the Company. The shares were valued at $569,400 ($0.022 and $0.014 per share), which was the fair value of the Company’s common stock on the date of issuance.
 
On February 3, 2012 the Board of Directors approved a resolution for the issuance of a total of 15,720,000 shares of the Company’s restricted common stock to the Directors and Employees of the Company. The issuance was valued at $259,380 ($0.0165 per share), which was the fair value of the Company’s common stock on the date of issuance.
 
Common Stock Issued for Services
 
During November, 2013, the Company issued 1,000,000 shares of the Company’s restricted common stock to a consultant for investor relation services for two months. The shares were valued at $0.0175 per share. The Company recorded an equity compensation charge of $17,500 during the year ended December 31, 2013.
 
During October, 2013, the Company issued 15,000,000 shares of the Company’s restricted common stock to a consultant for investor relation services for three months. The shares were valued at $0.0178 per share. The Company recorded an equity compensation charge of $267,000 during the year ended December 31, 2013.
 
During September, 2013, the Company issued 1,500,000 shares of the Company’s restricted common stock to a consultant for consulting services rendered. The shares were valued at $0.016 per share. The Company recorded an equity compensation charge of $24,000 during the year ended December 31, 2013.
 
During September, 2013, the Company issued a total of 1,500,000 shares of the Company’s restricted common stock to two consultants for consulting services rendered. The shares were valued at $0.0229 per share. The Company recorded an equity compensation charge of $34,350 during the year ended December 31, 2013.
 
During August, 2013, the Company issued a total of 6,000,000 shares of the Company’s restricted common stock to two consultants for investor relation services for six months. The shares were valued at $0.0173 per share. The Company recorded an equity compensation charge of $70,902 during the four months ended December 31, 2013. The remaining unrecognized compensation cost of $32,898 related to non-vested equity-based compensation to be recognized by the Company over the remaining vesting period of two months.
 
During August, 2013, the Company issued 2,000,000 shares of the Company’s restricted common stock to a consultant for investor relation services for one year. The shares were valued at $0.012 per share. The Company recorded an equity compensation charge of $8,351 during the four months ended December 31, 2013. The remaining unrecognized compensation cost of $15,649 related to non-vested equity-based compensation to be recognized by the Company over the remaining vesting period of eight months.
 
During August, 2013, the Company issued 2,000,000 shares of the Company’s restricted common stock to a consultant for consulting services for six months. The shares were valued at $0.0056 per share. The Company recorded an equity compensation charge of $8,446 during the four and one half months ended December 31, 2013. The remaining unrecognized compensation cost of $2,754 related to non-vested equity-based compensation to be recognized by the Company over the remaining vesting period of one and half months.
 
During July, 2013, the Company issued 2,000,000 shares of the Company’s restricted common stock to a consultant for consulting services for six months. The shares were valued at $0.0042 per share. The Company recorded an equity compensation charge of $8,400 during the year ended December 31, 2013.
 
During July, 2013, the Company issued 100,000 shares of the Company’s restricted common stock to a consultant for consulting services rendered. The shares were valued at $0.0042 per share. The Company recorded an equity compensation charge of $420 during the year ended December 31, 2013
 
During July 2013, the Company signed an agreement with a consultant for investor relation services for three months. A $30,000 convertible note convertible at $0.005 per share was also issued (See Note 5). The Company also paid a total of $10,000 cash and issued a total of 15,000,000 shares of company’s restricted common stocks. The shares were valued at $0.0057 per share. The Company recorded an equity compensation charge of $85,500 during the year ended December 31, 2013.
 
During June, 2013, the Company issued 2,000,000 shares of the Company’s restricted common stock to a consultant for investor relation services for six months. The shares were valued at $0.0042 per share. The Company recorded an equity compensation charge of $8,400 during the year ended December 31, 2013.
 
During May, 2013, the Company issued 1,000,000 shares of the Company’s restricted common stock to a consultant for investor relation services for six months. The shares were valued at $0.0053 per share. The Company recorded an equity compensation charge of $5,300 in May 2013.
 
During February, 2013, the Company issued 8,000,000 shares of the Company’s restricted common stock to a consultant for investor relation services for a year. The shares were valued at $0.008 per share. The Company recorded an equity compensation charge of $61,019 during the year ended December 31, 2013. The remaining unrecognized compensation cost of $2,981 related to non-vested equity-based compensation to be recognized by the Company over the remaining vesting period of one half month.
 
During February 2013, the Company issued 1,500,000 shares of the Company’s restricted common stock to a consultant for investor relation services for two months. The shares were valued at $0.007 per share. The Company recorded an equity compensation charge of $10,500 during the year ended December 31, 2013.
 
During February 2013, the Company issued a total of 3,000,000 shares of the Company’s restricted common stock to three consultants for marketing services for six months. The shares were valued at $0.009 per share. The Company recorded an equity compensation charge of $27,000 during the year ended December 31, 2013.
 
During January, 2013, the Company issued 10,000,000 shares of the Company’s restricted common stock to a consultant for investor relation services for a year. The shares were valued at $0.005 per share. The Company recorded an equity compensation charge of $50,000 during the year ended December 31, 2013.
 
On December 14, 2012 the Company issued a total of 1,000,000 shares of the Company’s restricted common stock to Roetzell & Andress for legal services for a one year term. The shares were valued at $0.014 per share. The Company recorded a prepaid equity compensation charge of $14,000 during the year ended December 31, 2012, and recognized an equity compensation charge of $14,000 during the year ended December 31, 2013.
 
During October, 2012 the Company issued a total of 15,100,000 shares of the Company’s restricted common stock to five consultants for marketing services for six months terms. The shares were valued at $0.0125 per share. The Company recorded an equity compensation charge of $108,534 and $80,216 during the year ended December 31, 2013 and year ended December 31, 2012.
 
During December, 2012 the Company issued 500,000 shares of the Company’s restricted common stock to a consultant for real estate consulting services for a six months term. The shares were valued at $0.0125 per share. The Company recorded an equity compensation charge of $1,042 during the year ended December 31, 2012. The remaining unrecognized compensation cost of $5,208 was recognized during the year ended December 31, 2013.
 
During August, 2012 the Company issued 3,000,000 shares of the Company’s restricted common stock to JPU Ventures, Inc. under agreement dated August 13, 2012. The agreement was for investor relations services for a nine months term. The shares were valued at $0.0125 per share. The Company recorded an equity compensation charge of $21,875 during the year ended December 31, 2012. The remaining unrecognized compensation cost of $15,625 was recognized by the Company during the year ended December 31, 2013.
 
On October 1, 2012, the Company issued 5,500,000 shares of the Company’s restricted common stock under the amended agreement with Mark Bergman, a consultant. The contract is for six months term. The shares were valued at $0.0125 per share. The Company recorded an equity compensation charge of $28,646 and $40,104 for the agreement during the year ended December 31, 2013 and the year ended December 31, 2012.
 
During October, 2012, the Company entered into an agreement for investor relations services with a Consultant. The contract was for a six months term and calls for the issuance of 1,000,000 shares of restricted common stock. The share was valued at $0.0125 per share. The Company recorded an equity compensation charge of $8,697 during the year ended December 31, 2012. The remaining unrecognized compensation cost of $3,533 was recognized by the Company during the year ended December 31, 2013.
 
On February 22, 2012 the Company engaged Capital Path Securities, LLC (“CPS”) as its exclusive advisor on a proposed placement by way of an equity line of approximately $10,000,000 of the Company’s equity or equity linked securities. All upfront fees have been waived by CPS. The Company will pay CPS a cash placement fee equal to 5% of all principal amounts invested from the source originated by CPS. In addition, 10,000,000 restricted shares were issued on October 26, 2012, and valued at $0.0125 per share. The Company recorded an equity compensation charge of $151,375 during the year ended December 31, 2012. The remaining unrecognized compensation cost of $21,625 and 125,000 non-vested shares was recognized by the Company during the year ended December 31, 2013.
 
Common Stock Issued for Debt Modification
 
On April 30, 2013, the Company amended the maturity dates of two notes of $250,000 each (aggregating $500,000) from two non-related parties to November 3, 2013. The Company issued a total of 4,000,000 restricted shares to the note holders in connection with the amendment at a fair value of $20,800.
 
On October 30, 2013 and November 1, 2013, the parties amended the note of $75,000 and $150,000 to further extend the maturity dates to May 3, 2014 and August 3, 2014. The Company issued a total of 500,000 and 1,250,000 restricted shares to the note holders in connection with the amendment at a fair value of $9,500 and $13,750, respectively (See Note 5).
 
On October 19, 2012 the Company amended the notes $250,000 each (aggregating $500,000) from two non-related parties originated in September and October 2011to include a conversion feature that would allow the holders to convert some or all of their outstanding notes into restricted Company stock at a 15% discount to the average closing market price of the Company's stock traded over the previous 5 days. The Company issued a total of 4,000,000 restricted shares to the note holders per the amendment. The shares were valued at $0.025 per share. (See note 5).
 
Common Stock Issued with Promissory Note
 
In July 2013, in connection with the issuance of this promissory note to Michael McDonald Trust in the amount of $75,000 which is due in six months from the funding of the note, the Company issued 1,000,000 shares of the Company's common stocks. The Company has recorded a debt discount in the amount of $3,977 to reflect the value of the common stocks as a reduction to the carrying amount of the convertible debt and a corresponding increase to common stocks and additional paid-in capital. The total discount of $3,977 was amortized over the term of the debt.  Amortization for the year ended December 31, 2013 was $3,977 (See Note 5).
 
Common Stock Held in Escrow
 
On July 27, 2011 the Company issued 5,714,286 shares of free trading common stock in certificate form which is held in escrow as security under an agreement reached with Liquid Packaging Resources, Inc. (“LPR”) on August 2, 2011(See note 3 and 5).
 
Common Stock Issued for Settlement of Accounts Payable & Debt
 
Following the agreements with Coventry Enterprises, LLC (see Note 3) for $80,000, Coventry made the following conversions for a total of 15,119,481 shares of the company’s restricted stock during the first quarter of 2013 satisfying the notes in full and recorded a loss of $65,039 (See note 3): 
 
Date
 
Number of shares
converted
 
Fair Value
of Debt
Converted
 
January 21, 2013
 
 
4,032,258
 
$
37,619
 
February 11, 2013
 
 
5,405,405
 
$
42,510
 
March 20, 2013
 
 
5,681,818
 
$
40,414
 
 
Following the agreement with Coventry Enterprises, LLC (see Note 5) for $88,500, Coventry made the following conversions for a total of 31,416,845 shares of the company’s restricted stock during the second quarter of 2013 satisfying the notes in full:
 
Date
 
Number of shares converted
 
Fair Value
of Debt
Converted
 
4/17/2013
 
 
7,133,333
 
$
49,586
 
5/16/2013
 
 
11,101,694
 
$
64,930
 
6/12/2013
 
 
13,181,818
 
$
70,130
 
 
Following the agreement with Coventry Enterprises, LLC (see Note 5) for $60,000, Coventry made the conversion for a total of 27,272,727 shares of the company’s restricted stock during the second quarter of 2013 satisfying the notes in full with a fair value of $167,495. The Company recorded a loss of $2,200 (See note 5).
 
Following the agreement with Coventry Enterprises, LLC (see Note 5) for $20,000, Coventry made the conversion for a total of 8,810,572 shares of the company’s restricted stock during September 2013 satisfying the notes in full with a fair value of $188,747.
 
During June and August, 2013, one of the convertible Notes holders made the following conversions of a total of 34,254,004 shares of the company’s restricted stock satisfying the notes in the amount of $125,000 with a fair value of $317,391 on the date of conversion (See Note 5).
 
Date
 
Number of shares converted
 
Fair Value
of Debt
Converted
 
6/25/2013
 
 
22,058,882
 
$
188,352
 
8/30/2013
 
 
12,195,122
 
$
129,039
 
  
During August and September, 2013, $150,000 of the convertible notes were assigned to third parties in the form bearing interest of 8% annum at with a conversion price for each share of Common Stock equal to 55% of the average of the daily volume weighted average prices of the Common Stock for the 3 trading days with the lowest volume weighted average prices during the 15 to 20 trading days immediately preceding the Conversion Date. Immediately following the assignments, the conversions for a total of 64,052,862 shares of the company’s restricted stock were made as followings in satisfying the notes of $150,000 at the fair value of $475,519(See Note 5).
 
Date
 
Number of shares converted
 
Fair Value
of Debt
Converted
 
8/28/2013
 
 
22,026,431
 
$
167,493
 
9/3/2013
 
 
20,000,000
 
$
163,909
 
9/4/2013
 
 
22,026,431
 
$
144,117
 
 
On September 16, 2013, one of the non-related party promissory note holders accepted a total of 8,472,750 shares of the Company’s restricted common stock as a repayment to discharge $25,000 of his outstanding loan and accrued interest of $11,120 with the Company (See note 5). The Company recorded a loss of $90,971 on the settlement date.
 
On November 25, 2013, one of the non-related party promissory note holders accepted a total of 4,360,000 shares of the Company’s restricted common stock as a repayment to discharge $25,000 of his outstanding loan and accrued interest of $11,956 with the Company (See note 5). The Company recorded a loss of $28,444 on the settlement date.
 
During September, 2013, Mr. Harold H. Rumph (ReceptoPharm’s CEO) accepted 14,800,000 shares of the Company’s restricted common stock as a repayment to discharge $37,000 of his accrued salary to the Company(See Note 3).
 
During June and September, 2013, Mr. Deitsch (Our CEO) accepted a total of 50,000,000 shares of the Company’s restricted common stock as a repayment to discharge $162,500 of his outstanding loan to the Company (See note 4).
 
During August and September, 2013, the Company issued 3,000,000 shares of the company’s restricted stock to settle the outstanding accounts payable in aggregate of $38,528 with two vendors. The shares were valued at $0.018 per share. The Company recorded a loss of $15,472 (See Note 3).
 
During September, 2013, the Company issued 25,000,000 shares of the company’s restricted stock and 25,000,000 warrants to purchase stock at an exercise price of $0.030 to settle the outstanding accounts payable of $112,621. The shares were valued at $0.015 per share. The Company recorded a loss of $505,525 (See Note 3).
 
During December 2012, the Board of Directors approved resolutions for the issuance of a total of 10,000,000 shares of the Company’s restricted common stock to Mr. Deitsch to discharge $100,000 of his outstanding loan the Company (See note 4). The shares were valued at the note payable amount due to the fact that it was a related party transaction. 10,000,000 warrants to purchase stock at an exercise price of $0.10 per share were also issued to Mr. Dietsch. The warrants expire on December 31, 2014.
 
Following the agreements with Coventry Enterprises, LLC (see Note 3), the conversions for 8,672,090 and 2,564,102 shares of the Company’s restricted common stocks were issued for settlement of accounts payable and a convertible note payable on March 29, 2012 and December 20, 2012, respectively. The shares were valued at $168,889 and $33,720, respectively, which was the fair value of convertible debts on the date of conversion.
 
Following the agreement with Southridge (see Note 5), the conversion for a total of 6,416,733 shares of the Company’s restricted common stock satisfying the note in full was made in October 2012. The shares were valued at $157,179, which was the fair value of convertible debts on the date of conversion.
 
Following the agreement with Asher Enterprises, LLC (see Note 5), the conversion for a total of 20,000,000 shares of the Company’s restricted common stock satisfying the note in full was made in October 2012. The shares were valued at $356,779, which was the fair value of convertible debts on the date of conversion.
 
Following the agreement with Redwood and TCN (see Note 5), the conversion for a total of 7,500,000 shares of the Company’s restricted common stock satisfying the note in full was made in October 2012. The shares were valued at $273,144, which was the fair value of convertible debts on the date of conversion.
 
Following the agreement with Redwood (see Note 3), conversions were made for a total of 18,737,894 shares of the Company’s restricted stock, satisfying the note in full. The shares were valued at a total amount of $320,531, which was the fair value of convertible debts on the date of conversion.
XML 55 R16.htm IDEA: XBRL DOCUMENT v2.4.0.8
INCOME TAXES
 12 Months Ended
Dec. 31, 2013
Income Tax Disclosure [Abstract]  
Income Tax Disclosure [Text Block]
8. INCOME TAXES
 
The Company’s tax expense differs from the “expected” tax expense for the years ended December 31, 2013 and 2012, (computed by applying the Federal Corporate tax rate of 34% to loss before taxes and 8.84% for California State Corporate Taxes, the blended rate used was 39.83%), are approximately as follows:
 
 
 
December 31,
 
 
 
2013
 
2012
 
 
 
 
 
 
 
 
 
Computed "expected" tax expense (benefit) - Federal
 
$
(1,346,076)
 
$
(1,115,374)
 
Computed "expected" tax expense (benefit) - State
 
 
(322,564)
 
 
(318,119)
 
Stock-based compensation
 
 
558,448
 
 
674,914
 
Change in fair value of derivatives
 
 
452,390
 
 
159,500
 
Change in valuation allowance
 
 
657,802
 
 
599,079
 
 
 
$
-
 
$
-
 
 
Current portion of net deferred income tax assets:
 
2013
 
2012
 
 
 
 
 
 
 
 
 
Allowance for doubtful accounts
 
$
242,000
 
$
242,000
 
Reserve for inventory obsolescence
 
 
313,925
 
 
313,925
 
Accrued salary
 
 
101,877
 
 
43,154
 
Subtotal
 
 
657,802
 
 
599,079
 
Valuation allowance
 
 
(657,802)
 
 
(599,079)
 
Current net deferred income tax asset
 
$
-
 
$
-
 
 
 
 
 
 
 
 
 
Non- current portion of net deferred income tax asset
 
 
 
 
 
 
 
Net operating loss carryforwards
 
$
6,232,881
 
$
5,575,079
 
Valuation allowance
 
 
(6,232,881)
 
 
(5,575,079)
 
Non-current net deferred income tax asset
 
$
-
 
$
-
 
 
Due to the uncertainty of the utilization and recoverability of the loss carry-forwards and other deferred tax assets, we have provided a valuation allowance to fully reserve such assets.
 
As of December 31, 2013, the Company has net operating loss carryforwards of approximately $15,580,000 available to offset future taxable income in various years through December 31, 2033.  The significant difference between such net operating loss carryforwards and our accumulated deficit of approximately $41,987,000 results primarily from stock based compensation which is considered to be a permanent difference.
 
The valuation allowances increased by approximately $658,000 and $599,000 for the years ended December 31, 2013 and 2012, respectively. The Company’s 2011 to 2013 tax returns are subject to examination by Internal Revenue Services and State Taxing Agency’s.
XML 56 R34.htm IDEA: XBRL DOCUMENT v2.4.0.8
FAIR VALUE MEASUREMENTS (Details 3) (USD $)
 12 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Fair Value Measurements [Line Items]    
Beginning balance $ 588,091 [1]  
Purchases, issuances, and settlements 243,147 0
Day one loss on value of hybrid instrument 729,093 0
Ending balance 767,056 [1] 588,091 [1]
Fair Value, Inputs, Level 3 [Member]
    
Fair Value Measurements [Line Items]    
Beginning balance 588,091 206,863
Purchases, issuances, and settlements 751,419 902,369
Day one loss on value of hybrid instrument 1,656,802 479,422
(Gain) loss from change in fair value (582,423) 309,680
Conversion to common stock (1,646,832) (1,310,243)
Ending balance $ 767,056 $ 588,091
[1] At December 31, 2013 and 2012, the balance of $767,056 and $588,091 consisted of the following convertible loans: In September and October 2011, the Company borrowed $250,000 each (aggregating $500,000) from two non-related parties. The principal of these loans were to be repaid with a balloon payment on or before October 1, 2012. On October 19, 2012 the parties amended the notes to extend the due date to May 1, 2013 and include a conversion feature that would allow the holders to convert some or all of their outstanding notes into restricted Company stock at a 15% discount to the average closing market price of the Company's stock traded over the previous 10 days. Interest on these loans is payable monthly beginning in November 2011 with interest calculated at 20% and 12%, each, respectively. At December 31, 2013 and 2012, the accrued interest payable was $6,664. During year ended December 31, 2013, one of the Note holders made conversions of a total of 34,254,004 shares of the company’s restricted stock satisfying the notes in the amount of $125,000 with a fair value of $317,391 on the date of conversion. During August and September, 2013, $150,000 of the debts were assigned to three non-related parties in the form of a Convertible Redeemable Note bearing interest of 8% annum with a conversion price for each share of Common Stock equal to 55% of the average of the daily volume weighted average prices of the Common Stock for the 3 trading days with the lowest volume weighted average prices during the 15 to 20 trading days immediately preceding the Conversion Date. Following the assignments, the conversions for a total of 64,052,862 shares of the company’s restricted stock were made in satisfying the notes of $150,000 at the fair value of $475,519 (See note 6). At December 31, 2013, the remaining balance of these two convertible notes payable of $75,000 and $150,000 were recorded at a fair value of $90,260 and $189,781, respectively. At December 31, 2012, these two convertible note payable of $250,000 each were recorded at fair value of $290,289 and $297,802, respectively. On April 30, 2013, the parties amended the notes to further extend the maturity date to November 3, 2013. The Company issued a total of 4,000,000 restricted shares to the note holders in connection with the amendment at a fair value of $20,800. On October 30, 2013 and November 1, 2013, the parties amended the note of $75,000 and $150,000 to further extend the maturity dates to May 3, 2014 and August 3, 2014, respectively. The Company issued a total of 500,000 and 1,250,000 restricted shares to the note holders in connection with the amendment at a fair value of $9,500 and $13,750 (See note 6), respectively. On March 22, 2013, the Company issued a Convertible Debenture in the amount of $20,000 to Coventry Enterprises, LLC (“Coventry”). The note carries interest at 10% and is due on March 22, 2014, unless previously converted into shares of restricted common stock. Coventry has the right to convert the note, until is no longer outstanding into shares of Common Stock at a price which is lesser of $.0075, or (ii) fifty-five percent (55%) of the average of the three lowest VWAP prices of the Company’s Common Stock for the twenty trading days preceding the conversion date. In connection with the issuance of this convertible note payable, the Company encountered a day-one derivative loss of $24,931. Coventry made the conversions into a total of 8,810,572 shares of the company’s restricted stock satisfying the notes in full with a fair value of $188,747on September 4, 2013(See note 7). In connection with the issuances of the Note, the Company also granted five-year warrants to purchase an aggregate of 2,600,000 shares of the Company’s common stock at an exercise price of $0.01 per share. The Company classified embedded conversion features in these warrants as a derivative liability. The warrants were valued at their fair value of $21,226 and $17,895, respectively using the Black-Scholes method at the commitment and re-measurement dates of March 22, 2013 and December 31, 2013, respectively. On July 10, 2013 and October 10, 2013, the Company issued two Convertible Debentures in the amount of $30,000 each (total $60,000) to Christopher Castaldo in connection with the agreements for investor relation services (See Note 6). The notes carry interest at 8% and are due on January 10, 2014 and April 10, 2014, respectively. The notes’ holder has the right to convert the notes into shares of Common Stock at a price of $0.005. In connection with the issuance of this convertible notes payable, the Company encountered a day-one derivative loss of $83,157. At December 31, 2013, these convertible notes payable, at fair value, was recorded at $90,684. On September 3, 2013, the Company issued a Convertible Debenture in the amount of $100,000 to Coventry Enterprises, LLC (“Coventry”). The note carries interest at 10% and is due on September 3, 2014, unless previously converted into shares of restricted common stock. Coventry has the right to convert the note, until is no longer outstanding into shares of Common Stock at a price lesser of $.018, or (ii) fifty-five percent (55%) of the average of the three lowest VWAP prices of the Company’s Common Stock for the twenty trading days preceding the conversion date. In connection with the issuance of this convertible note payable, the Company encountered a day-one derivative loss of $957,567. At December 31, 2013, this convertible note payable, at fair value, was recorded at $185,971. In connection with the issuances of the Note, the Company also granted five-year warrants to purchase an aggregate of 20,000,000 shares of the Company’s common stock at an exercise price of $0.025 per share. The Company classified embedded conversion features in these warrants as a derivative liability. The warrants were valued at their fair value of $445,638 and $137,681, respectively using the Black-Scholes method at the commitment and re-measurement dates of September 3, 2013 and December 31, 2013, respectively. On September 12, 2013, the Company issued a Convertible Debenture in the amount of $70,000 to Coventry Enterprises, LLC (“Coventry”). The note carries interest at 10% and is due on September 12, 2014, unless previously converted into shares of restricted common stock. Coventry has the right to convert the note, until is no longer outstanding into shares of Common Stock at a price lesser of $.02, or (ii) fifty-five percent (55%) of the average of the three lowest VWAP prices of the Company’s Common Stock for the twenty trading days preceding the conversion date. In connection with the issuance of this convertible note payable, the Company encountered a day-one derivative loss of $309,055. At December 31, 2013, this convertible note payable, at fair value, was recorded at $130,303. In connection with the issuances of the Note, the Company also granted five-year warrants to purchase an aggregate of 15,000,000 shares of the Company’s common stock at an exercise price of $0.025 per share. The Company classified embedded conversion features in these warrants as a derivative liability. The warrants were valued at their fair value of $262,230 and $101,140, respectively using the Black-Scholes method at the commitment and re-measurement dates of September 12, 2013 and December 31, 2013, respectively. On October 7, 2013, the Company signed a secured convertible Promissory Note in the amount of $35,000 in favor of Southridge Partners II, LLC. The note was due on demand and carries interest at 10% annum. Southridge Partners II, LLC was entitled to convert the principal into shares of common stock at the lesser of $0.015 or a 50% discount from the lowest closing bid price in the 30 trading days prior to the day that the conversion is requested; and interest accrued was entitled to convert into shares of common stock at $0.001. In the evaluation of these financing arrangements, the Company concluded that these conversion features did not meet the conditions set forth in current accounting standards for equity classification. Since equity classification is not available for the conversion feature, it requires bifurcation and liability classification, at fair value. The Company also concluded that the Default Put required bifurcation because, while puts on debt instruments are generally considered clearly and closely related to the host, the Default Put is indexed to certain events that are not associated with the convertible note payable. In connection with the issuance of this convertible note payable, the Company encountered a day-one derivative loss of $81,667. At December 31, 2013, this convertible note payable, at fair value, was recorded at $80,057. On October 27, 2011 the Company entered into a convertible note payable with a corporation. The convertible note payable, with a face value of $53,000, bears interest at 8.0% per annum and was due on July 31, 2012. On December 5, 2011 the Company entered into a convertible note payable with a corporation which had a face value of $37,500, a coupon rate of 8.0% per annum and maturity date of September 5, 2012. The convertible note payable is convertible, at the holder’s option, into the Company’s common shares at a variable conversion price which is 58% multiplied by the average of the lowest three (3) trading prices for the Common Stock during the ten (10) Trading Day period ending one Trading Day prior to the date the Conversion Notice is sent by the Holder to the Borrower. The conversion feature is subject to full-ratchet, anti-dilution protection if the Company sells shares or share-indexed financing instruments at less than the conversion price. The holder has the option to redeem the convertible note payable for cash in the event of defaults or certain other contingent events (the “Default Put”). During October 2012, both of these notes were acquired by a third party from Asher Enterprises for an aggregate amount of $100,000, and then converted into 20,000,000 restricted common shares (See note 6). On February 3, 2012, the Company issued a Convertible Debenture in the amount of $40,000 to Redwood Management, LLC. The note carries interest at 12% and is due on February 13, 2013, unless converted into shares of restricted common stock. Redwood Management, LLC has the right to convert the note, until it is no longer outstanding, into shares of Common Stock at a price of Fifty Percent (50%) of the lowest closing price, determined on the then current trading market for the Company’s common stock, during the 15 trading days prior to conversion (the “Set Price”). On September 12, 2012, TCN International (TCN) completed the purchase and transfer of this note including penalties and unpaid interest, for the sum of $52,500. Redwood Management, LLC has acknowledged the full payment of the Note, in favor of Nutra Pharma Corporation and releases Nutra Pharma Corporation from all obligations under the Note. Upon the request of TCN, the Board of Directors of the Company approved the conversion of these notes into Restricted Common Stock of the Company,providing 7,500,000 shares of Nutra Pharma common stock to relinquish the total debt of $52,500 (See note 6). On March 16, 2012 the Company signed a secured convertible Promissory Note in the amount of $75,000 in favor of Southridge Partners II, LLC. The note was due November 16, 2012 and carries interest at 8% annum. Southridge Partners II, LLC was entitled after nine months to convert all or a portion of the principal and interest accrued into shares of common stock at a conversion price of each share equal to the Market Price multiplied times 70%. (the “conversion price”). The Market Price is equal to the average of the two lowest bids closing prices for the five trading days ending before the conversion date. In the evaluation of these financing arrangements, the Company concluded that these conversion features did not meet the conditions set forth in current accounting standards for equity classification. Since equity classification is not available for the conversion feature, it requires bifurcation and liability classification, at fair value. The Company also concluded that the Default Put required bifurcation because, while puts on debt instruments are generally considered clearly and closely related to the host, the Default Put is indexed to certain events that are not associated with the convertible note payable. On October 26, 2012, Southridge converted the note into 5,919,495 shares of the Company's restricted common stock (See note 6). In the evaluation of these financing arrangements, the Company concluded that these conversion features did not meet the conditions set forth in current accounting standards for equity classification. Since equity classification is not available for the conversion feature, it requires bifurcation and liability classification, at fair value. The Company also concluded that the Default Put required bifurcation because, while puts on debt instruments are generally considered clearly and closely related to the host, the Default Put is indexed to certain events that are not associated with the convertible note payable. The Company elected to account for these hybrid contracts under the guidance of ASC 815-15-25-4. The fair value has been defined as the common stock equivalent value, enhanced by the fair value of the default put plus the present value of the coupon. The holder of this convertible note has substantial rights and protections regarding dilution if certain events, including a default were to occur. There are a number of events that could trigger a default, including but not limited to failure to pay principal or interest, failure to issue shares under the conversion feature, breach of covenants, breach of representations and warranties, appointment of a receiver or trustee, judgments, bankruptcy, delisting of common stock, failure to comply with the exchange act, liquidation, cessation of operations, failure to maintain assets, material financial statement restatement, reverse split of borrowers stock, etc. In the event of these events the lender may be entitled to receive significant amounts of additional stock above the amounts for conversion. Furthermore, there are additional events that could cause the lender to be due additional shares of common stock above and beyond the shares due from a conversion. Some of these events include, but are not limited to a merger or consolidation of the Company, dividend distribution or spin off, dilutive issuances of the Company’s stock, etc. If the lender receives additional shares of the Company’s commons stock due to any of the foregoing events or for other reasons, then this may have an extremely dilutive effect on the shareholders of the Company. Such dilution would likely result in a significant drop in the per share price of the Company’s common stock. The potential dilutive nature of this note presents a very high degree of risk to the Company and its shareholders
XML 57 R51.htm IDEA: XBRL DOCUMENT v2.4.0.8
SUBSEQUENT EVENTS (Details Textual) (USD $)
 12 Months Ended 1 Months Ended 0 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Dec. 31, 2013
Involuntary Petition Of Bankruptcy [Member]
Dec. 31, 2013
Convertible Note One [Member]
Dec. 31, 2012
Convertible Note One [Member]
Dec. 31, 2013
Convertible Note Two [Member]
Dec. 31, 2012
Convertible Note Two [Member]
Feb. 12, 2014
Subsequent Event [Member]
Involuntary Petition Of Bankruptcy [Member]
Sep. 12, 2013
Coventry Enterprises LlC [Member]
Sep. 03, 2013
Coventry Enterprises LlC [Member]
Mar. 12, 2014
Coventry Enterprises LlC [Member]
Subsequent Event [Member]
Convertible Note One [Member]
Mar. 12, 2014
Coventry Enterprises LlC [Member]
Subsequent Event [Member]
Convertible Note Two [Member]
Mar. 12, 2014
Chief Executive Officer [Member]
Subsequent Event [Member]
Jan. 31, 2014
Investor [Member]
Subsequent Event [Member]
Jan. 17, 2014
Michael Mcdonald Trust [Member]
Subsequent Event [Member]
Subsequent Event [Line Items]                              
Warants Expiry Period                           Dec. 31, 2015  
Stock Issued During Period, Shares, Restricted Stock Award, Gross                           12,000,000 1,000,000
Share Price                           $ 0.005  
Class of Warrant or Right, Number of Securities Called by Warrants or Rights                           12,000,000  
Class Of Warrant Or Right, Exercise Price Of Warrants Or Rights                           0.03  
Equity, Fair Value Disclosure, Total                             $ 9,900
Convertible Debt 767,056 588,091   75,000 250,000 150,000 250,000   70,000 100,000 10,000 10,000      
Debt Conversion, Converted Instrument, Amount                     60,000 90,000      
Debt Conversion, Converted Instrument, Shares Issued                     15,584,415 23,376,623      
Proceeds from Issuance of Unsecured Debt                         16,008    
Repayments of Unsecured Debt                         14,600    
Debt Instrument, Interest Rate, Stated Percentage                         4.00%    
Proceeds from private placement                           60,000  
Debt Instrument, Debt Default, Amount                             75,000
Litigation Settlement, Amount     350,000                        
Payments for Legal Settlements               $ 35,000              
XML 58 R21.htm IDEA: XBRL DOCUMENT v2.4.0.8
FAIR VALUE MEASUREMENTS (Tables)
 12 Months Ended
Dec. 31, 2013
Fair Value Disclosures [Abstract]  
Schedule Of Financial Instruments [Table Text Block]
The following table summarizes our financial instruments measured at fair value as of December 31, 2013 and 2012:
 
 
 
Fair Value Measurements at December 31, 2013
 
Liabilities:
 
Total
 
Level 1
 
Level 2
 
Level 3
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Warrant liability
 
$
323,172
 
$
-
 
$
-
 
$
323,172
 
Convertible notes at fair value
 
$
767,056
 
$
-
 
$
-
 
$
767,056
 
 
 
 
Fair Value Measurements at December 31, 2012
 
Liabilities:
 
Total
 
Level 1
 
Level 2
 
Level 3
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Warrant liability
 
$
18,727
 
$
-
 
$
-
 
$
18,727
 
Convertible notes at fair value
 
$
588,091
 
$
-
 
$
-
 
$
588,091
 
Schedule Of Changes In Financial Instruments [Table Text Block]
The following table shows the changes in fair value measurements using significant unobservable inputs (Level 3) during the years ended December 31, 2013 and 2012:
 
Description
 
2013
 
2012
 
 
 
 
 
 
 
 
 
Beginning balance
 
$
18,727
 
$
28,833
 
Purchases, issuances, and settlements
 
 
243,147
 
 
-
 
Day one loss on value of hybrid instrument
 
 
729,093
 
 
-
 
Total gain included in earnings (1)
 
 
(667,795)
 
 
(10,106)
 
 
 
 
 
 
 
 
 
Ending balance
 
$
323,172
 
$
18,727
 
 
(1) The gain or loss related to the revaluation of our warrant liability is included in “Change in fair value of derivatives” in the accompanying consolidated statement of operations.
Schedule Of Hybrid Financial Instrument Disclosure [Table Text Block]
The following table summarizes the significant terms of each of the debentures for which the entire hybrid instrument is recorded at fair value as of December 31, 2013 and 2012:
 
 
 
 
 
 
 
 
 
Conversion Price -
Lower of Fixed Price
or Percentage of
VWAP for Look-back
Period
 
 
 
Debenture
Issuance
 
Face
 
 
 
Default
Interest
 
Anti-
Dilution
Adjusted
 
 
 
Look-back
 
Year
 
Amount
 
Interest Rate
 
Rate
 
Price
 
%
 
Period
 
2013
 
564,376
 
8%-20%
 
n/a
 
$0.0036-$0.0064
 
50%-85%
 
10 to 30 Days
 
2012
 
902,369
 
6%-12%
 
n/a
 
$0.0070-$0.0137
 
15%-70%
 
5 to 20 Days
 
Schedule Of Changes In Hybrid Financial Instruments [Table Text Block]
The following table shows the changes in fair value measurements using significant unobservable inputs (Level 3) during the years ended December 31, 2013 and 2012 for the Convertible Notes:
 
 
 
Years Ended December 31,
 
 
 
2013
 
2012
 
Description
 
 
 
 
 
 
 
Beginning balance
 
$
588,091
 
$
206,863
 
Purchases, issuances, and settlements
 
 
751,419
 
 
902,369
 
Day one loss on value of hybrid instrument
 
 
1,656,802
 
 
479,422
 
(Gain) loss from change in fair value
 
 
(582,423)
 
 
309,680
 
Conversion to common stock
 
 
(1,646,832)
 
 
(1,310,243)
 
Ending balance
 
$
767,057
 
$
588,091
 
XML 59 R26.htm IDEA: XBRL DOCUMENT v2.4.0.8
INCOME TAXES (Tables)
 12 Months Ended
Dec. 31, 2013
Income Tax Disclosure [Abstract]  
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]
The Company’s tax expense differs from the “expected” tax expense for the years ended December 31, 2013 and 2012, (computed by applying the Federal Corporate tax rate of 34% to loss before taxes and 8.84% for California State Corporate Taxes, the blended rate used was 39.83%), are approximately as follows:
 
 
 
December 31,
 
 
 
2013
 
2012
 
 
 
 
 
 
 
 
 
Computed "expected" tax expense (benefit) - Federal
 
$
(1,346,076)
 
$
(1,115,374)
 
Computed "expected" tax expense (benefit) - State
 
 
(322,564)
 
 
(318,119)
 
Stock-based compensation
 
 
558,448
 
 
674,914
 
Change in fair value of derivatives
 
 
452,390
 
 
159,500
 
Change in valuation allowance
 
 
657,802
 
 
599,079
 
 
 
$
-
 
$
-
 
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]
Current portion of net deferred income tax assets:
 
2013
 
2012
 
 
 
 
 
 
 
 
 
Allowance for doubtful accounts
 
$
242,000
 
$
242,000
 
Reserve for inventory obsolescence
 
 
313,925
 
 
313,925
 
Accrued salary
 
 
101,877
 
 
43,154
 
Subtotal
 
 
657,802
 
 
599,079
 
Valuation allowance
 
 
(657,802)
 
 
(599,079)
 
Current net deferred income tax asset
 
$
-
 
$
-
 
 
 
 
 
 
 
 
 
Non- current portion of net deferred income tax asset
 
 
 
 
 
 
 
Net operating loss carryforwards
 
$
6,232,881
 
$
5,575,079
 
Valuation allowance
 
 
(6,232,881)
 
 
(5,575,079)
 
Non-current net deferred income tax asset
 
$
-
 
$
-
 
XML 60 R49.htm IDEA: XBRL DOCUMENT v2.4.0.8
COMMITMENTS AND CONTINGENCIES (Details) (USD $)
Dec. 31, 2013
Operating Leased Assets [Line Items]  
2014 $ 116,345
2015 120,218
2016 79,892
2017 45,249
Total $ 361,704
XML 61 R41.htm IDEA: XBRL DOCUMENT v2.4.0.8
STOCKHOLDERS' DEFICIT (Details) (Coventry Enterprises Llc [Member], Restricted Stock [Member], USD $)
 3 Months Ended 6 Months Ended 12 Months Ended 3 Months Ended 2 Months Ended
Jun. 30, 2013
Mar. 31, 2013
Jun. 30, 2013
Dec. 31, 2012
Mar. 31, 2013
January 21 2013 [Member]
Mar. 31, 2013
February 11 2013 [Member]
Mar. 31, 2013
Mar 20 2013 [Member]
Jun. 30, 2013
April 17 2013 [Member]
Jun. 30, 2013
May 16 2013 [Member]
Jun. 30, 2013
June 12 2013 [Member]
Aug. 31, 2013
June 25 2013 [Member]
Aug. 31, 2013
August 30 2013 [Member]
Sep. 30, 2013
August 28 2013 [Member]
Sep. 30, 2013
September 3 2013 [Member]
Sep. 30, 2013
September 4 2013 [Member]
Debt Conversion [Line Items]                              
Debt Conversion, Converted Instrument, Shares Issued 31,416,845 15,119,481 31,416,845 8,672,090 4,032,258 5,405,405 5,681,818 7,133,333 11,101,694 13,181,818 22,058,882 12,195,122 22,026,431 20,000,000 22,026,431
Debt Conversion, Converted Instrument, Amount $ 88,500 $ 80,000 $ 186,646   $ 37,619 $ 42,510 $ 40,414 $ 49,586 $ 64,930 $ 70,130 $ 188,352 $ 129,039 $ 167,493 $ 163,909 $ 144,117
XML 62 R5.htm IDEA: XBRL DOCUMENT v2.4.0.8
Consolidated Statements of Operations [Parenthetical] (USD $)
 12 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Stock-based compensation $ 1,391,979 $ 1,799,461
XML 63 R10.htm IDEA: XBRL DOCUMENT v2.4.0.8
FAIR VALUE MEASUREMENTS
 12 Months Ended
Dec. 31, 2013
Fair Value Disclosures [Abstract]  
Fair Value Disclosures [Text Block]
2. FAIR VALUE MEASUREMENTS
 
Certain assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2013 are measured in accordance with FASB ASC Topic 820-10-05, Fair Value Measurements. FASB ASC Topic 820-10-05 defines fair value, establishes a framework for measuring fair value and expands the disclosure requirements regarding fair value measurements for financial assets and liabilities as well as for non-financial assets and liabilities that are recognized or disclosed at fair value on a recurring basis in the financial statements.
 
The statement requires fair value measurement be classified and disclosed in one of the following three categories:
 
Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;
 
Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and
 
Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).
 
The following table summarizes our financial instruments measured at fair value as of December 31, 2013 and 2012:
 
 
 
Fair Value Measurements at December 31, 2013
 
Liabilities:
 
Total
 
Level 1
 
Level 2
 
Level 3
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Warrant liability
 
$
323,172
 
$
-
 
$
-
 
$
323,172
 
Convertible notes at fair value
 
$
767,056
 
$
-
 
$
-
 
$
767,056
 
 
 
 
Fair Value Measurements at December 31, 2012
 
Liabilities:
 
Total
 
Level 1
 
Level 2
 
Level 3
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Warrant liability
 
$
18,727
 
$
-
 
$
-
 
$
18,727
 
Convertible notes at fair value
 
$
588,091
 
$
-
 
$
-
 
$
588,091
 
 
The following table shows the changes in fair value measurements using significant unobservable inputs (Level 3) during the years ended December 31, 2013 and 2012:
 
Description
 
2013
 
2012
 
 
 
 
 
 
 
 
 
Beginning balance
 
$
18,727
 
$
28,833
 
Purchases, issuances, and settlements
 
 
243,147
 
 
-
 
Day one loss on value of hybrid instrument
 
 
729,093
 
 
-
 
Total gain included in earnings (1)
 
 
(667,795)
 
 
(10,106)
 
 
 
 
 
 
 
 
 
Ending balance
 
$
323,172
 
$
18,727
 
 
(1) The gain or loss related to the revaluation of our warrant liability is included in “Change in fair value of derivatives” in the accompanying consolidated statement of operations.
 
The Company values its warrants using a Dilution-Adjusted Black-Scholes Model. Assumptions used include (1) 0.13% to 1.75% risk-free rate, (2) warrant life is the remaining contractual life of the warrants, (3) expected volatility of 124% to 236% (4) zero expected dividends (5) exercise price set forth in the agreements (6) common stock price of the underlying share on the valuation date, and (7) number of shares to be issued if the instrument is converted (See note 5).
 
The following table summarizes the significant terms of each of the debentures for which the entire hybrid instrument is recorded at fair value as of December 31, 2013 and 2012:
 
 
 
 
 
 
 
 
 
Conversion Price -
Lower of Fixed Price
or Percentage of
VWAP for Look-back
Period
 
 
 
Debenture
Issuance
 
Face
 
 
 
Default
Interest
 
Anti-
Dilution
Adjusted
 
 
 
Look-back
 
Year
 
Amount
 
Interest Rate
 
Rate
 
Price
 
%
 
Period
 
2013
 
564,376
 
8%-20%
 
n/a
 
$0.0036-$0.0064
 
50%-85%
 
10 to 30 Days
 
2012
 
902,369
 
6%-12%
 
n/a
 
$0.0070-$0.0137
 
15%-70%
 
5 to 20 Days
 
 
The following table shows the changes in fair value measurements using significant unobservable inputs (Level 3) during the years ended December 31, 2013 and 2012 for the Convertible Notes:
 
 
 
Years Ended December 31,
 
 
 
2013
 
2012
 
Description
 
 
 
 
 
 
 
Beginning balance
 
$
588,091
 
$
206,863
 
Purchases, issuances, and settlements
 
 
751,419
 
 
902,369
 
Day one loss on value of hybrid instrument
 
 
1,656,802
 
 
479,422
 
(Gain) loss from change in fair value
 
 
(582,423)
 
 
309,680
 
Conversion to common stock
 
 
(1,646,832)
 
 
(1,310,243)
 
Ending balance
 
$
767,057
 
$
588,091
 
XML 64 R27.htm IDEA: XBRL DOCUMENT v2.4.0.8
COMMITMENTS AND CONTINGENCIES (Tables)
 12 Months Ended
Dec. 31, 2013
Commitments and Contingencies [Abstract]  
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]
Future minimum payments under these lease agreements, including the extension period, are approximately as follows:
 
Years ended
December 31,
 
Amounts
 
2014
 
$
116,345
 
2015
 
 
120,218
 
2016
 
 
79,892
 
2017
 
 
45,249
 
Total
 
$
361,704
 
XML 65 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.8 Html 342 312 1 true 120 0 false 5 false false R1.htm 101 - Document - Document And Entity Information Sheet http://www.nutrapharma.com/role/DocumentAndEntityInformation Document And Entity Information true false R2.htm 102 - Statement - Consolidated Balance Sheets Sheet http://www.nutrapharma.com/role/ConsolidatedBalanceSheets Consolidated Balance Sheets false false R3.htm 103 - Statement - Consolidated Balance Sheets [Parenthetical] Sheet http://www.nutrapharma.com/role/ConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets [Parenthetical] false false R4.htm 104 - Statement - Consolidated Statements of Operations Sheet http://www.nutrapharma.com/role/ConsolidatedStatementsOfOperations Consolidated Statements of Operations false false R5.htm 105 - Statement - Consolidated Statements of Operations [Parenthetical] Sheet http://www.nutrapharma.com/role/ConsolidatedStatementsOfOperationsParenthetical Consolidated Statements of Operations [Parenthetical] false false R6.htm 106 - Statement - Consolidated Statements of Changes in Stockholders' Deficit Sheet http://www.nutrapharma.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficit Consolidated Statements of Changes in Stockholders' Deficit false false R7.htm 107 - Statement - Consolidated Statements of Changes in Stockholders' Deficit [Parenthetical] Sheet http://www.nutrapharma.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficitParenthetical Consolidated Statements of Changes in Stockholders' Deficit [Parenthetical] false false R8.htm 108 - Statement - Consolidated Statements of Cash Flows Sheet http://www.nutrapharma.com/role/ConsolidatedStatementsOfCashFlows Consolidated Statements of Cash Flows false false R9.htm 109 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://www.nutrapharma.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES false false R10.htm 110 - Disclosure - FAIR VALUE MEASUREMENTS Sheet http://www.nutrapharma.com/role/FairValueMeasurements FAIR VALUE MEASUREMENTS false false R11.htm 111 - Disclosure - SETTLEMENT OF ACCOUNTS AND NOTE PAYABLE Sheet http://www.nutrapharma.com/role/SettlementOfAccountsAndNotePayable SETTLEMENT OF ACCOUNTS AND NOTE PAYABLE false false R12.htm 112 - Disclosure - DUE TO OFFICERS Sheet http://www.nutrapharma.com/role/DueToOfficers DUE TO OFFICERS false false R13.htm 113 - Disclosure - OTHER DEBT Sheet http://www.nutrapharma.com/role/OtherDebt OTHER DEBT false false R14.htm 114 - Disclosure - STOCKHOLDERS' DEFICIT Sheet http://www.nutrapharma.com/role/StockholdersDeficit STOCKHOLDERS' DEFICIT false false R15.htm 115 - Disclosure - STOCK OPTIONS AND WARRANTS Sheet http://www.nutrapharma.com/role/StockOptionsAndWarrants STOCK OPTIONS AND WARRANTS false false R16.htm 116 - Disclosure - INCOME TAXES Sheet http://www.nutrapharma.com/role/IncomeTaxes INCOME TAXES false false R17.htm 117 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://www.nutrapharma.com/role/CommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES false false R18.htm 118 - Disclosure - SUBSEQUENT EVENTS Sheet http://www.nutrapharma.com/role/SubsequentEvents SUBSEQUENT EVENTS false false R19.htm 119 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://www.nutrapharma.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) false false R20.htm 120 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://www.nutrapharma.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) false false R21.htm 121 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) Sheet http://www.nutrapharma.com/role/FairValueMeasurementsTables FAIR VALUE MEASUREMENTS (Tables) false false R22.htm 122 - Disclosure - DUE TO OFFICERS (Tables) Sheet http://www.nutrapharma.com/role/DueToOfficersTables DUE TO OFFICERS (Tables) false false R23.htm 123 - Disclosure - OTHER DEBT (Tables) Sheet http://www.nutrapharma.com/role/OtherDebtTables OTHER DEBT (Tables) false false R24.htm 124 - Disclosure - STOCKHOLDERS' DEFICIT (Tables) Sheet http://www.nutrapharma.com/role/StockholdersDeficitTables STOCKHOLDERS' DEFICIT (Tables) false false R25.htm 125 - Disclosure - STOCK OPTIONS AND WARRANTS (Tables) Sheet http://www.nutrapharma.com/role/StockOptionsAndWarrantsTables STOCK OPTIONS AND WARRANTS (Tables) false false R26.htm 126 - Disclosure - INCOME TAXES (Tables) Sheet http://www.nutrapharma.com/role/IncomeTaxesTables INCOME TAXES (Tables) false false R27.htm 127 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables) Sheet http://www.nutrapharma.com/role/CommitmentsAndContingenciesTables COMMITMENTS AND CONTINGENCIES (Tables) false false R28.htm 129 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) Sheet http://www.nutrapharma.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetails BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) false false R29.htm 130 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1) Sheet http://www.nutrapharma.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetails1 BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1) false false R30.htm 132 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Textual) Sheet http://www.nutrapharma.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsTextual BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Textual) false false R31.htm 133 - Disclosure - FAIR VALUE MEASUREMENTS (Details) Sheet http://www.nutrapharma.com/role/FairValueMeasurementsDetails FAIR VALUE MEASUREMENTS (Details) false false R32.htm 134 - Disclosure - FAIR VALUE MEASUREMENTS (Details 1) Sheet http://www.nutrapharma.com/role/FairValueMeasurementsDetails1 FAIR VALUE MEASUREMENTS (Details 1) false false R33.htm 135 - Disclosure - FAIR VALUE MEASUREMENTS (Details 2) Sheet http://www.nutrapharma.com/role/FairValueMeasurementsDetails2 FAIR VALUE MEASUREMENTS (Details 2) false false R34.htm 136 - Disclosure - FAIR VALUE MEASUREMENTS (Details 3) Sheet http://www.nutrapharma.com/role/FairValueMeasurementsDetails3 FAIR VALUE MEASUREMENTS (Details 3) false false R35.htm 137 - Disclosure - FAIR VALUE MEASUREMENTS (Details Textual) Sheet http://www.nutrapharma.com/role/FairValueMeasurementsDetailsTextual FAIR VALUE MEASUREMENTS (Details Textual) false false R36.htm 138 - Disclosure - SETTLEMENT OF ACCOUNTS AND NOTE PAYABLE (Details Textual) Sheet http://www.nutrapharma.com/role/SettlementOfAccountsAndNotePayableDetailsTextual SETTLEMENT OF ACCOUNTS AND NOTE PAYABLE (Details Textual) false false R37.htm 139 - Disclosure - DUE TO OFFICERS (Details) Sheet http://www.nutrapharma.com/role/DueToOfficersDetails DUE TO OFFICERS (Details) false false R38.htm 140 - Disclosure - DUE TO OFFICERS (Details Textual) Sheet http://www.nutrapharma.com/role/DueToOfficersDetailsTextual DUE TO OFFICERS (Details Textual) false false R39.htm 141 - Disclosure - OTHER DEBT (Details) Sheet http://www.nutrapharma.com/role/OtherDebtDetails OTHER DEBT (Details) false false R40.htm 142 - Disclosure - OTHER DEBT (Details Textual) Sheet http://www.nutrapharma.com/role/OtherDebtDetailsTextual OTHER DEBT (Details Textual) false false R41.htm 143 - Disclosure - STOCKHOLDERS' DEFICIT (Details) Sheet http://www.nutrapharma.com/role/StockholdersDeficitDetails STOCKHOLDERS' DEFICIT (Details) false false R42.htm 144 - Disclosure - STOCKHOLDERS' DEFICIT (Details Textual) Sheet http://www.nutrapharma.com/role/StockholdersDeficitDetailsTextual STOCKHOLDERS' DEFICIT (Details Textual) false false R43.htm 145 - Disclosure - STOCK OPTIONS AND WARRANTS (Details) Sheet http://www.nutrapharma.com/role/StockOptionsAndWarrantsDetails STOCK OPTIONS AND WARRANTS (Details) false false R44.htm 146 - Disclosure - STOCK OPTIONS AND WARRANTS (Details 1) Sheet http://www.nutrapharma.com/role/StockOptionsAndWarrantsDetails1 STOCK OPTIONS AND WARRANTS (Details 1) false false R45.htm 147 - Disclosure - STOCK OPTIONS AND WARRANTS (Details Textual) Sheet http://www.nutrapharma.com/role/StockOptionsAndWarrantsDetailsTextual STOCK OPTIONS AND WARRANTS (Details Textual) false false R46.htm 148 - Disclosure - INCOME TAXES (Details) Sheet http://www.nutrapharma.com/role/IncomeTaxesDetails INCOME TAXES (Details) false false R47.htm 149 - Disclosure - INCOME TAXES (Details 1) Sheet http://www.nutrapharma.com/role/IncomeTaxesDetails1 INCOME TAXES (Details 1) false false R48.htm 150 - Disclosure - INCOME TAXES (Details Textual) Sheet http://www.nutrapharma.com/role/IncomeTaxesDetailsTextual INCOME TAXES (Details Textual) false false R49.htm 151 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) Sheet http://www.nutrapharma.com/role/CommitmentsAndContingenciesDetails COMMITMENTS AND CONTINGENCIES (Details) false false R50.htm 152 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Textual) Sheet http://www.nutrapharma.com/role/CommitmentsAndContingenciesDetailsTextual COMMITMENTS AND CONTINGENCIES (Details Textual) false false R51.htm 154 - Disclosure - SUBSEQUENT EVENTS (Details Textual) Sheet http://www.nutrapharma.com/role/SubsequentEventsDetailsTextual SUBSEQUENT EVENTS (Details Textual) false false All Reports Book All Reports Element nphc_CommonStockIssuableForSubscriptionAgreementValuePerShare had a mix of decimals attribute values: 2 3 4. Element nphc_DebtInstrumentVolumeWeightedAveragePriceVwap had a mix of decimals attribute values: 1 2. Element nphc_WarrantsToPurchaseCommonStockPerShareValue had a mix of decimals attribute values: 2 3. Element us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights had a mix of decimals attribute values: 2 3. Element us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice had a mix of decimals attribute values: 2 3. Process Flow-Through: 102 - Statement - Consolidated Balance Sheets Process Flow-Through: Removing column 'Dec. 31, 2011' Process Flow-Through: 103 - Statement - Consolidated Balance Sheets [Parenthetical] Process Flow-Through: 104 - Statement - Consolidated Statements of Operations Process Flow-Through: 105 - Statement - Consolidated Statements of Operations [Parenthetical] Process Flow-Through: 107 - Statement - Consolidated Statements of Changes in Stockholders' Deficit [Parenthetical] Process Flow-Through: 108 - Statement - Consolidated Statements of Cash Flows nphc-20131231.xml nphc-20131231.xsd nphc-20131231_cal.xml nphc-20131231_def.xml nphc-20131231_lab.xml nphc-20131231_pre.xml true true XML 66 R38.htm IDEA: XBRL DOCUMENT v2.4.0.8
DUE TO OFFICERS (Details Textual) (USD $)
 12 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Due To Officers Disclosure [Line Items]    
Loans from officers $ 181,718 $ 164,779
Repayment of stockholder loans 83,600 49,478
Warrants Maturity Date Dec. 31, 2014  
Rik Deitsch [Member]
    
Due To Officers Disclosure [Line Items]    
Loans from officers 151,718 164,779
Repayment of stockholder loans 53,600 324,478
Amount Of Debt Assigned To Third Party Total   175,000
Class Of Warrant Or Right, Exercise Price Of Warrants Or Rights   0.10
Restricted Stock [Member] | Rik Deitsch [Member]
    
Due To Officers Disclosure [Line Items]    
Debt Conversion, Converted Instrument, Shares Issued 50,000,000 10,000,000
Debt Conversion, Original Debt, Amount 162,500 100,000
Management [Member]
    
Due To Officers Disclosure [Line Items]    
Debt Instrument, Interest Rate, Stated Percentage 4.00% 4.00%
Interest Payable 349,466 324,853
President [Member]
    
Due To Officers Disclosure [Line Items]    
Debt Instrument, Interest Rate, Stated Percentage 5.00% 5.00%
Interest Payable $ 43,363 $ 37,392
Chief Executive Officer [Member]
    
Due To Officers Disclosure [Line Items]    
Class of Warrant or Right, Number of Securities Called by Warrants or Rights 25,000,000  
Class Of Warrant Or Right, Exercise Price Of Warrants Or Rights 0.10  
XML 67 R20.htm IDEA: XBRL DOCUMENT v2.4.0.8
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
 12 Months Ended
Dec. 31, 2013
Basis Of Presentation and Summary Of Significant Accounting Policies [Abstract]  
Property, Plant and Equipment [Table Text Block]
Property and equipment consists of the following at December 31,
 
 
 
2013
 
2012
 
 
 
 
 
 
 
 
 
Computer equipment
 
$
21,918
 
$
21,918
 
Furniture and fixtures
 
 
34,757
 
 
34,757
 
Lab equipment
 
 
42,129
 
 
42,129
 
Telephone equipment
 
 
12,421
 
 
12,421
 
Office equipment – other
 
 
2,629
 
 
2,629
 
Leasehold improvements
 
 
67,417
 
 
67,417
 
Total
 
 
181,271
 
 
181,271
 
Less: Accumulated depreciation and amortization
 
 
(156,737)
 
 
(141,756)
 
 
 
 
 
 
 
 
 
Property and equipment, net
 
$
24,534
 
$
39,515
 
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]
As of December 31, 2013 and 2012, the following items were not included in dilutive loss as the effect is anti-dilutive:
 
 
 
2013
 
2012
 
Options and warrants
 
154,916,667
 
57,256,667
 
Convertible notes payable
 
98,506,398
 
44,642,858
 
Total
 
253,423,065
 
101,899,525
 

?BW;[17O?M=0=$>VLFFHNIJV5A3)[,ZTH&F^S MG$1S6UP^N'P<9*(HH=#H-V29NO;;HSM?S(ZTT&B;!;S0R'*H1JF:JTHJB6:[M;!!"\1O5:#W)44W%_MC,GKS/].B#H*C5@W M"`]11VZ?DI/[A;>^Y,JVOER#>%)@SY"%HQB<8V2[%O[%)X\]LOJZU6?!(>BW M)7S_[T^7"5].;+,G2\,O\$3Y[WZ!";\\40(CH[!$`(ZN`GWUSIUC"SFF%<5\ M;M*"#(]^8\R`E]@PY\1('S*+U=$QM[]T]6E@YCEYZ/7NFL^[3PA%E$ID3V[-S0Z']H@^HWI&/:F]JY M@'DOB3']`^DN%GR1?\23:,`GGS":KVF\H[U()P(=G#U'!570L$KF2+=_/A%/ M?AGV^^.?/A<:><6BJLA50N3*J>3V!CUQ1W+/5=4$LV4_8A7#*[2@"#L7KF71 M%]5.K`<>A)Y:BCAW\-D*4E/)*;5_U4:@++ M&?SVDB.'^3!(';D/3E2^P1\LO$!$N_I8@$>"BV)EF$J%+(JCP6A#1^Q8NQ(4 M9LLHE:#!2!Q+!>DYMVWLV$49,TYG3&\P#.$T.$99`L*,D,14"D:CT5#.2<"# M98*7XBP?=+!,H).H/EI0)5]$4J1T7:V,^U(_N#+)0U9$7H1=Z;I9[O657CGR M[IT9MCS^WIF&6A!'4KHVE@8#.8"CV+%V)2C"J`P%W!_W^P4)\C[/SY)TI:N( M\F@XC$*[\)B16:>K6TD>*X,M>4ZR?WX_PZ(J14I7MB.J;,5MVQ<>;6>:(GQ) MU[>2*(TEI0Q1EHNU6X)>:;MZ@@NK7RE=_XX'H("5$%GQ`U9!6<0'3-?+X_YP M,))+4';IXF?3+_NS[RU65S`S=0U^*\H\.<.MEA5E--B0F#URI;1&V)FNMP>C M<7\TVHE6;('G2&LJKQ&QF-=]/]G\<;4PR_S_!*R8TP-UV)G_:D\0C\-W$7)7WYNIBOT M4P6\2Z47<'RWQ]J)F@BSTC7Z:4^6QKW>N`@U`:4/RG473J4'"-$@,FO<"NF, MI#O3PX5HX%F4SH"0/R"+.L04F$RA/F"+[4OE9FDO8DD"6UL!HI637\0S491B M-7D2#=62'>&PO`^RV>?VN>O,3(O\$VOYN1PT1O[F9X#.F[MKEG?U_Q=+;G3L M:LB,<+77/)DWMNT6X60_FT3F_BC#X2B%0F_8W:F+,'"031TX13U%4D1IO#MY M]ZY#2YTTL%'Y.3BLAH.!L2NB,\++446\3"'T">G8?L1OV'#Q5N)Y7?L5.JH3 MIC%CQT!4Y'%`3B+#E:,F5(D6WM?*,CM@ND>YJ;DP;>=^\JMI:LPJ8>N-J-A^ M`L-4F$W]]'!%ZH&_.`RN8-+(.].8PKR,?5Y)&O3+D/BK9=KV@V5.H@YK'KZE MQS#]_B#H%@9&*DY$"F/20Q,([Y5\1#QA70<9_!4;V$(ZL.UFLB]GMP;2KL2?[^@=2[P'H4M!:S_ MG%VB)(X'L=0 MMQFT/%W)3!NDFXY3&0*67BC1F4W7#3VHB6VGK&`/,JQ&7^D%D]>1X;FU-)4D#'#*N9@4U?!`_1N/J@6':)/:,OT4V/U^+F>I"1%NOU MA_)8#E.>2D%5)*=P.R,U-A2'@[ZT`\EWIF&&545I=9"1)I-$29+[`?8F#KTK MC2GLS$B>@?\M]>5!&1JQLX/9&628'=#NLA)HEN,Y:;QRC#H"H] M49'Z8C%@%4C;5H"KD92M##UPC?M1D8W+[WIW$E-ZO$3ZI6O!IP_LF!K;[/'^ M?&U:J]3=O5'<(QVEAX3CH3@8@?8K14SM,ZE@T=)#35@MND?4TME7JDE&Z3'K M6!PJK0)"LM$XS#*5!JR`=GGVUD$YW5@:#\;!6 M(`2W0?>BW'+L/C(-)V8A(GDFM?"A:HD8YPA3J%C4S(=X,#V_FX6M]CCCC)4\ M&HY*(1N(J7TFNR_H.#VKWI/[XWYK9U^IBANGNV_#T4`:M8D5R59[G+%/+`Z' M#&QJ)D/7F$EVY7##SI2O2X3A2UVYB&3?BZW/$I(K3.H8!'3\U-LVJV; M=:7J3!+3?35E+(FMX$&R:9;$K-JW;!EL?@J[@U<2,^KIY#9.NV+TIKMEXU%] M+/#4]G[TEB3FV-KRE'8^ZU,[`RK'?HXB]9XLY@Z:2PO!VFY??:@S9$PQ_!CL M-5NJS$42,XH6^[UAL319"G6-3[6*Y4_/G4G#?'+?3O94K"(SBC658;>@E.8( MI+MSTD#.Y\6V;9Q2#)WWXNZF1"5'+U2=)67VOT>@,JH!N1K(OGV5K=M850S>C+JT_ MJHT%GA+?D](*-5E+K/K-;8IJGW_5R)=S%,'UA[FS)DGS#Q4!)F#G@EUN;K,. M^A>;B\Z?L`I/.EM-D?*8XHR>;Y+2&PR#AV-V(J_QN5:Q_%GE=*,.LZ=:#9G1 MUDZ21_(XV)^B]H.1TB5@5*XV,^K\Q\JP/^HL?RH6G(S,9*^O MB,'&<4TPR[-6K='"N>K^1F-Q)$5[8)6>6B.,JESL MKI(C,2C)L<%8OGGL?,"YHM-34D;KS;K/1ES>[+FV,F1?HB5H"M7HZ=QIANBMF="8OT3:QB'GGL M?4RWQ9Q'<*OS;2)DYR@UJ\1-8>]N6@T]8(%6/`=+/\//^N8_D"[!LY-"*W_67)7/:/K*7P^#KAJ>6BHD.X4!F?U1^V- M1]*N=*\ZD,5U)2O385;*Z)VZU=`MDX2J:$YC='K@O-W#K3#1GA_U[\305HWV M2G`VZX8(,7@IVO:(I6E*XUS639G!]A?9)$&`9V%D@WKP_GMCK%0N`)G=5;.Y M9+/$GEY&Z]7(K:.%B*EC)FE\SS!F\E`*7CU6\5165WV6VEC-:,D*PC8\5 M31F^"EK3V)QNXJ(7H.Y$J']/*%A&;%EXU=5UM3YQ5PGFXG96`]?1(.CGER.K MULFE+$]&%]AQKS>H?VH[N]-9?6,'8UE*G4>"6[HKR6F,SSHL-1Z)J:@J0W+D MBL(2C$XWH)(R2!?G;1HJI#N-VQD=S97!8+P;W?3":F3/'BR3WNFN?5O^;F,P MTNNFR>=`R)MW"YI)KQISX6_^AZ919B4R(LBA+,G!MMR[T=?(;-/6+\-8]Q5) M#+:AJW:V\#4JQII];9ESED-@E>!WAA$/',PL1DKULTA9 M@HQ&NKO-(&[A=C\Y&.VNNUW,-`RVY$P;O`)"TWB;L?4[@JF,RA&Z7@/[?E(! M1]-M<&_<"[JC:6-70&<:0S-M;E!=%*$SR/M`T4A)=F94VTG]1+46&7MW,M.X MF7$"5ZZ$3)I?+.^&9[2['8X320R.NR-]:3Q,MV##9!:FT1=$[H[\R[CL,$Q? MTK@[TI?"OXRVLR5H2_#3KHD![D(-7O,HZ\KTT4B4,MW(G.0U,MFTY4JW:'UY M)`4M6K63I5]%[U6&_]"MR#>D4S1X^V[1^*K$.J;;P&$_F#0M0DH-TTA;H8Q" M)'DLU3J/GN$N#(:.DZC.2H-V.5 MH"-M=3/,(;P@YJ6#5FT]HP^J2$NQ)'.C,6&H`]'71D7U);%4W;=?"SS"/;WJI1--X!-M9ZOCGD^_GC[_>W'T1Q(4#___X*ES?WSU_$23Z^S.98UNXP^_"HSE' MQB?O#Y^$)S",$^'D+U/GJQ#YNHO;J_/'+Z^F,_.^Z?3Z_/O-[7]\B7S55_;9 MT\W_OO*&^KHF@QC>_Q?.YOLG,,_5`)$7V4/2F?#M_.GF2;B_%AX>KYZN[I[/ MGV_N[X3SNTOAZ??O\.7_03][NOGU[N;ZYN+\[EDXO[BX__WN^>;N5^'A_O;F MXN;JB0[UF8Y%OY/]`A-KS23_@N:+K_]#&HA?]TLG68V:17`0[MLD$\[D;3H% MI).I\?/)?[JV0R;+D[RLOG,="PD/,V3-D7!A6HLSX5]/@G\\^5^?!&(+2*#U MGEX!Y'R!C*7@S)`CF.\0!!'0);J.5<=%NK"PZ$UJH#>1H0G>I6J8/@+/8^&5 M@*E49X:IF],E_%$#:JWEF1"B@H"/82U,^J(&BE3#%GM71^^V8$[8SS95;O27 M"YCVQ+0,@@33$*[QJ^4B:RE(GP1:;?@I\+IID2GH1ETPT)R]>O5A.D0]_48L M[0SF=-:I9>LHVIYGENE.9P)Q;.$=`*4O3P%!L,RV^VH3C<#:?1)H%GSAF`P- MGP3P.`&2WGQ'LBQ^#7Z\_K/T%6`:0A%8.,U581S-"!C;0?,,`#6HMD:7. M&#XU_(9U<\&*7M$ZE#Z#085[U3%?`3N`HW'DJW7D&NH,J*;3F!#+JS"RW3D\ M#O"GPPHJ`HG00*)>+?.#,"UFNXO`T@U[WFKY?_T$]`B4PE,`ZRG;1:;?AH#A M%M8)T&D!M39P';[5,04'(DI'F)L:$S#Z%YL^`^$BL-@@*GN53>0[6L(D)#%M M$C:F[$J6#K]GF21P?N'VNU#[' M/N-3(/PU0L-?/_W5IE[?7WU*(]\EA.9,+\QC6C[HU;*U#KF]>W8*CDYK8]". MOMWWST#X:P&"-UE%')Y59B$'M>&ZJV%F>6$E7=UAJQK20$R"$PT!+2FY](3; M$BX)FAHF4*W:GD&@[P8-@?"OJLE<$`(*?2FE:05-S)OP=KWP;`<',##I+<%DX2Q(8"BG`-+*6N)$6`UO).AQZH2R=`H;00D M5YCK.=^2/UV0%]_?_M6DX@FJ4L76OI5D5\Q?61#>NU;`*"4I0@2NR,*S9?`( MM67"U/1U*%TDT`!@\3Z!$B3@D[*TS'RA,Y>.J4X@SC]G`>H3>06E=*7IM:CV MQ%,E]",]4(GG!UN&"5I6A^]T+9M%/*^N30QLVTQ],86#/T")$0R4:#"6ZEKT M'-8G@6I=UK`*.*"S6\:%B67.?95'E=EK\`A@Q>)0\?[ MGU7"OB=]&H\>:RN*V>@F/0GT]M\D_\A:WXMD(#%_$2+`<]GB8D:KGRR>Y M/_XT5D9AME`"JQY'&G_J]<9A(5W+[H99^K)CL724V`-56.#&@3("]YKZ6`[( M-E55FNF^.H#T*;)8=@>4A>!IDB4-J51O5YEY.5'-Y:DL8OL/36D0[2ZH.@I_ MATT5"UZ+%PPZ66U??Z*.HK=/2]T_RYZ1A8"]D\\4PGT1N]5@@E&A-'FH.>P5S[O:5WJQ^E^(S^J$X%4 MF#4XG*!"O6C7^RYL4VJ)3>/K.;)^K+0V_6KZ'=@A3*U@XXU`F,KR#V3%T?>U M;]DQ.>JF6)RSR&1+43,KH)E@11W/SMGNA.IU=CX:V3.&;!B*XI-B;P-,86)Z M*4<#?SC"$B.+K?T[@6B`(H8D"`-%@&FQ?*4)L`.IH3G.S5?#$^`9�$^%] M)CR!4'EOVH@>PZ(^")T&M>\>7)$&=/AYHXE+$[6A&;"YKX>`9RP:5"W`.5#) M`D&P1AT9C9;,45I\>:7?`V1\%6;F.\OT+/Q:+<]WL%V`MO^,QU!*$HMX`IR- MS'SEL;")GPG4Y6(L`*4#3X)V`&?)">D8?UZK@4`FB>ZS`5:9?N?"URA>=A`% MWXKG!G.7P!>B]((KIQ'5`4G%]#!-_#JRE0;]@MX0T:G68M[29T#%^C6(!4,, M6;WBNVZ`H#FEUV/M)\;K3S0F14`$_0+Z`%.`]&G\QEA'$VOP*^C2#2DV3(6& MESZ0YS!+BU"?$K.O(Q.ZTI0'K@'TP)/VQ*4QZTHOKTR"1<=P?2WHJ6,/)2O" M78.I9^`@`17IM1&@+_J88\OF208H5/B1Z6QZ4&GI<1NTY=07'X`T3&,)WTIK M#02-HCP#\IU2.!W5DUM9H%#PN!%_EKGZ-?S<8)#%QF3.;_TI5 M-<4^W3JR9Z:K:Q3:(5271Q_/RNP7URU(TOSNQ=]70!C5P#9/7[=<0P M1^1\#N!1D>_QK[Q"X`2:>K835,X<_<`TDO`PX\5#MNW.%[Y7\LQL?>(#`II, M("#W-2M-3E.EN5*7H6124"^R;=%UQ1!],!#>);WCC:+YF_+,@XEEJQ\"Q9'C M>QB>1^G%7-23W22B-A-=V9.4D"^DH#_%61<8D@3.T+,IF<;T5(>XS#\4;4^JC=,&JEC>!:-`+^V%`@'YHEJ[K*>H6F+9'7VP?`28@ MJWQSMFFR(0;T[0Z+QSR97FM3"#@-*M>V"[$<33C18R0L.S!AB7NJFGR+@S^( M356>[=\M'=B2A`C.2Y.9F](0#5--"0[SC&Z`JBS.TSQ-ZX7;8!A5O'+M59B5 M22M+"*V8^?"^2L,0C=*]SE6(+/B;N"L=36B,@&R3/K%DM@W&.!/8:1A6,4+C M26\T"SNN16O1[+7"H[NKMK?I0BW%#*9G4J.K^P\'=C_.A!6.B1W8KC&PXYDF M[[N9@=5U\]U3MW1P_Z-#4XP')D,MT)/G&X^1XN9I1A8+^@O%U&_P+]US3$$" MN?IL.CCP"T5\W6D+=G!Q9JO%4>GB4-^3:3JO-L-F^H%IH&-1`;EE24A#1"L@ MW0*U0(_@>>5M](?`8;R6LNQ`M<#?-YN!U,*#KS"=@<>AL^(:%B>N^&]L MRLG!TZ"W8BR]P-?"$,7#8#.6D=3IU@5X0'2OD:XOWJSOH:D+'DI5Y2+80J`; M#54-YRN7DWD.EW3#GF[2K![GFF)?_L*4YG5LX?^S]^_-;2-'HSC\?ZKR'5`^ M<<6N@K0$>+>35,F2G?5S9$O'TF9_3]5;E8*`H8@8!+BX2&(^_=O=,[@2)'4! MQ"$YJ>RN1(&#Z>F>OE]LC`G&Q!F")"8;!L-LP!LP&H8/".,GR@V20GYJ(74( M;)>2H\G2YE88NW;B66&V2NGY]-U!&$]%;E M'IH',>/)(6)UD0)6VKQUF[GZLK7",MU6X^Q2E/8"(-X#BP:H8$$XU0E6):3YP@`/FP#8<='@=1C8Q(Y@W<70 M:.$-I24C>"I=,7VGP]!0QD/E#CV68Z,>&>2@P_SAY";BF26IT])-H_@L)K?I M+6`KBM-,E8(QO(S@S)=:HMS,4^T$L#0E!TRM\);Q=&7LF1OX=8A5D=;7R$A9 M0<3D2<>DJ(*+`UT4(DL4'\.[PU9?`_16A^05QG30-/<<(^Q$HSFC$IZ/_#T5 M1E*A=O&ZO55J'J\=R&+S/&/KK2DVA7[!LIS*GG*.PDFGT9XRXZ!"VN`>Y!^J M%Q@.NV7"CQ&*3,74$POF4(05AA$FC*$7U+K78'429;R$+XE=S"1RLF`EKGYR M^55[9_&LZ3D5^M@,'D2WJ^O?HHB'';[GX@B73'S*$XN0*?'ET:&,.5X^)E)C MX!3LL`D7F4E5D(7L%I4C;T'A+G8?94&]A?9'@CFN%*`$889^'%".)H54#S?. M7#Y618ZR!WR(US#?1(''8E98F6M"P$GAQ%R>#8=J2AZAI*BIF/(B%HAL=#3K M!?_YC/S)/)\*/\)WBT@PV9K'VN^@8K`CAXJLB7V3C'9XL)/[GFZ#`#U6@>=0 MFAHH4Y@:AF&_LAJ%'O`<`(<&KA"^*#\1_?M.3;(Z[@X[;]`/6;@P#B@%/I<( M3>>T5U+\&\]E-XRA/NJ4WZ)K3\A@WSE)MJ,:E$Q2+$\4^0JZ=YCD*0U4;^7' M86:WG7)+YH<;_50"K_4BK-P0=`N(29-$T/&FUYDRA0_GO!$B?8(MQ;.D?QV$ M)>:M9@\X/!\ZP(1EU)-Y$X%T0DK]5HXU:KR/8M//TD/2K!`A:]->H"40WFU: M^?U2)@[/U29I3ZX#^.C=A!*/J58CAO=&F*$;HH2VT^3&5'!I$\L-N0V10IKX M8L>8D$GK4TB94D/2W%]>B^8R+LVPM8#]D^(B[LQ%ST6\F+-RZ:M(..$*QQR' M?+W7>D$$W! MX-.#"&?;K@C05)Q'WMV>7&K"C4?&E3J-A/,@8E6W75I! MLDXYHUP+=&WAO^+[H&"]DX(NMB><>HW*16-\/"A1R5NZ^/OGSJLP!Q@WS?Z+Q=YP0MPW2L\8F(.9XS@P<( M!JP`-#^,#E\2+0]N./$:79_AKTX0EDY/*;12LSD)]-M\T)M6J^I*&F?:HWR$ MI\2>,K\]ZC4%_:0H:$!9FS+GELK\*9N;/B+I.`';7<\4JZ\"A@*`+T/L%YZD4"'=Y(]T0>[CBLJ'!'G-]OU,^X0`Q9A3W#H@7EF3/:VK-$;Q>ZHES2 M&?(2I)B?0:XUBZY4\92R)H_H0^ZQMRC/'_/>D;%CJKS.DPGL/+&;$N?SQ?(T M^4BX?OA!D75)A^Q2.UY^"`&E_8NT](BJ\#8>3%FV)!&=.M,^H09_=&5/`ZJ; MY`MC/B=N'7N.46B3;W+EF5%9`%:BSK/<^$)@*X]S.CR__0N1`.[ZH1;3-5NU MM#/72VAS)U16!M\H;WW&XFG@-+]9O(G+Y67U*^O"%*4R3U'_N70?1-59,2F_ M3)P:)]>T()0R8X^P2H$HI>Q2'4>8@Y67!8@X$>R1 M8<%=E-5TPI9\./OTURP^G$))?X\QEG1$3"?*9@ZGJE#]9;/SLR!OJ$,7!79C MF%ERS:1F:\[FDOF=TW-V.`0EL:YS66Q2BEEWH@4D_':.14#G5`3$1R5*>HH[ MJNANVG8),RS##/&[7.IB].-8H\F6(`I)6R!SR_H/VMXSC.442LY2NSJM]N!2)#><#K7GWE-D\H5:W41J3`4YH867RD8?ZDQ!BP9WH9)L'Y4MO2;-Q M>(D>_-;D]>FFVG._\U$;DG%=OA@J,:05I]SK<,#\GHFP;T9-DP"C?)0+7VYF MI=!=O^WKS__?]=')^==_?O]PSB:P+GWP]?O99^R-#X!\U'[_>G;]ZP?RW^2( M$9TC^_ZA]NOAQ]OG'T>G%^?G)Y16\E+(-YQ%;POE'[>)?GW]\.;_X M_8.&@6U8_HUF,\^+YA;J\3B+@'Z?(WL4OXOS]6#GA:V%Z;Y^_?SUG[]BBW]S M_E#XNY/^O0"\AA$Q%J;;NO[?<]@7[TA7/M#JJ(`:0`".ZZ^G)^?ITH"5.)B) M!W\7>^IU8/_WKA-/__YFV"^)&J@4"-%<`AT]HCN`P*%"X&H$FCN`P&9N MX"]QJ-BH',`T<0M?&19QZ:\O+FMOO`(50.WL'JP*;X<%JB+19D2A1_;4TZ'^ M='+Z?__YX^*W[V>`.-N>3&R[+>EXRGTY86Y1/P._KPOGS'4494(7HKZL'Z_+D[.SK]W\>_>`O[Z>C\EX?U!I.9!KZV!A)CT9%I8I*#YI* M)1&?$_I?6^+S2Q+Z%,XAK_3$?:#0SK;0_FA8=Y,Y-8?*IL%KCTLU"',-E^KV M]&%_*#T^%;DJE7C)DO_X![*H=,1CJ/>.@HUR*Y!7)'QC)2R+M?,L(O7?ZULL/*!:G3*B&G>B)'&8'EG]`?ZL#M\KRA<4?B> M4GC/T(?]P4%3N"0RO5VK?(>T>66LR&*L2`E^TWT+%''+A%U%W#N,_?T7TNT: MWO7=+W5L57W("MI&#;P+5PM'#./[)4;Y"[HE/!'P70T1FCV]W^TI6E>TOO^T MWAWK?:-_R+1>E.F_4*?A_-?B=W9N.L(.-(1NCBIP*-)!:+I M._;`QS;Y.->9AGHL28?-2,[89V,HOB='B>@W-,6+&#/,[-NV&8 M.&CA#(YC[22N&T+WN*F-RWO%IOC97CU6Z8LOVN67!N%%F\<4XW3+9B<%]_3Q MR"C3<_/CB.$EXU[I)?L]C7CUSG?CGDHPP>3$H9&Q.#)B^6BD&%!R0(/93CQ/ MLW*$T'B2\M@/')OD^C0I"3GITK,TQ+,PQ-9;-,MBQIVV9ZH/.TLCU9_(O17/ MDX'G9>M+P.2^TG@[[=IZ8&H,TVMKFF(ND9@QJ,6(!-0<<81BZ-`D))I?F`\+ M/>'#%9&K78%BZ5BAHWT*\-_OTF&W9N?CEY.K3]FOQL?WM5\[#9Q\M%[QVR=7 MIZ4O7P=SU]:&O8Z>$^T2V="GU67RKQ87/-9^`S85:J4'=,UA$X:\6QQ#JKS> M^NY_Q2Q)FDQL/=`$'1H;:(N93&PV#T(K7&@`$2S"_W"S0&[OD:;,?,O&W!]0 MQN,D#N#)D$_9A`?R&>V3A!HC,8_MHI^S!C0@+J89>GBT/8LN+`CZ&D<&[[9B/22\=#"QC"3.#Q@?" M^AP8,>(,2W M9V,0K=`%@V(>@GP-79"O-"U9S.JBZ8UBO5@,W*)3YD/'X(PP->M&',HO@.[( MPOF2(0.D^)'.YW[Z:&@1_ACP.)Q.NE-W?D=9U04FRL'__030#L3L1F24IM-J MB0KF020FP!&%T83W&[HQUD_X-\[6%,H:W41`_`T3?X/=H0'+:8FPO33=%HAH M00ODX[X]]R?J<'RA"""RX%E'/(R+$44F0&L'`1E%7_# M)W$2'NR1YG^"=FMYM$;(>`8CO(6FFV8KJ$OP"MN^PMFU^0!;/<,]47F4W/P' M^37@ACC^`AVI4VW"0-()7DG"HDJ8Q/5_`]'L50F3RRK.\#UWYL86IQ:X0B[< M@7=\+J)P(8'M,T.2@/\VJ2N:%6N#BT8^O3$%/_$3M+Y\!M0*,H;K$UZ`*'@-\6YX.Y*/3_*9\06636HHMABAZO8P-"_QCA"%NP*-YJR\O1ZKH#, MF!6!K<$'=1-KY`.ZTQ.F/>,A%[8[MQ9\A'(8HO*?#]_-H$<`X5.N<0"K)?L' M=!-\_Q&]7RQ5?/WC7EHZ*\(I6`E>L&#IK/;<%++`AGD6^&3C%=^3R0!0]P@N M`,86L-X&:#_@;OGA1QS'."T]VQDNL`F8O14JN\)V))`@WT%W.0>-1;N$NWV% M!*-D1ZNZ-!XXJHC(,?D-I3'=EF>+(JT:&9(S?G-0=$5]MD(?.!=?*T<>_>U8 M`[4`OK'V73?HZ+AS<4(O:;'T,'R(C.J>848&!A3&\Q=G11]-(YIPC78/(+3/F"+8=>-_[0 M<7N28[.3HCQ3W`6A+&)?B)K,\0=XS@Z?2$U(9G'Z;E1&T(>=8B_[,(Q\O&$6 M^>&.'A_LX&3+;617RCBYNJM&C^\[`M7H\<>ST2V5]#R)M5[4*$S/0+%D=:5[ MV"8ES6Y^=L'6AKMM]'OZV!CH@\%S&I_)1NJ*`)Y,`/VA;O9W!/]2E^_)UDZA MCNV?!CYE4**9`I8C[&-N+:BN84N\?T_[9[Q67<_F"['A]H]'>K\ST+OCYPP) MEHWB%0D\AP1Z/7W0,_51?P=(X``$0+MZ_V[T/MWF37_]*DYI5$&SW]5[9E?O M#)Y3]2D;^2L::<5>[!CZ:#S6^^8.T,AV2H-;B1$M;69W^VT'_@0X M(:4:8Z8;5CS"3D1]QQPK(WR>+*QRFU1N$S`!I(Y"!=AE&/@!UB+DDXHDX)PS]"^^)_JZH;.O]`UZX0(;6LXG>1)Y_5LX@:+$S6#`DY>:K)31)3FL:" MQ2(3`_,S"NF9D:C>PQQ,^#X^*^I/L*0Y1!Z"W21X_@QFJ6QD-.WEJBPK1:G> MY*7Y#S>8;QM2+\-;R14OP_`3AEQ/?N2PPV(M)=J17V8F>N9'M M!9C?>LT>XD]>8/_\QY__].<_:=K?TO6_6&[X+TR(S9^-LH>1PR/-E3>/M2\G M7W]H_SHY_^VS]NWSR=5O/SY_^_S]^FJ[7%U&5M6DOE);FRJ85I@E;SL:_%Y( M[<9N^LC00!U!3D5E@B(KKR9=K;C.YH*!D=DY,CI'G7XA[Q/OD$:72/N6IY,7 MJI&/5ZZ");54"YAO7R]EK%O:)+1F[#X(?U(V)]\JY786$#&+\.3YUS MLKN<9N1S32YDM\"Q*U\N9,#SDK]"76W]^5N8QH==,/CSF.B^\3L9S@J%P?!= ML=/'H7!-,<1VZ@[W_1Z6JRFRXHYZXL%4VH)YP!.`4^QB8:W/TES8/"DTGH8, M^TC%[#8(@4ZVD]VY[W@\9W?,TXP/VF^^Y>"7`2-_)`'^9QZZ=MKJ@52\F17^ MQ`N<75A@B"RBO$Y-5#05D8[J'"\4=K`NQK8\74M\K!B&A>.\`Q@\46`'DM>7 M[32:S0_:_ZOB=@FIJ*YSA.L:57G/DSA*2YS@[\$-%C.A.@KBR,71['"9@1^C MA4#/I[_IO$XKN4%[(`:F[/%"@4D"`@+-C/3.$QT4R6!!?8D4(;1&"-T/8&`3 M!02<7?.BR)C94]_](TF%LF#K*0UD)$)5XQ&\G[QV?IQZ>59P?^3WB9_3C?;. M/6;'.I#&')MR\+H20'OL48V%'PBBY&0(Y/!>R?!67):M^7.NRY*K4Z&^-WWIHE#_0_`[U[,V%9!O#:'"LJ627A9E!K&%'7[.K& M\#D^*D6FBDQ?C4R/I,>@(E!%H%)C4!'H01.H$O2R6"#-]4^JLT"6.X:5,@VW MA7\9.@;)`-[NLZD&0:UA4\/!4._T!]+C49'I09/IUM0]1:"*0!6!*@+=>0)5 M@GY=2S*IJZI4L<^^%?ML*A78J7!ET\FLLL`B0;'/X>0RJV*?/4#B/B:DJV*? M7<>@*O;97V0>CH`\`&2J8A]Y+195[",/+"H'6.4`2PZ+(E%%HI+#HDA4D:CD ML"@2520JN_M4%?OL7-2*@.X(2[5'XWTSO@YZ0^*3!69JDH*1:"*0!6!2@">(E`E MZ#O\TW:F#3W:U-E"%5&V?A2'@7^;;O0:=-0:CFLG2DV#>S[5U)Y: M_BVC>7:KQI$_Q\-^X?V#IY:Y52+?*S]$IMN?UD4G+'(#MTY#AI\AJC;S<3AG_(4"N%P#4(/)PZ MC-U.W:_CHP>8+K5[:6X'!&IG]V!5>#LL4!6)-B,*)4MCJ)..G]BMZ_MHN=]8 MGN7;6POSRA#FEP&\W??^-@AJ#2-2R2@R@*>H=#V5FB-]U'V.V;\W5"J)]&PN M%%4G/2^3T)Y:$8MTS8VB!.4G_(@>[HC%L2>Z(^UWH$IZ\%[=BFD_L'IZ<7[Q M(U/J6V-BO:YN]+8F:Q7][BW]MD.O!YVY(HF\356/)W.HC4=3&R.S%EK@,\T+ MH@A^$''L8*)-%S>AZVBN'\5A@E+XD%6Q@P2O?1*O8VI#/M"OP==W2:)4&[7"*86HMJMY?H@;VTOP;0O^)E9(?J5(^V=\?Z0%;/GID1( MAOG7/X`U'%`:D^/=8##4A^.^HG!%X7M*X49'-SJ#@R9P2<1XNY%@I8S+`IYL MJ2K-L*G7`[_I]!5%W#)A5Q'W#F-__X5TN[;V9]^1(%=+!IULH\[=A=OD!`D5 M(4F,Y1 M72D\;G*,YSOCO89%YQ0'"$(>D@^99\7,T>*`"L-#A@%Z"TM:,4@?)*%V7VUZ MK+E1*8S`CV-DFIV/IU2U7BE:AW4<%KIWL.H=B[*GC8_X'+[4LNU@-K?\!2I. M=N"3ADV[BF+X#R8'T&;F+*2=1<>UX#ZS*G\9A[N"T!VE0Z3!4XYP3B%`3G&4 MTEG:U\#2SEPO070?G3CX"B"'3YYE_SRZLJ>!!U_Z%CC,.]9.HBB941$V?I5( MDF@3HUKUU_FY[1LZQZ)..#WIMWAM&GV%<3SL5UX1NM'/HTG(X'+"9="U=^;[ MPIV<,+R._.K.X&*+*Q2'EATGEL>?@,N#3Z0G#&MTWVOL8-=[K_V7A4$.(-"_ZS#?B;1W?82;A;8;,6T>NC;#-&!M M$H3Q-.-&MW#6O,/&N\%[.,S9#)AA%`?V3_$5<9R)#VS-(Z853:V087H3?IYS M4(<0ALG&[X;O-3^A-AOP;7H\PK.X8926C%3+%\WSH1"O-F_X"']^=\5XST>M M__YX_75/?R%-A!I0W`0A;)6:,8@S)QW@`Q^*3,\<>=8B2.(/$_>!.1\W-G7( MU@^SGYQL,\4?P_S'5%&HL*2,MW/O MD)6++K6/268S*W3_RSA'*+:&B5DXBY#VF&5/4PIVV`T06H*T"%=`NY^Z\#?\ M`WSJ`D$OY>@A38;,1G)RRKU'-8M65\UDGM1,)BV[7-].)B41_O2*[C(YB3]\ ML)(XR)88C]H:?+ZTG^UU(Q@]KPF#E&6TSX1ECT!1:)$2%"E;=RBTJ-OR&#=D MFVV-G@=LURQV->JNZ/8>87>Q[`PNT0#)?Z74W9OP%_KJ>7#/POQOH(U]066^ M^N7"-X+"XY=@%<%96+>LN$3QZ7_]?G*9_VU2_/)Y$/P\N@'CO/@\K.@&SN$1 MH"R@*'9=\57OA7YZEMILQ:OV590V'PI6Y0.E!E-?+(40Q?T46C9SM(F5>'&) MG^$&6?2`\I0FC:?RF^%D:RMFOTS@06'/S%,KD1EF-29$YK!7.Y,19#:]\J_"U4_@ZK"C--L,!F^KQ&K/8 M-W:-?.UY-\^"?`_[.6T#V?U!3^\.!PK?VX;OQ.WA[9)A;E*O-`;?OR)/-I%'7[K&86V6S##MD MLQC=YW0_V7"9\=#;?I+E+,\P78ZZ/186[;Z)#@_JUI/U3Z3BL- M8M+]MMD*`!M%[7L3F"81I)4@KVV,,`WN>4\$FSH4194613-F14DHNG[P_C/% MY@F)']S`!NYH+=>?)]@;Y)S=,4_KOM><)*0WP>H+9H61QGQLC["Z%0(U6XBI M"PZU]\"B>^U[$+-H.TT2Y.\_M++E0`,GTDX[AFI.P)C=#&R&W1E2EY-XXOSS ME^O:OZ]LZ##L/+&A0\7[M7(KPEI?>F`7&T(\L^%?3\H$]YT9E_#:T!:30LQN ML9RZ7YLL'>7P?T8FG?^:UG,K4/ ML4+_D]#_NH&9W>;1$HRX&6Y@VVCL3=D*HG\;&Z0:YW\O$Q">VI%V&7>%9W[(CXG(&)Q[/$XY"%K43*`]^I) M*.W7'YY>G%_\R#3]MKC8L&_H/>,Y";:*?A7]M@QSHPGA>T.ODDC==JW6,VNA M!3[C<\\"/Y].MC3FY)`5,!G`VR/6E<+\.J+7T`=],"$Z:A2KHN#=,'E[P['> M,P^:7B41ONV:O._^:;G^>RY[)V$P$XFXY3S<0U;!9`!/)JXEC7GPKC\R@45U MWTN//D6=NR)3VZ78;F>L#T8=Z1&Z_S*U78,V'Q"%I6'%0;6'K$X]-P]2,H2_ M_@$T6\'Z.@;O.[!X>V#Q=LVMB6=%\XKF6S61@<:[1D]M3066@<4E$>KMF M\F??D2"M2@8-;N.-[L*-=H*$ZANWC^4&$TD?F_'RQ'.1.+S<9!KJ<##4._WG M="A15T==G6U=G:UWK6`-K+T^HV_T+E3,X&;('182"7V M8BL$\0?L0_"1][8X\JQ%D,0?)CCK^>/&4OUL_3#[RZQ= M?;Z^/O_\[?/W:^WBBW9R>@HWY/I*._E^IGV_N/X,3.9_3SZ=?R9LO'9SD$?# ML:.-:$YB[7\L/['"A692GQ;X-^_-,IM;_D(+[IFC?;+\GY@I MZ\,'(*I<'[;E8(9+D_N">S./>4,;G'LZ#T,+Z3^T=IZB1:78^%A_./C8^ MOC_6+GSM"[L)"8'=%(&EM;-]X,FE;__!G/L@<+1OEF_=4L*MKIV?GY9>*IXI MOP_H9?E]2P1S&40Q[,)R$L"%]BNSO'AJ6R'3/CN)3>`MOZ[TG>)+FR4PHS/6 M^T^CL#A`W-#1P>_-[J:WO)OCRO$]!8''&O9_XANV:-8>;KF`G_1@C>%'08OY M\OFJ]U;4,)R@:PTZHPJNK[MSI$B?"??#^+821CN"Q@YGO]"2WR/1;Q36'ZB M^*#-SYI3232%JQSATL6@"^8R6+8-*AO='`)>4*Q8R,H1>C^%3=PLM"BQIX4G M["`!/GG#"N^#_1;?&"1A^:VP?0M!A%>R/Q(`$AX?]M^F9.\!/P)@44O#N\T? M?.\+#Q1@7Z"QW_V8_CTZ M%F"7I#9Y4"+D"$49?AK1$J[ST^P)(D*Y/[7J"R3WN'?WISRCZ[PHS?ON:#*!4(JBMX4 MTAAHX"<\BC3'++A<]#:.L7RM7,[UXY0C7T&9.^F3A(,[@ M[YS&Z>3O,W'DE(,I$\]?9+/$#VW/1_HR=7-R695+^6'N":=31NZ/QXP63 MZ]\%=+>0PG%KK@U,`-ORXJ?U`L%OWS=#]S,U@1HV<:J\'#A>CIFE6X_G%21Q M%%L\B(RV2((-C<7NCIL]#'/Y,/2&]=^:XT;5NVTP,AF":LH]"UG)1?!\I049 M=\UM3=V/0]XFFA>"<]W2Z*:?P;68,]"^[D!L%*3YS'+(=-,F;HA67BY!&E8K M-%/O@SICB-*B&C%0YU\I*06H/)`,6^2GV[3&58O-FE.O91?Q?;!.@XRR6Q;" MIR[UORDHCIQ:.8'R;>";'X'<.G26$9EZX)K&J0$(-<9Z;V2L0BK?RS)BE^QE M@=F4;^+#"-0(EG/A#PA!PH5I0>4T[KH*'"DAZZ-^A;.D`ZQ2TXV@TG_\** M&;N96(D7@_T%_WA))*PNDH?E)P'T.7I4BC3.EFE9T11-UYF_U* MEWW8DE,XZG9MKYX^&O7+VWTL\>V4!KBCBNL9Q\5)W(;O%P$;3--\=Z7VSXC#DABM(-A`Q3A`* M15D`2E[ M!/>Z6]G2$_A?X[<:+*B!:=3P/&SUP7G>J[*\_@J65V8J)?YG>VA?DFL/J=]! M5E@P`"8,HY.YPI01`"B>5D&CTCS7NG$]-U[PY;/G*B##&J"2E?6R9HVP7EN7X;/.&^Z"KF^-AQ?]0-)/%("<\LD^>9?\\NK*G@0=OF+%X&J1'07J[&V?: M:\B."M.@2!X0(\C37XQ!89[3DO98-=5?4T?O=_J@`/2?*..&2L9M4\9]`_[T MJQ5B?M2OQ]J/9#:?:N]^,(R%!Y?`.68EN7/Z^>)]6Y%R,)DV"\,Z-T]!&)93 M$Y!!A0QX/]$=B`G'C4!@A6`:-JOX#FN=>!BY@K,*D?%%EH=^&!&!3&_D$S2] MWL7;VVV?M^D*[^/+E MZ^GG'U=;836/WN^.LL0F64`)\&)8K#1^L?JI"):E829,!P,.$8B+@?$Y5(NN'*6:O+DU/+,!>>OQI@K8998?B)&-Z%*6?-8'BW)U$J M1KQ=6&09YR0SJ$V/;E(DJDA4D6@+>-N[AC=UTO'$UQ(_PO(W,+(=-D,CW0LL MGS>)Q=*V-]=Y@P&,<7;.GC_HBB^1`VRK(`-[N M#YMJMTMH?S#0N^.#'GLA`WB*3->3Z:`ST(W!2'H\[G_GN^:Z'#9N)N]-DT,9 MP).IS_9VX)-RNK$B3T6>BCQW05"V;#$7[.-+*_&T'\QU=!&=#F>L:#&#<5K, M)%HN/J>:[%#DHO??4KHB58SK%`L/_-0FY\-)N9E^L]!L%L86U2#&S,.J'"S( MGH++UV:MU1,JCV7Q9BQ3E_\2,C],?%6`A:\TNF^./7XGU]>EV].^@* M:WT(1E#%[%>F^S-";)+='*E:B4MM8!EF5S=&R@^@:/Z`:-X8ZJ:AG`K;UY64 M4^&PK#99PI];,NJD"8DJXI8)NXJX=QC[^R^DVW5HE&?>1(>LE.W8Y(XV8I:[ M.YKC:6'-T5COCP[:`E'$?BC$/C2[>GI6%^]34LK..C+0I_R8O5V^IBU^\\IHF+E'7KQL!+;50HXE?L!&94=Y3UOJ/-,VETSX,G;1=Y0 M;&$+^_*I5V36KK;4Q(8]S-V0-3W5J'IM*D,B\DNDFJ1()%C--@7KH*8"3B1\V61) M$RR\?>QBTS_6+JY__?Q#._O\Z7HK8N#16]VRN'K\/IOD6250B8XY4WV'LU@B M;.)TA%.ZWJ=M:**E+C3KB]FVTZ-&1IPWTI3&]D`CX2]7_6E46X06'-X[V+U$ MM9_9?03N0G<96>+IBHUN'8F[U\_B@$!5K3MV$V\'!*HBT69$H61I&'72\7MQ M.%\ZJ[;S4?O!/`L=?I?DLWQGO'\&VOT*LD`K==0[8XEMHO"E\=0\"%66[O MNLJ659T<#J>3PW`PU#O]@RXM431_8#3?'XWTSM@X9)J71.BK[B6'98_($EY3 M#1X4<1^&.0^-/3^ ML'?(Y/[8#B:[4E:TJK:G5,Y3?4&Q3')3\4Y&4*6*HO`1U\CI.1U[E*FDYY^_ M7!<^3:]*^C@5(>7D@K5'%S\^:'%H^;"]D/EQ_AV^5+%LJ7-L]O'7R@7DBQ95 MXLJFQ'-+NZ*'.]@2YDY4+\7!/#L,L[>I/'(5[IM$_>.8F<+"\["0IE/NPO&W M>][/..0&&B?PGWFK,>!69:E]L]UG[S08CP)UDX MR^IZJ<+?N@T9PY8#.N_V0!_BW`KV@!,J>">5F^P0@6Y\%PYZ!GN;1KPA`[7. M(!10HP8QWB-_@Q?`/N_=>%HO4)]Y:MD\#MOR[(3G@%DQ_/TM#B;AA:4.KAWBHA2!V7`0IK^NPO'OS?JX`89B+(X MG8>-@DZDO7)Y)'(*M>HL;-&%!(3D4AL2%+S1AG8C2K0?Q:[&T04<) MEKT3+*E.?+68W03>"C.0HV;4W1W4[(W0^>IKWZP%BAA#+S6J`QN+@1#![G]\ M=B487,WZ(&K:%)(A:6E^X!^%HB*)6A1B7]'-9K4?:/@=-%LM?TF6PK]WU8C. M@8?_WB86=E=E?*@G?!;P7GN5?HG'VH6O?0_N1*O!?MK?%A]9.M_V>SWV].Y@ M-UL]UM'IJDZ/HFUFRUX)0Q^+[.F:IK?81C(3==2.MW"C43WA-SJ*&M^7.=)[ MO4HSWH!WOXQ8''OD("//EC0.C6UT[U6:I=(L)<&!TBSE0\TA:98@L+"!JM(O M=U6_O$*ED0[!&&Q9P03E8VCJP[Y2,)M0,`VSLJ$5"N9KZI?CCCX>&CNE7S[> MJSGH/H75/D'V*7U4Z:/2*SU*'Y46-?NDC_Y/XBT*6DHVDX,/.[*T.:A(\$L0 M+KBH$].[OKD@]IFG?;//`M_R'.TZA'?ST2Y,3'9I7-K537&Y`>:,JD`F^7%8 ME!:*7*%&=9+2B]_2>"C2+OF$)SH=3,5)*+4G])(H`L@R948B?A&!/7 MP[;"<$&#+;(M\Z_F[4\(0M)=X>,00]0!IP?7MT.&P\]@K[(` M5<&'^Y43!+MC'#212%>^!O=!`HR)+@/:;(63>[6;L<[(*N-6:.V4Y`BV=(RL M9.*"M5M+<9&R_]0O^C4!<)"_>`9Y$]_&8R8#`&IX#AW@E'D4DBB@E0Y`H((K>OQ)LJ_0^L`@AF7_3$V5('1O750"IX$' M\C%2ZL6V]R[8W/_ITO_JJ1)NU4JF*[Q& M2.Y%)G4:H%T'5L%GU*H!S`C'DIZ?GVKO4NYF=CZF3V4?&1_?IS<3+@%9FY96 M[#CZ@SF,S8A-D,*_Y#MJV&-4'HC\%HQ0/YD=-_J*[*@H1.O'+O!&AWL."&X- M9W!B79B_J(@+L@:YT\J'YQ_CR-'>X=_>G/*/KO"C-^^YPXV_+D(6S\>SOWMS MFG]TB1_!H\B;J.8P,XZ+:VD,.**'F^_WWZ8[L6`-ZS8SI!T+^2'RQAF.9<=& M#"@=Q$/TZB(0^=II5+B+Z@.9PV159_+(`_L.*&##R@6GA=$OK^3.9LQQ02#` M_N88SW?2)PL'<09_K\C'+UGU`8&;5DV*K:7XU?-+,;,<5O`F121R$+RVPL@@ MPGK&0!_U^NM\?_;Z.#(GH,+Y12#:_6IQ:1=4@MB-)HOT*9^:!,.M1L<2DAK= M[MQ!T'B<=S30![UR)N$&B;AM<;'+HFYE4,)GK4BV_E`?K9L#OU(2\?M%I4.. MT/,:I[VZ9&"*'7RR?L(-`9')O`C>^PG$%JRFG8($O6=P+0C;^`_\*?P)S"3^ MKZY=GAY7I>$:61BU+@RU%=+P5=-Q=7,)^\O9$H]T3$LCQUF4\TDER9\FR3WCX,L)(45$04AR"A;G2RM^9<2; M"I4\R4V/9_U:3OJ1:@:Q?Z&2:OKY$[RD*AK23#3DPF]4CSI);M'W:/)"A;+8 M2*BOE56T"C+=CXN_<_>/Q,79@/9/ZQ8%R0\6!4EHHZ/RJV\?ESR5YY<_BD[* M?$FN02H'$^EQOO:%W824)2+^;HKRC")ZN$UT7\HBB[1;YH/6[XG,J1FH M**`!6]@)A.I9_(B5,V^$?I`O3!DU#A6ZQ*#J_^2J?J;-T&9!UR^DL9B:*(_@ MBE-0R'$9I"&\>WB%\#%DT2`+ON.D9145D[1`?%/,G^'T><\JQ-.LS-TV6'@C4/)>ZN"600)R M5\V0D?$"WEYV`C7?5;&.1DI]#N$:I>FZW-_SS0J!TO/H;7&')7Y`CAG.-K*+ MS^]GE,`*^;4F'E0PM^9)B$F]\5(@MN[BZR09IA;G&-2`&K\7D?NO2>]"7Q\: M/;UK5HKI-]>,3?`(4U\*=R]0V`_(@T5V&-QC`!"^[()@C>,@]-F"CD24/FJV M%4T+H)=]*"UE_O;JI!*YQD!2Q"YVQ6Q=`%-IHDC6%2F;G'NYK'DI;-1D9K[G MQ-WZ>S+PTFI2'Q,:,C\<7C*D\2CPG,P;54E9P5',(-`I&'Q94K'RATKA8*2A M=IWVYLC0AT-S2:FZL.-`:`B/2L-(>4N>*C_>)*UD9.3*+Z'\$KMB&>^C7T(Y M)K:0IDER>E.?RI3!4QT!+LMF^.7??)<`)T<4?.M:L M^3P,'MP9SR^1MN-XOZ_WC#4=Q_6"!9G%V?&HT//BC.Q,[> MLB9^7:PHEJM[M>I3K9BM$GF[C055("BW./Q:;#>'LJC@=:QT&&QI:%:=1YM/ ME;)N;['U0(Q2JN%(HL0M0DC!>Y`]D8\Q>("!,!Q*-*S"ED M;<+^V4,,G_)@=I*VD@BHXV1151)QV'*J[X1A4PG1>H(WSD#@[VDU41E83$>. M@AFC?.0L^N6&I3AP(2&YD'::4J-H)XCYQD;_;=ZE1!CU::ZN[041+C:SPI\L M%OG(2XG-?#$,/14;CLQ#=N<&V/:QLYS:BV6I:9J[7R(&-R\E3?,B\C0%M]@^ M'$/_C?>UU%8TMC0[;PEYAOE6IPM6GFI2`>X1:O)2XXH4ZL;+@IM<:Z`/!KUE M.?/(Y.%#4'Z;]F"9H+]@C*)YB$0]]+H:"SV=O8@4BV4J&2NBK/MB4C(5>[94 M_];3S7X/9$ZED7N#"?L.^WC?&9;C*K17;5@WVK7;J91I,?:^X=?50V-7Q/BAY M;3DEI=KW:[1,;=QI72>0^.W)<['C=M6-<4YU"L]D_I=N6H9?S,S.VE:W-;&MMK5I47/@:H;P8_E%D]6M M;X162!!OF4>:G:7F%S2Q)/4TIIBB^YF=L_$8]-%>N:SAMSO5BAZ!53JM)N%$ MAR>GCMXRWVGR1<)8K7M752R\(I'6^<<;!QW(HE;`[,A5&"\W.&M>6^@NC]XI M:NN'(Z!40'[W0\$J("\#%E1`7NZ`_(4O"@=-LZ@V+4G^HO?TC-W`N22\:W^+ M@0"S1ER_J-EF8>X)SKO@;N)\"DNSZD9YXSP8*J:M!)5#[^E:XGLLBK(8L+=( M[6X>\2PVR5HQZZ[9>'Y^RE-1.YV5<*81]51)PLW'8#=1=TX-IR>R[_K] MM^]7>*YY=$"XF?_U^\GELK=ZR:E:Z\&.[^%5B[+;N>QJ+OC=G657\V.'Y*SR MM90O)?,I]P#HE@;/6(LC##J"ZN'>\4X![;2BZ^GCKE$!;'U3,4)\>[,B1T9' M[U!:-Z[GQL*GDSU'3G7B:(X(!0*':].99^AFM4E# M\RZ,H3ZJ]&RVT)$KY_"?/LG\>7=G3`&:T!A:HQB`RO+?.VL\ M*1A1K_6EM)U5V>1:W4TZ'2^HX'9?VQWGWY-/:!JZH!_.,6QW:F%70"=8&;3) M)U:@?>\",N"KH489A"X-;`KOR$U0GE1YG=F&-"RU-=?11Z_2C:BROR=UEIU!0T468;+.K:*GA^RI?4-/4#TIXI[^:8)4Y+>?F MG^LWBV1RG(VZNM$ONW=636WEIMP::$JY3WJE>VC3HV<[^F#4>\H]D9*&E/5R M.'JSLEYDP(*R7J2W7O+@0E>ZL&]M*\Y]B?M6#UZ%?E'=+T5\C='.!WR5.2'E MYORZ4_T@& M+"C_T0[YCPSYZ@:&!^$_,E3MP`H'DKF#_J,:S4CYCV3;_#[XC[J=L=[I5T:8 M[X#_J-O1NYVN\A])3/\[X#_"@:RU'3%D=/,LNV8.QQMC#DS=[+;=\:#9L*6A M&[VUHX1>PQMCJ&($Y8[9$T>`'9.6'@SK?#'IT#HM8G829IH! MU^@OPV`&^EL`QCHENK?KF>G6-'?$0FOK+B#CO69RKO;U*SEI"CX8-#2$.\1A M,TJ/AW^VX9GQD]GQNDWSR<%^[,8>[U=<]'_DXQTJ3HZJIDF]7#8]@<_`R%L!I^,3;EQ'Z-2"'AO=3U6MK'AI7/3A!*+U\8(/ MF*AX;%RT=/](&(ZX^BAF5*14)\84K,+\!EPW7O50[=CPE1\H0[4]&S#-C8*) MZX,9AR=!6O\M*W1#SBR-@`_C<+)SB5BMJ9&-G&6#`FV13KE<14KA*FRQP_' M$E3VN`Q84/;XSMCC)C?(C8J\Y+)2=$=;V5]?=!X#230/0J'T7J_1MO2\5YG- M6G++][M+!KQ.TW-:M+M'QU7[<4[#(W&"#BJZ!7<`-65(AQA(HWV6QI.EK$>I MI-5+DVEN_48OC>@K.;6<=J]&=[C4HENGG21SV$381C!ST\THSR(HA8GZC[HC M4I+*3M-YD_A?)PRTLLFCIWY$WJFC%-@.YMRC05=K4_2;.ZXH\^K."EUZU=+, ML:R3:W_T5ILE7NS./8Q-WRSJDJZ$[X_G7KWKOL_\<2+W*O7=E!*M"E/!8N9K M[XS.>^U:?._,6N!%<`,'QS3B)VB0EOY:=O+%3+P@@^-[$)/W$7U5@"RQ\5]Y MFQ/QO4]\0'%8L4&O:]U,M%1R\Q^PN?F("<\[`IY@3UD,N/%C]\AQO23F9PAX MY*:Y6TI'@+V`"90Y#T4FP%'JN,G==R5?44R^8W3B^%47&!TPWW&E@PNG"8UF MX>*HO+5N'L*0;473U%M+?B-$K\-=3+39U*D4T&P-6`M=??B<\#*](S]OGHA9 M<$^5/UBMF_+QB5;E.4A)@\*L9LXV*Z15U9G7)N/QJ;W]$GLK14-X( MY1/:'2PHGY#T/J$F1>UF=(RA-)4ZOOA+G!W/N`]#.OUF^Q:/, MU12/]I,YRF=6+;/)#MC(^N.(*INGEM8TN>OC52?WA$*;>&6MC?Z$YHQ?L*Y& MN\Q*:CIY24TEE8.^HH,E`(B=H[^.@]C9SP6"QF M#1:RVAW.[B8\C8>"DCY/N<)$`3HK!LOP<87P=.+/+3?/+-&S4XF26?..77/) M>[6>VBS[IQ_<>\RY%9#2M`RP"&?"]LL+`8H97M\3.`3M$FALABPI]]+Q[&;0 M`=$H6/D4&1$6O"BX`49L\722Q">K7+SO6/MM+DA,Y.C@>P$UNK#:+3!)X),S M,%/`I@FK2?^:-0<+_$Y`5:"=BKE#E^5'?NE+MZ6\I(X+NH3B1ID8>1S7U3*4 MSK&4:D26O>?Z8*U%//K/N_52KLDK$-=3;)Q#R!-1IM#N*^'*%)(!"\H4DMX4 MXF-3C`%7I61-5A\VFJS>J.#/9UT/:@S`5TF'7^Y23\GP3;[BT8GUU@1@U'RP M+C30<.)I5+2`2%O$G'90(@OYSH7T^]K\[0UYVM9RU`N>HKD']"5,3(:E1:CH M&S=KR-(H!L1B.H]AY^WQDF5277ZY'T5I43`F2F^L-C:X#U+#[,9UHK)UEH?8 MJ%%"R8@2`;0;!H]4!_RMF'2HTLM5>OGKI)=KQ52K06J8%]A&[JQ)_2`MA'?Z M^M@8Z[W*V+'ZBO*_1JO\1,H@VH'`EN)NBKM)4CPCY?W8ZB_TSD!W MZ@UC2*L3\I`+9WY)/"#)P^-XV46A"O.G^(8LK:K&P@SQ%#A>(6V#UI M[&D*F3NIL"&]$&6P,KJ@C!V@[,`&.4)DB1D\^(\&QMP-WUN1CP&9>!C&<&\Q M=I0M5%S]!F@-69WGSEQQ<8`PO82_:P.1 M$<4,7O*?Q+D5XOS&\G^&R3RV%QC3\MR(9&[%0"P!0_&@1<[OV8,]1?T`^`E` M[;E_(*?@8A%,L2A3*X(YXT&/J+3<#)!*B`59PG!',Q`G(9*'T$#@)Z"8F#>( MP:,5/V/K%SP^.%@P/@G<&Y'!&*7;9K%=,.'R0$[$<-*1<[B M],B+0^(>51/RSI`BC.YH$2L3AO1-<,<*/ARNL^1X5C+PE3?_)0DQ/7,6A+S( M,^4'.>*6V0&I747"`$*XX>,*BPA?X4HA"L!K><,6`<_&2Y_%%7C`KT@28-_- MV!)=<@:$#"')U:T"#[)`EPYO^;U&G2_PQ*VKANJ`B=Z!0@@[<5PTU&XX1\5L MVSEFKTXFNN"S=S6=S^H"UJ6[-2D>E+@N4?TYK0^`BW7ID!`^4)W%=]!3W"DL!PHY^IMI^9).@?C*,2Z$UZ M$);YQ&K+7_R2APP+(4"Q%0JK?.`10WKFR+,601)_F+A@HGS<&"K,U@^SGYQL M,\4?P_S'U._PMU_\^=3^<(&D=@:6US70TRFW":&Y+>N9U>P7=LZ:!%;")IELY;>H" MNLI+2Z(VGQE=R(K+A5?[PXM%MA1I#V0,VHPYS??8Z"\?4=E9)Y)+7P4WM;UB MM]*4M=R%N-J3-=LG>YB[(6635GN2](_EOXG[P37:[25LO("+4*@UY2-1/2.A M.`(W@1IG*)64`=A1VXWE7H=G]9:S-FIYEB42'ALG"LFY5Z6+X3.X5T]QKWW@ M7N9+N!?FDVR1>1FM,Z].KR:G:CO<2WX*WKW;9KZZKC#4!S7J].-N6^U-:Z,5 M[`K14";^9LNRAX.:PI/7E-997$3^&_#_>U5&A^&A8OL1Q?BVM=?407[%66M6SXK9+2"F>'`V3>HL-GUNBSMV>_J@^ZRA M6VLDFI,#Z./8JY0`JS'IZR*06#:23[%JUG0;]?216:UR;5RX]E8PR?>Z:+MV M+[('E],!-TXU$R'^M%M@>FJ*BS9]>9>&IS=P>5_#B_FB"XMJCKBE6[NDP"S' M2Y7HC0_M,\?JDN[X):UTO2L-T\N-OW47-K^NT:L*VV;MFH$^JJF#;9`K4#%% M291_7BO*QL6&0^E%*_*.%)P;L) M7[W#HGSE.VE5LTO])W43,UM):VO#HJ)2AL3#`C&BG\6PLSVTH=A6D.?58KE$S M35NQQA9MKE>[F'T9;B8-/]C&W1S)?#?-P7`9,>IR;O%R9I[+UY.;&WI<-G$[ MQ:_4/B.]EB'5Z#'G5:_C0.K;V%.748Z]/N$RMI?GW/R]1/TTOYF15%=SM5-? MBKO9[>G=OD1WLS+SKCSR[E#OZTERFV"KBU>_K(,65-RZR[I!RXW[ZK6]TK'NY2G58:];N$VUDTJWM-XA^2WL%ZO=<_*`5=7W% M7:.D0>J[+]@9C:+XCEOJOZ_ISD]C*0NNZH;GM->*"-#DKV*2_G->CT;XW#O M9%_J:'!?[];,G`3*4/>NM7N7UE.]UN4;27#YK%>/:W:DSC0>`$51`<:HV.=4^Y5Y+6;/4&ZSK>NR:^JD)#E MHEX4NG<:O4)?D^V.;7C1C?T1L/B_S/-X?QG\1SOQ'?@"OZ`>N\5Y?^4[FV8< M:S$+9Z^:=KRJH\^JRXN3]"@2N.$.&U0U^,BK9NIIE^#4%'UES5J5.$JRUYIF M`*_+$/IZ\XDX-/3GR8HU\8+7+9DRI1;E1F>D][L5AM5XF[-11S>K!=F/Y`6T MF75L3C&+-IA%>LRKN46C+.(5G&,APY'+-,-[90*M5645BE/DG$)?BL$_4A'9 MLE>_KYO5@`EF:17VH-02.6J+VN1Y M%J5#,20.J69TB]>BD&IIK:C\CJI,"FX14URJWE]H8)?=76136$Y9/=L*GZK$ M$A7;VI)[)6UEG1G:K:M'34N`B5VQXM+NQ`4Q]`23:R.WE/^F[A)7 MJ?/1E/D*(!!KBD`]X`,@75]EOQL?W&B#=I2%TMI=$Z-ZUG#LW MHMXQ%",)Y@'FV\T]R^:,#^CBWEI0U_WLJGEH&^$GV+'_P9V!Y>4MVJBK6N95 M:_0PL3F`)=_F3X`ERH[G6#OQ/"V93T+N389S"]17P[#@NLAJ]$/DOLOZB2BDT[:`PTG!0 M#'T=K"@P^H;>W4TK&.SW)2L8<=FLKF$NS^$IIO>F1*:DD'Q[]3;,?#AC-['V M+7#"TEZSRL2T@*%N16B&H%R/IMGVBU6 M5;Q2L+]7KQLMBW`Q?@BI0)L&GL-"5!;0*O6930*&[-;,1T7Z#(W;+@_D^8O9 MT4>=CN*S;7DYT_M-+G\HWEZ MZNK#2D-Q'<]GCF#?H7E:ZA(B/W/8449FC&N\%E66%34]S:[F;LBG-12,<;MGC M(.W+HT7!##T`Y#/@;A.XX4$21S&\$0^$HX)\W05.DG4J(JV?>(/1?ZLY;F2C MMR%E,1:\PP*[VO:""!?C:8'HG+"K,_S^&J6!_-!",LCJ,^[H4/-B8`]YZ-I8'(YCZ!?=%\2*?,6*7MMV)=EW"7<4:"L(%R0-E.G:SEZ_ M^L46:"MTD&*D*YZZ$3J@4^30_4!ES[6G%O.T;_99X%O`]*Y#5/9<7]Q`8DJO MH0/SB:6P20=T)'A](9"7^5TG"6>M@@$B#')U1_EK>8IJ=)S35)'Y3H5;3M1. M..CPR21`NT??U7RGT[X]ZS2H.2U60?X-O%BI0^_ MLA#ZE7FD^7V.[#"X5W*G-5N$RYTAD;Q1QWW[^M#HZ>9H4."1$RPB1P45+WTI MCPOO-+()! MR.PVBZ2O4Y#9?@P*ZV=,'@/[-\KR,*)4PG;?$Y$T7>]55?GT?#,SL+3%X(AT M\[DK(4U%:Z\4T1CKO6J;I[(^NJ$U+6>]Q0$8;@C,[H_$"N&4<1'29S!,'DT6 MZ4.I1P/T<,_+2G.%$NL%$0^%#4"Y[XX+5GCW_8>=HO16]TJ%_B?G7__Y_<,Y M\(&/6KGR'^O^?_]Z=OTK/MYYFU^7F!B=>+GM@1;*7Y[!#FC)_CDV^X6%QIVW M'[5/%S_./O\X.KTX/S^YO(+=V$"YUCQB2V3V4;OXU^\Y3#?\Z^>O__P546+.'PI_=]*_B]U] MNKB^OOCV0?L_'?J?9LP?M"CP7$<<$S\WS:.#X]N^_M]SV+^YU`+Y[UXFG?W\SZ!90(BCCS!)NCB*E_!([ M-6`6@;`I&W8[8!C+4*RA^GI8GH:RK4(+X"*Y`_T"B9I+H']/T(K+#P"8&&>F M^,Q-^`L]+ZQ9YBA4RXSJ[GI4?['<`J+_A9Z.(I*#2?['5)-,_W9Z<`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`7A[)$3;34LQNKJA\E)D`&_W MA6B[>2G#CFYL3XC*0*6/S4N1.L*K,EZDRG@9/*['2+%):8MI+N90-X>F/C0K M[>%>/^-R/L^JN2=Y9Q-3-SL=U5[TP&ZI*=4M'8&ZV-'[ M0[.I2YIW2I;B8HY&^K!7YD#JDNU()R\Q`?)_$I\5!@>D4Q8"G]6U!OU.%):V M?MZ0YHDSNMK*\NSI9A_;5O=>?+-6W:$6V[K6SH-J_[IVC:'>'5[QW**(EXDYB M8A-&GK*@9AI\J@8]3B_.+WX`M73I?V^R.]KJ`.Y@4OZ]&@KC@2*:;VI%$8") M0WUQQIX;YG-N11R)YF3=,"OD4_1`Y6)1W'10;%3:[ULX6C^9X=!5$5EJ\EV% M,!&?'D^__S:-SJ53<]/)?I;K+;2[P$MF#(X5 M^2DF=(B'Z"W%`8[YVNFPOVXVL@P'Z.:#-;W@'D][P\J%+!BCCSLU.^7UW-F, M.:X5X_SL>B4KH=T>.8.>WNF; M^FCP\KP$HG^*`UM1#AX1?FU@M?%0:MW5M?ALS!9#J;UA7^^+9M3I:U6\5,5+ M5;QT7X(GNX@T%2\].(RK>.D>NE.W&B\=_6*.5+Q4`O!4O/35XJ7F0.]U#>DI M0A&\BI<^/UY*530'S=6E$?#MQDO'OW15N%0"\%2X]+$BF'QXF1]/9IPJDI5< MQK8<+AUT]7%'A4ME$*+M-J@9_])35K`$X.V1$&VW/XVR8V4!;_>%:+O]:8Q> M3S>,H?1XE"#G2#6HD7*O%WZA$X,QJ"F:]P/_*&2>A9D2F`R$.2/!S(VB(%SP M?B1I$;UEV[B4TV(3BAYVBNE7DB3*R1ZGZY,];)YPPW,^+-@T_'%N+:C?1QQH MCAO9L-PM:[B91TV9/.QWZL*VDSB*+9]R<+S`\BF1#(XR3&"WQ0RKOV#S4[.3 MIP.E/6-*G6$V=I-I$JQQ1Q\/Z\OP(Q;''F^CXF2I1%)?A1V[MM^#.]$_I2_W MK>WIW9J.4X=T:\?]@4RWU@0^VNNI6[NMA.&E+.%OX;'VJQ7"A=1^/=9^)+/Y M5'OW@^&]#"Z!KF>E:W'Z^>)]?FN-GC[B'L>V;E1W2*L+PD]I/+(\"U@)Y0EG M+\L3![LJ<;`5VLF:'-42T1ES8\";]NXB"2MT4N#N_O42AB`A0$O-S=%03RJ$1J0"X7(_25(NZ!&+$+500:R8*R8UV0 MF[>W(;L5/9N:;1(UTOMFN91`2.'[0+MCOA.$$1>\`DC*`*X8 M(VT.*A8]L%E(&WTT4'+R4.SPU45I#3%S+>ZYU(Q7IK#"O16&%I(P4/D\"8'A M12Q]$N^7QAY8:+N1J,8@L@`ZZG:>'2`(4!MX29Q5 MX>#S>"DLGU-F0233%*2L*#T@E^$! M<_2(9K_1X[O]=M_7%[F-],'0U#OC M#A<:>G_0TXV.^?P+)>A=$`^^HF"?X_VM"@YR0BS5=N9RQ=>^64#)FCDFNC+I M"P6FH@O&`ON9`S-Q[YBW6"LHC`'VYQG3.G_I=O4AKE'\MJ[=3UUX(]Z\Y4JV MXDX==@.0K&SB*>D5V"5I\NB6UU?`G*>AZP#;+O:XKE)]M;)SH/>,@3[L=E\@ M0FI*+?,VT)9HU`L?7("H2P7A>@KM#W5C.%9T*.=>U]+A230%%*_MN[Z))LTF M])K&B;+;AWNBB%+6O:XERA_,N0\"AT3>]>GW)U'C$+UBLA&C.>SJF,B@B%'* MO3Z*&,O*:5$QS=L:5&C1&(&H'NJC<>]IQ$A4J*\CPW74EFZ@T(^^"SRZCY9. M:_27_D+I.*0)WZ`'(Z1">(%L2H3Y@"7\'S5ZYLBS%J`'?9BX#\SYN+&@/EL_ MS'YRLGR5XH]A_F.:+?.W7Y+HZ-:RYA^H#XB(S'[^(W'C!2+U#*QH+XB2D%VS MA_B3!\_\X\]_^O.?-.UOV1?QM$M?//$=^O`3V*W.)7?31]GW\;QB^.4'F_S] MS67'^#?\'SUHUX%A_KO+?WZCN<[?WWQ!V]B!#\PW_ZA/W7"I%<[OPBNRO/=D*U!(?MK/)9(O83#38G@AN'Q4>GEIWP%X9\XMN"]N*IB@=@.G\)_')UY8G1(!J?X=,?.Y9 M=N;:R$72TAMWZH!WE"YJ_,WUP96VDH:,1S^$?3_RM*@LJ4:>J_$;ORZ'(`T5/-4XN>FO^!. MZAYLY1YT^34H)UEI&$Y[I=NQ0F7"_30KA39 MOX;#M#:U6Q](K8EVC&=<>9X3M3)]XK6OO,C5J+M]ZKYMZ;YA_OVJYNY[JMNN M-NJ*V4EX.3Y?E,L07-P=[-CGO=%+`O15;M"2MKSJ$O74)7J5;3>(VQ+@)UJ4 MS&98D`1TEA%5T<"J\SXO>1^$SE<05V(J@F@(7VJNOV!6J#$?,Z&K=,:-`(R\ M?]AN\$4B.FJDCWH!V+Q;^GA]M_37;XXN2P/A8=/=1W:S&_).ML.NZ3;RB*;G M"J42HW1#A_/?Q3R7_`C$8)?\@U37RS\AI>]@T/[RCFVK^^ZDC8;./W_!M;I; M:S14Q[4_61X9J%5%0_X.68?<]:S)IL>]H3XV#7TP..AN4S*`IYI[MTGGF;]! M9A*0NBGI8T6<.=A:0]HZ$?=9Z#;/F=(B?VMA245:NSV&CZ1'Y6Z**D6IBE)W M4N1TQU)955\I="&]MK%'M[C==KS]GC[H;W7Z@@P:I`S@J<;1RLK9ELB1QJ+Y M$H03YL;,^>4S1;>59?,,C_V:&RZ-]OBNU]>[/"ORO?0XWDW)(Q<)*Y-GQRE5 M!9(J@213>FUDCR[V5AWL_:%N]@]\U)35:5'*%MH#0;0C,:*N]&K)-@43X%!S@N0&J5%2 MO;3),)+1[^EC0\61)`!/65@;+:R1_/'M5Y)D>==Y;>D[K;3F2/=[*'TN7K;/ M!K&@E4#%;CN3?)0$;ZI!/5/<_\*BKC]!VJ;>*-9-D,0:S3TXXDV%:CNJ6-0M M977K$WQ]%(>!?XOOYXU0\M\EQ\/N]D7)_SGN%[X\ZJ@N*?5\U>RK+BERPK*A M8<;GI6X8EP?5#4-"6%9WK8$/;L)?Z(\7N1#9-?CV'%=9"YH"MDY$$YK"1Z<@ M#D/+CA/+*WY\[D[4Y9.773X2N2E7U0Z+F;[L4FYUPXRE_3=O^ M&IE\,\;13H2\]RAHU"Y*=\DS+!-2Y4'@\7A(W6V?TT]228K]DA12LQKEV9=% M:VTN#V&%UKHU-,N0BB`#>!+PHNV`M:(R#;76_EYB35*MM5V4;K\L=B=Q*@W^ MS.-.;[M*JQ(4T@@*J3G--KT=,M"HRD;9T>D])_4)'WSNG'5[&[);G*;C^G'H M^I%K:W>6E_"A:IZG\7DZP1Q33")*$JG/*H$_L`<<+,B'2MVQ*(8GHV:G6C6Y M5F<9B>DO?,A5S8$PRYZ*LTC'TD5TC(Z+\X\9IM_>L/B>,9\^GEANF'\[2,+* M4#TX-'QL>198E%1?!&?*'XUQ$JT;XYLY08Y,L_/1]8_@ST>P-EMD'QL`R&H!WH+$<[2I=8?0`"@AT(Y[!XB]6="CT\!S6$AD57QO M1B53B^!:9(#1KW`4Z0,!/Q[/`B*)0XLHR+%H"E0VH@D/)X(7T2>)#R_T%O@< M'YF"4]3P#[871/0I':@X/Y^?'ZQ8CTG;\NS$XUE3<(PW%NY0[*GI@8:=87F* MJ5Z_Y1KJJ!D;W#T&<-();GY0/OWL7L+1+']Q/-B4?9^F'VDY-MIOACF/^8BIF__9)$1[>6 M-?]PA>@7!/CYC\2-%R>^0Q]^0C1>6@N:"'8-%^63!\?XCS__Z<]_TK2_I=__ MZL,ALVOKX&^>\N__F-YCI` M%)8=NPY\T'WSCPK+SUCW/(9_A`;#::(JY77^@:Y=(0UI;UJ1($_=QG*"V.A8 M^_K]].+;9^WZY/_[?-6JO'OY;M>H,U)L=*/X;BQO5,R43<6!,?P(G-YZ(#GM M1ZG0BK1)&,R(]Q7D22K+"[*D]-U)$&:L.MHX3D_7WL&MFRGIM]WR(,FW*%2!!8`$8``/O9A%S<]D'AV/JB_& MXSL%@H#_^JZE7<4(;GX"U[@1KJ`!`Z3#I<\3%%2H535[+./C4;>\P?>ZADH' M("H,'MP9O-M;%.8I?I#S:KT2#VAM)"*7K2K;5\U$;+K.^K6A'18C0\-B@EM_ M"?14;.1'`/+C8#"ZS5"@NI;[?RV?4CPZ?$):ZC,S$F6&6*'_2>A_3FA_-Z^W MXM'2`+.#L#0X<')O0:V)M\D.J\+;88&J2+0942A9*FZ==#Q-?95O4C?HFY+S M\]T-\]G$C=]K1ZG[\AD$L#?9K#*`)T'VRG;`JFM89^C=WD#O#`=;:UFGR%*1 M90U9&D9?[PY[!TV6DDC0=INB/D6"4O!K6Q0A0V:=#."IY.0ZCM4U3;T_V!Z_ M4M2IJ',-=1HCD*CC@Z9.2:1IN_;H%>8#'O$T1B/I$:KH5=$K_CP88B^,GO0(W7_!VK*9.K7\6ZP/J%1J."QT[T#$ MWC%5EB@[7G>'9[5K#O3ZIMX='W2)H@S@*7I]=+^IL=[?WIPW&>A5$AG;(%QHP0UH7"RRV1:SZF0(G,@`GLH!?B3+ZAI=?6S*/XY-T:NB M5T6O,HG8E@U6VPX3!KNW/"M<'+)&I1)V#RQAU^@8^F@H_PAX1?.*YINB^5Y7 M-_JJVGO[4KU=P_DJN8F#>'N].F50WV0`3[8HF4362)/1M"V7FREJ5]3^BM2^ MY4(S&:A=$B'>KFG^+U5$KFR5=FT5:>R2=T*$'W2_9$7A^TSA0FP?-(5+(K=; M;K7&ZUDTG\5:6J"B\;H4Z@Q.52B'K+VILEA5%JO*8M4E49=$79*]T"?:]0-L MWP,H@^HH`WCK[F^1[1=Z[C/_]%]3M&O[?`_](LX7U M+YI88(]UY0B0&#R9,H*W`Y^43$N1IR)/19Z[(%/;-7Z_@^P,YBRT8M>_U;P@ MBC3;"L/%)`COK=!1%=6R(_7`2U4'NMDU]='(D!Z3BE`/FE#[>G_85PW,I1"I M[9JI$N65R:!&;37K1BX[8!M9-^U:"N\R^7O0LX,5C>\SC6>B^Z!I7!+9W;(Y M'/A'MLSY93)H<=M-G6DDW'0HJ3.O=U@RI,JTQ+=9&%NN'R\PAX`^BEW/_:]P MW?B.%C([N&.A=0,?YT_E,9*C-$A"3P-H+,P5QDQ3A`W=,VUJW3%M'@9WK@-_ MM.HFV.+.)HGG+>#%O"]?E-A3L[2X1P$B$ZSYC-9C>`M:ZA:SCX0B<, MGP:SN>4O`&<1&0'KXF.XC#4'Q#ZX,RMF@+R_-'GY#;`]1YVL&6?&!JP[R_5H M_@X033"9`(D`[<1)2"8*_4%8+#0M.72#)-(6S`HC@#`,DMMI%?AN][B`P.RG M:SB/"([/G;BV!3`Y[@0('%M#:C M3UT`U`7``C^":TRW/(!C@.L,D,-&6.F`U)5M=*](B35<,T)"#QFAZV91I:-! M?X2()^K["U4(PB_8[A3O.;\/S$>.O,0*Z"LX2T5'0IDS.W;O8,EC[3KG$/SX M1J8Q_!CALP;2`WT9N7_(X#[Z0/DA9]R]-^ ML#OF@WR"$[AS$2[JI-;(*O22Y=)+/V%E$?B`S=!"+1*P[,$ M/DEM^\"G<]$S1YZU")+XP\1]8,['C4.XLO7#["]+=?DNCH MUK+F'[X2?P+0SMS(!H8!O.N:/<2?/+A^__CSG_[\)TW[6_HLG/?,C6=POZ(3 MWSF%&PQ;@<-P653S;;R@,?SR@TW^_N:R8_P;_H]8N0X,\]]=_O,;S76`K5B` M5@<^Z+WY1X7HGTV\VIM6[A#P)X-"67U1E$%F9 MR$C@9]!60.,"%JTACV1<(O#'V,/\I/D<:Y73Z*X]#=#M[FL/Y)4!Z>K]J@K'T1(R('"O58`LFYA&02#%IV`L!?Z`>(R\L%O7]TE+2&[A;FAD7]!#0B+T$M37B6:`)@0V#ZB:0O!LX.FFD9?($2W<2H$HMIG?NS,F_&L%D M6^33H1I5\@J^W73VU/H9O*OV4C^2=_[PP4KB(%MBT%\_EG?)(_S\.;U+&WQ6 MX/C960(O#Q+W.\O.[?]%N9!3'AF0^.>;\!=Z-+4E\T?`J'R&FW\WYY!)",N& MB:DGL^<.#]M-#+T\DT.VAE!UMQ2TGX-NQ"P#>"HI?$.+?&.@=WM;FP(B`YG* MPHR:RR%M:+#.#)5.HI]6PBP^SHIC&2'J$'P)5:5Y$&ARQ[9`!OC[A2 MN[K2<*R/QEN;02`#N M,(68$K%+>:7%"+S3<-:XT=-'HW$9CY0"V^A;1MVE/)1*LJS?OUCI'VZ9SS]>@[L=/;\]W?:%G^76C3"YKC/0R_F&]U@O M9,VPO@NS#K$4S'>P:`9>W`BIX+\=]J!]#XYA7R.S-_RE,]#>(?C_&X0_M:MD M'K(9EBO.>)BP'HC"Z6&X#LL1GM1;,]R\5=QU,K+D,4 MW-/'3+OTL%+.G4Q*V65+0%F8/#EC8645RI8-20)%\`F;!IZ3_LZPPL[3[""< M!R$QLXAO)(+7TLXBJG&Z]WEQ5I3@@DW+RY$^-D?'(D:7B2Q#T7!=AD5$P7XPT(\A=(&.>:SEQ&5VB;B&'-P2#K5Z3&OPXH2J"AUFNY3IYS!_01C*\*;- M`BHYP>Q6.,,9IO[^)W%N*>45]N.Y+*&T52IZHJ_I6$B19Q("/%CBR#A4]$Y* M=)U8=DQ/LM#/<@Y]>(_-*J63U4,BL+]9BQ3FD5XA-FWB>@@8'/2,U^EDF\,] M\XHL^`J63&*=9!AS>G7#G-`%#>%19X]@1K/X/&+L)^[:L6;6+0?(#\"0B`B% M?K.$-AR,]'YG4*8R0`K?-(`'2#*N@F26/N?Q&=X/+WRM;H!F.VI2&>> MN$X"-Q%.UDG@P$61:^$D@245[A[!65YMH=VCHL`K4&TLK?*(.?`J68%"V.4\ MP9N*IUCZ/BU.3U.I(&'W*Y`5UB_QA/LB6H%JL5HVQ:J`/\,M79F,ZDKON7,# M7CQ86`[K?4*@P@3034PEMN(D1C(C"SE"X#A$!!*2D^.X>!W@"TWB5S-T$W7O M:G;V\N'0/B>62QL";&$!H1M7D4;E8BR$2\TT!VX.H\*G$A,5$-Z[\335O3GV M`_A.'5)0"J3$#A` M_0'FP+*BPB]:@3V@.&M8+E#E[7*RO3M9NEU4XV?;P#;@`O'#!"+.;PT_O^,= M57UV=-ME!@?\#)2-2&@1+HI-0A2R6-!97"[AL>@[ESI^=$]%_5R:XC?17`^1 M^HA'"85%R+=E(562.IFR`(^C(@$+I<+I%IZ.EJY_Q@;%8RB[0<1[%BA*04%^ MZ]HDM!)'%R*!A'))'NCB=D5I:X/$Q[,$,0V7%O5%#@UEP M!W#AMN962'=R2;6H2K<0#BW,:A.VP8=!A;T!E`-(FS;'%;=EW4X4@S6\XV&_ MKM!?["'E@%\S/9'7(QD5E>FOF:*'UHC`"@CTVQ`,$>;0`E=P*7BQ,Z]O+EX3 M^+X5`W'Y;)'=`^T;7Y$7NX/>25BWHE0;)K[LAL47PXUQX1GX[03XOZ>9`U%5 M[>0=.-(^:U_]N\"#VX!D\\GR?X;)/+87&I;FHK[*]R`N2+%,C8L#FS1@O+69 M%@SB?X$R2-"P,'/@-.!VIKB%2T_M$02I+[VW4DKFYHHBZ8["#$`I-9^CI*5W MK;@#Q]KO)-+@]?B-._7<^[^D;B@55KV M3XMX[@\6`6G9R"[()`=#O50D>0H6ZS$QT\^A^U-[\\/]^48[8Z",VU/ET]F1 M;5]D#(K72QKZ*B2CD77Z^4+GV!9XUKDMG#E],I<)[Z/3@F8(]._W5DC,?]@7FL M;=SCNS?GES_>O"][BU;L^EMXG!^1XX9@E&`%;9@UG^'-DFQJH^'B*T!?LE%@ MA&2BPJ"R(.P3BMCP"W?Y8'YF#X]$ZUQ,'Q?*B((5G MGO@NQE@R2^XU]]ROLXE(TQ6:`R@1Z"!3M<>OL.W"52,/4B?P](%>-G_\!B&LU6^%,I6,,!MVCB[//Q]K) M)$8O!;[=\G1.R+G7ASKI<%,)6PV0I?18SL)Y+U?4\1WL-L@M,:$V5_A,QG_N MI\0N\L8\*>/!)04OPM>1PQ/8!;I2R/7!'15I^R=@/NEC6@1@'6N/0(?`0X`> M';0K*N>`[@[A%+^%S?I.5/"X<\\6J:UD\@'G1"<2]?T*Z*_8C8I8M$[O_T\2 MNI'C<@2]"WSL<@75QO/2F]]U6WS:T6>X6XG55W@VL#]^FM$ M$A/DAIZ;)>AG`S/($@YRI+TY$M(-IVZ\EN@]#/C%Y(Q!F'W7`=Y]I%2XS=Q' MP9>"/Y;?.D6!U',!R&U!N$CN''TWF9C,Z)GZT\%S+$1_C(VV7]I?+Q&> M1P+($0Y-M'(;U@1(JAY7!>O<6M!&L!5EHRZ'8?D]U,.$%`D@'CBCAE6&6M@X M'NAXW:A(,!;2,(]N`-V`*G3#;`N;[P"FLBZ:L>7?DKL8V\)1@@U[``KQ;_-^ M/1EA<:2%%LD#H@B@A20,\R89/$L'2,++TBIT$6'B1.JY/[%5Q@T)#6"UW`F- M=(.Z%C8+!6W<`6-_ZL*>:FA]:CD5O]\]$QYU+OFH4VC.:9'%DEMNCL$-UX:W MP1T-O(0[**@U(XMCCY\9=<2#4TDH;!!;/]%5#LM&D1B36KE2ORI=R*A`[7!AOLXUJJ=G"'%+O?E MH`\(`SWB=&@[-O9S\@7F`H^BK]AKC_>=1)O-*CH]Q4%$2'R)E[9WRFB"N[CRD;W'/5MT M8J@,6-&4J.EW$=>E@%UV?<1AH-?NPHX#W+/1Y^(F:VH%@D9XRVT*USC\G%)6 MKO/#3L@-"0N*"!Q[P/O1=END..#=1TFE%-"0%*OV>ZPW_/'&DKMG1K= MN=FIV3L/(I5BE:T3!V5\D).8%&)2RI&O"*X2_73G1!C9\8DC$8H]%Y#40HUK MWF622/4`X')"[F/H+Q"!QVQ-)*RT?5I*@:T?1MU94`Q>:$CIAHR!:*R5W9C$ M3Q6%&3)=XML%=HK+9,W@Q)>II6XYL:'*=S3>3*==`EB&&6^^).$3$F[+P%O^U`45.&-`9V M'7X9>[VGK[BP%7=QB!T"=TR[J#,@L_;@]-M*M(6)DW6E[.A[N`@X>4XSP MFQ52^@PWB8M_P89W!3)'$Y/?:T'A3'RW2.8(>@XDY9!X'I>0%1%[DNIYQ]IO M:1^S/%\GTP)UC+,#J\#8^O(BA<>0]4S3=`34_(E5,=!J1(:!T$XFV"@0>+RP MI)%^B$)0'XCL$+C226&`T:VV0:HD)7B`^G#>WQ52+W M*4NT*AA:R)I6O?98RP]\1<-\OCSU8\9L0-C75("UQ*N)DU`Z$H_[`H?PV6T0 MN[P+IU6T95+_/S"(N6!:A;\*#@"[1BN,;C.>((?UWO4\T7I[:1N<&PCO1G87 M=HF4)+T!CXYN%F/]ERPFN8[XS./O*G2Z(]O.,Y:[&5]+DT7KLL#9;.X%"R92 M'^LSQ=&U#C(><^;3W).,2E#8KDH5$=DA218'*\)`E-@K!"*RDP<"L9$V2KIZKP1-*?B61Q5W/498:E!X^ M.<122IAE64C%P(F(99&CCC3&/`U3%U:F=1>X0B:A*_"&44H=3S&)V5A'I=I-W5A MM@T"V+QL,N&%?UJ2"FV>G"7097F9[L[/M4P>0`;DB:3$:+($<.Y*-!$(1@KW MTFS^\MEPU<`IVQ:UIU'2V--*DM3Q7IA9UK!C?UF#1W/E!H?GD`['&6+$@"8= MS4MF<]I;:ES!T:(FC_#`%1JECGIB"$WNLVT2H;`3FNE+E%$*2R\+P5(I?S([J@H]/HG0 M2OALK._'V@^XOGB?\P*_>:'`CV'`9EWMI]1$)">:'J&QY@:L")IK=2A[]T;\ M].:]=A/RC*M,?4B5S1JDPO<*'\*7EY(I0'B+J8*M3LJHBY3Q@D0K*M8CNN2D M]P++Y^Z]4GD.B,K@7I0GI2DA8%.X\9!*"(TQ<.V;N"8CASTS+DWI/GDNG^-CE:-AF9Z0%8EY_-W MI'GEZ:3%P,.BD%RWR.;:%3,;J*ILSFQWXJ:UG>3G3[5/=#K`E MF3I$^DUADZDC6"^?*^JF$]<154YU0"TSCCV]LN7-OLZTNL89)/'T2ROQM"\H M"T#AN].U7ZT0/66_PB>@\$V+`B&IE9V[`^_.;+LH$,R1$`@E1"%'=]>*@2H> MX1OXWS?O]8J$V)8LJ`L*O4P6X,$\41#@5Y04:%T*[.@HR*>-=ZP.A[S*7$J? M,=$D>LDWR'CV2ZX MC`_=.W1P7&(">1;B/^4U[%<8!'LE&^_@A@-_+0U<[%7\@RB@FY2IFF'6-P;( M\PVP;`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`1J_U.<:ONXHE:0=QO7(:HW=YV8[GMS] MK.3K[#2D2KSFR=*-Y4=_83%Q)+&Y266I+"=OA1(.5J0+5G(+3P*?)9>23 MOX2?[,5+T@H&TJ<5U(WO<1^;1_7)BERRC"YY67(>R2B=X[*)X+8N.0XWN8TZ M5MG"3A453P(7C#-ZWZ;,(JR1XRX'WF>."IRP6LI:2WNAWD\#SUL8 M+H957:[C6M3=_(Q1=XM0.W.M6S^`7=L1SX_&[Y;J_=YA=6XZ+4Q[4Y`M;W0M MM:W-SL"I"#.:-6$19/1@-5.@@YSXJ8 M:-9\`M*.5-FLG40(=AN7"CP'3-CKH@DZR2GFN3,X4C'8^X)#6>V<@8^1P3 MDFV\J[VEW0:"IR*2@".`!$S5<2)O;.<9IZP4-O=?*].F0=.,13)I1='V7#XQ M"=FH\"WP`::DJ/+V=#>@;OH,FS$".R,&A+WK@//ZV+0T9**KG4X]ABBO`$[` MHTYPPK%!+!"9F2XF7MPQT;XKF25\N([#X(MN"^U,#'T\&N@CL^+S@H`CB:%(!6]N M>@+467*Y[47CYZ*;_;$^[M9X>YI^CS'6>[WR;-#\[FY_>FBX.L00L?\E+F7)D'P4[3KF/N0JBLP;U]17>IX)3( M:M+13SBF#^[1U)UC$]%4GEDQ-868A\'$Y1I.SH(J=_8)&Y]A#DRY'3.-L1;(4_,.E8!"^7M.9EH"H6[=2.L&YA9X<^4:Z?Q M'W)O(/_U[]PP\--)>J)G:*9K[M@]VLUKL:(_$4D!)Z`.K23GH@2#,2ZBBEIE M(67#JRPQLBPGS*P'I@^:JK9@%N]+*-H+T4""VLO`)_>)WHG";51<&IX`S<`7 MA+B2O(^U*Y="@MA5U?(8UT$0C+Q]DN5@I]Z8\2:NV&FP!('.V\N*5U"U$7;@ M3)L@\WYPU'H*]R+N*ZX#V_BH38-[[$*>)P>3[A`E0-KB&7Z@N"6R@`HG6X$\ MU5@(<-[KCX[`I0PWG'HSF\G&\U:6+K!(T6T+Q_")44V(-GXS@*'"C\2S*>.0 MGS9PRW0D&N_'ATUW:F@WD?Q.,9P=Y9-+7J&2\?.ESO@15)#I8+?VU_KM%(XFN MRXQD_@VR:J1]=/>+:0W43KM`U<^GOMWQTJSSO%2]-+]%[&+R&2AH1GVRGNZ7 M&>V27V;5G7FTF^8W;H%G!Z8OAP[E6O&&TC8I_*24<;T( M50RP@;!?)&I8-`V)73^5"^$D[!NLTZ=U#.799=,C`1- M0.?A>@G/K%CY@&91:%?P5C%Z.6.8)7=2D3-2DD3&`?C(T6`IA)EC=%78M%ZG7RAP<.H.@5A"K87^+=' M'L_N(4#U;,=8=I`)$G+]'-W02!&RY_PHCUREK0PS!5G4914/[!@G'_%P,`^6 M\&$.C@L8"],I)4$1N.OZ$D'-#.YFA.8]J'HXS%I-872SHN'-Q MA]D:Y:D4-RP7ING,2YP)YU0&I`L][*R+JR_*I*MQ^<%'\`Y+>^VTPD M=WQ0`D^&@%I%(C"X& M9%A"#K$'-T)&&+'PSBV'+D/L!TK3S,+4H@:NA_P3%&E,Q`ELLO\%DABR, MX[.8"RR^-HE=S,47.:!!F/YI;]CE1H:XE`9C15/LR`'_^0RJ#4A/E/\OYJ)& MYZ"XZ"GUY,=L&/RA<)"*E[[FMG_/8P64T3AU;W$HAL<'W_*6#(72&^IJ)&92 M`,/AHZ](*\8Q$B+)$)@$GS%'#?G)H\QR_.X-XW@4'Z@RC^O0G):?'/&2DU14\;);#`"BTS=]7+&6UW9-I$G1 MM[Q[!^]IELU(+8RA0.\Z/B"4IBA79`KY;Z7",E8R6RW>C\Q./"O,5BD]G[X; M1_>*7)%2E+6BYC@I\5@IK5GDQ'!]M(!%8?<\B$4K,K&Z2"DI;=ZZ97F:N5@K M+--M);=P%$>8#DV MZI%!YK['BIWSA0O$3:."+"8GC.A(*"+?!25Z&<&99Z9$N9G?RPE@:0HV3JWP MEN65/8%?AU@5N7F-"/<*(B:_'+76R$TC-&U$UEDV'W7U-4#?5T@^)DPO2W-; M,6)'-)HS*F$QY>^I,)(*M8O7[8T6]"B%IJH%?17.R<7+K29SEQ2?;/U':SI? MQBJD)Y?N#)Y5?MG<73,JG%K&6SA,\XACN+,A]V M^%X4RL.2B4^)*%2DQ9='SQ2UTL-,38S+@"4WX3(TJ4JVD-VBMD2M7N]<=A]E M,8.%]@=V7.7Q#Y!N4RPGU;Y."K%D-Q9^-SZ*N2A8V0,^Q*=\WD2!Q[!P/UN9 MJT;`6N'$7)YN@WI+'@"AH(P8R"P6B&ST6.D%1]R,'%,\80,_4`B/X% MB"]*@.*#@Y:S87%W--94M!7DT0@Q%S$7$8VWTBM=NN:390UCJ(\JA="Z]H04 MV=T1;:ND5$U=G(W=/XAB?KC1SU-2S_&G9PBT[GX+M#PD_17T\C#)@Z>E8Z0> ML=S*P7-4LJ_U@H_<2'0+B$G#T>C%T^O,G,*'$%WZ M`MX#1,3E&34*1ME7NY5CC51,E*!^%HA.X\]"[&+K'5*SBR"\V[3R^Z68/\\+ M)<&?MCE_-Z$D1\H+YVWB73`0\-+::2)5*L.*S?P$I(DO=HS)7[0^A:GXP#R1 M9\CK7ER6EG;C%":*R+LS%[T:\6+.RF5W(K3-=8\Y]E=^K_/T+L]E=Z*8&TZ( M$D-H/_G8WUIL%UKNBU%X.2A8>VY;2<3XKDDWF@8AZ$4LG.%6?/0',PJ8<3P7 M>E%0?NLF/'`Y#?MUTZZ(,V91`*RPC>V8U?O.`#ZE!BZL